ID   MARTX_VIBCH             Reviewed;        4558 AA.
AC   Q9KS12; Q9X4W2;
DT   14-OCT-2015, integrated into UniProtKB/Swiss-Prot.
DT   14-OCT-2015, sequence version 2.
DT   17-FEB-2016, entry version 95.
DE   RecName: Full=Multifunctional-autoprocessing repeats-in-toxin {ECO:0000303|PubMed:26185092};
DE            Short=MARTX {ECO:0000303|PubMed:26185092};
DE            EC=3.4.22.- {ECO:0000269|PubMed:17464284};
DE   Contains:
DE     RecName: Full=Actin cross-linking toxin F1 {ECO:0000305|PubMed:19620709};
DE              EC=6.3.2.- {ECO:0000269|PubMed:23029200};
DE   Contains:
DE     RecName: Full=Actin cross-linking toxin F4 {ECO:0000305|PubMed:19620709};
DE              EC=6.3.2.- {ECO:0000269|PubMed:23029200};
DE   Contains:
DE     RecName: Full=Rho inactivation domain-containing toxin F2 {ECO:0000305|PubMed:19620709};
DE   Contains:
DE     RecName: Full=ABH effector region toxin F5 {ECO:0000305|PubMed:19620709};
DE   Contains:
DE     RecName: Full=Cysteine protease domain-containing toxin F3 {ECO:0000305|PubMed:19620709};
DE              EC=3.4.22.- {ECO:0000269|PubMed:17464284};
DE   Flags: Precursor;
GN   Name=rtxA {ECO:0000303|PubMed:11032799};
GN   Synonyms=rtx {ECO:0000303|PubMed:9927695};
GN   OrderedLocusNames=VC_1451 {ECO:0000312|EMBL:AAF94608.1};
OS   Vibrio cholerae serotype O1 (strain ATCC 39315 / El Tor Inaba N16961).
OC   Bacteria; Proteobacteria; Gammaproteobacteria; Vibrionales;
OC   Vibrionaceae; Vibrio.
OX   NCBI_TaxID=243277;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=ATCC 39315 / El Tor Inaba N16961;
RX   PubMed=9927695; DOI=10.1073/pnas.96.3.1071;
RA   Lin W., Fullner K.J., Clayton R., Sexton J.A., Rogers M.B.,
RA   Calia K.E., Calderwood S.B., Fraser C., Mekalanos J.J.;
RT   "Identification of a vibrio cholerae RTX toxin gene cluster that is
RT   tightly linked to the cholera toxin prophage.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:1071-1076(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=ATCC 39315 / El Tor Inaba N16961
RC   {ECO:0000312|Proteomes:UP000000584};
RX   PubMed=10952301; DOI=10.1038/35020000;
RA   Heidelberg J.F., Eisen J.A., Nelson W.C., Clayton R.A., Gwinn M.L.,
RA   Dodson R.J., Haft D.H., Hickey E.K., Peterson J.D., Umayam L.A.,
RA   Gill S.R., Nelson K.E., Read T.D., Tettelin H., Richardson D.L.,
RA   Ermolaeva M.D., Vamathevan J.J., Bass S., Qin H., Dragoi I.,
RA   Sellers P., McDonald L.A., Utterback T.R., Fleischmann R.D.,
RA   Nierman W.C., White O., Salzberg S.L., Smith H.O., Colwell R.R.,
RA   Mekalanos J.J., Venter J.C., Fraser C.M.;
RT   "DNA sequence of both chromosomes of the cholera pathogen Vibrio
RT   cholerae.";
RL   Nature 406:477-483(2000).
RN   [3]
RP   FUNCTION (ACTIN CROSS-LINKING TOXIN F1 AND ACTIN CROSS-LINKING TOXIN
RP   F4), AND SUBCELLULAR LOCATION.
RX   PubMed=11032799; DOI=10.1093/emboj/19.20.5315;
RA   Fullner K.J., Mekalanos J.J.;
RT   "In vivo covalent cross-linking of cellular actin by the Vibrio
RT   cholerae RTX toxin.";
RL   EMBO J. 19:5315-5323(2000).
RN   [4]
RP   FUNCTION (MULTIFUNCTIONAL-AUTOPROCESSING REPEATS-IN-TOXIN).
RX   PubMed=11553575; DOI=10.1128/IAI.69.10.6310-6317.2001;
RA   Fullner K.J., Lencer W.I., Mekalanos J.J.;
RT   "Vibrio cholerae-induced cellular responses of polarized T84
RT   intestinal epithelial cells are dependent on production of cholera
RT   toxin and the RTX toxin.";
RL   Infect. Immun. 69:6310-6317(2001).
RN   [5]
RP   FUNCTION (MULTIFUNCTIONAL-AUTOPROCESSING REPEATS-IN-TOXIN).
RX   PubMed=12045243; DOI=10.1084/jem.20020318;
RA   Fullner K.J., Boucher J.C., Hanes M.A., Haines G.K. III, Meehan B.M.,
RA   Walchle C., Sansonetti P.J., Mekalanos J.J.;
RT   "The contribution of accessory toxins of Vibrio cholerae O1 El Tor to
RT   the proinflammatory response in a murine pulmonary cholera model.";
RL   J. Exp. Med. 195:1455-1462(2002).
RN   [6]
RP   SUBCELLULAR LOCATION (MULTIFUNCTIONAL-AUTOPROCESSING
RP   REPEATS-IN-TOXIN).
RX   PubMed=15547287; DOI=10.1128/JB.186.23.8137-8143.2004;
RA   Boardman B.K., Satchell K.J.;
RT   "Vibrio cholerae strains with mutations in an atypical type I
RT   secretion system accumulate RTX toxin intracellularly.";
RL   J. Bacteriol. 186:8137-8143(2004).
RN   [7]
RP   FUNCTION (ACTIN CROSS-LINKING TOXIN F1 AND ACTIN CROSS-LINKING TOXIN
RP   F4).
RX   PubMed=15199181; DOI=10.1073/pnas.0401104101;
RA   Sheahan K.L., Cordero C.L., Satchell K.J.;
RT   "Identification of a domain within the multifunctional Vibrio cholerae
RT   RTX toxin that covalently cross-links actin.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:9798-9803(2004).
RN   [8]
RP   FUNCTION (ACTIN CROSS-LINKING TOXIN F1 AND ACTIN CROSS-LINKING TOXIN
RP   F4), AND COFACTOR.
RX   PubMed=16954226; DOI=10.1074/jbc.M605275200;
RA   Cordero C.L., Kudryashov D.S., Reisler E., Satchell K.J.;
RT   "The Actin cross-linking domain of the Vibrio cholerae RTX toxin
RT   directly catalyzes the covalent cross-linking of actin.";
RL   J. Biol. Chem. 281:32366-32374(2006).
RN   [9]
RP   FUNCTION (RHO INACTIVATION DOMAIN-CONTAINING TOXIN F2).
RX   PubMed=17474905; DOI=10.1111/j.1462-5822.2006.00876.x;
RA   Sheahan K.L., Satchell K.J.;
RT   "Inactivation of small Rho GTPases by the multifunctional RTX toxin
RT   from Vibrio cholerae.";
RL   Cell. Microbiol. 9:1324-1335(2007).
RN   [10]
RP   FUNCTION (MULTIFUNCTIONAL-AUTOPROCESSING REPEATS-IN-TOXIN), ACTIVE
RP   SITE, CLEAVAGE SITE, ENZYME REGULATION, AND MUTAGENESIS OF HIS-3532;
RP   GLU-3551 AND CYS-3581.
RX   PubMed=17464284; DOI=10.1038/sj.emboj.7601700;
RA   Sheahan K.L., Cordero C.L., Satchell K.J.;
RT   "Autoprocessing of the Vibrio cholerae RTX toxin by the cysteine
RT   protease domain.";
RL   EMBO J. 26:2552-2561(2007).
RN   [11]
RP   FUNCTION (MULTIFUNCTIONAL-AUTOPROCESSING REPEATS-IN-TOXIN AND CYSTEINE
RP   PROTEASE DOMAIN-CONTAINING TOXIN F3).
RX   PubMed=17698573; DOI=10.1128/IAI.00506-07;
RA   Olivier V., Haines G.K. III, Tan Y., Satchell K.J.;
RT   "Hemolysin and the multifunctional autoprocessing RTX toxin are
RT   virulence factors during intestinal infection of mice with Vibrio
RT   cholerae El Tor O1 strains.";
RL   Infect. Immun. 75:5035-5042(2007).
RN   [12]
RP   FUNCTION (MULTIFUNCTIONAL-AUTOPROCESSING REPEATS-IN-TOXIN AND CYSTEINE
RP   PROTEASE DOMAIN-CONTAINING TOXIN F3).
RX   PubMed=17698571; DOI=10.1128/IAI.00508-07;
RA   Olivier V., Salzman N.H., Satchell K.J.;
RT   "Prolonged colonization of mice by Vibrio cholerae El Tor O1 depends
RT   on accessory toxins.";
RL   Infect. Immun. 75:5043-5051(2007).
RN   [13]
RP   FUNCTION (ACTIN CROSS-LINKING TOXIN F1 AND ACTIN CROSS-LINKING TOXIN
RP   F4).
RX   PubMed=17951576; DOI=10.1074/jbc.M703910200;
RA   Kudryashov D.S., Cordero C.L., Reisler E., Satchell K.J.;
RT   "Characterization of the enzymatic activity of the actin cross-linking
RT   domain from the Vibrio cholerae MARTX Vc toxin.";
RL   J. Biol. Chem. 283:445-452(2008).
RN   [14]
RP   FUNCTION (MULTIFUNCTIONAL-AUTOPROCESSING REPEATS-IN-TOXIN), ENZYME
RP   REGULATION, CLEAVAGE SITE, AND MUTAGENESIS OF PRO-3462; ARG-3470;
RP   ILE-3476; GLN-3478; GLU-3480; ASP-3482; ALA-3488; LEU-3492; LYS-3495;
RP   3499-SER-SER-3500; LYS-3524; ARG-3526; HIS-3532; ARG-3534; SER-3537;
RP   LEU-3552; LYS-3572; CYS-3581; ARG-3606; VAL-3609; ARG-3612; ARG-3623;
RP   LYS-3624 AND LYS-3641.
RX   PubMed=18591243; DOI=10.1074/jbc.M803334200;
RA   Prochazkova K., Satchell K.J.;
RT   "Structure-function analysis of inositol hexakisphosphate-induced
RT   autoprocessing of the Vibrio cholerae multifunctional autoprocessing
RT   RTX toxin.";
RL   J. Biol. Chem. 283:23656-23664(2008).
RN   [15]
RP   FUNCTION (ACTIN CROSS-LINKING TOXIN F1 AND ACTIN CROSS-LINKING TOXIN
RP   F4).
RX   PubMed=19015515; DOI=10.1073/pnas.0808082105;
RA   Kudryashov D.S., Durer Z.A., Ytterberg A.J., Sawaya M.R., Pashkov I.,
RA   Prochazkova K., Yeates T.O., Loo R.R., Loo J.A., Satchell K.J.,
RA   Reisler E.;
RT   "Connecting actin monomers by iso-peptide bond is a toxicity mechanism
RT   of the Vibrio cholerae MARTX toxin.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:18537-18542(2008).
RN   [16]
RP   FUNCTION (ACTIN CROSS-LINKING TOXIN F1 AND ACTIN CROSS-LINKING TOXIN
RP   F4), AND MUTAGENESIS OF GLU-2003; GLU-2005; LEU-2035; ASP-2038;
RP   GLY-2055; GLU-2065; THR-2068; LEU-2089; HIS-2096; LEU-2117; GLN-2149;
RP   ALA-2153; TRP-2175; LEU-2206; VAL-2209; TRP-2250; VAL-2259; GLU-2326
RP   AND ARG-2328.
RX   PubMed=19656298; DOI=10.1111/j.1365-2958.2009.06810.x;
RA   Geissler B., Bonebrake A., Sheahan K.L., Walker M.E., Satchell K.J.;
RT   "Genetic determination of essential residues of the Vibrio cholerae
RT   actin cross-linking domain reveals functional similarity with
RT   glutamine synthetases.";
RL   Mol. Microbiol. 73:858-868(2009).
RN   [17]
RP   FUNCTION (MULTIFUNCTIONAL-AUTOPROCESSING REPEATS-IN-TOXIN).
RX   PubMed=19812690; DOI=10.1371/journal.pone.0007352;
RA   Olivier V., Queen J., Satchell K.J.;
RT   "Successful small intestine colonization of adult mice by Vibrio
RT   cholerae requires ketamine anesthesia and accessory toxins.";
RL   PLoS ONE 4:E7352-E7352(2009).
RN   [18]
RP   FUNCTION (RHO INACTIVATION DOMAIN-CONTAINING TOXIN F2).
RX   PubMed=19434753; DOI=10.1002/prot.22447;
RA   Pei J., Grishin N.V.;
RT   "The Rho GTPase inactivation domain in Vibrio cholerae MARTX toxin has
RT   a circularly permuted papain-like thiol protease fold.";
RL   Proteins 77:413-419(2009).
RN   [19]
RP   SUBCELLULAR LOCATION (RHO INACTIVATION DOMAIN-CONTAINING TOXIN F2),
RP   AND MUTAGENESIS OF TYR-2596; SER-2641 AND ARG-2643.
RX   PubMed=20212166; DOI=10.1073/pnas.0908700107;
RA   Geissler B., Tungekar R., Satchell K.J.;
RT   "Identification of a conserved membrane localization domain within
RT   numerous large bacterial protein toxins.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:5581-5586(2010).
RN   [20]
RP   SUBCELLULAR LOCATION (RHO INACTIVATION DOMAIN-CONTAINING TOXIN F2).
RX   PubMed=22044757; DOI=10.1111/j.1462-5822.2011.01718.x;
RA   Geissler B., Ahrens S., Satchell K.J.;
RT   "Plasma membrane association of three classes of bacterial toxins is
RT   mediated by a basic-hydrophobic motif.";
RL   Cell. Microbiol. 14:286-298(2012).
RN   [21]
RP   FUNCTION (ACTIN CROSS-LINKING TOXIN F1 AND ACTIN CROSS-LINKING TOXIN
RP   F4), BIOPHYSICOCHEMICAL PROPERTIES, AND COFACTOR.
RX   PubMed=23029200; DOI=10.1371/journal.pone.0045721;
RA   Kudryashova E., Kalda C., Kudryashov D.S.;
RT   "Glutamyl phosphate is an activated intermediate in actin crosslinking
RT   by actin crosslinking domain (ACD) toxin.";
RL   PLoS ONE 7:E45721-E45721(2012).
RN   [22]
RP   FUNCTION (RHO INACTIVATION DOMAIN-CONTAINING TOXIN F2), AND
RP   MUTAGENESIS OF GLU-2734; TYR-2735; ASP-2760; LEU-2764; LYS-2766;
RP   HIS-2768; GLU-2772; SER-2776; SER-2779; THR-2781; LYS-2786; SER-2788;
RP   HIS-2790; SER-2791; LEU-2793; HIS-2795; LEU-2798; ARG-2804; TYR-2820;
RP   SER-2822; LYS-2829; SER-2830; ARG-2850; LEU-2864; ASP-2867; GLU-2871;
RP   GLU-2872; ASP-2874; ARG-2887; LEU-2914; ARG-2950; ARG-2956; ARG-2961;
RP   ARG-2971; ARG-2977; GLU-2981; ARG-2982; LYS-2991; SER-2993; ASP-2996;
RP   ARG-2999; ARG-3002; LEU-3008; GLU-3016; ARG-3019; ARG-3027; TYR-3028;
RP   LEU-3031; CYS-3035; SER-3036; SER-3037; LEU-3043; LYS-3044; ASP-3049;
RP   HIS-3054; THR-3064 AND GLU-3077.
RX   PubMed=23184949; DOI=10.1074/jbc.M112.396309;
RA   Ahrens S., Geissler B., Satchell K.J.;
RT   "Identification of a His-Asp-Cys catalytic triad essential for
RT   function of the Rho inactivation domain (RID) of Vibrio cholerae MARTX
RT   toxin.";
RL   J. Biol. Chem. 288:1397-1408(2013).
RN   [23]
RP   REVIEW.
RX   PubMed=26185092; DOI=10.1128/microbiolspec.VE-0002-2014;
RA   Satchell K.J.;
RT   "Multifunctional-autoprocessing repeats-in-toxin (MARTX) Toxins of
RT   Vibrios.";
RL   Microbiol. Spectr. 3:0-0(2015).
RN   [24]
RP   FUNCTION (ABH EFFECTOR REGION TOXIN F5).
RX   PubMed=25427654; DOI=10.1111/mmi.12879;
RA   Dolores J.S., Agarwal S., Egerer M., Satchell K.J.;
RT   "Vibrio cholerae MARTX toxin heterologous translocation of beta-
RT   lactamase and roles of individual effector domains on cytoskeleton
RT   dynamics.";
RL   Mol. Microbiol. 95:590-604(2015).
RN   [25]
RP   FUNCTION (ACTIN CROSS-LINKING TOXIN F1 AND ACTIN CROSS-LINKING TOXIN
RP   F4).
RX   PubMed=26228148; DOI=10.1126/science.aab4090;
RA   Heisler D.B., Kudryashova E., Grinevich D.O., Suarez C.,
RA   Winkelman J.D., Birukov K.G., Kotha S.R., Parinandi N.L.,
RA   Vavylonis D., Kovar D.R., Kudryashov D.S.;
RT   "ACD toxin-produced actin oligomers poison formin-controlled actin
RT   polymerization.";
RL   Science 349:535-539(2015).
RN   [26] {ECO:0000244|PDB:3EEB}
RP   X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 3442-3650 IN COMPLEX WITH
RP   INOSITOL HEXAKISPHOSPHATE, FUNCTION (MULTIFUNCTIONAL-AUTOPROCESSING
RP   REPEATS-IN-TOXIN), ENZYME REGULATION, AND MUTAGENESIS OF ASP-3619;
RP   GLU-3620; ARG-3623; LYS-3624; ASP-3632; TRP-3633 AND LYS-3636.
RX   PubMed=18845756; DOI=10.1126/science.1162403;
RA   Lupardus P.J., Shen A., Bogyo M., Garcia K.C.;
RT   "Small molecule-induced allosteric activation of the Vibrio cholerae
RT   RTX cysteine protease domain.";
RL   Science 322:265-268(2008).
RN   [27] {ECO:0000244|PDB:3FZY}
RP   X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 3440-3650 IN COMPLEX WITH
RP   INOSITOL HEXAKISPHOSPHATE, PARTIAL PROTEIN SEQUENCE, SUBCELLULAR
RP   LOCATION, FUNCTION (MULTIFUNCTIONAL-AUTOPROCESSING REPEATS-IN-TOXIN
RP   AND CYSTEINE PROTEASE DOMAIN-CONTAINING TOXIN F3), ENZYME REGULATION,
RP   AND CLEAVAGE SITES.
RX   PubMed=19620709; DOI=10.1074/jbc.M109.025510;
RA   Prochazkova K., Shuvalova L.A., Minasov G., Voburka Z., Anderson W.F.,
RA   Satchell K.J.;
RT   "Structural and molecular mechanism for autoprocessing of MARTX toxin
RT   of Vibrio cholerae at multiple sites.";
RL   J. Biol. Chem. 284:26557-26568(2009).
RN   [28] {ECO:0000244|PDB:3GCD}
RP   X-RAY CRYSTALLOGRAPHY (2.35 ANGSTROMS) OF 3442-3650 IN COMPLEX WITH
RP   INOSITOL HEXAKISPHOSPHATE AND INHIBITOR, FUNCTION
RP   (MULTIFUNCTIONAL-AUTOPROCESSING REPEATS-IN-TOXIN), ENZYME REGULATION,
RP   CLEAVAGE SITES, AND MUTAGENESIS OF LEU-2447; LEU-3098; LEU-3441 AND
RP   CYS-3581.
RX   PubMed=19465933; DOI=10.1038/nchembio.178;
RA   Shen A., Lupardus P.J., Albrow V.E., Guzzetta A., Powers J.C.,
RA   Garcia K.C., Bogyo M.;
RT   "Mechanistic and structural insights into the proteolytic activation
RT   of Vibrio cholerae MARTX toxin.";
RL   Nat. Chem. Biol. 5:469-478(2009).
CC   -!- FUNCTION: Multifunctional-autoprocessing repeats-in-toxin:
CC       Precursor of a multifunctional toxin that causes destruction of
CC       the actin cytoskeleton by covalent cross-linking of actin and
CC       inactivation of Rho GTPases when translocated into the host
CC       cytoplasm (PubMed:26185092). Upon translocation into the host
CC       cell, undergoes autoprocessing in cis mediated by the peptidase
CC       C80 domain (also named CPD domain): the protease activity is
CC       activated upon binding inositol hexakisphosphate (InsP6) present
CC       at the host cell membrane and delivers the Cysteine protease
CC       domain-containing toxin F3 chain to the host cytosol
CC       (PubMed:17464284, PubMed:18591243, PubMed:18845756,
CC       PubMed:19620709, PubMed:19465933). The Cysteine protease domain-
CC       containing toxin F3 chain will then further cleave and release
CC       effector toxin chains that cause disassembly of the actin
CC       cytoskeleton and enhance V.cholerae colonization of the small
CC       intestine, possibly by facilitating evasion of phagocytic cells
CC       (PubMed:11553575, PubMed:12045243, PubMed:17698573,
CC       PubMed:17698571, PubMed:19812690, PubMed:19620709).
CC       {ECO:0000269|PubMed:11553575, ECO:0000269|PubMed:12045243,
CC       ECO:0000269|PubMed:17464284, ECO:0000269|PubMed:18591243,
CC       ECO:0000269|PubMed:18845756, ECO:0000269|PubMed:19465933,
CC       ECO:0000269|PubMed:19620709, ECO:0000269|PubMed:19812690,
CC       ECO:0000303|PubMed:26185092}.
CC   -!- FUNCTION: Cysteine protease domain-containing toxin F3: Following
CC       autocatalytic cleavage in cis at the Leu-3441-Ala-3442 site, this
CC       chain mediates processing in trans to release other individual
CC       toxin chains to the host cytosol (PubMed:19620709). Released
CC       effector toxin chains cause disassembly of the actin cytoskeleton
CC       and enhance V.cholerae colonization of the small intestine,
CC       possibly by facilitating evasion of phagocytic cells
CC       (PubMed:17698573, PubMed:17698571). {ECO:0000269|PubMed:17698571,
CC       ECO:0000269|PubMed:17698573, ECO:0000269|PubMed:19620709}.
CC   -!- FUNCTION: Actin cross-linking toxin F1: Actin-directed toxin that
CC       catalyzes the covalent cross-linking of host cytoplasmic monomeric
CC       actin (PubMed:11032799, PubMed:15199181, PubMed:16954226,
CC       PubMed:17951576, PubMed:19015515, PubMed:19656298,
CC       PubMed:23029200, PubMed:26228148). Mediates the cross-link between
CC       'Lys-50' of one monomer and 'Glu-270' of another actin monomer,
CC       resulting in formation of highly toxic actin oligomers that cause
CC       cell rounding (PubMed:19015515). The toxin can be highly efficient
CC       at very low concentrations by acting on formin homology family
CC       proteins: toxic actin oligomers bind with high affinity to formins
CC       and adversely affect both nucleation and elongation abilities of
CC       formins, causing their potent inhibition in both profilin-
CC       dependent and independent manners (PubMed:26228148). Acts as an
CC       acid--amino-acid ligase that transfers the gamma-phosphoryl group
CC       of ATP to the 'Glu-270' actin residue, resulting in the formation
CC       of an activated acyl phosphate intermediate. This intermediate is
CC       further hydrolyzed and the energy of hydrolysis is utilized for
CC       the formation of the amide bond between actin subunits
CC       (PubMed:23029200). {ECO:0000269|PubMed:11032799,
CC       ECO:0000269|PubMed:15199181, ECO:0000269|PubMed:16954226,
CC       ECO:0000269|PubMed:17951576, ECO:0000269|PubMed:19015515,
CC       ECO:0000269|PubMed:19656298, ECO:0000269|PubMed:23029200,
CC       ECO:0000269|PubMed:26228148}.
CC   -!- FUNCTION: Actin cross-linking toxin F4: Actin-directed toxin that
CC       catalyzes the covalent cross-linking of host cytoplasmic monomeric
CC       actin (PubMed:11032799, PubMed:15199181, PubMed:16954226,
CC       PubMed:17951576, PubMed:19015515, PubMed:19656298,
CC       PubMed:23029200, PubMed:26228148). Mediates the cross-link between
CC       'Lys-50' of one monomer and 'Glu-270' of another actin monomer,
CC       resulting in formation of highly toxic actin oligomers that cause
CC       cell rounding (PubMed:19015515). The toxin can be highly efficient
CC       at very low concentrations by acting on formin homology family
CC       proteins: toxic actin oligomers bind with high affinity to formins
CC       and adversely affect both nucleation and elongation abilities of
CC       formins, causing their potent inhibition in both profilin-
CC       dependent and independent manners (PubMed:26228148). Acts as an
CC       acid--amino-acid ligase that transfers the gamma-phosphoryl group
CC       of ATP to the 'Glu-270' actin residue, resulting in the formation
CC       of an activated acyl phosphate intermediate. This intermediate is
CC       further hydrolyzed and the energy of hydrolysis is utilized for
CC       the formation of the amide bond between actin subunits
CC       (PubMed:23029200). {ECO:0000269|PubMed:11032799,
CC       ECO:0000269|PubMed:15199181, ECO:0000269|PubMed:16954226,
CC       ECO:0000269|PubMed:17951576, ECO:0000269|PubMed:19015515,
CC       ECO:0000269|PubMed:19656298, ECO:0000269|PubMed:23029200,
CC       ECO:0000269|PubMed:26228148}.
CC   -!- FUNCTION: Rho inactivation domain-containing toxin F2: After
CC       delivery to the host cytosol, localizes to the host cell membrane
CC       where it modifies some cellular signaling resulting in loss of all
CC       active GTP-bound Rho and subsequent actin depolymerization.
CC       Although both this chain and the Actin cross-linking toxin F4
CC       chain independently affect polymerized actin, the domains are not
CC       synergistic (PubMed:17474905, PubMed:19434753, PubMed:23184949).
CC       Its similarity with members of the circular permuted thiol
CC       peptidase family, suggests that it acts by mediating modification
CC       of some protein at the host cell membrane (PubMed:26185092).
CC       {ECO:0000269|PubMed:17474905, ECO:0000269|PubMed:19434753,
CC       ECO:0000269|PubMed:23184949, ECO:0000303|PubMed:26185092}.
CC   -!- FUNCTION: ABH effector region toxin F5: Indirectly activates the
CC       small GTPase CDC42. {ECO:0000269|PubMed:25427654}.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:16954226,
CC         ECO:0000269|PubMed:23029200};
CC       Note=Binds 2 Mg(2+) ions per subunit. Mg(2+) is required for actin
CC       cross-linking activity. Can also use Mn(2+) ions instead of
CC       Mg(2+). {ECO:0000250|UniProtKB:A0A0H3AIG7};
CC   -!- ENZYME REGULATION: Protease activity is inhibited by N-
CC       ethylmaleimide but not other protease inhibitors
CC       (PubMed:17464284). Protease activity is inhibited by aza-leucine
CC       epoxide (PubMed:19465933). Protease activity is activated upon
CC       binding inositol hexakisphosphate (InsP6) via an allosteric
CC       mechanism: the active site is disordered or occluded in the
CC       absence of InsP6, protecting the protease active-site sulfhydryl
CC       until the toxin enters a eukaryotic cell (PubMed:18845756,
CC       PubMed:19620709). Upon processing at the Leu-3441-Ala-3442 site,
CC       the peptidase C80 domain is converted to a form with much reduced
CC       affinity for InsP6, but is reactivated for high affinity binding
CC       of InsP6 by cooperative binding of both a new substrate and InsP6.
CC       Reactivation allows cleavage at other sites, specifically at Leu
CC       residues between the effector domains (PubMed:19620709).
CC       {ECO:0000269|PubMed:17464284, ECO:0000269|PubMed:18845756,
CC       ECO:0000269|PubMed:19465933, ECO:0000269|PubMed:19620709}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=7.8 uM for ATP (for actin cross-linking activity)
CC         {ECO:0000269|PubMed:23029200};
CC         KM=49.9 uM for GTP (for actin cross-linking activity)
CC         {ECO:0000269|PubMed:23029200};
CC       pH dependence:
CC         Optimum pH is 7.0-9.0. {ECO:0000269|PubMed:23029200};
CC   -!- SUBCELLULAR LOCATION: Multifunctional-autoprocessing repeats-in-
CC       toxin: Secreted {ECO:0000269|PubMed:11032799,
CC       ECO:0000269|PubMed:15547287}. Host cytoplasm, host cytosol
CC       {ECO:0000303|PubMed:26185092}. Note=Secreted via the type I
CC       secretion system. {ECO:0000269|PubMed:11032799}.
CC   -!- SUBCELLULAR LOCATION: Rho inactivation domain-containing toxin F2:
CC       Host cell membrane {ECO:0000269|PubMed:20212166,
CC       ECO:0000269|PubMed:22044757}. Note=Targeted to the host cell
CC       membrane via the membrane localization region (MLD).
CC       {ECO:0000269|PubMed:20212166}.
CC   -!- SUBCELLULAR LOCATION: Actin cross-linking toxin F1: Host
CC       cytoplasm, host cytosol {ECO:0000305|PubMed:19620709}.
CC   -!- SUBCELLULAR LOCATION: Actin cross-linking toxin F4: Host
CC       cytoplasm, host cytosol {ECO:0000305|PubMed:19620709}.
CC   -!- SIMILARITY: Contains 1 ACD (actin cross-linking) domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU01108}.
CC   -!- SIMILARITY: Contains 1 peptidase C80 domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU01107, ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAD21057.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF119150; AAD21057.1; ALT_INIT; Genomic_DNA.
DR   EMBL; AE003852; AAF94608.1; -; Genomic_DNA.
DR   PIR; C82199; C82199.
DR   RefSeq; NP_231094.1; NC_002505.1.
DR   RefSeq; WP_010895441.1; NC_002505.1.
DR   PDB; 3EEB; X-ray; 2.10 A; A/B=3442-3650.
DR   PDB; 3FZY; X-ray; 1.95 A; A/B=3440-3650.
DR   PDB; 3GCD; X-ray; 2.35 A; A/B/C/D=3442-3650.
DR   PDBsum; 3EEB; -.
DR   PDBsum; 3FZY; -.
DR   PDBsum; 3GCD; -.
DR   ProteinModelPortal; Q9KS12; -.
DR   DIP; DIP-48626N; -.
DR   STRING; 243277.VC1451; -.
DR   MEROPS; C80.001; -.
DR   EnsemblBacteria; AAF94608; AAF94608; VC_1451.
DR   GeneID; 2613957; -.
DR   KEGG; vch:VC1451; -.
DR   PATRIC; 20081964; VBIVibCho83274_1381.
DR   eggNOG; ENOG4105EUK; Bacteria.
DR   eggNOG; COG2931; LUCA.
DR   KO; K10953; -.
DR   OMA; IMTKVGN; -.
DR   OrthoDB; EOG6BS8KR; -.
DR   BioCyc; VCHO:VC1451-MONOMER; -.
DR   EvolutionaryTrace; Q9KS12; -.
DR   Proteomes; UP000000584; Chromosome 1.
DR   GO; GO:0005576; C:extracellular region; IDA:UniProtKB.
DR   GO; GO:0044164; C:host cell cytosol; IEA:UniProtKB-SubCell.
DR   GO; GO:0020002; C:host cell plasma membrane; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; IEA:UniProtKB-KW.
DR   GO; GO:0016881; F:acid-amino acid ligase activity; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0005509; F:calcium ion binding; ISS:TIGR.
DR   GO; GO:0004197; F:cysteine-type endopeptidase activity; IDA:UniProtKB.
DR   GO; GO:0008234; F:cysteine-type peptidase activity; IEA:UniProtKB-KW.
DR   GO; GO:0000822; F:inositol hexakisphosphate binding; IDA:UniProtKB.
DR   GO; GO:0016874; F:ligase activity; IEA:UniProtKB-KW.
DR   GO; GO:0008289; F:lipid binding; IEA:UniProtKB-KW.
DR   GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB.
DR   GO; GO:0030042; P:actin filament depolymerization; IDA:UniProtKB.
DR   GO; GO:0090527; P:actin filament reorganization; IEA:InterPro.
DR   GO; GO:0019836; P:hemolysis by symbiont of host erythrocytes; ISS:TIGR.
DR   GO; GO:0018262; P:isopeptide cross-linking; IDA:UniProtKB.
DR   GO; GO:0018153; P:isopeptide cross-linking via N6-(L-isoglutamyl)-L-lysine; IDA:UniProtKB.
DR   GO; GO:0031640; P:killing of cells of other organism; ISS:TIGR.
DR   GO; GO:0009405; P:pathogenesis; IDA:UniProtKB.
DR   GO; GO:0016540; P:protein autoprocessing; IDA:UniProtKB.
DR   Gene3D; 1.20.1440.20; -; 1.
DR   Gene3D; 2.150.10.10; -; 3.
DR   Gene3D; 3.40.50.1820; -; 2.
DR   InterPro; IPR029058; AB_hydrolase.
DR   InterPro; IPR029059; AB_hydrolase_5.
DR   InterPro; IPR032074; ACD_dom.
DR   InterPro; IPR020972; Dermonecrotic/RTX_toxin_C.
DR   InterPro; IPR023353; LemA-like_dom.
DR   InterPro; IPR020974; Pept_C80_RTX.
DR   InterPro; IPR011509; RtxA_toxin.
DR   InterPro; IPR011049; Serralysin-like_metalloprot_C.
DR   Pfam; PF12695; Abhydrolase_5; 1.
DR   Pfam; PF16671; ACD; 1.
DR   Pfam; PF11713; Peptidase_C80; 1.
DR   Pfam; PF11647; PMT_C; 1.
DR   Pfam; PF07634; RtxA; 39.
DR   SUPFAM; SSF51120; SSF51120; 2.
DR   SUPFAM; SSF53474; SSF53474; 1.
DR   PROSITE; PS51772; ACD; 1.
DR   PROSITE; PS51771; CGT_MARTX_CPD; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Autocatalytic cleavage; Complete proteome;
KW   Direct protein sequencing; Host cell membrane; Host cytoplasm;
KW   Host membrane; Hydrolase; Ligase; Lipid-binding; Magnesium; Membrane;
KW   Metal-binding; Multifunctional enzyme; Nucleotide-binding; Protease;
KW   Reference proteome; Repeat; Secreted; Signal; Thiol protease; Toxin;
KW   Virulence.
FT   SIGNAL        1     32       {ECO:0000255}.
FT   CHAIN        33   4558       Multifunctional-autoprocessing repeats-
FT                                in-toxin.
FT                                /FTId=PRO_0000434113.
FT   CHAIN        33   2447       Actin cross-linking toxin F1.
FT                                {ECO:0000305|PubMed:19620709}.
FT                                /FTId=PRO_0000434114.
FT   CHAIN      1972   2447       Actin cross-linking toxin F4.
FT                                {ECO:0000305|PubMed:19620709}.
FT                                /FTId=PRO_0000434115.
FT   CHAIN      2448   3098       Rho inactivation domain-containing toxin
FT                                F2. {ECO:0000305|PubMed:19620709}.
FT                                /FTId=PRO_0000434116.
FT   CHAIN      3099   3441       ABH effector region toxin F5.
FT                                {ECO:0000305|PubMed:19620709}.
FT                                /FTId=PRO_0000434117.
FT   CHAIN      3442   4558       Cysteine protease domain-containing toxin
FT                                F3. {ECO:0000305|PubMed:19620709}.
FT                                /FTId=PRO_0000434118.
FT   REPEAT      114    131       RtxA 1. {ECO:0000255}.
FT   REPEAT      134    151       RtxA 2. {ECO:0000255}.
FT   REPEAT      154    170       RtxA 3. {ECO:0000255}.
FT   REPEAT      174    197       RtxA 4. {ECO:0000255}.
FT   REPEAT      200    217       RtxA 5. {ECO:0000255}.
FT   REPEAT      220    237       RtxA 6. {ECO:0000255}.
FT   REPEAT      268    285       RtxA 7. {ECO:0000255}.
FT   REPEAT      288    304       RtxA 8. {ECO:0000255}.
FT   REPEAT      594    611       RtxA 9. {ECO:0000255}.
FT   REPEAT      614    630       RtxA 10. {ECO:0000255}.
FT   REPEAT      634    651       RtxA 11. {ECO:0000255}.
FT   REPEAT      654    668       RtxA 12. {ECO:0000255}.
FT   REPEAT      751    763       RtxA 13. {ECO:0000255}.
FT   REPEAT      769    781       RtxA 14. {ECO:0000255}.
FT   REPEAT      792    808       RtxA 15. {ECO:0000255}.
FT   REPEAT      811    826       RtxA 16. {ECO:0000255}.
FT   REPEAT      830    845       RtxA 17. {ECO:0000255}.
FT   REPEAT      851    865       RtxA 18. {ECO:0000255}.
FT   REPEAT      868    885       RtxA 19. {ECO:0000255}.
FT   REPEAT      887    901       RtxA 20. {ECO:0000255}.
FT   REPEAT      906    920       RtxA 21. {ECO:0000255}.
FT   REPEAT      925    942       RtxA 22. {ECO:0000255}.
FT   REPEAT      944    960       RtxA 23. {ECO:0000255}.
FT   REPEAT      982    994       RtxA 24. {ECO:0000255}.
FT   REPEAT     1001   1016       RtxA 25. {ECO:0000255}.
FT   REPEAT     1041   1053       RtxA 26. {ECO:0000255}.
FT   REPEAT     1077   1089       RtxA 27. {ECO:0000255}.
FT   REPEAT     1097   1112       RtxA 28. {ECO:0000255}.
FT   REPEAT     1120   1132       RtxA 29. {ECO:0000255}.
FT   REPEAT     1135   1152       RtxA 30. {ECO:0000255}.
FT   REPEAT     1155   1169       RtxA 31. {ECO:0000255}.
FT   REPEAT     1173   1189       RtxA 32. {ECO:0000255}.
FT   REPEAT     1194   1209       RtxA 33. {ECO:0000255}.
FT   REPEAT     1211   1227       RtxA 34. {ECO:0000255}.
FT   REPEAT     1230   1246       RtxA 35. {ECO:0000255}.
FT   REPEAT     1252   1266       RtxA 36. {ECO:0000255}.
FT   REPEAT     1268   1285       RtxA 37. {ECO:0000255}.
FT   REPEAT     1306   1323       RtxA 38. {ECO:0000255}.
FT   REPEAT     1325   1342       RtxA 39. {ECO:0000255}.
FT   DOMAIN     1988   2422       ACD. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01108,
FT                                ECO:0000305|PubMed:15199181}.
FT   DOMAIN     3462   3646       Peptidase C80. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01107}.
FT   NP_BIND    1999   2003       ATP. {ECO:0000250|UniProtKB:A0A0H3AIG7}.
FT   REGION     2574   2658       Membrane localization region (MLD).
FT                                {ECO:0000269|PubMed:20212166}.
FT   REGION     2734   3098       Rho inactivation domain (RID).
FT                                {ECO:0000305}.
FT   REGION     3195   3310       ABH effector region. {ECO:0000305}.
FT   REGION     3468   3470       Inositol hexakisphosphate binding.
FT                                {ECO:0000244|PDB:3EEB,
FT                                ECO:0000244|PDB:3FZY,
FT                                ECO:0000244|PDB:3GCD,
FT                                ECO:0000269|PubMed:18845756,
FT                                ECO:0000269|PubMed:19465933,
FT                                ECO:0000269|PubMed:19620709}.
FT   REGION     3495   3496       Inositol hexakisphosphate binding.
FT                                {ECO:0000244|PDB:3EEB,
FT                                ECO:0000244|PDB:3FZY,
FT                                ECO:0000244|PDB:3GCD,
FT                                ECO:0000269|PubMed:18845756,
FT                                ECO:0000269|PubMed:19465933,
FT                                ECO:0000269|PubMed:19620709}.
FT   REGION     3532   3533       Inhibitor binding. {ECO:0000244|PDB:3GCD,
FT                                ECO:0000269|PubMed:19465933}.
FT   REGION     3610   3612       Inositol hexakisphosphate binding.
FT                                {ECO:0000244|PDB:3EEB,
FT                                ECO:0000244|PDB:3FZY,
FT                                ECO:0000244|PDB:3GCD,
FT                                ECO:0000269|PubMed:18845756,
FT                                ECO:0000269|PubMed:19465933,
FT                                ECO:0000269|PubMed:19620709}.
FT   REGION     3616   3618       Inhibitor binding. {ECO:0000244|PDB:3GCD,
FT                                ECO:0000269|PubMed:19465933}.
FT   REGION     3623   3624       Inositol hexakisphosphate binding.
FT                                {ECO:0000244|PDB:3EEB,
FT                                ECO:0000244|PDB:3FZY,
FT                                ECO:0000244|PDB:3GCD,
FT                                ECO:0000269|PubMed:18845756,
FT                                ECO:0000269|PubMed:19465933,
FT                                ECO:0000269|PubMed:19620709}.
FT   COMPBIAS     43    301       Gly-rich. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00008}.
FT   COMPBIAS    584   1224       Gly-rich. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00008}.
FT   COMPBIAS   3709   3712       Poly-Ser. {ECO:0000255}.
FT   COMPBIAS   4187   4408       Gly-rich. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00008}.
FT   ACT_SITE   3532   3532       For cysteine protease activity.
FT                                {ECO:0000255|PROSITE-ProRule:PRU01107,
FT                                ECO:0000269|PubMed:17698571}.
FT   ACT_SITE   3581   3581       Nucleophile; for cysteine protease
FT                                activity. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01107,
FT                                ECO:0000269|PubMed:17698571}.
FT   METAL      2003   2003       Magnesium 1; catalytic; for actin cross-
FT                                linking activity.
FT                                {ECO:0000250|UniProtKB:A0A0H3AIG7}.
FT   METAL      2003   2003       Magnesium 2; catalytic; for actin cross-
FT                                linking activity.
FT                                {ECO:0000250|UniProtKB:A0A0H3AIG7}.
FT   METAL      2065   2065       Magnesium 2; catalytic; for actin cross-
FT                                linking activity.
FT                                {ECO:0000250|UniProtKB:A0A0H3AIG7}.
FT   METAL      2149   2149       Magnesium 1; catalytic; for actin cross-
FT                                linking activity.
FT                                {ECO:0000250|UniProtKB:A0A0H3AIG7}.
FT   METAL      2326   2326       Magnesium 1; catalytic; for actin cross-
FT                                linking activity.
FT                                {ECO:0000250|UniProtKB:A0A0H3AIG7}.
FT   BINDING    2255   2255       ATP; via carbonyl oxygen.
FT                                {ECO:0000250|UniProtKB:A0A0H3AIG7}.
FT   BINDING    3526   3526       Inositol hexakisphosphate.
FT                                {ECO:0000244|PDB:3EEB,
FT                                ECO:0000244|PDB:3FZY,
FT                                ECO:0000244|PDB:3GCD,
FT                                ECO:0000269|PubMed:18845756,
FT                                ECO:0000269|PubMed:19465933,
FT                                ECO:0000269|PubMed:19620709}.
FT   BINDING    3577   3577       Inositol hexakisphosphate.
FT                                {ECO:0000244|PDB:3EEB,
FT                                ECO:0000244|PDB:3FZY,
FT                                ECO:0000244|PDB:3GCD,
FT                                ECO:0000269|PubMed:18845756,
FT                                ECO:0000269|PubMed:19465933,
FT                                ECO:0000269|PubMed:19620709}.
FT   BINDING    3581   3581       Inhibitor. {ECO:0000244|PDB:3GCD,
FT                                ECO:0000269|PubMed:19465933}.
FT   BINDING    3636   3636       Inositol hexakisphosphate.
FT                                {ECO:0000244|PDB:3EEB,
FT                                ECO:0000244|PDB:3FZY,
FT                                ECO:0000244|PDB:3GCD,
FT                                ECO:0000269|PubMed:18845756,
FT                                ECO:0000269|PubMed:19465933,
FT                                ECO:0000269|PubMed:19620709}.
FT   BINDING    3641   3641       Inositol hexakisphosphate.
FT                                {ECO:0000244|PDB:3EEB,
FT                                ECO:0000244|PDB:3FZY,
FT                                ECO:0000244|PDB:3GCD,
FT                                ECO:0000269|PubMed:18845756,
FT                                ECO:0000269|PubMed:19465933,
FT                                ECO:0000269|PubMed:19620709}.
FT   SITE       1971   1972       Cleavage; by autolysis.
FT                                {ECO:0000269|PubMed:19620709}.
FT   SITE       2447   2448       Cleavage; by autolysis.
FT                                {ECO:0000269|PubMed:19465933,
FT                                ECO:0000269|PubMed:19620709}.
FT   SITE       3098   3099       Cleavage; by autolysis.
FT                                {ECO:0000269|PubMed:19465933,
FT                                ECO:0000269|PubMed:19620709}.
FT   SITE       3441   3442       Cleavage; by autolysis.
FT                                {ECO:0000269|PubMed:17464284,
FT                                ECO:0000269|PubMed:18591243,
FT                                ECO:0000269|PubMed:19465933,
FT                                ECO:0000269|PubMed:19620709}.
FT   MUTAGEN    2003   2003       E->A: Abolished actin cross-linking
FT                                activity and ability to round host cells.
FT                                {ECO:0000269|PubMed:19656298}.
FT   MUTAGEN    2005   2005       E->A: Impaired actin cross-linking
FT                                activity and ability to round host cells.
FT                                {ECO:0000269|PubMed:19656298}.
FT   MUTAGEN    2005   2005       E->G: Reduced actin cross-linking
FT                                activity. {ECO:0000269|PubMed:19656298}.
FT   MUTAGEN    2035   2035       L->P: Reduced actin cross-linking
FT                                activity. {ECO:0000269|PubMed:19656298}.
FT   MUTAGEN    2038   2038       D->A: Impaired actin cross-linking
FT                                activity and ability to round host cells.
FT                                {ECO:0000269|PubMed:19656298}.
FT   MUTAGEN    2055   2055       G->E: Reduced actin cross-linking
FT                                activity. {ECO:0000269|PubMed:19656298}.
FT   MUTAGEN    2065   2065       E->A: Abolished actin cross-linking
FT                                activity. {ECO:0000269|PubMed:19656298}.
FT   MUTAGEN    2065   2065       E->G: Reduced actin cross-linking
FT                                activity. {ECO:0000269|PubMed:19656298}.
FT   MUTAGEN    2068   2068       T->P: Reduced actin cross-linking
FT                                activity. {ECO:0000269|PubMed:19656298}.
FT   MUTAGEN    2089   2089       L->P: Reduced actin cross-linking
FT                                activity. {ECO:0000269|PubMed:19656298}.
FT   MUTAGEN    2096   2096       H->A: Abolished actin cross-linking
FT                                activity. {ECO:0000269|PubMed:19656298}.
FT   MUTAGEN    2117   2117       L->P: Reduced actin cross-linking
FT                                activity. {ECO:0000269|PubMed:19656298}.
FT   MUTAGEN    2149   2149       Q->R: Reduced actin cross-linking
FT                                activity. {ECO:0000269|PubMed:19656298}.
FT   MUTAGEN    2153   2153       A->T: Reduced actin cross-linking
FT                                activity. {ECO:0000269|PubMed:19656298}.
FT   MUTAGEN    2175   2175       W->R: Reduced actin cross-linking
FT                                activity. {ECO:0000269|PubMed:19656298}.
FT   MUTAGEN    2206   2206       L->P: Reduced actin cross-linking
FT                                activity. {ECO:0000269|PubMed:19656298}.
FT   MUTAGEN    2209   2209       V->A: Reduced actin cross-linking
FT                                activity. {ECO:0000269|PubMed:19656298}.
FT   MUTAGEN    2250   2250       W->R: Reduced actin cross-linking
FT                                activity. {ECO:0000269|PubMed:19656298}.
FT   MUTAGEN    2259   2259       V->I: Reduced actin cross-linking
FT                                activity. {ECO:0000269|PubMed:19656298}.
FT   MUTAGEN    2326   2326       E->A: Abolished actin cross-linking
FT                                activity. {ECO:0000269|PubMed:19656298}.
FT   MUTAGEN    2328   2328       R->A: Impaired actin cross-linking
FT                                activity and ability to round host cells.
FT                                {ECO:0000269|PubMed:19656298}.
FT   MUTAGEN    2328   2328       R->H: Reduced actin cross-linking
FT                                activity. {ECO:0000269|PubMed:19656298}.
FT   MUTAGEN    2447   2447       L->A: Impaired cleavage of the Rho
FT                                inactivation domain-containing toxin F2
FT                                chain; when associated with A-3098.
FT                                {ECO:0000269|PubMed:19465933}.
FT   MUTAGEN    2596   2596       Y->F: Abolished localization to the host
FT                                cell membrane.
FT                                {ECO:0000269|PubMed:20212166}.
FT   MUTAGEN    2641   2641       S->T: Abolished localization to the host
FT                                cell membrane.
FT                                {ECO:0000269|PubMed:20212166}.
FT   MUTAGEN    2643   2643       R->K: Abolished localization to the host
FT                                cell membrane.
FT                                {ECO:0000269|PubMed:20212166}.
FT   MUTAGEN    2734   2734       E->A: Does not affect the activity of the
FT                                Rho inactivation domain-containing toxin
FT                                F2 chain. {ECO:0000269|PubMed:23184949}.
FT   MUTAGEN    2735   2735       Y->A: Does not affect the activity of the
FT                                Rho inactivation domain-containing toxin
FT                                F2 chain. {ECO:0000269|PubMed:23184949}.
FT   MUTAGEN    2760   2760       D->A: Does not affect the activity of the
FT                                Rho inactivation domain-containing toxin
FT                                F2 chain. {ECO:0000269|PubMed:23184949}.
FT   MUTAGEN    2764   2764       L->A: Does not affect the activity of the
FT                                Rho inactivation domain-containing toxin
FT                                F2 chain. {ECO:0000269|PubMed:23184949}.
FT   MUTAGEN    2766   2766       K->A: Does not affect the activity of the
FT                                Rho inactivation domain-containing toxin
FT                                F2 chain. {ECO:0000269|PubMed:23184949}.
FT   MUTAGEN    2768   2768       H->A: Does not affect the activity of the
FT                                Rho inactivation domain-containing toxin
FT                                F2 chain. {ECO:0000269|PubMed:23184949}.
FT   MUTAGEN    2772   2772       E->A: Does not affect the activity of the
FT                                Rho inactivation domain-containing toxin
FT                                F2 chain. {ECO:0000269|PubMed:23184949}.
FT   MUTAGEN    2776   2776       S->A: Does not affect the activity of the
FT                                Rho inactivation domain-containing toxin
FT                                F2 chain. {ECO:0000269|PubMed:23184949}.
FT   MUTAGEN    2779   2779       S->A: Does not affect the activity of the
FT                                Rho inactivation domain-containing toxin
FT                                F2 chain. {ECO:0000269|PubMed:23184949}.
FT   MUTAGEN    2781   2781       T->A: Does not affect the activity of the
FT                                Rho inactivation domain-containing toxin
FT                                F2 chain. {ECO:0000269|PubMed:23184949}.
FT   MUTAGEN    2786   2786       K->A: Does not affect the activity of the
FT                                Rho inactivation domain-containing toxin
FT                                F2 chain. {ECO:0000269|PubMed:23184949}.
FT   MUTAGEN    2788   2788       S->A: Does not affect the activity of the
FT                                Rho inactivation domain-containing toxin
FT                                F2 chain. {ECO:0000269|PubMed:23184949}.
FT   MUTAGEN    2790   2790       H->A: Does not affect the activity of the
FT                                Rho inactivation domain-containing toxin
FT                                F2 chain. {ECO:0000269|PubMed:23184949}.
FT   MUTAGEN    2791   2791       S->A: Does not affect the activity of the
FT                                Rho inactivation domain-containing toxin
FT                                F2 chain. {ECO:0000269|PubMed:23184949}.
FT   MUTAGEN    2793   2793       L->A: Does not affect the activity of the
FT                                Rho inactivation domain-containing toxin
FT                                F2 chain. {ECO:0000269|PubMed:23184949}.
FT   MUTAGEN    2795   2795       H->A: Impaired activity of the Rho
FT                                inactivation domain-containing toxin F2
FT                                chain. {ECO:0000269|PubMed:23184949}.
FT   MUTAGEN    2798   2798       L->A: Does not affect the activity of the
FT                                Rho inactivation domain-containing toxin
FT                                F2 chain. {ECO:0000269|PubMed:23184949}.
FT   MUTAGEN    2804   2804       R->A: Does not affect the activity of the
FT                                Rho inactivation domain-containing toxin
FT                                F2 chain. {ECO:0000269|PubMed:23184949}.
FT   MUTAGEN    2820   2820       Y->A: Impaired activity of the Rho
FT                                inactivation domain-containing toxin F2
FT                                chain. {ECO:0000269|PubMed:23184949}.
FT   MUTAGEN    2820   2820       Y->F: Does not affect the activity of the
FT                                Rho inactivation domain-containing toxin
FT                                F2 chain. {ECO:0000269|PubMed:23184949}.
FT   MUTAGEN    2822   2822       S->A: Does not affect the activity of the
FT                                Rho inactivation domain-containing toxin
FT                                F2 chain. {ECO:0000269|PubMed:23184949}.
FT   MUTAGEN    2829   2829       K->A: Does not affect the activity of the
FT                                Rho inactivation domain-containing toxin
FT                                F2 chain. {ECO:0000269|PubMed:23184949}.
FT   MUTAGEN    2830   2830       S->A: Does not affect the activity of the
FT                                Rho inactivation domain-containing toxin
FT                                F2 chain. {ECO:0000269|PubMed:23184949}.
FT   MUTAGEN    2850   2850       R->A: Does not affect the activity of the
FT                                Rho inactivation domain-containing toxin
FT                                F2 chain. {ECO:0000269|PubMed:23184949}.
FT   MUTAGEN    2864   2864       L->A: Impaired activity of the Rho
FT                                inactivation domain-containing toxin F2
FT                                chain. {ECO:0000269|PubMed:23184949}.
FT   MUTAGEN    2867   2867       D->A: Impaired activity of the Rho
FT                                inactivation domain-containing toxin F2
FT                                chain. {ECO:0000269|PubMed:23184949}.
FT   MUTAGEN    2871   2871       E->A: Does not affect the activity of the
FT                                Rho inactivation domain-containing toxin
FT                                F2 chain. {ECO:0000269|PubMed:23184949}.
FT   MUTAGEN    2872   2872       E->A: Does not affect the activity of the
FT                                Rho inactivation domain-containing toxin
FT                                F2 chain. {ECO:0000269|PubMed:23184949}.
FT   MUTAGEN    2874   2874       D->A: Does not affect the activity of the
FT                                Rho inactivation domain-containing toxin
FT                                F2 chain. {ECO:0000269|PubMed:23184949}.
FT   MUTAGEN    2887   2887       R->A: Does not affect the activity of the
FT                                Rho inactivation domain-containing toxin
FT                                F2 chain. {ECO:0000269|PubMed:23184949}.
FT   MUTAGEN    2914   2914       L->A: Does not affect the activity of the
FT                                Rho inactivation domain-containing toxin
FT                                F2 chain. {ECO:0000269|PubMed:23184949}.
FT   MUTAGEN    2950   2950       R->A: Does not affect the activity of the
FT                                Rho inactivation domain-containing toxin
FT                                F2 chain. {ECO:0000269|PubMed:23184949}.
FT   MUTAGEN    2956   2956       R->A: Does not affect the activity of the
FT                                Rho inactivation domain-containing toxin
FT                                F2 chain. {ECO:0000269|PubMed:23184949}.
FT   MUTAGEN    2961   2961       R->A: Does not affect the activity of the
FT                                Rho inactivation domain-containing toxin
FT                                F2 chain. {ECO:0000269|PubMed:23184949}.
FT   MUTAGEN    2971   2971       R->A: Does not affect the activity of the
FT                                Rho inactivation domain-containing toxin
FT                                F2 chain. {ECO:0000269|PubMed:23184949}.
FT   MUTAGEN    2977   2977       R->A: Does not affect the activity of the
FT                                Rho inactivation domain-containing toxin
FT                                F2 chain. {ECO:0000269|PubMed:23184949}.
FT   MUTAGEN    2981   2981       E->A: Does not affect the activity of the
FT                                Rho inactivation domain-containing toxin
FT                                F2 chain. {ECO:0000269|PubMed:23184949}.
FT   MUTAGEN    2982   2982       R->A: Does not affect the activity of the
FT                                Rho inactivation domain-containing toxin
FT                                F2 chain. {ECO:0000269|PubMed:23184949}.
FT   MUTAGEN    2991   2991       K->A: Does not affect the activity of the
FT                                Rho inactivation domain-containing toxin
FT                                F2 chain. {ECO:0000269|PubMed:23184949}.
FT   MUTAGEN    2993   2993       S->A: Does not affect the activity of the
FT                                Rho inactivation domain-containing toxin
FT                                F2 chain. {ECO:0000269|PubMed:23184949}.
FT   MUTAGEN    2996   2996       D->A: Does not affect the activity of the
FT                                Rho inactivation domain-containing toxin
FT                                F2 chain. {ECO:0000269|PubMed:23184949}.
FT   MUTAGEN    2999   2999       R->A: Does not affect the activity of the
FT                                Rho inactivation domain-containing toxin
FT                                F2 chain. {ECO:0000269|PubMed:23184949}.
FT   MUTAGEN    3002   3002       R->A: Does not affect the activity of the
FT                                Rho inactivation domain-containing toxin
FT                                F2 chain. {ECO:0000269|PubMed:23184949}.
FT   MUTAGEN    3005   3005       L->A: Does not affect the activity of the
FT                                Rho inactivation domain-containing toxin
FT                                F2 chain. {ECO:0000269|PubMed:23184949}.
FT   MUTAGEN    3008   3008       L->A: Does not affect the activity of the
FT                                Rho inactivation domain-containing toxin
FT                                F2 chain. {ECO:0000269|PubMed:23184949}.
FT   MUTAGEN    3016   3016       E->A: Does not affect the activity of the
FT                                Rho inactivation domain-containing toxin
FT                                F2 chain. {ECO:0000269|PubMed:23184949}.
FT   MUTAGEN    3019   3019       R->A: Does not affect the activity of the
FT                                Rho inactivation domain-containing toxin
FT                                F2 chain. {ECO:0000269|PubMed:23184949}.
FT   MUTAGEN    3027   3027       R->A: Does not affect the activity of the
FT                                Rho inactivation domain-containing toxin
FT                                F2 chain. {ECO:0000269|PubMed:23184949}.
FT   MUTAGEN    3028   3028       Y->A: Impaired activity of the Rho
FT                                inactivation domain-containing toxin F2
FT                                chain. {ECO:0000269|PubMed:23184949}.
FT   MUTAGEN    3028   3028       Y->F: Does not affect the activity of the
FT                                Rho inactivation domain-containing toxin
FT                                F2 chain. {ECO:0000269|PubMed:23184949}.
FT   MUTAGEN    3031   3031       L->A: Does not affect the activity of the
FT                                Rho inactivation domain-containing toxin
FT                                F2 chain. {ECO:0000269|PubMed:23184949}.
FT   MUTAGEN    3035   3035       C->A,S: Impaired activity of the Rho
FT                                inactivation domain-containing toxin F2
FT                                chain. {ECO:0000269|PubMed:23184949}.
FT   MUTAGEN    3036   3036       S->A: Does not affect the activity of the
FT                                Rho inactivation domain-containing toxin
FT                                F2 chain. {ECO:0000269|PubMed:23184949}.
FT   MUTAGEN    3037   3037       S->A: Does not affect the activity of the
FT                                Rho inactivation domain-containing toxin
FT                                F2 chain. {ECO:0000269|PubMed:23184949}.
FT   MUTAGEN    3043   3043       L->A: Does not affect the activity of the
FT                                Rho inactivation domain-containing toxin
FT                                F2 chain. {ECO:0000269|PubMed:23184949}.
FT   MUTAGEN    3044   3044       K->A: Does not affect the activity of the
FT                                Rho inactivation domain-containing toxin
FT                                F2 chain. {ECO:0000269|PubMed:23184949}.
FT   MUTAGEN    3049   3049       D->A: Does not affect the activity of the
FT                                Rho inactivation domain-containing toxin
FT                                F2 chain. {ECO:0000269|PubMed:23184949}.
FT   MUTAGEN    3054   3054       H->A: Does not affect the activity of the
FT                                Rho inactivation domain-containing toxin
FT                                F2 chain. {ECO:0000269|PubMed:23184949}.
FT   MUTAGEN    3064   3064       T->A: Does not affect the activity of the
FT                                Rho inactivation domain-containing toxin
FT                                F2 chain. {ECO:0000269|PubMed:23184949}.
FT   MUTAGEN    3077   3077       E->A: Does not affect the activity of the
FT                                Rho inactivation domain-containing toxin
FT                                F2 chain. {ECO:0000269|PubMed:23184949}.
FT   MUTAGEN    3098   3098       L->A: Impaired cleavage of the Rho
FT                                inactivation domain-containing toxin F2
FT                                chain; when associated with A-2447.
FT                                {ECO:0000269|PubMed:19465933}.
FT   MUTAGEN    3441   3441       L->A: Modified autocatalytic cleavage
FT                                site, leading to cleavage at another
FT                                site. {ECO:0000269|PubMed:19465933}.
FT   MUTAGEN    3462   3462       P->A: No effect in autocatalytic
FT                                cleavage. {ECO:0000269|PubMed:18591243}.
FT   MUTAGEN    3470   3470       R->A: Decreased autocatalytic cleavage.
FT                                {ECO:0000269|PubMed:18591243}.
FT   MUTAGEN    3476   3476       I->A: No effect in autocatalytic
FT                                cleavage. {ECO:0000269|PubMed:18591243}.
FT   MUTAGEN    3478   3478       Q->A: No effect in autocatalytic
FT                                cleavage. {ECO:0000269|PubMed:18591243}.
FT   MUTAGEN    3480   3480       E->A: No effect in autocatalytic
FT                                cleavage. Impaired autocatalytic
FT                                cleavage; when associated with A-3482.
FT                                {ECO:0000269|PubMed:18591243}.
FT   MUTAGEN    3482   3482       D->A: No effect in autocatalytic
FT                                cleavage. Impaired autocatalytic
FT                                cleavage; when associated with A-3480.
FT                                {ECO:0000269|PubMed:18591243}.
FT   MUTAGEN    3488   3488       A->I: Decreased autocatalytic cleavage.
FT                                {ECO:0000269|PubMed:18591243}.
FT   MUTAGEN    3492   3492       L->D: Decreased autocatalytic cleavage.
FT                                {ECO:0000269|PubMed:18591243}.
FT   MUTAGEN    3495   3495       K->A: Decreased autocatalytic cleavage.
FT                                {ECO:0000269|PubMed:18591243}.
FT   MUTAGEN    3499   3500       SS->AA: No effect in autocatalytic
FT                                cleavage. {ECO:0000269|PubMed:18591243}.
FT   MUTAGEN    3524   3524       K->A: No effect in autocatalytic
FT                                cleavage. {ECO:0000269|PubMed:18591243}.
FT   MUTAGEN    3526   3526       R->A: Decreased autocatalytic cleavage.
FT                                {ECO:0000269|PubMed:18591243}.
FT   MUTAGEN    3532   3532       H->A: Abolishes autocatalytic cleavage.
FT                                {ECO:0000269|PubMed:17464284,
FT                                ECO:0000269|PubMed:18591243}.
FT   MUTAGEN    3534   3534       R->A: Increased autocatalytic cleavage.
FT                                {ECO:0000269|PubMed:18591243}.
FT   MUTAGEN    3537   3537       S->A: No effect in autocatalytic
FT                                cleavage. {ECO:0000269|PubMed:18591243}.
FT   MUTAGEN    3551   3551       E->A: Does not affect autocatalytic
FT                                cleavage. {ECO:0000269|PubMed:17464284}.
FT   MUTAGEN    3552   3552       L->A: No effect in autocatalytic
FT                                cleavage. {ECO:0000269|PubMed:18591243}.
FT   MUTAGEN    3572   3572       K->A: No effect in autocatalytic
FT                                cleavage. {ECO:0000269|PubMed:18591243}.
FT   MUTAGEN    3581   3581       C->S,A: Abolishes autocatalytic cleavage.
FT                                {ECO:0000269|PubMed:17464284,
FT                                ECO:0000269|PubMed:18591243,
FT                                ECO:0000269|PubMed:19465933}.
FT   MUTAGEN    3606   3606       R->A: Increased autocatalytic cleavage.
FT                                {ECO:0000269|PubMed:18591243}.
FT   MUTAGEN    3609   3609       V->A: No effect in autocatalytic
FT                                cleavage. {ECO:0000269|PubMed:18591243}.
FT   MUTAGEN    3612   3612       R->A: Decreased autocatalytic cleavage.
FT                                {ECO:0000269|PubMed:18591243}.
FT   MUTAGEN    3619   3619       D->A,N: Slightly reduced inositol
FT                                hexakisphosphate-binding and strongly
FT                                decreased autocatalytic cleavage.
FT                                {ECO:0000269|PubMed:18845756}.
FT   MUTAGEN    3620   3620       E->A: Does not affect inositol
FT                                hexakisphosphate-binding.
FT                                {ECO:0000269|PubMed:18845756}.
FT   MUTAGEN    3623   3623       R->A: Decreased autocatalytic cleavage.
FT                                {ECO:0000269|PubMed:18591243}.
FT   MUTAGEN    3623   3623       R->Q: Slightly reduced inositol
FT                                hexakisphosphate-binding and strongly
FT                                decreased autocatalytic cleavage.
FT                                {ECO:0000269|PubMed:18845756}.
FT   MUTAGEN    3624   3624       K->A: Decreased autocatalytic cleavage.
FT                                {ECO:0000269|PubMed:18591243}.
FT   MUTAGEN    3624   3624       K->N: Abolishes inositol
FT                                hexakisphosphate-binding and
FT                                autocatalytic cleavage.
FT                                {ECO:0000269|PubMed:18845756}.
FT   MUTAGEN    3632   3632       D->A: Does not affect inositol
FT                                hexakisphosphate-binding.
FT                                {ECO:0000269|PubMed:18845756}.
FT   MUTAGEN    3633   3633       W->A: Reduced inositol hexakisphosphate-
FT                                binding and autocatalytic cleavage.
FT                                {ECO:0000269|PubMed:18845756}.
FT   MUTAGEN    3633   3633       W->F: Slightly reduced inositol
FT                                hexakisphosphate-binding and strongly
FT                                decreased autocatalytic cleavage.
FT                                {ECO:0000269|PubMed:18845756}.
FT   MUTAGEN    3636   3636       K->N: Abolishes inositol
FT                                hexakisphosphate-binding and
FT                                autocatalytic cleavage.
FT                                {ECO:0000269|PubMed:18845756}.
FT   MUTAGEN    3641   3641       K->A: Decreased autocatalytic cleavage.
FT                                {ECO:0000269|PubMed:18591243}.
FT   HELIX      3452   3454       {ECO:0000244|PDB:3FZY}.
FT   STRAND     3472   3478       {ECO:0000244|PDB:3FZY}.
FT   HELIX      3483   3495       {ECO:0000244|PDB:3FZY}.
FT   HELIX      3496   3499       {ECO:0000244|PDB:3FZY}.
FT   STRAND     3500   3505       {ECO:0000244|PDB:3FZY}.
FT   STRAND     3511   3516       {ECO:0000244|PDB:3FZY}.
FT   HELIX      3518   3520       {ECO:0000244|PDB:3FZY}.
FT   STRAND     3523   3530       {ECO:0000244|PDB:3FZY}.
FT   STRAND     3533   3535       {ECO:0000244|PDB:3FZY}.
FT   HELIX      3549   3567       {ECO:0000244|PDB:3FZY}.
FT   STRAND     3574   3582       {ECO:0000244|PDB:3FZY}.
FT   STRAND     3588   3591       {ECO:0000244|PDB:3FZY}.
FT   HELIX      3592   3602       {ECO:0000244|PDB:3FZY}.
FT   STRAND     3608   3614       {ECO:0000244|PDB:3FZY}.
FT   STRAND     3616   3618       {ECO:0000244|PDB:3FZY}.
FT   STRAND     3624   3627       {ECO:0000244|PDB:3FZY}.
FT   STRAND     3629   3631       {ECO:0000244|PDB:3FZY}.
FT   STRAND     3633   3636       {ECO:0000244|PDB:3FZY}.
FT   HELIX      3638   3640       {ECO:0000244|PDB:3FZY}.
FT   STRAND     3641   3644       {ECO:0000244|PDB:3FZY}.
SQ   SEQUENCE   4558 AA;  485355 MW;  800DD5D1D119AE19 CRC64;
     MVFYLIPKRR VWLMGKPFWR SVEYFFTGNY SADDGNNNIV AIGFGGQIHA YGGDDHVTVG
     SIGATVYTGS GNDTVVGGSA YLKVEDSTGH LIVKGAAGYA DINKSGDGNV SFAGAAGGVS
     IDHLGNHGDV SYGGAAAYNG ITRKGLSGNV TFAGAGGYNA LWHETNQGNL SFTGAGAGNK
     LDRTWSNRYQ GSHGDVTFDG AGAANSISSR VETGNITFRG AGADNHLVRK GKVGDITLQG
     AGASNRIERT HQAEDVYTQT RGNIRFEGVG GYNSLYSDVA HGDIHFSGGG AYNTIIRKGS
     GNDFAKEGMT NAKADEIVLT KAVMSGSWIG QDHHVTAVKS ASEPNTYLFA FADSTYTKIN
     KVQLRNDPQT GELKYYSTAW YKEVNHLSNL ANQDISDNGG FTAVNINGAY TLSDLKVEHQ
     QSVTVHAVEK SLTEYEWVTY ANGAVIDAKE VSLSDAKMGG HAIYADGTKV DVKAVKSNRQ
     PNTYIYAKVL GPYTKIVVVE LANDPETGAL KYQARSWYKE GDHTANIANQ DISSATGYNP
     MGKGGYSLSD LHYSVNAVRS TSETVADIEE YTDQTLFKPA NDSGESSGDV RFNGAGGGNV
     IKSNVTRGNV HFNGGGIANV ILHSSQFGNT EFNGGGAANV IVKSGEEGDL TFRGAGLANV
     LVHQSEQGKM DVYAGGAVNV LVRLGDGQYL AHLLAYGNIS VQKGSGDSRV VMLGGYNTHT
     QIGSGNGLWL AAGGFNVMTQ VGKGDVAAVL AGGANVLTKM GEGELTSGML GGANVITHIS
     NDDQLSNTTA VALGGANILT KKGKGNTLAV MGGGANVLTH VGDGTTTGVM VGGANILTKV
     GNGDTTGILL GVGNVLTHVG DGQTLGVMGA AGNIFTKVGD GTSIAVMIGA GNIFTHVGEG
     NAWALMGGLG NVFTKVGNGD ALALMVAEAN VFTHIGDGMS VALMLAKGNV ATKVGNGTTL
     AAMVGNVNIF THIGHGSTFA AMIGQANIMT KVGNDLTAAL MVGKANIMTH VGDGTSLGLF
     AGEVNVMTKV GNGTTLAAMF GKANIMTHVG DGLTGVLALG EANIVTKLGD DFMGVVAAAK
     ANVVTHVGDA TTAAVLAGKG NILTKVGEGT TVGLLISDVG NVMTHVGDGT TIGIAKGKAN
     LITKVGDGLG VNVTWGQANV FTQVGDGDRY NFAKGEANLI TKVGDGQEVS VVQGEANIIT
     HVGNGDDYTG AWGKANVITK VGHGQNVVLA KGEANIVTQV GDGDSFNALW SKGNIVTKVG
     DGMQVTAAKG QANITTTVGN GLNVTAAYGD ANINTKVGDG VSVNVAWGKY NINTKVGDGL
     NVAVMKGKAN ANIHVGDGLN INASYAQNNV AIKVGNGDFY SLAVASSNTS SNKLSALFDN
     IKQTVLGVGG SQAINYLVQG DEASSSGTHK GRGAIATPEI TKLDGFQMDA IKEVSSDLGD
     SLTGSVTKVD TPDLNKMQHA LNVDDSSVQA PNLIVNGDFE LGEHGWQSTH GVEASYAGSV
     YGVEGEGHGA RVTELDTYTN TSLYQDLANL AQGEVIAVSF DFAKRAGLSN NEGIEVLWNG
     EVVFSSSGDE SAWQQKNLKL TAQAGSNRIE FKGTGHNDGL GYILDNVVAT SESSQQANAI
     REHATQNPAA QNALSDKERA EADRQRLEQE KQKQLDAVAG SQSQLESTDQ QALENNGQAQ
     RDAVKEESEA VTAELAKLAQ GLDVLDGQAT HTGESGDQWR NDFAGGLLDG VQSQLDDAKQ
     LANDKIAAAK QTLSDNNSKV KESVAKSEAG VAQGEQNRAG VEQDIADAQA DAEKRKADAL
     AKGKDAQQAE SDAHHAVNNA QSRGDRDVQL AENKANQAQA DAQGAKQNEG DRPDRQGVTG
     SGLSGNAHSV EGAGETDSHV NTDSQTNADG RFSEGLTEQE QEALEGATNA VNRLQINAGI
     RAKNSVSSMT SMFSETNSKS IVVPTKVSPE PERQEVTRRD VRISGVNLES LSAVQGSQPT
     GQLASKSVPG FKSHFASTSI GIENELSGLV VVLPKNSAQT FGYVHDSQGN PLFMLTKDMN
     QGGYSNPVGI NDIQGVNNWQ THTIELVTYP SEISDTAAVE SRKEAMLWLA KEFTDHINQS
     NHQSLPHLVS DDGRFTLVIS NSKHLIAAGN GTSIDAQGKT IGMTPSGQQA TMAISAKEFG
     TSSSPEVRLL ESAPWYQAGL RDEFLANAKN TTLDDPATAQ NVYAYLTSVY SKTADLAKEY
     GIYINDWDPA SEGFSPNAQG LTDPKVKNAW SILPRTKPVR MLELLSAEDS RYVRQQIAEK
     LKGTYSESLA KNVFEYFQYG GEVAGHGINN ATTGSVQQPE PAILFEFRSV PSALSDFVPK
     TASTVKVDVK ALDHFDSASR KAIITEVNAL VSGSEDFDAW YQEYRASKGQ PPVKNPKSSA
     SANHKAEWLM TQHAEQWAKI TAPYTDNHET LTSTKLASND KEELHALGET SNLENNKQQE
     NVASIINTML NDMLPFYALR TERNLLVQEG DEGFEVRAWP GTEDKSKTII LEDPEDAAQH
     KAIERFILAN FDNFEQMPDE LFLVDNKVIS HHEGRTHVLA QKVDGAWQYN ATVELMSVTE
     LLDAANVTGK IRGESYQQVI DALTDYHASI TEHADYEPES VEKLLNLRKK IEGYVLGHPD
     SGRVEAMNSL LNQVNTRLDE VSLLSVAEQT IQAQNSFSRL YDQLEAANLK ESKHLYLDQN
     GDFVTKGKGN LANIDLLGSR EAVLEKVKLT VSNEYGQTVA DTIFAGLSAK DLAKDGKGVD
     IAGLNKVHQA IEQHLSPVSA TLYIWKPSDH SALGHAALQI GQGRTQLEGQ AAADFNQQNY
     VSWWPLGSKS SNISNILNVA TKDQPDLKLR WSDFSQPAHQ NDTLEHDVAS EENDGFGLHD
     GDIKLKRFIE KLNAAKGIDA SFKEASEGYA SVLLGNPDML ETTSIPAHVF QPFVEQWNDT
     SYDMMDVAHR FAQELRLQAQ RSDDPELLEK RIGNVIRQFA ERALEEIETF KASQADQGRV
     FRINLEGLDV AAMQAEWHRL SNDPDARYQL LTKNCSSTVA KVLKAGGADK LIGHTWLPKF
     GVWTPTELFN FGQALQEAQL EIAAKKQSHQ VTDVLDALSG NEKPKENVAI ENDGTPPRDK
     ESLSPLTRFL NNELYGDKEA RRKIGEITQT LLDHAVEKGE SQKITLQGEA GRLTGYYHQG
     TAPSEGETSS PSGKVVLFLH GSGSSAEEQA SAIRNHYQKQ GIDMLAVNLR GYGESDGGPS
     EKGLYQDART MFNYLVNDKG IDPSNIIIHG YSMGGPIAAD LARYAAQNGQ AVSGLLLDRP
     MPSMTKAITA HEVANPAGIV GAIAKAVNGQ FSVEKNLEGL PKETSILLLT DNEGLGNEGE
     KLRTKLTASG YNVTGEQTFY GHEASNRLMS QYADQIVSGL SSSASVDEDL DQQGLDTTST
     KDQGISNKND HLQVVDSKEA LADGKILHNQ NVNSWGPITV TPTTDGGETR FDGQIIVQME
     NDPVVAKAAA NLAGKHAESS VVVQLDSDGN YRVVYGDPSK LDGKLRWQLV GHGRDHSETN
     NTRLSGYSAD ELAVKLAKFQ QSFNQAENIN NKPDHISIVG CSLVSDDKQK GFGHQFINAM
     DANGLRVDVS VRSSELAVDE AGRKHTKDAN GDWVQKAENN KVSLSWDAQG EVVAKDERIR
     NGIAEGDIDL SRIGVNNVDE PARGAIGDNN DVFDAPEKRK PETEVIANSS SSNQFSYSGN
     IQVNVGEGEF TAVNWGTSNV GIKVGTGGFK SLAFGDNNVM VHIGDGESKH SVDIGGYQAL
     EGAQMFLGNR NVSFNFGHSN DLILMMDKSI PTPPLVNPFD GAARISGVLQ GIATSGEGED
     WLAAQEQQWT LSGAKKFVKD MSGLDQSSSV DYTTLVELDS QNERDSRGLK HDAEATLNKQ
     YNQWLSGNGN SGTSQLSRAD KLRQANEKLA FNFAVGGQGA DIQVTTGNWN FMFGDNIQSI
     LDTNLGSLFG LMTQQFTATG QAKTTFTYTP QDLPRQLKNK LLGQLAGVGA ETTLADIFGV
     DYTASGQIVS RNGQAVDGVA ILKEMLEVIG EFSGDQLQAF VDPAKLLDSL KAGIDMGADG
     IKSFAETHGL KEKAPEEEKD NSSVSVNGAN VNSAQGATVA DGNTETAETQ DRAFGFNSLN
     LPNLFATIFS QDKQKEMKSL VENLKQNLTA DLLNMKEKTF DFLRNSGHLQ GDGDINISLG
     NYNFNWGGDG KDLGAYLGDN NNFWGGRGDD VFYATGKSNI FTGGEGNDMG VLMGRENMMF
     GGDGNDTAVV AGRINHVFLG AGDDQSFVFG EGGEIDTGSG RDYVVTSGNF NRVDTGDDQD
     YSVTIGNNNQ VELGAGNDFA NIFGNYNRIN AGAGNDVVKL MGYHAVLNGG DGDDHLIATA
     ISKFSQFNGG EGRDLMVLGG YQNTFKGGTD VDSFVVSGDV IDNLVEDIRS EDNIVFNGID
     WQKLWFERSG YDLKLSILRD PSNDSDQSKF EHIGSVTFSD YFNGNRAQVV IGMSEKDLSG
     EREYTMLSDS AIDALVQAMS GFEPQAGDNG FIDSLESKSQ AAISMAWSDV VHKKGLMV
//
ID   WNTG_DROME              Reviewed;         468 AA.
AC   P09615; Q27768; Q27769; Q8IPI1; Q8MQP9; Q9VM27;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   01-JUL-1989, sequence version 1.
DT   17-FEB-2016, entry version 173.
DE   RecName: Full=Protein wingless;
DE   AltName: Full=Protein Wnt-1;
DE   AltName: Full=Protein int-1;
DE   AltName: Full=dInt-1;
DE   AltName: Full=dWnt-1;
DE   Flags: Precursor;
GN   Name=wg; ORFNames=CG4889;
OS   Drosophila melanogaster (Fruit fly).
OC   Eukaryota; Metazoa; Ecdysozoa; Arthropoda; Hexapoda; Insecta;
OC   Pterygota; Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;
OC   Ephydroidea; Drosophilidae; Drosophila; Sophophora.
OX   NCBI_TaxID=7227;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM A), TISSUE SPECIFICITY, AND
RP   DEVELOPMENTAL STAGE.
RX   PubMed=3111720; DOI=10.1016/0092-8674(87)90038-9;
RA   Rijsewijk F., Schuermann M., Wagenaar E., Parren P., Weigel D.,
RA   Nusse R.;
RT   "The Drosophila homolog of the mouse mammary oncogene int-1 is
RT   identical to the segment polarity gene wingless.";
RL   Cell 50:649-657(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM A), AND DEVELOPMENTAL STAGE.
RX   PubMed=3129722; DOI=10.1073/pnas.85.9.3034;
RA   Uzvoelgyi E., Kiss I., Pitt A., Arsenian S., Ingvarsson S.,
RA   Udvardy A., Hamada M., Klein G., Suemegi J.;
RT   "Drosophila homolog of the murine Int-1 protooncogene.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:3034-3038(1988).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM A), SUBCELLULAR LOCATION, AND
RP   MUTAGENESIS OF CYS-104 AND GLY-221.
RX   PubMed=8262072;
RA   van den Heuvel M., Harryman-Samos C., Klingensmith J., Perrimon N.,
RA   Nusse R.;
RT   "Mutations in the segment polarity genes wingless and porcupine impair
RT   secretion of the wingless protein.";
RL   EMBO J. 12:5293-5302(1993).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Berkeley;
RX   PubMed=10731132; DOI=10.1126/science.287.5461.2185;
RA   Adams M.D., Celniker S.E., Holt R.A., Evans C.A., Gocayne J.D.,
RA   Amanatides P.G., Scherer S.E., Li P.W., Hoskins R.A., Galle R.F.,
RA   George R.A., Lewis S.E., Richards S., Ashburner M., Henderson S.N.,
RA   Sutton G.G., Wortman J.R., Yandell M.D., Zhang Q., Chen L.X.,
RA   Brandon R.C., Rogers Y.-H.C., Blazej R.G., Champe M., Pfeiffer B.D.,
RA   Wan K.H., Doyle C., Baxter E.G., Helt G., Nelson C.R., Miklos G.L.G.,
RA   Abril J.F., Agbayani A., An H.-J., Andrews-Pfannkoch C., Baldwin D.,
RA   Ballew R.M., Basu A., Baxendale J., Bayraktaroglu L., Beasley E.M.,
RA   Beeson K.Y., Benos P.V., Berman B.P., Bhandari D., Bolshakov S.,
RA   Borkova D., Botchan M.R., Bouck J., Brokstein P., Brottier P.,
RA   Burtis K.C., Busam D.A., Butler H., Cadieu E., Center A., Chandra I.,
RA   Cherry J.M., Cawley S., Dahlke C., Davenport L.B., Davies P.,
RA   de Pablos B., Delcher A., Deng Z., Mays A.D., Dew I., Dietz S.M.,
RA   Dodson K., Doup L.E., Downes M., Dugan-Rocha S., Dunkov B.C., Dunn P.,
RA   Durbin K.J., Evangelista C.C., Ferraz C., Ferriera S., Fleischmann W.,
RA   Fosler C., Gabrielian A.E., Garg N.S., Gelbart W.M., Glasser K.,
RA   Glodek A., Gong F., Gorrell J.H., Gu Z., Guan P., Harris M.,
RA   Harris N.L., Harvey D.A., Heiman T.J., Hernandez J.R., Houck J.,
RA   Hostin D., Houston K.A., Howland T.J., Wei M.-H., Ibegwam C.,
RA   Jalali M., Kalush F., Karpen G.H., Ke Z., Kennison J.A., Ketchum K.A.,
RA   Kimmel B.E., Kodira C.D., Kraft C.L., Kravitz S., Kulp D., Lai Z.,
RA   Lasko P., Lei Y., Levitsky A.A., Li J.H., Li Z., Liang Y., Lin X.,
RA   Liu X., Mattei B., McIntosh T.C., McLeod M.P., McPherson D.,
RA   Merkulov G., Milshina N.V., Mobarry C., Morris J., Moshrefi A.,
RA   Mount S.M., Moy M., Murphy B., Murphy L., Muzny D.M., Nelson D.L.,
RA   Nelson D.R., Nelson K.A., Nixon K., Nusskern D.R., Pacleb J.M.,
RA   Palazzolo M., Pittman G.S., Pan S., Pollard J., Puri V., Reese M.G.,
RA   Reinert K., Remington K., Saunders R.D.C., Scheeler F., Shen H.,
RA   Shue B.C., Siden-Kiamos I., Simpson M., Skupski M.P., Smith T.J.,
RA   Spier E., Spradling A.C., Stapleton M., Strong R., Sun E.,
RA   Svirskas R., Tector C., Turner R., Venter E., Wang A.H., Wang X.,
RA   Wang Z.-Y., Wassarman D.A., Weinstock G.M., Weissenbach J.,
RA   Williams S.M., Woodage T., Worley K.C., Wu D., Yang S., Yao Q.A.,
RA   Ye J., Yeh R.-F., Zaveri J.S., Zhan M., Zhang G., Zhao Q., Zheng L.,
RA   Zheng X.H., Zhong F.N., Zhong W., Zhou X., Zhu S.C., Zhu X.,
RA   Smith H.O., Gibbs R.A., Myers E.W., Rubin G.M., Venter J.C.;
RT   "The genome sequence of Drosophila melanogaster.";
RL   Science 287:2185-2195(2000).
RN   [5]
RP   GENOME REANNOTATION, AND ALTERNATIVE SPLICING.
RC   STRAIN=Berkeley;
RX   PubMed=12537572; DOI=10.1186/gb-2002-3-12-research0083;
RA   Misra S., Crosby M.A., Mungall C.J., Matthews B.B., Campbell K.S.,
RA   Hradecky P., Huang Y., Kaminker J.S., Millburn G.H., Prochnik S.E.,
RA   Smith C.D., Tupy J.L., Whitfield E.J., Bayraktaroglu L., Berman B.P.,
RA   Bettencourt B.R., Celniker S.E., de Grey A.D.N.J., Drysdale R.A.,
RA   Harris N.L., Richter J., Russo S., Schroeder A.J., Shu S.Q.,
RA   Stapleton M., Yamada C., Ashburner M., Gelbart W.M., Rubin G.M.,
RA   Lewis S.E.;
RT   "Annotation of the Drosophila melanogaster euchromatic genome: a
RT   systematic review.";
RL   Genome Biol. 3:RESEARCH0083.1-RESEARCH0083.22(2002).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM A).
RC   STRAIN=Berkeley; TISSUE=Embryo;
RX   PubMed=12537569; DOI=10.1186/gb-2002-3-12-research0080;
RA   Stapleton M., Carlson J.W., Brokstein P., Yu C., Champe M.,
RA   George R.A., Guarin H., Kronmiller B., Pacleb J.M., Park S., Wan K.H.,
RA   Rubin G.M., Celniker S.E.;
RT   "A Drosophila full-length cDNA resource.";
RL   Genome Biol. 3:RESEARCH0080.1-RESEARCH0080.8(2002).
RN   [7]
RP   SECRETION.
RX   PubMed=2582493; DOI=10.1016/0092-8674(89)90020-2;
RA   van den Heuvel M., Nusse R., Johnston P., Lawrence P.A.;
RT   "Distribution of the wingless gene product in Drosophila embryos: a
RT   protein involved in cell-cell communication.";
RL   Cell 59:739-749(1989).
RN   [8]
RP   INTERACTION WITH EN.
RC   TISSUE=Embryo;
RX   PubMed=1335365; DOI=10.1016/S0092-8674(05)80065-0;
RA   Siegfried E., Chou T.B., Perrimon N.;
RT   "wingless signaling acts through zeste-white 3, the Drosophila homolog
RT   of glycogen synthase kinase-3, to regulate engrailed and establish
RT   cell fate.";
RL   Cell 71:1167-1179(1992).
RN   [9]
RP   MUTANTS ALLELES WG-S21 AND WG-IL114.
RX   PubMed=7954794; DOI=10.1016/0092-8674(94)90195-3;
RA   Couso J.P., Martinez Arias A.;
RT   "Notch is required for wingless signaling in the epidermis of
RT   Drosophila.";
RL   Cell 79:259-272(1994).
RN   [10]
RP   PHOSPHORYLATION OF ARM.
RX   PubMed=7529201; DOI=10.1006/dbio.1994.1336;
RA   Peifer M., Pai L.-M., Casey M.;
RT   "Phosphorylation of the Drosophila adherens junction protein
RT   Armadillo: roles for wingless signal and zeste-white 3 kinase.";
RL   Dev. Biol. 166:543-556(1994).
RN   [11]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=11717401; DOI=10.1073/pnas.251304398;
RA   Llimargas M., Lawrence P.A.;
RT   "Seven Wnt homologues in Drosophila: a case study of the developing
RT   tracheae.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:14487-14492(2001).
RN   [12]
RP   SUBUNIT, INTERACTION WITH PORCUPINE, GLYCOSYLATION AT ASN-103 AND
RP   ASN-414, AND MUTAGENESIS OF THR-51; SER-105; SER-110 AND THR-416.
RX   PubMed=11821428; DOI=10.1074/jbc.M200187200;
RA   Tanaka K., Kitagawa Y., Kadowaki T.;
RT   "Drosophila segment polarity gene product porcupine stimulates the
RT   posttranslational N-glycosylation of wingless in the endoplasmic
RT   reticulum.";
RL   J. Biol. Chem. 277:12816-12823(2002).
RN   [13]
RP   PALMITOLEYLATION BY PORCUPINE, AND SUBCELLULAR LOCATION.
RX   PubMed=15166250; DOI=10.1074/jbc.M403407200;
RA   Zhai L., Chaturvedi D., Cumberledge S.;
RT   "Drosophila wnt-1 undergoes a hydrophobic modification and is targeted
RT   to lipid rafts, a process that requires porcupine.";
RL   J. Biol. Chem. 279:33220-33227(2004).
RN   [14]
RP   ROLE OF LIPOPHORIN IN MOVEMENT.
RX   PubMed=15875013; DOI=10.1038/nature03504;
RA   Panakova D., Sprong H., Marois E., Thiele C., Eaton S.;
RT   "Lipoprotein particles are required for Hedgehog and Wingless
RT   signalling.";
RL   Nature 435:58-65(2005).
RN   [15]
RP   FUNCTION, INTERACTION WITH WLS, AND SUBCELLULAR LOCATION.
RX   PubMed=18193037; DOI=10.1038/ncb1678;
RA   Franch-Marro X., Wendler F., Guidato S., Griffith J., Baena-Lopez A.,
RA   Itasaki N., Maurice M.M., Vincent J.P.;
RT   "Wingless secretion requires endosome-to-Golgi retrieval of
RT   Wntless/Evi/Sprinter by the retromer complex.";
RL   Nat. Cell Biol. 10:170-177(2008).
RN   [16]
RP   FUNCTION, AND DISRUPTION PHENOTYPE.
RX   PubMed=18193032; DOI=10.1038/ncb1687;
RA   Port F., Kuster M., Herr P., Furger E., Banziger C., Hausmann G.,
RA   Basler K.;
RT   "Wingless secretion promotes and requires retromer-dependent cycling
RT   of Wntless.";
RL   Nat. Cell Biol. 10:178-185(2008).
RN   [17]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=19837038; DOI=10.1016/j.cell.2009.07.051;
RA   Korkut C., Ataman B., Ramachandran P., Ashley J., Barria R.,
RA   Gherbesi N., Budnik V.;
RT   "Trans-synaptic transmission of vesicular Wnt signals through
RT   Evi/Wntless.";
RL   Cell 139:393-404(2009).
RN   [18]
RP   DEPALMITOLEYLATION.
RX   PubMed=25731175; DOI=10.1038/nature14259;
RA   Kakugawa S., Langton P.F., Zebisch M., Howell S.A., Chang T.H.,
RA   Liu Y., Feizi T., Bineva G., O'Reilly N., Snijders A.P., Jones E.Y.,
RA   Vincent J.P.;
RT   "Notum deacylates Wnt proteins to suppress signalling activity.";
RL   Nature 519:187-192(2015).
CC   -!- FUNCTION: Binds as a ligand to a family of frizzled seven-
CC       transmembrane receptors and acts through a cascade of genes on the
CC       nucleus. Segment polarity protein. May be a growth factor. Acts on
CC       neighboring cells to regulate at least one gene, the homeobox
CC       segmentation gene engrailed. Wg signal represses arm
CC       phosphorylation. Wg signaling operates by inactivating the sgg
CC       repression of engrailed autoactivation. Wg and Wnt2 have a role in
CC       the developing trachea and together are responsible for all dorsal
CC       trunk formation. Wg also acts in the developing epidermis. Acts as
CC       a morphogen, and diffuses long distances despite its lipidation.
CC       Lipophorin is required for diffusion, probably by acting as
CC       vehicle for its movement, explaining how it can spread over long
CC       distances despite its lipidation. In non-neuronal cells, wls
CC       directs wg secretion via clathrin-mediated endocytosis and the
CC       retromer complex (a conserved protein complex consisting of Vps26
CC       and Vps35) to sustain a wls traffic loop encompassing the Golgi,
CC       the cell surface, an endocytic compartment and a retrograde route
CC       leading back to the Golgi. In neuronal cells (the larval
CC       motorneuron NMJ), wg signal moves across the synapse through the
CC       release of wls-containing exosome-like vesicles.
CC       {ECO:0000269|PubMed:11717401, ECO:0000269|PubMed:18193032,
CC       ECO:0000269|PubMed:18193037, ECO:0000269|PubMed:19837038}.
CC   -!- SUBUNIT: Monomer; folds by intramolecular disulfide bonds.
CC       Interacts with porcupine (por). Interacts with wls; in the Golgi.
CC       {ECO:0000269|PubMed:11821428, ECO:0000269|PubMed:1335365,
CC       ECO:0000269|PubMed:18193037}.
CC   -!- INTERACTION:
CC       Q9VXY9:opm; NbExp=2; IntAct=EBI-98242, EBI-7560899;
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:15166250,
CC       ECO:0000269|PubMed:18193037, ECO:0000269|PubMed:8262072}. Cell
CC       junction, synapse {ECO:0000269|PubMed:19837038}. Membrane; Lipid-
CC       anchor. Secreted, extracellular space, extracellular matrix
CC       {ECO:0000269|PubMed:15166250}. Note=Palmitoleylation converts wg
CC       into a membrane-anchored protein that is partitioned into
CC       specialized lipid raft microdomains before secretion. Possibly
CC       associated with the extracellular matrix.
CC       {ECO:0000269|PubMed:15166250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=A;
CC         IsoId=P09615-1; Sequence=Displayed;
CC       Name=B;
CC         IsoId=P09615-2; Sequence=VSP_016535;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Segmented expression in embryos. In embryonic
CC       tracheal cells, expression is in stripes flanking the tracheal
CC       placode. {ECO:0000269|PubMed:11717401,
CC       ECO:0000269|PubMed:3111720}.
CC   -!- DEVELOPMENTAL STAGE: Expressed throughout development, but barely
CC       detectable in adults. {ECO:0000269|PubMed:3111720,
CC       ECO:0000269|PubMed:3129722}.
CC   -!- PTM: Palmitoleylated by porcupine. The lipid group functions as a
CC       sorting signal, targeting the ligand to polarized vesicles that
CC       transport wg to unique sites at the cell surface.
CC       Depalmitoleylated by notum, leading to inhibit Wnt signaling
CC       pathway. {ECO:0000305|PubMed:11821428,
CC       ECO:0000305|PubMed:15166250, ECO:0000305|PubMed:25731175}.
CC   -!- PTM: Major form is glycosylated at 2 sites, glycosylation is
CC       stimulated by porcupine at the ER. {ECO:0000269|PubMed:11821428}.
CC   -!- DISRUPTION PHENOTYPE: Accumulation in the Golgi, thereby
CC       preventing secretion. {ECO:0000269|PubMed:18193032}.
CC   -!- SIMILARITY: Belongs to the Wnt family. {ECO:0000305}.
CC   -!- CAUTION: Was initially thought to be palmitoylated at Ser-239. It
CC       was later shown that it is palmitoleylated. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M17230; AAA28647.1; -; mRNA.
DR   EMBL; J03650; AAA28646.1; -; mRNA.
DR   EMBL; S67382; AAB29368.1; -; mRNA.
DR   EMBL; S67383; AAB29369.1; -; mRNA.
DR   EMBL; AE014134; AAF52501.1; -; Genomic_DNA.
DR   EMBL; AE014134; AAN10628.1; -; Genomic_DNA.
DR   EMBL; AY128458; AAM75051.1; -; mRNA.
DR   PIR; A29650; A29650.
DR   PIR; A31337; TVFFT1.
DR   RefSeq; NP_523502.1; NM_078778.5. [P09615-1]
DR   UniGene; Dm.6628; -.
DR   ProteinModelPortal; P09615; -.
DR   SMR; P09615; 85-277, 386-467.
DR   BioGrid; 60155; 62.
DR   DIP; DIP-21777N; -.
DR   IntAct; P09615; 1.
DR   MINT; MINT-1645341; -.
DR   STRING; 7227.FBpp0079060; -.
DR   SwissPalm; P09615; -.
DR   PaxDb; P09615; -.
DR   PRIDE; P09615; -.
DR   EnsemblMetazoa; FBtr0079432; FBpp0079060; FBgn0004009. [P09615-1]
DR   GeneID; 34009; -.
DR   KEGG; dme:Dmel_CG4889; -.
DR   CTD; 474168; -.
DR   FlyBase; FBgn0004009; wg.
DR   eggNOG; KOG3913; Eukaryota.
DR   eggNOG; ENOG410XQZ1; LUCA.
DR   GeneTree; ENSGT00760000118943; -.
DR   InParanoid; P09615; -.
DR   KO; K03209; -.
DR   OMA; NNSGRWW; -.
DR   OrthoDB; EOG7C8GJ8; -.
DR   PhylomeDB; P09615; -.
DR   Reactome; R-DME-3238698; WNT ligand biogenesis and trafficking.
DR   Reactome; R-DME-4086400; PCP/CE pathway.
DR   Reactome; R-DME-4641262; Disassembly of the destruction complex and recruitment of AXIN to the membrane.
DR   SignaLink; P09615; -.
DR   GenomeRNAi; 34009; -.
DR   NextBio; 786411; -.
DR   PRO; PR:P09615; -.
DR   Proteomes; UP000000803; Chromosome 2L.
DR   Bgee; P09615; -.
DR   ExpressionAtlas; P09615; differential.
DR   Genevisible; P09615; DM.
DR   GO; GO:0030054; C:cell junction; IEA:UniProtKB-KW.
DR   GO; GO:0009986; C:cell surface; IDA:FlyBase.
DR   GO; GO:0016023; C:cytoplasmic membrane-bounded vesicle; NAS:FlyBase.
DR   GO; GO:0030139; C:endocytic vesicle; IDA:FlyBase.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:FlyBase.
DR   GO; GO:0005576; C:extracellular region; IDA:FlyBase.
DR   GO; GO:0005615; C:extracellular space; IDA:FlyBase.
DR   GO; GO:0045121; C:membrane raft; IDA:FlyBase.
DR   GO; GO:0005771; C:multivesicular body; IDA:FlyBase.
DR   GO; GO:0005886; C:plasma membrane; IDA:FlyBase.
DR   GO; GO:0005578; C:proteinaceous extracellular matrix; IEA:UniProtKB-SubCell.
DR   GO; GO:0043195; C:terminal bouton; IDA:FlyBase.
DR   GO; GO:0050840; F:extracellular matrix binding; IDA:FlyBase.
DR   GO; GO:0005109; F:frizzled binding; IPI:FlyBase.
DR   GO; GO:0005110; F:frizzled-2 binding; IDA:FlyBase.
DR   GO; GO:0005539; F:glycosaminoglycan binding; IDA:FlyBase.
DR   GO; GO:0043395; F:heparan sulfate proteoglycan binding; IPI:FlyBase.
DR   GO; GO:0016015; F:morphogen activity; TAS:FlyBase.
DR   GO; GO:0005112; F:Notch binding; TAS:FlyBase.
DR   GO; GO:0051017; P:actin filament bundle assembly; IMP:FlyBase.
DR   GO; GO:0035288; P:anterior head segmentation; TAS:FlyBase.
DR   GO; GO:0008595; P:anterior/posterior axis specification, embryo; NAS:FlyBase.
DR   GO; GO:0007448; P:anterior/posterior pattern specification, imaginal disc; IMP:FlyBase.
DR   GO; GO:0035147; P:branch fusion, open tracheal system; IMP:FlyBase.
DR   GO; GO:0048754; P:branching morphogenesis of an epithelial tube; IMP:FlyBase.
DR   GO; GO:0060070; P:canonical Wnt signaling pathway; IDA:FlyBase.
DR   GO; GO:0010002; P:cardioblast differentiation; IMP:FlyBase.
DR   GO; GO:0048749; P:compound eye development; TAS:FlyBase.
DR   GO; GO:0001745; P:compound eye morphogenesis; IMP:FlyBase.
DR   GO; GO:0035017; P:cuticle pattern formation; IMP:FlyBase.
DR   GO; GO:0035225; P:determination of genital disc primordium; IMP:FlyBase.
DR   GO; GO:0007391; P:dorsal closure; IMP:FlyBase.
DR   GO; GO:0007394; P:dorsal closure, elongation of leading edge cells; IMP:FlyBase.
DR   GO; GO:0007450; P:dorsal/ventral pattern formation, imaginal disc; IMP:FlyBase.
DR   GO; GO:0007398; P:ectoderm development; IMP:FlyBase.
DR   GO; GO:0008544; P:epidermis development; IMP:FlyBase.
DR   GO; GO:0061331; P:epithelial cell proliferation involved in Malpighian tubule morphogenesis; IMP:FlyBase.
DR   GO; GO:0035153; P:epithelial cell type specification, open tracheal system; IMP:FlyBase.
DR   GO; GO:0046847; P:filopodium assembly; IMP:FlyBase.
DR   GO; GO:0035224; P:genital disc anterior/posterior pattern formation; IEP:FlyBase.
DR   GO; GO:0035215; P:genital disc development; TAS:FlyBase.
DR   GO; GO:0035263; P:genital disc sexually dimorphic development; IMP:FlyBase.
DR   GO; GO:0007507; P:heart development; IMP:FlyBase.
DR   GO; GO:0060914; P:heart formation; IMP:FlyBase.
DR   GO; GO:0007442; P:hindgut morphogenesis; IMP:FlyBase.
DR   GO; GO:0007488; P:histoblast morphogenesis; IMP:FlyBase.
DR   GO; GO:0007444; P:imaginal disc development; IMP:FlyBase.
DR   GO; GO:0007446; P:imaginal disc growth; TAS:FlyBase.
DR   GO; GO:0007447; P:imaginal disc pattern formation; TAS:FlyBase.
DR   GO; GO:0007476; P:imaginal disc-derived wing morphogenesis; IMP:FlyBase.
DR   GO; GO:0002168; P:instar larval development; TAS:FlyBase.
DR   GO; GO:0035217; P:labial disc development; IMP:FlyBase.
DR   GO; GO:0030032; P:lamellipodium assembly; IMP:FlyBase.
DR   GO; GO:0035167; P:larval lymph gland hemopoiesis; IMP:FlyBase.
DR   GO; GO:0007523; P:larval visceral muscle development; IMP:FlyBase.
DR   GO; GO:0007479; P:leg disc proximal/distal pattern formation; NAS:FlyBase.
DR   GO; GO:0007616; P:long-term memory; IMP:FlyBase.
DR   GO; GO:0035170; P:lymph gland crystal cell differentiation; IMP:FlyBase.
DR   GO; GO:0048542; P:lymph gland development; IMP:FlyBase.
DR   GO; GO:0061332; P:Malpighian tubule bud morphogenesis; IMP:FlyBase.
DR   GO; GO:0061382; P:Malpighian tubule tip cell differentiation; IMP:FlyBase.
DR   GO; GO:0007498; P:mesoderm development; IMP:FlyBase.
DR   GO; GO:0048332; P:mesoderm morphogenesis; IMP:FlyBase.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; TAS:FlyBase.
DR   GO; GO:0009996; P:negative regulation of cell fate specification; IMP:FlyBase.
DR   GO; GO:0032876; P:negative regulation of DNA endoreduplication; IMP:FlyBase.
DR   GO; GO:0003136; P:negative regulation of heart induction by canonical Wnt signaling pathway; IMP:FlyBase.
DR   GO; GO:0045611; P:negative regulation of hemocyte differentiation; IMP:FlyBase.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IMP:FlyBase.
DR   GO; GO:0014019; P:neuroblast development; IMP:FlyBase.
DR   GO; GO:0030182; P:neuron differentiation; IBA:GO_Central.
DR   GO; GO:0016318; P:ommatidial rotation; TAS:FlyBase.
DR   GO; GO:0030707; P:ovarian follicle cell development; IMP:FlyBase.
DR   GO; GO:0061320; P:pericardial nephrocyte differentiation; IMP:FlyBase.
DR   GO; GO:0010942; P:positive regulation of cell death; IMP:FlyBase.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IMP:FlyBase.
DR   GO; GO:0046672; P:positive regulation of compound eye retinal cell programmed cell death; IMP:FlyBase.
DR   GO; GO:0042691; P:positive regulation of crystal cell differentiation; IMP:FlyBase.
DR   GO; GO:2000648; P:positive regulation of stem cell proliferation; IMP:FlyBase.
DR   GO; GO:0035289; P:posterior head segmentation; TAS:FlyBase.
DR   GO; GO:0061328; P:posterior Malpighian tubule development; IMP:FlyBase.
DR   GO; GO:0048728; P:proboscis development; IMP:FlyBase.
DR   GO; GO:0042127; P:regulation of cell proliferation; NAS:FlyBase.
DR   GO; GO:0048076; P:regulation of compound eye pigmentation; IMP:FlyBase.
DR   GO; GO:0044719; P:regulation of imaginal disc-derived wing size; IMP:FlyBase.
DR   GO; GO:0007346; P:regulation of mitotic cell cycle; TAS:FlyBase.
DR   GO; GO:0072091; P:regulation of stem cell proliferation; IMP:FlyBase.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IMP:FlyBase.
DR   GO; GO:0007367; P:segment polarity determination; IMP:FlyBase.
DR   GO; GO:0007423; P:sensory organ development; TAS:FlyBase.
DR   GO; GO:0060061; P:Spemann organizer formation; IMP:BHF-UCL.
DR   GO; GO:0035277; P:spiracle morphogenesis, open tracheal system; IMP:FlyBase.
DR   GO; GO:0050808; P:synapse organization; IMP:FlyBase.
DR   GO; GO:0051124; P:synaptic growth at neuromuscular junction; IMP:FlyBase.
DR   GO; GO:0035290; P:trunk segmentation; TAS:FlyBase.
DR   GO; GO:0007419; P:ventral cord development; TAS:FlyBase.
DR   GO; GO:0007418; P:ventral midline development; IMP:FlyBase.
DR   GO; GO:0035311; P:wing cell fate specification; IMP:FlyBase.
DR   GO; GO:0035220; P:wing disc development; IGI:FlyBase.
DR   GO; GO:0048190; P:wing disc dorsal/ventral pattern formation; TAS:FlyBase.
DR   GO; GO:0007223; P:Wnt signaling pathway, calcium modulating pathway; IDA:FlyBase.
DR   InterPro; IPR005817; Wnt.
DR   InterPro; IPR018161; Wnt_CS.
DR   PANTHER; PTHR12027; PTHR12027; 2.
DR   Pfam; PF00110; wnt; 1.
DR   PRINTS; PR01349; WNTPROTEIN.
DR   SMART; SM00097; WNT1; 1.
DR   PROSITE; PS00246; WNT1; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Cell junction; Complete proteome;
KW   Developmental protein; Disulfide bond; Extracellular matrix;
KW   Glycoprotein; Lipoprotein; Membrane; Morphogen; Reference proteome;
KW   Secreted; Segmentation polarity protein; Signal; Synapse;
KW   Wnt signaling pathway.
FT   SIGNAL        1     17
FT   CHAIN        18    468       Protein wingless.
FT                                /FTId=PRO_0000041476.
FT   REGION       83    106       Binds porcupine.
FT   LIPID       239    239       O-palmitoleyl serine; by PORCN.
FT                                {ECO:0000250|UniProtKB:P56704}.
FT   CARBOHYD    103    103       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:11821428}.
FT   CARBOHYD    108    108       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    414    414       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:11821428}.
FT   DISULFID     93    104       {ECO:0000250|UniProtKB:Q9VFX1}.
FT   DISULFID    146    154       {ECO:0000250|UniProtKB:Q9VFX1}.
FT   DISULFID    156    185       {ECO:0000250|UniProtKB:Q9VFX1}.
FT   DISULFID    233    247       {ECO:0000250|UniProtKB:Q9VFX1}.
FT   DISULFID    235    242       {ECO:0000250|UniProtKB:Q9VFX1}.
FT   DISULFID    413    428       {ECO:0000250}.
FT   DISULFID    443    458       {ECO:0000250}.
FT   DISULFID    445    455       {ECO:0000250}.
FT   DISULFID    450    451       {ECO:0000250}.
FT   VAR_SEQ       1     53       Missing (in isoform B). {ECO:0000305}.
FT                                /FTId=VSP_016535.
FT   MUTAGEN      51     51       T->A: No effect on glycosylation.
FT                                {ECO:0000269|PubMed:11821428}.
FT   MUTAGEN      93     93       C->Y: In allele wg-S21; results in
FT                                lethality.
FT   MUTAGEN     104    104       C->S: In allele wg-IL114; temperature
FT                                sensitive lethal.
FT                                {ECO:0000269|PubMed:8262072}.
FT   MUTAGEN     105    105       S->A: Glycosylation disrupted.
FT                                {ECO:0000269|PubMed:11821428}.
FT   MUTAGEN     110    110       S->A: No effect on glycosylation.
FT                                {ECO:0000269|PubMed:11821428}.
FT   MUTAGEN     221    221       G->D: In allele wg-IN67; embryonic
FT                                lethal. {ECO:0000269|PubMed:8262072}.
FT   MUTAGEN     416    416       T->A: Glycosylation disrupted.
FT                                {ECO:0000269|PubMed:11821428}.
FT   CONFLICT     92     92       E -> K (in Ref. 6; AAM75051).
FT                                {ECO:0000305}.
FT   CONFLICT    182    182       W -> C (in Ref. 2; AAA28646).
FT                                {ECO:0000305}.
FT   CONFLICT    204    204       E -> D (in Ref. 2; AAA28646).
FT                                {ECO:0000305}.
FT   CONFLICT    275    275       N -> T (in Ref. 2; AAA28646).
FT                                {ECO:0000305}.
FT   CONFLICT    297    297       G -> A (in Ref. 2; AAA28646).
FT                                {ECO:0000305}.
FT   CONFLICT    315    315       E -> EE (in Ref. 2; AAA28646).
FT                                {ECO:0000305}.
FT   CONFLICT    364    364       K -> N (in Ref. 2; AAA28646).
FT                                {ECO:0000305}.
FT   CONFLICT    391    391       E -> D (in Ref. 2; AAA28646).
FT                                {ECO:0000305}.
FT   CONFLICT    441    441       E -> D (in Ref. 2; AAA28646).
FT                                {ECO:0000305}.
SQ   SEQUENCE   468 AA;  51986 MW;  F766972A731E6171 CRC64;
     MDISYIFVIC LMALCSGGSS LSQVEGKQKS GRGRGSMWWG IAKVGEPNNI TPIMYMDPAI
     HSTLRRKQRR LVRDNPGVLG ALVKGANLAI SECQHQFRNR RWNCSTRNFS RGKNLFGKIV
     DRGCRETSFI YAITSAAVTH SIARACSEGT IESCTCDYSH QSRSPQANHQ AGSVAGVRDW
     EWGGCSDNIG FGFKFSREFV DTGERGRNLR EKMNLHNNEA GRAHVQAEMR QECKCHGMSG
     SCTVKTCWMR LANFRVIGDN LKARFDGATR VQVTNSLRAT NALAPVSPNA AGSNSVGSNG
     LIIPQSGLVY GEEEERMLND HMPDILLENS HPISKIHHPN MPSPNSLPQA GQRGGRNGRR
     QGRKHNRYHF QLNPHNPEHK PPGSKDLVYL EPSPSFCEKN LRQGILGTHG RQCNETSLGV
     DGCGLMCCGR GYRRDEVVVV ERCACTFHWC CEVKCKLCRT KKVIYTCL
//
ID   ITB1_HUMAN              Reviewed;         798 AA.
AC   P05556; A8K6N2; D3DRX9; D3DRY3; D3DRY4; D3DRY5; P78466; P78467;
AC   Q13089; Q13090; Q13091; Q13212; Q14622; Q14647; Q29RW2; Q7Z3V1;
AC   Q8WUM6;
DT   01-NOV-1988, integrated into UniProtKB/Swiss-Prot.
DT   16-DEC-2008, sequence version 2.
DT   17-FEB-2016, entry version 202.
DE   RecName: Full=Integrin beta-1;
DE   AltName: Full=Fibronectin receptor subunit beta;
DE   AltName: Full=Glycoprotein IIa;
DE            Short=GPIIA;
DE   AltName: Full=VLA-4 subunit beta;
DE   AltName: CD_antigen=CD29;
DE   Flags: Precursor;
GN   Name=ITGB1; Synonyms=FNRB, MDF2, MSK12;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RX   PubMed=2958481; DOI=10.1083/jcb.105.3.1183;
RA   Argraves W.S., Suzuki S., Arai H., Thompson K., Pierschbacher M.D.,
RA   Ruoslahti E.;
RT   "Amino acid sequence of the human fibronectin receptor.";
RL   J. Cell Biol. 105:1183-1190(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Endometrium;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Cahill P., Camire D.,
RA   Carter N.P., Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Corby N., Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L.,
RA   Frankish A., Frankland J.A., Garner P., Garnett J., Gribble S.,
RA   Griffiths C., Grocock R., Gustafson E., Hammond S., Harley J.L.,
RA   Hart E., Heath P.D., Ho T.P., Hopkins B., Horne J., Howden P.J.,
RA   Huckle E., Hynds C., Johnson C., Johnson D., Kana A., Kay M.,
RA   Kimberley A.M., Kershaw J.K., Kokkinaki M., Laird G.K., Lawlor S.,
RA   Lee H.M., Leongamornlert D.A., Laird G., Lloyd C., Lloyd D.M.,
RA   Loveland J., Lovell J., McLaren S., McLay K.E., McMurray A.,
RA   Mashreghi-Mohammadi M., Matthews L., Milne S., Nickerson T.,
RA   Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V., Peck A.I.,
RA   Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A., Ross M.T.,
RA   Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W.,
RA   Tracey A., Tromans A., Tsolas J., Wall M., Walsh J., Wang H.,
RA   Weinstock K., West A.P., Willey D.L., Whitehead S.L., Wilming L.,
RA   Wray P.W., Young L., Chen Y., Lovering R.C., Moschonas N.K.,
RA   Siebert R., Fechtel K., Bentley D., Durbin R.M., Hubbard T.,
RA   Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 717-757, CHARACTERIZATION OF
RP   BETA-1B, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=7681433; DOI=10.1083/jcb.121.1.171;
RA   Balzac F., Belkin A.M., Koteliansky V.E., Balabanov Y.V., Altruda F.,
RA   Silengo L., Tarone G.;
RT   "Expression and functional analysis of a cytoplasmic domain variant of
RT   the beta 1 integrin subunit.";
RL   J. Cell Biol. 121:171-178(1993).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 717-757, AND FUNCTION.
RX   PubMed=7523423; DOI=10.1083/jcb.127.2.557;
RA   Balzac F., Retta S.F., Albini A., Melchiorri A., Koteliansky V.E.,
RA   Geuna M., Silengo L., Tarone G.;
RT   "Expression of beta 1B integrin isoform in CHO cells results in a
RT   dominant negative effect on cell adhesion and motility.";
RL   J. Cell Biol. 127:557-565(1994).
RN   [9]
RP   PARTIAL NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Skeletal muscle;
RX   PubMed=2249781; DOI=10.1016/0378-1119(90)90369-3;
RA   Altruda F., Cervella P., Tarone G., Botta C., Balzac F., Stefanuto G.,
RA   Silengo L.;
RT   "A human integrin beta 1 subunit with a unique cytoplasmic domain
RT   generated by alternative mRNA processing.";
RL   Gene 95:261-266(1990).
RN   [10]
RP   PARTIAL NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 3), SUBCELLULAR
RP   LOCATION, AND TISSUE SPECIFICITY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=1551917;
RA   Languino L.R., Ruoslahti E.;
RT   "An alternative form of the integrin beta 1 subunit with a variant
RT   cytoplasmic domain.";
RL   J. Biol. Chem. 267:7116-7120(1992).
RN   [11]
RP   PARTIAL NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND TISSUE SPECIFICITY.
RC   TISSUE=Skeletal muscle;
RX   PubMed=7545396; DOI=10.1006/bbrc.1995.2285;
RA   Zhidkova N.I., Belkin A.M., Mayne R.;
RT   "Novel isoform of beta 1 integrin expressed in skeletal and cardiac
RT   muscle.";
RL   Biochem. Biophys. Res. Commun. 214:279-285(1995).
RN   [12]
RP   PARTIAL NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 5), AND TISSUE
RP   SPECIFICITY.
RX   PubMed=7544298; DOI=10.1016/0014-5793(95)00814-P;
RA   van der Flier A., Kuikman I., Baudoin C., van der Neut R.,
RA   Sonnenberg A.;
RT   "A novel beta 1 integrin isoform produced by alternative splicing:
RT   unique expression in cardiac and skeletal muscle.";
RL   FEBS Lett. 369:340-344(1995).
RN   [13]
RP   PARTIAL NUCLEOTIDE SEQUENCE (ISOFORM 4), AND TISSUE SPECIFICITY.
RX   PubMed=9494094;
RA   Svineng G., Faessler R., Johansson S.;
RT   "Identification of beta1C-2, a novel variant of the integrin beta1
RT   subunit generated by utilization of an alternative splice acceptor
RT   site in exon C.";
RL   Biochem. J. 330:1255-1263(1998).
RN   [14]
RP   PROTEIN SEQUENCE OF 775-784 (ISOFORM 5), IDENTIFICATION BY MASS
RP   SPECTROMETRY, AND INTERACTION WITH ACE2.
RX   PubMed=15276642; DOI=10.1016/j.bbadis.2004.05.005;
RA   Lin Q., Keller R.S., Weaver B., Zisman L.S.;
RT   "Interaction of ACE2 and integrin beta1 in failing human heart.";
RL   Biochim. Biophys. Acta 1689:175-178(2004).
RN   [15]
RP   FUNCTION (MICROBIAL INFECTION), AND INTERACTION WITH HUMAN ECHOVIRUS 1
RP   AND HUMAN ECHOVIRUS 8 CAPSID PROTEINS.
RX   PubMed=8411387;
RA   Bergelson J.M., St John N., Kawaguchi S., Chan M., Stubdal H.,
RA   Modlin J., Finberg R.W.;
RT   "Infection by echoviruses 1 and 8 depends on the alpha 2 subunit of
RT   human VLA-2.";
RL   J. Virol. 67:6847-6852(1993).
RN   [16]
RP   SUBCELLULAR LOCATION.
RX   PubMed=8567725; DOI=10.1083/jcb.132.1.211;
RA   Belkin A.M., Zhidkova N.I., Balzac F., Altruda F., Tomatis D.,
RA   Maier A., Tarone G., Koteliansky V.E., Burridge K.;
RT   "Beta 1D integrin displaces the beta 1A isoform in striated muscles:
RT   localization at junctional structures and signaling potential in
RT   nonmuscle cells.";
RL   J. Cell Biol. 132:211-226(1996).
RN   [17]
RP   INTERACTION WITH LGALS3BP.
RX   PubMed=9501082; DOI=10.1093/emboj/17.6.1606;
RA   Sasaki T., Brakebusch C., Engel J., Timpl R.;
RT   "Mac-2 binding protein is a cell-adhesive protein of the extracellular
RT   matrix which self-assembles into ring-like structures and binds beta1
RT   integrins, collagens and fibronectin.";
RL   EMBO J. 17:1606-1613(1998).
RN   [18]
RP   FUNCTION (MICROBIAL INFECTION), AND INTERACTION WITH HIV-1 TAT.
RX   PubMed=10397733;
RA   Barillari G., Sgadari C., Fiorelli V., Samaniego F., Colombini S.,
RA   Manzari V., Modesti A., Nair B.C., Cafaro A., Stuerzl M., Ensoli B.;
RT   "The Tat protein of human immunodeficiency virus type-1 promotes
RT   vascular cell growth and locomotion by engaging the alpha5beta1 and
RT   alphavbeta3 integrins and by mobilizing sequestered basic fibroblast
RT   growth factor.";
RL   Blood 94:663-672(1999).
RN   [19]
RP   FUNCTION, SUBUNIT, INTERACTION WITH FAP, AND SUBCELLULAR LOCATION.
RX   PubMed=10455171; DOI=10.1074/jbc.274.35.24947;
RA   Mueller S.C., Ghersi G., Akiyama S.K., Sang Q.X., Howard L.,
RA   Pineiro-Sanchez M., Nakahara H., Yeh Y., Chen W.T.;
RT   "A novel protease-docking function of integrin at invadopodia.";
RL   J. Biol. Chem. 274:24947-24952(1999).
RN   [20]
RP   INTERACTION WITH NMRK2.
RC   TISSUE=Heart;
RX   PubMed=10613898; DOI=10.1083/jcb.147.7.1391;
RA   Li J., Mayne R., Wu C.;
RT   "A novel muscle-specific beta 1 integrin binding protein (MIBP) that
RT   modulates myogenic differentiation.";
RL   J. Cell Biol. 147:1391-1398(1999).
RN   [21]
RP   INTERACTION WITH ITGB1BP1.
RX   PubMed=11741838; DOI=10.1093/hmg/10.25.2953;
RA   Zhang J., Clatterbuck R.E., Rigamonti D., Chang D.D., Dietz H.C.;
RT   "Interaction between krit1 and icap1alpha infers perturbation of
RT   integrin beta1-mediated angiogenesis in the pathogenesis of cerebral
RT   cavernous malformation.";
RL   Hum. Mol. Genet. 10:2953-2960(2001).
RN   [22]
RP   SUBCELLULAR LOCATION.
RX   PubMed=11919189; DOI=10.1074/jbc.M200200200;
RA   Fournier H.N., Dupe-Manet S., Bouvard D., Lacombe M.L., Marie C.,
RA   Block M.R., Albiges-Rizo C.;
RT   "Integrin cytoplasmic domain-associated protein 1alpha (ICAP-1alpha)
RT   interacts directly with the metastasis suppressor nm23-H2, and both
RT   proteins are targeted to newly formed cell adhesion sites upon
RT   integrin engagement.";
RL   J. Biol. Chem. 277:20895-20902(2002).
RN   [23]
RP   INTERACTION WITH FLNA AND FLNB, AND MUTAGENESIS OF GLY-778 AND
RP   ALA-786.
RX   PubMed=11807098; DOI=10.1083/jcb.200103037;
RA   van Der Flier A., Kuikman I., Kramer D., Geerts D., Kreft M.,
RA   Takafuta T., Shapiro S.S., Sonnenberg A.;
RT   "Different splice variants of filamin-B affect myogenesis, subcellular
RT   distribution, and determine binding to integrin (beta) subunits.";
RL   J. Cell Biol. 156:361-376(2002).
RN   [24]
RP   INTERACTION WITH ITGB1BP1, AND MUTAGENESIS OF 786-ALA--VAL-791.
RX   PubMed=11807099; DOI=10.1083/jcb.200108030;
RA   Degani S., Balzac F., Brancaccio M., Guazzone S., Retta S.F.,
RA   Silengo L., Eva A., Tarone G.;
RT   "The integrin cytoplasmic domain-associated protein ICAP-1 binds and
RT   regulates Rho family GTPases during cell spreading.";
RL   J. Cell Biol. 156:377-387(2002).
RN   [25]
RP   FUNCTION (MICROBIAL INFECTION), AND INTERACTION WITH HUMAN PARVOVIRUS
RP   B19 CAPSID PROTEIN.
RX   PubMed=12907437; DOI=10.1182/blood-2003-05-1522;
RA   Weigel-Kelley K.A., Yoder M.C., Srivastava A.;
RT   "Alpha5beta1 integrin as a cellular coreceptor for human parvovirus
RT   B19: requirement of functional activation of beta1 integrin for viral
RT   entry.";
RL   Blood 102:3927-3933(2003).
RN   [26]
RP   FUNCTION, AND INTERACTION WITH ITGB1BP1.
RX   PubMed=12473654; DOI=10.1074/jbc.M211258200;
RA   Bouvard D., Vignoud L., Dupe-Manet S., Abed N., Fournier H.N.,
RA   Vincent-Monegat C., Retta S.F., Fassler R., Block M.R.;
RT   "Disruption of focal adhesions by integrin cytoplasmic domain-
RT   associated protein-1 alpha.";
RL   J. Biol. Chem. 278:6567-6574(2003).
RN   [27]
RP   INTERACTION WITH NOV.
RX   PubMed=12695522; DOI=10.1074/jbc.M302028200;
RA   Lin C.G., Leu S.J., Chen N., Tebeau C.M., Lin S.X., Yeung C.Y.,
RA   Lau L.F.;
RT   "CCN3 (NOV) is a novel angiogenic regulator of the CCN protein
RT   family.";
RL   J. Biol. Chem. 278:24200-24208(2003).
RN   [28]
RP   FUNCTION (MICROBIAL INFECTION), AND INTERACTION WITH HUMAN ROTAVIRUS
RP   VP4 PROTEIN.
RX   PubMed=12941907; DOI=10.1128/JVI.77.18.9969-9978.2003;
RA   Graham K.L., Halasz P., Tan Y., Hewish M.J., Takada Y., Mackow E.R.,
RA   Robinson M.K., Coulson B.S.;
RT   "Integrin-using rotaviruses bind alpha2beta1 integrin alpha2 I domain
RT   via VP4 DGE sequence and recognize alphaXbeta2 and alphaVbeta3 by
RT   using VP7 during cell entry.";
RL   J. Virol. 77:9969-9978(2003).
RN   [29]
RP   INTERACTION WITH RANBP9.
RX   PubMed=14722085; DOI=10.1074/jbc.M313515200;
RA   Denti S., Sirri A., Cheli A., Rogge L., Innamorati G., Putignano S.,
RA   Fabbri M., Pardi R., Bianchi E.;
RT   "RanBPM is a phosphoprotein that associates with the plasma membrane
RT   and interacts with the integrin LFA-1.";
RL   J. Biol. Chem. 279:13027-13034(2004).
RN   [30]
RP   INTERACTION WITH ITGA3; LGALS3 AND CSPG4.
RX   PubMed=15181153; DOI=10.1091/mbc.E04-03-0236;
RA   Fukushi J., Makagiansar I.T., Stallcup W.B.;
RT   "NG2 proteoglycan promotes endothelial cell motility and angiogenesis
RT   via engagement of galectin-3 and alpha3beta1 integrin.";
RL   Mol. Biol. Cell 15:3580-3590(2004).
RN   [31]
RP   INTERACTION WITH MYO10.
RX   PubMed=15156152; DOI=10.1038/ncb1136;
RA   Zhang H., Berg J.S., Li Z., Wang Y., Lang P., Sousa A.D., Bhaskar A.,
RA   Cheney R.E., Stromblad S.;
RT   "Myosin-X provides a motor-based link between integrins and the
RT   cytoskeleton.";
RL   Nat. Cell Biol. 6:523-531(2004).
RN   [32]
RP   FUNCTION, INTERACTION WITH ACAP1, AND SUBCELLULAR LOCATION.
RX   PubMed=16256741; DOI=10.1016/j.devcel.2005.09.012;
RA   Li J., Ballif B.A., Powelka A.M., Dai J., Gygi S.P., Hsu V.W.;
RT   "Phosphorylation of ACAP1 by Akt regulates the stimulation-dependent
RT   recycling of integrin beta1 to control cell migration.";
RL   Dev. Cell 9:663-673(2005).
RN   [33]
RP   INTERACTION WITH FLNB AND FLNC.
RX   PubMed=16076904; DOI=10.1242/jcs.02484;
RA   Gontier Y., Taivainen A., Fontao L., Sonnenberg A., van der Flier A.,
RA   Carpen O., Faulkner G., Borradori L.;
RT   "The Z-disc proteins myotilin and FATZ-1 interact with each other and
RT   are connected to the sarcolemma via muscle-specific filamins.";
RL   J. Cell Sci. 118:3739-3749(2005).
RN   [34]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-406.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [35]
RP   INTERACTION WITH RAB21.
RX   PubMed=16754960; DOI=10.1083/jcb.200509019;
RA   Pellinen T., Arjonen A., Vuoriluoto K., Kallio K., Fransen J.A.M.,
RA   Ivaska J.;
RT   "Small GTPase Rab21 regulates cell adhesion and controls endosomal
RT   traffic of beta1-integrins.";
RL   J. Cell Biol. 173:767-780(2006).
RN   [36]
RP   SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS].
RC   TISSUE=Melanoma;
RX   PubMed=17081065; DOI=10.1021/pr060363j;
RA   Chi A., Valencia J.C., Hu Z.-Z., Watabe H., Yamaguchi H.,
RA   Mangini N.J., Huang H., Canfield V.A., Cheng K.C., Yang F., Abe R.,
RA   Yamagishi S., Shabanowitz J., Hearing V.J., Wu C., Appella E.,
RA   Hunt D.F.;
RT   "Proteomic and bioinformatic characterization of the biogenesis and
RT   function of melanosomes.";
RL   J. Proteome Res. 5:3135-3144(2006).
RN   [37]
RP   FUNCTION (MICROBIAL INFECTION), AND INTERACTION WITH MAMMALIAN
RP   REOVIRUS CAPSID PROTEINS.
RX   PubMed=16501085; DOI=10.1128/JVI.80.6.2760-2770.2006;
RA   Maginnis M.S., Forrest J.C., Kopecky-Bromberg S.A., Dickeson S.K.,
RA   Santoro S.A., Zutter M.M., Nemerow G.R., Bergelson J.M., Dermody T.S.;
RT   "Beta1 integrin mediates internalization of mammalian reovirus.";
RL   J. Virol. 80:2760-2770(2006).
RN   [38]
RP   FUNCTION, INTERACTION WITH KRT1, AND SUBCELLULAR LOCATION.
RX   PubMed=17956333; DOI=10.1042/BST0351292;
RA   Chuang N.N., Huang C.C.;
RT   "Interaction of integrin beta1 with cytokeratin 1 in neuroblastoma
RT   NMB7 cells.";
RL   Biochem. Soc. Trans. 35:1292-1294(2007).
RN   [39]
RP   INTERACTION WITH RAB25.
RX   PubMed=17925226; DOI=10.1016/j.devcel.2007.08.012;
RA   Caswell P.T., Spence H.J., Parsons M., White D.P., Clark K.,
RA   Cheng K.W., Mills G.B., Humphries M.J., Messent A.J., Anderson K.I.,
RA   McCaffrey M.W., Ozanne B.W., Norman J.C.;
RT   "Rab25 associates with alpha5beta1 integrin to promote invasive
RT   migration in 3D microenvironments.";
RL   Dev. Cell 13:496-510(2007).
RN   [40]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=18804435; DOI=10.1016/j.devcel.2008.08.001;
RA   Pellinen T., Tuomi S., Arjonen A., Wolf M., Edgren H., Meyer H.,
RA   Grosse R., Kitzing T., Rantala J.K., Kallioniemi O., Faessler R.,
RA   Kallio M., Ivaska J.;
RT   "Integrin trafficking regulated by Rab21 is necessary for
RT   cytokinesis.";
RL   Dev. Cell 15:371-385(2008).
RN   [41]
RP   FUNCTION IN LEUKOCYTE TO ENDOTHELIAL CELLS ADHESION, AND INTERACTION
RP   WITH AMICA1.
RX   PubMed=19064666; DOI=10.1083/jcb.200805061;
RA   Luissint A.C., Lutz P.G., Calderwood D.A., Couraud P.O.,
RA   Bourdoulous S.;
RT   "JAM-L-mediated leukocyte adhesion to endothelial cells is regulated
RT   in cis by alpha4beta1 integrin activation.";
RL   J. Cell Biol. 183:1159-1173(2008).
RN   [42]
RP   FUNCTION (MICROBIAL INFECTION), AND INTERACTION WITH EPSTEIN-BARR
RP   VIRUS/HHV-4 GB PROTEIN.
RX   PubMed=17945327; DOI=10.1016/j.virol.2007.09.012;
RA   Xiao J., Palefsky J.M., Herrera R., Berline J., Tugizov S.M.;
RT   "The Epstein-Barr virus BMRF-2 protein facilitates virus attachment to
RT   oral epithelial cells.";
RL   Virology 370:430-442(2008).
RN   [43]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-212; ASN-481 AND ASN-669.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [44]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-403; ASN-406 AND ASN-411.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19349973; DOI=10.1038/nbt.1532;
RA   Wollscheid B., Bausch-Fluck D., Henderson C., O'Brien R., Bibel M.,
RA   Schiess R., Aebersold R., Watts J.D.;
RT   "Mass-spectrometric identification and relative quantification of N-
RT   linked cell surface glycoproteins.";
RL   Nat. Biotechnol. 27:378-386(2009).
RN   [45]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-777, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [46]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-794, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [47]
RP   FUNCTION (MICROBIAL INFECTION), AND INTERACTION WITH HHV-5 GB.
RX   PubMed=20660204; DOI=10.1128/JVI.00710-10;
RA   Feire A.L., Roy R.M., Manley K., Compton T.;
RT   "The glycoprotein B disintegrin-like domain binds beta 1 integrin to
RT   mediate cytomegalovirus entry.";
RL   J. Virol. 84:10026-10037(2010).
RN   [48]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [49]
RP   INTERACTION WITH ASAP3.
RX   PubMed=22027826; DOI=10.1074/jbc.M111.278770;
RA   Yu X., Wang F., Liu H., Adams G., Aikhionbare F., Liu D., Cao X.,
RA   Fan L., Hu G., Chen Y., Frost A., Partridge E., Ding X., Yao X.;
RT   "ACAP4 protein cooperates with Grb2 protein to orchestrate epidermal
RT   growth factor-stimulated integrin beta1 recycling in cell migration.";
RL   J. Biol. Chem. 286:43735-43747(2011).
RN   [50]
RP   FUNCTION, INTERACTION WITH FERMT2 AND TLN1, AND MUTAGENESIS OF
RP   VAL-787.
RX   PubMed=21768292; DOI=10.1083/jcb.201007108;
RA   Brunner M., Millon-Fremillon A., Chevalier G., Nakchbandi I.A.,
RA   Mosher D., Block M.R., Albiges-Rizo C., Bouvard D.;
RT   "Osteoblast mineralization requires beta1 integrin/ICAP-1-dependent
RT   fibronectin deposition.";
RL   J. Cell Biol. 194:307-322(2011).
RN   [51]
RP   INTERACTION WITH FERMT2.
RX   PubMed=21325030; DOI=10.1242/jcs.076976;
RA   Qu H., Tu Y., Shi X., Larjava H., Saleem M.A., Shattil S.J.,
RA   Fukuda K., Qin J., Kretzler M., Wu C.;
RT   "Kindlin-2 regulates podocyte adhesion and fibronectin matrix
RT   deposition through interactions with phosphoinositides and
RT   integrins.";
RL   J. Cell Sci. 124:879-891(2011).
RN   [52]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-785 AND THR-789, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [53]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [54]
RP   X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 758-769 IN COMPLEX WITH
RP   ACAP1, INTERACTION WITH ACAP1 AND ITGA5, SUBCELLULAR LOCATION, AND
RP   MUTAGENESIS OF 760-ARG-ARG-761; 762-GLU--PHE-767 AND 768-LYS-GLU-769.
RX   PubMed=22645133; DOI=10.1074/jbc.M112.378810;
RA   Bai M., Pang X., Lou J., Zhou Q., Zhang K., Ma J., Li J., Sun F.,
RA   Hsu V.W.;
RT   "Mechanistic insights into regulated cargo binding by ACAP1 protein.";
RL   J. Biol. Chem. 287:28675-28685(2012).
RN   [55]
RP   X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 21-465 IN COMPLEX WITH
RP   ANTIBODY; ITGA5 AND RGD PEPTIDE, DISULFIDE BONDS, GLYCOSYLATION AT
RP   ASN-269 AND ASN-406, METAL-BINDING SITES, AND SUBUNIT.
RX   PubMed=22451694; DOI=10.1083/jcb.201111077;
RA   Nagae M., Re S., Mihara E., Nogi T., Sugita Y., Takagi J.;
RT   "Crystal structure of alpha5beta1 integrin ectodomain: atomic details
RT   of the fibronectin receptor.";
RL   J. Cell Biol. 197:131-140(2012).
RN   [56]
RP   X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF 784-798 IN COMPLEX WITH
RP   ITGB1BP1, INTERACTION WITH ITGB1BP1, AND MUTAGENESIS OF THR-788;
RP   VAL-790; ASN-792 AND TYR-795.
RX   PubMed=23317506; DOI=10.1016/j.molcel.2012.12.005;
RA   Liu W., Draheim K.M., Zhang R., Calderwood D.A., Boggon T.J.;
RT   "Mechanism for KRIT1 release of ICAP1-mediated suppression of integrin
RT   activation.";
RL   Mol. Cell 49:719-729(2013).
CC   -!- FUNCTION: Integrins alpha-1/beta-1, alpha-2/beta-1, alpha-10/beta-
CC       1 and alpha-11/beta-1 are receptors for collagen. Integrins alpha-
CC       1/beta-1 and alpha-2/beta-2 recognize the proline-hydroxylated
CC       sequence G-F-P-G-E-R in collagen. Integrins alpha-2/beta-1, alpha-
CC       3/beta-1, alpha-4/beta-1, alpha-5/beta-1, alpha-8/beta-1, alpha-
CC       10/beta-1, alpha-11/beta-1 and alpha-V/beta-1 are receptors for
CC       fibronectin. Alpha-4/beta-1 recognizes one or more domains within
CC       the alternatively spliced CS-1 and CS-5 regions of fibronectin.
CC       Integrin alpha-5/beta-1 is a receptor for fibrinogen. Integrin
CC       alpha-1/beta-1, alpha-2/beta-1, alpha-6/beta-1 and alpha-7/beta-1
CC       are receptors for lamimin. Integrin alpha-4/beta-1 is a receptor
CC       for VCAM1. It recognizes the sequence Q-I-D-S in VCAM1. Integrin
CC       alpha-9/beta-1 is a receptor for VCAM1, cytotactin and
CC       osteopontin. It recognizes the sequence A-E-I-D-G-I-E-L in
CC       cytotactin. Integrin alpha-3/beta-1 is a receptor for epiligrin,
CC       thrombospondin and CSPG4. Alpha-3/beta-1 may mediate with LGALS3
CC       the stimulation by CSPG4 of endothelial cells migration. Integrin
CC       alpha-V/beta-1 is a receptor for vitronectin. Beta-1 integrins
CC       recognize the sequence R-G-D in a wide array of ligands. Isoform 2
CC       interferes with isoform 1 resulting in a dominant negative effect
CC       on cell adhesion and migration (in vitro). When associated with
CC       alpha-7/beta-1 integrin, regulates cell adhesion and laminin
CC       matrix deposition. Involved in promoting endothelial cell motility
CC       and angiogenesis. Involved in osteoblast compaction through the
CC       fibronectin fibrillogenesis cell-mediated matrix assembly process
CC       and the formation of mineralized bone nodules. May be involved in
CC       up-regulation of the activity of kinases such as PKC via binding
CC       to KRT1. Together with KRT1 and GNB2L1/RACK1, serves as a platform
CC       for SRC activation or inactivation. Plays a mechanistic adhesive
CC       role during telophase, required for the successful completion of
CC       cytokinesis. Integrin alpha-3/beta-1 provides a docking site for
CC       FAP (seprase) at invadopodia plasma membranes in a collagen-
CC       dependent manner and hence may participate in the adhesion,
CC       formation of invadopodia and matrix degradation processes,
CC       promoting cell invasion. {ECO:0000269|PubMed:10455171,
CC       ECO:0000269|PubMed:12473654, ECO:0000269|PubMed:16256741,
CC       ECO:0000269|PubMed:18804435, ECO:0000269|PubMed:19064666,
CC       ECO:0000269|PubMed:21768292, ECO:0000269|PubMed:7523423}.
CC   -!- FUNCTION: Isoform 5: Isoform 5 displaces isoform 1 in striated
CC       muscles. {ECO:0000250}.
CC   -!- FUNCTION: (Microbial infection) Integrin ITGA2:ITGB1 acts as a
CC       receptor for human echoviruses 1 and 8 (PubMed:8411387). Acts as a
CC       receptor for cytomegalovirus/HHV-5 (PubMed:20660204). Acts as a
CC       receptor for Epstein-Barr virus/HHV-4 (PubMed:17945327). Integrin
CC       ITGA5:ITGB1 acts as a receptor for human parvovirus B19
CC       (PubMed:12907437). Integrin ITGA2:ITGB1 acts as a receptor for
CC       human rotavirus (PubMed:12941907). Acts as a receptor for
CC       mammalian reovirus (PubMed:16501085). In case of HIV-1 infection,
CC       integrin ITGA5:ITGB1 binding to extracellular viral Tat protein
CC       seems to enhance angiogenesis in Kaposi's sarcoma lesions
CC       (PubMed:10397733). {ECO:0000269|PubMed:10397733,
CC       ECO:0000269|PubMed:12907437, ECO:0000269|PubMed:12941907,
CC       ECO:0000269|PubMed:16501085, ECO:0000269|PubMed:17945327,
CC       ECO:0000269|PubMed:20660204, ECO:0000269|PubMed:8411387}.
CC   -!- SUBUNIT: Heterodimer of an alpha and a beta subunit. Beta-1
CC       associates with either alpha-1, alpha-2, alpha-3, alpha-4, alpha-
CC       5, alpha-6, alpha-7, alpha-8, alpha-9, alpha-10, alpha-11 or
CC       alpha-V. Interacts with seprase FAP (seprase); the interaction
CC       occurs at the cell surface of invadopodia membrane in a collagen-
CC       dependent manner. Binds LGALS3BP and NMRK2, when associated with
CC       alpha-7, but not with alpha-5. Interacts with FGR and HCK.
CC       Interacts (via the cytoplasmic region) with RAB25 (via the
CC       hypervariable C-terminal region). Interacts with RAB21. Interacts
CC       with KRT1 in the presence of GNB2L1 and SRC. Interacts with
CC       AMICA1; integrin alpha-4/beta-1 may regulate leukocyte to
CC       endothelial cells adhesion by controlling AMICA1 homodimerization.
CC       Interacts with FLNA, FLNB and RANBP9. Isoform 5 interacts with
CC       ACE2. Isoform 1 interacts with the C-terminal region of FLNC.
CC       Interacts with MYO10. Interacts with DAB2. Interacts with FERMT2;
CC       the interaction is inhibited in presence of ITGB1BP1. Interacts
CC       with ITGB1BP1 (via C-terminal region); the interaction is a
CC       prerequisite for focal adhesion disassembly. Interacts with TLN1;
CC       the interaction is prevented by competitive binding of ITGB1BP1.
CC       Interacts with ACAP1; required for ITGB1 recycling. Interacts with
CC       ASAP3. Isoform 5 interacts with alpha-7A and alpha-7B in adult
CC       skeletal muscle. Isoform 5 interacts with alpha-7B in
CC       cardiomyocytes of adult heart. Interacts with EMP2; the
CC       interaction may be direct or indirect and ITGB1 has an heterodimer
CC       form (By similarity). ITGA5:ITGB1 interacts with NOV
CC       (PubMed:12695522). (Microbial infection) Integrin ITGA2:ITGB1
CC       interacts with human echoviruses 1 and 8 capsid proteins
CC       (PubMed:8411387). (Microbial infection) Interacts with human
CC       cytomegalovirus/HHV-5 envelope glycoprotein B/gB
CC       (PubMed:20660204). (Microbial infection) Interacts with Epstein-
CC       Barr virus/HHV-4 gB protein (PubMed:17945327). (Microbial
CC       infection) Integrin ITGA5:ITGB1 interacts with human parvovirus
CC       B19 capsid protein (PubMed:12907437). (Microbial infection)
CC       Integrin ITGA2:ITGB1 interacts with human rotavirus VP4 protein
CC       (PubMed:12941907). (Microbial infection) Interacts with mammalian
CC       reovirus capsid proteins (PubMed:16501085). (Microbial infection)
CC       Integrin ITGA5:ITGB1 interacts with HIV-1 Tat (PubMed:10397733).
CC       {ECO:0000250|UniProtKB:P09055, ECO:0000269|PubMed:10397733,
CC       ECO:0000269|PubMed:10455171, ECO:0000269|PubMed:10613898,
CC       ECO:0000269|PubMed:11741838, ECO:0000269|PubMed:11807098,
CC       ECO:0000269|PubMed:11807099, ECO:0000269|PubMed:12473654,
CC       ECO:0000269|PubMed:12695522, ECO:0000269|PubMed:12907437,
CC       ECO:0000269|PubMed:12941907, ECO:0000269|PubMed:14722085,
CC       ECO:0000269|PubMed:15156152, ECO:0000269|PubMed:15181153,
CC       ECO:0000269|PubMed:15276642, ECO:0000269|PubMed:16076904,
CC       ECO:0000269|PubMed:16256741, ECO:0000269|PubMed:16501085,
CC       ECO:0000269|PubMed:16754960, ECO:0000269|PubMed:17925226,
CC       ECO:0000269|PubMed:17945327, ECO:0000269|PubMed:19064666,
CC       ECO:0000269|PubMed:20660204, ECO:0000269|PubMed:21325030,
CC       ECO:0000269|PubMed:21768292, ECO:0000269|PubMed:22027826,
CC       ECO:0000269|PubMed:22451694, ECO:0000269|PubMed:22645133,
CC       ECO:0000269|PubMed:23317506, ECO:0000269|PubMed:8411387,
CC       ECO:0000269|PubMed:9501082}.
CC   -!- INTERACTION:
CC       Q9BY76:ANGPTL4; NbExp=2; IntAct=EBI-703066, EBI-2968146;
CC       P03192:BMRF2 (xeno); NbExp=2; IntAct=EBI-703066, EBI-9348955;
CC       P32927:CSF2RB; NbExp=5; IntAct=EBI-703066, EBI-1809771;
CC       P17813:ENG; NbExp=3; IntAct=EBI-703066, EBI-2834630;
CC       P05413:FABP3; NbExp=2; IntAct=EBI-703066, EBI-704216;
CC       P21333:FLNA; NbExp=5; IntAct=EBI-703066, EBI-350432;
CC       P17301:ITGA2; NbExp=3; IntAct=EBI-703066, EBI-702960;
CC       P13612:ITGA4; NbExp=3; IntAct=EBI-703066, EBI-703044;
CC       P07948:LYN; NbExp=4; IntAct=EBI-703066, EBI-79452;
CC       P18031:PTPN1; NbExp=2; IntAct=EBI-703066, EBI-968788;
CC       P49023:PXN; NbExp=2; IntAct=EBI-6082935, EBI-702209;
CC       P35282:Rab21 (xeno); NbExp=3; IntAct=EBI-703066, EBI-1993555;
CC       Q9Y490:TLN1; NbExp=2; IntAct=EBI-703066, EBI-2462036;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000303|PubMed:10455171};
CC       Single-pass type I membrane protein {ECO:0000255}. Cell
CC       projection, invadopodium membrane {ECO:0000269|PubMed:10455171};
CC       Single-pass type I membrane protein {ECO:0000255}. Cell
CC       projection, ruffle membrane {ECO:0000303|PubMed:10455171}; Single-
CC       pass type I membrane protein {ECO:0000255}. Recycling endosome.
CC       Melanosome. Cleavage furrow. Cell projection, lamellipodium. Cell
CC       projection, ruffle. Note=Isoform 2 does not localize to focal
CC       adhesions. Highly enriched in stage I melanosomes. Located on
CC       plasma membrane of neuroblastoma NMB7 cells. In a lung cancer cell
CC       line, in prometaphase and metaphase, localizes diffusely at the
CC       membrane and in a few intracellular vesicles. In early telophase,
CC       detected mainly on the matrix-facing side of the cells. By mid-
CC       telophase, concentrated to the ingressing cleavage furrow, mainly
CC       to the basal side of the furrow. In late telophase, concentrated
CC       to the extending protrusions formed at the opposite ends of the
CC       spreading daughter cells, in vesicles at the base of the
CC       lamellipodia formed by the separating daughter cells. Colocalizes
CC       with ITGB1BP1 and metastatic suppressor protein NME2 at the edge
CC       or peripheral ruffles and lamellipodia during the early stages of
CC       cell spreading on fibronectin or collagen. Translocates from
CC       peripheral focal adhesions sites to fibrillar adhesions in a
CC       ITGB1BP1-dependent manner. Enriched preferentially at invadopodia,
CC       cell membrane protrusions that correspond to sites of cell
CC       invasion, in a collagen-dependent manner. Localized at plasma and
CC       ruffle membranes in a collagen-independent manner.
CC       {ECO:0000269|PubMed:10455171, ECO:0000303|PubMed:10455171}.
CC   -!- SUBCELLULAR LOCATION: Isoform 5: Cell membrane, sarcolemma
CC       {ECO:0000250}. Cell junction {ECO:0000250}. Note=In cardiac
CC       muscle, isoform 5 is found in costameres and intercalated disks.
CC       {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=1; Synonyms=Beta-1A;
CC         IsoId=P05556-1; Sequence=Displayed;
CC       Name=2; Synonyms=Beta-1B;
CC         IsoId=P05556-2; Sequence=VSP_002741;
CC       Name=3; Synonyms=Beta-1C;
CC         IsoId=P05556-3; Sequence=VSP_002742;
CC       Name=4; Synonyms=Beta-1C-2;
CC         IsoId=P05556-4; Sequence=VSP_002743;
CC       Name=5; Synonyms=Beta-1D;
CC         IsoId=P05556-5; Sequence=VSP_002744;
CC   -!- TISSUE SPECIFICITY: Isoform 1 is widely expressed, other isoforms
CC       are generally coexpressed with a more restricted distribution.
CC       Isoform 2 is expressed in skin, liver, skeletal muscle, cardiac
CC       muscle, placenta, umbilical vein endothelial cells, neuroblastoma
CC       cells, lymphoma cells, hepatoma cells and astrocytoma cells.
CC       Isoform 3 and isoform 4 are expressed in muscle, kidney, liver,
CC       placenta, cervical epithelium, umbilical vein endothelial cells,
CC       fibroblast cells, embryonal kidney cells, platelets and several
CC       blood cell lines. Isoform 4, rather than isoform 3, is selectively
CC       expressed in peripheral T-cells. Isoform 3 is expressed in non-
CC       proliferating and differentiated prostate gland epithelial cells
CC       and in platelets, on the surface of erythroleukemia cells and in
CC       various hematopoietic cell lines. Isoform 5 is expressed
CC       specifically in striated muscle (skeletal and cardiac muscle).
CC       {ECO:0000269|PubMed:1551917, ECO:0000269|PubMed:2249781,
CC       ECO:0000269|PubMed:7544298, ECO:0000269|PubMed:7545396,
CC       ECO:0000269|PubMed:7681433, ECO:0000269|PubMed:9494094}.
CC   -!- PTM: The cysteine residues are involved in intrachain disulfide
CC       bonds. {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the integrin beta chain family.
CC       {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 VWFA domain. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAD97649.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=CD29 entry;
CC       URL="https://en.wikipedia.org/wiki/CD29";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X07979; CAA30790.1; -; mRNA.
DR   EMBL; AK291697; BAF84386.1; -; mRNA.
DR   EMBL; BX537407; CAD97649.1; ALT_INIT; mRNA.
DR   EMBL; AL365203; CAI14426.1; -; Genomic_DNA.
DR   EMBL; CH471072; EAW85948.1; -; Genomic_DNA.
DR   EMBL; CH471072; EAW85949.1; -; Genomic_DNA.
DR   EMBL; CH471072; EAW85950.1; -; Genomic_DNA.
DR   EMBL; CH471072; EAW85951.1; -; Genomic_DNA.
DR   EMBL; CH471072; EAW85952.1; -; Genomic_DNA.
DR   EMBL; CH471072; EAW85953.1; -; Genomic_DNA.
DR   EMBL; CH471072; EAW85954.1; -; Genomic_DNA.
DR   EMBL; CH471072; EAW85955.1; -; Genomic_DNA.
DR   EMBL; CH471072; EAW85957.1; -; Genomic_DNA.
DR   EMBL; CH471072; EAW85958.1; -; Genomic_DNA.
DR   EMBL; CH471072; EAW85959.1; -; Genomic_DNA.
DR   EMBL; BC020057; AAH20057.1; -; mRNA.
DR   EMBL; BC113901; AAI13902.1; -; mRNA.
DR   EMBL; U33879; AAA79832.1; -; Genomic_DNA.
DR   EMBL; U33880; AAA79833.1; -; Genomic_DNA.
DR   EMBL; U33879; AAA79833.1; JOINED; Genomic_DNA.
DR   EMBL; U33882; AAA79834.1; -; Genomic_DNA.
DR   EMBL; U33879; AAA79834.1; JOINED; Genomic_DNA.
DR   EMBL; U33881; AAA79834.1; JOINED; Genomic_DNA.
DR   EMBL; U33882; AAA79835.1; -; Genomic_DNA.
DR   EMBL; U33879; AAA79835.1; JOINED; Genomic_DNA.
DR   EMBL; M34189; AAA59182.1; -; mRNA.
DR   EMBL; M84237; AAA74402.1; -; mRNA.
DR   EMBL; M84237; AAA74403.1; -; mRNA.
DR   EMBL; U28252; AAA81366.1; -; mRNA.
DR   CCDS; CCDS7174.1; -. [P05556-1]
DR   PIR; B27079; B27079.
DR   RefSeq; NP_002202.2; NM_002211.3. [P05556-1]
DR   RefSeq; NP_391988.1; NM_033668.2. [P05556-5]
DR   RefSeq; NP_596867.1; NM_133376.2. [P05556-1]
DR   RefSeq; XP_005252505.1; XM_005252448.1. [P05556-5]
DR   UniGene; Hs.643813; -.
DR   PDB; 1K11; Model; -; B=786-797.
DR   PDB; 1LHA; Model; -; A=86-543.
DR   PDB; 3G9W; X-ray; 2.16 A; C/D=752-785.
DR   PDB; 3T9K; X-ray; 2.30 A; A/B=758-769.
DR   PDB; 3VI3; X-ray; 2.90 A; B/D=21-465.
DR   PDB; 3VI4; X-ray; 2.90 A; B/D=21-465.
DR   PDB; 4DX9; X-ray; 3.00 A; 6/7/8/9/B/D/F/H/J/L/N/P/R/T/V/X/Z/b/d/f/h/j/l/n/p/r/t/v/x/z=784-798.
DR   PDB; 4WJK; X-ray; 1.85 A; B=21-465.
DR   PDB; 4WK0; X-ray; 1.78 A; B=21-465.
DR   PDB; 4WK2; X-ray; 2.50 A; B=21-465.
DR   PDB; 4WK4; X-ray; 2.50 A; B=21-465.
DR   PDBsum; 1K11; -.
DR   PDBsum; 1LHA; -.
DR   PDBsum; 3G9W; -.
DR   PDBsum; 3T9K; -.
DR   PDBsum; 3VI3; -.
DR   PDBsum; 3VI4; -.
DR   PDBsum; 4DX9; -.
DR   PDBsum; 4WJK; -.
DR   PDBsum; 4WK0; -.
DR   PDBsum; 4WK2; -.
DR   PDBsum; 4WK4; -.
DR   ProteinModelPortal; P05556; -.
DR   SMR; P05556; 24-787.
DR   BioGrid; 109894; 79.
DR   DIP; DIP-312N; -.
DR   IntAct; P05556; 46.
DR   MINT; MINT-140089; -.
DR   STRING; 9606.ENSP00000303351; -.
DR   BindingDB; P05556; -.
DR   ChEMBL; CHEMBL2111407; -.
DR   DrugBank; DB00098; Anti-thymocyte Globulin (Rabbit).
DR   TCDB; 9.B.87.1.8; the selenoprotein p receptor (selp-receptor) family.
DR   iPTMnet; P05556; -.
DR   PhosphoSite; P05556; -.
DR   SwissPalm; P05556; -.
DR   UniCarbKB; P05556; -.
DR   BioMuta; ITGB1; -.
DR   DMDM; 218563324; -.
DR   MaxQB; P05556; -.
DR   PaxDb; P05556; -.
DR   PRIDE; P05556; -.
DR   DNASU; 3688; -.
DR   Ensembl; ENST00000302278; ENSP00000303351; ENSG00000150093. [P05556-1]
DR   Ensembl; ENST00000396033; ENSP00000379350; ENSG00000150093. [P05556-1]
DR   Ensembl; ENST00000423113; ENSP00000388694; ENSG00000150093. [P05556-5]
DR   GeneID; 3688; -.
DR   KEGG; hsa:3688; -.
DR   UCSC; uc001iwr.4; human. [P05556-5]
DR   UCSC; uc001iws.4; human. [P05556-1]
DR   CTD; 3688; -.
DR   GeneCards; ITGB1; -.
DR   HGNC; HGNC:6153; ITGB1.
DR   HPA; CAB003434; -.
DR   MIM; 135630; gene.
DR   neXtProt; NX_P05556; -.
DR   PharmGKB; PA29953; -.
DR   eggNOG; KOG1226; Eukaryota.
DR   eggNOG; ENOG410XP60; LUCA.
DR   GeneTree; ENSGT00760000119064; -.
DR   HOVERGEN; HBG006190; -.
DR   InParanoid; P05556; -.
DR   KO; K05719; -.
DR   OMA; ADENRCL; -.
DR   OrthoDB; EOG7T7GSB; -.
DR   PhylomeDB; P05556; -.
DR   TreeFam; TF105392; -.
DR   Reactome; R-HSA-1566948; Elastic fibre formation.
DR   Reactome; R-HSA-1566977; Fibronectin matrix formation.
DR   Reactome; R-HSA-198933; Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell.
DR   Reactome; R-HSA-202733; Cell surface interactions at the vascular wall.
DR   Reactome; R-HSA-210991; Basigin interactions.
DR   Reactome; R-HSA-2129379; Molecules associated with elastic fibres.
DR   Reactome; R-HSA-216083; Integrin cell surface interactions.
DR   Reactome; R-HSA-3000157; Laminin interactions.
DR   Reactome; R-HSA-3000170; Syndecan interactions.
DR   Reactome; R-HSA-3000178; ECM proteoglycans.
DR   Reactome; R-HSA-416700; Other semaphorin interactions.
DR   Reactome; R-HSA-445144; Signal transduction by L1.
DR   Reactome; R-HSA-446343; Localization of the PINCH-ILK-PARVIN complex to focal adhesions.
DR   Reactome; R-HSA-447041; CHL1 interactions.
DR   Reactome; R-HSA-5663220; RHO GTPases Activate Formins.
DR   Reactome; R-HSA-75892; Platelet Adhesion to exposed collagen.
DR   SABIO-RK; P05556; -.
DR   SignaLink; P05556; -.
DR   ChiTaRS; ITGB1; human.
DR   EvolutionaryTrace; P05556; -.
DR   GeneWiki; CD29; -.
DR   GenomeRNAi; 3688; -.
DR   NextBio; 14435; -.
DR   PMAP-CutDB; Q8WUM6; -.
DR   PRO; PR:P05556; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   Bgee; P05556; -.
DR   ExpressionAtlas; P05556; baseline and differential.
DR   Genevisible; P05556; HS.
DR   GO; GO:0001669; C:acrosomal vesicle; IEA:Ensembl.
DR   GO; GO:0005604; C:basement membrane; IEA:Ensembl.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0032154; C:cleavage furrow; IEA:UniProtKB-SubCell.
DR   GO; GO:0005737; C:cytoplasm; IDA:BHF-UCL.
DR   GO; GO:0043197; C:dendritic spine; IEA:Ensembl.
DR   GO; GO:0009897; C:external side of plasma membrane; IEA:Ensembl.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0030175; C:filopodium; IDA:BHF-UCL.
DR   GO; GO:0005925; C:focal adhesion; IDA:UniProtKB.
DR   GO; GO:0030056; C:hemidesmosome; IEA:Ensembl.
DR   GO; GO:0034665; C:integrin alpha1-beta1 complex; IDA:UniProtKB.
DR   GO; GO:0034680; C:integrin alpha10-beta1 complex; IDA:UniProtKB.
DR   GO; GO:0034681; C:integrin alpha11-beta1 complex; IDA:UniProtKB.
DR   GO; GO:0034666; C:integrin alpha2-beta1 complex; IDA:UniProtKB.
DR   GO; GO:0034667; C:integrin alpha3-beta1 complex; IDA:UniProtKB.
DR   GO; GO:0034677; C:integrin alpha7-beta1 complex; IEA:Ensembl.
DR   GO; GO:0034678; C:integrin alpha8-beta1 complex; TAS:BHF-UCL.
DR   GO; GO:0034679; C:integrin alpha9-beta1 complex; IEA:Ensembl.
DR   GO; GO:0008305; C:integrin complex; NAS:UniProtKB.
DR   GO; GO:0014704; C:intercalated disc; IEA:Ensembl.
DR   GO; GO:0071438; C:invadopodium membrane; IDA:UniProtKB.
DR   GO; GO:0030027; C:lamellipodium; IEA:UniProtKB-SubCell.
DR   GO; GO:0042470; C:melanosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0045121; C:membrane raft; IDA:BHF-UCL.
DR   GO; GO:0035748; C:myelin sheath abaxonal region; IEA:Ensembl.
DR   GO; GO:0031594; C:neuromuscular junction; IDA:MGI.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0043235; C:receptor complex; IDA:MGI.
DR   GO; GO:0055037; C:recycling endosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0001726; C:ruffle; TAS:HGNC.
DR   GO; GO:0032587; C:ruffle membrane; NAS:UniProtKB.
DR   GO; GO:0042383; C:sarcolemma; IDA:MGI.
DR   GO; GO:0097060; C:synaptic membrane; IEA:Ensembl.
DR   GO; GO:0003779; F:actin binding; IDA:BHF-UCL.
DR   GO; GO:0050839; F:cell adhesion molecule binding; IPI:UniProtKB.
DR   GO; GO:0098639; F:collagen binding involved in cell-matrix adhesion; IMP:UniProtKB.
DR   GO; GO:0001968; F:fibronectin binding; IPI:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0042277; F:peptide binding; IEA:Ensembl.
DR   GO; GO:0002020; F:protease binding; IPI:UniProtKB.
DR   GO; GO:0032403; F:protein complex binding; IPI:UniProtKB.
DR   GO; GO:0046982; F:protein heterodimerization activity; IDA:UniProtKB.
DR   GO; GO:0001618; F:virus receptor activity; IEA:UniProtKB-KW.
DR   GO; GO:0048675; P:axon extension; IEA:Ensembl.
DR   GO; GO:0007411; P:axon guidance; TAS:Reactome.
DR   GO; GO:0030183; P:B cell differentiation; IC:BHF-UCL.
DR   GO; GO:0070830; P:bicellular tight junction assembly; IEA:Ensembl.
DR   GO; GO:0007596; P:blood coagulation; TAS:Reactome.
DR   GO; GO:0007161; P:calcium-independent cell-matrix adhesion; IGI:MGI.
DR   GO; GO:0055007; P:cardiac muscle cell differentiation; IEA:Ensembl.
DR   GO; GO:0001708; P:cell fate specification; IEA:Ensembl.
DR   GO; GO:0034329; P:cell junction assembly; TAS:Reactome.
DR   GO; GO:0016477; P:cell migration; TAS:HGNC.
DR   GO; GO:0002042; P:cell migration involved in sprouting angiogenesis; IEA:Ensembl.
DR   GO; GO:0033631; P:cell-cell adhesion mediated by integrin; IEP:BHF-UCL.
DR   GO; GO:0007160; P:cell-matrix adhesion; IMP:UniProtKB.
DR   GO; GO:0031589; P:cell-substrate adhesion; IMP:UniProtKB.
DR   GO; GO:0006874; P:cellular calcium ion homeostasis; IEA:Ensembl.
DR   GO; GO:0006968; P:cellular defense response; TAS:ProtInc.
DR   GO; GO:0071479; P:cellular response to ionizing radiation; IEA:Ensembl.
DR   GO; GO:0071404; P:cellular response to low-density lipoprotein particle stimulus; ISS:UniProtKB.
DR   GO; GO:0071260; P:cellular response to mechanical stimulus; IEA:Ensembl.
DR   GO; GO:0071305; P:cellular response to vitamin D; IEA:Ensembl.
DR   GO; GO:0048813; P:dendrite morphogenesis; IEA:Ensembl.
DR   GO; GO:0030198; P:extracellular matrix organization; TAS:Reactome.
DR   GO; GO:0021943; P:formation of radial glial scaffolds; IEA:Ensembl.
DR   GO; GO:0000082; P:G1/S transition of mitotic cell cycle; IEA:Ensembl.
DR   GO; GO:0008354; P:germ cell migration; IEA:Ensembl.
DR   GO; GO:0034113; P:heterotypic cell-cell adhesion; IMP:UniProtKB.
DR   GO; GO:0007156; P:homophilic cell adhesion via plasma membrane adhesion molecules; TAS:ProtInc.
DR   GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl.
DR   GO; GO:0007229; P:integrin-mediated signaling pathway; IMP:UniProtKB.
DR   GO; GO:0007159; P:leukocyte cell-cell adhesion; IDA:BHF-UCL.
DR   GO; GO:0050900; P:leukocyte migration; TAS:Reactome.
DR   GO; GO:0050901; P:leukocyte tethering or rolling; IMP:UniProtKB.
DR   GO; GO:0060135; P:maternal process involved in female pregnancy; IEA:Ensembl.
DR   GO; GO:0048333; P:mesodermal cell differentiation; IEP:UniProtKB.
DR   GO; GO:2000811; P:negative regulation of anoikis; IMP:UniProtKB.
DR   GO; GO:0031345; P:negative regulation of cell projection organization; IEA:Ensembl.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IEA:Ensembl.
DR   GO; GO:0045665; P:negative regulation of neuron differentiation; IEA:Ensembl.
DR   GO; GO:0035024; P:negative regulation of Rho protein signal transduction; IEA:Ensembl.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IGI:MGI.
DR   GO; GO:0030335; P:positive regulation of cell migration; IEA:Ensembl.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IEA:Ensembl.
DR   GO; GO:0010811; P:positive regulation of cell-substrate adhesion; IEA:Ensembl.
DR   GO; GO:0045807; P:positive regulation of endocytosis; IEA:Ensembl.
DR   GO; GO:0090004; P:positive regulation of establishment of protein localization to plasma membrane; IDA:UniProtKB.
DR   GO; GO:0043547; P:positive regulation of GTPase activity; IMP:UniProtKB.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IEA:Ensembl.
DR   GO; GO:0010976; P:positive regulation of neuron projection development; IEA:Ensembl.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; IEA:Ensembl.
DR   GO; GO:0032594; P:protein transport within lipid bilayer; IEA:Ensembl.
DR   GO; GO:0031623; P:receptor internalization; ISS:UniProtKB.
DR   GO; GO:0051726; P:regulation of cell cycle; IEA:Ensembl.
DR   GO; GO:0010710; P:regulation of collagen catabolic process; IDA:UniProtKB.
DR   GO; GO:0008277; P:regulation of G-protein coupled receptor protein signaling pathway; IEA:Ensembl.
DR   GO; GO:0050776; P:regulation of immune response; TAS:Reactome.
DR   GO; GO:0014823; P:response to activity; IEA:Ensembl.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0034698; P:response to gonadotropin; IEA:Ensembl.
DR   GO; GO:0071559; P:response to transforming growth factor beta; IEA:Ensembl.
DR   GO; GO:0045214; P:sarcomere organization; IEA:Ensembl.
DR   GO; GO:0007264; P:small GTPase mediated signal transduction; TAS:Reactome.
DR   GO; GO:0001894; P:tissue homeostasis; IEA:Ensembl.
DR   GO; GO:0008542; P:visual learning; IEA:Ensembl.
DR   Gene3D; 1.20.5.630; -; 1.
DR   Gene3D; 3.40.50.410; -; 1.
DR   InterPro; IPR013111; EGF_extracell.
DR   InterPro; IPR027071; Integrin_beta-1.
DR   InterPro; IPR015812; Integrin_bsu.
DR   InterPro; IPR014836; Integrin_bsu_cyt_dom.
DR   InterPro; IPR002369; Integrin_bsu_N.
DR   InterPro; IPR012896; Integrin_bsu_tail.
DR   InterPro; IPR032695; Integrin_dom.
DR   InterPro; IPR016201; Plexin-like_fold.
DR   InterPro; IPR002035; VWF_A.
DR   PANTHER; PTHR10082; PTHR10082; 1.
DR   PANTHER; PTHR10082:SF28; PTHR10082:SF28; 1.
DR   Pfam; PF07974; EGF_2; 1.
DR   Pfam; PF08725; Integrin_b_cyt; 1.
DR   Pfam; PF07965; Integrin_B_tail; 1.
DR   Pfam; PF00362; Integrin_beta; 1.
DR   PIRSF; PIRSF002512; Integrin_B; 1.
DR   PRINTS; PR01186; INTEGRINB.
DR   SMART; SM00187; INB; 1.
DR   SMART; SM00423; PSI; 1.
DR   SMART; SM00327; VWA; 1.
DR   SUPFAM; SSF103575; SSF103575; 1.
DR   SUPFAM; SSF53300; SSF53300; 1.
DR   SUPFAM; SSF69179; SSF69179; 1.
DR   SUPFAM; SSF69687; SSF69687; 1.
DR   PROSITE; PS00022; EGF_1; 2.
DR   PROSITE; PS00243; INTEGRIN_BETA; 3.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Calcium;
KW   Cell adhesion; Cell junction; Cell membrane; Cell projection;
KW   Complete proteome; Direct protein sequencing; Disulfide bond;
KW   Endosome; Glycoprotein; Host cell receptor for virus entry;
KW   Host-virus interaction; Integrin; Magnesium; Membrane; Metal-binding;
KW   Phosphoprotein; Receptor; Reference proteome; Repeat; Signal;
KW   Transmembrane; Transmembrane helix.
FT   SIGNAL        1     20
FT   CHAIN        21    798       Integrin beta-1.
FT                                /FTId=PRO_0000016334.
FT   TOPO_DOM     21    728       Extracellular. {ECO:0000255}.
FT   TRANSMEM    729    751       Helical. {ECO:0000255}.
FT   TOPO_DOM    752    798       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      140    378       VWFA.
FT   REPEAT      466    515       I.
FT   REPEAT      516    559       II.
FT   REPEAT      560    598       III.
FT   REPEAT      599    635       IV.
FT   REGION      466    635       Cysteine-rich tandem repeats.
FT   REGION      762    767       Signal for sorting from recycling
FT                                endosomes; interaction with ACAP1.
FT   REGION      785    792       Interaction with ITGB1BP1.
FT   METAL       152    152       Magnesium.
FT   METAL       154    154       Calcium 1; via carbonyl oxygen.
FT   METAL       156    156       Calcium 1.
FT   METAL       157    157       Calcium 1.
FT   METAL       189    189       Calcium 2.
FT   METAL       244    244       Calcium 2.
FT   METAL       246    246       Calcium 2.
FT   METAL       248    248       Calcium 2; via carbonyl oxygen.
FT   METAL       249    249       Calcium 2.
FT   METAL       249    249       Magnesium.
FT   METAL       362    362       Calcium 1; via carbonyl oxygen.
FT   MOD_RES     777    777       Phosphothreonine.
FT                                {ECO:0000244|PubMed:19690332}.
FT   MOD_RES     783    783       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:P09055}.
FT   MOD_RES     785    785       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     789    789       Phosphothreonine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     794    794       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   CARBOHYD     50     50       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD     94     94       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD     97     97       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    212    212       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19159218}.
FT   CARBOHYD    269    269       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:22451694}.
FT   CARBOHYD    363    363       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    403    403       N-linked (GlcNAc...); atypical.
FT                                {ECO:0000269|PubMed:19349973}.
FT   CARBOHYD    406    406       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:19349973,
FT                                ECO:0000269|PubMed:22451694}.
FT   CARBOHYD    411    411       N-linked (GlcNAc...); atypical.
FT                                {ECO:0000269|PubMed:19349973}.
FT   CARBOHYD    417    417       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    481    481       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19159218}.
FT   CARBOHYD    520    520       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    584    584       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    669    669       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19159218}.
FT   DISULFID     27     45       {ECO:0000269|PubMed:22451694}.
FT   DISULFID     35    464       {ECO:0000269|PubMed:22451694}.
FT   DISULFID     38     64       {ECO:0000269|PubMed:22451694}.
FT   DISULFID     48     75       {ECO:0000269|PubMed:22451694}.
FT   DISULFID    207    213       {ECO:0000269|PubMed:22451694}.
FT   DISULFID    261    301       {ECO:0000269|PubMed:22451694}.
FT   DISULFID    401    415       {ECO:0000269|PubMed:22451694}.
FT   DISULFID    435    462       {ECO:0000269|PubMed:22451694}.
FT   DISULFID    466    691       {ECO:0000305|PubMed:22451694}.
FT   DISULFID    477    489       {ECO:0000250}.
FT   DISULFID    486    525       {ECO:0000250}.
FT   DISULFID    491    500       {ECO:0000250}.
FT   DISULFID    502    516       {ECO:0000250}.
FT   DISULFID    531    536       {ECO:0000250}.
FT   DISULFID    533    568       {ECO:0000250}.
FT   DISULFID    538    553       {ECO:0000250}.
FT   DISULFID    555    560       {ECO:0000250}.
FT   DISULFID    574    579       {ECO:0000250}.
FT   DISULFID    576    607       {ECO:0000250}.
FT   DISULFID    581    590       {ECO:0000250}.
FT   DISULFID    592    599       {ECO:0000250}.
FT   DISULFID    613    618       {ECO:0000250}.
FT   DISULFID    615    661       {ECO:0000250}.
FT   DISULFID    620    630       {ECO:0000250}.
FT   DISULFID    633    636       {ECO:0000250}.
FT   DISULFID    640    649       {ECO:0000250}.
FT   DISULFID    646    723       {ECO:0000250}.
FT   DISULFID    665    699       {ECO:0000250}.
FT   VAR_SEQ     778    798       GENPIYKSAVTTVVNPKYEGK -> VSYKTSKKQSGL (in
FT                                isoform 2). {ECO:0000305}.
FT                                /FTId=VSP_002741.
FT   VAR_SEQ     778    798       GENPIYKSAVTTVVNPKYEGK -> SLSVAQPGVQWCDISS
FT                                LQPLTSRFQQFSCLSLPSTWDYRVKILFIRVP (in
FT                                isoform 3). {ECO:0000305}.
FT                                /FTId=VSP_002742.
FT   VAR_SEQ     778    798       GENPIYKSAVTTVVNPKYEGK -> PGVQWCDISSLQPLTS
FT                                RFQQFSCLSLPSTWDYRVKILFIRVP (in isoform
FT                                4). {ECO:0000305}.
FT                                /FTId=VSP_002743.
FT   VAR_SEQ     778    798       GENPIYKSAVTTVVNPKYEGK -> QENPIYKSPINNFKNP
FT                                NYGRKAGL (in isoform 5). {ECO:0000305}.
FT                                /FTId=VSP_002744.
FT   MUTAGEN     760    761       RR->AA: No effect on interaction with
FT                                ACAP1. {ECO:0000269|PubMed:22645133}.
FT   MUTAGEN     762    767       EFAKFE->AAAAAA: Strongly reduces
FT                                interaction with ACAP1 and ability to
FT                                recycle; does not affect
FT                                heterodimerization with ITGA5.
FT                                {ECO:0000269|PubMed:22645133}.
FT   MUTAGEN     762    763       EF->AA: Slightly reduces interaction with
FT                                ACAP1.
FT   MUTAGEN     765    765       K->A: Reduces interaction with ACAP1.
FT   MUTAGEN     766    767       FE->AA: Slightly reduces interaction with
FT                                ACAP1.
FT   MUTAGEN     768    769       KE->AA: No effect on interaction with
FT                                ACAP1. {ECO:0000269|PubMed:22645133}.
FT   MUTAGEN     778    778       G->Q: Loss of beta-1A interaction with
FT                                FLNA and FLNB.
FT                                {ECO:0000269|PubMed:11807098}.
FT   MUTAGEN     786    791       AVTTVV->PINNFK: Does not interact with
FT                                ITGB1BP1. {ECO:0000269|PubMed:11807099}.
FT   MUTAGEN     786    786       A->P: Loss of beta-1A interaction with
FT                                FLNA and FLNB.
FT                                {ECO:0000269|PubMed:11807098}.
FT   MUTAGEN     787    787       V->T: Reduces interaction with ITGB1BP1,
FT                                but not with FERMT2 or TLN1. Inhibits
FT                                fibronectin deposition and mineralized
FT                                bone nodules formation.
FT                                {ECO:0000269|PubMed:21768292}.
FT   MUTAGEN     788    788       T->D: Strongly reduces ITGB1BP1 binding;
FT                                when associated with D-790.
FT                                {ECO:0000269|PubMed:23317506}.
FT   MUTAGEN     790    790       V->D: Strongly reduces ITGB1BP1 binding;
FT                                when associated with D-788.
FT                                {ECO:0000269|PubMed:23317506}.
FT   MUTAGEN     792    792       N->A: Strongly reduces ITGB1BP1 binding;
FT                                when associated with A-795.
FT                                {ECO:0000269|PubMed:23317506}.
FT   MUTAGEN     795    795       Y->A: Strongly reduces ITGB1BP1 binding;
FT                                when associated with A-792.
FT                                {ECO:0000269|PubMed:23317506}.
FT   CONFLICT    112    112       T -> H (in Ref. 1; CAA30790).
FT                                {ECO:0000305}.
FT   CONFLICT    215    215       S -> T (in Ref. 1; CAA30790).
FT                                {ECO:0000305}.
FT   CONFLICT    261    265       CGSLI -> VWMLL (in Ref. 6; AAI13902).
FT                                {ECO:0000305}.
FT   CONFLICT    385    386       EN -> DG (in Ref. 6; AAI13902).
FT                                {ECO:0000305}.
FT   CONFLICT    463    463       E -> V (in Ref. 2; BAF84386).
FT                                {ECO:0000305}.
FT   TURN         26     31       {ECO:0000244|PDB:4WK0}.
FT   HELIX        35     40       {ECO:0000244|PDB:4WK0}.
FT   STRAND       45     47       {ECO:0000244|PDB:4WK0}.
FT   HELIX        61     63       {ECO:0000244|PDB:4WK0}.
FT   STRAND       64     66       {ECO:0000244|PDB:4WK0}.
FT   HELIX        67     71       {ECO:0000244|PDB:4WK0}.
FT   TURN         72     74       {ECO:0000244|PDB:4WK0}.
FT   TURN         77     79       {ECO:0000244|PDB:4WK0}.
FT   STRAND       86     91       {ECO:0000244|PDB:4WK0}.
FT   HELIX       108    110       {ECO:0000244|PDB:4WK0}.
FT   STRAND      118    124       {ECO:0000244|PDB:4WK0}.
FT   STRAND      129    136       {ECO:0000244|PDB:4WK0}.
FT   STRAND      143    150       {ECO:0000244|PDB:4WK0}.
FT   HELIX       153    155       {ECO:0000244|PDB:4WK0}.
FT   HELIX       156    161       {ECO:0000244|PDB:4WK0}.
FT   HELIX       162    164       {ECO:0000244|PDB:4WK0}.
FT   HELIX       165    173       {ECO:0000244|PDB:4WK0}.
FT   TURN        174    176       {ECO:0000244|PDB:4WK0}.
FT   STRAND      180    187       {ECO:0000244|PDB:4WK0}.
FT   TURN        193    195       {ECO:0000244|PDB:4WK0}.
FT   HELIX       200    204       {ECO:0000244|PDB:4WK0}.
FT   STRAND      209    211       {ECO:0000244|PDB:4WK0}.
FT   STRAND      218    227       {ECO:0000244|PDB:4WK0}.
FT   HELIX       229    236       {ECO:0000244|PDB:4WK0}.
FT   STRAND      245    249       {ECO:0000244|PDB:4WK0}.
FT   HELIX       251    260       {ECO:0000244|PDB:4WK0}.
FT   HELIX       262    264       {ECO:0000244|PDB:4WK0}.
FT   STRAND      269    280       {ECO:0000244|PDB:4WK0}.
FT   HELIX       287    291       {ECO:0000244|PDB:4WK0}.
FT   TURN        311    313       {ECO:0000244|PDB:4WK0}.
FT   HELIX       319    328       {ECO:0000244|PDB:4WK0}.
FT   STRAND      331    337       {ECO:0000244|PDB:4WK0}.
FT   HELIX       339    341       {ECO:0000244|PDB:4WK0}.
FT   HELIX       342    351       {ECO:0000244|PDB:4WK0}.
FT   STRAND      352    359       {ECO:0000244|PDB:4WK0}.
FT   STRAND      362    364       {ECO:0000244|PDB:4WK4}.
FT   HELIX       367    379       {ECO:0000244|PDB:4WK0}.
FT   STRAND      382    386       {ECO:0000244|PDB:4WK0}.
FT   STRAND      393    400       {ECO:0000244|PDB:4WK0}.
FT   HELIX       402    404       {ECO:0000244|PDB:4WK0}.
FT   STRAND      406    408       {ECO:0000244|PDB:4WJK}.
FT   HELIX       409    413       {ECO:0000244|PDB:4WK0}.
FT   STRAND      423    432       {ECO:0000244|PDB:4WK0}.
FT   STRAND      437    439       {ECO:0000244|PDB:4WJK}.
FT   STRAND      441    447       {ECO:0000244|PDB:4WK0}.
FT   STRAND      454    461       {ECO:0000244|PDB:4WK0}.
FT   HELIX       752    769       {ECO:0000244|PDB:3G9W}.
FT   HELIX       770    772       {ECO:0000244|PDB:3G9W}.
SQ   SEQUENCE   798 AA;  88415 MW;  DE35979C1625578C CRC64;
     MNLQPIFWIG LISSVCCVFA QTDENRCLKA NAKSCGECIQ AGPNCGWCTN STFLQEGMPT
     SARCDDLEAL KKKGCPPDDI ENPRGSKDIK KNKNVTNRSK GTAEKLKPED ITQIQPQQLV
     LRLRSGEPQT FTLKFKRAED YPIDLYYLMD LSYSMKDDLE NVKSLGTDLM NEMRRITSDF
     RIGFGSFVEK TVMPYISTTP AKLRNPCTSE QNCTSPFSYK NVLSLTNKGE VFNELVGKQR
     ISGNLDSPEG GFDAIMQVAV CGSLIGWRNV TRLLVFSTDA GFHFAGDGKL GGIVLPNDGQ
     CHLENNMYTM SHYYDYPSIA HLVQKLSENN IQTIFAVTEE FQPVYKELKN LIPKSAVGTL
     SANSSNVIQL IIDAYNSLSS EVILENGKLS EGVTISYKSY CKNGVNGTGE NGRKCSNISI
     GDEVQFEISI TSNKCPKKDS DSFKIRPLGF TEEVEVILQY ICECECQSEG IPESPKCHEG
     NGTFECGACR CNEGRVGRHC ECSTDEVNSE DMDAYCRKEN SSEICSNNGE CVCGQCVCRK
     RDNTNEIYSG KFCECDNFNC DRSNGLICGG NGVCKCRVCE CNPNYTGSAC DCSLDTSTCE
     ASNGQICNGR GICECGVCKC TDPKFQGQTC EMCQTCLGVC AEHKECVQCR AFNKGEKKDT
     CTQECSYFNI TKVESRDKLP QPVQPDPVSH CKEKDVDDCW FYFTYSVNGN NEVMVHVVEN
     PECPTGPDII PIVAGVVAGI VLIGLALLLI WKLLMIIHDR REFAKFEKEK MNAKWDTGEN
     PIYKSAVTTV VNPKYEGK
//
ID   FA9_HUMAN               Reviewed;         461 AA.
AC   P00740; A8K9N4; F2RM36; Q5FBE1; Q5JYJ8;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   07-JUN-2005, sequence version 2.
DT   20-JAN-2016, entry version 221.
DE   RecName: Full=Coagulation factor IX {ECO:0000303|PubMed:3857619};
DE            EC=3.4.21.22 {ECO:0000269|PubMed:12444082, ECO:0000269|PubMed:20121197, ECO:0000269|PubMed:20121198, ECO:0000269|PubMed:2592373};
DE   AltName: Full=Christmas factor;
DE   AltName: Full=Plasma thromboplastin component;
DE            Short=PTC;
DE   Contains:
DE     RecName: Full=Coagulation factor IXa light chain;
DE   Contains:
DE     RecName: Full=Coagulation factor IXa heavy chain;
DE   Flags: Precursor;
GN   Name=F9;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Liver;
RX   PubMed=6959130; DOI=10.1073/pnas.79.21.6461;
RA   Kurachi K., Davie E.W.;
RT   "Isolation and characterization of a cDNA coding for human factor
RT   IX.";
RL   Proc. Natl. Acad. Sci. U.S.A. 79:6461-6464(1982).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Liver;
RX   PubMed=6687940; DOI=10.1093/nar/11.8.2325;
RA   Jaye M., de la Salle H., Schamber F., Balland A., Kohli V.,
RA   Findeli A., Tolstoshev P., Lecocq J.-P.;
RT   "Isolation of a human anti-haemophilic factor IX cDNA clone using a
RT   unique 52-base synthetic oligonucleotide probe deduced from the amino
RT   acid sequence of bovine factor IX.";
RL   Nucleic Acids Res. 11:2325-2335(1983).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT ALA-194.
RX   PubMed=6329734;
RA   Anson D.S., Choo K.H., Rees D.J.G., Giannelli F., Gould K.G.,
RA   Huddleston J.A., Brownlee G.G.;
RT   "The gene structure of human anti-haemophilic factor IX.";
RL   EMBO J. 3:1053-1060(1984).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT ALA-194.
RX   PubMed=2994716; DOI=10.1021/bi00335a049;
RA   Yoshitake S., Schach B.G., Foster D.C., Davie E.W., Kurachi K.;
RT   "Nucleotide sequence of the gene for human factor IX (antihemophilic
RT   factor B).";
RL   Biochemistry 24:3736-3750(1985).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), VARIANT ALA-194, SUBCELLULAR
RP   LOCATION, TISSUE SPECIFICITY, AND PARTIAL PROTEIN SEQUENCE.
RX   PubMed=3857619; DOI=10.1073/pnas.82.9.2847;
RA   McGraw R.A., Davis L.M., Noyes C.M., Lundblad R.L., Roberts H.R.,
RA   Graham J.B., Stafford D.W.;
RT   "Evidence for a prevalent dimorphism in the activation peptide of
RT   human coagulation factor IX.";
RL   Proc. Natl. Acad. Sci. U.S.A. 82:2847-2851(1985).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND ALTERNATIVE SPLICING.
RC   TISSUE=Liver;
RA   Sata S., Yonemitsu Y., Nakagawa K., Sueishi K.;
RT   "Alternative splicing variant of Homo sapiens coagulation factor IX
RT   lacking EGF like domain.";
RL   Submitted (AUG-2004) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT PRO-461.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (AUG-2002) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Liver;
RA   Nguyen D.T., Nguyen P.V., Nong H.V.;
RT   "Homo sapiens coagulation factor IX (F9), mRNA.";
RL   Submitted (MAR-2011) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Liver;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A.,
RA   Lovell F.L., Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G.,
RA   Jones M.C., Hurles M.E., Andrews T.D., Scott C.E., Searle S.,
RA   Ramser J., Whittaker A., Deadman R., Carter N.P., Hunt S.E., Chen R.,
RA   Cree A., Gunaratne P., Havlak P., Hodgson A., Metzker M.L.,
RA   Richards S., Scott G., Steffen D., Sodergren E., Wheeler D.A.,
RA   Worley K.C., Ainscough R., Ambrose K.D., Ansari-Lari M.A., Aradhya S.,
RA   Ashwell R.I., Babbage A.K., Bagguley C.L., Ballabio A., Banerjee R.,
RA   Barker G.E., Barlow K.F., Barrett I.P., Bates K.N., Beare D.M.,
RA   Beasley H., Beasley O., Beck A., Bethel G., Blechschmidt K., Brady N.,
RA   Bray-Allen S., Bridgeman A.M., Brown A.J., Brown M.J., Bonnin D.,
RA   Bruford E.A., Buhay C., Burch P., Burford D., Burgess J., Burrill W.,
RA   Burton J., Bye J.M., Carder C., Carrel L., Chako J., Chapman J.C.,
RA   Chavez D., Chen E., Chen G., Chen Y., Chen Z., Chinault C.,
RA   Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J.,
RA   Delgado O., Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S.,
RA   Draper H., Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I.,
RA   Eades T., Ellwood M., Emery-Cohen A., Errington H., Evans K.L.,
RA   Faulkner L., Francis F., Frankland J., Fraser A.E., Galgoczy P.,
RA   Gilbert J., Gill R., Gloeckner G., Gregory S.G., Gribble S.,
RA   Griffiths C., Grocock R., Gu Y., Gwilliam R., Hamilton C., Hart E.A.,
RA   Hawes A., Heath P.D., Heitmann K., Hennig S., Hernandez J.,
RA   Hinzmann B., Ho S., Hoffs M., Howden P.J., Huckle E.J., Hume J.,
RA   Hunt P.J., Hunt A.R., Isherwood J., Jacob L., Johnson D., Jones S.,
RA   de Jong P.J., Joseph S.S., Keenan S., Kelly S., Kershaw J.K., Khan Z.,
RA   Kioschis P., Klages S., Knights A.J., Kosiura A., Kovar-Smith C.,
RA   Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., Liu W.,
RA   Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T.,
RA   Milne S., Miner G., Mistry S.L., Morgan M., Morris S., Mueller I.,
RA   Mullikin J.C., Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N.,
RA   Okwuonu G., Palmer S., Pandian R., Parker D., Parrish J.,
RA   Pasternak S., Patel D., Pearce A.V., Pearson D.M., Pelan S.E.,
RA   Perez L., Porter K.M., Ramsey Y., Reichwald K., Rhodes S.,
RA   Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T.,
RA   Teague B., Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S.,
RA   Tromans A.C., d'Urso M., Verduzco D., Villasana D., Waldron L.,
RA   Wall M., Wang Q., Warren J., Warry G.L., Wei X., West A.,
RA   Whitehead S.L., Whiteley M.N., Wilkinson J.E., Willey D.L.,
RA   Williams G., Williams L., Williamson A., Williamson H., Wilming L.,
RA   Woodmansey R.L., Wray P.W., Yen J., Zhang J., Zhou J., Zoghbi H.,
RA   Zorilla S., Buck D., Reinhardt R., Poustka A., Rosenthal A.,
RA   Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A.,
RA   Nelson D.L., Weinstock G., Sulston J.E., Durbin R.M., Hubbard T.,
RA   Gibbs R.A., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 30-84, VARIANT HEMB GLN-43,
RP   FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND PROTEOLYTIC
RP   CLEAVAGE.
RX   PubMed=8295821;
RA   de la Salle C., Charmantier J.L., Ravanat C., Ohlmann P.,
RA   Hartmann M.L., Schuhler S., Bischoff R., Ebel C., Roecklin D.,
RA   Balland A.;
RT   "The Arg-4 mutant factor IX Strasbourg 2 shows a delayed activation by
RT   factor XIa.";
RL   Nouv. Rev. Fr. Hematol. 35:473-480(1993).
RN   [14]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 36-326 (ISOFORM 1).
RC   TISSUE=Liver;
RX   PubMed=6089357; DOI=10.1007/BF01534851;
RA   Jagadeeswaran P., Lavelle D.E., Kaul R., Mohandas T., Warren S.T.;
RT   "Isolation and characterization of human factor IX cDNA:
RT   identification of Taq I polymorphism and regional assignment.";
RL   Somat. Cell Mol. Genet. 10:465-473(1984).
RN   [15]
RP   PROTEIN SEQUENCE OF 47-461, VARIANT HEMB TRP-226, FUNCTION, CATALYTIC
RP   ACTIVITY, PROTEOLYTIC CLEAVAGE, SUBCELLULAR LOCATION, SUBUNIT, AND
RP   TISSUE SPECIFICITY.
RX   PubMed=2592373;
RA   Suehiro K., Kawabata S., Miyata T., Takeya H., Takamatsu J., Ogata K.,
RA   Kamiya T., Saito H., Niho Y., Iwanaga S.;
RT   "Blood clotting factor IX BM Nagoya. Substitution of arginine 180 by
RT   tryptophan and its activation by alpha-chymotrypsin and rat mast cell
RT   chymase.";
RL   J. Biol. Chem. 264:21257-21265(1989).
RN   [16]
RP   PROTEIN SEQUENCE OF 47-52, TISSUE SPECIFICITY, SUBCELLULAR LOCATION,
RP   CHARACTERIZATION OF VARIANTS HEMB GLN-43; LEU-43 AND TRP-43,
RP   CALCIUM-BINDING, AND PROTEOLYTIC CLEAVAGE.
RX   PubMed=9169594;
RA   Wojcik E.G., Van Den Berg M., Poort S.R., Bertina R.M.;
RT   "Modification of the N-terminus of human factor IX by defective
RT   propeptide cleavage or acetylation results in a destabilized calcium-
RT   induced conformation: effects on phospholipid binding and activation
RT   by factor XIa.";
RL   Biochem. J. 323:629-636(1997).
RN   [17]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 290-359.
RX   PubMed=3340835; DOI=10.1126/science.3340835;
RA   Stoflet E.S., Koeberl D.D., Sarkar G., Sommer S.S.;
RT   "Genomic amplification with transcript sequencing.";
RL   Science 239:491-494(1988).
RN   [18]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 444-461.
RX   PubMed=8236150;
RA   de la Salle C., Charmantier J.L., Baas M.-J., Schwartz A.,
RA   Wiesel M.L., Grunebaum L., Cazenave J.-P.;
RT   "A deletion located in the 3' non translated part of the factor IX
RT   gene responsible for mild haemophilia B.";
RL   Thromb. Haemost. 70:370-371(1993).
RN   [19]
RP   HYDROXYLATION AT ASP-110.
RX   PubMed=6688526; DOI=10.1016/0006-291X(83)90961-0;
RA   McMullen B.A., Fujikawa K., Kisiel W.;
RT   "The occurrence of beta-hydroxyaspartic acid in the vitamin K-
RT   dependent blood coagulation zymogens.";
RL   Biochem. Biophys. Res. Commun. 115:8-14(1983).
RN   [20]
RP   PROTEOLYTIC PROCESSING, AND ACTIVE SITE.
RX   PubMed=659613; DOI=10.1172/JCI109073;
RA   di Scipio R.G., Kurachi K., Davie E.W.;
RT   "Activation of human factor IX (Christmas factor).";
RL   J. Clin. Invest. 61:1528-1538(1978).
RN   [21]
RP   CALCIUM-BINDING, AND DOMAIN.
RX   PubMed=6425296;
RA   Morita T., Isaacs B.S., Esmon C.T., Johnson A.E.;
RT   "Derivatives of blood coagulation factor IX contain a high affinity
RT   Ca2+-binding site that lacks gamma-carboxyglutamic acid.";
RL   J. Biol. Chem. 259:5698-5704(1984).
RN   [22]
RP   ERRATUM.
RA   Morita T., Isaacs B.S., Esmon C.T., Johnson A.E.;
RL   J. Biol. Chem. 260:2583-2583(1985).
RN   [23]
RP   STRUCTURE OF CARBOHYDRATE ON SER-99.
RX   PubMed=2511201;
RA   Nishimura H., Kawabata S., Kisiel W., Hase S., Ikenaka T., Takao T.,
RA   Shimonishi Y., Iwanaga S.;
RT   "Identification of a disaccharide (Xyl-Glc) and a trisaccharide (Xyl2-
RT   Glc) O-glycosidically linked to a serine residue in the first
RT   epidermal growth factor-like domain of human factors VII and IX and
RT   protein Z and bovine protein Z.";
RL   J. Biol. Chem. 264:20320-20325(1989).
RN   [24]
RP   STRUCTURE OF CARBOHYDRATE ON SER-99.
RX   PubMed=2129367;
RA   Iwanaga S., Nishimura H., Kawabata S., Kisiel W., Hase S., Ikenaka T.;
RT   "A new trisaccharide sugar chain linked to a serine residue in the
RT   first EGF-like domain of clotting factors VII and IX and protein Z.";
RL   Adv. Exp. Med. Biol. 281:121-131(1990).
RN   [25]
RP   FUNCTION, AND PROTEOLYTIC CLEAVAGE.
RX   PubMed=1730085;
RA   Rawala-Sheikh R., Ahmad S.S., Monroe D.M., Roberts H.R., Walsh P.N.;
RT   "Role of gamma-carboxyglutamic acid residues in the binding of factor
RT   IXa to platelets and in factor-X activation.";
RL   Blood 79:398-405(1992).
RN   [26]
RP   STRUCTURE OF CARBOHYDRATE ON SER-107.
RX   PubMed=1517205;
RA   Nishimura H., Takao T., Hase S., Shimonishi Y., Iwanaga S.;
RT   "Human factor IX has a tetrasaccharide O-glycosidically linked to
RT   serine 61 through the fucose residue.";
RL   J. Biol. Chem. 267:17520-17525(1992).
RN   [27]
RP   GLYCOSYLATION AT THR-205 AND THR-215.
RX   PubMed=8172892; DOI=10.1021/bi00183a021;
RA   Agarwala K.L., Kawabata S., Takao T., Murata H., Shimonishi Y.,
RA   Nishimura H., Iwanaga S.;
RT   "Activation peptide of human factor IX has oligosaccharides O-
RT   glycosidically linked to threonine residues at 159 and 169.";
RL   Biochemistry 33:5167-5171(1994).
RN   [28]
RP   PHOSPHORYLATION AT SER-114.
RA   Harris R.J., Papac D.I., Truong L., Smith K.J.;
RT   "Partial phosphorylation of serine-68 in EGF-1 of human factor IX.";
RL   (In) Proceedings of XIth international conference on methods in
RL   protein structure analysis, pp.50-50, Annecy (1996).
RN   [29]
RP   SULFATION AT TYR-201, AND PHOSPHORYLATION AT SER-204.
RX   PubMed=11133752; DOI=10.1182/blood.V97.1.130;
RA   Arruda V.R., Hagstrom J.N., Deitch J., Heiman-Patterson T.,
RA   Camire R.M., Chu K., Fields P.A., Herzog R.W., Couto L.B.,
RA   Larson P.J., High K.A.;
RT   "Posttranslational modifications of recombinant myotube-synthesized
RT   human factor IX.";
RL   Blood 97:130-138(2001).
RN   [30]
RP   CATALYTIC ACTIVITY, AND MUTAGENESIS OF TYR-305; LYS-311; TYR-312 AND
RP   TYR-391.
RX   PubMed=12444082; DOI=10.1074/jbc.M210722200;
RA   Sichler K., Kopetzki E., Huber R., Bode W., Hopfner K.P.,
RA   Brandstetter H.;
RT   "Physiological fIXa activation involves a cooperative conformational
RT   rearrangement of the 99-loop.";
RL   J. Biol. Chem. 278:4121-4126(2003).
RN   [31]
RP   GLYCOSYLATION AT SER-99.
RX   PubMed=21949356; DOI=10.1073/pnas.1109696108;
RA   Takeuchi H., Fernandez-Valdivia R.C., Caswell D.S., Nita-Lazar A.,
RA   Rana N.A., Garner T.P., Weldeghiorghis T.K., Macnaughtan M.A.,
RA   Jafar-Nejad H., Haltiwanger R.S.;
RT   "Rumi functions as both a protein O-glucosyltransferase and a protein
RT   O-xylosyltransferase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:16600-16605(2011).
RN   [32]
RP   GLYCOSYLATION AT THR-85; SER-99; SER-107; THR-205; THR-215 AND
RP   THR-225, PHOSPHORYLATION AT SER-204 AND THR-205, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY.
RX   PubMed=25456591; DOI=10.1016/j.chroma.2014.10.046;
RA   Huang L.J., Lin J.H., Tsai J.H., Chu Y.Y., Chen Y.W., Chen S.L.,
RA   Chen S.H.;
RT   "Identification of protein O-glycosylation site and corresponding
RT   glycans using liquid chromatography-tandem mass spectrometry via
RT   mapping accurate mass and retention time shift.";
RL   J. Chromatogr. A 1371:136-145(2014).
RN   [33]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [34]
RP   STRUCTURE BY NMR OF 47-93.
RX   PubMed=7713897; DOI=10.1074/jbc.270.14.7980;
RA   Freedman S.J., Furie B.C., Furie B., Baleja J.D.;
RT   "Structure of the metal-free gamma-carboxyglutamic acid-rich membrane
RT   binding region of factor IX by two-dimensional NMR spectroscopy.";
RL   J. Biol. Chem. 270:7980-7987(1995).
RN   [35]
RP   STRUCTURE BY NMR OF 47-93.
RX   PubMed=7547952; DOI=10.1021/bi00038a005;
RA   Freedman S.J., Furie B.C., Furie B., Baleja J.D.;
RT   "Structure of the calcium ion-bound gamma-carboxyglutamic acid-rich
RT   domain of factor IX.";
RL   Biochemistry 34:12126-12137(1995).
RN   [36]
RP   STRUCTURE BY NMR OF 47-93.
RX   PubMed=8663165; DOI=10.1074/jbc.271.27.16227;
RA   Freedman S.J., Blostein M.D., Baleja J.D., Jacobs M., Furie B.C.,
RA   Furie B.;
RT   "Identification of the phospholipid binding site in the vitamin K-
RT   dependent blood coagulation protein factor IX.";
RL   J. Biol. Chem. 271:16227-16236(1996).
RN   [37]
RP   STRUCTURE BY NMR OF 47-93.
RX   PubMed=9047312; DOI=10.1021/bi962250r;
RA   Li L., Darden T.A., Freedman S.J., Furie B.C., Furie B., Baleja J.D.,
RA   Smith H., Hiskey R.G., Pedersen L.G.;
RT   "Refinement of the NMR solution structure of the gamma-carboxyglutamic
RT   acid domain of coagulation factor IX using molecular dynamics
RT   simulation with initial Ca2+ positions determined by a genetic
RT   algorithm.";
RL   Biochemistry 36:2132-2138(1997).
RN   [38]
RP   STRUCTURE BY NMR OF 91-133.
RX   PubMed=1854745; DOI=10.1021/bi00244a006;
RA   Huang L.H., Cheng H., Pardi A., Tam J.P., Sweeney W.V.;
RT   "Sequence-specific 1H NMR assignments, secondary structure, and
RT   location of the calcium binding site in the first epidermal growth
RT   factor like domain of blood coagulation factor IX.";
RL   Biochemistry 30:7402-7409(1991).
RN   [39]
RP   STRUCTURE BY NMR OF 92-130, AND DISULFIDE BOND.
RX   PubMed=1304885; DOI=10.1002/pro.5560010109;
RA   Baron M., Norman D.G., Harvey T.S., Handford P.A., Mayhew M.,
RA   Tse A.G.D., Brownlee G.G., Campbell I.D.C.;
RT   "The three-dimensional structure of the first EGF-like module of human
RT   factor IX: comparison with EGF and TGF-alpha.";
RL   Protein Sci. 1:81-90(1992).
RN   [40]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 92-130 IN COMPLEX WITH
RP   CALCIUM, AND DISULFIDE BOND.
RX   PubMed=7606779; DOI=10.1016/0092-8674(95)90059-4;
RA   Rao Z., Handford P., Mayhew M., Knott V., Brownlee G.G., Stuart D.;
RT   "The structure of a Ca(2+)-binding epidermal growth factor-like
RT   domain: its role in protein-protein interactions.";
RL   Cell 82:131-141(1995).
RN   [41]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 133-461 IN COMPLEX WITH
RP   CALCIUM.
RX   PubMed=10467148; DOI=10.1016/S0969-2126(99)80125-7;
RA   Hopfner K.-P., Lang A., Karcher A., Sichler K., Kopetzki E.,
RA   Brandstetter H., Huber R., Bode W., Engh R.A.;
RT   "Coagulation factor IXa: the relaxed conformation of Tyr99 blocks
RT   substrate binding.";
RL   Structure 7:989-996(1999).
RN   [42]
RP   X-RAY CRYSTALLOGRAPHY (2.20 ANGSTROMS) OF 47-91 IN COMPLEX WITH
RP   CALCIUM.
RX   PubMed=14722079; DOI=10.1074/jbc.M314011200;
RA   Huang M., Furie B.C., Furie B.;
RT   "Crystal structure of the calcium-stabilized human factor IX Gla
RT   domain bound to a conformation-specific anti-factor IX antibody.";
RL   J. Biol. Chem. 279:14338-14346(2004).
RN   [43]
RP   X-RAY CRYSTALLOGRAPHY (1.50 ANGSTROMS) OF 133-191 AND 227-461 OF
RP   MUTANTS PHE-305/THR-311/ALA-365/THR-391 IN COMPLEX WITH CALCIUM AND
RP   SYNTHETIC INHIBITOR, ACTIVE SITE, DISULFIDE BOND, SUBUNIT, AND
RP   PROTEOLYTIC CLEAVAGE.
RX   PubMed=20004170; DOI=10.1016/j.str.2009.10.011;
RA   Zogg T., Brandstetter H.;
RT   "Structural basis of the cofactor- and substrate-assisted activation
RT   of human coagulation factor IXa.";
RL   Structure 17:1669-1678(2009).
RN   [44]
RP   X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) OF 133-461 IN COMPLEX WITH
RP   CALCIUM, FUNCTION, CATALYTIC ACTIVITY, SUBUNIT, AND DISULFIDE BOND.
RX   PubMed=20121198; DOI=10.1021/jm901475e;
RA   Wang S., Beck R., Blench T., Burd A., Buxton S., Malic M., Ayele T.,
RA   Shaikh S., Chahwala S., Chander C., Holland R., Merette S., Zhao L.,
RA   Blackney M., Watts A.;
RT   "Studies of benzothiophene template as potent factor IXa (FIXa)
RT   inhibitors in thrombosis.";
RL   J. Med. Chem. 53:1465-1472(2010).
RN   [45]
RP   X-RAY CRYSTALLOGRAPHY (2.62 ANGSTROMS) OF 133-188 AND 227-461 IN
RP   COMPLEX WITH CALCIUM, FUNCTION, CATALYTIC ACTIVITY, SUBUNIT, AND
RP   DISULFIDE BOND.
RX   PubMed=20121197; DOI=10.1021/jm901476x;
RA   Wang S., Beck R., Burd A., Blench T., Marlin F., Ayele T., Buxton S.,
RA   Dagostin C., Malic M., Joshi R., Barry J., Sajad M., Cheung C.,
RA   Shaikh S., Chahwala S., Chander C., Baumgartner C., Holthoff H.P.,
RA   Murray E., Blackney M., Giddings A.;
RT   "Structure based drug design: development of potent and selective
RT   factor IXa (FIXa) inhibitors.";
RL   J. Med. Chem. 53:1473-1482(2010).
RN   [46]
RP   X-RAY CRYSTALLOGRAPHY (1.70 ANGSTROMS) OF 131-188 AND 227-461 IN
RP   COMPLEX WITH SERPINC1 AND CALCIUM, DISULFIDE BOND, PROTEOLYTIC
RP   CLEAVAGE, AND SUBUNIT.
RX   PubMed=20080729; DOI=10.1073/pnas.0910144107;
RA   Johnson D.J., Langdown J., Huntington J.A.;
RT   "Molecular basis of factor IXa recognition by heparin-activated
RT   antithrombin revealed by a 1.7-A structure of the ternary complex.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:645-650(2010).
RN   [47]
RP   MOLECULAR PATHOLOGY OF HEMB B.
RX   PubMed=2743975;
RA   Green P.M., Bentley D.R., Mibashan R.S., Nilsson I.M., Giannelli F.;
RT   "Molecular pathology of haemophilia B.";
RL   EMBO J. 8:1067-1072(1989).
RN   [48]
RP   REVIEW ON HEMB VARIANTS.
RX   PubMed=1634040;
RA   Sommer S.S.;
RT   "Assessing the underlying pattern of human germline mutations: lessons
RT   from the factor IX gene.";
RL   FASEB J. 6:2767-2774(1992).
RN   [49]
RP   REVIEW ON HEMB VARIANTS.
RX   PubMed=8392713; DOI=10.1093/nar/21.13.3075;
RA   Giannelli F., Green P.M., High K.A., Sommer S., Poon M.-C., Ludwig M.,
RA   Schwaab R., Reitsma P.H., Goossens M., Yoshioka A., Brownlee G.G.;
RT   "Haemophilia B: database of point mutations and short additions and
RT   deletions -- fourth edition, 1993.";
RL   Nucleic Acids Res. 21:3075-3087(1993).
RN   [50]
RP   VARIANT HEMB HIS-191.
RX   PubMed=6603618; DOI=10.1073/pnas.80.14.4200;
RA   Noyes C.M., Griffith M.J., Roberts H.R., Lundblad R.L.;
RT   "Identification of the molecular defect in factor IX Chapel Hill:
RT   substitution of histidine for arginine at position 145.";
RL   Proc. Natl. Acad. Sci. U.S.A. 80:4200-4202(1983).
RN   [51]
RP   VARIANT HEMB GLN-43, AND CHARACTERIZATION OF VARIANT HEMB GLN-43.
RX   PubMed=3009023; DOI=10.1016/0092-8674(86)90319-3;
RA   Bentley A.K., Rees D.J., Rizza C., Brownlee G.G.;
RT   "Defective propeptide processing of blood clotting factor IX caused by
RT   mutation of arginine to glutamine at position -4.";
RL   Cell 45:343-348(1986).
RN   [52]
RP   VARIANT HEMB GLY-93.
RX   PubMed=3790720;
RA   Davis L.M., McGraw R.A., Ware J.L., Roberts H.R., Stafford D.W.;
RT   "Factor IXAlabama: a point mutation in a clotting protein results in
RT   hemophilia B.";
RL   Blood 69:140-143(1987).
RN   [53]
RP   VARIANT HEMB THR-443.
RX   PubMed=3401602;
RA   Ware J., Davis L., Frazier D., Bajaj S.P., Stafford D.W.;
RT   "Genetic defect responsible for the dysfunctional protein: factor IX
RT   (Long Beach).";
RL   Blood 72:820-822(1988).
RN   [54]
RP   VARIANT HEMB VAL-436.
RX   PubMed=3243764;
RA   Sugimoto M., Miyata T., Kawabata S., Yoshioka A., Fukui H.,
RA   Takahashi H., Iwanaga S.;
RT   "Blood clotting factor IX Niigata: substitution of alanine-390 by
RT   valine in the catalytic domain.";
RL   J. Biochem. 104:878-880(1988).
RN   [55]
RP   VARIANT HEMB GLN-226.
RX   PubMed=2713493;
RA   Monroe D.M., McCord D.M., Huang M.N., High K.A., Lundblad R.L.,
RA   Kasper C.K., Roberts H.R.;
RT   "Functional consequences of an arginine180 to glutamine mutation in
RT   factor IX Hilo.";
RL   Blood 73:1540-1544(1989).
RN   [56]
RP   VARIANT HEMB ARG-442.
RX   PubMed=2714791; DOI=10.1016/0888-7543(89)90330-3;
RA   Attree O., Vidaud D., Vidaud M., Amselem S., Lavergne J.-M.,
RA   Goossens M.;
RT   "Mutations in the catalytic domain of human coagulation factor IX:
RT   rapid characterization by direct genomic sequencing of DNA fragments
RT   displaying an altered melting behavior.";
RL   Genomics 4:266-272(1989).
RN   [57]
RP   VARIANTS HEMB GLN-75; ASP-79; TRP-268; THR-279; SER-306; MET-342;
RP   ARG-357 AND ARG-453, AND VARIANT PHE-7.
RX   PubMed=2773937;
RA   Koeberl D.D., Bottema C.D., Buerstedde J.-M., Sommer S.S.;
RT   "Functionally important regions of the factor IX gene have a low rate
RT   of polymorphism and a high rate of mutation in the dinucleotide CpG.";
RL   Am. J. Hum. Genet. 45:448-457(1989).
RN   [58]
RP   VARIANT HEMB CYS-191.
RX   PubMed=2775660; DOI=10.1111/j.1365-2141.1989.tb04323.x;
RA   Liddell M.B., Peake I.R., Taylor S.A., Lillicrap D.P., Giddings J.C.,
RA   Bloom A.L.;
RT   "Factor IX Cardiff: a variant factor IX protein that shows abnormal
RT   activation is caused by an arginine to cysteine substitution at
RT   position 145.";
RL   Br. J. Haematol. 72:556-560(1989).
RN   [59]
RP   VARIANT HEMB PHE-228.
RX   PubMed=2753873;
RA   Sakai T., Yoshioka A., Yamamoto K., Niinomi K., Fujimura Y., Fukui H.,
RA   Miyata T., Iwanaga S.;
RT   "Blood clotting factor IX Kashihara: amino acid substitution of
RT   valine-182 by phenylalanine.";
RL   J. Biochem. 105:756-759(1989).
RN   [60]
RP   VARIANT HEMB GLN-43.
RX   PubMed=2738071;
RA   Ware J., Diuguid D.L., Liebman H.A., Rabiet M.J., Kasper C.K.,
RA   Furie B.C., Furie B., Stafford D.W.;
RT   "Factor IX San Dimas. Substitution of glutamine for Arg-4 in the
RT   propeptide leads to incomplete gamma-carboxylation and altered
RT   phospholipid binding properties.";
RL   J. Biol. Chem. 264:11401-11406(1989).
RN   [61]
RP   VARIANTS HEMB LYS-73; SER-106 AND GLN-294.
RX   PubMed=2472424; DOI=10.1172/JCI114130;
RA   Chen S.H., Thompson A.R., Zhang M., Scott C.R.;
RT   "Three point mutations in the factor IX genes of five hemophilia B
RT   patients. Identification strategy using localization by altered
RT   epitopes in their hemophilic proteins.";
RL   J. Clin. Invest. 84:113-118(1989).
RN   [62]
RP   VARIANT HEMB VAL-73.
RX   PubMed=2339358;
RA   Wang N.S., Zhang M., Thompson A.R., Chen S.H.;
RT   "Factor IX Chongqing: a new mutation in the calcium-binding domain of
RT   factor IX resulting in severe hemophilia B.";
RL   Thromb. Haemost. 63:24-26(1990).
RN   [63]
RP   VARIANT HEMB LEU-228.
RX   PubMed=2372509; DOI=10.1111/j.1365-2141.1990.tb02652.x;
RA   Taylor S.A., Liddell M.B., Peake I.R., Bloom A.L., Lillicrap D.P.;
RT   "A mutation adjacent to the beta cleavage site of factor IX (valine
RT   182 to leucine) results in mild haemophilia Bm.";
RL   Br. J. Haematol. 75:217-221(1990).
RN   [64]
RP   VARIANTS HEMB GLN-226; TRP-226; PHE-227 AND THR-414.
RX   PubMed=2162822;
RA   Bertina R.M., van der Linden I.K., Mannucci P.M., Reinalda-Poot H.H.,
RA   Cupers R., Poort S.R., Reitsma P.H.;
RT   "Mutations in hemophilia Bm occur at the Arg180-Val activation site or
RT   in the catalytic domain of factor IX.";
RL   J. Biol. Chem. 265:10876-10883(1990).
RN   [65]
RP   VARIANT HEMB GLU-357.
RX   PubMed=1958666; DOI=10.1021/bi00111a014;
RA   Miyata T., Sakai T., Sugimoto M., Naka H., Yamamoto K., Yoshioka A.,
RA   Fukui H., Mitsui K., Kamiya K., Umeyama H., Iwanaga S.;
RT   "Factor IX Amagasaki: a new mutation in the catalytic domain resulting
RT   in the loss of both coagulant and esterase activities.";
RL   Biochemistry 30:11286-11291(1991).
RN   [66]
RP   VARIANT HEMB THR-443.
RX   PubMed=1902289; DOI=10.1093/nar/19.5.1165;
RA   Sarkar G., Cassady J.D., Pyeritz R.E., Gilchrist G.S., Sommer S.S.;
RT   "Isoleucine-397 is changed to threonine in two females with hemophilia
RT   B.";
RL   Nucleic Acids Res. 19:1165-1165(1991).
RN   [67]
RP   VARIANTS HEMB VAL-291; GLN-294; HIS-410; GLY-411 AND ILE-411.
RX   PubMed=1346975;
RA   Ludwig M., Sabharwal A.K., Brackmann H.H., Olek K., Smith K.J.,
RA   Birktoft J.J., Bajaj S.P.;
RT   "Hemophilia B caused by five different nondeletion mutations in the
RT   protease domain of factor IX.";
RL   Blood 79:1225-1232(1992).
RN   [68]
RP   VARIANT HEMB SER-252.
RX   PubMed=1615485;
RA   Taylor S.A., Duffin J., Cameron C., Teitel J., Garvey B.,
RA   Lillicrap D.P.;
RT   "Characterization of the original Christmas disease mutation (cysteine
RT   206-->serine): from clinical recognition to molecular pathogenesis.";
RL   Thromb. Haemost. 67:63-65(1992).
RN   [69]
RP   VARIANTS HEMB ARG-253; GLN-294; GLN-379; PRO-426 AND ILE-TYR-THR-445
RP   INS.
RX   PubMed=8257988; DOI=10.1002/humu.1380020506;
RA   David D., Rosa H.A.V., Pemberton S., Diniz M.J., Campos M.,
RA   Lavinha J.;
RT   "Single-strand conformation polymorphism (SSCP) analysis of the
RT   molecular pathology of hemophilia B.";
RL   Hum. Mutat. 2:355-361(1993).
RN   [70]
RP   VARIANTS HEMB HIS-191; GLY-226; THR-279; GLN-379; GLU-419 AND GLN-449.
RX   PubMed=8076946; DOI=10.1007/BF00208285;
RA   Aguilar-Martinez P., Romey M.-C., Schved J.-F., Gris J.-C.,
RA   Demaille J., Claustres M.;
RT   "Factor IX gene mutations causing haemophilia B: comparison of SSC
RT   screening versus systematic DNA sequencing and diagnostic
RT   applications.";
RL   Hum. Genet. 94:287-290(1994).
RN   [71]
RP   VARIANT HEMB GLU-419.
RX   PubMed=8199596; DOI=10.1002/humu.1380030211;
RA   Aguilar-Martinez P., Romey M.-C., Gris J.-C., Schved J.-F.,
RA   Demaille J., Claustres M.;
RT   "A novel mutation (Val-373 to Glu) in the catalytic domain of factor
RT   IX, resulting in moderately/severe hemophilia B in a southern French
RT   patient.";
RL   Hum. Mutat. 3:156-158(1994).
RN   [72]
RP   VARIANTS HEMB GLN-294 AND ARG-413.
RX   PubMed=7981722; DOI=10.1002/humu.1380040214;
RA   Caglayan S.H., Vielhaber E., Guersel T., Aktuglu G., Sommer S.S.;
RT   "Identification of mutations in four hemophilia B patients of Turkish
RT   origin, including a novel deletion of base 6411.";
RL   Hum. Mutat. 4:163-165(1994).
RN   [73]
RP   VARIANTS HEMB.
RX   PubMed=8680410; DOI=10.1002/humu.1380060410;
RA   Wulff K., Schroeder W., Wehnert M., Herrmann F.H.;
RT   "Twenty-five novel mutations of the factor IX gene in haemophilia B.";
RL   Hum. Mutat. 6:346-348(1995).
RN   [74]
RP   VARIANT WARFARIN SENSITIVITY THR-37.
RX   PubMed=8833911; DOI=10.1172/JCI118956;
RA   Chu K., Wu S.M., Stanley T., Stafford D.W., High K.A.;
RT   "A mutation in the propeptide of factor IX leads to warfarin
RT   sensitivity by a novel mechanism.";
RL   J. Clin. Invest. 98:1619-1625(1996).
RN   [75]
RP   VARIANTS HEMB LYS-113; MET-342; ARG-413 AND VAL-424.
RX   PubMed=9222764;
RX   DOI=10.1002/(SICI)1098-1004(1997)10:1<76::AID-HUMU11>3.3.CO;2-0;
RA   Caglayan S.H., Goekmen Y., Aktuglu G., Guergey A., Sommer S.S.;
RT   "Mutations associated with hemophilia B in Turkish patients.";
RL   Hum. Mutat. 10:76-79(1997).
RN   [76]
RP   VARIANT HEMB PRO-397.
RX   PubMed=9590153;
RX   DOI=10.1002/(SICI)1096-8652(199805)58:1<72::AID-AJH13>3.0.CO;2-7;
RA   Chan V., Chan V.W.Y., Yip B., Chim C.S., Chan T.K.;
RT   "Hemophilia B in a female carrier due to skewed inactivation of the
RT   normal X-chromosome.";
RL   Am. J. Hematol. 58:72-76(1998).
RN   [77]
RP   VARIANTS HEMB ARG-119 AND THR-454.
RX   PubMed=9452115;
RA   David D., Moreira I., Morais S., de Deus G.;
RT   "Five novel factor IX mutations in unrelated hemophilia B patients.";
RL   Hum. Mutat. Suppl. 1:S301-S303(1998).
RN   [78]
RP   VARIANTS HEMB GLN-43; TRP-43; THR-46; SER-106; CYS-115; PHE-155;
RP   GLN-379; GLU-387; VAL-432 AND CYS-450.
RX   PubMed=9600455;
RX   DOI=10.1002/(SICI)1098-1004(1998)11:5<372::AID-HUMU4>3.0.CO;2-M;
RA   Heit J.A., Thorland E.C., Ketterling R.P., Lind T.J., Daniels T.M.,
RA   Zapata R.E., Ordonez S.M., Kasper C.K., Sommer S.S.;
RT   "Germline mutations in Peruvian patients with hemophilia B: pattern of
RT   mutation in Amerindians is similar to the putative endogenous germline
RT   pattern.";
RL   Hum. Mutat. 11:372-376(1998).
RN   [79]
RP   VARIANTS HEMB.
RX   PubMed=10698280;
RA   Wulff K., Bykowska K., Lopaciuk S., Herrmann F.H.;
RT   "Molecular analysis of hemophilia B in Poland: 12 novel mutations of
RT   the factor IX gene.";
RL   Acta Biochim. Pol. 46:721-726(1999).
RN   [80]
RP   VARIANTS HEMB.
RX   PubMed=10094553;
RX   DOI=10.1002/(SICI)1098-1004(1999)13:2<160::AID-HUMU9>3.0.CO;2-C;
RA   Montejo J.M., Magallon M., Tizzano E., Solera J.;
RT   "Identification of twenty-one new mutations in the factor IX gene by
RT   SSCP analysis.";
RL   Hum. Mutat. 13:160-165(1999).
RN   [81]
RP   VARIANT ALA-194.
RX   PubMed=10391209; DOI=10.1038/10290;
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RT   "Characterization of single-nucleotide polymorphisms in coding regions
RT   of human genes.";
RL   Nat. Genet. 22:231-238(1999).
RN   [82]
RP   ERRATUM.
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RL   Nat. Genet. 23:373-373(1999).
RN   [83]
RP   VARIANTS HEMB CYS-169 AND THR-333.
RX   PubMed=11122099; DOI=10.1046/j.1365-2141.2000.02389.x;
RA   Vidal F., Farssac E., Altisent C., Puig L., Gallardo D.;
RT   "Factor IX gene sequencing by a simple and sensitive 15-hour procedure
RT   for haemophilia B diagnosis: identification of two novel mutations.";
RL   Br. J. Haematol. 111:549-551(2000).
RN   [84]
RP   VARIANTS HEMB TYR-28; LEU-43; GLN-43; SER-52; ASP-106; LYS-124;
RP   TYR-134; GLN-226; GLY-226; TRP-226; LYS-241; TYR-252; GLN-294;
RP   PHE-316; ARG-318; GLY-379; ILE-383; PHE-383; ILE-395; PHE-396; ARG-407
RP   AND GLU-412.
RX   PubMed=12588353; DOI=10.1046/j.1365-2141.2003.04141.x;
RA   Onay U.V., Kavakli K., Kilinc Y., Gurgey A., Aktuglu G., Kemahli S.,
RA   Ozbek U., Caglayan S.H.;
RT   "Molecular pathology of haemophilia B in Turkish patients:
RT   identification of a large deletion and 33 independent point
RT   mutations.";
RL   Br. J. Haematol. 120:656-659(2003).
RN   [85]
RP   VARIANTS HEMB TRP-43; ARG-84; ARG-125; VAL-125; PHE-170; ARG-302;
RP   MET-342; LEU-344; LEU-395; THR-414; TYR-435; GLU-442 AND TRP-449.
RX   PubMed=12604421;
RA   Espinos C., Casana P., Haya S., Cid A.R., Aznar J.A.;
RT   "Molecular analyses in hemophilia B families: identification of six
RT   new mutations in the factor IX gene.";
RL   Haematologica 88:235-236(2003).
RN   [86]
RP   VARIANT THPH8 LEU-384, CHARACTERIZATION OF VARIANT THPH8 LEU-384,
RP   FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=19846852; DOI=10.1056/NEJMoa0904377;
RA   Simioni P., Tormene D., Tognin G., Gavasso S., Bulato C.,
RA   Iacobelli N.P., Finn J.D., Spiezia L., Radu C., Arruda V.R.;
RT   "X-linked thrombophilia with a mutant factor IX (factor IX Padua).";
RL   N. Engl. J. Med. 361:1671-1675(2009).
RN   [87]
RP   VARIANTS HEMB ALA-194 AND HIS-241.
RX   PubMed=25470321; DOI=10.1111/hae.12553;
RA   Saini S., Hamasaki-Katagiri N., Pandey G.S., Yanover C., Guelcher C.,
RA   Simhadri V.L., Dandekar S., Guerrera M.F., Kimchi-Sarfaty C.,
RA   Sauna Z.E.;
RT   "Genetic determinants of immunogenicity to factor IX during the
RT   treatment of haemophilia B.";
RL   Haemophilia 21:210-218(2015).
RN   [88]
RP   VARIANTS HEMB SER-20; TYR-28; SER-46; ASP-54; GLU-58; ARG-84; HIS-138;
RP   GLN-226; ILE-284 DEL; MET-296; LYS-328; TYR-328; THR-414 AND
RP   TYR-LYS-THR-VAL-447 INS, AND CHARACTERIZATION OF VARIANTS HEMB SER-20;
RP   TYR-28; SER-46; ASP-54; GLU-58; ARG-84; HIS-138; GLN-226; ILE-284 DEL;
RP   MET-296; LYS-328; TYR-328; THR-414 AND TYR-LYS-THR-VAL-447 INS.
RX   PubMed=25251685; DOI=10.1111/hae.12534;
RA   Guo Z.P., Yang L.H., Qin X.Y., Liu X.E., Chen J.F., Zhang Y.F.;
RT   "Comprehensive analysis of phenotypes and genetics in 21 Chinese
RT   families with haemophilia B: characterization of five novel
RT   mutations.";
RL   Haemophilia 20:859-865(2014).
CC   -!- FUNCTION: Factor IX is a vitamin K-dependent plasma protein that
CC       participates in the intrinsic pathway of blood coagulation by
CC       converting factor X to its active form in the presence of Ca(2+)
CC       ions, phospholipids, and factor VIIIa.
CC       {ECO:0000269|PubMed:1730085, ECO:0000269|PubMed:19846852,
CC       ECO:0000269|PubMed:20121197, ECO:0000269|PubMed:20121198,
CC       ECO:0000269|PubMed:2592373, ECO:0000269|PubMed:8295821}.
CC   -!- CATALYTIC ACTIVITY: Selective cleavage of Arg-|-Ile bond in factor
CC       X to form factor Xa. {ECO:0000269|PubMed:12444082,
CC       ECO:0000269|PubMed:20121197, ECO:0000269|PubMed:20121198,
CC       ECO:0000269|PubMed:2592373}.
CC   -!- SUBUNIT: Heterodimer of a light chain and a heavy chain;
CC       disulfide-linked (PubMed:20121198, PubMed:20121197,
CC       PubMed:20080729). Interacts with SERPINC1.
CC       {ECO:0000269|PubMed:20004170, ECO:0000269|PubMed:20080729,
CC       ECO:0000269|PubMed:20121197, ECO:0000269|PubMed:20121198,
CC       ECO:0000269|PubMed:2592373}.
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:19846852,
CC       ECO:0000269|PubMed:2592373, ECO:0000269|PubMed:3857619,
CC       ECO:0000269|PubMed:8295821, ECO:0000269|PubMed:9169594}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P00740-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P00740-2; Sequence=VSP_047689;
CC   -!- TISSUE SPECIFICITY: Detected in blood plasma (at protein level)
CC       (PubMed:3857619, PubMed:8295821, PubMed:2592373, PubMed:9169594,
CC       PubMed:19846852). Synthesized primarily in the liver and secreted
CC       in plasma. {ECO:0000269|PubMed:19846852,
CC       ECO:0000269|PubMed:2592373, ECO:0000269|PubMed:3857619}.
CC   -!- DOMAIN: Calcium binds to the gamma-carboxyglutamic acid (Gla)
CC       residues in the Gla domain. Calcium can also bind, with stronger
CC       affinity, to another site beyond the Gla domain (PubMed:6425296).
CC       Under physiological ion concentrations, Ca(2+) is displaced by
CC       Mg(2+) from some of the gammaglutamate residues in the N-terminal
CC       Gla domain. This leads to a subtle conformation change that may
CC       affect the interaction with its binding protein (By similarity).
CC       {ECO:0000250|UniProtKB:P00741, ECO:0000269|PubMed:14722079,
CC       ECO:0000269|PubMed:1730085, ECO:0000269|PubMed:6425296}.
CC   -!- PTM: Activated by factor XIa, which excises the activation peptide
CC       (PubMed:9169594, PubMed:1730085). The propeptide can also be
CC       removed by snake venom protease (PubMed:20004170,
CC       PubMed:20080729). {ECO:0000269|PubMed:1730085,
CC       ECO:0000269|PubMed:20004170, ECO:0000269|PubMed:20080729,
CC       ECO:0000269|PubMed:2592373, ECO:0000269|PubMed:8295821,
CC       ECO:0000269|PubMed:9169594}.
CC   -!- PTM: The iron and 2-oxoglutarate dependent 3-hydroxylation of
CC       aspartate and asparagine is (R) stereospecific within EGF domains.
CC       {ECO:0000269|PubMed:6688526}.
CC   -!- PTM: Predominantly O-glucosylated at Ser-99 by POGLUT1 in vitro.
CC       Xylosylation at this site is minor.
CC   -!- DISEASE: Hemophilia B (HEMB) [MIM:306900]: An X-linked blood
CC       coagulation disorder characterized by a permanent tendency to
CC       hemorrhage, due to factor IX deficiency. It is phenotypically
CC       similar to hemophilia A, but patients present with fewer symptoms.
CC       Many patients are asymptomatic until the hemostatic system is
CC       stressed by surgery or trauma. {ECO:0000269|PubMed:10094553,
CC       ECO:0000269|PubMed:10698280, ECO:0000269|PubMed:11122099,
CC       ECO:0000269|PubMed:12588353, ECO:0000269|PubMed:12604421,
CC       ECO:0000269|PubMed:1346975, ECO:0000269|PubMed:1615485,
CC       ECO:0000269|PubMed:1902289, ECO:0000269|PubMed:1958666,
CC       ECO:0000269|PubMed:2162822, ECO:0000269|PubMed:2339358,
CC       ECO:0000269|PubMed:2372509, ECO:0000269|PubMed:2472424,
CC       ECO:0000269|PubMed:25251685, ECO:0000269|PubMed:25470321,
CC       ECO:0000269|PubMed:2592373, ECO:0000269|PubMed:2713493,
CC       ECO:0000269|PubMed:2714791, ECO:0000269|PubMed:2738071,
CC       ECO:0000269|PubMed:2753873, ECO:0000269|PubMed:2773937,
CC       ECO:0000269|PubMed:2775660, ECO:0000269|PubMed:3009023,
CC       ECO:0000269|PubMed:3243764, ECO:0000269|PubMed:3401602,
CC       ECO:0000269|PubMed:3790720, ECO:0000269|PubMed:6603618,
CC       ECO:0000269|PubMed:7981722, ECO:0000269|PubMed:8076946,
CC       ECO:0000269|PubMed:8199596, ECO:0000269|PubMed:8257988,
CC       ECO:0000269|PubMed:8295821, ECO:0000269|PubMed:8680410,
CC       ECO:0000269|PubMed:9222764, ECO:0000269|PubMed:9452115,
CC       ECO:0000269|PubMed:9590153, ECO:0000269|PubMed:9600455}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Note=Mutations in position 43 (Oxford-3, San Dimas) and
CC       46 (Cambridge) prevents cleavage of the propeptide
CC       (PubMed:12588353, PubMed:2738071, PubMed:3009023, PubMed:8295821,
CC       PubMed:9169594, PubMed:9600455, PubMed:25251685). Mutation in
CC       position 93 (Alabama) probably fails to bind to cell membranes
CC       (PubMed:3790720). Mutation in position 191 (Chapel-Hill) or in
CC       position 226 (Nagoya or Hilo) prevent cleavage of the activation
CC       peptide (PubMed:6603618, PubMed:8076946, PubMed:12588353,
CC       PubMed:2162822, PubMed:25251685, PubMed:2713493).
CC       {ECO:0000269|PubMed:12588353, ECO:0000269|PubMed:2162822,
CC       ECO:0000269|PubMed:25251685, ECO:0000269|PubMed:2713493,
CC       ECO:0000269|PubMed:2738071, ECO:0000269|PubMed:3009023,
CC       ECO:0000269|PubMed:3790720, ECO:0000269|PubMed:6603618,
CC       ECO:0000269|PubMed:8076946, ECO:0000269|PubMed:8295821,
CC       ECO:0000269|PubMed:9169594, ECO:0000269|PubMed:9600455}.
CC   -!- DISEASE: Thrombophilia, X-linked, due to factor IX defect (THPH8)
CC       [MIM:300807]: A hemostatic disorder characterized by a tendency to
CC       thrombosis. {ECO:0000269|PubMed:19846852}. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- PHARMACEUTICAL: Available under the name BeneFix (Baxter and
CC       American Home Products). Used to treat hemophilia B.
CC   -!- MISCELLANEOUS: In 1952, one of the earliest researchers of the
CC       disease, Dr. R.G. Macfarlane used the patient's surname,
CC       Christmas, to refer to the disease and also to refer to the
CC       clotting factor which he called the 'Christmas Factor' At the time
CC       Stephen Christmas was a 5-year-old boy. He died in 1993 at the age
CC       of 46 from acquired immunodeficiency syndrome contracted through
CC       treatment with blood products.
CC   -!- SIMILARITY: Belongs to the peptidase S1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00274}.
CC   -!- SIMILARITY: Contains 2 EGF-like domains. {ECO:0000255|PROSITE-
CC       ProRule:PRU00076}.
CC   -!- SIMILARITY: Contains 1 Gla (gamma-carboxy-glutamate) domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00463}.
CC   -!- SIMILARITY: Contains 1 peptidase S1 domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00274}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Factor IX entry;
CC       URL="https://en.wikipedia.org/wiki/Factor_IX";
CC   -!- WEB RESOURCE: Name=Factor IX Mutation Database;
CC       URL="http://www.factorix.org/";
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/f9/";
CC   -!- WEB RESOURCE: Name=BeneFix; Note=Clinical information on BeneFix;
CC       URL="http://www.pfizer.com/products/rx/rx_product_benefix.jsp";
CC   -!- WEB RESOURCE: Name=Protein Spotlight; Note=The Christmas Factor -
CC       Issue 41 of December 2003;
CC       URL="http://web.expasy.org/spotlight/back_issues/041";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; J00136; AAA98726.1; -; mRNA.
DR   EMBL; J00137; AAA52763.1; -; mRNA.
DR   EMBL; K02053; AAA56822.1; -; Genomic_DNA.
DR   EMBL; K02048; AAA56822.1; JOINED; Genomic_DNA.
DR   EMBL; K02049; AAA56822.1; JOINED; Genomic_DNA.
DR   EMBL; K02051; AAA56822.1; JOINED; Genomic_DNA.
DR   EMBL; K02052; AAA56822.1; JOINED; Genomic_DNA.
DR   EMBL; K02402; AAB59620.1; -; Genomic_DNA.
DR   EMBL; M11309; AAA52023.1; -; mRNA.
DR   EMBL; AL033403; CAI42103.1; -; Genomic_DNA.
DR   EMBL; AB186358; BAD89383.1; -; mRNA.
DR   EMBL; AF536327; AAM96188.1; -; Genomic_DNA.
DR   EMBL; FR846239; CCA61111.1; -; mRNA.
DR   EMBL; AK292749; BAF85438.1; -; mRNA.
DR   EMBL; CH471150; EAW88433.1; -; Genomic_DNA.
DR   EMBL; BC109214; AAI09215.1; -; mRNA.
DR   EMBL; BC109215; AAI09216.1; -; mRNA.
DR   EMBL; S68634; AAB29758.1; -; Genomic_DNA.
DR   EMBL; M35672; AAA51981.1; -; mRNA.
DR   EMBL; M19063; AAA52456.1; -; Genomic_DNA.
DR   EMBL; S66752; AAB28588.1; -; Genomic_DNA.
DR   CCDS; CCDS14666.1; -. [P00740-1]
DR   PIR; A00922; KFHU.
DR   RefSeq; NP_000124.1; NM_000133.3. [P00740-1]
DR   RefSeq; NP_001300842.1; NM_001313913.1. [P00740-2]
DR   UniGene; Hs.522798; -.
DR   PDB; 1CFH; NMR; -; A=47-93.
DR   PDB; 1CFI; NMR; -; A=47-93.
DR   PDB; 1EDM; X-ray; 1.50 A; B/C=92-130.
DR   PDB; 1IXA; NMR; -; A=92-130.
DR   PDB; 1MGX; NMR; -; A=47-93.
DR   PDB; 1NL0; X-ray; 2.20 A; G=47-91.
DR   PDB; 1RFN; X-ray; 2.80 A; A=227-461, B=133-188.
DR   PDB; 2WPH; X-ray; 1.50 A; E=133-191, S=227-461.
DR   PDB; 2WPI; X-ray; 1.99 A; E=133-191, S=227-461.
DR   PDB; 2WPJ; X-ray; 1.60 A; E=133-191, S=227-461.
DR   PDB; 2WPK; X-ray; 2.21 A; E=133-191, S=227-461.
DR   PDB; 2WPL; X-ray; 1.82 A; E=133-191, S=227-461.
DR   PDB; 2WPM; X-ray; 2.00 A; E=133-191, S=227-461.
DR   PDB; 3KCG; X-ray; 1.70 A; H=227-461, L=131-188.
DR   PDB; 3LC3; X-ray; 1.90 A; A/C=227-461, B/D=133-188.
DR   PDB; 3LC5; X-ray; 2.62 A; A=227-461, B=133-188.
DR   PDB; 4WM0; X-ray; 2.37 A; D=92-130.
DR   PDB; 4WMA; X-ray; 1.62 A; D=92-130.
DR   PDB; 4WMB; X-ray; 2.05 A; D=92-130.
DR   PDB; 4WMI; X-ray; 1.87 A; D=92-130.
DR   PDB; 4WMK; X-ray; 2.08 A; D=92-130.
DR   PDB; 4WN2; X-ray; 1.95 A; D=92-130.
DR   PDB; 4WNH; X-ray; 1.95 A; D=92-130.
DR   PDB; 4YZU; X-ray; 1.41 A; A=227-461, B=131-191.
DR   PDB; 4Z0K; X-ray; 1.41 A; A=227-461, B=131-191.
DR   PDB; 4ZAE; X-ray; 1.86 A; A=227-461, B=131-191.
DR   PDB; 5EGM; X-ray; 1.84 A; A=227-461, B=131-191.
DR   PDBsum; 1CFH; -.
DR   PDBsum; 1CFI; -.
DR   PDBsum; 1EDM; -.
DR   PDBsum; 1IXA; -.
DR   PDBsum; 1MGX; -.
DR   PDBsum; 1NL0; -.
DR   PDBsum; 1RFN; -.
DR   PDBsum; 2WPH; -.
DR   PDBsum; 2WPI; -.
DR   PDBsum; 2WPJ; -.
DR   PDBsum; 2WPK; -.
DR   PDBsum; 2WPL; -.
DR   PDBsum; 2WPM; -.
DR   PDBsum; 3KCG; -.
DR   PDBsum; 3LC3; -.
DR   PDBsum; 3LC5; -.
DR   PDBsum; 4WM0; -.
DR   PDBsum; 4WMA; -.
DR   PDBsum; 4WMB; -.
DR   PDBsum; 4WMI; -.
DR   PDBsum; 4WMK; -.
DR   PDBsum; 4WN2; -.
DR   PDBsum; 4WNH; -.
DR   PDBsum; 4YZU; -.
DR   PDBsum; 4Z0K; -.
DR   PDBsum; 4ZAE; -.
DR   PDBsum; 5EGM; -.
DR   ProteinModelPortal; P00740; -.
DR   SMR; P00740; 47-191, 227-461.
DR   BioGrid; 108456; 33.
DR   DIP; DIP-58520N; -.
DR   IntAct; P00740; 1.
DR   STRING; 9606.ENSP00000218099; -.
DR   BindingDB; P00740; -.
DR   ChEMBL; CHEMBL2016; -.
DR   DrugBank; DB00025; Antihemophilic Factor (Recombinant).
DR   DrugBank; DB00170; Menadione.
DR   GuidetoPHARMACOLOGY; 2364; -.
DR   Allergome; 9616; Hom s Factor IX.
DR   MEROPS; S01.214; -.
DR   iPTMnet; P00740; -.
DR   PhosphoSite; P00740; -.
DR   UniCarbKB; P00740; -.
DR   BioMuta; F9; -.
DR   PaxDb; P00740; -.
DR   PeptideAtlas; P00740; -.
DR   PRIDE; P00740; -.
DR   DNASU; 2158; -.
DR   Ensembl; ENST00000218099; ENSP00000218099; ENSG00000101981. [P00740-1]
DR   Ensembl; ENST00000394090; ENSP00000377650; ENSG00000101981. [P00740-2]
DR   GeneID; 2158; -.
DR   KEGG; hsa:2158; -.
DR   UCSC; uc004fas.1; human. [P00740-1]
DR   CTD; 2158; -.
DR   GeneCards; F9; -.
DR   GeneReviews; F9; -.
DR   HGNC; HGNC:3551; F9.
DR   MalaCards; F9; -.
DR   MIM; 300746; gene.
DR   MIM; 300807; phenotype.
DR   MIM; 306900; phenotype.
DR   neXtProt; NX_P00740; -.
DR   Orphanet; 169799; Mild hemophilia B.
DR   Orphanet; 169796; Moderately severe hemophilia B.
DR   Orphanet; 169793; Severe hemophilia B.
DR   Orphanet; 177929; Symptomatic form of hemophilia B in female carriers.
DR   PharmGKB; PA27954; -.
DR   eggNOG; ENOG410IGPV; Eukaryota.
DR   eggNOG; COG5640; LUCA.
DR   GeneTree; ENSGT00760000118890; -.
DR   HOGENOM; HOG000251821; -.
DR   HOVERGEN; HBG013304; -.
DR   InParanoid; P00740; -.
DR   KO; K01321; -.
DR   OMA; MKGKYGI; -.
DR   OrthoDB; EOG75B84T; -.
DR   PhylomeDB; P00740; -.
DR   TreeFam; TF327329; -.
DR   BRENDA; 3.4.21.22; 2681.
DR   Reactome; R-HSA-140834; Extrinsic Pathway of Fibrin Clot Formation.
DR   Reactome; R-HSA-140837; Intrinsic Pathway of Fibrin Clot Formation.
DR   Reactome; R-HSA-159740; Gamma-carboxylation of protein precursors.
DR   Reactome; R-HSA-159763; Transport of gamma-carboxylated protein precursors from the endoplasmic reticulum to the Golgi apparatus.
DR   Reactome; R-HSA-159782; Removal of aminoterminal propeptides from gamma-carboxylated proteins.
DR   SABIO-RK; P00740; -.
DR   EvolutionaryTrace; P00740; -.
DR   GeneWiki; Factor_IX; -.
DR   GenomeRNAi; 2158; -.
DR   NextBio; 8719; -.
DR   PMAP-CutDB; P00740; -.
DR   PRO; PR:P00740; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   Bgee; P00740; -.
DR   CleanEx; HS_F9; -.
DR   Genevisible; P00740; HS.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; NAS:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0005796; C:Golgi lumen; TAS:Reactome.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0005509; F:calcium ion binding; IDA:UniProtKB.
DR   GO; GO:0004175; F:endopeptidase activity; IDA:UniProtKB.
DR   GO; GO:0004252; F:serine-type endopeptidase activity; TAS:ProtInc.
DR   GO; GO:0007596; P:blood coagulation; IDA:UniProtKB.
DR   GO; GO:0007598; P:blood coagulation, extrinsic pathway; TAS:Reactome.
DR   GO; GO:0007597; P:blood coagulation, intrinsic pathway; TAS:Reactome.
DR   GO; GO:0044267; P:cellular protein metabolic process; TAS:Reactome.
DR   GO; GO:0017187; P:peptidyl-glutamic acid carboxylation; TAS:Reactome.
DR   GO; GO:0043687; P:post-translational protein modification; TAS:Reactome.
DR   GO; GO:0006508; P:proteolysis; IDA:UniProtKB.
DR   GO; GO:0031638; P:zymogen activation; IDA:UniProtKB.
DR   Gene3D; 4.10.740.10; -; 1.
DR   InterPro; IPR017857; Coagulation_fac_subgr_Gla_dom.
DR   InterPro; IPR001881; EGF-like_Ca-bd_dom.
DR   InterPro; IPR013032; EGF-like_CS.
DR   InterPro; IPR000742; EGF-like_dom.
DR   InterPro; IPR000152; EGF-type_Asp/Asn_hydroxyl_site.
DR   InterPro; IPR018097; EGF_Ca-bd_CS.
DR   InterPro; IPR000294; GLA_domain.
DR   InterPro; IPR012224; Pept_S1A_FX.
DR   InterPro; IPR018114; Peptidase_S1_AS.
DR   InterPro; IPR009003; Peptidase_S1_PA.
DR   InterPro; IPR001314; Peptidase_S1A.
DR   InterPro; IPR001254; Trypsin_dom.
DR   Pfam; PF00008; EGF; 1.
DR   Pfam; PF00594; Gla; 1.
DR   Pfam; PF00089; Trypsin; 1.
DR   PIRSF; PIRSF001143; Factor_X; 1.
DR   PRINTS; PR00722; CHYMOTRYPSIN.
DR   PRINTS; PR00001; GLABLOOD.
DR   SMART; SM00181; EGF; 1.
DR   SMART; SM00179; EGF_CA; 1.
DR   SMART; SM00069; GLA; 1.
DR   SMART; SM00020; Tryp_SPc; 1.
DR   SUPFAM; SSF50494; SSF50494; 1.
DR   SUPFAM; SSF57630; SSF57630; 1.
DR   PROSITE; PS00010; ASX_HYDROXYL; 1.
DR   PROSITE; PS00022; EGF_1; 1.
DR   PROSITE; PS01186; EGF_2; 2.
DR   PROSITE; PS50026; EGF_3; 1.
DR   PROSITE; PS01187; EGF_CA; 1.
DR   PROSITE; PS00011; GLA_1; 1.
DR   PROSITE; PS50998; GLA_2; 1.
DR   PROSITE; PS50240; TRYPSIN_DOM; 1.
DR   PROSITE; PS00134; TRYPSIN_HIS; 1.
DR   PROSITE; PS00135; TRYPSIN_SER; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Blood coagulation; Calcium;
KW   Cleavage on pair of basic residues; Complete proteome;
KW   Direct protein sequencing; Disease mutation; Disulfide bond;
KW   EGF-like domain; Gamma-carboxyglutamic acid; Glycoprotein; Hemophilia;
KW   Hemostasis; Hydrolase; Hydroxylation; Magnesium; Metal-binding;
KW   Pharmaceutical; Phosphoprotein; Polymorphism; Protease;
KW   Reference proteome; Repeat; Secreted; Serine protease; Signal;
KW   Sulfation; Thrombophilia; Zymogen.
FT   SIGNAL        1     28       {ECO:0000255}.
FT   PROPEP       29     46       {ECO:0000269|PubMed:2592373}.
FT                                /FTId=PRO_0000027755.
FT   CHAIN        47    461       Coagulation factor IX.
FT                                /FTId=PRO_0000027756.
FT   CHAIN        47    191       Coagulation factor IXa light chain.
FT                                /FTId=PRO_0000027757.
FT   PROPEP      192    226       Activation peptide.
FT                                /FTId=PRO_0000027758.
FT   CHAIN       227    461       Coagulation factor IXa heavy chain.
FT                                /FTId=PRO_0000027759.
FT   DOMAIN       47     92       Gla. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00463}.
FT   DOMAIN       93    129       EGF-like 1; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      130    171       EGF-like 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      227    459       Peptidase S1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00274}.
FT   ACT_SITE    267    267       Charge relay system.
FT                                {ECO:0000269|PubMed:20004170,
FT                                ECO:0000269|PubMed:659613}.
FT   ACT_SITE    315    315       Charge relay system.
FT                                {ECO:0000269|PubMed:659613}.
FT   ACT_SITE    411    411       Charge relay system.
FT                                {ECO:0000269|PubMed:20004170,
FT                                ECO:0000269|PubMed:659613}.
FT   METAL        47     47       Calcium 1; via carbonyl oxygen.
FT                                {ECO:0000244|PDB:1NL0,
FT                                ECO:0000269|PubMed:14722079}.
FT   METAL        48     48       Calcium 2. {ECO:0000244|PDB:1NL0,
FT                                ECO:0000269|PubMed:14722079}.
FT   METAL        53     53       Calcium 1; via 4-carboxyglutamate.
FT                                {ECO:0000244|PDB:1NL0,
FT                                ECO:0000305|PubMed:14722079}.
FT   METAL        53     53       Calcium 2; via 4-carboxyglutamate.
FT                                {ECO:0000244|PDB:1NL0,
FT                                ECO:0000305|PubMed:14722079}.
FT   METAL        54     54       Calcium 2; via 4-carboxyglutamate.
FT                                {ECO:0000244|PDB:1NL0,
FT                                ECO:0000305|PubMed:14722079}.
FT   METAL        54     54       Calcium 3; via 4-carboxyglutamate.
FT                                {ECO:0000244|PDB:1NL0,
FT                                ECO:0000305|PubMed:14722079}.
FT   METAL        61     61       Calcium 4 or magnesium 1; via 4-
FT                                carboxyglutamate. {ECO:0000244|PDB:1NL0,
FT                                ECO:0000250|UniProtKB:P00741,
FT                                ECO:0000305|PubMed:14722079}.
FT   METAL        63     63       Calcium 1; via 4-carboxyglutamate.
FT                                {ECO:0000244|PDB:1NL0,
FT                                ECO:0000305|PubMed:14722079}.
FT   METAL        63     63       Calcium 2; via 4-carboxyglutamate.
FT                                {ECO:0000244|PDB:1NL0,
FT                                ECO:0000305|PubMed:14722079}.
FT   METAL        63     63       Calcium 3; via 4-carboxyglutamate.
FT                                {ECO:0000244|PDB:1NL0,
FT                                ECO:0000305|PubMed:14722079}.
FT   METAL        66     66       Calcium 4 or magnesium 1; via 4-
FT                                carboxyglutamate. {ECO:0000244|PDB:1NL0,
FT                                ECO:0000250|UniProtKB:P00741,
FT                                ECO:0000305|PubMed:14722079}.
FT   METAL        67     67       Calcium 1; via 4-carboxyglutamate.
FT                                {ECO:0000244|PDB:1NL0,
FT                                ECO:0000305|PubMed:14722079}.
FT   METAL        72     72       Calcium 5 or magnesium 2; via 4-
FT                                carboxyglutamate. {ECO:0000244|PDB:1NL0,
FT                                ECO:0000250|UniProtKB:P00741,
FT                                ECO:0000305|PubMed:14722079}.
FT   METAL        73     73       Calcium 2; via 4-carboxyglutamate.
FT                                {ECO:0000244|PDB:1NL0,
FT                                ECO:0000305|PubMed:14722079}.
FT   METAL        73     73       Calcium 3; via 4-carboxyglutamate.
FT                                {ECO:0000244|PDB:1NL0,
FT                                ECO:0000305|PubMed:14722079}.
FT   METAL        76     76       Calcium 3; via 4-carboxyglutamate.
FT                                {ECO:0000244|PDB:1NL0,
FT                                ECO:0000305|PubMed:14722079}.
FT   METAL        76     76       Calcium 5 or magnesium 2; via 4-
FT                                carboxyglutamate. {ECO:0000244|PDB:1NL0,
FT                                ECO:0000305|PubMed:14722079}.
FT   METAL        76     76       Calcium 5; via 4-carboxyglutamate.
FT                                {ECO:0000244|PDB:1NL0,
FT                                ECO:0000305|PubMed:14722079}.
FT   METAL        82     82       Calcium 6 or magnesium 3; via 4-
FT                                carboxyglutamate.
FT                                {ECO:0000250|UniProtKB:P00741}.
FT   METAL        86     86       Calcium 6 or magnesium 3; via 4-
FT                                carboxyglutamate.
FT                                {ECO:0000250|UniProtKB:P00741}.
FT   METAL        93     93       Calcium 7. {ECO:0000244|PDB:1EDM,
FT                                ECO:0000269|PubMed:7606779}.
FT   METAL        94     94       Calcium 7; via carbonyl oxygen.
FT                                {ECO:0000244|PDB:1EDM,
FT                                ECO:0000269|PubMed:7606779}.
FT   METAL        96     96       Calcium 7. {ECO:0000244|PDB:1EDM,
FT                                ECO:0000269|PubMed:7606779}.
FT   METAL       110    110       Calcium 7. {ECO:0000244|PDB:1EDM,
FT                                ECO:0000269|PubMed:7606779}.
FT   METAL       111    111       Calcium 7; via carbonyl oxygen.
FT                                {ECO:0000244|PDB:1EDM,
FT                                ECO:0000269|PubMed:7606779}.
FT   METAL       281    281       Calcium 8. {ECO:0000244|PDB:1RFN,
FT                                ECO:0000244|PDB:2WPH,
FT                                ECO:0000244|PDB:2WPI,
FT                                ECO:0000244|PDB:2WPJ,
FT                                ECO:0000244|PDB:2WPK,
FT                                ECO:0000244|PDB:2WPM,
FT                                ECO:0000244|PDB:3KCG,
FT                                ECO:0000244|PDB:3LC3,
FT                                ECO:0000244|PDB:3LC5,
FT                                ECO:0000269|PubMed:10467148,
FT                                ECO:0000269|PubMed:20004170,
FT                                ECO:0000269|PubMed:20080729,
FT                                ECO:0000269|PubMed:20121197,
FT                                ECO:0000269|PubMed:20121198}.
FT   METAL       283    283       Calcium 8; via carbonyl oxygen.
FT                                {ECO:0000244|PDB:1RFN,
FT                                ECO:0000244|PDB:2WPH,
FT                                ECO:0000244|PDB:2WPI,
FT                                ECO:0000244|PDB:2WPJ,
FT                                ECO:0000244|PDB:2WPK,
FT                                ECO:0000244|PDB:2WPM,
FT                                ECO:0000244|PDB:3KCG,
FT                                ECO:0000244|PDB:3LC3,
FT                                ECO:0000244|PDB:3LC5,
FT                                ECO:0000269|PubMed:10467148,
FT                                ECO:0000269|PubMed:20004170,
FT                                ECO:0000269|PubMed:20080729,
FT                                ECO:0000269|PubMed:20121197,
FT                                ECO:0000269|PubMed:20121198}.
FT   METAL       286    286       Calcium 8; via carbonyl oxygen.
FT                                {ECO:0000244|PDB:1RFN,
FT                                ECO:0000244|PDB:2WPH,
FT                                ECO:0000244|PDB:2WPI,
FT                                ECO:0000244|PDB:2WPJ,
FT                                ECO:0000244|PDB:2WPK,
FT                                ECO:0000244|PDB:2WPM,
FT                                ECO:0000244|PDB:3KCG,
FT                                ECO:0000244|PDB:3LC3,
FT                                ECO:0000244|PDB:3LC5,
FT                                ECO:0000269|PubMed:10467148,
FT                                ECO:0000269|PubMed:20004170,
FT                                ECO:0000269|PubMed:20080729,
FT                                ECO:0000269|PubMed:20121197,
FT                                ECO:0000269|PubMed:20121198}.
FT   METAL       288    288       Calcium 8. {ECO:0000244|PDB:1RFN,
FT                                ECO:0000244|PDB:2WPH,
FT                                ECO:0000244|PDB:2WPI,
FT                                ECO:0000244|PDB:2WPJ,
FT                                ECO:0000244|PDB:2WPK,
FT                                ECO:0000244|PDB:2WPM,
FT                                ECO:0000244|PDB:3KCG,
FT                                ECO:0000244|PDB:3LC3,
FT                                ECO:0000244|PDB:3LC5,
FT                                ECO:0000269|PubMed:10467148,
FT                                ECO:0000269|PubMed:20004170,
FT                                ECO:0000269|PubMed:20080729,
FT                                ECO:0000269|PubMed:20121197,
FT                                ECO:0000269|PubMed:20121198}.
FT   METAL       291    291       Calcium 8. {ECO:0000244|PDB:2WPH,
FT                                ECO:0000244|PDB:2WPI,
FT                                ECO:0000244|PDB:2WPJ,
FT                                ECO:0000244|PDB:2WPK,
FT                                ECO:0000244|PDB:2WPM,
FT                                ECO:0000244|PDB:3KCG,
FT                                ECO:0000244|PDB:3LC3,
FT                                ECO:0000244|PDB:3LC5,
FT                                ECO:0000269|PubMed:10467148,
FT                                ECO:0000269|PubMed:20004170,
FT                                ECO:0000269|PubMed:20080729,
FT                                ECO:0000269|PubMed:20121197,
FT                                ECO:0000269|PubMed:20121198}.
FT   SITE        191    192       Cleavage; by factor XIa.
FT   SITE        226    227       Cleavage; by factor XIa.
FT   MOD_RES      53     53       4-carboxyglutamate.
FT                                {ECO:0000250|UniProtKB:P00741,
FT                                ECO:0000255|PROSITE-ProRule:PRU00463}.
FT   MOD_RES      54     54       4-carboxyglutamate.
FT                                {ECO:0000250|UniProtKB:P00741,
FT                                ECO:0000255|PROSITE-ProRule:PRU00463}.
FT   MOD_RES      61     61       4-carboxyglutamate.
FT                                {ECO:0000250|UniProtKB:P00741,
FT                                ECO:0000255|PROSITE-ProRule:PRU00463}.
FT   MOD_RES      63     63       4-carboxyglutamate.
FT                                {ECO:0000250|UniProtKB:P00741,
FT                                ECO:0000255|PROSITE-ProRule:PRU00463}.
FT   MOD_RES      66     66       4-carboxyglutamate.
FT                                {ECO:0000250|UniProtKB:P00741,
FT                                ECO:0000255|PROSITE-ProRule:PRU00463}.
FT   MOD_RES      67     67       4-carboxyglutamate.
FT                                {ECO:0000250|UniProtKB:P00741,
FT                                ECO:0000255|PROSITE-ProRule:PRU00463}.
FT   MOD_RES      72     72       4-carboxyglutamate.
FT                                {ECO:0000250|UniProtKB:P00741,
FT                                ECO:0000255|PROSITE-ProRule:PRU00463}.
FT   MOD_RES      73     73       4-carboxyglutamate.
FT                                {ECO:0000250|UniProtKB:P00741,
FT                                ECO:0000255|PROSITE-ProRule:PRU00463}.
FT   MOD_RES      76     76       4-carboxyglutamate.
FT                                {ECO:0000250|UniProtKB:P00741,
FT                                ECO:0000255|PROSITE-ProRule:PRU00463}.
FT   MOD_RES      79     79       4-carboxyglutamate.
FT                                {ECO:0000250|UniProtKB:P00741,
FT                                ECO:0000255|PROSITE-ProRule:PRU00463}.
FT   MOD_RES      82     82       4-carboxyglutamate.
FT                                {ECO:0000250|UniProtKB:P00741,
FT                                ECO:0000255|PROSITE-ProRule:PRU00463}.
FT   MOD_RES      86     86       4-carboxyglutamate.
FT                                {ECO:0000250|UniProtKB:P00741,
FT                                ECO:0000255|PROSITE-ProRule:PRU00463}.
FT   MOD_RES     110    110       (3R)-3-hydroxyaspartate.
FT                                {ECO:0000269|PubMed:6688526}.
FT   MOD_RES     114    114       Phosphoserine. {ECO:0000269|Ref.28}.
FT   MOD_RES     201    201       Sulfotyrosine.
FT                                {ECO:0000269|PubMed:11133752}.
FT   MOD_RES     204    204       Phosphoserine.
FT                                {ECO:0000269|PubMed:11133752,
FT                                ECO:0000269|PubMed:25456591}.
FT   MOD_RES     205    205       Phosphothreonine; alternate.
FT                                {ECO:0000269|PubMed:25456591}.
FT   CARBOHYD     85     85       O-linked (GalNAc...).
FT                                {ECO:0000269|PubMed:25456591}.
FT   CARBOHYD     99     99       O-linked (Glc...); alternate.
FT                                {ECO:0000269|PubMed:21949356,
FT                                ECO:0000269|PubMed:25456591}.
FT                                /FTId=CAR_000009.
FT   CARBOHYD     99     99       O-linked (Xyl...); alternate.
FT                                {ECO:0000269|PubMed:21949356}.
FT   CARBOHYD    107    107       O-linked (Fuc...).
FT                                {ECO:0000269|PubMed:25456591}.
FT                                /FTId=CAR_000010.
FT   CARBOHYD    203    203       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    205    205       O-linked (GalNAc...); alternate.
FT                                {ECO:0000269|PubMed:25456591,
FT                                ECO:0000269|PubMed:8172892}.
FT   CARBOHYD    213    213       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    215    215       O-linked (GalNAc...).
FT                                {ECO:0000269|PubMed:25456591,
FT                                ECO:0000269|PubMed:8172892}.
FT   CARBOHYD    225    225       O-linked (GalNAc...).
FT                                {ECO:0000269|PubMed:25456591}.
FT   DISULFID     64     69       {ECO:0000250|UniProtKB:P00741}.
FT   DISULFID     97    108       {ECO:0000244|PDB:1EDM,
FT                                ECO:0000244|PDB:1IXA,
FT                                ECO:0000269|PubMed:1304885,
FT                                ECO:0000269|PubMed:7606779}.
FT   DISULFID    102    117       {ECO:0000244|PDB:1EDM,
FT                                ECO:0000244|PDB:1IXA,
FT                                ECO:0000269|PubMed:1304885,
FT                                ECO:0000269|PubMed:7606779}.
FT   DISULFID    119    128       {ECO:0000244|PDB:1EDM,
FT                                ECO:0000244|PDB:1IXA,
FT                                ECO:0000269|PubMed:1304885,
FT                                ECO:0000269|PubMed:7606779}.
FT   DISULFID    134    145       {ECO:0000244|PDB:1RFN,
FT                                ECO:0000244|PDB:2WPH,
FT                                ECO:0000244|PDB:2WPI,
FT                                ECO:0000244|PDB:2WPJ,
FT                                ECO:0000244|PDB:2WPK,
FT                                ECO:0000244|PDB:2WPL,
FT                                ECO:0000244|PDB:2WPM,
FT                                ECO:0000244|PDB:3KCG,
FT                                ECO:0000244|PDB:3LC3,
FT                                ECO:0000244|PDB:3LC5,
FT                                ECO:0000269|PubMed:20004170,
FT                                ECO:0000269|PubMed:20080729,
FT                                ECO:0000269|PubMed:20121197,
FT                                ECO:0000269|PubMed:20121198}.
FT   DISULFID    141    155       {ECO:0000244|PDB:1RFN,
FT                                ECO:0000244|PDB:2WPH,
FT                                ECO:0000244|PDB:2WPI,
FT                                ECO:0000244|PDB:2WPJ,
FT                                ECO:0000244|PDB:2WPK,
FT                                ECO:0000244|PDB:2WPL,
FT                                ECO:0000244|PDB:2WPM,
FT                                ECO:0000244|PDB:3KCG,
FT                                ECO:0000244|PDB:3LC3,
FT                                ECO:0000244|PDB:3LC5,
FT                                ECO:0000269|PubMed:20004170,
FT                                ECO:0000269|PubMed:20080729,
FT                                ECO:0000269|PubMed:20121197,
FT                                ECO:0000269|PubMed:20121198}.
FT   DISULFID    157    170       {ECO:0000244|PDB:1RFN,
FT                                ECO:0000244|PDB:2WPH,
FT                                ECO:0000244|PDB:2WPI,
FT                                ECO:0000244|PDB:2WPJ,
FT                                ECO:0000244|PDB:2WPK,
FT                                ECO:0000244|PDB:2WPL,
FT                                ECO:0000244|PDB:2WPM,
FT                                ECO:0000244|PDB:3KCG,
FT                                ECO:0000244|PDB:3LC3,
FT                                ECO:0000244|PDB:3LC5,
FT                                ECO:0000269|PubMed:20004170,
FT                                ECO:0000269|PubMed:20080729,
FT                                ECO:0000269|PubMed:20121197,
FT                                ECO:0000269|PubMed:20121198}.
FT   DISULFID    178    335       Interchain (between light and heavy
FT                                chains). {ECO:0000244|PDB:1RFN,
FT                                ECO:0000244|PDB:2WPH,
FT                                ECO:0000244|PDB:2WPI,
FT                                ECO:0000244|PDB:2WPJ,
FT                                ECO:0000244|PDB:2WPK,
FT                                ECO:0000244|PDB:2WPL,
FT                                ECO:0000244|PDB:2WPM,
FT                                ECO:0000244|PDB:3KCG,
FT                                ECO:0000244|PDB:3LC3,
FT                                ECO:0000244|PDB:3LC5,
FT                                ECO:0000269|PubMed:20004170,
FT                                ECO:0000269|PubMed:20080729,
FT                                ECO:0000269|PubMed:20121197,
FT                                ECO:0000269|PubMed:20121198}.
FT   DISULFID    252    268       {ECO:0000244|PDB:1RFN,
FT                                ECO:0000244|PDB:2WPH,
FT                                ECO:0000244|PDB:2WPI,
FT                                ECO:0000244|PDB:2WPJ,
FT                                ECO:0000244|PDB:2WPK,
FT                                ECO:0000244|PDB:2WPL,
FT                                ECO:0000244|PDB:2WPM,
FT                                ECO:0000244|PDB:3KCG,
FT                                ECO:0000244|PDB:3LC3,
FT                                ECO:0000244|PDB:3LC5,
FT                                ECO:0000269|PubMed:20004170,
FT                                ECO:0000269|PubMed:20080729,
FT                                ECO:0000269|PubMed:20121197,
FT                                ECO:0000269|PubMed:20121198}.
FT   DISULFID    382    396       {ECO:0000244|PDB:1RFN,
FT                                ECO:0000244|PDB:2WPH,
FT                                ECO:0000244|PDB:2WPI,
FT                                ECO:0000244|PDB:2WPJ,
FT                                ECO:0000244|PDB:2WPK,
FT                                ECO:0000244|PDB:2WPL,
FT                                ECO:0000244|PDB:2WPM,
FT                                ECO:0000244|PDB:3KCG,
FT                                ECO:0000244|PDB:3LC3,
FT                                ECO:0000244|PDB:3LC5,
FT                                ECO:0000269|PubMed:20004170,
FT                                ECO:0000269|PubMed:20080729,
FT                                ECO:0000269|PubMed:20121197,
FT                                ECO:0000269|PubMed:20121198}.
FT   DISULFID    407    435       {ECO:0000244|PDB:1RFN,
FT                                ECO:0000244|PDB:2WPH,
FT                                ECO:0000244|PDB:2WPI,
FT                                ECO:0000244|PDB:2WPJ,
FT                                ECO:0000244|PDB:2WPK,
FT                                ECO:0000244|PDB:2WPL,
FT                                ECO:0000244|PDB:2WPM,
FT                                ECO:0000244|PDB:3KCG,
FT                                ECO:0000244|PDB:3LC3,
FT                                ECO:0000244|PDB:3LC5,
FT                                ECO:0000269|PubMed:20004170,
FT                                ECO:0000269|PubMed:20080729,
FT                                ECO:0000269|PubMed:20121197,
FT                                ECO:0000269|PubMed:20121198}.
FT   VAR_SEQ      93    130       Missing (in isoform 2).
FT                                {ECO:0000303|Ref.6}.
FT                                /FTId=VSP_047689.
FT   VARIANT       7      7       I -> F (in dbSNP:rs150190385).
FT                                {ECO:0000269|PubMed:2773937}.
FT                                /FTId=VAR_006520.
FT   VARIANT      17     17       I -> N (in HEMB; severe; UK 22).
FT                                /FTId=VAR_006521.
FT   VARIANT      20     20       L -> S (in HEMB; unknown pathological
FT                                significance; decreased protein
FT                                abundance; decreased function in blood
FT                                coagulation).
FT                                {ECO:0000269|PubMed:25251685}.
FT                                /FTId=VAR_073975.
FT   VARIANT      28     28       C -> R (in HEMB; moderate; HB130).
FT                                /FTId=VAR_006522.
FT   VARIANT      28     28       C -> Y (in HEMB; decreased protein
FT                                abundance; decreased function in blood
FT                                coagulation).
FT                                {ECO:0000269|PubMed:12588353,
FT                                ECO:0000269|PubMed:25251685}.
FT                                /FTId=VAR_017343.
FT   VARIANT      30     30       V -> I (in HEMB).
FT                                /FTId=VAR_006523.
FT   VARIANT      37     37       A -> T (in warfarin sensitivity; reduced
FT                                affinity of the glutamate carboxylase for
FT                                the factor IX precursor).
FT                                {ECO:0000269|PubMed:8833911}.
FT                                /FTId=VAR_017307.
FT   VARIANT      43     43       R -> L (in HEMB; severe; Bendorf, Beuten,
FT                                Gleiwitz; impairs removal of propeptide).
FT                                {ECO:0000269|PubMed:12588353,
FT                                ECO:0000269|PubMed:9169594}.
FT                                /FTId=VAR_006525.
FT   VARIANT      43     43       R -> Q (in HEMB; severe; San Dimas,
FT                                Oxford-3, Strasbourg-2; impairs removal
FT                                of propeptide).
FT                                {ECO:0000269|PubMed:12588353,
FT                                ECO:0000269|PubMed:2738071,
FT                                ECO:0000269|PubMed:3009023,
FT                                ECO:0000269|PubMed:8295821,
FT                                ECO:0000269|PubMed:9169594,
FT                                ECO:0000269|PubMed:9600455}.
FT                                /FTId=VAR_006524.
FT   VARIANT      43     43       R -> W (in HEMB; severe; Boxtel, Heiden,
FT                                Lienen; impairs removal of propeptide).
FT                                {ECO:0000269|PubMed:12604421,
FT                                ECO:0000269|PubMed:9169594,
FT                                ECO:0000269|PubMed:9600455}.
FT                                /FTId=VAR_006526.
FT   VARIANT      45     45       K -> N (in HEMB; severe; Seattle E).
FT                                /FTId=VAR_006527.
FT   VARIANT      46     46       R -> S (in HEMB; severe; Cambridge;
FT                                impaired processing of the propeptide;
FT                                impaired gamma-carboxylation; decreased
FT                                protein abundance; loss of function in
FT                                blood coagulation).
FT                                {ECO:0000269|PubMed:25251685}.
FT                                /FTId=VAR_006528.
FT   VARIANT      46     46       R -> T (in HEMB; severe).
FT                                {ECO:0000269|PubMed:9600455}.
FT                                /FTId=VAR_006529.
FT   VARIANT      48     48       N -> I (in HEMB; severe; Calgary-16).
FT                                /FTId=VAR_006530.
FT   VARIANT      49     49       S -> P (in HEMB).
FT                                /FTId=VAR_006531.
FT   VARIANT      52     52       L -> S (in HEMB; severe; Gla mutant).
FT                                {ECO:0000269|PubMed:12588353}.
FT                                /FTId=VAR_017344.
FT   VARIANT      53     53       E -> A (in HEMB; severe; Oxford-B2; Gla
FT                                mutant).
FT                                /FTId=VAR_006532.
FT   VARIANT      54     54       E -> D (in HEMB; unknown pathological
FT                                significance; no effect on protein
FT                                abundance; loss of function in blood
FT                                coagulation).
FT                                {ECO:0000269|PubMed:25251685}.
FT                                /FTId=VAR_073976.
FT   VARIANT      54     54       E -> G (in HEMB; severe; HB151; Gla
FT                                mutant).
FT                                /FTId=VAR_006533.
FT   VARIANT      55     55       F -> C (in HEMB).
FT                                /FTId=VAR_006534.
FT   VARIANT      58     58       G -> A (in HEMB; severe; Hong Kong-1).
FT                                /FTId=VAR_006535.
FT   VARIANT      58     58       G -> E (in HEMB; unknown pathological
FT                                significance; no effect on protein
FT                                abundance; loss of function in blood
FT                                coagulation).
FT                                {ECO:0000269|PubMed:25251685}.
FT                                /FTId=VAR_073977.
FT   VARIANT      58     58       G -> R (in HEMB; severe; Los Angeles-4).
FT                                /FTId=VAR_006536.
FT   VARIANT      62     63       Missing (in HEMB; severe).
FT                                /FTId=VAR_006537.
FT   VARIANT      66     66       E -> V (in HEMB; moderate).
FT                                /FTId=VAR_006538.
FT   VARIANT      67     67       E -> K (in HEMB; severe; Nagoya-4; Gla
FT                                mutant).
FT                                /FTId=VAR_006539.
FT   VARIANT      71     71       F -> S (in HEMB; severe).
FT                                /FTId=VAR_006540.
FT   VARIANT      73     73       E -> K (in HEMB; severe; Seattle-3; Gla
FT                                mutant). {ECO:0000269|PubMed:2472424}.
FT                                /FTId=VAR_006541.
FT   VARIANT      73     73       E -> V (in HEMB; severe; Chongqing; Gla
FT                                mutant). {ECO:0000269|PubMed:2339358}.
FT                                /FTId=VAR_006542.
FT   VARIANT      75     75       R -> Q (in HEMB; mild).
FT                                {ECO:0000269|PubMed:2773937}.
FT                                /FTId=VAR_017308.
FT   VARIANT      79     79       E -> D (in HEMB).
FT                                {ECO:0000269|PubMed:2773937}.
FT                                /FTId=VAR_017309.
FT   VARIANT      84     84       T -> R (in HEMB; decreased protein
FT                                abundance; loss of function in blood
FT                                coagulation).
FT                                {ECO:0000269|PubMed:12604421,
FT                                ECO:0000269|PubMed:25251685}.
FT                                /FTId=VAR_017345.
FT   VARIANT      91     91       Y -> C (in HEMB; moderate).
FT                                /FTId=VAR_006543.
FT   VARIANT      93     93       D -> G (in HEMB; moderate; Alabama).
FT                                {ECO:0000269|PubMed:3790720}.
FT                                /FTId=VAR_006544.
FT   VARIANT      96     96       Q -> P (in HEMB; severe; New London).
FT                                /FTId=VAR_006545.
FT   VARIANT      97     97       C -> S (in HEMB).
FT                                /FTId=VAR_006546.
FT   VARIANT     101    101       P -> R (in HEMB).
FT                                /FTId=VAR_006547.
FT   VARIANT     102    102       C -> R (in HEMB; severe; Basel).
FT                                /FTId=VAR_006548.
FT   VARIANT     106    106       G -> D (in HEMB).
FT                                {ECO:0000269|PubMed:12588353}.
FT                                /FTId=VAR_017346.
FT   VARIANT     106    106       G -> S (in HEMB; mild; Durham).
FT                                {ECO:0000269|PubMed:2472424,
FT                                ECO:0000269|PubMed:9600455}.
FT                                /FTId=VAR_006549.
FT   VARIANT     108    108       C -> S (in HEMB).
FT                                /FTId=VAR_006550.
FT   VARIANT     110    110       D -> N (in HEMB; severe; Oxford-D1).
FT                                /FTId=VAR_006551.
FT   VARIANT     112    112       I -> S (in HEMB).
FT                                /FTId=VAR_006552.
FT   VARIANT     113    113       N -> K (in HEMB; mild).
FT                                {ECO:0000269|PubMed:9222764}.
FT                                /FTId=VAR_006553.
FT   VARIANT     115    115       Y -> C (in HEMB; severe).
FT                                {ECO:0000269|PubMed:9600455}.
FT                                /FTId=VAR_006554.
FT   VARIANT     119    119       C -> F (in HEMB; severe).
FT                                /FTId=VAR_006555.
FT   VARIANT     119    119       C -> R (in HEMB; Iran).
FT                                {ECO:0000269|PubMed:9452115}.
FT                                /FTId=VAR_006556.
FT   VARIANT     124    124       E -> K (in HEMB).
FT                                {ECO:0000269|PubMed:12588353}.
FT                                /FTId=VAR_017347.
FT   VARIANT     125    125       G -> E (in HEMB).
FT                                /FTId=VAR_006557.
FT   VARIANT     125    125       G -> R (in HEMB).
FT                                {ECO:0000269|PubMed:12604421}.
FT                                /FTId=VAR_017348.
FT   VARIANT     125    125       G -> V (in HEMB).
FT                                {ECO:0000269|PubMed:12604421}.
FT                                /FTId=VAR_006558.
FT   VARIANT     129    130       Missing (in HEMB).
FT                                /FTId=VAR_006559.
FT   VARIANT     134    134       C -> Y (in HEMB).
FT                                {ECO:0000269|PubMed:12588353}.
FT                                /FTId=VAR_017349.
FT   VARIANT     136    136       I -> T (in HEMB; mild).
FT                                /FTId=VAR_006560.
FT   VARIANT     138    138       N -> H (in HEMB; unknown pathological
FT                                significance; decreased protein
FT                                abundance; decreased function in blood
FT                                coagulation).
FT                                {ECO:0000269|PubMed:25251685}.
FT                                /FTId=VAR_073978.
FT   VARIANT     139    139       G -> D (in HEMB; severe).
FT                                /FTId=VAR_006561.
FT   VARIANT     139    139       G -> S (in HEMB).
FT                                /FTId=VAR_006562.
FT   VARIANT     155    155       C -> F (in HEMB; severe).
FT                                {ECO:0000269|PubMed:9600455}.
FT                                /FTId=VAR_006563.
FT   VARIANT     160    160       G -> E (in HEMB; mild).
FT                                /FTId=VAR_006564.
FT   VARIANT     167    167       Q -> H (in HEMB; mild).
FT                                /FTId=VAR_006565.
FT   VARIANT     169    169       S -> C (in HEMB).
FT                                {ECO:0000269|PubMed:11122099}.
FT                                /FTId=VAR_017350.
FT   VARIANT     170    170       C -> F (in HEMB).
FT                                {ECO:0000269|PubMed:12604421}.
FT                                /FTId=VAR_017351.
FT   VARIANT     178    178       C -> R (in HEMB).
FT                                /FTId=VAR_006566.
FT   VARIANT     178    178       C -> W (in HEMB; severe).
FT                                /FTId=VAR_006567.
FT   VARIANT     191    191       R -> C (in HEMB; moderate; Albuquerque,
FT                                Cardiff-1). {ECO:0000269|PubMed:2775660}.
FT                                /FTId=VAR_006569.
FT   VARIANT     191    191       R -> H (in HEMB; moderate; Chapel-Hill,
FT                                Chicago-2). {ECO:0000269|PubMed:6603618,
FT                                ECO:0000269|PubMed:8076946}.
FT                                /FTId=VAR_006568.
FT   VARIANT     194    194       T -> A (in dbSNP:rs6048).
FT                                {ECO:0000269|PubMed:10391209,
FT                                ECO:0000269|PubMed:25470321,
FT                                ECO:0000269|PubMed:2994716,
FT                                ECO:0000269|PubMed:3857619,
FT                                ECO:0000269|PubMed:6329734}.
FT                                /FTId=VAR_011773.
FT   VARIANT     226    226       R -> G (in HEMB; severe; Madrid).
FT                                {ECO:0000269|PubMed:12588353,
FT                                ECO:0000269|PubMed:8076946}.
FT                                /FTId=VAR_006571.
FT   VARIANT     226    226       R -> Q (in HEMB; severe; Hilo and Novara;
FT                                no effect on protein abundance; loss of
FT                                function in blood coagulation).
FT                                {ECO:0000269|PubMed:12588353,
FT                                ECO:0000269|PubMed:2162822,
FT                                ECO:0000269|PubMed:25251685,
FT                                ECO:0000269|PubMed:2713493}.
FT                                /FTId=VAR_006572.
FT   VARIANT     226    226       R -> W (in HEMB; severe; Nagoya-1,
FT                                Dernbach, Deventer, Idaho).
FT                                {ECO:0000269|PubMed:12588353,
FT                                ECO:0000269|PubMed:2162822,
FT                                ECO:0000269|PubMed:2592373}.
FT                                /FTId=VAR_006570.
FT   VARIANT     227    227       V -> D (in HEMB; mild).
FT                                /FTId=VAR_006573.
FT   VARIANT     227    227       V -> F (in HEMB; Milano).
FT                                {ECO:0000269|PubMed:2162822}.
FT                                /FTId=VAR_017310.
FT   VARIANT     228    228       V -> F (in HEMB; severe; Kashihara).
FT                                {ECO:0000269|PubMed:2753873}.
FT                                /FTId=VAR_017311.
FT   VARIANT     228    228       V -> L (in HEMB; mild; Cardiff-2).
FT                                {ECO:0000269|PubMed:2372509}.
FT                                /FTId=VAR_006574.
FT   VARIANT     241    241       Q -> H (in HEMB).
FT                                {ECO:0000269|PubMed:25470321}.
FT                                /FTId=VAR_006575.
FT   VARIANT     241    241       Q -> K (in HEMB).
FT                                {ECO:0000269|PubMed:12588353}.
FT                                /FTId=VAR_017352.
FT   VARIANT     252    252       C -> S (in HEMB; severe).
FT                                {ECO:0000269|PubMed:1615485}.
FT                                /FTId=VAR_017312.
FT   VARIANT     252    252       C -> Y (in HEMB).
FT                                {ECO:0000269|PubMed:12588353}.
FT                                /FTId=VAR_017353.
FT   VARIANT     253    253       G -> E (in HEMB; severe).
FT                                /FTId=VAR_006576.
FT   VARIANT     253    253       G -> R (in HEMB; severe; Luanda).
FT                                {ECO:0000269|PubMed:8257988}.
FT                                /FTId=VAR_006577.
FT   VARIANT     265    265       A -> T (in HEMB; mild).
FT                                /FTId=VAR_006578.
FT   VARIANT     268    268       C -> W (in HEMB; moderate).
FT                                {ECO:0000269|PubMed:2773937}.
FT                                /FTId=VAR_017313.
FT   VARIANT     279    279       A -> T (in HEMB; mild).
FT                                {ECO:0000269|PubMed:2773937,
FT                                ECO:0000269|PubMed:8076946}.
FT                                /FTId=VAR_006579.
FT   VARIANT     283    283       N -> D (in HEMB; severe).
FT                                /FTId=VAR_006580.
FT   VARIANT     284    284       Missing (in HEMB; severe; decreased
FT                                protein abundance; loss of function in
FT                                blood coagulation).
FT                                {ECO:0000269|PubMed:25251685}.
FT                                /FTId=VAR_073979.
FT   VARIANT     286    286       Missing (in HEMB; severe).
FT                                /FTId=VAR_006581.
FT   VARIANT     291    291       E -> V (in HEMB; Monschau).
FT                                {ECO:0000269|PubMed:1346975}.
FT                                /FTId=VAR_017314.
FT   VARIANT     294    294       R -> G (in HEMB; severe).
FT                                /FTId=VAR_006582.
FT   VARIANT     294    294       R -> Q (in HEMB; mild to moderate;
FT                                Dreihacken, Penafiel and Seattle-4).
FT                                {ECO:0000269|PubMed:12588353,
FT                                ECO:0000269|PubMed:1346975,
FT                                ECO:0000269|PubMed:2472424,
FT                                ECO:0000269|PubMed:7981722,
FT                                ECO:0000269|PubMed:8257988}.
FT                                /FTId=VAR_006583.
FT   VARIANT     296    296       V -> M (in HEMB; unknown pathological
FT                                significance; decreased protein
FT                                abundance; decreased function in blood
FT                                coagulation).
FT                                {ECO:0000269|PubMed:25251685}.
FT                                /FTId=VAR_073980.
FT   VARIANT     302    302       H -> R (in HEMB).
FT                                {ECO:0000269|PubMed:12604421}.
FT                                /FTId=VAR_006584.
FT   VARIANT     306    306       N -> S (in HEMB; mild).
FT                                {ECO:0000269|PubMed:2773937}.
FT                                /FTId=VAR_017315.
FT   VARIANT     316    316       I -> F (in HEMB).
FT                                {ECO:0000269|PubMed:12588353}.
FT                                /FTId=VAR_006585.
FT   VARIANT     318    318       L -> R (in HEMB).
FT                                {ECO:0000269|PubMed:12588353}.
FT                                /FTId=VAR_017354.
FT   VARIANT     321    321       L -> Q (in HEMB; severe).
FT                                /FTId=VAR_006586.
FT   VARIANT     328    328       N -> K (in HEMB; unknown pathological
FT                                significance; decreased protein
FT                                abundance; decreased function in blood
FT                                coagulation).
FT                                {ECO:0000269|PubMed:25251685}.
FT                                /FTId=VAR_073981.
FT   VARIANT     328    328       N -> Y (in HEMB; moderate; decreased
FT                                protein abundance; decreased function in
FT                                blood coagulation).
FT                                {ECO:0000269|PubMed:25251685}.
FT                                /FTId=VAR_073982.
FT   VARIANT     333    333       P -> H (in HEMB; severe).
FT                                /FTId=VAR_006587.
FT   VARIANT     333    333       P -> T (in HEMB).
FT                                {ECO:0000269|PubMed:11122099}.
FT                                /FTId=VAR_017355.
FT   VARIANT     342    342       T -> K (in HEMB; mild).
FT                                /FTId=VAR_006588.
FT   VARIANT     342    342       T -> M (in HEMB; moderate).
FT                                {ECO:0000269|PubMed:12604421,
FT                                ECO:0000269|PubMed:2773937,
FT                                ECO:0000269|PubMed:9222764}.
FT                                /FTId=VAR_006589.
FT   VARIANT     344    344       I -> L (in HEMB).
FT                                {ECO:0000269|PubMed:12604421}.
FT                                /FTId=VAR_017356.
FT   VARIANT     351    351       G -> D (in HEMB).
FT                                /FTId=VAR_006590.
FT   VARIANT     356    356       W -> C (in HEMB; severe).
FT                                /FTId=VAR_006591.
FT   VARIANT     357    357       G -> E (in HEMB; severe; Amagasaki).
FT                                {ECO:0000269|PubMed:1958666}.
FT                                /FTId=VAR_006592.
FT   VARIANT     357    357       G -> R (in HEMB).
FT                                {ECO:0000269|PubMed:2773937}.
FT                                /FTId=VAR_017316.
FT   VARIANT     362    362       K -> E (in HEMB; moderate).
FT                                /FTId=VAR_006593.
FT   VARIANT     363    363       G -> W (in HEMB).
FT                                /FTId=VAR_006594.
FT   VARIANT     366    366       A -> D (in HEMB).
FT                                /FTId=VAR_006595.
FT   VARIANT     379    379       R -> G (in HEMB; moderate).
FT                                {ECO:0000269|PubMed:12588353}.
FT                                /FTId=VAR_006596.
FT   VARIANT     379    379       R -> Q (in HEMB; severe; Iceland-1,
FT                                London and Sesimbra).
FT                                {ECO:0000269|PubMed:8076946,
FT                                ECO:0000269|PubMed:8257988,
FT                                ECO:0000269|PubMed:9600455}.
FT                                /FTId=VAR_006597.
FT   VARIANT     382    382       C -> Y (in HEMB).
FT                                /FTId=VAR_006598.
FT   VARIANT     383    383       L -> F (in HEMB).
FT                                {ECO:0000269|PubMed:12588353}.
FT                                /FTId=VAR_017358.
FT   VARIANT     383    383       L -> I (in HEMB).
FT                                {ECO:0000269|PubMed:12588353}.
FT                                /FTId=VAR_017357.
FT   VARIANT     384    384       R -> L (in THPH8; factor IX Padua; higher
FT                                specific activity than wild-type).
FT                                {ECO:0000269|PubMed:19846852}.
FT                                /FTId=VAR_062999.
FT   VARIANT     387    387       K -> E (in HEMB; mild).
FT                                {ECO:0000269|PubMed:9600455}.
FT                                /FTId=VAR_006599.
FT   VARIANT     390    390       I -> F (in HEMB; severe).
FT                                /FTId=VAR_006600.
FT   VARIANT     394    394       M -> K (in HEMB).
FT                                /FTId=VAR_006601.
FT   VARIANT     395    395       F -> I (in HEMB).
FT                                {ECO:0000269|PubMed:12588353}.
FT                                /FTId=VAR_017359.
FT   VARIANT     395    395       F -> L (in HEMB).
FT                                {ECO:0000269|PubMed:12604421}.
FT                                /FTId=VAR_017360.
FT   VARIANT     396    396       C -> F (in HEMB).
FT                                {ECO:0000269|PubMed:12588353}.
FT                                /FTId=VAR_017361.
FT   VARIANT     396    396       C -> S (in HEMB; severe).
FT                                /FTId=VAR_006602.
FT   VARIANT     397    397       A -> P (in HEMB; mild; Hong Kong-11).
FT                                {ECO:0000269|PubMed:9590153}.
FT                                /FTId=VAR_017317.
FT   VARIANT     404    404       R -> T (in HEMB).
FT                                /FTId=VAR_006603.
FT   VARIANT     407    407       C -> R (in HEMB).
FT                                {ECO:0000269|PubMed:12588353}.
FT                                /FTId=VAR_017362.
FT   VARIANT     407    407       C -> S (in HEMB; severe).
FT                                /FTId=VAR_006604.
FT   VARIANT     410    410       D -> H (in HEMB; Mechtal).
FT                                {ECO:0000269|PubMed:1346975}.
FT                                /FTId=VAR_017318.
FT   VARIANT     411    411       S -> G (in HEMB; Varel).
FT                                {ECO:0000269|PubMed:1346975}.
FT                                /FTId=VAR_017320.
FT   VARIANT     411    411       S -> I (in HEMB; Schmallenberg).
FT                                {ECO:0000269|PubMed:1346975}.
FT                                /FTId=VAR_017319.
FT   VARIANT     412    412       G -> E (in HEMB).
FT                                {ECO:0000269|PubMed:12588353}.
FT                                /FTId=VAR_017363.
FT   VARIANT     413    413       G -> R (in HEMB; moderate to severe).
FT                                {ECO:0000269|PubMed:7981722,
FT                                ECO:0000269|PubMed:9222764}.
FT                                /FTId=VAR_006605.
FT   VARIANT     414    414       P -> T (in HEMB; Bergamo; increased
FT                                protein abundance; loss of function in
FT                                blood coagulation).
FT                                {ECO:0000269|PubMed:12604421,
FT                                ECO:0000269|PubMed:2162822,
FT                                ECO:0000269|PubMed:25251685}.
FT                                /FTId=VAR_017321.
FT   VARIANT     419    419       V -> E (in HEMB; moderately severe).
FT                                {ECO:0000269|PubMed:8076946,
FT                                ECO:0000269|PubMed:8199596}.
FT                                /FTId=VAR_006606.
FT   VARIANT     424    424       F -> V (in HEMB).
FT                                {ECO:0000269|PubMed:9222764}.
FT                                /FTId=VAR_006607.
FT   VARIANT     426    426       T -> P (in HEMB; severe; Barcelos).
FT                                {ECO:0000269|PubMed:8257988}.
FT                                /FTId=VAR_006608.
FT   VARIANT     430    430       S -> T (in HEMB).
FT                                /FTId=VAR_006609.
FT   VARIANT     431    431       W -> G (in HEMB).
FT                                /FTId=VAR_006610.
FT   VARIANT     431    431       W -> R (in HEMB; moderate).
FT                                /FTId=VAR_006611.
FT   VARIANT     432    432       G -> S (in HEMB; severe).
FT                                /FTId=VAR_006612.
FT   VARIANT     432    432       G -> V (in HEMB; severe).
FT                                {ECO:0000269|PubMed:9600455}.
FT                                /FTId=VAR_006613.
FT   VARIANT     433    433       E -> A (in HEMB).
FT                                /FTId=VAR_006614.
FT   VARIANT     433    433       E -> K (in HEMB).
FT                                /FTId=VAR_006615.
FT   VARIANT     435    435       C -> Y (in HEMB).
FT                                {ECO:0000269|PubMed:12604421}.
FT                                /FTId=VAR_017364.
FT   VARIANT     436    436       A -> V (in HEMB; moderately severe;
FT                                Niigata). {ECO:0000269|PubMed:3243764}.
FT                                /FTId=VAR_006616.
FT   VARIANT     442    442       G -> E (in HEMB).
FT                                {ECO:0000269|PubMed:12604421}.
FT                                /FTId=VAR_017365.
FT   VARIANT     442    442       G -> R (in HEMB; severe; Angers).
FT                                {ECO:0000269|PubMed:2714791}.
FT                                /FTId=VAR_017322.
FT   VARIANT     443    443       I -> T (in HEMB; moderately severe; Long
FT                                Beach, Los Angeles and Vancouver).
FT                                {ECO:0000269|PubMed:1902289,
FT                                ECO:0000269|PubMed:3401602}.
FT                                /FTId=VAR_017323.
FT   VARIANT     445    445       T -> TIYT (in HEMB; severe; Lousada).
FT                                /FTId=VAR_006617.
FT   VARIANT     447    447       V -> VYKTV (in HEMB; reduced protein
FT                                abundance; loss of function in blood
FT                                coagulation).
FT                                {ECO:0000269|PubMed:25251685}.
FT                                /FTId=VAR_073983.
FT   VARIANT     449    449       R -> Q (in HEMB; mild).
FT                                {ECO:0000269|PubMed:8076946}.
FT                                /FTId=VAR_006618.
FT   VARIANT     449    449       R -> W (in HEMB; mild).
FT                                {ECO:0000269|PubMed:12604421}.
FT                                /FTId=VAR_006619.
FT   VARIANT     450    450       Y -> C (in HEMB; severe).
FT                                {ECO:0000269|PubMed:9600455}.
FT                                /FTId=VAR_006620.
FT   VARIANT     453    453       W -> R (in HEMB).
FT                                {ECO:0000269|PubMed:2773937}.
FT                                /FTId=VAR_017324.
FT   VARIANT     454    454       I -> T (in HEMB; Italy).
FT                                {ECO:0000269|PubMed:9452115}.
FT                                /FTId=VAR_006621.
FT   VARIANT     461    461       T -> P (in dbSNP:rs4149751).
FT                                {ECO:0000269|Ref.7}.
FT                                /FTId=VAR_014308.
FT   MUTAGEN     305    305       Y->F: Strongly increases enzyme activity
FT                                with a synthetic peptide substrate; when
FT                                associated with T-311; A-365 and T-391.
FT                                {ECO:0000269|PubMed:12444082}.
FT   MUTAGEN     311    311       K->T: Strongly increases enzyme activity
FT                                with a synthetic peptide substrate; when
FT                                associated with F-305; A-365 and T-391.
FT                                {ECO:0000269|PubMed:12444082}.
FT   MUTAGEN     312    312       Y->A: Strongly decreases enzyme activity
FT                                with a synthetic peptide substrate.
FT                                {ECO:0000269|PubMed:12444082}.
FT   MUTAGEN     391    391       Y->T: Strongly increases enzyme activity
FT                                with a synthetic peptide substrate; when
FT                                associated with F-305; T-311 and A-365.
FT                                {ECO:0000269|PubMed:12444082}.
FT   STRAND       50     52       {ECO:0000244|PDB:1NL0}.
FT   HELIX        60     64       {ECO:0000244|PDB:1NL0}.
FT   STRAND       65     67       {ECO:0000244|PDB:1CFH}.
FT   HELIX        71     75       {ECO:0000244|PDB:1NL0}.
FT   STRAND       78     80       {ECO:0000244|PDB:1NL0}.
FT   HELIX        81     90       {ECO:0000244|PDB:1NL0}.
FT   TURN         96     99       {ECO:0000244|PDB:1EDM}.
FT   STRAND      102    105       {ECO:0000244|PDB:4WMA}.
FT   STRAND      107    111       {ECO:0000244|PDB:1EDM}.
FT   STRAND      114    118       {ECO:0000244|PDB:1EDM}.
FT   TURN        125    128       {ECO:0000244|PDB:4WMA}.
FT   TURN        134    136       {ECO:0000244|PDB:2WPH}.
FT   HELIX       137    140       {ECO:0000244|PDB:4YZU}.
FT   STRAND      142    147       {ECO:0000244|PDB:4YZU}.
FT   STRAND      149    151       {ECO:0000244|PDB:4YZU}.
FT   STRAND      153    156       {ECO:0000244|PDB:4YZU}.
FT   STRAND      161    163       {ECO:0000244|PDB:4YZU}.
FT   STRAND      165    168       {ECO:0000244|PDB:2WPI}.
FT   STRAND      170    172       {ECO:0000244|PDB:4YZU}.
FT   STRAND      174    176       {ECO:0000244|PDB:4YZU}.
FT   STRAND      187    189       {ECO:0000244|PDB:2WPJ}.
FT   STRAND      241    250       {ECO:0000244|PDB:4YZU}.
FT   STRAND      252    258       {ECO:0000244|PDB:4YZU}.
FT   STRAND      261    264       {ECO:0000244|PDB:4YZU}.
FT   HELIX       266    268       {ECO:0000244|PDB:4YZU}.
FT   STRAND      271    273       {ECO:0000244|PDB:2WPL}.
FT   STRAND      276    280       {ECO:0000244|PDB:4YZU}.
FT   STRAND      282    286       {ECO:0000244|PDB:1RFN}.
FT   STRAND      292    301       {ECO:0000244|PDB:4YZU}.
FT   TURN        303    306       {ECO:0000244|PDB:2WPH}.
FT   TURN        307    309       {ECO:0000244|PDB:4YZU}.
FT   TURN        311    314       {ECO:0000244|PDB:4YZU}.
FT   STRAND      317    323       {ECO:0000244|PDB:4YZU}.
FT   HELIX       339    347       {ECO:0000244|PDB:4YZU}.
FT   STRAND      350    360       {ECO:0000244|PDB:4YZU}.
FT   STRAND      370    376       {ECO:0000244|PDB:4YZU}.
FT   HELIX       379    384       {ECO:0000244|PDB:4YZU}.
FT   STRAND      394    397       {ECO:0000244|PDB:4YZU}.
FT   STRAND      414    419       {ECO:0000244|PDB:4YZU}.
FT   STRAND      422    431       {ECO:0000244|PDB:4YZU}.
FT   STRAND      433    436       {ECO:0000244|PDB:2WPH}.
FT   STRAND      442    446       {ECO:0000244|PDB:4YZU}.
FT   HELIX       447    450       {ECO:0000244|PDB:4YZU}.
FT   HELIX       451    458       {ECO:0000244|PDB:4YZU}.
SQ   SEQUENCE   461 AA;  51778 MW;  C4720C1234477EF5 CRC64;
     MQRVNMIMAE SPGLITICLL GYLLSAECTV FLDHENANKI LNRPKRYNSG KLEEFVQGNL
     ERECMEEKCS FEEAREVFEN TERTTEFWKQ YVDGDQCESN PCLNGGSCKD DINSYECWCP
     FGFEGKNCEL DVTCNIKNGR CEQFCKNSAD NKVVCSCTEG YRLAENQKSC EPAVPFPCGR
     VSVSQTSKLT RAETVFPDVD YVNSTEAETI LDNITQSTQS FNDFTRVVGG EDAKPGQFPW
     QVVLNGKVDA FCGGSIVNEK WIVTAAHCVE TGVKITVVAG EHNIEETEHT EQKRNVIRII
     PHHNYNAAIN KYNHDIALLE LDEPLVLNSY VTPICIADKE YTNIFLKFGS GYVSGWGRVF
     HKGRSALVLQ YLRVPLVDRA TCLRSTKFTI YNNMFCAGFH EGGRDSCQGD SGGPHVTEVE
     GTSFLTGIIS WGEECAMKGK YGIYTKVSRY VNWIKEKTKL T
//
ID   A4_MOUSE                Reviewed;         770 AA.
AC   P12023; P97487; P97942; Q99K32;
DT   01-OCT-1989, integrated into UniProtKB/Swiss-Prot.
DT   09-MAY-2003, sequence version 3.
DT   17-FEB-2016, entry version 199.
DE   RecName: Full=Amyloid beta A4 protein;
DE   AltName: Full=ABPP;
DE            Short=APP;
DE   AltName: Full=Alzheimer disease amyloid A4 protein homolog;
DE   AltName: Full=Amyloid precursor protein {ECO:0000305};
DE   AltName: Full=Amyloidogenic glycoprotein;
DE            Short=AG;
DE   AltName: Full=Beta-amyloid precursor protein {ECO:0000305};
DE   Contains:
DE     RecName: Full=N-APP;
DE   Contains:
DE     RecName: Full=Soluble APP-alpha;
DE              Short=S-APP-alpha;
DE   Contains:
DE     RecName: Full=Soluble APP-beta;
DE              Short=S-APP-beta;
DE   Contains:
DE     RecName: Full=C99;
DE     AltName: Full=APP-C99;
DE   Contains:
DE     RecName: Full=Beta-amyloid protein 42;
DE     AltName: Full=Beta-APP42;
DE   Contains:
DE     RecName: Full=Beta-amyloid protein 40;
DE     AltName: Full=Beta-APP40;
DE   Contains:
DE     RecName: Full=C83;
DE   Contains:
DE     RecName: Full=P3(42);
DE   Contains:
DE     RecName: Full=P3(40);
DE   Contains:
DE     RecName: Full=C80;
DE   Contains:
DE     RecName: Full=Gamma-secretase C-terminal fragment 59;
DE     AltName: Full=APP-C59;
DE     AltName: Full=Amyloid intracellular domain 59;
DE              Short=AID(59);
DE     AltName: Full=Gamma-CTF(59);
DE   Contains:
DE     RecName: Full=Gamma-secretase C-terminal fragment 57;
DE     AltName: Full=APP-C57;
DE     AltName: Full=Amyloid intracellular domain 57;
DE              Short=AID(57);
DE     AltName: Full=Gamma-CTF(57);
DE   Contains:
DE     RecName: Full=Gamma-secretase C-terminal fragment 50;
DE     AltName: Full=Amyloid intracellular domain 50;
DE              Short=AID(50);
DE     AltName: Full=Gamma-CTF(50);
DE   Contains:
DE     RecName: Full=C31;
DE   Flags: Precursor;
GN   Name=App;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM APP695).
RC   TISSUE=Brain;
RX   PubMed=3322280; DOI=10.1016/0006-291X(87)90419-0;
RA   Yamada T., Sasaki H., Furuya H., Miyata T., Goto I., Sakaki Y.;
RT   "Complementary DNA for the mouse homolog of the human amyloid beta
RT   protein precursor.";
RL   Biochem. Biophys. Res. Commun. 149:665-671(1987).
RN   [2]
RP   SEQUENCE REVISION.
RA   Yamada T.;
RL   Submitted (MAR-1988) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM APP695).
RC   STRAIN=BALB/cJ; TISSUE=Brain;
RX   PubMed=1756177; DOI=10.1016/0167-4781(91)90231-A;
RA   de Strooper B., van Leuven F., van den Berghe H.;
RT   "The amyloid beta protein precursor or proteinase nexin II from mouse
RT   is closer related to its human homolog than previously reported.";
RL   Biochim. Biophys. Acta 1129:141-143(1991).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM APP695).
RC   STRAIN=SAMP8; TISSUE=Hippocampus;
RX   PubMed=11235921; DOI=10.1139/o00-094;
RA   Kumar V.B., Vyas K., Franko M., Choudhary V., Buddhiraju C.,
RA   Alvarez J., Morley J.E.;
RT   "Molecular cloning, expression, and regulation of hippocampal amyloid
RT   precursor protein of senescence accelerated mouse (SAMP8).";
RL   Biochem. Cell Biol. 79:57-67(2001).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-19.
RX   PubMed=1555768; DOI=10.1016/0378-1119(92)90375-Y;
RA   Izumi R., Yamada T., Yoshikai S., Sasaki H., Hattori M., Sakai Y.;
RT   "Positive and negative regulatory elements for the expression of the
RT   Alzheimer's disease amyloid precursor-encoding gene in mouse.";
RL   Gene 112:189-195(1992).
RN   [6]
RP   PARTIAL NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM APP770).
RC   TISSUE=Mammary tumor;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 281-380, AND ALTERNATIVE SPLICING.
RC   TISSUE=Brain, and Kidney;
RX   PubMed=2493250; DOI=10.1016/0006-291X(89)92808-8;
RA   Yamada T., Sasaki H., Dohura K., Goto I., Sakaki Y.;
RT   "Structure and expression of the alternatively-spliced forms of mRNA
RT   for the mouse homolog of Alzheimer's disease amyloid beta protein
RT   precursor.";
RL   Biochem. Biophys. Res. Commun. 158:906-912(1989).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 289-364.
RC   STRAIN=CD-1; TISSUE=Placenta;
RX   PubMed=2569710; DOI=10.1093/nar/17.13.5396;
RA   Fukuchi K., Martin G.M., Deeb S.S.;
RT   "Sequence of the protease inhibitor domain of the A4 amyloid protein
RT   precursor of Mus domesticus.";
RL   Nucleic Acids Res. 17:5396-5396(1989).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 656-737.
RC   STRAIN=129/Sv;
RA   Wragg M.A., Busfield F., Duff K., Korenblat K., Capecchi M.,
RA   Loring J.F., Goate A.M.;
RT   "Introduction of six mutations into the mouse genome using 'Hit and
RT   Run' gene-targeting: introduction of familial Alzheimer's disease
RT   mutations into the mouse amyloid precursor protein gene and
RT   humanization of the A-beta fragment.";
RL   Submitted (DEC-1996) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   TISSUE SPECIFICITY OF ALTERNATIVE SPLICED FORMS.
RX   PubMed=8510506; DOI=10.1016/0169-328X(93)90020-P;
RA   Sola C., Mengod G., Ghetti B., Palacios J.M., Triarhou L.C.;
RT   "Regional distribution of the alternatively spliced isoforms of beta
RT   APP RNA transcript in the brain of normal, heterozygous and homozygous
RT   weaver mutant mice as revealed by in situ hybridization
RT   histochemistry.";
RL   Brain Res. Mol. Brain Res. 17:340-346(1993).
RN   [11]
RP   INTERACTION WITH KNS2.
RX   PubMed=11144355; DOI=10.1016/S0896-6273(00)00124-0;
RA   Kamal A., Stokin G.B., Yang Z., Xia C.-H., Goldstein L.S.;
RT   "Axonal transport of amyloid precursor protein is mediated by direct
RT   binding to the kinesin light chain subunit of kinesin-I.";
RL   Neuron 28:449-459(2000).
RN   [12]
RP   PHOSPHORYLATION AT TYR-757.
RX   PubMed=11279131; DOI=10.1074/jbc.M100792200;
RA   Zambrano N., Bruni P., Minopoli G., Mosca R., Molino D., Russo C.,
RA   Schettini G., Sudol M., Russo T.;
RT   "The beta-amyloid precursor protein APP is tyrosine-phosphorylated in
RT   cells expressing a constitutively active form of the Abl
RT   protoncogene.";
RL   J. Biol. Chem. 276:19787-19792(2001).
RN   [13]
RP   C-TERMINAL PROTEIN-PROTEIN INTERACTION, AND MUTAGENESIS OF TYR-728;
RP   THR-743; TYR-757; ASN-759 AND TYR-762.
RX   PubMed=11517249;
RA   Matsuda S., Yasukawa T., Homma Y., Ito Y., Niikura T., Hiraki T.,
RA   Hirai S., Ohno S., Kita Y., Kawasumi M., Kouyama K., Yamamoto T.,
RA   Kyriakis J.M., Nishimoto I.;
RT   "C-jun N-terminal kinase (JNK)-interacting protein-1b/islet-brain-1
RT   scaffolds Alzheimer's amyloid precursor protein with JNK.";
RL   J. Neurosci. 21:6597-6607(2001).
RN   [14]
RP   INTERACTION WITH DAB2, AND MUTAGENESIS OF GLY-756; TYR-757; ASN-759;
RP   PRO-760 AND TYR-762.
RX   PubMed=11247302; DOI=10.1034/j.1600-0854.2001.020206.x;
RA   Morris S.M., Cooper J.A.;
RT   "Disabled-2 colocalizes with the LDLR in clathrin-coated pits and
RT   interacts with AP-2.";
RL   Traffic 2:111-123(2001).
RN   [15]
RP   INTERACTION WITH MAPK8IP1, AND PHOSPHORYLATION.
RX   PubMed=11912189; DOI=10.1074/jbc.M108372200;
RA   Taru H., Iijima K., Hase M., Kirino Y., Yagi Y., Suzuki T.;
RT   "Interaction of Alzheimer's beta-amyloid precursor family proteins
RT   with scaffold proteins of the JNK signaling cascade.";
RL   J. Biol. Chem. 277:20070-20078(2002).
RN   [16]
RP   INTERACTION OF CTF PEPTIDES WITH NUMB.
RX   PubMed=12011466; DOI=10.1073/pnas.102192599;
RA   Roncarati R., Sestan N., Scheinfeld M.H., Berechid B.E., Lopez P.A.,
RA   Meucci O., McGlade J.C., Rakic P., D'Adamio L.;
RT   "The gamma-secretase-generated intracellular domain of beta-amyloid
RT   precursor protein binds Numb and inhibits Notch signaling.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:7102-7107(2002).
RN   [17]
RP   PROTEOLYTIC PROCESSING BY GAMMA SECRETASE, AND INTERACTION WITH APBB1.
RX   PubMed=11553691; DOI=10.1046/j.1471-4159.2001.00516.x;
RA   Cupers P., Orlans I., Craessaerts K., Annaert W., De Strooper B.;
RT   "The amyloid precursor protein (APP)-cytoplasmic fragment generated by
RT   gamma-secretase is rapidly degraded but distributes partially in a
RT   nuclear fraction of neurons in culture.";
RL   J. Neurochem. 78:1168-1178(2001).
RN   [18]
RP   SUBCELLULAR LOCATION, AND FUNCTION.
RX   PubMed=15677459; DOI=10.1074/jbc.M409179200;
RA   Cappai R., Cheng F., Ciccotosto G.D., Needham B.E., Masters C.L.,
RA   Multhaup G., Fransson L.A., Mani K.;
RT   "The amyloid precursor protein (APP) of Alzheimer disease and its
RT   paralog, APLP2, modulate the Cu/Zn-nitric oxide-catalyzed degradation
RT   of glypican-1 heparan sulfate in vivo.";
RL   J. Biol. Chem. 280:13913-13920(2005).
RN   [19]
RP   INTERACTION WITH CPEB1.
RX   PubMed=16314516; DOI=10.1128/MCB.25.24.10930-10939.2005;
RA   Cao Q., Huang Y.-S., Kan M.-C., Richter J.D.;
RT   "Amyloid precursor proteins anchor CPEB to membranes and promote
RT   polyadenylation-induced translation.";
RL   Mol. Cell. Biol. 25:10930-10939(2005).
RN   [20]
RP   INTERACTION WITH APP.
RX   PubMed=16174740; DOI=10.1073/pnas.0503689102;
RA   Andersen O.M., Reiche J., Schmidt V., Gotthardt M., Spoelgen R.,
RA   Behlke J., von Arnim C.A., Breiderhoff T., Jansen P., Wu X.,
RA   Bales K.R., Cappai R., Masters C.L., Gliemann J., Mufson E.J.,
RA   Hyman B.T., Paul S.M., Nykjaer A., Willnow T.E.;
RT   "Neuronal sorting protein-related receptor sorLA/LR11 regulates
RT   processing of the amyloid precursor protein.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:13461-13466(2005).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-441, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Brain, Kidney, Lung, Pancreas, and Testis;
RX   PubMed=21183079; DOI=10.1016/j.cell.2010.12.001;
RA   Huttlin E.L., Jedrychowski M.P., Elias J.E., Goswami T., Rad R.,
RA   Beausoleil S.A., Villen J., Haas W., Sowa M.E., Gygi S.P.;
RT   "A tissue-specific atlas of mouse protein phosphorylation and
RT   expression.";
RL   Cell 143:1174-1189(2010).
RN   [22]
RP   INTERACTION WITH VDAC1.
RX   PubMed=25168729; DOI=10.1016/j.neuroscience.2014.07.079;
RA   Fernandez-Echevarria C., Diaz M., Ferrer I., Canerina-Amaro A.,
RA   Marin R.;
RT   "Abeta promotes VDAC1 channel dephosphorylation in neuronal lipid
RT   rafts. Relevance to the mechanisms of neurotoxicity in Alzheimer's
RT   disease.";
RL   Neuroscience 278:354-366(2014).
CC   -!- FUNCTION: Functions as a cell surface receptor and performs
CC       physiological functions on the surface of neurons relevant to
CC       neurite growth, neuronal adhesion and axonogenesis. Involved in
CC       cell mobility and transcription regulation through protein-protein
CC       interactions. Can promote transcription activation through binding
CC       to APBB1-KAT5 and inhibit Notch signaling through interaction with
CC       Numb. Couples to apoptosis-inducing pathways such as those
CC       mediated by G(O) and JIP. Inhibits G(o) alpha ATPase activity (By
CC       similarity). Acts as a kinesin I membrane receptor, mediating the
CC       axonal transport of beta-secretase and presenilin 1. May be
CC       involved in copper homeostasis/oxidative stress through copper ion
CC       reduction. Can regulate neurite outgrowth through binding to
CC       components of the extracellular matrix such as heparin and
CC       collagen I and IV (By similarity). The splice isoforms that
CC       contain the BPTI domain possess protease inhibitor activity.
CC       Induces a AGER-dependent pathway that involves activation of p38
CC       MAPK, resulting in internalization of amyloid-beta peptide and
CC       leading to mitochondrial dysfunction in cultured cortical neurons
CC       (By similarity). Provides Cu(2+) ions for GPC1 which are required
CC       for release of nitric oxide (NO) and subsequent degradation of the
CC       heparan sulfate chains on GPC1. {ECO:0000250,
CC       ECO:0000269|PubMed:15677459}.
CC   -!- FUNCTION: Beta-amyloid peptides are lipophilic metal chelators
CC       with metal-reducing activity. Binds transient metals such as
CC       copper, zinc and iron. Rat and mouse beta-amyloid peptides bind
CC       only weakly transient metals and have little reducing activity due
CC       to substitutions of transient metal chelating residues. Beta-APP42
CC       may activate mononuclear phagocytes in the brain and elicit
CC       inflammatory responses. Promotes both tau aggregation and TPK II-
CC       mediated phosphorylation. Also binds GPC1 in lipid rafts (By
CC       similarity). {ECO:0000250}.
CC   -!- FUNCTION: The gamma-CTF peptides as well as the caspase-cleaved
CC       peptides, including C31, are potent enhancers of neuronal
CC       apoptosis. {ECO:0000269|PubMed:15677459}.
CC   -!- FUNCTION: N-APP binds TNFRSF21 triggering caspase activation and
CC       degeneration of both neuronal cell bodies (via caspase-3) and
CC       axons (via caspase-6). {ECO:0000250}.
CC   -!- SUBUNIT: Binds, via its C-terminus, to the PID domain of several
CC       cytoplasmic proteins, including APBB family members, the APBA
CC       family, MAPK8IP1, SHC1, NUMB and DAB1. Binding to DAB1 inhibits
CC       its serine phosphorylation. Interacts (via NPXY motif) with DAB2
CC       (via PID domain); the interaction is impaired by tyrosine
CC       phosphorylation of the NPXY motif. Also interacts with GPCR-like
CC       protein BPP, FPRL1, APPBP1, IB1, KNS2 (via its TPR domains),
CC       APPBP2 (via BaSS) and DDB1 (By similarity). In vitro, it binds
CC       MAPT via the MT-binding domains (By similarity). Associates with
CC       microtubules in the presence of ATP and in a kinesin-dependent
CC       manner (By similarity). Interacts, through a C-terminal domain,
CC       with GNAO1 (By similarity). Amyloid beta-42 binds CHRNA7 in
CC       hippocampal neurons (By similarity). Beta-amyloid associates with
CC       HADH2 (By similarity). Interacts with ANKS1B, TNFRSF21 and AGER
CC       (By similarity). Interacts with CPEB1. Interacts with ITM2B.
CC       Interacts with ITM2C. Interacts with IDE. Can form homodimers;
CC       this is promoted by heparin binding (By similarity). Beta-amyloid
CC       protein 40 interacts with S100A9 (By similarity). CTF-alpha
CC       product of APP interacts with GSAP (By similarity). Interacts with
CC       SORL1. Interacts with PLD3 (By similarity). Interacts with VDAC1
CC       (PubMed:25168729). {ECO:0000250, ECO:0000269|PubMed:25168729}.
CC   -!- INTERACTION:
CC       P98084:Apba2; NbExp=2; IntAct=EBI-78814, EBI-81669;
CC       Q9QXJ1:Apbb1; NbExp=2; IntAct=EBI-78814, EBI-81338;
CC       Q03157:Aplp1; NbExp=4; IntAct=EBI-78814, EBI-399929;
CC       Q06335:Aplp2; NbExp=3; IntAct=EBI-78814, EBI-446708;
CC       P15253:CALR (xeno); NbExp=2; IntAct=EBI-78814, EBI-9005200;
CC       P14211:Calr; NbExp=4; IntAct=EBI-78814, EBI-644340;
CC       P97318:Dab1; NbExp=3; IntAct=EBI-78814, EBI-81680;
CC       Q62108:Dlg4; NbExp=4; IntAct=EBI-78814, EBI-300895;
CC       Q9D1T0:Lingo1; NbExp=2; IntAct=EBI-78814, EBI-2012981;
CC       Q9UQF2:MAPK8IP1 (xeno); NbExp=2; IntAct=EBI-78814, EBI-78404;
CC       Q9WVI9-1:Mapk8ip1; NbExp=3; IntAct=EBI-78814, EBI-288461;
CC       Q61120:Shc3; NbExp=2; IntAct=EBI-78814, EBI-79107;
CC       Q9JHI9:Slc40a1; NbExp=2; IntAct=EBI-78814, EBI-2931424;
CC   -!- SUBCELLULAR LOCATION: Membrane {ECO:0000269|PubMed:15677459};
CC       Single-pass type I membrane protein {ECO:0000269|PubMed:15677459}.
CC       Membrane, clathrin-coated pit {ECO:0000269|PubMed:15677459}.
CC       Note=Cell surface protein that rapidly becomes internalized via
CC       clathrin-coated pits. During maturation, the immature APP (N-
CC       glycosylated in the endoplasmic reticulum) moves to the Golgi
CC       complex where complete maturation occurs (O-glycosylated and
CC       sulfated). After alpha-secretase cleavage, soluble APP is released
CC       into the extracellular space and the C-terminal is internalized to
CC       endosomes and lysosomes. Some APP accumulates in secretory
CC       transport vesicles leaving the late Golgi compartment and returns
CC       to the cell surface. Gamma-CTF(59) peptide is located to both the
CC       cytoplasm and nuclei of neurons. It can be translocated to the
CC       nucleus through association with APBB1 (Fe65). Beta-APP42
CC       associates with FPRL1 at the cell surface and the complex is then
CC       rapidly internalized (By similarity). APP sorts to the basolateral
CC       surface in epithelial cells (By similarity). During neuronal
CC       differentiation, the Thr-743 phosphorylated form is located mainly
CC       in growth cones, moderately in neurites and sparingly in the cell
CC       body. Casein kinase phosphorylation can occur either at the cell
CC       surface or within a post-Golgi compartment. Associates with GPC1
CC       in perinuclear compartments. {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC         Comment=Additional isoforms seem to exist.;
CC       Name=APP770;
CC         IsoId=P12023-1; Sequence=Displayed;
CC       Name=APP695;
CC         IsoId=P12023-2; Sequence=VSP_000012, VSP_000013;
CC       Name=APP751;
CC         IsoId=P12023-3; Sequence=VSP_000014;
CC       Name=APP714;
CC         IsoId=P12023-4; Sequence=Not described;
CC   -!- TISSUE SPECIFICITY: Isoform APP770 is expressed in kidney. Isoform
CC       APP751 is widely expressed. Isoform APP695 is expressed in brain,
CC       kidney and liver. Isoform APP695, isoform APP714 and isoform
CC       APP751 are expressed in several different brain regions including
CC       hippocampus, substania nigra pars compacta and cerebellum. In the
CC       cerebellum, these isoforms are abundantly expressed in Purkinje
CC       cells. {ECO:0000269|PubMed:8510506}.
CC   -!- DOMAIN: The basolateral sorting signal (BaSS) is required for
CC       sorting of membrane proteins to the basolateral surface of
CC       epithelial cells.
CC   -!- DOMAIN: The NPXY sequence motif found in many tyrosine-
CC       phosphorylated proteins is required for the specific binding of
CC       the PID domain. However, additional amino acids either N- or C-
CC       terminal to the NPXY motif are often required for complete
CC       interaction. The PID domain-containing proteins which bind APP
CC       require the YENPTY motif for full interaction. These interactions
CC       are independent of phosphorylation on the terminal tyrosine
CC       residue. The NPXY site is also involved in clathrin-mediated
CC       endocytosis (By similarity). {ECO:0000250}.
CC   -!- PTM: Proteolytically processed under normal cellular conditions.
CC       Cleavage either by alpha-secretase, beta-secretase or theta-
CC       secretase leads to generation and extracellular release of soluble
CC       APP peptides, S-APP-alpha and S-APP-beta, and the retention of
CC       corresponding membrane-anchored C-terminal fragments, C80, C83 and
CC       C99. Subsequent processing of C80 and C83 by gamma-secretase
CC       yields P3 peptides. This is the major secretory pathway and is
CC       non-amyloidogenic. Alternatively, presenilin/nicastrin-mediated
CC       gamma-secretase processing of C99 releases the amyloid beta
CC       proteins, amyloid-beta 40 (Abeta40) and amyloid-beta 42 (Abeta42),
CC       major components of amyloid plaques, and the cytotoxic C-terminal
CC       fragments, gamma-CTF(50), gamma-CTF(57) and gamma-CTF(59) (By
CC       similarity). {ECO:0000250}.
CC   -!- PTM: Proteolytically cleaved by caspases during neuronal
CC       apoptosis. Cleavage at Asp-739 by either caspase-3, -8 or -9
CC       results in the production of the neurotoxic C31 peptide and the
CC       increased production of beta-amyloid peptides (By similarity).
CC       {ECO:0000250}.
CC   -!- PTM: N- and O-glycosylated. {ECO:0000250}.
CC   -!- PTM: Phosphorylation in the C-terminal on tyrosine, threonine and
CC       serine residues is neuron-specific. Phosphorylation can affect APP
CC       processing, neuronal differentiation and interaction with other
CC       proteins. The Thr-743 phosphorylated form causes a conformational
CC       change which reduces binding of Fe65 family members (By
CC       similarity). Phosphorylation on Tyr-757 is required for SHC
CC       binding (By similarity). {ECO:0000250}.
CC   -!- PTM: Extracellular binding and reduction of copper, results in a
CC       corresponding oxidation of Cys-144 and Cys-158, and the formation
CC       of a disulfide bond. {ECO:0000250}.
CC   -!- PTM: Trophic-factor deprivation triggers the cleavage of surface
CC       APP by beta-secretase to release sAPP-beta which is further
CC       cleaved to release an N-terminal fragment of APP (N-APP).
CC       {ECO:0000250}.
CC   -!- PTM: Beta-amyloid peptides are degraded by IDE. {ECO:0000250}.
CC   -!- MISCELLANEOUS: Chelation of metal ions, notably copper, iron and
CC       zinc, can induce histidine-bridging between beta-amyloid molecules
CC       resulting in beta-amyloid-metal aggregates. Rat and mouse beta-
CC       amyloid peptides have an arginine residue substituted for the
CC       bridging histidine residue and are thus less capable of forming
CC       amyloid aggregates. Extracellular zinc-binding increases binding
CC       of heparin to APP and inhibits collagen-binding (By similarity).
CC       {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the APP family. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 BPTI/Kunitz inhibitor domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00031}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M18373; AAA37139.1; -; mRNA.
DR   EMBL; X59379; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; U84012; AAB41502.1; -; mRNA.
DR   EMBL; D10603; BAA01456.1; -; Genomic_DNA.
DR   EMBL; BC005490; AAH05490.1; -; mRNA.
DR   EMBL; M24397; AAA39929.1; -; mRNA.
DR   EMBL; X15210; CAA33280.1; -; mRNA.
DR   EMBL; U82624; AAB40919.1; -; Genomic_DNA.
DR   CCDS; CCDS28285.1; -. [P12023-2]
DR   PIR; A27485; A27485.
DR   PIR; A32282; A32282.
DR   PIR; S04855; S04855.
DR   RefSeq; NP_001185752.1; NM_001198823.1. [P12023-1]
DR   UniGene; Mm.277585; -.
DR   UniGene; Mm.489029; -.
DR   UniGene; Mm.490986; -.
DR   PDB; 2ROZ; NMR; -; A=739-770.
DR   PDB; 2YSZ; NMR; -; A=739-770.
DR   PDB; 2YT0; NMR; -; A=739-770.
DR   PDB; 2YT1; NMR; -; A=739-770.
DR   PDB; 4YN0; X-ray; 2.20 A; B=370-592.
DR   PDBsum; 2ROZ; -.
DR   PDBsum; 2YSZ; -.
DR   PDBsum; 2YT0; -.
DR   PDBsum; 2YT1; -.
DR   PDBsum; 4YN0; -.
DR   ProteinModelPortal; P12023; -.
DR   SMR; P12023; 28-189, 287-342, 381-582, 686-726, 741-768.
DR   BioGrid; 198167; 7.
DR   IntAct; P12023; 79.
DR   MINT; MINT-208509; -.
DR   STRING; 10090.ENSMUSP00000005406; -.
DR   MEROPS; I02.015; -.
DR   iPTMnet; P12023; -.
DR   PhosphoSite; P12023; -.
DR   MaxQB; P12023; -.
DR   PaxDb; P12023; -.
DR   PRIDE; P12023; -.
DR   Ensembl; ENSMUST00000005406; ENSMUSP00000005406; ENSMUSG00000022892. [P12023-2]
DR   GeneID; 11820; -.
DR   KEGG; mmu:11820; -.
DR   UCSC; uc007ztn.2; mouse. [P12023-1]
DR   CTD; 351; -.
DR   MGI; MGI:88059; App.
DR   eggNOG; KOG3540; Eukaryota.
DR   eggNOG; ENOG410ZW2A; LUCA.
DR   HOGENOM; HOG000232190; -.
DR   HOVERGEN; HBG000051; -.
DR   InParanoid; P12023; -.
DR   KO; K04520; -.
DR   OMA; TKTCIGT; -.
DR   OrthoDB; EOG7RNJZP; -.
DR   PhylomeDB; P12023; -.
DR   TreeFam; TF317274; -.
DR   ChiTaRS; App; mouse.
DR   EvolutionaryTrace; P12023; -.
DR   NextBio; 279717; -.
DR   PRO; PR:P12023; -.
DR   Proteomes; UP000000589; Chromosome 16.
DR   Bgee; P12023; -.
DR   CleanEx; MM_APP; -.
DR   ExpressionAtlas; P12023; baseline and differential.
DR   Genevisible; P12023; MM.
DR   GO; GO:0045177; C:apical part of cell; IDA:MGI.
DR   GO; GO:0097449; C:astrocyte projection; IEA:Ensembl.
DR   GO; GO:0030424; C:axon; IDA:MGI.
DR   GO; GO:0009986; C:cell surface; ISO:MGI.
DR   GO; GO:0005911; C:cell-cell junction; IDA:MGI.
DR   GO; GO:0035253; C:ciliary rootlet; IDA:MGI.
DR   GO; GO:0005905; C:coated pit; IEA:UniProtKB-SubCell.
DR   GO; GO:0005737; C:cytoplasm; IDA:MGI.
DR   GO; GO:0031410; C:cytoplasmic vesicle; IDA:MGI.
DR   GO; GO:0043198; C:dendritic shaft; IEA:Ensembl.
DR   GO; GO:0043197; C:dendritic spine; IEA:Ensembl.
DR   GO; GO:0005768; C:endosome; ISO:MGI.
DR   GO; GO:0030134; C:ER to Golgi transport vesicle; IDA:MGI.
DR   GO; GO:0070062; C:extracellular exosome; ISO:MGI.
DR   GO; GO:0005615; C:extracellular space; ISO:MGI.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:MGI.
DR   GO; GO:1990812; C:growth cone filopodium; IEA:Ensembl.
DR   GO; GO:1990761; C:growth cone lamellipodium; IEA:Ensembl.
DR   GO; GO:0016021; C:integral component of membrane; IDA:MGI.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; ISO:MGI.
DR   GO; GO:0044304; C:main axon; IEA:Ensembl.
DR   GO; GO:0016020; C:membrane; IDA:MGI.
DR   GO; GO:0045121; C:membrane raft; ISO:MGI.
DR   GO; GO:0031594; C:neuromuscular junction; IDA:MGI.
DR   GO; GO:0043005; C:neuron projection; IDA:MGI.
DR   GO; GO:0005641; C:nuclear envelope lumen; ISO:MGI.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:MGI.
DR   GO; GO:0005886; C:plasma membrane; IDA:MGI.
DR   GO; GO:0043235; C:receptor complex; ISO:MGI.
DR   GO; GO:0005791; C:rough endoplasmic reticulum; IEA:Ensembl.
DR   GO; GO:0005790; C:smooth endoplasmic reticulum; IGI:GOC.
DR   GO; GO:0051233; C:spindle midzone; IDA:MGI.
DR   GO; GO:0043195; C:terminal bouton; IEA:Ensembl.
DR   GO; GO:0033130; F:acetylcholine receptor binding; ISO:MGI.
DR   GO; GO:0003677; F:DNA binding; IDA:MGI.
DR   GO; GO:0019899; F:enzyme binding; ISO:MGI.
DR   GO; GO:0008201; F:heparin binding; IEA:UniProtKB-KW.
DR   GO; GO:0042802; F:identical protein binding; ISO:MGI.
DR   GO; GO:0016504; F:peptidase activator activity; IEA:Ensembl.
DR   GO; GO:0051425; F:PTB domain binding; ISO:MGI.
DR   GO; GO:0005102; F:receptor binding; ISO:MGI.
DR   GO; GO:0004867; F:serine-type endopeptidase inhibitor activity; ISO:MGI.
DR   GO; GO:0046914; F:transition metal ion binding; IEA:InterPro.
DR   GO; GO:0008344; P:adult locomotory behavior; IMP:MGI.
DR   GO; GO:0019731; P:antibacterial humoral response; ISO:MGI.
DR   GO; GO:0019732; P:antifungal humoral response; ISO:MGI.
DR   GO; GO:0008088; P:axon cargo transport; IMP:MGI.
DR   GO; GO:0016199; P:axon midline choice point recognition; IMP:MGI.
DR   GO; GO:0007409; P:axonogenesis; IMP:MGI.
DR   GO; GO:0007155; P:cell adhesion; IEA:UniProtKB-KW.
DR   GO; GO:0006878; P:cellular copper ion homeostasis; IMP:MGI.
DR   GO; GO:0071320; P:cellular response to cAMP; IEA:Ensembl.
DR   GO; GO:1990090; P:cellular response to nerve growth factor stimulus; IEA:Ensembl.
DR   GO; GO:0071874; P:cellular response to norepinephrine stimulus; IEA:Ensembl.
DR   GO; GO:0008203; P:cholesterol metabolic process; IMP:MGI.
DR   GO; GO:0048669; P:collateral sprouting in absence of injury; IGI:MGI.
DR   GO; GO:0050829; P:defense response to Gram-negative bacterium; ISO:MGI.
DR   GO; GO:0050830; P:defense response to Gram-positive bacterium; ISO:MGI.
DR   GO; GO:0016358; P:dendrite development; IMP:MGI.
DR   GO; GO:0006897; P:endocytosis; IMP:MGI.
DR   GO; GO:0030198; P:extracellular matrix organization; IGI:MGI.
DR   GO; GO:0030900; P:forebrain development; IMP:MGI.
DR   GO; GO:0045087; P:innate immune response; ISO:MGI.
DR   GO; GO:0035235; P:ionotropic glutamate receptor signaling pathway; IMP:MGI.
DR   GO; GO:0007626; P:locomotory behavior; IGI:MGI.
DR   GO; GO:0007617; P:mating behavior; IGI:MGI.
DR   GO; GO:0006378; P:mRNA polyadenylation; IDA:MGI.
DR   GO; GO:0010951; P:negative regulation of endopeptidase activity; ISO:MGI.
DR   GO; GO:0045665; P:negative regulation of neuron differentiation; IDA:MGI.
DR   GO; GO:0050885; P:neuromuscular process controlling balance; IGI:MGI.
DR   GO; GO:0051402; P:neuron apoptotic process; IGI:MGI.
DR   GO; GO:0031175; P:neuron projection development; IDA:MGI.
DR   GO; GO:0016322; P:neuron remodeling; IMP:MGI.
DR   GO; GO:0007219; P:Notch signaling pathway; IEA:UniProtKB-KW.
DR   GO; GO:0010971; P:positive regulation of G2/M transition of mitotic cell cycle; IMP:MGI.
DR   GO; GO:0045931; P:positive regulation of mitotic cell cycle; IMP:MGI.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:MGI.
DR   GO; GO:0051260; P:protein homooligomerization; ISO:MGI.
DR   GO; GO:0006468; P:protein phosphorylation; IMP:MGI.
DR   GO; GO:0007176; P:regulation of epidermal growth factor-activated receptor activity; IGI:MGI.
DR   GO; GO:0010468; P:regulation of gene expression; IDA:MGI.
DR   GO; GO:0040014; P:regulation of multicellular organism growth; IMP:MGI.
DR   GO; GO:0043393; P:regulation of protein binding; IMP:MGI.
DR   GO; GO:0050803; P:regulation of synapse structure or activity; IMP:MGI.
DR   GO; GO:0006417; P:regulation of translation; IDA:MGI.
DR   GO; GO:0010288; P:response to lead ion; IEA:Ensembl.
DR   GO; GO:0006979; P:response to oxidative stress; IGI:MGI.
DR   GO; GO:0001878; P:response to yeast; ISO:MGI.
DR   GO; GO:0051563; P:smooth endoplasmic reticulum calcium ion homeostasis; IGI:MGI.
DR   GO; GO:0001967; P:suckling behavior; IGI:MGI.
DR   GO; GO:0051124; P:synaptic growth at neuromuscular junction; IGI:MGI.
DR   GO; GO:0008542; P:visual learning; IMP:MGI.
DR   Gene3D; 3.30.1490.140; -; 1.
DR   Gene3D; 3.90.570.10; -; 1.
DR   Gene3D; 4.10.230.10; -; 1.
DR   Gene3D; 4.10.410.10; -; 1.
DR   InterPro; IPR008155; Amyloid_glyco.
DR   InterPro; IPR013803; Amyloid_glyco_Abeta.
DR   InterPro; IPR011178; Amyloid_glyco_Cu-bd.
DR   InterPro; IPR024329; Amyloid_glyco_E2_domain.
DR   InterPro; IPR008154; Amyloid_glyco_extra.
DR   InterPro; IPR019744; Amyloid_glyco_extracell_CS.
DR   InterPro; IPR015849; Amyloid_glyco_heparin-bd.
DR   InterPro; IPR019745; Amyloid_glyco_intracell_CS.
DR   InterPro; IPR028866; APP.
DR   InterPro; IPR019543; APP_amyloid_C.
DR   InterPro; IPR002223; Kunitz_BPTI.
DR   InterPro; IPR020901; Prtase_inh_Kunz-CS.
DR   PANTHER; PTHR23103:SF7; PTHR23103:SF7; 2.
DR   Pfam; PF10515; APP_amyloid; 1.
DR   Pfam; PF12924; APP_Cu_bd; 1.
DR   Pfam; PF12925; APP_E2; 1.
DR   Pfam; PF02177; APP_N; 1.
DR   Pfam; PF03494; Beta-APP; 1.
DR   Pfam; PF00014; Kunitz_BPTI; 1.
DR   PRINTS; PR00203; AMYLOIDA4.
DR   PRINTS; PR00759; BASICPTASE.
DR   PRINTS; PR00204; BETAAMYLOID.
DR   SMART; SM00006; A4_EXTRA; 1.
DR   SMART; SM00131; KU; 1.
DR   SUPFAM; SSF109843; SSF109843; 1.
DR   SUPFAM; SSF56491; SSF56491; 1.
DR   SUPFAM; SSF57362; SSF57362; 1.
DR   SUPFAM; SSF89811; SSF89811; 1.
DR   PROSITE; PS00319; A4_EXTRA; 1.
DR   PROSITE; PS00320; A4_INTRA; 1.
DR   PROSITE; PS00280; BPTI_KUNITZ_1; 1.
DR   PROSITE; PS50279; BPTI_KUNITZ_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Amyloid; Apoptosis; Cell adhesion;
KW   Coated pit; Complete proteome; Copper; Disulfide bond; Endocytosis;
KW   Glycoprotein; Heparin-binding; Iron; Isopeptide bond; Membrane;
KW   Metal-binding; Notch signaling pathway; Phosphoprotein;
KW   Protease inhibitor; Reference proteome; Serine protease inhibitor;
KW   Signal; Transmembrane; Transmembrane helix; Ubl conjugation; Zinc.
FT   SIGNAL        1     17       {ECO:0000250}.
FT   CHAIN        18    770       Amyloid beta A4 protein.
FT                                /FTId=PRO_0000000114.
FT   CHAIN        18    687       Soluble APP-alpha. {ECO:0000255}.
FT                                /FTId=PRO_0000000115.
FT   CHAIN        18    671       Soluble APP-beta. {ECO:0000255}.
FT                                /FTId=PRO_0000000116.
FT   CHAIN        18    286       N-APP. {ECO:0000250}.
FT                                /FTId=PRO_0000381968.
FT   CHAIN       672    770       C99. {ECO:0000250}.
FT                                /FTId=PRO_0000000117.
FT   CHAIN       672    713       Beta-amyloid protein 42. {ECO:0000250}.
FT                                /FTId=PRO_0000000118.
FT   CHAIN       672    711       Beta-amyloid protein 40. {ECO:0000250}.
FT                                /FTId=PRO_0000000119.
FT   CHAIN       688    770       C83. {ECO:0000250}.
FT                                /FTId=PRO_0000000120.
FT   PEPTIDE     688    713       P3(42). {ECO:0000250}.
FT                                /FTId=PRO_0000000121.
FT   PEPTIDE     688    711       P3(40). {ECO:0000250}.
FT                                /FTId=PRO_0000000122.
FT   CHAIN       691    770       C80.
FT                                /FTId=PRO_0000384576.
FT   CHAIN       712    770       Gamma-secretase C-terminal fragment 59.
FT                                /FTId=PRO_0000000123.
FT   CHAIN       714    770       Gamma-secretase C-terminal fragment 57.
FT                                /FTId=PRO_0000000124.
FT   CHAIN       721    770       Gamma-secretase C-terminal fragment 50.
FT                                /FTId=PRO_0000000125.
FT   CHAIN       740    770       C31. {ECO:0000250}.
FT                                /FTId=PRO_0000000126.
FT   TOPO_DOM     18    699       Extracellular. {ECO:0000255}.
FT   TRANSMEM    700    723       Helical. {ECO:0000255}.
FT   TOPO_DOM    724    770       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      291    341       BPTI/Kunitz inhibitor.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00031}.
FT   REGION       96    110       Heparin-binding. {ECO:0000250}.
FT   REGION      181    188       Zinc-binding. {ECO:0000250}.
FT   REGION      391    423       Heparin-binding. {ECO:0000250}.
FT   REGION      491    522       Heparin-binding. {ECO:0000250}.
FT   REGION      523    540       Collagen-binding. {ECO:0000250}.
FT   REGION      732    751       Interaction with G(o)-alpha.
FT                                {ECO:0000250}.
FT   REGION      756    770       Interaction with DAB2.
FT   MOTIF       724    734       Basolateral sorting signal.
FT   MOTIF       759    762       NPXY motif; contains endocytosis signal.
FT   COMPBIAS    230    260       Asp/Glu-rich (acidic).
FT   COMPBIAS    274    280       Poly-Thr.
FT   METAL       147    147       Copper 1. {ECO:0000250}.
FT   METAL       151    151       Copper 1. {ECO:0000250}.
FT   METAL       168    168       Copper 1. {ECO:0000250}.
FT   METAL       677    677       Copper or zinc 2. {ECO:0000250}.
FT   METAL       685    685       Copper or zinc 2. {ECO:0000250}.
FT   SITE        144    144       Required for Cu(2+) reduction.
FT                                {ECO:0000250}.
FT   SITE        301    302       Reactive bond. {ECO:0000250}.
FT   SITE        671    672       Cleavage; by beta-secretase.
FT                                {ECO:0000250}.
FT   SITE        672    673       Cleavage; by caspase-6. {ECO:0000250}.
FT   SITE        687    688       Cleavage; by alpha-secretase.
FT                                {ECO:0000250}.
FT   SITE        690    691       Cleavage; by theta-secretase.
FT                                {ECO:0000250}.
FT   SITE        704    704       Implicated in free radical propagation.
FT                                {ECO:0000250}.
FT   SITE        711    712       Cleavage; by gamma-secretase; site 1.
FT                                {ECO:0000250}.
FT   SITE        713    714       Cleavage; by gamma-secretase; site 2.
FT                                {ECO:0000250}.
FT   SITE        720    721       Cleavage; by gamma-secretase; site 3.
FT                                {ECO:0000250}.
FT   SITE        739    740       Cleavage; by caspase-6, caspase-8 or
FT                                caspase-9. {ECO:0000250}.
FT   MOD_RES     198    198       Phosphoserine; by CK2. {ECO:0000250}.
FT   MOD_RES     206    206       Phosphoserine; by CK1. {ECO:0000250}.
FT   MOD_RES     441    441       Phosphoserine.
FT                                {ECO:0000244|PubMed:21183079}.
FT   MOD_RES     497    497       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:P05067}.
FT   MOD_RES     729    729       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:P08592}.
FT   MOD_RES     730    730       Phosphoserine; by APP-kinase I.
FT                                {ECO:0000250}.
FT   MOD_RES     743    743       Phosphothreonine; by CDK5 and MAPK10.
FT                                {ECO:0000269|PubMed:11912189}.
FT   MOD_RES     757    757       Phosphotyrosine; by ABL1.
FT                                {ECO:0000269|PubMed:11279131}.
FT   CARBOHYD    542    542       N-linked (GlcNAc...). {ECO:0000305}.
FT   CARBOHYD    571    571       N-linked (GlcNAc...). {ECO:0000305}.
FT   DISULFID     38     62       {ECO:0000255|PROSITE-ProRule:PRU00031}.
FT   DISULFID     73    117       {ECO:0000255|PROSITE-ProRule:PRU00031}.
FT   DISULFID     98    105       {ECO:0000255|PROSITE-ProRule:PRU00031}.
FT   DISULFID    133    187       {ECO:0000255|PROSITE-ProRule:PRU00031}.
FT   DISULFID    144    174       {ECO:0000255|PROSITE-ProRule:PRU00031}.
FT   DISULFID    158    186       {ECO:0000255|PROSITE-ProRule:PRU00031}.
FT   DISULFID    291    341       {ECO:0000255|PROSITE-ProRule:PRU00031}.
FT   DISULFID    300    324       {ECO:0000255|PROSITE-ProRule:PRU00031}.
FT   DISULFID    316    337       {ECO:0000255|PROSITE-ProRule:PRU00031}.
FT   CROSSLNK    763    763       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000250|UniProtKB:P08592}.
FT   VAR_SEQ     289    289       E -> V (in isoform APP695).
FT                                {ECO:0000303|PubMed:11235921,
FT                                ECO:0000303|PubMed:1756177,
FT                                ECO:0000303|PubMed:3322280}.
FT                                /FTId=VSP_000012.
FT   VAR_SEQ     290    364       Missing (in isoform APP695).
FT                                {ECO:0000303|PubMed:11235921,
FT                                ECO:0000303|PubMed:1756177,
FT                                ECO:0000303|PubMed:3322280}.
FT                                /FTId=VSP_000013.
FT   VAR_SEQ     346    380       Missing (in isoform APP751).
FT                                {ECO:0000305}.
FT                                /FTId=VSP_000014.
FT   MUTAGEN     728    728       Y->A: No effect on MAPK8IP1 binding.
FT                                {ECO:0000269|PubMed:11517249}.
FT   MUTAGEN     732    733       HH->GL,GP: Almost complete loss of
FT                                binding to G(o) alpha subunit. No
FT                                inhibition of GTPase activity.
FT   MUTAGEN     743    743       T->E: No effect on MAPK8IP1 binding.
FT                                {ECO:0000269|PubMed:11517249}.
FT   MUTAGEN     756    756       G->F,H,N,S,W: Greatly impairs interaction
FT                                with DAB2. {ECO:0000269|PubMed:11247302}.
FT   MUTAGEN     756    756       G->Y: Impairs interaction with DAB2.
FT                                {ECO:0000269|PubMed:11247302}.
FT   MUTAGEN     757    757       Y->F: Greatly promotes interaction with
FT                                DAB2. {ECO:0000269|PubMed:11247302,
FT                                ECO:0000269|PubMed:11517249}.
FT   MUTAGEN     757    757       Y->G,H,V: Greatly impairs interaction
FT                                with DAB2. {ECO:0000269|PubMed:11247302,
FT                                ECO:0000269|PubMed:11517249}.
FT   MUTAGEN     757    757       Y->G: No MAPK8IP1 nor APBA1 nor APBB1 nor
FT                                DAB1 binding.
FT                                {ECO:0000269|PubMed:11247302,
FT                                ECO:0000269|PubMed:11517249}.
FT   MUTAGEN     757    757       Y->I,W: Impairs interaction with DAB2.
FT                                {ECO:0000269|PubMed:11247302,
FT                                ECO:0000269|PubMed:11517249}.
FT   MUTAGEN     759    759       N->A: No MAPK8IP1 nor APBA1 nor Dab1
FT                                binding. No effect on APBB1 binding.
FT                                {ECO:0000269|PubMed:11247302,
FT                                ECO:0000269|PubMed:11517249}.
FT   MUTAGEN     759    759       N->G,L,M,P: Greatly impairs interaction
FT                                with DAB2. {ECO:0000269|PubMed:11247302,
FT                                ECO:0000269|PubMed:11517249}.
FT   MUTAGEN     760    760       P->E,F,I,K,L,Q,R,V,W,Y: Greatly impairs
FT                                interaction with DAB2.
FT                                {ECO:0000269|PubMed:11247302}.
FT   MUTAGEN     762    762       Y->A: No MAPK8IP1 nor APBA1 nor Dab1
FT                                binding. No effect on APBB1 binding.
FT                                {ECO:0000269|PubMed:11247302,
FT                                ECO:0000269|PubMed:11517249}.
FT   MUTAGEN     762    762       Y->W: Greatly impairs interaction with
FT                                DAB2. {ECO:0000269|PubMed:11247302,
FT                                ECO:0000269|PubMed:11517249}.
FT   CONFLICT    211    211       G -> V (in Ref. 1; AAA37139).
FT                                {ECO:0000305}.
FT   CONFLICT    375    375       V -> A (in Ref. 4; AAB41502).
FT                                {ECO:0000305}.
FT   HELIX       382    419       {ECO:0000244|PDB:4YN0}.
FT   TURN        420    422       {ECO:0000244|PDB:4YN0}.
FT   HELIX       425    481       {ECO:0000244|PDB:4YN0}.
FT   HELIX       487    518       {ECO:0000244|PDB:4YN0}.
FT   HELIX       520    550       {ECO:0000244|PDB:4YN0}.
FT   HELIX       552    581       {ECO:0000244|PDB:4YN0}.
FT   HELIX       744    753       {ECO:0000244|PDB:2ROZ}.
SQ   SEQUENCE   770 AA;  86722 MW;  988D89E089092A3E CRC64;
     MLPSLALLLL AAWTVRALEV PTDGNAGLLA EPQIAMFCGK LNMHMNVQNG KWESDPSGTK
     TCIGTKEGIL QYCQEVYPEL QITNVVEANQ PVTIQNWCKR GRKQCKTHTH IVIPYRCLVG
     EFVSDALLVP DKCKFLHQER MDVCETHLHW HTVAKETCSE KSTNLHDYGM LLPCGIDKFR
     GVEFVCCPLA EESDSVDSAD AEEDDSDVWW GGADTDYADG GEDKVVEVAE EEEVADVEEE
     EADDDEDVED GDEVEEEAEE PYEEATERTT STATTTTTTT ESVEEVVREV CSEQAETGPC
     RAMISRWYFD VTEGKCVPFF YGGCGGNRNN FDTEEYCMAV CGSVSTQSLL KTTSEPLPQD
     PDKLPTTAAS TPDAVDKYLE TPGDENEHAH FQKAKERLEA KHRERMSQVM REWEEAERQA
     KNLPKADKKA VIQHFQEKVE SLEQEAANER QQLVETHMAR VEAMLNDRRR LALENYITAL
     QAVPPRPHHV FNMLKKYVRA EQKDRQHTLK HFEHVRMVDP KKAAQIRSQV MTHLRVIYER
     MNQSLSLLYN VPAVAEEIQD EVDELLQKEQ NYSDDVLANM ISEPRISYGN DALMPSLTET
     KTTVELLPVN GEFSLDDLQP WHPFGVDSVP ANTENEVEPV DARPAADRGL TTRPGSGLTN
     IKTEEISEVK MDAEFGHDSG FEVRHQKLVF FAEDVGSNKG AIIGLMVGGV VIATVIVITL
     VMLKKKQYTS IHHGVVEVDA AVTPEERHLS KMQQNGYENP TYKFFEQMQN
//
ID   MET_HUMAN               Reviewed;        1390 AA.
AC   P08581; A1L467; B5A932; E7EQ94; O60366; Q12875; Q9UDX7; Q9UPL8;
DT   01-AUG-1988, integrated into UniProtKB/Swiss-Prot.
DT   07-JUL-2009, sequence version 4.
DT   17-FEB-2016, entry version 213.
DE   RecName: Full=Hepatocyte growth factor receptor;
DE            Short=HGF receptor;
DE            EC=2.7.10.1;
DE   AltName: Full=HGF/SF receptor;
DE   AltName: Full=Proto-oncogene c-Met;
DE   AltName: Full=Scatter factor receptor;
DE            Short=SF receptor;
DE   AltName: Full=Tyrosine-protein kinase Met;
DE   Flags: Precursor;
GN   Name=MET;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=2819873; DOI=10.1073/pnas.84.18.6379;
RA   Park M., Dean M., Kaul K., Braun M.J., Gonda M.A., Vande Woude G.;
RT   "Sequence of MET protooncogene cDNA has features characteristic of the
RT   tyrosine kinase family of growth-factor receptors.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:6379-6383(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Giordano S.;
RL   Submitted (NOV-1990) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), AND ALTERNATIVE SPLICING.
RX   PubMed=18593464; DOI=10.1186/ar2447;
RA   Jin P., Zhang J., Sumariwalla P.F., Ni I., Jorgensen B., Crawford D.,
RA   Phillips S., Feldmann M., Shepard H.M., Paleolog E.M.;
RT   "Novel splice variants derived from the receptor tyrosine kinase
RT   superfamily are potential therapeutics for rheumatoid arthritis.";
RL   Arthritis Res. Ther. 10:R73-R73(2008).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R.,
RA   Wylie K., Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H.,
RA   Sun H., Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A.,
RA   Vanbrunt A., Nguyen C., Du F., Lamar B., Courtney L., Kalicki J.,
RA   Ozersky P., Bielicki L., Scott K., Holmes A., Harkins R., Harris A.,
RA   Strong C.M., Hou S., Tomlinson C., Dauphin-Kohlberg S.,
RA   Kozlowicz-Reilly A., Leonard S., Rohlfing T., Rock S.M.,
RA   Tin-Wollam A.-M., Abbott A., Minx P., Maupin R., Strowmatt C.,
RA   Latreille P., Miller N., Johnson D., Murray J., Woessner J.P.,
RA   Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W., Spieth J.,
RA   Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E., Cook L.L.,
RA   Hickenbotham M.T., Eldred J., Williams D., Bedell J.A., Mardis E.R.,
RA   Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K.,
RA   Simms E., Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S.,
RA   Baertsch R.A., Brent M.R., Keibler E., Flicek P., Bork P., Suyama M.,
RA   Bailey J.A., Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R.,
RA   Eddy S.R., McPherson J.D., Olson M.V., Eichler E.E., Green E.D.,
RA   Waterston R.H., Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12690205; DOI=10.1126/science.1083423;
RA   Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K.,
RA   Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R.,
RA   Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A.,
RA   Kanematsu E., Gentles S., Christopoulos C.C., Choufani S.,
RA   Kwasnicka D., Zheng X.H., Lai Z., Nusskern D.R., Zhang Q., Gu Z.,
RA   Lu F., Zeesman S., Nowaczyk M.J., Teshima I., Chitayat D., Shuman C.,
RA   Weksberg R., Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J.,
RA   Rahman N., Friedman J.M., Heng H.H.Q., Pelicci P.G., Lo-Coco F.,
RA   Belloni E., Shaffer L.G., Pober B., Morton C.C., Gusella J.F.,
RA   Bruns G.A.P., Korf B.R., Quade B.J., Ligon A.H., Ferguson H.,
RA   Higgins A.W., Leach N.T., Herrick S.R., Lemyre E., Farra C.G.,
RA   Kim H.-G., Summers A.M., Gripp K.W., Roberts W., Szatmari P.,
RA   Winsor E.J.T., Grzeschik K.-H., Teebi A., Minassian B.A., Kere J.,
RA   Armengol L., Pujana M.A., Estivill X., Wilson M.D., Koop B.F.,
RA   Tosi S., Moore G.E., Boright A.P., Zlotorynski E., Kerem B.,
RA   Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Doehner H.,
RA   Doehner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W.,
RA   Mural R.J., Adams M.D., Tsui L.-C.;
RT   "Human chromosome 7: DNA sequence and biology.";
RL   Science 300:767-772(2003).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Cerebellum;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1010-1390.
RX   PubMed=3325883;
RA   Chan A.M.-L., King H.W.S., Tempest P.R., Deakin E.A., Cooper C.S.,
RA   Brookes P.;
RT   "Primary structure of the met protein tyrosine kinase domain.";
RL   Oncogene 1:229-233(1987).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1206-1264.
RX   PubMed=8247543;
RA   Lee S.-T., Strunk K.M., Spritz R.A.;
RT   "A survey of protein tyrosine kinase mRNAs expressed in normal human
RT   melanocytes.";
RL   Oncogene 8:3403-3410(1993).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1267-1390.
RX   PubMed=4069211; DOI=10.1038/318385a0;
RA   Dean M., Park M., le Beau M.M., Robins T.S., Diaz M.O., Rowley J.D.,
RA   Blair D.G., Vande Woude G.F.;
RT   "The human met oncogene is related to the tyrosine kinase oncogenes.";
RL   Nature 318:385-388(1985).
RN   [11]
RP   TISSUE SPECIFICITY.
RX   PubMed=1917129; DOI=10.1002/ijc.2910490302;
RA   Prat M., Narsimhan R.P., Crepaldi T., Nicotra M.R., Natali P.G.,
RA   Comoglio P.M.;
RT   "The receptor encoded by the human c-MET oncogene is expressed in
RT   hepatocytes, epithelial cells and solid tumors.";
RL   Int. J. Cancer 49:323-328(1991).
RN   [12]
RP   INTERACTION WITH PIK3R1.
RX   PubMed=1718989;
RA   Graziani A., Gramaglia D., Cantley L.C., Comoglio P.M.;
RT   "The tyrosine-phosphorylated hepatocyte growth factor/scatter factor
RT   receptor associates with phosphatidylinositol 3-kinase.";
RL   J. Biol. Chem. 266:22087-22090(1991).
RN   [13]
RP   TISSUE SPECIFICITY.
RX   PubMed=1719465;
RA   Di Renzo M.F., Narsimhan R.P., Olivero M., Bretti S., Giordano S.,
RA   Medico E., Gaglia P., Zara P., Comoglio P.M.;
RT   "Expression of the Met/HGF receptor in normal and neoplastic human
RT   tissues.";
RL   Oncogene 6:1997-2003(1991).
RN   [14]
RP   FUNCTION.
RX   PubMed=1846706; DOI=10.1126/science.1846706;
RA   Bottaro D.P., Rubin J.S., Faletto D.L., Chan A.M.-L., Kmiecik T.E.,
RA   Vande Woude G.F., Aaronson S.A.;
RT   "Identification of the hepatocyte growth factor receptor as the c-met
RT   proto-oncogene product.";
RL   Science 251:802-804(1991).
RN   [15]
RP   PHOSPHORYLATION AT TYR-1235, AND ATP-BINDING SITE LYS-1110.
RX   PubMed=1655790;
RA   Ferracini R., Longati P., Naldini L., Vigna E., Comoglio P.M.;
RT   "Identification of the major autophosphorylation site of the
RT   Met/hepatocyte growth factor receptor tyrosine kinase.";
RL   J. Biol. Chem. 266:19558-19564(1991).
RN   [16]
RP   PHOSPHORYLATION AT TYR-1349 AND TYR-1356, AND INTERACTION WITH SRC;
RP   PLCG1 AND GRB2.
RX   PubMed=7513258; DOI=10.1016/0092-8674(94)90318-2;
RA   Ponzetto C., Bardelli A., Zhen Z., Maina F., dalla Zonca P.,
RA   Giordano S., Graziani A., Panayotou G., Comoglio P.M.;
RT   "A multifunctional docking site mediates signaling and transformation
RT   by the hepatocyte growth factor/scatter factor receptor family.";
RL   Cell 77:261-271(1994).
RN   [17]
RP   FUNCTION IN WOUND HEALING.
RX   PubMed=8182137; DOI=10.1172/JCI117200;
RA   Nusrat A., Parkos C.A., Bacarra A.E., Godowski P.J., Delp-Archer C.,
RA   Rosen E.M., Madara J.L.;
RT   "Hepatocyte growth factor/scatter factor effects on epithelia.
RT   Regulation of intercellular junctions in transformed and
RT   nontransformed cell lines, basolateral polarization of c-met receptor
RT   in transformed and natural intestinal epithelia, and induction of
RT   rapid wound repair in a transformed model epithelium.";
RL   J. Clin. Invest. 93:2056-2065(1994).
RN   [18]
RP   INTERACTION WITH STAT3.
RX   PubMed=9440692; DOI=10.1038/34657;
RA   Boccaccio C., Ando M., Tamagnone L., Bardelli A., Michieli P.,
RA   Battistini C., Comoglio P.M.;
RT   "Induction of epithelial tubules by growth factor HGF depends on the
RT   STAT pathway.";
RL   Nature 391:285-288(1998).
RN   [19]
RP   INTERACTION WITH GRB10.
RX   PubMed=10454568;
RA   Wang J., Dai H., Yousaf N., Moussaif M., Deng Y., Boufelliga A.,
RA   Swamy O.R., Leone M.E., Riedel H.;
RT   "Grb10, a positive, stimulatory signaling adapter in platelet-derived
RT   growth factor BB-, insulin-like growth factor I-, and insulin-mediated
RT   mitogenesis.";
RL   Mol. Cell. Biol. 19:6217-6228(1999).
RN   [20]
RP   INTERACTION WITH RANBP9.
RX   PubMed=12147692; DOI=10.1074/jbc.M205111200;
RA   Wang D., Li Z., Messing E.M., Wu G.;
RT   "Activation of Ras/Erk pathway by a novel MET-interacting protein
RT   RanBPM.";
RL   J. Biol. Chem. 277:36216-36222(2002).
RN   [21]
RP   UBIQUITINATION.
RX   PubMed=12244174; DOI=10.4049/jimmunol.169.7.3793;
RA   Taher T.E., Tjin E.P., Beuling E.A., Borst J., Spaargaren M.,
RA   Pals S.T.;
RT   "c-Cbl is involved in Met signaling in B cells and mediates hepatocyte
RT   growth factor-induced receptor ubiquitination.";
RL   J. Immunol. 169:3793-3800(2002).
RN   [22]
RP   INTERACTION WITH PLXNB1.
RX   PubMed=12198496; DOI=10.1038/ncb843;
RA   Giordano S., Corso S., Conrotto P., Artigiani S., Gilestro G.,
RA   Barberis D., Tamagnone L., Comoglio P.M.;
RT   "The semaphorin 4D receptor controls invasive growth by coupling with
RT   Met.";
RL   Nat. Cell Biol. 4:720-724(2002).
RN   [23]
RP   PHOSPHORYLATION AT TYR-1230; TYR-1234; TYR-1235; TYR-1349 AND
RP   TYR-1365, AND DEPHOSPHORYLATION AT TYR-1349 AND TYR-1365 BY PTPRJ.
RX   PubMed=12475979; DOI=10.1074/jbc.M210656200;
RA   Palka H.L., Park M., Tonks N.K.;
RT   "Hepatocyte growth factor receptor tyrosine kinase met is a substrate
RT   of the receptor protein-tyrosine phosphatase DEP-1.";
RL   J. Biol. Chem. 278:5728-5735(2003).
RN   [24]
RP   INTERACTION WITH RANBP9 AND RANBP10.
RX   PubMed=14684163; DOI=10.1016/j.bbrc.2003.11.124;
RA   Wang D., Li Z., Schoen S.R., Messing E.M., Wu G.;
RT   "A novel MET-interacting protein shares high sequence similarity with
RT   RanBPM, but fails to stimulate MET-induced Ras/Erk signaling.";
RL   Biochem. Biophys. Res. Commun. 313:320-326(2004).
RN   [25]
RP   FUNCTION, AND INTERACTION WITH MUC20.
RX   PubMed=15314156; DOI=10.1128/MCB.24.17.7456-7468.2004;
RA   Higuchi T., Orita T., Katsuya K., Yamasaki Y., Akiyama K., Li H.,
RA   Yamamoto T., Saito Y., Nakamura M.;
RT   "MUC20 suppresses the hepatocyte growth factor-induced Grb2-Ras
RT   pathway by binding to a multifunctional docking site of met.";
RL   Mol. Cell. Biol. 24:7456-7468(2004).
RN   [26]
RP   PHOSPHORYLATION AT TYR-1356, AND INTERACTION WITH INPPL1.
RX   PubMed=15735664; DOI=10.1038/sj.onc.1208558;
RA   Koch A., Mancini A., El Bounkari O., Tamura T.;
RT   "The SH2-domain-containing inositol 5-phosphatase (SHIP)-2 binds to c-
RT   Met directly via tyrosine residue 1356 and involves hepatocyte growth
RT   factor (HGF)-induced lamellipodium formation, cell scattering and cell
RT   spreading.";
RL   Oncogene 24:3436-3447(2005).
RN   [27]
RP   REVIEW ON FUNCTION IN ANGIOGENESIS.
RX   PubMed=16862193; DOI=10.1038/nrc1912;
RA   Boccaccio C., Comoglio P.M.;
RT   "Invasive growth: a MET-driven genetic programme for cancer and stem
RT   cells.";
RL   Nat. Rev. Cancer 6:637-645(2006).
RN   [28]
RP   PHOSPHORYLATION, DEPHOSPHORYLATION BY PTPN1 AND PTPN2, INTERACTION
RP   WITH PTPN1 AND PTPN2, AND MUTAGENESIS OF TYR-1234 AND TYR-1235.
RX   PubMed=18819921; DOI=10.1074/jbc.M805916200;
RA   Sangwan V., Paliouras G.N., Abella J.V., Dube N., Monast A.,
RA   Tremblay M.L., Park M.;
RT   "Regulation of the Met receptor-tyrosine kinase by the protein-
RT   tyrosine phosphatase 1B and T-cell phosphatase.";
RL   J. Biol. Chem. 283:34374-34383(2008).
RN   [29]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-977 AND TYR-1003, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [30]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-990; SER-997 AND
RP   SER-1000, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [31]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-106.
RC   TISSUE=Hepatoma;
RX   PubMed=19196183; DOI=10.1021/pr800826u;
RA   Cao J., Shen C., Wang H., Shen H., Chen Y., Nie A., Yan G., Lu H.,
RA   Liu Y., Yang P.;
RT   "Identification of N-glycosylation sites on secreted proteins of human
RT   hepatocellular carcinoma cells with a complementary proteomics
RT   approach.";
RL   J. Proteome Res. 8:662-672(2009).
RN   [32]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-1003 AND THR-1289, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [33]
RP   REVIEW ON FUNCTION.
RX   PubMed=20655987; DOI=10.1016/j.bbcan.2010.07.006;
RA   Mahtouk K., Tjin E.P., Spaargaren M., Pals S.T.;
RT   "The HGF/MET pathway as target for the treatment of multiple myeloma
RT   and B-cell lymphomas.";
RL   Biochim. Biophys. Acta 1806:208-219(2010).
RN   [34]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [35]
RP   INTERACTION WITH GAB1.
RX   PubMed=21784853; DOI=10.1074/jbc.M111.239384;
RA   Chaudhuri A., Xie M.H., Yang B., Mahapatra K., Liu J., Marsters S.,
RA   Bodepudi S., Ashkenazi A.;
RT   "Distinct involvement of the Gab1 and Grb2 adaptor proteins in signal
RT   transduction by the related receptor tyrosine kinases RON and MET.";
RL   J. Biol. Chem. 286:32762-32774(2011).
RN   [36]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-966, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [37]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 1356-1359 IN COMPLEX WITH
RP   GRB2.
RX   PubMed=11063574; DOI=10.1021/bi0012336;
RA   Schiering N., Casale E., Caccia P., Giordano P., Battistini C.;
RT   "Dimer formation through domain swapping in the crystal structure of
RT   the Grb2-SH2-Ac-pYVNV complex.";
RL   Biochemistry 39:13376-13382(2000).
RN   [38]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 1049-1360 IN COMPLEX WITH
RP   INHIBITOR.
RX   PubMed=14559966; DOI=10.1073/pnas.1734128100;
RA   Schiering N., Knapp S., Marconi M., Flocco M.M., Cui J., Perego R.,
RA   Rusconi L., Cristiani C.;
RT   "Crystal structure of the tyrosine kinase domain of the hepatocyte
RT   growth factor receptor c-Met and its complex with the microbial
RT   alkaloid K-252a.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:12654-12659(2003).
RN   [39]
RP   STRUCTURE BY NMR OF 519-562, AND DISULFIDE BONDS.
RX   PubMed=15358240; DOI=10.1016/j.bbrc.2004.06.132;
RA   Kozlov G., Perreault A., Schrag J.D., Park M., Cygler M., Gehring K.,
RA   Ekiel I.;
RT   "Insights into function of PSI domains from structure of the Met
RT   receptor PSI domain.";
RL   Biochem. Biophys. Res. Commun. 321:234-240(2004).
RN   [40]
RP   X-RAY CRYSTALLOGRAPHY (3.22 ANGSTROMS) OF 25-567 IN COMPLEX WITH HGF,
RP   AND DISULFIDE BONDS.
RX   PubMed=15167892; DOI=10.1038/sj.emboj.7600243;
RA   Stamos J., Lazarus R.A., Yao X., Kirchhofer D., Wiesmann C.;
RT   "Crystal structure of the HGF beta-chain in complex with the Sema
RT   domain of the Met receptor.";
RL   EMBO J. 23:2325-2335(2004).
RN   [41]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 25-740 IN COMPLEX WITH
RP   L.MONOCYTOGENES INLB, AND DISULFIDE BONDS.
RX   PubMed=17662939; DOI=10.1016/j.cell.2007.05.037;
RA   Niemann H.H., Jager V., Butler P.J., van den Heuvel J., Schmidt S.,
RA   Ferraris D., Gherardi E., Heinz D.W.;
RT   "Structure of the human receptor tyrosine kinase met in complex with
RT   the Listeria invasion protein InlB.";
RL   Cell 130:235-246(2007).
RN   [42]
RP   VARIANTS RCCP THR-1131; LEU-1188; VAL-1195; ILE-1220; HIS-1228;
RP   ASN-1228; CYS-1230; HIS-1230 AND THR-1250, AND VARIANT VAL-320.
RX   PubMed=9140397; DOI=10.1038/ng0597-68;
RA   Schmidt L., Duh F.-M., Chen F., Kishida T., Glenn G., Choyke P.,
RA   Scherer S.W., Zhuang Z., Lubensky I., Dean M., Allikmets R.,
RA   Chidambaram A., Bergerheim U.R., Feltis J.T., Casadevall C.,
RA   Zamarron A., Bernues M., Richard S., Lips C.J.M., Walther M.M.,
RA   Tsui L.-C., Geil L., Orcutt M.L., Stackhouse T., Lipan J., Slife L.,
RA   Brauch H., Decker J., Niehans G., Hughson M.D., Moch H., Storkel S.,
RA   Lerman M.I., Linehan W.M., Zbar B.;
RT   "Germline and somatic mutations in the tyrosine kinase domain of the
RT   MET proto-oncogene in papillary renal carcinomas.";
RL   Nat. Genet. 16:68-73(1997).
RN   [43]
RP   VARIANT RCCP ARG-1094, AND CHARACTERIZATION OF VARIANT RCCP ARG-1094.
RX   PubMed=9563489;
RA   Schmidt L., Junker K., Weirich G., Glenn G., Choyke P., Lubensky I.,
RA   Zhuang Z., Jeffers M., Vande Woude G., Neumann H., Walther M.,
RA   Linehan W.M., Zbar B.;
RT   "Two North American families with hereditary papillary renal carcinoma
RT   and identical novel mutations in the MET proto-oncogene.";
RL   Cancer Res. 58:1719-1722(1998).
RN   [44]
RP   VARIANTS RCCP ILE-1092; ARG-1094; ASP-1106; THR-1131; LEU-1188;
RP   ASP-1230; CYS-1230 AND THR-1250.
RX   PubMed=10433944; DOI=10.1016/S0002-9440(10)65147-4;
RA   Lubensky I.A., Schmidt L., Zhuang Z., Weirich G., Pack S.,
RA   Zambrano N., Walther M.M., Choyke P., Linehan W.M., Zbar B.;
RT   "Hereditary and sporadic papillary renal carcinomas with c-met
RT   mutations share a distinct morphological phenotype.";
RL   Am. J. Pathol. 155:517-526(1999).
RN   [45]
RP   VARIANTS HCC ILE-1173; ARG-1244 AND ILE-1250.
RX   PubMed=9927037;
RA   Park W.S., Dong S.M., Kim S.Y., Na E.Y., Shin M.S., Pi J.H., Kim B.J.,
RA   Bae J.H., Hong Y.K., Lee K.S., Lee S.H., Yoo N.J., Jang J.J., Pack S.,
RA   Zhuang Z., Schmidt L., Zbar B., Lee J.Y.;
RT   "Somatic mutations in the kinase domain of the Met/hepatocyte growth
RT   factor receptor gene in childhood hepatocellular carcinomas.";
RL   Cancer Res. 59:307-310(1999).
RN   [46]
RP   VARIANT RCCP ILE-1092, AND CHARACTERIZATION OF VARIANT RCCP ILE-1092.
RX   PubMed=10417759;
RX   DOI=10.1002/(SICI)1097-0215(19990827)82:5<640::AID-IJC4>3.0.CO;2-6;
RA   Olivero M., Valente G., Bardelli A., Longati P., Ferrero N.,
RA   Cracco C., Terrone C., Rocca-Rossetti S., Comoglio P.M.,
RA   Di Renzo M.F.;
RT   "Novel mutation in the ATP-binding site of the MET oncogene tyrosine
RT   kinase in a HPRCC family.";
RL   Int. J. Cancer 82:640-643(1999).
RN   [47]
RP   VARIANTS RCCP ILE-1092; LEU-1094; TYR-1094; ASP-1106 AND ASP-1230, AND
RP   CHARACTERIZATION OF VARIANTS RCCP ILE-1092; LEU-1094; TYR-1094;
RP   ASP-1106 AND ASP-1230.
RX   PubMed=10327054; DOI=10.1038/sj.onc.1202547;
RA   Schmidt L., Junker K., Nakaigawa N., Kinjerski T., Weirich G.,
RA   Miller M., Lubensky I., Neumann H.P.H., Brauch H., Decker J.,
RA   Vocke C., Brown J.A., Jenkins R., Richard S., Bergerheim U.,
RA   Gerrard B., Dean M., Linehan W.M., Zbar B.;
RT   "Novel mutations of the MET proto-oncogene in papillary renal
RT   carcinomas.";
RL   Oncogene 18:2343-2350(1999).
RN   [48]
RP   VARIANT GASTRIC CANCER SER-991, VARIANT ILE-992, CHARACTERIZATION OF
RP   VARIANT GASTRIC CANCER SER-991, AND CHARACTERIZATION OF VARIANT
RP   ILE-992.
RX   PubMed=11042681; DOI=10.1038/sj.onc.1203874;
RA   Lee J.-H., Han S.-U., Cho H., Jennings B., Gerrard B., Dean M.,
RA   Schmidt L., Zbar B., Vande Woude G.F.V.;
RT   "A novel germ line juxtamembrane Met mutation in human gastric
RT   cancer.";
RL   Oncogene 19:4947-4953(2000).
RN   [49]
RP   VARIANT GASTRIC CANCER LEU-773.
RX   PubMed=12920089; DOI=10.1136/jmg.40.8.e97;
RA   Kim I.-J., Park J.-H., Kang H.C., Shin Y., Lim S.-B., Ku J.-L.,
RA   Yang H.-K., Lee K.U., Park J.-G.;
RT   "A novel germline mutation in the MET extracellular domain in a Korean
RT   patient with the diffuse type of familial gastric cancer.";
RL   J. Med. Genet. 40:E97-E97(2003).
RN   [50]
RP   INTERACTION WITH SPSB1; SPSB2; SPSB3 AND SPSB4.
RX   PubMed=15713673; DOI=10.1074/jbc.M413897200;
RA   Wang D., Li Z., Messing E.M., Wu G.;
RT   "The SPRY domain-containing SOCS box protein 1 (SSB-1) interacts with
RT   MET and enhances the hepatocyte growth factor-induced Erk-Elk-1-serum
RT   response element pathway.";
RL   J. Biol. Chem. 280:16393-16401(2005).
RN   [51]
RP   POSSIBLE INVOLVEMENT IN SUSCEPTIBILITY TO AUTS9, AND VARIANTS CYS-970
RP   AND ILE-992.
RX   PubMed=17053076; DOI=10.1073/pnas.0605296103;
RA   Campbell D.B., Sutcliffe J.S., Ebert P.J., Militerni R., Bravaccio C.,
RA   Trillo S., Elia M., Schneider C., Melmed R., Sacco R., Persico A.M.,
RA   Levitt P.;
RT   "A genetic variant that disrupts MET transcription is associated with
RT   autism.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:16834-16839(2006).
RN   [52]
RP   VARIANTS [LARGE SCALE ANALYSIS] GLN-143; LEU-156; ASP-168; SER-375;
RP   CYS-970 AND ILE-992.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [53]
RP   VARIANTS TYR-150; ASP-168; TYR-385; ILE-992 AND ILE-1294,
RP   CHARACTERIZATION OF VARIANTS TYR-150; ASP-168; TYR-385; ILE-992 AND
RP   ILE-1294, AND POSSIBLE INVOLVEMENT IN CUP.
RX   PubMed=20949619; DOI=10.1002/humu.21374;
RA   Stella G.M., Benvenuti S., Gramaglia D., Scarpa A., Tomezzoli A.,
RA   Cassoni P., Senetta R., Venesio T., Pozzi E., Bardelli A.,
RA   Comoglio P.M.;
RT   "MET mutations in cancers of unknown primary origin (CUPs).";
RL   Hum. Mutat. 32:44-50(2011).
CC   -!- FUNCTION: Receptor tyrosine kinase that transduces signals from
CC       the extracellular matrix into the cytoplasm by binding to
CC       hepatocyte growth factor/HGF ligand. Regulates many physiological
CC       processes including proliferation, scattering, morphogenesis and
CC       survival. Ligand binding at the cell surface induces
CC       autophosphorylation of MET on its intracellular domain that
CC       provides docking sites for downstream signaling molecules.
CC       Following activation by ligand, interacts with the PI3-kinase
CC       subunit PIK3R1, PLCG1, SRC, GRB2, STAT3 or the adapter GAB1.
CC       Recruitment of these downstream effectors by MET leads to the
CC       activation of several signaling cascades including the RAS-ERK,
CC       PI3 kinase-AKT, or PLCgamma-PKC. The RAS-ERK activation is
CC       associated with the morphogenetic effects while PI3K/AKT
CC       coordinates prosurvival effects. During embryonic development, MET
CC       signaling plays a role in gastrulation, development and migration
CC       of muscles and neuronal precursors, angiogenesis and kidney
CC       formation. In adults, participates in wound healing as well as
CC       organ regeneration and tissue remodeling. Promotes also
CC       differentiation and proliferation of hematopoietic cells.
CC   -!- FUNCTION: Acts as a receptor for Listeria internalin inlB,
CC       mediating entry of the pathogen into cells.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028}.
CC   -!- ENZYME REGULATION: In its inactive state, the C-terminal tail
CC       interacts with the catalytic domain and inhibits the kinase
CC       activity. Upon ligand binding, the C-terminal tail is displaced
CC       and becomes phosphorylated, thus increasing the kinase activity.
CC   -!- SUBUNIT: Heterodimer made of an alpha chain (50 kDa) and a beta
CC       chain (145 kDa) which are disulfide linked. Binds PLXNB1.
CC       Interacts when phosphorylated with downstream effectors including
CC       STAT3, PIK3R1, SRC, PCLG1, GRB2 and GAB1. Interacts with SPSB1,
CC       SPSB2 and SPSB4 (By similarity). Interacts with INPP5D/SHIP1. When
CC       phosphorylated at Tyr-1356, interacts with INPPL1/SHIP2. Interacts
CC       with RANBP9 and RANBP10, as well as SPSB1, SPSB2, SPSB3 and SPSB4.
CC       SPSB1 binding occurs in the presence and in the absence of HGF,
CC       however HGF treatment has a positive effect on this interaction.
CC       Interacts with MUC20; prevents interaction with GRB2 and
CC       suppresses hepatocyte growth factor-induced cell proliferation.
CC       Interacts with GRB10. Interacts with PTPN1 and PTPN2.
CC       {ECO:0000250, ECO:0000269|PubMed:10454568,
CC       ECO:0000269|PubMed:11063574, ECO:0000269|PubMed:12147692,
CC       ECO:0000269|PubMed:12198496, ECO:0000269|PubMed:14559966,
CC       ECO:0000269|PubMed:14684163, ECO:0000269|PubMed:15167892,
CC       ECO:0000269|PubMed:15314156, ECO:0000269|PubMed:15713673,
CC       ECO:0000269|PubMed:15735664, ECO:0000269|PubMed:1718989,
CC       ECO:0000269|PubMed:17662939, ECO:0000269|PubMed:18819921,
CC       ECO:0000269|PubMed:21784853, ECO:0000269|PubMed:7513258,
CC       ECO:0000269|PubMed:9440692}.
CC   -!- INTERACTION:
CC       P22681:CBL; NbExp=15; IntAct=EBI-1039152, EBI-518228;
CC       Q96EY1-2:DNAJA3; NbExp=2; IntAct=EBI-1039152, EBI-3952284;
CC       P00533:EGFR; NbExp=7; IntAct=EBI-1039152, EBI-297353;
CC       P09769:FGR; NbExp=2; IntAct=EBI-1039152, EBI-1383732;
CC       P14210:HGF; NbExp=4; IntAct=EBI-1039152, EBI-1039104;
CC       P14210-6:HGF; NbExp=2; IntAct=EBI-1039152, EBI-6280319;
CC       P25147:inlB (xeno); NbExp=4; IntAct=EBI-1039152, EBI-1379295;
CC       O15357:INPPL1; NbExp=2; IntAct=EBI-1039152, EBI-1384248;
CC       P35968:KDR; NbExp=3; IntAct=EBI-1039152, EBI-1005487;
CC       P35918:Kdr (xeno); NbExp=3; IntAct=EBI-1039152, EBI-1555005;
CC       P06239:LCK; NbExp=3; IntAct=EBI-1039152, EBI-1348;
CC       P07948:LYN; NbExp=2; IntAct=EBI-1039152, EBI-79452;
CC       P15941:MUC1; NbExp=2; IntAct=EBI-1039152, EBI-2804728;
CC       P16333:NCK1; NbExp=2; IntAct=EBI-1039152, EBI-389883;
CC       O43639:NCK2; NbExp=2; IntAct=EBI-1039152, EBI-713635;
CC       P27986:PIK3R1; NbExp=6; IntAct=EBI-1039152, EBI-79464;
CC       O00459:PIK3R2; NbExp=11; IntAct=EBI-1039152, EBI-346930;
CC       Q92569:PIK3R3; NbExp=11; IntAct=EBI-1039152, EBI-79893;
CC       P19174:PLCG1; NbExp=10; IntAct=EBI-1039152, EBI-79387;
CC       O43157:PLXNB1; NbExp=7; IntAct=EBI-1039152, EBI-1111488;
CC       O15031:PLXNB2; NbExp=2; IntAct=EBI-1039152, EBI-722004;
CC       Q9ULL4:PLXNB3; NbExp=2; IntAct=EBI-1039152, EBI-311073;
CC       Q00944:PTK2 (xeno); NbExp=5; IntAct=EBI-1039152, EBI-2896409;
CC       P18031:PTPN1; NbExp=3; IntAct=EBI-1039152, EBI-968788;
CC       Q06124:PTPN11; NbExp=13; IntAct=EBI-1039152, EBI-297779;
CC       P23467:PTPRB; NbExp=2; IntAct=EBI-1039152, EBI-1265766;
CC       Q12913:PTPRJ; NbExp=5; IntAct=EBI-1039152, EBI-2264500;
CC       P20936:RASA1; NbExp=15; IntAct=EBI-1039152, EBI-1026476;
CC       Q9UQQ2:SH2B3; NbExp=2; IntAct=EBI-1039152, EBI-7879749;
CC       O60880:SH2D1A; NbExp=3; IntAct=EBI-1039152, EBI-6983382;
CC       O14796:SH2D1B; NbExp=6; IntAct=EBI-1039152, EBI-3923013;
CC       Q9NP31:SH2D2A; NbExp=7; IntAct=EBI-1039152, EBI-490630;
CC       Q8N5H7:SH2D3C; NbExp=4; IntAct=EBI-1039152, EBI-745980;
CC       Q15464:SHB; NbExp=4; IntAct=EBI-1039152, EBI-4402156;
CC       P29353:SHC1; NbExp=5; IntAct=EBI-1039152, EBI-78835;
CC       P98077:SHC2; NbExp=2; IntAct=EBI-1039152, EBI-7256023;
CC       Q6S5L8:SHC4; NbExp=3; IntAct=EBI-1039152, EBI-9453524;
CC       Q96IW2:SHD; NbExp=2; IntAct=EBI-1039152, EBI-4402781;
CC       Q9H6Q3:SLA2; NbExp=4; IntAct=EBI-1039152, EBI-1222854;
CC       O75159:SOCS5; NbExp=2; IntAct=EBI-1039152, EBI-970130;
CC       O14544:SOCS6; NbExp=4; IntAct=EBI-1039152, EBI-3929549;
CC       P12931:SRC; NbExp=4; IntAct=EBI-1039152, EBI-621482;
CC       Q9ULZ2:STAP1; NbExp=3; IntAct=EBI-1039152, EBI-6083058;
CC       P43405:SYK; NbExp=3; IntAct=EBI-1039152, EBI-78302;
CC       P42680:TEC; NbExp=2; IntAct=EBI-1039152, EBI-1383480;
CC       Q9HBL0:TNS1; NbExp=2; IntAct=EBI-1039152, EBI-3389814;
CC       Q63HR2:TNS2; NbExp=2; IntAct=EBI-1039152, EBI-949753;
CC       Q68CZ2:TNS3; NbExp=3; IntAct=EBI-1039152, EBI-1220488;
CC       Q9UKW4:VAV3; NbExp=2; IntAct=EBI-1039152, EBI-297568;
CC       P07947:YES1; NbExp=3; IntAct=EBI-1039152, EBI-515331;
CC       P43403:ZAP70; NbExp=2; IntAct=EBI-1039152, EBI-1211276;
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane
CC       protein.
CC   -!- SUBCELLULAR LOCATION: Isoform 3: Secreted.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC         Comment=Additional soluble isoforms seem to exist.;
CC       Name=1;
CC         IsoId=P08581-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P08581-2; Sequence=VSP_005005;
CC         Note=No experimental confirmation available.;
CC       Name=3; Synonyms=Soluble MET variant 4;
CC         IsoId=P08581-3; Sequence=VSP_042447, VSP_042448;
CC   -!- TISSUE SPECIFICITY: Expressed in normal hepatocytes as well as in
CC       epithelial cells lining the stomach, the small and the large
CC       intestine. Found also in basal keratinocytes of esophagus and
CC       skin. High levels are found in liver, gastrointestinal tract,
CC       thyroid and kidney. Also present in the brain.
CC       {ECO:0000269|PubMed:1719465, ECO:0000269|PubMed:1917129}.
CC   -!- DOMAIN: The kinase domain is involved in SPSB1 binding.
CC   -!- DOMAIN: The beta-propeller Sema domain mediates binding to HGF.
CC   -!- PTM: Autophosphorylated in response to ligand binding on Tyr-1234
CC       and Tyr-1235 in the kinase domain leading to further
CC       phosphorylation of Tyr-1349 and Tyr-1356 in the C-terminal
CC       multifunctional docking site. Dephosphorylated by PTPRJ at Tyr-
CC       1349 and Tyr-1365. Dephosphorylated by PTPN1 and PTPN2.
CC       {ECO:0000269|PubMed:12475979, ECO:0000269|PubMed:15735664,
CC       ECO:0000269|PubMed:1655790, ECO:0000269|PubMed:18819921,
CC       ECO:0000269|PubMed:7513258}.
CC   -!- PTM: Ubiquitinated. Ubiquitination by CBL regulates the receptor
CC       stability and activity through proteasomal degradation.
CC       {ECO:0000269|PubMed:12244174}.
CC   -!- DISEASE: Note=Activation of MET after rearrangement with the TPR
CC       gene produces an oncogenic protein.
CC   -!- DISEASE: Note=Defects in MET may be associated with gastric
CC       cancer.
CC   -!- DISEASE: Hepatocellular carcinoma (HCC) [MIM:114550]: A primary
CC       malignant neoplasm of epithelial liver cells. The major risk
CC       factors for HCC are chronic hepatitis B virus (HBV) infection,
CC       chronic hepatitis C virus (HCV) infection, prolonged dietary
CC       aflatoxin exposure, alcoholic cirrhosis, and cirrhosis due to
CC       other causes. {ECO:0000269|PubMed:9927037}. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Renal cell carcinoma papillary (RCCP) [MIM:605074]: A
CC       subtype of renal cell carcinoma tending to show a tubulo-papillary
CC       architecture formed by numerous, irregular, finger-like
CC       projections of connective tissue. Renal cell carcinoma is a
CC       heterogeneous group of sporadic or hereditary carcinoma derived
CC       from cells of the proximal renal tubular epithelium.
CC       {ECO:0000269|PubMed:10327054, ECO:0000269|PubMed:10417759,
CC       ECO:0000269|PubMed:10433944, ECO:0000269|PubMed:9140397,
CC       ECO:0000269|PubMed:9563489}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Note=A common allele in the promoter region of the MET
CC       shows genetic association with susceptibility to autism in some
CC       families. Functional assays indicate a decrease in MET promoter
CC       activity and altered binding of specific transcription factor
CC       complexes.
CC   -!- DISEASE: Note=MET activating mutations may be involved in the
CC       development of a highly malignant, metastatic syndrome known as
CC       cancer of unknown primary origin (CUP) or primary occult
CC       malignancy. Systemic neoplastic spread is generally a late event
CC       in cancer progression. However, in some instances, distant
CC       dissemination arises at a very early stage, so that metastases
CC       reach clinical relevance before primary lesions. Sometimes, the
CC       primary lesions cannot be identified in spite of the progresses in
CC       the diagnosis of malignancies.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- SIMILARITY: Contains 3 IPT/TIG domains. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- SIMILARITY: Contains 1 Sema domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00352}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/METID131.html";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=C-MET entry;
CC       URL="https://en.wikipedia.org/wiki/C-MET";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; J02958; AAA59591.1; -; mRNA.
DR   EMBL; X54559; CAB56793.1; -; mRNA.
DR   EMBL; EU826570; ACF47606.1; -; mRNA.
DR   EMBL; AC002080; AAB54047.1; -; Genomic_DNA.
DR   EMBL; AC002543; AAC60383.1; -; Genomic_DNA.
DR   EMBL; AC004416; AAF66137.2; -; Genomic_DNA.
DR   EMBL; CH236947; EAL24359.1; -; Genomic_DNA.
DR   EMBL; CH471070; EAW83509.1; -; Genomic_DNA.
DR   EMBL; BC130420; AAI30421.1; -; mRNA.
DR   EMBL; U08818; AAB60323.1; ALT_SEQ; mRNA.
DR   EMBL; M35074; AAA59590.1; -; mRNA.
DR   CCDS; CCDS43636.1; -. [P08581-1]
DR   CCDS; CCDS47689.1; -. [P08581-2]
DR   PIR; A40175; TVHUME.
DR   RefSeq; NP_000236.2; NM_000245.2. [P08581-1]
DR   RefSeq; NP_001120972.1; NM_001127500.1. [P08581-2]
DR   UniGene; Hs.132966; -.
DR   PDB; 1FYR; X-ray; 2.40 A; I/J/K/L=1356-1359.
DR   PDB; 1R0P; X-ray; 1.80 A; A=1049-1360.
DR   PDB; 1R1W; X-ray; 1.80 A; A=1049-1360.
DR   PDB; 1SHY; X-ray; 3.22 A; B=25-567.
DR   PDB; 1SSL; NMR; -; A=519-562.
DR   PDB; 1UX3; Model; -; A=25-656.
DR   PDB; 2G15; X-ray; 2.15 A; A=1038-1346.
DR   PDB; 2RFN; X-ray; 2.50 A; A/B=1048-1351.
DR   PDB; 2RFS; X-ray; 2.20 A; A=1048-1351.
DR   PDB; 2UZX; X-ray; 2.80 A; B/D=25-740.
DR   PDB; 2UZY; X-ray; 4.00 A; B/D=25-740.
DR   PDB; 2WD1; X-ray; 2.00 A; A=1055-1346.
DR   PDB; 2WGJ; X-ray; 2.00 A; A=1051-1348.
DR   PDB; 2WKM; X-ray; 2.20 A; A=1051-1348.
DR   PDB; 3A4P; X-ray; 2.54 A; A=1049-1360.
DR   PDB; 3BUX; X-ray; 1.35 A; A/C=997-1009.
DR   PDB; 3C1X; X-ray; 2.17 A; A=1049-1360.
DR   PDB; 3CCN; X-ray; 1.90 A; A=1048-1350.
DR   PDB; 3CD8; X-ray; 2.00 A; A=1048-1350.
DR   PDB; 3CE3; X-ray; 2.40 A; A=1049-1360.
DR   PDB; 3CTH; X-ray; 2.30 A; A=1049-1360.
DR   PDB; 3CTJ; X-ray; 2.50 A; A=1049-1360.
DR   PDB; 3DKC; X-ray; 1.52 A; A=1049-1360.
DR   PDB; 3DKF; X-ray; 1.80 A; A=1049-1360.
DR   PDB; 3DKG; X-ray; 1.91 A; A=1049-1360.
DR   PDB; 3EFJ; X-ray; 2.60 A; A/B=1048-1351.
DR   PDB; 3EFK; X-ray; 2.20 A; A/B=1048-1351.
DR   PDB; 3F66; X-ray; 1.40 A; A/B=1052-1349.
DR   PDB; 3F82; X-ray; 2.50 A; A=1049-1360.
DR   PDB; 3I5N; X-ray; 2.00 A; A=1048-1350.
DR   PDB; 3L8V; X-ray; 2.40 A; A=1049-1360.
DR   PDB; 3LQ8; X-ray; 2.02 A; A=1051-1348.
DR   PDB; 3Q6U; X-ray; 1.60 A; A=1048-1348.
DR   PDB; 3Q6W; X-ray; 1.75 A; A=1048-1348.
DR   PDB; 3QTI; X-ray; 2.00 A; A/B=1050-1360.
DR   PDB; 3R7O; X-ray; 2.30 A; A=1048-1348.
DR   PDB; 3RHK; X-ray; 1.94 A; A/B=1038-1346.
DR   PDB; 3U6H; X-ray; 2.00 A; A=1048-1351.
DR   PDB; 3U6I; X-ray; 2.10 A; A=1048-1351.
DR   PDB; 3VW8; X-ray; 2.10 A; A=1024-1352.
DR   PDB; 3ZBX; X-ray; 2.20 A; A=1051-1348.
DR   PDB; 3ZC5; X-ray; 2.20 A; A=1051-1348.
DR   PDB; 3ZCL; X-ray; 1.40 A; A=1051-1348.
DR   PDB; 3ZXZ; X-ray; 1.80 A; A=1051-1348.
DR   PDB; 3ZZE; X-ray; 1.87 A; A=1051-1348.
DR   PDB; 4AOI; X-ray; 1.90 A; A=1051-1348.
DR   PDB; 4AP7; X-ray; 1.80 A; A=1051-1348.
DR   PDB; 4DEG; X-ray; 2.00 A; A=1048-1351.
DR   PDB; 4DEH; X-ray; 2.00 A; A=1048-1351.
DR   PDB; 4DEI; X-ray; 2.05 A; A=1048-1351.
DR   PDB; 4EEV; X-ray; 1.80 A; A=1038-1346.
DR   PDB; 4GG5; X-ray; 2.42 A; A=1038-1346.
DR   PDB; 4GG7; X-ray; 2.27 A; A=1038-1346.
DR   PDB; 4IWD; X-ray; 1.99 A; A=1048-1348.
DR   PDB; 4K3J; X-ray; 2.80 A; B=39-564.
DR   PDB; 4KNB; X-ray; 2.40 A; A/B/C/D=1060-1346.
DR   PDB; 4MXC; X-ray; 1.63 A; A=1038-1346.
DR   PDB; 4O3T; X-ray; 2.99 A; B=25-567.
DR   PDB; 4O3U; X-ray; 3.04 A; B=25-567.
DR   PDB; 4R1V; X-ray; 1.20 A; A=1055-1345.
DR   PDB; 4R1Y; X-ray; 2.00 A; A=1055-1346.
DR   PDB; 4XMO; X-ray; 1.75 A; A=1048-1350.
DR   PDB; 4XYF; X-ray; 1.85 A; A=1048-1351.
DR   PDBsum; 1FYR; -.
DR   PDBsum; 1R0P; -.
DR   PDBsum; 1R1W; -.
DR   PDBsum; 1SHY; -.
DR   PDBsum; 1SSL; -.
DR   PDBsum; 1UX3; -.
DR   PDBsum; 2G15; -.
DR   PDBsum; 2RFN; -.
DR   PDBsum; 2RFS; -.
DR   PDBsum; 2UZX; -.
DR   PDBsum; 2UZY; -.
DR   PDBsum; 2WD1; -.
DR   PDBsum; 2WGJ; -.
DR   PDBsum; 2WKM; -.
DR   PDBsum; 3A4P; -.
DR   PDBsum; 3BUX; -.
DR   PDBsum; 3C1X; -.
DR   PDBsum; 3CCN; -.
DR   PDBsum; 3CD8; -.
DR   PDBsum; 3CE3; -.
DR   PDBsum; 3CTH; -.
DR   PDBsum; 3CTJ; -.
DR   PDBsum; 3DKC; -.
DR   PDBsum; 3DKF; -.
DR   PDBsum; 3DKG; -.
DR   PDBsum; 3EFJ; -.
DR   PDBsum; 3EFK; -.
DR   PDBsum; 3F66; -.
DR   PDBsum; 3F82; -.
DR   PDBsum; 3I5N; -.
DR   PDBsum; 3L8V; -.
DR   PDBsum; 3LQ8; -.
DR   PDBsum; 3Q6U; -.
DR   PDBsum; 3Q6W; -.
DR   PDBsum; 3QTI; -.
DR   PDBsum; 3R7O; -.
DR   PDBsum; 3RHK; -.
DR   PDBsum; 3U6H; -.
DR   PDBsum; 3U6I; -.
DR   PDBsum; 3VW8; -.
DR   PDBsum; 3ZBX; -.
DR   PDBsum; 3ZC5; -.
DR   PDBsum; 3ZCL; -.
DR   PDBsum; 3ZXZ; -.
DR   PDBsum; 3ZZE; -.
DR   PDBsum; 4AOI; -.
DR   PDBsum; 4AP7; -.
DR   PDBsum; 4DEG; -.
DR   PDBsum; 4DEH; -.
DR   PDBsum; 4DEI; -.
DR   PDBsum; 4EEV; -.
DR   PDBsum; 4GG5; -.
DR   PDBsum; 4GG7; -.
DR   PDBsum; 4IWD; -.
DR   PDBsum; 4K3J; -.
DR   PDBsum; 4KNB; -.
DR   PDBsum; 4MXC; -.
DR   PDBsum; 4O3T; -.
DR   PDBsum; 4O3U; -.
DR   PDBsum; 4R1V; -.
DR   PDBsum; 4R1Y; -.
DR   PDBsum; 4XMO; -.
DR   PDBsum; 4XYF; -.
DR   DisProt; DP00317; -.
DR   ProteinModelPortal; P08581; -.
DR   SMR; P08581; 40-741, 1024-1352.
DR   BioGrid; 110391; 35.
DR   DIP; DIP-6023N; -.
DR   IntAct; P08581; 86.
DR   MINT; MINT-4837114; -.
DR   STRING; 9606.ENSP00000317272; -.
DR   BindingDB; P08581; -.
DR   ChEMBL; CHEMBL3717; -.
DR   DrugBank; DB08875; Cabozantinib.
DR   DrugBank; DB08865; Crizotinib.
DR   GuidetoPHARMACOLOGY; 1815; -.
DR   iPTMnet; P08581; -.
DR   PhosphoSite; P08581; -.
DR   UniCarbKB; P08581; -.
DR   BioMuta; MET; -.
DR   DMDM; 251757497; -.
DR   OGP; P08581; -.
DR   MaxQB; P08581; -.
DR   PaxDb; P08581; -.
DR   PRIDE; P08581; -.
DR   DNASU; 4233; -.
DR   Ensembl; ENST00000318493; ENSP00000317272; ENSG00000105976. [P08581-2]
DR   Ensembl; ENST00000397752; ENSP00000380860; ENSG00000105976. [P08581-1]
DR   Ensembl; ENST00000436117; ENSP00000410980; ENSG00000105976. [P08581-3]
DR   GeneID; 4233; -.
DR   KEGG; hsa:4233; -.
DR   UCSC; uc003vij.3; human. [P08581-1]
DR   UCSC; uc010lkh.3; human. [P08581-2]
DR   UCSC; uc011knc.1; human. [P08581-3]
DR   CTD; 4233; -.
DR   GeneCards; MET; -.
DR   HGNC; HGNC:7029; MET.
DR   HPA; CAB005282; -.
DR   HPA; CAB018577; -.
DR   HPA; HPA055607; -.
DR   MalaCards; MET; -.
DR   MIM; 114550; phenotype.
DR   MIM; 164860; gene.
DR   MIM; 605074; phenotype.
DR   neXtProt; NX_P08581; -.
DR   Orphanet; 106; Autism.
DR   Orphanet; 47044; Familial papillary renal cell carcinoma.
DR   PharmGKB; PA30763; -.
DR   eggNOG; KOG1095; Eukaryota.
DR   eggNOG; KOG3610; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00810000125384; -.
DR   HOGENOM; HOG000220900; -.
DR   HOVERGEN; HBG006348; -.
DR   InParanoid; P08581; -.
DR   KO; K05099; -.
DR   OMA; QRVDLFM; -.
DR   OrthoDB; EOG7J70DR; -.
DR   PhylomeDB; P08581; -.
DR   TreeFam; TF317402; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   Reactome; R-HSA-416550; Sema4D mediated inhibition of cell attachment and migration.
DR   SignaLink; P08581; -.
DR   ChiTaRS; MET; human.
DR   EvolutionaryTrace; P08581; -.
DR   GeneWiki; C-Met; -.
DR   GenomeRNAi; 4233; -.
DR   NextBio; 16689; -.
DR   PRO; PR:P08581; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   Bgee; P08581; -.
DR   CleanEx; HS_MET; -.
DR   ExpressionAtlas; P08581; baseline and differential.
DR   Genevisible; P08581; HS.
DR   GO; GO:0009925; C:basal plasma membrane; IDA:MGI.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral component of membrane; NAS:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005008; F:hepatocyte growth factor-activated receptor activity; TAS:ProtInc.
DR   GO; GO:0019903; F:protein phosphatase binding; IPI:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; NAS:UniProtKB.
DR   GO; GO:0000187; P:activation of MAPK activity; IEA:Ensembl.
DR   GO; GO:0030534; P:adult behavior; IEA:Ensembl.
DR   GO; GO:0007411; P:axon guidance; TAS:Reactome.
DR   GO; GO:0007420; P:brain development; IEA:Ensembl.
DR   GO; GO:0048754; P:branching morphogenesis of an epithelial tube; IMP:UniProtKB.
DR   GO; GO:0055013; P:cardiac muscle cell development; IEA:Ensembl.
DR   GO; GO:0060048; P:cardiac muscle contraction; IEA:Ensembl.
DR   GO; GO:0008283; P:cell proliferation; TAS:ProtInc.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; NAS:UniProtKB.
DR   GO; GO:0001886; P:endothelial cell morphogenesis; IDA:UniProtKB.
DR   GO; GO:0042593; P:glucose homeostasis; IEA:Ensembl.
DR   GO; GO:0001889; P:liver development; IEA:Ensembl.
DR   GO; GO:0014812; P:muscle cell migration; IEA:Ensembl.
DR   GO; GO:0051450; P:myoblast proliferation; IEA:Ensembl.
DR   GO; GO:0014902; P:myotube differentiation; IEA:Ensembl.
DR   GO; GO:0010507; P:negative regulation of autophagy; NAS:ParkinsonsUK-UCL.
DR   GO; GO:0010629; P:negative regulation of gene expression; IEA:Ensembl.
DR   GO; GO:1901299; P:negative regulation of hydrogen peroxide-mediated programmed cell death; IMP:BHF-UCL.
DR   GO; GO:0071635; P:negative regulation of transforming growth factor beta production; IEA:Ensembl.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; NAS:GOC.
DR   GO; GO:0001890; P:placenta development; IEA:Ensembl.
DR   GO; GO:0050918; P:positive chemotaxis; IDA:UniProtKB.
DR   GO; GO:2001028; P:positive regulation of endothelial cell chemotaxis; IMP:UniProtKB.
DR   GO; GO:0010828; P:positive regulation of glucose transport; IEA:Ensembl.
DR   GO; GO:1900745; P:positive regulation of p38MAPK cascade; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:BHF-UCL.
DR   GO; GO:0046777; P:protein autophosphorylation; IEA:Ensembl.
DR   GO; GO:0072593; P:reactive oxygen species metabolic process; IEA:Ensembl.
DR   GO; GO:0060665; P:regulation of branching involved in salivary gland morphogenesis by mesenchymal-epithelial signaling; IEA:Ensembl.
DR   GO; GO:0071526; P:semaphorin-plexin signaling pathway; IDA:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0007519; P:skeletal muscle tissue development; IEA:Ensembl.
DR   Gene3D; 2.130.10.10; -; 1.
DR   Gene3D; 2.60.40.10; -; 3.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR014756; Ig_E-set.
DR   InterPro; IPR002909; IPT.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR016201; Plexin-like_fold.
DR   InterPro; IPR002165; Plexin_repeat.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001627; Semap_dom.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR016244; Tyr_kinase_HGF/MSP_rcpt.
DR   InterPro; IPR015943; WD40/YVTN_repeat-like_dom.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF01437; PSI; 1.
DR   Pfam; PF01403; Sema; 1.
DR   Pfam; PF01833; TIG; 3.
DR   PIRSF; PIRSF000617; TyrPK_HGF-R; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00429; IPT; 4.
DR   SMART; SM00423; PSI; 1.
DR   SMART; SM00630; Sema; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF101912; SSF101912; 1.
DR   SUPFAM; SSF103575; SSF103575; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF81296; SSF81296; 3.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS51004; SEMA; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding;
KW   Chromosomal rearrangement; Complete proteome; Disease mutation;
KW   Disulfide bond; Glycoprotein; Kinase; Membrane; Nucleotide-binding;
KW   Phosphoprotein; Polymorphism; Proto-oncogene; Receptor;
KW   Reference proteome; Repeat; Secreted; Signal; Transferase;
KW   Transmembrane; Transmembrane helix; Tyrosine-protein kinase;
KW   Ubl conjugation.
FT   SIGNAL        1     24       {ECO:0000255}.
FT   CHAIN        25   1390       Hepatocyte growth factor receptor.
FT                                /FTId=PRO_0000024440.
FT   TOPO_DOM     25    932       Extracellular. {ECO:0000255}.
FT   TRANSMEM    933    955       Helical. {ECO:0000255}.
FT   TOPO_DOM    956   1390       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       27    515       Sema. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00352}.
FT   DOMAIN      563    655       IPT/TIG 1.
FT   DOMAIN      657    739       IPT/TIG 2.
FT   DOMAIN      742    836       IPT/TIG 3.
FT   DOMAIN     1078   1345       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND    1084   1092       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION     1212   1390       Interaction with RANBP9.
FT   REGION     1320   1359       Interaction with MUC20.
FT   ACT_SITE   1204   1204       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING    1110   1110       ATP.
FT   SITE        307    308       Cleavage. {ECO:0000255}.
FT   SITE       1009   1010       Breakpoint for translocation to form TPR-
FT                                MET oncogene.
FT   MOD_RES     966    966       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     977    977       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18691976}.
FT   MOD_RES     990    990       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     997    997       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES    1000   1000       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES    1003   1003       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195}.
FT   MOD_RES    1230   1230       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:12475979}.
FT   MOD_RES    1234   1234       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:12475979}.
FT   MOD_RES    1235   1235       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:12475979,
FT                                ECO:0000269|PubMed:1655790}.
FT   MOD_RES    1289   1289       Phosphothreonine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES    1349   1349       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:12475979,
FT                                ECO:0000269|PubMed:7513258}.
FT   MOD_RES    1356   1356       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:15735664,
FT                                ECO:0000269|PubMed:7513258}.
FT   MOD_RES    1365   1365       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:12475979}.
FT   CARBOHYD     45     45       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    106    106       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19196183}.
FT   CARBOHYD    149    149       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    202    202       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    399    399       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    405    405       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    607    607       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    635    635       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    785    785       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    879    879       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    930    930       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     95    101
FT   DISULFID     98    160
FT   DISULFID    133    141
FT   DISULFID    172    175
FT   DISULFID    298    363
FT   DISULFID    385    397
FT   DISULFID    520    538
FT   DISULFID    526    561
FT   DISULFID    529    545
FT   DISULFID    541    551
FT   VAR_SEQ     755    764       SGGSTITGVG -> RHVNIALIQR (in isoform 3).
FT                                {ECO:0000303|PubMed:18593464}.
FT                                /FTId=VSP_042447.
FT   VAR_SEQ     755    755       S -> STWWKEPLNIVSFLFCFAS (in isoform 2).
FT                                {ECO:0000303|PubMed:2819873}.
FT                                /FTId=VSP_005005.
FT   VAR_SEQ     765   1390       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:18593464}.
FT                                /FTId=VSP_042448.
FT   VARIANT     143    143       R -> Q (in dbSNP:rs35469582).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041738.
FT   VARIANT     150    150       H -> Y (found in a case of cancer of
FT                                unknown primary origin; the mutated
FT                                receptor is still functional and can
FT                                sustain the transformed phenotype;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:20949619}.
FT                                /FTId=VAR_064855.
FT   VARIANT     156    156       S -> L (in dbSNP:rs56311081).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041739.
FT   VARIANT     168    168       E -> D (found in a case of cancer of
FT                                unknown primary origin; the mutated
FT                                receptor is still functional and can
FT                                sustain the transformed phenotype;
FT                                somatic mutation; dbSNP:rs55985569).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:20949619}.
FT                                /FTId=VAR_041740.
FT   VARIANT     238    238       L -> S (in dbSNP:rs34349517).
FT                                /FTId=VAR_032478.
FT   VARIANT     316    316       I -> M (in dbSNP:rs35225896).
FT                                /FTId=VAR_032479.
FT   VARIANT     320    320       A -> V (in dbSNP:rs35776110).
FT                                {ECO:0000269|PubMed:9140397}.
FT                                /FTId=VAR_006285.
FT   VARIANT     375    375       N -> S (in dbSNP:rs33917957).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_032480.
FT   VARIANT     385    385       C -> Y (found in a case of cancer of
FT                                unknown primary origin; the mutated
FT                                receptor is still functional and can
FT                                sustain the transformed phenotype;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:20949619}.
FT                                /FTId=VAR_064856.
FT   VARIANT     773    773       P -> L (in gastric cancer).
FT                                {ECO:0000269|PubMed:12920089}.
FT                                /FTId=VAR_032481.
FT   VARIANT     970    970       R -> C (in dbSNP:rs34589476).
FT                                {ECO:0000269|PubMed:17053076,
FT                                ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_032482.
FT   VARIANT     991    991       P -> S (in gastric cancer; prolonged
FT                                tyrosine phosphorylation in response to
FT                                HGF/SF; transforming activity in athymic
FT                                nude mice).
FT                                {ECO:0000269|PubMed:11042681}.
FT                                /FTId=VAR_032483.
FT   VARIANT     992    992       T -> I (found in a case of cancer of
FT                                unknown primary origin; the mutated
FT                                receptor is still functional and can
FT                                sustain the transformed phenotype;
FT                                somatic mutation; dbSNP:rs56391007).
FT                                {ECO:0000269|PubMed:11042681,
FT                                ECO:0000269|PubMed:17053076,
FT                                ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:20949619}.
FT                                /FTId=VAR_032484.
FT   VARIANT    1092   1092       V -> I (in RCCP; constitutive
FT                                autophosphorylation).
FT                                {ECO:0000269|PubMed:10327054,
FT                                ECO:0000269|PubMed:10417759,
FT                                ECO:0000269|PubMed:10433944}.
FT                                /FTId=VAR_032485.
FT   VARIANT    1094   1094       H -> L (in RCCP; constitutive
FT                                autophosphorylation; causes malignant
FT                                transformation in cell lines).
FT                                {ECO:0000269|PubMed:10327054}.
FT                                /FTId=VAR_032486.
FT   VARIANT    1094   1094       H -> R (in RCCP; causes malignant
FT                                transformation in cell lines).
FT                                {ECO:0000269|PubMed:10433944,
FT                                ECO:0000269|PubMed:9563489}.
FT                                /FTId=VAR_032487.
FT   VARIANT    1094   1094       H -> Y (in RCCP; constitutive
FT                                autophosphorylation; causes malignant
FT                                transformation in cell lines).
FT                                {ECO:0000269|PubMed:10327054}.
FT                                /FTId=VAR_032488.
FT   VARIANT    1106   1106       H -> D (in RCCP; constitutive
FT                                autophosphorylation; causes malignant
FT                                transformation in cell lines).
FT                                {ECO:0000269|PubMed:10327054,
FT                                ECO:0000269|PubMed:10433944}.
FT                                /FTId=VAR_032489.
FT   VARIANT    1131   1131       M -> T (in RCCP; germline mutation).
FT                                {ECO:0000269|PubMed:10433944,
FT                                ECO:0000269|PubMed:9140397}.
FT                                /FTId=VAR_006286.
FT   VARIANT    1173   1173       T -> I (in HCC).
FT                                {ECO:0000269|PubMed:9927037}.
FT                                /FTId=VAR_032490.
FT   VARIANT    1188   1188       V -> L (in RCCP; germline mutation).
FT                                {ECO:0000269|PubMed:10433944,
FT                                ECO:0000269|PubMed:9140397}.
FT                                /FTId=VAR_006287.
FT   VARIANT    1195   1195       L -> V (in RCCP; somatic mutation).
FT                                {ECO:0000269|PubMed:9140397}.
FT                                /FTId=VAR_006288.
FT   VARIANT    1220   1220       V -> I (in RCCP; germline mutation).
FT                                {ECO:0000269|PubMed:9140397}.
FT                                /FTId=VAR_006289.
FT   VARIANT    1228   1228       D -> H (in RCCP; somatic mutation).
FT                                {ECO:0000269|PubMed:9140397}.
FT                                /FTId=VAR_006291.
FT   VARIANT    1228   1228       D -> N (in RCCP; germline mutation).
FT                                {ECO:0000269|PubMed:9140397}.
FT                                /FTId=VAR_006290.
FT   VARIANT    1230   1230       Y -> C (in RCCP; germline mutation).
FT                                {ECO:0000269|PubMed:10433944,
FT                                ECO:0000269|PubMed:9140397}.
FT                                /FTId=VAR_006292.
FT   VARIANT    1230   1230       Y -> D (in RCCP; constitutive
FT                                autophosphorylation; causes malignant
FT                                transformation in cell lines).
FT                                {ECO:0000269|PubMed:10327054,
FT                                ECO:0000269|PubMed:10433944}.
FT                                /FTId=VAR_032491.
FT   VARIANT    1230   1230       Y -> H (in RCCP; somatic mutation).
FT                                {ECO:0000269|PubMed:9140397}.
FT                                /FTId=VAR_006293.
FT   VARIANT    1244   1244       K -> R (in HCC).
FT                                {ECO:0000269|PubMed:9927037}.
FT                                /FTId=VAR_032492.
FT   VARIANT    1250   1250       M -> I (in HCC).
FT                                {ECO:0000269|PubMed:9927037}.
FT                                /FTId=VAR_032493.
FT   VARIANT    1250   1250       M -> T (in RCCP; somatic mutation).
FT                                {ECO:0000269|PubMed:10433944,
FT                                ECO:0000269|PubMed:9140397}.
FT                                /FTId=VAR_006294.
FT   VARIANT    1294   1294       V -> I (found in a case of cancer of
FT                                unknown primary origin; the mutated
FT                                receptor is still functional and can
FT                                sustain the transformed phenotype;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:20949619}.
FT                                /FTId=VAR_064857.
FT   MUTAGEN    1234   1234       Y->F: Alters interaction with PTPN1 and
FT                                PTPN2. Loss of interaction with PTPN1 and
FT                                PTPN2; when associated with F-1235.
FT                                {ECO:0000269|PubMed:18819921}.
FT   MUTAGEN    1235   1235       Y->F: Alters interaction with PTPN1 and
FT                                PTPN2. Loss of interaction with PTPN1 and
FT                                PTPN2; when associated with F-1234.
FT                                {ECO:0000269|PubMed:18819921}.
FT   CONFLICT    237    237       V -> A (in Ref. 3; ACF47606).
FT                                {ECO:0000305}.
FT   CONFLICT    508    508       K -> R (in Ref. 3; ACF47606).
FT                                {ECO:0000305}.
FT   CONFLICT    720    720       F -> S (in Ref. 3; ACF47606).
FT                                {ECO:0000305}.
FT   CONFLICT   1191   1191       G -> A (in Ref. 1; AAA59591).
FT                                {ECO:0000305}.
FT   CONFLICT   1272   1272       L -> V (in Ref. 1; AAA59591, 2; CAB56793
FT                                and 6; AAA59590). {ECO:0000305}.
FT   STRAND       45     47       {ECO:0000244|PDB:2UZX}.
FT   STRAND       52     58       {ECO:0000244|PDB:2UZX}.
FT   STRAND       61     66       {ECO:0000244|PDB:2UZX}.
FT   STRAND       69     74       {ECO:0000244|PDB:2UZX}.
FT   TURN         75     77       {ECO:0000244|PDB:2UZX}.
FT   STRAND       80     84       {ECO:0000244|PDB:2UZX}.
FT   STRAND       89     91       {ECO:0000244|PDB:4K3J}.
FT   STRAND       93     95       {ECO:0000244|PDB:4K3J}.
FT   STRAND       97     99       {ECO:0000244|PDB:1SHY}.
FT   HELIX       103    105       {ECO:0000244|PDB:4O3T}.
FT   STRAND      111    113       {ECO:0000244|PDB:4K3J}.
FT   STRAND      119    123       {ECO:0000244|PDB:2UZX}.
FT   STRAND      125    133       {ECO:0000244|PDB:2UZX}.
FT   STRAND      135    139       {ECO:0000244|PDB:2UZX}.
FT   STRAND      141    145       {ECO:0000244|PDB:2UZX}.
FT   STRAND      155    160       {ECO:0000244|PDB:4K3J}.
FT   STRAND      182    189       {ECO:0000244|PDB:2UZX}.
FT   STRAND      192    199       {ECO:0000244|PDB:2UZX}.
FT   STRAND      213    219       {ECO:0000244|PDB:2UZX}.
FT   HELIX       231    233       {ECO:0000244|PDB:2UZX}.
FT   HELIX       239    241       {ECO:0000244|PDB:2UZX}.
FT   TURN        242    244       {ECO:0000244|PDB:2UZX}.
FT   STRAND      247    255       {ECO:0000244|PDB:2UZX}.
FT   STRAND      258    268       {ECO:0000244|PDB:2UZX}.
FT   STRAND      272    274       {ECO:0000244|PDB:2UZX}.
FT   STRAND      277    281       {ECO:0000244|PDB:2UZX}.
FT   STRAND      284    286       {ECO:0000244|PDB:2UZX}.
FT   STRAND      292    300       {ECO:0000244|PDB:2UZX}.
FT   STRAND      312    314       {ECO:0000244|PDB:2UZX}.
FT   STRAND      316    323       {ECO:0000244|PDB:2UZX}.
FT   HELIX       327    333       {ECO:0000244|PDB:2UZX}.
FT   STRAND      341    349       {ECO:0000244|PDB:2UZX}.
FT   STRAND      356    366       {ECO:0000244|PDB:2UZX}.
FT   HELIX       367    374       {ECO:0000244|PDB:2UZX}.
FT   HELIX       380    382       {ECO:0000244|PDB:4K3J}.
FT   STRAND      383    385       {ECO:0000244|PDB:4K3J}.
FT   HELIX       387    390       {ECO:0000244|PDB:2UZX}.
FT   STRAND      392    394       {ECO:0000244|PDB:1SHY}.
FT   TURN        395    397       {ECO:0000244|PDB:4O3T}.
FT   STRAND      418    422       {ECO:0000244|PDB:2UZX}.
FT   STRAND      424    427       {ECO:0000244|PDB:2UZX}.
FT   TURN        429    436       {ECO:0000244|PDB:2UZX}.
FT   STRAND      439    447       {ECO:0000244|PDB:2UZX}.
FT   STRAND      450    457       {ECO:0000244|PDB:2UZX}.
FT   STRAND      462    466       {ECO:0000244|PDB:2UZX}.
FT   STRAND      469    471       {ECO:0000244|PDB:4K3J}.
FT   STRAND      476    480       {ECO:0000244|PDB:4K3J}.
FT   STRAND      490    493       {ECO:0000244|PDB:2UZX}.
FT   TURN        496    498       {ECO:0000244|PDB:4O3T}.
FT   STRAND      501    506       {ECO:0000244|PDB:2UZX}.
FT   STRAND      509    514       {ECO:0000244|PDB:2UZX}.
FT   HELIX       518    521       {ECO:0000244|PDB:4K3J}.
FT   HELIX       526    531       {ECO:0000244|PDB:2UZX}.
FT   HELIX       534    536       {ECO:0000244|PDB:2UZX}.
FT   STRAND      538    540       {ECO:0000244|PDB:2UZX}.
FT   STRAND      545    548       {ECO:0000244|PDB:2UZX}.
FT   STRAND      552    554       {ECO:0000244|PDB:2UZX}.
FT   STRAND      557    559       {ECO:0000244|PDB:2UZX}.
FT   STRAND      564    572       {ECO:0000244|PDB:2UZX}.
FT   STRAND      580    586       {ECO:0000244|PDB:2UZX}.
FT   STRAND      590    592       {ECO:0000244|PDB:2UZX}.
FT   STRAND      595    598       {ECO:0000244|PDB:2UZX}.
FT   STRAND      602    605       {ECO:0000244|PDB:2UZX}.
FT   HELIX       614    616       {ECO:0000244|PDB:2UZX}.
FT   STRAND      619    625       {ECO:0000244|PDB:2UZX}.
FT   STRAND      637    641       {ECO:0000244|PDB:2UZX}.
FT   STRAND      646    650       {ECO:0000244|PDB:2UZX}.
FT   HELIX      1048   1050       {ECO:0000244|PDB:4EEV}.
FT   HELIX      1055   1057       {ECO:0000244|PDB:3F66}.
FT   HELIX      1060   1066       {ECO:0000244|PDB:4R1V}.
FT   HELIX      1067   1069       {ECO:0000244|PDB:4R1V}.
FT   HELIX      1073   1075       {ECO:0000244|PDB:4R1V}.
FT   STRAND     1076   1087       {ECO:0000244|PDB:4R1V}.
FT   STRAND     1090   1098       {ECO:0000244|PDB:4R1V}.
FT   STRAND     1100   1102       {ECO:0000244|PDB:4EEV}.
FT   STRAND     1104   1111       {ECO:0000244|PDB:4R1V}.
FT   HELIX      1118   1132       {ECO:0000244|PDB:4R1V}.
FT   STRAND     1144   1146       {ECO:0000244|PDB:4R1V}.
FT   STRAND     1149   1151       {ECO:0000244|PDB:3F66}.
FT   STRAND     1154   1158       {ECO:0000244|PDB:4R1V}.
FT   HELIX      1165   1170       {ECO:0000244|PDB:4R1V}.
FT   TURN       1172   1174       {ECO:0000244|PDB:3ZCL}.
FT   HELIX      1178   1197       {ECO:0000244|PDB:4R1V}.
FT   HELIX      1207   1209       {ECO:0000244|PDB:4R1V}.
FT   STRAND     1210   1212       {ECO:0000244|PDB:4R1V}.
FT   STRAND     1218   1220       {ECO:0000244|PDB:4R1V}.
FT   HELIX      1224   1226       {ECO:0000244|PDB:4R1V}.
FT   HELIX      1232   1234       {ECO:0000244|PDB:4R1V}.
FT   STRAND     1236   1238       {ECO:0000244|PDB:4KNB}.
FT   TURN       1239   1241       {ECO:0000244|PDB:4R1V}.
FT   STRAND     1243   1245       {ECO:0000244|PDB:4KNB}.
FT   HELIX      1247   1249       {ECO:0000244|PDB:4R1V}.
FT   HELIX      1252   1257       {ECO:0000244|PDB:4R1V}.
FT   HELIX      1262   1277       {ECO:0000244|PDB:4R1V}.
FT   STRAND     1283   1287       {ECO:0000244|PDB:4EEV}.
FT   HELIX      1289   1291       {ECO:0000244|PDB:4R1V}.
FT   HELIX      1292   1297       {ECO:0000244|PDB:4R1V}.
FT   HELIX      1310   1319       {ECO:0000244|PDB:4R1V}.
FT   HELIX      1324   1326       {ECO:0000244|PDB:4R1V}.
FT   HELIX      1330   1342       {ECO:0000244|PDB:4R1V}.
FT   TURN       1354   1358       {ECO:0000244|PDB:1R0P}.
SQ   SEQUENCE   1390 AA;  155541 MW;  9CF896D1273905C3 CRC64;
     MKAPAVLAPG ILVLLFTLVQ RSNGECKEAL AKSEMNVNMK YQLPNFTAET PIQNVILHEH
     HIFLGATNYI YVLNEEDLQK VAEYKTGPVL EHPDCFPCQD CSSKANLSGG VWKDNINMAL
     VVDTYYDDQL ISCGSVNRGT CQRHVFPHNH TADIQSEVHC IFSPQIEEPS QCPDCVVSAL
     GAKVLSSVKD RFINFFVGNT INSSYFPDHP LHSISVRRLK ETKDGFMFLT DQSYIDVLPE
     FRDSYPIKYV HAFESNNFIY FLTVQRETLD AQTFHTRIIR FCSINSGLHS YMEMPLECIL
     TEKRKKRSTK KEVFNILQAA YVSKPGAQLA RQIGASLNDD ILFGVFAQSK PDSAEPMDRS
     AMCAFPIKYV NDFFNKIVNK NNVRCLQHFY GPNHEHCFNR TLLRNSSGCE ARRDEYRTEF
     TTALQRVDLF MGQFSEVLLT SISTFIKGDL TIANLGTSEG RFMQVVVSRS GPSTPHVNFL
     LDSHPVSPEV IVEHTLNQNG YTLVITGKKI TKIPLNGLGC RHFQSCSQCL SAPPFVQCGW
     CHDKCVRSEE CLSGTWTQQI CLPAIYKVFP NSAPLEGGTR LTICGWDFGF RRNNKFDLKK
     TRVLLGNESC TLTLSESTMN TLKCTVGPAM NKHFNMSIII SNGHGTTQYS TFSYVDPVIT
     SISPKYGPMA GGTLLTLTGN YLNSGNSRHI SIGGKTCTLK SVSNSILECY TPAQTISTEF
     AVKLKIDLAN RETSIFSYRE DPIVYEIHPT KSFISGGSTI TGVGKNLNSV SVPRMVINVH
     EAGRNFTVAC QHRSNSEIIC CTTPSLQQLN LQLPLKTKAF FMLDGILSKY FDLIYVHNPV
     FKPFEKPVMI SMGNENVLEI KGNDIDPEAV KGEVLKVGNK SCENIHLHSE AVLCTVPNDL
     LKLNSELNIE WKQAISSTVL GKVIVQPDQN FTGLIAGVVS ISTALLLLLG FFLWLKKRKQ
     IKDLGSELVR YDARVHTPHL DRLVSARSVS PTTEMVSNES VDYRATFPED QFPNSSQNGS
     CRQVQYPLTD MSPILTSGDS DISSPLLQNT VHIDLSALNP ELVQAVQHVV IGPSSLIVHF
     NEVIGRGHFG CVYHGTLLDN DGKKIHCAVK SLNRITDIGE VSQFLTEGII MKDFSHPNVL
     SLLGICLRSE GSPLVVLPYM KHGDLRNFIR NETHNPTVKD LIGFGLQVAK GMKYLASKKF
     VHRDLAARNC MLDEKFTVKV ADFGLARDMY DKEYYSVHNK TGAKLPVKWM ALESLQTQKF
     TTKSDVWSFG VLLWELMTRG APPYPDVNTF DITVYLLQGR RLLQPEYCPD PLYEVMLKCW
     HPKAEMRPSF SELVSRISAI FSTFIGEHYV HVNATYVNVK CVAPYPSLLS SEDNADDEVD
     TRPASFWETS
//
ID   NOTC1_HUMAN             Reviewed;        2555 AA.
AC   P46531; Q59ED8; Q5SXM3;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   23-SEP-2008, sequence version 4.
DT   17-FEB-2016, entry version 195.
DE   RecName: Full=Neurogenic locus notch homolog protein 1;
DE            Short=Notch 1;
DE            Short=hN1;
DE   AltName: Full=Translocation-associated notch protein TAN-1;
DE   Contains:
DE     RecName: Full=Notch 1 extracellular truncation;
DE              Short=NEXT;
DE   Contains:
DE     RecName: Full=Notch 1 intracellular domain;
DE              Short=NICD;
DE   Flags: Precursor;
GN   Name=NOTCH1; Synonyms=TAN1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Brain;
RA   Mann R.S., Blaumueller C.M., Zagouras P.;
RT   "Complete human notch 1 (hN1) cDNA sequence.";
RL   Submitted (SEP-2000) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E.,
RA   Howe K.L., Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Ashwell R.I.S.,
RA   Babbage A.K., Babbage S., Bagguley C.L., Bailey J., Banerjee R.,
RA   Barker D.J., Barlow K.F., Bates K., Beasley H., Beasley O., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burford D., Burrill W.,
RA   Burton J., Carder C., Carter N.P., Chapman J.C., Chen Y., Clarke G.,
RA   Clark S.Y., Clee C.M., Clegg S., Collier R.E., Corby N., Crosier M.,
RA   Cummings A.T., Davies J., Dhami P., Dunn M., Dutta I., Dyer L.W.,
RA   Earthrowl M.E., Faulkner L., Fleming C.J., Frankish A.,
RA   Frankland J.A., French L., Fricker D.G., Garner P., Garnett J.,
RA   Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M.,
RA   Lovell J., Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S.,
RA   McLay K.E., McMurray A., Milne S., Nickerson T., Nisbett J.,
RA   Nordsiek G., Pearce A.V., Peck A.I., Porter K.M., Pandian R.,
RA   Pelan S., Phillimore B., Povey S., Ramsey Y., Rand V., Scharfe M.,
RA   Sehra H.K., Shownkeen R., Sims S.K., Skuce C.D., Smith M.,
RA   Steward C.A., Swarbreck D., Sycamore N., Tester J., Thorpe A.,
RA   Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Williams S.A., Wilming L., Wray P.W.,
RA   Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S.,
RA   Rogers J., Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-2443.
RX   PubMed=1831692; DOI=10.1016/0092-8674(91)90111-B;
RA   Ellisen L.W., Bird J., West D.C., Soreng A.L., Reynolds T.C.,
RA   Smith S.D., Sklar J.;
RT   "TAN-1, the human homolog of the Drosophila notch gene, is broken by
RT   chromosomal translocations in T lymphoblastic neoplasms.";
RL   Cell 66:649-661(1991).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 489-2555.
RC   TISSUE=Aortic endothelium;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   PROTEIN SEQUENCE OF 1947-1962, INTERACTION WITH HIF1AN, HYDROXYLATION
RP   AT ASN-1955, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=17573339; DOI=10.1074/jbc.M704102200;
RA   Coleman M.L., McDonough M.A., Hewitson K.S., Coles C., Mecinovic J.,
RA   Edelmann M., Cook K.M., Cockman M.E., Lancaster D.E., Kessler B.M.,
RA   Oldham N.J., Ratcliffe P.J., Schofield C.J.;
RT   "Asparaginyl hydroxylation of the Notch ankyrin repeat domain by
RT   factor inhibiting hypoxia-inducible factor.";
RL   J. Biol. Chem. 282:24027-24038(2007).
RN   [6]
RP   IDENTIFICATION OF LIGANDS.
RX   PubMed=10079256; DOI=10.1016/S0002-9440(10)65325-4;
RA   Gray G.E., Mann R.S., Mitsiadis E., Henrique D., Carcangiu M.-L.,
RA   Banks A., Leiman J., Ward D., Ish-Horowitz D., Artavanis-Tsakonas S.;
RT   "Human ligands of the Notch receptor.";
RL   Am. J. Pathol. 154:785-794(1999).
RN   [7]
RP   INTERACTION WITH DTX1.
RX   PubMed=9590294; DOI=10.1038/ng0598-74;
RA   Matsuno K., Eastman D., Mitsiades T., Quinn A.M., Carcanciu M.L.,
RA   Ordentlich P., Kadesch T., Artavanis-Tsakonas S.;
RT   "Human deltex is a conserved regulator of Notch signalling.";
RL   Nat. Genet. 19:74-78(1998).
RN   [8]
RP   INTERACTION WITH SNW1.
RX   PubMed=10713164; DOI=10.1128/MCB.20.7.2400-2410.2000;
RA   Zhou S., Fujimuro M., Hsieh J.J., Chen L., Miyamoto A., Weinmaster G.,
RA   Hayward S.D.;
RT   "SKIP, a CBF1-associated protein, interacts with the ankyrin repeat
RT   domain of NotchIC To facilitate NotchIC function.";
RL   Mol. Cell. Biol. 20:2400-2410(2000).
RN   [9]
RP   INTERACTION WITH MAML1.
RX   PubMed=11101851; DOI=10.1038/82644;
RA   Wu L., Aster J.C., Blacklow S.C., Lake R., Artavanis-Tsakonas S.,
RA   Griffin J.D.;
RT   "MAML1, a human homologue of Drosophila mastermind, is a
RT   transcriptional co-activator for NOTCH receptors.";
RL   Nat. Genet. 26:484-489(2000).
RN   [10]
RP   INTERACTION WITH MAML2 AND MAML3.
RX   PubMed=12370315; DOI=10.1128/MCB.22.21.7688-7700.2002;
RA   Wu L., Sun T., Kobayashi K., Gao P., Griffin J.D.;
RT   "Identification of a family of mastermind-like transcriptional
RT   coactivators for mammalian notch receptors.";
RL   Mol. Cell. Biol. 22:7688-7700(2002).
RN   [11]
RP   INTERACTION WITH NOV.
RX   PubMed=12050162; DOI=10.1074/jbc.M203727200;
RA   Sakamoto K., Yamaguchi S., Ando R., Miyawaki A., Kabasawa Y.,
RA   Takagi M., Li C.L., Perbal B., Katsube K.;
RT   "The nephroblastoma overexpressed gene (NOV/ccn3) protein associates
RT   with Notch1 extracellular domain and inhibits myoblast differentiation
RT   via Notch signaling pathway.";
RL   J. Biol. Chem. 277:29399-29405(2002).
RN   [12]
RP   UBIQUITINATION BY ITCH.
RX   PubMed=18628966; DOI=10.1371/journal.pone.0002735;
RA   Chastagner P., Israel A., Brou C.;
RT   "AIP4/Itch regulates Notch receptor degradation in the absence of
RT   ligand.";
RL   PLoS ONE 3:E2735-E2735(2008).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [14]
RP   FUNCTION.
RX   PubMed=20616313; DOI=10.1161/CIRCRESAHA.110.217257;
RA   Brutsch R., Liebler S.S., Wustehube J., Bartol A., Herberich S.E.,
RA   Adam M.G., Telzerow A., Augustin H.G., Fischer A.;
RT   "Integrin cytoplasmic domain-associated protein-1 attenuates sprouting
RT   angiogenesis.";
RL   Circ. Res. 107:592-601(2010).
RN   [15]
RP   INTERACTION WITH SNAI1 AND MDM2A.
RX   PubMed=22128911; DOI=10.1186/1741-7007-9-83;
RA   Lim S.O., Kim H.S., Quan X., Ahn S.M., Kim H., Hsieh D., Seong J.K.,
RA   Jung G.;
RT   "Notch1 binds and induces degradation of Snail in hepatocellular
RT   carcinoma.";
RL   BMC Biol. 9:83-83(2011).
RN   [16]
RP   INTERACTION WITH AAK1.
RX   PubMed=21464124; DOI=10.1074/jbc.M110.190769;
RA   Gupta-Rossi N., Ortica S., Meas-Yedid V., Heuss S., Moretti J.,
RA   Olivo-Marin J.C., Israel A.;
RT   "The adaptor-associated kinase 1, AAK1, is a positive regulator of the
RT   Notch pathway.";
RL   J. Biol. Chem. 286:18720-18730(2011).
RN   [17]
RP   INTERACTION WITH SGK1 AND FBXW7.
RX   PubMed=21147854; DOI=10.1242/jcs.073924;
RA   Mo J.S., Ann E.J., Yoon J.H., Jung J., Choi Y.H., Kim H.Y., Ahn J.S.,
RA   Kim S.M., Kim M.Y., Hong J.A., Seo M.S., Lang F., Choi E.J.,
RA   Park H.S.;
RT   "Serum- and glucocorticoid-inducible kinase 1 (SGK1) controls Notch1
RT   signaling by downregulation of protein stability through Fbw7
RT   ubiquitin ligase.";
RL   J. Cell Sci. 124:100-112(2011).
RN   [18]
RP   INTERACTION WITH SNW1.
RX   PubMed=21245387; DOI=10.1128/MCB.00360-10;
RA   Vasquez-Del Carpio R., Kaplan F.M., Weaver K.L., VanWye J.D.,
RA   Alves-Guerra M.C., Robbins D.J., Capobianco A.J.;
RT   "Assembly of a Notch transcriptional activation complex requires
RT   multimerization.";
RL   Mol. Cell. Biol. 31:1396-1408(2011).
RN   [19]
RP   GLYCOSYLATION AT THR-232; THR-1402 AND THR-1725, AND PROTEOLYTIC
RP   PROCESSING.
RX   PubMed=24226769; DOI=10.1038/nature12723;
RA   Boskovski M.T., Yuan S., Pedersen N.B., Goth C.K., Makova S.,
RA   Clausen H., Brueckner M., Khokha M.K.;
RT   "The heterotaxy gene GALNT11 glycosylates Notch to orchestrate cilia
RT   type and laterality.";
RL   Nature 504:456-459(2013).
RN   [20]
RP   ANKYRIN REPEATS.
RX   PubMed=25547411; DOI=10.1186/s12859-014-0440-9;
RA   Chakrabarty B., Parekh N.;
RT   "Identifying tandem Ankyrin repeats in protein structures.";
RL   BMC Bioinformatics 15:6599-6599(2014).
RN   [21]
RP   STRUCTURE BY NMR OF 1446-1480 IN COMPLEX WITH CALCIUM IONS, AND
RP   DISULFIDE BONDS.
RX   PubMed=12795601; DOI=10.1021/bi034156y;
RA   Vardar D., North C.L., Sanchez-Irizarry C., Aster J.C., Blacklow S.C.;
RT   "Nuclear magnetic resonance structure of a prototype Lin12-Notch
RT   repeat module from human Notch1.";
RL   Biochemistry 42:7061-7067(2003).
RN   [22]
RP   STRUCTURE BY NMR OF 411-526.
RX   PubMed=15576031; DOI=10.1016/j.str.2004.09.012;
RA   Hambleton S., Valeyev N.V., Muranyi A., Knott V., Werner J.M.,
RA   McMichael A.J., Handford P.A., Downing A.K.;
RT   "Structural and functional properties of the human notch-1 ligand
RT   binding region.";
RL   Structure 12:2173-2183(2004).
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 1872-2114.
RX   PubMed=16011479; DOI=10.1042/BJ20050515;
RA   Ehebauer M.T., Chirgadze D.Y., Hayward P., Martinez Arias A.,
RA   Blundell T.L.;
RT   "High-resolution crystal structure of the human Notch 1 ankyrin
RT   domain.";
RL   Biochem. J. 392:13-20(2005).
RN   [24]
RP   X-RAY CRYSTALLOGRAPHY (3.25 ANGSTROMS) OF 1872-2126 IN COMPLEX WITH
RP   RBPSUH AND MAML1.
RX   PubMed=16530044; DOI=10.1016/j.cell.2005.12.037;
RA   Nam Y., Sliz P., Song L., Aster J.C., Blacklow S.C.;
RT   "Structural basis for cooperativity in recruitment of MAML
RT   coactivators to Notch transcription complexes.";
RL   Cell 124:973-983(2006).
RN   [25]
RP   INVOLVEMENT IN AOVD1.
RX   PubMed=16025100; DOI=10.1038/nature03940;
RA   Garg V., Muth A.N., Ransom J.F., Schluterman M.K., Barnes R.,
RA   King I.N., Grossfeld P.D., Srivastava D.;
RT   "Mutations in NOTCH1 cause aortic valve disease.";
RL   Nature 437:270-274(2005).
RN   [26]
RP   INVOLVEMENT IN AOS5, AND VARIANTS AOS5 ARG-429; TYR-1496 AND ASN-1989.
RX   PubMed=25132448; DOI=10.1016/j.ajhg.2014.07.011;
RA   Stittrich A.B., Lehman A., Bodian D.L., Ashworth J., Zong Z., Li H.,
RA   Lam P., Khromykh A., Iyer R.K., Vockley J.G., Baveja R., Silva E.S.,
RA   Dixon J., Leon E.L., Solomon B.D., Glusman G., Niederhuber J.E.,
RA   Roach J.C., Patel M.S.;
RT   "Mutations in NOTCH1 cause Adams-Oliver syndrome.";
RL   Am. J. Hum. Genet. 95:275-284(2014).
CC   -!- FUNCTION: Functions as a receptor for membrane-bound ligands
CC       Jagged1, Jagged2 and Delta1 to regulate cell-fate determination.
CC       Upon ligand activation through the released notch intracellular
CC       domain (NICD) it forms a transcriptional activator complex with
CC       RBPJ/RBPSUH and activates genes of the enhancer of split locus.
CC       Affects the implementation of differentiation, proliferation and
CC       apoptotic programs. Involved in angiogenesis; negatively regulates
CC       endothelial cell proliferation and migration and angiogenic
CC       sprouting. Involved in the maturation of both CD4+ and CD8+ cells
CC       in the thymus. Important for follicular differentiation and
CC       possibly cell fate selection within the follicle. During
CC       cerebellar development, functions as a receptor for neuronal DNER
CC       and is involved in the differentiation of Bergmann glia. Represses
CC       neuronal and myogenic differentiation. May play an essential role
CC       in postimplantation development, probably in some aspect of cell
CC       specification and/or differentiation. May be involved in mesoderm
CC       development, somite formation and neurogenesis. May enhance HIF1A
CC       function by sequestering HIF1AN away from HIF1A. Required for the
CC       THBS4 function in regulating protective astrogenesis from the
CC       subventricular zone (SVZ) niche after injury. Involved in
CC       determination of left/right symmetry by modulating the balance
CC       between motile and immotile (sensory) cilia at the left-right
CC       organiser (LRO). {ECO:0000269|PubMed:20616313}.
CC   -!- SUBUNIT: Heterodimer of a C-terminal fragment N(TM) and an N-
CC       terminal fragment N(EC) which are probably linked by disulfide
CC       bonds. Interacts with DNER, DTX1, DTX2 and RBPJ/RBPSUH. Also
CC       interacts with MAML1, MAML2 and MAML3 which act as transcriptional
CC       coactivators for NOTCH1 (PubMed:11101851, PubMed:12370315). Notch
CC       1 intracellular domain interacts with SNW1; the interaction
CC       involves multimerized NOTCH1 NICD and is implicated in a formation
CC       of an intermediate preactivation complex which associates with
CC       DNA-bound CBF-1/RBPJ (PubMed:10713164). The activated membrane-
CC       bound form interacts with AAK1 which promotes NOTCH1
CC       stabilization. Forms a trimeric complex with FBXW7 and SGK1.
CC       Interacts with HIF1AN. HIF1AN negatively regulates the function of
CC       notch intracellular domain (NICD), accelerating myogenic
CC       differentiation (PubMed:17573339). Interacts (via NICD) with SNAI1
CC       (via zinc fingers); the interaction induces SNAI1 degradation via
CC       MDM2-mediated ubiquitination and inhibits SNAI1-induced cell
CC       invasion. Interacts (via NICD) with MDM2A. Interacts (via NICD)
CC       with BCL6; the interaction decreases MAML1 recruitment by NOTCH1
CC       NICD on target genes DNA and inhibits NOTCH1 transcractivation
CC       activity. Interacts with THBS4 (By similarity). Interacts (via the
CC       EGF-like repeat region) with NOV (via CTCK domain)
CC       (PubMed:12050162). {ECO:0000250|UniProtKB:Q01705,
CC       ECO:0000269|PubMed:10713164, ECO:0000269|PubMed:11101851,
CC       ECO:0000269|PubMed:12050162, ECO:0000269|PubMed:12370315,
CC       ECO:0000269|PubMed:17573339, ECO:0000269|PubMed:9590294}.
CC   -!- INTERACTION:
CC       P19838:NFKB1; NbExp=2; IntAct=EBI-636374, EBI-300010;
CC       Q13526:PIN1; NbExp=9; IntAct=EBI-636374, EBI-714158;
CC       Q06330:RBPJ; NbExp=5; IntAct=EBI-636374, EBI-632552;
CC       Q13573:SNW1; NbExp=3; IntAct=EBI-636374, EBI-632715;
CC       P98170:XIAP; NbExp=4; IntAct=EBI-636374, EBI-517127;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000250}; Single-pass
CC       type I membrane protein {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Notch 1 intracellular domain: Nucleus
CC       {ECO:0000250}. Note=Following proteolytical processing NICD is
CC       translocated to the nucleus. {ECO:0000250}.
CC   -!- TISSUE SPECIFICITY: In fetal tissues most abundant in spleen,
CC       brain stem and lung. Also present in most adult tissues where it
CC       is found mainly in lymphoid tissues.
CC   -!- PTM: Synthesized in the endoplasmic reticulum as an inactive form
CC       which is proteolytically cleaved by a furin-like convertase in the
CC       trans-Golgi network before it reaches the plasma membrane to yield
CC       an active, ligand-accessible form. Cleavage results in a C-
CC       terminal fragment N(TM) and a N-terminal fragment N(EC). Following
CC       ligand binding, it is cleaved by ADAM17 to yield a membrane-
CC       associated intermediate fragment called notch extracellular
CC       truncation (NEXT). Following endocytosis, this fragment is then
CC       cleaved by presenilin dependent gamma-secretase to release a
CC       notch-derived peptide containing the intracellular domain (NICD)
CC       from the membrane (By similarity). {ECO:0000250}.
CC   -!- PTM: Phosphorylated. {ECO:0000250}.
CC   -!- PTM: O-glycosylated on the EGF-like domains. Contains both O-
CC       linked fucose and O-linked glucose. O-linked glycosylation by
CC       GALNT11 is involved in determination of left/right symmetry:
CC       glycosylation promotes activation of NOTCH1, possibly by promoting
CC       cleavage by ADAM17, modulating the balance between motile and
CC       immotile (sensory) cilia at the left-right organiser (LRO).
CC       {ECO:0000269|PubMed:24226769}.
CC   -!- PTM: Ubiquitinated; undergoes 'Lys-29'-linked polyubiquitination
CC       catalyzed by ITCH. Monoubiquitination at Lys-1759 is required for
CC       activation by gamma-secretase cleavage, it promotes interaction
CC       with AAK1, which stabilizes it. Deubiquitination by EIF3F is
CC       necessary for nuclear import of activated Notch.
CC       {ECO:0000269|PubMed:18628966, ECO:0000269|PubMed:24226769}.
CC   -!- PTM: Hydroxylated at Asn-1955 by HIF1AN. Hydroxylated at Asn-2022
CC       by HIF1AN (By similarity). Hydroxylation reduces affinity for
CC       HI1AN and may thus indirectly modulate negative regulation of NICD
CC       (By similarity). {ECO:0000250}.
CC   -!- DISEASE: Aortic valve disease 1 (AOVD1) [MIM:109730]: A common
CC       defect in the aortic valve in which two rather than three leaflets
CC       are present. It is often associated with aortic valve
CC       calcification, stenosis and insufficiency. In extreme cases, the
CC       blood flow may be so restricted that the left ventricle fails to
CC       grow, resulting in hypoplastic left heart syndrome.
CC       {ECO:0000269|PubMed:16025100}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Adams-Oliver syndrome 5 (AOS5) [MIM:616028]: A form of
CC       Adams-Oliver syndrome, a disorder characterized by the congenital
CC       absence of skin (aplasia cutis congenita) in combination with
CC       transverse limb defects. Aplasia cutis congenita can be located
CC       anywhere on the body, but in the vast majority of the cases, it is
CC       present on the posterior parietal region where it is often
CC       associated with an underlying defect of the parietal bones. Limb
CC       abnormalities are typically limb truncation defects affecting the
CC       distal phalanges or entire digits (true ectrodactyly). Only
CC       rarely, metatarsals/metacarpals or more proximal limb structures
CC       are also affected. Apart from transverse limb defects, syndactyly,
CC       most commonly of second and third toes, can also be observed. The
CC       clinical features are highly variable and can also include
CC       cardiovascular malformations, brain abnormalities and vascular
CC       defects such as cutis marmorata and dilated scalp veins.
CC       {ECO:0000269|PubMed:25132448}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the NOTCH family. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 6 ANK repeats. {ECO:0000255|PROSITE-
CC       ProRule:PRU00023, ECO:0000305|PubMed:25547411}.
CC   -!- SIMILARITY: Contains 36 EGF-like domains. {ECO:0000255|PROSITE-
CC       ProRule:PRU00076}.
CC   -!- SIMILARITY: Contains 3 LNR (Lin/Notch) repeats.
CC       {ECO:0000255|PROSITE-ProRule:PRU00525}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/NOTCH1ID30ch9q34.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF308602; AAG33848.1; -; mRNA.
DR   EMBL; AL592301; CAI13934.1; -; Genomic_DNA.
DR   EMBL; AL354671; CAI13934.1; JOINED; Genomic_DNA.
DR   EMBL; AL354671; CAI16149.1; -; Genomic_DNA.
DR   EMBL; AL592301; CAI16149.1; JOINED; Genomic_DNA.
DR   EMBL; M73980; AAA60614.1; -; mRNA.
DR   EMBL; AB209873; BAD93110.1; -; mRNA.
DR   CCDS; CCDS43905.1; -.
DR   PIR; A40043; A40043.
DR   RefSeq; NP_060087.3; NM_017617.3.
DR   UniGene; Hs.495473; -.
DR   PDB; 1PB5; NMR; -; A=1446-1480.
DR   PDB; 1TOZ; NMR; -; A=411-526.
DR   PDB; 1YYH; X-ray; 1.90 A; A/B=1872-2114.
DR   PDB; 2F8X; X-ray; 3.25 A; K=1872-2126.
DR   PDB; 2F8Y; X-ray; 1.55 A; A/B=1905-2126.
DR   PDB; 2HE0; X-ray; 1.90 A; A/B=1872-2114.
DR   PDB; 2VJ3; X-ray; 2.60 A; A=411-526.
DR   PDB; 3ETO; X-ray; 2.00 A; A/B=1446-1733.
DR   PDB; 3I08; X-ray; 3.20 A; A/C=1446-1664, B/D=1665-1733.
DR   PDB; 3L95; X-ray; 2.19 A; X/Y=1448-1728.
DR   PDB; 3NBN; X-ray; 3.45 A; B/E=1872-2126.
DR   PDB; 3V79; X-ray; 3.85 A; K=1872-2126, R=1759-1777.
DR   PDB; 4CUD; X-ray; 1.85 A; A=411-526.
DR   PDB; 4CUE; X-ray; 3.00 A; A=411-526.
DR   PDB; 4CUF; X-ray; 2.29 A; A=411-526.
DR   PDB; 4D0E; X-ray; 1.61 A; A=411-526.
DR   PDB; 4D0F; X-ray; 2.80 A; A=411-526.
DR   PDBsum; 1PB5; -.
DR   PDBsum; 1TOZ; -.
DR   PDBsum; 1YYH; -.
DR   PDBsum; 2F8X; -.
DR   PDBsum; 2F8Y; -.
DR   PDBsum; 2HE0; -.
DR   PDBsum; 2VJ3; -.
DR   PDBsum; 3ETO; -.
DR   PDBsum; 3I08; -.
DR   PDBsum; 3L95; -.
DR   PDBsum; 3NBN; -.
DR   PDBsum; 3V79; -.
DR   PDBsum; 4CUD; -.
DR   PDBsum; 4CUE; -.
DR   PDBsum; 4CUF; -.
DR   PDBsum; 4D0E; -.
DR   PDBsum; 4D0F; -.
DR   ProteinModelPortal; P46531; -.
DR   SMR; P46531; 411-526, 1448-1728, 1883-2122.
DR   BioGrid; 110913; 180.
DR   DIP; DIP-29919N; -.
DR   IntAct; P46531; 23.
DR   MINT; MINT-1417018; -.
DR   STRING; 9606.ENSP00000277541; -.
DR   ChEMBL; CHEMBL2146346; -.
DR   iPTMnet; P46531; -.
DR   PhosphoSite; P46531; -.
DR   BioMuta; NOTCH1; -.
DR   DMDM; 206729936; -.
DR   MaxQB; P46531; -.
DR   PaxDb; P46531; -.
DR   PRIDE; P46531; -.
DR   Ensembl; ENST00000277541; ENSP00000277541; ENSG00000148400.
DR   GeneID; 4851; -.
DR   KEGG; hsa:4851; -.
DR   UCSC; uc004chz.3; human.
DR   CTD; 4851; -.
DR   GeneCards; NOTCH1; -.
DR   H-InvDB; HIX0008549; -.
DR   HGNC; HGNC:7881; NOTCH1.
DR   HPA; CAB008112; -.
DR   HPA; CAB022466; -.
DR   MalaCards; NOTCH1; -.
DR   MIM; 109730; phenotype.
DR   MIM; 190198; gene.
DR   MIM; 616028; phenotype.
DR   neXtProt; NX_P46531; -.
DR   Orphanet; 974; Adams-Oliver syndrome.
DR   Orphanet; 402075; Familial bicuspid aortic valve.
DR   PharmGKB; PA31683; -.
DR   eggNOG; ENOG410IR7G; Eukaryota.
DR   eggNOG; COG0666; LUCA.
DR   GeneTree; ENSGT00810000125346; -.
DR   HOGENOM; HOG000234369; -.
DR   HOVERGEN; HBG052650; -.
DR   InParanoid; P46531; -.
DR   KO; K02599; -.
DR   OMA; ILDYSFV; -.
DR   OrthoDB; EOG7992RD; -.
DR   PhylomeDB; P46531; -.
DR   TreeFam; TF351641; -.
DR   Reactome; R-HSA-1912399; Pre-NOTCH Processing in the Endoplasmic Reticulum.
DR   Reactome; R-HSA-1912408; Pre-NOTCH Transcription and Translation.
DR   Reactome; R-HSA-1912420; Pre-NOTCH Processing in Golgi.
DR   Reactome; R-HSA-210744; Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells.
DR   Reactome; R-HSA-2122947; NOTCH1 Intracellular Domain Regulates Transcription.
DR   Reactome; R-HSA-2122948; Activated NOTCH1 Transmits Signal to the Nucleus.
DR   Reactome; R-HSA-2644606; Constitutive Signaling by NOTCH1 PEST Domain Mutants.
DR   Reactome; R-HSA-2644607; Loss of Function of FBXW7 in Cancer and NOTCH1 Signaling.
DR   Reactome; R-HSA-2660826; Constitutive Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant.
DR   Reactome; R-HSA-2691232; Constitutive Signaling by NOTCH1 HD Domain Mutants.
DR   Reactome; R-HSA-2894862; Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants.
DR   Reactome; R-HSA-350054; Notch-HLH transcription pathway.
DR   SignaLink; P46531; -.
DR   ChiTaRS; NOTCH1; human.
DR   EvolutionaryTrace; P46531; -.
DR   GeneWiki; Notch-1; -.
DR   GenomeRNAi; 4851; -.
DR   NextBio; 18684; -.
DR   PRO; PR:P46531; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   Bgee; P46531; -.
DR   CleanEx; HS_NOTCH1; -.
DR   Genevisible; P46531; HS.
DR   GO; GO:0001669; C:acrosomal vesicle; IEA:Ensembl.
DR   GO; GO:0005912; C:adherens junction; ISS:UniProtKB.
DR   GO; GO:0016324; C:apical plasma membrane; ISS:UniProtKB.
DR   GO; GO:0009986; C:cell surface; IEA:Ensembl.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0002193; C:MAML1-RBP-Jkappa- ICN1 complex; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; ISS:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0043235; C:receptor complex; IDA:MGI.
DR   GO; GO:0005509; F:calcium ion binding; IEA:InterPro.
DR   GO; GO:0031490; F:chromatin DNA binding; IEA:Ensembl.
DR   GO; GO:0001047; F:core promoter binding; ISS:UniProtKB.
DR   GO; GO:0019899; F:enzyme binding; ISS:UniProtKB.
DR   GO; GO:0004857; F:enzyme inhibitor activity; ISS:UniProtKB.
DR   GO; GO:0004872; F:receptor activity; IEA:InterPro.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0003700; F:transcription factor activity, sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0001190; F:transcriptional activator activity, RNA polymerase II transcription factor binding; ISS:BHF-UCL.
DR   GO; GO:0003180; P:aortic valve morphogenesis; IMP:BHF-UCL.
DR   GO; GO:1902263; P:apoptotic process involved in embryonic digit morphogenesis; IEA:Ensembl.
DR   GO; GO:0060842; P:arterial endothelial cell differentiation; ISS:BHF-UCL.
DR   GO; GO:0048708; P:astrocyte differentiation; IEA:Ensembl.
DR   GO; GO:0003162; P:atrioventricular node development; IEA:Ensembl.
DR   GO; GO:0003181; P:atrioventricular valve morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0009912; P:auditory receptor cell fate commitment; IEA:Ensembl.
DR   GO; GO:0007409; P:axonogenesis; IEA:Ensembl.
DR   GO; GO:0048754; P:branching morphogenesis of an epithelial tube; IEA:Ensembl.
DR   GO; GO:0003209; P:cardiac atrium morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0003207; P:cardiac chamber formation; ISS:BHF-UCL.
DR   GO; GO:0060317; P:cardiac epithelial to mesenchymal transition; ISS:BHF-UCL.
DR   GO; GO:0003214; P:cardiac left ventricle morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0060038; P:cardiac muscle cell proliferation; IEA:Ensembl.
DR   GO; GO:0055008; P:cardiac muscle tissue morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0003213; P:cardiac right atrium morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0003219; P:cardiac right ventricle formation; IEA:Ensembl.
DR   GO; GO:0060411; P:cardiac septum morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0060948; P:cardiac vascular smooth muscle cell development; ISS:BHF-UCL.
DR   GO; GO:0003208; P:cardiac ventricle morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0021515; P:cell differentiation in spinal cord; IEA:Ensembl.
DR   GO; GO:0001708; P:cell fate specification; IEA:Ensembl.
DR   GO; GO:0003273; P:cell migration involved in endocardial cushion formation; ISS:BHF-UCL.
DR   GO; GO:0071372; P:cellular response to follicle-stimulating hormone stimulus; IDA:BHF-UCL.
DR   GO; GO:0035924; P:cellular response to vascular endothelial growth factor stimulus; IDA:UniProtKB.
DR   GO; GO:0060271; P:cilium morphogenesis; ISS:UniProtKB.
DR   GO; GO:0072044; P:collecting duct development; IEA:Ensembl.
DR   GO; GO:0007386; P:compartment pattern specification; IEA:Ensembl.
DR   GO; GO:0060982; P:coronary artery morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0003169; P:coronary vein morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0007368; P:determination of left/right symmetry; ISS:BHF-UCL.
DR   GO; GO:0072017; P:distal tubule development; IEA:Ensembl.
DR   GO; GO:0035116; P:embryonic hindlimb morphogenesis; IEA:Ensembl.
DR   GO; GO:0060956; P:endocardial cell differentiation; ISS:BHF-UCL.
DR   GO; GO:0003203; P:endocardial cushion morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0003157; P:endocardium development; ISS:BHF-UCL.
DR   GO; GO:0003160; P:endocardium morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0007492; P:endoderm development; IEA:Ensembl.
DR   GO; GO:0001837; P:epithelial to mesenchymal transition; ISS:BHF-UCL.
DR   GO; GO:0003198; P:epithelial to mesenchymal transition involved in endocardial cushion formation; ISS:BHF-UCL.
DR   GO; GO:0030900; P:forebrain development; IEA:Ensembl.
DR   GO; GO:0007440; P:foregut morphogenesis; IEA:Ensembl.
DR   GO; GO:0010467; P:gene expression; TAS:Reactome.
DR   GO; GO:0072144; P:glomerular mesangial cell development; IEA:Ensembl.
DR   GO; GO:0003241; P:growth involved in heart morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0031069; P:hair follicle morphogenesis; IEA:Ensembl.
DR   GO; GO:0007507; P:heart development; IMP:DFLAT.
DR   GO; GO:0001947; P:heart looping; ISS:BHF-UCL.
DR   GO; GO:0061384; P:heart trabecula morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0006959; P:humoral immune response; IEA:Ensembl.
DR   GO; GO:0006955; P:immune response; NAS:UniProtKB.
DR   GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl.
DR   GO; GO:0002437; P:inflammatory response to antigenic stimulus; IEA:Ensembl.
DR   GO; GO:0072602; P:interleukin-4 secretion; IEA:Ensembl.
DR   GO; GO:0030216; P:keratinocyte differentiation; IEA:Ensembl.
DR   GO; GO:0070986; P:left/right axis specification; IEA:Ensembl.
DR   GO; GO:0001889; P:liver development; IEA:Ensembl.
DR   GO; GO:0030324; P:lung development; IEA:Ensembl.
DR   GO; GO:0014031; P:mesenchymal cell development; ISS:BHF-UCL.
DR   GO; GO:0003192; P:mitral valve formation; IMP:BHF-UCL.
DR   GO; GO:2000811; P:negative regulation of anoikis; IMP:BHF-UCL.
DR   GO; GO:0045608; P:negative regulation of auditory receptor cell differentiation; IEA:Ensembl.
DR   GO; GO:0030514; P:negative regulation of BMP signaling pathway; ISS:BHF-UCL.
DR   GO; GO:0045955; P:negative regulation of calcium ion-dependent exocytosis; IEA:Ensembl.
DR   GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IEA:Ensembl.
DR   GO; GO:0043086; P:negative regulation of catalytic activity; ISS:UniProtKB.
DR   GO; GO:0090051; P:negative regulation of cell migration involved in sprouting angiogenesis; IDA:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IDA:UniProtKB.
DR   GO; GO:0010812; P:negative regulation of cell-substrate adhesion; IDA:BHF-UCL.
DR   GO; GO:2001027; P:negative regulation of endothelial cell chemotaxis; IDA:UniProtKB.
DR   GO; GO:0060253; P:negative regulation of glial cell proliferation; ISS:UniProtKB.
DR   GO; GO:0045662; P:negative regulation of myoblast differentiation; IMP:UniProtKB.
DR   GO; GO:0010832; P:negative regulation of myotube differentiation; ISS:UniProtKB.
DR   GO; GO:0050768; P:negative regulation of neurogenesis; ISS:UniProtKB.
DR   GO; GO:0048715; P:negative regulation of oligodendrocyte differentiation; ISS:UniProtKB.
DR   GO; GO:0030279; P:negative regulation of ossification; ISS:BHF-UCL.
DR   GO; GO:0045668; P:negative regulation of osteoblast differentiation; ISS:BHF-UCL.
DR   GO; GO:0046533; P:negative regulation of photoreceptor cell differentiation; IEA:Ensembl.
DR   GO; GO:2000974; P:negative regulation of pro-B cell differentiation; ISS:UniProtKB.
DR   GO; GO:2000737; P:negative regulation of stem cell differentiation; IMP:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; ISS:UniProtKB.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; ISS:BHF-UCL.
DR   GO; GO:0021915; P:neural tube development; IEA:Ensembl.
DR   GO; GO:0097150; P:neuronal stem cell population maintenance; IEP:UniProtKB.
DR   GO; GO:0007220; P:Notch receptor processing; TAS:Reactome.
DR   GO; GO:0061314; P:Notch signaling involved in heart development; IMP:BHF-UCL.
DR   GO; GO:0007219; P:Notch signaling pathway; IMP:UniProtKB.
DR   GO; GO:0003270; P:Notch signaling pathway involved in regulation of secondary heart field cardioblast proliferation; IEA:Ensembl.
DR   GO; GO:0048709; P:oligodendrocyte differentiation; IEA:Ensembl.
DR   GO; GO:0031100; P:organ regeneration; IEA:Ensembl.
DR   GO; GO:0003344; P:pericardium morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0048711; P:positive regulation of astrocyte differentiation; ISS:UniProtKB.
DR   GO; GO:0030513; P:positive regulation of BMP signaling pathway; ISS:UniProtKB.
DR   GO; GO:0060045; P:positive regulation of cardiac muscle cell proliferation; ISS:BHF-UCL.
DR   GO; GO:0030335; P:positive regulation of cell migration; ISS:BHF-UCL.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IDA:UniProtKB.
DR   GO; GO:0045603; P:positive regulation of endothelial cell differentiation; IEA:Ensembl.
DR   GO; GO:0050679; P:positive regulation of epithelial cell proliferation; IEA:Ensembl.
DR   GO; GO:0010718; P:positive regulation of epithelial to mesenchymal transition; IMP:BHF-UCL.
DR   GO; GO:0046427; P:positive regulation of JAK-STAT cascade; ISS:UniProtKB.
DR   GO; GO:0045618; P:positive regulation of keratinocyte differentiation; IEA:Ensembl.
DR   GO; GO:0002052; P:positive regulation of neuroblast proliferation; IEA:Ensembl.
DR   GO; GO:0045747; P:positive regulation of Notch signaling pathway; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:UniProtKB.
DR   GO; GO:0061419; P:positive regulation of transcription from RNA polymerase II promoter in response to hypoxia; ISS:UniProtKB.
DR   GO; GO:0007221; P:positive regulation of transcription of Notch receptor target; ISS:BHF-UCL.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; ISS:UniProtKB.
DR   GO; GO:0045070; P:positive regulation of viral genome replication; IEA:Ensembl.
DR   GO; GO:0050434; P:positive regulation of viral transcription; IEA:Ensembl.
DR   GO; GO:0060740; P:prostate gland epithelium morphogenesis; IEA:Ensembl.
DR   GO; GO:0003184; P:pulmonary valve morphogenesis; IMP:BHF-UCL.
DR   GO; GO:0060768; P:regulation of epithelial cell proliferation involved in prostate gland development; IEA:Ensembl.
DR   GO; GO:1901201; P:regulation of extracellular matrix assembly; ISS:BHF-UCL.
DR   GO; GO:0014807; P:regulation of somitogenesis; IEA:Ensembl.
DR   GO; GO:0003256; P:regulation of transcription from RNA polymerase II promoter involved in myocardial precursor cell differentiation; ISS:BHF-UCL.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; TAS:UniProtKB.
DR   GO; GO:0031960; P:response to corticosteroid; IEA:Ensembl.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IEA:Ensembl.
DR   GO; GO:0032495; P:response to muramyl dipeptide; IEA:Ensembl.
DR   GO; GO:0060528; P:secretory columnal luminar epithelial cell differentiation involved in prostate glandular acinus development; IEA:Ensembl.
DR   GO; GO:0035914; P:skeletal muscle cell differentiation; IEA:Ensembl.
DR   GO; GO:0048103; P:somatic stem cell division; IEA:Ensembl.
DR   GO; GO:0007283; P:spermatogenesis; IEA:Ensembl.
DR   GO; GO:0002040; P:sprouting angiogenesis; IEA:Ensembl.
DR   GO; GO:0042246; P:tissue regeneration; IEA:Ensembl.
DR   GO; GO:0006367; P:transcription initiation from RNA polymerase II promoter; TAS:Reactome.
DR   GO; GO:0035148; P:tube formation; IMP:UniProtKB.
DR   GO; GO:0060979; P:vasculogenesis involved in coronary vascular morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0060843; P:venous endothelial cell differentiation; ISS:BHF-UCL.
DR   GO; GO:0060412; P:ventricular septum morphogenesis; IMP:BHF-UCL.
DR   GO; GO:0003222; P:ventricular trabecula myocardium morphogenesis; ISS:BHF-UCL.
DR   Gene3D; 1.25.40.20; -; 1.
DR   InterPro; IPR002110; Ankyrin_rpt.
DR   InterPro; IPR020683; Ankyrin_rpt-contain_dom.
DR   InterPro; IPR024600; DUF3454_notch.
DR   InterPro; IPR001881; EGF-like_Ca-bd_dom.
DR   InterPro; IPR013032; EGF-like_CS.
DR   InterPro; IPR000742; EGF-like_dom.
DR   InterPro; IPR000152; EGF-type_Asp/Asn_hydroxyl_site.
DR   InterPro; IPR018097; EGF_Ca-bd_CS.
DR   InterPro; IPR009030; Growth_fac_rcpt_.
DR   InterPro; IPR008297; Notch.
DR   InterPro; IPR022362; Notch_1.
DR   InterPro; IPR000800; Notch_dom.
DR   InterPro; IPR010660; Notch_NOD_dom.
DR   InterPro; IPR011656; Notch_NODP_dom.
DR   Pfam; PF12796; Ank_2; 1.
DR   Pfam; PF11936; DUF3454; 1.
DR   Pfam; PF00008; EGF; 26.
DR   Pfam; PF07645; EGF_CA; 4.
DR   Pfam; PF12661; hEGF; 2.
DR   Pfam; PF06816; NOD; 1.
DR   Pfam; PF07684; NODP; 1.
DR   Pfam; PF00066; Notch; 3.
DR   PIRSF; PIRSF002279; Notch; 1.
DR   PRINTS; PR01452; LNOTCHREPEAT.
DR   PRINTS; PR01984; NOTCH1.
DR   SMART; SM00248; ANK; 6.
DR   SMART; SM00181; EGF; 12.
DR   SMART; SM00179; EGF_CA; 24.
DR   SMART; SM00004; NL; 3.
DR   SUPFAM; SSF48403; SSF48403; 1.
DR   SUPFAM; SSF57184; SSF57184; 6.
DR   SUPFAM; SSF90193; SSF90193; 3.
DR   PROSITE; PS50297; ANK_REP_REGION; 1.
DR   PROSITE; PS50088; ANK_REPEAT; 4.
DR   PROSITE; PS00010; ASX_HYDROXYL; 22.
DR   PROSITE; PS00022; EGF_1; 35.
DR   PROSITE; PS01186; EGF_2; 27.
DR   PROSITE; PS50026; EGF_3; 36.
DR   PROSITE; PS01187; EGF_CA; 20.
DR   PROSITE; PS50258; LNR; 3.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; Angiogenesis; ANK repeat; Calcium;
KW   Cell membrane; Complete proteome; Developmental protein;
KW   Differentiation; Direct protein sequencing; Disease mutation;
KW   Disulfide bond; EGF-like domain; Glycoprotein; Hydroxylation;
KW   Isopeptide bond; Membrane; Metal-binding; Notch signaling pathway;
KW   Nucleus; Phosphoprotein; Polymorphism; Receptor; Reference proteome;
KW   Repeat; Signal; Transcription; Transcription regulation;
KW   Transmembrane; Transmembrane helix; Ubl conjugation.
FT   SIGNAL        1     18       {ECO:0000255}.
FT   CHAIN        19   2555       Neurogenic locus notch homolog protein 1.
FT                                /FTId=PRO_0000007674.
FT   CHAIN      1721   2555       Notch 1 extracellular truncation.
FT                                {ECO:0000250}.
FT                                /FTId=PRO_0000007675.
FT   CHAIN      1754   2555       Notch 1 intracellular domain.
FT                                {ECO:0000250}.
FT                                /FTId=PRO_0000007676.
FT   TOPO_DOM     19   1735       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1736   1756       Helical. {ECO:0000255}.
FT   TOPO_DOM   1757   2555       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       20     58       EGF-like 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN       59     99       EGF-like 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      102    139       EGF-like 3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      140    176       EGF-like 4. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      178    216       EGF-like 5; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      218    255       EGF-like 6. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      257    293       EGF-like 7; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      295    333       EGF-like 8; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      335    371       EGF-like 9; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      372    410       EGF-like 10. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      412    450       EGF-like 11; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      452    488       EGF-like 12; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      490    526       EGF-like 13; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      528    564       EGF-like 14; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      566    601       EGF-like 15; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      603    639       EGF-like 16; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      641    676       EGF-like 17; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      678    714       EGF-like 18; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      716    751       EGF-like 19; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      753    789       EGF-like 20. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      791    827       EGF-like 21; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      829    867       EGF-like 22. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      869    905       EGF-like 23; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      907    943       EGF-like 24. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      945    981       EGF-like 25; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      983   1019       EGF-like 26. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN     1021   1057       EGF-like 27. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN     1059   1095       EGF-like 28. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN     1097   1143       EGF-like 29. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN     1145   1181       EGF-like 30. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN     1183   1219       EGF-like 31; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN     1221   1265       EGF-like 32; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN     1267   1305       EGF-like 33. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN     1307   1346       EGF-like 34. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN     1348   1384       EGF-like 35. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN     1387   1426       EGF-like 36. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   REPEAT     1449   1489       LNR 1.
FT   REPEAT     1490   1531       LNR 2.
FT   REPEAT     1532   1571       LNR 3.
FT   REPEAT     1928   1960       ANK 1.
FT   REPEAT     1961   1994       ANK 2.
FT   REPEAT     1995   2027       ANK 3.
FT   REPEAT     2028   2060       ANK 4.
FT   REPEAT     2061   2094       ANK 5.
FT   REPEAT     2095   2122       ANK 6.
FT   REGION     1947   1955       HIF1AN-binding. {ECO:0000250}.
FT   REGION     2014   2022       HIF1AN-binding. {ECO:0000250}.
FT   COMPBIAS   1575   1578       Poly-Val.
FT   COMPBIAS   1661   1664       Poly-Arg.
FT   COMPBIAS   1728   1731       Poly-Pro.
FT   COMPBIAS   1740   1743       Poly-Ala.
FT   COMPBIAS   1901   1904       Poly-Glu.
FT   COMPBIAS   2259   2262       Poly-Gly.
FT   COMPBIAS   2403   2406       Poly-Gln.
FT   COMPBIAS   2410   2417       Poly-Pro.
FT   COMPBIAS   2521   2524       Poly-Ser.
FT   METAL      1457   1457       Calcium; via carbonyl oxygen.
FT   METAL      1460   1460       Calcium.
FT   METAL      1475   1475       Calcium.
FT   METAL      1478   1478       Calcium.
FT   SITE       1664   1665       Cleavage; by furin-like protease.
FT                                {ECO:0000250}.
FT   SITE       1710   1711       Cleavage; by ADAM17. {ECO:0000250}.
FT   SITE       1720   1721       Cleavage; by ADAM17.
FT   MOD_RES    1861   1861       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:Q01705}.
FT   MOD_RES    1955   1955       (3S)-3-hydroxyasparagine; by HIF1AN;
FT                                partial. {ECO:0000269|PubMed:17573339}.
FT   MOD_RES    2022   2022       (3S)-3-hydroxyasparagine; by HIF1AN.
FT                                {ECO:0000250}.
FT   CARBOHYD     41     41       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD     65     65       O-linked (Glc...). {ECO:0000250}.
FT   CARBOHYD     73     73       O-linked (Fuc...). {ECO:0000250}.
FT   CARBOHYD    116    116       O-linked (Fuc...). {ECO:0000250}.
FT   CARBOHYD    146    146       O-linked (Glc...). {ECO:0000250}.
FT   CARBOHYD    194    194       O-linked (Fuc...). {ECO:0000250}.
FT   CARBOHYD    232    232       O-linked (Fuc...); alternate.
FT                                {ECO:0000269|PubMed:24226769}.
FT   CARBOHYD    232    232       O-linked (GalNAc...); alternate.
FT                                {ECO:0000269|PubMed:24226769}.
FT   CARBOHYD    341    341       O-linked (Glc...). {ECO:0000250}.
FT   CARBOHYD    378    378       O-linked (Glc...). {ECO:0000250}.
FT   CARBOHYD    458    458       O-linked (Glc...). {ECO:0000250}.
FT   CARBOHYD    466    466       O-linked (Fuc...). {ECO:0000250}.
FT   CARBOHYD    496    496       O-linked (Glc...). {ECO:0000250}.
FT   CARBOHYD    534    534       O-linked (Glc...). {ECO:0000250}.
FT   CARBOHYD    609    609       O-linked (Glc...). {ECO:0000250}.
FT   CARBOHYD    647    647       O-linked (Glc...). {ECO:0000250}.
FT   CARBOHYD    722    722       O-linked (Glc...). {ECO:0000250}.
FT   CARBOHYD    759    759       O-linked (Glc...). {ECO:0000250}.
FT   CARBOHYD    767    767       O-linked (Fuc...). {ECO:0000250}.
FT   CARBOHYD    797    797       O-linked (Glc...). {ECO:0000250}.
FT   CARBOHYD    805    805       O-linked (Fuc...). {ECO:0000250}.
FT   CARBOHYD    951    951       O-linked (Glc...). {ECO:0000250}.
FT   CARBOHYD    959    959       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1027   1027       O-linked (Glc...). {ECO:0000250}.
FT   CARBOHYD   1035   1035       O-linked (Fuc...). {ECO:0000250}.
FT   CARBOHYD   1065   1065       O-linked (Glc...). {ECO:0000250}.
FT   CARBOHYD   1179   1179       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1189   1189       O-linked (Glc...). {ECO:0000250}.
FT   CARBOHYD   1197   1197       O-linked (Fuc...). {ECO:0000250}.
FT   CARBOHYD   1241   1241       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1273   1273       O-linked (Glc...). {ECO:0000250}.
FT   CARBOHYD   1362   1362       O-linked (Fuc...). {ECO:0000250}.
FT   CARBOHYD   1402   1402       O-linked (Fuc...); alternate.
FT                                {ECO:0000269|PubMed:24226769}.
FT   CARBOHYD   1402   1402       O-linked (GalNAc...); alternate.
FT                                {ECO:0000269|PubMed:24226769}.
FT   CARBOHYD   1489   1489       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1587   1587       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1725   1725       O-linked (GalNAc...).
FT                                {ECO:0000269|PubMed:24226769}.
FT   DISULFID     24     37       {ECO:0000250}.
FT   DISULFID     31     46       {ECO:0000250}.
FT   DISULFID     48     57       {ECO:0000250}.
FT   DISULFID     63     74       {ECO:0000250}.
FT   DISULFID     68     87       {ECO:0000250}.
FT   DISULFID     89     98       {ECO:0000250}.
FT   DISULFID    106    117       {ECO:0000250}.
FT   DISULFID    111    127       {ECO:0000250}.
FT   DISULFID    129    138       {ECO:0000250}.
FT   DISULFID    144    155       {ECO:0000250}.
FT   DISULFID    149    164       {ECO:0000250}.
FT   DISULFID    166    175       {ECO:0000250}.
FT   DISULFID    182    195       {ECO:0000250}.
FT   DISULFID    189    204       {ECO:0000250}.
FT   DISULFID    206    215       {ECO:0000250}.
FT   DISULFID    222    233       {ECO:0000250}.
FT   DISULFID    227    243       {ECO:0000250}.
FT   DISULFID    245    254       {ECO:0000250}.
FT   DISULFID    261    272       {ECO:0000250}.
FT   DISULFID    266    281       {ECO:0000250}.
FT   DISULFID    283    292       {ECO:0000250}.
FT   DISULFID    299    312       {ECO:0000250}.
FT   DISULFID    306    321       {ECO:0000250}.
FT   DISULFID    323    332       {ECO:0000250}.
FT   DISULFID    339    350       {ECO:0000250}.
FT   DISULFID    344    359       {ECO:0000250}.
FT   DISULFID    361    370       {ECO:0000250}.
FT   DISULFID    376    387       {ECO:0000250}.
FT   DISULFID    381    398       {ECO:0000250}.
FT   DISULFID    400    409       {ECO:0000250}.
FT   DISULFID    416    429       {ECO:0000250}.
FT   DISULFID    423    438       {ECO:0000250}.
FT   DISULFID    440    449       {ECO:0000250}.
FT   DISULFID    456    467       {ECO:0000250}.
FT   DISULFID    461    476       {ECO:0000250}.
FT   DISULFID    478    487       {ECO:0000250}.
FT   DISULFID    494    505       {ECO:0000250}.
FT   DISULFID    499    514       {ECO:0000250}.
FT   DISULFID    516    525       {ECO:0000250}.
FT   DISULFID    532    543       {ECO:0000250}.
FT   DISULFID    537    552       {ECO:0000250}.
FT   DISULFID    554    563       {ECO:0000250}.
FT   DISULFID    570    580       {ECO:0000250}.
FT   DISULFID    575    589       {ECO:0000250}.
FT   DISULFID    591    600       {ECO:0000250}.
FT   DISULFID    607    618       {ECO:0000250}.
FT   DISULFID    612    627       {ECO:0000250}.
FT   DISULFID    629    638       {ECO:0000250}.
FT   DISULFID    645    655       {ECO:0000250}.
FT   DISULFID    650    664       {ECO:0000250}.
FT   DISULFID    666    675       {ECO:0000250}.
FT   DISULFID    682    693       {ECO:0000250}.
FT   DISULFID    687    702       {ECO:0000250}.
FT   DISULFID    704    713       {ECO:0000250}.
FT   DISULFID    720    730       {ECO:0000250}.
FT   DISULFID    725    739       {ECO:0000250}.
FT   DISULFID    741    750       {ECO:0000250}.
FT   DISULFID    757    768       {ECO:0000250}.
FT   DISULFID    762    777       {ECO:0000250}.
FT   DISULFID    779    788       {ECO:0000250}.
FT   DISULFID    795    806       {ECO:0000250}.
FT   DISULFID    800    815       {ECO:0000250}.
FT   DISULFID    817    826       {ECO:0000250}.
FT   DISULFID    833    844       {ECO:0000250}.
FT   DISULFID    838    855       {ECO:0000250}.
FT   DISULFID    857    866       {ECO:0000250}.
FT   DISULFID    873    884       {ECO:0000250}.
FT   DISULFID    878    893       {ECO:0000250}.
FT   DISULFID    895    904       {ECO:0000250}.
FT   DISULFID    911    922       {ECO:0000250}.
FT   DISULFID    916    931       {ECO:0000250}.
FT   DISULFID    933    942       {ECO:0000250}.
FT   DISULFID    949    960       {ECO:0000250}.
FT   DISULFID    954    969       {ECO:0000250}.
FT   DISULFID    971    980       {ECO:0000250}.
FT   DISULFID    987    998       {ECO:0000250}.
FT   DISULFID    992   1007       {ECO:0000250}.
FT   DISULFID   1009   1018       {ECO:0000250}.
FT   DISULFID   1025   1036       {ECO:0000250}.
FT   DISULFID   1030   1045       {ECO:0000250}.
FT   DISULFID   1047   1056       {ECO:0000250}.
FT   DISULFID   1063   1074       {ECO:0000250}.
FT   DISULFID   1068   1083       {ECO:0000250}.
FT   DISULFID   1085   1094       {ECO:0000250}.
FT   DISULFID   1101   1122       {ECO:0000250}.
FT   DISULFID   1116   1131       {ECO:0000250}.
FT   DISULFID   1133   1142       {ECO:0000250}.
FT   DISULFID   1149   1160       {ECO:0000250}.
FT   DISULFID   1154   1169       {ECO:0000250}.
FT   DISULFID   1171   1180       {ECO:0000250}.
FT   DISULFID   1187   1198       {ECO:0000250}.
FT   DISULFID   1192   1207       {ECO:0000250}.
FT   DISULFID   1209   1218       {ECO:0000250}.
FT   DISULFID   1225   1244       {ECO:0000250}.
FT   DISULFID   1238   1253       {ECO:0000250}.
FT   DISULFID   1255   1264       {ECO:0000250}.
FT   DISULFID   1271   1284       {ECO:0000250}.
FT   DISULFID   1276   1293       {ECO:0000250}.
FT   DISULFID   1295   1304       {ECO:0000250}.
FT   DISULFID   1311   1322       {ECO:0000250}.
FT   DISULFID   1316   1334       {ECO:0000250}.
FT   DISULFID   1336   1345       {ECO:0000250}.
FT   DISULFID   1352   1363       {ECO:0000250}.
FT   DISULFID   1357   1372       {ECO:0000250}.
FT   DISULFID   1374   1383       {ECO:0000250}.
FT   DISULFID   1391   1403       {ECO:0000250}.
FT   DISULFID   1397   1414       {ECO:0000250}.
FT   DISULFID   1416   1425       {ECO:0000250}.
FT   DISULFID   1449   1472       {ECO:0000269|PubMed:12795601}.
FT   DISULFID   1454   1467       {ECO:0000269|PubMed:12795601}.
FT   DISULFID   1463   1479       {ECO:0000269|PubMed:12795601}.
FT   DISULFID   1490   1514       {ECO:0000250}.
FT   DISULFID   1496   1509       {ECO:0000250}.
FT   DISULFID   1505   1521       {ECO:0000250}.
FT   DISULFID   1536   1549       {ECO:0000250}.
FT   DISULFID   1545   1561       {ECO:0000250}.
FT   CROSSLNK   1759   1759       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000250}.
FT   VARIANT     300    300       Q -> R (in dbSNP:rs11574885).
FT                                /FTId=VAR_034898.
FT   VARIANT     429    429       C -> R (in AOS5).
FT                                {ECO:0000269|PubMed:25132448}.
FT                                /FTId=VAR_071960.
FT   VARIANT     879    879       R -> W (in dbSNP:rs11574895).
FT                                /FTId=VAR_048990.
FT   VARIANT    1496   1496       C -> Y (in AOS5).
FT                                {ECO:0000269|PubMed:25132448}.
FT                                /FTId=VAR_071961.
FT   VARIANT    1671   1671       V -> I (in dbSNP:rs2229968).
FT                                /FTId=VAR_046618.
FT   VARIANT    1989   1989       D -> N (in AOS5).
FT                                {ECO:0000269|PubMed:25132448}.
FT                                /FTId=VAR_071962.
FT   CONFLICT    187    187       G -> R (in Ref. 1; AAG33848 and 3;
FT                                AAA60614). {ECO:0000305}.
FT   CONFLICT    282    282       R -> P (in Ref. 1; AAG33848 and 3;
FT                                AAA60614). {ECO:0000305}.
FT   CONFLICT    477    477       I -> M (in Ref. 1; AAG33848 and 3;
FT                                AAA60614). {ECO:0000305}.
FT   CONFLICT    614    615       HG -> LR (in Ref. 1; AAG33848 and 3;
FT                                AAA60614). {ECO:0000305}.
FT   CONFLICT    621    621       R -> P (in Ref. 1; AAG33848 and 3;
FT                                AAA60614). {ECO:0000305}.
FT   CONFLICT    677    677       I -> S (in Ref. 1; AAG33848 and 3;
FT                                AAA60614). {ECO:0000305}.
FT   CONFLICT    775    775       Y -> I (in Ref. 1; AAG33848 and 3;
FT                                AAA60614). {ECO:0000305}.
FT   CONFLICT    803    803       Q -> K (in Ref. 1; AAG33848 and 3;
FT                                AAA60614). {ECO:0000305}.
FT   CONFLICT    860    862       GWQ -> AGAK (in Ref. 1; AAG33848 and 3;
FT                                AAA60614). {ECO:0000305}.
FT   CONFLICT   1021   1021       D -> V (in Ref. 1; AAG33848 and 3;
FT                                AAA60614). {ECO:0000305}.
FT   CONFLICT   1028   1028       Q -> R (in Ref. 1; AAG33848 and 3;
FT                                AAA60614). {ECO:0000305}.
FT   CONFLICT   1032   1032       H -> L (in Ref. 1; AAG33848 and 3;
FT                                AAA60614). {ECO:0000305}.
FT   CONFLICT   1040   1043       CGSY -> RGLH (in Ref. 1; AAG33848 and 3;
FT                                AAA60614). {ECO:0000305}.
FT   HELIX       415    417       {ECO:0000244|PDB:4D0E}.
FT   STRAND      418    420       {ECO:0000244|PDB:4D0E}.
FT   STRAND      422    424       {ECO:0000244|PDB:4D0E}.
FT   STRAND      428    432       {ECO:0000244|PDB:4D0E}.
FT   STRAND      435    439       {ECO:0000244|PDB:4D0E}.
FT   STRAND      444    446       {ECO:0000244|PDB:4D0E}.
FT   TURN        455    458       {ECO:0000244|PDB:4D0E}.
FT   STRAND      466    470       {ECO:0000244|PDB:4D0E}.
FT   STRAND      473    477       {ECO:0000244|PDB:4D0E}.
FT   STRAND      482    484       {ECO:0000244|PDB:4D0E}.
FT   TURN        493    496       {ECO:0000244|PDB:4D0E}.
FT   TURN        500    502       {ECO:0000244|PDB:2VJ3}.
FT   STRAND      504    507       {ECO:0000244|PDB:4D0E}.
FT   STRAND      512    515       {ECO:0000244|PDB:4D0E}.
FT   STRAND      520    522       {ECO:0000244|PDB:4D0E}.
FT   HELIX      1448   1450       {ECO:0000244|PDB:3L95}.
FT   HELIX      1452   1457       {ECO:0000244|PDB:3ETO}.
FT   STRAND     1460   1462       {ECO:0000244|PDB:3ETO}.
FT   HELIX      1465   1467       {ECO:0000244|PDB:3ETO}.
FT   HELIX      1470   1472       {ECO:0000244|PDB:3ETO}.
FT   HELIX      1473   1476       {ECO:0000244|PDB:3ETO}.
FT   TURN       1477   1482       {ECO:0000244|PDB:3ETO}.
FT   TURN       1486   1489       {ECO:0000244|PDB:3ETO}.
FT   HELIX      1492   1494       {ECO:0000244|PDB:3ETO}.
FT   HELIX      1496   1498       {ECO:0000244|PDB:3ETO}.
FT   TURN       1499   1501       {ECO:0000244|PDB:3ETO}.
FT   STRAND     1502   1504       {ECO:0000244|PDB:3ETO}.
FT   HELIX      1507   1509       {ECO:0000244|PDB:3ETO}.
FT   HELIX      1512   1519       {ECO:0000244|PDB:3ETO}.
FT   TURN       1530   1532       {ECO:0000244|PDB:3ETO}.
FT   HELIX      1533   1539       {ECO:0000244|PDB:3ETO}.
FT   STRAND     1542   1544       {ECO:0000244|PDB:3ETO}.
FT   HELIX      1547   1549       {ECO:0000244|PDB:3ETO}.
FT   HELIX      1552   1559       {ECO:0000244|PDB:3ETO}.
FT   STRAND     1563   1565       {ECO:0000244|PDB:3L95}.
FT   STRAND     1571   1580       {ECO:0000244|PDB:3ETO}.
FT   HELIX      1582   1587       {ECO:0000244|PDB:3ETO}.
FT   HELIX      1589   1600       {ECO:0000244|PDB:3ETO}.
FT   STRAND     1602   1606       {ECO:0000244|PDB:3ETO}.
FT   STRAND     1616   1620       {ECO:0000244|PDB:3ETO}.
FT   STRAND     1672   1681       {ECO:0000244|PDB:3ETO}.
FT   HELIX      1685   1688       {ECO:0000244|PDB:3ETO}.
FT   HELIX      1696   1708       {ECO:0000244|PDB:3ETO}.
FT   STRAND     1714   1716       {ECO:0000244|PDB:3ETO}.
FT   STRAND     1718   1724       {ECO:0000244|PDB:3ETO}.
FT   HELIX      1884   1890       {ECO:0000244|PDB:2F8X}.
FT   HELIX      1909   1914       {ECO:0000244|PDB:2F8X}.
FT   TURN       1925   1927       {ECO:0000244|PDB:2F8Y}.
FT   HELIX      1931   1937       {ECO:0000244|PDB:2F8Y}.
FT   HELIX      1941   1949       {ECO:0000244|PDB:2F8Y}.
FT   HELIX      1964   1970       {ECO:0000244|PDB:2F8Y}.
FT   HELIX      1974   1982       {ECO:0000244|PDB:2F8Y}.
FT   STRAND     1983   1985       {ECO:0000244|PDB:2F8X}.
FT   HELIX      1998   2005       {ECO:0000244|PDB:2F8Y}.
FT   HELIX      2008   2016       {ECO:0000244|PDB:2F8Y}.
FT   HELIX      2031   2037       {ECO:0000244|PDB:2F8Y}.
FT   HELIX      2041   2049       {ECO:0000244|PDB:2F8Y}.
FT   HELIX      2064   2071       {ECO:0000244|PDB:2F8Y}.
FT   HELIX      2074   2082       {ECO:0000244|PDB:2F8Y}.
FT   HELIX      2097   2103       {ECO:0000244|PDB:2F8Y}.
FT   HELIX      2107   2115       {ECO:0000244|PDB:2F8Y}.
SQ   SEQUENCE   2555 AA;  272505 MW;  E173C872D195F028 CRC64;
     MPPLLAPLLC LALLPALAAR GPRCSQPGET CLNGGKCEAA NGTEACVCGG AFVGPRCQDP
     NPCLSTPCKN AGTCHVVDRR GVADYACSCA LGFSGPLCLT PLDNACLTNP CRNGGTCDLL
     TLTEYKCRCP PGWSGKSCQQ ADPCASNPCA NGGQCLPFEA SYICHCPPSF HGPTCRQDVN
     ECGQKPGLCR HGGTCHNEVG SYRCVCRATH TGPNCERPYV PCSPSPCQNG GTCRPTGDVT
     HECACLPGFT GQNCEENIDD CPGNNCKNGG ACVDGVNTYN CRCPPEWTGQ YCTEDVDECQ
     LMPNACQNGG TCHNTHGGYN CVCVNGWTGE DCSENIDDCA SAACFHGATC HDRVASFYCE
     CPHGRTGLLC HLNDACISNP CNEGSNCDTN PVNGKAICTC PSGYTGPACS QDVDECSLGA
     NPCEHAGKCI NTLGSFECQC LQGYTGPRCE IDVNECVSNP CQNDATCLDQ IGEFQCICMP
     GYEGVHCEVN TDECASSPCL HNGRCLDKIN EFQCECPTGF TGHLCQYDVD ECASTPCKNG
     AKCLDGPNTY TCVCTEGYTG THCEVDIDEC DPDPCHYGSC KDGVATFTCL CRPGYTGHHC
     ETNINECSSQ PCRHGGTCQD RDNAYLCFCL KGTTGPNCEI NLDDCASSPC DSGTCLDKID
     GYECACEPGY TGSMCNINID ECAGNPCHNG GTCEDGINGF TCRCPEGYHD PTCLSEVNEC
     NSNPCVHGAC RDSLNGYKCD CDPGWSGTNC DINNNECESN PCVNGGTCKD MTSGYVCTCR
     EGFSGPNCQT NINECASNPC LNQGTCIDDV AGYKCNCLLP YTGATCEVVL APCAPSPCRN
     GGECRQSEDY ESFSCVCPTG WQGQTCEVDI NECVLSPCRH GASCQNTHGG YRCHCQAGYS
     GRNCETDIDD CRPNPCHNGG SCTDGINTAF CDCLPGFRGT FCEEDINECA SDPCRNGANC
     TDCVDSYTCT CPAGFSGIHC ENNTPDCTES SCFNGGTCVD GINSFTCLCP PGFTGSYCQH
     DVNECDSQPC LHGGTCQDGC GSYRCTCPQG YTGPNCQNLV HWCDSSPCKN GGKCWQTHTQ
     YRCECPSGWT GLYCDVPSVS CEVAAQRQGV DVARLCQHGG LCVDAGNTHH CRCQAGYTGS
     YCEDLVDECS PSPCQNGATC TDYLGGYSCK CVAGYHGVNC SEEIDECLSH PCQNGGTCLD
     LPNTYKCSCP RGTQGVHCEI NVDDCNPPVD PVSRSPKCFN NGTCVDQVGG YSCTCPPGFV
     GERCEGDVNE CLSNPCDARG TQNCVQRVND FHCECRAGHT GRRCESVING CKGKPCKNGG
     TCAVASNTAR GFICKCPAGF EGATCENDAR TCGSLRCLNG GTCISGPRSP TCLCLGPFTG
     PECQFPASSP CLGGNPCYNQ GTCEPTSESP FYRCLCPAKF NGLLCHILDY SFGGGAGRDI
     PPPLIEEACE LPECQEDAGN KVCSLQCNNH ACGWDGGDCS LNFNDPWKNC TQSLQCWKYF
     SDGHCDSQCN SAGCLFDGFD CQRAEGQCNP LYDQYCKDHF SDGHCDQGCN SAECEWDGLD
     CAEHVPERLA AGTLVVVVLM PPEQLRNSSF HFLRELSRVL HTNVVFKRDA HGQQMIFPYY
     GREEELRKHP IKRAAEGWAA PDALLGQVKA SLLPGGSEGG RRRRELDPMD VRGSIVYLEI
     DNRQCVQASS QCFQSATDVA AFLGALASLG SLNIPYKIEA VQSETVEPPP PAQLHFMYVA
     AAAFVLLFFV GCGVLLSRKR RRQHGQLWFP EGFKVSEASK KKRREPLGED SVGLKPLKNA
     SDGALMDDNQ NEWGDEDLET KKFRFEEPVV LPDLDDQTDH RQWTQQHLDA ADLRMSAMAP
     TPPQGEVDAD CMDVNVRGPD GFTPLMIASC SGGGLETGNS EEEEDAPAVI SDFIYQGASL
     HNQTDRTGET ALHLAARYSR SDAAKRLLEA SADANIQDNM GRTPLHAAVS ADAQGVFQIL
     IRNRATDLDA RMHDGTTPLI LAARLAVEGM LEDLINSHAD VNAVDDLGKS ALHWAAAVNN
     VDAAVVLLKN GANKDMQNNR EETPLFLAAR EGSYETAKVL LDHFANRDIT DHMDRLPRDI
     AQERMHHDIV RLLDEYNLVR SPQLHGAPLG GTPTLSPPLC SPNGYLGSLK PGVQGKKVRK
     PSSKGLACGS KEAKDLKARR KKSQDGKGCL LDSSGMLSPV DSLESPHGYL SDVASPPLLP
     SPFQQSPSVP LNHLPGMPDT HLGIGHLNVA AKPEMAALGG GGRLAFETGP PRLSHLPVAS
     GTSTVLGSSS GGALNFTVGG STSLNGQCEW LSRLQSGMVP NQYNPLRGSV APGPLSTQAP
     SLQHGMVGPL HSSLAASALS QMMSYQGLPS TRLATQPHLV QTQQVQPQNL QMQQQNLQPA
     NIQQQQSLQP PPPPPQPHLG VSSAASGHLG RSFLSGEPSQ ADVQPLGPSS LAVHTILPQE
     SPALPTSLPS SLVPPVTAAQ FLTPPSQHSY SSPVDNTPSH QLQVPEHPFL TPSPESPDQW
     SSSSPHSNVS DWSEGVSSPP TSMQSQIARI PEAFK
//
ID   FGF10_MOUSE             Reviewed;         209 AA.
AC   O35565; Q543V5;
DT   15-JUL-1999, integrated into UniProtKB/Swiss-Prot.
DT   01-JAN-1998, sequence version 1.
DT   09-DEC-2015, entry version 134.
DE   RecName: Full=Fibroblast growth factor 10;
DE            Short=FGF-10;
DE   AltName: Full=Keratinocyte growth factor 2;
DE   Flags: Precursor;
GN   Name=Fgf10;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=9332392; DOI=10.1016/S0378-1119(97)00187-X;
RA   Tagashira S., Harada H., Katsumata T., Itoh N., Nakatsuka M.;
RT   "Cloning of mouse FGF10 and up-regulation of its gene expression
RT   during wound healing.";
RL   Gene 197:399-404(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Lung;
RA   Duan D.R., Florence C.;
RL   Submitted (MAR-1997) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=C57BL/6J; TISSUE=Hippocampus, and Stomach;
RX   PubMed=16141072; DOI=10.1126/science.1112014;
RA   Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N.,
RA   Oyama R., Ravasi T., Lenhard B., Wells C., Kodzius R., Shimokawa K.,
RA   Bajic V.B., Brenner S.E., Batalov S., Forrest A.R., Zavolan M.,
RA   Davis M.J., Wilming L.G., Aidinis V., Allen J.E.,
RA   Ambesi-Impiombato A., Apweiler R., Aturaliya R.N., Bailey T.L.,
RA   Bansal M., Baxter L., Beisel K.W., Bersano T., Bono H., Chalk A.M.,
RA   Chiu K.P., Choudhary V., Christoffels A., Clutterbuck D.R.,
RA   Crowe M.L., Dalla E., Dalrymple B.P., de Bono B., Della Gatta G.,
RA   di Bernardo D., Down T., Engstrom P., Fagiolini M., Faulkner G.,
RA   Fletcher C.F., Fukushima T., Furuno M., Futaki S., Gariboldi M.,
RA   Georgii-Hemming P., Gingeras T.R., Gojobori T., Green R.E.,
RA   Gustincich S., Harbers M., Hayashi Y., Hensch T.K., Hirokawa N.,
RA   Hill D., Huminiecki L., Iacono M., Ikeo K., Iwama A., Ishikawa T.,
RA   Jakt M., Kanapin A., Katoh M., Kawasawa Y., Kelso J., Kitamura H.,
RA   Kitano H., Kollias G., Krishnan S.P., Kruger A., Kummerfeld S.K.,
RA   Kurochkin I.V., Lareau L.F., Lazarevic D., Lipovich L., Liu J.,
RA   Liuni S., McWilliam S., Madan Babu M., Madera M., Marchionni L.,
RA   Matsuda H., Matsuzawa S., Miki H., Mignone F., Miyake S., Morris K.,
RA   Mottagui-Tabar S., Mulder N., Nakano N., Nakauchi H., Ng P.,
RA   Nilsson R., Nishiguchi S., Nishikawa S., Nori F., Ohara O.,
RA   Okazaki Y., Orlando V., Pang K.C., Pavan W.J., Pavesi G., Pesole G.,
RA   Petrovsky N., Piazza S., Reed J., Reid J.F., Ring B.Z., Ringwald M.,
RA   Rost B., Ruan Y., Salzberg S.L., Sandelin A., Schneider C.,
RA   Schoenbach C., Sekiguchi K., Semple C.A., Seno S., Sessa L., Sheng Y.,
RA   Shibata Y., Shimada H., Shimada K., Silva D., Sinclair B.,
RA   Sperling S., Stupka E., Sugiura K., Sultana R., Takenaka Y., Taki K.,
RA   Tammoja K., Tan S.L., Tang S., Taylor M.S., Tegner J., Teichmann S.A.,
RA   Ueda H.R., van Nimwegen E., Verardo R., Wei C.L., Yagi K.,
RA   Yamanishi H., Zabarovsky E., Zhu S., Zimmer A., Hide W., Bult C.,
RA   Grimmond S.M., Teasdale R.D., Liu E.T., Brusic V., Quackenbush J.,
RA   Wahlestedt C., Mattick J.S., Hume D.A., Kai C., Sasaki D., Tomaru Y.,
RA   Fukuda S., Kanamori-Katayama M., Suzuki M., Aoki J., Arakawa T.,
RA   Iida J., Imamura K., Itoh M., Kato T., Kawaji H., Kawagashira N.,
RA   Kawashima T., Kojima M., Kondo S., Konno H., Nakano K., Ninomiya N.,
RA   Nishio T., Okada M., Plessy C., Shibata K., Shiraki T., Suzuki S.,
RA   Tagami M., Waki K., Watahiki A., Okamura-Oho Y., Suzuki H., Kawai J.,
RA   Hayashizaki Y.;
RT   "The transcriptional landscape of the mammalian genome.";
RL   Science 309:1559-1563(2005).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Olfactory epithelium;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
CC   -!- FUNCTION: Plays an important role in the regulation of embryonic
CC       development, cell proliferation and cell differentiation. Required
CC       for normal branching morphogenesis. May play a role in wound
CC       healing.
CC   -!- SUBUNIT: Interacts with FGFR1 and FGFR2. Interacts with FGFBP1 (By
CC       similarity). {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000305}.
CC   -!- TISSUE SPECIFICITY: Expressed abundantly in embryos and the lung,
CC       and at much lower levels in brain and heart.
CC   -!- SIMILARITY: Belongs to the heparin-binding growth factors family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D89080; BAA22836.1; -; mRNA.
DR   EMBL; U94517; AAD00761.1; -; mRNA.
DR   EMBL; AK034742; BAC28816.1; -; mRNA.
DR   EMBL; AK045267; BAC32287.1; -; mRNA.
DR   EMBL; AK085244; BAC39398.1; -; mRNA.
DR   EMBL; AK141633; BAE24777.1; -; mRNA.
DR   EMBL; BC048229; AAH48229.1; -; mRNA.
DR   CCDS; CCDS26795.1; -.
DR   RefSeq; NP_032028.1; NM_008002.4.
DR   UniGene; Mm.317323; -.
DR   ProteinModelPortal; O35565; -.
DR   SMR; O35565; 70-208.
DR   BioGrid; 199639; 1.
DR   STRING; 10090.ENSMUSP00000022246; -.
DR   PhosphoSite; O35565; -.
DR   PaxDb; O35565; -.
DR   PRIDE; O35565; -.
DR   Ensembl; ENSMUST00000022246; ENSMUSP00000022246; ENSMUSG00000021732.
DR   GeneID; 14165; -.
DR   KEGG; mmu:14165; -.
DR   UCSC; uc007ryv.2; mouse.
DR   CTD; 2255; -.
DR   MGI; MGI:1099809; Fgf10.
DR   eggNOG; KOG3885; Eukaryota.
DR   eggNOG; ENOG4111IPH; LUCA.
DR   GeneTree; ENSGT00760000118859; -.
DR   HOGENOM; HOG000236341; -.
DR   HOVERGEN; HBG007580; -.
DR   InParanoid; O35565; -.
DR   KO; K04358; -.
DR   OMA; SSIPVTC; -.
DR   OrthoDB; EOG7992S1; -.
DR   PhylomeDB; O35565; -.
DR   TreeFam; TF317805; -.
DR   Reactome; R-MMU-109704; PI3K Cascade.
DR   Reactome; R-MMU-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-MMU-190370; FGFR1b ligand binding and activation.
DR   Reactome; R-MMU-190377; FGFR2b ligand binding and activation.
DR   Reactome; R-MMU-5654219; Phospholipase C-mediated cascade: FGFR1.
DR   Reactome; R-MMU-5654221; Phospholipase C-mediated cascade, FGFR2.
DR   Reactome; R-MMU-5654688; SHC-mediated cascade:FGFR1.
DR   Reactome; R-MMU-5654689; PI-3K cascade:FGFR1.
DR   Reactome; R-MMU-5654693; FRS-mediated FGFR1 signaling.
DR   Reactome; R-MMU-5654695; PI-3K cascade:FGFR2.
DR   Reactome; R-MMU-5654699; SHC-mediated cascade:FGFR2.
DR   Reactome; R-MMU-5654700; FRS-mediated FGFR2 signaling.
DR   Reactome; R-MMU-5654726; Negative regulation of FGFR1 signaling.
DR   Reactome; R-MMU-5654727; Negative regulation of FGFR2 signaling.
DR   Reactome; R-MMU-5673001; RAF/MAP kinase cascade.
DR   NextBio; 285306; -.
DR   PRO; PR:O35565; -.
DR   Proteomes; UP000000589; Chromosome 13.
DR   Bgee; O35565; -.
DR   CleanEx; MM_FGF10; -.
DR   Genevisible; O35565; MM.
DR   GO; GO:0009986; C:cell surface; ISO:MGI.
DR   GO; GO:0031012; C:extracellular matrix; IEA:Ensembl.
DR   GO; GO:0005615; C:extracellular space; IDA:MGI.
DR   GO; GO:0005634; C:nucleus; ISO:MGI.
DR   GO; GO:0005886; C:plasma membrane; ISO:MGI.
DR   GO; GO:0042056; F:chemoattractant activity; IDA:MGI.
DR   GO; GO:0005104; F:fibroblast growth factor receptor binding; ISO:MGI.
DR   GO; GO:0008083; F:growth factor activity; ISO:MGI.
DR   GO; GO:0008201; F:heparin binding; ISO:MGI.
DR   GO; GO:0005111; F:type 2 fibroblast growth factor receptor binding; ISO:MGI.
DR   GO; GO:0031532; P:actin cytoskeleton reorganization; ISO:MGI.
DR   GO; GO:0000187; P:activation of MAPK activity; ISO:MGI.
DR   GO; GO:0001525; P:angiogenesis; IEA:Ensembl.
DR   GO; GO:0048514; P:blood vessel morphogenesis; IMP:MGI.
DR   GO; GO:0001974; P:blood vessel remodeling; IGI:MGI.
DR   GO; GO:0060667; P:branch elongation involved in salivary gland morphogenesis; IMP:MGI.
DR   GO; GO:0060445; P:branching involved in salivary gland morphogenesis; IDA:MGI.
DR   GO; GO:0048754; P:branching morphogenesis of an epithelial tube; ISO:MGI.
DR   GO; GO:0060436; P:bronchiole morphogenesis; IMP:MGI.
DR   GO; GO:0060449; P:bud elongation involved in lung branching; IGI:MGI.
DR   GO; GO:0060447; P:bud outgrowth involved in lung branching; ISO:MGI.
DR   GO; GO:0007267; P:cell-cell signaling; IDA:MGI.
DR   GO; GO:0006935; P:chemotaxis; IDA:MGI.
DR   GO; GO:0007368; P:determination of left/right symmetry; IMP:MGI.
DR   GO; GO:0048565; P:digestive tract development; IMP:MGI.
DR   GO; GO:0031076; P:embryonic camera-type eye development; IMP:MGI.
DR   GO; GO:0048566; P:embryonic digestive tract development; IMP:MGI.
DR   GO; GO:0048557; P:embryonic digestive tract morphogenesis; IMP:MGI.
DR   GO; GO:0030538; P:embryonic genitalia morphogenesis; IMP:MGI.
DR   GO; GO:0009880; P:embryonic pattern specification; IMP:MGI.
DR   GO; GO:0008544; P:epidermis development; IMP:MGI.
DR   GO; GO:0048730; P:epidermis morphogenesis; IMP:MGI.
DR   GO; GO:0030855; P:epithelial cell differentiation; IMP:MGI.
DR   GO; GO:0010631; P:epithelial cell migration; IMP:MGI.
DR   GO; GO:0050673; P:epithelial cell proliferation; IMP:MGI.
DR   GO; GO:0060664; P:epithelial cell proliferation involved in salivary gland morphogenesis; IMP:MGI.
DR   GO; GO:0060441; P:epithelial tube branching involved in lung morphogenesis; IDA:MGI.
DR   GO; GO:0070371; P:ERK1 and ERK2 cascade; ISO:MGI.
DR   GO; GO:0000132; P:establishment of mitotic spindle orientation; IGI:MGI.
DR   GO; GO:0048807; P:female genitalia morphogenesis; IMP:MGI.
DR   GO; GO:0060595; P:fibroblast growth factor receptor signaling pathway involved in mammary gland specification; IDA:MGI.
DR   GO; GO:0031069; P:hair follicle morphogenesis; IMP:MGI.
DR   GO; GO:0070384; P:Harderian gland development; IMP:MGI.
DR   GO; GO:0050930; P:induction of positive chemotaxis; IDA:MGI.
DR   GO; GO:0042472; P:inner ear morphogenesis; IMP:MGI.
DR   GO; GO:0043616; P:keratinocyte proliferation; IMP:MGI.
DR   GO; GO:0032808; P:lacrimal gland development; IMP:MGI.
DR   GO; GO:0060174; P:limb bud formation; IMP:MGI.
DR   GO; GO:0060173; P:limb development; IMP:MGI.
DR   GO; GO:0035108; P:limb morphogenesis; IMP:MGI.
DR   GO; GO:0048286; P:lung alveolus development; IMP:MGI.
DR   GO; GO:0030324; P:lung development; IDA:MGI.
DR   GO; GO:0060428; P:lung epithelium development; ISO:MGI.
DR   GO; GO:0060425; P:lung morphogenesis; IMP:MGI.
DR   GO; GO:0061115; P:lung proximal/distal axis specification; IDA:MGI.
DR   GO; GO:0060430; P:lung saccule development; ISO:MGI.
DR   GO; GO:0048808; P:male genitalia morphogenesis; IMP:MGI.
DR   GO; GO:0060615; P:mammary gland bud formation; IMP:MGI.
DR   GO; GO:0060594; P:mammary gland specification; IGI:MGI.
DR   GO; GO:0060915; P:mesenchymal cell differentiation involved in lung development; IGI:MGI.
DR   GO; GO:0060496; P:mesenchymal-epithelial cell signaling involved in lung development; IDA:MGI.
DR   GO; GO:0001823; P:mesonephros development; IEA:Ensembl.
DR   GO; GO:0003338; P:metanephros morphogenesis; IMP:MGI.
DR   GO; GO:0042693; P:muscle cell fate commitment; IMP:MGI.
DR   GO; GO:0071157; P:negative regulation of cell cycle arrest; ISO:MGI.
DR   GO; GO:0045596; P:negative regulation of cell differentiation; IDA:MGI.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IDA:MGI.
DR   GO; GO:2001240; P:negative regulation of extrinsic apoptotic signaling pathway in absence of ligand; IMP:MGI.
DR   GO; GO:0042475; P:odontogenesis of dentin-containing tooth; IMP:MGI.
DR   GO; GO:0048645; P:organ formation; IMP:MGI.
DR   GO; GO:0035265; P:organ growth; IMP:MGI.
DR   GO; GO:0001759; P:organ induction; IGI:MGI.
DR   GO; GO:0009887; P:organ morphogenesis; IDA:MGI.
DR   GO; GO:0030916; P:otic vesicle formation; IGI:MGI.
DR   GO; GO:0031016; P:pancreas development; IMP:MGI.
DR   GO; GO:0021983; P:pituitary gland development; IMP:MGI.
DR   GO; GO:0050918; P:positive chemotaxis; IDA:MGI.
DR   GO; GO:0032781; P:positive regulation of ATPase activity; ISO:MGI.
DR   GO; GO:0090263; P:positive regulation of canonical Wnt signaling pathway; IMP:MGI.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IDA:MGI.
DR   GO; GO:0031659; P:positive regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle; ISO:MGI.
DR   GO; GO:0045739; P:positive regulation of DNA repair; ISO:MGI.
DR   GO; GO:0045740; P:positive regulation of DNA replication; ISO:MGI.
DR   GO; GO:0010634; P:positive regulation of epithelial cell migration; IDA:MGI.
DR   GO; GO:0050679; P:positive regulation of epithelial cell proliferation; IMP:MGI.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IMP:MGI.
DR   GO; GO:0048146; P:positive regulation of fibroblast proliferation; IMP:MGI.
DR   GO; GO:0071338; P:positive regulation of hair follicle cell proliferation; ISO:MGI.
DR   GO; GO:0051549; P:positive regulation of keratinocyte migration; ISO:MGI.
DR   GO; GO:0010838; P:positive regulation of keratinocyte proliferation; ISO:MGI.
DR   GO; GO:0050671; P:positive regulation of lymphocyte proliferation; ISO:MGI.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; ISO:MGI.
DR   GO; GO:0045931; P:positive regulation of mitotic cell cycle; IMP:MGI.
DR   GO; GO:0045747; P:positive regulation of Notch signaling pathway; IGI:MGI.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; ISO:MGI.
DR   GO; GO:0046579; P:positive regulation of Ras protein signal transduction; ISO:MGI.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:MGI.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:CACAO.
DR   GO; GO:0050677; P:positive regulation of urothelial cell proliferation; ISO:MGI.
DR   GO; GO:0030949; P:positive regulation of vascular endothelial growth factor receptor signaling pathway; IMP:MGI.
DR   GO; GO:0070352; P:positive regulation of white fat cell proliferation; IMP:MGI.
DR   GO; GO:0030177; P:positive regulation of Wnt signaling pathway; IMP:MGI.
DR   GO; GO:0060513; P:prostatic bud formation; IGI:MGI.
DR   GO; GO:0034394; P:protein localization to cell surface; ISO:MGI.
DR   GO; GO:0060019; P:radial glial cell differentiation; IMP:UniProtKB.
DR   GO; GO:0032925; P:regulation of activin receptor signaling pathway; IMP:MGI.
DR   GO; GO:0060665; P:regulation of branching involved in salivary gland morphogenesis by mesenchymal-epithelial signaling; IDA:MGI.
DR   GO; GO:0050678; P:regulation of epithelial cell proliferation; IMP:MGI.
DR   GO; GO:0010468; P:regulation of gene expression; IMP:MGI.
DR   GO; GO:0046877; P:regulation of saliva secretion; ISO:MGI.
DR   GO; GO:0008589; P:regulation of smoothened signaling pathway; IMP:MGI.
DR   GO; GO:0060541; P:respiratory system development; IDA:MGI.
DR   GO; GO:0032355; P:response to estradiol; IEA:Ensembl.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IEA:Ensembl.
DR   GO; GO:0007431; P:salivary gland development; ISO:MGI.
DR   GO; GO:0007435; P:salivary gland morphogenesis; IMP:MGI.
DR   GO; GO:0061033; P:secretion by lung epithelial cell involved in lung growth; ISO:MGI.
DR   GO; GO:0060879; P:semicircular canal fusion; IMP:MGI.
DR   GO; GO:0048752; P:semicircular canal morphogenesis; IGI:MGI.
DR   GO; GO:0051145; P:smooth muscle cell differentiation; IMP:MGI.
DR   GO; GO:0035019; P:somatic stem cell population maintenance; IMP:MGI.
DR   GO; GO:0048536; P:spleen development; IMP:MGI.
DR   GO; GO:0060661; P:submandibular salivary gland formation; IMP:MGI.
DR   GO; GO:0070075; P:tear secretion; ISO:MGI.
DR   GO; GO:0048538; P:thymus development; ISO:MGI.
DR   GO; GO:0030878; P:thyroid gland development; IMP:MGI.
DR   GO; GO:0042246; P:tissue regeneration; IEA:Ensembl.
DR   GO; GO:0060510; P:Type II pneumocyte differentiation; IDA:MGI.
DR   GO; GO:0050674; P:urothelial cell proliferation; ISO:MGI.
DR   GO; GO:0050872; P:white fat cell differentiation; IMP:MGI.
DR   GO; GO:0042060; P:wound healing; ISO:MGI.
DR   InterPro; IPR008996; Cytokine_IL1-like.
DR   InterPro; IPR028252; FGF10.
DR   InterPro; IPR002209; Fibroblast_GF_fam.
DR   InterPro; IPR028142; IL-1_fam/FGF_fam.
DR   PANTHER; PTHR11486; PTHR11486; 1.
DR   PANTHER; PTHR11486:SF21; PTHR11486:SF21; 1.
DR   Pfam; PF00167; FGF; 1.
DR   PRINTS; PR00263; HBGFFGF.
DR   PRINTS; PR00262; IL1HBGF.
DR   SMART; SM00442; FGF; 1.
DR   SUPFAM; SSF50353; SSF50353; 1.
DR   PROSITE; PS00247; HBGF_FGF; 1.
PE   2: Evidence at transcript level;
KW   Complete proteome; Glycoprotein; Growth factor; Reference proteome;
KW   Secreted; Signal.
FT   SIGNAL        1     36       {ECO:0000255}.
FT   CHAIN        37    209       Fibroblast growth factor 10.
FT                                /FTId=PRO_0000008982.
FT   COMPBIAS     52     63       Poly-Ser.
FT   CARBOHYD     50     50       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    197    197       N-linked (GlcNAc...). {ECO:0000255}.
SQ   SEQUENCE   209 AA;  23597 MW;  7FD22227BF4943CC CRC64;
     MWKWILTHCA SAFPHLPGCC CCFLLLFLVS SFPVTCQALG QDMVSQEATN CSSSSSSFSS
     PSSAGRHVRS YNHLQGDVRW RRLFSFTKYF LTIEKNGKVS GTKNEDCPYS VLEITSVEIG
     VVAVKAINSN YYLAMNKKGK LYGSKEFNND CKLKERIEEN GYNTYASFNW QHNGRQMYVA
     LNGKGAPRRG QKTRRKNTSA HFLPMTIQT
//
ID   ITB3_HUMAN              Reviewed;         788 AA.
AC   P05106; A0PJW2; D3DXJ8; O15495; Q12806; Q13413; Q14648; Q16499;
DT   13-AUG-1987, integrated into UniProtKB/Swiss-Prot.
DT   06-FEB-2007, sequence version 2.
DT   17-FEB-2016, entry version 222.
DE   RecName: Full=Integrin beta-3;
DE   AltName: Full=Platelet membrane glycoprotein IIIa;
DE            Short=GPIIIa;
DE   AltName: CD_antigen=CD61;
DE   Flags: Precursor;
GN   Name=ITGB3; Synonyms=GP3A;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM BETA-3A).
RX   PubMed=3494014;
RA   Fitzgerald L.A., Steiner B., Rall S.C. Jr., Lo S., Phillips D.R.;
RT   "Protein sequence of endothelial glycoprotein IIIa derived from a cDNA
RT   clone. Identity with platelet glycoprotein IIIa and similarity to
RT   'integrin'.";
RL   J. Biol. Chem. 262:3936-3939(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM BETA-3A).
RX   PubMed=2452834; DOI=10.1172/JCI113478;
RA   Zimrin A.B., Eisman R., Vilaire G., Schwartz E., Bennett J.S.,
RA   Poncz M.;
RT   "Structure of platelet glycoprotein IIIa. A common subunit for two
RT   different membrane receptors.";
RL   J. Clin. Invest. 81:1470-1475(1988).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM BETA-3A).
RX   PubMed=2345548; DOI=10.1007/BF00422712;
RA   Frachet P., Uzan G., Thevenon D., Denarier E., Prandini M.H.,
RA   Marguerie G.;
RT   "GPIIb and GPIIIa amino acid sequences deduced from human
RT   megakaryocyte cDNAs.";
RL   Mol. Biol. Rep. 14:27-33(1990).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM BETA-3C), FUNCTION, AND
RP   SUBCELLULAR LOCATION.
RC   TISSUE=Osteoclastoma;
RX   PubMed=9195946; DOI=10.1074/jbc.272.26.16390;
RA   Kumar C.S., James I.E., Wong A., Mwangi V., Feild J.A.,
RA   Nuthulaganti P., Connor J.R., Eichman C., Ali F., Hwang S.M.,
RA   Rieman D.J., Drake F.H., Gowen M.;
RT   "Cloning and characterization of a novel integrin beta3 subunit.";
RL   J. Biol. Chem. 272:16390-16397(1997).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM BETA-3A).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-26.
RC   TISSUE=Blood;
RX   PubMed=8298129;
RA   Villa-Garcia M., Li L., Riely G., Bray P.F.;
RT   "Isolation and characterization of a TATA-less promoter for the human
RT   beta 3 integrin gene.";
RL   Blood 83:668-676(1994).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 11-788.
RC   TISSUE=Erythroleukemia;
RX   PubMed=3165296;
RA   Rosa J.P., Bray P.F., Gayet O., Johnston G.I., Cook R.G.,
RA   Jackson K.W., Shuman M.A., McEver R.P.;
RT   "Cloning of glycoprotein IIIa cDNA from human erythroleukemia cells
RT   and localization of the gene to chromosome 17.";
RL   Blood 72:593-600(1988).
RN   [9]
RP   PROTEIN SEQUENCE OF 27-37.
RC   TISSUE=Platelet;
RX   PubMed=1953640;
RA   Catimel B., Parmentier S., Leung L.L., McGregor J.L.;
RT   "Separation of important new platelet glycoproteins (GPIa, GPIc,
RT   GPIc*, GPIIa and GMP-140) by F.P.L.C. Characterization by monoclonal
RT   antibodies and gas-phase sequencing.";
RL   Biochem. J. 279:419-425(1991).
RN   [10]
RP   PROTEIN SEQUENCE OF 27-34.
RC   TISSUE=Platelet;
RX   PubMed=12665801; DOI=10.1038/nbt810;
RA   Gevaert K., Goethals M., Martens L., Van Damme J., Staes A.,
RA   Thomas G.R., Vandekerckhove J.;
RT   "Exploring proteomes and analyzing protein processing by mass
RT   spectrometric identification of sorted N-terminal peptides.";
RL   Nat. Biotechnol. 21:566-569(2003).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 28-788.
RX   PubMed=2341395;
RA   Zimrin A.B., Gidwitz S., Lord S., Schwartz E., Bennett J.S.,
RA   White G.C. II, Poncz M.;
RT   "The genomic organization of platelet glycoprotein IIIa.";
RL   J. Biol. Chem. 265:8590-8595(1990).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 28-788.
RX   PubMed=2145280;
RA   Lanza F., Kieffer N., Phillips D.R., Fitzgerald L.A.;
RT   "Characterization of the human platelet glycoprotein IIIa gene.
RT   Comparison with the fibronectin receptor beta-subunit gene.";
RL   J. Biol. Chem. 265:18098-18103(1990).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 56-120, AND VARIANTS PRO-59 AND
RP   ARG-66.
RC   TISSUE=Blood;
RA   Pascual C., Balas A., Garcia-Sanchez F., Rodriguez de la Rua A.,
RA   Vicario J.L.;
RT   "A new exon II polymorphism in the platelet glycoprotein IIIa.";
RL   Submitted (DEC-1993) to the EMBL/GenBank/DDBJ databases.
RN   [14]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 122-204.
RX   PubMed=1382574; DOI=10.1093/intimm/4.9.1031;
RA   Jiang W.-M., Jenkins D., Yuan Q., Leung E., Choo K.H., Watson J.D.,
RA   Krissansen G.W.;
RT   "The gene organization of the human beta 7 subunit, the common beta
RT   subunit of the leukocyte integrins HML-1 and LPAM-1.";
RL   Int. Immunol. 4:1031-1040(1992).
RN   [15]
RP   PROTEIN SEQUENCE OF 218-234 AND 439-443.
RX   PubMed=3801670;
RA   Hiraiwa A., Matsukage A., Shiku H., Takahashi T., Naito K., Yamada K.;
RT   "Purification and partial amino acid sequence of human platelet
RT   membrane glycoproteins IIb and IIIa.";
RL   Blood 69:560-564(1987).
RN   [16]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 707-788 (ISOFORM BETA-3B).
RC   TISSUE=Placenta;
RX   PubMed=2787511; DOI=10.1073/pnas.86.14.5415;
RA   Van Kuppevelt T.H.M.S.M., Languino L.R., Gailit J.O., Suzuki S.,
RA   Ruoslahti E.;
RT   "An alternative cytoplasmic domain of the integrin beta 3 subunit.";
RL   Proc. Natl. Acad. Sci. U.S.A. 86:5415-5418(1989).
RN   [17]
RP   PARTIAL PROTEIN SEQUENCE, AND DISULFIDE BONDS.
RX   PubMed=2001252;
RA   Calvete J.J., Henschen A., Gonzalez-Rodriguez J.;
RT   "Assignment of disulphide bonds in human platelet GPIIIa. A disulphide
RT   pattern for the beta-subunits of the integrin family.";
RL   Biochem. J. 274:63-71(1991).
RN   [18]
RP   FUNCTION (MICROBIAL INFECTION), AND INTERACTION WITH COXSACKIEVIRUS A9
RP   CAPSID PROTEINS.
RX   PubMed=7519807; DOI=10.1006/viro.1994.1494;
RA   Roivainen M., Piirainen L., Hovi T., Virtanen I., Riikonen T.,
RA   Heino J., Hyypiae T.;
RT   "Entry of coxsackievirus A9 into host cells: specific interactions
RT   with alpha v beta 3 integrin, the vitronectin receptor.";
RL   Virology 203:357-365(1994).
RN   [19]
RP   PHOSPHORYLATION AT TYR-773 AND TYR-785 (ISOFORM BETA-3A).
RX   PubMed=8631894; DOI=10.1074/jbc.271.18.10811;
RA   Law D.A., Nannizzi-Alaimo L., Phillips D.R.;
RT   "Outside-in integrin signal transduction. Alpha IIb beta 3-(GP IIb
RT   IIIa) tyrosine phosphorylation induced by platelet aggregation.";
RL   J. Biol. Chem. 271:10811-10815(1996).
RN   [20]
RP   FUNCTION (MICROBIAL INFECTION), AND INTERACTION WITH HANTAAN
RP   GLYCOPROTEIN G.
RX   PubMed=9618541; DOI=10.1073/pnas.95.12.7074;
RA   Gavrilovskaya I.N., Shepley M., Shaw R., Ginsberg M.H., Mackow E.R.;
RT   "beta3 Integrins mediate the cellular entry of hantaviruses that cause
RT   respiratory failure.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:7074-7079(1998).
RN   [21]
RP   FUNCTION (MICROBIAL INFECTION), AND INTERACTION WITH HIV-1 TAT.
RX   PubMed=10397733;
RA   Barillari G., Sgadari C., Fiorelli V., Samaniego F., Colombini S.,
RA   Manzari V., Modesti A., Nair B.C., Cafaro A., Stuerzl M., Ensoli B.;
RT   "The Tat protein of human immunodeficiency virus type-1 promotes
RT   vascular cell growth and locomotion by engaging the alpha5beta1 and
RT   alphavbeta3 integrins and by mobilizing sequestered basic fibroblast
RT   growth factor.";
RL   Blood 94:663-672(1999).
RN   [22]
RP   PHOSPHORYLATION AT THR-779.
RX   PubMed=10896934; DOI=10.1074/jbc.M001908200;
RA   Kirk R.I., Sanderson M.R., Lerea K.M.;
RT   "Threonine phosphorylation of the beta 3 integrin cytoplasmic tail, at
RT   a site recognized by PDK1 and Akt/PKB in vitro, regulates Shc
RT   binding.";
RL   J. Biol. Chem. 275:30901-30906(2000).
RN   [23]
RP   FUNCTION (MICROBIAL INFECTION), AND INTERACTION WITH HUMAN
RP   PARECHOVIRUS 1 CAPSID PROTEINS.
RX   PubMed=11160695; DOI=10.1128/JVI.75.4.1958-1967.2001;
RA   Joki-Korpela P., Marjomaki V., Krogerus C., Heino J., Hyypia T.;
RT   "Entry of human parechovirus 1.";
RL   J. Virol. 75:1958-1967(2001).
RN   [24]
RP   INTERACTION WITH SYK.
RX   PubMed=11940607; DOI=10.1083/jcb.200112113;
RA   Obergfell A., Eto K., Mocsai A., Buensuceso C., Moores S.L.,
RA   Brugge J.S., Lowell C.A., Shattil S.J.;
RT   "Coordinate interactions of Csk, Src, and Syk kinases with
RT   [alpha]IIb[beta]3 initiate integrin signaling to the cytoskeleton.";
RL   J. Cell Biol. 157:265-275(2002).
RN   [25]
RP   INTERACTION WITH FLNB.
RC   TISSUE=Keratinocyte, and Skeletal muscle;
RX   PubMed=11807098; DOI=10.1083/jcb.200103037;
RA   van Der Flier A., Kuikman I., Kramer D., Geerts D., Kreft M.,
RA   Takafuta T., Shapiro S.S., Sonnenberg A.;
RT   "Different splice variants of filamin-B affect myogenesis, subcellular
RT   distribution, and determine binding to integrin (beta) subunits.";
RL   J. Cell Biol. 156:361-376(2002).
RN   [26]
RP   INTERACTION WITH NOV.
RX   PubMed=12695522; DOI=10.1074/jbc.M302028200;
RA   Lin C.G., Leu S.J., Chen N., Tebeau C.M., Lin S.X., Yeung C.Y.,
RA   Lau L.F.;
RT   "CCN3 (NOV) is a novel angiogenic regulator of the CCN protein
RT   family.";
RL   J. Biol. Chem. 278:24200-24208(2003).
RN   [27]
RP   INTERACTION WITH MYO10.
RX   PubMed=15156152; DOI=10.1038/ncb1136;
RA   Zhang H., Berg J.S., Li Z., Wang Y., Lang P., Sousa A.D., Bhaskar A.,
RA   Cheney R.E., Stromblad S.;
RT   "Myosin-X provides a motor-based link between integrins and the
RT   cytoskeleton.";
RL   Nat. Cell Biol. 6:523-531(2004).
RN   [28]
RP   FUNCTION (MICROBIAL INFECTION), AND INTERACTION WITH
RP   CYTOMEGALOVIRUS/HHV-5 GH:GL PROTEINS.
RX   PubMed=15834425; DOI=10.1038/nm1236;
RA   Wang X., Huang D.Y., Huong S.M., Huang E.S.;
RT   "Integrin alphavbeta3 is a coreceptor for human cytomegalovirus.";
RL   Nat. Med. 11:515-521(2005).
RN   [29]
RP   INTERACTION WITH PDIA6.
RX   PubMed=15466936; DOI=10.1182/blood-2004-02-0608;
RA   Jordan P.A., Stevens J.M., Hubbard G.P., Barrett N.E., Sage T.,
RA   Authi K.S., Gibbins J.M.;
RT   "A role for the thiol isomerase protein ERP5 in platelet function.";
RL   Blood 105:1500-1507(2005).
RN   [30]
RP   INTERACTION WITH EMP2.
RX   PubMed=16216233; DOI=10.1016/j.ydbio.2005.09.003;
RA   Wadehra M., Forbes A., Pushkarna N., Goodglick L., Gordon L.K.,
RA   Williams C.J., Braun J.;
RT   "Epithelial membrane protein-2 regulates surface expression of
RT   alphavbeta3 integrin in the endometrium.";
RL   Dev. Biol. 287:336-345(2005).
RN   [31]
RP   INTERACTION WITH COMP.
RX   PubMed=16051604; DOI=10.1074/jbc.M504778200;
RA   Chen F.-H., Thomas A.O., Hecht J.T., Goldring M.B., Lawler J.;
RT   "Cartilage oligomeric matrix protein/thrombospondin 5 supports
RT   chondrocyte attachment through interaction with integrins.";
RL   J. Biol. Chem. 280:32655-32661(2005).
RN   [32]
RP   REVIEW.
RX   PubMed=16322781; DOI=10.1172/JCI26989;
RA   Bennett J.S.;
RT   "Structure and function of the platelet integrin alphaIIbbeta3.";
RL   J. Clin. Invest. 115:3363-3369(2005).
RN   [33]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-125.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [34]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-125.
RC   TISSUE=Platelet;
RX   PubMed=16263699; DOI=10.1074/mcp.M500324-MCP200;
RA   Lewandrowski U., Moebius J., Walter U., Sickmann A.;
RT   "Elucidation of N-glycosylation sites on human platelet proteins: a
RT   glycoproteomic approach.";
RL   Mol. Cell. Proteomics 5:226-233(2006).
RN   [35]
RP   REVIEW.
RX   PubMed=17635696; DOI=10.1111/j.1538-7836.2007.02537.x;
RA   Ma Y.Q., Qin J., Plow E.F.;
RT   "Platelet integrin alpha(IIb)beta(3): activation mechanisms.";
RL   J. Thromb. Haemost. 5:1345-1352(2007).
RN   [36]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-773, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [37]
RP   FUNCTION (MICROBIAL INFECTION), AND INTERACTION WITH HHV-8
RP   GLYCOPROTEIN B.
RX   PubMed=18045938; DOI=10.1128/JVI.01673-07;
RA   Garrigues H.J., Rubinchikova Y.E., Dipersio C.M., Rose T.M.;
RT   "Integrin alphaVbeta3 Binds to the RGD motif of glycoprotein B of
RT   Kaposi's sarcoma-associated herpesvirus and functions as an RGD-
RT   dependent entry receptor.";
RL   J. Virol. 82:1570-1580(2008).
RN   [38]
RP   IDENTIFICATION OF ALLOANTIGEN HPA-1A BY MASS SPECTROMETRY, AND
RP   ASSOCIATION TO ALLELE HLA-DRB3*01:01.
RX   PubMed=19494351; DOI=10.1182/blood-2009-04-211839;
RA   Anani Sarab G., Moss M., Barker R.N., Urbaniak S.J.;
RT   "Naturally processed peptides spanning the HPA-1a polymorphism are
RT   efficiently generated and displayed from platelet glycoprotein by HLA-
RT   DRB3*0101-positive antigen-presenting cells.";
RL   Blood 114:1954-1957(2009).
RN   [39]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-680.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [40]
RP   INTERACTION WITH FERMT2, AND SUBCELLULAR LOCATION.
RX   PubMed=20702409; DOI=10.1074/jbc.C110.134247;
RA   Bledzka K., Bialkowska K., Nie H., Qin J., Byzova T., Wu C.,
RA   Plow E.F., Ma Y.Q.;
RT   "Tyrosine phosphorylation of integrin beta3 regulates kindlin-2
RT   binding and integrin activation.";
RL   J. Biol. Chem. 285:30370-30374(2010).
RN   [41]
RP   FUNCTION (MICROBIAL INFECTION), AND INTERACTION WITH WEST NILE VIRUS
RP   ENVELOPE PROTEIN E.
RX   PubMed=23658209; DOI=10.1099/vir.0.052613-0;
RA   Schmidt K., Keller M., Bader B.L., Korytar T., Finke S., Ziegler U.,
RA   Groschup M.H.;
RT   "Integrins modulate the infection efficiency of West Nile virus into
RT   cells.";
RL   J. Gen. Virol. 94:1723-1733(2013).
RN   [42]
RP   FUNCTION (MICROBIAL INFECTION), AND INTERACTION WITH HUMAN
RP   METAPNEUMOVIRUS FUSION PROTEIN.
RX   PubMed=24478423; DOI=10.1128/JVI.03491-13;
RA   Wei Y., Zhang Y., Cai H., Mirza A.M., Iorio R.M., Peeples M.E.,
RA   Niewiesk S., Li J.;
RT   "Roles of the putative integrin-binding motif of the human
RT   metapneumovirus fusion (f) protein in cell-cell fusion, viral
RT   infectivity, and pathogenesis.";
RL   J. Virol. 88:4338-4352(2014).
RN   [43]
RP   X-RAY CRYSTALLOGRAPHY (3.10 ANGSTROMS) OF 27-718, AND GLYCOSYLATION AT
RP   ASN-346; ASN-397; ASN-585 AND ASN-680.
RX   PubMed=11546839; DOI=10.1126/science.1064535;
RA   Xiong J.P., Stehle T., Diefenbach B., Zhang R., Dunker R., Scott D.L.,
RA   Joachimiak A., Goodman S.L., Arnaout M.A.;
RT   "Crystal structure of the extracellular segment of integrin alpha
RT   Vbeta3.";
RL   Science 294:339-345(2001).
RN   [44]
RP   X-RAY CRYSTALLOGRAPHY (2.25 ANGSTROMS) OF 50-61 (ALLOANTIGEN HPA-1A)
RP   IN COMPLEX WITH HLA-DRA/HLA-DRB3 HETERODIMER.
RX   PubMed=17583734; DOI=10.1016/j.jmb.2007.05.025;
RA   Parry C.S., Gorski J., Stern L.J.;
RT   "Crystallographic structure of the human leukocyte antigen DRA,
RT   DRB3*0101: models of a directional alloimmune response and
RT   autoimmunity.";
RL   J. Mol. Biol. 371:435-446(2007).
RN   [45]
RP   REVIEW ON GT VARIANTS.
RX   PubMed=7878622;
RA   Bray P.F.;
RT   "Inherited diseases of platelet glycoproteins: considerations for
RT   rapid molecular characterization.";
RL   Thromb. Haemost. 72:492-502(1994).
RN   [46]
RP   VARIANT HPA-1B PRO-59, AND DESCRIPTION OF ALLOANTIGEN SYSTEM PL(A).
RX   PubMed=2565345; DOI=10.1172/JCI114082;
RA   Newman P.J., Derbes R.S., Aster R.H.;
RT   "The human platelet alloantigens, PlA1 and PlA2, are associated with a
RT   leucine33/proline33 amino acid polymorphism in membrane glycoprotein
RT   IIIa, and are distinguishable by DNA typing.";
RL   J. Clin. Invest. 83:1778-1781(1989).
RN   [47]
RP   VARIANT HPA-4B GLN-169, AND DESCRIPTION OF ALLOANTIGEN SYSTEM PEN.
RX   PubMed=1430225; DOI=10.1172/JCI116084;
RA   Wang R., Furihata K., McFarland J.G., Friedman K., Aster R.H.,
RA   Newman P.J.;
RT   "An amino acid polymorphism within the RGD binding domain of platelet
RT   membrane glycoprotein IIIa is responsible for the formation of the
RT   Pena/Penb alloantigen system.";
RL   J. Clin. Invest. 90:2038-2043(1992).
RN   [48]
RP   VARIANT MO(+) ALA-433.
RX   PubMed=8093349;
RA   Kuijpers R.W.A.M., Simsek S., Faber N.M., Goldschmeding R.,
RA   van Wermerkerken R.K.V., von Dem Borne A.E.G.K.;
RT   "Single point mutation in human glycoprotein IIIa is associated with a
RT   new platelet-specific alloantigen (Mo) involved in neonatal alloimmune
RT   thrombocytopenia.";
RL   Blood 81:70-76(1993).
RN   [49]
RP   VARIANT CA(+)/TU(+) GLN-515, AND DESCRIPTION OF ALLOANTIGEN SYSTEM
RP   CA/TU.
RX   PubMed=7694683;
RA   Wang R., McFarland J.G., Kekomaki R., Newman P.J.;
RT   "Amino acid 489 is encoded by a mutational 'hot spot' on the beta 3
RT   integrin chain: the CA/TU human platelet alloantigen system.";
RL   Blood 82:3386-3391(1993).
RN   [50]
RP   VARIANT SR(A) CYS-662, AND DESCRIPTION OF ALLOANTIGEN SYSTEM SR(A).
RX   PubMed=8132570;
RA   Santoso S., Kalb R., Kroll H., Walka M., Kiefel V.,
RA   Mueller-Eckhardt C., Newman P.J.;
RT   "A point mutation leads to an unpaired cysteine residue and a
RT   molecular weight polymorphism of a functional platelet beta 3 integrin
RT   subunit. The Sra alloantigen system of GPIIIa.";
RL   J. Biol. Chem. 269:8439-8444(1994).
RN   [51]
RP   VARIANT GT TYR-145.
RX   PubMed=2392682; DOI=10.1126/science.2392682;
RA   Loftus J.C., O'Toole T.E., Plow E.F., Glass A., Frelinger A.L. III,
RA   Ginsberg M.H.;
RT   "A beta 3 integrin mutation abolishes ligand binding and alters
RT   divalent cation-dependent conformation.";
RL   Science 249:915-918(1990).
RN   [52]
RP   VARIANT GT GLN-240.
RX   PubMed=1371279;
RA   Bajt M.L., Ginsberg M.H., Frelinger A.L. III, Berndt M.C.,
RA   Loftus J.C.;
RT   "A spontaneous mutation of integrin alpha IIb beta 3 (platelet
RT   glycoprotein IIb-IIIa) helps define a ligand binding site.";
RL   J. Biol. Chem. 267:3789-3794(1992).
RN   [53]
RP   VARIANT GT TRP-240.
RX   PubMed=1602006; DOI=10.1172/JCI115808;
RA   Lanza F., Stierle A., Fournier D., Morales M., Andre G., Nurden A.T.,
RA   Cazenave J.-P.;
RT   "A new variant of Glanzmann's thrombasthenia (Strasbourg I). Platelets
RT   with functionally defective glycoprotein IIb-IIIa complexes and a
RT   glycoprotein IIIa 214Arg-->214Trp mutation.";
RL   J. Clin. Invest. 89:1995-2004(1992).
RN   [54]
RP   VARIANT GT PRO-778.
RX   PubMed=1438206; DOI=10.1073/pnas.89.21.10169;
RA   Chen Y.-P., Djaffar I., Pidard D., Steiner B., Cieutat A.-M.,
RA   Caen J.P., Rosa J.-P.;
RT   "Ser-752-->Pro mutation in the cytoplasmic domain of integrin beta 3
RT   subunit and defective activation of platelet integrin alpha IIb beta 3
RT   (glycoprotein IIb-IIIa) in a variant of Glanzmann thrombasthenia.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:10169-10173(1992).
RN   [55]
RP   VARIANT GT TYR-400.
RX   PubMed=8781422;
RA   Grimaldi C.M., Chen F., Scudder L.E., Coller B.S., French D.L.;
RT   "A Cys374Tyr homozygous mutation of platelet glycoprotein IIIa (beta
RT   3) in a Chinese patient with Glanzmann's thrombasthenia.";
RL   Blood 88:1666-1675(1996).
RN   [56]
RP   VARIANT GT TRP-143.
RX   PubMed=9376589;
RA   Basani R.B., Brown D.L., Vilaire G., Bennett J.S., Poncz M.;
RT   "A Leu117-->Trp mutation within the RGD-peptide cross-linking region
RT   of beta3 results in Glanzmann thrombasthenia by preventing alphaIIb
RT   beta3 export to the platelet surface.";
RL   Blood 90:3082-3088(1997).
RN   [57]
RP   VARIANTS GT ASN-145; GLN-242 AND PRO-288.
RX   PubMed=9215749; DOI=10.1006/bcmd.1997.0117;
RA   French D.L., Coller B.S.;
RT   "Hematologically important mutations: Glanzmann thrombasthenia.";
RL   Blood Cells Mol. Dis. 23:39-51(1997).
RN   [58]
RP   VARIANTS GT PRO-306; PHE-586; SER-598 AND SER-605.
RX   PubMed=9790984; DOI=10.1006/bbrc.1998.9526;
RA   Ambo H., Kamata T., Handa M., Taki M., Kuwajima M., Kawai Y., Oda A.,
RA   Murata M., Takada Y., Watanabe K., Ikeda Y.;
RT   "Three novel integrin beta3 subunit missense mutations (H280P, C560F,
RT   and G579S) in thrombasthenia, including one (H280P) prevalent in
RT   Japanese patients.";
RL   Biochem. Biophys. Res. Commun. 251:763-768(1998).
RN   [59]
RP   VARIANT GT LEU-188.
RX   PubMed=9684783;
RA   Jackson D.E., White M.M., Jennings L.K., Newman P.J.;
RT   "A Ser162-->Leu mutation within glycoprotein (GP) IIIa (integrin
RT   beta3) results in an unstable alphaIIbbeta3 complex that retains
RT   partial function in a novel form of type II Glanzmann
RT   thrombasthenia.";
RL   Thromb. Haemost. 80:42-48(1998).
RN   [60]
RP   VARIANT GT ARG-568.
RX   PubMed=10233432; DOI=10.1111/j.1365-2141.1999.01376.x;
RA   Ruan J., Schmugge M., Clemetson K.J., Cazes E., Combrie R., Bourre F.,
RA   Nurden A.T.;
RT   "Homozygous Cys542-->Arg substitution in GPIIIa in a Swiss patient
RT   with type I Glanzmann's thrombasthenia.";
RL   Br. J. Haematol. 105:523-531(1999).
RN   [61]
RP   VARIANTS PRO-59; GLN-169 AND ILE-453.
RX   PubMed=10391209; DOI=10.1038/10290;
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RT   "Characterization of single-nucleotide polymorphisms in coding regions
RT   of human genes.";
RL   Nat. Genet. 22:231-238(1999).
RN   [62]
RP   ERRATUM.
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RL   Nat. Genet. 23:373-373(1999).
RN   [63]
RP   VARIANT GT ARG-586, AND CHARACTERIZATION OF VARIANT GT ARG-586.
RX   PubMed=11588040; DOI=10.1182/blood.V98.8.2432;
RA   Ruiz C., Liu C.-Y., Sun Q.-H., Sigaud-Fiks M., Fressinaud E.,
RA   Muller J.-Y., Nurden P., Nurden A.T., Newman P.J., Valentin N.;
RT   "A point mutation in the cysteine-rich domain of glycoprotein (GP)
RT   IIIa results in the expression of a GPIIb-IIIa (alphaIIbbeta3)
RT   integrin receptor locked in a high-affinity state and a Glanzmann
RT   thrombasthenia-like phenotype.";
RL   Blood 98:2432-2441(2001).
RN   [64]
RP   VARIANT ILE-166, AND CHARACTERIZATION OF VARIANT ILE-166.
RX   PubMed=12036875; DOI=10.1182/blood.V99.12.4449;
RA   Jallu V., Meunier M., Brement M., Kaplan C.;
RT   "A new platelet polymorphism Duv(a+), localized within the RGD binding
RT   domain of glycoprotein IIIa, is associated with neonatal
RT   thrombocytopenia.";
RL   Blood 99:4449-4456(2002).
RN   [65]
RP   VARIANT GT PRO-222.
RX   PubMed=11897046; DOI=10.1080/09537100220122466;
RA   Nurden A.T., Ruan J., Pasquet J.-M., Gauthier B., Combrie R.,
RA   Kunicki T., Nurden P.;
RT   "A novel 196Leu to Pro substitution in the beta3 subunit of the
RT   alphaIIbbeta3 integrin in a patient with a variant form of Glanzmann
RT   thrombasthenia.";
RL   Platelets 13:101-111(2002).
RN   [66]
RP   VARIANTS GT TRP-119; VAL-243 AND ARG-601.
RX   PubMed=12083483;
RA   D'Andrea G., Colaizzo D., Vecchione G., Grandone E., Di Minno G.,
RA   Margaglione M.;
RT   "Glanzmann's thrombasthenia: identification of 19 new mutations in 30
RT   patients.";
RL   Thromb. Haemost. 87:1034-1042(2002).
RN   [67]
RP   VARIANT GT TYR-532.
RX   PubMed=12353082; DOI=10.1267/THRO88030503;
RA   Nair S., Li J., Mitchell W.B., Mohanty D., Coller B.S., French D.L.;
RT   "Two new beta3 integrin mutations in Indian patients with Glanzmann
RT   thrombasthenia: localization of mutations affecting cysteine residues
RT   in integrin beta3.";
RL   Thromb. Haemost. 88:503-509(2002).
RN   [68]
RP   VARIANT GT VAL-150, AND CHARACTERIZATION OF VARIANT GT VAL-150.
RX   PubMed=15583747; DOI=10.1267/THRO04061377;
RA   Gonzalez-Manchon C., Butta N., Larrucea S., Arias-Salgado E.G.,
RA   Alonso S., Lopez A., Parrilla R.;
RT   "A variant thrombasthenic phenotype associated with compound
RT   heterozygosity of integrin beta3-subunit: (Met124Val)beta3 alters the
RT   subunit dimerization rendering a decreased number of constitutive
RT   active alphaIIbbeta3 receptors.";
RL   Thromb. Haemost. 92:1377-1386(2004).
RN   [69]
RP   VARIANTS GT PRO-306 AND ASN-330, AND CHARACTERIZATION OF VARIANT GT
RP   ASN-330.
RX   PubMed=15634267; DOI=10.1111/j.1538-7836.2004.00990.x;
RA   Tanaka S., Hayashi T., Yoshimura K., Nakayama M., Fujita T., Amano T.,
RA   Tani Y.;
RT   "Double heterozygosity for a novel missense mutation of Ile304 to Asn
RT   in addition to the missense mutation His280 to Pro in the integrin
RT   beta3 gene as a cause of the absence of platelet alphaIIbbeta3 in
RT   Glanzmann's thrombasthenia.";
RL   J. Thromb. Haemost. 3:68-73(2005).
RN   [70]
RP   VARIANTS GT CYS-141 AND LEU-321.
RX   PubMed=15748237; DOI=10.1111/j.1538-7836.2005.01159.x;
RA   Nair S., Ghosh K., Shetty S., Mohanty D.;
RT   "Mutations in GPIIIa molecule as a cause for Glanzmann thrombasthenia
RT   in Indian patients.";
RL   J. Thromb. Haemost. 3:482-488(2005).
RN   [71]
RP   VARIANT BDPLT16 HIS-749, AND CHARACTERIZATION OF VARIANT BDPLT16
RP   HIS-749.
RX   PubMed=18065693; DOI=10.1182/blood-2007-09-112615;
RA   Ghevaert C., Salsmann A., Watkins N.A., Schaffner-Reckinger E.,
RA   Rankin A., Garner S.F., Stephens J., Smith G.A., Debili N.,
RA   Vainchenker W., de Groot P.G., Huntington J.A., Laffan M., Kieffer N.,
RA   Ouwehand W.H.;
RT   "A nonsynonymous SNP in the ITGB3 gene disrupts the conserved
RT   membrane-proximal cytoplasmic salt bridge in the alphaIIbbeta3
RT   integrin and cosegregates dominantly with abnormal proplatelet
RT   formation and macrothrombocytopenia.";
RL   Blood 111:3407-3414(2008).
RN   [72]
RP   VARIANTS GT TYR-64; ARG-144; PRO-222; ASP-247 AND MET-279,
RP   CHARACTERIZATION OF VARIANTS TYR-64; PRO-222; ASP-247 AND MET-279, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=20020534; DOI=10.1002/humu.21179;
RA   Jallu V., Dusseaux M., Panzer S., Torchet M.F., Hezard N.,
RA   Goudemand J., de Brevern A.G., Kaplan C.;
RT   "AlphaIIbbeta3 integrin: new allelic variants in Glanzmann
RT   thrombasthenia, effects on ITGA2B and ITGB3 mRNA splicing, expression,
RT   and structure-function.";
RL   Hum. Mutat. 31:237-246(2010).
CC   -!- FUNCTION: Integrin alpha-V/beta-3 (ITGAV:ITGB3) is a receptor for
CC       cytotactin, fibronectin, laminin, matrix metalloproteinase-2,
CC       osteopontin, osteomodulin, prothrombin, thrombospondin,
CC       vitronectin and von Willebrand factor. Integrin alpha-IIb/beta-3
CC       (ITGA2B:ITGB3) is a receptor for fibronectin, fibrinogen,
CC       plasminogen, prothrombin, thrombospondin and vitronectin.
CC       Integrins alpha-IIb/beta-3 and alpha-V/beta-3 recognize the
CC       sequence R-G-D in a wide array of ligands. Integrin alpha-
CC       IIb/beta-3 recognizes the sequence H-H-L-G-G-G-A-K-Q-A-G-D-V in
CC       fibrinogen gamma chain. Following activation integrin alpha-
CC       IIb/beta-3 brings about platelet/platelet interaction through
CC       binding of soluble fibrinogen. This step leads to rapid platelet
CC       aggregation which physically plugs ruptured endothelial surface.
CC       Fibrinogen binding enhances SELP expression in activated platelets
CC       (By similarity). {ECO:0000250|UniProtKB:O54890,
CC       ECO:0000269|PubMed:9195946, ECO:0000303|PubMed:16322781,
CC       ECO:0000303|PubMed:17635696}.
CC   -!- FUNCTION: (Microbial infection) Integrin ITGAV:ITGB3 acts as a
CC       receptor for herpes virus 8/HHV-8 (PubMed:18045938). Integrin
CC       ITGAV:ITGB3 acts as a receptor for coxsackievirus A9
CC       (PubMed:7519807). Acts as a receptor for Hantaan virus
CC       (PubMed:9618541). Integrin ITGAV:ITGB3 acts as a receptor for
CC       cytomegalovirus/HHV-5 (PubMed:15834425). Integrin ITGA5:ITGB3 acts
CC       as a receptor for human metapneumovirus (PubMed:24478423).
CC       Integrin ITGAV:ITGB3 acts aP05556s a receptor for human
CC       parechovirus 1 (PubMed:11160695). Integrin ITGAV:ITGB3 acts as a
CC       receptor for west nile virus (PubMed:23658209). In case of HIV-1
CC       infection, the interaction with extracellular viral Tat protein
CC       seems to enhance angiogenesis in Kaposi's sarcoma lesions
CC       (PubMed:10397733). {ECO:0000269|PubMed:10397733,
CC       ECO:0000269|PubMed:11160695, ECO:0000269|PubMed:15834425,
CC       ECO:0000269|PubMed:18045938, ECO:0000269|PubMed:23658209,
CC       ECO:0000269|PubMed:24478423, ECO:0000269|PubMed:7519807,
CC       ECO:0000269|PubMed:9618541}.
CC   -!- SUBUNIT: Heterodimer of an alpha and a beta subunit. Beta-3
CC       (ITGB3) associates with either alpha-IIb (ITGA2B) or alpha-V
CC       (ITGAV). Isoform Beta-3C interacts with FLNB. Interacts with COMP.
CC       Interacts with PDIA6 following platelet stimulation. Interacts
CC       with SYK; upon activation by ITGB3 promotes platelet adhesion.
CC       Interacts with MYO10. Interacts with DAB2. Interacts with FERMT2.
CC       Interacts with EMP2; regulates the levels of the heterodimer
CC       ITGA5:ITGB3 integrin expression on the plasma membrane
CC       (PubMed:16216233). Integrin ITGAV:ITGB3 interacts with FBLN5 (via
CC       N-terminus) (By similarity). ITGAV:ITGB3 interacts with NOV
CC       (PubMed:12695522). (Microbial infection) Integrin ITGAV:ITGB3
CC       interacts with herpes virus 8/HHV-8 glycoprotein B
CC       (PubMed:18045938). (Microbial infection) Integrin ITGAV:ITGB3
CC       interacts with coxsackievirus A9 capsid proteins (PubMed:7519807).
CC       (Microbial infection) Interacts with Hantaan virus glycoprotein G
CC       (PubMed:9618541). (Microbial infection) Integrin ITGAV:ITGB3
CC       interacts with cytomegalovirus/HHV-5 gH:gL proteins
CC       (PubMed:15834425). (Microbial infection) Integrin ITGA5:ITGB3
CC       interacts with human metapneumovirus fusion protein
CC       (PubMed:24478423). (Microbial infection) Integrin ITGAV:ITGB3
CC       interacts with human parechovirus 1 capsid proteins
CC       (PubMed:11160695). (Microbial infection) Integrin ITGAV:ITGB3
CC       interacts with west nile virus envelope protein E
CC       (PubMed:23658209). (Microbial infection) Interacts with HIV-1 Tat
CC       (PubMed:10397733). {ECO:0000250|UniProtKB:O54890,
CC       ECO:0000269|PubMed:10397733, ECO:0000269|PubMed:11160695,
CC       ECO:0000269|PubMed:11807098, ECO:0000269|PubMed:11940607,
CC       ECO:0000269|PubMed:12695522, ECO:0000269|PubMed:15156152,
CC       ECO:0000269|PubMed:15466936, ECO:0000269|PubMed:15834425,
CC       ECO:0000269|PubMed:16051604, ECO:0000269|PubMed:16216233,
CC       ECO:0000269|PubMed:17583734, ECO:0000269|PubMed:18045938,
CC       ECO:0000269|PubMed:20702409, ECO:0000269|PubMed:23658209,
CC       ECO:0000269|PubMed:24478423, ECO:0000269|PubMed:7519807,
CC       ECO:0000269|PubMed:9618541}.
CC   -!- INTERACTION:
CC       Self; NbExp=4; IntAct=EBI-702847, EBI-702847;
CC       P06935:- (xeno); NbExp=4; IntAct=EBI-702847, EBI-981051;
CC       P05094:ACTN1 (xeno); NbExp=2; IntAct=EBI-702847, EBI-5847257;
CC       P08514:ITGA2B; NbExp=11; IntAct=EBI-702847, EBI-702693;
CC       P06756:ITGAV; NbExp=11; IntAct=EBI-702847, EBI-298282;
CC       F5HB81:ORF8 (xeno); NbExp=2; IntAct=EBI-702847, EBI-9027696;
CC       Q62101:Prkd1 (xeno); NbExp=2; IntAct=EBI-702847, EBI-6903636;
CC       P18031:PTPN1; NbExp=4; IntAct=EBI-702847, EBI-968788;
CC       P05480:Src (xeno); NbExp=5; IntAct=EBI-702847, EBI-298680;
CC       P54939:TLN1 (xeno); NbExp=2; IntAct=EBI-702847, EBI-1035421;
CC       Q9Y490:TLN1; NbExp=4; IntAct=EBI-702847, EBI-2462036;
CC       P26039:Tln1 (xeno); NbExp=3; IntAct=EBI-702847, EBI-1039593;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:20020534,
CC       ECO:0000269|PubMed:20702409, ECO:0000269|PubMed:9195946}; Single-
CC       pass type I membrane protein {ECO:0000269|PubMed:20020534,
CC       ECO:0000269|PubMed:20702409, ECO:0000269|PubMed:9195946}. Cell
CC       projection, lamellipodium membrane {ECO:0000269|PubMed:20702409}.
CC       Cell junction, focal adhesion {ECO:0000269|PubMed:20702409}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=Beta-3A;
CC         IsoId=P05106-1; Sequence=Displayed;
CC       Name=Beta-3B;
CC         IsoId=P05106-2; Sequence=VSP_002745;
CC       Name=Beta-3C;
CC         IsoId=P05106-3; Sequence=VSP_002746;
CC   -!- TISSUE SPECIFICITY: Isoform beta-3A and isoform beta-3C are widely
CC       expressed. Isoform beta-3A is specifically expressed in osteoblast
CC       cells; isoform beta-3C is specifically expressed in prostate and
CC       testis.
CC   -!- PTM: Phosphorylated on tyrosine residues in response to thrombin-
CC       induced platelet aggregation. Probably involved in outside-in
CC       signaling. A peptide (AA 740-762) is capable of binding GRB2 only
CC       when both Tyr-773 and Tyr-785 are phosphorylated. Phosphorylation
CC       of Thr-779 inhibits SHC binding. {ECO:0000269|PubMed:10896934}.
CC   -!- POLYMORPHISM: Position 59 is associated with platelet-specific
CC       alloantigen HPA-1 (ZW or PL(A)). HPA-1A/ZW(A)/PL(A1) has Leu-59
CC       and HPA-1B/ZW(B)/PL(A2) has Pro-59. HPA-1A is involved in fetal-
CC       maternal alloimmune thromobocytopenia (FMAIT) as well as in
CC       neonatal alloimmune thrombocytopenia (NAIT).
CC   -!- POLYMORPHISM: Position 169 is associated with platelet-specific
CC       alloantigen HPA-4 (PEN or YUK). HPA-4A/PEN(A)/YUK(A) has Arg-169
CC       and HPA-4B/PEN(B)/YUK(B) has Gln-169. HPA-4B is involved in
CC       neonatal alloimmune thrombocytopenia (NAIT or NATP).
CC   -!- POLYMORPHISM: Position 433 is associated with platelet-specific
CC       alloantigen MO. MO(-) has Pro-433 and MO(+) has Ala-433. MO(+) is
CC       involved in NAIT.
CC   -!- POLYMORPHISM: Position 515 is associated with platelet-specific
CC       alloantigen CA/TU. CA(-)/TU(-) has Arg-515 and CA(+)/TU(+) has
CC       Gln-515. CA(+) is involved in NAIT.
CC   -!- POLYMORPHISM: Position 662 is associated with platelet-specific
CC       alloantigen SR(A). SR(A)(-) has Arg-662 and SR(A)(+) has Cys-662.
CC   -!- DISEASE: Glanzmann thrombasthenia (GT) [MIM:273800]: A common
CC       inherited disease of platelet aggregation. It is characterized by
CC       mucocutaneous bleeding of mild-to-moderate severity. GT has been
CC       classified clinically into types I and II. In type I, platelets
CC       show absence of the glycoprotein IIb-IIIa complexes at their
CC       surface and lack fibrinogen and clot retraction capability. In
CC       type II, the platelets express the GPIIb-IIIa complex at reduced
CC       levels, have detectable amounts of fibrinogen, and have low or
CC       moderate clot retraction capability. {ECO:0000269|PubMed:10233432,
CC       ECO:0000269|PubMed:11588040, ECO:0000269|PubMed:11897046,
CC       ECO:0000269|PubMed:12083483, ECO:0000269|PubMed:12353082,
CC       ECO:0000269|PubMed:1371279, ECO:0000269|PubMed:1438206,
CC       ECO:0000269|PubMed:15583747, ECO:0000269|PubMed:15634267,
CC       ECO:0000269|PubMed:15748237, ECO:0000269|PubMed:1602006,
CC       ECO:0000269|PubMed:20020534, ECO:0000269|PubMed:2392682,
CC       ECO:0000269|PubMed:8781422, ECO:0000269|PubMed:9215749,
CC       ECO:0000269|PubMed:9376589, ECO:0000269|PubMed:9684783,
CC       ECO:0000269|PubMed:9790984}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Bleeding disorder, platelet-type 16 (BDPLT16)
CC       [MIM:187800]: An autosomal dominant form of congenital
CC       macrothrombocytopenia associated with platelet anisocytosis. It is
CC       a disorder of platelet production. Affected individuals may have
CC       no or only mildly increased bleeding tendency. In vitro studies
CC       show mild platelet functional abnormalities.
CC       {ECO:0000269|PubMed:18065693}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the integrin beta chain family.
CC       {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 VWFA domain. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation and
CC       polymorphism database;
CC       URL="http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=ITGB3";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; J02703; AAA52589.1; -; mRNA.
DR   EMBL; M20311; AAA60122.1; -; mRNA.
DR   EMBL; M35999; AAA35927.1; -; mRNA.
DR   EMBL; U95204; AAB71380.1; -; mRNA.
DR   EMBL; CH471231; EAW57682.1; -; Genomic_DNA.
DR   EMBL; BC127666; AAI27667.1; -; mRNA.
DR   EMBL; BC127667; AAI27668.1; -; mRNA.
DR   EMBL; L28832; AAA20880.2; -; Genomic_DNA.
DR   EMBL; M32686; AAA67537.1; -; Genomic_DNA.
DR   EMBL; M32667; AAA67537.1; JOINED; Genomic_DNA.
DR   EMBL; M32672; AAA67537.1; JOINED; Genomic_DNA.
DR   EMBL; M32673; AAA67537.1; JOINED; Genomic_DNA.
DR   EMBL; M32674; AAA67537.1; JOINED; Genomic_DNA.
DR   EMBL; M32675; AAA67537.1; JOINED; Genomic_DNA.
DR   EMBL; M32680; AAA67537.1; JOINED; Genomic_DNA.
DR   EMBL; M32681; AAA67537.1; JOINED; Genomic_DNA.
DR   EMBL; M32682; AAA67537.1; JOINED; Genomic_DNA.
DR   EMBL; M32685; AAA67537.1; JOINED; Genomic_DNA.
DR   EMBL; M57494; AAA52600.1; -; Genomic_DNA.
DR   EMBL; M57481; AAA52600.1; JOINED; Genomic_DNA.
DR   EMBL; M57482; AAA52600.1; JOINED; Genomic_DNA.
DR   EMBL; M57483; AAA52600.1; JOINED; Genomic_DNA.
DR   EMBL; M57484; AAA52600.1; JOINED; Genomic_DNA.
DR   EMBL; M57485; AAA52600.1; JOINED; Genomic_DNA.
DR   EMBL; M57486; AAA52600.1; JOINED; Genomic_DNA.
DR   EMBL; M57487; AAA52600.1; JOINED; Genomic_DNA.
DR   EMBL; M57488; AAA52600.1; JOINED; Genomic_DNA.
DR   EMBL; M57489; AAA52600.1; JOINED; Genomic_DNA.
DR   EMBL; M57490; AAA52600.1; JOINED; Genomic_DNA.
DR   EMBL; M57491; AAA52600.1; JOINED; Genomic_DNA.
DR   EMBL; M57492; AAA52600.1; JOINED; Genomic_DNA.
DR   EMBL; M57493; AAA52600.1; JOINED; Genomic_DNA.
DR   EMBL; U03881; AAA16076.1; -; Genomic_DNA.
DR   EMBL; S49379; AAB23689.2; -; Genomic_DNA.
DR   EMBL; M25108; AAA36121.1; -; mRNA.
DR   CCDS; CCDS11511.1; -. [P05106-1]
DR   PIR; A26547; A26547.
DR   PIR; A60798; A60798.
DR   PIR; B36268; B36268.
DR   PIR; I77349; I77349.
DR   PIR; S14324; S14324.
DR   RefSeq; NP_000203.2; NM_000212.2. [P05106-1]
DR   UniGene; Hs.218040; -.
DR   PDB; 1JV2; X-ray; 3.10 A; B=27-718.
DR   PDB; 1KUP; NMR; -; B=742-766.
DR   PDB; 1KUZ; NMR; -; B=742-766.
DR   PDB; 1L5G; X-ray; 3.20 A; B=27-718.
DR   PDB; 1M1X; X-ray; 3.30 A; B=27-718.
DR   PDB; 1M8O; NMR; -; B=742-788.
DR   PDB; 1MIZ; X-ray; 1.90 A; A=765-769.
DR   PDB; 1MK7; X-ray; 2.20 A; A/C=765-775.
DR   PDB; 1MK9; X-ray; 2.80 A; A/C/E/G=765-776.
DR   PDB; 1RN0; Model; -; B=135-378.
DR   PDB; 1S4X; NMR; -; A=742-788.
DR   PDB; 1TYE; X-ray; 2.90 A; B/D/F=27-466.
DR   PDB; 1U8C; X-ray; 3.10 A; B=27-718.
DR   PDB; 2INI; Model; -; B=81-460, B=558-716.
DR   PDB; 2K9J; NMR; -; B=711-753.
DR   PDB; 2KNC; NMR; -; B=715-788.
DR   PDB; 2KV9; NMR; -; B=739-788.
DR   PDB; 2L1C; NMR; -; B=762-788.
DR   PDB; 2L91; NMR; -; A=711-753.
DR   PDB; 2LJD; NMR; -; A=742-788.
DR   PDB; 2LJE; NMR; -; A=742-788.
DR   PDB; 2LJF; NMR; -; A=742-788.
DR   PDB; 2MTP; NMR; -; C=742-788.
DR   PDB; 2Q6W; X-ray; 2.25 A; C/F=50-61.
DR   PDB; 2RMZ; NMR; -; A=711-753.
DR   PDB; 2RN0; NMR; -; A=711-753.
DR   PDB; 2VC2; X-ray; 3.10 A; B=27-487.
DR   PDB; 2VDK; X-ray; 2.80 A; B=27-487.
DR   PDB; 2VDL; X-ray; 2.75 A; B=27-487.
DR   PDB; 2VDM; X-ray; 2.90 A; B=27-487.
DR   PDB; 2VDN; X-ray; 2.90 A; B=27-487.
DR   PDB; 2VDO; X-ray; 2.51 A; B=27-487.
DR   PDB; 2VDP; X-ray; 2.80 A; B=27-487.
DR   PDB; 2VDQ; X-ray; 2.59 A; B=27-487.
DR   PDB; 2VDR; X-ray; 2.40 A; B=27-487.
DR   PDB; 3FCS; X-ray; 2.55 A; B/D=27-716.
DR   PDB; 3FCU; X-ray; 2.90 A; B/D/F=27-487.
DR   PDB; 3IJE; X-ray; 2.90 A; B=27-721.
DR   PDB; 3NID; X-ray; 2.30 A; B/D=27-497.
DR   PDB; 3NIF; X-ray; 2.40 A; B/D=27-497.
DR   PDB; 3NIG; X-ray; 2.25 A; B/D=27-497.
DR   PDB; 3T3M; X-ray; 2.60 A; B/D=27-498.
DR   PDB; 3T3P; X-ray; 2.20 A; B/D=27-498.
DR   PDB; 3ZDX; X-ray; 2.45 A; B/D=27-498.
DR   PDB; 3ZDY; X-ray; 2.45 A; B/D=27-498.
DR   PDB; 3ZDZ; X-ray; 2.75 A; B/D=27-498.
DR   PDB; 3ZE0; X-ray; 2.95 A; B/D=27-498.
DR   PDB; 3ZE1; X-ray; 3.00 A; B/D=27-498.
DR   PDB; 3ZE2; X-ray; 2.35 A; B/D=27-498.
DR   PDB; 4CAK; EM; 20.50 A; B=27-716.
DR   PDB; 4G1E; X-ray; 3.00 A; B=27-717.
DR   PDB; 4G1M; X-ray; 2.90 A; B=27-718.
DR   PDB; 4MMX; X-ray; 3.32 A; B=27-718.
DR   PDB; 4MMY; X-ray; 3.18 A; B=27-718.
DR   PDB; 4MMZ; X-ray; 3.10 A; B=27-718.
DR   PDB; 4O02; X-ray; 3.60 A; B=27-718.
DR   PDB; 4Z7N; X-ray; 2.60 A; B/D=29-497.
DR   PDB; 4Z7Q; X-ray; 2.70 A; B/D=27-497.
DR   PDB; 4Z7S; X-ray; 2.70 A; B/D=27-497.
DR   PDBsum; 1JV2; -.
DR   PDBsum; 1KUP; -.
DR   PDBsum; 1KUZ; -.
DR   PDBsum; 1L5G; -.
DR   PDBsum; 1M1X; -.
DR   PDBsum; 1M8O; -.
DR   PDBsum; 1MIZ; -.
DR   PDBsum; 1MK7; -.
DR   PDBsum; 1MK9; -.
DR   PDBsum; 1RN0; -.
DR   PDBsum; 1S4X; -.
DR   PDBsum; 1TYE; -.
DR   PDBsum; 1U8C; -.
DR   PDBsum; 2INI; -.
DR   PDBsum; 2K9J; -.
DR   PDBsum; 2KNC; -.
DR   PDBsum; 2KV9; -.
DR   PDBsum; 2L1C; -.
DR   PDBsum; 2L91; -.
DR   PDBsum; 2LJD; -.
DR   PDBsum; 2LJE; -.
DR   PDBsum; 2LJF; -.
DR   PDBsum; 2MTP; -.
DR   PDBsum; 2Q6W; -.
DR   PDBsum; 2RMZ; -.
DR   PDBsum; 2RN0; -.
DR   PDBsum; 2VC2; -.
DR   PDBsum; 2VDK; -.
DR   PDBsum; 2VDL; -.
DR   PDBsum; 2VDM; -.
DR   PDBsum; 2VDN; -.
DR   PDBsum; 2VDO; -.
DR   PDBsum; 2VDP; -.
DR   PDBsum; 2VDQ; -.
DR   PDBsum; 2VDR; -.
DR   PDBsum; 3FCS; -.
DR   PDBsum; 3FCU; -.
DR   PDBsum; 3IJE; -.
DR   PDBsum; 3NID; -.
DR   PDBsum; 3NIF; -.
DR   PDBsum; 3NIG; -.
DR   PDBsum; 3T3M; -.
DR   PDBsum; 3T3P; -.
DR   PDBsum; 3ZDX; -.
DR   PDBsum; 3ZDY; -.
DR   PDBsum; 3ZDZ; -.
DR   PDBsum; 3ZE0; -.
DR   PDBsum; 3ZE1; -.
DR   PDBsum; 3ZE2; -.
DR   PDBsum; 4CAK; -.
DR   PDBsum; 4G1E; -.
DR   PDBsum; 4G1M; -.
DR   PDBsum; 4MMX; -.
DR   PDBsum; 4MMY; -.
DR   PDBsum; 4MMZ; -.
DR   PDBsum; 4O02; -.
DR   PDBsum; 4Z7N; -.
DR   PDBsum; 4Z7Q; -.
DR   PDBsum; 4Z7S; -.
DR   ProteinModelPortal; P05106; -.
DR   SMR; P05106; 27-788.
DR   BioGrid; 109896; 18.
DR   DIP; DIP-304N; -.
DR   IntAct; P05106; 18.
DR   MINT; MINT-209501; -.
DR   STRING; 9606.ENSP00000262017; -.
DR   BindingDB; P05106; -.
DR   ChEMBL; CHEMBL2111443; -.
DR   DrugBank; DB00054; Abciximab.
DR   DrugBank; DB00098; Anti-thymocyte Globulin (Rabbit).
DR   DrugBank; DB00063; Eptifibatide.
DR   DrugBank; DB00775; Tirofiban.
DR   iPTMnet; P05106; -.
DR   PhosphoSite; P05106; -.
DR   BioMuta; ITGB3; -.
DR   DMDM; 125987835; -.
DR   MaxQB; P05106; -.
DR   PaxDb; P05106; -.
DR   PRIDE; P05106; -.
DR   Ensembl; ENST00000559488; ENSP00000452786; ENSG00000259207. [P05106-1]
DR   GeneID; 3690; -.
DR   KEGG; hsa:3690; -.
DR   UCSC; uc002ilj.3; human. [P05106-1]
DR   CTD; 3690; -.
DR   GeneCards; ITGB3; -.
DR   HGNC; HGNC:6156; ITGB3.
DR   HPA; HPA027852; -.
DR   MalaCards; ITGB3; -.
DR   MIM; 173470; gene+phenotype.
DR   MIM; 187800; phenotype.
DR   MIM; 273800; phenotype.
DR   neXtProt; NX_P05106; -.
DR   Orphanet; 140957; Autosomal dominant macrothrombocytopenia.
DR   Orphanet; 853; Fetal and neonatal alloimmune thrombocytopenia.
DR   Orphanet; 849; Glanzmann thrombasthenia.
DR   PharmGKB; PA205; -.
DR   eggNOG; KOG1226; Eukaryota.
DR   eggNOG; ENOG410XP60; LUCA.
DR   GeneTree; ENSGT00760000119064; -.
DR   HOVERGEN; HBG006190; -.
DR   InParanoid; P05106; -.
DR   KO; K06493; -.
DR   OMA; GHGQCSC; -.
DR   OrthoDB; EOG7T7GSB; -.
DR   PhylomeDB; P05106; -.
DR   TreeFam; TF105392; -.
DR   Reactome; R-HSA-114608; Platelet degranulation.
DR   Reactome; R-HSA-1566948; Elastic fibre formation.
DR   Reactome; R-HSA-210990; PECAM1 interactions.
DR   Reactome; R-HSA-2129379; Molecules associated with elastic fibres.
DR   Reactome; R-HSA-216083; Integrin cell surface interactions.
DR   Reactome; R-HSA-3000170; Syndecan interactions.
DR   Reactome; R-HSA-3000178; ECM proteoglycans.
DR   Reactome; R-HSA-354192; Integrin alphaIIb beta3 signaling.
DR   Reactome; R-HSA-354194; GRB2:SOS provides linkage to MAPK signaling for Integrins.
DR   Reactome; R-HSA-372708; p130Cas linkage to MAPK signaling for integrins.
DR   Reactome; R-HSA-4420097; VEGFA-VEGFR2 Pathway.
DR   Reactome; R-HSA-445144; Signal transduction by L1.
DR   Reactome; R-HSA-5674135; MAP2K and MAPK activation.
DR   SignaLink; P05106; -.
DR   ChiTaRS; ITGB3; human.
DR   EvolutionaryTrace; P05106; -.
DR   GeneWiki; CD61; -.
DR   GenomeRNAi; 3690; -.
DR   NextBio; 14453; -.
DR   PMAP-CutDB; P05106; -.
DR   PRO; PR:P05106; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   Bgee; P05106; -.
DR   CleanEx; HS_ITGB3; -.
DR   ExpressionAtlas; P05106; baseline and differential.
DR   Genevisible; P05106; HS.
DR   GO; GO:0071062; C:alphav-beta3 integrin-vitronectin complex; TAS:BHF-UCL.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0031527; C:filopodium membrane; IDA:UniProtKB.
DR   GO; GO:0005925; C:focal adhesion; IDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0034683; C:integrin alphav-beta3 complex; IDA:UniProtKB.
DR   GO; GO:0008305; C:integrin complex; IDA:BHF-UCL.
DR   GO; GO:0031258; C:lamellipodium membrane; IDA:UniProtKB.
DR   GO; GO:0042470; C:melanosome; IDA:UniProtKB.
DR   GO; GO:0031528; C:microvillus membrane; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:MGI.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0031092; C:platelet alpha granule membrane; TAS:Reactome.
DR   GO; GO:0043235; C:receptor complex; IDA:MGI.
DR   GO; GO:0032587; C:ruffle membrane; IDA:UniProtKB.
DR   GO; GO:0050839; F:cell adhesion molecule binding; IPI:BHF-UCL.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0050840; F:extracellular matrix binding; IDA:UniProtKB.
DR   GO; GO:0001968; F:fibronectin binding; IMP:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0005161; F:platelet-derived growth factor receptor binding; TAS:BHF-UCL.
DR   GO; GO:0002020; F:protease binding; IDA:UniProtKB.
DR   GO; GO:0003756; F:protein disulfide isomerase activity; IDA:UniProtKB.
DR   GO; GO:0043184; F:vascular endothelial growth factor receptor 2 binding; IPI:BHF-UCL.
DR   GO; GO:0001618; F:virus receptor activity; IEA:UniProtKB-KW.
DR   GO; GO:0032147; P:activation of protein kinase activity; IMP:BHF-UCL.
DR   GO; GO:0060055; P:angiogenesis involved in wound healing; TAS:BHF-UCL.
DR   GO; GO:0038027; P:apolipoprotein A-I-mediated signaling pathway; IMP:UniProtKB.
DR   GO; GO:0007411; P:axon guidance; TAS:Reactome.
DR   GO; GO:0007596; P:blood coagulation; TAS:Reactome.
DR   GO; GO:0007155; P:cell adhesion; TAS:ProtInc.
DR   GO; GO:0016049; P:cell growth; IMP:UniProtKB.
DR   GO; GO:0016477; P:cell migration; IMP:UniProtKB.
DR   GO; GO:0007160; P:cell-matrix adhesion; IDA:UniProtKB.
DR   GO; GO:0031589; P:cell-substrate adhesion; IMP:UniProtKB.
DR   GO; GO:0007044; P:cell-substrate junction assembly; IEA:InterPro.
DR   GO; GO:0030198; P:extracellular matrix organization; TAS:Reactome.
DR   GO; GO:0034113; P:heterotypic cell-cell adhesion; IMP:UniProtKB.
DR   GO; GO:0007229; P:integrin-mediated signaling pathway; IDA:UniProtKB.
DR   GO; GO:0050900; P:leukocyte migration; TAS:Reactome.
DR   GO; GO:0048333; P:mesodermal cell differentiation; IEP:UniProtKB.
DR   GO; GO:0050919; P:negative chemotaxis; IMP:UniProtKB.
DR   GO; GO:0010888; P:negative regulation of lipid storage; IMP:BHF-UCL.
DR   GO; GO:0032369; P:negative regulation of lipid transport; IMP:BHF-UCL.
DR   GO; GO:0050748; P:negative regulation of lipoprotein metabolic process; IMP:BHF-UCL.
DR   GO; GO:0045715; P:negative regulation of low-density lipoprotein particle receptor biosynthetic process; IMP:BHF-UCL.
DR   GO; GO:0010745; P:negative regulation of macrophage derived foam cell differentiation; IMP:BHF-UCL.
DR   GO; GO:0030168; P:platelet activation; IMP:UniProtKB.
DR   GO; GO:0070527; P:platelet aggregation; IMP:UniProtKB.
DR   GO; GO:0002576; P:platelet degranulation; TAS:Reactome.
DR   GO; GO:0010595; P:positive regulation of endothelial cell migration; IMP:BHF-UCL.
DR   GO; GO:0001938; P:positive regulation of endothelial cell proliferation; IMP:BHF-UCL.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; IMP:BHF-UCL.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; TAS:BHF-UCL.
DR   GO; GO:0030949; P:positive regulation of vascular endothelial growth factor receptor signaling pathway; TAS:BHF-UCL.
DR   GO; GO:0006457; P:protein folding; IDA:GOC.
DR   GO; GO:0045124; P:regulation of bone resorption; TAS:BHF-UCL.
DR   GO; GO:0014909; P:smooth muscle cell migration; IMP:BHF-UCL.
DR   GO; GO:0034446; P:substrate adhesion-dependent cell spreading; IDA:UniProtKB.
DR   GO; GO:0035295; P:tube development; TAS:BHF-UCL.
DR   GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0046718; P:viral entry into host cell; IMP:UniProtKB.
DR   GO; GO:0042060; P:wound healing; IC:BHF-UCL.
DR   Gene3D; 1.20.5.630; -; 1.
DR   Gene3D; 3.40.50.410; -; 1.
DR   InterPro; IPR013111; EGF_extracell.
DR   InterPro; IPR027068; Integrin_beta-3.
DR   InterPro; IPR015812; Integrin_bsu.
DR   InterPro; IPR014836; Integrin_bsu_cyt_dom.
DR   InterPro; IPR002369; Integrin_bsu_N.
DR   InterPro; IPR012896; Integrin_bsu_tail.
DR   InterPro; IPR032695; Integrin_dom.
DR   InterPro; IPR016201; Plexin-like_fold.
DR   InterPro; IPR002035; VWF_A.
DR   PANTHER; PTHR10082; PTHR10082; 1.
DR   PANTHER; PTHR10082:SF25; PTHR10082:SF25; 1.
DR   Pfam; PF07974; EGF_2; 1.
DR   Pfam; PF08725; Integrin_b_cyt; 1.
DR   Pfam; PF07965; Integrin_B_tail; 1.
DR   Pfam; PF00362; Integrin_beta; 1.
DR   PIRSF; PIRSF002512; Integrin_B; 1.
DR   PRINTS; PR01186; INTEGRINB.
DR   SMART; SM00187; INB; 1.
DR   SMART; SM00423; PSI; 1.
DR   SMART; SM00327; VWA; 1.
DR   SUPFAM; SSF103575; SSF103575; 1.
DR   SUPFAM; SSF53300; SSF53300; 1.
DR   SUPFAM; SSF69179; SSF69179; 1.
DR   SUPFAM; SSF69687; SSF69687; 1.
DR   PROSITE; PS00022; EGF_1; 2.
DR   PROSITE; PS01186; EGF_2; 1.
DR   PROSITE; PS00243; INTEGRIN_BETA; 3.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell adhesion; Cell junction;
KW   Cell membrane; Cell projection; Complete proteome;
KW   Direct protein sequencing; Disease mutation; Disulfide bond;
KW   Glycoprotein; Host cell receptor for virus entry;
KW   Host-virus interaction; Integrin; Membrane; Phosphoprotein;
KW   Polymorphism; Receptor; Reference proteome; Repeat; Signal;
KW   Transmembrane; Transmembrane helix.
FT   SIGNAL        1     26       {ECO:0000255}.
FT   CHAIN        27    788       Integrin beta-3.
FT                                /FTId=PRO_0000016344.
FT   TOPO_DOM     27    718       Extracellular. {ECO:0000255}.
FT   TRANSMEM    719    741       Helical. {ECO:0000255}.
FT   TOPO_DOM    742    788       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      135    377       VWFA.
FT   REPEAT      463    511       I.
FT   REPEAT      512    553       II.
FT   REPEAT      554    592       III.
FT   REPEAT      593    629       IV.
FT   REGION      463    629       Cysteine-rich tandem repeats.
FT   MOD_RES     767    767       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:O54890}.
FT   MOD_RES     773    773       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:18088087}.
FT   MOD_RES     779    779       Phosphothreonine; by PDPK1 and PKB/AKT1;
FT                                in vitro. {ECO:0000269|PubMed:10896934}.
FT   MOD_RES     785    785       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:8631894}.
FT   CARBOHYD    125    125       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16263699,
FT                                ECO:0000269|PubMed:16335952}.
FT   CARBOHYD    346    346       N-linked (GlcNAc...). {ECO:0000255,
FT                                ECO:0000269|PubMed:11546839}.
FT   CARBOHYD    397    397       N-linked (GlcNAc...). {ECO:0000255,
FT                                ECO:0000269|PubMed:11546839}.
FT   CARBOHYD    478    478       N-linked (GlcNAc...).
FT   CARBOHYD    585    585       N-linked (GlcNAc...). {ECO:0000255,
FT                                ECO:0000269|PubMed:11546839}.
FT   CARBOHYD    680    680       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:11546839,
FT                                ECO:0000269|PubMed:19159218}.
FT   DISULFID     31    461       {ECO:0000269|PubMed:2001252}.
FT   DISULFID     39     49       {ECO:0000269|PubMed:2001252}.
FT   DISULFID     42     75       {ECO:0000269|PubMed:2001252}.
FT   DISULFID     52     64       {ECO:0000269|PubMed:2001252}.
FT   DISULFID    203    210       {ECO:0000269|PubMed:2001252}.
FT   DISULFID    258    299       {ECO:0000269|PubMed:2001252}.
FT   DISULFID    400    412       {ECO:0000269|PubMed:2001252}.
FT   DISULFID    432    681       {ECO:0000269|PubMed:2001252}.
FT   DISULFID    459    463       {ECO:0000269|PubMed:2001252}.
FT   DISULFID    474    486       {ECO:0000305|PubMed:2001252}.
FT   DISULFID    483    521       {ECO:0000305|PubMed:2001252}.
FT   DISULFID    488    497       {ECO:0000305|PubMed:2001252}.
FT   DISULFID    499    512       {ECO:0000305|PubMed:2001252}.
FT   DISULFID    527    532       {ECO:0000305|PubMed:2001252}.
FT   DISULFID    529    562       {ECO:0000305|PubMed:2001252}.
FT   DISULFID    534    547       {ECO:0000305|PubMed:2001252}.
FT   DISULFID    549    554       {ECO:0000269|PubMed:2001252}.
FT   DISULFID    568    573       {ECO:0000305|PubMed:2001252}.
FT   DISULFID    570    601       {ECO:0000305|PubMed:2001252}.
FT   DISULFID    575    584       {ECO:0000305|PubMed:2001252}.
FT   DISULFID    586    593       {ECO:0000305|PubMed:2001252}.
FT   DISULFID    607    612       {ECO:0000305|PubMed:2001252}.
FT   DISULFID    609    657       {ECO:0000305|PubMed:2001252}.
FT   DISULFID    614    624       {ECO:0000305|PubMed:2001252}.
FT   DISULFID    627    630       {ECO:0000305|PubMed:2001252}.
FT   DISULFID    634    643       {ECO:0000305|PubMed:2001252}.
FT   DISULFID    640    713       {ECO:0000305|PubMed:2001252}.
FT   DISULFID    661    689       {ECO:0000269|PubMed:2001252}.
FT   VAR_SEQ     768    788       ANNPLYKEATSTFTNITYRGT -> VRDGAGRFLKSLV
FT                                (in isoform Beta-3B).
FT                                {ECO:0000303|PubMed:2787511}.
FT                                /FTId=VSP_002745.
FT   VAR_SEQ     768    788       ANNPLYKEATSTFTNITYRGT -> HYAQSLRKWNQPVSID
FT                                G (in isoform Beta-3C).
FT                                {ECO:0000303|PubMed:9195946}.
FT                                /FTId=VSP_002746.
FT   VARIANT      59     59       L -> P (in alloantigen HPA-1B;
FT                                dbSNP:rs5918).
FT                                {ECO:0000269|PubMed:10391209,
FT                                ECO:0000269|PubMed:2565345,
FT                                ECO:0000269|Ref.13}.
FT                                /FTId=VAR_003993.
FT   VARIANT      64     64       C -> Y (in GT; severe type 1 phenotype;
FT                                the mutation prevents normal ITGA2B/ITGB3
FT                                complex expression).
FT                                {ECO:0000269|PubMed:20020534}.
FT                                /FTId=VAR_069920.
FT   VARIANT      66     66       L -> R (in dbSNP:rs36080296).
FT                                {ECO:0000269|Ref.13}.
FT                                /FTId=VAR_049633.
FT   VARIANT     119    119       R -> W (in GT).
FT                                {ECO:0000269|PubMed:12083483}.
FT                                /FTId=VAR_030473.
FT   VARIANT     141    141       Y -> C (in GT).
FT                                {ECO:0000269|PubMed:15748237}.
FT                                /FTId=VAR_030474.
FT   VARIANT     143    143       L -> W (in GT).
FT                                {ECO:0000269|PubMed:9376589}.
FT                                /FTId=VAR_010649.
FT   VARIANT     144    144       M -> R (in GT; severe type 1 phenotype;
FT                                the mutation prevented normal ITGA2B/
FT                                ITGB3 complex expression on the cell
FT                                surface). {ECO:0000269|PubMed:20020534}.
FT                                /FTId=VAR_069921.
FT   VARIANT     145    145       D -> N (in GT).
FT                                {ECO:0000269|PubMed:9215749}.
FT                                /FTId=VAR_030475.
FT   VARIANT     145    145       D -> Y (in GT; type B).
FT                                {ECO:0000269|PubMed:2392682}.
FT                                /FTId=VAR_003998.
FT   VARIANT     150    150       M -> V (in GT; may confer constitutive
FT                                activity to the alpha-IIb/(mutated)beta-3
FT                                receptor). {ECO:0000269|PubMed:15583747}.
FT                                /FTId=VAR_030476.
FT   VARIANT     166    166       T -> I (associated with neonatal
FT                                thrombocytopenia; alloantigen Duv(a+);
FT                                does not affect significantly the
FT                                integrin function).
FT                                {ECO:0000269|PubMed:12036875}.
FT                                /FTId=VAR_030477.
FT   VARIANT     169    169       R -> Q (in alloantigen HPA-4B;
FT                                dbSNP:rs5917).
FT                                {ECO:0000269|PubMed:10391209,
FT                                ECO:0000269|PubMed:1430225}.
FT                                /FTId=VAR_003994.
FT   VARIANT     188    188       S -> L (in GT; type II).
FT                                {ECO:0000269|PubMed:9684783}.
FT                                /FTId=VAR_010651.
FT   VARIANT     222    222       L -> P (in GT; variant form).
FT                                {ECO:0000269|PubMed:11897046,
FT                                ECO:0000269|PubMed:20020534}.
FT                                /FTId=VAR_030478.
FT   VARIANT     240    240       R -> Q (in GT; type B).
FT                                {ECO:0000269|PubMed:1371279}.
FT                                /FTId=VAR_003999.
FT   VARIANT     240    240       R -> W (in GT; variant Strasbourg-1).
FT                                {ECO:0000269|PubMed:1602006}.
FT                                /FTId=VAR_004000.
FT   VARIANT     242    242       R -> Q (in GT).
FT                                {ECO:0000269|PubMed:9215749}.
FT                                /FTId=VAR_030479.
FT   VARIANT     243    243       D -> V (in GT).
FT                                {ECO:0000269|PubMed:12083483}.
FT                                /FTId=VAR_030480.
FT   VARIANT     247    247       G -> D (in GT; severe type 1 phenotype;
FT                                the mutation prevents normal ITGA2B/ITGB3
FT                                complex expression on the cell surface;
FT                                the mutation may interfere with correct
FT                                folding of the protein).
FT                                {ECO:0000269|PubMed:20020534}.
FT                                /FTId=VAR_069922.
FT   VARIANT     279    279       K -> M (in GT; severe type 1 phenotype;
FT                                the mutation prevents normal ITGA2B/ITGB3
FT                                complex expression on the cell surface;
FT                                the mutation interupts the interaction of
FT                                the ITGA2B/ITGB3 complex).
FT                                {ECO:0000269|PubMed:20020534}.
FT                                /FTId=VAR_069923.
FT   VARIANT     288    288       L -> P (in GT).
FT                                {ECO:0000269|PubMed:9215749}.
FT                                /FTId=VAR_030481.
FT   VARIANT     306    306       H -> P (in GT; dbSNP:rs13306476).
FT                                {ECO:0000269|PubMed:15634267,
FT                                ECO:0000269|PubMed:9790984}.
FT                                /FTId=VAR_004001.
FT   VARIANT     321    321       M -> L (in GT).
FT                                {ECO:0000269|PubMed:15748237}.
FT                                /FTId=VAR_030482.
FT   VARIANT     330    330       I -> N (in GT; not expressed on the
FT                                surface and absent inside the transfected
FT                                cells). {ECO:0000269|PubMed:15634267}.
FT                                /FTId=VAR_030483.
FT   VARIANT     400    400       C -> Y (in GT).
FT                                {ECO:0000269|PubMed:8781422}.
FT                                /FTId=VAR_004002.
FT   VARIANT     433    433       P -> A (in alloantigen MO(+); in a case
FT                                of neonatal alloimmune thrombocytopenia;
FT                                dbSNP:rs121918448).
FT                                {ECO:0000269|PubMed:8093349}.
FT                                /FTId=VAR_003995.
FT   VARIANT     453    453       V -> I (in dbSNP:rs5921).
FT                                {ECO:0000269|PubMed:10391209}.
FT                                /FTId=VAR_014178.
FT   VARIANT     515    515       R -> Q (in alloantigen CA(+)/TU(+);
FT                                dbSNP:rs13306487).
FT                                {ECO:0000269|PubMed:7694683}.
FT                                /FTId=VAR_003996.
FT   VARIANT     532    532       C -> Y (in GT).
FT                                {ECO:0000269|PubMed:12353082}.
FT                                /FTId=VAR_030484.
FT   VARIANT     568    568       C -> R (in GT; type I).
FT                                {ECO:0000269|PubMed:10233432}.
FT                                /FTId=VAR_010671.
FT   VARIANT     586    586       C -> F (in GT).
FT                                {ECO:0000269|PubMed:9790984}.
FT                                /FTId=VAR_004003.
FT   VARIANT     586    586       C -> R (in GT; gain-of-function mutation;
FT                                constitutively binds ligand-induced
FT                                binding sites antibodies and the
FT                                fibrinogen-mimetic antibody PAC-1).
FT                                {ECO:0000269|PubMed:11588040}.
FT                                /FTId=VAR_030485.
FT   VARIANT     598    598       G -> S (in GT).
FT                                {ECO:0000269|PubMed:9790984}.
FT                                /FTId=VAR_004004.
FT   VARIANT     601    601       C -> R (in GT).
FT                                {ECO:0000269|PubMed:12083483}.
FT                                /FTId=VAR_030486.
FT   VARIANT     605    605       G -> S (in GT; type II).
FT                                {ECO:0000269|PubMed:9790984}.
FT                                /FTId=VAR_010672.
FT   VARIANT     662    662       R -> C (in alloantigen SR(A);
FT                                dbSNP:rs151219882).
FT                                {ECO:0000269|PubMed:8132570}.
FT                                /FTId=VAR_003997.
FT   VARIANT     749    749       D -> H (in BDPLT16; the mutant protein is
FT                                constitutively active).
FT                                {ECO:0000269|PubMed:18065693}.
FT                                /FTId=VAR_069924.
FT   VARIANT     778    778       S -> P (in GT; variant Strasbourg-1).
FT                                {ECO:0000269|PubMed:1438206}.
FT                                /FTId=VAR_004005.
FT   CONFLICT     12     12       A -> V (in Ref. 1; AAA52589 and 3;
FT                                AAA35927). {ECO:0000305}.
FT   CONFLICT    151    151       K -> P (in Ref. 11; AAA67537 and 14;
FT                                AAB23689). {ECO:0000305}.
FT   CONFLICT    205    205       D -> EY (in Ref. 11; AAA67537).
FT                                {ECO:0000305}.
FT   CONFLICT    649    653       GALHD -> EPYMT (in Ref. 1; AAA52589, 2;
FT                                AAA60122 and 4; AAB71380). {ECO:0000305}.
FT   CONFLICT    716    716       G -> H (in Ref. 8). {ECO:0000305}.
FT   CONFLICT    737    741       ALLIW -> PCSSG (in Ref. 11; AAA67537).
FT                                {ECO:0000305}.
FT   HELIX        30     33       {ECO:0000244|PDB:3T3P}.
FT   HELIX        35     37       {ECO:0000244|PDB:4MMX}.
FT   HELIX        39     45       {ECO:0000244|PDB:3T3P}.
FT   STRAND       50     52       {ECO:0000244|PDB:3T3P}.
FT   STRAND       54     57       {ECO:0000244|PDB:3IJE}.
FT   STRAND       59     61       {ECO:0000244|PDB:2VDO}.
FT   STRAND       63     65       {ECO:0000244|PDB:3T3P}.
FT   HELIX        67     72       {ECO:0000244|PDB:3T3P}.
FT   HELIX        77     79       {ECO:0000244|PDB:3T3P}.
FT   STRAND       86     91       {ECO:0000244|PDB:3T3P}.
FT   STRAND       99    101       {ECO:0000244|PDB:3T3P}.
FT   HELIX       103    105       {ECO:0000244|PDB:3ZE2}.
FT   STRAND      109    111       {ECO:0000244|PDB:3NID}.
FT   STRAND      113    118       {ECO:0000244|PDB:3T3P}.
FT   STRAND      123    131       {ECO:0000244|PDB:3T3P}.
FT   STRAND      138    145       {ECO:0000244|PDB:3T3P}.
FT   HELIX       148    150       {ECO:0000244|PDB:3T3P}.
FT   HELIX       151    156       {ECO:0000244|PDB:3T3P}.
FT   TURN        157    159       {ECO:0000244|PDB:3T3P}.
FT   HELIX       160    168       {ECO:0000244|PDB:3T3P}.
FT   TURN        169    171       {ECO:0000244|PDB:3T3P}.
FT   STRAND      175    182       {ECO:0000244|PDB:3T3P}.
FT   TURN        188    190       {ECO:0000244|PDB:3T3P}.
FT   HELIX       196    200       {ECO:0000244|PDB:3T3P}.
FT   TURN        202    207       {ECO:0000244|PDB:3T3P}.
FT   STRAND      215    224       {ECO:0000244|PDB:3T3P}.
FT   HELIX       226    235       {ECO:0000244|PDB:3T3P}.
FT   STRAND      242    246       {ECO:0000244|PDB:3T3P}.
FT   HELIX       248    257       {ECO:0000244|PDB:3T3P}.
FT   HELIX       259    262       {ECO:0000244|PDB:3T3P}.
FT   STRAND      266    278       {ECO:0000244|PDB:3T3P}.
FT   HELIX       285    289       {ECO:0000244|PDB:3T3P}.
FT   STRAND      305    307       {ECO:0000244|PDB:1TYE}.
FT   TURN        308    312       {ECO:0000244|PDB:3T3P}.
FT   HELIX       318    327       {ECO:0000244|PDB:3T3P}.
FT   STRAND      331    336       {ECO:0000244|PDB:3T3P}.
FT   HELIX       338    340       {ECO:0000244|PDB:3T3P}.
FT   HELIX       341    349       {ECO:0000244|PDB:3T3P}.
FT   STRAND      355    358       {ECO:0000244|PDB:3T3P}.
FT   TURN        361    363       {ECO:0000244|PDB:3ZE2}.
FT   HELIX       366    377       {ECO:0000244|PDB:3T3P}.
FT   STRAND      381    387       {ECO:0000244|PDB:3T3P}.
FT   STRAND      392    400       {ECO:0000244|PDB:3T3P}.
FT   TURN        401    403       {ECO:0000244|PDB:3T3P}.
FT   STRAND      404    407       {ECO:0000244|PDB:3T3P}.
FT   STRAND      411    415       {ECO:0000244|PDB:2VDR}.
FT   STRAND      420    429       {ECO:0000244|PDB:3T3P}.
FT   STRAND      434    444       {ECO:0000244|PDB:3T3P}.
FT   STRAND      451    457       {ECO:0000244|PDB:3T3P}.
FT   HELIX       462    466       {ECO:0000244|PDB:3T3P}.
FT   STRAND      468    470       {ECO:0000244|PDB:3NID}.
FT   TURN        472    478       {ECO:0000244|PDB:3T3P}.
FT   STRAND      479    482       {ECO:0000244|PDB:3T3P}.
FT   STRAND      485    488       {ECO:0000244|PDB:3T3P}.
FT   STRAND      489    491       {ECO:0000244|PDB:3IJE}.
FT   TURN        494    497       {ECO:0000244|PDB:3FCS}.
FT   STRAND      500    504       {ECO:0000244|PDB:3IJE}.
FT   STRAND      513    518       {ECO:0000244|PDB:3FCS}.
FT   HELIX       520    523       {ECO:0000244|PDB:3FCS}.
FT   STRAND      524    527       {ECO:0000244|PDB:3FCS}.
FT   STRAND      529    534       {ECO:0000244|PDB:3FCS}.
FT   STRAND      538    540       {ECO:0000244|PDB:4G1M}.
FT   STRAND      542    544       {ECO:0000244|PDB:3IJE}.
FT   STRAND      549    552       {ECO:0000244|PDB:3IJE}.
FT   STRAND      556    561       {ECO:0000244|PDB:3FCS}.
FT   HELIX       562    564       {ECO:0000244|PDB:3FCS}.
FT   STRAND      565    569       {ECO:0000244|PDB:3FCS}.
FT   STRAND      572    575       {ECO:0000244|PDB:3FCS}.
FT   STRAND      579    584       {ECO:0000244|PDB:3FCS}.
FT   TURN        591    593       {ECO:0000244|PDB:3FCS}.
FT   STRAND      598    600       {ECO:0000244|PDB:3FCS}.
FT   STRAND      602    604       {ECO:0000244|PDB:3FCS}.
FT   STRAND      606    608       {ECO:0000244|PDB:3FCS}.
FT   STRAND      611    613       {ECO:0000244|PDB:3FCS}.
FT   TURN        616    618       {ECO:0000244|PDB:3IJE}.
FT   STRAND      620    624       {ECO:0000244|PDB:1U8C}.
FT   STRAND      628    630       {ECO:0000244|PDB:4G1E}.
FT   TURN        633    635       {ECO:0000244|PDB:3FCS}.
FT   HELIX       639    641       {ECO:0000244|PDB:3FCS}.
FT   TURN        642    646       {ECO:0000244|PDB:3FCS}.
FT   STRAND      649    655       {ECO:0000244|PDB:3FCS}.
FT   TURN        658    660       {ECO:0000244|PDB:3FCS}.
FT   STRAND      664    666       {ECO:0000244|PDB:3FCS}.
FT   STRAND      669    671       {ECO:0000244|PDB:1M1X}.
FT   STRAND      674    678       {ECO:0000244|PDB:3FCS}.
FT   STRAND      680    684       {ECO:0000244|PDB:3FCS}.
FT   STRAND      688    694       {ECO:0000244|PDB:3FCS}.
FT   STRAND      698    700       {ECO:0000244|PDB:3FCS}.
FT   STRAND      704    706       {ECO:0000244|PDB:3FCS}.
FT   STRAND      707    710       {ECO:0000244|PDB:1U8C}.
FT   STRAND      715    717       {ECO:0000244|PDB:2KNC}.
FT   TURN        743    759       {ECO:0000244|PDB:1KUP}.
FT   TURN        761    765       {ECO:0000244|PDB:1KUP}.
FT   STRAND      767    770       {ECO:0000244|PDB:1S4X}.
FT   HELIX       771    774       {ECO:0000244|PDB:1MK7}.
FT   HELIX       776    779       {ECO:0000244|PDB:2LJD}.
FT   TURN        782    786       {ECO:0000244|PDB:1S4X}.
SQ   SEQUENCE   788 AA;  87058 MW;  F246623608E05F9E CRC64;
     MRARPRPRPL WATVLALGAL AGVGVGGPNI CTTRGVSSCQ QCLAVSPMCA WCSDEALPLG
     SPRCDLKENL LKDNCAPESI EFPVSEARVL EDRPLSDKGS GDSSQVTQVS PQRIALRLRP
     DDSKNFSIQV RQVEDYPVDI YYLMDLSYSM KDDLWSIQNL GTKLATQMRK LTSNLRIGFG
     AFVDKPVSPY MYISPPEALE NPCYDMKTTC LPMFGYKHVL TLTDQVTRFN EEVKKQSVSR
     NRDAPEGGFD AIMQATVCDE KIGWRNDASH LLVFTTDAKT HIALDGRLAG IVQPNDGQCH
     VGSDNHYSAS TTMDYPSLGL MTEKLSQKNI NLIFAVTENV VNLYQNYSEL IPGTTVGVLS
     MDSSNVLQLI VDAYGKIRSK VELEVRDLPE ELSLSFNATC LNNEVIPGLK SCMGLKIGDT
     VSFSIEAKVR GCPQEKEKSF TIKPVGFKDS LIVQVTFDCD CACQAQAEPN SHRCNNGNGT
     FECGVCRCGP GWLGSQCECS EEDYRPSQQD ECSPREGQPV CSQRGECLCG QCVCHSSDFG
     KITGKYCECD DFSCVRYKGE MCSGHGQCSC GDCLCDSDWT GYYCNCTTRT DTCMSSNGLL
     CSGRGKCECG SCVCIQPGSY GDTCEKCPTC PDACTFKKEC VECKKFDRGA LHDENTCNRY
     CRDEIESVKE LKDTGKDAVN CTYKNEDDCV VRFQYYEDSS GKSILYVVEE PECPKGPDIL
     VVLLSVMGAI LLIGLAALLI WKLLITIHDR KEFAKFEEER ARAKWDTANN PLYKEATSTF
     TNITYRGT
//
ID   TIE2_HUMAN              Reviewed;        1124 AA.
AC   Q02763; A8K6W0; B4DH20; B4DHD3; D3DRK5; E7EWI2; Q5TCU2; Q8IV34;
DT   01-FEB-1994, integrated into UniProtKB/Swiss-Prot.
DT   16-DEC-2008, sequence version 2.
DT   17-FEB-2016, entry version 183.
DE   RecName: Full=Angiopoietin-1 receptor;
DE            EC=2.7.10.1;
DE   AltName: Full=Endothelial tyrosine kinase;
DE   AltName: Full=Tunica interna endothelial cell kinase;
DE   AltName: Full=Tyrosine kinase with Ig and EGF homology domains-2;
DE   AltName: Full=Tyrosine-protein kinase receptor TEK;
DE   AltName: Full=Tyrosine-protein kinase receptor TIE-2;
DE            Short=hTIE2;
DE   AltName: Full=p140 TEK;
DE   AltName: CD_antigen=CD202b;
DE   Flags: Precursor;
GN   Name=TEK; Synonyms=TIE2, VMCM, VMCM1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), CATALYTIC ACTIVITY, TISSUE
RP   SPECIFICITY, AND VARIANT PRO-346.
RC   TISSUE=Placenta;
RX   PubMed=8382358;
RA   Ziegler S.F., Bird T.A., Schneringer J.A., Schooley K.A., Baum P.R.;
RT   "Molecular cloning and characterization of a novel receptor protein
RT   tyrosine kinase from human placenta.";
RL   Oncogene 8:663-670(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2 AND 3), AND
RP   VARIANT PRO-346.
RC   TISSUE=Brain, and Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E.,
RA   Howe K.L., Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Ashwell R.I.S.,
RA   Babbage A.K., Babbage S., Bagguley C.L., Bailey J., Banerjee R.,
RA   Barker D.J., Barlow K.F., Bates K., Beasley H., Beasley O., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burford D., Burrill W.,
RA   Burton J., Carder C., Carter N.P., Chapman J.C., Chen Y., Clarke G.,
RA   Clark S.Y., Clee C.M., Clegg S., Collier R.E., Corby N., Crosier M.,
RA   Cummings A.T., Davies J., Dhami P., Dunn M., Dutta I., Dyer L.W.,
RA   Earthrowl M.E., Faulkner L., Fleming C.J., Frankish A.,
RA   Frankland J.A., French L., Fricker D.G., Garner P., Garnett J.,
RA   Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M.,
RA   Lovell J., Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S.,
RA   McLay K.E., McMurray A., Milne S., Nickerson T., Nisbett J.,
RA   Nordsiek G., Pearce A.V., Peck A.I., Porter K.M., Pandian R.,
RA   Pelan S., Phillimore B., Povey S., Ramsey Y., Rand V., Scharfe M.,
RA   Sehra H.K., Shownkeen R., Sims S.K., Skuce C.D., Smith M.,
RA   Steward C.A., Swarbreck D., Sycamore N., Tester J., Thorpe A.,
RA   Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Williams S.A., Wilming L., Wray P.W.,
RA   Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S.,
RA   Rogers J., Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT PRO-346.
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   PRO-346.
RC   TISSUE=Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PROTEIN SEQUENCE OF 23-37.
RX   PubMed=15340161; DOI=10.1110/ps.04682504;
RA   Zhang Z., Henzel W.J.;
RT   "Signal peptide prediction based on analysis of experimentally
RT   verified cleavage sites.";
RL   Protein Sci. 13:2819-2824(2004).
RN   [7]
RP   FUNCTION AS RECEPTOR FOR ANGPT1 AND ANGPT2, INTERACTION WITH ANGPT1
RP   AND ANGPT2, AND AUTOPHOSPHORYLATION.
RX   PubMed=9204896; DOI=10.1126/science.277.5322.55;
RA   Maisonpierre P.C., Suri C., Jones P.F., Bartunkova S., Wiegand S.J.,
RA   Radziejewski C., Compton D.L., McClain J., Aldrich T.H.,
RA   Papadopoulos N., Daly T.J., Davis S., Sato T.N., Yancopoulos G.D.;
RT   "Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo
RT   angiogenesis.";
RL   Science 277:55-60(1997).
RN   [8]
RP   SUBCELLULAR LOCATION, PROTEOLYTIC PROCESSING, AND TISSUE SPECIFICITY.
RX   PubMed=11806244; DOI=10.1023/A:1012226627813;
RA   Reusch P., Barleon B., Weindel K., Martiny-Baron G., Godde A.,
RA   Siemeister G., Marme D.;
RT   "Identification of a soluble form of the angiopoietin receptor TIE-2
RT   released from endothelial cells and present in human blood.";
RL   Angiogenesis 4:123-131(2001).
RN   [9]
RP   CATALYTIC ACTIVITY, ENZYME REGULATION, IDENTIFICATION BY MASS
RP   SPECTROMETRY, AND PHOSPHORYLATION AT TYR-860; TYR-992 AND TYR-1108.
RX   PubMed=11513602; DOI=10.1021/bi010959e;
RA   Murray B.W., Padrique E.S., Pinko C., McTigue M.A.;
RT   "Mechanistic effects of autophosphorylation on receptor tyrosine
RT   kinase catalysis: enzymatic characterization of Tie2 and phospho-
RT   Tie2.";
RL   Biochemistry 40:10243-10253(2001).
RN   [10]
RP   FUNCTION IN REGULATION OF PHOSPHATIDYLINOSITOL 3-KINASE ACTIVITY;
RP   ENDOTHELIAL CELL MIGRATION AND REORGANIZATION OF THE ACTIN
RP   CYTOSKELETON.
RX   PubMed=12816861; DOI=10.1182/blood-2003-03-0670;
RA   Cascone I., Audero E., Giraudo E., Napione L., Maniero F.,
RA   Philips M.R., Collard J.G., Serini G., Bussolino F.;
RT   "Tie-2-dependent activation of RhoA and Rac1 participates in
RT   endothelial cell motility triggered by angiopoietin-1.";
RL   Blood 102:2482-2490(2003).
RN   [11]
RP   INTERACTION WITH TNIP2, AUTOPHOSPHORYLATION, CATALYTIC ACTIVITY, AND
RP   MUTAGENESIS OF LYS-855.
RX   PubMed=12609966; DOI=10.1161/01.RES.0000063422.38690.DC;
RA   Hughes D.P., Marron M.B., Brindle N.P.;
RT   "The antiinflammatory endothelial tyrosine kinase Tie2 interacts with
RT   a novel nuclear factor-kappaB inhibitor ABIN-2.";
RL   Circ. Res. 92:630-636(2003).
RN   [12]
RP   FUNCTION IN REGULATION OF ANGIOGENESIS; CELL SURVIVAL; CELL MIGRATION
RP   AND ACTIVATION OF AKT1, DOMAIN, AND INTERACTION WITH ANGPT1; ANGPT2
RP   AND ANGPT4.
RX   PubMed=15284220; DOI=10.1096/fj.03-1466com;
RA   Lee H.J., Cho C.H., Hwang S.J., Choi H.H., Kim K.T., Ahn S.Y.,
RA   Kim J.H., Oh J.L., Lee G.M., Koh G.Y.;
RT   "Biological characterization of angiopoietin-3 and angiopoietin-4.";
RL   FASEB J. 18:1200-1208(2004).
RN   [13]
RP   FUNCTION AS ANGPT1 RECEPTOR IN PHOSPHORYLATION OF SHC1 AND PIK3R1;
RP   REGULATION OF CELL MIGRATION AND ANGIOGENESIS, AUTOPHOSPHORYLATION,
RP   MUTAGENESIS OF TYR-1102, PHOSPHORYLATION AT TYR-1102, CATALYTIC
RP   ACTIVITY, AND INTERACTION WITH SHC1.
RX   PubMed=14665640; DOI=10.1074/jbc.M307456200;
RA   Audero E., Cascone I., Maniero F., Napione L., Arese M.,
RA   Lanfrancone L., Bussolino F.;
RT   "Adaptor ShcA protein binds tyrosine kinase Tie2 receptor and
RT   regulates migration and sprouting but not survival of endothelial
RT   cells.";
RL   J. Biol. Chem. 279:13224-13233(2004).
RN   [14]
RP   INTERACTION WITH TIE1, SUBCELLULAR LOCATION, FUNCTION AS RECEPTOR FOR
RP   ANGPT1 IN PHOSPHORYLATION OF TIE1, AUTOPHOSPHORYLATION, CATALYTIC
RP   ACTIVITY, AND MUTAGENESIS OF LYS-855.
RX   PubMed=15851516; DOI=10.1083/jcb.200411105;
RA   Saharinen P., Kerkela K., Ekman N., Marron M., Brindle N., Lee G.M.,
RA   Augustin H., Koh G.Y., Alitalo K.;
RT   "Multiple angiopoietin recombinant proteins activate the Tie1 receptor
RT   tyrosine kinase and promote its interaction with Tie2.";
RL   J. Cell Biol. 169:239-243(2005).
RN   [15]
RP   FUNCTION AS ANGPT1 RECEPTOR IN ACTIVATION OF AKT1 OR MAPK1/ERK2 AND
RP   MAPK3/ERK1; REGULATION OF ENDOTHELIAL CELL MIGRATION AND CELL
RP   SPREADING, AND SUBCELLULAR LOCATION.
RX   PubMed=18425120; DOI=10.1038/ncb1714;
RA   Fukuhara S., Sako K., Minami T., Noda K., Kim H.Z., Kodama T.,
RA   Shibuya M., Takakura N., Koh G.Y., Mochizuki N.;
RT   "Differential function of Tie2 at cell-cell contacts and cell-
RT   substratum contacts regulated by angiopoietin-1.";
RL   Nat. Cell Biol. 10:513-526(2008).
RN   [16]
RP   FUNCTION AS ANGPT1 RECEPTOR IN ACTIVATION OF AKT1 OR MAPK1/ERK2 AND
RP   MAPK3/ERK1; REGULATION OF ENDOTHELIAL CELL MIGRATION AND REGULATION OF
RP   FOCAL ADHESION ASSEMBLY, INTERACTION WITH TIE1, AUTOPHOSPHORYLATION,
RP   AND SUBCELLULAR LOCATION.
RX   PubMed=18425119; DOI=10.1038/ncb1715;
RA   Saharinen P., Eklund L., Miettinen J., Wirkkala R., Anisimov A.,
RA   Winderlich M., Nottebaum A., Vestweber D., Deutsch U., Koh G.Y.,
RA   Olsen B.R., Alitalo K.;
RT   "Angiopoietins assemble distinct Tie2 signalling complexes in
RT   endothelial cell-cell and cell-matrix contacts.";
RL   Nat. Cell Biol. 10:527-537(2008).
RN   [17]
RP   PHOSPHORYLATION, AND DEPHOSPHORYLATION BY PTPRB.
RX   PubMed=19116766; DOI=10.1007/s10456-008-9126-0;
RA   Yacyshyn O.K., Lai P.F.H., Forse K., Teichert-Kuliszewska K.,
RA   Jurasz P., Stewart D.J.;
RT   "Tyrosine phosphatase beta regulates angiopoietin-Tie2 signaling in
RT   human endothelial cells.";
RL   Angiogenesis 12:25-33(2009).
RN   [18]
RP   INTERACTION WITH CBL, SUBCELLULAR LOCATION, AND UBIQUITINATION.
RX   PubMed=19689429; DOI=10.1042/BJ20091010;
RA   Wehrle C., Van Slyke P., Dumont D.J.;
RT   "Angiopoietin-1-induced ubiquitylation of Tie2 by c-Cbl is required
RT   for internalization and degradation.";
RL   Biochem. J. 423:375-380(2009).
RN   [19]
RP   INTERACTION WITH PTPRB.
RX   PubMed=19451274; DOI=10.1083/jcb.200811159;
RA   Winderlich M., Keller L., Cagna G., Broermann A., Kamenyeva O.,
RA   Kiefer F., Deutsch U., Nottebaum A.F., Vestweber D.;
RT   "VE-PTP controls blood vessel development by balancing Tie-2
RT   activity.";
RL   J. Cell Biol. 185:657-671(2009).
RN   [20]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-596.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [21]
RP   FUNCTION AS RECEPTOR FOR ANGPT1 AND ANGPT2 IN ACTIVATION OF
RP   PHOSPHATIDYLINOSITOL 3-KINASE AND AKT1; STIMULATION OF ENDOTHELIAL
RP   CELL SURVIVAL AND MIGRATION, CATALYTIC ACTIVITY, AND
RP   AUTOPHOSPHORYLATION.
RX   PubMed=19223473; DOI=10.1128/MCB.01472-08;
RA   Yuan H.T., Khankin E.V., Karumanchi S.A., Parikh S.M.;
RT   "Angiopoietin 2 is a partial agonist/antagonist of Tie2 signaling in
RT   the endothelium.";
RL   Mol. Cell. Biol. 29:2011-2022(2009).
RN   [22]
RP   REVIEW ON FUNCTION; INTERACTION WITH EFFECTOR AND SCAFFOLDING
RP   PROTEINS, AND ROLE IN DISEASE.
RX   PubMed=18366015;
RA   Martin V., Liu D., Fueyo J., Gomez-Manzano C.;
RT   "Tie2: a journey from normal angiogenesis to cancer and beyond.";
RL   Histol. Histopathol. 23:773-780(2008).
RN   [23]
RP   REVIEW ON SUBCELLULAR LOCATION AND CONTEXT-SPECIFIC SIGNALING.
RX   PubMed=19293632; DOI=10.3858/emm.2009.41.3.016;
RA   Fukuhara S., Sako K., Noda K., Nagao K., Miura K., Mochizuki N.;
RT   "Tie2 is tied at the cell-cell contacts and to extracellular matrix by
RT   angiopoietin-1.";
RL   Exp. Mol. Med. 41:133-139(2009).
RN   [24]
RP   REVIEW.
RX   PubMed=19234476; DOI=10.1038/nrm2639;
RA   Augustin H.G., Koh G.Y., Thurston G., Alitalo K.;
RT   "Control of vascular morphogenesis and homeostasis through the
RT   angiopoietin-Tie system.";
RL   Nat. Rev. Mol. Cell Biol. 10:165-177(2009).
RN   [25]
RP   REVIEW.
RX   PubMed=20054809;
RA   Fukuhara S., Sako K., Noda K., Zhang J., Minami M., Mochizuki N.;
RT   "Angiopoietin-1/Tie2 receptor signaling in vascular quiescence and
RT   angiogenesis.";
RL   Histol. Histopathol. 25:387-396(2010).
RN   [26]
RP   REVIEW ON SIGNALING, ENZYME REGULATION, AND ROLE IN DISEASE.
RX   PubMed=20651738; DOI=10.1038/nrc2894;
RA   Huang H., Bhat A., Woodnutt G., Lappe R.;
RT   "Targeting the ANGPT-TIE2 pathway in malignancy.";
RL   Nat. Rev. Cancer 10:575-585(2010).
RN   [27]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 808-1124, ACTIVE SITE, ENZYME
RP   REGULATION, AND PREDICTION OF ATP-BINDING REGION.
RX   PubMed=11080633; DOI=10.1016/S0969-2126(00)00516-5;
RA   Shewchuk L.M., Hassell A.M., Ellis B., Holmes W.D., Davis R.,
RA   Horne E.L., Kadwell S.H., McKee D.D., Moore J.T.;
RT   "Structure of the Tie2 RTK domain: self-inhibition by the nucleotide
RT   binding loop, activation loop, and C-terminal tail.";
RL   Structure 8:1105-1113(2000).
RN   [28]
RP   X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 23-445 ALONE AND IN COMPLEX
RP   WITH ANGPT2, GLYCOSYLATION AT ASN-140, AND DISULFIDE BONDS.
RX   PubMed=16732286; DOI=10.1038/nsmb1101;
RA   Barton W.A., Tzvetkova-Robev D., Miranda E.P., Kolev M.V.,
RA   Rajashankar K.R., Himanen J.P., Nikolov D.B.;
RT   "Crystal structures of the Tie2 receptor ectodomain and the
RT   angiopoietin-2-Tie2 complex.";
RL   Nat. Struct. Mol. Biol. 13:524-532(2006).
RN   [29]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 808-1124 IN COMPLEX WITH
RP   TRIAZINE DERIVATIVE, AND ENZYME REGULATION.
RX   PubMed=17350837; DOI=10.1016/j.bmcl.2007.02.067;
RA   Hodous B.L., Geuns-Meyer S.D., Hughes P.E., Albrecht B.K., Bellon S.,
RA   Caenepeel S., Cee V.J., Chaffee S.C., Emery M., Fretland J.,
RA   Gallant P., Gu Y., Johnson R.E., Kim J.L., Long A.M., Morrison M.,
RA   Olivieri P.R., Patel V.F., Polverino A., Rose P., Wang L., Zhao H.;
RT   "Synthesis, structural analysis, and SAR studies of triazine
RT   derivatives as potent, selective Tie-2 inhibitors.";
RL   Bioorg. Med. Chem. Lett. 17:2886-2889(2007).
RN   [30]
RP   X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 808-1124 IN COMPLEX WITH
RP   TRIAZINE DERIVATIVE, AND ENZYME REGULATION.
RX   PubMed=17253678; DOI=10.1021/jm061107l;
RA   Hodous B.L., Geuns-Meyer S.D., Hughes P.E., Albrecht B.K., Bellon S.,
RA   Bready J., Caenepeel S., Cee V.J., Chaffee S.C., Coxon A., Emery M.,
RA   Fretland J., Gallant P., Gu Y., Hoffman D., Johnson R.E., Kendall R.,
RA   Kim J.L., Long A.M., Morrison M., Olivieri P.R., Patel V.F.,
RA   Polverino A., Rose P., Tempest P., Wang L., Whittington D.A., Zhao H.;
RT   "Evolution of a highly selective and potent 2-(pyridin-2-yl)-1,3,5-
RT   triazine Tie-2 kinase inhibitor.";
RL   J. Med. Chem. 50:611-626(2007).
RN   [31]
RP   X-RAY CRYSTALLOGRAPHY (2.95 ANGSTROMS) OF 802-1124 IN COMPLEX WITH
RP   THIAZOLOPYRIMIDINE DERIVATIVE, AND ENZYME REGULATION.
RX   PubMed=19854647; DOI=10.1016/j.bmcl.2009.10.001;
RA   Luke R.W., Ballard P., Buttar D., Campbell L., Curwen J., Emery S.C.,
RA   Griffen A.M., Hassall L., Hayter B.R., Jones C.D., McCoull W.,
RA   Mellor M., Swain M.L., Tucker J.A.;
RT   "Novel thienopyrimidine and thiazolopyrimidine kinase inhibitors with
RT   activity against Tie-2 in vitro and in vivo.";
RL   Bioorg. Med. Chem. Lett. 19:6670-6674(2009).
RN   [32]
RP   X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS) OF 808-1124 IN COMPLEX WITH
RP   CEP11207.
RA   Fedorov A.A., Fedorov E.V., Pauletti D., Meyer S.L., Hudkins R.L.,
RA   Almo S.C.;
RT   "Crystal structure of cytoplasmic kinase domain of Tie2 complexed with
RT   inhibitor CEP11207.";
RL   Submitted (JAN-2010) to the PDB data bank.
RN   [33]
RP   VARIANT VMCM TRP-849.
RX   PubMed=8980225; DOI=10.1016/S0092-8674(00)81814-0;
RA   Vikkula M., Boon L.M., Carraway K.L. III, Calvert J.T., Diamonti A.J.,
RA   Goumnerov B., Pasyk K.A., Marchuk D.A., Warman M.L., Cantley L.C.,
RA   Mulliken J.B., Olse B.R.;
RT   "Vascular dysmorphogenesis caused by an activating mutation in the
RT   receptor tyrosine kinase TIE2.";
RL   Cell 87:1181-1190(1996).
RN   [34]
RP   VARIANTS VMCM TRP-849 AND SER-897.
RX   PubMed=10369874; DOI=10.1093/hmg/8.7.1279;
RA   Calvert J.T., Riney T.J., Kontos C.D., Cha E.H., Prieto V.G.,
RA   Shea C.R., Berg J.N., Nevin N.C., Simpson S.A., Pasyk K.A.,
RA   Speer M.C., Peters K.G., Marchuk D.A.;
RT   "Allelic and locus heterogeneity in inherited venous malformations.";
RL   Hum. Mol. Genet. 8:1279-1289(1999).
RN   [35]
RP   VARIANT [LARGE SCALE ANALYSIS] ASN-117.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
RN   [36]
RP   VARIANTS [LARGE SCALE ANALYSIS] ASN-117; THR-148; VAL-226; ILE-486;
RP   LEU-600; PHE-634; ILE-676; THR-724; ALA-883 AND VAL-1124.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [37]
RP   VARIANTS VMCM TRP-849; CYS-897; HIS-915; CYS-918; LEU-919; SER-925 AND
RP   ASN-1100, AND CHARACTERIZATION OF VARIANTS VMCM TRP-849; SER-897;
RP   HIS-915; CYS-918; LEU-919; SER-925 AND ASN-1100.
RX   PubMed=19888299; DOI=10.1038/ejhg.2009.193;
RA   Wouters V., Limaye N., Uebelhoer M., Irrthum A., Boon L.M.,
RA   Mulliken J.B., Enjolras O., Baselga E., Berg J., Dompmartin A.,
RA   Ivarsson S.A., Kangesu L., Lacassie Y., Murphy J., Teebi A.S.,
RA   Penington A., Rieu P., Vikkula M.;
RT   "Hereditary cutaneomucosal venous malformations are caused by TIE2
RT   mutations with widely variable hyper-phosphorylating effects.";
RL   Eur. J. Hum. Genet. 18:414-420(2010).
CC   -!- FUNCTION: Tyrosine-protein kinase that acts as cell-surface
CC       receptor for ANGPT1, ANGPT2 and ANGPT4 and regulates angiogenesis,
CC       endothelial cell survival, proliferation, migration, adhesion and
CC       cell spreading, reorganization of the actin cytoskeleton, but also
CC       maintenance of vascular quiescence. Has anti-inflammatory effects
CC       by preventing the leakage of proinflammatory plasma proteins and
CC       leukocytes from blood vessels. Required for normal angiogenesis
CC       and heart development during embryogenesis. Required for post-
CC       natal hematopoiesis. After birth, activates or inhibits
CC       angiogenesis, depending on the context. Inhibits angiogenesis and
CC       promotes vascular stability in quiescent vessels, where
CC       endothelial cells have tight contacts. In quiescent vessels,
CC       ANGPT1 oligomers recruit TEK to cell-cell contacts, forming
CC       complexes with TEK molecules from adjoining cells, and this leads
CC       to preferential activation of phosphatidylinositol 3-kinase and
CC       the AKT1 signaling cascades. In migrating endothelial cells that
CC       lack cell-cell adhesions, ANGT1 recruits TEK to contacts with the
CC       extracellular matrix, leading to the formation of focal adhesion
CC       complexes, activation of PTK2/FAK and of the downstream kinases
CC       MAPK1/ERK2 and MAPK3/ERK1, and ultimately to the stimulation of
CC       sprouting angiogenesis. ANGPT1 signaling triggers receptor
CC       dimerization and autophosphorylation at specific tyrosine residues
CC       that then serve as binding sites for scaffold proteins and
CC       effectors. Signaling is modulated by ANGPT2 that has lower
CC       affinity for TEK, can promote TEK autophosphorylation in the
CC       absence of ANGPT1, but inhibits ANGPT1-mediated signaling by
CC       competing for the same binding site. Signaling is also modulated
CC       by formation of heterodimers with TIE1, and by proteolytic
CC       processing that gives rise to a soluble TEK extracellular domain.
CC       The soluble extracellular domain modulates signaling by
CC       functioning as decoy receptor for angiopoietins. TEK
CC       phosphorylates DOK2, GRB7, GRB14, PIK3R1; SHC1 and TIE1.
CC       {ECO:0000269|PubMed:12816861, ECO:0000269|PubMed:14665640,
CC       ECO:0000269|PubMed:15284220, ECO:0000269|PubMed:15851516,
CC       ECO:0000269|PubMed:18366015, ECO:0000269|PubMed:18425119,
CC       ECO:0000269|PubMed:18425120, ECO:0000269|PubMed:19223473,
CC       ECO:0000269|PubMed:20651738, ECO:0000269|PubMed:9204896}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028, ECO:0000269|PubMed:11513602,
CC       ECO:0000269|PubMed:12609966, ECO:0000269|PubMed:14665640,
CC       ECO:0000269|PubMed:15851516, ECO:0000269|PubMed:19223473,
CC       ECO:0000269|PubMed:8382358}.
CC   -!- ENZYME REGULATION: Angiopoietin binding leads to receptor
CC       dimerization and activation by autophosphorylation at Tyr-992 on
CC       the kinase activation loop. Inhibited by staurosporine, K252a,
CC       PP2, damnacanthal, SB203580, CEP-11207, CEP-11981 and CE-245677.
CC       Inhibited by triazine, thienopyrimidine and thiazolopyrimidine
CC       derivatives. {ECO:0000269|PubMed:11080633,
CC       ECO:0000269|PubMed:11513602, ECO:0000269|PubMed:17253678,
CC       ECO:0000269|PubMed:17350837, ECO:0000269|PubMed:19854647,
CC       ECO:0000269|PubMed:20651738}.
CC   -!- SUBUNIT: Homodimer. Heterodimer with TIE1. Interacts with ANGPT1,
CC       ANGPT2 and ANGPT4. At cell-cell contacts in quiescent cells, forms
CC       a signaling complex composed of ANGPT1 plus TEK molecules from two
CC       adjoining cells. In the absence of endothelial cell-cell contacts,
CC       interaction with ANGPT1 mediates contacts with the extracellular
CC       matrix. Interacts with PTPRB; this promotes endothelial cell-cell
CC       adhesion. Interacts with DOK2, GRB2, GRB7, GRB14, PIK3R1 and
CC       PTPN11/SHP2. Colocalizes with DOK2 at contacts with the
CC       extracellular matrix in migrating cells. Interacts (tyrosine
CC       phosphorylated) with TNIP2. Interacts (tyrosine phosphorylated)
CC       with SHC1 (via SH2 domain). {ECO:0000269|PubMed:12609966,
CC       ECO:0000269|PubMed:14665640, ECO:0000269|PubMed:15284220,
CC       ECO:0000269|PubMed:15851516, ECO:0000269|PubMed:16732286,
CC       ECO:0000269|PubMed:17253678, ECO:0000269|PubMed:17350837,
CC       ECO:0000269|PubMed:18425119, ECO:0000269|PubMed:19451274,
CC       ECO:0000269|PubMed:19689429, ECO:0000269|PubMed:19854647,
CC       ECO:0000269|PubMed:9204896, ECO:0000269|Ref.32}.
CC   -!- INTERACTION:
CC       O15123:ANGPT2; NbExp=4; IntAct=EBI-2257090, EBI-2912111;
CC       Q05209:PTPN12; NbExp=2; IntAct=EBI-2257090, EBI-2266035;
CC       P23467:PTPRB; NbExp=3; IntAct=EBI-2257090, EBI-1265766;
CC       P08575:PTPRC; NbExp=3; IntAct=EBI-2257090, EBI-1341;
CC       Q12913:PTPRJ; NbExp=2; IntAct=EBI-2257090, EBI-2264500;
CC       Q15262:PTPRK; NbExp=2; IntAct=EBI-2257090, EBI-474052;
CC       Q16827:PTPRO; NbExp=2; IntAct=EBI-2257090, EBI-723739;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane
CC       protein. Cell junction. Cell junction, focal adhesion. Cytoplasm,
CC       cytoskeleton. Secreted. Note=Recruited to cell-cell contacts in
CC       quiescent endothelial cells. Colocalizes with the actin
CC       cytoskeleton and at actin stress fibers during cell spreading.
CC       Recruited to the lower surface of migrating cells, especially the
CC       rear end of the cell. Proteolytic processing gives rise to a
CC       soluble extracellular domain that is secreted.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q02763-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q02763-2; Sequence=VSP_042138;
CC       Name=3;
CC         IsoId=Q02763-3; Sequence=VSP_042137, VSP_042138, VSP_042139;
CC   -!- TISSUE SPECIFICITY: Detected in umbilical vein endothelial cells.
CC       Proteolytic processing gives rise to a soluble extracellular
CC       domain that is detected in blood plasma (at protein level).
CC       Predominantly expressed in endothelial cells and their
CC       progenitors, the angioblasts. Has been directly found in placenta
CC       and lung, with a lower level in umbilical vein endothelial cells,
CC       brain and kidney. {ECO:0000269|PubMed:11806244,
CC       ECO:0000269|PubMed:8382358}.
CC   -!- DOMAIN: The soluble extracellular domain is functionally active in
CC       angiopoietin binding and can modulate the activity of the
CC       membrane-bound form by competing for angiopoietins.
CC       {ECO:0000269|PubMed:15284220}.
CC   -!- PTM: Proteolytic processing leads to the shedding of the
CC       extracellular domain (soluble TIE-2 alias sTIE-2).
CC       {ECO:0000269|PubMed:11806244}.
CC   -!- PTM: Autophosphorylated on tyrosine residues in response to ligand
CC       binding. Autophosphorylation occurs in trans, i.e. one subunit of
CC       the dimeric receptor phosphorylates tyrosine residues on the other
CC       subunit. Autophosphorylation occurs in a sequential manner, where
CC       Tyr-992 in the kinase activation loop is phosphorylated first,
CC       followed by autophosphorylation at Tyr-1108 and at additional
CC       tyrosine residues. ANGPT1-induced phosphorylation is impaired
CC       during hypoxia, due to increased expression of ANGPT2.
CC       Phosphorylation is important for interaction with GRB14, PIK3R1
CC       and PTPN11. Phosphorylation at Tyr-1102 is important for
CC       interaction with SHC1, GRB2 and GRB7. Phosphorylation at Tyr-1108
CC       is important for interaction with DOK2 and for coupling to
CC       downstream signal transduction pathways in endothelial cells.
CC       Dephosphorylated by PTPRB. {ECO:0000269|PubMed:11513602,
CC       ECO:0000269|PubMed:14665640}.
CC   -!- PTM: Ubiquitinated. The phosphorylated receptor is ubiquitinated
CC       and internalized, leading to its degradation.
CC       {ECO:0000269|PubMed:19689429}.
CC   -!- DISEASE: Dominantly inherited venous malformations (VMCM)
CC       [MIM:600195]: An error of vascular morphogenesis characterized by
CC       dilated, serpiginous channels. {ECO:0000269|PubMed:10369874,
CC       ECO:0000269|PubMed:19888299, ECO:0000269|PubMed:8980225}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Note=May play a role in a range of diseases with a
CC       vascular component, including neovascularization of tumors,
CC       psoriasis and inflammation.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Tie subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- SIMILARITY: Contains 3 EGF-like domains. {ECO:0000255|PROSITE-
CC       ProRule:PRU00076}.
CC   -!- SIMILARITY: Contains 3 fibronectin type-III domains.
CC       {ECO:0000255|PROSITE-ProRule:PRU00316}.
CC   -!- SIMILARITY: Contains 2 Ig-like C2-type (immunoglobulin-like)
CC       domains. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/TEKID42517ch9p21.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L06139; AAA61139.1; -; mRNA.
DR   EMBL; AK291775; BAF84464.1; -; mRNA.
DR   EMBL; AK294887; BAG57981.1; -; mRNA.
DR   EMBL; AK295043; BAG58094.1; -; mRNA.
DR   EMBL; AL133411; CAI16055.1; -; Genomic_DNA.
DR   EMBL; AL355432; CAI16055.1; JOINED; Genomic_DNA.
DR   EMBL; AL355433; CAI16055.1; JOINED; Genomic_DNA.
DR   EMBL; CH471071; EAW58571.1; -; Genomic_DNA.
DR   EMBL; CH471071; EAW58572.1; -; Genomic_DNA.
DR   EMBL; BC035514; AAH35514.2; -; mRNA.
DR   CCDS; CCDS6519.1; -. [Q02763-1]
DR   CCDS; CCDS75825.1; -. [Q02763-2]
DR   CCDS; CCDS78389.1; -. [Q02763-3]
DR   PIR; I58388; I58388.
DR   RefSeq; NP_000450.2; NM_000459.4.
DR   RefSeq; NP_001277006.1; NM_001290077.1.
DR   RefSeq; NP_001277007.1; NM_001290078.1.
DR   UniGene; Hs.89640; -.
DR   PDB; 1FVR; X-ray; 2.20 A; A/B=808-1124.
DR   PDB; 2GY5; X-ray; 2.90 A; A=23-445.
DR   PDB; 2GY7; X-ray; 3.70 A; B=23-445.
DR   PDB; 2OO8; X-ray; 2.20 A; X=808-1124.
DR   PDB; 2OSC; X-ray; 2.80 A; A=808-1124.
DR   PDB; 2P4I; X-ray; 2.50 A; A/B=808-1124.
DR   PDB; 2WQB; X-ray; 2.95 A; A=802-1124.
DR   PDB; 3BEA; X-ray; 2.02 A; A=917-935.
DR   PDB; 3L8P; X-ray; 2.40 A; A=808-1124.
DR   PDB; 4K0V; X-ray; 4.51 A; A=23-542.
DR   PDB; 4X3J; X-ray; 2.50 A; A=802-1122.
DR   PDBsum; 1FVR; -.
DR   PDBsum; 2GY5; -.
DR   PDBsum; 2GY7; -.
DR   PDBsum; 2OO8; -.
DR   PDBsum; 2OSC; -.
DR   PDBsum; 2P4I; -.
DR   PDBsum; 2WQB; -.
DR   PDBsum; 3BEA; -.
DR   PDBsum; 3L8P; -.
DR   PDBsum; 4K0V; -.
DR   PDBsum; 4X3J; -.
DR   ProteinModelPortal; Q02763; -.
DR   SMR; Q02763; 23-536, 813-1121.
DR   BioGrid; 112869; 10.
DR   DIP; DIP-6047N; -.
DR   IntAct; Q02763; 21.
DR   STRING; 9606.ENSP00000369375; -.
DR   BindingDB; Q02763; -.
DR   ChEMBL; CHEMBL4128; -.
DR   DrugBank; DB00415; Ampicillin.
DR   DrugBank; DB08901; Ponatinib.
DR   DrugBank; DB08896; Regorafenib.
DR   DrugBank; DB05294; Vandetanib.
DR   GuidetoPHARMACOLOGY; 1842; -.
DR   iPTMnet; Q02763; -.
DR   PhosphoSite; Q02763; -.
DR   UniCarbKB; Q02763; -.
DR   BioMuta; TEK; -.
DR   DMDM; 218511853; -.
DR   PaxDb; Q02763; -.
DR   PRIDE; Q02763; -.
DR   DNASU; 7010; -.
DR   Ensembl; ENST00000380036; ENSP00000369375; ENSG00000120156. [Q02763-1]
DR   Ensembl; ENST00000406359; ENSP00000383977; ENSG00000120156. [Q02763-2]
DR   Ensembl; ENST00000519097; ENSP00000430686; ENSG00000120156. [Q02763-3]
DR   GeneID; 7010; -.
DR   KEGG; hsa:7010; -.
DR   UCSC; uc003zqj.1; human. [Q02763-2]
DR   UCSC; uc011lnp.2; human. [Q02763-3]
DR   CTD; 7010; -.
DR   GeneCards; TEK; -.
DR   GeneReviews; TEK; -.
DR   HGNC; HGNC:11724; TEK.
DR   HPA; CAB010359; -.
DR   HPA; HPA011738; -.
DR   MalaCards; TEK; -.
DR   MIM; 600195; phenotype.
DR   MIM; 600221; gene.
DR   neXtProt; NX_Q02763; -.
DR   Orphanet; 2451; Mucocutaneous venous malformations.
DR   PharmGKB; PA36441; -.
DR   eggNOG; KOG0200; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00830000128295; -.
DR   HOGENOM; HOG000049232; -.
DR   HOVERGEN; HBG007316; -.
DR   InParanoid; Q02763; -.
DR   KO; K05121; -.
DR   OMA; CHEDTGE; -.
DR   OrthoDB; EOG7966FR; -.
DR   PhylomeDB; Q02763; -.
DR   TreeFam; TF317568; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   Reactome; R-HSA-210993; Tie2 Signaling.
DR   Reactome; R-HSA-5673001; RAF/MAP kinase cascade.
DR   SignaLink; Q02763; -.
DR   ChiTaRS; TEK; human.
DR   EvolutionaryTrace; Q02763; -.
DR   GeneWiki; TEK_tyrosine_kinase; -.
DR   GenomeRNAi; 7010; -.
DR   NextBio; 27384; -.
DR   PRO; PR:Q02763; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   Bgee; Q02763; -.
DR   CleanEx; HS_TEK; -.
DR   ExpressionAtlas; Q02763; baseline and differential.
DR   Genevisible; Q02763; HS.
DR   GO; GO:0016324; C:apical plasma membrane; IDA:UniProtKB.
DR   GO; GO:0009925; C:basal plasma membrane; IDA:UniProtKB.
DR   GO; GO:0016323; C:basolateral plasma membrane; IDA:UniProtKB.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0005911; C:cell-cell junction; IDA:UniProtKB.
DR   GO; GO:0005856; C:cytoskeleton; IEA:UniProtKB-SubCell.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0005925; C:focal adhesion; IEA:UniProtKB-SubCell.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0045121; C:membrane raft; IDA:UniProtKB.
DR   GO; GO:0005902; C:microvillus; IDA:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004672; F:protein kinase activity; TAS:ProtInc.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0004872; F:receptor activity; TAS:ProtInc.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; TAS:ProtInc.
DR   GO; GO:0000186; P:activation of MAPKK activity; TAS:Reactome.
DR   GO; GO:0001525; P:angiogenesis; ISS:UniProtKB.
DR   GO; GO:0007411; P:axon guidance; TAS:Reactome.
DR   GO; GO:0007596; P:blood coagulation; TAS:Reactome.
DR   GO; GO:0007267; P:cell-cell signaling; TAS:ProtInc.
DR   GO; GO:0007160; P:cell-matrix adhesion; IEA:Ensembl.
DR   GO; GO:0060216; P:definitive hemopoiesis; TAS:UniProtKB.
DR   GO; GO:0001958; P:endochondral ossification; IEA:Ensembl.
DR   GO; GO:0001935; P:endothelial cell proliferation; ISS:UniProtKB.
DR   GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0008543; P:fibroblast growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0072012; P:glomerulus vasculature development; ISS:UniProtKB.
DR   GO; GO:0007507; P:heart development; ISS:UniProtKB.
DR   GO; GO:0060347; P:heart trabecula formation; ISS:UniProtKB.
DR   GO; GO:0045087; P:innate immune response; TAS:Reactome.
DR   GO; GO:0008286; P:insulin receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0050900; P:leukocyte migration; TAS:Reactome.
DR   GO; GO:0000165; P:MAPK cascade; TAS:Reactome.
DR   GO; GO:0016525; P:negative regulation of angiogenesis; IMP:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; TAS:UniProtKB.
DR   GO; GO:2000352; P:negative regulation of endothelial cell apoptotic process; ISS:UniProtKB.
DR   GO; GO:0050728; P:negative regulation of inflammatory response; TAS:UniProtKB.
DR   GO; GO:0048011; P:neurotrophin TRK receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0031100; P:organ regeneration; IEA:Ensembl.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:2000251; P:positive regulation of actin cytoskeleton reorganization; IMP:UniProtKB.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; IDA:UniProtKB.
DR   GO; GO:0002741; P:positive regulation of cytokine secretion involved in immune response; IEA:Ensembl.
DR   GO; GO:0010595; P:positive regulation of endothelial cell migration; IDA:UniProtKB.
DR   GO; GO:0001938; P:positive regulation of endothelial cell proliferation; TAS:UniProtKB.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:UniProtKB.
DR   GO; GO:0051894; P:positive regulation of focal adhesion assembly; IMP:UniProtKB.
DR   GO; GO:1902533; P:positive regulation of intracellular signal transduction; IMP:UniProtKB.
DR   GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; IEA:Ensembl.
DR   GO; GO:0043552; P:positive regulation of phosphatidylinositol 3-kinase activity; IMP:UniProtKB.
DR   GO; GO:0014068; P:positive regulation of phosphatidylinositol 3-kinase signaling; IMP:UniProtKB.
DR   GO; GO:0042307; P:positive regulation of protein import into nucleus; IEA:Ensembl.
DR   GO; GO:0051897; P:positive regulation of protein kinase B signaling; IDA:UniProtKB.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0051259; P:protein oligomerization; IDA:UniProtKB.
DR   GO; GO:0007265; P:Ras protein signal transduction; TAS:Reactome.
DR   GO; GO:2000351; P:regulation of endothelial cell apoptotic process; TAS:UniProtKB.
DR   GO; GO:0032878; P:regulation of establishment or maintenance of cell polarity; IMP:UniProtKB.
DR   GO; GO:1901222; P:regulation of NIK/NF-kappaB signaling; IEA:Ensembl.
DR   GO; GO:0043114; P:regulation of vascular permeability; TAS:UniProtKB.
DR   GO; GO:0051591; P:response to cAMP; IEA:Ensembl.
DR   GO; GO:0043627; P:response to estrogen; IEA:Ensembl.
DR   GO; GO:0001666; P:response to hypoxia; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0016337; P:single organismal cell-cell adhesion; IEA:Ensembl.
DR   GO; GO:0007264; P:small GTPase mediated signal transduction; TAS:Reactome.
DR   GO; GO:0002040; P:sprouting angiogenesis; IMP:UniProtKB.
DR   GO; GO:0034446; P:substrate adhesion-dependent cell spreading; IMP:UniProtKB.
DR   GO; GO:0048014; P:Tie signaling pathway; IDA:UniProtKB.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IDA:UniProtKB.
DR   GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; TAS:Reactome.
DR   Gene3D; 2.60.40.10; -; 6.
DR   InterPro; IPR013032; EGF-like_CS.
DR   InterPro; IPR000742; EGF-like_dom.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR018941; Tyr_kin_Tie2_Ig-like_dom-1_N.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   Pfam; PF00041; fn3; 3.
DR   Pfam; PF10430; Ig_Tie2_1; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00181; EGF; 2.
DR   SMART; SM00060; FN3; 3.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF48726; SSF48726; 1.
DR   SUPFAM; SSF49265; SSF49265; 2.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00022; EGF_1; 3.
DR   PROSITE; PS01186; EGF_2; 3.
DR   PROSITE; PS50026; EGF_3; 1.
DR   PROSITE; PS50853; FN3; 3.
DR   PROSITE; PS50835; IG_LIKE; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Angiogenesis; ATP-binding;
KW   Cell junction; Cell membrane; Complete proteome; Cytoplasm;
KW   Cytoskeleton; Direct protein sequencing; Disease mutation;
KW   Disulfide bond; EGF-like domain; Glycoprotein; Immunoglobulin domain;
KW   Kinase; Membrane; Nucleotide-binding; Phosphoprotein; Polymorphism;
KW   Receptor; Reference proteome; Repeat; Secreted; Signal; Transferase;
KW   Transmembrane; Transmembrane helix; Tyrosine-protein kinase;
KW   Ubl conjugation.
FT   SIGNAL        1     22       {ECO:0000269|PubMed:15340161}.
FT   CHAIN        23   1124       Angiopoietin-1 receptor.
FT                                /FTId=PRO_0000024474.
FT   TOPO_DOM     23    748       Extracellular. {ECO:0000255}.
FT   TRANSMEM    749    769       Helical. {ECO:0000255}.
FT   TOPO_DOM    770   1124       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       44    123       Ig-like C2-type 1.
FT   DOMAIN      210    252       EGF-like 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      254    299       EGF-like 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      301    341       EGF-like 3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      350    440       Ig-like C2-type 2.
FT   DOMAIN      447    541       Fibronectin type-III 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      545    636       Fibronectin type-III 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      641    735       Fibronectin type-III 3.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      824   1096       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     830    838       ATP. {ECO:0000305}.
FT   ACT_SITE    964    964       Proton acceptor.
FT                                {ECO:0000305|PubMed:11080633}.
FT   BINDING     855    855       ATP. {ECO:0000305}.
FT   MOD_RES     860    860       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:11513602}.
FT   MOD_RES     992    992       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:11513602}.
FT   MOD_RES    1102   1102       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:14665640}.
FT   MOD_RES    1108   1108       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:11513602}.
FT   CARBOHYD    140    140       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16732286}.
FT   CARBOHYD    158    158       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    399    399       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    438    438       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    464    464       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    560    560       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    596    596       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19159218}.
FT   CARBOHYD    649    649       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    691    691       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     44    102       {ECO:0000269|PubMed:16732286}.
FT   DISULFID    211    220       {ECO:0000269|PubMed:16732286}.
FT   DISULFID    224    233       {ECO:0000269|PubMed:16732286}.
FT   DISULFID    227    240       {ECO:0000269|PubMed:16732286}.
FT   DISULFID    242    251       {ECO:0000269|PubMed:16732286}.
FT   DISULFID    255    264       {ECO:0000269|PubMed:16732286}.
FT   DISULFID    268    274       {ECO:0000269|PubMed:16732286}.
FT   DISULFID    280    287       {ECO:0000269|PubMed:16732286}.
FT   DISULFID    289    298       {ECO:0000269|PubMed:16732286}.
FT   DISULFID    302    311       {ECO:0000269|PubMed:16732286}.
FT   DISULFID    315    323       {ECO:0000269|PubMed:16732286}.
FT   DISULFID    317    329       {ECO:0000269|PubMed:16732286}.
FT   DISULFID    331    340       {ECO:0000269|PubMed:16732286}.
FT   DISULFID    370    424       {ECO:0000269|PubMed:16732286}.
FT   VAR_SEQ      18    121       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_042137.
FT   VAR_SEQ     300    342       Missing (in isoform 2 and isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_042138.
FT   VAR_SEQ     788    788       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_042139.
FT   VARIANT     117    117       K -> N (in breast cancer samples;
FT                                infiltrating ductal carcinoma; somatic
FT                                mutation). {ECO:0000269|PubMed:16959974,
FT                                ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_035714.
FT   VARIANT     148    148       I -> T (in dbSNP:rs35969327).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041855.
FT   VARIANT     226    226       A -> V (in dbSNP:rs35814893).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041856.
FT   VARIANT     346    346       Q -> P (in dbSNP:rs682632).
FT                                {ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:8382358,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_048002.
FT   VARIANT     391    391       T -> I (in dbSNP:rs34032300).
FT                                /FTId=VAR_048003.
FT   VARIANT     486    486       V -> I (in dbSNP:rs1334811).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_024578.
FT   VARIANT     600    600       V -> L (in dbSNP:rs35030851).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041857.
FT   VARIANT     634    634       L -> F (in dbSNP:rs35378598).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041858.
FT   VARIANT     676    676       V -> I (in dbSNP:rs56367117).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041859.
FT   VARIANT     724    724       A -> T (in dbSNP:rs4631561).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041860.
FT   VARIANT     849    849       R -> W (in VMCM; increased ligand-
FT                                independent autophosphorylation and
FT                                kinase activation).
FT                                {ECO:0000269|PubMed:10369874,
FT                                ECO:0000269|PubMed:19888299,
FT                                ECO:0000269|PubMed:8980225}.
FT                                /FTId=VAR_006352.
FT   VARIANT     883    883       P -> A (in an ovarian serous carcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041861.
FT   VARIANT     897    897       Y -> C (in VMCM; increased ligand-
FT                                independent autophosphorylation and
FT                                kinase activation).
FT                                {ECO:0000269|PubMed:19888299}.
FT                                /FTId=VAR_066606.
FT   VARIANT     897    897       Y -> S (in VMCM; increased ligand-
FT                                independent autophosphorylation and
FT                                kinase activation).
FT                                {ECO:0000269|PubMed:10369874,
FT                                ECO:0000269|PubMed:19888299}.
FT                                /FTId=VAR_008716.
FT   VARIANT     915    915       R -> H (in VMCM; strongly increased
FT                                ligand-independent autophosphorylation
FT                                and kinase activation).
FT                                {ECO:0000269|PubMed:19888299}.
FT                                /FTId=VAR_066607.
FT   VARIANT     918    918       R -> C (in VMCM; strongly increased
FT                                ligand-independent autophosphorylation
FT                                and kinase activation).
FT                                {ECO:0000269|PubMed:19888299}.
FT                                /FTId=VAR_066608.
FT   VARIANT     919    919       V -> L (in VMCM; increased ligand-
FT                                independent autophosphorylation and
FT                                kinase activation).
FT                                {ECO:0000269|PubMed:19888299}.
FT                                /FTId=VAR_066609.
FT   VARIANT     925    925       A -> S (in VMCM; increased ligand-
FT                                independent autophosphorylation and
FT                                kinase activation).
FT                                {ECO:0000269|PubMed:19888299}.
FT                                /FTId=VAR_066610.
FT   VARIANT    1100   1100       K -> N (in VMCM; strongly increased
FT                                ligand-independent autophosphorylation
FT                                and kinase activation).
FT                                {ECO:0000269|PubMed:19888299}.
FT                                /FTId=VAR_066611.
FT   VARIANT    1124   1124       A -> V (in a renal clear cell carcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041862.
FT   MUTAGEN     855    855       K->R: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:12609966,
FT                                ECO:0000269|PubMed:15851516}.
FT   MUTAGEN    1102   1102       Y->F: Abolishes interaction with SHC1.
FT                                {ECO:0000269|PubMed:14665640}.
FT   CONFLICT    536    536       F -> L (in Ref. 2; BAG58094).
FT                                {ECO:0000305}.
FT   CONFLICT    695    695       T -> I (in Ref. 1; AAA61139).
FT                                {ECO:0000305}.
FT   CONFLICT    939    940       QQ -> HH (in Ref. 5; AAH35514).
FT                                {ECO:0000305}.
FT   STRAND       26     29       {ECO:0000244|PDB:2GY5}.
FT   STRAND       33     35       {ECO:0000244|PDB:2GY5}.
FT   STRAND       40     46       {ECO:0000244|PDB:2GY5}.
FT   STRAND       56     59       {ECO:0000244|PDB:2GY5}.
FT   TURN         61     63       {ECO:0000244|PDB:2GY5}.
FT   STRAND       64     66       {ECO:0000244|PDB:2GY5}.
FT   STRAND       74     76       {ECO:0000244|PDB:2GY5}.
FT   STRAND       80     88       {ECO:0000244|PDB:2GY5}.
FT   STRAND       98    106       {ECO:0000244|PDB:2GY5}.
FT   STRAND      109    119       {ECO:0000244|PDB:2GY5}.
FT   STRAND      123    125       {ECO:0000244|PDB:2GY5}.
FT   STRAND      127    133       {ECO:0000244|PDB:2GY5}.
FT   STRAND      139    145       {ECO:0000244|PDB:2GY5}.
FT   STRAND      153    157       {ECO:0000244|PDB:2GY5}.
FT   STRAND      160    165       {ECO:0000244|PDB:2GY5}.
FT   HELIX       167    169       {ECO:0000244|PDB:2GY5}.
FT   STRAND      172    178       {ECO:0000244|PDB:2GY5}.
FT   HELIX       183    185       {ECO:0000244|PDB:2GY5}.
FT   STRAND      187    193       {ECO:0000244|PDB:2GY5}.
FT   HELIX       198    200       {ECO:0000244|PDB:2GY5}.
FT   STRAND      202    208       {ECO:0000244|PDB:2GY5}.
FT   STRAND      215    217       {ECO:0000244|PDB:2GY5}.
FT   TURN        235    237       {ECO:0000244|PDB:2GY5}.
FT   STRAND      246    248       {ECO:0000244|PDB:2GY5}.
FT   STRAND      259    261       {ECO:0000244|PDB:2GY5}.
FT   TURN        271    276       {ECO:0000244|PDB:2GY5}.
FT   STRAND      279    281       {ECO:0000244|PDB:2GY5}.
FT   TURN        282    285       {ECO:0000244|PDB:2GY5}.
FT   STRAND      286    288       {ECO:0000244|PDB:2GY5}.
FT   HELIX       296    298       {ECO:0000244|PDB:2GY5}.
FT   STRAND      322    324       {ECO:0000244|PDB:2GY5}.
FT   TURN        325    327       {ECO:0000244|PDB:2GY5}.
FT   STRAND      328    330       {ECO:0000244|PDB:2GY5}.
FT   STRAND      361    366       {ECO:0000244|PDB:2GY5}.
FT   STRAND      369    373       {ECO:0000244|PDB:2GY5}.
FT   HELIX       380    382       {ECO:0000244|PDB:2GY5}.
FT   STRAND      383    386       {ECO:0000244|PDB:2GY5}.
FT   STRAND      396    400       {ECO:0000244|PDB:2GY5}.
FT   STRAND      405    408       {ECO:0000244|PDB:2GY5}.
FT   STRAND      411    414       {ECO:0000244|PDB:2GY5}.
FT   HELIX       416    418       {ECO:0000244|PDB:2GY5}.
FT   STRAND      420    428       {ECO:0000244|PDB:2GY5}.
FT   STRAND      431    439       {ECO:0000244|PDB:2GY5}.
FT   STRAND      816    818       {ECO:0000244|PDB:1FVR}.
FT   HELIX       821    823       {ECO:0000244|PDB:1FVR}.
FT   STRAND      825    831       {ECO:0000244|PDB:1FVR}.
FT   HELIX       833    835       {ECO:0000244|PDB:1FVR}.
FT   STRAND      837    845       {ECO:0000244|PDB:1FVR}.
FT   STRAND      848    858       {ECO:0000244|PDB:1FVR}.
FT   HELIX       864    866       {ECO:0000244|PDB:2P4I}.
FT   HELIX       868    876       {ECO:0000244|PDB:1FVR}.
FT   STRAND      888    894       {ECO:0000244|PDB:1FVR}.
FT   STRAND      897    902       {ECO:0000244|PDB:1FVR}.
FT   HELIX       910    915       {ECO:0000244|PDB:1FVR}.
FT   HELIX       919    922       {ECO:0000244|PDB:1FVR}.
FT   HELIX       924    929       {ECO:0000244|PDB:1FVR}.
FT   STRAND      932    936       {ECO:0000244|PDB:2OO8}.
FT   HELIX       938    957       {ECO:0000244|PDB:1FVR}.
FT   HELIX       967    969       {ECO:0000244|PDB:1FVR}.
FT   STRAND      970    972       {ECO:0000244|PDB:1FVR}.
FT   HELIX       974    976       {ECO:0000244|PDB:1FVR}.
FT   STRAND      978    980       {ECO:0000244|PDB:1FVR}.
FT   STRAND      986    989       {ECO:0000244|PDB:1FVR}.
FT   TURN       1002   1004       {ECO:0000244|PDB:1FVR}.
FT   HELIX      1007   1012       {ECO:0000244|PDB:1FVR}.
FT   HELIX      1017   1032       {ECO:0000244|PDB:1FVR}.
FT   TURN       1038   1041       {ECO:0000244|PDB:1FVR}.
FT   HELIX      1044   1050       {ECO:0000244|PDB:1FVR}.
FT   HELIX      1051   1053       {ECO:0000244|PDB:1FVR}.
FT   HELIX      1065   1074       {ECO:0000244|PDB:1FVR}.
FT   HELIX      1079   1081       {ECO:0000244|PDB:1FVR}.
FT   HELIX      1085   1097       {ECO:0000244|PDB:1FVR}.
FT   STRAND     1098   1100       {ECO:0000244|PDB:1FVR}.
FT   HELIX      1118   1120       {ECO:0000244|PDB:1FVR}.
SQ   SEQUENCE   1124 AA;  125830 MW;  E739DEC3E4FEB124 CRC64;
     MDSLASLVLC GVSLLLSGTV EGAMDLILIN SLPLVSDAET SLTCIASGWR PHEPITIGRD
     FEALMNQHQD PLEVTQDVTR EWAKKVVWKR EKASKINGAY FCEGRVRGEA IRIRTMKMRQ
     QASFLPATLT MTVDKGDNVN ISFKKVLIKE EDAVIYKNGS FIHSVPRHEV PDILEVHLPH
     AQPQDAGVYS ARYIGGNLFT SAFTRLIVRR CEAQKWGPEC NHLCTACMNN GVCHEDTGEC
     ICPPGFMGRT CEKACELHTF GRTCKERCSG QEGCKSYVFC LPDPYGCSCA TGWKGLQCNE
     ACHPGFYGPD CKLRCSCNNG EMCDRFQGCL CSPGWQGLQC EREGIQRMTP KIVDLPDHIE
     VNSGKFNPIC KASGWPLPTN EEMTLVKPDG TVLHPKDFNH TDHFSVAIFT IHRILPPDSG
     VWVCSVNTVA GMVEKPFNIS VKVLPKPLNA PNVIDTGHNF AVINISSEPY FGDGPIKSKK
     LLYKPVNHYE AWQHIQVTNE IVTLNYLEPR TEYELCVQLV RRGEGGEGHP GPVRRFTTAS
     IGLPPPRGLN LLPKSQTTLN LTWQPIFPSS EDDFYVEVER RSVQKSDQQN IKVPGNLTSV
     LLNNLHPREQ YVVRARVNTK AQGEWSEDLT AWTLSDILPP QPENIKISNI THSSAVISWT
     ILDGYSISSI TIRYKVQGKN EDQHVDVKIK NATITQYQLK GLEPETAYQV DIFAENNIGS
     SNPAFSHELV TLPESQAPAD LGGGKMLLIA ILGSAGMTCL TVLLAFLIIL QLKRANVQRR
     MAQAFQNVRE EPAVQFNSGT LALNRKVKNN PDPTIYPVLD WNDIKFQDVI GEGNFGQVLK
     ARIKKDGLRM DAAIKRMKEY ASKDDHRDFA GELEVLCKLG HHPNIINLLG ACEHRGYLYL
     AIEYAPHGNL LDFLRKSRVL ETDPAFAIAN STASTLSSQQ LLHFAADVAR GMDYLSQKQF
     IHRDLAARNI LVGENYVAKI ADFGLSRGQE VYVKKTMGRL PVRWMAIESL NYSVYTTNSD
     VWSYGVLLWE IVSLGGTPYC GMTCAELYEK LPQGYRLEKP LNCDDEVYDL MRQCWREKPY
     ERPSFAQILV SLNRMLEERK TYVNTTLYEK FTYAGIDCSA EEAA
//
ID   VGFR2_HUMAN             Reviewed;        1356 AA.
AC   P35968; A2RRS0; B5A925; C5IFA0; O60723; Q14178;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-2000, sequence version 2.
DT   17-FEB-2016, entry version 185.
DE   RecName: Full=Vascular endothelial growth factor receptor 2;
DE            Short=VEGFR-2;
DE            EC=2.7.10.1;
DE   AltName: Full=Fetal liver kinase 1;
DE            Short=FLK-1;
DE   AltName: Full=Kinase insert domain receptor;
DE            Short=KDR;
DE   AltName: Full=Protein-tyrosine kinase receptor flk-1;
DE   AltName: CD_antigen=CD309;
DE   Flags: Precursor;
GN   Name=KDR; Synonyms=FLK1, VEGFR2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), INTERACTION WITH VEGFC, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=18593464; DOI=10.1186/ar2447;
RA   Jin P., Zhang J., Sumariwalla P.F., Ni I., Jorgensen B., Crawford D.,
RA   Phillips S., Feldmann M., Shepard H.M., Paleolog E.M.;
RT   "Novel splice variants derived from the receptor tyrosine kinase
RT   superfamily are potential therapeutics for rheumatoid arthritis.";
RL   Arthritis Res. Ther. 10:R73-R73(2008).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION IN INHIBITION OF
RP   LYMPHANGIOGENESIS, INTERACTION WITH VEGFC, AND TISSUE SPECIFICITY.
RX   PubMed=19668192; DOI=10.1038/nm.2018;
RA   Albuquerque R.J., Hayashi T., Cho W.G., Kleinman M.E., Dridi S.,
RA   Takeda A., Baffi J.Z., Yamada K., Kaneko H., Green M.G., Chappell J.,
RA   Wilting J., Weich H.A., Yamagami S., Amano S., Mizuki N.,
RA   Alexander J.S., Peterson M.L., Brekken R.A., Hirashima M., Capoor S.,
RA   Usui T., Ambati B.K., Ambati J.;
RT   "Alternatively spliced vascular endothelial growth factor receptor-2
RT   is an essential endogenous inhibitor of lymphatic vessel growth.";
RL   Nat. Med. 15:1023-1030(2009).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Yin L.Y., Wu Y., Patterson C.;
RT   "Full length human KDR/flk-1 sequence.";
RL   Submitted (DEC-1997) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Umbilical vein;
RA   Yu Y., Whitney R.G., Sato J.D.;
RT   "Coding region for human VEGF receptor KDR (VEGFR-2).";
RL   Submitted (MAY-1998) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   HIS-472.
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 3-1356 (ISOFORM 1), AND VARIANT GLU-848.
RC   TISSUE=Umbilical vein;
RX   PubMed=1656371;
RA   Terman B.I., Carrion M.E., Kovacs E., Rasmussen B.A., Eddy R.L.,
RA   Shows T.B.;
RT   "Identification of a new endothelial cell growth factor receptor
RT   tyrosine kinase.";
RL   Oncogene 6:1677-1683(1991).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-22.
RX   PubMed=7559454; DOI=10.1074/jbc.270.39.23111;
RA   Patterson C., Perrella M.A., Hsieh C.-M., Yoshizumi M., Lee M.-E.,
RA   Harber E.;
RT   "Cloning and functional analysis of the promoter for KDR/flk-1, a
RT   receptor for vascular endothelial growth factor.";
RL   J. Biol. Chem. 270:23111-23118(1995).
RN   [9]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH VEGFA.
RX   PubMed=1417831; DOI=10.1016/0006-291X(92)90483-2;
RA   Terman B.I., Dougher-Vermazen M., Carrion M.E., Dimitrov D.,
RA   Armellino D.C., Gospodarowicz D., Boehlen P.;
RT   "Identification of the KDR tyrosine kinase as a receptor for vascular
RT   endothelial cell growth factor.";
RL   Biochem. Biophys. Res. Commun. 187:1579-1586(1992).
RN   [10]
RP   FUNCTION AS VEGFA RECEPTOR; IN REGULATION OF CELL SHAPE; ACTIN
RP   CYTOSKELETON REORGANIZATION; CELL MIGRATION AND CELL PROLIFERATION,
RP   AND AUTOPHOSPHORYLATION.
RX   PubMed=7929439;
RA   Waltenberger J., Claesson-Welsh L., Siegbahn A., Shibuya M.,
RA   Heldin C.H.;
RT   "Different signal transduction properties of KDR and Flt1, two
RT   receptors for vascular endothelial growth factor.";
RL   J. Biol. Chem. 269:26988-26995(1994).
RN   [11]
RP   FUNCTION IN VEGFA SIGNALING; PHOSPHORYLATION OF PLCG1; ACTIVATION OF
RP   MAP KINASES AND IN PROMOTING PROLIFERATION OF ENDOTHELIAL CELLS,
RP   INTERACTION WITH VEGFA AND PLCG1, AUTOPHOSPHORYLATION, SUBCELLULAR
RP   LOCATION, AND GLYCOSYLATION.
RX   PubMed=9160888; DOI=10.1038/sj.onc.1201047;
RA   Takahashi T., Shibuya M.;
RT   "The 230 kDa mature form of KDR/Flk-1 (VEGF receptor-2) activates the
RT   PLC-gamma pathway and partially induces mitotic signals in NIH3T3
RT   fibroblasts.";
RL   Oncogene 14:2079-2089(1997).
RN   [12]
RP   FUNCTION IN INDUCTION OF NOS2 AND NOS3.
RX   PubMed=9837777; DOI=10.1006/bbrc.1998.9719;
RA   Kroll J., Waltenberger J.;
RT   "VEGF-A induces expression of eNOS and iNOS in endothelial cells via
RT   VEGF receptor-2 (KDR).";
RL   Biochem. Biophys. Res. Commun. 252:743-746(1998).
RN   [13]
RP   FUNCTION IN ACTIVATION OF THE PHOSPHATIDYLINOSITOL 3-KINASE AND AKT1
RP   SIGNALING PATHWAY.
RX   PubMed=9804796; DOI=10.1074/jbc.273.46.30336;
RA   Gerber H.P., McMurtrey A., Kowalski J., Yan M., Keyt B.A., Dixit V.,
RA   Ferrara N.;
RT   "Vascular endothelial growth factor regulates endothelial cell
RT   survival through the phosphatidylinositol 3'-kinase/Akt signal
RT   transduction pathway. Requirement for Flk-1/KDR activation.";
RL   J. Biol. Chem. 273:30336-30343(1998).
RN   [14]
RP   FUNCTION IN NITRIC OXIDE RELEASE.
RX   PubMed=10600473; DOI=10.1006/bbrc.1999.1729;
RA   Kroll J., Waltenberger J.;
RT   "A novel function of VEGF receptor-2 (KDR): rapid release of nitric
RT   oxide in response to VEGF-A stimulation in endothelial cells.";
RL   Biochem. Biophys. Res. Commun. 265:636-639(1999).
RN   [15]
RP   CATALYTIC ACTIVITY, CHARACTERIZATION OF VARIANT GLU-848,
RP   PHOSPHORYLATION AT TYR-1054 AND TYR-1059, AND ENZYME REGULATION.
RX   PubMed=10037737; DOI=10.1074/jbc.274.10.6453;
RA   Kendall R.L., Rutledge R.Z., Mao X., Tebben A.J., Hungate R.W.,
RA   Thomas K.A.;
RT   "Vascular endothelial growth factor receptor KDR tyrosine kinase
RT   activity is increased by autophosphorylation of two activation loop
RT   tyrosine residues.";
RL   J. Biol. Chem. 274:6453-6460(1999).
RN   [16]
RP   FUNCTION IN PHOSPHORYLATION OF PLCG1 AND PTK2/FAK1, INTERACTION WITH
RP   VEGFA, CATALYTIC ACTIVITY, PHOSPHORYLATION AT TYR-996; TYR-1054 AND
RP   TYR-1059, MUTAGENESIS OF TYR-996; TYR-1054 AND TYR-1059, SUBCELLULAR
RP   LOCATION, AND ENZYME REGULATION.
RX   PubMed=10102632; DOI=10.1038/sj.onc.1202478;
RA   Dougher M., Terman B.I.;
RT   "Autophosphorylation of KDR in the kinase domain is required for
RT   maximal VEGF-stimulated kinase activity and receptor
RT   internalization.";
RL   Oncogene 18:1619-1627(1999).
RN   [17]
RP   INTERACTION WITH HIV-1 TAT.
RX   PubMed=10590123; DOI=10.1128/JVI.74.1.344-353.2000;
RA   Mitola S., Soldi R., Zanon I., Barra L., Gutierrez M.I., Berkhout B.,
RA   Giacca M., Bussolino F.;
RT   "Identification of specific molecular structures of human
RT   immunodeficiency virus type 1 Tat relevant for its biological effects
RT   on vascular endothelial cells.";
RL   J. Virol. 74:344-353(2000).
RN   [18]
RP   FUNCTION IN ENDOTHELIAL CELL PROLIFERATION; PHOSPHORYLATION OF PLCG1
RP   AND ACTIVATION OF MAP KINASES, PHOSPHORYLATION AT TYR-1175 AND
RP   TYR-1214, AND MUTAGENESIS OF LYS-868 AND TYR-1175.
RX   PubMed=11387210; DOI=10.1093/emboj/20.11.2768;
RA   Takahashi T., Yamaguchi S., Chida K., Shibuya M.;
RT   "A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-
RT   A-dependent activation of PLC-gamma and DNA synthesis in vascular
RT   endothelial cells.";
RL   EMBO J. 20:2768-2778(2001).
RN   [19]
RP   UBIQUITINATION, FUNCTION IN NITRIC OXIDE PRODUCTION, SUBCELLULAR
RP   LOCATION, AND INTERACTION WITH CBL.
RX   PubMed=12649282; DOI=10.1074/jbc.M301410200;
RA   Duval M., Bedard-Goulet S., Delisle C., Gratton J.P.;
RT   "Vascular endothelial growth factor-dependent down-regulation of Flk-
RT   1/KDR involves Cbl-mediated ubiquitination. Consequences on nitric
RT   oxide production from endothelial cells.";
RL   J. Biol. Chem. 278:20091-20097(2003).
RN   [20]
RP   INTERACTION WITH FLT4.
RX   PubMed=12881528; DOI=10.1074/jbc.M304499200;
RA   Dixelius J., Makinen T., Wirzenius M., Karkkainen M.J., Wernstedt C.,
RA   Alitalo K., Claesson-Welsh L.;
RT   "Ligand-induced vascular endothelial growth factor receptor-3 (VEGFR-
RT   3) heterodimerization with VEGFR-2 in primary lymphatic endothelial
RT   cells regulates tyrosine phosphorylation sites.";
RL   J. Biol. Chem. 278:40973-40979(2003).
RN   [21]
RP   INTERACTION WITH SHB, AND FUNCTION IN CELL MIGRATION.
RX   PubMed=15026417; DOI=10.1074/jbc.M312729200;
RA   Holmqvist K., Cross M.J., Rolny C., Haegerkvist R., Rahimi N.,
RA   Matsumoto T., Claesson-Welsh L., Welsh M.;
RT   "The adaptor protein shb binds to tyrosine 1175 in vascular
RT   endothelial growth factor (VEGF) receptor-2 and regulates VEGF-
RT   dependent cellular migration.";
RL   J. Biol. Chem. 279:22267-22275(2004).
RN   [22]
RP   SUBCELLULAR LOCATION, AND PHOSPHORYLATION.
RX   PubMed=14991896; DOI=10.1002/path.1520;
RA   Fox S.B., Turley H., Cheale M., Blazquez C., Roberts H., James N.,
RA   Cook N., Harris A., Gatter K.;
RT   "Phosphorylated KDR is expressed in the neoplastic and stromal
RT   elements of human renal tumours and shuttles from cell membrane to
RT   nucleus.";
RL   J. Pathol. 202:313-320(2004).
RN   [23]
RP   INTERACTION WITH VEGFA AND VEGFD, PHOSPHORYLATION AT TYR-1054 AND
RP   TYR-1059, FUNCTION IN VEGFA AND VEGFD SIGNALING; ACTIVATION OF
RP   MAPK1/ERK2 AND MAPK3/ERK1; ACTIVATION OF AKT1; PHOSPHORYLATION OF
RP   PLCG1 AND NOS3; MODULATION OF INTRACELLULAR CA(2+) LEVELS; CELL
RP   SURVIVAL AND POSITIVE REGULATION OF CELL PROLIFERATION; CELL MIGRATION
RP   AND ANGIOGENESIS, AND ENZYME REGULATION.
RX   PubMed=15215251; DOI=10.1074/jbc.M401538200;
RA   Jia H., Bagherzadeh A., Bicknell R., Duchen M.R., Liu D., Zachary I.;
RT   "Vascular endothelial growth factor (VEGF)-D and VEGF-A differentially
RT   regulate KDR-mediated signaling and biological function in vascular
RT   endothelial cells.";
RL   J. Biol. Chem. 279:36148-36157(2004).
RN   [24]
RP   FUNCTION IN CELL MIGRATION; PHOSPHORYLATION OF PLCG1; ACTIVATION OF
RP   MAPK1/ERK2; MAPK3/ERK1 AND THE MAP KINASES AND IN REGULATION OF ACTIN
RP   CYTOSKELETON REORGANIZATION, INTERACTION WITH SH2D2A/TSAD,
RP   PHOSPHORYLATION AT TYR-951; TYR-1054; TYR-1059; TYR-1214; TYR-1305;
RP   TYR-1309 AND TYR-1319, AND MUTAGENESIS OF TYR-951.
RX   PubMed=15962004; DOI=10.1038/sj.emboj.7600709;
RA   Matsumoto T., Bohman S., Dixelius J., Berge T., Dimberg A.,
RA   Magnusson P., Wang L., Wikner C., Qi J.H., Wernstedt C., Wu J.,
RA   Bruheim S., Mugishima H., Mukhopadhyay D., Spurkland A.,
RA   Claesson-Welsh L.;
RT   "VEGF receptor-2 Y951 signaling and a role for the adapter molecule
RT   TSAd in tumor angiogenesis.";
RL   EMBO J. 24:2342-2353(2005).
RN   [25]
RP   FUNCTION IN ENDOTHELIAL CELL MIGRATION; ACTIVATION OF MAP KINASES AND
RP   IN PHOSPHORYLATION OF FYN; SRC AND NCK1, INTERACTION WITH GRB2; FYN
RP   AND NCK1, AND MUTAGENESIS OF TYR-1214.
RX   PubMed=16966330; DOI=10.1074/jbc.M603928200;
RA   Lamalice L., Houle F., Huot J.;
RT   "Phosphorylation of Tyr1214 within VEGFR-2 triggers the recruitment of
RT   Nck and activation of Fyn leading to SAPK2/p38 activation and
RT   endothelial cell migration in response to VEGF.";
RL   J. Biol. Chem. 281:34009-34020(2006).
RN   [26]
RP   SUBCELLULAR LOCATION, UBIQUITINATION, AND DEGRADATION.
RX   PubMed=17004325; DOI=10.1111/j.1600-0854.2006.00462.x;
RA   Ewan L.C., Jopling H.M., Jia H., Mittar S., Bagherzadeh A.,
RA   Howell G.J., Walker J.H., Zachary I.C., Ponnambalam S.;
RT   "Intrinsic tyrosine kinase activity is required for vascular
RT   endothelial growth factor receptor 2 ubiquitination, sorting and
RT   degradation in endothelial cells.";
RL   Traffic 7:1270-1282(2006).
RN   [27]
RP   FUNCTION IN ACTIVATION OF AKT1; PHOSPHORYLATION OF PLCG1 AND NOS3 AND
RP   REGULATION OF NITRIC OXIDE PRODUCTION, PHOSPHORYLATION AT TYR-801, AND
RP   MUTAGENESIS OF TYR-801.
RX   PubMed=17303569; DOI=10.1074/jbc.M609048200;
RA   Blanes M.G., Oubaha M., Rautureau Y., Gratton J.P.;
RT   "Phosphorylation of tyrosine 801 of vascular endothelial growth factor
RT   receptor-2 is necessary for Akt-dependent endothelial nitric-oxide
RT   synthase activation and nitric oxide release from endothelial cells.";
RL   J. Biol. Chem. 282:10660-10669(2007).
RN   [28]
RP   INTERACTION WITH DAB2IP.
RX   PubMed=19033661; DOI=10.1172/JCI36168;
RA   Zhang H., He Y., Dai S., Xu Z., Luo Y., Wan T., Luo D., Jones D.,
RA   Tang S., Chen H., Sessa W.C., Min W.;
RT   "AIP1 functions as an endogenous inhibitor of VEGFR2-mediated
RT   signaling and inflammatory angiogenesis in mice.";
RL   J. Clin. Invest. 118:3904-3916(2008).
RN   [29]
RP   PHOSPHORYLATION AT TYR-951; TYR-1175 AND TYR-1214, AND
RP   DEPHOSPHORYLATION BY PTPRB.
RX   PubMed=19136612; DOI=10.1096/fj.08-123810;
RA   Mellberg S., Dimberg A., Bahram F., Hayashi M., Rennel E., Ameur A.,
RA   Westholm J.O., Larsson E., Lindahl P., Cross M.J., Claesson-Welsh L.;
RT   "Transcriptional profiling reveals a critical role for tyrosine
RT   phosphatase VE-PTP in regulation of VEGFR2 activity and endothelial
RT   cell morphogenesis.";
RL   FASEB J. 23:1490-1502(2009).
RN   [30]
RP   PHOSPHORYLATION AT TYR-801; TYR-951; TYR-996; TYR-1054; TYR-1059;
RP   TYR-1175 AND TYR-1214; DEPHOSPHORYLATION AT TYR-951; TYR-996;
RP   TYR-1054; TYR-1059; TYR-1175 AND TYR-1214 BY PTPRJ.
RX   PubMed=18936167; DOI=10.1128/MCB.01374-08;
RA   Chabot C., Spring K., Gratton J.P., Elchebly M., Royal I.;
RT   "New role for the protein tyrosine phosphatase DEP-1 in Akt activation
RT   and endothelial cell survival.";
RL   Mol. Cell. Biol. 29:241-253(2009).
RN   [31]
RP   FUNCTION AS VEGFA RECEPTOR IN TUMOR ANGIOGENESIS, SUBCELLULAR
RP   LOCATION, AND UBIQUITINATION.
RX   PubMed=19834490; DOI=10.1038/cdd.2009.152;
RA   Zhang Z., Neiva K.G., Lingen M.W., Ellis L.M., Nor J.E.;
RT   "VEGF-dependent tumor angiogenesis requires inverse and reciprocal
RT   regulation of VEGFR1 and VEGFR2.";
RL   Cell Death Differ. 17:499-512(2010).
RN   [32]
RP   FUNCTION IN LYMPHANGIOGENESIS (ISOFORM 2).
RX   PubMed=20179233; DOI=10.1158/1078-0432.CCR-09-1936;
RA   Becker J., Pavlakovic H., Ludewig F., Wilting F., Weich H.A.,
RA   Albuquerque R., Ambati J., Wilting J.;
RT   "Neuroblastoma progression correlates with downregulation of the
RT   lymphangiogenesis inhibitor sVEGFR-2.";
RL   Clin. Cancer Res. 16:1431-1441(2010).
RN   [33]
RP   INTERACTION WITH VEGFC AND FLT4, SUBCELLULAR LOCATION, AND FUNCTION IN
RP   ANGIOGENESIS.
RX   PubMed=20224550; DOI=10.1038/emboj.2010.30;
RA   Nilsson I., Bahram F., Li X., Gualandi L., Koch S., Jarvius M.,
RA   Soderberg O., Anisimov A., Kholova I., Pytowski B., Baldwin M.,
RA   Yla-Herttuala S., Alitalo K., Kreuger J., Claesson-Welsh L.;
RT   "VEGF receptor 2/-3 heterodimers detected in situ by proximity
RT   ligation on angiogenic sprouts.";
RL   EMBO J. 29:1377-1388(2010).
RN   [34]
RP   SUBCELLULAR LOCATION.
RX   PubMed=21539813; DOI=10.1016/j.bbrc.2011.04.093;
RA   Jopling H.M., Howell G.J., Gamper N., Ponnambalam S.;
RT   "The VEGFR2 receptor tyrosine kinase undergoes constitutive endosome-
RT   to-plasma membrane recycling.";
RL   Biochem. Biophys. Res. Commun. 410:170-176(2011).
RN   [35]
RP   FUNCTION IN LYMPHANGIOGENESIS, AND INTERACTION WITH FLT4 AND VEGFC.
RX   PubMed=20705758; DOI=10.1182/blood-2010-02-267427;
RA   Nakao S., Zandi S., Hata Y., Kawahara S., Arita R., Schering A.,
RA   Sun D., Melhorn M.I., Ito Y., Lara-Castillo N., Ishibashi T.,
RA   Hafezi-Moghadam A.;
RT   "Blood vessel endothelial VEGFR-2 delays lymphangiogenesis: an
RT   endogenous trapping mechanism links lymph- and angiogenesis.";
RL   Blood 117:1081-1090(2011).
RN   [36]
RP   REVIEW ON ROLE IN ANGIOGENESIS.
RX   PubMed=17002866;
RA   Shibuya M.;
RT   "Differential roles of vascular endothelial growth factor receptor-1
RT   and receptor-2 in angiogenesis.";
RL   J. Biochem. Mol. Biol. 39:469-478(2006).
RN   [37]
RP   REVIEW.
RX   PubMed=17658244; DOI=10.1016/j.cellsig.2007.05.013;
RA   Holmes K., Roberts O.L., Thomas A.M., Cross M.J.;
RT   "Vascular endothelial growth factor receptor-2: structure, function,
RT   intracellular signalling and therapeutic inhibition.";
RL   Cell. Signal. 19:2003-2012(2007).
RN   [38]
RP   REVIEW ON STRUCTURE AND FUNCTION.
RX   PubMed=18680722; DOI=10.1016/j.bbrc.2008.07.121;
RA   Roskoski R. Jr.;
RT   "VEGF receptor protein-tyrosine kinases: structure and regulation.";
RL   Biochem. Biophys. Res. Commun. 375:287-291(2008).
RN   [39]
RP   REVIEW ON ROLE IN ANGIOGENESIS AND CANCER.
RX   PubMed=19230644; DOI=10.1016/j.ceb.2008.12.012;
RA   Lohela M., Bry M., Tammela T., Alitalo K.;
RT   "VEGFs and receptors involved in angiogenesis versus
RT   lymphangiogenesis.";
RL   Curr. Opin. Cell Biol. 21:154-165(2009).
RN   [40]
RP   REVIEW ON LIGAND SPECIFICITY; FUNCTION; STRUCTURE; PHOSPHORYLATION AND
RP   SIGNALING.
RX   PubMed=19761875; DOI=10.1016/j.bbapap.2009.09.002;
RA   Grunewald F.S., Prota A.E., Giese A., Ballmer-Hofer K.;
RT   "Structure-function analysis of VEGF receptor activation and the role
RT   of coreceptors in angiogenic signaling.";
RL   Biochim. Biophys. Acta 1804:567-580(2010).
RN   [41]
RP   REVIEW ON ROLE IN ANGIOGENESIS AND CANCER.
RX   PubMed=20462514; DOI=10.1016/j.bbcan.2010.04.004;
RA   Guo S., Colbert L.S., Fuller M., Zhang Y., Gonzalez-Perez R.R.;
RT   "Vascular endothelial growth factor receptor-2 in breast cancer.";
RL   Biochim. Biophys. Acta 1806:108-121(2010).
RN   [42]
RP   REVIEW ON ROLE IN ANGIOGENESIS AND CANCER.
RX   PubMed=21779435; DOI=10.1177/1947601910392987;
RA   Shibuya M.;
RT   "Tyrosine kinase receptor Flt/VEGFR family: its characterization
RT   related to angiogenesis and cancer.";
RL   Genes Cancer 1:1119-1123(2010).
RN   [43]
RP   REVIEW ON LIGAND SPECIFICITY; FUNCTION; STRUCTURE; PHOSPHORYLATION AND
RP   SIGNALING.
RX   PubMed=21711246; DOI=10.1042/BJ20110301;
RA   Koch S., Tugues S., Li X., Gualandi L., Claesson-Welsh L.;
RT   "Signal transduction by vascular endothelial growth factor
RT   receptors.";
RL   Biochem. J. 437:169-183(2011).
RN   [44]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-982 AND SER-984, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [45]
RP   FUNCTION, AND INTERACTION WITH PDCD6.
RX   PubMed=21893193; DOI=10.1016/j.cellsig.2011.08.013;
RA   Rho S.B., Song Y.J., Lim M.C., Lee S.H., Kim B.R., Park S.Y.;
RT   "Programmed cell death 6 (PDCD6) inhibits angiogenesis through
RT   PI3K/mTOR/p70S6K pathway by interacting of VEGFR-2.";
RL   Cell. Signal. 24:131-139(2012).
RN   [46]
RP   ENZYME REGULATION, REDOX-ACTIVE DISULFIDE BOND, AND MUTAGENESIS OF
RP   CYS-1045.
RX   PubMed=23199280; DOI=10.1089/ars.2012.4565;
RA   Tao B.B., Liu S.Y., Zhang C.C., Fu W., Cai W.J., Wang Y., Shen Q.,
RA   Wang M.J., Chen Y., Zhang L.J., Zhu Y.Z., Zhu Y.C.;
RT   "VEGFR2 functions as an H(2)S-targeting receptor protein kinase with
RT   its novel Cys1045-Cys1024 disulfide bond serving as a specific
RT   molecular switch for hydrogen sulfide actions in vascular endothelial
RT   cells.";
RL   Antioxid. Redox Signal. 19:448-464(2013).
RN   [47]
RP   INTERACTION WITH ERN1, AND SUBCELLULAR LOCATION.
RX   PubMed=23529610; DOI=10.1161/CIRCULATIONAHA.112.001337;
RA   Zeng L., Xiao Q., Chen M., Margariti A., Martin D., Ivetic A., Xu H.,
RA   Mason J., Wang W., Cockerill G., Mori K., Li J.Y., Chien S., Hu Y.,
RA   Xu Q.;
RT   "Vascular endothelial cell growth-activated XBP1 splicing in
RT   endothelial cells is crucial for angiogenesis.";
RL   Circulation 127:1712-1722(2013).
RN   [48]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 806-1171, FUNCTION,
RP   PHOSPHORYLATION AT TYR-1059, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=10368301; DOI=10.1016/S0969-2126(99)80042-2;
RA   McTigue M.A., Wickersham J.A., Pinko C., Showalter R.E., Parast C.V.,
RA   Tempczyk-Russell A., Gehring M.R., Mroczkowski B., Kan C.-C.,
RA   Villafranca J.E., Appelt K.;
RT   "Crystal structure of the kinase domain of human vascular endothelial
RT   growth factor receptor 2: a key enzyme in angiogenesis.";
RL   Structure 7:319-330(1999).
RN   [49]
RP   X-RAY CRYSTALLOGRAPHY (1.71 ANGSTROMS) OF 806-1171 IN COMPLEX WITH
RP   SYNTHETIC INHIBITOR.
RX   PubMed=15837294; DOI=10.1016/j.bmcl.2005.03.034;
RA   Miyazaki Y., Matsunaga S., Tang J., Maeda Y., Nakano M.,
RA   Philippe R.J., Shibahara M., Liu W., Sato H., Wang L., Nolte R.T.;
RT   "Novel 4-amino-furo[2,3-d]pyrimidines as Tie-2 and VEGFR2 dual
RT   inhibitors.";
RL   Bioorg. Med. Chem. Lett. 15:2203-2207(2005).
RN   [50]
RP   X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 815-1171 IN COMPLEX WITH
RP   SYNTHETIC INHIBITOR.
RX   PubMed=17253678; DOI=10.1021/jm061107l;
RA   Hodous B.L., Geuns-Meyer S.D., Hughes P.E., Albrecht B.K., Bellon S.,
RA   Bready J., Caenepeel S., Cee V.J., Chaffee S.C., Coxon A., Emery M.,
RA   Fretland J., Gallant P., Gu Y., Hoffman D., Johnson R.E., Kendall R.,
RA   Kim J.L., Long A.M., Morrison M., Olivieri P.R., Patel V.F.,
RA   Polverino A., Rose P., Tempest P., Wang L., Whittington D.A., Zhao H.;
RT   "Evolution of a highly selective and potent 2-(pyridin-2-yl)-1,3,5-
RT   triazine Tie-2 kinase inhibitor.";
RL   J. Med. Chem. 50:611-626(2007).
RN   [51]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 806-1171 IN COMPLEX WITH
RP   SYNTHETIC INHIBITOR, AND FUNCTION.
RX   PubMed=18529047; DOI=10.1021/jm8001185;
RA   Peifer C., Selig R., Kinkel K., Ott D., Totzke F., Schaechtele C.,
RA   Heidenreich R., Roecken M., Schollmeyer D., Laufer S.;
RT   "Design, synthesis, and biological evaluation of novel 3-aryl-4-(1H-
RT   indole-3yl)-1,5-dihydro-2H-pyrrole-2-ones as vascular endothelial
RT   growth factor receptor (VEGF-R) inhibitors.";
RL   J. Med. Chem. 51:3814-3824(2008).
RN   [52]
RP   X-RAY CRYSTALLOGRAPHY (2.70 ANGSTROMS) OF 657-764, SUBUNIT,
RP   AUTOPHOSPHORYLATION, FUNCTION IN VEGFA SIGNALING AND ACTIVATION OF
RP   MAPK1/ERK2 AND MAPK3/ERK1, AND MUTAGENESIS OF ARG-726 AND ASP-731.
RX   PubMed=20080685; DOI=10.1073/pnas.0914052107;
RA   Yang Y., Xie P., Opatowsky Y., Schlessinger J.;
RT   "Direct contacts between extracellular membrane-proximal domains are
RT   required for VEGF receptor activation and cell signaling.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:1906-1911(2010).
RN   [53]
RP   X-RAY CRYSTALLOGRAPHY (2.70 ANGSTROMS) OF 120-326 IN COMPLEX WITH
RP   VEGFC, INTERACTION WITH VEGFC, DOMAIN, DISULFIDE BONDS, AND
RP   GLYCOSYLATION AT ASN-143; ASN-245 AND ASN-318.
RX   PubMed=20145116; DOI=10.1073/pnas.0914318107;
RA   Leppanen V.M., Prota A.E., Jeltsch M., Anisimov A., Kalkkinen N.,
RA   Strandin T., Lankinen H., Goldman A., Ballmer-Hofer K., Alitalo K.;
RT   "Structural determinants of growth factor binding and specificity by
RT   VEGF receptor 2.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:2425-2430(2010).
RN   [54]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 220-338 IN COMPLEX WITH
RP   ANTIBODY FRAGMENT, DISULFIDE BOND, AND GLYCOSYLATION AT ASN-245 AND
RP   ASN-318.
RX   PubMed=21827946; DOI=10.1016/j.str.2011.01.019;
RA   Franklin M.C., Navarro E.C., Wang Y., Patel S., Singh P., Zhang Y.,
RA   Persaud K., Bari A., Griffith H., Shen L., Balderes P., Kussie P.;
RT   "The structural basis for the function of two anti-VEGF receptor 2
RT   antibodies.";
RL   Structure 19:1097-1107(2011).
RN   [55]
RP   VARIANT HCI SER-1147.
RX   PubMed=11807987; DOI=10.1002/gcc.10028;
RA   Walter J.W., North P.E., Waner M., Mizeracki A., Blei F.,
RA   Walker J.W.T., Reinisch J.F., Marchuk D.A.;
RT   "Somatic mutation of vascular endothelial growth factor receptors in
RT   juvenile hemangioma.";
RL   Genes Chromosomes Cancer 33:295-303(2002).
RN   [56]
RP   VARIANTS [LARGE SCALE ANALYSIS] LEU-275 AND ARG-873.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
RN   [57]
RP   VARIANTS [LARGE SCALE ANALYSIS] ARG-2; MET-136; GLY-248; ILE-297;
RP   VAL-462; HIS-472; ARG-482; ARG-539; MET-689; ASN-814 AND THR-1065.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [58]
RP   VARIANT HCI SUSCEPTIBILITY ARG-482.
RX   PubMed=18931684; DOI=10.1038/nm.1877;
RA   Jinnin M., Medici D., Park L., Limaye N., Liu Y., Boscolo E.,
RA   Bischoff J., Vikkula M., Boye E., Olsen B.R.;
RT   "Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2
RT   signaling in infantile hemangioma.";
RL   Nat. Med. 14:1236-1246(2008).
CC   -!- FUNCTION: Tyrosine-protein kinase that acts as a cell-surface
CC       receptor for VEGFA, VEGFC and VEGFD. Plays an essential role in
CC       the regulation of angiogenesis, vascular development, vascular
CC       permeability, and embryonic hematopoiesis. Promotes proliferation,
CC       survival, migration and differentiation of endothelial cells.
CC       Promotes reorganization of the actin cytoskeleton. Isoforms
CC       lacking a transmembrane domain, such as isoform 2 and isoform 3,
CC       may function as decoy receptors for VEGFA, VEGFC and/or VEGFD.
CC       Isoform 2 plays an important role as negative regulator of VEGFA-
CC       and VEGFC-mediated lymphangiogenesis by limiting the amount of
CC       free VEGFA and/or VEGFC and preventing their binding to FLT4.
CC       Modulates FLT1 and FLT4 signaling by forming heterodimers. Binding
CC       of vascular growth factors to isoform 1 leads to the activation of
CC       several signaling cascades. Activation of PLCG1 leads to the
CC       production of the cellular signaling molecules diacylglycerol and
CC       inositol 1,4,5-trisphosphate and the activation of protein kinase
CC       C. Mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP
CC       kinase signaling pathway, as well as of the AKT1 signaling
CC       pathway. Mediates phosphorylation of PIK3R1, the regulatory
CC       subunit of phosphatidylinositol 3-kinase, reorganization of the
CC       actin cytoskeleton and activation of PTK2/FAK1. Required for
CC       VEGFA-mediated induction of NOS2 and NOS3, leading to the
CC       production of the signaling molecule nitric oxide (NO) by
CC       endothelial cells. Phosphorylates PLCG1. Promotes phosphorylation
CC       of FYN, NCK1, NOS3, PIK3R1, PTK2/FAK1 and SRC.
CC       {ECO:0000269|PubMed:10102632, ECO:0000269|PubMed:10368301,
CC       ECO:0000269|PubMed:10600473, ECO:0000269|PubMed:11387210,
CC       ECO:0000269|PubMed:12649282, ECO:0000269|PubMed:1417831,
CC       ECO:0000269|PubMed:15026417, ECO:0000269|PubMed:15215251,
CC       ECO:0000269|PubMed:15962004, ECO:0000269|PubMed:16966330,
CC       ECO:0000269|PubMed:17303569, ECO:0000269|PubMed:18529047,
CC       ECO:0000269|PubMed:19668192, ECO:0000269|PubMed:19834490,
CC       ECO:0000269|PubMed:20080685, ECO:0000269|PubMed:20224550,
CC       ECO:0000269|PubMed:20705758, ECO:0000269|PubMed:21893193,
CC       ECO:0000269|PubMed:7929439, ECO:0000269|PubMed:9160888,
CC       ECO:0000269|PubMed:9804796, ECO:0000269|PubMed:9837777}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028, ECO:0000269|PubMed:10037737,
CC       ECO:0000269|PubMed:10102632}.
CC   -!- ENZYME REGULATION: Present in an inactive conformation in the
CC       absence of bound ligand. Binding of VEGFA, VEGFC or VEGFD leads to
CC       dimerization and activation by autophosphorylation on tyrosine
CC       residues. Inhibited by the small molecule PTK inhibitor SU5614
CC       ((3Z)-5-Chloro-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-
CC       dihydro-2H-indol-2-one). May be regulated by hydrogen sulfide
CC       (H(2)S) levels via a H(2)S-sensitive intracellular disulfide bond.
CC       {ECO:0000269|PubMed:10037737, ECO:0000269|PubMed:10102632,
CC       ECO:0000269|PubMed:15215251, ECO:0000269|PubMed:23199280}.
CC   -!- SUBUNIT: Homodimer in the presence of bound dimeric VEGFA, VEGFC
CC       or VEGFD ligands; monomeric in the absence of bound ligands. Can
CC       also form heterodimers with FLT1/VEGFR1 and FLT4/VEGFR2. Interacts
CC       (tyrosine phosphorylated) with LFYN, NCK1, PLCG1. Interacts
CC       (tyrosine-phosphorylated active form preferentially) with DAB2IP
CC       (via C2 domain and active form preferentially); the interaction
CC       occurs at the late phase of VEGFA response and inhibits KDR/VEGFR2
CC       activity. Interacts with SHBSH2D2A/TSAD, GRB2, MYOF, CBL and
CC       PDCD6. Interacts with HIV-1 Tat (PubMed:10102632, PubMed:10590123,
CC       PubMed:12649282, PubMed:12881528, PubMed:1417831, PubMed:15026417,
CC       PubMed:15215251, PubMed:15837294, PubMed:15962004,
CC       PubMed:16966330, PubMed:17253678, PubMed:18529047,
CC       PubMed:18593464, PubMed:19033661, PubMed:19668192,
CC       PubMed:20080685, PubMed:20145116, PubMed:20224550,
CC       PubMed:20705758, PubMed:21827946, PubMed:21893193,
CC       PubMed:9160888). Interacts (via C-terminus domain) with ERN1 (via
CC       kinase domain); the interaction is facilitated in a XBP1 isoform
CC       1- and vascular endothelial growth factor (VEGF)-dependent manner
CC       in endothelial cells (PubMed:23529610).
CC       {ECO:0000269|PubMed:10102632, ECO:0000269|PubMed:10590123,
CC       ECO:0000269|PubMed:12649282, ECO:0000269|PubMed:12881528,
CC       ECO:0000269|PubMed:1417831, ECO:0000269|PubMed:15026417,
CC       ECO:0000269|PubMed:15215251, ECO:0000269|PubMed:15837294,
CC       ECO:0000269|PubMed:15962004, ECO:0000269|PubMed:16966330,
CC       ECO:0000269|PubMed:17253678, ECO:0000269|PubMed:18529047,
CC       ECO:0000269|PubMed:18593464, ECO:0000269|PubMed:19033661,
CC       ECO:0000269|PubMed:19668192, ECO:0000269|PubMed:20080685,
CC       ECO:0000269|PubMed:20145116, ECO:0000269|PubMed:20224550,
CC       ECO:0000269|PubMed:20705758, ECO:0000269|PubMed:21827946,
CC       ECO:0000269|PubMed:21893193, ECO:0000269|PubMed:23529610,
CC       ECO:0000269|PubMed:9160888}.
CC   -!- INTERACTION:
CC       P46108:CRK; NbExp=2; IntAct=EBI-1005487, EBI-886;
CC       P35916:FLT4; NbExp=5; IntAct=EBI-1005487, EBI-1005467;
CC       O60565:GREM1; NbExp=4; IntAct=EBI-1005487, EBI-944395;
CC       P98160:HSPG2; NbExp=5; IntAct=EBI-1005487, EBI-947664;
CC       P17301:ITGA2; NbExp=2; IntAct=EBI-1005487, EBI-702960;
CC       P09382:LGALS1; NbExp=3; IntAct=EBI-1005487, EBI-1048875;
CC       P08581:MET; NbExp=3; IntAct=EBI-1005487, EBI-1039152;
CC       P16333:NCK1; NbExp=3; IntAct=EBI-1005487, EBI-389883;
CC       O14786:NRP1; NbExp=2; IntAct=EBI-1005487, EBI-1187100;
CC       O75340:PDCD6; NbExp=4; IntAct=EBI-1005487, EBI-352915;
CC       Q12913:PTPRJ; NbExp=4; IntAct=EBI-1005487, EBI-2264500;
CC       P12931:SRC; NbExp=2; IntAct=EBI-1005487, EBI-621482;
CC       P15692:VEGFA; NbExp=5; IntAct=EBI-1005487, EBI-1026643;
CC       P15692-4:VEGFA; NbExp=6; IntAct=EBI-1005487, EBI-1026691;
CC   -!- SUBCELLULAR LOCATION: Cell junction {ECO:0000250}. Endoplasmic
CC       reticulum {ECO:0000269|PubMed:23529610}. Note=Localized with RAP1A
CC       at cell-cell junctions (By similarity). Colocalizes with ERN1 and
CC       XBP1 in the endoplasmic reticulum in endothelial cells in a
CC       vascular endothelial growth factor (VEGF)-dependent manner
CC       (PubMed:23529610). {ECO:0000250, ECO:0000269|PubMed:23529610}.
CC   -!- SUBCELLULAR LOCATION: Isoform 1: Cell membrane; Single-pass type I
CC       membrane protein. Cytoplasm. Nucleus. Cytoplasmic vesicle. Early
CC       endosome. Note=Detected on caveolae-enriched lipid rafts at the
CC       cell surface. Is recycled from the plasma membrane to endosomes
CC       and back again. Phosphorylation triggered by VEGFA binding
CC       promotes internalization and subsequent degradation. VEGFA binding
CC       triggers internalization and translocation to the nucleus.
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Secreted {ECO:0000305}.
CC   -!- SUBCELLULAR LOCATION: Isoform 3: Secreted.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1; Synonyms=mbVegfr-2;
CC         IsoId=P35968-1; Sequence=Displayed;
CC       Name=2; Synonyms=sVegfr-2;
CC         IsoId=P35968-2; Sequence=VSP_041988, VSP_041989;
CC       Name=3; Synonyms=VEGFR2-712;
CC         IsoId=P35968-3; Sequence=VSP_041990, VSP_041991;
CC   -!- TISSUE SPECIFICITY: Detected in cornea (at protein level). Widely
CC       expressed. {ECO:0000269|PubMed:19668192}.
CC   -!- DOMAIN: The second and third Ig-like C2-type (immunoglobulin-like)
CC       domains are sufficient for VEGFC binding.
CC       {ECO:0000269|PubMed:20145116}.
CC   -!- PTM: N-glycosylated. {ECO:0000269|PubMed:20145116,
CC       ECO:0000269|PubMed:21827946, ECO:0000269|PubMed:9160888}.
CC   -!- PTM: Ubiquitinated. Tyrosine phosphorylation of the receptor
CC       promotes its poly-ubiquitination, leading to its degradation via
CC       the proteasome or lysosomal proteases.
CC       {ECO:0000269|PubMed:12649282, ECO:0000269|PubMed:17004325,
CC       ECO:0000269|PubMed:19834490}.
CC   -!- PTM: Autophosphorylated on tyrosine residues upon ligand binding.
CC       Autophosphorylation occurs in trans, i.e. one subunit of the
CC       dimeric receptor phosphorylates tyrosine residues on the other
CC       subunit. Phosphorylation at Tyr-951 is important for interaction
CC       with SH2D2A/TSAD and VEGFA-mediated reorganization of the actin
CC       cytoskeleton. Phosphorylation at Tyr-1175 is important for
CC       interaction with PLCG1 and SHB. Phosphorylation at Tyr-1214 is
CC       important for interaction with NCK1 and FYN. Dephosphorylated by
CC       PTPRB. Dephosphorylated by PTPRJ at Tyr-951, Tyr-996, Tyr-1054,
CC       Tyr-1059, Tyr-1175 and Tyr-1214. {ECO:0000269|PubMed:10037737,
CC       ECO:0000269|PubMed:10102632, ECO:0000269|PubMed:10368301,
CC       ECO:0000269|PubMed:11387210, ECO:0000269|PubMed:15215251,
CC       ECO:0000269|PubMed:15962004, ECO:0000269|PubMed:18936167,
CC       ECO:0000269|PubMed:19136612}.
CC   -!- PTM: The inhibitory disulfide bond between Cys-1024 and Cys-1045
CC       may serve as a specific molecular switch for H(2)S-induced
CC       modification that regulates VEGFR2 function.
CC   -!- DISEASE: Hemangioma, capillary infantile (HCI) [MIM:602089]: A
CC       condition characterized by dull red, firm, dome-shaped
CC       hemangiomas, sharply demarcated from surrounding skin, usually
CC       presenting at birth or occurring within the first two or three
CC       months of life. They result from highly proliferative, localized
CC       growth of capillary endothelium and generally undergo regression
CC       and involution without scarring. {ECO:0000269|PubMed:11807987,
CC       ECO:0000269|PubMed:18931684}. Note=Disease susceptibility is
CC       associated with variations affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Note=Plays a major role in tumor angiogenesis. In case of
CC       HIV-1 infection, the interaction with extracellular viral Tat
CC       protein seems to enhance angiogenesis in Kaposi's sarcoma lesions.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. CSF-1/PDGF receptor subfamily.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- SIMILARITY: Contains 7 Ig-like C2-type (immunoglobulin-like)
CC       domains. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; EU826563; ACF47599.1; -; mRNA.
DR   EMBL; FJ899739; ACR78514.1; -; mRNA.
DR   EMBL; AF035121; AAB88005.1; -; mRNA.
DR   EMBL; AF063658; AAC16450.1; -; mRNA.
DR   EMBL; AC021220; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC111194; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC131822; AAI31823.1; -; mRNA.
DR   EMBL; L04947; AAA59459.1; -; mRNA.
DR   EMBL; X61656; CAA43837.1; -; mRNA.
DR   EMBL; X89776; CAA61916.1; -; Genomic_DNA.
DR   CCDS; CCDS3497.1; -. [P35968-1]
DR   PIR; JC1402; JC1402.
DR   RefSeq; NP_002244.1; NM_002253.2. [P35968-1]
DR   UniGene; Hs.479756; -.
DR   PDB; 1VR2; X-ray; 2.40 A; A=806-1171.
DR   PDB; 1Y6A; X-ray; 2.10 A; A=806-1171.
DR   PDB; 1Y6B; X-ray; 2.10 A; A=806-1171.
DR   PDB; 1YWN; X-ray; 1.71 A; A=806-1171.
DR   PDB; 2M59; NMR; -; A/B=759-795.
DR   PDB; 2MET; NMR; -; A/B/C=759-795.
DR   PDB; 2MEU; NMR; -; A/B=759-795.
DR   PDB; 2OH4; X-ray; 2.05 A; A=806-1171.
DR   PDB; 2P2H; X-ray; 1.95 A; A=815-1171.
DR   PDB; 2P2I; X-ray; 2.40 A; A/B=815-1171.
DR   PDB; 2QU5; X-ray; 2.95 A; A=815-1171.
DR   PDB; 2QU6; X-ray; 2.10 A; A/B=815-1171.
DR   PDB; 2RL5; X-ray; 2.65 A; A=815-1171.
DR   PDB; 2X1W; X-ray; 2.70 A; L/M/N/O=120-326.
DR   PDB; 2X1X; X-ray; 3.10 A; R=120-326.
DR   PDB; 2XIR; X-ray; 1.50 A; A=806-1171.
DR   PDB; 3B8Q; X-ray; 2.75 A; A/B=815-1171.
DR   PDB; 3B8R; X-ray; 2.70 A; A/B=815-1171.
DR   PDB; 3BE2; X-ray; 1.75 A; A=815-1171.
DR   PDB; 3C7Q; X-ray; 2.10 A; A=806-1171.
DR   PDB; 3CJF; X-ray; 2.15 A; A=806-1168.
DR   PDB; 3CJG; X-ray; 2.25 A; A=806-1168.
DR   PDB; 3CP9; X-ray; 2.50 A; A/B=815-1171.
DR   PDB; 3CPB; X-ray; 2.70 A; A/B=815-1171.
DR   PDB; 3CPC; X-ray; 2.40 A; A/B=815-1171.
DR   PDB; 3DTW; X-ray; 2.90 A; A/B=815-1171.
DR   PDB; 3EFL; X-ray; 2.20 A; A/B=815-1171.
DR   PDB; 3EWH; X-ray; 1.60 A; A=815-1171.
DR   PDB; 3KVQ; X-ray; 2.70 A; A=657-764.
DR   PDB; 3S35; X-ray; 2.20 A; X=220-338.
DR   PDB; 3S36; X-ray; 3.20 A; X=220-338.
DR   PDB; 3S37; X-ray; 2.70 A; X=220-338.
DR   PDB; 3U6J; X-ray; 2.15 A; A=815-1171.
DR   PDB; 3V2A; X-ray; 3.20 A; R=2-764.
DR   PDB; 3V6B; X-ray; 3.20 A; R=132-548.
DR   PDB; 3VHE; X-ray; 1.55 A; A=811-1169.
DR   PDB; 3VHK; X-ray; 2.49 A; A=806-1171.
DR   PDB; 3VID; X-ray; 2.30 A; A=813-1168.
DR   PDB; 3VNT; X-ray; 1.64 A; A=806-1171.
DR   PDB; 3VO3; X-ray; 1.52 A; A=806-1171.
DR   PDB; 3WZD; X-ray; 1.57 A; A=814-1172.
DR   PDB; 3WZE; X-ray; 1.90 A; A=814-1172.
DR   PDB; 4AG8; X-ray; 1.95 A; A=806-1171.
DR   PDB; 4AGC; X-ray; 2.00 A; A=787-1171.
DR   PDB; 4AGD; X-ray; 2.81 A; A=787-1171.
DR   PDB; 4ASD; X-ray; 2.03 A; A=787-1171.
DR   PDB; 4ASE; X-ray; 1.83 A; A=787-1171.
DR   PDB; 5EW3; X-ray; 2.50 A; A/B=806-1171.
DR   PDBsum; 1VR2; -.
DR   PDBsum; 1Y6A; -.
DR   PDBsum; 1Y6B; -.
DR   PDBsum; 1YWN; -.
DR   PDBsum; 2M59; -.
DR   PDBsum; 2MET; -.
DR   PDBsum; 2MEU; -.
DR   PDBsum; 2OH4; -.
DR   PDBsum; 2P2H; -.
DR   PDBsum; 2P2I; -.
DR   PDBsum; 2QU5; -.
DR   PDBsum; 2QU6; -.
DR   PDBsum; 2RL5; -.
DR   PDBsum; 2X1W; -.
DR   PDBsum; 2X1X; -.
DR   PDBsum; 2XIR; -.
DR   PDBsum; 3B8Q; -.
DR   PDBsum; 3B8R; -.
DR   PDBsum; 3BE2; -.
DR   PDBsum; 3C7Q; -.
DR   PDBsum; 3CJF; -.
DR   PDBsum; 3CJG; -.
DR   PDBsum; 3CP9; -.
DR   PDBsum; 3CPB; -.
DR   PDBsum; 3CPC; -.
DR   PDBsum; 3DTW; -.
DR   PDBsum; 3EFL; -.
DR   PDBsum; 3EWH; -.
DR   PDBsum; 3KVQ; -.
DR   PDBsum; 3S35; -.
DR   PDBsum; 3S36; -.
DR   PDBsum; 3S37; -.
DR   PDBsum; 3U6J; -.
DR   PDBsum; 3V2A; -.
DR   PDBsum; 3V6B; -.
DR   PDBsum; 3VHE; -.
DR   PDBsum; 3VHK; -.
DR   PDBsum; 3VID; -.
DR   PDBsum; 3VNT; -.
DR   PDBsum; 3VO3; -.
DR   PDBsum; 3WZD; -.
DR   PDBsum; 3WZE; -.
DR   PDBsum; 4AG8; -.
DR   PDBsum; 4AGC; -.
DR   PDBsum; 4AGD; -.
DR   PDBsum; 4ASD; -.
DR   PDBsum; 4ASE; -.
DR   PDBsum; 5EW3; -.
DR   ProteinModelPortal; P35968; -.
DR   SMR; P35968; 122-330, 667-756, 759-795, 815-1171.
DR   BioGrid; 109992; 31.
DR   DIP; DIP-486N; -.
DR   IntAct; P35968; 32.
DR   MINT; MINT-127732; -.
DR   STRING; 9606.ENSP00000263923; -.
DR   BindingDB; P35968; -.
DR   ChEMBL; CHEMBL2111336; -.
DR   DrugBank; DB06626; Axitinib.
DR   DrugBank; DB08875; Cabozantinib.
DR   DrugBank; DB09078; Lenvatinib.
DR   DrugBank; DB09079; Nintedanib.
DR   DrugBank; DB06589; Pazopanib.
DR   DrugBank; DB08901; Ponatinib.
DR   DrugBank; DB05578; Ramucirumab.
DR   DrugBank; DB08896; Regorafenib.
DR   DrugBank; DB00398; Sorafenib.
DR   DrugBank; DB01268; Sunitinib.
DR   GuidetoPHARMACOLOGY; 1813; -.
DR   iPTMnet; P35968; -.
DR   PhosphoSite; P35968; -.
DR   BioMuta; KDR; -.
DR   DMDM; 9087218; -.
DR   PaxDb; P35968; -.
DR   PRIDE; P35968; -.
DR   DNASU; 3791; -.
DR   Ensembl; ENST00000263923; ENSP00000263923; ENSG00000128052. [P35968-1]
DR   GeneID; 3791; -.
DR   KEGG; hsa:3791; -.
DR   UCSC; uc003has.3; human. [P35968-1]
DR   UCSC; uc011bzx.2; human. [P35968-2]
DR   CTD; 3791; -.
DR   GeneCards; KDR; -.
DR   HGNC; HGNC:6307; KDR.
DR   HPA; CAB004028; -.
DR   HPA; HPA030893; -.
DR   MalaCards; KDR; -.
DR   MIM; 191306; gene.
DR   MIM; 602089; phenotype.
DR   neXtProt; NX_P35968; -.
DR   Orphanet; 91415; Familial capillary hemangioma.
DR   PharmGKB; PA30086; -.
DR   eggNOG; KOG0200; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00760000118923; -.
DR   HOVERGEN; HBG053432; -.
DR   InParanoid; P35968; -.
DR   KO; K05098; -.
DR   OMA; PSYMISY; -.
DR   OrthoDB; EOG75F4CC; -.
DR   PhylomeDB; P35968; -.
DR   TreeFam; TF325768; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   Reactome; R-HSA-194306; Neurophilin interactions with VEGF and VEGFR.
DR   Reactome; R-HSA-195399; VEGF binds to VEGFR leading to receptor dimerization.
DR   Reactome; R-HSA-216083; Integrin cell surface interactions.
DR   Reactome; R-HSA-3928663; EPHA-mediated growth cone collapse.
DR   Reactome; R-HSA-4420097; VEGFA-VEGFR2 Pathway.
DR   Reactome; R-HSA-5218921; VEGFR2 mediated cell proliferation.
DR   SignaLink; P35968; -.
DR   EvolutionaryTrace; P35968; -.
DR   GeneWiki; Kinase_insert_domain_receptor; -.
DR   GenomeRNAi; 3791; -.
DR   NextBio; 14887; -.
DR   PRO; PR:P35968; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   Bgee; P35968; -.
DR   CleanEx; HS_KDR; -.
DR   ExpressionAtlas; P35968; baseline and differential.
DR   Genevisible; P35968; HS.
DR   GO; GO:0030054; C:cell junction; ISS:UniProtKB.
DR   GO; GO:0016023; C:cytoplasmic membrane-bounded vesicle; IEA:UniProtKB-SubCell.
DR   GO; GO:0005769; C:early endosome; ISS:BHF-UCL.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB.
DR   GO; GO:0005768; C:endosome; IDA:UniProtKB.
DR   GO; GO:0009897; C:external side of plasma membrane; IEA:Ensembl.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0045121; C:membrane raft; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0097443; C:sorting endosome; ISS:BHF-UCL.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0019838; F:growth factor binding; IPI:BHF-UCL.
DR   GO; GO:0051879; F:Hsp90 protein binding; TAS:BHF-UCL.
DR   GO; GO:0005178; F:integrin binding; IPI:BHF-UCL.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0004716; F:receptor signaling protein tyrosine kinase activity; TAS:BHF-UCL.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; TAS:BHF-UCL.
DR   GO; GO:0038085; F:vascular endothelial growth factor binding; IPI:BHF-UCL.
DR   GO; GO:0005021; F:vascular endothelial growth factor-activated receptor activity; IDA:UniProtKB.
DR   GO; GO:0001525; P:angiogenesis; TAS:BHF-UCL.
DR   GO; GO:0048754; P:branching morphogenesis of an epithelial tube; IEA:Ensembl.
DR   GO; GO:0055074; P:calcium ion homeostasis; IEA:Ensembl.
DR   GO; GO:0035584; P:calcium-mediated signaling using intracellular calcium source; IMP:UniProtKB.
DR   GO; GO:0045165; P:cell fate commitment; IEA:Ensembl.
DR   GO; GO:0048469; P:cell maturation; IEA:Ensembl.
DR   GO; GO:0002042; P:cell migration involved in sprouting angiogenesis; ISS:BHF-UCL.
DR   GO; GO:0035924; P:cellular response to vascular endothelial growth factor stimulus; IDA:UniProtKB.
DR   GO; GO:0035162; P:embryonic hemopoiesis; ISS:UniProtKB.
DR   GO; GO:0045446; P:endothelial cell differentiation; IEA:Ensembl.
DR   GO; GO:0003158; P:endothelium development; ISS:UniProtKB.
DR   GO; GO:0030198; P:extracellular matrix organization; TAS:Reactome.
DR   GO; GO:0048286; P:lung alveolus development; IEA:Ensembl.
DR   GO; GO:0001945; P:lymph vessel development; IEA:Ensembl.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:2000352; P:negative regulation of endothelial cell apoptotic process; IDA:UniProtKB.
DR   GO; GO:0001541; P:ovarian follicle development; IEA:Ensembl.
DR   GO; GO:0038083; P:peptidyl-tyrosine autophosphorylation; ISS:BHF-UCL.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; IMP:UniProtKB.
DR   GO; GO:0030335; P:positive regulation of cell migration; IMP:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IMP:UniProtKB.
DR   GO; GO:0038033; P:positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0010595; P:positive regulation of endothelial cell migration; IMP:BHF-UCL.
DR   GO; GO:0001938; P:positive regulation of endothelial cell proliferation; IMP:UniProtKB.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IMP:UniProtKB.
DR   GO; GO:0051894; P:positive regulation of focal adhesion assembly; IDA:BHF-UCL.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IDA:UniProtKB.
DR   GO; GO:0002053; P:positive regulation of mesenchymal cell proliferation; IEA:Ensembl.
DR   GO; GO:0051770; P:positive regulation of nitric-oxide synthase biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0014068; P:positive regulation of phosphatidylinositol 3-kinase signaling; IDA:UniProtKB.
DR   GO; GO:0050927; P:positive regulation of positive chemotaxis; IDA:BHF-UCL.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:2001214; P:positive regulation of vasculogenesis; ISS:UniProtKB.
DR   GO; GO:0048597; P:post-embryonic camera-type eye morphogenesis; IEA:Ensembl.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0008360; P:regulation of cell shape; IDA:BHF-UCL.
DR   GO; GO:0045601; P:regulation of endothelial cell differentiation; IEA:Ensembl.
DR   GO; GO:1901532; P:regulation of hematopoietic progenitor cell differentiation; IEA:Ensembl.
DR   GO; GO:0023014; P:signal transduction by protein phosphorylation; TAS:GOC.
DR   GO; GO:0043129; P:surfactant homeostasis; IEA:Ensembl.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; TAS:ProtInc.
DR   GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0001570; P:vasculogenesis; ISS:UniProtKB.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   Gene3D; 2.60.40.10; -; 8.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR013098; Ig_I-set.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR013151; Immunoglobulin.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR001824; Tyr_kinase_rcpt_3_CS.
DR   InterPro; IPR009136; VEGFR2_rcpt.
DR   PANTHER; PTHR24416:SF45; PTHR24416:SF45; 3.
DR   Pfam; PF07679; I-set; 2.
DR   Pfam; PF00047; ig; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   PRINTS; PR01834; VEGFRECEPTR2.
DR   SMART; SM00409; IG; 4.
DR   SMART; SM00408; IGc2; 2.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF48726; SSF48726; 7.
DR   SUPFAM; SSF56112; SSF56112; 2.
DR   PROSITE; PS50835; IG_LIKE; 5.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00240; RECEPTOR_TYR_KIN_III; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Angiogenesis; ATP-binding;
KW   Cell junction; Cell membrane; Complete proteome; Cytoplasm;
KW   Cytoplasmic vesicle; Developmental protein; Differentiation;
KW   Disulfide bond; Endoplasmic reticulum; Endosome; Glycoprotein;
KW   Host-virus interaction; Immunoglobulin domain; Kinase; Membrane;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Polymorphism; Receptor;
KW   Reference proteome; Repeat; Secreted; Signal; Transferase;
KW   Transmembrane; Transmembrane helix; Tyrosine-protein kinase;
KW   Ubl conjugation.
FT   SIGNAL        1     19       {ECO:0000255}.
FT   CHAIN        20   1356       Vascular endothelial growth factor
FT                                receptor 2.
FT                                /FTId=PRO_0000016771.
FT   TOPO_DOM     20    764       Extracellular. {ECO:0000255}.
FT   TRANSMEM    765    785       Helical. {ECO:0000255}.
FT   TOPO_DOM    786   1356       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       46    110       Ig-like C2-type 1.
FT   DOMAIN      141    207       Ig-like C2-type 2.
FT   DOMAIN      224    320       Ig-like C2-type 3.
FT   DOMAIN      328    414       Ig-like C2-type 4.
FT   DOMAIN      421    548       Ig-like C2-type 5.
FT   DOMAIN      551    660       Ig-like C2-type 6.
FT   DOMAIN      667    753       Ig-like C2-type 7.
FT   DOMAIN      834   1162       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     840    848       ATP. {ECO:0000305}.
FT   ACT_SITE   1028   1028       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING     868    868       ATP. {ECO:0000305}.
FT   SITE       1175   1175       Interaction with SHB. {ECO:0000250}.
FT   MOD_RES     801    801       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:17303569,
FT                                ECO:0000269|PubMed:18936167}.
FT   MOD_RES     951    951       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:15962004,
FT                                ECO:0000269|PubMed:18936167,
FT                                ECO:0000269|PubMed:19136612}.
FT   MOD_RES     982    982       Phosphoserine.
FT                                {ECO:0000244|PubMed:21406692}.
FT   MOD_RES     984    984       Phosphoserine.
FT                                {ECO:0000244|PubMed:21406692}.
FT   MOD_RES     996    996       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:10102632,
FT                                ECO:0000269|PubMed:18936167}.
FT   MOD_RES    1054   1054       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:10037737,
FT                                ECO:0000269|PubMed:10102632,
FT                                ECO:0000269|PubMed:15215251,
FT                                ECO:0000269|PubMed:15962004,
FT                                ECO:0000269|PubMed:18936167}.
FT   MOD_RES    1059   1059       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:10037737,
FT                                ECO:0000269|PubMed:10102632,
FT                                ECO:0000269|PubMed:10368301,
FT                                ECO:0000269|PubMed:15215251,
FT                                ECO:0000269|PubMed:15962004,
FT                                ECO:0000269|PubMed:18936167}.
FT   MOD_RES    1175   1175       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:11387210,
FT                                ECO:0000269|PubMed:18936167,
FT                                ECO:0000269|PubMed:19136612}.
FT   MOD_RES    1214   1214       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:11387210,
FT                                ECO:0000269|PubMed:15962004,
FT                                ECO:0000269|PubMed:18936167,
FT                                ECO:0000269|PubMed:19136612}.
FT   MOD_RES    1231   1231       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P35918}.
FT   MOD_RES    1235   1235       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P35918}.
FT   MOD_RES    1238   1238       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:P35918}.
FT   MOD_RES    1305   1305       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:15962004}.
FT   MOD_RES    1309   1309       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:15962004}.
FT   MOD_RES    1319   1319       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:15962004}.
FT   CARBOHYD     46     46       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD     66     66       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD     96     96       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    143    143       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:20145116}.
FT   CARBOHYD    158    158       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    245    245       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:20145116,
FT                                ECO:0000269|PubMed:21827946}.
FT   CARBOHYD    318    318       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:20145116,
FT                                ECO:0000269|PubMed:21827946}.
FT   CARBOHYD    374    374       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    395    395       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    511    511       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    523    523       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    580    580       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    613    613       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    619    619       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    631    631       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    675    675       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    704    704       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    721    721       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     53    103       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    150    200
FT   DISULFID    246    307
FT   DISULFID    445    530       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    571    642       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    688    737       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID   1024   1045       Redox-active.
FT   VAR_SEQ     663    678       ERVAPTITGNLENQTT -> GRETILDHCAEAVGMP (in
FT                                isoform 2).
FT                                {ECO:0000303|PubMed:19668192}.
FT                                /FTId=VSP_041988.
FT   VAR_SEQ     679   1356       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:19668192}.
FT                                /FTId=VSP_041989.
FT   VAR_SEQ     712    712       G -> E (in isoform 3).
FT                                {ECO:0000303|PubMed:18593464}.
FT                                /FTId=VSP_041990.
FT   VAR_SEQ     713   1356       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:18593464}.
FT                                /FTId=VSP_041991.
FT   VARIANT       2      2       Q -> R (in a lung adenocarcinoma sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042053.
FT   VARIANT     136    136       V -> M (in dbSNP:rs35636987).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042054.
FT   VARIANT     248    248       A -> G (in a renal clear cell carcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042055.
FT   VARIANT     275    275       R -> L (in a colorectal cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036126.
FT   VARIANT     297    297       V -> I (in dbSNP:rs2305948).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_022071.
FT   VARIANT     462    462       L -> V (in dbSNP:rs56286620).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042056.
FT   VARIANT     472    472       Q -> H (in dbSNP:rs1870377).
FT                                {ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_020353.
FT   VARIANT     482    482       C -> R (in HCI susceptibility; expression
FT                                of FLT1 in hemangioma endothelial cells
FT                                is markedly reduced and KDR activity is
FT                                increased compared to controls; low FLT1
FT                                expression in hemangioma cells is caused
FT                                by reduced activity of a pathway
FT                                involving ITGB1, ANTXR1, KDR and
FT                                NFATC2IP; the mutation predicts to result
FT                                in loss-of-function and disruption of the
FT                                normal association of these molecules;
FT                                dbSNP:rs34231037).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:18931684}.
FT                                /FTId=VAR_042057.
FT   VARIANT     539    539       G -> R (in dbSNP:rs55716939).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042058.
FT   VARIANT     689    689       T -> M (in dbSNP:rs34038364).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042059.
FT   VARIANT     814    814       D -> N (in dbSNP:rs35603373).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042060.
FT   VARIANT     848    848       V -> E (strongly reduced
FT                                autophosphorylation and kinase activity;
FT                                dbSNP:rs1139776).
FT                                {ECO:0000269|PubMed:10037737,
FT                                ECO:0000269|PubMed:1656371}.
FT                                /FTId=VAR_046679.
FT   VARIANT     873    873       G -> R (in a colorectal cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036127.
FT   VARIANT     952    952       V -> I (in dbSNP:rs13129474).
FT                                /FTId=VAR_046680.
FT   VARIANT    1065   1065       A -> T (in dbSNP:rs56302315).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042061.
FT   VARIANT    1147   1147       P -> S (in HCI; somatic mutation).
FT                                {ECO:0000269|PubMed:11807987}.
FT                                /FTId=VAR_063147.
FT   MUTAGEN     726    726       R->A: Strongly reduced
FT                                autophosphorylation and activation of MAP
FT                                kinases. {ECO:0000269|PubMed:20080685}.
FT   MUTAGEN     731    731       D->A: Strongly reduced
FT                                autophosphorylation and activation of MAP
FT                                kinases. {ECO:0000269|PubMed:20080685}.
FT   MUTAGEN     801    801       Y->F: Abolishes stimulation of nitric
FT                                oxide synthesis.
FT                                {ECO:0000269|PubMed:17303569}.
FT   MUTAGEN     868    868       K->M: Loss of enzyme activity.
FT                                {ECO:0000269|PubMed:11387210}.
FT   MUTAGEN     951    951       Y->F: Abolishes reorganization of the
FT                                actin cytoskeleton and cell migration in
FT                                response to VEGFA.
FT                                {ECO:0000269|PubMed:15962004}.
FT   MUTAGEN     996    996       Y->F: Strongly reduced
FT                                autophosphorylation. Reduces
FT                                phosphorylation of PLCG1.
FT                                {ECO:0000269|PubMed:10102632}.
FT   MUTAGEN    1045   1045       C->A: Significantly higher kinase
FT                                activity. {ECO:0000269|PubMed:23199280}.
FT   MUTAGEN    1054   1054       Y->F: Strongly reduced
FT                                autophosphorylation. Abolishes
FT                                phosphorylation of downstream signaling
FT                                proteins; when associated with F-1059.
FT                                {ECO:0000269|PubMed:10102632}.
FT   MUTAGEN    1059   1059       Y->F: Strongly reduced
FT                                autophosphorylation. Abolishes
FT                                phosphorylation of downstream signaling
FT                                proteins; when associated with F-1054.
FT                                {ECO:0000269|PubMed:10102632}.
FT   MUTAGEN    1175   1175       Y->F: Abolishes phosphorylation of PLCG1
FT                                and MAP kinases in response to VEGFA.
FT                                {ECO:0000269|PubMed:11387210}.
FT   MUTAGEN    1214   1214       Y->F: Loss of phosphorylation site.
FT                                Abolishes reorganization of the actin
FT                                cytoskeleton in response to VEGFA.
FT                                {ECO:0000269|PubMed:16966330}.
FT   CONFLICT      2      2       Q -> E (in Ref. 4; AAC16450).
FT                                {ECO:0000305}.
FT   CONFLICT    772    772       A -> T (in Ref. 7; AAA59459/CAA43837).
FT                                {ECO:0000305}.
FT   CONFLICT    787    787       R -> G (in Ref. 7; AAA59459/CAA43837).
FT                                {ECO:0000305}.
FT   CONFLICT    835    835       K -> N (in Ref. 7; AAA59459/CAA43837).
FT                                {ECO:0000305}.
FT   CONFLICT   1347   1347       S -> T (in Ref. 7; AAA59459/CAA43837).
FT                                {ECO:0000305}.
FT   STRAND      134    138       {ECO:0000244|PDB:2X1W}.
FT   STRAND      145    148       {ECO:0000244|PDB:2X1W}.
FT   STRAND      152    154       {ECO:0000244|PDB:2X1W}.
FT   STRAND      159    164       {ECO:0000244|PDB:2X1W}.
FT   TURN        165    167       {ECO:0000244|PDB:2X1W}.
FT   STRAND      168    170       {ECO:0000244|PDB:2X1W}.
FT   STRAND      174    176       {ECO:0000244|PDB:2X1W}.
FT   STRAND      178    180       {ECO:0000244|PDB:2X1W}.
FT   TURN        181    183       {ECO:0000244|PDB:2X1W}.
FT   STRAND      184    188       {ECO:0000244|PDB:2X1W}.
FT   HELIX       189    191       {ECO:0000244|PDB:2X1W}.
FT   TURN        192    194       {ECO:0000244|PDB:2X1W}.
FT   STRAND      196    202       {ECO:0000244|PDB:2X1W}.
FT   STRAND      214    218       {ECO:0000244|PDB:2X1W}.
FT   STRAND      223    230       {ECO:0000244|PDB:3S35}.
FT   STRAND      234    238       {ECO:0000244|PDB:3S35}.
FT   STRAND      242    250       {ECO:0000244|PDB:3S35}.
FT   STRAND      257    261       {ECO:0000244|PDB:3S35}.
FT   HELIX       269    272       {ECO:0000244|PDB:3S35}.
FT   STRAND      279    282       {ECO:0000244|PDB:3S35}.
FT   STRAND      285    296       {ECO:0000244|PDB:3S35}.
FT   HELIX       299    301       {ECO:0000244|PDB:3S35}.
FT   STRAND      303    310       {ECO:0000244|PDB:3S35}.
FT   STRAND      315    328       {ECO:0000244|PDB:3S35}.
FT   STRAND      676    679       {ECO:0000244|PDB:3KVQ}.
FT   STRAND      684    687       {ECO:0000244|PDB:3KVQ}.
FT   STRAND      697    706       {ECO:0000244|PDB:3KVQ}.
FT   STRAND      713    716       {ECO:0000244|PDB:3KVQ}.
FT   TURN        717    720       {ECO:0000244|PDB:3KVQ}.
FT   STRAND      721    724       {ECO:0000244|PDB:3KVQ}.
FT   HELIX       729    731       {ECO:0000244|PDB:3KVQ}.
FT   STRAND      733    740       {ECO:0000244|PDB:3KVQ}.
FT   STRAND      746    755       {ECO:0000244|PDB:3KVQ}.
FT   HELIX       760    794       {ECO:0000244|PDB:2M59}.
FT   STRAND      804    806       {ECO:0000244|PDB:4AGC}.
FT   TURN        808    810       {ECO:0000244|PDB:4ASE}.
FT   TURN        813    815       {ECO:0000244|PDB:3VHE}.
FT   HELIX       817    819       {ECO:0000244|PDB:2XIR}.
FT   HELIX       824    827       {ECO:0000244|PDB:2XIR}.
FT   HELIX       831    833       {ECO:0000244|PDB:2XIR}.
FT   STRAND      834    842       {ECO:0000244|PDB:2XIR}.
FT   STRAND      844    858       {ECO:0000244|PDB:2XIR}.
FT   STRAND      862    870       {ECO:0000244|PDB:2XIR}.
FT   HELIX       876    892       {ECO:0000244|PDB:2XIR}.
FT   STRAND      901    905       {ECO:0000244|PDB:2XIR}.
FT   STRAND      907    910       {ECO:0000244|PDB:3WZD}.
FT   STRAND      913    917       {ECO:0000244|PDB:2XIR}.
FT   HELIX       924    929       {ECO:0000244|PDB:2XIR}.
FT   TURN        930    933       {ECO:0000244|PDB:3VO3}.
FT   STRAND      934    936       {ECO:0000244|PDB:2XIR}.
FT   TURN        995    998       {ECO:0000244|PDB:3VO3}.
FT   HELIX      1002   1021       {ECO:0000244|PDB:2XIR}.
FT   STRAND     1024   1026       {ECO:0000244|PDB:4AGC}.
FT   HELIX      1031   1033       {ECO:0000244|PDB:2XIR}.
FT   STRAND     1034   1036       {ECO:0000244|PDB:2XIR}.
FT   HELIX      1038   1040       {ECO:0000244|PDB:2XIR}.
FT   STRAND     1042   1044       {ECO:0000244|PDB:2XIR}.
FT   HELIX      1048   1050       {ECO:0000244|PDB:2XIR}.
FT   TURN       1053   1055       {ECO:0000244|PDB:2XIR}.
FT   STRAND     1059   1062       {ECO:0000244|PDB:2XIR}.
FT   STRAND     1065   1067       {ECO:0000244|PDB:2XIR}.
FT   HELIX      1069   1071       {ECO:0000244|PDB:2XIR}.
FT   HELIX      1074   1079       {ECO:0000244|PDB:2XIR}.
FT   HELIX      1084   1099       {ECO:0000244|PDB:2XIR}.
FT   STRAND     1105   1108       {ECO:0000244|PDB:3C7Q}.
FT   HELIX      1113   1121       {ECO:0000244|PDB:2XIR}.
FT   HELIX      1133   1142       {ECO:0000244|PDB:2XIR}.
FT   HELIX      1147   1149       {ECO:0000244|PDB:2XIR}.
FT   HELIX      1153   1167       {ECO:0000244|PDB:2XIR}.
SQ   SEQUENCE   1356 AA;  151527 MW;  59E7C44B05CFEBB3 CRC64;
     MQSKVLLAVA LWLCVETRAA SVGLPSVSLD LPRLSIQKDI LTIKANTTLQ ITCRGQRDLD
     WLWPNNQSGS EQRVEVTECS DGLFCKTLTI PKVIGNDTGA YKCFYRETDL ASVIYVYVQD
     YRSPFIASVS DQHGVVYITE NKNKTVVIPC LGSISNLNVS LCARYPEKRF VPDGNRISWD
     SKKGFTIPSY MISYAGMVFC EAKINDESYQ SIMYIVVVVG YRIYDVVLSP SHGIELSVGE
     KLVLNCTART ELNVGIDFNW EYPSSKHQHK KLVNRDLKTQ SGSEMKKFLS TLTIDGVTRS
     DQGLYTCAAS SGLMTKKNST FVRVHEKPFV AFGSGMESLV EATVGERVRI PAKYLGYPPP
     EIKWYKNGIP LESNHTIKAG HVLTIMEVSE RDTGNYTVIL TNPISKEKQS HVVSLVVYVP
     PQIGEKSLIS PVDSYQYGTT QTLTCTVYAI PPPHHIHWYW QLEEECANEP SQAVSVTNPY
     PCEEWRSVED FQGGNKIEVN KNQFALIEGK NKTVSTLVIQ AANVSALYKC EAVNKVGRGE
     RVISFHVTRG PEITLQPDMQ PTEQESVSLW CTADRSTFEN LTWYKLGPQP LPIHVGELPT
     PVCKNLDTLW KLNATMFSNS TNDILIMELK NASLQDQGDY VCLAQDRKTK KRHCVVRQLT
     VLERVAPTIT GNLENQTTSI GESIEVSCTA SGNPPPQIMW FKDNETLVED SGIVLKDGNR
     NLTIRRVRKE DEGLYTCQAC SVLGCAKVEA FFIIEGAQEK TNLEIIILVG TAVIAMFFWL
     LLVIILRTVK RANGGELKTG YLSIVMDPDE LPLDEHCERL PYDASKWEFP RDRLKLGKPL
     GRGAFGQVIE ADAFGIDKTA TCRTVAVKML KEGATHSEHR ALMSELKILI HIGHHLNVVN
     LLGACTKPGG PLMVIVEFCK FGNLSTYLRS KRNEFVPYKT KGARFRQGKD YVGAIPVDLK
     RRLDSITSSQ SSASSGFVEE KSLSDVEEEE APEDLYKDFL TLEHLICYSF QVAKGMEFLA
     SRKCIHRDLA ARNILLSEKN VVKICDFGLA RDIYKDPDYV RKGDARLPLK WMAPETIFDR
     VYTIQSDVWS FGVLLWEIFS LGASPYPGVK IDEEFCRRLK EGTRMRAPDY TTPEMYQTML
     DCWHGEPSQR PTFSELVEHL GNLLQANAQQ DGKDYIVLPI SETLSMEEDS GLSLPTSPVS
     CMEEEEVCDP KFHYDNTAGI SQYLQNSKRK SRPVSVKTFE DIPLEEPEVK VIPDDNQTDS
     GMVLASEELK TLEDRTKLSP SFGGMVPSKS RESVASEGSN QTSGYQSGYH SDDTDTTVYS
     SEEAELLKLI EIGVQTGSTA QILQPDSGTT LSSPPV
//
ID   LYAG_HUMAN              Reviewed;         952 AA.
AC   P10253; Q09GN4; Q14351; Q16302; Q8IWE7;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   11-JAN-2011, sequence version 4.
DT   20-JAN-2016, entry version 188.
DE   RecName: Full=Lysosomal alpha-glucosidase;
DE            EC=3.2.1.20;
DE   AltName: Full=Acid maltase;
DE   AltName: Full=Aglucosidase alfa;
DE   Contains:
DE     RecName: Full=76 kDa lysosomal alpha-glucosidase;
DE   Contains:
DE     RecName: Full=70 kDa lysosomal alpha-glucosidase;
DE   Flags: Precursor;
GN   Name=GAA;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 70-89; 123-145;
RP   204-215; 230-249; 332-345; 349-370; 394-409; 480-513; 520-545;
RP   703-719; 726-731 AND 795-803, AND VARIANTS ARG-199; HIS-223 AND
RP   ILE-780.
RC   TISSUE=Placenta, Testis, and Urine;
RX   PubMed=3049072;
RA   Hoefsloot L.H., Hoogeveen-Westerveld M., Kroos M.A., van Beeumen J.,
RA   Reuser A.J.J., Oostra B.A.;
RT   "Primary structure and processing of lysosomal alpha-glucosidase;
RT   homology with the intestinal sucrase-isomaltase complex.";
RL   EMBO J. 7:1697-1704(1988).
RN   [2]
RP   SEQUENCE REVISION.
RA   Reuser A.J.J.;
RL   Submitted (JUN-1990) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT ILE-780.
RX   PubMed=2268276;
RA   Hoefsloot L.H., Hoogeveen-Westerveld M., Reuser A.J.J., Oostra B.A.;
RT   "Characterization of the human lysosomal alpha-glucosidase gene.";
RL   Biochem. J. 272:493-497(1990).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT ILE-780.
RX   PubMed=2111708; DOI=10.1089/dna.1990.9.85;
RA   Martiniuk F., Mehler M., Tzall S., Meredith G., Hirschhorn R.;
RT   "Sequence of the cDNA and 5'-flanking region for human acid alpha-
RT   glucosidase, detection of an intron in the 5' untranslated leader
RT   sequence, definition of 18-bp polymorphisms, and differences with
RT   previous cDNA and amino acid sequences.";
RL   DNA Cell Biol. 9:85-94(1990).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA], VARIANT GSD2 LEU-457, AND VARIANTS
RP   ARG-199; HIS-223 AND ILE-780.
RA   Ghaffari S.R., Sabokbar T., Tahmasebi S., Dastan J.;
RT   "Identification of a novel mutation in the acid alpha glucosidase gene
RT   causing juvenile form of Pompe disease in Iranian population.";
RL   Submitted (AUG-2006) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R.,
RA   Gnerre S., Goldstein S., Grafham D.V., Grocock R., Hafez N.,
RA   Hagopian D.S., Hart E., Norman C.H., Humphray S., Jaffe D.B.,
RA   Jones M., Kamal M., Khodiyar V.K., LaButti K., Laird G., Lehoczky J.,
RA   Liu X., Lokyitsang T., Loveland J., Lui A., Macdonald P., Major J.E.,
RA   Matthews L., Mauceli E., McCarroll S.A., Mihalev A.H., Mudge J.,
RA   Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., Schwartz D.C.,
RA   Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in
RT   the human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Duodenum;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 631-680, AND VARIANT GSD2 HIS-645.
RX   PubMed=7695647; DOI=10.1006/bbrc.1995.1418;
RA   Lin C.-Y., Shieh J.-J.;
RT   "Identification of a de novo point mutation resulting in infantile
RT   form of Pompe's disease.";
RL   Biochem. Biophys. Res. Commun. 208:886-893(1995).
RN   [9]
RP   MUTAGENESIS OF TRP-516 AND ASP-518, AND ACTIVE SITE.
RX   PubMed=1856189;
RA   Hermans M.M.P., Kroos M.A., van Beeumen J., Oostra B.A.,
RA   Reuser A.J.J.;
RT   "Human lysosomal alpha-glucosidase. Characterization of the catalytic
RT   site.";
RL   J. Biol. Chem. 266:13507-13512(1991).
RN   [10]
RP   GLYCOSYLATION AT ASN-140; ASN-233; ASN-390; ASN-470; ASN-652; ASN-882
RP   AND ASN-925.
RX   PubMed=8435067;
RA   Hermans M.M.P., Wisselaar H.A., Kroos M.A., Oostra B.A.,
RA   Reuser A.J.J.;
RT   "Human lysosomal alpha-glucosidase: functional characterization of the
RT   glycosylation sites.";
RL   Biochem. J. 289:681-686(1993).
RN   [11]
RP   GLYCOSYLATION AT ASN-470.
RX   PubMed=12754519; DOI=10.1038/nbt827;
RA   Zhang H., Li X.-J., Martin D.B., Aebersold R.;
RT   "Identification and quantification of N-linked glycoproteins using
RT   hydrazide chemistry, stable isotope labeling and mass spectrometry.";
RL   Nat. Biotechnol. 21:660-666(2003).
RN   [12]
RP   REVIEW ON VARIANTS.
RX   PubMed=7603530; DOI=10.1002/mus.880181414;
RA   Reuser A.J.J., Kroos M.A., Hermans M.M.P., Bijvoet A.G.A.,
RA   Verbeet M.P., van Diggelen O.P., Kleijer W.J., van der Ploeg A.T.;
RT   "Glycogenosis type II (acid maltase deficiency).";
RL   Muscle Nerve 3:S61-S69(1995).
RN   [13]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-390.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [14]
RP   SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS].
RC   TISSUE=Placenta;
RX   PubMed=17897319; DOI=10.1111/j.1600-0854.2007.00643.x;
RA   Schroeder B., Wrocklage C., Pan C., Jaeger R., Koesters B.,
RA   Schaefer H., Elsaesser H.-P., Mann M., Hasilik A.;
RT   "Integral and associated lysosomal membrane proteins.";
RL   Traffic 8:1676-1686(2007).
RN   [15]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-140; ASN-470; ASN-882 AND
RP   ASN-925.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [19]
RP   VARIANT ASN-91.
RX   PubMed=2203258;
RA   Martiniuk F., Bodkin M., Tzall S., Hirschhorn R.;
RT   "Identification of the base-pair substitution responsible for a human
RT   acid alpha glucosidase allele with lower 'affinity' for glycogen (GAA
RT   2) and transient gene expression in deficient cells.";
RL   Am. J. Hum. Genet. 47:440-445(1990).
RN   [20]
RP   VARIANT GSD2 THR-318.
RX   PubMed=1652892;
RA   Zhong N., Martiniuk F., Tzall S., Hirschhorn R.;
RT   "Identification of a missense mutation in one allele of a patient with
RT   Pompe disease, and use of endonuclease digestion of PCR-amplified RNA
RT   to demonstrate lack of mRNA expression from the second allele.";
RL   Am. J. Hum. Genet. 49:635-645(1991).
RN   [21]
RP   VARIANT GSD2 LYS-521.
RX   PubMed=1898413; DOI=10.1016/0006-291X(91)91906-S;
RA   Hermans M.M.P., de Graaff E., Kroos M.A., Wisselaar H.A., Oostra B.A.,
RA   Reuser A.J.J.;
RT   "Identification of a point mutation in the human lysosomal alpha-
RT   glucosidase gene causing infantile glycogenosis type II.";
RL   Biochem. Biophys. Res. Commun. 179:919-926(1991).
RN   [22]
RP   VARIANTS GSD2 ARG-643 AND TRP-725.
RX   PubMed=8401535; DOI=10.1002/humu.1380020406;
RA   Hermans M.M.P., Kroos M.A., de Graaff E., Oostra B.A., Reuser A.J.J.;
RT   "Two mutations affecting the transport and maturation of lysosomal
RT   alpha-glucosidase in an adult case of glycogen storage disease type
RT   II.";
RL   Hum. Mutat. 2:268-273(1993).
RN   [23]
RP   VARIANT GSD2 GLU-645, AND VARIANTS ILE-816 AND ILE-927.
RX   PubMed=8094613;
RA   Hermans M.M.P., de Graaff E., Kroos M.A., Wisselaar H.A.,
RA   Willemsen R., Oostra B.A., Reuser A.J.J.;
RT   "The conservative substitution Asp-645-->Glu in lysosomal alpha-
RT   glucosidase affects transport and phosphorylation of the enzyme in an
RT   adult patient with glycogen-storage disease type II.";
RL   Biochem. J. 289:687-693(1993).
RN   [24]
RP   VARIANT GSD2 GLU-645, AND VARIANTS ILE-816 AND ILE-927.
RX   PubMed=1684505; DOI=10.1089/dna.1991.10.681;
RA   Martiniuk F., Mehler M., Bodkin M., Tzall S., Hirschhorn K., Zhong N.,
RA   Hirschhorn R.;
RT   "Identification of a missense mutation in an adult-onset patient with
RT   glycogenosis type II expressing only one allele.";
RL   DNA Cell Biol. 10:681-687(1991).
RN   [25]
RP   VARIANTS ILE-816 AND ILE-927.
RX   PubMed=8486380; DOI=10.1006/geno.1993.1185;
RA   Hermans M.M.P., Svetkey L.P., Oostra B.A., Chen Y.T., Reuser A.J.J.;
RT   "The loss of a polymorphic glycosylation site caused by Thr-927-->Ile
RT   is linked to a second polymorphic Val-816-->Ile substitution in
RT   lysosomal alpha-glucosidase of American blacks.";
RL   Genomics 16:300-301(1993).
RN   [26]
RP   VARIANT GSD2 VAL-519.
RX   PubMed=7866409; DOI=10.1002/humu.1380040410;
RA   Huie M.L., Hirschhorn R., Chen A.S., Martiniuk F., Zhong N.;
RT   "Mutation at the catalytic site (M519V) in glycogen storage disease
RT   type II (Pompe disease).";
RL   Hum. Mutat. 4:291-293(1994).
RN   [27]
RP   VARIANT GSD2 TRP-647.
RX   PubMed=7981676; DOI=10.1093/hmg/3.7.1081;
RA   Huie M.L., Chen A.S., Brooks S.S., Grix A., Hirschhorn R.;
RT   "A de novo 13 nt deletion, a newly identified C647W missense mutation
RT   and a deletion of exon 18 in infantile onset glycogen storage disease
RT   type II (GSDII).";
RL   Hum. Mol. Genet. 3:1081-1087(1994).
RN   [28]
RP   VARIANT GSD2 LEU-545.
RX   PubMed=7881422; DOI=10.1093/hmg/3.12.2213;
RA   Hermans M.M.P., de Graaff E., Kroos M.A., Mohkamsing S., Eussen B.J.,
RA   Joosse M., Willemsen R., Kleijer W.J., Oostra B.A., Reuser A.J.J.;
RT   "The effect of a single base pair deletion (delta T525) and a C1634T
RT   missense mutation (Pro545Leu) on the expression of lysosomal alpha-
RT   glucosidase in patients with glycogen storage disease type II.";
RL   Hum. Mol. Genet. 3:2213-2218(1994).
RN   [29]
RP   VARIANTS GSD2 ARG-299 AND LYS-903 DEL, AND VARIANTS ARG-199; HIS-223
RP   AND ILE-780.
RX   PubMed=7717400;
RA   Boerkoel C.F., Exelbert R., Nicastri C., Nichols R.C., Miller F.W.,
RA   Plotz P.H., Raben N.;
RT   "Leaky splicing mutation in the acid maltase gene is associated with
RT   delayed onset of glycogenosis type II.";
RL   Am. J. Hum. Genet. 56:887-897(1995).
RN   [30]
RP   VARIANT LYS-689.
RX   PubMed=8912788; DOI=10.1111/j.1469-1809.1996.tb00433.x;
RA   Huie M.L., Menaker M., McAlpine P.J., Hirschhorn R.;
RT   "Identification of an E689K substitution as the molecular basis of the
RT   human acid alpha-glucosidase type 4 allozyme (GAA*4).";
RL   Ann. Hum. Genet. 60:365-368(1996).
RN   [31]
RP   VARIANT GSD2 VAL-529.
RX   PubMed=8834250; DOI=10.1007/BF02267074;
RA   Tsunoda H., Ohshima T., Tohyama J., Sasaki M., Sakuragawa N.,
RA   Martiniuk F.;
RT   "Acid alpha-glucosidase deficiency: identification and expression of a
RT   missense mutation (S529V) in a Japanese adult phenotype.";
RL   Hum. Genet. 97:496-499(1996).
RN   [32]
RP   VARIANTS GSD2 ASN-645; TRP-647; SER-648; GLN-672 AND TRP-672.
RX   PubMed=9535769; DOI=10.1006/bbrc.1998.8255;
RA   Huie M.L., Tsujino S., Brooks S.S., Engel A., Elias E., Bonthron D.T.,
RA   Bessley C., Shanske S., Dimauro S., Goto Y., Hirschhorn R.;
RT   "Glycogen storage disease type II: identification of four novel
RT   missense mutations (D645N, G648S, R672W, R672Q) and two
RT   insertions/deletions in the acid alpha-glucosidase locus of patients
RT   of differing phenotype.";
RL   Biochem. Biophys. Res. Commun. 244:921-927(1998).
RN   [33]
RP   VARIANT GSD2 ARG-309.
RX   PubMed=9660056;
RA   Kroos M.A., van Leenen D., Verbiest J., Reuser A.J.J., Hermans M.M.P.;
RT   "Glycogen storage disease type II: identification of a dinucleotide
RT   deletion and a common missense mutation in the lysosomal alpha-
RT   glucosidase gene.";
RL   Clin. Genet. 53:379-382(1998).
RN   [34]
RP   VARIANTS GSD2 PRO-566; ARG-643 AND ARG-768, AND VARIANTS ASN-91;
RP   ARG-199 AND HIS-223.
RX   PubMed=9521422;
RX   DOI=10.1002/(SICI)1098-1004(1998)11:3<209::AID-HUMU5>3.3.CO;2-R;
RA   Hermans M.M.P., Kroos M.A., Smeitink J.A.M., van der Ploeg A.T.,
RA   Kleijer W.J., Reuser A.J.J.;
RT   "Glycogen storage disease type II: genetic and biochemical analysis of
RT   novel mutations in infantile patients from Turkish ancestry.";
RL   Hum. Mutat. 11:209-215(1998).
RN   [35]
RP   VARIANT GSD2 GLY-VAL-PRO-VAL-SER-ASN-925 INS.
RX   PubMed=10206684;
RX   DOI=10.1002/(SICI)1098-1004(1998)11:5<413::AID-HUMU16>3.0.CO;2-I;
RA   Beesley C.E., Child A.H., Yacoub M.Y.;
RT   "The identification of five novel mutations in the lysosomal acid
RT   alpha-(1,4) glucosidase gene from patients with glycogen storage
RT   disease type II.";
RL   Hum. Mutat. 11:413-413(1998).
RN   [36]
RP   VARIANTS GSD2 LEU-545 AND TRP-638.
RX   PubMed=10737124; DOI=10.1007/s100480050030;
RA   Vorgerd M., Burwinkel B., Reichmann H., Malin J.-P., Kilimann M.W.;
RT   "Adult-onset glycogen storage disease type II: phenotypic and allelic
RT   heterogeneity in German patients.";
RL   Neurogenetics 1:205-211(1998).
RN   [37]
RP   VARIANT GSD2 ARG-481.
RX   PubMed=10189220;
RX   DOI=10.1002/(SICI)1098-1004(1999)13:1<83::AID-HUMU13>3.0.CO;2-2;
RA   Raben N., Lee E., Lee L., Hirschhorn R., Plotz P.H.;
RT   "Novel mutations in African American patients with glycogen storage
RT   disease Type II.";
RL   Hum. Mutat. 13:83-84(1999).
RN   [38]
RP   VARIANTS GSD2, AND VARIANTS.
RX   PubMed=10338092;
RX   DOI=10.1002/(SICI)1098-1004(1999)13:5<380::AID-HUMU6>3.0.CO;2-A;
RA   Ko T.-M., Hwu W.-L., Lin Y.-W., Tseng L.-H., Hwa H.-L., Wang T.-R.,
RA   Chuang S.-M.;
RT   "Molecular genetic study of Pompe disease in Chinese patients in
RT   Taiwan.";
RL   Hum. Mutat. 13:380-384(1999).
RN   [39]
RP   VARIANTS GSD2 PRO-208; LEU-308; LEU-324; MET-585; 607-GLY--HIS-612
RP   DEL; ARG-643 AND THR-672.
RX   PubMed=11071489; DOI=10.1212/WNL.55.8.1122;
RA   Laforet P., Nicolino M., Eymard P.B., Puech J.P., Caillaud C.,
RA   Poenaru L., Fardeau M.;
RT   "Juvenile and adult-onset acid maltase deficiency in France: genotype-
RT   phenotype correlation.";
RL   Neurology 55:1122-1128(2000).
RN   [40]
RP   VARIANTS GSD2 ARG-219; LYS-262 AND VAL-408.
RX   PubMed=11738358; DOI=10.1016/S0960-8966(01)00247-4;
RA   Fernandez-Hojas R., Huie M.L., Navarro C., Dominguez C., Roig M.,
RA   Lopez-Coronas D., Teijeira S., Anyane-Yeboa K., Hirschhorn R.;
RT   "Identification of six novel mutations in the acid alpha-glucosidase
RT   gene in three Spanish patients with infantile onset glycogen storage
RT   disease type II (Pompe disease).";
RL   Neuromuscul. Disord. 12:159-166(2002).
RN   [41]
RP   VARIANT GSD2 TRP-224, AND CHARACTERIZATION OF VARIANT GSD2 TRP-224.
RX   PubMed=12923862; DOI=10.1002/ajmg.a.20164;
RA   Pittis M.G., Montalvo A.L., Miocic S., Martini C., Deganuto M.,
RA   Candusso M., Ciana G., Bembi B.;
RT   "Identification of four novel mutations in the alpha glucosidase gene
RT   in five Italian patients with infantile onset glycogen storage disease
RT   type II.";
RL   Am. J. Med. Genet. A 121:225-230(2003).
RN   [42]
RP   VARIANTS GSD2 LEU-361 AND CYS-437.
RX   PubMed=12601120; DOI=10.1212/01.WNL.0000048661.95327.BF;
RA   Lam C.W., Yuen Y.P., Chan K.Y., Tong S.F., Lai C.K., Chow T.C.,
RA   Lee K.C., Chan Y.W., Martiniuk F.;
RT   "Juvenile-onset glycogen storage disease type II with novel mutations
RT   in acid alpha-glucosidase gene.";
RL   Neurology 60:715-717(2003).
RN   [43]
RP   VARIANTS GSD2 TRP-224; CYS-600; ARG-619 AND HIS-660, CHARACTERIZATION
RP   OF VARIANTS GSD2 TRP-224; ARG-619 AND HIS-660, AND CHARACTERIZATION OF
RP   VARIANT SER-576.
RX   PubMed=14643388; DOI=10.1016/S0887-8994(03)00267-4;
RA   Pipo J.R., Feng J.-H., Yamamoto T., Ohsaki Y., Nanba E., Tsujino S.,
RA   Sakuragawa N., Martiniuk F., Ninomiya H., Oka A., Ohno K.;
RT   "New GAA mutations in Japanese patients with GSDII (Pompe disease).";
RL   Pediatr. Neurol. 29:284-287(2003).
RN   [44]
RP   VARIANTS GSD2 GLY-103; ARG-219; ARG-285; CYS-292; ARG-293; PRO-308;
RP   ARG-312; PRO-355; ARG-374; PRO-405; PHE-455; ASP-459 DEL; ARG-478;
RP   ARG-481; THR-519; LEU-545; ARG-549; PRO-552; SER-575; LYS-579;
RP   CYS-600; ASP-607 AND ASP-880, AND CHARACTERIZATION OF VARIANTS.
RX   PubMed=14695532; DOI=10.1002/humu.10286;
RA   Hermans M.M.P., van Leenen D., Kroos M.A., Beesley C.E.,
RA   Van der Ploeg A.T., Sakuraba H., Wevers R., Kleijer W.J.,
RA   Michelakakis H., Kirk E.P., Fletcher J., Bosshard N.,
RA   Basel-Vanagaite L., Besley G., Reuser A.J.J.;
RT   "Twenty-two novel mutations in the lysosomal alpha-glucosidase gene
RT   (GAA) underscore the genotype-phenotype correlation in glycogen
RT   storage disease type II.";
RL   Hum. Mutat. 23:47-56(2004).
RN   [45]
RP   VARIANTS GSD2 PRO-355 AND CYS-702, AND CHARACTERIZATION OF VARIANTS
RP   GSD2 PRO-355 AND CYS-702.
RX   PubMed=14972326; DOI=10.1016/j.ymgme.2003.11.011;
RA   Montalvo A.L.E., Cariati R., Deganuto M., Guerci V., Garcia R.,
RA   Ciana G., Bembi B., Pittis M.G.;
RT   "Glycogenosis type II: identification and expression of three novel
RT   mutations in the acid alpha-glucosidase gene causing the infantile
RT   form of the disease.";
RL   Mol. Genet. Metab. 81:203-208(2004).
RN   [46]
RP   VARIANT GSD2 GLN-901, AND VARIANT ASN-645.
RX   PubMed=15145338; DOI=10.1016/j.nmd.2004.02.012;
RA   Kroos M.A., Kirschner J., Gellerich F.N., Hermans M.M.,
RA   Van der Ploeg A.T., Reuser A.J., Korinthenberg R.;
RT   "A case of childhood Pompe disease demonstrating phenotypic
RT   variability of p.Asp645Asn.";
RL   Neuromuscul. Disord. 14:371-374(2004).
RN   [47]
RP   VARIANTS GSD2 VAL-237 AND ARG-293.
RX   PubMed=15668445; DOI=10.1212/01.WNL.0000149528.95362.20;
RA   Anneser J.M., Pongratz D.E., Podskarbi T., Shin Y.S., Schoser B.G.;
RT   "Mutations in the acid alpha-glucosidase gene (M. Pompe) in a patient
RT   with an unusual phenotype.";
RL   Neurology 64:368-370(2005).
RN   [48]
RP   VARIANT GSD2 GLY-330.
RX   PubMed=16782080; DOI=10.1016/j.cca.2006.04.007;
RA   Dou W., Gu X., Fu L., Peng C., Zheng J., Martiniuk F., Sheng H.Z.;
RT   "A novel missense mutation in the acid alpha-glucosidase gene causing
RT   the classic infantile form of Pompe disease.";
RL   Clin. Chim. Acta 374:145-146(2006).
RN   [49]
RP   VARIANT GSD2 GLY-ASN-404.
RX   PubMed=16433701; DOI=10.1111/j.1399-0004.2005.00557.x;
RA   Amartino H., Painceira D., Pomponio R.J., Niizawa G., Sabio Paz V.,
RA   Blanco M., Chamoles N.;
RT   "Two clinical forms of glycogen-storage disease type II in two
RT   generations of the same family.";
RL   Clin. Genet. 69:187-188(2006).
RN   [50]
RP   VARIANTS GSD2 ARG-309; PRO-355; LEU-361; PRO-445; ASN-489; ARG-549;
RP   GLN-612; ARG-643; TRP-672 AND CYS-746.
RX   PubMed=16917947; DOI=10.1002/humu.20374;
RA   Montalvo A.L., Bembi B., Donnarumma M., Filocamo M., Parenti G.,
RA   Rossi M., Merlini L., Buratti E., De Filippi P., Dardis A.,
RA   Stroppiano M., Ciana G., Pittis M.G.;
RT   "Mutation profile of the GAA gene in 40 Italian patients with late
RT   onset glycogen storage disease type II.";
RL   Hum. Mutat. 27:999-1006(2006).
RN   [51]
RP   VARIANTS GSD2 PRO-355; ALA-522 AND VAL-610, AND VARIANT ARG-359.
RX   PubMed=17643989; DOI=10.1016/j.nmd.2007.06.002;
RA   Muller-Felber W., Horvath R., Gempel K., Podskarbi T., Shin Y.,
RA   Pongratz D., Walter M.C., Baethmann M., Schlotter-Weigel B.,
RA   Lochmuller H., Schoser B.;
RT   "Late onset Pompe disease: clinical and neurophysiological spectrum of
RT   38 patients including long-term follow-up in 18 patients.";
RL   Neuromuscul. Disord. 17:698-706(2007).
RN   [52]
RP   VARIANTS GSD2 HIS-190; SER-285; PHE-291; PRO-291; LYS-318; ARG-335;
RP   ARG-347; ARG-482; VAL-483; GLN-521; SER-522; LYS-570; GLN-572;
RP   PRO-594; LYS-614; ASN-737; SER-746 AND PRO-935, AND VARIANT LYS-585.
RX   PubMed=18425781; DOI=10.1002/humu.20745;
RA   Kroos M., Pomponio R.J., van Vliet L., Palmer R.E., Phipps M.,
RA   Van der Helm R., Halley D., Reuser A.;
RT   "Update of the Pompe disease mutation database with 107 sequence
RT   variants and a format for severity rating.";
RL   Hum. Mutat. 29:E13-E26(2008).
RN   [53]
RP   VARIANTS GSD2 GLY-103; CYS-191; ARG-219; TRP-224; LYS-262; ARG-293;
RP   PRO-355; LEU-375; ARG-401; ASN-489; ALA-522; PRO-552; TYR-599;
RP   TRP-638; ARG-643 AND ASN-645, AND CHARACTERIZATION OF VARIANTS GSD2
RP   CYS-191; LEU-375; ARG-401; ALA-522 AND TYR-599.
RX   PubMed=18429042; DOI=10.1002/humu.20753;
RA   Pittis M.G., Donnarumma M., Montalvo A.L.E., Dominissini S., Kroos M.,
RA   Rosano C., Stroppiano M., Bianco M.G., Donati M.A., Parenti G.,
RA   D'Amico A., Ciana G., Di Rocco M., Reuser A., Bembi B., Filocamo M.;
RT   "Molecular and functional characterization of eight novel GAA
RT   mutations in Italian infants with Pompe disease.";
RL   Hum. Mutat. 29:E27-E36(2008).
RN   [54]
RP   VARIANTS GSD2 PRO-46; LEU-217; PRO-486; PRO-594; TYR-612; LYS-635 AND
RP   VAL-638.
RX   PubMed=19588081; DOI=10.1007/s00415-009-5219-y;
RA   Oba-Shinjo S.M., da Silva R., Andrade F.G., Palmer R.E.,
RA   Pomponio R.J., Ciociola K.M., Carvalho S.M., Gutierrez P.S., Porta G.,
RA   Marrone C.D., Munoz V., Grzesiuk A.K., Llerena J.C. Jr.,
RA   Berditchevsky C.R., Sobreira C., Horovitz D., Hatem T.P., Frota E.R.,
RA   Pecchini R., Kouyoumdjian J.A., Werneck L., Amado V.M.,
RA   Camelo J.S. Jr., Mattaliano R.J., Marie S.K.;
RT   "Pompe disease in a Brazilian series: clinical and molecular analyses
RT   with identification of nine new mutations.";
RL   J. Neurol. 256:1881-1890(2009).
RN   [55]
RP   VARIANT GSD2 SER-558.
RX   PubMed=20350966; DOI=10.1177/0883073809356035;
RA   Alcantara-Ortigoza M.A., Gonzalez-del Angel A., Barrientos-Rios R.,
RA   Cupples C., Garrido-Garcia L.M., de Leon-Bojorge B.,
RA   Alva-Chaire Adel C.;
RT   "Screening of late-onset Pompe disease in a sample of Mexican patients
RT   with myopathies of unknown etiology: identification of a novel
RT   mutation in the acid alpha-glucosidase gene.";
RL   J. Child Neurol. 25:1034-1037(2010).
RN   [56]
RP   VARIANTS GSD2 PRO-224; LEU-251; LEU-254; LYS-262; SER-266; PRO-291;
RP   VAL-408; ARG-478; TYR-525; LEU-545; PHE-557; ARG-615; GLU-645; GLY-746
RP   AND CYS-746, AND VARIANTS ALA-271 AND ARG-711.
RX   PubMed=20080426; DOI=10.1016/j.ymgme.2009.12.014;
RA   Labrousse P., Chien Y.H., Pomponio R.J., Keutzer J., Lee N.C.,
RA   Akmaev V.R., Scholl T., Hwu W.L.;
RT   "Genetic heterozygosity and pseudodeficiency in the Pompe disease
RT   newborn screening pilot program.";
RL   Mol. Genet. Metab. 99:379-383(2010).
RN   [57]
RP   VARIANT GSD2 GLY-103, AND VARIANT ASN-91.
RX   PubMed=21109266; DOI=10.1016/j.jns.2010.10.031;
RA   Fidzianska A., Lugowska A., Tylki-Szymanska A.;
RT   "Late form of Pompe disease with glycogen storage in peripheral nerves
RT   axons.";
RL   J. Neurol. Sci. 301:59-62(2011).
RN   [58]
RP   VARIANTS HIS-74; HIS-89; LEU-220; MET-222; ASP-290; GLY-310; VAL-391;
RP   CYS-458; ASP-611; LEU-629; 700-THR-LEU-701 DEL AND ILE-718, AND
RP   VARIANTS GSD2 ARG-103; GLY-108; PHE-127; GLN-224; ARG-234; LYS-234;
RP   ILE-316; GLU-335; LEU-361; LEU-397; VAL-419; HIS-457; TYR-523;
RP   SER-558; CYS-575; ARG-576; HIS-594; LEU-601; ALA-602; PRO-627;
RP   ASP-648; LEU-702; LYS-743; PRO-819 AND PHE-916.
RX   PubMed=22644586; DOI=10.1002/humu.22108;
RA   Kroos M., Hoogeveen-Westerveld M., Michelakakis H., Pomponio R.,
RA   Van der Ploeg A., Halley D., Reuser A., Augoustides-Savvopoulou P.,
RA   Ausems M., Llona J.B., Bautista Lorite J., van der Beek N., Bonafe L.,
RA   Cuk M., D'Hooghe M., Engelen B., Farouk A., Fumic K.,
RA   Garcia-Delgado E., Herzog A., Hurst J., Jones S., Kariminejad M.H.,
RA   Kucukcongar A., Lissens W., Lund A., Majoor-Krakauer D., Kumamoto S.,
RA   Maravi E., Marie S., Mengel E., Mavridou I., Munteis Olivas E.,
RA   Najmabadi H., Okumiya T., Peric S., Paschke E., Plecko B.,
RA   Robberecht W., Serdaroglu P., Shboul M., Tansek M.Z., Tarnutzer A.,
RA   Stojanovic V.R., Tylki-Szymanska A., Venancio M., Verhoeven K.;
RT   "Update of the pompe disease mutation database with 60 novel GAA
RT   sequence variants and additional studies on the functional effect of
RT   34 previously reported variants.";
RL   Hum. Mutat. 33:1161-1165(2012).
RN   [59]
RP   VARIANTS GSD2 LYS-234; 431-LEU--GLN-433 DEL; LEU-568; LEU-601; CYS-766
RP   AND ARG-913.
RX   PubMed=22676651; DOI=10.1186/1750-1172-7-35;
RA   Herzog A., Hartung R., Reuser A.J., Hermanns P., Runz H., Karabul N.,
RA   Goekce S., Pohlenz J., Kampmann C., Lampe C., Beck M., Mengel E.;
RT   "A cross-sectional single-centre study on the spectrum of Pompe
RT   disease, German patients: molecular analysis of the GAA gene,
RT   manifestation and genotype-phenotype correlations.";
RL   Orphanet J. Rare Dis. 7:35-35(2012).
RN   [60]
RP   VARIANTS GSD2 VAL-391; HIS-437; PRO-552; ASP-611; VAL-641; TRP-647 AND
RP   PRO-705, AND VARIANTS ASN-91; ARG-199; HIS-223; SER-576; LYS-689;
RP   ILE-780 AND ILE-816.
RX   PubMed=25681614; DOI=10.1016/j.gene.2015.02.023;
RA   Turaca L.T., de Faria D.O., Kyosen S.O., Teixeira V.D., Motta F.L.,
RA   Pessoa J.G., Rodrigues E Silva M., de Almeida S.S., D'Almeida V.,
RA   Munoz Rojas M.V., Martins A.M., Pesquero J.B.;
RT   "Novel GAA mutations in patients with Pompe disease.";
RL   Gene 561:124-131(2015).
CC   -!- FUNCTION: Essential for the degradation of glygogen to glucose in
CC       lysosomes.
CC   -!- CATALYTIC ACTIVITY: Hydrolysis of terminal, non-reducing (1->4)-
CC       linked alpha-D-glucose residues with release of alpha-D-glucose.
CC   -!- SUBCELLULAR LOCATION: Lysosome {ECO:0000269|PubMed:17897319}.
CC       Lysosome membrane {ECO:0000269|PubMed:17897319}.
CC   -!- PTM: The different forms of acid glucosidase are obtained by
CC       proteolytic processing.
CC   -!- PTM: Phosphorylation of mannose residues ensures efficient
CC       transport of the enzyme to the lysosomes via the mannose 6-
CC       phosphate receptor.
CC   -!- POLYMORPHISM: There are three common alleles of GAA: GAA*1, GAA*2
CC       and GAA*4. The sequence shown is that of allele GAA*1, which is
CC       the most common. Alleles GAA*2 and GAA*4 are much rarer.
CC       {ECO:0000269|PubMed:21109266, ECO:0000269|PubMed:2203258,
CC       ECO:0000269|PubMed:25681614, ECO:0000269|PubMed:8912788,
CC       ECO:0000269|PubMed:9521422}.
CC   -!- DISEASE: Glycogen storage disease 2 (GSD2) [MIM:232300]: A
CC       metabolic disorder with a broad clinical spectrum. The severe
CC       infantile form, or Pompe disease, presents at birth with massive
CC       accumulation of glycogen in muscle, heart and liver.
CC       Cardiomyopathy and muscular hypotonia are the cardinal features of
CC       this form whose life expectancy is less than two years. The
CC       juvenile and adult forms present as limb-girdle muscular dystrophy
CC       beginning in the lower limbs. Final outcome depends on respiratory
CC       muscle failure. Patients with the adult form can be free of
CC       clinical symptoms for most of their life but finally develop a
CC       slowly progressive myopathy. {ECO:0000269|PubMed:10189220,
CC       ECO:0000269|PubMed:10206684, ECO:0000269|PubMed:10338092,
CC       ECO:0000269|PubMed:10737124, ECO:0000269|PubMed:11071489,
CC       ECO:0000269|PubMed:11738358, ECO:0000269|PubMed:12601120,
CC       ECO:0000269|PubMed:12923862, ECO:0000269|PubMed:14643388,
CC       ECO:0000269|PubMed:14695532, ECO:0000269|PubMed:14972326,
CC       ECO:0000269|PubMed:15145338, ECO:0000269|PubMed:15668445,
CC       ECO:0000269|PubMed:16433701, ECO:0000269|PubMed:1652892,
CC       ECO:0000269|PubMed:16782080, ECO:0000269|PubMed:1684505,
CC       ECO:0000269|PubMed:16917947, ECO:0000269|PubMed:17643989,
CC       ECO:0000269|PubMed:18425781, ECO:0000269|PubMed:18429042,
CC       ECO:0000269|PubMed:1898413, ECO:0000269|PubMed:19588081,
CC       ECO:0000269|PubMed:20080426, ECO:0000269|PubMed:20350966,
CC       ECO:0000269|PubMed:21109266, ECO:0000269|PubMed:22644586,
CC       ECO:0000269|PubMed:22676651, ECO:0000269|PubMed:25681614,
CC       ECO:0000269|PubMed:7695647, ECO:0000269|PubMed:7717400,
CC       ECO:0000269|PubMed:7866409, ECO:0000269|PubMed:7881422,
CC       ECO:0000269|PubMed:7981676, ECO:0000269|PubMed:8094613,
CC       ECO:0000269|PubMed:8401535, ECO:0000269|PubMed:8834250,
CC       ECO:0000269|PubMed:9521422, ECO:0000269|PubMed:9535769,
CC       ECO:0000269|PubMed:9660056, ECO:0000269|Ref.5}. Note=The disease
CC       is caused by mutations affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the glycosyl hydrolase 31 family.
CC       {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 P-type (trefoil) domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00779}.
CC   -!- WEB RESOURCE: Name=GAA; Note=Mutations in alpha-glucosidase;
CC       URL="http://cluster15.erasmusmc.nl/klgn/pompe/mutations.html";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Alpha-glucosidase entry;
CC       URL="https://en.wikipedia.org/wiki/Alpha-glucosidase";
CC   -!- WEB RESOURCE: Name=Glucosidase, alpha, acid (Pompe disease) (GAA);
CC       Note=Leiden Open Variation Database (LOVD);
CC       URL="http://www.lovd.nl/GAA";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Y00839; CAA68763.1; -; mRNA.
DR   EMBL; Y00839; CAA68764.1; -; mRNA.
DR   EMBL; X55080; CAC12967.1; -; Genomic_DNA.
DR   EMBL; X55081; CAC12967.1; JOINED; Genomic_DNA.
DR   EMBL; X55095; CAC12967.1; JOINED; Genomic_DNA.
DR   EMBL; X55082; CAC12967.1; JOINED; Genomic_DNA.
DR   EMBL; X55084; CAC12967.1; JOINED; Genomic_DNA.
DR   EMBL; X55083; CAC12967.1; JOINED; Genomic_DNA.
DR   EMBL; X55098; CAC12967.1; JOINED; Genomic_DNA.
DR   EMBL; X55085; CAC12967.1; JOINED; Genomic_DNA.
DR   EMBL; X55086; CAC12967.1; JOINED; Genomic_DNA.
DR   EMBL; X55087; CAC12967.1; JOINED; Genomic_DNA.
DR   EMBL; X55088; CAC12967.1; JOINED; Genomic_DNA.
DR   EMBL; X55089; CAC12967.1; JOINED; Genomic_DNA.
DR   EMBL; X55090; CAC12967.1; JOINED; Genomic_DNA.
DR   EMBL; X55096; CAC12967.1; JOINED; Genomic_DNA.
DR   EMBL; X55091; CAC12967.1; JOINED; Genomic_DNA.
DR   EMBL; X55092; CAC12967.1; JOINED; Genomic_DNA.
DR   EMBL; X55093; CAC12967.1; JOINED; Genomic_DNA.
DR   EMBL; X55094; CAC12967.1; JOINED; Genomic_DNA.
DR   EMBL; X55097; CAC12967.1; JOINED; Genomic_DNA.
DR   EMBL; M34424; AAA52506.1; -; mRNA.
DR   EMBL; DQ907243; ABI53718.1; -; mRNA.
DR   EMBL; AC087741; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC040431; AAH40431.1; -; mRNA.
DR   EMBL; S76893; AAB33842.1; -; mRNA.
DR   CCDS; CCDS32760.1; -.
DR   PIR; A40577; A32609.
DR   RefSeq; NP_000143.2; NM_000152.3.
DR   RefSeq; NP_001073271.1; NM_001079803.1.
DR   RefSeq; NP_001073272.1; NM_001079804.1.
DR   RefSeq; XP_005257250.1; XM_005257193.1.
DR   RefSeq; XP_005257251.1; XM_005257194.3.
DR   UniGene; Hs.1437; -.
DR   ProteinModelPortal; P10253; -.
DR   SMR; P10253; 89-951.
DR   BioGrid; 108823; 42.
DR   IntAct; P10253; 8.
DR   STRING; 9606.ENSP00000305692; -.
DR   BindingDB; P10253; -.
DR   ChEMBL; CHEMBL2608; -.
DR   DrugBank; DB00284; Acarbose.
DR   DrugBank; DB00491; Miglitol.
DR   GuidetoPHARMACOLOGY; 2611; -.
DR   Allergome; 9614; Hom s Glucosidase.
DR   CAZy; GH31; Glycoside Hydrolase Family 31.
DR   iPTMnet; P10253; -.
DR   PhosphoSite; P10253; -.
DR   UniCarbKB; P10253; -.
DR   BioMuta; GAA; -.
DR   DMDM; 317373572; -.
DR   MaxQB; P10253; -.
DR   PaxDb; P10253; -.
DR   PRIDE; P10253; -.
DR   DNASU; 2548; -.
DR   Ensembl; ENST00000302262; ENSP00000305692; ENSG00000171298.
DR   Ensembl; ENST00000390015; ENSP00000374665; ENSG00000171298.
DR   GeneID; 2548; -.
DR   KEGG; hsa:2548; -.
DR   UCSC; uc002jxo.3; human.
DR   CTD; 2548; -.
DR   GeneCards; GAA; -.
DR   GeneReviews; GAA; -.
DR   HGNC; HGNC:4065; GAA.
DR   HPA; HPA026970; -.
DR   HPA; HPA029126; -.
DR   MalaCards; GAA; -.
DR   MIM; 232300; phenotype.
DR   MIM; 606800; gene.
DR   neXtProt; NX_P10253; -.
DR   Orphanet; 308604; Glycogen storage disease due to acid maltase deficiency, adult onset.
DR   Orphanet; 308552; Glycogen storage disease due to acid maltase deficiency, infantile onset.
DR   Orphanet; 308573; Glycogen storage disease due to acid maltase deficiency, juvenile onset.
DR   PharmGKB; PA28476; -.
DR   eggNOG; KOG1065; Eukaryota.
DR   eggNOG; COG1501; LUCA.
DR   GeneTree; ENSGT00760000119229; -.
DR   HOGENOM; HOG000041175; -.
DR   HOVERGEN; HBG006297; -.
DR   InParanoid; P10253; -.
DR   KO; K12316; -.
DR   OMA; PYESASH; -.
DR   OrthoDB; EOG77HDD0; -.
DR   PhylomeDB; P10253; -.
DR   TreeFam; TF314577; -.
DR   BRENDA; 3.2.1.20; 2681.
DR   Reactome; R-HSA-5357572; Lysosomal glycogen catabolism.
DR   Reactome; R-HSA-5357609; Glycogen storage disease type II (GAA).
DR   GeneWiki; Acid_alpha-glucosidase; -.
DR   GenomeRNAi; 2548; -.
DR   NextBio; 10047; -.
DR   PRO; PR:P10253; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   Bgee; P10253; -.
DR   CleanEx; HS_GAA; -.
DR   ExpressionAtlas; P10253; baseline and differential.
DR   Genevisible; P10253; HS.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0043202; C:lysosomal lumen; TAS:Reactome.
DR   GO; GO:0005765; C:lysosomal membrane; IDA:UniProtKB.
DR   GO; GO:0005764; C:lysosome; IDA:BHF-UCL.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0004558; F:alpha-1,4-glucosidase activity; IDA:BHF-UCL.
DR   GO; GO:0030246; F:carbohydrate binding; IEA:Ensembl.
DR   GO; GO:0032450; F:maltose alpha-glucosidase activity; IEA:UniProtKB-EC.
DR   GO; GO:0005975; P:carbohydrate metabolic process; TAS:Reactome.
DR   GO; GO:0060048; P:cardiac muscle contraction; IMP:BHF-UCL.
DR   GO; GO:0002086; P:diaphragm contraction; IMP:BHF-UCL.
DR   GO; GO:0006006; P:glucose metabolic process; IC:BHF-UCL.
DR   GO; GO:0005980; P:glycogen catabolic process; IDA:BHF-UCL.
DR   GO; GO:0003007; P:heart morphogenesis; IEA:Ensembl.
DR   GO; GO:0007626; P:locomotory behavior; IEA:Ensembl.
DR   GO; GO:0007040; P:lysosome organization; IMP:BHF-UCL.
DR   GO; GO:0000023; P:maltose metabolic process; IC:BHF-UCL.
DR   GO; GO:0046716; P:muscle cell cellular homeostasis; IEA:Ensembl.
DR   GO; GO:0050885; P:neuromuscular process controlling balance; IEA:Ensembl.
DR   GO; GO:0050884; P:neuromuscular process controlling posture; IEA:Ensembl.
DR   GO; GO:0002026; P:regulation of the force of heart contraction; IEA:Ensembl.
DR   GO; GO:0044281; P:small molecule metabolic process; TAS:Reactome.
DR   GO; GO:0005985; P:sucrose metabolic process; IC:BHF-UCL.
DR   GO; GO:0009888; P:tissue development; IEA:Ensembl.
DR   GO; GO:0043181; P:vacuolar sequestering; IMP:BHF-UCL.
DR   Gene3D; 4.10.110.10; -; 1.
DR   InterPro; IPR031727; Gal_mutarotase_N.
DR   InterPro; IPR011013; Gal_mutarotase_SF_dom.
DR   InterPro; IPR000322; Glyco_hydro_31.
DR   InterPro; IPR030458; Glyco_hydro_31_AS.
DR   InterPro; IPR030459; Glyco_hydro_31_CS.
DR   InterPro; IPR025887; Glyco_hydro_31_N_dom.
DR   InterPro; IPR017853; Glycoside_hydrolase_SF.
DR   InterPro; IPR017957; P_trefoil_CS.
DR   InterPro; IPR000519; P_trefoil_dom.
DR   Pfam; PF13802; Gal_mutarotas_2; 1.
DR   Pfam; PF01055; Glyco_hydro_31; 1.
DR   Pfam; PF16863; NtCtMGAM_N; 1.
DR   Pfam; PF00088; Trefoil; 1.
DR   SMART; SM00018; PD; 1.
DR   SUPFAM; SSF51445; SSF51445; 2.
DR   SUPFAM; SSF57492; SSF57492; 1.
DR   SUPFAM; SSF74650; SSF74650; 1.
DR   PROSITE; PS00129; GLYCOSYL_HYDROL_F31_1; 1.
DR   PROSITE; PS00707; GLYCOSYL_HYDROL_F31_2; 1.
DR   PROSITE; PS00025; P_TREFOIL_1; 1.
DR   PROSITE; PS51448; P_TREFOIL_2; 1.
PE   1: Evidence at protein level;
KW   Complete proteome; Direct protein sequencing; Disease mutation;
KW   Disulfide bond; Glycogen storage disease; Glycoprotein; Glycosidase;
KW   Hydrolase; Lysosome; Membrane; Phosphoprotein; Polymorphism;
KW   Reference proteome; Signal.
FT   SIGNAL        1     27       {ECO:0000255}.
FT   PROPEP       28     69       {ECO:0000269|PubMed:3049072}.
FT                                /FTId=PRO_0000018565.
FT   CHAIN        70    952       Lysosomal alpha-glucosidase.
FT                                /FTId=PRO_0000018566.
FT   CHAIN       123    952       76 kDa lysosomal alpha-glucosidase.
FT                                /FTId=PRO_0000018567.
FT   CHAIN       204    952       70 kDa lysosomal alpha-glucosidase.
FT                                /FTId=PRO_0000018568.
FT   DOMAIN       80    131       P-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00779}.
FT   ACT_SITE    518    518       Nucleophile. {ECO:0000255|PROSITE-
FT                                ProRule:PRU10066,
FT                                ECO:0000269|PubMed:1856189}.
FT   ACT_SITE    521    521       {ECO:0000250}.
FT   CARBOHYD    140    140       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19159218,
FT                                ECO:0000269|PubMed:8435067}.
FT   CARBOHYD    233    233       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:8435067}.
FT   CARBOHYD    390    390       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:8435067}.
FT   CARBOHYD    470    470       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:12754519,
FT                                ECO:0000269|PubMed:19159218,
FT                                ECO:0000269|PubMed:8435067}.
FT   CARBOHYD    652    652       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:8435067}.
FT   CARBOHYD    882    882       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19159218,
FT                                ECO:0000269|PubMed:8435067}.
FT   CARBOHYD    925    925       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19159218,
FT                                ECO:0000269|PubMed:8435067}.
FT   DISULFID     82    109       {ECO:0000255|PROSITE-ProRule:PRU00779}.
FT   DISULFID     92    108       {ECO:0000255|PROSITE-ProRule:PRU00779}.
FT   DISULFID    103    127       {ECO:0000255|PROSITE-ProRule:PRU00779}.
FT   VARIANT      46     46       S -> P (in GSD2).
FT                                {ECO:0000269|PubMed:19588081}.
FT                                /FTId=VAR_068564.
FT   VARIANT      74     74       R -> H. {ECO:0000269|PubMed:22644586}.
FT                                /FTId=VAR_068565.
FT   VARIANT      89     89       R -> H. {ECO:0000269|PubMed:22644586}.
FT                                /FTId=VAR_068566.
FT   VARIANT      91     91       D -> N (in allele GAA*2; lower affinity
FT                                for glycogen and starch but not for
FT                                lower-molecular weight substrates;
FT                                dbSNP:rs1800299).
FT                                {ECO:0000269|PubMed:21109266,
FT                                ECO:0000269|PubMed:2203258,
FT                                ECO:0000269|PubMed:25681614,
FT                                ECO:0000269|PubMed:9521422}.
FT                                /FTId=VAR_004285.
FT   VARIANT     103    103       C -> G (in GSD2; infantile form; severe;
FT                                loss of activity; shows enzyme
FT                                localization primarily in the ER-Golgi
FT                                compartment suggesting that mutation
FT                                could affect the normal processing and
FT                                stability of the enzyme).
FT                                {ECO:0000269|PubMed:14695532,
FT                                ECO:0000269|PubMed:18429042,
FT                                ECO:0000269|PubMed:21109266}.
FT                                /FTId=VAR_018078.
FT   VARIANT     103    103       C -> R (in GSD2).
FT                                {ECO:0000269|PubMed:22644586}.
FT                                /FTId=VAR_068567.
FT   VARIANT     108    108       C -> G (in GSD2).
FT                                {ECO:0000269|PubMed:22644586}.
FT                                /FTId=VAR_068568.
FT   VARIANT     127    127       C -> F (in GSD2).
FT                                {ECO:0000269|PubMed:22644586}.
FT                                /FTId=VAR_068569.
FT   VARIANT     190    190       R -> H (in GSD2).
FT                                {ECO:0000269|PubMed:18425781}.
FT                                /FTId=VAR_068570.
FT   VARIANT     191    191       Y -> C (in GSD2; extremely low residual
FT                                enzymatic activity).
FT                                {ECO:0000269|PubMed:18429042}.
FT                                /FTId=VAR_046467.
FT   VARIANT     199    199       H -> R (in dbSNP:rs1042393).
FT                                {ECO:0000269|PubMed:25681614,
FT                                ECO:0000269|PubMed:3049072,
FT                                ECO:0000269|PubMed:7717400,
FT                                ECO:0000269|PubMed:9521422,
FT                                ECO:0000269|Ref.5}.
FT                                /FTId=VAR_004286.
FT   VARIANT     208    208       L -> P (in GSD2).
FT                                {ECO:0000269|PubMed:11071489}.
FT                                /FTId=VAR_029025.
FT   VARIANT     217    217       P -> L (in GSD2).
FT                                {ECO:0000269|PubMed:19588081}.
FT                                /FTId=VAR_068571.
FT   VARIANT     219    219       G -> R (in GSD2; infantile form; severe;
FT                                loss of activity).
FT                                {ECO:0000269|PubMed:11738358,
FT                                ECO:0000269|PubMed:14695532,
FT                                ECO:0000269|PubMed:18429042}.
FT                                /FTId=VAR_018079.
FT   VARIANT     220    220       V -> L. {ECO:0000269|PubMed:22644586}.
FT                                /FTId=VAR_068572.
FT   VARIANT     222    222       V -> M (in dbSNP:rs374569672).
FT                                {ECO:0000269|PubMed:22644586}.
FT                                /FTId=VAR_068573.
FT   VARIANT     223    223       R -> H (in dbSNP:rs1042395).
FT                                {ECO:0000269|PubMed:25681614,
FT                                ECO:0000269|PubMed:3049072,
FT                                ECO:0000269|PubMed:7717400,
FT                                ECO:0000269|PubMed:9521422,
FT                                ECO:0000269|Ref.5}.
FT                                /FTId=VAR_004287.
FT   VARIANT     224    224       R -> P (in GSD2).
FT                                {ECO:0000269|PubMed:20080426}.
FT                                /FTId=VAR_068574.
FT   VARIANT     224    224       R -> Q (in GSD2; dbSNP:rs200210219).
FT                                {ECO:0000269|PubMed:22644586}.
FT                                /FTId=VAR_068575.
FT   VARIANT     224    224       R -> W (in GSD2; infantile; mild partial
FT                                loss of activity).
FT                                {ECO:0000269|PubMed:12923862,
FT                                ECO:0000269|PubMed:14643388,
FT                                ECO:0000269|PubMed:18429042}.
FT                                /FTId=VAR_029026.
FT   VARIANT     234    234       T -> K (in GSD2).
FT                                {ECO:0000269|PubMed:22644586,
FT                                ECO:0000269|PubMed:22676651}.
FT                                /FTId=VAR_068576.
FT   VARIANT     234    234       T -> R (in GSD2).
FT                                {ECO:0000269|PubMed:22644586}.
FT                                /FTId=VAR_068577.
FT   VARIANT     237    237       A -> V (in GSD2).
FT                                {ECO:0000269|PubMed:15668445}.
FT                                /FTId=VAR_029027.
FT   VARIANT     251    251       S -> L (in GSD2; dbSNP:rs200856561).
FT                                {ECO:0000269|PubMed:20080426}.
FT                                /FTId=VAR_068578.
FT   VARIANT     254    254       S -> L (in GSD2; dbSNP:rs577915581).
FT                                {ECO:0000269|PubMed:20080426}.
FT                                /FTId=VAR_068579.
FT   VARIANT     262    262       E -> K (in GSD2; infantile; severe;
FT                                dbSNP:rs201896815).
FT                                {ECO:0000269|PubMed:11738358,
FT                                ECO:0000269|PubMed:18429042,
FT                                ECO:0000269|PubMed:20080426}.
FT                                /FTId=VAR_029028.
FT   VARIANT     266    266       P -> S (in GSD2).
FT                                {ECO:0000269|PubMed:20080426}.
FT                                /FTId=VAR_068580.
FT   VARIANT     271    271       T -> A. {ECO:0000269|PubMed:20080426}.
FT                                /FTId=VAR_068581.
FT   VARIANT     285    285       P -> R (in GSD2; juvenile form; mild;
FT                                partial loss of activity).
FT                                {ECO:0000269|PubMed:14695532}.
FT                                /FTId=VAR_018080.
FT   VARIANT     285    285       P -> S (in GSD2).
FT                                {ECO:0000269|PubMed:18425781}.
FT                                /FTId=VAR_068582.
FT   VARIANT     290    290       N -> D (in dbSNP:rs552929702).
FT                                {ECO:0000269|PubMed:22644586}.
FT                                /FTId=VAR_068583.
FT   VARIANT     291    291       L -> F (in GSD2).
FT                                {ECO:0000269|PubMed:18425781}.
FT                                /FTId=VAR_068584.
FT   VARIANT     291    291       L -> P (in GSD2).
FT                                {ECO:0000269|PubMed:18425781,
FT                                ECO:0000269|PubMed:20080426}.
FT                                /FTId=VAR_068585.
FT   VARIANT     292    292       Y -> C (in GSD2; juvenile form; mild;
FT                                partial loss of activity).
FT                                {ECO:0000269|PubMed:14695532}.
FT                                /FTId=VAR_018081.
FT   VARIANT     293    293       G -> R (in GSD2; infantile form; severe;
FT                                almost complete loss of activity).
FT                                {ECO:0000269|PubMed:14695532,
FT                                ECO:0000269|PubMed:15668445,
FT                                ECO:0000269|PubMed:18429042}.
FT                                /FTId=VAR_018082.
FT   VARIANT     299    299       L -> R (in GSD2; infantile form).
FT                                {ECO:0000269|PubMed:7717400}.
FT                                /FTId=VAR_004288.
FT   VARIANT     308    308       H -> L (in GSD2).
FT                                {ECO:0000269|PubMed:11071489}.
FT                                /FTId=VAR_046468.
FT   VARIANT     308    308       H -> P (in GSD2; infantile form; severe;
FT                                complete loss of activity).
FT                                {ECO:0000269|PubMed:14695532}.
FT                                /FTId=VAR_018083.
FT   VARIANT     309    309       G -> R (in GSD2; severe;
FT                                dbSNP:rs543300039).
FT                                {ECO:0000269|PubMed:16917947,
FT                                ECO:0000269|PubMed:9660056}.
FT                                /FTId=VAR_018084.
FT   VARIANT     310    310       V -> G (found in a patient with GSD2;
FT                                unknown pathological significance).
FT                                {ECO:0000269|PubMed:22644586}.
FT                                /FTId=VAR_068586.
FT   VARIANT     312    312       L -> R (in GSD2; infantile form; severe;
FT                                loss of activity).
FT                                {ECO:0000269|PubMed:14695532}.
FT                                /FTId=VAR_018085.
FT   VARIANT     316    316       N -> I (in GSD2).
FT                                {ECO:0000269|PubMed:22644586}.
FT                                /FTId=VAR_068587.
FT   VARIANT     318    318       M -> K (in GSD2).
FT                                {ECO:0000269|PubMed:18425781}.
FT                                /FTId=VAR_068588.
FT   VARIANT     318    318       M -> T (in GSD2; severe).
FT                                {ECO:0000269|PubMed:1652892}.
FT                                /FTId=VAR_004289.
FT   VARIANT     324    324       P -> L (in GSD2).
FT                                {ECO:0000269|PubMed:11071489}.
FT                                /FTId=VAR_029029.
FT   VARIANT     330    330       W -> G (in GSD2; infantile form; severe).
FT                                {ECO:0000269|PubMed:16782080}.
FT                                /FTId=VAR_029030.
FT   VARIANT     335    335       G -> E (in GSD2).
FT                                {ECO:0000269|PubMed:22644586}.
FT                                /FTId=VAR_068589.
FT   VARIANT     335    335       G -> R (in GSD2).
FT                                {ECO:0000269|PubMed:18425781}.
FT                                /FTId=VAR_068590.
FT   VARIANT     347    347       P -> R (in GSD2).
FT                                {ECO:0000269|PubMed:18425781}.
FT                                /FTId=VAR_068591.
FT   VARIANT     355    355       L -> P (in GSD2; infantile form; severe;
FT                                loss of activity).
FT                                {ECO:0000269|PubMed:14695532,
FT                                ECO:0000269|PubMed:14972326,
FT                                ECO:0000269|PubMed:16917947,
FT                                ECO:0000269|PubMed:17643989,
FT                                ECO:0000269|PubMed:18429042}.
FT                                /FTId=VAR_018086.
FT   VARIANT     359    359       G -> R. {ECO:0000269|PubMed:17643989}.
FT                                /FTId=VAR_068592.
FT   VARIANT     361    361       P -> L (in GSD2; juvenile form; severe).
FT                                {ECO:0000269|PubMed:12601120,
FT                                ECO:0000269|PubMed:16917947,
FT                                ECO:0000269|PubMed:22644586}.
FT                                /FTId=VAR_029031.
FT   VARIANT     374    374       C -> R (in GSD2; infantile form; severe;
FT                                loss of activity).
FT                                {ECO:0000269|PubMed:14695532}.
FT                                /FTId=VAR_018087.
FT   VARIANT     375    375       R -> L (in GSD2; extremely low residual
FT                                enzymatic activity).
FT                                {ECO:0000269|PubMed:18429042}.
FT                                /FTId=VAR_046469.
FT   VARIANT     377    377       G -> R (in GSD2; severe).
FT                                /FTId=VAR_029032.
FT   VARIANT     391    391       M -> V (found in a patient with GSD2;
FT                                unknown pathological significance).
FT                                {ECO:0000269|PubMed:22644586,
FT                                ECO:0000269|PubMed:25681614}.
FT                                /FTId=VAR_068593.
FT   VARIANT     397    397       P -> L (in GSD2).
FT                                {ECO:0000269|PubMed:22644586}.
FT                                /FTId=VAR_068594.
FT   VARIANT     401    401       Q -> R (in GSD2; extremely low residual
FT                                enzymatic activity).
FT                                {ECO:0000269|PubMed:18429042}.
FT                                /FTId=VAR_046470.
FT   VARIANT     402    402       W -> R (in GSD2; severe).
FT                                /FTId=VAR_004290.
FT   VARIANT     404    404       D -> N (in GSD2; severe).
FT                                /FTId=VAR_029033.
FT   VARIANT     405    405       L -> P (in GSD2; infantile form; severe;
FT                                loss of activity).
FT                                {ECO:0000269|PubMed:14695532}.
FT                                /FTId=VAR_018088.
FT   VARIANT     408    408       M -> V (in GSD2; juvenile form; severe).
FT                                {ECO:0000269|PubMed:11738358,
FT                                ECO:0000269|PubMed:20080426}.
FT                                /FTId=VAR_029034.
FT   VARIANT     419    419       D -> V (in GSD2).
FT                                {ECO:0000269|PubMed:22644586}.
FT                                /FTId=VAR_068595.
FT   VARIANT     431    433       Missing (in GSD2).
FT                                {ECO:0000269|PubMed:22676651}.
FT                                /FTId=VAR_070017.
FT   VARIANT     437    437       R -> C (in GSD2; juvenile form; severe).
FT                                {ECO:0000269|PubMed:12601120}.
FT                                /FTId=VAR_029035.
FT   VARIANT     437    437       R -> H (in GSD2; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:25681614}.
FT                                /FTId=VAR_074277.
FT   VARIANT     445    445       A -> P (in GSD2).
FT                                {ECO:0000269|PubMed:16917947}.
FT                                /FTId=VAR_029036.
FT   VARIANT     455    455       Y -> F (in GSD2; juvenile form; almost
FT                                complete loss of activity).
FT                                {ECO:0000269|PubMed:14695532}.
FT                                /FTId=VAR_018089.
FT   VARIANT     457    457       P -> H (in GSD2).
FT                                {ECO:0000269|PubMed:22644586}.
FT                                /FTId=VAR_068596.
FT   VARIANT     457    457       P -> L (in GSD2; juvenile form).
FT                                {ECO:0000269|Ref.5}.
FT                                /FTId=VAR_029040.
FT   VARIANT     458    458       Y -> C. {ECO:0000269|PubMed:22644586}.
FT                                /FTId=VAR_068597.
FT   VARIANT     459    459       Missing (in GSD2; infantile form;
FT                                severe). {ECO:0000269|PubMed:14695532}.
FT                                /FTId=VAR_018090.
FT   VARIANT     478    478       G -> R (in GSD2; severe; loss of
FT                                activity). {ECO:0000269|PubMed:14695532,
FT                                ECO:0000269|PubMed:20080426}.
FT                                /FTId=VAR_004291.
FT   VARIANT     481    481       W -> R (in GSD2; severe; loss of
FT                                activity). {ECO:0000269|PubMed:10189220,
FT                                ECO:0000269|PubMed:14695532}.
FT                                /FTId=VAR_004292.
FT   VARIANT     482    482       P -> R (in GSD2).
FT                                {ECO:0000269|PubMed:18425781}.
FT                                /FTId=VAR_068598.
FT   VARIANT     483    483       G -> V (in GSD2).
FT                                {ECO:0000269|PubMed:18425781}.
FT                                /FTId=VAR_068599.
FT   VARIANT     486    486       A -> P (in GSD2).
FT                                {ECO:0000269|PubMed:19588081}.
FT                                /FTId=VAR_068600.
FT   VARIANT     489    489       D -> N (in GSD2; severe).
FT                                {ECO:0000269|PubMed:16917947,
FT                                ECO:0000269|PubMed:18429042}.
FT                                /FTId=VAR_029037.
FT   VARIANT     519    519       M -> T (in GSD2; severe; loss of
FT                                activity). {ECO:0000269|PubMed:14695532}.
FT                                /FTId=VAR_004293.
FT   VARIANT     519    519       M -> V (in GSD2).
FT                                {ECO:0000269|PubMed:7866409}.
FT                                /FTId=VAR_004294.
FT   VARIANT     521    521       E -> K (in GSD2; severe).
FT                                {ECO:0000269|PubMed:1898413}.
FT                                /FTId=VAR_004295.
FT   VARIANT     521    521       E -> Q (in GSD2).
FT                                {ECO:0000269|PubMed:18425781}.
FT                                /FTId=VAR_068601.
FT   VARIANT     522    522       P -> A (in GSD2; no residual enzymatic
FT                                activity). {ECO:0000269|PubMed:17643989,
FT                                ECO:0000269|PubMed:18429042}.
FT                                /FTId=VAR_046471.
FT   VARIANT     522    522       P -> S (in GSD2).
FT                                {ECO:0000269|PubMed:18425781}.
FT                                /FTId=VAR_068602.
FT   VARIANT     523    523       S -> Y (in GSD2).
FT                                {ECO:0000269|PubMed:22644586}.
FT                                /FTId=VAR_068603.
FT   VARIANT     525    525       F -> Y (in GSD2).
FT                                {ECO:0000269|PubMed:20080426}.
FT                                /FTId=VAR_068604.
FT   VARIANT     529    529       S -> V (in GSD2; mild; requires 2
FT                                nucleotide substitutions).
FT                                {ECO:0000269|PubMed:8834250}.
FT                                /FTId=VAR_004296.
FT   VARIANT     545    545       P -> L (in GSD2; mild; partial loss of
FT                                activity). {ECO:0000269|PubMed:10737124,
FT                                ECO:0000269|PubMed:14695532,
FT                                ECO:0000269|PubMed:20080426,
FT                                ECO:0000269|PubMed:7881422}.
FT                                /FTId=VAR_004297.
FT   VARIANT     549    549       G -> R (in GSD2; juvenile form; mild;
FT                                partial loss of activity).
FT                                {ECO:0000269|PubMed:14695532,
FT                                ECO:0000269|PubMed:16917947}.
FT                                /FTId=VAR_018091.
FT   VARIANT     552    552       L -> P (in GSD2; infantile/juvenile form;
FT                                severe; loss of activity).
FT                                {ECO:0000269|PubMed:14695532,
FT                                ECO:0000269|PubMed:18429042,
FT                                ECO:0000269|PubMed:25681614}.
FT                                /FTId=VAR_018092.
FT   VARIANT     557    557       I -> F (in GSD2).
FT                                {ECO:0000269|PubMed:20080426}.
FT                                /FTId=VAR_068605.
FT   VARIANT     558    558       C -> S (in GSD2).
FT                                {ECO:0000269|PubMed:20350966,
FT                                ECO:0000269|PubMed:22644586}.
FT                                /FTId=VAR_068606.
FT   VARIANT     566    566       S -> P (in GSD2; infantile form).
FT                                {ECO:0000269|PubMed:9521422}.
FT                                /FTId=VAR_004298.
FT   VARIANT     568    568       H -> L (in GSD2).
FT                                {ECO:0000269|PubMed:22676651}.
FT                                /FTId=VAR_070018.
FT   VARIANT     570    570       N -> K (in GSD2).
FT                                {ECO:0000269|PubMed:18425781}.
FT                                /FTId=VAR_068607.
FT   VARIANT     572    572       H -> Q (in GSD2).
FT                                {ECO:0000269|PubMed:18425781}.
FT                                /FTId=VAR_068608.
FT   VARIANT     575    575       Y -> C (in GSD2).
FT                                {ECO:0000269|PubMed:22644586}.
FT                                /FTId=VAR_068609.
FT   VARIANT     575    575       Y -> S (in GSD2; juvenile form).
FT                                {ECO:0000269|PubMed:14695532}.
FT                                /FTId=VAR_018093.
FT   VARIANT     576    576       G -> A.
FT                                /FTId=VAR_004299.
FT   VARIANT     576    576       G -> R (in GSD2).
FT                                {ECO:0000269|PubMed:22644586}.
FT                                /FTId=VAR_068610.
FT   VARIANT     576    576       G -> S (retains about half of the
FT                                activity compared with the wild-type;
FT                                dbSNP:rs1800307).
FT                                {ECO:0000269|PubMed:14643388,
FT                                ECO:0000269|PubMed:25681614}.
FT                                /FTId=VAR_004300.
FT   VARIANT     579    579       E -> K (in GSD2; infantile form; severe;
FT                                loss of activity).
FT                                {ECO:0000269|PubMed:14695532}.
FT                                /FTId=VAR_018094.
FT   VARIANT     585    585       R -> K. {ECO:0000269|PubMed:18425781}.
FT                                /FTId=VAR_068611.
FT   VARIANT     585    585       R -> M (in GSD2).
FT                                {ECO:0000269|PubMed:11071489}.
FT                                /FTId=VAR_046472.
FT   VARIANT     594    594       R -> H (in GSD2).
FT                                {ECO:0000269|PubMed:22644586}.
FT                                /FTId=VAR_068612.
FT   VARIANT     594    594       R -> P (in GSD2).
FT                                {ECO:0000269|PubMed:18425781,
FT                                ECO:0000269|PubMed:19588081}.
FT                                /FTId=VAR_068613.
FT   VARIANT     599    599       S -> Y (in GSD2; no residual enzymatic
FT                                activity). {ECO:0000269|PubMed:18429042}.
FT                                /FTId=VAR_046473.
FT   VARIANT     600    600       R -> C (in GSD2; juvenile form; loss of
FT                                activity). {ECO:0000269|PubMed:14643388,
FT                                ECO:0000269|PubMed:14695532}.
FT                                /FTId=VAR_018095.
FT   VARIANT     600    600       R -> H (in GSD2; infantile form).
FT                                /FTId=VAR_008689.
FT   VARIANT     601    601       S -> L (in GSD2).
FT                                {ECO:0000269|PubMed:22644586,
FT                                ECO:0000269|PubMed:22676651}.
FT                                /FTId=VAR_068614.
FT   VARIANT     602    602       T -> A (in GSD2).
FT                                {ECO:0000269|PubMed:22644586}.
FT                                /FTId=VAR_068615.
FT   VARIANT     607    612       Missing (in GSD2).
FT                                {ECO:0000269|PubMed:11071489}.
FT                                /FTId=VAR_046474.
FT   VARIANT     607    607       G -> D (in GSD2; infantile form; severe;
FT                                loss of activity).
FT                                {ECO:0000269|PubMed:14695532}.
FT                                /FTId=VAR_018096.
FT   VARIANT     610    610       A -> V (in GSD2).
FT                                {ECO:0000269|PubMed:17643989}.
FT                                /FTId=VAR_068616.
FT   VARIANT     611    611       G -> D (found in a patient with GSD2;
FT                                unknown pathological significance).
FT                                {ECO:0000269|PubMed:22644586,
FT                                ECO:0000269|PubMed:25681614}.
FT                                /FTId=VAR_068617.
FT   VARIANT     612    612       H -> Q (in GSD2).
FT                                {ECO:0000269|PubMed:16917947}.
FT                                /FTId=VAR_029038.
FT   VARIANT     612    612       H -> Y (in GSD2).
FT                                {ECO:0000269|PubMed:19588081}.
FT                                /FTId=VAR_068618.
FT   VARIANT     614    614       T -> K (in GSD2).
FT                                {ECO:0000269|PubMed:18425781}.
FT                                /FTId=VAR_068619.
FT   VARIANT     615    615       G -> R (in GSD2; infantile/adult form;
FT                                dbSNP:rs549029029).
FT                                {ECO:0000269|PubMed:20080426}.
FT                                /FTId=VAR_008690.
FT   VARIANT     619    619       S -> R (in GSD2; loss of function of the
FT                                mutant enzyme).
FT                                {ECO:0000269|PubMed:14643388}.
FT                                /FTId=VAR_046475.
FT   VARIANT     627    627       S -> P (in GSD2).
FT                                {ECO:0000269|PubMed:22644586}.
FT                                /FTId=VAR_068620.
FT   VARIANT     629    629       P -> L. {ECO:0000269|PubMed:22644586}.
FT                                /FTId=VAR_068621.
FT   VARIANT     635    635       N -> K (in GSD2).
FT                                {ECO:0000269|PubMed:19588081}.
FT                                /FTId=VAR_068622.
FT   VARIANT     638    638       G -> V (in GSD2).
FT                                {ECO:0000269|PubMed:19588081}.
FT                                /FTId=VAR_068623.
FT   VARIANT     638    638       G -> W (in GSD2).
FT                                {ECO:0000269|PubMed:10737124,
FT                                ECO:0000269|PubMed:18429042}.
FT                                /FTId=VAR_046476.
FT   VARIANT     641    641       L -> V (in GSD2; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:25681614}.
FT                                /FTId=VAR_074278.
FT   VARIANT     643    643       G -> R (in GSD2; infantile form;
FT                                dbSNP:rs28937909).
FT                                {ECO:0000269|PubMed:11071489,
FT                                ECO:0000269|PubMed:16917947,
FT                                ECO:0000269|PubMed:18429042,
FT                                ECO:0000269|PubMed:8401535,
FT                                ECO:0000269|PubMed:9521422}.
FT                                /FTId=VAR_004301.
FT   VARIANT     645    645       D -> E (in GSD2; infantile form; most
FT                                common mutation; deficient in
FT                                phosphorylation and in proteolytic
FT                                processing; dbSNP:rs28940868).
FT                                {ECO:0000269|PubMed:1684505,
FT                                ECO:0000269|PubMed:20080426,
FT                                ECO:0000269|PubMed:8094613}.
FT                                /FTId=VAR_004302.
FT   VARIANT     645    645       D -> H (in GSD2; almost complete loss of
FT                                activity). {ECO:0000269|PubMed:7695647}.
FT                                /FTId=VAR_004303.
FT   VARIANT     645    645       D -> N (in GSD2).
FT                                {ECO:0000269|PubMed:15145338,
FT                                ECO:0000269|PubMed:18429042,
FT                                ECO:0000269|PubMed:9535769}.
FT                                /FTId=VAR_004304.
FT   VARIANT     647    647       C -> W (in GSD2).
FT                                {ECO:0000269|PubMed:25681614,
FT                                ECO:0000269|PubMed:7981676,
FT                                ECO:0000269|PubMed:9535769}.
FT                                /FTId=VAR_004305.
FT   VARIANT     648    648       G -> D (in GSD2).
FT                                {ECO:0000269|PubMed:22644586}.
FT                                /FTId=VAR_068624.
FT   VARIANT     648    648       G -> S (in GSD2; dbSNP:rs536906561).
FT                                {ECO:0000269|PubMed:9535769}.
FT                                /FTId=VAR_004306.
FT   VARIANT     660    660       R -> H (in GSD2; loss of function of the
FT                                mutant enzyme).
FT                                {ECO:0000269|PubMed:14643388}.
FT                                /FTId=VAR_046477.
FT   VARIANT     672    672       R -> Q (in GSD2).
FT                                {ECO:0000269|PubMed:9535769}.
FT                                /FTId=VAR_004307.
FT   VARIANT     672    672       R -> T (in GSD2).
FT                                {ECO:0000269|PubMed:11071489}.
FT                                /FTId=VAR_046478.
FT   VARIANT     672    672       R -> W (in GSD2).
FT                                {ECO:0000269|PubMed:16917947,
FT                                ECO:0000269|PubMed:9535769}.
FT                                /FTId=VAR_004308.
FT   VARIANT     675    675       Missing (in GSD2; infantile form).
FT                                /FTId=VAR_008692.
FT   VARIANT     689    689       E -> K (in allele GAA*4;
FT                                dbSNP:rs1800309).
FT                                {ECO:0000269|PubMed:25681614,
FT                                ECO:0000269|PubMed:8912788}.
FT                                /FTId=VAR_004309.
FT   VARIANT     700    701       Missing (found in a patient with GSD2;
FT                                unknown pathological significance).
FT                                {ECO:0000269|PubMed:22644586}.
FT                                /FTId=VAR_068625.
FT   VARIANT     702    702       R -> C (in GSD2; no enzymatic activity;
FT                                shows enzyme localization primarily in
FT                                the ER-Golgi compartment suggesting that
FT                                mutation could affect the normal
FT                                processing and stability of the enzyme).
FT                                {ECO:0000269|PubMed:14972326}.
FT                                /FTId=VAR_046479.
FT   VARIANT     702    702       R -> L (in GSD2).
FT                                {ECO:0000269|PubMed:22644586}.
FT                                /FTId=VAR_068626.
FT   VARIANT     705    705       L -> P (in GSD2; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:25681614}.
FT                                /FTId=VAR_074279.
FT   VARIANT     711    711       T -> R. {ECO:0000269|PubMed:20080426}.
FT                                /FTId=VAR_068627.
FT   VARIANT     718    718       V -> I. {ECO:0000269|PubMed:22644586}.
FT                                /FTId=VAR_068628.
FT   VARIANT     725    725       R -> W (in GSD2; adult form;
FT                                dbSNP:rs28939100).
FT                                {ECO:0000269|PubMed:8401535}.
FT                                /FTId=VAR_004310.
FT   VARIANT     737    737       T -> N (in GSD2).
FT                                {ECO:0000269|PubMed:18425781}.
FT                                /FTId=VAR_068629.
FT   VARIANT     743    743       Q -> K (in GSD2).
FT                                {ECO:0000269|PubMed:22644586}.
FT                                /FTId=VAR_068630.
FT   VARIANT     746    746       W -> C (in dbSNP:rs1800312).
FT                                {ECO:0000269|PubMed:16917947,
FT                                ECO:0000269|PubMed:20080426}.
FT                                /FTId=VAR_004311.
FT   VARIANT     746    746       W -> G (in GSD2).
FT                                {ECO:0000269|PubMed:20080426}.
FT                                /FTId=VAR_068631.
FT   VARIANT     746    746       W -> S (in GSD2).
FT                                {ECO:0000269|PubMed:18425781}.
FT                                /FTId=VAR_068632.
FT   VARIANT     766    766       Y -> C (in GSD2).
FT                                {ECO:0000269|PubMed:22676651}.
FT                                /FTId=VAR_070019.
FT   VARIANT     768    768       P -> R (in GSD2; infantile form).
FT                                {ECO:0000269|PubMed:9521422}.
FT                                /FTId=VAR_004312.
FT   VARIANT     780    780       V -> I (in dbSNP:rs1126690).
FT                                {ECO:0000269|PubMed:2111708,
FT                                ECO:0000269|PubMed:2268276,
FT                                ECO:0000269|PubMed:25681614,
FT                                ECO:0000269|PubMed:3049072,
FT                                ECO:0000269|PubMed:7717400,
FT                                ECO:0000269|Ref.5}.
FT                                /FTId=VAR_004313.
FT   VARIANT     816    816       V -> I (in dbSNP:rs1800314).
FT                                {ECO:0000269|PubMed:1684505,
FT                                ECO:0000269|PubMed:25681614,
FT                                ECO:0000269|PubMed:8094613,
FT                                ECO:0000269|PubMed:8486380}.
FT                                /FTId=VAR_004314.
FT   VARIANT     819    819       R -> P (in GSD2).
FT                                {ECO:0000269|PubMed:22644586}.
FT                                /FTId=VAR_068633.
FT   VARIANT     880    880       A -> D (in GSD2; infantile form; severe;
FT                                loss of activity).
FT                                {ECO:0000269|PubMed:14695532}.
FT                                /FTId=VAR_018097.
FT   VARIANT     901    901       L -> Q (in GSD2; infantile form; severe).
FT                                {ECO:0000269|PubMed:15145338}.
FT                                /FTId=VAR_029039.
FT   VARIANT     903    903       Missing (in GSD2; infantile form; severe;
FT                                loss of activity).
FT                                {ECO:0000269|PubMed:7717400}.
FT                                /FTId=VAR_004315.
FT   VARIANT     913    913       P -> R (in GSD2).
FT                                {ECO:0000269|PubMed:22676651}.
FT                                /FTId=VAR_070020.
FT   VARIANT     916    916       V -> F (in GSD2).
FT                                {ECO:0000269|PubMed:22644586}.
FT                                /FTId=VAR_068634.
FT   VARIANT     925    925       N -> NGVPVSN (in GSD2).
FT                                {ECO:0000269|PubMed:10206684}.
FT                                /FTId=VAR_004316.
FT   VARIANT     927    927       T -> I (loss of glycosylation site;
FT                                dbSNP:rs1800315).
FT                                {ECO:0000269|PubMed:1684505,
FT                                ECO:0000269|PubMed:8094613,
FT                                ECO:0000269|PubMed:8486380}.
FT                                /FTId=VAR_004317.
FT   VARIANT     935    935       L -> P (in GSD2).
FT                                {ECO:0000269|PubMed:18425781}.
FT                                /FTId=VAR_068635.
FT   VARIANT     949    949       V -> D (in GSD2).
FT                                /FTId=VAR_004318.
FT   MUTAGEN     516    516       W->R: Loss of activity.
FT                                {ECO:0000269|PubMed:1856189}.
FT   MUTAGEN     518    518       D->G,N,E: Loss of activity.
FT                                {ECO:0000269|PubMed:1856189}.
SQ   SEQUENCE   952 AA;  105324 MW;  6E2717BF7201F469 CRC64;
     MGVRHPPCSH RLLAVCALVS LATAALLGHI LLHDFLLVPR ELSGSSPVLE ETHPAHQQGA
     SRPGPRDAQA HPGRPRAVPT QCDVPPNSRF DCAPDKAITQ EQCEARGCCY IPAKQGLQGA
     QMGQPWCFFP PSYPSYKLEN LSSSEMGYTA TLTRTTPTFF PKDILTLRLD VMMETENRLH
     FTIKDPANRR YEVPLETPHV HSRAPSPLYS VEFSEEPFGV IVRRQLDGRV LLNTTVAPLF
     FADQFLQLST SLPSQYITGL AEHLSPLMLS TSWTRITLWN RDLAPTPGAN LYGSHPFYLA
     LEDGGSAHGV FLLNSNAMDV VLQPSPALSW RSTGGILDVY IFLGPEPKSV VQQYLDVVGY
     PFMPPYWGLG FHLCRWGYSS TAITRQVVEN MTRAHFPLDV QWNDLDYMDS RRDFTFNKDG
     FRDFPAMVQE LHQGGRRYMM IVDPAISSSG PAGSYRPYDE GLRRGVFITN ETGQPLIGKV
     WPGSTAFPDF TNPTALAWWE DMVAEFHDQV PFDGMWIDMN EPSNFIRGSE DGCPNNELEN
     PPYVPGVVGG TLQAATICAS SHQFLSTHYN LHNLYGLTEA IASHRALVKA RGTRPFVISR
     STFAGHGRYA GHWTGDVWSS WEQLASSVPE ILQFNLLGVP LVGADVCGFL GNTSEELCVR
     WTQLGAFYPF MRNHNSLLSL PQEPYSFSEP AQQAMRKALT LRYALLPHLY TLFHQAHVAG
     ETVARPLFLE FPKDSSTWTV DHQLLWGEAL LITPVLQAGK AEVTGYFPLG TWYDLQTVPV
     EALGSLPPPP AAPREPAIHS EGQWVTLPAP LDTINVHLRA GYIIPLQGPG LTTTESRQQP
     MALAVALTKG GEARGELFWD DGESLEVLER GAYTQVIFLA RNNTIVNELV RVTSEGAGLQ
     LQKVTVLGVA TAPQQVLSNG VPVSNFTYSP DTKVLDICVS LLMGEQFLVS WC
//
ID   ANGT_HUMAN              Reviewed;         485 AA.
AC   P01019; Q16358; Q16359; Q96F91;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   21-JUL-1986, sequence version 1.
DT   17-FEB-2016, entry version 193.
DE   RecName: Full=Angiotensinogen;
DE   AltName: Full=Serpin A8;
DE   Contains:
DE     RecName: Full=Angiotensin-1;
DE     AltName: Full=Angiotensin 1-10;
DE     AltName: Full=Angiotensin I;
DE              Short=Ang I;
DE   Contains:
DE     RecName: Full=Angiotensin-2;
DE     AltName: Full=Angiotensin 1-8;
DE     AltName: Full=Angiotensin II;
DE              Short=Ang II;
DE   Contains:
DE     RecName: Full=Angiotensin-3;
DE     AltName: Full=Angiotensin 2-8;
DE     AltName: Full=Angiotensin III;
DE              Short=Ang III;
DE     AltName: Full=Des-Asp[1]-angiotensin II;
DE   Contains:
DE     RecName: Full=Angiotensin-4;
DE     AltName: Full=Angiotensin 3-8;
DE     AltName: Full=Angiotensin IV;
DE              Short=Ang IV;
DE   Contains:
DE     RecName: Full=Angiotensin 1-9;
DE   Contains:
DE     RecName: Full=Angiotensin 1-7;
DE   Contains:
DE     RecName: Full=Angiotensin 1-5;
DE   Contains:
DE     RecName: Full=Angiotensin 1-4;
DE   Flags: Precursor;
GN   Name=AGT; Synonyms=SERPINA8;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=6089875; DOI=10.1021/bi00311a006;
RA   Kageyama R., Ohkubo H., Nakanishi S.;
RT   "Primary structure of human preangiotensinogen deduced from the cloned
RT   cDNA sequence.";
RL   Biochemistry 23:3603-3609(1984).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=2924688; DOI=10.1089/dna.1.1989.8.87;
RA   Gaillard I., Clauser E., Corvol P.;
RT   "Structure of human angiotensinogen gene.";
RL   DNA 8:87-99(1989).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=1692023;
RA   Fukamizu A., Takahashi S., Seo M.S., Tada M., Tanimoto K., Uehara S.,
RA   Murakami K.;
RT   "Structure and expression of the human angiotensinogen gene.
RT   Identification of a unique and highly active promoter.";
RL   J. Biol. Chem. 265:7576-7582(1990).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT SER-335.
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-338.
RX   PubMed=2885106; DOI=10.1161/01.RES.60.5.786;
RA   Kunapuli S.P., Kumar A.;
RT   "Molecular cloning of human angiotensinogen cDNA and evidence for the
RT   presence of its mRNA in rat heart.";
RL   Circ. Res. 60:786-790(1987).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 32-184.
RX   PubMed=3579322; DOI=10.1016/0003-9861(87)90148-2;
RA   Kunapuli S.P., Benedict C.R., Kumar A.;
RT   "Tissue specific hormonal regulation of the rat angiotensinogen gene
RT   expression.";
RL   Arch. Biochem. Biophys. 254:642-646(1987).
RN   [7]
RP   PROTEIN SEQUENCE OF 34-58.
RX   PubMed=7259779; DOI=10.1016/0006-291X(81)90762-2;
RA   Tewksbury D.A., Dart R.A., Travis J.;
RT   "The amino terminal amino acid sequence of human angiotensinogen.";
RL   Biochem. Biophys. Res. Commun. 99:1311-1315(1981).
RN   [8]
RP   PROTEIN SEQUENCE OF 34-45, AND SUBUNIT.
RC   TISSUE=Serum;
RX   PubMed=7539791; DOI=10.1074/jbc.270.23.13645;
RA   Oxvig C., Haaning J., Kristensen L., Wagner J.M., Rubin I.,
RA   Stigbrand T., Gleich G.J., Sottrup-Jensen L.;
RT   "Identification of angiotensinogen and complement C3dg as novel
RT   proteins binding the proform of eosinophil major basic protein in
RT   human pregnancy serum and plasma.";
RL   J. Biol. Chem. 270:13645-13651(1995).
RN   [9]
RP   PROTEIN SEQUENCE OF 34-43.
RX   PubMed=4300938;
RA   Arakawa K., Minohara A., Yamada J., Nakamura M.;
RT   "Enzymatic degradation and electrophoresis of human angiotensin I.";
RL   Biochim. Biophys. Acta 168:106-112(1968).
RN   [10]
RP   GLYCOSYLATION AT ASN-47; ASN-170; ASN-304 AND ASN-328.
RX   PubMed=3934016; DOI=10.1016/0303-7207(85)90039-5;
RA   Campbell D.J., Bouhnik J., Coezy E., Menard J., Corvol P.;
RT   "Processing of rat and human angiotensinogen precursors by microsomal
RT   membranes.";
RL   Mol. Cell. Endocrinol. 43:31-40(1985).
RN   [11]
RP   FUNCTION OF ANGIOTENSIN-3.
RX   PubMed=1132082; DOI=10.1161/01.RES.36.6.38;
RA   Goodfriend T.L., Peach M.J.;
RT   "Angiotensin III: (DES-Aspartic Acid-1)-Angiotensin II. Evidence and
RT   speculation for its role as an important agonist in the renin -
RT   angiotensin system.";
RL   Circ. Res. 36:38-48(1975).
RN   [12]
RP   FUNCTION OF ANGIOTENSIN-2.
RX   PubMed=10619573; DOI=10.1016/S0895-7061(99)00103-X;
RA   Weir M.R., Dzau V.J.;
RT   "The renin-angiotensin-aldosterone system: a specific target for
RT   hypertension management.";
RL   Am. J. Hypertens. 12:205S-213S(1999).
RN   [13]
RP   CLEAVAGE BY ACE AND ACE2.
RX   PubMed=10969042; DOI=10.1161/01.RES.87.5.e1;
RA   Donoghue M., Hsieh F., Baronas E., Godbout K., Gosselin M.,
RA   Stagliano N., Donovan M., Woolf B., Robison K., Jeyaseelan R.,
RA   Breitbart R.E., Acton S.;
RT   "A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2)
RT   converts angiotensin I to angiotensin 1-9.";
RL   Circ. Res. 87:E1-E9(2000).
RN   [14]
RP   CLEAVAGE OF ANGIOTENSIN-1 AND ANGIOTENSIN-2 BY ACE2.
RX   PubMed=11815627; DOI=10.1074/jbc.M200581200;
RA   Vickers C., Hales P., Kaushik V., Dick L., Gavin J., Tang J.,
RA   Godbout K., Parsons T., Baronas E., Hsieh F., Acton S., Patane M.A.,
RA   Nichols A., Tummino P.;
RT   "Hydrolysis of biological peptides by human angiotensin-converting
RT   enzyme-related carboxypeptidase.";
RL   J. Biol. Chem. 277:14838-14843(2002).
RN   [15]
RP   ANGIOTENSIN PEPTIDES METABOLISM.
RX   PubMed=15283675; DOI=10.1042/BJ20040634;
RA   Rice G.I., Thomas D.A., Grant P.J., Turner A.J., Hooper N.M.;
RT   "Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2
RT   and neprilysin in angiotensin peptide metabolism.";
RL   Biochem. J. 383:45-51(2004).
RN   [16]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-47.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [17]
RP   DECARBOXYLATION AT ASP-34, FUNCTION, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RX   PubMed=17138938; DOI=10.1161/01.ATV.0000253889.09765.5f;
RA   Jankowski V., Vanholder R., van der Giet M., Tolle M., Karadogan S.,
RA   Gobom J., Furkert J., Oksche A., Krause E., Tran T.N., Tepel M.,
RA   Schuchardt M., Schluter H., Wiedon A., Beyermann M., Bader M.,
RA   Todiras M., Zidek W., Jankowski J.;
RT   "Mass-spectrometric identification of a novel angiotensin peptide in
RT   human plasma.";
RL   Arterioscler. Thromb. Vasc. Biol. 27:297-302(2007).
RN   [18]
RP   REVIEW ON THE RENIN-ANGIOTENSIN SYSTEM.
RX   PubMed=18793332; DOI=10.1111/j.1365-2796.2008.01981.x;
RA   Fyhrquist F., Saijonmaa O.;
RT   "Renin-angiotensin system revisited.";
RL   J. Intern. Med. 264:224-236(2008).
RN   [19]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-47.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [22]
RP   STRUCTURE BY NMR OF ANGIOTENSIN-2.
RX   PubMed=9492317; DOI=10.1046/j.1432-1327.1998.2510448.x;
RA   Carpenter K.A., Wilkes B.C., Schiller P.W.;
RT   "The octapeptide angiotensin II adopts a well-defined structure in a
RT   phospholipid environment.";
RL   Eur. J. Biochem. 251:448-453(1998).
RN   [23]
RP   STRUCTURE BY NMR OF 34-43, AND STRUCTURE BY NMR OF 34-41.
RX   PubMed=12752436; DOI=10.1046/j.1432-1033.2003.03573.x;
RA   Spyroulias G.A., Nikolakopoulou P., Tzakos A., Gerothanassis I.P.,
RA   Magafa V., Manessi-Zoupa E., Cordopatis P.;
RT   "Comparison of the solution structures of angiotensin I & II.
RT   Implication for structure-function relationship.";
RL   Eur. J. Biochem. 270:2163-2173(2003).
RN   [24]
RP   X-RAY CRYSTALLOGRAPHY (4.33 ANGSTROMS) OF 34-485 IN COMPLEX WITH
RP   RENIN, AND DISULFIDE BOND.
RX   PubMed=20927107; DOI=10.1038/nature09505;
RA   Zhou A., Carrell R.W., Murphy M.P., Wei Z., Yan Y., Stanley P.L.,
RA   Stein P.E., Broughton Pipkin F., Read R.J.;
RT   "A redox switch in angiotensinogen modulates angiotensin release.";
RL   Nature 468:108-111(2010).
RN   [25]
RP   VARIANTS MET-207; THR-268 AND CYS-281.
RX   PubMed=1394429; DOI=10.1016/0092-8674(92)90275-H;
RA   Jeunemaitre X., Soubrier F., Kotelevtsev Y.V., Lifton R.P.,
RA   Williams C.S., Charru A., Hunt S.C., Hopkins P.N., Williams R.R.,
RA   Lalouel J.-M., Corvol P.;
RT   "Molecular basis of human hypertension: role of angiotensinogen.";
RL   Cell 71:169-180(1992).
RN   [26]
RP   VARIANT THR-268.
RX   PubMed=8513325; DOI=10.1038/ng0593-59;
RA   Ward K., Hata A., Jeunemaitre X., Helin C., Nelson L., Namikawa C.,
RA   Farrington P.F., Ogasawara M., Suzumori K., Tomoda S., Berrebi S.,
RA   Sasaki M., Corvol P., Lifton R.P., Lalouel J.-M.;
RT   "A molecular variant of angiotensinogen associated with
RT   preeclampsia.";
RL   Nat. Genet. 4:59-61(1993).
RN   [27]
RP   VARIANTS ILE-242; ARG-244 AND CYS-281.
RX   PubMed=7607642; DOI=10.1007/BF00214197;
RA   Hixson J.E., Powers P.K.;
RT   "Detection and characterization of new mutations in the human
RT   angiotensinogen gene (AGT).";
RL   Hum. Genet. 96:110-112(1995).
RN   [28]
RP   VARIANT PHE-43.
RX   PubMed=7744780; DOI=10.1074/jbc.270.19.11430;
RA   Inoue I., Rohrwasser A., Helin C., Jeunemaitre X., Crain P.,
RA   Bohlender J., Lifton R.P., Corvol P., Ward K., Lalouel J.-M.;
RT   "A mutation of angiotensinogen in a patient with preeclampsia leads to
RT   altered kinetics of the renin-angiotensin system.";
RL   J. Biol. Chem. 270:11430-11436(1995).
RN   [29]
RP   CHARACTERIZATION OF VARIANT CYS-281.
RX   PubMed=8621667; DOI=10.1074/jbc.271.16.9838;
RA   Gimenez-Roqueplo A.P., Leconte I., Cohen P., Simon D., Guyene T.T.,
RA   Celerier J., Pau B., Corvol P., Clauser E., Jeunemaitre X.;
RT   "The natural mutation Y248C of human angiotensinogen leads to abnormal
RT   glycosylation and altered immunological recognition of the protein.";
RL   J. Biol. Chem. 271:9838-9844(1996).
RN   [30]
RP   VARIANT RTD GLN-375.
RX   PubMed=16116425; DOI=10.1038/ng1623;
RA   Gribouval O., Gonzales M., Neuhaus T., Aziza J., Bieth E., Laurent N.,
RA   Bouton J.M., Feuillet F., Makni S., Ben Amar H., Laube G.,
RA   Delezoide A.-L., Bouvier R., Dijoud F., Ollagnon-Roman E., Roume J.,
RA   Joubert M., Antignac C., Gubler M.-C.;
RT   "Mutations in genes in the renin-angiotensin system are associated
RT   with autosomal recessive renal tubular dysgenesis.";
RL   Nat. Genet. 37:964-968(2005).
CC   -!- FUNCTION: Essential component of the renin-angiotensin system
CC       (RAS), a potent regulator of blood pressure, body fluid and
CC       electrolyte homeostasis.
CC   -!- FUNCTION: Angiotensin-2: acts directly on vascular smooth muscle
CC       as a potent vasoconstrictor, affects cardiac contractility and
CC       heart rate through its action on the sympathetic nervous system,
CC       and alters renal sodium and water absorption through its ability
CC       to stimulate the zona glomerulosa cells of the adrenal cortex to
CC       synthesize and secrete aldosterone.
CC   -!- FUNCTION: Angiotensin-3: stimulates aldosterone release.
CC   -!- FUNCTION: Angiotensin 1-7: is a ligand for the G-protein coupled
CC       receptor MAS1. Has vasodilator and antidiuretic effects. Has an
CC       antithrombotic effect that involves MAS1-mediated release of
CC       nitric oxide from platelets. {ECO:0000250,
CC       ECO:0000269|PubMed:10619573, ECO:0000269|PubMed:1132082,
CC       ECO:0000269|PubMed:17138938}.
CC   -!- SUBUNIT: During pregnancy, exists as a disulfide-linked 2:2
CC       heterotetramer with the proform of PRG2 and as a complex (probably
CC       a 2:2:2 heterohexamer) with pro-PRG2 and C3dg.
CC       {ECO:0000269|PubMed:20927107, ECO:0000269|PubMed:7539791}.
CC   -!- INTERACTION:
CC       P30556:AGTR1; NbExp=2; IntAct=EBI-6622938, EBI-6623016;
CC       P25095:Agtr1 (xeno); NbExp=10; IntAct=EBI-751728, EBI-764979;
CC       P50052:AGTR2; NbExp=2; IntAct=EBI-2927577, EBI-1748067;
CC       Q10714:Ance (xeno); NbExp=2; IntAct=EBI-751728, EBI-115736;
CC   -!- SUBCELLULAR LOCATION: Secreted.
CC   -!- TISSUE SPECIFICITY: Expressed by the liver and secreted in plasma.
CC   -!- PTM: Beta-decarboxylation of Asp-34 in angiotensin-2, by
CC       mononuclear leukocytes produces alanine. The resulting peptide
CC       form, angiotensin-A, has the same affinity for the AT1 receptor as
CC       angiotensin-2, but a higher affinity for the AT2 receptor.
CC       {ECO:0000269|PubMed:17138938}.
CC   -!- PTM: In response to low blood pressure, the enzyme renin/REN
CC       cleaves angiotensinogen to produce angiotensin-1. Angiotensin-1 is
CC       a substrate of ACE (angiotensin converting enzyme) that removes a
CC       dipeptide to yield the physiologically active peptide angiotensin-
CC       2. Angiotensin-1 and angiotensin-2 can be further processed to
CC       generate angiotensin-3, angiotensin-4. Angiotensin 1-9 is cleaved
CC       from angiotensin-1 by ACE2 and can be further processed by ACE to
CC       produce angiotensin 1-7, angiotensin 1-5 and angiotensin 1-4.
CC       Angiotensin 1-7 has also been proposed to be cleaved from
CC       angiotensin-2 by ACE2 or from angiotensin-1 by MME (neprilysin).
CC       {ECO:0000269|PubMed:10969042, ECO:0000269|PubMed:11815627}.
CC   -!- PTM: The disulfide bond is labile. Angiotensinogen is present in
CC       the circulation in a near 40:60 ratio with the oxidized disulfide-
CC       bonded form, which preferentially interacts with receptor-bound
CC       renin.
CC   -!- DISEASE: Essential hypertension (EHT) [MIM:145500]: A condition in
CC       which blood pressure is consistently higher than normal with no
CC       identifiable cause. {ECO:0000269|PubMed:1394429,
CC       ECO:0000269|PubMed:8513325}. Note=Disease susceptibility is
CC       associated with variations affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Renal tubular dysgenesis (RTD) [MIM:267430]: Autosomal
CC       recessive severe disorder of renal tubular development
CC       characterized by persistent fetal anuria and perinatal death,
CC       probably due to pulmonary hypoplasia from early-onset
CC       oligohydramnios (the Potter phenotype).
CC       {ECO:0000269|PubMed:16116425}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the serpin family. {ECO:0000305}.
CC   -!- CAUTION: It is uncertain whether Met-1 or Met-10 is the initiator.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation and
CC       polymorphism database;
CC       URL="http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=AGT";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Angiotensin entry;
CC       URL="https://en.wikipedia.org/wiki/Angiotensin";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; K02215; AAA51731.1; -; mRNA.
DR   EMBL; M24689; AAA51679.1; -; Genomic_DNA.
DR   EMBL; M24686; AAA51679.1; JOINED; Genomic_DNA.
DR   EMBL; M24687; AAA51679.1; JOINED; Genomic_DNA.
DR   EMBL; M24688; AAA51679.1; JOINED; Genomic_DNA.
DR   EMBL; X15324; CAA33385.1; -; Genomic_DNA.
DR   EMBL; X15325; CAA33385.1; JOINED; Genomic_DNA.
DR   EMBL; X15326; CAA33385.1; JOINED; Genomic_DNA.
DR   EMBL; X15327; CAA33385.1; JOINED; Genomic_DNA.
DR   EMBL; BC011519; AAH11519.1; -; mRNA.
DR   EMBL; M69110; AAA52282.1; -; mRNA.
DR   EMBL; S78529; AAD14287.1; -; Genomic_DNA.
DR   EMBL; S78530; AAD14288.1; -; Genomic_DNA.
DR   CCDS; CCDS1585.1; -.
DR   PIR; A35203; ANHU.
DR   RefSeq; NP_000020.1; NM_000029.3.
DR   UniGene; Hs.19383; -.
DR   PDB; 1N9U; NMR; -; A=34-43.
DR   PDB; 1N9V; NMR; -; A=34-41.
DR   PDB; 2JP8; NMR; -; P=34-40.
DR   PDB; 2WXW; X-ray; 3.30 A; A=34-485.
DR   PDB; 2X0B; X-ray; 4.33 A; B/D/F/H=34-485.
DR   PDB; 3CK0; X-ray; 3.00 A; P=34-41.
DR   PDB; 3WOO; X-ray; 1.80 A; C/D=36-41.
DR   PDB; 3WOR; X-ray; 2.10 A; C/D=34-41.
DR   PDB; 4AA1; X-ray; 1.99 A; P=34-41.
DR   PDB; 4APH; X-ray; 1.99 A; P=34-41.
DR   PDB; 4FYS; X-ray; 2.01 A; C=36-41.
DR   PDBsum; 1N9U; -.
DR   PDBsum; 1N9V; -.
DR   PDBsum; 2JP8; -.
DR   PDBsum; 2WXW; -.
DR   PDBsum; 2X0B; -.
DR   PDBsum; 3CK0; -.
DR   PDBsum; 3WOO; -.
DR   PDBsum; 3WOR; -.
DR   PDBsum; 4AA1; -.
DR   PDBsum; 4APH; -.
DR   PDBsum; 4FYS; -.
DR   ProteinModelPortal; P01019; -.
DR   SMR; P01019; 34-482.
DR   BioGrid; 106690; 15.
DR   DIP; DIP-309N; -.
DR   IntAct; P01019; 9.
DR   MINT; MINT-1472115; -.
DR   STRING; 9606.ENSP00000355627; -.
DR   MEROPS; I04.953; -.
DR   iPTMnet; P01019; -.
DR   PhosphoSite; P01019; -.
DR   BioMuta; AGT; -.
DR   DMDM; 113880; -.
DR   SWISS-2DPAGE; P01019; -.
DR   MaxQB; P01019; -.
DR   PaxDb; P01019; -.
DR   PeptideAtlas; P01019; -.
DR   PRIDE; P01019; -.
DR   DNASU; 183; -.
DR   Ensembl; ENST00000366667; ENSP00000355627; ENSG00000135744.
DR   GeneID; 183; -.
DR   KEGG; hsa:183; -.
DR   UCSC; uc001hty.4; human.
DR   CTD; 183; -.
DR   GeneCards; AGT; -.
DR   HGNC; HGNC:333; AGT.
DR   HPA; HPA001557; -.
DR   MalaCards; AGT; -.
DR   MIM; 106150; gene.
DR   MIM; 145500; phenotype.
DR   MIM; 267430; phenotype.
DR   neXtProt; NX_P01019; -.
DR   Orphanet; 243761; Essential hypertension.
DR   Orphanet; 97369; Renal tubular dysgenesis of genetic origin.
DR   PharmGKB; PA42; -.
DR   eggNOG; KOG2392; Eukaryota.
DR   eggNOG; COG4826; LUCA.
DR   GeneTree; ENSGT00830000128420; -.
DR   HOVERGEN; HBG004233; -.
DR   InParanoid; P01019; -.
DR   KO; K09821; -.
DR   OMA; RFMQAVT; -.
DR   OrthoDB; EOG7QK0BN; -.
DR   PhylomeDB; P01019; -.
DR   TreeFam; TF343201; -.
DR   Reactome; R-HSA-1989781; PPARA activates gene expression.
DR   Reactome; R-HSA-2022377; Metabolism of Angiotensinogen to Angiotensins.
DR   Reactome; R-HSA-375276; Peptide ligand-binding receptors.
DR   Reactome; R-HSA-416476; G alpha (q) signalling events.
DR   Reactome; R-HSA-418594; G alpha (i) signalling events.
DR   ChiTaRS; AGT; human.
DR   EvolutionaryTrace; P01019; -.
DR   GeneWiki; Angiotensin; -.
DR   GenomeRNAi; 183; -.
DR   NextBio; 748; -.
DR   PMAP-CutDB; P01019; -.
DR   PRO; PR:P01019; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; P01019; -.
DR   CleanEx; HS_AGT; -.
DR   ExpressionAtlas; P01019; baseline and differential.
DR   Genevisible; P01019; HS.
DR   GO; GO:0072562; C:blood microparticle; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IEA:Ensembl.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; NAS:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0008083; F:growth factor activity; TAS:BHF-UCL.
DR   GO; GO:0005179; F:hormone activity; ISS:BHF-UCL.
DR   GO; GO:0004867; F:serine-type endopeptidase inhibitor activity; TAS:ProtInc.
DR   GO; GO:0017080; F:sodium channel regulator activity; IMP:BHF-UCL.
DR   GO; GO:0016176; F:superoxide-generating NADPH oxidase activator activity; TAS:BHF-UCL.
DR   GO; GO:0031702; F:type 1 angiotensin receptor binding; IPI:BHF-UCL.
DR   GO; GO:0031703; F:type 2 angiotensin receptor binding; IPI:BHF-UCL.
DR   GO; GO:0007250; P:activation of NF-kappaB-inducing kinase activity; IEA:Ensembl.
DR   GO; GO:0007202; P:activation of phospholipase C activity; IEA:Ensembl.
DR   GO; GO:0007568; P:aging; IEA:Ensembl.
DR   GO; GO:0002003; P:angiotensin maturation; TAS:Reactome.
DR   GO; GO:0001998; P:angiotensin mediated vasoconstriction involved in regulation of systemic arterial blood pressure; IEA:Ensembl.
DR   GO; GO:0003051; P:angiotensin-mediated drinking behavior; IEA:Ensembl.
DR   GO; GO:0014824; P:artery smooth muscle contraction; IEA:Ensembl.
DR   GO; GO:0048143; P:astrocyte activation; IEA:Ensembl.
DR   GO; GO:0001568; P:blood vessel development; IEA:Ensembl.
DR   GO; GO:0001974; P:blood vessel remodeling; TAS:BHF-UCL.
DR   GO; GO:0001658; P:branching involved in ureteric bud morphogenesis; IEA:Ensembl.
DR   GO; GO:0035411; P:catenin import into nucleus; IEA:Ensembl.
DR   GO; GO:0061049; P:cell growth involved in cardiac muscle cell development; IEA:Ensembl.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0007267; P:cell-cell signaling; TAS:ProtInc.
DR   GO; GO:0007160; P:cell-matrix adhesion; IEA:Ensembl.
DR   GO; GO:0044255; P:cellular lipid metabolic process; TAS:Reactome.
DR   GO; GO:0044267; P:cellular protein metabolic process; TAS:Reactome.
DR   GO; GO:0071260; P:cellular response to mechanical stimulus; IEA:Ensembl.
DR   GO; GO:0006883; P:cellular sodium ion homeostasis; IEA:Ensembl.
DR   GO; GO:0050663; P:cytokine secretion; IEA:Ensembl.
DR   GO; GO:0070371; P:ERK1 and ERK2 cascade; IEA:Ensembl.
DR   GO; GO:0008065; P:establishment of blood-nerve barrier; IEA:Ensembl.
DR   GO; GO:0007588; P:excretion; IEA:Ensembl.
DR   GO; GO:0030198; P:extracellular matrix organization; IEA:Ensembl.
DR   GO; GO:0007565; P:female pregnancy; IEA:Ensembl.
DR   GO; GO:0048144; P:fibroblast proliferation; IEA:Ensembl.
DR   GO; GO:0007186; P:G-protein coupled receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0007199; P:G-protein coupled receptor signaling pathway coupled to cGMP nucleotide second messenger; TAS:BHF-UCL.
DR   GO; GO:0001822; P:kidney development; IMP:BHF-UCL.
DR   GO; GO:0034374; P:low-density lipoprotein particle remodeling; NAS:BHF-UCL.
DR   GO; GO:0016525; P:negative regulation of angiogenesis; IEA:Ensembl.
DR   GO; GO:0030308; P:negative regulation of cell growth; IEA:Ensembl.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IEA:Ensembl.
DR   GO; GO:0010951; P:negative regulation of endopeptidase activity; TAS:GOC.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0051387; P:negative regulation of neurotrophin TRK receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:2000650; P:negative regulation of sodium ion transmembrane transporter activity; TAS:BHF-UCL.
DR   GO; GO:0034104; P:negative regulation of tissue remodeling; IEA:Ensembl.
DR   GO; GO:0007263; P:nitric oxide mediated signal transduction; TAS:BHF-UCL.
DR   GO; GO:0001543; P:ovarian follicle rupture; IEA:Ensembl.
DR   GO; GO:0030432; P:peristalsis; IEA:Ensembl.
DR   GO; GO:0007200; P:phospholipase C-activating G-protein coupled receptor signaling pathway; NAS:BHF-UCL.
DR   GO; GO:0010535; P:positive regulation of activation of JAK2 kinase activity; IMP:UniProtKB.
DR   GO; GO:0090190; P:positive regulation of branching involved in ureteric bud morphogenesis; IDA:UniProtKB.
DR   GO; GO:0010613; P:positive regulation of cardiac muscle hypertrophy; ISS:BHF-UCL.
DR   GO; GO:0032270; P:positive regulation of cellular protein metabolic process; IDA:BHF-UCL.
DR   GO; GO:0010873; P:positive regulation of cholesterol esterification; IDA:BHF-UCL.
DR   GO; GO:0001819; P:positive regulation of cytokine production; TAS:BHF-UCL.
DR   GO; GO:0010595; P:positive regulation of endothelial cell migration; IDA:BHF-UCL.
DR   GO; GO:0045742; P:positive regulation of epidermal growth factor receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0003331; P:positive regulation of extracellular matrix constituent secretion; IEA:Ensembl.
DR   GO; GO:2001238; P:positive regulation of extrinsic apoptotic signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0045723; P:positive regulation of fatty acid biosynthetic process; IEA:Ensembl.
DR   GO; GO:0048146; P:positive regulation of fibroblast proliferation; ISS:BHF-UCL.
DR   GO; GO:1903598; P:positive regulation of gap junction assembly; IGI:BHF-UCL.
DR   GO; GO:0050729; P:positive regulation of inflammatory response; TAS:BHF-UCL.
DR   GO; GO:0010744; P:positive regulation of macrophage derived foam cell differentiation; IC:BHF-UCL.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IEA:Ensembl.
DR   GO; GO:1902632; P:positive regulation of membrane hyperpolarization; IMP:BHF-UCL.
DR   GO; GO:0040018; P:positive regulation of multicellular organism growth; IEA:Ensembl.
DR   GO; GO:0033864; P:positive regulation of NAD(P)H oxidase activity; TAS:BHF-UCL.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; TAS:BHF-UCL.
DR   GO; GO:0045429; P:positive regulation of nitric oxide biosynthetic process; IEA:Ensembl.
DR   GO; GO:0046622; P:positive regulation of organ growth; IEA:Ensembl.
DR   GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; IEA:Ensembl.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0014068; P:positive regulation of phosphatidylinositol 3-kinase signaling; IDA:BHF-UCL.
DR   GO; GO:1900020; P:positive regulation of protein kinase C activity; IEA:Ensembl.
DR   GO; GO:0061098; P:positive regulation of protein tyrosine kinase activity; IMP:UniProtKB.
DR   GO; GO:2000379; P:positive regulation of reactive oxygen species metabolic process; TAS:BHF-UCL.
DR   GO; GO:0035815; P:positive regulation of renal sodium excretion; IEA:Ensembl.
DR   GO; GO:0032930; P:positive regulation of superoxide anion generation; IEA:Ensembl.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0045909; P:positive regulation of vasodilation; IEA:Ensembl.
DR   GO; GO:0008217; P:regulation of blood pressure; IGI:BHF-UCL.
DR   GO; GO:0002034; P:regulation of blood vessel size by renin-angiotensin; TAS:BHF-UCL.
DR   GO; GO:0002016; P:regulation of blood volume by renin-angiotensin; NAS:BHF-UCL.
DR   GO; GO:0051924; P:regulation of calcium ion transport; IEA:Ensembl.
DR   GO; GO:1903779; P:regulation of cardiac conduction; IGI:BHF-UCL.
DR   GO; GO:0001558; P:regulation of cell growth; NAS:BHF-UCL.
DR   GO; GO:0042127; P:regulation of cell proliferation; NAS:BHF-UCL.
DR   GO; GO:1901201; P:regulation of extracellular matrix assembly; IGI:BHF-UCL.
DR   GO; GO:0002027; P:regulation of heart rate; IEA:Ensembl.
DR   GO; GO:0048169; P:regulation of long-term neuronal synaptic plasticity; IEA:Ensembl.
DR   GO; GO:0014061; P:regulation of norepinephrine secretion; IEA:Ensembl.
DR   GO; GO:0002019; P:regulation of renal output by angiotensin; NAS:BHF-UCL.
DR   GO; GO:0035813; P:regulation of renal sodium excretion; NAS:BHF-UCL.
DR   GO; GO:0051969; P:regulation of transmission of nerve impulse; IEA:Ensembl.
DR   GO; GO:0019229; P:regulation of vasoconstriction; NAS:BHF-UCL.
DR   GO; GO:0001999; P:renal response to blood flow involved in circulatory renin-angiotensin regulation of systemic arterial blood pressure; IEA:Ensembl.
DR   GO; GO:0003014; P:renal system process; IDA:UniProtKB.
DR   GO; GO:0002018; P:renin-angiotensin regulation of aldosterone production; NAS:BHF-UCL.
DR   GO; GO:0009409; P:response to cold; IEA:Ensembl.
DR   GO; GO:0014873; P:response to muscle activity involved in regulation of muscle adaptation; ISS:BHF-UCL.
DR   GO; GO:0009651; P:response to salt stress; IEA:Ensembl.
DR   GO; GO:0044281; P:small molecule metabolic process; TAS:Reactome.
DR   GO; GO:0051145; P:smooth muscle cell differentiation; IEA:Ensembl.
DR   GO; GO:0048659; P:smooth muscle cell proliferation; IEA:Ensembl.
DR   GO; GO:0051403; P:stress-activated MAPK cascade; IEA:Ensembl.
DR   GO; GO:0070471; P:uterine smooth muscle contraction; IEA:Ensembl.
DR   GO; GO:0042311; P:vasodilation; IEA:Ensembl.
DR   InterPro; IPR000227; Angiotensinogen.
DR   InterPro; IPR023795; Serpin_CS.
DR   InterPro; IPR023796; Serpin_dom.
DR   InterPro; IPR000215; Serpin_fam.
DR   PANTHER; PTHR11461; PTHR11461; 2.
DR   Pfam; PF00079; Serpin; 1.
DR   PRINTS; PR00654; ANGIOTENSNGN.
DR   SMART; SM00093; SERPIN; 1.
DR   SUPFAM; SSF56574; SSF56574; 1.
DR   PROSITE; PS00284; SERPIN; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Complete proteome; Direct protein sequencing;
KW   Disease mutation; Disulfide bond; Glycoprotein; Polymorphism;
KW   Reference proteome; Secreted; Signal; Vasoactive; Vasoconstrictor.
FT   SIGNAL        1     33       {ECO:0000269|PubMed:4300938,
FT                                ECO:0000269|PubMed:7259779,
FT                                ECO:0000269|PubMed:7539791}.
FT   CHAIN        34    485       Angiotensinogen.
FT                                /FTId=PRO_0000032456.
FT   PEPTIDE      34     43       Angiotensin-1.
FT                                /FTId=PRO_0000032457.
FT   PEPTIDE      34     42       Angiotensin 1-9.
FT                                /FTId=PRO_0000420659.
FT   PEPTIDE      34     41       Angiotensin-2.
FT                                /FTId=PRO_0000032458.
FT   PEPTIDE      34     40       Angiotensin 1-7.
FT                                /FTId=PRO_0000420660.
FT   PEPTIDE      34     38       Angiotensin 1-5.
FT                                /FTId=PRO_0000420661.
FT   PEPTIDE      34     37       Angiotensin 1-4.
FT                                /FTId=PRO_0000420662.
FT   PEPTIDE      35     41       Angiotensin-3.
FT                                /FTId=PRO_0000032459.
FT   PEPTIDE      36     41       Angiotensin-4.
FT                                /FTId=PRO_0000420663.
FT   MOD_RES      34     34       Beta-decarboxylated aspartate; in form
FT                                angiotensin-A.
FT                                {ECO:0000269|PubMed:17138938}.
FT   CARBOHYD     47     47       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:19159218,
FT                                ECO:0000269|PubMed:3934016}.
FT   CARBOHYD    170    170       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:3934016}.
FT   CARBOHYD    304    304       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:3934016}.
FT   CARBOHYD    328    328       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:3934016}.
FT   DISULFID     51    171       {ECO:0000269|PubMed:20927107}.
FT   VARIANT      43     43       L -> F (associated with susceptibility to
FT                                pre-eclampsia; alters the reactions with
FT                                renin and angiotensin-converting enzyme;
FT                                dbSNP:rs41271499).
FT                                {ECO:0000269|PubMed:7744780}.
FT                                /FTId=VAR_022933.
FT   VARIANT      98     98       E -> K (in dbSNP:rs11568032).
FT                                /FTId=VAR_029166.
FT   VARIANT     114    114       G -> C (in dbSNP:rs2229389).
FT                                /FTId=VAR_051939.
FT   VARIANT     137    137       T -> M (in dbSNP:rs34829218).
FT                                /FTId=VAR_035431.
FT   VARIANT     207    207       T -> M (associated with hypertension;
FT                                dbSNP:rs4762).
FT                                {ECO:0000269|PubMed:1394429}.
FT                                /FTId=VAR_007093.
FT   VARIANT     242    242       T -> I (associated with susceptibility to
FT                                hypertension).
FT                                {ECO:0000269|PubMed:7607642}.
FT                                /FTId=VAR_007094.
FT   VARIANT     244    244       L -> R (associated with susceptibility to
FT                                hypertension; dbSNP:rs5041).
FT                                {ECO:0000269|PubMed:7607642}.
FT                                /FTId=VAR_007095.
FT   VARIANT     268    268       M -> I (in dbSNP:rs11568053).
FT                                /FTId=VAR_029167.
FT   VARIANT     268    268       M -> T (associated with essential
FT                                hypertension and pre-eclampsia;
FT                                dbSNP:rs699).
FT                                {ECO:0000269|PubMed:1394429,
FT                                ECO:0000269|PubMed:8513325}.
FT                                /FTId=VAR_007096.
FT   VARIANT     281    281       Y -> C (associated with susceptibility to
FT                                hypertension; alters the structure,
FT                                glycosylation and secretion of
FT                                angiotensinogen; dbSNP:rs56073403).
FT                                {ECO:0000269|PubMed:1394429,
FT                                ECO:0000269|PubMed:7607642,
FT                                ECO:0000269|PubMed:8621667}.
FT                                /FTId=VAR_007097.
FT   VARIANT     335    335       P -> S (in dbSNP:rs17856352).
FT                                {ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_035432.
FT   VARIANT     375    375       R -> Q (in RTD).
FT                                {ECO:0000269|PubMed:16116425}.
FT                                /FTId=VAR_035433.
FT   VARIANT     392    392       L -> M (in dbSNP:rs1805090).
FT                                /FTId=VAR_014573.
FT   CONFLICT     51     51       C -> S (in Ref. 7; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT     58     58       N -> D (in Ref. 7; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    333    333       Q -> E (in Ref. 2; AAA51679).
FT                                {ECO:0000305}.
FT   TURN         42     44       {ECO:0000244|PDB:2WXW}.
FT   HELIX        48     57       {ECO:0000244|PDB:2WXW}.
FT   STRAND       59     62       {ECO:0000244|PDB:2WXW}.
FT   HELIX        81     93       {ECO:0000244|PDB:2WXW}.
FT   HELIX        97    117       {ECO:0000244|PDB:2WXW}.
FT   HELIX       118    120       {ECO:0000244|PDB:2WXW}.
FT   TURN        124    126       {ECO:0000244|PDB:2WXW}.
FT   STRAND      129    134       {ECO:0000244|PDB:2WXW}.
FT   HELIX       136    148       {ECO:0000244|PDB:2WXW}.
FT   HELIX       154    162       {ECO:0000244|PDB:2WXW}.
FT   TURN        171    173       {ECO:0000244|PDB:2WXW}.
FT   HELIX       177    191       {ECO:0000244|PDB:2WXW}.
FT   TURN        195    197       {ECO:0000244|PDB:2WXW}.
FT   STRAND      203    212       {ECO:0000244|PDB:2WXW}.
FT   HELIX       221    230       {ECO:0000244|PDB:2WXW}.
FT   STRAND      234    236       {ECO:0000244|PDB:2WXW}.
FT   HELIX       244    259       {ECO:0000244|PDB:2WXW}.
FT   STRAND      277    288       {ECO:0000244|PDB:2WXW}.
FT   STRAND      291    293       {ECO:0000244|PDB:2WXW}.
FT   STRAND      302    305       {ECO:0000244|PDB:2WXW}.
FT   STRAND      313    322       {ECO:0000244|PDB:2WXW}.
FT   TURN        325    328       {ECO:0000244|PDB:2WXW}.
FT   STRAND      329    333       {ECO:0000244|PDB:2WXW}.
FT   TURN        337    339       {ECO:0000244|PDB:2WXW}.
FT   STRAND      340    349       {ECO:0000244|PDB:2WXW}.
FT   HELIX       353    358       {ECO:0000244|PDB:2WXW}.
FT   HELIX       365    368       {ECO:0000244|PDB:2WXW}.
FT   STRAND      374    381       {ECO:0000244|PDB:2WXW}.
FT   STRAND      385    391       {ECO:0000244|PDB:2WXW}.
FT   HELIX       392    395       {ECO:0000244|PDB:2WXW}.
FT   HELIX       402    406       {ECO:0000244|PDB:2WXW}.
FT   STRAND      407    409       {ECO:0000244|PDB:2WXW}.
FT   STRAND      425    434       {ECO:0000244|PDB:2WXW}.
FT   STRAND      452    455       {ECO:0000244|PDB:2WXW}.
FT   STRAND      460    466       {ECO:0000244|PDB:2WXW}.
FT   TURN        467    470       {ECO:0000244|PDB:2WXW}.
FT   STRAND      475    479       {ECO:0000244|PDB:2WXW}.
SQ   SEQUENCE   485 AA;  53154 MW;  5026C2DFB2DD236E CRC64;
     MRKRAPQSEM APAGVSLRAT ILCLLAWAGL AAGDRVYIHP FHLVIHNEST CEQLAKANAG
     KPKDPTFIPA PIQAKTSPVD EKALQDQLVL VAAKLDTEDK LRAAMVGMLA NFLGFRIYGM
     HSELWGVVHG ATVLSPTAVF GTLASLYLGA LDHTADRLQA ILGVPWKDKN CTSRLDAHKV
     LSALQAVQGL LVAQGRADSQ AQLLLSTVVG VFTAPGLHLK QPFVQGLALY TPVVLPRSLD
     FTELDVAAEK IDRFMQAVTG WKTGCSLMGA SVDSTLAFNT YVHFQGKMKG FSLLAEPQEF
     WVDNSTSVSV PMLSGMGTFQ HWSDIQDNFS VTQVPFTESA CLLLIQPHYA SDLDKVEGLT
     FQQNSLNWMK KLSPRTIHLT MPQLVLQGSY DLQDLLAQAE LPAILHTELN LQKLSNDRIR
     VGEVLNSIFF ELEADEREPT ESTQQLNKPE VLEVTLNRPF LFAVYDQSAT ALHFLGRVAN
     PLSTA
//
ID   VEGFA_MOUSE             Reviewed;         214 AA.
AC   Q00731; O70123; Q66S31; Q6GT23; Q6WZL9;
DT   01-APR-1993, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 2.
DT   11-NOV-2015, entry version 159.
DE   RecName: Full=Vascular endothelial growth factor A;
DE            Short=VEGF-A;
DE   AltName: Full=Vascular permeability factor;
DE            Short=VPF;
DE   Flags: Precursor;
GN   Name=Vegfa; Synonyms=Vegf;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS VEGF-1; VEGF-2 AND VEGF-3).
RX   PubMed=1592003;
RA   Breier G., Albrecht U., Sterrer S., Risau W.;
RT   "Expression of vascular endothelial growth factor during embryonic
RT   angiogenesis and endothelial cell differentiation.";
RL   Development 114:521-532(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM VEGF-1).
RX   PubMed=1644816;
RA   Claffey K.P., Wilkison W.O., Spiegelman B.M.;
RT   "Vascular endothelial growth factor. Regulation by cell
RT   differentiation and activated second messenger pathways.";
RL   J. Biol. Chem. 267:16317-16322(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM VEGF-4).
RC   STRAIN=ICR;
RX   PubMed=9446618; DOI=10.1074/jbc.273.5.3033;
RA   Sugihara T., Wadhwa R., Kaul S.C., Mitsui Y.;
RT   "A novel alternatively spliced form of murine vascular endothelial
RT   growth factor, VEGF 115.";
RL   J. Biol. Chem. 273:3033-3038(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM VEGF-5).
RC   STRAIN=FVB/N;
RA   Jankowsky J.A., Adamski F.M., Robertson F.M.;
RT   "Identification of a unique Mus musculus VEGF isoform of 102 amino
RT   acids.";
RL   Submitted (MAR-2003) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=C57BL/6J;
RX   PubMed=19468303; DOI=10.1371/journal.pbio.1000112;
RA   Church D.M., Goodstadt L., Hillier L.W., Zody M.C., Goldstein S.,
RA   She X., Bult C.J., Agarwala R., Cherry J.L., DiCuccio M., Hlavina W.,
RA   Kapustin Y., Meric P., Maglott D., Birtle Z., Marques A.C., Graves T.,
RA   Zhou S., Teague B., Potamousis K., Churas C., Place M., Herschleb J.,
RA   Runnheim R., Forrest D., Amos-Landgraf J., Schwartz D.C., Cheng Z.,
RA   Lindblad-Toh K., Eichler E.E., Ponting C.P.;
RT   "Lineage-specific biology revealed by a finished genome assembly of
RT   the mouse.";
RL   PLoS Biol. 7:E1000112-E1000112(2009).
RN   [6]
RP   PARTIAL NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM L-VEGF-1).
RC   STRAIN=C57BL/6J; TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-123 (ISOFORMS VEGF-1/VEGF-2/VEGF-3).
RC   STRAIN=C57BL/6J; TISSUE=Retina;
RA   Minchenko O.H., Minchenko D.O., Opentanova I.L.;
RT   "Alternatively spliced forms of mouse VEGF.";
RL   Submitted (SEP-2004) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-3 (ISOFORMS
RP   VEGF-1/VEGF-2/VEGF-3/VEGF-4/VEGF-5).
RX   PubMed=8632007; DOI=10.1074/jbc.271.7.3877;
RA   Shima D.T., Kuroki M., Deutsch U., Ng Y., Adamis A.P., D'Amore P.A.;
RT   "The mouse gene for vascular endothelial growth factor. Genomic
RT   structure, definition of the transcriptional unit, and
RT   characterization of transcriptional and post-transcriptional
RT   regulatory sequences.";
RL   J. Biol. Chem. 271:3877-3883(1996).
RN   [9]
RP   DEVELOPMENTAL STAGE.
RX   PubMed=10878616;
RX   DOI=10.1002/1097-0177(200007)218:3<507::AID-DVDY1012>3.0.CO;2-5;
RA   Pepper M.S., Baetens D., Mandriota S.J., Di Sanza C., Oikemus S.,
RA   Lane T.F., Soriano J.V., Montesano R., Iruela-Arispe M.L.;
RT   "Regulation of VEGF and VEGF receptor expression in the rodent mammary
RT   gland during pregnancy, lactation, and involution.";
RL   Dev. Dyn. 218:507-524(2000).
RN   [10]
RP   INDUCTION.
RX   PubMed=16259067; DOI=10.3349/ymj.2005.46.5.679;
RA   Shin S.-Y., Lee H.-J., Ko D.-S., Lee H.-C., Park W.I.;
RT   "The regulators of VEGF expression in mouse ovaries.";
RL   Yonsei Med. J. 46:679-686(2005).
CC   -!- FUNCTION: Growth factor active in angiogenesis, vasculogenesis and
CC       endothelial cell growth. Induces endothelial cell proliferation,
CC       promotes cell migration, inhibits apoptosis and induces
CC       permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and
CC       KDR/VEGFR2 receptors, heparan sulfate and heparin. May play a role
CC       in increasing vascular permeability during lactation, when
CC       increased transport of molecules from the blood is required for
CC       efficient milk protein synthesis (By similarity). {ECO:0000250}.
CC   -!- SUBUNIT: Homodimer; disulfide-linked. Also found as heterodimer
CC       with PGF (By similarity). {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Isoform VEGF-1: Secreted.
CC   -!- SUBCELLULAR LOCATION: Isoform VEGF-2: Secreted.
CC   -!- SUBCELLULAR LOCATION: Isoform VEGF-3: Cell membrane; Peripheral
CC       membrane protein. Note=Remains cell-surface associated unless
CC       released by heparin.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative promoter usage, Alternative splicing, Alternative initiation; Named isoforms=6;
CC       Name=VEGF-3; Synonyms=VEGF188;
CC         IsoId=Q00731-1; Sequence=Displayed;
CC       Name=VEGF-1; Synonyms=VEGF164;
CC         IsoId=Q00731-2; Sequence=VSP_004626, VSP_004627;
CC       Name=VEGF-2; Synonyms=VEGF120;
CC         IsoId=Q00731-3; Sequence=VSP_004628;
CC       Name=VEGF-4; Synonyms=VEGF115;
CC         IsoId=Q00731-4; Sequence=VSP_016418, VSP_016421;
CC       Name=VEGF-5; Synonyms=VEGF102;
CC         IsoId=Q00731-5; Sequence=VSP_016419, VSP_016420;
CC       Name=L-VEGF-1;
CC         IsoId=Q00731-6; Sequence=VSP_038746, VSP_004626, VSP_004627;
CC         Note=Gene prediction based on EST data. Produced by alternative
CC         promoter usage and alternative initiation. Starts at an
CC         alternative upstream CUG codon.;
CC   -!- TISSUE SPECIFICITY: In developing embryos, expressed mainly in the
CC       choroid plexus, paraventricular neuroepithelium, placenta and
CC       kidney glomeruli. Also found in bronchial epithelium, adrenal
CC       gland and in seminiferous tubules of testis. High expression of
CC       VEGF continues in kidney glomeruli and choroid plexus in adults.
CC   -!- DEVELOPMENTAL STAGE: Levels increase during pregnancy (maximum
CC       5.5-fold at 5 days) and a more marked increase occurs during
CC       lactation (maximal 9.7-fold at 7 days). Levels decrease
CC       progressively during the phase of involution.
CC       {ECO:0000269|PubMed:10878616}.
CC   -!- INDUCTION: By IL-6 and FSH in vitro.
CC       {ECO:0000269|PubMed:16259067}.
CC   -!- DOMAIN: Isoform VEGF-3 contains a basic insert which acts as a
CC       cell retention signal.
CC   -!- SIMILARITY: Belongs to the PDGF/VEGF growth factor family.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH61468.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; S37052; AAB22252.1; -; mRNA.
DR   EMBL; S38083; AAB22253.1; -; mRNA.
DR   EMBL; S38100; AAB22254.1; -; mRNA.
DR   EMBL; M95200; AAA40547.1; -; mRNA.
DR   EMBL; U50279; AAC05442.1; -; mRNA.
DR   EMBL; AY263146; AAP86647.1; -; mRNA.
DR   EMBL; AC127690; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC061468; AAH61468.1; ALT_INIT; mRNA.
DR   EMBL; AY707864; AAU11325.1; -; mRNA.
DR   EMBL; AY750956; AAU95484.1; -; mRNA.
DR   EMBL; AY750957; AAU95485.1; -; mRNA.
DR   EMBL; U41383; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   CCDS; CCDS28818.2; -. [Q00731-6]
DR   CCDS; CCDS70817.1; -. [Q00731-3]
DR   PIR; A44881; A44881.
DR   PIR; B44881; B44881.
DR   RefSeq; NP_001020421.2; NM_001025250.3.
DR   RefSeq; NP_001020428.2; NM_001025257.3.
DR   RefSeq; NP_001103736.1; NM_001110266.1.
DR   RefSeq; NP_001103737.1; NM_001110267.1.
DR   RefSeq; NP_001103738.1; NM_001110268.1.
DR   RefSeq; NP_001273985.1; NM_001287056.1. [Q00731-1]
DR   RefSeq; NP_001273986.1; NM_001287057.1. [Q00731-2]
DR   RefSeq; NP_001273987.1; NM_001287058.1. [Q00731-3]
DR   RefSeq; NP_033531.3; NM_009505.4. [Q00731-6]
DR   UniGene; Mm.282184; -.
DR   ProteinModelPortal; Q00731; -.
DR   SMR; Q00731; 37-134, 166-214.
DR   BioGrid; 204512; 3.
DR   DIP; DIP-31909N; -.
DR   IntAct; Q00731; 2.
DR   STRING; 10090.ENSMUSP00000115883; -.
DR   PhosphoSite; Q00731; -.
DR   MaxQB; Q00731; -.
DR   PaxDb; Q00731; -.
DR   PRIDE; Q00731; -.
DR   Ensembl; ENSMUST00000024747; ENSMUSP00000024747; ENSMUSG00000023951. [Q00731-3]
DR   GeneID; 22339; -.
DR   KEGG; mmu:22339; -.
DR   UCSC; uc008crn.4; mouse. [Q00731-1]
DR   UCSC; uc008cro.4; mouse. [Q00731-2]
DR   UCSC; uc008crp.4; mouse. [Q00731-3]
DR   UCSC; uc008crr.3; mouse. [Q00731-5]
DR   CTD; 7422; -.
DR   MGI; MGI:103178; Vegfa.
DR   eggNOG; ENOG410IGCM; Eukaryota.
DR   eggNOG; ENOG410ZWYU; LUCA.
DR   GeneTree; ENSGT00730000110791; -.
DR   HOGENOM; HOG000230896; -.
DR   HOVERGEN; HBG000105; -.
DR   InParanoid; Q00731; -.
DR   KO; K05448; -.
DR   OrthoDB; EOG74R1S0; -.
DR   PhylomeDB; Q00731; -.
DR   Reactome; R-MMU-114608; Platelet degranulation.
DR   Reactome; R-MMU-194313; VEGF ligand-receptor interactions.
DR   Reactome; R-MMU-195399; VEGF binds to VEGFR leading to receptor dimerization.
DR   Reactome; R-MMU-3928663; EPHA-mediated growth cone collapse.
DR   Reactome; R-MMU-4420097; VEGFA-VEGFR2 Pathway.
DR   Reactome; R-MMU-5218921; VEGFR2 mediated cell proliferation.
DR   ChiTaRS; Vegfa; mouse.
DR   NextBio; 302593; -.
DR   PRO; PR:Q00731; -.
DR   Proteomes; UP000000589; Chromosome 17.
DR   Bgee; Q00731; -.
DR   CleanEx; MM_VEGFA; -.
DR   ExpressionAtlas; Q00731; baseline and differential.
DR   Genevisible; Q00731; MM.
DR   GO; GO:0009986; C:cell surface; ISS:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:MGI.
DR   GO; GO:0005576; C:extracellular region; IDA:MGI.
DR   GO; GO:0005615; C:extracellular space; IDA:MGI.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0030141; C:secretory granule; ISS:UniProtKB.
DR   GO; GO:0042056; F:chemoattractant activity; IDA:BHF-UCL.
DR   GO; GO:0005125; F:cytokine activity; ISS:UniProtKB.
DR   GO; GO:0050840; F:extracellular matrix binding; IDA:MGI.
DR   GO; GO:0001968; F:fibronectin binding; ISS:UniProtKB.
DR   GO; GO:0008083; F:growth factor activity; ISS:UniProtKB.
DR   GO; GO:0008201; F:heparin binding; ISS:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; ISO:MGI.
DR   GO; GO:0038191; F:neuropilin binding; ISO:MGI.
DR   GO; GO:0005161; F:platelet-derived growth factor receptor binding; ISS:UniProtKB.
DR   GO; GO:0046982; F:protein heterodimerization activity; ISO:MGI.
DR   GO; GO:0048018; F:receptor agonist activity; ISS:UniProtKB.
DR   GO; GO:0005102; F:receptor binding; IDA:MGI.
DR   GO; GO:0043183; F:vascular endothelial growth factor receptor 1 binding; ISS:UniProtKB.
DR   GO; GO:0043184; F:vascular endothelial growth factor receptor 2 binding; ISS:UniProtKB.
DR   GO; GO:0005172; F:vascular endothelial growth factor receptor binding; ISS:UniProtKB.
DR   GO; GO:0032147; P:activation of protein kinase activity; ISS:UniProtKB.
DR   GO; GO:0001525; P:angiogenesis; IMP:CACAO.
DR   GO; GO:0048844; P:artery morphogenesis; IMP:MGI.
DR   GO; GO:0002575; P:basophil chemotaxis; ISO:MGI.
DR   GO; GO:0001568; P:blood vessel development; IMP:MGI.
DR   GO; GO:0002043; P:blood vessel endothelial cell proliferation involved in sprouting angiogenesis; IMP:CACAO.
DR   GO; GO:0048514; P:blood vessel morphogenesis; IDA:MGI.
DR   GO; GO:0048754; P:branching morphogenesis of an epithelial tube; IDA:MGI.
DR   GO; GO:0048593; P:camera-type eye morphogenesis; IMP:MGI.
DR   GO; GO:0048739; P:cardiac muscle fiber development; IMP:MGI.
DR   GO; GO:0060948; P:cardiac vascular smooth muscle cell development; IMP:BHF-UCL.
DR   GO; GO:0048469; P:cell maturation; IMP:MGI.
DR   GO; GO:0016477; P:cell migration; IDA:MGI.
DR   GO; GO:0002042; P:cell migration involved in sprouting angiogenesis; ISS:UniProtKB.
DR   GO; GO:0008283; P:cell proliferation; IMP:MGI.
DR   GO; GO:0071456; P:cellular response to hypoxia; ISS:UniProtKB.
DR   GO; GO:0035924; P:cellular response to vascular endothelial growth factor stimulus; ISS:UniProtKB.
DR   GO; GO:0071679; P:commissural neuron axon guidance; IDA:BHF-UCL.
DR   GO; GO:0060982; P:coronary artery morphogenesis; IMP:BHF-UCL.
DR   GO; GO:0003169; P:coronary vein morphogenesis; IMP:BHF-UCL.
DR   GO; GO:0071542; P:dopaminergic neuron differentiation; IGI:MGI.
DR   GO; GO:0035767; P:endothelial cell chemotaxis; ISS:UniProtKB.
DR   GO; GO:0043542; P:endothelial cell migration; IMP:MGI.
DR   GO; GO:0030855; P:epithelial cell differentiation; IMP:MGI.
DR   GO; GO:0042462; P:eye photoreceptor cell development; IMP:MGI.
DR   GO; GO:0040007; P:growth; IMP:MGI.
DR   GO; GO:0003007; P:heart morphogenesis; IMP:MGI.
DR   GO; GO:0001701; P:in utero embryonic development; IMP:MGI.
DR   GO; GO:0050930; P:induction of positive chemotaxis; ISO:MGI.
DR   GO; GO:0001822; P:kidney development; IMP:MGI.
DR   GO; GO:0007595; P:lactation; IMP:MGI.
DR   GO; GO:0030324; P:lung development; IDA:MGI.
DR   GO; GO:0060426; P:lung vasculature development; IDA:MGI.
DR   GO; GO:0036303; P:lymph vessel morphogenesis; IMP:BHF-UCL.
DR   GO; GO:0001946; P:lymphangiogenesis; IGI:MGI.
DR   GO; GO:0030225; P:macrophage differentiation; ISS:UniProtKB.
DR   GO; GO:0060749; P:mammary gland alveolus development; IMP:MGI.
DR   GO; GO:0007498; P:mesoderm development; IMP:MGI.
DR   GO; GO:0030224; P:monocyte differentiation; ISS:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; ISS:UniProtKB.
DR   GO; GO:0022408; P:negative regulation of cell-cell adhesion; IGI:MGI.
DR   GO; GO:0043154; P:negative regulation of cysteine-type endopeptidase activity involved in apoptotic process; ISO:MGI.
DR   GO; GO:2001237; P:negative regulation of extrinsic apoptotic signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; IDA:BHF-UCL.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; ISO:MGI.
DR   GO; GO:0048666; P:neuron development; IMP:BHF-UCL.
DR   GO; GO:0003151; P:outflow tract morphogenesis; IMP:BHF-UCL.
DR   GO; GO:0001541; P:ovarian follicle development; IMP:MGI.
DR   GO; GO:0001569; P:patterning of blood vessels; IMP:MGI.
DR   GO; GO:0050918; P:positive chemotaxis; IDA:BHF-UCL.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; ISS:UniProtKB.
DR   GO; GO:0048842; P:positive regulation of axon extension involved in axon guidance; IDA:BHF-UCL.
DR   GO; GO:0043536; P:positive regulation of blood vessel endothelial cell migration; ISS:UniProtKB.
DR   GO; GO:0090190; P:positive regulation of branching involved in ureteric bud morphogenesis; IDA:UniProtKB.
DR   GO; GO:0045785; P:positive regulation of cell adhesion; ISS:UniProtKB.
DR   GO; GO:0051781; P:positive regulation of cell division; IEA:UniProtKB-KW.
DR   GO; GO:0030335; P:positive regulation of cell migration; ISO:MGI.
DR   GO; GO:0090050; P:positive regulation of cell migration involved in sprouting angiogenesis; ISS:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IDA:MGI.
DR   GO; GO:0038091; P:positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0051272; P:positive regulation of cellular component movement; ISS:UniProtKB.
DR   GO; GO:0032793; P:positive regulation of CREB transcription factor activity; ISS:UniProtKB.
DR   GO; GO:0038033; P:positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway; ISS:BHF-UCL.
DR   GO; GO:0010595; P:positive regulation of endothelial cell migration; ISS:UniProtKB.
DR   GO; GO:0001938; P:positive regulation of endothelial cell proliferation; IDA:MGI.
DR   GO; GO:0050679; P:positive regulation of epithelial cell proliferation; IMP:MGI.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:BHF-UCL.
DR   GO; GO:0051894; P:positive regulation of focal adhesion assembly; ISS:UniProtKB.
DR   GO; GO:0010628; P:positive regulation of gene expression; ISO:MGI.
DR   GO; GO:1901727; P:positive regulation of histone deacetylase activity; ISO:MGI.
DR   GO; GO:1901492; P:positive regulation of lymphangiogenesis; IDA:MGI.
DR   GO; GO:0043406; P:positive regulation of MAP kinase activity; ISS:UniProtKB.
DR   GO; GO:0060754; P:positive regulation of mast cell chemotaxis; ISO:MGI.
DR   GO; GO:0002053; P:positive regulation of mesenchymal cell proliferation; IDA:MGI.
DR   GO; GO:0002052; P:positive regulation of neuroblast proliferation; IGI:MGI.
DR   GO; GO:1900745; P:positive regulation of p38MAPK cascade; ISO:MGI.
DR   GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; ISS:BHF-UCL.
DR   GO; GO:1900086; P:positive regulation of peptidyl-tyrosine autophosphorylation; ISS:UniProtKB.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; ISS:UniProtKB.
DR   GO; GO:0050927; P:positive regulation of positive chemotaxis; ISS:UniProtKB.
DR   GO; GO:0031954; P:positive regulation of protein autophosphorylation; ISS:UniProtKB.
DR   GO; GO:0031334; P:positive regulation of protein complex assembly; ISS:UniProtKB.
DR   GO; GO:0051897; P:positive regulation of protein kinase B signaling; IDA:BHF-UCL.
DR   GO; GO:0090037; P:positive regulation of protein kinase C signaling; ISS:UniProtKB.
DR   GO; GO:1903572; P:positive regulation of protein kinase D signaling; ISS:BHF-UCL.
DR   GO; GO:1902966; P:positive regulation of protein localization to early endosome; ISO:MGI.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; ISS:UniProtKB.
DR   GO; GO:0002092; P:positive regulation of receptor internalization; ISS:UniProtKB.
DR   GO; GO:1902336; P:positive regulation of retinal ganglion cell axon guidance; IMP:BHF-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; ISS:UniProtKB.
DR   GO; GO:0061419; P:positive regulation of transcription from RNA polymerase II promoter in response to hypoxia; ISO:MGI.
DR   GO; GO:0030949; P:positive regulation of vascular endothelial growth factor receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0043117; P:positive regulation of vascular permeability; IDA:MGI.
DR   GO; GO:0031077; P:post-embryonic camera-type eye development; IMP:MGI.
DR   GO; GO:0060319; P:primitive erythrocyte differentiation; IMP:MGI.
DR   GO; GO:0008360; P:regulation of cell shape; ISS:UniProtKB.
DR   GO; GO:0030823; P:regulation of cGMP metabolic process; ISO:MGI.
DR   GO; GO:0045601; P:regulation of endothelial cell differentiation; IDA:MGI.
DR   GO; GO:1901532; P:regulation of hematopoietic progenitor cell differentiation; IDA:MGI.
DR   GO; GO:0090259; P:regulation of retinal ganglion cell axon guidance; IDA:BHF-UCL.
DR   GO; GO:0006357; P:regulation of transcription from RNA polymerase II promoter; ISO:MGI.
DR   GO; GO:0001666; P:response to hypoxia; ISS:UniProtKB.
DR   GO; GO:0061304; P:retinal blood vessel morphogenesis; IMP:CACAO.
DR   GO; GO:0002040; P:sprouting angiogenesis; IDA:BHF-UCL.
DR   GO; GO:0043129; P:surfactant homeostasis; IMP:MGI.
DR   GO; GO:0035148; P:tube formation; ISS:UniProtKB.
DR   GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; IDA:MGI.
DR   GO; GO:0038084; P:vascular endothelial growth factor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0001944; P:vasculature development; IMP:MGI.
DR   GO; GO:0038190; P:VEGF-activated neuropilin signaling pathway; IMP:BHF-UCL.
DR   Gene3D; 2.10.160.10; -; 1.
DR   Gene3D; 2.10.90.10; -; 1.
DR   InterPro; IPR029034; Cystine-knot_cytokine.
DR   InterPro; IPR023581; PD_growth_factor_CS.
DR   InterPro; IPR000072; PDGF/VEGF_dom.
DR   InterPro; IPR027928; VEGF_C.
DR   Pfam; PF00341; PDGF; 1.
DR   Pfam; PF14554; VEGF_C; 1.
DR   SMART; SM00141; PDGF; 1.
DR   SUPFAM; SSF57501; SSF57501; 1.
DR   SUPFAM; SSF57593; SSF57593; 1.
DR   PROSITE; PS00249; PDGF_1; 1.
DR   PROSITE; PS50278; PDGF_2; 1.
PE   2: Evidence at transcript level;
KW   Alternative initiation; Alternative promoter usage;
KW   Alternative splicing; Angiogenesis; Cell membrane; Complete proteome;
KW   Developmental protein; Differentiation; Disulfide bond; Glycoprotein;
KW   Growth factor; Heparin-binding; Membrane; Mitogen; Reference proteome;
KW   Secreted; Signal.
FT   SIGNAL        1     26       {ECO:0000250}.
FT   CHAIN        27    214       Vascular endothelial growth factor A.
FT                                /FTId=PRO_0000023388.
FT   CARBOHYD    100    100       N-linked (GlcNAc...). {ECO:0000305}.
FT   DISULFID     51     93       {ECO:0000250}.
FT   DISULFID     76     76       Interchain. {ECO:0000250}.
FT   DISULFID     82    127       {ECO:0000250}.
FT   DISULFID     85     85       Interchain. {ECO:0000250}.
FT   DISULFID     86    129       {ECO:0000250}.
FT   VAR_SEQ       1      1       M -> MTDRQTDTAPSPSAHLLAGGLPTVDAAASREEPKPA
FT                                PGGGVEGVGARGIARKLFVQLLGSSRSVVAVVCAAGDKPIG
FT                                AGRSASSGLEKPGPEKRGEEEKEEERGPQWALGSQEPSSWT
FT                                GEAAVCADSAPAARAPQAPARASVPEGRGARQGAQESGLPR
FT                                SPSRRGSASRAGPGRASETM (in isoform L-VEGF-
FT                                1). {ECO:0000305}.
FT                                /FTId=VSP_038746.
FT   VAR_SEQ     105    141       IMRIKPHQSQHIGEMSFLQHSRCECRPKKDRTKPEKK ->
FT                                VGTCGTGDGAGAGGGRRTVVQGGALEGCLGLCLGNFW (in
FT                                isoform VEGF-4).
FT                                {ECO:0000303|PubMed:9446618}.
FT                                /FTId=VSP_016418.
FT   VAR_SEQ     105    128       IMRIKPHQSQHIGEMSFLQHSRCE -> VGTCGTGDGAGAG
FT                                GAGGQWYKEGH (in isoform VEGF-5).
FT                                {ECO:0000303|Ref.4}.
FT                                /FTId=VSP_016419.
FT   VAR_SEQ     129    214       Missing (in isoform VEGF-5).
FT                                {ECO:0000303|Ref.4}.
FT                                /FTId=VSP_016420.
FT   VAR_SEQ     140    140       K -> N (in isoform VEGF-1 and isoform L-
FT                                VEGF-1). {ECO:0000303|PubMed:1592003,
FT                                ECO:0000303|PubMed:1644816}.
FT                                /FTId=VSP_004626.
FT   VAR_SEQ     141    208       Missing (in isoform VEGF-2).
FT                                {ECO:0000303|PubMed:1592003}.
FT                                /FTId=VSP_004628.
FT   VAR_SEQ     141    164       Missing (in isoform VEGF-1 and isoform L-
FT                                VEGF-1). {ECO:0000303|PubMed:1592003,
FT                                ECO:0000303|PubMed:1644816}.
FT                                /FTId=VSP_004627.
FT   VAR_SEQ     142    214       Missing (in isoform VEGF-4).
FT                                {ECO:0000303|PubMed:9446618}.
FT                                /FTId=VSP_016421.
FT   CONFLICT     61     61       F -> I (in Ref. 3; AAC05442).
FT                                {ECO:0000305}.
FT   CONFLICT    117    118       GE -> ER (in Ref. 2; AAA40547).
FT                                {ECO:0000305}.
SQ   SEQUENCE   214 AA;  25283 MW;  B5540B51E4BB6E17 CRC64;
     MNFLLSWVHW TLALLLYLHH AKWSQAAPTT EGEQKSHEVI KFMDVYQRSY CRPIETLVDI
     FQEYPDEIEY IFKPSCVPLM RCAGCCNDEA LECVPTSESN ITMQIMRIKP HQSQHIGEMS
     FLQHSRCECR PKKDRTKPEK KSVRGKGKGQ KRKRKKSRFK SWSVHCEPCS ERRKHLFVQD
     PQTCKCSCKN TDSRCKARQL ELNERTCRCD KPRR
//
ID   CCL5_HUMAN              Reviewed;          91 AA.
AC   P13501; O43646; Q0QVW8; Q4ZGJ1; Q9NYA2; Q9UBG2; Q9UC99;
DT   01-JAN-1990, integrated into UniProtKB/Swiss-Prot.
DT   15-JUL-1999, sequence version 3.
DT   17-FEB-2016, entry version 175.
DE   RecName: Full=C-C motif chemokine 5;
DE   AltName: Full=EoCP;
DE   AltName: Full=Eosinophil chemotactic cytokine;
DE   AltName: Full=SIS-delta;
DE   AltName: Full=Small-inducible cytokine A5;
DE   AltName: Full=T cell-specific protein P228;
DE            Short=TCP228;
DE   AltName: Full=T-cell-specific protein RANTES;
DE   Contains:
DE     RecName: Full=RANTES(3-68);
DE   Contains:
DE     RecName: Full=RANTES(4-68);
DE   Flags: Precursor;
GN   Name=CCL5; Synonyms=D17S136E, SCYA5;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=2456327;
RA   Schall T.J., Jongstra J., Dyer B.J., Jorgensen J., Clayberger C.,
RA   Davis M.M., Krensky A.M.;
RT   "A human T cell-specific molecule is a member of a new gene family.";
RL   J. Immunol. 141:1018-1025(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=10213461; DOI=10.1089/107999099314153;
RA   Nomiyama H., Fukuda S., Iio M., Tanase S., Miura R., Yoshie O.;
RT   "Organization of the chemokine gene cluster on human chromosome
RT   17q11.2 containing the genes for CC chemokine MPIF-1, HCC-2, LEC, and
RT   RANTES.";
RL   J. Interferon Cytokine Res. 19:227-234(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, VARIANT PHE-24, AND
RP   CHARACTERIZATION OF VARIANT PHE-24.
RC   TISSUE=Blood;
RX   PubMed=16791620; DOI=10.1007/s00251-006-0133-2;
RA   Capoulade-Metay C., Ayouba A., Kfutwah A., Lole K., Petres S.,
RA   Dudoit Y., Deterre P., Menu E., Barre-Sinoussi F., Debre P.,
RA   Theodorou I.;
RT   "A natural CCL5/RANTES variant antagonist for CCR1 and CCR3.";
RL   Immunogenetics 58:533-541(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Leukocyte;
RA   Jang J.S., Kim B.E.;
RL   Submitted (JAN-1998) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Zeng Q.P., Yang R.Y., Fu L.C.;
RT   "The complete sequence of human beta-chemokine RANTES mRNA.";
RL   Submitted (MAY-2000) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NIEHS SNPs program;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   PROTEIN SEQUENCE OF 24-55, FUNCTION, MASS SPECTROMETRY, GLYCOSYLATION
RP   AT SER-27 AND SER-28, AND OXIDATION AT MET-90.
RX   PubMed=1380064; DOI=10.1084/jem.176.2.587;
RA   Kameyoshi Y., Doerschner A., Mallet A.I., Christophers E.,
RA   Schroeder J.-M.;
RT   "Cytokine RANTES released by thrombin-stimulated platelets is a potent
RT   attractant for human eosinophils.";
RL   J. Exp. Med. 176:587-592(1992).
RN   [9]
RP   PROTEIN SEQUENCE OF 24-55.
RX   PubMed=7524281;
RA   Schroeder J.-M., Kameyoshi Y., Christophers E.;
RT   "Platelets secrete an eosinophil-chemotactic cytokine which is a
RT   member of the C-C-chemokine family.";
RL   Adv. Exp. Med. Biol. 351:119-128(1993).
RN   [10]
RP   PROTEIN SEQUENCE OF 49-56; 71-79 AND 83-91, AND FUNCTION.
RX   PubMed=8525373; DOI=10.1126/science.270.5243.1811;
RA   Cocchi F., DeVico A.L., Garzino-Demo A., Arya S.K., Gallo R.C.,
RA   Lusso P.;
RT   "Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major
RT   HIV-suppressive factors produced by CD8+ T cells.";
RL   Science 270:1811-1815(1995).
RN   [11]
RP   IDENTIFICATION OF RANTES(3-68), PROTEOLYTIC PROCESSING OF N-TERMINUS,
RP   AND FUNCTION.
RX   PubMed=9516414; DOI=10.1074/jbc.273.13.7222;
RA   Proost P., De Meester I., Schols D., Struyf S., Lambeir A.-M.,
RA   Wuyts A., Opdenakker G., De Clercq E., Scharpe S., Van Damme J.;
RT   "Amino-terminal truncation of chemokines by CD26/dipeptidyl-peptidase
RT   IV. Conversion of RANTES into a potent inhibitor of monocyte
RT   chemotaxis and HIV-1-infection.";
RL   J. Biol. Chem. 273:7222-7227(1998).
RN   [12]
RP   IDENTIFICATION OF RANTES(4-68), MASS SPECTROMETRY, AND FUNCTION.
RX   PubMed=15923218; DOI=10.1189/jlb.0305161;
RA   Lim J.K., Burns J.M., Lu W., DeVico A.L.;
RT   "Multiple pathways of amino terminal processing produce two truncated
RT   variants of RANTES/CCL5.";
RL   J. Leukoc. Biol. 78:442-452(2005).
RN   [13]
RP   FUNCTION.
RX   PubMed=17001303; DOI=10.1038/sj.bjp.0706909;
RA   Ignatov A., Robert J., Gregory-Evans C., Schaller H.C.;
RT   "RANTES stimulates Ca2+ mobilization and inositol trisphosphate (IP3)
RT   formation in cells transfected with G protein-coupled receptor 75.";
RL   Br. J. Pharmacol. 149:490-497(2006).
RN   [14]
RP   FUNCTION.
RX   PubMed=23979485; DOI=10.1007/s00125-013-3022-x;
RA   Liu B., Hassan Z., Amisten S., King A.J., Bowe J.E., Huang G.C.,
RA   Jones P.M., Persaud S.J.;
RT   "The novel chemokine receptor, G-protein-coupled receptor 75, is
RT   expressed by islets and is coupled to stimulation of insulin secretion
RT   and improved glucose homeostasis.";
RL   Diabetologia 56:2467-2476(2013).
RN   [15]
RP   STRUCTURE BY NMR.
RX   PubMed=7537088; DOI=10.1021/bi00016a004;
RA   Skelton N.J., Aspiras F., Ogez J., Schall T.J.;
RT   "Proton NMR assignments and solution conformation of RANTES, a
RT   chemokine of the C-C type.";
RL   Biochemistry 34:5329-5342(1995).
RN   [16]
RP   STRUCTURE BY NMR.
RX   PubMed=7542919; DOI=10.1021/bi00029a005;
RA   Chung C.-W., Cooke R.M., Proudfoot A.E.I., Wells T.N.C.;
RT   "The three-dimensional solution structure of RANTES.";
RL   Biochemistry 34:9307-9314(1995).
RN   [17]
RP   SYNTHESIS, AND X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS).
RX   PubMed=9889151; DOI=10.1016/S1074-5521(99)80019-2;
RA   Wilken J., Hoover D., Thompson D.A., Barlow P.N., McSparron H.,
RA   Picard L., Wlodawer A., Lubkowski J., Kent S.B.;
RT   "Total chemical synthesis and high-resolution crystal structure of the
RT   potent anti-HIV protein AOP-RANTES.";
RL   Chem. Biol. 6:43-51(1999).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS).
RA   Hoover D.M., Shaw J., Gryczynski Z., Proudfoot A.E.I., Wells T.N.C.,
RA   Lubkowski J.;
RT   "The crystal structure of Met-RANTES: comparison with native RANTES
RT   and AOP-RANTES.";
RL   Protein Pept. Lett. 7:73-82(2000).
CC   -!- FUNCTION: Chemoattractant for blood monocytes, memory T-helper
CC       cells and eosinophils. Causes the release of histamine from
CC       basophils and activates eosinophils. May activate several
CC       chemokine receptors including CCR1, CCR3, CCR4 and CCR5. One of
CC       the major HIV-suppressive factors produced by CD8+ T-cells.
CC       Recombinant RANTES protein induces a dose-dependent inhibition of
CC       different strains of HIV-1, HIV-2, and simian immunodeficiency
CC       virus (SIV). The processed form RANTES(3-68) acts as a natural
CC       chemotaxis inhibitor and is a more potent inhibitor of HIV-1-
CC       infection. The second processed form RANTES(4-68) exhibits reduced
CC       chemotactic and HIV-suppressive activity compared with RANTES(1-
CC       68) and RANTES(3-68) and is generated by an unidentified enzyme
CC       associated with monocytes and neutrophils (PubMed:16791620,
CC       PubMed:1380064, PubMed:8525373, PubMed:9516414, PubMed:15923218).
CC       May also be an agonist of the G protein-coupled receptor GPR75,
CC       stimulating inositol trisphosphate production and calcium
CC       mobilization through its activation. Together with GPR75, may play
CC       a role in neuron survival through activation of a downstream
CC       signaling pathway involving the PI3, Akt and MAP kinases. By
CC       activating GPR75 may also play a role in insulin secretion by
CC       islet cells (PubMed:23979485). {ECO:0000269|PubMed:1380064,
CC       ECO:0000269|PubMed:15923218, ECO:0000269|PubMed:16791620,
CC       ECO:0000269|PubMed:17001303, ECO:0000269|PubMed:23979485,
CC       ECO:0000269|PubMed:8525373, ECO:0000269|PubMed:9516414}.
CC   -!- INTERACTION:
CC       P51681:CCR5; NbExp=4; IntAct=EBI-2848366, EBI-489374;
CC   -!- SUBCELLULAR LOCATION: Secreted.
CC   -!- TISSUE SPECIFICITY: T-cell and macrophage specific.
CC   -!- INDUCTION: By mitogens.
CC   -!- PTM: N-terminal processed form RANTES(3-68) is produced by
CC       proteolytic cleavage, probably by DPP4, after secretion from
CC       peripheral blood leukocytes and cultured sarcoma cells.
CC       {ECO:0000269|PubMed:9516414}.
CC   -!- PTM: The identity of the O-linked saccharides at Ser-27 and Ser-28
CC       are not reported in PubMed:1380064. They are assigned by
CC       similarity. {ECO:0000269|PubMed:1380064}.
CC   -!- MASS SPECTROMETRY: Mass=7515; Mass_error=1; Method=SELDI;
CC       Range=27-91; Evidence={ECO:0000269|PubMed:15923218};
CC   -!- MASS SPECTROMETRY: Mass=7862.8; Mass_error=1.1;
CC       Method=Electrospray; Range=24-91;
CC       Evidence={ECO:0000269|PubMed:1380064};
CC   -!- MASS SPECTROMETRY: Mass=8355; Mass_error=10; Method=Electrospray;
CC       Range=24-91; Note=O-glycosylated.;
CC       Evidence={ECO:0000269|PubMed:1380064};
CC   -!- SIMILARITY: Belongs to the intercrine beta (chemokine CC) family.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/ccl5/";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=RANTES entry;
CC       URL="https://en.wikipedia.org/wiki/RANTES";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M21121; AAA36725.1; -; mRNA.
DR   EMBL; AF088219; AAC63331.1; -; Genomic_DNA.
DR   EMBL; DQ230537; ABB69929.1; -; mRNA.
DR   EMBL; AF043341; AAC03541.1; -; mRNA.
DR   EMBL; AF266753; AAF73070.1; -; mRNA.
DR   EMBL; DQ017060; AAY22177.1; -; Genomic_DNA.
DR   EMBL; BC008600; AAH08600.1; -; mRNA.
DR   CCDS; CCDS11300.1; -.
DR   PIR; A28815; A28815.
DR   RefSeq; NP_002976.2; NM_002985.2.
DR   UniGene; Hs.514821; -.
DR   PDB; 1B3A; X-ray; 1.60 A; A/B=25-91.
DR   PDB; 1EQT; X-ray; 1.60 A; A/B=26-91.
DR   PDB; 1HRJ; NMR; -; A/B=24-91.
DR   PDB; 1RTN; NMR; -; A/B=24-91.
DR   PDB; 1RTO; NMR; -; A/B=24-91.
DR   PDB; 1U4L; X-ray; 2.00 A; A/B=24-91.
DR   PDB; 1U4M; X-ray; 2.00 A; A/B=24-91.
DR   PDB; 1U4P; X-ray; 1.70 A; A/B=24-91.
DR   PDB; 1U4R; X-ray; 2.20 A; A/B/C/D=24-91.
DR   PDB; 2L9H; Other; -; A/B/C/D=24-91.
DR   PDB; 2VXW; X-ray; 1.70 A; A/B/C/D=33-91.
DR   PDBsum; 1B3A; -.
DR   PDBsum; 1EQT; -.
DR   PDBsum; 1HRJ; -.
DR   PDBsum; 1RTN; -.
DR   PDBsum; 1RTO; -.
DR   PDBsum; 1U4L; -.
DR   PDBsum; 1U4M; -.
DR   PDBsum; 1U4P; -.
DR   PDBsum; 1U4R; -.
DR   PDBsum; 2L9H; -.
DR   PDBsum; 2VXW; -.
DR   ProteinModelPortal; P13501; -.
DR   SMR; P13501; 25-91.
DR   BioGrid; 112255; 24.
DR   DIP; DIP-31N; -.
DR   IntAct; P13501; 24.
DR   MINT; MINT-103226; -.
DR   STRING; 9606.ENSP00000293272; -.
DR   BindingDB; P13501; -.
DR   ChEMBL; CHEMBL1275217; -.
DR   iPTMnet; P13501; -.
DR   PhosphoSite; P13501; -.
DR   BioMuta; CCL5; -.
DR   DMDM; 6175077; -.
DR   PaxDb; P13501; -.
DR   PeptideAtlas; P13501; -.
DR   PRIDE; P13501; -.
DR   DNASU; 6352; -.
DR   Ensembl; ENST00000603197; ENSP00000474412; ENSG00000271503.
DR   Ensembl; ENST00000605140; ENSP00000475057; ENSG00000271503.
DR   Ensembl; ENST00000613606; ENSP00000479894; ENSG00000274233.
DR   Ensembl; ENST00000618639; ENSP00000484921; ENSG00000274233.
DR   GeneID; 6352; -.
DR   UCSC; uc002hkf.3; human.
DR   CTD; 6352; -.
DR   GeneCards; CCL5; -.
DR   HGNC; HGNC:10632; CCL5.
DR   MIM; 187011; gene.
DR   neXtProt; NX_P13501; -.
DR   PharmGKB; PA35564; -.
DR   eggNOG; ENOG410J0XH; Eukaryota.
DR   eggNOG; ENOG410ZUYI; LUCA.
DR   GeneTree; ENSGT00730000110278; -.
DR   HOVERGEN; HBG017871; -.
DR   InParanoid; P13501; -.
DR   OrthoDB; EOG7CVQ1F; -.
DR   PhylomeDB; P13501; -.
DR   TreeFam; TF334888; -.
DR   Reactome; R-HSA-380108; Chemokine receptors bind chemokines.
DR   Reactome; R-HSA-418594; G alpha (i) signalling events.
DR   EvolutionaryTrace; P13501; -.
DR   GeneWiki; CCL5; -.
DR   GenomeRNAi; 6352; -.
DR   NextBio; 24676; -.
DR   PMAP-CutDB; P13501; -.
DR   PRO; PR:P13501; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   Bgee; P13501; -.
DR   CleanEx; HS_CCL5; -.
DR   ExpressionAtlas; P13501; baseline and differential.
DR   Genevisible; P13501; HS.
DR   GO; GO:0005737; C:cytoplasm; IEA:Ensembl.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IBA:GO_Central.
DR   GO; GO:0031726; F:CCR1 chemokine receptor binding; IPI:UniProtKB.
DR   GO; GO:0031729; F:CCR4 chemokine receptor binding; TAS:BHF-UCL.
DR   GO; GO:0031730; F:CCR5 chemokine receptor binding; IPI:BHF-UCL.
DR   GO; GO:0042056; F:chemoattractant activity; IDA:UniProtKB.
DR   GO; GO:0008009; F:chemokine activity; NAS:UniProtKB.
DR   GO; GO:0046817; F:chemokine receptor antagonist activity; IDA:BHF-UCL.
DR   GO; GO:0042379; F:chemokine receptor binding; IPI:BHF-UCL.
DR   GO; GO:0008201; F:heparin binding; IEA:Ensembl.
DR   GO; GO:0004435; F:phosphatidylinositol phospholipase C activity; IDA:UniProtKB.
DR   GO; GO:0016004; F:phospholipase activator activity; IDA:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:BHF-UCL.
DR   GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB.
DR   GO; GO:0043621; F:protein self-association; IDA:BHF-UCL.
DR   GO; GO:0030298; F:receptor signaling protein tyrosine kinase activator activity; IDA:BHF-UCL.
DR   GO; GO:0031584; P:activation of phospholipase D activity; IDA:BHF-UCL.
DR   GO; GO:0007568; P:aging; IEA:Ensembl.
DR   GO; GO:0006816; P:calcium ion transport; IDA:UniProtKB.
DR   GO; GO:0007267; P:cell-cell signaling; IDA:BHF-UCL.
DR   GO; GO:0006874; P:cellular calcium ion homeostasis; IDA:UniProtKB.
DR   GO; GO:0043623; P:cellular protein complex assembly; IDA:BHF-UCL.
DR   GO; GO:0071448; P:cellular response to alkyl hydroperoxide; IEA:Ensembl.
DR   GO; GO:0071230; P:cellular response to amino acid stimulus; IEA:Ensembl.
DR   GO; GO:0071361; P:cellular response to ethanol; IEA:Ensembl.
DR   GO; GO:0044344; P:cellular response to fibroblast growth factor stimulus; IEP:UniProtKB.
DR   GO; GO:0071403; P:cellular response to high density lipoprotein particle stimulus; IEA:Ensembl.
DR   GO; GO:0071346; P:cellular response to interferon-gamma; IEP:UniProtKB.
DR   GO; GO:0071347; P:cellular response to interleukin-1; IEP:UniProtKB.
DR   GO; GO:0071315; P:cellular response to morphine; IEA:Ensembl.
DR   GO; GO:0071407; P:cellular response to organic cyclic compound; IDA:UniProtKB.
DR   GO; GO:0071560; P:cellular response to transforming growth factor beta stimulus; IEA:Ensembl.
DR   GO; GO:0071356; P:cellular response to tumor necrosis factor; IEP:UniProtKB.
DR   GO; GO:0071307; P:cellular response to vitamin K; IEA:Ensembl.
DR   GO; GO:0070098; P:chemokine-mediated signaling pathway; IDA:UniProtKB.
DR   GO; GO:0006935; P:chemotaxis; NAS:UniProtKB.
DR   GO; GO:0002544; P:chronic inflammatory response; IEA:Ensembl.
DR   GO; GO:0002407; P:dendritic cell chemotaxis; TAS:BHF-UCL.
DR   GO; GO:0018894; P:dibenzo-p-dioxin metabolic process; IEA:Ensembl.
DR   GO; GO:0048245; P:eosinophil chemotaxis; IDA:BHF-UCL.
DR   GO; GO:0006887; P:exocytosis; IDA:UniProtKB.
DR   GO; GO:0007186; P:G-protein coupled receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0006954; P:inflammatory response; IDA:UniProtKB.
DR   GO; GO:0007159; P:leukocyte cell-cell adhesion; IDA:BHF-UCL.
DR   GO; GO:0031663; P:lipopolysaccharide-mediated signaling pathway; IDA:UniProtKB.
DR   GO; GO:0048247; P:lymphocyte chemotaxis; IBA:GO_Central.
DR   GO; GO:0048246; P:macrophage chemotaxis; TAS:BHF-UCL.
DR   GO; GO:0000165; P:MAPK cascade; IMP:UniProtKB.
DR   GO; GO:0002548; P:monocyte chemotaxis; IC:UniProtKB.
DR   GO; GO:0043922; P:negative regulation by host of viral transcription; IDA:UniProtKB.
DR   GO; GO:0070100; P:negative regulation of chemokine-mediated signaling pathway; IDA:GOC.
DR   GO; GO:0045744; P:negative regulation of G-protein coupled receptor protein signaling pathway; IDA:UniProtKB.
DR   GO; GO:2000110; P:negative regulation of macrophage apoptotic process; IEA:Ensembl.
DR   GO; GO:1901215; P:negative regulation of neuron death; IEA:Ensembl.
DR   GO; GO:0070233; P:negative regulation of T cell apoptotic process; IDA:BHF-UCL.
DR   GO; GO:0045071; P:negative regulation of viral genome replication; IDA:BHF-UCL.
DR   GO; GO:0042119; P:neutrophil activation; IDA:BHF-UCL.
DR   GO; GO:0030593; P:neutrophil chemotaxis; IBA:GO_Central.
DR   GO; GO:0050918; P:positive chemotaxis; IDA:GOC.
DR   GO; GO:0010535; P:positive regulation of activation of JAK2 kinase activity; TAS:BHF-UCL.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; IEA:Ensembl.
DR   GO; GO:0051928; P:positive regulation of calcium ion transport; IDA:UniProtKB.
DR   GO; GO:0045785; P:positive regulation of cell adhesion; IDA:BHF-UCL.
DR   GO; GO:0030335; P:positive regulation of cell migration; IDA:UniProtKB.
DR   GO; GO:0033634; P:positive regulation of cell-cell adhesion mediated by integrin; IDA:BHF-UCL.
DR   GO; GO:0031328; P:positive regulation of cellular biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0050679; P:positive regulation of epithelial cell proliferation; IEA:Ensembl.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IBA:GO_Central.
DR   GO; GO:0031622; P:positive regulation of fever generation; IEA:Ensembl.
DR   GO; GO:0043547; P:positive regulation of GTPase activity; IBA:GO_Central.
DR   GO; GO:0034112; P:positive regulation of homotypic cell-cell adhesion; IDA:BHF-UCL.
DR   GO; GO:0050729; P:positive regulation of inflammatory response; IBA:GO_Central.
DR   GO; GO:0045089; P:positive regulation of innate immune response; TAS:BHF-UCL.
DR   GO; GO:0046427; P:positive regulation of JAK-STAT cascade; TAS:BHF-UCL.
DR   GO; GO:0010759; P:positive regulation of macrophage chemotaxis; IDA:BHF-UCL.
DR   GO; GO:0060754; P:positive regulation of mast cell chemotaxis; IEA:Ensembl.
DR   GO; GO:0090026; P:positive regulation of monocyte chemotaxis; IDA:BHF-UCL.
DR   GO; GO:2000503; P:positive regulation of natural killer cell chemotaxis; IDA:UniProtKB.
DR   GO; GO:0045666; P:positive regulation of neuron differentiation; IEA:Ensembl.
DR   GO; GO:0045672; P:positive regulation of osteoclast differentiation; IEA:Ensembl.
DR   GO; GO:0014068; P:positive regulation of phosphatidylinositol 3-kinase signaling; IDA:BHF-UCL.
DR   GO; GO:0042327; P:positive regulation of phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0061098; P:positive regulation of protein tyrosine kinase activity; IDA:GOC.
DR   GO; GO:0014911; P:positive regulation of smooth muscle cell migration; IDA:BHF-UCL.
DR   GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; IDA:BHF-UCL.
DR   GO; GO:0070234; P:positive regulation of T cell apoptotic process; IDA:BHF-UCL.
DR   GO; GO:0010820; P:positive regulation of T cell chemotaxis; IDA:BHF-UCL.
DR   GO; GO:2000406; P:positive regulation of T cell migration; IDA:MGI.
DR   GO; GO:0042102; P:positive regulation of T cell proliferation; IDA:BHF-UCL.
DR   GO; GO:0045948; P:positive regulation of translational initiation; NAS:BHF-UCL.
DR   GO; GO:0042531; P:positive regulation of tyrosine phosphorylation of STAT protein; IDA:BHF-UCL.
DR   GO; GO:0045070; P:positive regulation of viral genome replication; TAS:BHF-UCL.
DR   GO; GO:0043491; P:protein kinase B signaling; IMP:UniProtKB.
DR   GO; GO:0051262; P:protein tetramerization; IDA:BHF-UCL.
DR   GO; GO:0002676; P:regulation of chronic inflammatory response; TAS:BHF-UCL.
DR   GO; GO:0050796; P:regulation of insulin secretion; IDA:UniProtKB.
DR   GO; GO:1901214; P:regulation of neuron death; IDA:UniProtKB.
DR   GO; GO:0050863; P:regulation of T cell activation; IDA:BHF-UCL.
DR   GO; GO:0014823; P:response to activity; IEA:Ensembl.
DR   GO; GO:0070723; P:response to cholesterol; IEA:Ensembl.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0043627; P:response to estrogen; IEA:Ensembl.
DR   GO; GO:0051384; P:response to glucocorticoid; IEA:Ensembl.
DR   GO; GO:0032868; P:response to insulin; IEA:Ensembl.
DR   GO; GO:0009651; P:response to salt stress; IEA:Ensembl.
DR   GO; GO:0009636; P:response to toxic substance; IDA:UniProtKB.
DR   GO; GO:0009615; P:response to virus; TAS:BHF-UCL.
DR   InterPro; IPR030595; CCL5.
DR   InterPro; IPR000827; Chemokine_CC_CS.
DR   InterPro; IPR001811; Chemokine_IL8-like_dom.
DR   PANTHER; PTHR12015:SF82; PTHR12015:SF82; 1.
DR   Pfam; PF00048; IL8; 1.
DR   SMART; SM00199; SCY; 1.
DR   SUPFAM; SSF54117; SSF54117; 1.
DR   PROSITE; PS00472; SMALL_CYTOKINES_CC; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Chemotaxis; Complete proteome; Cytokine;
KW   Direct protein sequencing; Disulfide bond; Glycoprotein;
KW   Inflammatory response; Oxidation; Polymorphism; Reference proteome;
KW   Secreted; Signal.
FT   SIGNAL        1     23       {ECO:0000269|PubMed:1380064,
FT                                ECO:0000269|PubMed:7524281}.
FT   CHAIN        24     91       C-C motif chemokine 5.
FT                                /FTId=PRO_0000005175.
FT   CHAIN        26     91       RANTES(3-68).
FT                                /FTId=PRO_0000005176.
FT   CHAIN        27     91       RANTES(4-68).
FT                                /FTId=PRO_0000005177.
FT   SITE         25     26       Cleavage; by DPP4.
FT   MOD_RES      90     90       Methionine sulfoxide.
FT                                {ECO:0000269|PubMed:1380064}.
FT   CARBOHYD     27     27       O-linked (GalNAc...); partial.
FT                                {ECO:0000269|PubMed:1380064}.
FT   CARBOHYD     28     28       O-linked (GalNAc...); partial.
FT                                {ECO:0000269|PubMed:1380064}.
FT   DISULFID     33     57
FT   DISULFID     34     73
FT   VARIANT      24     24       S -> F (polymorphism; antagonist of the
FT                                chemokine receptors CCR1 and CCR3).
FT                                {ECO:0000269|PubMed:16791620}.
FT                                /FTId=VAR_043043.
FT   CONFLICT      7      7       A -> R (in Ref. 1; AAA36725 and 5;
FT                                AAF73070). {ECO:0000305}.
FT   CONFLICT     14     14       A -> V (in Ref. 5; AAF73070).
FT                                {ECO:0000305}.
FT   STRAND       31     33       {ECO:0000244|PDB:1B3A}.
FT   STRAND       35     40       {ECO:0000244|PDB:2VXW}.
FT   HELIX        44     46       {ECO:0000244|PDB:1B3A}.
FT   STRAND       47     52       {ECO:0000244|PDB:1B3A}.
FT   STRAND       57     59       {ECO:0000244|PDB:1B3A}.
FT   STRAND       62     66       {ECO:0000244|PDB:1B3A}.
FT   STRAND       71     74       {ECO:0000244|PDB:1B3A}.
FT   HELIX        79     89       {ECO:0000244|PDB:1B3A}.
SQ   SEQUENCE   91 AA;  9990 MW;  FB0BFAF9A87C620F CRC64;
     MKVSAAALAV ILIATALCAP ASASPYSSDT TPCCFAYIAR PLPRAHIKEY FYTSGKCSNP
     AVVFVTRKNR QVCANPEKKW VREYINSLEM S
//
ID   IGF1_HUMAN              Reviewed;         195 AA.
AC   P05019; B2RWM7; E9PD02; P01343; Q14620;
DT   13-AUG-1987, integrated into UniProtKB/Swiss-Prot.
DT   13-AUG-1987, sequence version 1.
DT   17-FEB-2016, entry version 192.
DE   RecName: Full=Insulin-like growth factor I;
DE            Short=IGF-I;
DE   AltName: Full=Mechano growth factor;
DE            Short=MGF;
DE   AltName: Full=Somatomedin-C;
DE   Flags: Precursor;
GN   Name=IGF1; Synonyms=IBP1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=6358902; DOI=10.1038/306609a0;
RA   Jansen M., van Schaik F.M.A., Ricker A.T., Bullock B., Woods D.E.,
RA   Gabbay K.H., Nussbaum A.L., Sussenbach J.S., van den Brande J.L.;
RT   "Sequence of cDNA encoding human insulin-like growth factor I
RT   precursor.";
RL   Nature 306:609-611(1983).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=3002851; DOI=10.1016/0014-5793(86)80156-9;
RA   de Pagter-Holthuizen P., van Schaik F.M.A., Verduijn G.M.,
RA   van Ommen G.J.B., Bouma B.N., Jansen M., Sussenbach J.S.;
RT   "Organization of the human genes for insulin-like growth factors I and
RT   II.";
RL   FEBS Lett. 195:179-184(1986).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=2935423; DOI=10.1016/0014-5793(86)80223-X;
RA   le Bouc Y., Dreyer D., Jaeger F., Binoux M., Sondermeyer P.;
RT   "Complete characterization of the human IGF-I nucleotide sequence
RT   isolated from a newly constructed adult liver cDNA library.";
RL   FEBS Lett. 196:108-112(1986).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=2937782;
RA   Rotwein P., Pollock K.M., Didier D.K., Krivi G.G.;
RT   "Organization and sequence of the human insulin-like growth factor I
RT   gene. Alternative RNA processing produces two insulin-like growth
RT   factor I precursor peptides.";
RL   J. Biol. Chem. 261:4828-4832(1986).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=3455760; DOI=10.1073/pnas.83.1.77;
RA   Rotwein P.;
RT   "Two insulin-like growth factor I messenger RNAs are expressed in
RT   human liver.";
RL   Proc. Natl. Acad. Sci. U.S.A. 83:77-81(1986).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RX   PubMed=2082190; DOI=10.1210/mend-4-12-1914;
RA   Tobin G., Yee D., Brunner N., Rotwein P.;
RT   "A novel human insulin-like growth factor I messenger RNA is expressed
RT   in normal and tumor cells.";
RL   Mol. Endocrinol. 4:1914-1920(1990).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=Liver;
RX   PubMed=2018498; DOI=10.1016/0006-291X(91)91593-2;
RA   Steenbergh P.H., Koonen-Reemst A.M.C.B., Cleutjens C.B.J.M.,
RA   Sussenbach J.S.;
RT   "Complete nucleotide sequence of the high molecular weight human IGF-I
RT   mRNA.";
RL   Biochem. Biophys. Res. Commun. 175:507-514(1991).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=Brain;
RX   PubMed=1372070; DOI=10.1016/0169-328X(92)90094-R;
RA   Sandberg-Nordqvist A.-C., Staehlbom P.-A., Lake M., Sara V.R.;
RT   "Characterization of two cDNAs encoding insulin-like growth factor 1
RT   (IGF-1) in the human fetal brain.";
RL   Brain Res. Mol. Brain Res. 12:275-277(1992).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=8495408;
RA   Sandberg-Nordqvist A.-C., Staehlbom P.-A., Reinecke M., Collins V.P.,
RA   von Holst H., Sara V.;
RT   "Characterization of insulin-like growth factor 1 in human primary
RT   brain tumors.";
RL   Cancer Res. 53:2475-2478(1993).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NIEHS SNPs program;
RL   Submitted (MAR-2003) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16541075; DOI=10.1038/nature04569;
RA   Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y.,
RA   Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C.,
RA   Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M.,
RA   Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L.,
RA   Milosavljevic A., Miner G.R., Montgomery K.T., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.-Z., Steffen D.,
RA   Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y., Zhang Z.,
RA   Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H., Draper H.,
RA   Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S., Kelly S.H.,
RA   Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V.,
RA   Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H., Santibanez J.,
RA   Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q., Williams G.A.,
RA   Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V., Bailey M.,
RA   Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E., Burkett C.E.,
RA   Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K.,
RA   Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D.,
RA   Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M.,
RA   Dathorne S.R., David R., Davis C.M., Davy-Carroll L., Deshazo D.R.,
RA   Donlin J.E., D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J.,
RA   Escotto M., Flagg N., Forbes L.D., Gabisi A.M., Garza M., Hamilton C.,
RA   Henderson N., Hernandez O., Hines S., Hogues M.E., Huang M.,
RA   Idlebird D.G., Johnson R., Jolivet A., Jones S., Kagan R., King L.M.,
RA   Leal B., Lebow H., Lee S., LeVan J.M., Lewis L.C., London P.,
RA   Lorensuhewa L.M., Loulseged H., Lovett D.A., Lucier A., Lucier R.L.,
RA   Ma J., Madu R.C., Mapua P., Martindale A.D., Martinez E., Massey E.,
RA   Mawhiney S., Meador M.G., Mendez S., Mercado C., Mercado I.C.,
RA   Merritt C.E., Miner Z.L., Minja E., Mitchell T., Mohabbat F.,
RA   Mohabbat K., Montgomery B., Moore N., Morris S., Munidasa M.,
RA   Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O., Nwokenkwo S.,
RA   Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J.,
RA   Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A.,
RA   Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M.,
RA   Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I.,
RA   Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A.,
RA   Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D.,
RA   Trejos Z.Y., Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I.,
RA   Vera V.A., Villasana D.M., Wang L., Ward-Moore S., Warren J.T.,
RA   Wei X., White F., Williamson A.L., Wleczyk R., Wooden H.S.,
RA   Wooden S.H., Yen J., Yoon L., Yoon V., Zorrilla S.E., Nelson D.,
RA   Kucherlapati R., Weinstock G., Gibbs R.A.;
RT   "The finished DNA sequence of human chromosome 12.";
RL   Nature 440:346-351(2006).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [14]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 22-73.
RX   PubMed=6382022; DOI=10.1038/310777a0;
RA   Dull T.J., Gray A., Hayflick J.S., Ullrich A.;
RT   "Insulin-like growth factor II precursor gene organization in relation
RT   to insulin gene family.";
RL   Nature 310:777-781(1984).
RN   [15]
RP   PROTEIN SEQUENCE OF 49-118 (ISOFORMS 1 AND 2).
RX   PubMed=632300;
RA   Rinderknecht E., Humbel R.E.;
RT   "The amino acid sequence of human insulin-like growth factor I and its
RT   structural homology with proinsulin.";
RL   J. Biol. Chem. 253:2769-2776(1978).
RN   [16]
RP   DISULFIDE BONDS.
RX   PubMed=3242681; DOI=10.1002/bms.1200160102;
RA   Raschdorf F., Dahinden R., Maerki W., Richter W.J., Merryweather J.P.;
RT   "Location of disulphide bonds in human insulin-like growth factors
RT   (IGFs) synthesized by recombinant DNA technology.";
RL   Biomed. Environ. Mass Spectrom. 16:3-8(1988).
RN   [17]
RP   FUNCTION.
RX   PubMed=21076856; DOI=10.1007/s11010-010-0634-z;
RA   Zoidis E., Ghirlanda-Keller C., Schmid C.;
RT   "Stimulation of glucose transport in osteoblastic cells by parathyroid
RT   hormone and insulin-like growth factor I.";
RL   Mol. Cell. Biochem. 348:33-42(2011).
RN   [18]
RP   FUNCTION IN SYNAPSE FORMATION.
RX   PubMed=24132240; DOI=10.1038/nature12618;
RA   Shcheglovitov A., Shcheglovitova O., Yazawa M., Portmann T., Shu R.,
RA   Sebastiano V., Krawisz A., Froehlich W., Bernstein J.A.,
RA   Hallmayer J.F., Dolmetsch R.E.;
RT   "SHANK3 and IGF1 restore synaptic deficits in neurons from 22q13
RT   deletion syndrome patients.";
RL   Nature 503:267-271(2013).
RN   [19]
RP   3D-STRUCTURE MODELING.
RX   PubMed=6189745;
RA   Blundell T.L., Bedarkar S., Humbel R.E.;
RT   "Tertiary structures, receptor binding, and antigenicity of
RT   insulinlike growth factors.";
RL   Fed. Proc. 42:2592-2597(1983).
RN   [20]
RP   STRUCTURE BY NMR.
RX   PubMed=2036417; DOI=10.1021/bi00236a022;
RA   Cooke R.M., Harvey T.S., Campbell I.D.;
RT   "Solution structure of human insulin-like growth factor 1: a nuclear
RT   magnetic resonance and restrained molecular dynamics study.";
RL   Biochemistry 30:5484-5491(1991).
RN   [21]
RP   STRUCTURE BY NMR.
RX   PubMed=1319992;
RA   Sato A., Nishimura S., Ohkubo T., Kyogoku Y., Koyama S., Kobayashi M.,
RA   Yasuda T., Kobayashi Y.;
RT   "1H-NMR assignment and secondary structure of human insulin-like
RT   growth factor-I (IGF-I) in solution.";
RL   J. Biochem. 111:529-536(1992).
RN   [22]
RP   INVOLVEMENT IN IGF1 DEFICIENCY.
RX   PubMed=8857020; DOI=10.1056/NEJM199610313351805;
RA   Woods K.A., Camacho-Hubner C., Savage M.O., Clark A.J.;
RT   "Intrauterine growth retardation and postnatal growth failure
RT   associated with deletion of the insulin-like growth factor I gene.";
RL   N. Engl. J. Med. 335:1363-1367(1996).
RN   [23]
RP   VARIANT ASP-187.
RX   PubMed=10391209; DOI=10.1038/10290;
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RT   "Characterization of single-nucleotide polymorphisms in coding regions
RT   of human genes.";
RL   Nat. Genet. 22:231-238(1999).
RN   [24]
RP   ERRATUM.
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RL   Nat. Genet. 23:373-373(1999).
CC   -!- FUNCTION: The insulin-like growth factors, isolated from plasma,
CC       are structurally and functionally related to insulin but have a
CC       much higher growth-promoting activity. May be a physiological
CC       regulator of [1-14C]-2-deoxy-D-glucose (2DG) transport and
CC       glycogen synthesis in osteoblasts. Stimulates glucose transport in
CC       rat bone-derived osteoblastic (PyMS) cells and is effective at
CC       much lower concentrations than insulin, not only regarding
CC       glycogen and DNA synthesis but also with regard to enhancing
CC       glucose uptake. May play a role in synapse maturation.
CC       {ECO:0000269|PubMed:21076856, ECO:0000269|PubMed:24132240}.
CC   -!- INTERACTION:
CC       P08069:IGF1R; NbExp=5; IntAct=EBI-7902275, EBI-475981;
CC       P06213:INSR; NbExp=4; IntAct=EBI-7902275, EBI-475899;
CC   -!- SUBCELLULAR LOCATION: Secreted.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1; Synonyms=IGF-IB;
CC         IsoId=P05019-1; Sequence=Displayed;
CC       Name=2; Synonyms=IGF-IA;
CC         IsoId=P05019-2; Sequence=VSP_039637;
CC       Name=3;
CC         IsoId=P05019-3; Sequence=VSP_043317, VSP_039637;
CC         Note=Expressed in liver.;
CC       Name=4;
CC         IsoId=P05019-4; Sequence=VSP_047399;
CC         Note=Gene prediction based on EST data.;
CC   -!- DISEASE: Insulin-like growth factor I deficiency (IGF1 deficiency)
CC       [MIM:608747]: Autosomal recessive disorder characterized by growth
CC       retardation, sensorineural deafness and mental retardation.
CC       {ECO:0000269|PubMed:8857020}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the insulin family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAA27250.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation and
CC       polymorphism database;
CC       URL="http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=HLA-DQB1";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/igf1/";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Insulin-like growth factor 1
CC       entry;
CC       URL="https://en.wikipedia.org/wiki/Insulin-like_growth_factor_1";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X00173; CAA24998.1; -; mRNA.
DR   EMBL; X03420; CAA27152.1; -; Genomic_DNA.
DR   EMBL; X03421; CAA27153.1; -; Genomic_DNA.
DR   EMBL; X03422; CAA27154.1; -; Genomic_DNA.
DR   EMBL; M27544; AAA52787.1; -; mRNA.
DR   EMBL; M14155; AAA52537.1; -; Genomic_DNA.
DR   EMBL; M12659; AAA52537.1; JOINED; Genomic_DNA.
DR   EMBL; M14153; AAA52537.1; JOINED; Genomic_DNA.
DR   EMBL; M14154; AAA52537.1; JOINED; Genomic_DNA.
DR   EMBL; M14156; AAA52538.1; -; Genomic_DNA.
DR   EMBL; M12659; AAA52538.1; JOINED; Genomic_DNA.
DR   EMBL; M14153; AAA52538.1; JOINED; Genomic_DNA.
DR   EMBL; M14154; AAA52538.1; JOINED; Genomic_DNA.
DR   EMBL; M11568; AAA52539.1; -; mRNA.
DR   EMBL; M37484; AAA52789.1; -; mRNA.
DR   EMBL; X57025; CAA40342.1; -; mRNA.
DR   EMBL; X56773; CAA40092.1; -; mRNA.
DR   EMBL; X56774; CAA40093.1; -; mRNA.
DR   EMBL; AY260957; AAO74829.1; -; Genomic_DNA.
DR   EMBL; AC010202; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC068648; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471054; EAW97696.1; -; Genomic_DNA.
DR   EMBL; CH471054; EAW97697.1; -; Genomic_DNA.
DR   EMBL; BC148266; AAI48267.1; -; mRNA.
DR   EMBL; X03563; CAA27250.1; ALT_SEQ; Genomic_DNA.
DR   CCDS; CCDS44960.1; -. [P05019-3]
DR   CCDS; CCDS44961.1; -. [P05019-4]
DR   CCDS; CCDS9091.1; -. [P05019-2]
DR   PIR; A01611; IGHU1B.
DR   PIR; A92581; IGHU1.
DR   RefSeq; NP_000609.1; NM_000618.4. [P05019-2]
DR   RefSeq; NP_001104754.1; NM_001111284.1. [P05019-3]
DR   UniGene; Hs.160562; -.
DR   PDB; 1B9G; NMR; -; A=49-118.
DR   PDB; 1BQT; NMR; -; A=49-118.
DR   PDB; 1GF1; Model; -; A=49-118.
DR   PDB; 1GZR; X-ray; 2.00 A; B=49-118.
DR   PDB; 1GZY; X-ray; 2.54 A; B=49-118.
DR   PDB; 1GZZ; X-ray; 2.30 A; B=49-118.
DR   PDB; 1H02; X-ray; 2.00 A; B=49-118.
DR   PDB; 1H59; X-ray; 2.10 A; A=49-118.
DR   PDB; 1IMX; X-ray; 1.82 A; A=49-118.
DR   PDB; 1PMX; NMR; -; A=49-118.
DR   PDB; 1TGR; X-ray; 1.42 A; A/B=49-77, A/B=90-110.
DR   PDB; 1WQJ; X-ray; 1.60 A; I=49-118.
DR   PDB; 2DSP; X-ray; 2.50 A; I=49-118.
DR   PDB; 2DSQ; X-ray; 2.80 A; C/I=49-118.
DR   PDB; 2DSR; X-ray; 2.10 A; I=49-118.
DR   PDB; 2GF1; NMR; -; A=49-118.
DR   PDB; 3GF1; NMR; -; A=49-118.
DR   PDB; 3LRI; NMR; -; A=49-118.
DR   PDB; 4XSS; X-ray; 3.00 A; B=49-118.
DR   PDBsum; 1B9G; -.
DR   PDBsum; 1BQT; -.
DR   PDBsum; 1GF1; -.
DR   PDBsum; 1GZR; -.
DR   PDBsum; 1GZY; -.
DR   PDBsum; 1GZZ; -.
DR   PDBsum; 1H02; -.
DR   PDBsum; 1H59; -.
DR   PDBsum; 1IMX; -.
DR   PDBsum; 1PMX; -.
DR   PDBsum; 1TGR; -.
DR   PDBsum; 1WQJ; -.
DR   PDBsum; 2DSP; -.
DR   PDBsum; 2DSQ; -.
DR   PDBsum; 2DSR; -.
DR   PDBsum; 2GF1; -.
DR   PDBsum; 3GF1; -.
DR   PDBsum; 3LRI; -.
DR   PDBsum; 4XSS; -.
DR   ProteinModelPortal; P05019; -.
DR   SMR; P05019; 50-111.
DR   BioGrid; 109700; 13.
DR   DIP; DIP-41933N; -.
DR   DIP; DIP-6021N; -.
DR   IntAct; P05019; 2.
DR   MINT; MINT-204184; -.
DR   STRING; 9606.ENSP00000302665; -.
DR   ChEMBL; CHEMBL3217394; -.
DR   Allergome; 11751; Hom s IGF-1.
DR   PhosphoSite; P05019; -.
DR   BioMuta; IGF1; -.
DR   DMDM; 124263; -.
DR   PaxDb; P05019; -.
DR   PRIDE; P05019; -.
DR   DNASU; 3479; -.
DR   Ensembl; ENST00000307046; ENSP00000302665; ENSG00000017427. [P05019-1]
DR   Ensembl; ENST00000337514; ENSP00000337612; ENSG00000017427. [P05019-2]
DR   Ensembl; ENST00000392904; ENSP00000376637; ENSG00000017427. [P05019-4]
DR   Ensembl; ENST00000424202; ENSP00000416811; ENSG00000017427. [P05019-3]
DR   Ensembl; ENST00000456098; ENSP00000394999; ENSG00000017427. [P05019-4]
DR   GeneID; 3479; -.
DR   KEGG; hsa:3479; -.
DR   UCSC; uc001tjm.2; human.
DR   UCSC; uc001tjn.2; human. [P05019-3]
DR   UCSC; uc001tjp.4; human. [P05019-1]
DR   CTD; 3479; -.
DR   GeneCards; IGF1; -.
DR   HGNC; HGNC:5464; IGF1.
DR   HPA; HPA048946; -.
DR   MalaCards; IGF1; -.
DR   MIM; 147440; gene.
DR   MIM; 608747; phenotype.
DR   neXtProt; NX_P05019; -.
DR   Orphanet; 73272; Growth delay due to insulin-like growth factor type 1 deficiency.
DR   PharmGKB; PA29697; -.
DR   eggNOG; ENOG410IJ2T; Eukaryota.
DR   eggNOG; ENOG4111MIV; LUCA.
DR   GeneTree; ENSGT00530000063856; -.
DR   HOGENOM; HOG000233362; -.
DR   HOVERGEN; HBG006137; -.
DR   InParanoid; P05019; -.
DR   KO; K05459; -.
DR   OMA; HTVSYIH; -.
DR   OrthoDB; EOG7TF7CG; -.
DR   PhylomeDB; P05019; -.
DR   TreeFam; TF332820; -.
DR   Reactome; R-HSA-114608; Platelet degranulation.
DR   Reactome; R-HSA-2404192; Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R).
DR   Reactome; R-HSA-2428928; IRS-related events triggered by IGF1R.
DR   Reactome; R-HSA-2428933; SHC-related events triggered by IGF1R.
DR   Reactome; R-HSA-381426; Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs).
DR   Reactome; R-HSA-422085; Synthesis, secretion, and deacylation of Ghrelin.
DR   SignaLink; P05019; -.
DR   ChiTaRS; IGF1; human.
DR   EvolutionaryTrace; P05019; -.
DR   GeneWiki; Insulin-like_growth_factor_1; -.
DR   GenomeRNAi; 3479; -.
DR   NextBio; 13678; -.
DR   PMAP-CutDB; P01343; -.
DR   PRO; PR:P05019; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   Bgee; P05019; -.
DR   CleanEx; HS_IGF1; -.
DR   ExpressionAtlas; P05019; baseline and differential.
DR   Genevisible; P05019; HS.
DR   GO; GO:0005576; C:extracellular region; NAS:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; IDA:AgBase.
DR   GO; GO:0016942; C:insulin-like growth factor binding protein complex; IC:BHF-UCL.
DR   GO; GO:0042567; C:insulin-like growth factor ternary complex; IDA:BHF-UCL.
DR   GO; GO:0005614; C:interstitial matrix; IEA:Ensembl.
DR   GO; GO:0043025; C:neuronal cell body; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0031093; C:platelet alpha granule lumen; TAS:Reactome.
DR   GO; GO:0005179; F:hormone activity; IDA:BHF-UCL.
DR   GO; GO:0005158; F:insulin receptor binding; IPI:BHF-UCL.
DR   GO; GO:0005159; F:insulin-like growth factor receptor binding; IMP:AgBase.
DR   GO; GO:0005178; F:integrin binding; IDA:BHF-UCL.
DR   GO; GO:0005496; F:steroid binding; IEA:Ensembl.
DR   GO; GO:0007568; P:aging; IEA:Ensembl.
DR   GO; GO:0007596; P:blood coagulation; TAS:Reactome.
DR   GO; GO:0001974; P:blood vessel remodeling; IEA:Ensembl.
DR   GO; GO:0035630; P:bone mineralization involved in bone maturation; IDA:BHF-UCL.
DR   GO; GO:0048754; P:branching morphogenesis of an epithelial tube; IEA:Ensembl.
DR   GO; GO:0001775; P:cell activation; IDA:MGI.
DR   GO; GO:0008283; P:cell proliferation; IMP:AgBase.
DR   GO; GO:0044267; P:cellular protein metabolic process; TAS:Reactome.
DR   GO; GO:0071257; P:cellular response to electrical stimulus; IEA:Ensembl.
DR   GO; GO:0071392; P:cellular response to estradiol stimulus; IEA:Ensembl.
DR   GO; GO:0071333; P:cellular response to glucose stimulus; IEA:Ensembl.
DR   GO; GO:0032869; P:cellular response to insulin stimulus; IEA:Ensembl.
DR   GO; GO:1990314; P:cellular response to insulin-like growth factor stimulus; IEA:Ensembl.
DR   GO; GO:0050650; P:chondroitin sulfate proteoglycan biosynthetic process; IEA:Ensembl.
DR   GO; GO:0050974; P:detection of mechanical stimulus involved in sensory perception; IEA:Ensembl.
DR   GO; GO:0006260; P:DNA replication; TAS:ProtInc.
DR   GO; GO:0070371; P:ERK1 and ERK2 cascade; IMP:AgBase.
DR   GO; GO:0031017; P:exocrine pancreas development; IEA:Ensembl.
DR   GO; GO:0097192; P:extrinsic apoptotic signaling pathway in absence of ligand; IEA:Ensembl.
DR   GO; GO:0007565; P:female pregnancy; IEA:Ensembl.
DR   GO; GO:0010001; P:glial cell differentiation; IEA:Ensembl.
DR   GO; GO:0009441; P:glycolate metabolic process; TAS:ProtInc.
DR   GO; GO:0048839; P:inner ear development; IEA:Ensembl.
DR   GO; GO:0048009; P:insulin-like growth factor receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0048286; P:lung alveolus development; IEA:Ensembl.
DR   GO; GO:0060463; P:lung lobe morphogenesis; IEA:Ensembl.
DR   GO; GO:0060426; P:lung vasculature development; IEA:Ensembl.
DR   GO; GO:0030879; P:mammary gland development; IEA:Ensembl.
DR   GO; GO:0007613; P:memory; IEA:Ensembl.
DR   GO; GO:0006928; P:movement of cell or subcellular component; TAS:ProtInc.
DR   GO; GO:0035264; P:multicellular organism growth; IEA:Ensembl.
DR   GO; GO:0014896; P:muscle hypertrophy; IMP:BHF-UCL.
DR   GO; GO:0007517; P:muscle organ development; TAS:ProtInc.
DR   GO; GO:0045445; P:myoblast differentiation; IDA:BHF-UCL.
DR   GO; GO:0051450; P:myoblast proliferation; IDA:BHF-UCL.
DR   GO; GO:0014904; P:myotube cell development; IDA:BHF-UCL.
DR   GO; GO:0060766; P:negative regulation of androgen receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:AgBase.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IEA:Ensembl.
DR   GO; GO:1904193; P:negative regulation of cholangiocyte apoptotic process; IEA:Ensembl.
DR   GO; GO:0070373; P:negative regulation of ERK1 and ERK2 cascade; IEA:Ensembl.
DR   GO; GO:2001237; P:negative regulation of extrinsic apoptotic signaling pathway; IDA:BHF-UCL.
DR   GO; GO:1901215; P:negative regulation of neuron death; IEA:Ensembl.
DR   GO; GO:0060283; P:negative regulation of oocyte development; IMP:AgBase.
DR   GO; GO:0050732; P:negative regulation of peptidyl-tyrosine phosphorylation; IEA:Ensembl.
DR   GO; GO:0090201; P:negative regulation of release of cytochrome c from mitochondria; ISS:UniProtKB.
DR   GO; GO:0034392; P:negative regulation of smooth muscle cell apoptotic process; IDA:BHF-UCL.
DR   GO; GO:0014065; P:phosphatidylinositol 3-kinase signaling; IMP:AgBase.
DR   GO; GO:0048015; P:phosphatidylinositol-mediated signaling; IDA:BHF-UCL.
DR   GO; GO:0030168; P:platelet activation; TAS:Reactome.
DR   GO; GO:0002576; P:platelet degranulation; TAS:Reactome.
DR   GO; GO:0042104; P:positive regulation of activated T cell proliferation; IDA:BHF-UCL.
DR   GO; GO:0070886; P:positive regulation of calcineurin-NFAT signaling cascade; IDA:UniProtKB.
DR   GO; GO:0010613; P:positive regulation of cardiac muscle hypertrophy; IDA:UniProtKB.
DR   GO; GO:0030307; P:positive regulation of cell growth; IEA:Ensembl.
DR   GO; GO:0030335; P:positive regulation of cell migration; IMP:AgBase.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IDA:BHF-UCL.
DR   GO; GO:0021940; P:positive regulation of cerebellar granule cell precursor proliferation; IEA:Ensembl.
DR   GO; GO:0043388; P:positive regulation of DNA binding; IDA:UniProtKB.
DR   GO; GO:0045740; P:positive regulation of DNA replication; IDA:BHF-UCL.
DR   GO; GO:0050679; P:positive regulation of epithelial cell proliferation; IDA:BHF-UCL.
DR   GO; GO:0045600; P:positive regulation of fat cell differentiation; IEA:Ensembl.
DR   GO; GO:0048146; P:positive regulation of fibroblast proliferation; IDA:BHF-UCL.
DR   GO; GO:0046326; P:positive regulation of glucose import; IDA:UniProtKB.
DR   GO; GO:0045725; P:positive regulation of glycogen biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0045821; P:positive regulation of glycolytic process; IDA:BHF-UCL.
DR   GO; GO:0010560; P:positive regulation of glycoprotein biosynthetic process; IMP:AgBase.
DR   GO; GO:0043568; P:positive regulation of insulin-like growth factor receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IDA:UniProtKB.
DR   GO; GO:0045840; P:positive regulation of mitotic nuclear division; IDA:UniProtKB.
DR   GO; GO:2000288; P:positive regulation of myoblast proliferation; IEA:Ensembl.
DR   GO; GO:0045669; P:positive regulation of osteoblast differentiation; IDA:BHF-UCL.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0014068; P:positive regulation of phosphatidylinositol 3-kinase signaling; IDA:BHF-UCL.
DR   GO; GO:0033160; P:positive regulation of protein import into nucleus, translocation; IDA:UniProtKB.
DR   GO; GO:0051897; P:positive regulation of protein kinase B signaling; IEA:Ensembl.
DR   GO; GO:0050714; P:positive regulation of protein secretion; IMP:AgBase.
DR   GO; GO:0046579; P:positive regulation of Ras protein signal transduction; IDA:BHF-UCL.
DR   GO; GO:0014911; P:positive regulation of smooth muscle cell migration; IDA:BHF-UCL.
DR   GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; IDA:BHF-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:BHF-UCL.
DR   GO; GO:2000679; P:positive regulation of transcription regulatory region DNA binding; IDA:AgBase.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:1904075; P:positive regulation of trophectodermal cell proliferation; IMP:AgBase.
DR   GO; GO:0042523; P:positive regulation of tyrosine phosphorylation of Stat5 protein; IDA:BHF-UCL.
DR   GO; GO:0060527; P:prostate epithelial cord arborization involved in prostate glandular acinus morphogenesis; IEA:Ensembl.
DR   GO; GO:0060736; P:prostate gland growth; IEA:Ensembl.
DR   GO; GO:0060741; P:prostate gland stromal morphogenesis; IEA:Ensembl.
DR   GO; GO:0043491; P:protein kinase B signaling; IMP:AgBase.
DR   GO; GO:0050821; P:protein stabilization; IMP:AgBase.
DR   GO; GO:0030166; P:proteoglycan biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0007265; P:Ras protein signal transduction; TAS:ProtInc.
DR   GO; GO:0051924; P:regulation of calcium ion transport; IEA:Ensembl.
DR   GO; GO:0032878; P:regulation of establishment or maintenance of cell polarity; IEA:Ensembl.
DR   GO; GO:0010468; P:regulation of gene expression; IMP:AgBase.
DR   GO; GO:0040014; P:regulation of multicellular organism growth; IEP:BHF-UCL.
DR   GO; GO:0045428; P:regulation of nitric oxide biosynthetic process; IEA:Ensembl.
DR   GO; GO:0006417; P:regulation of translation; IEA:Ensembl.
DR   GO; GO:0014823; P:response to activity; IEA:Ensembl.
DR   GO; GO:0031000; P:response to caffeine; IEA:Ensembl.
DR   GO; GO:0051384; P:response to glucocorticoid; IEA:Ensembl.
DR   GO; GO:0009408; P:response to heat; IDA:AgBase.
DR   GO; GO:0001666; P:response to hypoxia; IEA:Ensembl.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IEA:Ensembl.
DR   GO; GO:0035094; P:response to nicotine; IEA:Ensembl.
DR   GO; GO:0007584; P:response to nutrient; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0014834; P:skeletal muscle satellite cell maintenance involved in skeletal muscle regeneration; IDA:BHF-UCL.
DR   GO; GO:0001501; P:skeletal system development; TAS:ProtInc.
DR   GO; GO:0060509; P:Type I pneumocyte differentiation; IEA:Ensembl.
DR   GO; GO:0060510; P:Type II pneumocyte differentiation; IEA:Ensembl.
DR   GO; GO:0030104; P:water homeostasis; IEA:Ensembl.
DR   Gene3D; 1.10.100.10; -; 1.
DR   InterPro; IPR022341; IGF-I.
DR   InterPro; IPR016179; Insulin-like.
DR   InterPro; IPR022350; Insulin-like_growth_factor.
DR   InterPro; IPR022353; Insulin_CS.
DR   InterPro; IPR022352; Insulin_family.
DR   Pfam; PF00049; Insulin; 1.
DR   PRINTS; PR02002; INSLNLIKEGF.
DR   PRINTS; PR02005; INSLNLIKEGF1.
DR   PRINTS; PR00276; INSULINFAMLY.
DR   SMART; SM00078; IlGF; 1.
DR   SUPFAM; SSF56994; SSF56994; 1.
DR   PROSITE; PS00262; INSULIN; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Complete proteome; Deafness;
KW   Direct protein sequencing; Disulfide bond; Growth factor;
KW   Polymorphism; Reference proteome; Secreted; Signal.
FT   SIGNAL        1     21       {ECO:0000255}.
FT   PROPEP       22     48
FT                                /FTId=PRO_0000015663.
FT   CHAIN        49    118       Insulin-like growth factor I.
FT                                /FTId=PRO_0000015664.
FT   PROPEP      119    195       E peptide.
FT                                /FTId=PRO_0000015665.
FT   REGION       49     77       B.
FT   REGION       78     89       C.
FT   REGION       90    110       A.
FT   REGION      111    118       D.
FT   DISULFID     54     96       {ECO:0000269|PubMed:3242681}.
FT   DISULFID     66    109       {ECO:0000269|PubMed:3242681}.
FT   DISULFID     95    100       {ECO:0000269|PubMed:3242681}.
FT   VAR_SEQ       1     21       MGKISSLPTQLFKCCFCDFLK -> MITPT (in
FT                                isoform 3). {ECO:0000303|PubMed:2082190}.
FT                                /FTId=VSP_043317.
FT   VAR_SEQ     135    195       YQPPSTNKNTKSQRRKGWPKTHPGGEQKEGTEASLQIRGKK
FT                                KEQRREIGSRNAECRGKKGK -> EVHLKNASRGSAGNKNY
FT                                RM (in isoform 2 and isoform 3).
FT                                {ECO:0000303|PubMed:1372070,
FT                                ECO:0000303|PubMed:2018498,
FT                                ECO:0000303|PubMed:2082190,
FT                                ECO:0000303|PubMed:2935423,
FT                                ECO:0000303|PubMed:6358902}.
FT                                /FTId=VSP_039637.
FT   VAR_SEQ     152    195       WPKTHPGGEQKEGTEASLQIRGKKKEQRREIGSRNAECRGK
FT                                KGK -> STFEERK (in isoform 4).
FT                                {ECO:0000305}.
FT                                /FTId=VSP_047399.
FT   VARIANT     115    115       A -> T (in dbSNP:rs17884626).
FT                                /FTId=VAR_056113.
FT   VARIANT     187    187       A -> D (in dbSNP:rs6213).
FT                                {ECO:0000269|PubMed:10391209}.
FT                                /FTId=VAR_013945.
FT   HELIX        52     66       {ECO:0000244|PDB:1TGR}.
FT   HELIX        67     69       {ECO:0000244|PDB:1TGR}.
FT   STRAND       71     73       {ECO:0000244|PDB:1TGR}.
FT   STRAND       79     81       {ECO:0000244|PDB:1H02}.
FT   STRAND       82     85       {ECO:0000244|PDB:3LRI}.
FT   HELIX        90     95       {ECO:0000244|PDB:1TGR}.
FT   STRAND       96     98       {ECO:0000244|PDB:1TGR}.
FT   HELIX       102    108       {ECO:0000244|PDB:1TGR}.
FT   STRAND      109    111       {ECO:0000244|PDB:1BQT}.
FT   STRAND      112    116       {ECO:0000244|PDB:1B9G}.
SQ   SEQUENCE   195 AA;  21841 MW;  E88A8CFBD1CD1873 CRC64;
     MGKISSLPTQ LFKCCFCDFL KVKMHTMSSS HLFYLALCLL TFTSSATAGP ETLCGAELVD
     ALQFVCGDRG FYFNKPTGYG SSSRRAPQTG IVDECCFRSC DLRRLEMYCA PLKPAKSARS
     VRAQRHTDMP KTQKYQPPST NKNTKSQRRK GWPKTHPGGE QKEGTEASLQ IRGKKKEQRR
     EIGSRNAECR GKKGK
//
ID   TGFR1_HUMAN             Reviewed;         503 AA.
AC   P36897; Q6IR47; Q706C0; Q706C1;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1994, sequence version 1.
DT   17-FEB-2016, entry version 188.
DE   RecName: Full=TGF-beta receptor type-1;
DE            Short=TGFR-1;
DE            EC=2.7.11.30;
DE   AltName: Full=Activin A receptor type II-like protein kinase of 53kD;
DE   AltName: Full=Activin receptor-like kinase 5;
DE            Short=ALK-5;
DE            Short=ALK5;
DE   AltName: Full=Serine/threonine-protein kinase receptor R4;
DE            Short=SKR4;
DE   AltName: Full=TGF-beta type I receptor;
DE   AltName: Full=Transforming growth factor-beta receptor type I;
DE            Short=TGF-beta receptor type I;
DE            Short=TbetaR-I;
DE   Flags: Precursor;
GN   Name=TGFBR1; Synonyms=ALK5, SKR4;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=8242743; DOI=10.1016/0092-8674(93)90489-D;
RA   Franzen P., ten Dijke P., Ichijo H., Yamashita H., Schulz P.,
RA   Heldin C.-H., Miyazono K.;
RT   "Cloning of a TGF beta type I receptor that forms a heteromeric
RT   complex with the TGF beta type II receptor.";
RL   Cell 75:681-692(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=9417915; DOI=10.1006/geno.1997.5023;
RA   Vellucci V.F., Reiss M.;
RT   "Cloning and genomic organization of the human transforming growth
RT   factor-beta type I receptor gene.";
RL   Genomics 46:278-283(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Lynch M.A., Song H., DeGroff V.L., Alam K.Y., Adams E.M.,
RA   Weghorst C.M.;
RT   "The genomic structure of the gene encoding the human transforming
RT   growth factor beta type I receptor.";
RL   Submitted (NOV-1997) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NIEHS SNPs program;
RL   Submitted (DEC-2003) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E.,
RA   Howe K.L., Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Ashwell R.I.S.,
RA   Babbage A.K., Babbage S., Bagguley C.L., Bailey J., Banerjee R.,
RA   Barker D.J., Barlow K.F., Bates K., Beasley H., Beasley O., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burford D., Burrill W.,
RA   Burton J., Carder C., Carter N.P., Chapman J.C., Chen Y., Clarke G.,
RA   Clark S.Y., Clee C.M., Clegg S., Collier R.E., Corby N., Crosier M.,
RA   Cummings A.T., Davies J., Dhami P., Dunn M., Dutta I., Dyer L.W.,
RA   Earthrowl M.E., Faulkner L., Fleming C.J., Frankish A.,
RA   Frankland J.A., French L., Fricker D.G., Garner P., Garnett J.,
RA   Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M.,
RA   Lovell J., Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S.,
RA   McLay K.E., McMurray A., Milne S., Nickerson T., Nisbett J.,
RA   Nordsiek G., Pearce A.V., Peck A.I., Porter K.M., Pandian R.,
RA   Pelan S., Phillimore B., Povey S., Ramsey Y., Rand V., Scharfe M.,
RA   Sehra H.K., Shownkeen R., Sims S.K., Skuce C.D., Smith M.,
RA   Steward C.A., Swarbreck D., Sycamore N., Tester J., Thorpe A.,
RA   Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Williams S.A., Wilming L., Wray P.W.,
RA   Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S.,
RA   Rogers J., Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   PROTEIN SEQUENCE OF 34-40, SIGNAL SEQUENCE CLEAVAGE SITE,
RP   GLYCOSYLATION, CHARACTERIZATION OF VARIANT TGFBR1*6A ALA-24--26-ALA
RP   DEL, AND VARIANT TGFBR1*10A ALA-26 INS.
RX   PubMed=9661882;
RA   Pasche B., Luo Y., Rao P.H., Nimer S.D., Dmitrovsky E., Caron P.,
RA   Luzzatto L., Offit K., Cordon-Cardo C., Renault B., Satagopan J.M.,
RA   Murty V.V., Massague J.;
RT   "Type I transforming growth factor beta receptor maps to 9q22 and
RT   exhibits a polymorphism and a rare variant within a polyalanine
RT   tract.";
RL   Cancer Res. 58:2727-2732(1998).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), NUCLEOTIDE SEQUENCE [MRNA] OF
RP   61-155 (ISOFORM 1), AND ALTERNATIVE SPLICING.
RC   TISSUE=Prostate;
RX   PubMed=17845732; DOI=10.1186/1471-2164-8-318;
RA   Konrad L., Scheiber J.A., Volck-Badouin E., Keilani M.M., Laible L.,
RA   Brandt H., Schmidt A., Aumuller G., Hofmann R.;
RT   "Alternative splicing of TGF-betas and their high-affinity receptors T
RT   beta RI, T beta RII and T beta RIII (betaglycan) reveal new variants
RT   in human prostatic cells.";
RL   BMC Genomics 8:318-318(2007).
RN   [9]
RP   SEQUENCE REVISION (ISOFORM 1).
RA   Konrad L.;
RL   Submitted (MAR-2011) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   FUNCTION, PHOSPHORYLATION AT THR-185; THR-186; SER-187; SER-189 AND
RP   SER-191 BY TGFBR2, SUBCELLULAR LOCATION, SUBUNIT, AND MUTAGENESIS OF
RP   185-THR-THR-186; SER-187; SER-189; SER-191; THR-200 AND THR-204.
RX   PubMed=7774578;
RA   Wieser R., Wrana J.L., Massague J.;
RT   "GS domain mutations that constitutively activate T beta R-I, the
RT   downstream signaling component in the TGF-beta receptor complex.";
RL   EMBO J. 14:2199-2208(1995).
RN   [11]
RP   FUNCTION IN PHOSPHORYLATION OF SMAD2.
RX   PubMed=8752209; DOI=10.1016/S0092-8674(00)80128-2;
RA   Eppert K., Scherer S.W., Ozcelik H., Pirone R., Hoodless P., Kim H.,
RA   Tsui L.-C., Bapat B., Gallinger S., Andrulis I.L., Thomsen G.H.,
RA   Wrana J.L., Attisano L.;
RT   "MADR2 maps to 18q21 and encodes a TGFbeta-regulated MAD-related
RT   protein that is functionally mutated in colorectal carcinoma.";
RL   Cell 86:543-552(1996).
RN   [12]
RP   INTERACTION WITH SMAD2, FUNCTION IN PHOSPHORYLATION OF SMAD2, AND
RP   FUNCTION IN TRANSCRIPTION REGULATION.
RX   PubMed=8980228; DOI=10.1016/S0092-8674(00)81817-6;
RA   Macias-Silva M., Abdollah S., Hoodless P.A., Pirone R., Attisano L.,
RA   Wrana J.L.;
RT   "MADR2 is a substrate of the TGFbeta receptor and its phosphorylation
RT   is required for nuclear accumulation and signaling.";
RL   Cell 87:1215-1224(1996).
RN   [13]
RP   INTERACTION WITH FKBP1A, ENZYME REGULATION, AND MUTAGENESIS OF LEU-193
RP   AND PRO-194.
RX   PubMed=9233797; DOI=10.1093/emboj/16.13.3866;
RA   Chen Y.G., Liu F., Massague J.;
RT   "Mechanism of TGFbeta receptor inhibition by FKBP12.";
RL   EMBO J. 16:3866-3876(1997).
RN   [14]
RP   INTERACTION WITH SMAD3.
RX   PubMed=9311995; DOI=10.1093/emboj/16.17.5353;
RA   Nakao A., Imamura T., Souchelnytskyi S., Kawabata M., Ishisaki A.,
RA   Oeda E., Tamaki K., Hanai J., Heldin C.H., Miyazono K., ten Dijke P.;
RT   "TGF-beta receptor-mediated signalling through Smad2, Smad3 and
RT   Smad4.";
RL   EMBO J. 16:5353-5362(1997).
RN   [15]
RP   INTERACTION WITH SMAD2, FUNCTION IN PHOSPHORYLATION OF SMAD2, AND
RP   FUNCTION IN TRANSCRIPTION REGULATION.
RX   PubMed=9346908; DOI=10.1074/jbc.272.44.27678;
RA   Abdollah S., Macias-Silva M., Tsukazaki T., Hayashi H., Attisano L.,
RA   Wrana J.L.;
RT   "TbetaRI phosphorylation of Smad2 on Ser465 and Ser467 is required for
RT   Smad2-Smad4 complex formation and signaling.";
RL   J. Biol. Chem. 272:27678-27685(1997).
RN   [16]
RP   INTERACTION WITH ZFYVE9.
RX   PubMed=9865696; DOI=10.1016/S0092-8674(00)81701-8;
RA   Tsukazaki T., Chiang T.A., Davison A.F., Attisano L., Wrana J.L.;
RT   "SARA, a FYVE domain protein that recruits Smad2 to the TGFbeta
RT   receptor.";
RL   Cell 95:779-791(1998).
RN   [17]
RP   HOMODIMERIZATION, AND SUBCELLULAR LOCATION.
RX   PubMed=9472030; DOI=10.1083/jcb.140.4.767;
RA   Gilboa L., Wells R.G., Lodish H.F., Henis Y.I.;
RT   "Oligomeric structure of type I and type II transforming growth factor
RT   beta receptors: homodimers form in the ER and persist at the plasma
RT   membrane.";
RL   J. Cell Biol. 140:767-777(1998).
RN   [18]
RP   INTERACTION WITH SMAD7 AND SMURF2, AND PROTEASOMAL AND LYSOSOMAL
RP   DEGRADATION.
RX   PubMed=11163210; DOI=10.1016/S1097-2765(00)00134-9;
RA   Kavsak P., Rasmussen R.K., Causing C.G., Bonni S., Zhu H.,
RA   Thomsen G.H., Wrana J.L.;
RT   "Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the
RT   TGF-beta receptor for degradation.";
RL   Mol. Cell 6:1365-1375(2000).
RN   [19]
RP   INTERACTION WITH SMAD7 AND SMURF1, AND PROTEASOMAL DEGRADATION.
RX   PubMed=11278251; DOI=10.1074/jbc.C100008200;
RA   Ebisawa T., Fukuchi M., Murakami G., Chiba T., Tanaka K., Imamura T.,
RA   Miyazono K.;
RT   "Smurf1 interacts with transforming growth factor-beta type I receptor
RT   through Smad7 and induces receptor degradation.";
RL   J. Biol. Chem. 276:12477-12480(2001).
RN   [20]
RP   INTERACTION WITH VPS39.
RX   PubMed=12941698; DOI=10.1093/emboj/cdg428;
RA   Felici A., Wurthner J.U., Parks W.T., Giam L.R., Reiss M.,
RA   Karpova T.S., McNally J.G., Roberts A.B.;
RT   "TLP, a novel modulator of TGF-beta signaling, has opposite effects on
RT   Smad2- and Smad3-dependent signaling.";
RL   EMBO J. 22:4465-4477(2003).
RN   [21]
RP   INTERACTION WITH NEDD4L, AND UBIQUITINATION.
RX   PubMed=15496141; DOI=10.1042/BJ20040738;
RA   Kuratomi G., Komuro A., Goto K., Shinozaki M., Miyazawa K.,
RA   Miyazono K., Imamura T.;
RT   "NEDD4-2 (neural precursor cell expressed, developmentally down-
RT   regulated 4-2) negatively regulates TGF-beta (transforming growth
RT   factor-beta) signalling by inducing ubiquitin-mediated degradation of
RT   Smad2 and TGF-beta type I receptor.";
RL   Biochem. J. 386:461-470(2005).
RN   [22]
RP   FUNCTION IN EPITHELIAL TO MESENCHYMAL TRANSITION, SUBCELLULAR
RP   LOCATION, INTERACTION WITH PARD6A, AND FUNCTION IN PHOSPHORYLATION OF
RP   PARD6A.
RX   PubMed=15761148; DOI=10.1126/science.1105718;
RA   Ozdamar B., Bose R., Barrios-Rodiles M., Wang H.R., Zhang Y.,
RA   Wrana J.L.;
RT   "Regulation of the polarity protein Par6 by TGFbeta receptors controls
RT   epithelial cell plasticity.";
RL   Science 307:1603-1609(2005).
RN   [23]
RP   FUNCTION IN CELLULAR GROWTH INHIBITION, AND INTERACTION WITH CD109.
RX   PubMed=16754747; DOI=10.1096/fj.05-5229fje;
RA   Finnson K.W., Tam B.Y.Y., Liu K., Marcoux A., Lepage P., Roy S.,
RA   Bizet A.A., Philip A.;
RT   "Identification of CD109 as part of the TGF-beta receptor system in
RT   human keratinocytes.";
RL   FASEB J. 20:1525-1527(2006).
RN   [24]
RP   INTERACTION WITH RBPMS.
RX   PubMed=17099224; DOI=10.1093/nar/gkl914;
RA   Sun Y., Ding L., Zhang H., Han J., Yang X., Yan J., Zhu Y., Li J.,
RA   Song H., Ye Q.;
RT   "Potentiation of Smad-mediated transcriptional activation by the RNA-
RT   binding protein RBPMS.";
RL   Nucleic Acids Res. 34:6314-6326(2006).
RN   [25]
RP   FUNCTION IN APOPTOSIS, AND INTERACTION WITH TRAF6 AND MAP3K7.
RX   PubMed=18758450; DOI=10.1038/ncb1780;
RA   Sorrentino A., Thakur N., Grimsby S., Marcusson A., von Bulow V.,
RA   Schuster N., Zhang S., Heldin C.H., Landstrom M.;
RT   "The type I TGF-beta receptor engages TRAF6 to activate TAK1 in a
RT   receptor kinase-independent manner.";
RL   Nat. Cell Biol. 10:1199-1207(2008).
RN   [26]
RP   REVIEW ON PROCESSES REGULATED BY THE TGF-BETA CYTOKINES.
RX   PubMed=9759503; DOI=10.1146/annurev.biochem.67.1.753;
RA   Massague J.;
RT   "TGF-beta signal transduction.";
RL   Annu. Rev. Biochem. 67:753-791(1998).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-165, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [28]
RP   UBIQUITINATION, AND DEUBIQUITINATION BY USP15.
RX   PubMed=22344298; DOI=10.1038/nm.2619;
RA   Eichhorn P.J., Rodon L., Gonzalez-Junca A., Dirac A., Gili M.,
RA   Martinez-Saez E., Aura C., Barba I., Peg V., Prat A., Cuartas I.,
RA   Jimenez J., Garcia-Dorado D., Sahuquillo J., Bernards R., Baselga J.,
RA   Seoane J.;
RT   "USP15 stabilizes TGF-beta receptor I and promotes oncogenesis through
RT   the activation of TGF-beta signaling in glioblastoma.";
RL   Nat. Med. 18:429-435(2012).
RN   [29]
RP   3D-STRUCTURE MODELING OF 34-114.
RX   PubMed=8521960; DOI=10.1016/0014-5793(95)01239-7;
RA   Jokiranta T.S., Tissari J., Teleman O., Meri S.;
RT   "Extracellular domain of type I receptor for transforming growth
RT   factor-beta: molecular modelling using protectin (CD59) as a
RT   template.";
RL   FEBS Lett. 376:31-36(1995).
RN   [30]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 162-503 IN COMPLEX WITH
RP   FKBP1A.
RX   PubMed=10025408; DOI=10.1016/S0092-8674(00)80555-3;
RA   Huse M., Chen Y.-G., Massague J., Kuriyan J.;
RT   "Crystal structure of the cytoplasmic domain of the type I TGF beta
RT   receptor in complex with FKBP12.";
RL   Cell 96:425-436(1999).
RN   [31]
RP   X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 162-503, PHOSPHORYLATION, AND
RP   INTERACTION WITH SMAD2 AND FKBP1A.
RX   PubMed=11583628; DOI=10.1016/S1097-2765(01)00332-X;
RA   Huse M., Muir T.W., Xu L., Chen Y.-G., Kuriyan J., Massague J.;
RT   "The TGF beta receptor activation process: an inhibitor- to substrate-
RT   binding switch.";
RL   Mol. Cell 8:671-682(2001).
RN   [32]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 175-500 IN COMPLEX WITH
RP   SYNTHETIC INHIBITOR.
RX   PubMed=15177479; DOI=10.1016/j.bmcl.2004.04.007;
RA   Sawyer J.S., Beight D.W., Britt K.S., Anderson B.D., Campbell R.M.,
RA   Goodson T. Jr., Herron D.K., Li H.-Y., McMillen W.T., Mort N.,
RA   Parsons S., Smith E.C.R., Wagner J.R., Yan L., Zhang F.,
RA   Yingling J.M.;
RT   "Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-
RT   dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming
RT   growth factor-beta type I receptor kinase domain.";
RL   Bioorg. Med. Chem. Lett. 14:3581-3584(2004).
RN   [33]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 201-503 IN COMPLEX WITH
RP   SYNTHETIC INHIBITOR.
RX   PubMed=15317461; DOI=10.1021/jm0400247;
RA   Gellibert F., Woolven J., Fouchet M.-H., Mathews N., Goodland H.,
RA   Lovegrove V., Laroze A., Nguyen V.-L., Sautet S., Wang R., Janson C.,
RA   Smith W., Krysa G., Boullay V., De Gouville A.-C., Huet S.,
RA   Hartley D.;
RT   "Identification of 1,5-naphthyridine derivatives as a novel series of
RT   potent and selective TGF-beta type I receptor inhibitors.";
RL   J. Med. Chem. 47:4494-4506(2004).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (3.00 ANGSTROMS) OF 33-111 IN COMPLEX WITH
RP   TGFBR2 AND TGFB3, AND DISULFIDE BONDS.
RX   PubMed=18243111; DOI=10.1016/j.molcel.2007.11.039;
RA   Groppe J., Hinck C.S., Samavarchi-Tehrani P., Zubieta C.,
RA   Schuermann J.P., Taylor A.B., Schwarz P.M., Wrana J.L., Hinck A.P.;
RT   "Cooperative assembly of TGF-beta superfamily signaling complexes is
RT   mediated by two disparate mechanisms and distinct modes of receptor
RT   binding.";
RL   Mol. Cell 29:157-168(2008).
RN   [35]
RP   X-RAY CRYSTALLOGRAPHY (3.00 ANGSTROMS) OF 31-115 IN COMPLEX WITH
RP   TGFBR2 AND TGFB1, RECEPTOR AFFINITY FOR LIGANDS, AND DISULFIDE BONDS.
RX   PubMed=20207738; DOI=10.1074/jbc.M109.079921;
RA   Radaev S., Zou Z., Huang T., Lafer E.M., Hinck A.P., Sun P.D.;
RT   "Ternary complex of transforming growth factor-beta1 reveals isoform-
RT   specific ligand recognition and receptor recruitment in the
RT   superfamily.";
RL   J. Biol. Chem. 285:14806-14814(2010).
RN   [36]
RP   ANALYSIS OF VARIANT TGFBR1*6A ALA-24--26-ALA DEL IN CANCER RISK.
RX   PubMed=12947057; DOI=10.1200/JCO.2003.11.524;
RA   Kaklamani V.G., Hou N., Bian Y., Reich J., Offit K., Michel L.S.,
RA   Rubinstein W.S., Rademaker A., Pasche B.;
RT   "TGFBR1*6A and cancer risk: a meta-analysis of seven case-control
RT   studies.";
RL   J. Clin. Oncol. 21:3236-3243(2003).
RN   [37]
RP   ANALYSIS OF VARIANT TGFBR1*6A ALA-24--26-ALA DEL IN PROSTATE CANCER.
RX   PubMed=15385056; DOI=10.1186/1471-2156-5-28;
RA   Kaklamani V.G., Baddi L., Rosman D., Liu J., Ellis N., Oddoux C.,
RA   Ostrer H., Chen Y., Ahsan H., Offit K., Pasche B.;
RT   "No major association between TGFBR1*6A and prostate cancer.";
RL   BMC Genet. 5:28-28(2004).
RN   [38]
RP   VARIANTS LDS1 ILE-200; ARG-318; GLY-400 AND PRO-487.
RX   PubMed=15731757; DOI=10.1038/ng1511;
RA   Loeys B.L., Chen J., Neptune E.R., Judge D.P., Podowski M., Holm T.,
RA   Meyers J., Leitch C.C., Katsanis N., Sharifi N., Xu F.L., Myers L.A.,
RA   Spevak P.J., Cameron D.E., De Backer J.F., Hellemans J., Chen Y.,
RA   Davis E.C., Webb C.L., Kress W., Coucke P.J., Rifkin D.B.,
RA   De Paepe A.M., Dietz H.C.;
RT   "A syndrome of altered cardiovascular, craniofacial, neurocognitive
RT   and skeletal development caused by mutations in TGFBR1 or TGFBR2.";
RL   Nat. Genet. 37:275-281(2005).
RN   [39]
RP   ANALYSIS OF VARIANT TGFBR1*6A ALA-24--26-ALA DEL IN PROSTATE CANCER.
RX   PubMed=15505640; DOI=10.1038/sj.pcan.4500765;
RA   Suarez B.K., Pal P., Jin C.H., Kaushal R., Sun G., Jin L., Pasche B.,
RA   Deka R., Catalona W.J.;
RT   "TGFBR1(*)6A is not associated with prostate cancer in men of European
RT   ancestry.";
RL   Prostate Cancer Prostatic Dis. 8:50-53(2005).
RN   [40]
RP   VARIANT LDS1 LEU-241.
RX   PubMed=16596670; DOI=10.1002/ajmg.a.31202;
RA   Ades L.C., Sullivan K., Biggin A., Haan E.A., Brett M., Holman K.J.,
RA   Dixon J., Robertson S., Holmes A.D., Rogers J., Bennetts B.;
RT   "FBN1, TGFBR1, and the Marfan-craniosynostosis/mental retardation
RT   disorders revisited.";
RL   Am. J. Med. Genet. A 140:1047-1058(2006).
RN   [41]
RP   VARIANTS LDS1 LEU-241 AND GLN-487, AND VARIANT HIS-267.
RX   PubMed=16791849; DOI=10.1002/humu.20353;
RA   Matyas G., Arnold E., Carrel T., Baumgartner D., Boileau C.,
RA   Berger W., Steinmann B.;
RT   "Identification and in silico analyses of novel TGFBR1 and TGFBR2
RT   mutations in Marfan syndrome-related disorders.";
RL   Hum. Mutat. 27:760-769(2006).
RN   [42]
RP   VARIANTS LDS1 GLU-232; TRP-487; PRO-487 AND GLN-487.
RX   PubMed=16928994; DOI=10.1056/NEJMoa055695;
RA   Loeys B.L., Schwarze U., Holm T., Callewaert B.L., Thomas G.H.,
RA   Pannu H., De Backer J.F., Oswald G.L., Symoens S., Manouvrier S.,
RA   Roberts A.E., Faravelli F., Greco M.A., Pyeritz R.E., Milewicz D.M.,
RA   Coucke P.J., Cameron D.E., Braverman A.C., Byers P.H., De Paepe A.M.,
RA   Dietz H.C.;
RT   "Aneurysm syndromes caused by mutations in the TGF-beta receptor.";
RL   N. Engl. J. Med. 355:788-798(2006).
RN   [43]
RP   VARIANTS [LARGE SCALE ANALYSIS] ILE-153 AND CYS-291.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [44]
RP   VARIANT [LARGE SCALE ANALYSIS] VAL-139.
RX   PubMed=18987736; DOI=10.1038/nature07485;
RA   Ley T.J., Mardis E.R., Ding L., Fulton B., McLellan M.D., Chen K.,
RA   Dooling D., Dunford-Shore B.H., McGrath S., Hickenbotham M., Cook L.,
RA   Abbott R., Larson D.E., Koboldt D.C., Pohl C., Smith S., Hawkins A.,
RA   Abbott S., Locke D., Hillier L.W., Miner T., Fulton L., Magrini V.,
RA   Wylie T., Glasscock J., Conyers J., Sander N., Shi X., Osborne J.R.,
RA   Minx P., Gordon D., Chinwalla A., Zhao Y., Ries R.E., Payton J.E.,
RA   Westervelt P., Tomasson M.H., Watson M., Baty J., Ivanovich J.,
RA   Heath S., Shannon W.D., Nagarajan R., Walter M.J., Link D.C.,
RA   Graubert T.A., DiPersio J.F., Wilson R.K.;
RT   "DNA sequencing of a cytogenetically normal acute myeloid leukaemia
RT   genome.";
RL   Nature 456:66-72(2008).
RN   [45]
RP   VARIANT LDS1 GLY-351.
RX   PubMed=19883511; DOI=10.1186/1750-1172-4-24;
RA   Drera B., Ritelli M., Zoppi N., Wischmeijer A., Gnoli M., Fattori R.,
RA   Calzavara-Pinton P.G., Barlati S., Colombi M.;
RT   "Loeys-Dietz syndrome type I and type II: clinical findings and novel
RT   mutations in two Italian patients.";
RL   Orphanet J. Rare Dis. 4:24-24(2009).
RN   [46]
RP   VARIANTS LDS1 TYR-266; ILE-375 AND GLN-487.
RX   PubMed=22113417; DOI=10.1038/jhg.2011.130;
RA   Yang J.H., Ki C.S., Han H., Song B.G., Jang S.Y., Chung T.Y., Sung K.,
RA   Lee H.J., Kim D.K.;
RT   "Clinical features and genetic analysis of Korean patients with Loeys-
RT   Dietz syndrome.";
RL   J. Hum. Genet. 57:52-56(2012).
RN   [47]
RP   VARIANTS MSSE TYR-41; SER-45; ARG-52 AND LEU-83.
RX   PubMed=21358634; DOI=10.1038/ng.780;
RA   Goudie D.R., D'Alessandro M., Merriman B., Lee H., Szeverenyi I.,
RA   Avery S., O'Connor B.D., Nelson S.F., Coats S.E., Stewart A.,
RA   Christie L., Pichert G., Friedel J., Hayes I., Burrows N.,
RA   Whittaker S., Gerdes A.M., Broesby-Olsen S., Ferguson-Smith M.A.,
RA   Verma C., Lunny D.P., Reversade B., Lane E.B.;
RT   "Multiple self-healing squamous epithelioma is caused by a disease-
RT   specific spectrum of mutations in TGFBR1.";
RL   Nat. Genet. 43:365-369(2011).
CC   -!- FUNCTION: Transmembrane serine/threonine kinase forming with the
CC       TGF-beta type II serine/threonine kinase receptor, TGFBR2, the
CC       non-promiscuous receptor for the TGF-beta cytokines TGFB1, TGFB2
CC       and TGFB3. Transduces the TGFB1, TGFB2 and TGFB3 signal from the
CC       cell surface to the cytoplasm and is thus regulating a plethora of
CC       physiological and pathological processes including cell cycle
CC       arrest in epithelial and hematopoietic cells, control of
CC       mesenchymal cell proliferation and differentiation, wound healing,
CC       extracellular matrix production, immunosuppression and
CC       carcinogenesis. The formation of the receptor complex composed of
CC       2 TGFBR1 and 2 TGFBR2 molecules symmetrically bound to the
CC       cytokine dimer results in the phosphorylation and the activation
CC       of TGFBR1 by the constitutively active TGFBR2. Activated TGFBR1
CC       phosphorylates SMAD2 which dissociates from the receptor and
CC       interacts with SMAD4. The SMAD2-SMAD4 complex is subsequently
CC       translocated to the nucleus where it modulates the transcription
CC       of the TGF-beta-regulated genes. This constitutes the canonical
CC       SMAD-dependent TGF-beta signaling cascade. Also involved in non-
CC       canonical, SMAD-independent TGF-beta signaling pathways. For
CC       instance, TGFBR1 induces TRAF6 autoubiquitination which in turn
CC       results in MAP3K7 ubiquitination and activation to trigger
CC       apoptosis. Also regulates epithelial to mesenchymal transition
CC       through a SMAD-independent signaling pathway through PARD6A
CC       phosphorylation and activation. {ECO:0000269|PubMed:15761148,
CC       ECO:0000269|PubMed:16754747, ECO:0000269|PubMed:18758450,
CC       ECO:0000269|PubMed:7774578, ECO:0000269|PubMed:8752209,
CC       ECO:0000269|PubMed:8980228, ECO:0000269|PubMed:9346908}.
CC   -!- CATALYTIC ACTIVITY: ATP + [receptor-protein] = ADP + [receptor-
CC       protein] phosphate.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035; Evidence={ECO:0000250};
CC   -!- ENZYME REGULATION: Kept in an inactive conformation by FKBP1A
CC       preventing receptor activation in absence of ligand. CD109 is
CC       another inhibitor of the receptor. {ECO:0000269|PubMed:9233797}.
CC   -!- SUBUNIT: Homodimer; in the endoplasmic reticulum but also at the
CC       cell membrane. Heterohexamer; TGFB1, TGFB2 and TGFB3 homodimeric
CC       ligands assemble a functional receptor composed of two TGFBR1 and
CC       TGFBR2 heterodimers to form a ligand-receptor heterohexamer. The
CC       respective affinity of TGBRB1 and TGFBR2 for the ligands may
CC       modulate the kinetics of assembly of the receptor and may explain
CC       the different biological activities of TGFB1, TGFB2 and TGFB3.
CC       Interacts with CD109; inhibits TGF-beta receptor activation in
CC       keratinocytes. Interacts with RBPMS. Interacts (unphosphorylated)
CC       with FKBP1A; prevents TGFBR1 phosphorylation by TGFBR2 and
CC       stabilizes it in the inactive conformation. Interacts with SMAD2,
CC       SMAD3 and ZFYVE9; ZFYVE9 recruits SMAD2 and SMAD3 to the TGF-beta
CC       receptor. Interacts with TRAF6 and MAP3K7; induces MAP3K7
CC       activation by TRAF6. Interacts with PARD6A; involved in TGF-beta
CC       induced epithelial to mesenchymal transition. Interacts with
CC       SMAD7, NEDD4L, SMURF1 and SMURF2; SMAD7 recruits NEDD4L, SMURF1
CC       and SMURF2 to the TGF-beta receptor. Interacts with USP15 and
CC       VPS39. {ECO:0000269|PubMed:10025408, ECO:0000269|PubMed:11163210,
CC       ECO:0000269|PubMed:11278251, ECO:0000269|PubMed:11583628,
CC       ECO:0000269|PubMed:12941698, ECO:0000269|PubMed:15177479,
CC       ECO:0000269|PubMed:15317461, ECO:0000269|PubMed:15496141,
CC       ECO:0000269|PubMed:15761148, ECO:0000269|PubMed:16754747,
CC       ECO:0000269|PubMed:17099224, ECO:0000269|PubMed:18243111,
CC       ECO:0000269|PubMed:18758450, ECO:0000269|PubMed:20207738,
CC       ECO:0000269|PubMed:7774578, ECO:0000269|PubMed:8980228,
CC       ECO:0000269|PubMed:9233797, ECO:0000269|PubMed:9311995,
CC       ECO:0000269|PubMed:9346908, ECO:0000269|PubMed:9865696}.
CC   -!- INTERACTION:
CC       Q99IB8:- (xeno); NbExp=5; IntAct=EBI-1027557, EBI-6858501;
CC       P62942:FKBP1A; NbExp=2; IntAct=EBI-1027557, EBI-1027571;
CC       P01137:TGFB1; NbExp=2; IntAct=EBI-1027557, EBI-779636;
CC       P63104:YWHAZ; NbExp=4; IntAct=EBI-1027557, EBI-347088;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:9472030};
CC       Single-pass type I membrane protein {ECO:0000269|PubMed:9472030}.
CC       Cell junction, tight junction {ECO:0000269|PubMed:15761148}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P36897-1; Sequence=Displayed;
CC       Name=2; Synonyms=B;
CC         IsoId=P36897-2; Sequence=VSP_041326;
CC       Name=3;
CC         IsoId=P36897-3; Sequence=VSP_041327;
CC   -!- TISSUE SPECIFICITY: Found in all tissues examined, most abundant
CC       in placenta and least abundant in brain and heart.
CC   -!- PTM: Phosphorylated at basal levels in the absence of ligand.
CC       Activated upon phosphorylation by TGFBR2, mainly in the GS domain.
CC       Phosphorylation in the GS domain abrogates FKBP1A-binding.
CC       {ECO:0000269|PubMed:11583628, ECO:0000269|PubMed:7774578}.
CC   -!- PTM: N-Glycosylated. {ECO:0000269|PubMed:9661882}.
CC   -!- PTM: Ubiquitinated; undergoes ubiquitination catalyzed by several
CC       E3 ubiquitin ligases including SMURF1, SMURF2 and NEDD4L2. Results
CC       in the proteasomal and/or lysosomal degradation of the receptor
CC       thereby negatively regulating its activity. Deubiquitinated by
CC       USP15, leading to stabilization of the protein and enhanced TGF-
CC       beta signal. {ECO:0000269|PubMed:15496141,
CC       ECO:0000269|PubMed:22344298}.
CC   -!- DISEASE: Loeys-Dietz syndrome 1 (LDS1) [MIM:609192]: An aortic
CC       aneurysm syndrome with widespread systemic involvement,
CC       characterized by arterial tortuosity and aneurysms, hypertelorism,
CC       and bifid uvula or cleft palate. Physical findings include
CC       prominent joint laxity, easy bruising, wide and atrophic scars,
CC       velvety and translucent skin with easily visible veins,
CC       spontaneous rupture of the spleen or bowel, and catastrophic
CC       complications of pregnancy, including rupture of the gravid uterus
CC       and the arteries, either during pregnancy or in the immediate
CC       postpartum period. Some patients have craniosynostosis, exotropy,
CC       micrognathia and retrognathia, structural brain abnormalities, and
CC       intellectual deficit. {ECO:0000269|PubMed:15731757,
CC       ECO:0000269|PubMed:16596670, ECO:0000269|PubMed:16791849,
CC       ECO:0000269|PubMed:16928994, ECO:0000269|PubMed:19883511,
CC       ECO:0000269|PubMed:22113417}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry. TGFBR1
CC       mutation Gln-487 has been reported to be associated with thoracic
CC       aortic aneurysms and dissection (TAAD) (PubMed:16791849). This
CC       phenotype, also known as thoracic aortic aneurysms type 5 (AAT5),
CC       is distinguised from LDS1 by having aneurysms restricted to
CC       thoracic aorta. It is unclear, however, if this condition is
CC       fulfilled in individuals bearing Gln-487 mutation, that is why
CC       they are considered as LDS1 by the OMIM resource.
CC       {ECO:0000269|PubMed:16791849}.
CC   -!- DISEASE: Multiple self-healing squamous epithelioma (MSSE)
CC       [MIM:132800]: A disorder characterized by multiple skin tumors
CC       that undergo spontaneous regression. Tumors appear most often on
CC       sun-exposed regions, are locally invasive, and undergo spontaneous
CC       resolution over a period of months leaving pitted scars.
CC       {ECO:0000269|PubMed:21358634}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr
CC       protein kinase family. TGFB receptor subfamily. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 GS domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00585}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/tgfbr1/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L11695; AAA16073.1; -; mRNA.
DR   EMBL; AF054598; AAC08998.1; -; Genomic_DNA.
DR   EMBL; AF054590; AAC08998.1; JOINED; Genomic_DNA.
DR   EMBL; AF054591; AAC08998.1; JOINED; Genomic_DNA.
DR   EMBL; AF054592; AAC08998.1; JOINED; Genomic_DNA.
DR   EMBL; AF054593; AAC08998.1; JOINED; Genomic_DNA.
DR   EMBL; AF054594; AAC08998.1; JOINED; Genomic_DNA.
DR   EMBL; AF054595; AAC08998.1; JOINED; Genomic_DNA.
DR   EMBL; AF054596; AAC08998.1; JOINED; Genomic_DNA.
DR   EMBL; AF054597; AAC08998.1; JOINED; Genomic_DNA.
DR   EMBL; AF035670; AAD02042.1; -; Genomic_DNA.
DR   EMBL; AF035662; AAD02042.1; JOINED; Genomic_DNA.
DR   EMBL; AF035663; AAD02042.1; JOINED; Genomic_DNA.
DR   EMBL; AF035664; AAD02042.1; JOINED; Genomic_DNA.
DR   EMBL; AF035665; AAD02042.1; JOINED; Genomic_DNA.
DR   EMBL; AF035666; AAD02042.1; JOINED; Genomic_DNA.
DR   EMBL; AF035667; AAD02042.1; JOINED; Genomic_DNA.
DR   EMBL; AF035668; AAD02042.1; JOINED; Genomic_DNA.
DR   EMBL; AF035669; AAD02042.1; JOINED; Genomic_DNA.
DR   EMBL; AY497473; AAR32097.1; -; Genomic_DNA.
DR   EMBL; AL162427; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC071181; AAH71181.1; -; mRNA.
DR   EMBL; AJ619019; CAF02096.2; -; mRNA.
DR   EMBL; AJ619020; CAF02097.1; -; mRNA.
DR   CCDS; CCDS47998.1; -. [P36897-3]
DR   CCDS; CCDS6738.1; -. [P36897-1]
DR   CCDS; CCDS78413.1; -. [P36897-2]
DR   PIR; A49432; A49432.
DR   RefSeq; NP_001124388.1; NM_001130916.2. [P36897-3]
DR   RefSeq; NP_001293139.1; NM_001306210.1. [P36897-2]
DR   RefSeq; NP_004603.1; NM_004612.3. [P36897-1]
DR   UniGene; Hs.494622; -.
DR   PDB; 1B6C; X-ray; 2.60 A; B/D/F/H=162-503.
DR   PDB; 1IAS; X-ray; 2.90 A; A/B/C/D/E=162-503.
DR   PDB; 1PY5; X-ray; 2.30 A; A=175-500.
DR   PDB; 1RW8; X-ray; 2.40 A; A=200-500.
DR   PDB; 1TBI; Model; -; A=34-114.
DR   PDB; 1VJY; X-ray; 2.00 A; A=201-503.
DR   PDB; 2L5S; NMR; -; A=31-115.
DR   PDB; 2PJY; X-ray; 3.00 A; C=33-111.
DR   PDB; 2WOT; X-ray; 1.85 A; A=200-503.
DR   PDB; 2WOU; X-ray; 2.30 A; A=200-503.
DR   PDB; 2X7O; X-ray; 3.70 A; A/B/C/D/E=162-503.
DR   PDB; 3FAA; X-ray; 3.35 A; A/B/C/D/E=162-503.
DR   PDB; 3GXL; X-ray; 1.80 A; A=201-503.
DR   PDB; 3HMM; X-ray; 1.70 A; A=201-503.
DR   PDB; 3KCF; X-ray; 2.80 A; A/B/C/D/E=162-503.
DR   PDB; 3KFD; X-ray; 3.00 A; I/J/K/L=31-115.
DR   PDB; 3TZM; X-ray; 1.70 A; A=200-503.
DR   PDB; 4X0M; X-ray; 1.68 A; A=200-503.
DR   PDB; 4X2F; X-ray; 1.49 A; A=200-503.
DR   PDB; 4X2G; X-ray; 1.51 A; A=200-503.
DR   PDB; 4X2J; X-ray; 1.69 A; A=200-503.
DR   PDB; 4X2K; X-ray; 1.69 A; A=200-503.
DR   PDB; 4X2N; X-ray; 1.80 A; A=200-503.
DR   PDBsum; 1B6C; -.
DR   PDBsum; 1IAS; -.
DR   PDBsum; 1PY5; -.
DR   PDBsum; 1RW8; -.
DR   PDBsum; 1TBI; -.
DR   PDBsum; 1VJY; -.
DR   PDBsum; 2L5S; -.
DR   PDBsum; 2PJY; -.
DR   PDBsum; 2WOT; -.
DR   PDBsum; 2WOU; -.
DR   PDBsum; 2X7O; -.
DR   PDBsum; 3FAA; -.
DR   PDBsum; 3GXL; -.
DR   PDBsum; 3HMM; -.
DR   PDBsum; 3KCF; -.
DR   PDBsum; 3KFD; -.
DR   PDBsum; 3TZM; -.
DR   PDBsum; 4X0M; -.
DR   PDBsum; 4X2F; -.
DR   PDBsum; 4X2G; -.
DR   PDBsum; 4X2J; -.
DR   PDBsum; 4X2K; -.
DR   PDBsum; 4X2N; -.
DR   ProteinModelPortal; P36897; -.
DR   SMR; P36897; 31-115, 175-500.
DR   BioGrid; 112904; 174.
DR   DIP; DIP-5935N; -.
DR   IntAct; P36897; 14.
DR   MINT; MINT-152959; -.
DR   STRING; 9606.ENSP00000364133; -.
DR   BindingDB; P36897; -.
DR   ChEMBL; CHEMBL4439; -.
DR   GuidetoPHARMACOLOGY; 1788; -.
DR   iPTMnet; P36897; -.
DR   PhosphoSite; P36897; -.
DR   BioMuta; TGFBR1; -.
DR   DMDM; 547777; -.
DR   MaxQB; P36897; -.
DR   PaxDb; P36897; -.
DR   PRIDE; P36897; -.
DR   DNASU; 7046; -.
DR   Ensembl; ENST00000374990; ENSP00000364129; ENSG00000106799. [P36897-3]
DR   Ensembl; ENST00000374994; ENSP00000364133; ENSG00000106799. [P36897-1]
DR   Ensembl; ENST00000552516; ENSP00000447297; ENSG00000106799. [P36897-2]
DR   GeneID; 7046; -.
DR   KEGG; hsa:7046; -.
DR   UCSC; uc004azc.3; human. [P36897-1]
DR   UCSC; uc004azd.3; human. [P36897-3]
DR   UCSC; uc004aze.3; human. [P36897-2]
DR   CTD; 7046; -.
DR   GeneCards; TGFBR1; -.
DR   GeneReviews; TGFBR1; -.
DR   HGNC; HGNC:11772; TGFBR1.
DR   HPA; CAB002441; -.
DR   HPA; CAB031481; -.
DR   HPA; HPA056473; -.
DR   MalaCards; TGFBR1; -.
DR   MIM; 132800; phenotype.
DR   MIM; 190181; gene.
DR   MIM; 609192; phenotype.
DR   neXtProt; NX_P36897; -.
DR   Orphanet; 91387; Familial thoracic aortic aneurysm and aortic dissection.
DR   Orphanet; 60030; Loeys-Dietz syndrome.
DR   Orphanet; 65748; Multiple keratoacanthoma, Ferguson-Smith type.
DR   PharmGKB; PA36485; -.
DR   eggNOG; KOG2052; Eukaryota.
DR   eggNOG; ENOG410XQT0; LUCA.
DR   GeneTree; ENSGT00760000118876; -.
DR   HOGENOM; HOG000230587; -.
DR   HOVERGEN; HBG054502; -.
DR   InParanoid; P36897; -.
DR   KO; K04674; -.
DR   OMA; GATALQC; -.
DR   PhylomeDB; P36897; -.
DR   TreeFam; TF314724; -.
DR   BRENDA; 2.7.10.2; 2681.
DR   BRENDA; 2.7.11.30; 2681.
DR   Reactome; R-HSA-2173788; Downregulation of TGF-beta receptor signaling.
DR   Reactome; R-HSA-2173789; TGF-beta receptor signaling activates SMADs.
DR   Reactome; R-HSA-2173791; TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition).
DR   Reactome; R-HSA-3304356; SMAD2/3 Phosphorylation Motif Mutants in Cancer.
DR   Reactome; R-HSA-3315487; SMAD2/3 MH2 Domain Mutants in Cancer.
DR   Reactome; R-HSA-3645790; TGFBR2 Kinase Domain Mutants in Cancer.
DR   Reactome; R-HSA-3656532; TGFBR1 KD Mutants in Cancer.
DR   Reactome; R-HSA-3656535; TGFBR1 LBD Mutants in Cancer.
DR   SignaLink; P36897; -.
DR   ChiTaRS; TGFBR1; human.
DR   EvolutionaryTrace; P36897; -.
DR   GeneWiki; TGF_beta_receptor_1; -.
DR   GenomeRNAi; 7046; -.
DR   NextBio; 27533; -.
DR   PRO; PR:P36897; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   Bgee; P36897; -.
DR   CleanEx; HS_TGFBR1; -.
DR   ExpressionAtlas; P36897; baseline and differential.
DR   Genevisible; P36897; HS.
DR   GO; GO:0005923; C:bicellular tight junction; IDA:UniProtKB.
DR   GO; GO:0005623; C:cell; ISS:AgBase.
DR   GO; GO:0005768; C:endosome; IEA:Ensembl.
DR   GO; GO:0005622; C:intracellular; ISS:GOC.
DR   GO; GO:0016020; C:membrane; ISS:AgBase.
DR   GO; GO:0005886; C:plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0043235; C:receptor complex; IDA:BHF-UCL.
DR   GO; GO:0070022; C:transforming growth factor beta receptor homodimeric complex; IC:BHF-UCL.
DR   GO; GO:0005524; F:ATP binding; IDA:HGNC.
DR   GO; GO:0070411; F:I-SMAD binding; IPI:BHF-UCL.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004672; F:protein kinase activity; IDA:BHF-UCL.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:HGNC.
DR   GO; GO:0005057; F:receptor signaling protein activity; ISS:AgBase.
DR   GO; GO:0004702; F:receptor signaling protein serine/threonine kinase activity; IEA:Ensembl.
DR   GO; GO:0046332; F:SMAD binding; IDA:HGNC.
DR   GO; GO:0050431; F:transforming growth factor beta binding; IDA:BHF-UCL.
DR   GO; GO:0005025; F:transforming growth factor beta receptor activity, type I; IDA:BHF-UCL.
DR   GO; GO:0005024; F:transforming growth factor beta-activated receptor activity; IDA:BHF-UCL.
DR   GO; GO:0005114; F:type II transforming growth factor beta receptor binding; IDA:BHF-UCL.
DR   GO; GO:0000186; P:activation of MAPKK activity; IDA:BHF-UCL.
DR   GO; GO:0032924; P:activin receptor signaling pathway; ISS:AgBase.
DR   GO; GO:0001525; P:angiogenesis; IEA:Ensembl.
DR   GO; GO:0009952; P:anterior/posterior pattern specification; ISS:BHF-UCL.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0048844; P:artery morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0001824; P:blastocyst development; IEA:Ensembl.
DR   GO; GO:0060317; P:cardiac epithelial to mesenchymal transition; ISS:AgBase.
DR   GO; GO:0007050; P:cell cycle arrest; TAS:UniProtKB.
DR   GO; GO:0048870; P:cell motility; IMP:BHF-UCL.
DR   GO; GO:0071560; P:cellular response to transforming growth factor beta stimulus; IDA:BHF-UCL.
DR   GO; GO:0030199; P:collagen fibril organization; ISS:BHF-UCL.
DR   GO; GO:0048701; P:embryonic cranial skeleton morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0042118; P:endothelial cell activation; ISS:AgBase.
DR   GO; GO:0043542; P:endothelial cell migration; IEA:Ensembl.
DR   GO; GO:0001837; P:epithelial to mesenchymal transition; IDA:UniProtKB.
DR   GO; GO:0043062; P:extracellular structure organization; TAS:UniProtKB.
DR   GO; GO:0008354; P:germ cell migration; ISS:BHF-UCL.
DR   GO; GO:0007507; P:heart development; ISS:AgBase.
DR   GO; GO:0001701; P:in utero embryonic development; ISS:BHF-UCL.
DR   GO; GO:0035556; P:intracellular signal transduction; ISS:AgBase.
DR   GO; GO:0001822; P:kidney development; ISS:BHF-UCL.
DR   GO; GO:0002088; P:lens development in camera-type eye; IEA:Ensembl.
DR   GO; GO:0008584; P:male gonad development; IEA:Ensembl.
DR   GO; GO:0048762; P:mesenchymal cell differentiation; ISS:AgBase.
DR   GO; GO:0032331; P:negative regulation of chondrocyte differentiation; ISS:BHF-UCL.
DR   GO; GO:0001937; P:negative regulation of endothelial cell proliferation; IEA:Ensembl.
DR   GO; GO:2001237; P:negative regulation of extrinsic apoptotic signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0030512; P:negative regulation of transforming growth factor beta receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0048663; P:neuron fate commitment; ISS:BHF-UCL.
DR   GO; GO:0060021; P:palate development; ISS:BHF-UCL.
DR   GO; GO:0060017; P:parathyroid gland development; ISS:BHF-UCL.
DR   GO; GO:0060389; P:pathway-restricted SMAD protein phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0018107; P:peptidyl-threonine phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0060037; P:pharyngeal system development; ISS:BHF-UCL.
DR   GO; GO:2001235; P:positive regulation of apoptotic signaling pathway; IDA:UniProtKB.
DR   GO; GO:0030307; P:positive regulation of cell growth; IDA:BHF-UCL.
DR   GO; GO:0030335; P:positive regulation of cell migration; IDA:BHF-UCL.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IMP:HGNC.
DR   GO; GO:0051272; P:positive regulation of cellular component movement; IMP:BHF-UCL.
DR   GO; GO:0001938; P:positive regulation of endothelial cell proliferation; ISS:AgBase.
DR   GO; GO:0051491; P:positive regulation of filopodium assembly; IEA:Ensembl.
DR   GO; GO:0010628; P:positive regulation of gene expression; ISS:AgBase.
DR   GO; GO:0010862; P:positive regulation of pathway-restricted SMAD protein phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0051897; P:positive regulation of protein kinase B signaling; IDA:BHF-UCL.
DR   GO; GO:0060391; P:positive regulation of SMAD protein import into nucleus; IDA:BHF-UCL.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:BHF-UCL.
DR   GO; GO:0009791; P:post-embryonic development; IEA:Ensembl.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0010717; P:regulation of epithelial to mesenchymal transition; ISS:AgBase.
DR   GO; GO:0010468; P:regulation of gene expression; ISS:AgBase.
DR   GO; GO:0043393; P:regulation of protein binding; IEA:Ensembl.
DR   GO; GO:0031396; P:regulation of protein ubiquitination; IDA:UniProtKB.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IDA:HGNC.
DR   GO; GO:0070723; P:response to cholesterol; IDA:BHF-UCL.
DR   GO; GO:0007165; P:signal transduction; IDA:HGNC.
DR   GO; GO:0001501; P:skeletal system development; ISS:BHF-UCL.
DR   GO; GO:0048705; P:skeletal system morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0048538; P:thymus development; ISS:BHF-UCL.
DR   GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0042060; P:wound healing; TAS:UniProtKB.
DR   InterPro; IPR000472; Activin_recp.
DR   InterPro; IPR003605; GS_dom.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   InterPro; IPR000333; TGFB_receptor.
DR   PANTHER; PTHR23255; PTHR23255; 1.
DR   Pfam; PF01064; Activin_recp; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF08515; TGF_beta_GS; 1.
DR   SMART; SM00467; GS; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS51256; GS; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Aortic aneurysm; Apoptosis;
KW   ATP-binding; Cell junction; Cell membrane; Complete proteome;
KW   Craniosynostosis; Differentiation; Direct protein sequencing;
KW   Disease mutation; Disulfide bond; Glycoprotein; Growth regulation;
KW   Isopeptide bond; Kinase; Magnesium; Manganese; Membrane;
KW   Metal-binding; Nucleotide-binding; Phosphoprotein; Polymorphism;
KW   Receptor; Reference proteome; Serine/threonine-protein kinase; Signal;
KW   Tight junction; Transferase; Transmembrane; Transmembrane helix;
KW   Ubl conjugation.
FT   SIGNAL        1     33       {ECO:0000269|PubMed:9661882}.
FT   CHAIN        34    503       TGF-beta receptor type-1.
FT                                /FTId=PRO_0000024423.
FT   TOPO_DOM     34    126       Extracellular. {ECO:0000255}.
FT   TRANSMEM    127    147       Helical. {ECO:0000255}.
FT   TOPO_DOM    148    503       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      175    204       GS. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00585}.
FT   DOMAIN      205    495       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     211    219       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOTIF       193    194       FKBP1A-binding.
FT   ACT_SITE    333    333       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING     232    232       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES     165    165       Phosphoserine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES     185    185       Phosphothreonine; by TGFBR2.
FT                                {ECO:0000269|PubMed:7774578}.
FT   MOD_RES     186    186       Phosphothreonine; by TGFBR2.
FT                                {ECO:0000269|PubMed:7774578}.
FT   MOD_RES     187    187       Phosphoserine; by TGFBR2.
FT                                {ECO:0000269|PubMed:7774578}.
FT   MOD_RES     189    189       Phosphoserine; by TGFBR2.
FT                                {ECO:0000269|PubMed:7774578}.
FT   MOD_RES     191    191       Phosphoserine; by TGFBR2.
FT                                {ECO:0000269|PubMed:7774578}.
FT   CARBOHYD     45     45       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     36     54       {ECO:0000269|PubMed:18243111,
FT                                ECO:0000269|PubMed:20207738}.
FT   DISULFID     38     41       {ECO:0000269|PubMed:18243111,
FT                                ECO:0000269|PubMed:20207738}.
FT   DISULFID     48     71       {ECO:0000269|PubMed:18243111,
FT                                ECO:0000269|PubMed:20207738}.
FT   DISULFID     86    100       {ECO:0000269|PubMed:18243111,
FT                                ECO:0000269|PubMed:20207738}.
FT   DISULFID    101    106       {ECO:0000269|PubMed:18243111,
FT                                ECO:0000269|PubMed:20207738}.
FT   CROSSLNK    391    391       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO).
FT                                {ECO:0000250}.
FT   VAR_SEQ     114    114       T -> TGPFS (in isoform 2).
FT                                {ECO:0000303|PubMed:17845732}.
FT                                /FTId=VSP_041326.
FT   VAR_SEQ     115    191       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_041327.
FT   VARIANT      24     26       Missing (in allele TGFBR1*6A; could be a
FT                                tumor susceptibility allele).
FT                                /FTId=VAR_022342.
FT   VARIANT      26     26       A -> AA (in allele TGFBR1*10A; rare
FT                                polymorphism).
FT                                {ECO:0000269|PubMed:9661882}.
FT                                /FTId=VAR_022343.
FT   VARIANT      41     41       C -> Y (in MSSE; hypomorphic mutation).
FT                                {ECO:0000269|PubMed:21358634}.
FT                                /FTId=VAR_065826.
FT   VARIANT      45     45       N -> S (in MSSE; hypomorphic mutation).
FT                                {ECO:0000269|PubMed:21358634}.
FT                                /FTId=VAR_065827.
FT   VARIANT      52     52       G -> R (in MSSE; hypomorphic mutation).
FT                                {ECO:0000269|PubMed:21358634}.
FT                                /FTId=VAR_065828.
FT   VARIANT      83     83       P -> L (in MSSE; hypomorphic mutation).
FT                                {ECO:0000269|PubMed:21358634}.
FT                                /FTId=VAR_065829.
FT   VARIANT     139    139       I -> V. {ECO:0000269|PubMed:18987736}.
FT                                /FTId=VAR_054160.
FT   VARIANT     153    153       V -> I (in dbSNP:rs56014374).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041412.
FT   VARIANT     200    200       T -> I (in LDS1).
FT                                {ECO:0000269|PubMed:15731757}.
FT                                /FTId=VAR_022344.
FT   VARIANT     232    232       K -> E (in LDS1).
FT                                {ECO:0000269|PubMed:16928994}.
FT                                /FTId=VAR_029481.
FT   VARIANT     241    241       S -> L (in LDS1).
FT                                {ECO:0000269|PubMed:16596670,
FT                                ECO:0000269|PubMed:16791849}.
FT                                /FTId=VAR_029482.
FT   VARIANT     266    266       D -> Y (in LDS1).
FT                                {ECO:0000269|PubMed:22113417}.
FT                                /FTId=VAR_066720.
FT   VARIANT     267    267       N -> H (in a patient with Marfan
FT                                syndrome). {ECO:0000269|PubMed:16791849}.
FT                                /FTId=VAR_029483.
FT   VARIANT     291    291       Y -> C (in dbSNP:rs35974499).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041413.
FT   VARIANT     318    318       M -> R (in LDS1).
FT                                {ECO:0000269|PubMed:15731757}.
FT                                /FTId=VAR_022345.
FT   VARIANT     351    351       D -> G (in LDS1).
FT                                {ECO:0000269|PubMed:19883511}.
FT                                /FTId=VAR_066721.
FT   VARIANT     375    375       T -> I (in LDS1).
FT                                {ECO:0000269|PubMed:22113417}.
FT                                /FTId=VAR_066722.
FT   VARIANT     400    400       D -> G (in LDS1).
FT                                {ECO:0000269|PubMed:15731757}.
FT                                /FTId=VAR_022346.
FT   VARIANT     487    487       R -> P (in LDS1).
FT                                {ECO:0000269|PubMed:15731757,
FT                                ECO:0000269|PubMed:16928994}.
FT                                /FTId=VAR_022347.
FT   VARIANT     487    487       R -> Q (in LDS1).
FT                                {ECO:0000269|PubMed:16791849,
FT                                ECO:0000269|PubMed:16928994,
FT                                ECO:0000269|PubMed:22113417}.
FT                                /FTId=VAR_029484.
FT   VARIANT     487    487       R -> W (in LDS1).
FT                                {ECO:0000269|PubMed:16928994}.
FT                                /FTId=VAR_029485.
FT   MUTAGEN     185    186       TT->VV: Loss of phosphorylation on
FT                                threonine residues. Loss of threonine
FT                                phosphorylation, reduced phosphorylation
FT                                on serine residues and loss of response
FT                                to TGF-beta; when associated with A-187;
FT                                A-189 and A-191.
FT                                {ECO:0000269|PubMed:7774578}.
FT   MUTAGEN     187    187       S->A: Loss of threonine phosphorylation,
FT                                reduced phosphorylation on serine
FT                                residues and loss of response to TGF-
FT                                beta; when associated with 185-VV-186; A-
FT                                189 and A-191.
FT                                {ECO:0000269|PubMed:7774578}.
FT   MUTAGEN     189    189       S->A: Loss of threonine phosphorylation,
FT                                reduced phosphorylation on serine
FT                                residues and loss of response to TGF-
FT                                beta; when associated with 185-VV-186; A-
FT                                187 and A-191.
FT                                {ECO:0000269|PubMed:7774578}.
FT   MUTAGEN     191    191       S->A: Loss of threonine phosphorylation,
FT                                reduced phosphorylation on serine
FT                                residues and loss of response to TGF-
FT                                beta; when associated with 185-VV-186; A-
FT                                187 and A-189.
FT                                {ECO:0000269|PubMed:7774578}.
FT   MUTAGEN     193    193       L->G: Loss of interaction with FKBP1A.
FT                                {ECO:0000269|PubMed:9233797}.
FT   MUTAGEN     194    194       P->K: Loss of interaction with FKBP1A.
FT                                {ECO:0000269|PubMed:9233797}.
FT   MUTAGEN     200    200       T->D: Loss of response to TGF-beta.
FT                                {ECO:0000269|PubMed:7774578}.
FT   MUTAGEN     200    200       T->V: Loss of phosphorylation. Loss of
FT                                response to TGF-beta.
FT                                {ECO:0000269|PubMed:7774578}.
FT   MUTAGEN     204    204       T->D: Constitutive activation.
FT                                {ECO:0000269|PubMed:7774578}.
FT   MUTAGEN     204    204       T->V: Reduced phosphorylation. Reduced
FT                                response to TGF-beta.
FT                                {ECO:0000269|PubMed:7774578}.
FT   STRAND       35     37       {ECO:0000244|PDB:3KFD}.
FT   TURN         42     46       {ECO:0000244|PDB:3KFD}.
FT   STRAND       51     57       {ECO:0000244|PDB:3KFD}.
FT   STRAND       61     63       {ECO:0000244|PDB:2PJY}.
FT   STRAND       69     72       {ECO:0000244|PDB:3KFD}.
FT   TURN         74     76       {ECO:0000244|PDB:3KFD}.
FT   STRAND       77     82       {ECO:0000244|PDB:2PJY}.
FT   TURN         84     86       {ECO:0000244|PDB:3KFD}.
FT   HELIX        89     92       {ECO:0000244|PDB:2PJY}.
FT   STRAND       94    101       {ECO:0000244|PDB:2PJY}.
FT   STRAND      102    105       {ECO:0000244|PDB:3KFD}.
FT   HELIX       107    109       {ECO:0000244|PDB:2L5S}.
FT   HELIX       177    183       {ECO:0000244|PDB:1B6C}.
FT   STRAND      187    190       {ECO:0000244|PDB:3KCF}.
FT   STRAND      191    193       {ECO:0000244|PDB:1B6C}.
FT   HELIX       202    204       {ECO:0000244|PDB:4X2F}.
FT   STRAND      205    213       {ECO:0000244|PDB:4X2F}.
FT   STRAND      215    217       {ECO:0000244|PDB:1PY5}.
FT   STRAND      218    224       {ECO:0000244|PDB:4X2F}.
FT   STRAND      227    235       {ECO:0000244|PDB:4X2F}.
FT   HELIX       236    238       {ECO:0000244|PDB:4X2F}.
FT   HELIX       239    249       {ECO:0000244|PDB:4X2F}.
FT   STRAND      251    253       {ECO:0000244|PDB:3KCF}.
FT   STRAND      262    269       {ECO:0000244|PDB:4X2F}.
FT   STRAND      271    273       {ECO:0000244|PDB:1PY5}.
FT   STRAND      274    281       {ECO:0000244|PDB:4X2F}.
FT   HELIX       288    294       {ECO:0000244|PDB:4X2F}.
FT   HELIX       299    317       {ECO:0000244|PDB:4X2F}.
FT   STRAND      322    324       {ECO:0000244|PDB:2WOU}.
FT   STRAND      328    330       {ECO:0000244|PDB:3GXL}.
FT   HELIX       336    338       {ECO:0000244|PDB:4X2F}.
FT   STRAND      339    341       {ECO:0000244|PDB:4X2F}.
FT   STRAND      347    349       {ECO:0000244|PDB:4X2F}.
FT   HELIX       352    354       {ECO:0000244|PDB:4X2F}.
FT   STRAND      356    359       {ECO:0000244|PDB:4X2F}.
FT   TURN        360    363       {ECO:0000244|PDB:4X2F}.
FT   STRAND      364    366       {ECO:0000244|PDB:3HMM}.
FT   HELIX       376    378       {ECO:0000244|PDB:4X2F}.
FT   HELIX       381    384       {ECO:0000244|PDB:4X2F}.
FT   HELIX       393    413       {ECO:0000244|PDB:4X2F}.
FT   STRAND      417    419       {ECO:0000244|PDB:3KCF}.
FT   TURN        427    431       {ECO:0000244|PDB:4X2F}.
FT   HELIX       438    445       {ECO:0000244|PDB:4X2F}.
FT   HELIX       456    460       {ECO:0000244|PDB:4X2F}.
FT   HELIX       462    474       {ECO:0000244|PDB:4X2F}.
FT   HELIX       479    481       {ECO:0000244|PDB:4X2F}.
FT   HELIX       485    499       {ECO:0000244|PDB:4X2F}.
SQ   SEQUENCE   503 AA;  55960 MW;  179F11404725DDCB CRC64;
     MEAAVAAPRP RLLLLVLAAA AAAAAALLPG ATALQCFCHL CTKDNFTCVT DGLCFVSVTE
     TTDKVIHNSM CIAEIDLIPR DRPFVCAPSS KTGSVTTTYC CNQDHCNKIE LPTTVKSSPG
     LGPVELAAVI AGPVCFVCIS LMLMVYICHN RTVIHHRVPN EEDPSLDRPF ISEGTTLKDL
     IYDMTTSGSG SGLPLLVQRT IARTIVLQES IGKGRFGEVW RGKWRGEEVA VKIFSSREER
     SWFREAEIYQ TVMLRHENIL GFIAADNKDN GTWTQLWLVS DYHEHGSLFD YLNRYTVTVE
     GMIKLALSTA SGLAHLHMEI VGTQGKPAIA HRDLKSKNIL VKKNGTCCIA DLGLAVRHDS
     ATDTIDIAPN HRVGTKRYMA PEVLDDSINM KHFESFKRAD IYAMGLVFWE IARRCSIGGI
     HEDYQLPYYD LVPSDPSVEE MRKVVCEQKL RPNIPNRWQS CEALRVMAKI MRECWYANGA
     ARLTALRIKK TLSQLSQQEG IKM
//
ID   LRP6_MOUSE              Reviewed;        1613 AA.
AC   O88572;
DT   10-MAY-2004, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1998, sequence version 1.
DT   17-FEB-2016, entry version 133.
DE   RecName: Full=Low-density lipoprotein receptor-related protein 6;
DE            Short=LRP-6;
DE   Flags: Precursor;
GN   Name=Lrp6;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=BALB/cJ; TISSUE=Liver;
RX   PubMed=9704021; DOI=10.1006/bbrc.1998.9061;
RA   Brown S.D., Twells R.C., Hey P.J., Cox R.D., Levy E.R., Soderman A.R.,
RA   Metzker M.L., Caskey C.T., Todd J.A., Hess J.F.;
RT   "Isolation and characterization of LRP6, a novel member of the low
RT   density lipoprotein receptor gene family.";
RL   Biochem. Biophys. Res. Commun. 248:879-888(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=C57BL/6J; TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   INTERACTION WITH MESD, SUBUNIT, AND SUBCELLULAR LOCATION.
RX   PubMed=12581525; DOI=10.1016/S0092-8674(03)00045-X;
RA   Hsieh J.-C., Lee L., Zhang L., Wefer S., Brown K., DeRossi C.,
RA   Wines M.E., Rosenquist T., Holdener B.C.;
RT   "Mesd encodes an LRP5/6 chaperone essential for specification of mouse
RT   embryonic polarity.";
RL   Cell 112:355-367(2003).
RN   [4]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=15142971; DOI=10.1242/dev.01137;
RA   Kelly O.G., Pinson K.I., Skarnes W.C.;
RT   "The Wnt co-receptors Lrp5 and Lrp6 are essential for gastrulation in
RT   mice.";
RL   Development 131:2803-2815(2004).
RN   [5]
RP   INTERACTION WITH RSPO1 AND RSPO3.
RX   PubMed=16543246; DOI=10.1074/jbc.M508324200;
RA   Nam J.-S., Turcotte T.J., Smith P.F., Choi S., Yoon J.K.;
RT   "Mouse cristin/R-spondin family proteins are novel ligands for the
RT   Frizzled 8 and LRP6 receptors and activate beta-catenin-dependent gene
RT   expression.";
RL   J. Biol. Chem. 281:13247-13257(2006).
RN   [6]
RP   INTERACTION WITH GRB10.
RX   PubMed=17376403; DOI=10.1016/j.bbrc.2007.03.019;
RA   Tezuka N., Brown A.M., Yanagawa S.;
RT   "GRB10 binds to LRP6, the Wnt co-receptor and inhibits canonical Wnt
RT   signaling pathway.";
RL   Biochem. Biophys. Res. Commun. 356:648-654(2007).
RN   [7]
RP   PHOSPHORYLATION AT SER-1490, INDUCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=17698587; DOI=10.1128/MCB.00773-07;
RA   Khan Z., Vijayakumar S., de la Torre T.V., Rotolo S., Bafico A.;
RT   "Analysis of endogenous LRP6 function reveals a novel feedback
RT   mechanism by which Wnt negatively regulates its receptor.";
RL   Mol. Cell. Biol. 27:7291-7301(2007).
RN   [8]
RP   INTERACTION WITH DRAXIN.
RX   PubMed=19857465; DOI=10.1016/j.bbrc.2009.10.113;
RA   Miyake A., Takahashi Y., Miwa H., Shimada A., Konishi M., Itoh N.;
RT   "Neucrin is a novel neural-specific secreted antagonist to canonical
RT   Wnt signaling.";
RL   Biochem. Biophys. Res. Commun. 390:1051-1055(2009).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Kidney;
RX   PubMed=21183079; DOI=10.1016/j.cell.2010.12.001;
RA   Huttlin E.L., Jedrychowski M.P., Elias J.E., Goswami T., Rad R.,
RA   Beausoleil S.A., Villen J., Haas W., Sowa M.E., Gygi S.P.;
RT   "A tissue-specific atlas of mouse protein phosphorylation and
RT   expression.";
RL   Cell 143:1174-1189(2010).
RN   [10]
RP   VARIANT RS TRP-886.
RX   PubMed=15469977; DOI=10.1242/dev.01405;
RA   Kokubu C., Heinzmann U., Kokubu T., Sakai N., Kubota T., Kawai M.,
RA   Wahl M.B., Galceran J., Grosschedl R., Ozono K., Imai K.;
RT   "Skeletal defects in ringelschwanz mutant mice reveal that Lrp6 is
RT   required for proper somitogenesis and osteogenesis.";
RL   Development 131:5469-5480(2004).
RN   [11]
RP   CHARACTERIZATION OF VARIANT RS TRP-886, SUBCELLULAR LOCATION, AND
RP   INTERACTION WITH DKK1; WNT1 AND MESD.
RX   PubMed=18505367; DOI=10.1359/jbmr.080512;
RA   Kubota T., Michigami T., Sakaguchi N., Kokubu C., Suzuki A., Namba N.,
RA   Sakai N., Nakajima S., Imai K., Ozono K.;
RT   "Lrp6 hypomorphic mutation affects bone mass through bone resorption
RT   in mice and impairs interaction with Mesd.";
RL   J. Bone Miner. Res. 23:1661-1671(2008).
CC   -!- FUNCTION: Component of the Wnt-Fzd-LRP5-LRP6 complex that triggers
CC       beta-catenin signaling through inducing aggregation of receptor-
CC       ligand complexes into ribosome-sized signalsomes. Cell-surface
CC       coreceptor of Wnt/beta-catenin signaling, which plays a pivotal
CC       role in bone formation. The Wnt-induced Fzd/LRP6 coreceptor
CC       complex recruits DVL1 polymers to the plasma membrane which, in
CC       turn, recruits the AXIN1/GSK3B-complex to the cell surface
CC       promoting the formation of signalsomes and inhibiting AXIN1/GSK3-
CC       mediated phosphorylation and destruction of beta-catenin. Required
CC       for posterior patterning of the epiblast during gastrulation (By
CC       similarity). {ECO:0000250, ECO:0000269|PubMed:15142971}.
CC   -!- SUBUNIT: Homodimer; disulfide-linked (By similarity). Forms
CC       phosphorylated oligomer aggregates on Wnt-signaling (By
CC       similarity). Component of the Wnt-Fzd-LRP5-LRP6 complex. Interacts
CC       (via the extracellular domain) with WNT1; the interaction is
CC       enhanced by prior formation of the Wnt/Fzd complex. Interacts (via
CC       the beta-propeller regions 3 and 4) with WNT3A. Interacts (via the
CC       beta-propeller regions 1 and 2) with WNT9B. Interacts with FZD5;
CC       the interaction forms a coreceptor complex for Wnt signaling and
CC       is inhibited by DKK1 and DRAXIN. Interacts (via beta propeller
CC       region) with DKK1; the interaction inhibits FZD5/LRP6 complex
CC       formation. Interacts with DKK2. Interacts (via the phosphorylated
CC       PPPSP motifs) with AXIN1; the interaction recruits the AXIN1/GSK3B
CC       complex to cell surface LRP6 signalsomes. Interacts (via the
CC       extracellular domain) with RSPO1; the interaction activates
CC       Wnt/beta-catenin signaling. Interacts (via the extracellular
CC       domain) with RSPO3 (via the cysteine rich domain); the interaction
CC       activates Wnt/beta-catenin signaling. Interacts (via the beta-
CC       propeller regions 1 and 2) with SOST; the interaction competes
CC       with DKK1 for binding for inhibiting beta-catenin signaling.
CC       Interacts (via the cytoplasmic domain) with CSNKIE; the
CC       interaction phosphorylates LRP6, binds AXIN1 and inhibits
CC       AXIN1/GSK3B-mediated phosphorylation of beta-catenin (By
CC       similarity). Interacts with DRAXIN; the interaction inhibits Wnt
CC       signaling. Interacts with GRB10; the interaction prevents AXIN1
CC       binding, thus negatively regulating the Wnt signaling pathway.
CC       Interacts with MESD; the interaction prevents the formation of
CC       LRP6 aggregates and targets LRP6 to the plasma membrane. Interacts
CC       with MACF1. Interacts with DAB2; the interaction involves LRP6
CC       phosphorylation by CK2 and sequesters LRP6 towards clathrin-
CC       mediated endocytosis. Interacts with TMEM198 (By similarity).
CC       {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane
CC       protein. Endoplasmic reticulum. Note=On Wnt signaling, undergoes a
CC       cycle of caveolin- or clathrin-mediated endocytosis and plasma
CC       membrane location. Released from the endoplasmic reticulum on
CC       palmitoylation. Mono-ubiquitination retains it in the endoplasmic
CC       reticulum in the absence of palmitoylation. On Wnt signaling,
CC       phosphorylated, aggregates and colocalizes with AXIN1 and GSK3B at
CC       the plasma membrane in LRP6-signalsomes (By similarity).
CC       Chaperoned to the plasma membrane by MESD. {ECO:0000250}.
CC   -!- TISSUE SPECIFICITY: Expressed in early embryo. Broadly expressed
CC       throughout the embryonic ectoderm and in nascent mesoderm, and in
CC       endoderm emerging from the primitive streak.
CC       {ECO:0000269|PubMed:15142971}.
CC   -!- DOMAIN: The YWTD-EGF-like domains 1 and 2 are required for the
CC       interaction with Wnt-frizzled complex. The YWTD-EGF-like domains 3
CC       and 4 are required for the interaction with DKK1 (By similarity).
CC       {ECO:0000250}.
CC   -!- DOMAIN: The PPPSP motifs play a central role in signal
CC       transduction by being phosphorylated, leading to activate the Wnt
CC       signaling pathway.
CC   -!- PTM: Dual phosphorylation of cytoplasmic PPPSP motifs sequentially
CC       by GSK3 and CK1 is required for AXIN1-binding, and subsequent
CC       stabilization and activation of beta-catenin via preventing GSK3-
CC       mediated phosphorylation of beta-catenin. Phosphorylated, in
CC       vitro, by GRK5/6 within and outside the PPPSP motifs.
CC       Phosphorylation at Ser-1490 by CDK14 during G2/M phase leads to
CC       regulation of the Wnt signaling pathway during the cell cycle.
CC       Phosphorylation by GSK3B is induced by RPSO1 binding and inhibited
CC       by DKK1. Phosphorylated, in vitro, by casein kinase I on Thr-1479
CC       (By similarity). {ECO:0000250}.
CC   -!- PTM: Undergoes gamma-secretase-dependent regulated intramembrane
CC       proteolysis (RIP). The extracellular domain is first released by
CC       shedding, and then, through the action of gamma-secretase, the
CC       intracellular domain (ICD) is released into the cytoplasm where it
CC       is free to bind to GSK3B and to activate canonical Wnt signaling
CC       (By similarity). {ECO:0000250}.
CC   -!- PTM: Palmitoylation on the two sites near the transmembrane domain
CC       leads to release of LRP6 from the endoplasmic reticulum.
CC       {ECO:0000250}.
CC   -!- PTM: Mono-ubiquitinated which retains LRP6 in the endoplasmic
CC       reticulum. Ubiquitinated by ZNRF3, leading to its degradation by
CC       the proteasome (By similarity). {ECO:0000250}.
CC   -!- PTM: N-glycosylation is required for cell surface location.
CC       {ECO:0000250}.
CC   -!- DISEASE: Note=Defects in Lrp6 are the cause of Ringelschwanz (rs)
CC       phenotype. Rs phenotype is a spontaneous mutation that is
CC       characterized by a combination of multiple Wnt-deficient
CC       phenotypes including dysmorphologies of the axial skeleton, digits
CC       and the neural tube. The establishment of the anteroposterior
CC       somite compartments, the epithelialization of nascent somites, and
CC       the formation of segment borders are disturbed in (rs) mutants.
CC       There is delayed ossification at birth and a low bone mass
CC       phenotype in adults. Functional analyzes reveal impaired targeting
CC       to the plasma surface due to reduced interaction with MESD leading
CC       to inhibited Wnt/beta-catenin signaling.
CC       {ECO:0000269|PubMed:15469977, ECO:0000269|PubMed:18505367}.
CC   -!- SIMILARITY: Belongs to the LDLR family. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 4 EGF-like domains. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 3 LDL-receptor class A domains.
CC       {ECO:0000255|PROSITE-ProRule:PRU00124}.
CC   -!- SIMILARITY: Contains 20 LDL-receptor class B repeats.
CC       {ECO:0000255|PROSITE-ProRule:PRU00461}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF074265; AAC33007.1; -; mRNA.
DR   EMBL; BC060704; AAH60704.1; -; mRNA.
DR   CCDS; CCDS39678.1; -.
DR   PIR; JE0273; JE0273.
DR   RefSeq; NP_032540.2; NM_008514.4.
DR   UniGene; Mm.321990; -.
DR   ProteinModelPortal; O88572; -.
DR   SMR; O88572; 20-1360.
DR   BioGrid; 201203; 8.
DR   DIP; DIP-46460N; -.
DR   IntAct; O88572; 4.
DR   STRING; 10090.ENSMUSP00000032322; -.
DR   iPTMnet; O88572; -.
DR   PhosphoSite; O88572; -.
DR   MaxQB; O88572; -.
DR   PaxDb; O88572; -.
DR   PRIDE; O88572; -.
DR   GeneID; 16974; -.
DR   KEGG; mmu:16974; -.
DR   UCSC; uc009ekl.2; mouse.
DR   CTD; 4040; -.
DR   MGI; MGI:1298218; Lrp6.
DR   eggNOG; ENOG410IPT4; Eukaryota.
DR   eggNOG; ENOG410XSY5; LUCA.
DR   HOGENOM; HOG000230697; -.
DR   HOVERGEN; HBG049167; -.
DR   InParanoid; O88572; -.
DR   KO; K03068; -.
DR   OrthoDB; EOG75XGK3; -.
DR   PhylomeDB; O88572; -.
DR   TreeFam; TF315253; -.
DR   ChiTaRS; Lrp6; mouse.
DR   NextBio; 291034; -.
DR   PRO; PR:O88572; -.
DR   Proteomes; UP000000589; Unplaced.
DR   Bgee; O88572; -.
DR   GO; GO:0005901; C:caveola; IBA:GO_Central.
DR   GO; GO:0009986; C:cell surface; ISO:MGI.
DR   GO; GO:0031410; C:cytoplasmic vesicle; ISO:MGI.
DR   GO; GO:0005769; C:early endosome; IDA:MGI.
DR   GO; GO:0005783; C:endoplasmic reticulum; IEA:UniProtKB-SubCell.
DR   GO; GO:1990851; C:Frizzled-LRP5/6 complex; ISO:MGI.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0016020; C:membrane; IDA:MGI.
DR   GO; GO:0043025; C:neuronal cell body; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; IDA:MGI.
DR   GO; GO:0043235; C:receptor complex; IBA:GO_Central.
DR   GO; GO:0045202; C:synapse; IBA:GO_Central.
DR   GO; GO:0071936; F:coreceptor activity involved in Wnt signaling pathway; ISO:MGI.
DR   GO; GO:0005109; F:frizzled binding; ISO:MGI.
DR   GO; GO:0042802; F:identical protein binding; ISO:MGI.
DR   GO; GO:0019210; F:kinase inhibitor activity; ISO:MGI.
DR   GO; GO:0005041; F:low-density lipoprotein receptor activity; ISO:MGI.
DR   GO; GO:0042803; F:protein homodimerization activity; ISO:MGI.
DR   GO; GO:0005102; F:receptor binding; ISO:MGI.
DR   GO; GO:0019534; F:toxin transporter activity; IMP:BHF-UCL.
DR   GO; GO:0042813; F:Wnt-activated receptor activity; IBA:GO_Central.
DR   GO; GO:0017147; F:Wnt-protein binding; IPI:MGI.
DR   GO; GO:0009952; P:anterior/posterior pattern specification; IMP:MGI.
DR   GO; GO:0003401; P:axis elongation; IMP:MGI.
DR   GO; GO:0090245; P:axis elongation involved in somitogenesis; IGI:MGI.
DR   GO; GO:0046849; P:bone remodeling; IGI:MGI.
DR   GO; GO:0060444; P:branching involved in mammary gland duct morphogenesis; IMP:MGI.
DR   GO; GO:0060070; P:canonical Wnt signaling pathway; ISS:UniProtKB.
DR   GO; GO:0061310; P:canonical Wnt signaling pathway involved in cardiac neural crest cell differentiation involved in heart development; IMP:MGI.
DR   GO; GO:0061324; P:canonical Wnt signaling pathway involved in positive regulation of cardiac outflow tract cell proliferation; IMP:MGI.
DR   GO; GO:0042074; P:cell migration involved in gastrulation; IGI:MGI.
DR   GO; GO:0071397; P:cellular response to cholesterol; ISO:MGI.
DR   GO; GO:0021587; P:cerebellum morphogenesis; IMP:MGI.
DR   GO; GO:0021795; P:cerebral cortex cell migration; IMP:MGI.
DR   GO; GO:0021987; P:cerebral cortex development; IMP:MGI.
DR   GO; GO:0060026; P:convergent extension; IGI:MGI.
DR   GO; GO:0071542; P:dopaminergic neuron differentiation; IMP:MGI.
DR   GO; GO:0009950; P:dorsal/ventral axis specification; IMP:MGI.
DR   GO; GO:0048596; P:embryonic camera-type eye morphogenesis; IMP:MGI.
DR   GO; GO:0042733; P:embryonic digit morphogenesis; IMP:MGI.
DR   GO; GO:0035115; P:embryonic forelimb morphogenesis; IMP:MGI.
DR   GO; GO:0035116; P:embryonic hindlimb morphogenesis; IMP:MGI.
DR   GO; GO:0030326; P:embryonic limb morphogenesis; IGI:MGI.
DR   GO; GO:0009880; P:embryonic pattern specification; IMP:MGI.
DR   GO; GO:0060059; P:embryonic retina morphogenesis in camera-type eye; IMP:MGI.
DR   GO; GO:0035261; P:external genitalia morphogenesis; IMP:MGI.
DR   GO; GO:0060325; P:face morphogenesis; IMP:MGI.
DR   GO; GO:0030900; P:forebrain development; IMP:MGI.
DR   GO; GO:0021872; P:forebrain generation of neurons; IMP:MGI.
DR   GO; GO:0021861; P:forebrain radial glial cell differentiation; IGI:MGI.
DR   GO; GO:0021943; P:formation of radial glial scaffolds; IGI:MGI.
DR   GO; GO:0001702; P:gastrulation with mouth forming second; IGI:MGI.
DR   GO; GO:0048699; P:generation of neurons; IMP:MGI.
DR   GO; GO:0001947; P:heart looping; IGI:MGI.
DR   GO; GO:0035108; P:limb morphogenesis; IMP:MGI.
DR   GO; GO:0060603; P:mammary gland duct morphogenesis; IGI:MGI.
DR   GO; GO:0060596; P:mammary placode formation; IMP:MGI.
DR   GO; GO:0030901; P:midbrain development; IMP:MGI.
DR   GO; GO:0030917; P:midbrain-hindbrain boundary development; IMP:MGI.
DR   GO; GO:0050680; P:negative regulation of epithelial cell proliferation; IMP:MGI.
DR   GO; GO:0045599; P:negative regulation of fat cell differentiation; IMP:MGI.
DR   GO; GO:2000051; P:negative regulation of non-canonical Wnt signaling pathway; IGI:MGI.
DR   GO; GO:2000151; P:negative regulation of planar cell polarity pathway involved in cardiac muscle tissue morphogenesis; IGI:MGI.
DR   GO; GO:2000162; P:negative regulation of planar cell polarity pathway involved in cardiac right atrium morphogenesis; IGI:MGI.
DR   GO; GO:2000168; P:negative regulation of planar cell polarity pathway involved in neural tube closure; IGI:MGI.
DR   GO; GO:2000164; P:negative regulation of planar cell polarity pathway involved in outflow tract morphogenesis; IGI:MGI.
DR   GO; GO:2000166; P:negative regulation of planar cell polarity pathway involved in pericardium morphogenesis; IGI:MGI.
DR   GO; GO:2000149; P:negative regulation of planar cell polarity pathway involved in ventricular septum morphogenesis; IGI:MGI.
DR   GO; GO:0006469; P:negative regulation of protein kinase activity; ISO:MGI.
DR   GO; GO:0001933; P:negative regulation of protein phosphorylation; ISO:MGI.
DR   GO; GO:0071901; P:negative regulation of protein serine/threonine kinase activity; ISO:MGI.
DR   GO; GO:0034392; P:negative regulation of smooth muscle cell apoptotic process; ISO:MGI.
DR   GO; GO:0030178; P:negative regulation of Wnt signaling pathway; IGI:MGI.
DR   GO; GO:0014033; P:neural crest cell differentiation; ISO:MGI.
DR   GO; GO:0014029; P:neural crest formation; ISO:MGI.
DR   GO; GO:0001843; P:neural tube closure; IMP:MGI.
DR   GO; GO:0021915; P:neural tube development; IGI:MGI.
DR   GO; GO:0042475; P:odontogenesis of dentin-containing tooth; IMP:MGI.
DR   GO; GO:0060021; P:palate development; IMP:MGI.
DR   GO; GO:0003344; P:pericardium morphogenesis; IGI:MGI.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IMP:MGI.
DR   GO; GO:0045780; P:positive regulation of bone resorption; IMP:MGI.
DR   GO; GO:0090263; P:positive regulation of canonical Wnt signaling pathway; ISO:MGI.
DR   GO; GO:0045787; P:positive regulation of cell cycle; ISO:MGI.
DR   GO; GO:0002053; P:positive regulation of mesenchymal cell proliferation; IMP:MGI.
DR   GO; GO:0045778; P:positive regulation of ossification; IMP:MGI.
DR   GO; GO:0051091; P:positive regulation of sequence-specific DNA binding transcription factor activity; IMP:BHF-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; ISO:MGI.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:BHF-UCL.
DR   GO; GO:2000055; P:positive regulation of Wnt signaling pathway involved in dorsal/ventral axis specification; ISO:MGI.
DR   GO; GO:0036342; P:post-anal tail morphogenesis; IMP:MGI.
DR   GO; GO:0090009; P:primitive streak formation; IGI:MGI.
DR   GO; GO:0090118; P:receptor-mediated endocytosis of low-density lipoprotein particle involved in cholesterol transport; IMP:MGI.
DR   GO; GO:0060284; P:regulation of cell development; IMP:MGI.
DR   GO; GO:0042127; P:regulation of cell proliferation; IMP:MGI.
DR   GO; GO:0051593; P:response to folic acid; IMP:MGI.
DR   GO; GO:0060042; P:retina morphogenesis in camera-type eye; IMP:MGI.
DR   GO; GO:0048705; P:skeletal system morphogenesis; IMP:MGI.
DR   GO; GO:0001756; P:somitogenesis; IGI:MGI.
DR   GO; GO:0007268; P:synaptic transmission; IBA:GO_Central.
DR   GO; GO:0021794; P:thalamus development; IMP:MGI.
DR   GO; GO:1901998; P:toxin transport; ISO:MGI.
DR   GO; GO:0060535; P:trachea cartilage morphogenesis; IGI:MGI.
DR   GO; GO:0016055; P:Wnt signaling pathway; IGI:MGI.
DR   GO; GO:0044332; P:Wnt signaling pathway involved in dorsal/ventral axis specification; ISO:MGI.
DR   GO; GO:0021874; P:Wnt signaling pathway involved in forebrain neuroblast division; IMP:MGI.
DR   GO; GO:0090244; P:Wnt signaling pathway involved in somitogenesis; IMP:MGI.
DR   Gene3D; 2.120.10.30; -; 4.
DR   Gene3D; 4.10.400.10; -; 3.
DR   InterPro; IPR011042; 6-blade_b-propeller_TolB-like.
DR   InterPro; IPR000742; EGF-like_dom.
DR   InterPro; IPR023415; LDLR_class-A_CS.
DR   InterPro; IPR000033; LDLR_classB_rpt.
DR   InterPro; IPR002172; LDrepeatLR_classA_rpt.
DR   InterPro; IPR017049; LRP5/6.
DR   Pfam; PF00057; Ldl_recept_a; 3.
DR   Pfam; PF00058; Ldl_recept_b; 11.
DR   PIRSF; PIRSF036314; LDL_recpt-rel_p5/6; 1.
DR   PRINTS; PR00261; LDLRECEPTOR.
DR   SMART; SM00181; EGF; 4.
DR   SMART; SM00192; LDLa; 3.
DR   SMART; SM00135; LY; 20.
DR   SUPFAM; SSF57424; SSF57424; 3.
DR   PROSITE; PS01186; EGF_2; 1.
DR   PROSITE; PS01209; LDLRA_1; 3.
DR   PROSITE; PS50068; LDLRA_2; 3.
DR   PROSITE; PS51120; LDLRB; 20.
PE   1: Evidence at protein level;
KW   Complete proteome; Developmental protein; Disease mutation;
KW   Disulfide bond; EGF-like domain; Endocytosis; Endoplasmic reticulum;
KW   Glycoprotein; Isopeptide bond; Lipoprotein; Membrane; Palmitate;
KW   Phosphoprotein; Polymorphism; Receptor; Reference proteome; Repeat;
KW   Signal; Transmembrane; Transmembrane helix; Ubl conjugation;
KW   Wnt signaling pathway.
FT   SIGNAL        1     19       {ECO:0000255}.
FT   CHAIN        20   1613       Low-density lipoprotein receptor-related
FT                                protein 6.
FT                                /FTId=PRO_0000017331.
FT   TOPO_DOM     20   1370       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1371   1393       Helical. {ECO:0000255}.
FT   TOPO_DOM   1394   1613       Cytoplasmic. {ECO:0000255}.
FT   REPEAT       63    106       LDL-receptor class B 1.
FT   REPEAT      107    149       LDL-receptor class B 2.
FT   REPEAT      150    193       LDL-receptor class B 3.
FT   REPEAT      194    235       LDL-receptor class B 4.
FT   REPEAT      236    277       LDL-receptor class B 5.
FT   DOMAIN      282    324       EGF-like 1.
FT   REPEAT      372    414       LDL-receptor class B 6.
FT   REPEAT      415    457       LDL-receptor class B 7.
FT   REPEAT      458    501       LDL-receptor class B 8.
FT   REPEAT      502    542       LDL-receptor class B 9.
FT   REPEAT      543    587       LDL-receptor class B 10.
FT   DOMAIN      588    628       EGF-like 2.
FT   REPEAT      674    716       LDL-receptor class B 11.
FT   REPEAT      717    759       LDL-receptor class B 12.
FT   REPEAT      760    802       LDL-receptor class B 13.
FT   REPEAT      803    842       LDL-receptor class B 14.
FT   REPEAT      843    885       LDL-receptor class B 15.
FT   DOMAIN      889    930       EGF-like 3.
FT   REPEAT      977   1025       LDL-receptor class B 16.
FT   REPEAT     1026   1068       LDL-receptor class B 17.
FT   REPEAT     1069   1113       LDL-receptor class B 18.
FT   REPEAT     1114   1156       LDL-receptor class B 19.
FT   REPEAT     1157   1198       LDL-receptor class B 20.
FT   DOMAIN     1203   1244       EGF-like 4.
FT   DOMAIN     1248   1286       LDL-receptor class A 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DOMAIN     1287   1323       LDL-receptor class A 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DOMAIN     1325   1361       LDL-receptor class A 3.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   REGION       20    275       Beta-propeller 1.
FT   REGION      328    589       Beta-propeller 2.
FT   REGION      631    890       Beta-propeller 3.
FT   REGION      933   1202       Beta-propeller 4.
FT   MOTIF      1487   1493       PPPSP motif A.
FT   MOTIF      1527   1534       PPPSP motif B.
FT   MOTIF      1568   1575       PPPSP motif C.
FT   MOTIF      1588   1593       PPPSP motif D.
FT   MOTIF      1603   1610       PPPSP motif E.
FT   COMPBIAS   1469   1475       Poly-Ser.
FT   COMPBIAS   1566   1573       Poly-Pro.
FT   COMPBIAS   1603   1608       Poly-Pro.
FT   MOD_RES    1420   1420       Phosphoserine; by CK1. {ECO:0000250}.
FT   MOD_RES    1430   1430       Phosphoserine; by CK1. {ECO:0000250}.
FT   MOD_RES    1479   1479       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:O75581}.
FT   MOD_RES    1490   1490       Phosphoserine; by CDK14, GRK5 and GRK6.
FT                                {ECO:0000250}.
FT   MOD_RES    1493   1493       Phosphothreonine; by CK1. {ECO:0000250}.
FT   LIPID      1394   1394       S-palmitoyl cysteine. {ECO:0000250}.
FT   LIPID      1399   1399       S-palmitoyl cysteine. {ECO:0000250}.
FT   CARBOHYD     42     42       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD     81     81       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    281    281       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    433    433       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    486    486       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    692    692       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    859    859       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    865    865       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    926    926       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID    286    297       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID    293    308       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID    310    323       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID    592    603       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID    599    612       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID    614    627       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID    893    904       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID    900    914       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID    916    929       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID   1207   1218       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID   1214   1228       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID   1230   1243       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID   1249   1263       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID   1256   1276       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID   1270   1285       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID   1288   1300       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID   1295   1313       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID   1307   1322       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID   1326   1338       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID   1333   1351       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID   1345   1360       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   CROSSLNK   1403   1403       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000250}.
FT   VARIANT     886    886       R -> W (in rs).
FT                                {ECO:0000269|PubMed:15469977,
FT                                ECO:0000269|PubMed:18505367}.
FT   CONFLICT     83     83       S -> T (in Ref. 2; AAH60704).
FT                                {ECO:0000305}.
FT   CONFLICT    317    317       M -> L (in Ref. 2; AAH60704).
FT                                {ECO:0000305}.
FT   CONFLICT    586    586       V -> I (in Ref. 2; AAH60704).
FT                                {ECO:0000305}.
FT   CONFLICT    622    622       G -> S (in Ref. 2; AAH60704).
FT                                {ECO:0000305}.
FT   CONFLICT    933    933       S -> T (in Ref. 2; AAH60704).
FT                                {ECO:0000305}.
SQ   SEQUENCE   1613 AA;  180255 MW;  3C2ABC8EEEB17622 CRC64;
     MGAVLRSLLA CSFCVLLRAA PLLLYANRRD LRLVDATNGK ENATIVVGGL EDAAAVDFVF
     GHGLIYWSDV SEEAIKRTEF NKSESVQNVV VSGLLSPDGL ACDWLGEKLY WTDSETNRIE
     VSNLDGSLRK VLFWQELDQP RAIALDPSSG FMYWTDWGEV PKIERAGMDG SSRFVIINTE
     IYWPNGLTLD YQERKLYWAD AKLNFIHKSN LDGTNRQAVV KGSLPHPFAL TLFEDTLYWT
     DWNTHSILAC NKYTGEGLRE IHSNIFSPMD IHAFSQQRQP NATNPCGIDN GGCSHLCLMS
     PVKPFYQCAC PTGVKLMENG KTCKDGATEL LLLARRTDLR RISLDTPDFT DIVLQLEDIR
     HAIAIDYDPV EGYIYWTDDE VRAIRRSFID GSGSQFVVTA QIAHPDGIAV DWVARNLYWT
     DTGTDRIEVT RLNGTMRKIL ISEDLEEPRA IVLDPMVGYM YWTDWGEIPK IERAALDGSD
     RVVLVNTSLG WPNGLALDYD EGTIYWGDAK TDKIEVMNTD GTGRRVLVED KIPHIFGFTL
     LGDYVYWTDW QRRSIERVHK RSAEREVIID QLPDLMGLKA TSVHRVIGSN PCAEDNGGCS
     HLCLYRPQGL RCACPIGFEL IGDMKTCIVP EAFLLFSRRA DIRRISLETN NNNVAIPLTG
     VKEASALDFD VTDNRIYWTD ISLKTISRAF MNGSALEHVV EFGLDYPEGM AVDWLGKNLY
     WADTGTNRIE VSKLDGQHRQ VLVWKDLDSP RALALDPAEG FMYWTEWGGK PKIDRAAMDG
     SERTTLVPNV GRANGLTIDY AKRRLYWTDL DTNLIESSDM LGLNREVIAD DLPHPFGLTQ
     YQDYIYWTDW SRRSIERANK TSGQNRTIIQ GHLDYVMDIL VFHSSRQAGW NECASSNGHC
     SHLCLAVPVG GFVCGCPAHY SLNADNRTCS APSTFLLFSQ KSAINRMVID EQQSPDIILP
     IHSLRNVRAI DYDPLDKQLY WIDSRQNSIR KAHEDGGQGF NVVANSVANQ NLEIQPYDLS
     IDIYSRYIYW TCEATNVIDV TRLDGRSVGV VLKGEQDRPR AIVVNPEKGY MYFTNLQERS
     PKIERAALDG TEREVLFFSG LSKPIALALD SKLGKLFWAD SDLRRIESSD LSGANRIVLE
     DSNILQPVGL TVFENWLYWI DKQQQMIEKI DMTGREGRTK VQARIAQLSD IHAVKELNLQ
     EYRQHPCAQD NGGCSHICLV KGDGTTRCSC PMHLVLLQDE LSCGEPPTCS PQQFTCFTGD
     IDCIPVAWRC DGFTECEDHS DELNCPVCSE SQFQCASGQC IDGALRCNGD ANCQDKSDEK
     NCEVLCLIDQ FRCANGQCVG KHKKCDHSVD CSDRSDELDC YPTEEPAPQA TNTVGSVIGV
     IVTIFVSGTI YFICQRMLCP RMKGDGETMT NDYVVHSPAS VPLGYVPHPS SLSGSLPGMS
     RGKSMISSLS IMGGSSGPPY DRAHVTGASS SSSSSTKGTY FPAILNPPPS PATERSHYTM
     EFGYSSNSPS THRSYSYRPY SYRHFAPPTT PCSTDVCDSD YAPSRRMTSV ATAKGYTSDV
     NYDSEPVPPP PTPRSQYLSA EENYESCPPS PYTERSYSHH LYPPPPSPCT DSS
//
ID   TNR6_HUMAN              Reviewed;         335 AA.
AC   P25445; A9UJX4; B6VNV4; Q14292; Q14293; Q14294; Q14295; Q16652;
AC   Q5T9P1; Q5T9P2; Q5T9P3; Q6SSE9;
DT   01-MAY-1992, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1992, sequence version 1.
DT   17-FEB-2016, entry version 204.
DE   RecName: Full=Tumor necrosis factor receptor superfamily member 6;
DE   AltName: Full=Apo-1 antigen;
DE   AltName: Full=Apoptosis-mediating surface antigen FAS;
DE   AltName: Full=FASLG receptor;
DE   AltName: CD_antigen=CD95;
DE   Flags: Precursor;
GN   Name=FAS; Synonyms=APT1, FAS1, TNFRSF6;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=1713127; DOI=10.1016/0092-8674(91)90614-5;
RA   Itoh N., Yonehara S., Ishii A., Yonehara M., Mizushima S.,
RA   Sameshima M., Hase A., Seto Y., Nagata S.;
RT   "The polypeptide encoded by the cDNA for human cell surface antigen
RT   Fas can mediate apoptosis.";
RL   Cell 66:233-243(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND PROTEIN SEQUENCE OF
RP   226-240; 269-291 AND 321-335.
RX   PubMed=1375228;
RA   Oehm A., Behrmann I., Falk W., Pawlita M., Maier G., Klas C.,
RA   Li-Weber M., Richards S., Dhein J., Trauth B.C., Ponstingl H.,
RA   Krammer P.H.;
RT   "Purification and molecular cloning of the APO-1 cell surface antigen,
RT   a member of the tumor necrosis factor/nerve growth factor receptor
RT   superfamily. Sequence identity with the Fas antigen.";
RL   J. Biol. Chem. 267:10709-10715(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2; 3; 4 AND 6), AND TISSUE
RP   SPECIFICITY.
RX   PubMed=7575433;
RA   Liu C., Cheng J., Mountz J.D.;
RT   "Differential expression of human Fas mRNA species upon peripheral
RT   blood mononuclear cell activation.";
RL   Biochem. J. 310:957-963(1995).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2; 3 AND 6), AND FUNCTION.
RX   PubMed=7533181;
RA   Cascino I., Fiucci G., Papoff G., Ruberti G.;
RT   "Three functional soluble forms of the human apoptosis-inducing Fas
RT   molecule are produced by alternative splicing.";
RL   J. Immunol. 154:2706-2713(1995).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 7).
RX   PubMed=8598453;
RA   Cascino I., Papoff G., De Maria R., Testi R., Ruberti G.;
RT   "Fas/Apo-1 (CD95) receptor lacking the intracytoplasmic signaling
RT   domain protects tumor cells from Fas-mediated apoptosis.";
RL   J. Immunol. 156:13-17(1996).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 4 AND 5).
RX   PubMed=8648105;
RA   Papoff G., Cascino I., Eramo A., Starace G., Lynch D.H., Ruberti G.;
RT   "An N-terminal domain shared by Fas/Apo-1 (CD95) soluble variants
RT   prevents cell death in vitro.";
RL   J. Immunol. 156:4622-4630(1996).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ALPS1A SER-262.
RX   PubMed=17336828; DOI=10.1016/j.imbio.2006.12.003;
RA   Del-Rey M.J., Manzanares J., Bosque A., Aguilo J.I., Gomez-Rial J.,
RA   Roldan E., Serrano A., Anel A., Paz-Artal E., Allende L.M.;
RT   "Autoimmune lymphoproliferative syndrome (ALPS) in a patient with a
RT   new germline Fas gene mutation.";
RL   Immunobiology 212:73-83(2007).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 5).
RC   TISSUE=Peripheral blood lymphocyte;
RA   Schaetzlein C.E., Poehlmann R., Philippsen P., Eibel H.;
RL   Submitted (JUN-1995) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   De La Calle-Martin O.;
RL   Submitted (OCT-2008) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS THR-16; ILE-122 AND
RP   ILE-305.
RG   NIEHS SNPs program;
RL   Submitted (OCT-2003) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Cahill P., Camire D.,
RA   Carter N.P., Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Corby N., Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L.,
RA   Frankish A., Frankland J.A., Garner P., Garnett J., Gribble S.,
RA   Griffiths C., Grocock R., Gustafson E., Hammond S., Harley J.L.,
RA   Hart E., Heath P.D., Ho T.P., Hopkins B., Horne J., Howden P.J.,
RA   Huckle E., Hynds C., Johnson C., Johnson D., Kana A., Kay M.,
RA   Kimberley A.M., Kershaw J.K., Kokkinaki M., Laird G.K., Lawlor S.,
RA   Lee H.M., Leongamornlert D.A., Laird G., Lloyd C., Lloyd D.M.,
RA   Loveland J., Lovell J., McLaren S., McLay K.E., McMurray A.,
RA   Mashreghi-Mohammadi M., Matthews L., Milne S., Nickerson T.,
RA   Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V., Peck A.I.,
RA   Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A., Ross M.T.,
RA   Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W.,
RA   Tracey A., Tromans A., Tsolas J., Wall M., Walsh J., Wang H.,
RA   Weinstock K., West A.P., Willey D.L., Whitehead S.L., Wilming L.,
RA   Wray P.W., Young L., Chen Y., Lovering R.C., Moschonas N.K.,
RA   Siebert R., Fechtel K., Bentley D., Durbin R.M., Hubbard T.,
RA   Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [14]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Urinary bladder;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [15]
RP   INTERACTION WITH RIPK1.
RX   PubMed=7538908; DOI=10.1016/0092-8674(95)90072-1;
RA   Stanger B.Z., Leder P., Lee T.-H., Kim E., Seed B.;
RT   "RIP: a novel protein containing a death domain that interacts with
RT   Fas/APO-1 (CD95) in yeast and causes cell death.";
RL   Cell 81:513-523(1995).
RN   [16]
RP   INTERACTION WITH FEM1B.
RX   PubMed=10542291; DOI=10.1074/jbc.274.45.32461;
RA   Chan S.-L., Tan K.-O., Zhang L., Yee K.S.Y., Ronca F., Chan M.-Y.,
RA   Yu V.C.;
RT   "F1Aalpha, a death receptor-binding protein homologous to the
RT   Caenorhabditis elegans sex-determining protein, FEM-1, is a caspase
RT   substrate that mediates apoptosis.";
RL   J. Biol. Chem. 274:32461-32468(1999).
RN   [17]
RP   INTERACTION WITH FAIM2.
RX   PubMed=10535980; DOI=10.1073/pnas.96.22.12667;
RA   Somia N.V., Schmitt M.J., Vetter D.E., Van Antwerp D., Heinemann S.F.,
RA   Verma I.M.;
RT   "LFG: an anti-apoptotic gene that provides protection from fas-
RT   mediated cell death.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:12667-12672(1999).
RN   [18]
RP   SPLICE ISOFORM(S) THAT ARE POTENTIAL NMD TARGET(S).
RX   PubMed=14759258; DOI=10.1186/gb-2004-5-2-r8;
RA   Hillman R.T., Green R.E., Brenner S.E.;
RT   "An unappreciated role for RNA surveillance.";
RL   Genome Biol. 5:R8.1-R8.16(2004).
RN   [19]
RP   INTERACTION WITH BRE.
RX   PubMed=15465831; DOI=10.1074/jbc.M408678200;
RA   Li Q., Ching A.K.-K., Chan B.C.-L., Chow S.K.-Y., Lim P.-L.,
RA   Ho T.C.-Y., Ip W.-K., Wong C.-K., Lam C.W.-K., Lee K.K.-H.,
RA   Chan J.Y.-H., Chui Y.-L.;
RT   "A death receptor-associated anti-apoptotic protein, BRE, inhibits
RT   mitochondrial apoptotic pathway.";
RL   J. Biol. Chem. 279:52106-52116(2004).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-209, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [22]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-118.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [23]
RP   INTERACTION WITH FADD.
RX   PubMed=21109225; DOI=10.1016/j.ajhg.2010.10.028;
RA   Bolze A., Byun M., McDonald D., Morgan N.V., Abhyankar A.,
RA   Premkumar L., Puel A., Bacon C.M., Rieux-Laucat F., Pang K.,
RA   Britland A., Abel L., Cant A., Maher E.R., Riedl S.J., Hambleton S.,
RA   Casanova J.L.;
RT   "Whole-exome-sequencing-based discovery of human FADD deficiency.";
RL   Am. J. Hum. Genet. 87:873-881(2010).
RN   [24]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [25]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [26]
RP   GLYCOSYLATION AT THR-28, STRUCTURE OF CARBOHYDRATES, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=22171320; DOI=10.1074/mcp.M111.013649;
RA   Halim A., Nilsson J., Ruetschi U., Hesse C., Larson G.;
RT   "Human urinary glycoproteomics; attachment site specific analysis of
RT   N-and O-linked glycosylations by CID and ECD.";
RL   Mol. Cell. Proteomics 0:0-0(2011).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-225, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [28]
RP   STRUCTURE BY NMR OF 218-335.
RX   PubMed=8967952; DOI=10.1038/384638a0;
RA   Huang B., Eberstadt M., Olejniczak E.T., Meadows R.P., Fesik S.W.;
RT   "NMR structure and mutagenesis of the Fas (APO-1/CD95) death domain.";
RL   Nature 384:638-641(1996).
RN   [29]
RP   X-RAY CRYSTALLOGRAPHY (2.73 ANGSTROMS) OF 223-335 IN COMPLEX WITH
RP   FADD, FUNCTION, SUBUNIT, SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   TYR-291 AND ILE-313.
RX   PubMed=19118384; DOI=10.1038/nature07606;
RA   Scott F.L., Stec B., Pop C., Dobaczewska M.K., Lee J.J., Monosov E.,
RA   Robinson H., Salvesen G.S., Schwarzenbacher R., Riedl S.J.;
RT   "The Fas-FADD death domain complex structure unravels signalling by
RT   receptor clustering.";
RL   Nature 457:1019-1022(2009).
RN   [30]
RP   VARIANT ALPS1A PRO-241.
RX   PubMed=7540117; DOI=10.1016/0092-8674(95)90013-6;
RA   Fisher G.H., Rosenberg F.J., Straus S.E., Dale J.K., Middleton L.A.,
RA   Lin A.Y., Strober W., Lenardo M.J., Puck J.M.;
RT   "Dominant interfering Fas gene mutations impair apoptosis in a human
RT   autoimmune lymphoproliferative syndrome.";
RL   Cell 81:935-946(1995).
RN   [31]
RP   VARIANT ALPS1A TYR-260.
RX   PubMed=8929361; DOI=10.1056/NEJM199611283352204;
RA   Drappa J., Vaishnaw A.K., Sullivan K.E., Chu J.-L., Elkon K.B.;
RT   "Fas gene mutations in the Canale-Smith syndrome, an inherited
RT   lymphoproliferative disorder associated with autoimmunity.";
RL   N. Engl. J. Med. 335:1643-1649(1996).
RN   [32]
RP   VARIANTS ALPS1A TRP-121 AND CYS-232.
RX   PubMed=9028321;
RA   Bettinardi A., Brugnoni D., Quiros-Roldan E., Malagoli A.,
RA   La Grutta S., Correra A., Notarangelo L.D.;
RT   "Missense mutations in the Fas gene resulting in autoimmune
RT   lymphoproliferative syndrome: a molecular and immunological
RT   analysis.";
RL   Blood 89:902-909(1997).
RN   [33]
RP   VARIANTS ALPS1A ASP-257 AND SER-310.
RX   PubMed=9028957;
RA   Sneller M.C., Wang J., Dale J.K., Strober W., Middelton L.A., Choi Y.,
RA   Fleisher T.A., Lim M.S., Jaffe E.S., Puck J.M., Lenardo M.J.,
RA   Straus S.E.;
RT   "Clinical, immunologic, and genetic features of an autoimmune
RT   lymphoproliferative syndrome associated with abnormal lymphocyte
RT   apoptosis.";
RL   Blood 89:1341-1348(1997).
RN   [34]
RP   VARIANT ALPS1A ALA-28.
RX   PubMed=9322534;
RA   Pensati L., Costanzo A., Ianni A., Accapezzato D., Iorio R.,
RA   Natoli G., Nisini R., Almerighi C., Balsano C., Vajro P., Vegnente A.,
RA   Levrero M.;
RT   "Fas/Apo1 mutations and autoimmune lymphoproliferative syndrome in a
RT   patient with type 2 autoimmune hepatitis.";
RL   Gastroenterology 113:1384-1389(1997).
RN   [35]
RP   VARIANTS NON-HODGKIN LYMPHOMA THR-25; PHE-180; LEU-183; ILE-198;
RP   VAL-260; LYS-264; LYS-272; PHE-278 AND ASN-299.
RX   PubMed=9787134;
RA   Groenbaek K., Straten P.T., Ralfkiaer E., Ahrenkiel V., Andersen M.K.,
RA   Hansen N.E., Zeuthen J., Hou-Jensen K., Guldberg P.;
RT   "Somatic Fas mutations in non-Hodgkin's lymphoma: association with
RT   extranodal disease and autoimmunity.";
RL   Blood 92:3018-3024(1998).
RN   [36]
RP   VARIANT ALPS1A VAL-260.
RX   PubMed=9821419; DOI=10.1016/S0022-3476(98)70102-7;
RA   Infante A.J., Britton H.A., DeNapoli T., Middelton L.A., Lenardo M.J.,
RA   Jackson C.E., Wang J., Fleisher T., Straus S.E., Puck J.M.;
RT   "The clinical spectrum in a large kindred with autoimmune
RT   lymphoproliferative syndrome caused by a Fas mutation that impairs
RT   lymphocyte apoptosis.";
RL   J. Pediatr. 133:629-633(1998).
RN   [37]
RP   VARIANTS ALPS1A LYS-241 AND GLN-250.
RX   PubMed=10090885; DOI=10.1086/302333;
RA   Jackson C.E., Fischer R.E., Hsu A.P., Anderson S.M., Choi Y., Wang J.,
RA   Dale J.K., Fleisher T.A., Middelton L.A., Sneller M.C., Lenardo M.J.,
RA   Straus S.E., Puck J.M.;
RT   "Autoimmune lymphoproliferative syndrome with defective Fas: genotype
RT   influences penetrance.";
RL   Am. J. Hum. Genet. 64:1002-1014(1999).
RN   [38]
RP   VARIANTS ALPS1A LEU-249; PRO-250; ASP-253; SER-253; ARG-259; LYS-270
RP   AND LYS-272.
RX   PubMed=10515860;
RA   Rieux-Laucat F., Blachere S., Danielan S., De Villartay J.P.,
RA   Oleastro M., Solary E., Bader-Meunier B., Arkwright P., Pondare C.,
RA   Bernaudin F., Chapel H., Nielsen S., Berrah M., Fischer A.,
RA   Le Deist F.;
RT   "Lymphoproliferative syndrome with autoimmunity: A possible genetic
RT   basis for dominant expression of the clinical manifestations.";
RL   Blood 94:2575-2582(1999).
RN   [39]
RP   VARIANT ALPS1A GLY-272.
RX   PubMed=10340403; DOI=10.1016/S0301-472X(99)00033-8;
RA   Peters A.M., Kohfink B., Martin H., Griesinger F., Wormann B.,
RA   Gahr M., Roesler J.;
RT   "Defective apoptosis due to a point mutation in the death domain of
RT   CD95 associated with autoimmune lymphoproliferative syndrome, T-cell
RT   lymphoma, and Hodgkin's disease.";
RL   Exp. Hematol. 27:868-874(1999).
RN   [40]
RP   VARIANTS ALPS1A ARG-82; PRO-250; GLY-260 AND ILE-270.
RX   PubMed=9927496; DOI=10.1172/JCI5121;
RA   Vaishnaw A.K., Orlinick J.R., Chu J.-L., Krammer P.H., Chao M.V.,
RA   Elkon K.B.;
RT   "The molecular basis for apoptotic defects in patients with CD95
RT   (Fas/Apo-1) mutations.";
RL   J. Clin. Invest. 103:355-363(1999).
RN   [41]
RP   VARIANTS SQUAMOUS CELL CARCINOMA SER-118; ARG-178 AND ASP-255.
RX   PubMed=10620127; DOI=10.1046/j.1523-1747.2000.00819.x;
RA   Lee S.H., Shin M.S., Kim H.S., Park W.S., Kim S.Y., Jang J.J.,
RA   Rhim K.J., Jang J., Lee H.K., Park J.Y., Oh R.R., Han S.Y., Lee J.H.,
RA   Lee J.Y., Yoo N.J.;
RT   "Somatic mutations of Fas (Apo-1/CD95) gene in cutaneous squamous cell
RT   carcinoma arising from a burn scar.";
RL   J. Invest. Dermatol. 114:122-126(2000).
RN   [42]
RP   VARIANTS ALPS1A PRO-241; VAL-260; ILE-270 AND GLY-272.
RX   PubMed=11418480; DOI=10.1182/blood.V98.1.194;
RA   Straus S.E., Jaffe E.S., Puck J.M., Dale J.K., Elkon K.B.,
RA   Roesen-Wolff A., Peters A.M.J., Sneller M.C., Hallahan C.W., Wang J.,
RA   Fischer R.E., Jackson C.M., Lin A.Y., Baeumler C., Siegert E.,
RA   Marx A., Vaishnaw A.K., Grodzicky T., Fleisher T.A., Lenardo M.J.;
RT   "The development of lymphomas in families with autoimmune
RT   lymphoproliferative syndrome with germline Fas mutations and defective
RT   lymphocyte apoptosis.";
RL   Blood 98:194-200(2001).
RN   [43]
RP   CHARACTERIZATION OF VARIANTS ALPS1A CYS-232; GLN-250; ASP-257;
RP   TYR-260; VAL-260; LYS-270 AND LYS-272, AND MUTAGENESIS OF ARG-250;
RP   GLU-261; GLN-283 AND LYS-287.
RX   PubMed=20935634; DOI=10.1038/nsmb.1920;
RA   Wang L., Yang J.K., Kabaleeswaran V., Rice A.J., Cruz A.C., Park A.Y.,
RA   Yin Q., Damko E., Jang S.B., Raunser S., Robinson C.V., Siegel R.M.,
RA   Walz T., Wu H.;
RT   "The Fas-FADD death domain complex structure reveals the basis of DISC
RT   assembly and disease mutations.";
RL   Nat. Struct. Mol. Biol. 17:1324-1329(2010).
CC   -!- FUNCTION: Receptor for TNFSF6/FASLG. The adapter molecule FADD
CC       recruits caspase-8 to the activated receptor. The resulting death-
CC       inducing signaling complex (DISC) performs caspase-8 proteolytic
CC       activation which initiates the subsequent cascade of caspases
CC       (aspartate-specific cysteine proteases) mediating apoptosis. FAS-
CC       mediated apoptosis may have a role in the induction of peripheral
CC       tolerance, in the antigen-stimulated suicide of mature T-cells, or
CC       both. The secreted isoforms 2 to 6 block apoptosis (in vitro).
CC       {ECO:0000269|PubMed:19118384, ECO:0000269|PubMed:7533181}.
CC   -!- SUBUNIT: Binds DAXX. Interacts with HIPK3. Part of a complex
CC       containing HIPK3 and FADD (By similarity). Binds RIPK1 and FAIM2.
CC       Interacts with BRE and FEM1B. Interacts with FADD. Interacts
CC       directly (via DED domain) with NOL3 (via CARD domain); inhibits
CC       death-inducing signaling complex (DISC) assembly by inhibiting the
CC       increase in FAS-FADD binding induced by FAS activation (By
CC       similarity). {ECO:0000250, ECO:0000250|UniProtKB:Q63199,
CC       ECO:0000269|PubMed:10535980, ECO:0000269|PubMed:10542291,
CC       ECO:0000269|PubMed:15465831, ECO:0000269|PubMed:19118384,
CC       ECO:0000269|PubMed:21109225, ECO:0000269|PubMed:7538908}.
CC   -!- INTERACTION:
CC       Self; NbExp=3; IntAct=EBI-494743, EBI-494743;
CC       P62158:CALM3; NbExp=4; IntAct=EBI-494743, EBI-397435;
CC       Q14790:CASP8; NbExp=14; IntAct=EBI-494743, EBI-78060;
CC       Q03135:CAV1; NbExp=3; IntAct=EBI-494743, EBI-603614;
CC       Q9UER7:DAXX; NbExp=3; IntAct=EBI-494743, EBI-77321;
CC       Q13158:FADD; NbExp=33; IntAct=EBI-494743, EBI-494804;
CC       P48023:FASLG; NbExp=4; IntAct=EBI-494743, EBI-495538;
CC       Q99683:MAP3K5; NbExp=2; IntAct=EBI-494743, EBI-476263;
CC       P12815:Pdcd6 (xeno); NbExp=2; IntAct=EBI-494743, EBI-309164;
CC       P29590:PML; NbExp=4; IntAct=EBI-494743, EBI-295890;
CC       Q15156:PML-RAR; NbExp=6; IntAct=EBI-494743, EBI-867256;
CC       Q12923:PTPN13; NbExp=3; IntAct=EBI-494743, EBI-355227;
CC       P12931:SRC; NbExp=2; IntAct=EBI-494743, EBI-621482;
CC   -!- SUBCELLULAR LOCATION: Isoform 1: Cell membrane; Single-pass type I
CC       membrane protein.
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Secreted.
CC   -!- SUBCELLULAR LOCATION: Isoform 3: Secreted.
CC   -!- SUBCELLULAR LOCATION: Isoform 4: Secreted.
CC   -!- SUBCELLULAR LOCATION: Isoform 5: Secreted.
CC   -!- SUBCELLULAR LOCATION: Isoform 6: Secreted.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=7;
CC       Name=1;
CC         IsoId=P25445-1; Sequence=Displayed;
CC       Name=2; Synonyms=del2, D;
CC         IsoId=P25445-2; Sequence=VSP_006481, VSP_006482;
CC         Note=May be produced at very low levels due to a premature stop
CC         codon in the mRNA, leading to nonsense-mediated mRNA decay.;
CC       Name=3; Synonyms=del3, E;
CC         IsoId=P25445-3; Sequence=VSP_006483, VSP_006484;
CC         Note=May be produced at very low levels due to a premature stop
CC         codon in the mRNA, leading to nonsense-mediated mRNA decay.;
CC       Name=4; Synonyms=B;
CC         IsoId=P25445-4; Sequence=VSP_006485, VSP_006486;
CC         Note=May be produced at very low levels due to a premature stop
CC         codon in the mRNA, leading to nonsense-mediated mRNA decay.;
CC       Name=5; Synonyms=C;
CC         IsoId=P25445-5; Sequence=VSP_006487, VSP_006488;
CC         Note=May be produced at very low levels due to a premature stop
CC         codon in the mRNA, leading to nonsense-mediated mRNA decay.;
CC       Name=6; Synonyms=TMdel, A;
CC         IsoId=P25445-6; Sequence=VSP_006489;
CC       Name=7; Synonyms=FasExo8Del;
CC         IsoId=P25445-7; Sequence=VSP_045235, VSP_045236;
CC         Note=Dominant negative isoform, resistant to Fas-mediated
CC         apoptosis.;
CC   -!- TISSUE SPECIFICITY: Isoform 1 and isoform 6 are expressed at equal
CC       levels in resting peripheral blood mononuclear cells. After
CC       activation there is an increase in isoform 1 and decrease in the
CC       levels of isoform 6. {ECO:0000269|PubMed:7575433}.
CC   -!- DOMAIN: Contains a death domain involved in the binding of FADD,
CC       and maybe to other cytosolic adapter proteins.
CC   -!- PTM: N- and O-glycosylated. O-glycosylated with core 1 or possibly
CC       core 8 glycans. {ECO:0000269|PubMed:19159218,
CC       ECO:0000269|PubMed:22171320}.
CC   -!- DISEASE: Autoimmune lymphoproliferative syndrome 1A (ALPS1A)
CC       [MIM:601859]: A disorder of apoptosis that manifests in early
CC       childhood and results in the accumulation of autoreactive
CC       lymphocytes. It is characterized by non-malignant lymphadenopathy
CC       with hepatosplenomegaly, and autoimmune hemolytic anemia,
CC       thrombocytopenia and neutropenia. {ECO:0000269|PubMed:10090885,
CC       ECO:0000269|PubMed:10340403, ECO:0000269|PubMed:10515860,
CC       ECO:0000269|PubMed:11418480, ECO:0000269|PubMed:17336828,
CC       ECO:0000269|PubMed:7540117, ECO:0000269|PubMed:8929361,
CC       ECO:0000269|PubMed:9028321, ECO:0000269|PubMed:9028957,
CC       ECO:0000269|PubMed:9322534, ECO:0000269|PubMed:9821419,
CC       ECO:0000269|PubMed:9927496}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Contains 1 death domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00064}.
CC   -!- SIMILARITY: Contains 3 TNFR-Cys repeats. {ECO:0000255|PROSITE-
CC       ProRule:PRU00206}.
CC   -!- WEB RESOURCE: Name=Autoimmune Lymphoproliferative Syndrome
CC       Database (ALPSbase); Note=Mutations in TNFRSF6 causing ALPS type
CC       Ia;
CC       URL="http://research.nhgri.nih.gov/ALPS/alpsIa_mut.shtml";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/tnfrsf6/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M67454; AAA63174.1; -; mRNA.
DR   EMBL; X63717; CAA45250.1; -; mRNA.
DR   EMBL; X83490; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; X83491; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; X83492; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; X83493; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; Z47993; CAA88031.1; -; mRNA.
DR   EMBL; Z47994; CAA88032.1; -; mRNA.
DR   EMBL; Z47995; CAA88033.1; -; mRNA.
DR   EMBL; Z66556; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; Z70519; CAA94430.1; -; mRNA.
DR   EMBL; Z70520; CAA94431.1; -; mRNA.
DR   EMBL; AY495076; AAS76663.1; -; mRNA.
DR   EMBL; X89101; CAA61473.1; -; mRNA.
DR   EMBL; FM246458; CAR92543.1; -; mRNA.
DR   EMBL; AK290978; BAF83667.1; -; mRNA.
DR   EMBL; AY450925; AAR08906.1; -; Genomic_DNA.
DR   EMBL; AL157394; CAI13870.1; -; Genomic_DNA.
DR   EMBL; AL157394; CAI13871.1; -; Genomic_DNA.
DR   EMBL; AL157394; CAI13872.1; -; Genomic_DNA.
DR   EMBL; CH471066; EAW50151.1; -; Genomic_DNA.
DR   EMBL; BC012479; AAH12479.1; -; mRNA.
DR   CCDS; CCDS7393.1; -. [P25445-1]
DR   CCDS; CCDS7394.1; -. [P25445-6]
DR   CCDS; CCDS7395.1; -. [P25445-7]
DR   PIR; A40036; A40036.
DR   PIR; I37383; I37383.
DR   PIR; I37384; I37384.
DR   PIR; S58662; S58662.
DR   RefSeq; NP_000034.1; NM_000043.4. [P25445-1]
DR   RefSeq; NP_690610.1; NM_152871.2. [P25445-6]
DR   RefSeq; NP_690611.1; NM_152872.2. [P25445-7]
DR   UniGene; Hs.244139; -.
DR   UniGene; Hs.667309; -.
DR   PDB; 1BZI; Model; -; A=1-335.
DR   PDB; 1DDF; NMR; -; A=218-335.
DR   PDB; 3EWT; X-ray; 2.40 A; E=230-254.
DR   PDB; 3EZQ; X-ray; 2.73 A; A/C/E/G/I/K/M/O=223-335.
DR   PDB; 3THM; X-ray; 2.10 A; F=17-172.
DR   PDB; 3TJE; X-ray; 1.93 A; F=17-172.
DR   PDBsum; 1BZI; -.
DR   PDBsum; 1DDF; -.
DR   PDBsum; 3EWT; -.
DR   PDBsum; 3EZQ; -.
DR   PDBsum; 3THM; -.
DR   PDBsum; 3TJE; -.
DR   ProteinModelPortal; P25445; -.
DR   SMR; P25445; 52-163, 218-335.
DR   BioGrid; 106851; 99.
DR   DIP; DIP-924N; -.
DR   IntAct; P25445; 41.
DR   MINT; MINT-146256; -.
DR   STRING; 9606.ENSP00000347979; -.
DR   iPTMnet; P25445; -.
DR   PhosphoSite; P25445; -.
DR   SwissPalm; P25445; -.
DR   UniCarbKB; P25445; -.
DR   BioMuta; FAS; -.
DR   DMDM; 119833; -.
DR   MaxQB; P25445; -.
DR   PaxDb; P25445; -.
DR   PRIDE; P25445; -.
DR   DNASU; 355; -.
DR   Ensembl; ENST00000355279; ENSP00000347426; ENSG00000026103. [P25445-7]
DR   Ensembl; ENST00000355740; ENSP00000347979; ENSG00000026103. [P25445-1]
DR   Ensembl; ENST00000357339; ENSP00000349896; ENSG00000026103. [P25445-6]
DR   Ensembl; ENST00000479522; ENSP00000424113; ENSG00000026103. [P25445-3]
DR   Ensembl; ENST00000484444; ENSP00000420975; ENSG00000026103. [P25445-2]
DR   Ensembl; ENST00000488877; ENSP00000425159; ENSG00000026103. [P25445-4]
DR   Ensembl; ENST00000492756; ENSP00000422453; ENSG00000026103. [P25445-5]
DR   Ensembl; ENST00000494410; ENSP00000423755; ENSG00000026103. [P25445-4]
DR   GeneID; 355; -.
DR   KEGG; hsa:355; -.
DR   UCSC; uc001kfr.3; human. [P25445-1]
DR   UCSC; uc001kfs.3; human.
DR   UCSC; uc001kft.3; human. [P25445-6]
DR   UCSC; uc001kfw.3; human. [P25445-4]
DR   CTD; 355; -.
DR   GeneCards; FAS; -.
DR   GeneReviews; FAS; -.
DR   HGNC; HGNC:11920; FAS.
DR   HPA; HPA027444; -.
DR   MalaCards; FAS; -.
DR   MIM; 134637; gene.
DR   MIM; 601859; phenotype.
DR   neXtProt; NX_P25445; -.
DR   Orphanet; 3261; Autoimmune lymphoproliferative syndrome.
DR   Orphanet; 85408; Juvenile rheumatoid factor-negative polyarthritis.
DR   Orphanet; 85410; Oligoarticular juvenile arthritis.
DR   PharmGKB; PA36613; -.
DR   eggNOG; ENOG410J23A; Eukaryota.
DR   eggNOG; ENOG4112ADB; LUCA.
DR   GeneTree; ENSGT00730000111280; -.
DR   HOGENOM; HOG000139681; -.
DR   HOVERGEN; HBG004091; -.
DR   InParanoid; P25445; -.
DR   KO; K04390; -.
DR   OMA; CTTCEHG; -.
DR   OrthoDB; EOG7DVDC8; -.
DR   PhylomeDB; P25445; -.
DR   TreeFam; TF333916; -.
DR   Reactome; R-HSA-75157; FasL/ CD95L signaling.
DR   EvolutionaryTrace; P25445; -.
DR   GeneWiki; Fas_receptor; -.
DR   GenomeRNAi; 355; -.
DR   NextBio; 1471; -.
DR   PMAP-CutDB; P25445; -.
DR   PRO; PR:P25445; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   Bgee; P25445; -.
DR   CleanEx; HS_FAS; -.
DR   ExpressionAtlas; P25445; baseline and differential.
DR   Genevisible; P25445; HS.
DR   GO; GO:0097440; C:apical dendrite; IEA:Ensembl.
DR   GO; GO:0016324; C:apical plasma membrane; IEA:Ensembl.
DR   GO; GO:0031265; C:CD95 death-inducing signaling complex; IDA:UniProtKB.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:HPA.
DR   GO; GO:0005829; C:cytosol; NAS:UniProtKB.
DR   GO; GO:0031264; C:death-inducing signaling complex; IDA:UniProtKB.
DR   GO; GO:0009897; C:external side of plasma membrane; IEA:Ensembl.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; IEA:Ensembl.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0045121; C:membrane raft; IDA:UniProtKB.
DR   GO; GO:0043005; C:neuron projection; IBA:GO_Central.
DR   GO; GO:0043025; C:neuronal cell body; IEA:Ensembl.
DR   GO; GO:0005634; C:nucleus; IDA:HPA.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IMP:UniProtKB.
DR   GO; GO:0042383; C:sarcolemma; IEA:Ensembl.
DR   GO; GO:0030141; C:secretory granule; IEA:Ensembl.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0019900; F:kinase binding; IPI:BHF-UCL.
DR   GO; GO:0004872; F:receptor activity; NAS:UniProtKB.
DR   GO; GO:0004871; F:signal transducer activity; TAS:ProtInc.
DR   GO; GO:0005031; F:tumor necrosis factor-activated receptor activity; IBA:GO_Central.
DR   GO; GO:0006919; P:activation of cysteine-type endopeptidase activity involved in apoptotic process; TAS:Reactome.
DR   GO; GO:0097296; P:activation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway; TAS:Reactome.
DR   GO; GO:0006924; P:activation-induced cell death of T cells; IEA:Ensembl.
DR   GO; GO:0007568; P:aging; IEA:Ensembl.
DR   GO; GO:0006915; P:apoptotic process; IDA:MGI.
DR   GO; GO:0097190; P:apoptotic signaling pathway; TAS:Reactome.
DR   GO; GO:0019724; P:B cell mediated immunity; IEA:Ensembl.
DR   GO; GO:0007420; P:brain development; IBA:GO_Central.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0071279; P:cellular response to cobalt ion; IEA:Ensembl.
DR   GO; GO:0071391; P:cellular response to estrogen stimulus; IEA:Ensembl.
DR   GO; GO:0071333; P:cellular response to glucose stimulus; IEA:Ensembl.
DR   GO; GO:0070301; P:cellular response to hydrogen peroxide; IEA:Ensembl.
DR   GO; GO:0071464; P:cellular response to hydrostatic pressure; IEA:Ensembl.
DR   GO; GO:0071455; P:cellular response to hyperoxia; IMP:UniProtKB.
DR   GO; GO:0071456; P:cellular response to hypoxia; IEA:Ensembl.
DR   GO; GO:0071347; P:cellular response to interleukin-1; IEA:Ensembl.
DR   GO; GO:0071285; P:cellular response to lithium ion; IEA:Ensembl.
DR   GO; GO:0071260; P:cellular response to mechanical stimulus; IEP:UniProtKB.
DR   GO; GO:0071234; P:cellular response to phenylalanine; IEA:Ensembl.
DR   GO; GO:0043009; P:chordate embryonic development; IEA:Ensembl.
DR   GO; GO:0007623; P:circadian rhythm; IEA:Ensembl.
DR   GO; GO:0031104; P:dendrite regeneration; IEA:Ensembl.
DR   GO; GO:0097191; P:extrinsic apoptotic signaling pathway; IMP:UniProtKB.
DR   GO; GO:0097192; P:extrinsic apoptotic signaling pathway in absence of ligand; IEA:Ensembl.
DR   GO; GO:0008625; P:extrinsic apoptotic signaling pathway via death domain receptors; IBA:GO_Central.
DR   GO; GO:0097284; P:hepatocyte apoptotic process; IEA:Ensembl.
DR   GO; GO:0006955; P:immune response; IBA:GO_Central.
DR   GO; GO:0002377; P:immunoglobulin production; IEA:Ensembl.
DR   GO; GO:0006925; P:inflammatory cell apoptotic process; IEA:Ensembl.
DR   GO; GO:0006954; P:inflammatory response; IBA:GO_Central.
DR   GO; GO:0097421; P:liver regeneration; IEA:Ensembl.
DR   GO; GO:0060135; P:maternal process involved in female pregnancy; IEA:Ensembl.
DR   GO; GO:0097049; P:motor neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0070266; P:necroptotic process; TAS:Reactome.
DR   GO; GO:0097527; P:necroptotic signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; TAS:ProtInc.
DR   GO; GO:0050869; P:negative regulation of B cell activation; IEA:Ensembl.
DR   GO; GO:0043154; P:negative regulation of cysteine-type endopeptidase activity involved in apoptotic process; TAS:Reactome.
DR   GO; GO:0045060; P:negative thymic T cell selection; IEA:Ensembl.
DR   GO; GO:0001552; P:ovarian follicle atresia; IEA:Ensembl.
DR   GO; GO:0042698; P:ovulation cycle; IEA:Ensembl.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:2001241; P:positive regulation of extrinsic apoptotic signaling pathway in absence of ligand; IEA:Ensembl.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IBA:GO_Central.
DR   GO; GO:0032464; P:positive regulation of protein homooligomerization; IEA:Ensembl.
DR   GO; GO:0012501; P:programmed cell death; TAS:Reactome.
DR   GO; GO:0097300; P:programmed necrotic cell death; TAS:Reactome.
DR   GO; GO:0006461; P:protein complex assembly; TAS:ProtInc.
DR   GO; GO:0051260; P:protein homooligomerization; IEA:Ensembl.
DR   GO; GO:0042981; P:regulation of apoptotic process; NAS:UniProtKB.
DR   GO; GO:0042127; P:regulation of cell proliferation; IBA:GO_Central.
DR   GO; GO:0043281; P:regulation of cysteine-type endopeptidase activity involved in apoptotic process; IBA:GO_Central.
DR   GO; GO:1902041; P:regulation of extrinsic apoptotic signaling pathway via death domain receptors; TAS:Reactome.
DR   GO; GO:0010468; P:regulation of gene expression; IEA:Ensembl.
DR   GO; GO:0045619; P:regulation of lymphocyte differentiation; IEA:Ensembl.
DR   GO; GO:0045637; P:regulation of myeloid cell differentiation; IEA:Ensembl.
DR   GO; GO:0010939; P:regulation of necrotic cell death; TAS:Reactome.
DR   GO; GO:0003014; P:renal system process; IEA:Ensembl.
DR   GO; GO:0046898; P:response to cycloheximide; IEA:Ensembl.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:1902617; P:response to fluoride; IEA:Ensembl.
DR   GO; GO:0051384; P:response to glucocorticoid; IEA:Ensembl.
DR   GO; GO:0070848; P:response to growth factor; IEA:Ensembl.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IBA:GO_Central.
DR   GO; GO:0043434; P:response to peptide hormone; IEA:Ensembl.
DR   GO; GO:0009636; P:response to toxic substance; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0007283; P:spermatogenesis; IEA:Ensembl.
DR   GO; GO:0048536; P:spleen development; IEA:Ensembl.
DR   GO; GO:0021537; P:telencephalon development; IEA:Ensembl.
DR   GO; GO:0006927; P:transformed cell apoptotic process; IEA:Ensembl.
DR   Gene3D; 1.10.533.10; -; 1.
DR   InterPro; IPR011029; DEATH-like_dom.
DR   InterPro; IPR000488; Death_domain.
DR   InterPro; IPR008063; Fas_rcpt.
DR   InterPro; IPR001368; TNFR/NGFR_Cys_rich_reg.
DR   Pfam; PF00531; Death; 1.
DR   Pfam; PF00020; TNFR_c6; 2.
DR   PRINTS; PR01680; TNFACTORR6.
DR   SMART; SM00005; DEATH; 1.
DR   SMART; SM00208; TNFR; 3.
DR   SUPFAM; SSF47986; SSF47986; 1.
DR   PROSITE; PS50017; DEATH_DOMAIN; 1.
DR   PROSITE; PS00652; TNFR_NGFR_1; 2.
DR   PROSITE; PS50050; TNFR_NGFR_2; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Apoptosis; Cell membrane;
KW   Complete proteome; Direct protein sequencing; Disease mutation;
KW   Disulfide bond; Glycoprotein; Membrane; Phosphoprotein; Polymorphism;
KW   Receptor; Reference proteome; Repeat; Secreted; Signal; Transmembrane;
KW   Transmembrane helix.
FT   SIGNAL        1     25       {ECO:0000255}.
FT   CHAIN        26    335       Tumor necrosis factor receptor
FT                                superfamily member 6.
FT                                /FTId=PRO_0000034563.
FT   TOPO_DOM     26    173       Extracellular. {ECO:0000255}.
FT   TRANSMEM    174    190       Helical. {ECO:0000255}.
FT   TOPO_DOM    191    335       Cytoplasmic. {ECO:0000255}.
FT   REPEAT       47     83       TNFR-Cys 1.
FT   REPEAT       84    127       TNFR-Cys 2.
FT   REPEAT      128    166       TNFR-Cys 3.
FT   DOMAIN      230    314       Death. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00064}.
FT   REGION      212    317       Interaction with HIPK3. {ECO:0000250}.
FT   MOD_RES     209    209       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     214    214       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:P25446}.
FT   MOD_RES     225    225       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   CARBOHYD     28     28       O-linked (GalNAc...).
FT                                {ECO:0000269|PubMed:22171320}.
FT   CARBOHYD    118    118       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19159218}.
FT   CARBOHYD    136    136       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     59     73       {ECO:0000255|PROSITE-ProRule:PRU00206}.
FT   DISULFID     63     82       {ECO:0000255|PROSITE-ProRule:PRU00206}.
FT   DISULFID     85    101       {ECO:0000255|PROSITE-ProRule:PRU00206}.
FT   DISULFID    104    119       {ECO:0000255|PROSITE-ProRule:PRU00206}.
FT   DISULFID    107    127       {ECO:0000255|PROSITE-ProRule:PRU00206}.
FT   DISULFID    129    143       {ECO:0000255|PROSITE-ProRule:PRU00206}.
FT   DISULFID    146    157       {ECO:0000255|PROSITE-ProRule:PRU00206}.
FT   DISULFID    149    165       {ECO:0000255|PROSITE-ProRule:PRU00206}.
FT   VAR_SEQ      66    103       GERKARDCTVNGDEPDCVPCQEGKEYTDKAHFSSKCRR ->
FT                                DVNMESSRNAHSPATPSAKRKDPDLTWGGFVFFFCQFH
FT                                (in isoform 2).
FT                                {ECO:0000303|PubMed:7533181,
FT                                ECO:0000303|PubMed:7575433}.
FT                                /FTId=VSP_006481.
FT   VAR_SEQ      66     86       GERKARDCTVNGDEPDCVPCQ -> DVNMESSRNAHSPATP
FT                                SAKRK (in isoform 3).
FT                                {ECO:0000303|PubMed:7533181,
FT                                ECO:0000303|PubMed:7575433}.
FT                                /FTId=VSP_006483.
FT   VAR_SEQ      87    335       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:7533181,
FT                                ECO:0000303|PubMed:7575433}.
FT                                /FTId=VSP_006484.
FT   VAR_SEQ     104    335       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:7533181,
FT                                ECO:0000303|PubMed:7575433}.
FT                                /FTId=VSP_006482.
FT   VAR_SEQ     112    149       GLEVEINCTRTQNTKCRCKPNFFCNSTVCEHCDPCTKC ->
FT                                DVNMESSRNAHSPATPSAKRKDPDLTWGGFVFFFCQFH
FT                                (in isoform 4).
FT                                {ECO:0000303|PubMed:7575433,
FT                                ECO:0000303|PubMed:8648105}.
FT                                /FTId=VSP_006485.
FT   VAR_SEQ     112    132       GLEVEINCTRTQNTKCRCKPN -> DVNMESSRNAHSPATP
FT                                SAKRK (in isoform 5).
FT                                {ECO:0000303|PubMed:8648105,
FT                                ECO:0000303|Ref.8}.
FT                                /FTId=VSP_006487.
FT   VAR_SEQ     133    335       Missing (in isoform 5).
FT                                {ECO:0000303|PubMed:8648105,
FT                                ECO:0000303|Ref.8}.
FT                                /FTId=VSP_006488.
FT   VAR_SEQ     150    335       Missing (in isoform 4).
FT                                {ECO:0000303|PubMed:7575433,
FT                                ECO:0000303|PubMed:8648105}.
FT                                /FTId=VSP_006486.
FT   VAR_SEQ     169    189       Missing (in isoform 6).
FT                                {ECO:0000303|PubMed:7533181,
FT                                ECO:0000303|PubMed:7575433}.
FT                                /FTId=VSP_006489.
FT   VAR_SEQ     218    220       ETV -> MLT (in isoform 7).
FT                                {ECO:0000303|PubMed:8598453}.
FT                                /FTId=VSP_045235.
FT   VAR_SEQ     221    335       Missing (in isoform 7).
FT                                {ECO:0000303|PubMed:8598453}.
FT                                /FTId=VSP_045236.
FT   VARIANT      16     16       A -> T (in dbSNP:rs3218619).
FT                                {ECO:0000269|Ref.11}.
FT                                /FTId=VAR_020008.
FT   VARIANT      25     25       A -> T (in non-Hodgkin lymphoma; somatic
FT                                mutation). {ECO:0000269|PubMed:9787134}.
FT                                /FTId=VAR_013416.
FT   VARIANT      28     28       T -> A (in ALPS1A; associated with
FT                                autoimmune hepatitis type 2).
FT                                {ECO:0000269|PubMed:9322534}.
FT                                /FTId=VAR_013417.
FT   VARIANT      82     82       C -> R (in ALPS1A).
FT                                {ECO:0000269|PubMed:9927496}.
FT                                /FTId=VAR_013418.
FT   VARIANT     118    118       N -> S (in squamous cell carcinoma; burn-
FT                                scar related; somatic mutation).
FT                                {ECO:0000269|PubMed:10620127}.
FT                                /FTId=VAR_018321.
FT   VARIANT     121    121       R -> W (in ALPS1A).
FT                                {ECO:0000269|PubMed:9028321}.
FT                                /FTId=VAR_013419.
FT   VARIANT     122    122       T -> I (in dbSNP:rs3218614).
FT                                {ECO:0000269|Ref.11}.
FT                                /FTId=VAR_020009.
FT   VARIANT     178    178       C -> R (in squamous cell carcinoma; burn-
FT                                scar related; somatic mutation).
FT                                {ECO:0000269|PubMed:10620127}.
FT                                /FTId=VAR_018322.
FT   VARIANT     180    180       L -> F (in non-Hodgkin lymphoma; somatic
FT                                mutation). {ECO:0000269|PubMed:9787134}.
FT                                /FTId=VAR_013420.
FT   VARIANT     183    183       P -> L (in non-Hodgkin lymphoma; somatic
FT                                mutation). {ECO:0000269|PubMed:9787134}.
FT                                /FTId=VAR_013421.
FT   VARIANT     184    184       I -> V (in dbSNP:rs28362322).
FT                                /FTId=VAR_052347.
FT   VARIANT     198    198       T -> I (in non-Hodgkin lymphoma; somatic
FT                                mutation). {ECO:0000269|PubMed:9787134}.
FT                                /FTId=VAR_013422.
FT   VARIANT     232    232       Y -> C (in ALPS1A; no effect on
FT                                interaction with FADD).
FT                                {ECO:0000269|PubMed:20935634,
FT                                ECO:0000269|PubMed:9028321}.
FT                                /FTId=VAR_013423.
FT   VARIANT     241    241       T -> K (in ALPS1A).
FT                                {ECO:0000269|PubMed:10090885}.
FT                                /FTId=VAR_013424.
FT   VARIANT     241    241       T -> P (in ALPS1A).
FT                                {ECO:0000269|PubMed:11418480,
FT                                ECO:0000269|PubMed:7540117}.
FT                                /FTId=VAR_013425.
FT   VARIANT     249    249       V -> L (in ALPS1A).
FT                                {ECO:0000269|PubMed:10515860}.
FT                                /FTId=VAR_065128.
FT   VARIANT     250    250       R -> P (in ALPS1A).
FT                                {ECO:0000269|PubMed:10515860,
FT                                ECO:0000269|PubMed:9927496}.
FT                                /FTId=VAR_013426.
FT   VARIANT     250    250       R -> Q (in ALPS1A; no effect on
FT                                interaction with FADD).
FT                                {ECO:0000269|PubMed:10090885,
FT                                ECO:0000269|PubMed:20935634}.
FT                                /FTId=VAR_013427.
FT   VARIANT     253    253       G -> D (in ALPS1A).
FT                                {ECO:0000269|PubMed:10515860}.
FT                                /FTId=VAR_065129.
FT   VARIANT     253    253       G -> S (in ALPS1A).
FT                                {ECO:0000269|PubMed:10515860}.
FT                                /FTId=VAR_065130.
FT   VARIANT     255    255       N -> D (in squamous cell carcinoma; burn-
FT                                scar related; somatic mutation).
FT                                {ECO:0000269|PubMed:10620127}.
FT                                /FTId=VAR_018323.
FT   VARIANT     257    257       A -> D (in ALPS1A; loss of interaction
FT                                with FADD). {ECO:0000269|PubMed:20935634,
FT                                ECO:0000269|PubMed:9028957}.
FT                                /FTId=VAR_013428.
FT   VARIANT     259    259       I -> R (in ALPS1A).
FT                                {ECO:0000269|PubMed:10515860}.
FT                                /FTId=VAR_065131.
FT   VARIANT     260    260       D -> G (in ALPS1A).
FT                                {ECO:0000269|PubMed:9927496}.
FT                                /FTId=VAR_013429.
FT   VARIANT     260    260       D -> V (in ALPS1A; also found in non-
FT                                Hodgkin lymphoma; somatic mutation; loss
FT                                of interaction with FADD;
FT                                dbSNP:rs28929498).
FT                                {ECO:0000269|PubMed:11418480,
FT                                ECO:0000269|PubMed:20935634,
FT                                ECO:0000269|PubMed:9787134,
FT                                ECO:0000269|PubMed:9821419}.
FT                                /FTId=VAR_013431.
FT   VARIANT     260    260       D -> Y (in ALPS1A; loss of interaction
FT                                with FADD). {ECO:0000269|PubMed:20935634,
FT                                ECO:0000269|PubMed:8929361}.
FT                                /FTId=VAR_013430.
FT   VARIANT     262    262       I -> S (in ALPS1A).
FT                                {ECO:0000269|PubMed:17336828}.
FT                                /FTId=VAR_058910.
FT   VARIANT     264    264       N -> K (in non-Hodgkin lymphoma; somatic
FT                                mutation). {ECO:0000269|PubMed:9787134}.
FT                                /FTId=VAR_013432.
FT   VARIANT     270    270       T -> I (in ALPS1A).
FT                                {ECO:0000269|PubMed:11418480,
FT                                ECO:0000269|PubMed:9927496}.
FT                                /FTId=VAR_013433.
FT   VARIANT     270    270       T -> K (in ALPS1A; loss of interaction
FT                                with FADD). {ECO:0000269|PubMed:10515860,
FT                                ECO:0000269|PubMed:20935634}.
FT                                /FTId=VAR_065132.
FT   VARIANT     272    272       E -> G (in ALPS1A).
FT                                {ECO:0000269|PubMed:10340403,
FT                                ECO:0000269|PubMed:11418480}.
FT                                /FTId=VAR_013434.
FT   VARIANT     272    272       E -> K (in ALPS1A; also found in non-
FT                                Hodgkin lymphoma; somatic mutation; loss
FT                                of interaction with FADD).
FT                                {ECO:0000269|PubMed:10515860,
FT                                ECO:0000269|PubMed:20935634,
FT                                ECO:0000269|PubMed:9787134}.
FT                                /FTId=VAR_013435.
FT   VARIANT     278    278       L -> F (in non-Hodgkin lymphoma; somatic
FT                                mutation). {ECO:0000269|PubMed:9787134}.
FT                                /FTId=VAR_013436.
FT   VARIANT     299    299       K -> N (in non-Hodgkin lymphoma; somatic
FT                                mutation). {ECO:0000269|PubMed:9787134}.
FT                                /FTId=VAR_013437.
FT   VARIANT     305    305       T -> I (in dbSNP:rs3218611).
FT                                {ECO:0000269|Ref.11}.
FT                                /FTId=VAR_020942.
FT   VARIANT     310    310       I -> S (in ALPS1A).
FT                                {ECO:0000269|PubMed:9028957}.
FT                                /FTId=VAR_013438.
FT   MUTAGEN     250    250       R->E: Strongly decreased interaction with
FT                                FADD. {ECO:0000269|PubMed:20935634}.
FT   MUTAGEN     261    261       E->K: Loss of interaction with FADD.
FT                                {ECO:0000269|PubMed:20935634}.
FT   MUTAGEN     283    283       Q->K: Loss of interaction with FADD.
FT                                {ECO:0000269|PubMed:20935634}.
FT   MUTAGEN     287    287       K->D: Strongly decreased interaction with
FT                                FADD. {ECO:0000269|PubMed:20935634}.
FT   MUTAGEN     291    291       Y->D: Decreased interaction with FADD.
FT                                {ECO:0000269|PubMed:19118384}.
FT   MUTAGEN     313    313       I->D: Constitutive activation. Promotes
FT                                apoptosis, both in the presence and in
FT                                the absence of stimulation by a ligand.
FT                                {ECO:0000269|PubMed:19118384}.
FT   CONFLICT    224    224       L -> F (in Ref. 11; AAR08906).
FT                                {ECO:0000305}.
FT   CONFLICT    242    242       L -> P (in Ref. 9; CAR92543).
FT                                {ECO:0000305}.
FT   STRAND       67     71       {ECO:0000244|PDB:3TJE}.
FT   STRAND       75     77       {ECO:0000244|PDB:3TJE}.
FT   STRAND       82     84       {ECO:0000244|PDB:3TJE}.
FT   TURN         87     89       {ECO:0000244|PDB:3TJE}.
FT   HELIX       109    111       {ECO:0000244|PDB:3TJE}.
FT   STRAND      113    117       {ECO:0000244|PDB:3TJE}.
FT   STRAND      126    129       {ECO:0000244|PDB:3TJE}.
FT   STRAND      137    139       {ECO:0000244|PDB:3TJE}.
FT   HELIX       232    242       {ECO:0000244|PDB:3EWT}.
FT   TURN        251    253       {ECO:0000244|PDB:1DDF}.
FT   HELIX       256    265       {ECO:0000244|PDB:3EZQ}.
FT   HELIX       270    282       {ECO:0000244|PDB:3EZQ}.
FT   HELIX       287    319       {ECO:0000244|PDB:3EZQ}.
FT   HELIX       327    334       {ECO:0000244|PDB:3EZQ}.
SQ   SEQUENCE   335 AA;  37732 MW;  0139942535111410 CRC64;
     MLGIWTLLPL VLTSVARLSS KSVNAQVTDI NSKGLELRKT VTTVETQNLE GLHHDGQFCH
     KPCPPGERKA RDCTVNGDEP DCVPCQEGKE YTDKAHFSSK CRRCRLCDEG HGLEVEINCT
     RTQNTKCRCK PNFFCNSTVC EHCDPCTKCE HGIIKECTLT SNTKCKEEGS RSNLGWLCLL
     LLPIPLIVWV KRKEVQKTCR KHRKENQGSH ESPTLNPETV AINLSDVDLS KYITTIAGVM
     TLSQVKGFVR KNGVNEAKID EIKNDNVQDT AEQKVQLLRN WHQLHGKKEA YDTLIKDLKK
     ANLCTLAEKI QTIILKDITS DSENSNFRNE IQSLV
//
ID   GAS6_HUMAN              Reviewed;         721 AA.
AC   Q14393; B3KRQ7; B3KVL4; E9PBL7; Q6IMN1; Q7Z7N3;
DT   07-JUN-2004, integrated into UniProtKB/Swiss-Prot.
DT   07-JUN-2004, sequence version 2.
DT   20-JAN-2016, entry version 164.
DE   RecName: Full=Growth arrest-specific protein 6;
DE            Short=GAS-6;
DE   AltName: Full=AXL receptor tyrosine kinase ligand;
DE   Flags: Precursor;
GN   Name=GAS6; Synonyms=AXLLG;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND TISSUE SPECIFICITY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=8336730;
RA   Manfioletti G., Brancolini C., Avanzi G., Schneider C.;
RT   "The protein encoded by a growth arrest-specific gene (gas6) is a new
RT   member of the vitamin K-dependent proteins related to protein S, a
RT   negative coregulator in the blood coagulation cascade.";
RL   Mol. Cell. Biol. 13:4976-4985(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=15108283; DOI=10.1002/humu.20025;
RA   Munoz X., Sumoy L., Ramirez-Lorca R., Villar J., de Frutos P.G.,
RA   Sala N.;
RT   "Human vitamin K-dependent GAS6: gene structure, allelic variation,
RT   and association with stroke.";
RL   Hum. Mutat. 23:506-512(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2; 3; 4 AND 5).
RC   TISSUE=Kidney, and Uterus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS LEU-41; TYR-231;
RP   MET-390; ARG-543; LEU-623; LYS-655 AND GLN-659.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (MAY-2007) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057823; DOI=10.1038/nature02379;
RA   Dunham A., Matthews L.H., Burton J., Ashurst J.L., Howe K.L.,
RA   Ashcroft K.J., Beare D.M., Burford D.C., Hunt S.E.,
RA   Griffiths-Jones S., Jones M.C., Keenan S.J., Oliver K., Scott C.E.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Andrews D.T.,
RA   Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J., Bannerjee R.,
RA   Barlow K.F., Bates K., Beasley H., Bird C.P., Bray-Allen S.,
RA   Brown A.J., Brown J.Y., Burrill W., Carder C., Carter N.P.,
RA   Chapman J.C., Clamp M.E., Clark S.Y., Clarke G., Clee C.M.,
RA   Clegg S.C., Cobley V., Collins J.E., Corby N., Coville G.J.,
RA   Deloukas P., Dhami P., Dunham I., Dunn M., Earthrowl M.E.,
RA   Ellington A.G., Faulkner L., Frankish A.G., Frankland J., French L.,
RA   Garner P., Garnett J., Gilbert J.G.R., Gilson C.J., Ghori J.,
RA   Grafham D.V., Gribble S.M., Griffiths C., Hall R.E., Hammond S.,
RA   Harley J.L., Hart E.A., Heath P.D., Howden P.J., Huckle E.J.,
RA   Hunt P.J., Hunt A.R., Johnson C., Johnson D., Kay M., Kimberley A.M.,
RA   King A., Laird G.K., Langford C.J., Lawlor S., Leongamornlert D.A.,
RA   Lloyd D.M., Lloyd C., Loveland J.E., Lovell J., Martin S.,
RA   Mashreghi-Mohammadi M., McLaren S.J., McMurray A., Milne S.,
RA   Moore M.J.F., Nickerson T., Palmer S.A., Pearce A.V., Peck A.I.,
RA   Pelan S., Phillimore B., Porter K.M., Rice C.M., Searle S.,
RA   Sehra H.K., Shownkeen R., Skuce C.D., Smith M., Steward C.A.,
RA   Sycamore N., Tester J., Thomas D.W., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., Whitehead S.L., Willey D.L.,
RA   Wilming L., Wray P.W., Wright M.W., Young L., Coulson A., Durbin R.M.,
RA   Hubbard T., Sulston J.E., Beck S., Bentley D.R., Rogers J., Ross M.T.;
RT   "The DNA sequence and analysis of human chromosome 13.";
RL   Nature 428:522-528(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Fetal lung, and Fetal spleen;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-85.
RA   Maree A.O., Hillmann A., McRedmond J.P., Fitzgerald D.J.;
RL   Submitted (OCT-2002) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   RECEPTOR INTERACTION.
RX   PubMed=7854420; DOI=10.1038/373623a0;
RA   Varnum B.C., Young C., Elliott G., Garcia A., Bartley T.D.,
RA   Fridell Y.W., Hunt R.W., Trail G., Clogston C., Toso R.J.,
RA   Yanagihara D., Bennett L., Silber M., Merewether L.A., Tseng A.,
RA   Escobar E., Liu E.T., Yamane H.K.;
RT   "Axl receptor tyrosine kinase stimulated by the vitamin K-dependent
RT   protein encoded by growth-arrest-specific gene 6.";
RL   Nature 373:623-626(1995).
RN   [9]
RP   RECEPTOR INTERACTION.
RX   PubMed=7867073; DOI=10.1016/0092-8674(95)90520-0;
RA   Stitt T.N., Conn G., Gore M., Lai C., Bruno J., Radziejewski C.,
RA   Mattsson K., Fisher J., Gies D.R., Jones P.F., Masiakowski P.,
RA   Ryan T.E., Tobkes N.J., Chen D.H., DiStefano P.S., Long G.L.,
RA   Basilico C., Goldfarb M.P., Lemke G., Glass D.J., Yancopoulos G.D.;
RT   "The anticoagulation factor protein S and its relative, Gas6, are
RT   ligands for the Tyro 3/Axl family of receptor tyrosine kinases.";
RL   Cell 80:661-670(1995).
RN   [10]
RP   ALTERNATIVE SPLICING (ISOFORM 1), AND TISSUE SPECIFICITY.
RX   PubMed=9326368; DOI=10.1016/S0014-5793(97)01094-6;
RA   Marcandalli P., Gostissa M., Varnum B., Goruppi S., Schneider C.;
RT   "Identification and tissue expression of a splice variant for the
RT   growth arrest-specific gene gas6.";
RL   FEBS Lett. 415:56-58(1997).
RN   [11]
RP   RECEPTOR INTERACTION.
RX   PubMed=8939948; DOI=10.1074/jbc.271.47.30022;
RA   Nagata K., Ohashi K., Nakano T., Arita H., Zong C., Hanafusa H.,
RA   Mizuno K.;
RT   "Identification of the product of growth arrest-specific gene 6 as a
RT   common ligand for Axl, Sky, and Mer receptor tyrosine kinases.";
RL   J. Biol. Chem. 271:30022-30027(1996).
RN   [12]
RP   RECEPTOR INTERACTION, SUBCELLULAR LOCATION, AND PROTEOLYTIC
RP   PROCESSING.
RX   PubMed=9326369; DOI=10.1016/S0014-5793(97)01093-4;
RA   Goruppi S., Yamane H., Marcandalli P., Garcia A., Clogston C.,
RA   Gostissa M., Varnum B., Schneider C.;
RT   "The product of a gas6 splice variant allows the release of the domain
RT   responsible for Axl tyrosine kinase receptor activation.";
RL   FEBS Lett. 415:59-63(1997).
RN   [13]
RP   FUNCTION OF THE GAS6/AXL SIGNALING PATHWAY.
RX   PubMed=12364394; DOI=10.1161/01.RES.0000036753.50601.E9;
RA   D'Arcangelo D., Gaetano C., Capogrossi M.C.;
RT   "Acidification prevents endothelial cell apoptosis by Axl
RT   activation.";
RL   Circ. Res. 91:E4-12(2002).
RN   [14]
RP   FUNCTION OF THE GAS6/AXL SIGNALING PATHWAY.
RX   PubMed=18840707; DOI=10.1182/blood-2008-05-157073;
RA   Park I.K., Giovenzana C., Hughes T.L., Yu J., Trotta R.,
RA   Caligiuri M.A.;
RT   "The Axl/Gas6 pathway is required for optimal cytokine signaling
RT   during human natural killer cell development.";
RL   Blood 113:2470-2477(2009).
RN   [15]
RP   FUNCTION (MICROBIAL INFECTION).
RX   PubMed=21501828; DOI=10.1016/j.chom.2011.03.012;
RA   Morizono K., Xie Y., Olafsen T., Lee B., Dasgupta A., Wu A.M.,
RA   Chen I.S.;
RT   "The soluble serum protein Gas6 bridges virion envelope
RT   phosphatidylserine to the TAM receptor tyrosine kinase Axl to mediate
RT   viral entry.";
RL   Cell Host Microbe 9:286-298(2011).
RN   [16]
RP   FUNCTION (MICROBIAL INFECTION).
RX   PubMed=23084921; DOI=10.1016/j.chom.2012.08.009;
RA   Meertens L., Carnec X., Lecoin M.P., Ramdasi R., Guivel-Benhassine F.,
RA   Lew E., Lemke G., Schwartz O., Amara A.;
RT   "The TIM and TAM families of phosphatidylserine receptors mediate
RT   dengue virus entry.";
RL   Cell Host Microbe 12:544-557(2012).
RN   [17]
RP   FUNCTION (MICROBIAL INFECTION).
RX   PubMed=17005688; DOI=10.1128/JVI.01157-06;
RA   Shimojima M., Takada A., Ebihara H., Neumann G., Fujioka K.,
RA   Irimura T., Jones S., Feldmann H., Kawaoka Y.;
RT   "Tyro3 family-mediated cell entry of Ebola and Marburg viruses.";
RL   J. Virol. 80:10109-10116(2006).
RN   [18]
RP   PHOSPHORYLATION AT SER-71.
RX   PubMed=26091039; DOI=10.1016/j.cell.2015.05.028;
RA   Tagliabracci V.S., Wiley S.E., Guo X., Kinch L.N., Durrant E., Wen J.,
RA   Xiao J., Cui J., Nguyen K.B., Engel J.L., Coon J.J., Grishin N.,
RA   Pinna L.A., Pagliarini D.J., Dixon J.E.;
RT   "A single kinase generates the majority of the secreted
RT   phosphoproteome.";
RL   Cell 161:1619-1632(2015).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 261-721 (ISOFORM 2),
RP   MUTAGENESIS OF PHE-530; LEU-663 AND TYR-703, AND INTERACTION WITH AXL.
RX   PubMed=8621659; DOI=10.1074/jbc.271.16.9785;
RA   Mark M.R., Chen J., Hammonds R.G., Sadick M., Godowski P.J.;
RT   "Characterization of Gas6, a member of the superfamily of G domain-
RT   containing proteins, as a ligand for Rse and Axl.";
RL   J. Biol. Chem. 271:9785-9789(1996).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (3.3 ANGSTROMS) OF 322-721 IN COMPLEX WITH AXL,
RP   SUBUNIT, GLYCOSYLATION AT ASN-463, AND MUTAGENESIS OF ARG-353 AND
RP   LYS-355.
RX   PubMed=16362042; DOI=10.1038/sj.emboj.7600912;
RA   Sasaki T., Knyazev P.G., Clout N.J., Cheburkin Y., Goehring W.,
RA   Ullrich A., Timpl R., Hohenester E.;
RT   "Structural basis for Gas6-Axl signalling.";
RL   EMBO J. 25:80-87(2006).
CC   -!- FUNCTION: Ligand for tyrosine-protein kinase receptors AXL, TYRO3
CC       and MER whose signaling is implicated in cell growth and survival,
CC       cell adhesion and cell migration. GAS6/AXL signaling plays a role
CC       in various processes such as endothelial cell survival during
CC       acidification by preventing apoptosis, optimal cytokine signaling
CC       during human natural killer cell development, hepatic
CC       regeneration, gonadotropin-releasing hormone neuron survival and
CC       migration, platelet activation, or regulation of thrombotic
CC       responses. {ECO:0000269|PubMed:12364394,
CC       ECO:0000269|PubMed:18840707}.
CC   -!- FUNCTION: (Microbial infection) Can bridges virus envelope
CC       phosphatidylserine to the TAM receptor tyrosine kinase Axl to
CC       mediate viral entry by apoptotic mimicry (PubMed:21501828). Plays
CC       a role in Dengue cell entry by apoptotic mimicry
CC       (PubMed:23084921). Plays a role in Vaccinia virus cell entry by
CC       apoptotic mimicry (PubMed:21501828). Plays a role in ebolavirus
CC       and marburgvirus cell entry by apoptotic mimicry
CC       (PubMed:17005688). {ECO:0000269|PubMed:17005688,
CC       ECO:0000269|PubMed:21501828, ECO:0000269|PubMed:23084921}.
CC   -!- SUBUNIT: Heterodimer and heterotetramer with AXL.
CC       {ECO:0000269|PubMed:16362042}.
CC   -!- INTERACTION:
CC       P30530:AXL; NbExp=8; IntAct=EBI-2802811, EBI-2850927;
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:9326369}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=1; Synonyms=gas6SV;
CC         IsoId=Q14393-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q14393-2; Sequence=VSP_010494;
CC       Name=3;
CC         IsoId=Q14393-3; Sequence=VSP_010492, VSP_010493, VSP_010494;
CC         Note=No experimental confirmation available.;
CC       Name=4;
CC         IsoId=Q14393-4; Sequence=VSP_043832, VSP_010494;
CC       Name=5;
CC         IsoId=Q14393-5; Sequence=VSP_045685;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Plasma. Isoform 1 and isoform 2 are widely
CC       expressed. Isoform 1 is the predominant form in spleen.
CC       {ECO:0000269|PubMed:8336730, ECO:0000269|PubMed:9326368}.
CC   -!- PTM: Isoform 1 is proteolytically processed after secretion to
CC       yield a N-terminal 36 kDa protein and a C-terminal 50 kDa protein
CC       including the laminin G-like domains which activates AXL.
CC       {ECO:0000269|PubMed:9326369}.
CC   -!- PTM: Gamma-carboxyglutamate residues are formed by vitamin K
CC       dependent carboxylation. These residues are essential for the
CC       binding of calcium. {ECO:0000255|PROSITE-ProRule:PRU00463}.
CC   -!- SIMILARITY: Contains 4 EGF-like domains. {ECO:0000255|PROSITE-
CC       ProRule:PRU00076}.
CC   -!- SIMILARITY: Contains 1 Gla (gamma-carboxy-glutamate) domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00463}.
CC   -!- SIMILARITY: Contains 2 laminin G-like domains.
CC       {ECO:0000255|PROSITE-ProRule:PRU00122}.
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/gas6/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L13720; AAA58494.1; -; mRNA.
DR   EMBL; AY256843; AAO84057.1; -; Genomic_DNA.
DR   EMBL; AY256830; AAO84057.1; JOINED; Genomic_DNA.
DR   EMBL; AY256831; AAO84057.1; JOINED; Genomic_DNA.
DR   EMBL; AY256832; AAO84057.1; JOINED; Genomic_DNA.
DR   EMBL; AY256833; AAO84057.1; JOINED; Genomic_DNA.
DR   EMBL; AY256834; AAO84057.1; JOINED; Genomic_DNA.
DR   EMBL; AY256835; AAO84057.1; JOINED; Genomic_DNA.
DR   EMBL; AY256836; AAO84057.1; JOINED; Genomic_DNA.
DR   EMBL; AY256837; AAO84057.1; JOINED; Genomic_DNA.
DR   EMBL; AY256838; AAO84057.1; JOINED; Genomic_DNA.
DR   EMBL; AY256839; AAO84057.1; JOINED; Genomic_DNA.
DR   EMBL; AY256840; AAO84057.1; JOINED; Genomic_DNA.
DR   EMBL; AY256841; AAO84057.1; JOINED; Genomic_DNA.
DR   EMBL; AY256842; AAO84057.1; JOINED; Genomic_DNA.
DR   EMBL; AK092028; BAG52469.1; -; mRNA.
DR   EMBL; AK122969; BAG53826.1; -; mRNA.
DR   EMBL; AK126533; BAC86580.1; -; mRNA.
DR   EMBL; AK290803; BAF83492.1; -; mRNA.
DR   EMBL; EF631974; ABR09277.1; -; Genomic_DNA.
DR   EMBL; BX072579; CAH71174.1; -; Genomic_DNA.
DR   EMBL; BC038984; AAH38984.1; -; mRNA.
DR   EMBL; AY170372; AAO41859.1; -; Genomic_DNA.
DR   EMBL; BK001240; DAA01155.1; -; Genomic_DNA.
DR   CCDS; CCDS45072.1; -. [Q14393-2]
DR   PIR; B48089; B48089.
DR   RefSeq; NP_000811.1; NM_000820.3. [Q14393-2]
DR   UniGene; Hs.646346; -.
DR   PDB; 1H30; X-ray; 2.20 A; A=261-721.
DR   PDB; 2C5D; X-ray; 3.30 A; A/B=261-721.
DR   PDB; 4RA0; X-ray; 3.07 A; A/B=322-721.
DR   PDBsum; 1H30; -.
DR   PDBsum; 2C5D; -.
DR   PDBsum; 4RA0; -.
DR   ProteinModelPortal; Q14393; -.
DR   SMR; Q14393; 53-94, 118-721.
DR   BioGrid; 108891; 23.
DR   IntAct; Q14393; 3.
DR   MINT; MINT-2735698; -.
DR   PhosphoSite; Q14393; -.
DR   BioMuta; GAS6; -.
DR   DMDM; 48427995; -.
DR   MaxQB; Q14393; -.
DR   PRIDE; Q14393; -.
DR   Ensembl; ENST00000327773; ENSP00000331831; ENSG00000183087. [Q14393-2]
DR   GeneID; 2621; -.
DR   KEGG; hsa:2621; -.
DR   UCSC; uc001vud.3; human. [Q14393-2]
DR   UCSC; uc001vuf.3; human. [Q14393-4]
DR   UCSC; uc001vug.3; human. [Q14393-1]
DR   CTD; 2621; -.
DR   GeneCards; GAS6; -.
DR   HGNC; HGNC:4168; GAS6.
DR   HPA; HPA008275; -.
DR   HPA; HPA056080; -.
DR   MIM; 600441; gene.
DR   neXtProt; NX_Q14393; -.
DR   PharmGKB; PA28582; -.
DR   GeneTree; ENSGT00530000063339; -.
DR   HOGENOM; HOG000065758; -.
DR   HOVERGEN; HBG051702; -.
DR   InParanoid; Q14393; -.
DR   KO; K05464; -.
DR   OMA; PVIRLRF; -.
DR   OrthoDB; EOG7F5119; -.
DR   PhylomeDB; Q14393; -.
DR   TreeFam; TF352157; -.
DR   Reactome; R-HSA-114608; Platelet degranulation.
DR   Reactome; R-HSA-159740; Gamma-carboxylation of protein precursors.
DR   Reactome; R-HSA-159763; Transport of gamma-carboxylated protein precursors from the endoplasmic reticulum to the Golgi apparatus.
DR   Reactome; R-HSA-159782; Removal of aminoterminal propeptides from gamma-carboxylated proteins.
DR   Reactome; R-HSA-202733; Cell surface interactions at the vascular wall.
DR   SignaLink; Q14393; -.
DR   ChiTaRS; GAS6; human.
DR   EvolutionaryTrace; Q14393; -.
DR   GeneWiki; GAS6; -.
DR   GenomeRNAi; 2621; -.
DR   NextBio; 10323; -.
DR   PRO; PR:Q14393; -.
DR   Proteomes; UP000005640; Chromosome 13.
DR   Bgee; Q14393; -.
DR   CleanEx; HS_GAS6; -.
DR   Genevisible; Q14393; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0005796; C:Golgi lumen; TAS:Reactome.
DR   GO; GO:0031093; C:platelet alpha granule lumen; TAS:Reactome.
DR   GO; GO:0060090; F:binding, bridging; IDA:UniProtKB.
DR   GO; GO:0005509; F:calcium ion binding; IEA:InterPro.
DR   GO; GO:0043027; F:cysteine-type endopeptidase inhibitor activity involved in apoptotic process; IDA:UniProtKB.
DR   GO; GO:0001786; F:phosphatidylserine binding; IDA:UniProtKB.
DR   GO; GO:0030296; F:protein tyrosine kinase activator activity; IDA:UniProtKB.
DR   GO; GO:0048018; F:receptor agonist activity; IDA:MGI.
DR   GO; GO:0005102; F:receptor binding; IDA:UniProtKB.
DR   GO; GO:0030971; F:receptor tyrosine kinase binding; IPI:UniProtKB.
DR   GO; GO:0005245; F:voltage-gated calcium channel activity; IDA:UniProtKB.
DR   GO; GO:0032148; P:activation of protein kinase B activity; ISS:UniProtKB.
DR   GO; GO:0043277; P:apoptotic cell clearance; IDA:UniProtKB.
DR   GO; GO:0035754; P:B cell chemotaxis; IDA:UniProtKB.
DR   GO; GO:0007596; P:blood coagulation; TAS:Reactome.
DR   GO; GO:0070588; P:calcium ion transmembrane transport; IDA:UniProtKB.
DR   GO; GO:0007155; P:cell adhesion; TAS:UniProtKB.
DR   GO; GO:0007050; P:cell cycle arrest; TAS:UniProtKB.
DR   GO; GO:0016477; P:cell migration; TAS:UniProtKB.
DR   GO; GO:0008283; P:cell proliferation; TAS:UniProtKB.
DR   GO; GO:0031589; P:cell-substrate adhesion; IEA:Ensembl.
DR   GO; GO:0044267; P:cellular protein metabolic process; TAS:Reactome.
DR   GO; GO:0035690; P:cellular response to drug; IDA:UniProtKB.
DR   GO; GO:0071333; P:cellular response to glucose stimulus; ISS:UniProtKB.
DR   GO; GO:0071363; P:cellular response to growth factor stimulus; IEA:Ensembl.
DR   GO; GO:0035457; P:cellular response to interferon-alpha; IDA:UniProtKB.
DR   GO; GO:0009267; P:cellular response to starvation; IEA:Ensembl.
DR   GO; GO:0071307; P:cellular response to vitamin K; IDA:UniProtKB.
DR   GO; GO:0097028; P:dendritic cell differentiation; IEP:UniProtKB.
DR   GO; GO:0007167; P:enzyme linked receptor protein signaling pathway; IEA:Ensembl.
DR   GO; GO:0085029; P:extracellular matrix assembly; ISS:UniProtKB.
DR   GO; GO:0019064; P:fusion of virus membrane with host plasma membrane; IDA:UniProtKB.
DR   GO; GO:0097241; P:hematopoietic stem cell migration to bone marrow; IDA:UniProtKB.
DR   GO; GO:0050900; P:leukocyte migration; TAS:Reactome.
DR   GO; GO:0010934; P:macrophage cytokine production; IEA:Ensembl.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:0070168; P:negative regulation of biomineral tissue development; IDA:UniProtKB.
DR   GO; GO:0043154; P:negative regulation of cysteine-type endopeptidase activity involved in apoptotic process; IDA:UniProtKB.
DR   GO; GO:2000669; P:negative regulation of dendritic cell apoptotic process; IDA:UniProtKB.
DR   GO; GO:2000352; P:negative regulation of endothelial cell apoptotic process; IDA:UniProtKB.
DR   GO; GO:2000270; P:negative regulation of fibroblast apoptotic process; IDA:UniProtKB.
DR   GO; GO:0032689; P:negative regulation of interferon-gamma production; IDA:UniProtKB.
DR   GO; GO:0050711; P:negative regulation of interleukin-1 secretion; IDA:UniProtKB.
DR   GO; GO:0032715; P:negative regulation of interleukin-6 production; IDA:UniProtKB.
DR   GO; GO:1900165; P:negative regulation of interleukin-6 secretion; IDA:UniProtKB.
DR   GO; GO:1900142; P:negative regulation of oligodendrocyte apoptotic process; IDA:UniProtKB.
DR   GO; GO:0033159; P:negative regulation of protein import into nucleus, translocation; IDA:UniProtKB.
DR   GO; GO:2000533; P:negative regulation of renal albumin absorption; ISS:UniProtKB.
DR   GO; GO:0043433; P:negative regulation of sequence-specific DNA binding transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0032720; P:negative regulation of tumor necrosis factor production; IDA:UniProtKB.
DR   GO; GO:0010804; P:negative regulation of tumor necrosis factor-mediated signaling pathway; IDA:UniProtKB.
DR   GO; GO:0001764; P:neuron migration; IEA:Ensembl.
DR   GO; GO:0031100; P:organ regeneration; IEA:Ensembl.
DR   GO; GO:0017187; P:peptidyl-glutamic acid carboxylation; TAS:Reactome.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0006909; P:phagocytosis; IDA:UniProtKB.
DR   GO; GO:0030168; P:platelet activation; TAS:UniProtKB.
DR   GO; GO:0070527; P:platelet aggregation; TAS:UniProtKB.
DR   GO; GO:0002576; P:platelet degranulation; TAS:Reactome.
DR   GO; GO:0001961; P:positive regulation of cytokine-mediated signaling pathway; IMP:UniProtKB.
DR   GO; GO:2000510; P:positive regulation of dendritic cell chemotaxis; IDA:UniProtKB.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:MGI.
DR   GO; GO:0048146; P:positive regulation of fibroblast proliferation; IDA:UniProtKB.
DR   GO; GO:0010628; P:positive regulation of gene expression; IDA:UniProtKB.
DR   GO; GO:0003104; P:positive regulation of glomerular filtration; ISS:UniProtKB.
DR   GO; GO:0032825; P:positive regulation of natural killer cell differentiation; IDA:UniProtKB.
DR   GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0050766; P:positive regulation of phagocytosis; IDA:UniProtKB.
DR   GO; GO:0046827; P:positive regulation of protein export from nucleus; IDA:UniProtKB.
DR   GO; GO:0045860; P:positive regulation of protein kinase activity; IDA:UniProtKB.
DR   GO; GO:0051897; P:positive regulation of protein kinase B signaling; IDA:UniProtKB.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0061098; P:positive regulation of protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0032008; P:positive regulation of TOR signaling; ISS:UniProtKB.
DR   GO; GO:0043687; P:post-translational protein modification; TAS:Reactome.
DR   GO; GO:0043491; P:protein kinase B signaling; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0072661; P:protein targeting to plasma membrane; IDA:UniProtKB.
DR   GO; GO:0006508; P:proteolysis; TAS:Reactome.
DR   GO; GO:0046813; P:receptor-mediated virion attachment to host cell; IDA:UniProtKB.
DR   GO; GO:0040008; P:regulation of growth; IEA:UniProtKB-KW.
DR   GO; GO:0007165; P:signal transduction; IDA:UniProtKB.
DR   GO; GO:0046718; P:viral entry into host cell; IDA:UniProtKB.
DR   GO; GO:0019079; P:viral genome replication; IDA:UniProtKB.
DR   Gene3D; 2.60.120.200; -; 2.
DR   Gene3D; 4.10.740.10; -; 1.
DR   InterPro; IPR017857; Coagulation_fac_subgr_Gla_dom.
DR   InterPro; IPR013320; ConA-like_dom.
DR   InterPro; IPR001881; EGF-like_Ca-bd_dom.
DR   InterPro; IPR013032; EGF-like_CS.
DR   InterPro; IPR000742; EGF-like_dom.
DR   InterPro; IPR000152; EGF-type_Asp/Asn_hydroxyl_site.
DR   InterPro; IPR018097; EGF_Ca-bd_CS.
DR   InterPro; IPR000294; GLA_domain.
DR   InterPro; IPR009030; Growth_fac_rcpt_.
DR   InterPro; IPR001791; Laminin_G.
DR   Pfam; PF07645; EGF_CA; 2.
DR   Pfam; PF00594; Gla; 1.
DR   Pfam; PF00054; Laminin_G_1; 1.
DR   Pfam; PF02210; Laminin_G_2; 1.
DR   PRINTS; PR00001; GLABLOOD.
DR   SMART; SM00181; EGF; 1.
DR   SMART; SM00179; EGF_CA; 3.
DR   SMART; SM00069; GLA; 1.
DR   SMART; SM00282; LamG; 2.
DR   SUPFAM; SSF49899; SSF49899; 3.
DR   SUPFAM; SSF57184; SSF57184; 1.
DR   SUPFAM; SSF57630; SSF57630; 1.
DR   PROSITE; PS00010; ASX_HYDROXYL; 4.
DR   PROSITE; PS00022; EGF_1; 1.
DR   PROSITE; PS01186; EGF_2; 3.
DR   PROSITE; PS50026; EGF_3; 4.
DR   PROSITE; PS01187; EGF_CA; 3.
DR   PROSITE; PS00011; GLA_1; 1.
DR   PROSITE; PS50998; GLA_2; 1.
DR   PROSITE; PS50025; LAM_G_DOMAIN; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Calcium; Complete proteome;
KW   Disulfide bond; EGF-like domain; Gamma-carboxyglutamic acid;
KW   Glycoprotein; Growth regulation; Host-virus interaction;
KW   Metal-binding; Phosphoprotein; Polymorphism; Reference proteome;
KW   Repeat; Secreted; Signal.
FT   SIGNAL        1     30       {ECO:0000255}.
FT   CHAIN        31    721       Growth arrest-specific protein 6.
FT                                /FTId=PRO_0000007589.
FT   DOMAIN       53     94       Gla. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00463}.
FT   DOMAIN      116    154       EGF-like 1; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      156    196       EGF-like 2; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      197    237       EGF-like 3; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      238    278       EGF-like 4; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      341    513       Laminin G-like 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00122}.
FT   DOMAIN      520    713       Laminin G-like 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00122}.
FT   METAL       372    372       Calcium.
FT   METAL       374    374       Calcium; via carbonyl oxygen.
FT   METAL       483    483       Calcium; via carbonyl oxygen.
FT   METAL       699    699       Calcium.
FT   MOD_RES      71     71       Phosphoserine; by FAM20C.
FT                                {ECO:0000269|PubMed:26091039}.
FT   MOD_RES     664    664       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:Q63772}.
FT   MOD_RES     680    680       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:Q63772}.
FT   MOD_RES     683    683       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:Q63772}.
FT   CARBOHYD    463    463       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16362042}.
FT   DISULFID     65     70       {ECO:0000250}.
FT   DISULFID    120    133       {ECO:0000250}.
FT   DISULFID    125    142       {ECO:0000250}.
FT   DISULFID    144    153       {ECO:0000250}.
FT   DISULFID    160    171       {ECO:0000250}.
FT   DISULFID    167    180       {ECO:0000250}.
FT   DISULFID    182    195       {ECO:0000250}.
FT   DISULFID    201    212       {ECO:0000250}.
FT   DISULFID    207    221       {ECO:0000250}.
FT   DISULFID    223    236       {ECO:0000250}.
FT   DISULFID    242    251       {ECO:0000250}.
FT   DISULFID    247    260       {ECO:0000250}.
FT   DISULFID    262    277
FT   DISULFID    326    613
FT   DISULFID    487    513
FT   DISULFID    686    713
FT   VAR_SEQ       1    342       Missing (in isoform 5).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_045685.
FT   VAR_SEQ       1    273       Missing (in isoform 4).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_043832.
FT   VAR_SEQ       1     54       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_010492.
FT   VAR_SEQ      55     94       EAKQGHLERECVEELCSREEAREVFENDPETDYFYPRYLD
FT                                -> MCMCQASPPPAALAGCLLSSCVQPAREHGGAFSKAEWL
FT                                SN (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_010493.
FT   VAR_SEQ     279    321       Missing (in isoform 2, isoform 3 and
FT                                isoform 4). {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:8336730}.
FT                                /FTId=VSP_010494.
FT   VARIANT      41     41       F -> L. {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_038823.
FT   VARIANT     231    231       S -> Y (in dbSNP:rs146159446).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_038824.
FT   VARIANT     390    390       V -> M. {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_038825.
FT   VARIANT     543    543       G -> R. {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_038826.
FT   VARIANT     623    623       S -> L. {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_038827.
FT   VARIANT     655    655       E -> K. {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_038828.
FT   VARIANT     659    659       R -> Q. {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_038829.
FT   MUTAGEN     353    353       R->E: Strongly reduced affinity for AXL.
FT                                Abolishes phosphorylation of AXL.
FT                                {ECO:0000269|PubMed:16362042}.
FT   MUTAGEN     355    355       K->E: Strongly reduced affinity for AXL.
FT                                Abolishes phosphorylation of AXL.
FT                                {ECO:0000269|PubMed:16362042}.
FT   MUTAGEN     530    530       F->A: Decreases activation of AXL.
FT                                {ECO:0000269|PubMed:8621659}.
FT   MUTAGEN     663    663       L->A: Reduces affinity for AXL 15-fold
FT                                and decreases activation of AXL.
FT                                {ECO:0000269|PubMed:8621659}.
FT   MUTAGEN     703    703       Y->A: Reduces affinity for AXL 3-fold.
FT                                {ECO:0000269|PubMed:8621659}.
FT   CONFLICT    399    399       E -> K (in Ref. 3; BAG52469).
FT                                {ECO:0000305}.
FT   HELIX       264    266       {ECO:0000244|PDB:1H30}.
FT   STRAND      268    271       {ECO:0000244|PDB:1H30}.
FT   TURN        272    275       {ECO:0000244|PDB:1H30}.
FT   STRAND      276    278       {ECO:0000244|PDB:1H30}.
FT   STRAND      337    339       {ECO:0000244|PDB:1H30}.
FT   STRAND      350    353       {ECO:0000244|PDB:1H30}.
FT   STRAND      356    358       {ECO:0000244|PDB:1H30}.
FT   STRAND      363    370       {ECO:0000244|PDB:1H30}.
FT   STRAND      373    382       {ECO:0000244|PDB:1H30}.
FT   STRAND      386    394       {ECO:0000244|PDB:1H30}.
FT   STRAND      397    404       {ECO:0000244|PDB:1H30}.
FT   STRAND      407    416       {ECO:0000244|PDB:1H30}.
FT   STRAND      419    421       {ECO:0000244|PDB:4RA0}.
FT   STRAND      423    429       {ECO:0000244|PDB:1H30}.
FT   STRAND      431    438       {ECO:0000244|PDB:1H30}.
FT   STRAND      441    447       {ECO:0000244|PDB:1H30}.
FT   STRAND      452    456       {ECO:0000244|PDB:1H30}.
FT   STRAND      459    461       {ECO:0000244|PDB:1H30}.
FT   STRAND      463    468       {ECO:0000244|PDB:1H30}.
FT   HELIX       473    475       {ECO:0000244|PDB:1H30}.
FT   STRAND      476    478       {ECO:0000244|PDB:1H30}.
FT   STRAND      486    493       {ECO:0000244|PDB:1H30}.
FT   HELIX       501    507       {ECO:0000244|PDB:4RA0}.
FT   HELIX       509    511       {ECO:0000244|PDB:1H30}.
FT   STRAND      512    516       {ECO:0000244|PDB:1H30}.
FT   STRAND      518    523       {ECO:0000244|PDB:1H30}.
FT   STRAND      529    531       {ECO:0000244|PDB:1H30}.
FT   STRAND      550    561       {ECO:0000244|PDB:1H30}.
FT   STRAND      563    570       {ECO:0000244|PDB:1H30}.
FT   HELIX       571    573       {ECO:0000244|PDB:1H30}.
FT   STRAND      575    584       {ECO:0000244|PDB:1H30}.
FT   STRAND      588    590       {ECO:0000244|PDB:4RA0}.
FT   STRAND      595    600       {ECO:0000244|PDB:1H30}.
FT   STRAND      603    609       {ECO:0000244|PDB:1H30}.
FT   STRAND      618    625       {ECO:0000244|PDB:1H30}.
FT   STRAND      628    633       {ECO:0000244|PDB:1H30}.
FT   STRAND      639    642       {ECO:0000244|PDB:1H30}.
FT   HELIX       644    658       {ECO:0000244|PDB:1H30}.
FT   STRAND      663    667       {ECO:0000244|PDB:1H30}.
FT   STRAND      676    678       {ECO:0000244|PDB:1H30}.
FT   STRAND      685    691       {ECO:0000244|PDB:1H30}.
FT   HELIX       698    700       {ECO:0000244|PDB:1H30}.
FT   STRAND      701    704       {ECO:0000244|PDB:1H30}.
FT   STRAND      708    711       {ECO:0000244|PDB:4RA0}.
SQ   SEQUENCE   721 AA;  79677 MW;  E7B22B0E010930F9 CRC64;
     MAPSLSPGPA ALRRAPQLLL LLLAAECALA ALLPAREATQ FLRPRQRRAF QVFEEAKQGH
     LERECVEELC SREEAREVFE NDPETDYFYP RYLDCINKYG SPYTKNSGFA TCVQNLPDQC
     TPNPCDRKGT QACQDLMGNF FCLCKAGWGG RLCDKDVNEC SQENGGCLQI CHNKPGSFHC
     SCHSGFELSS DGRTCQDIDE CADSEACGEA RCKNLPGSYS CLCDEGFAYS SQEKACRDVD
     ECLQGRCEQV CVNSPGSYTC HCDGRGGLKL SQDMDTCELE AGWPCPRHRR DGSPAARPGR
     GAQGSRSEGH IPDRRGPRPW QDILPCVPFS VAKSVKSLYL GRMFSGTPVI RLRFKRLQPT
     RLVAEFDFRT FDPEGILLFA GGHQDSTWIV LALRAGRLEL QLRYNGVGRV TSSGPVINHG
     MWQTISVEEL ARNLVIKVNR DAVMKIAVAG DLFQPERGLY HLNLTVGGIP FHEKDLVQPI
     NPRLDGCMRS WNWLNGEDTT IQETVKVNTR MQCFSVTERG SFYPGSGFAF YSLDYMRTPL
     DVGTESTWEV EVVAHIRPAA DTGVLFALWA PDLRAVPLSV ALVDYHSTKK LKKQLVVLAV
     EHTALALMEI KVCDGQEHVV TVSLRDGEAT LEVDGTRGQS EVSAAQLQER LAVLERHLRS
     PVLTFAGGLP DVPVTSAPVT AFYRGCMTLE VNRRLLDLDE AAYKHSDITA HSCPPVEPAA
     A
//
ID   EGFR_DROME              Reviewed;        1426 AA.
AC   P04412; O18370; O61601; P81868; Q9W2G0;
DT   13-AUG-1987, integrated into UniProtKB/Swiss-Prot.
DT   15-DEC-1998, sequence version 3.
DT   17-FEB-2016, entry version 183.
DE   RecName: Full=Epidermal growth factor receptor;
DE            Short=Egfr;
DE            EC=2.7.10.1;
DE   AltName: Full=Drosophila relative of ERBB;
DE   AltName: Full=Gurken receptor;
DE   AltName: Full=Protein torpedo;
DE   Flags: Precursor;
GN   Name=Egfr; Synonyms=c-erbB, DER, top; ORFNames=CG10079;
OS   Drosophila melanogaster (Fruit fly).
OC   Eukaryota; Metazoa; Ecdysozoa; Arthropoda; Hexapoda; Insecta;
OC   Pterygota; Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;
OC   Ephydroidea; Drosophilidae; Drosophila; Sophophora.
OX   NCBI_TaxID=7227;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS TYPE I AND TYPE II).
RX   PubMed=8070664;
RA   Clifford R., Schuepbach T.;
RT   "Molecular analysis of the Drosophila EGF receptor homolog reveals
RT   that several genetically defined classes of alleles cluster in
RT   subdomains of the receptor protein.";
RL   Genetics 137:531-550(1994).
RN   [2]
RP   SEQUENCE REVISION.
RA   Clifford R., Schuepbach T.;
RL   Submitted (MAR-1998) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND ALTERNATIVE SPLICING.
RX   PubMed=2982499; DOI=10.1016/0092-8674(85)90208-9;
RA   Livneh E., Glazer L., Segal D., Schlessinger J., Shilo B.-Z.;
RT   "The Drosophila EGF receptor gene homolog: conservation of both
RT   hormone binding and kinase domains.";
RL   Cell 40:599-607(1985).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA], CHARACTERIZATION, AND ALTERNATIVE
RP   SPLICING.
RC   STRAIN=Oregon-R; TISSUE=Embryo;
RX   PubMed=3093080; DOI=10.1016/0092-8674(86)90709-9;
RA   Schejter E.D., Segal D., Glazer L., Shilo B.-Z.;
RT   "Alternative 5' exons and tissue-specific expression of the Drosophila
RT   EGF receptor homolog transcripts.";
RL   Cell 46:1091-1101(1986).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS TYPE I AND TYPE II),
RP   TISSUE SPECIFICITY, AND MUTANTS.
RX   PubMed=9882502; DOI=10.1006/dbio.1998.9121;
RA   Lesokhin A.M., Yu S.-Y., Katz J., Baker N.E.;
RT   "Several levels of EGF receptor signaling during photoreceptor
RT   specification in wild-type, Ellipse, and null mutant Drosophila.";
RL   Dev. Biol. 205:129-144(1999).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA] (ISOFORM TYPE I).
RC   STRAIN=Berkeley;
RX   PubMed=10731132; DOI=10.1126/science.287.5461.2185;
RA   Adams M.D., Celniker S.E., Holt R.A., Evans C.A., Gocayne J.D.,
RA   Amanatides P.G., Scherer S.E., Li P.W., Hoskins R.A., Galle R.F.,
RA   George R.A., Lewis S.E., Richards S., Ashburner M., Henderson S.N.,
RA   Sutton G.G., Wortman J.R., Yandell M.D., Zhang Q., Chen L.X.,
RA   Brandon R.C., Rogers Y.-H.C., Blazej R.G., Champe M., Pfeiffer B.D.,
RA   Wan K.H., Doyle C., Baxter E.G., Helt G., Nelson C.R., Miklos G.L.G.,
RA   Abril J.F., Agbayani A., An H.-J., Andrews-Pfannkoch C., Baldwin D.,
RA   Ballew R.M., Basu A., Baxendale J., Bayraktaroglu L., Beasley E.M.,
RA   Beeson K.Y., Benos P.V., Berman B.P., Bhandari D., Bolshakov S.,
RA   Borkova D., Botchan M.R., Bouck J., Brokstein P., Brottier P.,
RA   Burtis K.C., Busam D.A., Butler H., Cadieu E., Center A., Chandra I.,
RA   Cherry J.M., Cawley S., Dahlke C., Davenport L.B., Davies P.,
RA   de Pablos B., Delcher A., Deng Z., Mays A.D., Dew I., Dietz S.M.,
RA   Dodson K., Doup L.E., Downes M., Dugan-Rocha S., Dunkov B.C., Dunn P.,
RA   Durbin K.J., Evangelista C.C., Ferraz C., Ferriera S., Fleischmann W.,
RA   Fosler C., Gabrielian A.E., Garg N.S., Gelbart W.M., Glasser K.,
RA   Glodek A., Gong F., Gorrell J.H., Gu Z., Guan P., Harris M.,
RA   Harris N.L., Harvey D.A., Heiman T.J., Hernandez J.R., Houck J.,
RA   Hostin D., Houston K.A., Howland T.J., Wei M.-H., Ibegwam C.,
RA   Jalali M., Kalush F., Karpen G.H., Ke Z., Kennison J.A., Ketchum K.A.,
RA   Kimmel B.E., Kodira C.D., Kraft C.L., Kravitz S., Kulp D., Lai Z.,
RA   Lasko P., Lei Y., Levitsky A.A., Li J.H., Li Z., Liang Y., Lin X.,
RA   Liu X., Mattei B., McIntosh T.C., McLeod M.P., McPherson D.,
RA   Merkulov G., Milshina N.V., Mobarry C., Morris J., Moshrefi A.,
RA   Mount S.M., Moy M., Murphy B., Murphy L., Muzny D.M., Nelson D.L.,
RA   Nelson D.R., Nelson K.A., Nixon K., Nusskern D.R., Pacleb J.M.,
RA   Palazzolo M., Pittman G.S., Pan S., Pollard J., Puri V., Reese M.G.,
RA   Reinert K., Remington K., Saunders R.D.C., Scheeler F., Shen H.,
RA   Shue B.C., Siden-Kiamos I., Simpson M., Skupski M.P., Smith T.J.,
RA   Spier E., Spradling A.C., Stapleton M., Strong R., Sun E.,
RA   Svirskas R., Tector C., Turner R., Venter E., Wang A.H., Wang X.,
RA   Wang Z.-Y., Wassarman D.A., Weinstock G.M., Weissenbach J.,
RA   Williams S.M., Woodage T., Worley K.C., Wu D., Yang S., Yao Q.A.,
RA   Ye J., Yeh R.-F., Zaveri J.S., Zhan M., Zhang G., Zhao Q., Zheng L.,
RA   Zheng X.H., Zhong F.N., Zhong W., Zhou X., Zhu S.C., Zhu X.,
RA   Smith H.O., Gibbs R.A., Myers E.W., Rubin G.M., Venter J.C.;
RT   "The genome sequence of Drosophila melanogaster.";
RL   Science 287:2185-2195(2000).
RN   [7]
RP   GENOME REANNOTATION.
RC   STRAIN=Berkeley;
RX   PubMed=12537572; DOI=10.1186/gb-2002-3-12-research0083;
RA   Misra S., Crosby M.A., Mungall C.J., Matthews B.B., Campbell K.S.,
RA   Hradecky P., Huang Y., Kaminker J.S., Millburn G.H., Prochnik S.E.,
RA   Smith C.D., Tupy J.L., Whitfield E.J., Bayraktaroglu L., Berman B.P.,
RA   Bettencourt B.R., Celniker S.E., de Grey A.D.N.J., Drysdale R.A.,
RA   Harris N.L., Richter J., Russo S., Schroeder A.J., Shu S.Q.,
RA   Stapleton M., Yamada C., Ashburner M., Gelbart W.M., Rubin G.M.,
RA   Lewis S.E.;
RT   "Annotation of the Drosophila melanogaster euchromatic genome: a
RT   systematic review.";
RL   Genome Biol. 3:RESEARCH0083.1-RESEARCH0083.22(2002).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 959-1078.
RC   STRAIN=Daekwanryeong;
RX   PubMed=2983232; DOI=10.1038/314178a0;
RA   Wadsworth S.C., Vincent W.S. III, Bilodeau-Wentworth D.;
RT   "A Drosophila genomic sequence with homology to human epidermal growth
RT   factor receptor.";
RL   Nature 314:178-180(1985).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1069-1121.
RC   TISSUE=Embryo;
RX   PubMed=9731193; DOI=10.1006/bbrc.1998.9003;
RA   Oates A.C., Wollberg P., Achen M.G., Wilks A.F.;
RT   "Sampling the genomic pool of protein tyrosine kinase genes using the
RT   polymerase chain reaction with genomic DNA.";
RL   Biochem. Biophys. Res. Commun. 249:660-667(1998).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1133-1137; 1155-1167 AND
RP   1209-1216, AND MUTANTS.
RX   PubMed=1936959;
RA   Raz E., Schejter E.D., Shilo B.Z.;
RT   "Interallelic complementation among DER/flb alleles: implications for
RT   the mechanism of signal transduction by receptor-tyrosine kinases.";
RL   Genetics 129:191-201(1991).
RN   [11]
RP   REVIEW.
RX   PubMed=9094709; DOI=10.1016/S0092-8674(00)80177-4;
RA   Perrimon N., Perkins L.A.;
RT   "There must be 50 ways to rule the signal: the case of the Drosophila
RT   EGF receptor.";
RL   Cell 89:13-16(1997).
RN   [12]
RP   INTERACTION WITH VAV.
RX   PubMed=10781813; DOI=10.1016/S0014-5793(00)01413-7;
RA   Dekel I., Russek N., Jones T., Mortin M.A., Katzav S.;
RT   "Identification of the Drosophila melanogaster homologue of the
RT   mammalian signal transducer protein, Vav.";
RL   FEBS Lett. 472:99-104(2000).
RN   [13]
RP   FUNCTION, AND DISRUPTION PHENOTYPE.
RX   PubMed=22140578; DOI=10.1371/journal.pone.0028349;
RA   Geiger J.A., Carvalho L., Campos I., Santos A.C., Jacinto A.;
RT   "Hole-in-one mutant phenotypes link EGFR/ERK signaling to epithelial
RT   tissue repair in Drosophila.";
RL   PLoS ONE 6:E28349-E28349(2011).
CC   -!- FUNCTION: Binds to four ligands: Spitz, Gurken, Vein and Argos,
CC       which is an antagonist. Transduces the signal through the ras-raf-
CC       MAPK pathway. Involved in a myriad of developmental decisions.
CC       Critical for the proliferation of imaginal tissues, and for the
CC       determination of both the antero-posterior and dorso-ventral
CC       polarities of the oocyte. In the embryo, plays a role in the
CC       establishment of ventral cell fates, maintenance of amnioserosa
CC       and ventral neuroectodermal cells, germ band retraction, cell fate
CC       specification in the central nervous system and production of
CC       cuticle. Required for embryonic epithelial tissue repair.
CC       {ECO:0000269|PubMed:22140578}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028}.
CC   -!- SUBUNIT: Interacts (when phosphorylated on tyrosine residues) with
CC       Vav (via SH2 domain). {ECO:0000269|PubMed:10781813}.
CC   -!- INTERACTION:
CC       P91643:kek1; NbExp=2; IntAct=EBI-197863, EBI-6896313;
CC       Q01083:spi; NbExp=4; IntAct=EBI-197863, EBI-91342;
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane
CC       protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=Type I;
CC         IsoId=P04412-1; Sequence=Displayed;
CC       Name=Type II;
CC         IsoId=P04412-2; Sequence=VSP_002897;
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed in embryos. In larvae,
CC       uniform expression is seen in wing disks, genital disk, anlagen of
CC       testis and ovary, and brain cortex. In eye-antenna disk, highest
CC       expression is anterior to morphogenetic furrow, levels remain high
CC       in photoreceptor precursor cells. This pattern is reversed in
CC       posterior eye disk. In adults expression is high in brain cortex
CC       and thoracic and abdominal ganglia. {ECO:0000269|PubMed:9882502}.
CC   -!- DISRUPTION PHENOTYPE: Embryonic wound healing defects.
CC       {ECO:0000269|PubMed:22140578}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. EGF receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF052754; AAC08536.1; -; Genomic_DNA.
DR   EMBL; AF052753; AAC08536.1; JOINED; Genomic_DNA.
DR   EMBL; AF052754; AAC08535.1; -; Genomic_DNA.
DR   EMBL; AF052752; AAC08535.1; JOINED; Genomic_DNA.
DR   EMBL; K03054; AAA51462.1; -; Genomic_DNA.
DR   EMBL; K03417; AAA51460.1; -; mRNA.
DR   EMBL; K03416; AAA50965.1; -; mRNA.
DR   EMBL; AF109077; AAD26134.1; -; Genomic_DNA.
DR   EMBL; AF109078; AAD26132.1; -; Genomic_DNA.
DR   EMBL; AF109082; AAD26132.1; JOINED; Genomic_DNA.
DR   EMBL; AF109078; AAD26133.1; -; Genomic_DNA.
DR   EMBL; AF109084; AAD26133.1; JOINED; Genomic_DNA.
DR   EMBL; AF109079; AAD26130.1; -; Genomic_DNA.
DR   EMBL; AF109081; AAD26130.1; JOINED; Genomic_DNA.
DR   EMBL; AF109079; AAD26131.1; -; Genomic_DNA.
DR   EMBL; AF109083; AAD26131.1; JOINED; Genomic_DNA.
DR   EMBL; AF109080; AAD26135.1; -; Genomic_DNA.
DR   EMBL; AE013599; AAF46732.1; -; Genomic_DNA.
DR   EMBL; X02293; CAA26157.1; -; Genomic_DNA.
DR   EMBL; AJ002912; CAA05747.1; -; Genomic_DNA.
DR   EMBL; X78920; CAA55523.1; -; Genomic_DNA.
DR   EMBL; X78918; CAA55521.1; -; Genomic_DNA.
DR   EMBL; X78919; CAA55522.1; -; Genomic_DNA.
DR   PIR; A00640; GQFFE.
DR   RefSeq; NP_476759.1; NM_057411.4.
DR   PDB; 3I2T; X-ray; 2.70 A; A=100-644.
DR   PDB; 3LTF; X-ray; 3.20 A; A/C=100-688.
DR   PDB; 3LTG; X-ray; 3.40 A; A/C=100-688.
DR   PDBsum; 3I2T; -.
DR   PDBsum; 3LTF; -.
DR   PDBsum; 3LTG; -.
DR   ProteinModelPortal; P04412; -.
DR   SMR; P04412; 100-644, 926-1210.
DR   BioGrid; 63083; 72.
DR   DIP; DIP-17316N; -.
DR   IntAct; P04412; 5.
DR   MINT; MINT-806082; -.
DR   STRING; 7227.FBpp0071571; -.
DR   PaxDb; P04412; -.
DR   GeneID; 37455; -.
DR   CTD; 1956; -.
DR   FlyBase; FBgn0003731; Egfr.
DR   eggNOG; KOG1025; Eukaryota.
DR   eggNOG; ENOG410XNSR; LUCA.
DR   InParanoid; P04412; -.
DR   OrthoDB; EOG7SV0TH; -.
DR   PhylomeDB; P04412; -.
DR   BRENDA; 2.7.10.1; 1994.
DR   Reactome; R-DME-1227986; Signaling by ERBB2.
DR   Reactome; R-DME-179812; GRB2 events in EGFR signaling.
DR   Reactome; R-DME-180292; GAB1 signalosome.
DR   Reactome; R-DME-180336; SHC1 events in EGFR signaling.
DR   Reactome; R-DME-182971; EGFR downregulation.
DR   Reactome; R-DME-2179392; EGFR Transactivation by Gastrin.
DR   Reactome; R-DME-445144; Signal transduction by L1.
DR   Reactome; R-DME-5673001; RAF/MAP kinase cascade.
DR   SignaLink; P04412; -.
DR   ChiTaRS; Egfr; fly.
DR   EvolutionaryTrace; P04412; -.
DR   GenomeRNAi; 37455; -.
DR   NextBio; 803734; -.
DR   PRO; PR:P04412; -.
DR   Proteomes; UP000000803; Chromosome 2R.
DR   Bgee; P04412; -.
DR   ExpressionAtlas; P04412; differential.
DR   Genevisible; P04412; DM.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; IDA:FlyBase.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005006; F:epidermal growth factor-activated receptor activity; ISS:FlyBase.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; NAS:FlyBase.
DR   GO; GO:0004888; F:transmembrane signaling receptor activity; TAS:FlyBase.
DR   GO; GO:0007469; P:antennal development; NAS:FlyBase.
DR   GO; GO:0009952; P:anterior/posterior pattern specification; TAS:FlyBase.
DR   GO; GO:0048149; P:behavioral response to ethanol; IMP:FlyBase.
DR   GO; GO:0007350; P:blastoderm segmentation; TAS:FlyBase.
DR   GO; GO:0007298; P:border follicle cell migration; IMP:FlyBase.
DR   GO; GO:0007420; P:brain development; TAS:FlyBase.
DR   GO; GO:0046845; P:branched duct epithelial cell fate determination, open tracheal system; TAS:FlyBase.
DR   GO; GO:0045165; P:cell fate commitment; NAS:FlyBase.
DR   GO; GO:0001709; P:cell fate determination; TAS:FlyBase.
DR   GO; GO:0030031; P:cell projection assembly; IMP:FlyBase.
DR   GO; GO:0030381; P:chorion-containing eggshell pattern formation; IGI:FlyBase.
DR   GO; GO:0042676; P:compound eye cone cell fate commitment; TAS:FlyBase.
DR   GO; GO:0048749; P:compound eye development; IMP:FlyBase.
DR   GO; GO:0001745; P:compound eye morphogenesis; TAS:FlyBase.
DR   GO; GO:0001751; P:compound eye photoreceptor cell differentiation; IMP:FlyBase.
DR   GO; GO:0001752; P:compound eye photoreceptor fate commitment; TAS:FlyBase.
DR   GO; GO:0008340; P:determination of adult lifespan; IMP:FlyBase.
DR   GO; GO:0035225; P:determination of genital disc primordium; IMP:FlyBase.
DR   GO; GO:0048546; P:digestive tract morphogenesis; IMP:FlyBase.
DR   GO; GO:0046843; P:dorsal appendage formation; IMP:FlyBase.
DR   GO; GO:0007391; P:dorsal closure; IMP:FlyBase.
DR   GO; GO:0009953; P:dorsal/ventral pattern formation; TAS:FlyBase.
DR   GO; GO:0009792; P:embryo development ending in birth or egg hatching; IMP:CACAO.
DR   GO; GO:0000578; P:embryonic axis specification; NAS:FlyBase.
DR   GO; GO:0009880; P:embryonic pattern specification; IGI:FlyBase.
DR   GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; TAS:FlyBase.
DR   GO; GO:0061331; P:epithelial cell proliferation involved in Malpighian tubule morphogenesis; IMP:FlyBase.
DR   GO; GO:0035088; P:establishment or maintenance of apical/basal cell polarity; IMP:FlyBase.
DR   GO; GO:0001654; P:eye development; IMP:FlyBase.
DR   GO; GO:0007455; P:eye-antennal disc morphogenesis; IMP:FlyBase.
DR   GO; GO:0048139; P:female germ-line cyst encapsulation; TAS:FlyBase.
DR   GO; GO:0000086; P:G2/M transition of mitotic cell cycle; TAS:FlyBase.
DR   GO; GO:0007369; P:gastrulation; TAS:FlyBase.
DR   GO; GO:0007390; P:germ-band shortening; IMP:FlyBase.
DR   GO; GO:0030718; P:germ-line stem cell population maintenance; IGI:FlyBase.
DR   GO; GO:0008406; P:gonad development; IMP:FlyBase.
DR   GO; GO:0007482; P:haltere development; IMP:FlyBase.
DR   GO; GO:0003015; P:heart process; IMP:FlyBase.
DR   GO; GO:0007444; P:imaginal disc development; IMP:FlyBase.
DR   GO; GO:0007447; P:imaginal disc pattern formation; NAS:FlyBase.
DR   GO; GO:0007476; P:imaginal disc-derived wing morphogenesis; IMP:FlyBase.
DR   GO; GO:0008586; P:imaginal disc-derived wing vein morphogenesis; IMP:FlyBase.
DR   GO; GO:0007474; P:imaginal disc-derived wing vein specification; TAS:FlyBase.
DR   GO; GO:0007479; P:leg disc proximal/distal pattern formation; IMP:FlyBase.
DR   GO; GO:0035160; P:maintenance of epithelial integrity, open tracheal system; IMP:FlyBase.
DR   GO; GO:0048140; P:male germ-line cyst encapsulation; TAS:FlyBase.
DR   GO; GO:0007443; P:Malpighian tubule morphogenesis; IMP:FlyBase.
DR   GO; GO:0008071; P:maternal determination of dorsal/ventral axis, ovarian follicular epithelium, soma encoded; IMP:FlyBase.
DR   GO; GO:0002009; P:morphogenesis of an epithelium; IMP:FlyBase.
DR   GO; GO:0016333; P:morphogenesis of follicular epithelium; IMP:FlyBase.
DR   GO; GO:0016203; P:muscle attachment; TAS:FlyBase.
DR   GO; GO:0042694; P:muscle cell fate specification; TAS:FlyBase.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:FlyBase.
DR   GO; GO:2001234; P:negative regulation of apoptotic signaling pathway; IGI:FlyBase.
DR   GO; GO:0046673; P:negative regulation of compound eye retinal cell programmed cell death; IMP:FlyBase.
DR   GO; GO:2000134; P:negative regulation of G1/S transition of mitotic cell cycle; IMP:FlyBase.
DR   GO; GO:0022008; P:neurogenesis; IGI:FlyBase.
DR   GO; GO:0035310; P:notum cell fate specification; IMP:FlyBase.
DR   GO; GO:0007477; P:notum development; IMP:FlyBase.
DR   GO; GO:0001742; P:oenocyte differentiation; TAS:FlyBase.
DR   GO; GO:0008355; P:olfactory learning; IMP:FlyBase.
DR   GO; GO:0016318; P:ommatidial rotation; IMP:FlyBase.
DR   GO; GO:0007314; P:oocyte anterior/posterior axis specification; NAS:FlyBase.
DR   GO; GO:0007309; P:oocyte axis specification; IMP:FlyBase.
DR   GO; GO:0007310; P:oocyte dorsal/ventral axis specification; NAS:FlyBase.
DR   GO; GO:0048477; P:oogenesis; NAS:FlyBase.
DR   GO; GO:0007424; P:open tracheal system development; TAS:FlyBase.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; NAS:GOC.
DR   GO; GO:0007422; P:peripheral nervous system development; IMP:FlyBase.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IMP:FlyBase.
DR   GO; GO:0090303; P:positive regulation of wound healing; IMP:FlyBase.
DR   GO; GO:0007458; P:progression of morphogenetic furrow involved in compound eye morphogenesis; TAS:FlyBase.
DR   GO; GO:0006468; P:protein phosphorylation; NAS:FlyBase.
DR   GO; GO:0045466; P:R7 cell differentiation; TAS:FlyBase.
DR   GO; GO:0045610; P:regulation of hemocyte differentiation; IMP:FlyBase.
DR   GO; GO:0007346; P:regulation of mitotic cell cycle; TAS:FlyBase.
DR   GO; GO:0045468; P:regulation of R8 cell spacing in compound eye; NAS:FlyBase.
DR   GO; GO:0007431; P:salivary gland development; IMP:FlyBase.
DR   GO; GO:0016330; P:second mitotic wave involved in compound eye morphogenesis; IMP:FlyBase.
DR   GO; GO:0007367; P:segment polarity determination; IMP:FlyBase.
DR   GO; GO:0016337; P:single organismal cell-cell adhesion; IMP:FlyBase.
DR   GO; GO:0035277; P:spiracle morphogenesis, open tracheal system; IMP:FlyBase.
DR   GO; GO:0048865; P:stem cell fate commitment; IMP:FlyBase.
DR   GO; GO:0007421; P:stomatogastric nervous system development; TAS:FlyBase.
DR   GO; GO:0035202; P:tracheal pit formation in open tracheal system; TAS:FlyBase.
DR   GO; GO:0035309; P:wing and notum subfield formation; IMP:FlyBase.
DR   GO; GO:0007472; P:wing disc morphogenesis; IMP:FlyBase.
DR   GO; GO:0007473; P:wing disc proximal/distal pattern formation; TAS:FlyBase.
DR   Gene3D; 3.80.20.20; -; 4.
DR   InterPro; IPR006211; Furin-like_Cys-rich_dom.
DR   InterPro; IPR006212; Furin_repeat.
DR   InterPro; IPR032778; GF_recep_IV.
DR   InterPro; IPR009030; Growth_fac_rcpt_.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR032675; L_dom-like.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR000494; Rcpt_L-dom.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   Pfam; PF00757; Furin-like; 1.
DR   Pfam; PF14843; GF_recep_IV; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF01030; Recep_L_domain; 2.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00261; FU; 7.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF52058; SSF52058; 2.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF57184; SSF57184; 3.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Complete proteome;
KW   Developmental protein; Glycoprotein; Kinase; Membrane;
KW   Nucleotide-binding; Phosphoprotein; Receptor; Reference proteome;
KW   Signal; Transferase; Transmembrane; Transmembrane helix;
KW   Tyrosine-protein kinase.
FT   SIGNAL        1     30       {ECO:0000255}.
FT   CHAIN        31   1426       Epidermal growth factor receptor.
FT                                /FTId=PRO_0000016676.
FT   TOPO_DOM     31    868       Extracellular. {ECO:0000255}.
FT   TRANSMEM    869    889       Helical. {ECO:0000255}.
FT   TOPO_DOM    890   1426       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      938   1198       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     944    952       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ACT_SITE   1063   1063       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING     971    971       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES     902    902       Phosphothreonine; by PKC. {ECO:0000250}.
FT   MOD_RES    1310   1310       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   CARBOHYD    128    128       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    241    241       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    419    419       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    443    443       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    482    482       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    569    569       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    599    599       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    617    617       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    816    816       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    823    823       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    828    828       N-linked (GlcNAc...). {ECO:0000255}.
FT   VAR_SEQ       1    101       MLLRRRNGPCPFPLLLLLLAHCICIWPASAARDRYARQNNR
FT                                QRHQDIDRDRDRDRFLYRSSSAQNRQRGGANFALGLGANGV
FT                                TIPTSLEDKNKNEFVKGKI -> MMIISMWMSISRGLWDSS
FT                                SILSVLLILACMASITTSSSVSNAGYVDNGNMKV (in
FT                                isoform Type II). {ECO:0000305}.
FT                                /FTId=VSP_002897.
FT   MUTAGEN     793    793       C->R: In EGFR-ELP-1.
FT   MUTAGEN     936    936       A->T: In EGFR-ELP-B1 and EGFR-ELP-B1RB1.
FT   MUTAGEN    1058   1058       R->Q: In EGFR-ELP-B1RB1.
FT   MUTAGEN    1135   1135       T->I: In EGFR-2W74.
FT   MUTAGEN    1156   1156       G->S: In EGFR-2C82.
FT   MUTAGEN    1162   1162       P->L: In EGFR-1F26.
FT   MUTAGEN    1166   1166       S->L: In EGFR-2L65.
FT   MUTAGEN    1210   1216       DKFTRLP->EKVHPAA: In EGFR-2X51.
FT   CONFLICT    137    137       K -> E (in Ref. 5 and 6). {ECO:0000305}.
FT   CONFLICT    329    331       AVS -> GVC (in Ref. 5 and 6).
FT                                {ECO:0000305}.
FT   CONFLICT    458    458       R -> L (in Ref. 5 and 6). {ECO:0000305}.
FT   CONFLICT    789    789       R -> C (in Ref. 5 and 6). {ECO:0000305}.
FT   CONFLICT    959    959       P -> A (in Ref. 8; CAA26157).
FT                                {ECO:0000305}.
FT   CONFLICT    995    995       E -> V (in Ref. 5 and 6). {ECO:0000305}.
FT   CONFLICT   1072   1080       QTPSLVKIT -> RLLAGEDH (in Ref. 3, 4 and
FT                                9). {ECO:0000305}.
FT   CONFLICT   1097   1098       AA -> I (in Ref. 9; CAA05747).
FT                                {ECO:0000305}.
FT   CONFLICT   1118   1118       T -> R (in Ref. 9; CAA05747).
FT                                {ECO:0000305}.
FT   CONFLICT   1242   1242       K -> E (in Ref. 5 and 6). {ECO:0000305}.
FT   CONFLICT   1265   1265       M -> I (in Ref. 5 and 6). {ECO:0000305}.
FT   CONFLICT   1287   1287       R -> T (in Ref. 5 and 6). {ECO:0000305}.
FT   CONFLICT   1325   1325       M -> I (in Ref. 6; AAF46732).
FT                                {ECO:0000305}.
FT   CONFLICT   1383   1383       G -> V (in Ref. 5 and 6). {ECO:0000305}.
FT   CONFLICT   1412   1426       ELQPLHRNRNTETRV -> SCSHASKPQHGDEGVGSSRVGA
FT                                IANEEGESCQVPLEAMRYAFAGCYLR (in Ref. 3 and
FT                                4). {ECO:0000305}.
FT   STRAND      101    103       {ECO:0000244|PDB:3I2T}.
FT   HELIX       115    126       {ECO:0000244|PDB:3I2T}.
FT   STRAND      131    134       {ECO:0000244|PDB:3I2T}.
FT   STRAND      136    141       {ECO:0000244|PDB:3I2T}.
FT   HELIX       149    151       {ECO:0000244|PDB:3I2T}.
FT   STRAND      156    159       {ECO:0000244|PDB:3I2T}.
FT   STRAND      161    166       {ECO:0000244|PDB:3I2T}.
FT   STRAND      169    172       {ECO:0000244|PDB:3I2T}.
FT   STRAND      194    200       {ECO:0000244|PDB:3I2T}.
FT   STRAND      204    207       {ECO:0000244|PDB:3I2T}.
FT   STRAND      216    223       {ECO:0000244|PDB:3I2T}.
FT   TURN        230    232       {ECO:0000244|PDB:3I2T}.
FT   HELIX       235    237       {ECO:0000244|PDB:3I2T}.
FT   STRAND      239    241       {ECO:0000244|PDB:3LTF}.
FT   STRAND      246    248       {ECO:0000244|PDB:3I2T}.
FT   STRAND      269    273       {ECO:0000244|PDB:3I2T}.
FT   HELIX       274    276       {ECO:0000244|PDB:3I2T}.
FT   STRAND      281    285       {ECO:0000244|PDB:3I2T}.
FT   STRAND      287    289       {ECO:0000244|PDB:3I2T}.
FT   STRAND      290    292       {ECO:0000244|PDB:3LTF}.
FT   STRAND      295    300       {ECO:0000244|PDB:3I2T}.
FT   STRAND      305    316       {ECO:0000244|PDB:3I2T}.
FT   STRAND      319    327       {ECO:0000244|PDB:3I2T}.
FT   STRAND      330    334       {ECO:0000244|PDB:3I2T}.
FT   STRAND      338    342       {ECO:0000244|PDB:3I2T}.
FT   TURN        343    346       {ECO:0000244|PDB:3I2T}.
FT   STRAND      347    350       {ECO:0000244|PDB:3I2T}.
FT   STRAND      356    358       {ECO:0000244|PDB:3I2T}.
FT   STRAND      361    365       {ECO:0000244|PDB:3I2T}.
FT   STRAND      370    373       {ECO:0000244|PDB:3I2T}.
FT   STRAND      376    380       {ECO:0000244|PDB:3I2T}.
FT   STRAND      385    394       {ECO:0000244|PDB:3I2T}.
FT   STRAND      396    398       {ECO:0000244|PDB:3I2T}.
FT   STRAND      402    404       {ECO:0000244|PDB:3I2T}.
FT   TURN        411    413       {ECO:0000244|PDB:3I2T}.
FT   HELIX       414    417       {ECO:0000244|PDB:3I2T}.
FT   STRAND      421    425       {ECO:0000244|PDB:3I2T}.
FT   STRAND      427    429       {ECO:0000244|PDB:3I2T}.
FT   HELIX       431    435       {ECO:0000244|PDB:3I2T}.
FT   STRAND      438    440       {ECO:0000244|PDB:3I2T}.
FT   TURN        442    444       {ECO:0000244|PDB:3LTG}.
FT   STRAND      446    449       {ECO:0000244|PDB:3I2T}.
FT   HELIX       455    463       {ECO:0000244|PDB:3I2T}.
FT   STRAND      466    469       {ECO:0000244|PDB:3I2T}.
FT   STRAND      471    473       {ECO:0000244|PDB:3I2T}.
FT   HELIX       484    486       {ECO:0000244|PDB:3I2T}.
FT   STRAND      491    493       {ECO:0000244|PDB:3LTF}.
FT   TURN        499    502       {ECO:0000244|PDB:3I2T}.
FT   STRAND      503    509       {ECO:0000244|PDB:3I2T}.
FT   STRAND      525    531       {ECO:0000244|PDB:3I2T}.
FT   TURN        539    541       {ECO:0000244|PDB:3I2T}.
FT   HELIX       544    547       {ECO:0000244|PDB:3I2T}.
FT   STRAND      555    561       {ECO:0000244|PDB:3I2T}.
FT   HELIX       563    567       {ECO:0000244|PDB:3I2T}.
FT   TURN        568    570       {ECO:0000244|PDB:3I2T}.
FT   STRAND      575    577       {ECO:0000244|PDB:3LTG}.
FT   STRAND      582    586       {ECO:0000244|PDB:3I2T}.
FT   STRAND      590    598       {ECO:0000244|PDB:3I2T}.
FT   STRAND      601    604       {ECO:0000244|PDB:3I2T}.
FT   STRAND      608    610       {ECO:0000244|PDB:3I2T}.
FT   STRAND      616    618       {ECO:0000244|PDB:3I2T}.
FT   STRAND      628    630       {ECO:0000244|PDB:3I2T}.
FT   STRAND      632    636       {ECO:0000244|PDB:3LTF}.
FT   STRAND      638    640       {ECO:0000244|PDB:3I2T}.
SQ   SEQUENCE   1426 AA;  159718 MW;  4D424C3C99DA4AF4 CRC64;
     MLLRRRNGPC PFPLLLLLLA HCICIWPASA ARDRYARQNN RQRHQDIDRD RDRDRFLYRS
     SSAQNRQRGG ANFALGLGAN GVTIPTSLED KNKNEFVKGK ICIGTKSRLS VPSNKEHHYR
     NLRDRYTNCT YVDGNLKLTW LPNENLDLSF LDNIREVTGY ILISHVDVKK VVFPKLQIIR
     GRTLFSLSVE EEKYALFVTY SKMYTLEIPD LRDVLNGQVG FHNNYNLCHM RTIQWSEIVS
     NGTDAYYNYD FTAPERECPK CHESCTHGCW GEGPKNCQKF SKLTCSPQCA GGRCYGPKPR
     ECCHLFCAGG CTGPTQKDCI ACKNFFDEAV SKEECPPMRK YNPTTYVLET NPEGKYAYGA
     TCVKECPGHL LRDNGACVRS CPQDKMDKGG ECVPCNGPCP KTCPGVTVLH AGNIDSFRNC
     TVIDGNIRIL DQTFSGFQDV YANYTMGPRY IPLDPERREV FSTVKEITGY LNIEGTHPQF
     RNLSYFRNLE TIHGRQLMES MFAALAIVKS SLYSLEMRNL KQISSGSVVI QHNRDLCYVS
     NIRWPAIQKE PEQKVWVNEN LRADLCEKNG TICSDQCNED GCWGAGTDQC LTCKNFNFNG
     TCIADCGYIS NAYKFDNRTC KICHPECRTC NGAGADHCQE CVHVRDGQHC VSECPKNKYN
     DRGVCRECHA TCDGCTGPKD TIGIGACTTC NLAIINNDAT VKRCLLKDDK CPDGYFWEYV
     HPQEQGSLKP LAGRAVCRKC HPLCELCTNY GYHEQVCSKC THYKRREQCE TECPADHYTD
     EEQRECFQRH PECNGCTGPG ADDCKSCRNF KLFDANETGP YVNSTMFNCT SKCPLEMRHV
     NYQYTAIGPY CAASPPRSSK ITANLDVNMI FIITGAVLVP TICILCVVTY ICRQKQKAKK
     ETVKMTMALS GCEDSEPLRP SNIGANLCKL RIVKDAELRK GGVLGMGAFG RVYKGVWVPE
     GENVKIPVAI KELLKSTGAE SSEEFLREAY IMASEEHVNL LKLLAVCMSS QMMLITQLMP
     LGCLLDYVRN NRDKIGSKAL LNWSTQIAKG MSYLEEKRLV HRDLAARNVL VQTPSLVKIT
     DFGLAKLLSS DSNEYKAAGG KMPIKWLALE CIRNRVFTSK SDVWAFGVTI WELLTFGQRP
     HENIPAKDIP DLIEVGLKLE QPEICSLDIY CTLLSCWHLD AAMRPTFKQL TTVFAEFARD
     PGRYLAIPGD KFTRLPAYTS QDEKDLIRKL APTTDGSEAI AKPDDYLQPK AAPGPSHRTD
     CTDEMPKLNR YCKDPSNKNS STGDDERDSS AREVGVGNLR LDLPVDEDDY LMPTCQPGPN
     NNNNMNNPNQ NNMAAVGVAA GYMDLIGVPV SVDNPEYLLN AQTLGVGESP IPTQTIGIPV
     MGGPGTMEVK VPMPGSEPTS SDHEYYNDTQ RELQPLHRNR NTETRV
//
ID   APOB_HUMAN              Reviewed;        4563 AA.
AC   P04114; O00502; P78479; P78480; P78481; Q13779; Q13785; Q13786;
AC   Q13787; Q13788; Q4ZG63; Q53QC8; Q7Z600; Q9UMN0;
DT   01-NOV-1986, integrated into UniProtKB/Swiss-Prot.
DT   13-JUL-2010, sequence version 2.
DT   17-FEB-2016, entry version 195.
DE   RecName: Full=Apolipoprotein B-100;
DE            Short=Apo B-100;
DE   Contains:
DE     RecName: Full=Apolipoprotein B-48;
DE              Short=Apo B-48;
DE   Flags: Precursor;
GN   Name=APOB;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS ASN-273; GLU-1218; CYS-1422;
RP   RP VAL-2092; VAL-2313; THR-2365; GLN-2680; HIS-3319; LYS-3427;
RP   GLU-3432; THR-3732; LEU-3949; PHE-3964; LYS-4181 AND ASN-4338.
RX   PubMed=3763409; DOI=10.1093/nar/14.18.7501;
RA   Knott T.C., Wallis S.C., Powell L.M., Pease R.J., Lusis A.J.,
RA   Blackhart B., McCarthy B.J., Mahley R.W., Levy-Wilson B., Scott J.;
RT   "Complete cDNA and derived protein sequence of human apolipoprotein B-
RT   100.";
RL   Nucleic Acids Res. 14:7501-7503(1986).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS CYS-1422; VAL-2313;
RP   HIS-3319; LYS-3427; GLU-3432 AND ASN-4338.
RX   PubMed=3652907; DOI=10.1089/dna.1987.6.363;
RA   Ludwig E.H., Blackhart B.D., Pierotti V.R., Caiati L., Fortier C.,
RA   Knott T., Scott J., Mahley R.W., Levy-Wilson B., McCarthy B.J.;
RT   "DNA sequence of the human apolipoprotein B gene.";
RL   DNA 6:363-372(1987).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS ILE-98; VAL-618; CYS-1422;
RP   VAL-2313; HIS-3319; LYS-3427; GLU-3432 AND ASN-4338.
RX   PubMed=3759943;
RA   Chen S.-H., Yang C.-Y., Chen P.-F., Setzer D., Tanimura M., Li W.-H.,
RA   Gotto A.M. Jr., Chan L.;
RT   "The complete cDNA and amino acid sequence of human apolipoprotein B-
RT   100.";
RL   J. Biol. Chem. 261:12918-12921(1986).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS CYS-1422; ASN-2037; VAL-2313;
RP   HIS-3319; LYS-3427; GLU-3432; LEU-3949; LYS-4181 AND ASN-4338.
RX   PubMed=3464946; DOI=10.1073/pnas.83.21.8142;
RA   Law S.W., Grant S.M., Higuchi K., Hospattankar A.V., Lackner K.J.,
RA   Lee N., Brewer H.B. Jr.;
RT   "Human liver apolipoprotein B-100 cDNA: complete nucleic acid and
RT   derived amino acid sequence.";
RL   Proc. Natl. Acad. Sci. U.S.A. 83:8142-8146(1986).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA], NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-40,
RP   AND VARIANTS VAL-618; CYS-1422; VAL-2313; HIS-3319; LYS-3427;
RP   GLU-3432; THR-3732; LEU-3949; PHE-3964; LYS-4181 AND ASN-4338.
RX   PubMed=3030729;
RA   Cladaras C., Hadzopoulou-Cladaras M., Nolte R.T., Atkinson D.,
RA   Zannis V.I.;
RT   "The complete sequence and structural analysis of human apolipoprotein
RT   B-100: relationship between apoB-100 and apoB-48 forms.";
RL   EMBO J. 5:3495-3507(1986).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS CYS-1422; VAL-2313 AND
RP   ASN-4338.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-1670, AND VARIANTS ILE-98; CYS-1422
RP   AND ASP-1670.
RX   PubMed=3461454; DOI=10.1073/pnas.83.15.5678;
RA   Protter A.A., Hardman D.A., Sato K.Y., Schilling J.W., Yamanaka M.,
RA   Hort Y.J., Hjerrild K.A., Chen G.C., Kane J.P.;
RT   "Analysis of cDNA clones encoding the entire B-26 region of human
RT   apolipoprotein B.";
RL   Proc. Natl. Acad. Sci. U.S.A. 83:5678-5682(1986).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-291.
RX   PubMed=3513177; DOI=10.1073/pnas.83.5.1467;
RA   Protter A.A., Hardman D.A., Schilling J.W., Miller J., Appleby V.,
RA   Chen G.C., Kirsher S.W., McEnroe G., Kane J.P.;
RT   "Isolation of a cDNA clone encoding the amino-terminal region of human
RT   apolipoprotein B.";
RL   Proc. Natl. Acad. Sci. U.S.A. 83:1467-1471(1986).
RN   [10]
RP   PARTIAL PROTEIN SEQUENCE, DISULFIDE BONDS, AND VARIANT ILE-98.
RX   PubMed=2115173; DOI=10.1073/pnas.87.14.5523;
RA   Yang C.Y., Kim T.W., Weng S.A., Lee B.R., Yang M.L., Gotto A.M. Jr.;
RT   "Isolation and characterization of sulfhydryl and disulfide peptides
RT   of human apolipoprotein B-100.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:5523-5527(1990).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 485-1044.
RC   TISSUE=Liver;
RX   PubMed=3001697; DOI=10.1073/pnas.82.24.8340;
RA   Law S.W., Lackner K.J., Hospattankar A.V., Anchors J.M.,
RA   Sakaguchi A.Y., Naylor S.L., Brewer H.B. Jr.;
RT   "Human apolipoprotein B-100: cloning, analysis of liver mRNA, and
RT   assignment of the gene to chromosome 2.";
RL   Proc. Natl. Acad. Sci. U.S.A. 82:8340-8344(1985).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 709-906.
RX   PubMed=3860836; DOI=10.1073/pnas.82.15.4983;
RA   Deeb S.S., Motulsky A.G., Albers J.J.;
RT   "A partial cDNA clone for human apolipoprotein B.";
RL   Proc. Natl. Acad. Sci. U.S.A. 82:4983-4986(1985).
RN   [13]
RP   PROTEIN SEQUENCE OF 873-896 AND 3113-3137.
RX   PubMed=6373369; DOI=10.1016/0014-5793(84)81378-2;
RA   LeBoeuf R.C., Miller C., Shively J.E., Schumaker V.N., Balla M.A.,
RA   Lusis A.J.;
RT   "Human apolipoprotein B: partial amino acid sequence.";
RL   FEBS Lett. 170:105-108(1984).
RN   [14]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1042-1232.
RX   PubMed=2567736;
RA   Huang L.S., Ripps M.E., Korman S.H., Deckelbaum R.J., Breslow J.L.;
RT   "Hypobetalipoproteinemia due to an apolipoprotein B gene exon 21
RT   deletion derived by Alu-Alu recombination.";
RL   J. Biol. Chem. 264:11394-11400(1989).
RN   [15]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1282-4503, AND VARIANTS CYS-1422;
RP   VAL-2313; HIS-3319; LYS-3427; GLU-3432; THR-3732 AND ASN-4338.
RX   PubMed=2883086; DOI=10.1016/0378-1119(86)90383-5;
RA   Carlsson P., Darnfors C., Olofsson S.O., Bjursell G.;
RT   "Analysis of the human apolipoprotein B gene; complete structure of
RT   the B-74 region.";
RL   Gene 49:29-51(1986).
RN   [16]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1671-2398, AND VARIANT VAL-2313.
RX   PubMed=3676265; DOI=10.1021/bi00391a040;
RA   Hardman D.A., Protter A.A., Chen G.C., Schilling J.W., Sato K.Y.,
RA   Lau K., Yamanaka M., Mikita T., Miller J., Crisp T., McEnroe G.,
RA   Scarborough R.M., Kane J.P.;
RT   "Structural comparison of human apolipoproteins B-48 and B-100.";
RL   Biochemistry 26:5478-5486(1987).
RN   [17]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1937-2018 AND 3811-4334.
RX   PubMed=3841204; DOI=10.1093/nar/13.24.8813;
RA   Carlsson P., Olofsson S.O., Bondjers G., Darnfors C., Wiklund O.,
RA   Bjursell G.;
RT   "Molecular cloning of human apolipoprotein B cDNA.";
RL   Nucleic Acids Res. 13:8813-8826(1985).
RN   [18]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 2115-2179.
RC   TISSUE=Small intestine;
RX   PubMed=3621347; DOI=10.1016/0092-8674(87)90510-1;
RA   Powell L.M., Wallis S.C., Pease R.J., Edwards Y.H., Knott T.J.,
RA   Scott J.;
RT   "A novel form of tissue-specific RNA processing produces
RT   apolipoprotein-B48 in intestine.";
RL   Cell 50:831-840(1987).
RN   [19]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 2127-2179.
RX   PubMed=2450346; DOI=10.1073/pnas.85.6.1772;
RA   Higuchi K., Hospattankar A.V., Law S.W., Meglin N., Cortright J.,
RA   Brewer H.B. Jr.;
RT   "Human apolipoprotein B (apoB) mRNA: identification of two distinct
RT   apoB mRNAs, an mRNA with the apoB-100 sequence and an apoB mRNA
RT   containing a premature in-frame translational stop codon, in both
RT   liver and intestine.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:1772-1776(1988).
RN   [20]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 2129-2235.
RX   PubMed=3426612; DOI=10.1016/0006-291X(87)90537-7;
RA   Hardman D.A., Protter A.A., Schilling J.W., Kane J.P.;
RT   "Carboxyl terminal analysis of human B-48 protein confirms the novel
RT   mechanism proposed for chain termination.";
RL   Biochem. Biophys. Res. Commun. 149:1214-1219(1987).
RN   [21]
RP   PROTEIN SEQUENCE OF 2169-2179.
RX   PubMed=2445342; DOI=10.1016/0006-291X(87)91107-7;
RA   Hospattankar A.V., Higuchi K., Law S.W., Meglin N., Brewer H.B. Jr.;
RT   "Identification of a novel in-frame translational stop codon in human
RT   intestine apoB mRNA.";
RL   Biochem. Biophys. Res. Commun. 148:279-285(1987).
RN   [22]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 3056-3159.
RX   PubMed=3903660; DOI=10.1093/nar/13.19.6937;
RA   Mehrabian M., Schumaker V.N., Fareed G.C., West R., Johnson D.F.,
RA   Kirchgessner T.G., Lin H.-C., Wang X., Ma Y., Mendiaz E., Lusis A.J.;
RT   "Human apolipoprotein B: identification of cDNA clones and
RT   characterization of mRNA.";
RL   Nucleic Acids Res. 13:6937-6953(1985).
RN   [23]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 3109-4563, AND VARIANTS HIS-3319;
RP   LYS-3427; GLU-3432; THR-3732; LEU-3949; PHE-3964; LYS-4181 AND
RP   ASN-4338.
RX   PubMed=2994225; DOI=10.1126/science.2994225;
RA   Knott T.J., Rall S.C. Jr., Innerarity T.L., Jacobson S.F., Urdea M.S.,
RA   Levy-Wilson B., Powell L.M., Pease R.J., Eddy R., Nakai H., Byers M.,
RA   Priestley L.M., Robertson E., Rall L.B., Betsholtz C., Shows T.B.,
RA   Mahley R.W., Scott J.;
RT   "Human apolipoprotein B: structure of carboxyl-terminal domains, sites
RT   of gene expression, and chromosomal localization.";
RL   Science 230:37-43(1985).
RN   [24]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 3728-4563, AND VARIANT ASN-4338.
RX   PubMed=2932736; DOI=10.1073/pnas.82.21.7265;
RA   Wei C.F., Chen S.H., Yang C.Y., Marcel Y.L., Milne R.W., Li W.H.,
RA   Sparrow J.T., Gotto A.M. Jr., Chan L.;
RT   "Molecular cloning and expression of partial cDNAs and deduced amino
RT   acid sequence of a carboxyl-terminal fragment of human apolipoprotein
RT   B-100.";
RL   Proc. Natl. Acad. Sci. U.S.A. 82:7265-7269(1985).
RN   [25]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 3846-4298, AND VARIANTS LEU-3949;
RP   PHE-3964 AND LYS-4181.
RC   TISSUE=Liver;
RX   PubMed=3841481; DOI=10.1016/0021-9150(85)90073-5;
RA   Shoulders C.C., Myant N.B., Sidoli A., Rodriguez J.C., Cortese C.,
RA   Baralle F.E., Cortese R.;
RT   "Molecular cloning of human LDL apolipoprotein B cDNA. Evidence for
RT   more than one gene per haploid genome.";
RL   Atherosclerosis 58:277-289(1985).
RN   [26]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 4217-4563.
RX   PubMed=3024665;
RA   Pfitzner R., Wagener R., Stoffel W.;
RT   "Isolation, expression and characterization of a human apolipoprotein
RT   B 100-specific cDNA clone.";
RL   Biol. Chem. Hoppe-Seyler 367:1077-1083(1986).
RN   [27]
RP   PARTIAL PROTEIN SEQUENCE, AND IDENTIFICATION OF APO-B48.
RX   PubMed=3659919; DOI=10.1126/science.3659919;
RA   Chen S.-H., Habib G., Yang C.-H., Gu Z.-W., Lee B.R., Weng S.-H.,
RA   Silberman S.R., Cai S.-J., Deslypere J.P., Rosseneu M.,
RA   Gotto A.M. Jr., Li W.-H., Chan L.;
RT   "Apolipoprotein B-48 is the product of a messenger RNA with an organ-
RT   specific in-frame stop codon.";
RL   Science 238:363-366(1987).
RN   [28]
RP   DOMAINS.
RX   PubMed=3773997; DOI=10.1038/323734a0;
RA   Knott T.C., Pease R.J., Powell L.M., Wallis S.C., Rall S.C. Jr.,
RA   Innerarity T.L., Blackhart B., Taylor W.R., Marcel Y., Milne R.,
RA   Johnson D., Fuller M., Lusis A.J., McCarthy B.J., Mahley R.W.,
RA   Levy-Wilson B., Scott J.;
RT   "Complete protein sequence and identification of structural domains of
RT   human apolipoprotein B.";
RL   Nature 323:734-738(1986).
RN   [29]
RP   DOMAINS.
RX   PubMed=3095664; DOI=10.1038/323738a0;
RA   Yang C.-Y., Chen S.-H., Gianturco S.H., Bradley W.A., Sparrow J.T.,
RA   Tanimura M., Li W.-H., Sparrow D.A., Deloof H., Rosseneu M.,
RA   Lee F.-S., Gu Z.-W., Gotto A.M. Jr., Chan L.;
RT   "Sequence, structure, receptor-binding domains and internal repeats of
RT   human apolipoprotein B-100.";
RL   Nature 323:738-742(1986).
RN   [30]
RP   CALCIUM-BINDING.
RX   PubMed=3087360; DOI=10.1016/0006-291X(86)91237-4;
RA   Dashti N., Lee D.M., Mok T.;
RT   "Apolipoprotein B is a calcium binding protein.";
RL   Biochem. Biophys. Res. Commun. 137:493-499(1986).
RN   [31]
RP   PALMITOYLATION AT CYS-1112.
RX   PubMed=10679026; DOI=10.1091/mbc.11.2.721;
RA   Zhao Y., McCabe J.B., Vance J., Berthiaume L.G.;
RT   "Palmitoylation of apolipoprotein B is required for proper
RT   intracellular sorting and transport of cholesteroyl esters and
RT   triglycerides.";
RL   Mol. Biol. Cell 11:721-734(2000).
RN   [32]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-3358.
RC   TISSUE=Plasma;
RX   PubMed=14760718; DOI=10.1002/pmic.200300556;
RA   Bunkenborg J., Pilch B.J., Podtelejnikov A.V., Wisniewski J.R.;
RT   "Screening for N-glycosylated proteins by liquid chromatography mass
RT   spectrometry.";
RL   Proteomics 4:454-465(2004).
RN   [33]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-1523; ASN-2982; ASN-3465
RP   AND ASN-3895.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [34]
RP   INDUCTION, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=16548883; DOI=10.1111/j.1462-5822.2005.00644.x;
RA   Leong W.F., Chow V.T.;
RT   "Transcriptomic and proteomic analyses of rhabdomyosarcoma cells
RT   reveal differential cellular gene expression in response to
RT   enterovirus 71 infection.";
RL   Cell. Microbiol. 8:565-580(2006).
RN   [35]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-185; ASN-1523; ASN-2239;
RP   ASN-2779; ASN-2982; ASN-3101; ASN-3224; ASN-3411; ASN-3465 AND
RP   ASN-3895.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [36]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-2004, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [37]
RP   INVOLVEMENT IN LDLCQ4, AND VARIANT ILE-98.
RX   PubMed=20686565; DOI=10.1038/nature09270;
RA   Teslovich T.M., Musunuru K., Smith A.V., Edmondson A.C.,
RA   Stylianou I.M., Koseki M., Pirruccello J.P., Ripatti S., Chasman D.I.,
RA   Willer C.J., Johansen C.T., Fouchier S.W., Isaacs A., Peloso G.M.,
RA   Barbalic M., Ricketts S.L., Bis J.C., Aulchenko Y.S., Thorleifsson G.,
RA   Feitosa M.F., Chambers J., Orho-Melander M., Melander O., Johnson T.,
RA   Li X., Guo X., Li M., Shin Cho Y., Jin Go M., Jin Kim Y., Lee J.Y.,
RA   Park T., Kim K., Sim X., Twee-Hee Ong R., Croteau-Chonka D.C.,
RA   Lange L.A., Smith J.D., Song K., Hua Zhao J., Yuan X., Luan J.,
RA   Lamina C., Ziegler A., Zhang W., Zee R.Y., Wright A.F., Witteman J.C.,
RA   Wilson J.F., Willemsen G., Wichmann H.E., Whitfield J.B.,
RA   Waterworth D.M., Wareham N.J., Waeber G., Vollenweider P.,
RA   Voight B.F., Vitart V., Uitterlinden A.G., Uda M., Tuomilehto J.,
RA   Thompson J.R., Tanaka T., Surakka I., Stringham H.M., Spector T.D.,
RA   Soranzo N., Smit J.H., Sinisalo J., Silander K., Sijbrands E.J.,
RA   Scuteri A., Scott J., Schlessinger D., Sanna S., Salomaa V.,
RA   Saharinen J., Sabatti C., Ruokonen A., Rudan I., Rose L.M.,
RA   Roberts R., Rieder M., Psaty B.M., Pramstaller P.P., Pichler I.,
RA   Perola M., Penninx B.W., Pedersen N.L., Pattaro C., Parker A.N.,
RA   Pare G., Oostra B.A., O'Donnell C.J., Nieminen M.S., Nickerson D.A.,
RA   Montgomery G.W., Meitinger T., McPherson R., McCarthy M.I.,
RA   McArdle W., Masson D., Martin N.G., Marroni F., Mangino M.,
RA   Magnusson P.K., Lucas G., Luben R., Loos R.J., Lokki M.L., Lettre G.,
RA   Langenberg C., Launer L.J., Lakatta E.G., Laaksonen R., Kyvik K.O.,
RA   Kronenberg F., Konig I.R., Khaw K.T., Kaprio J., Kaplan L.M.,
RA   Johansson A., Jarvelin M.R., Janssens A.C., Ingelsson E., Igl W.,
RA   Kees Hovingh G., Hottenga J.J., Hofman A., Hicks A.A.,
RA   Hengstenberg C., Heid I.M., Hayward C., Havulinna A.S., Hastie N.D.,
RA   Harris T.B., Haritunians T., Hall A.S., Gyllensten U., Guiducci C.,
RA   Groop L.C., Gonzalez E., Gieger C., Freimer N.B., Ferrucci L.,
RA   Erdmann J., Elliott P., Ejebe K.G., Doring A., Dominiczak A.F.,
RA   Demissie S., Deloukas P., de Geus E.J., de Faire U., Crawford G.,
RA   Collins F.S., Chen Y.D., Caulfield M.J., Campbell H., Burtt N.P.,
RA   Bonnycastle L.L., Boomsma D.I., Boekholdt S.M., Bergman R.N.,
RA   Barroso I., Bandinelli S., Ballantyne C.M., Assimes T.L.,
RA   Quertermous T., Altshuler D., Seielstad M., Wong T.Y., Tai E.S.,
RA   Feranil A.B., Kuzawa C.W., Adair L.S., Taylor H.A. Jr., Borecki I.B.,
RA   Gabriel S.B., Wilson J.G., Holm H., Thorsteinsdottir U., Gudnason V.,
RA   Krauss R.M., Mohlke K.L., Ordovas J.M., Munroe P.B., Kooner J.S.,
RA   Tall A.R., Hegele R.A., Kastelein J.J., Schadt E.E., Rotter J.I.,
RA   Boerwinkle E., Strachan D.P., Mooser V., Stefansson K., Reilly M.P.,
RA   Samani N.J., Schunkert H., Cupples L.A., Sandhu M.S., Ridker P.M.,
RA   Rader D.J., van Duijn C.M., Peltonen L., Abecasis G.R., Boehnke M.,
RA   Kathiresan S.;
RT   "Biological, clinical and population relevance of 95 loci for blood
RT   lipids.";
RL   Nature 466:707-713(2010).
RN   [38]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [39]
RP   INVOLVEMENT IN FHBL1.
RX   PubMed=21981844; DOI=10.1016/j.jacl.2011.06.014;
RA   Gangloff A., Bergeron J., Couture P., Martins R., Hegele R.A.,
RA   Gagne C.;
RT   "A novel mutation of apolipoprotein B in a French Canadian family with
RT   homozygous hypobetalipoproteinemia.";
RL   J. Clin. Lipidol. 5:414-417(2011).
RN   [40]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH PCSK9.
RX   PubMed=22580899; DOI=10.1161/ATVBAHA.112.250043;
RA   Sun H., Samarghandi A., Zhang N., Yao Z., Xiong M., Teng B.B.;
RT   "Proprotein convertase subtilisin/kexin type 9 interacts with
RT   apolipoprotein B and prevents its intracellular degradation,
RT   irrespective of the low-density lipoprotein receptor.";
RL   Arterioscler. Thromb. Vasc. Biol. 32:1585-1595(2012).
RN   [41]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-3279; SER-4048 AND
RP   THR-4052, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [42]
RP   PHOSPHORYLATION AT SER-4048.
RX   PubMed=26091039; DOI=10.1016/j.cell.2015.05.028;
RA   Tagliabracci V.S., Wiley S.E., Guo X., Kinch L.N., Durrant E., Wen J.,
RA   Xiao J., Cui J., Nguyen K.B., Engel J.L., Coon J.J., Grishin N.,
RA   Pinna L.A., Pagliarini D.J., Dixon J.E.;
RT   "A single kinase generates the majority of the secreted
RT   phosphoproteome.";
RL   Cell 161:1619-1632(2015).
RN   [43]
RP   INTERACTION WITH MTTP, AND SUBCELLULAR LOCATION.
RX   PubMed=26224785; DOI=10.1161/CIRCGENETICS.115.001106;
RA   Walsh M.T., Iqbal J., Josekutty J., Soh J., Di Leo E., Oezaydin E.,
RA   Guenduez M., Tarugi P., Hussain M.M.;
RT   "A novel abetalipoproteinemia missense mutation highlights the
RT   importance of N-Terminal beta-barrel in microsomal triglyceride
RT   transfer protein function.";
RL   Circ. Cardiovasc. Genet. 8:677-687(2015).
RN   [44]
RP   VARIANT ASN-4338.
RX   PubMed=1979313; DOI=10.1007/BF00205183;
RA   Navajas M., Laurent A.-M., Moreel J.-F., Ragab A., Cambou J.-P.,
RA   Cunny G., Cambien F., Roizes G.;
RT   "Detection by denaturing gradient gel electrophoresis of a new
RT   polymorphism in the apolipoprotein B gene.";
RL   Hum. Genet. 86:91-93(1990).
RN   [45]
RP   VARIANT FDB GLN-3527.
RX   PubMed=2563166; DOI=10.1073/pnas.86.2.587;
RA   Soria L.F., Ludwig E.H., Clarke H.R.G., Vega G.L., Grundy S.M.,
RA   McCarthy B.J.;
RT   "Association between a specific apolipoprotein B mutation and familial
RT   defective apolipoprotein B-100.";
RL   Proc. Natl. Acad. Sci. U.S.A. 86:587-591(1989).
RN   [46]
RP   VARIANT LEU-2739.
RX   PubMed=2216805; DOI=10.1093/nar/18.19.5922-a;
RA   Huang L.-S., Gavish D., Breslow J.L.;
RT   "Sequence polymorphism in the human apoB gene at position 8344.";
RL   Nucleic Acids Res. 18:5922-5922(1990).
RN   [47]
RP   VARIANT FDB CYS-3558.
RX   PubMed=7883971; DOI=10.1172/JCI117772;
RA   Pullinger C.R., Hennessy L.K., Chatterton J.E., Liu W., Love J.A.,
RA   Mendel C.M., Frost P.H., Malloy M.J., Schumaker V.N., Kane J.P.;
RT   "Familial ligand-defective apolipoprotein B. Identification of a new
RT   mutation that decreases LDL receptor binding affinity.";
RL   J. Clin. Invest. 95:1225-1234(1995).
RN   [48]
RP   VARIANTS LEU-1437; SER-1914; LYS-2566; THR-3121; ALA-3945; MET-4128
RP   AND THR-4481.
RX   PubMed=8889592;
RX   DOI=10.1002/(SICI)1098-1004(1996)8:3<282::AID-HUMU16>3.3.CO;2-Y;
RA   Poirier O., Ricard S., Behague I., Souriau C., Evans A.E.,
RA   Arveiler D., Marques-Vidal P., Luc G., Roizes G., Cambien F.;
RT   "Detection of new variants in the apolipoprotein B (Apo B) gene by
RT   PCR-SSCP.";
RL   Hum. Mutat. 8:282-285(1996).
RN   [49]
RP   VARIANTS FDB GLN-3527 AND CYS-3558.
RX   PubMed=9259199;
RX   DOI=10.1002/(SICI)1098-1004(1997)10:2<160::AID-HUMU8>3.0.CO;2-O;
RA   Rabes J.P., Varret M., Saint-Jore B., Erlich D., Jondeau G.,
RA   Krempf M., Giraudet P., Junien C., Boileau C.;
RT   "Familial ligand-defective apolipoprotein B-100: simultaneous
RT   detection of the Arg3500-->Gln and Arg3531-->Cys mutations in a French
RT   population.";
RL   Hum. Mutat. 10:160-163(1997).
RN   [50]
RP   VARIANTS SER-1914; ARG-1923; LEU-2739; HIS-3319; LYS-3427; GLU-3432
RP   AND ILE-3921.
RX   PubMed=9490296; DOI=10.1007/s004390050651;
RA   Leren T.P., Bakken K.S., Hoel V., Hjermann I., Berg K.;
RT   "Screening for mutations of the apolipoprotein B gene causing
RT   hypocholesterolemia.";
RL   Hum. Genet. 102:44-49(1998).
RN   [51]
RP   VARIANT FHBL1 TRP-490, VARIANT ILE-98, CHARACTERIZATION OF VARIANT
RP   TRP-490, AND MUTAGENESIS OF ASP-483 AND ARG-490.
RX   PubMed=12551903; DOI=10.1074/jbc.M300235200;
RA   Burnett J.R., Shan J., Miskie B.A., Whitfield A.J., Yuan J., Tran K.,
RA   McKnight C.J., Hegele R.A., Yao Z.;
RT   "A novel nontruncating APOB gene mutation, R463W, causes familial
RT   hypobetalipoproteinemia.";
RL   J. Biol. Chem. 278:13442-13452(2003).
RN   [52]
RP   VARIANT HIS-1128.
RX   PubMed=14732481;
RA   Lancellotti S., Di Leo E., Penacchioni J.Y., Balli F., Viola L.,
RA   Bertolini S., Calandra S., Tarugi P.;
RT   "Hypobetalipoproteinemia with an apparently recessive inheritance due
RT   to a 'de novo' mutation of apolipoprotein B.";
RL   Biochim. Biophys. Acta 1688:61-67(2004).
RN   [53]
RP   VARIANT [LARGE SCALE ANALYSIS] CYS-2564.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
RN   [54]
RP   VARIANT FDB GLN-3527.
RX   PubMed=21382890; DOI=10.1161/CIRCULATIONAHA.110.979450;
RA   van der Graaf A., Avis H.J., Kusters D.M., Vissers M.N., Hutten B.A.,
RA   Defesche J.C., Huijgen R., Fouchier S.W., Wijburg F.A.,
RA   Kastelein J.J., Wiegman A.;
RT   "Molecular basis of autosomal dominant hypercholesterolemia:
RT   assessment in a large cohort of hypercholesterolemic children.";
RL   Circulation 123:1167-1173(2011).
RN   [55]
RP   VARIANTS GLU-1218; ASP-1670; ASN-2037; CYS-2564 AND LYS-2566, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=22028381; DOI=10.1093/jmcb/mjr024;
RA   Su Z.D., Sun L., Yu D.X., Li R.X., Li H.X., Yu Z.J., Sheng Q.H.,
RA   Lin X., Zeng R., Wu J.R.;
RT   "Quantitative detection of single amino acid polymorphisms by targeted
RT   proteomics.";
RL   J. Mol. Cell Biol. 3:309-315(2011).
RN   [56]
RP   VARIANTS 12-LEU--LEU-14 DEL; ILE-98; VAL-618; ILE-730; THR-1613;
RP   ARG-1923; LYS-2566; LEU-2739; GLN-3638; LEU-3835; LYS-4181; THR-4270;
RP   VAL-4314; ASN-4338; THR-4481 AND VAL-4482.
RX   PubMed=22095935; DOI=10.1002/humu.21660;
RA   Huijgen R., Sjouke B., Vis K., de Randamie J.S., Defesche J.C.,
RA   Kastelein J.J., Hovingh G.K., Fouchier S.W.;
RT   "Genetic variation in APOB, PCSK9, and ANGPTL3 in carriers of
RT   pathogenic autosomal dominant hypercholesterolemic mutations with
RT   unexpected low LDL-Cl Levels.";
RL   Hum. Mutat. 33:448-455(2012).
CC   -!- FUNCTION: Apolipoprotein B is a major protein constituent of
CC       chylomicrons (apo B-48), LDL (apo B-100) and VLDL (apo B-100). Apo
CC       B-100 functions as a recognition signal for the cellular binding
CC       and internalization of LDL particles by the apoB/E receptor.
CC   -!- SUBUNIT: Interacts with PCSK9. Interacts with MTTP
CC       (PubMed:26224785). {ECO:0000269|PubMed:22580899,
CC       ECO:0000269|PubMed:26224785}.
CC   -!- INTERACTION:
CC       P29991:- (xeno); NbExp=3; IntAct=EBI-3926040, EBI-8826488;
CC       P01130:LDLR; NbExp=4; IntAct=EBI-3926040, EBI-988319;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:22580899}.
CC       Secreted {ECO:0000269|PubMed:22580899,
CC       ECO:0000269|PubMed:26224785}.
CC   -!- INDUCTION: Up-regulated in response to enterovirus 71 (EV71)
CC       infection (at protein level). {ECO:0000269|PubMed:16548883}.
CC   -!- PTM: Palmitoylated; structural requirement for proper assembly of
CC       the hydrophobic core of the lipoprotein particle.
CC       {ECO:0000269|PubMed:10679026}.
CC   -!- RNA EDITING: Modified_positions=2180; Note=The stop codon (UAA) at
CC       position 2180 is created by RNA editing. Apo B-48, derived from
CC       the fully edited RNA, is produced only in the intestine and is
CC       found in chylomicrons. Apo B-48 is a shortened form of apo B-100
CC       which lacks the LDL-receptor region. The unedited version (apo B-
CC       100) is produced by the liver and is found in the VLDL and LDL.;
CC   -!- POLYMORPHISM: Genetic variations in APOB define the low density
CC       lipoprotein cholesterol level quantitative trait locus 4 (LDLCQ4)
CC       [MIM:107730].
CC   -!- DISEASE: Hypobetalipoproteinemia, familial, 1 (FHBL1)
CC       [MIM:615558]: A disorder of lipid metabolism characterized by less
CC       than 5th percentile age- and sex-specific levels of low density
CC       lipoproteins, and dietary fat malabsorption. Clinical presentation
CC       may vary from no symptoms to severe gastrointestinal and
CC       neurological dysfunction similar to abetalipoproteinemia.
CC       {ECO:0000269|PubMed:12551903, ECO:0000269|PubMed:21981844}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry. Most cases of FHBL1 result from
CC       nonsense mutations in the APOB gene that lead to a premature stop
CC       codon, which generate prematurely truncated apo B protein products
CC       (PubMed:21981844). {ECO:0000269|PubMed:21981844}.
CC   -!- DISEASE: Familial ligand-defective apolipoprotein B-100 (FDB)
CC       [MIM:144010]: Dominantly inherited disorder of lipoprotein
CC       metabolism leading to hypercholesterolemia and increased proneness
CC       to coronary artery disease (CAD). The plasma cholesterol levels
CC       are dramatically elevated due to impaired clearance of LDL
CC       particles by defective APOB/E receptors.
CC       {ECO:0000269|PubMed:21382890, ECO:0000269|PubMed:2563166,
CC       ECO:0000269|PubMed:7883971, ECO:0000269|PubMed:9259199}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Note=Defects in APOB associated with defects in other
CC       genes (polygenic) can contribute to hypocholesterolemia.
CC   -!- SIMILARITY: Contains 1 vitellogenin domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00557}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA51752.1; Type=Frameshift; Positions=942, 951, 1139, 1165, 1164, 1371, 1385; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation and
CC       polymorphism database;
CC       URL="http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=APOB";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Apolipoprotein B entry;
CC       URL="https://en.wikipedia.org/wiki/Apolipoprotein_B";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X04506; CAA28191.1; -; mRNA.
DR   EMBL; M19828; AAB00481.1; -; Genomic_DNA.
DR   EMBL; M19808; AAB00481.1; JOINED; Genomic_DNA.
DR   EMBL; M19809; AAB00481.1; JOINED; Genomic_DNA.
DR   EMBL; M19810; AAB00481.1; JOINED; Genomic_DNA.
DR   EMBL; M19811; AAB00481.1; JOINED; Genomic_DNA.
DR   EMBL; M19812; AAB00481.1; JOINED; Genomic_DNA.
DR   EMBL; M19813; AAB00481.1; JOINED; Genomic_DNA.
DR   EMBL; M19815; AAB00481.1; JOINED; Genomic_DNA.
DR   EMBL; M19816; AAB00481.1; JOINED; Genomic_DNA.
DR   EMBL; M19818; AAB00481.1; JOINED; Genomic_DNA.
DR   EMBL; M19820; AAB00481.1; JOINED; Genomic_DNA.
DR   EMBL; M19821; AAB00481.1; JOINED; Genomic_DNA.
DR   EMBL; M19823; AAB00481.1; JOINED; Genomic_DNA.
DR   EMBL; M19824; AAB00481.1; JOINED; Genomic_DNA.
DR   EMBL; M19825; AAB00481.1; JOINED; Genomic_DNA.
DR   EMBL; M19827; AAB00481.1; JOINED; Genomic_DNA.
DR   EMBL; J02610; AAA35549.1; -; mRNA.
DR   EMBL; M14162; AAB04636.1; -; mRNA.
DR   EMBL; M15053; AAB60718.1; -; Genomic_DNA.
DR   EMBL; X04714; CAA28420.1; -; mRNA.
DR   EMBL; AY324608; AAP72970.1; -; Genomic_DNA.
DR   EMBL; AC010872; AAX88848.1; -; Genomic_DNA.
DR   EMBL; AC115619; AAX93246.1; -; Genomic_DNA.
DR   EMBL; M14081; AAA51752.1; ALT_FRAME; mRNA.
DR   EMBL; M12681; AAA51753.1; -; mRNA.
DR   EMBL; M12480; AAA51751.1; -; mRNA.
DR   EMBL; K03175; AAA51759.1; -; mRNA.
DR   EMBL; M15421; AAA51758.1; -; mRNA.
DR   EMBL; M17367; AAA51741.1; -; mRNA.
DR   EMBL; M31030; AAA51756.1; -; mRNA.
DR   EMBL; X03325; CAA27044.1; -; mRNA.
DR   EMBL; X03326; CAA27045.1; -; mRNA.
DR   EMBL; M17779; AAA51755.1; -; mRNA.
DR   EMBL; M19734; AAA35544.1; -; mRNA.
DR   EMBL; M18471; AAA35541.1; -; mRNA.
DR   EMBL; X03045; CAA26850.1; -; mRNA.
DR   EMBL; M10374; AAA51750.1; -; mRNA.
DR   EMBL; M12413; AAA51742.1; -; mRNA.
DR   EMBL; M36676; AAA35548.1; -; mRNA.
DR   CCDS; CCDS1703.1; -.
DR   PIR; A27850; LPHUB.
DR   RefSeq; NP_000375.2; NM_000384.2.
DR   UniGene; Hs.120759; -.
DR   ProteinModelPortal; P04114; -.
DR   BioGrid; 106835; 54.
DR   DIP; DIP-44767N; -.
DR   IntAct; P04114; 27.
DR   MINT; MINT-1506918; -.
DR   STRING; 9606.ENSP00000233242; -.
DR   ChEMBL; CHEMBL4549; -.
DR   iPTMnet; P04114; -.
DR   PhosphoSite; P04114; -.
DR   SwissPalm; P04114; -.
DR   UniCarbKB; P04114; -.
DR   BioMuta; APOB; -.
DR   DMDM; 300669605; -.
DR   MaxQB; P04114; -.
DR   PaxDb; P04114; -.
DR   PeptideAtlas; P04114; -.
DR   PRIDE; P04114; -.
DR   Ensembl; ENST00000233242; ENSP00000233242; ENSG00000084674.
DR   GeneID; 338; -.
DR   KEGG; hsa:338; -.
DR   CTD; 338; -.
DR   GeneCards; APOB; -.
DR   GeneReviews; APOB; -.
DR   H-InvDB; HIX0024005; -.
DR   HGNC; HGNC:603; APOB.
DR   HPA; CAB016070; -.
DR   HPA; HPA049793; -.
DR   MalaCards; APOB; -.
DR   MIM; 107730; gene+phenotype.
DR   MIM; 144010; phenotype.
DR   MIM; 615558; phenotype.
DR   neXtProt; NX_P04114; -.
DR   Orphanet; 426; Familial hypobetalipoproteinemia.
DR   Orphanet; 406; Heterozygous familial hypercholesterolemia.
DR   Orphanet; 391665; Homozygous familial hypercholesterolemia.
DR   PharmGKB; PA50; -.
DR   eggNOG; KOG4338; Eukaryota.
DR   eggNOG; ENOG411104F; LUCA.
DR   HOVERGEN; HBG050546; -.
DR   InParanoid; P04114; -.
DR   KO; K14462; -.
DR   OrthoDB; EOG7VB2DG; -.
DR   PhylomeDB; P04114; -.
DR   TreeFam; TF331316; -.
DR   Reactome; R-HSA-171052; LDL-mediated lipid transport.
DR   Reactome; R-HSA-174800; Chylomicron-mediated lipid transport.
DR   Reactome; R-HSA-202733; Cell surface interactions at the vascular wall.
DR   Reactome; R-HSA-3000471; Scavenging by Class B Receptors.
DR   Reactome; R-HSA-3000480; Scavenging by Class A Receptors.
DR   Reactome; R-HSA-3000484; Scavenging by Class F Receptors.
DR   Reactome; R-HSA-3000497; Scavenging by Class H Receptors.
DR   Reactome; R-HSA-432142; Platelet sensitization by LDL.
DR   Reactome; R-HSA-975634; Retinoid metabolism and transport.
DR   ChiTaRS; APOB; human.
DR   GeneWiki; Apolipoprotein_B; -.
DR   GenomeRNAi; 338; -.
DR   NextBio; 1399; -.
DR   PRO; PR:P04114; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   Bgee; P04114; -.
DR   ExpressionAtlas; P04114; baseline and differential.
DR   Genevisible; P04114; HS.
DR   GO; GO:0015629; C:actin cytoskeleton; IDA:HPA.
DR   GO; GO:0042627; C:chylomicron; IDA:BHF-UCL.
DR   GO; GO:0034360; C:chylomicron remnant; TAS:BHF-UCL.
DR   GO; GO:0030669; C:clathrin-coated endocytic vesicle membrane; TAS:Reactome.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005769; C:early endosome; TAS:Reactome.
DR   GO; GO:0071682; C:endocytic vesicle lumen; TAS:Reactome.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0031904; C:endosome lumen; TAS:Reactome.
DR   GO; GO:0010008; C:endosome membrane; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; ISS:BHF-UCL.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:HPA.
DR   GO; GO:0034363; C:intermediate-density lipoprotein particle; IDA:BHF-UCL.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; TAS:ProtInc.
DR   GO; GO:0034362; C:low-density lipoprotein particle; IDA:BHF-UCL.
DR   GO; GO:0034359; C:mature chylomicron; IDA:BHF-UCL.
DR   GO; GO:0043025; C:neuronal cell body; IDA:MGI.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0034361; C:very-low-density lipoprotein particle; IDA:BHF-UCL.
DR   GO; GO:0017127; F:cholesterol transporter activity; IMP:BHF-UCL.
DR   GO; GO:0008201; F:heparin binding; IDA:BHF-UCL.
DR   GO; GO:0035473; F:lipase binding; IPI:BHF-UCL.
DR   GO; GO:0050750; F:low-density lipoprotein particle receptor binding; IMP:BHF-UCL.
DR   GO; GO:0005543; F:phospholipid binding; IDA:BHF-UCL.
DR   GO; GO:0048844; P:artery morphogenesis; IEA:Ensembl.
DR   GO; GO:0007596; P:blood coagulation; TAS:Reactome.
DR   GO; GO:0071379; P:cellular response to prostaglandin stimulus; IEA:Ensembl.
DR   GO; GO:0071356; P:cellular response to tumor necrosis factor; IEA:Ensembl.
DR   GO; GO:0033344; P:cholesterol efflux; IEA:Ensembl.
DR   GO; GO:0042632; P:cholesterol homeostasis; IMP:BHF-UCL.
DR   GO; GO:0008203; P:cholesterol metabolic process; IMP:BHF-UCL.
DR   GO; GO:0030301; P:cholesterol transport; IMP:BHF-UCL.
DR   GO; GO:0009566; P:fertilization; IEA:Ensembl.
DR   GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl.
DR   GO; GO:0050900; P:leukocyte migration; TAS:Reactome.
DR   GO; GO:0042158; P:lipoprotein biosynthetic process; IEA:Ensembl.
DR   GO; GO:0042159; P:lipoprotein catabolic process; IEA:Ensembl.
DR   GO; GO:0042157; P:lipoprotein metabolic process; TAS:Reactome.
DR   GO; GO:0042953; P:lipoprotein transport; IEA:Ensembl.
DR   GO; GO:0034383; P:low-density lipoprotein particle clearance; IMP:BHF-UCL.
DR   GO; GO:0034374; P:low-density lipoprotein particle remodeling; IMP:BHF-UCL.
DR   GO; GO:0007399; P:nervous system development; IEA:Ensembl.
DR   GO; GO:0007603; P:phototransduction, visible light; TAS:Reactome.
DR   GO; GO:0010886; P:positive regulation of cholesterol storage; IDA:BHF-UCL.
DR   GO; GO:0010628; P:positive regulation of gene expression; IEA:Ensembl.
DR   GO; GO:0010884; P:positive regulation of lipid storage; IDA:BHF-UCL.
DR   GO; GO:0010744; P:positive regulation of macrophage derived foam cell differentiation; IDA:BHF-UCL.
DR   GO; GO:0009791; P:post-embryonic development; IEA:Ensembl.
DR   GO; GO:0006898; P:receptor-mediated endocytosis; TAS:Reactome.
DR   GO; GO:0045540; P:regulation of cholesterol biosynthetic process; IEA:Ensembl.
DR   GO; GO:0009743; P:response to carbohydrate; IEA:Ensembl.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IEA:Ensembl.
DR   GO; GO:0010269; P:response to selenium ion; IEA:Ensembl.
DR   GO; GO:0009615; P:response to virus; IEP:UniProtKB.
DR   GO; GO:0001523; P:retinoid metabolic process; TAS:Reactome.
DR   GO; GO:0044281; P:small molecule metabolic process; TAS:Reactome.
DR   GO; GO:0030317; P:sperm motility; IEA:Ensembl.
DR   GO; GO:0007283; P:spermatogenesis; IEA:Ensembl.
DR   GO; GO:0019433; P:triglyceride catabolic process; IEA:Ensembl.
DR   GO; GO:0006642; P:triglyceride mobilization; IEA:Ensembl.
DR   GO; GO:0034379; P:very-low-density lipoprotein particle assembly; IC:BHF-UCL.
DR   Gene3D; 1.25.10.20; -; 1.
DR   Gene3D; 2.20.50.20; -; 2.
DR   Gene3D; 2.20.80.10; -; 1.
DR   Gene3D; 2.30.230.10; -; 1.
DR   InterPro; IPR022176; ApoB100_C.
DR   InterPro; IPR016024; ARM-type_fold.
DR   InterPro; IPR015819; Lipid_transp_b-sht_shell.
DR   InterPro; IPR001747; Lipid_transpt_N.
DR   InterPro; IPR009454; Lipid_transpt_open_b-sht.
DR   InterPro; IPR015816; Vitellinogen_b-sht_N.
DR   InterPro; IPR015255; Vitellinogen_open_b-sht.
DR   InterPro; IPR015817; Vitellinogen_open_b-sht_sub1.
DR   InterPro; IPR015818; Vitellinogen_open_b-sht_sub2.
DR   InterPro; IPR011030; Vitellinogen_superhlx.
DR   Pfam; PF12491; ApoB100_C; 1.
DR   Pfam; PF06448; DUF1081; 1.
DR   Pfam; PF09172; DUF1943; 1.
DR   Pfam; PF01347; Vitellogenin_N; 1.
DR   SMART; SM00638; LPD_N; 1.
DR   SUPFAM; SSF48371; SSF48371; 2.
DR   SUPFAM; SSF48431; SSF48431; 1.
DR   SUPFAM; SSF56968; SSF56968; 2.
DR   PROSITE; PS51211; VITELLOGENIN; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Atherosclerosis; Cholesterol metabolism; Chylomicron;
KW   Complete proteome; Cytoplasm; Direct protein sequencing;
KW   Disease mutation; Disulfide bond; Glycoprotein; Heparin-binding; LDL;
KW   Lipid metabolism; Lipid transport; Lipoprotein; Palmitate;
KW   Phosphoprotein; Polymorphism; Reference proteome; RNA editing;
KW   Secreted; Signal; Steroid metabolism; Sterol metabolism; Transport;
KW   VLDL.
FT   SIGNAL        1     27
FT   CHAIN        28   4563       Apolipoprotein B-100.
FT                                /FTId=PRO_0000020750.
FT   CHAIN        28   2179       Apolipoprotein B-48.
FT                                /FTId=PRO_0000020751.
FT   DOMAIN       46    672       Vitellogenin. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00557}.
FT   REGION       32    126       Heparin-binding.
FT   REGION      232    306       Heparin-binding.
FT   REGION      902    959       Heparin-binding.
FT   REGION     2043   2178       Heparin-binding.
FT   REGION     3161   3236       Heparin-binding.
FT   REGION     3174   3184       Basic (possible receptor binding region).
FT   REGION     3373   3393       LDL receptor binding.
FT   REGION     3383   3516       Heparin-binding.
FT   REGION     3386   3394       Basic (possible receptor binding region).
FT   MOD_RES    2004   2004       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES    3279   3279       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES    4048   4048       Phosphoserine; by FAM20C.
FT                                {ECO:0000244|PubMed:24275569,
FT                                ECO:0000269|PubMed:26091039}.
FT   MOD_RES    4052   4052       Phosphothreonine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   LIPID      1112   1112       S-palmitoyl cysteine.
FT                                {ECO:0000269|PubMed:10679026}.
FT   CARBOHYD     34     34       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    185    185       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19159218}.
FT   CARBOHYD    983    983       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1368   1368       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1377   1377       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1523   1523       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:19159218}.
FT   CARBOHYD   2239   2239       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19159218}.
FT   CARBOHYD   2560   2560       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2779   2779       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19159218}.
FT   CARBOHYD   2982   2982       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:19159218}.
FT   CARBOHYD   3101   3101       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19159218}.
FT   CARBOHYD   3224   3224       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19159218}.
FT   CARBOHYD   3336   3336       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   3358   3358       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:14760718}.
FT   CARBOHYD   3411   3411       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19159218}.
FT   CARBOHYD   3465   3465       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:19159218}.
FT   CARBOHYD   3895   3895       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:19159218}.
FT   CARBOHYD   4237   4237       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   4431   4431       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     39     88       {ECO:0000255|PROSITE-ProRule:PRU00557,
FT                                ECO:0000269|PubMed:2115173}.
FT   DISULFID     78     97       {ECO:0000255|PROSITE-ProRule:PRU00557,
FT                                ECO:0000269|PubMed:2115173}.
FT   DISULFID    186    212       {ECO:0000255|PROSITE-ProRule:PRU00557,
FT                                ECO:0000269|PubMed:2115173}.
FT   DISULFID    245    261       {ECO:0000255|PROSITE-ProRule:PRU00557,
FT                                ECO:0000269|PubMed:2115173}.
FT   DISULFID    385    390       {ECO:0000255|PROSITE-ProRule:PRU00557,
FT                                ECO:0000269|PubMed:2115173}.
FT   DISULFID    478    513       {ECO:0000255|PROSITE-ProRule:PRU00557,
FT                                ECO:0000269|PubMed:2115173}.
FT   DISULFID    966    976       {ECO:0000255|PROSITE-ProRule:PRU00557,
FT                                ECO:0000269|PubMed:2115173}.
FT   DISULFID   3194   3324       {ECO:0000255|PROSITE-ProRule:PRU00557,
FT                                ECO:0000269|PubMed:2115173}.
FT   VARIANT      12     14       Missing. {ECO:0000269|PubMed:22095935}.
FT                                /FTId=VAR_067277.
FT   VARIANT      98     98       T -> I (polymorphism that influences
FT                                plasma concentrations of low density
FT                                lipoprotein cholesterol;
FT                                dbSNP:rs1367117).
FT                                {ECO:0000269|PubMed:12551903,
FT                                ECO:0000269|PubMed:20686565,
FT                                ECO:0000269|PubMed:2115173,
FT                                ECO:0000269|PubMed:22095935,
FT                                ECO:0000269|PubMed:3461454,
FT                                ECO:0000269|PubMed:3759943}.
FT                                /FTId=VAR_016184.
FT   VARIANT     103    103       Y -> H (in dbSNP:rs9282603).
FT                                /FTId=VAR_022036.
FT   VARIANT     145    145       P -> S (in dbSNP:rs6752026).
FT                                /FTId=VAR_022037.
FT   VARIANT     194    194       T -> M (in dbSNP:rs13306198).
FT                                /FTId=VAR_056737.
FT   VARIANT     273    273       K -> N (in dbSNP:rs1126419).
FT                                {ECO:0000269|PubMed:3763409}.
FT                                /FTId=VAR_019827.
FT   VARIANT     408    408       I -> T (in dbSNP:rs12714225).
FT                                /FTId=VAR_029341.
FT   VARIANT     490    490       R -> W (in FHBL1; reduced protein
FT                                secretion).
FT                                {ECO:0000269|PubMed:12551903}.
FT                                /FTId=VAR_022610.
FT   VARIANT     554    554       P -> L (in dbSNP:rs12714214).
FT                                /FTId=VAR_020135.
FT   VARIANT     618    618       A -> V (in dbSNP:rs679899).
FT                                {ECO:0000269|PubMed:22095935,
FT                                ECO:0000269|PubMed:3030729,
FT                                ECO:0000269|PubMed:3759943}.
FT                                /FTId=VAR_019828.
FT   VARIANT     730    730       V -> I (in dbSNP:rs12691202).
FT                                {ECO:0000269|PubMed:22095935}.
FT                                /FTId=VAR_020136.
FT   VARIANT     733    733       V -> I (in dbSNP:rs1800476).
FT                                /FTId=VAR_016185.
FT   VARIANT     741    741       T -> N (in dbSNP:rs12714192).
FT                                /FTId=VAR_020137.
FT   VARIANT     877    877       P -> L (in dbSNP:rs12714097).
FT                                /FTId=VAR_029342.
FT   VARIANT     955    955       P -> S (in dbSNP:rs13306206).
FT                                /FTId=VAR_056738.
FT   VARIANT    1086   1086       G -> S (in dbSNP:rs12720801).
FT                                /FTId=VAR_029343.
FT   VARIANT    1113   1113       D -> H (in dbSNP:rs12713844).
FT                                /FTId=VAR_029344.
FT   VARIANT    1128   1128       R -> H (in dbSNP:rs12713843).
FT                                {ECO:0000269|PubMed:14732481}.
FT                                /FTId=VAR_022611.
FT   VARIANT    1218   1218       Q -> E (polymorphism; confirmed at
FT                                protein level; dbSNP:rs1041956).
FT                                {ECO:0000269|PubMed:22028381,
FT                                ECO:0000269|PubMed:3763409}.
FT                                /FTId=VAR_019829.
FT   VARIANT    1388   1388       R -> H (in dbSNP:rs13306187).
FT                                /FTId=VAR_029345.
FT   VARIANT    1422   1422       Y -> C (in dbSNP:rs568413).
FT                                {ECO:0000269|PubMed:2883086,
FT                                ECO:0000269|PubMed:3030729,
FT                                ECO:0000269|PubMed:3461454,
FT                                ECO:0000269|PubMed:3464946,
FT                                ECO:0000269|PubMed:3652907,
FT                                ECO:0000269|PubMed:3759943,
FT                                ECO:0000269|PubMed:3763409,
FT                                ECO:0000269|Ref.6}.
FT                                /FTId=VAR_061558.
FT   VARIANT    1437   1437       F -> L (in dbSNP:rs1801697).
FT                                {ECO:0000269|PubMed:8889592}.
FT                                /FTId=VAR_005016.
FT   VARIANT    1613   1613       S -> T. {ECO:0000269|PubMed:22095935}.
FT                                /FTId=VAR_067278.
FT   VARIANT    1670   1670       E -> D (polymorphism; confirmed at
FT                                protein level).
FT                                {ECO:0000269|PubMed:22028381,
FT                                ECO:0000269|PubMed:3461454}.
FT                                /FTId=VAR_068911.
FT   VARIANT    1914   1914       N -> S (in dbSNP:rs1801699).
FT                                {ECO:0000269|PubMed:8889592,
FT                                ECO:0000269|PubMed:9490296}.
FT                                /FTId=VAR_005017.
FT   VARIANT    1923   1923       H -> R (in dbSNP:rs533617).
FT                                {ECO:0000269|PubMed:22095935,
FT                                ECO:0000269|PubMed:9490296}.
FT                                /FTId=VAR_005018.
FT   VARIANT    2037   2037       I -> N (polymorphism; confirmed at
FT                                protein level).
FT                                {ECO:0000269|PubMed:22028381,
FT                                ECO:0000269|PubMed:3464946}.
FT                                /FTId=VAR_068912.
FT   VARIANT    2092   2092       L -> V (in dbSNP:rs1041960).
FT                                {ECO:0000269|PubMed:3763409}.
FT                                /FTId=VAR_019830.
FT   VARIANT    2299   2299       D -> H (in dbSNP:rs12713681).
FT                                /FTId=VAR_029346.
FT   VARIANT    2313   2313       I -> V (in dbSNP:rs584542).
FT                                {ECO:0000269|PubMed:2883086,
FT                                ECO:0000269|PubMed:3030729,
FT                                ECO:0000269|PubMed:3464946,
FT                                ECO:0000269|PubMed:3652907,
FT                                ECO:0000269|PubMed:3676265,
FT                                ECO:0000269|PubMed:3759943,
FT                                ECO:0000269|PubMed:3763409,
FT                                ECO:0000269|Ref.6}.
FT                                /FTId=VAR_059582.
FT   VARIANT    2365   2365       A -> T (in dbSNP:rs1041971).
FT                                {ECO:0000269|PubMed:3763409}.
FT                                /FTId=VAR_019831.
FT   VARIANT    2456   2456       A -> D (in dbSNP:rs12713675).
FT                                /FTId=VAR_020138.
FT   VARIANT    2564   2564       F -> C (in a colorectal cancer sample;
FT                                somatic mutation; confirmed at protein
FT                                level). {ECO:0000269|PubMed:16959974,
FT                                ECO:0000269|PubMed:22028381}.
FT                                /FTId=VAR_035795.
FT   VARIANT    2566   2566       E -> K (polymorphism; confirmed at
FT                                protein level; dbSNP:rs1801696).
FT                                {ECO:0000269|PubMed:22028381,
FT                                ECO:0000269|PubMed:22095935,
FT                                ECO:0000269|PubMed:8889592}.
FT                                /FTId=VAR_005019.
FT   VARIANT    2680   2680       L -> Q (in dbSNP:rs1042013).
FT                                {ECO:0000269|PubMed:3763409}.
FT                                /FTId=VAR_019832.
FT   VARIANT    2739   2739       P -> L (in dbSNP:rs676210).
FT                                {ECO:0000269|PubMed:22095935,
FT                                ECO:0000269|PubMed:2216805,
FT                                ECO:0000269|PubMed:9490296}.
FT                                /FTId=VAR_005020.
FT   VARIANT    2785   2785       N -> H (in dbSNP:rs2163204).
FT                                /FTId=VAR_022038.
FT   VARIANT    3121   3121       A -> T (in dbSNP:rs1801694).
FT                                {ECO:0000269|PubMed:8889592}.
FT                                /FTId=VAR_005021.
FT   VARIANT    3182   3182       H -> N (in dbSNP:rs12720848).
FT                                /FTId=VAR_029347.
FT   VARIANT    3279   3279       S -> G (in dbSNP:rs12720854).
FT                                /FTId=VAR_029348.
FT   VARIANT    3294   3294       S -> P (in dbSNP:rs12720855).
FT                                /FTId=VAR_020139.
FT   VARIANT    3319   3319       D -> H. {ECO:0000269|PubMed:2883086,
FT                                ECO:0000269|PubMed:2994225,
FT                                ECO:0000269|PubMed:3030729,
FT                                ECO:0000269|PubMed:3464946,
FT                                ECO:0000269|PubMed:3652907,
FT                                ECO:0000269|PubMed:3759943,
FT                                ECO:0000269|PubMed:3763409,
FT                                ECO:0000269|PubMed:9490296}.
FT                                /FTId=VAR_005022.
FT   VARIANT    3427   3427       T -> K. {ECO:0000269|PubMed:2883086,
FT                                ECO:0000269|PubMed:2994225,
FT                                ECO:0000269|PubMed:3030729,
FT                                ECO:0000269|PubMed:3464946,
FT                                ECO:0000269|PubMed:3652907,
FT                                ECO:0000269|PubMed:3759943,
FT                                ECO:0000269|PubMed:3763409,
FT                                ECO:0000269|PubMed:9490296}.
FT                                /FTId=VAR_005023.
FT   VARIANT    3432   3432       Q -> E (in dbSNP:rs1042023).
FT                                {ECO:0000269|PubMed:2883086,
FT                                ECO:0000269|PubMed:2994225,
FT                                ECO:0000269|PubMed:3030729,
FT                                ECO:0000269|PubMed:3464946,
FT                                ECO:0000269|PubMed:3652907,
FT                                ECO:0000269|PubMed:3759943,
FT                                ECO:0000269|PubMed:3763409,
FT                                ECO:0000269|PubMed:9490296}.
FT                                /FTId=VAR_005024.
FT   VARIANT    3527   3527       R -> Q (in FDB; dbSNP:rs5742904).
FT                                {ECO:0000269|PubMed:21382890,
FT                                ECO:0000269|PubMed:2563166,
FT                                ECO:0000269|PubMed:9259199}.
FT                                /FTId=VAR_005025.
FT   VARIANT    3558   3558       R -> C (in FDB; dbSNP:rs12713559).
FT                                {ECO:0000269|PubMed:7883971,
FT                                ECO:0000269|PubMed:9259199}.
FT                                /FTId=VAR_005026.
FT   VARIANT    3638   3638       R -> Q (in dbSNP:rs1801701).
FT                                {ECO:0000269|PubMed:22095935}.
FT                                /FTId=VAR_016186.
FT   VARIANT    3732   3732       I -> T (in dbSNP:rs1042025).
FT                                {ECO:0000269|PubMed:2883086,
FT                                ECO:0000269|PubMed:2994225,
FT                                ECO:0000269|PubMed:3030729,
FT                                ECO:0000269|PubMed:3763409}.
FT                                /FTId=VAR_019833.
FT   VARIANT    3801   3801       S -> T (in dbSNP:rs12713540).
FT                                /FTId=VAR_029349.
FT   VARIANT    3835   3835       I -> L. {ECO:0000269|PubMed:22095935}.
FT                                /FTId=VAR_067279.
FT   VARIANT    3921   3921       V -> I (in dbSNP:rs72654409).
FT                                {ECO:0000269|PubMed:9490296}.
FT                                /FTId=VAR_005027.
FT   VARIANT    3945   3945       T -> A (in dbSNP:rs1801698).
FT                                {ECO:0000269|PubMed:8889592}.
FT                                /FTId=VAR_005028.
FT   VARIANT    3949   3949       F -> L (in dbSNP:rs1042027).
FT                                {ECO:0000269|PubMed:2994225,
FT                                ECO:0000269|PubMed:3030729,
FT                                ECO:0000269|PubMed:3464946,
FT                                ECO:0000269|PubMed:3763409,
FT                                ECO:0000269|PubMed:3841481}.
FT                                /FTId=VAR_019834.
FT   VARIANT    3964   3964       Y -> F (in dbSNP:rs1126468).
FT                                {ECO:0000269|PubMed:2994225,
FT                                ECO:0000269|PubMed:3030729,
FT                                ECO:0000269|PubMed:3763409,
FT                                ECO:0000269|PubMed:3841481}.
FT                                /FTId=VAR_019835.
FT   VARIANT    4128   4128       V -> M (in dbSNP:rs1801703).
FT                                {ECO:0000269|PubMed:8889592}.
FT                                /FTId=VAR_005029.
FT   VARIANT    4181   4181       E -> K (in dbSNP:rs1042031).
FT                                {ECO:0000269|PubMed:22095935,
FT                                ECO:0000269|PubMed:2994225,
FT                                ECO:0000269|PubMed:3030729,
FT                                ECO:0000269|PubMed:3464946,
FT                                ECO:0000269|PubMed:3763409,
FT                                ECO:0000269|PubMed:3841481}.
FT                                /FTId=VAR_016187.
FT   VARIANT    4270   4270       R -> T (in dbSNP:rs1801702).
FT                                {ECO:0000269|PubMed:22095935}.
FT                                /FTId=VAR_016188.
FT   VARIANT    4314   4314       I -> V (in dbSNP:rs72654423).
FT                                {ECO:0000269|PubMed:22095935}.
FT                                /FTId=VAR_067280.
FT   VARIANT    4338   4338       S -> N (in dbSNP:rs1042034).
FT                                {ECO:0000269|PubMed:1979313,
FT                                ECO:0000269|PubMed:22095935,
FT                                ECO:0000269|PubMed:2883086,
FT                                ECO:0000269|PubMed:2932736,
FT                                ECO:0000269|PubMed:2994225,
FT                                ECO:0000269|PubMed:3030729,
FT                                ECO:0000269|PubMed:3464946,
FT                                ECO:0000269|PubMed:3652907,
FT                                ECO:0000269|PubMed:3759943,
FT                                ECO:0000269|PubMed:3763409,
FT                                ECO:0000269|Ref.6}.
FT                                /FTId=VAR_005030.
FT   VARIANT    4394   4394       V -> A (in dbSNP:rs12720843).
FT                                /FTId=VAR_029350.
FT   VARIANT    4481   4481       A -> T (in dbSNP:rs1801695).
FT                                {ECO:0000269|PubMed:22095935,
FT                                ECO:0000269|PubMed:8889592}.
FT                                /FTId=VAR_005031.
FT   VARIANT    4482   4482       I -> V. {ECO:0000269|PubMed:22095935}.
FT                                /FTId=VAR_067281.
FT   VARIANT    4484   4484       T -> M (in dbSNP:rs12713450).
FT                                /FTId=VAR_020140.
FT   MUTAGEN     483    483       D->N: Impairs protein secretion.
FT                                {ECO:0000269|PubMed:12551903}.
FT   MUTAGEN     483    483       D->Q: Does not affect protein secretion.
FT                                {ECO:0000269|PubMed:12551903}.
FT   MUTAGEN     490    490       R->A: Impairs protein secretion.
FT                                {ECO:0000269|PubMed:12551903}.
FT   MUTAGEN     490    490       R->K: Does not affect protein secretion.
FT                                {ECO:0000269|PubMed:12551903}.
FT   CONFLICT     11     13       Missing (in Ref. 5; AAB60718/CAA28420).
FT                                {ECO:0000305}.
FT   CONFLICT    329    329       L -> V (in Ref. 3; AAA35549).
FT                                {ECO:0000305}.
FT   CONFLICT    645    645       L -> I (in Ref. 3; AAA35549).
FT                                {ECO:0000305}.
FT   CONFLICT    704    704       L -> P (in Ref. 4; AAB04636).
FT                                {ECO:0000305}.
FT   CONFLICT    792    809       LQLLGKLLLMGARTLQGI -> SSSWKAASHGCPHSAGD
FT                                (in Ref. 12; AAA51759). {ECO:0000305}.
FT   CONFLICT    793    793       Q -> R (in Ref. 4; AAB04636).
FT                                {ECO:0000305}.
FT   CONFLICT    893    893       D -> K (in Ref. 13; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    919    919       A -> P (in Ref. 3; AAA35549).
FT                                {ECO:0000305}.
FT   CONFLICT   1109   1109       H -> D (in Ref. 5; CAA28420).
FT                                {ECO:0000305}.
FT   CONFLICT   1180   1180       T -> R (in Ref. 8; AAA51752).
FT                                {ECO:0000305}.
FT   CONFLICT   1271   1271       F -> S (in Ref. 4; AAB04636).
FT                                {ECO:0000305}.
FT   CONFLICT   1418   1418       F -> S (in Ref. 5; CAA28420).
FT                                {ECO:0000305}.
FT   CONFLICT   1445   1445       N -> I (in Ref. 8; AAA51752).
FT                                {ECO:0000305}.
FT   CONFLICT   1535   1535       G -> E (in Ref. 8; AAA51752).
FT                                {ECO:0000305}.
FT   CONFLICT   1867   1867       R -> G (in Ref. 4; AAB04636).
FT                                {ECO:0000305}.
FT   CONFLICT   2098   2098       N -> K (in Ref. 5; CAA28420).
FT                                {ECO:0000305}.
FT   CONFLICT   2218   2218       I -> T (in Ref. 4; AAB04636).
FT                                {ECO:0000305}.
FT   CONFLICT   2221   2221       N -> I (in Ref. 5; CAA28420).
FT                                {ECO:0000305}.
FT   CONFLICT   2324   2326       LIG -> PYW (in Ref. 16; AAA51741).
FT                                {ECO:0000305}.
FT   CONFLICT   2353   2353       Q -> H (in Ref. 16; AAA51741).
FT                                {ECO:0000305}.
FT   CONFLICT   2540   2540       G -> S (in Ref. 5; CAA28420).
FT                                {ECO:0000305}.
FT   CONFLICT   2718   2737       Missing (in Ref. 15; AAA51758).
FT                                {ECO:0000305}.
FT   CONFLICT   2933   2933       C -> S (in Ref. 4; AAB04636).
FT                                {ECO:0000305}.
FT   CONFLICT   3114   3114       H -> L (in Ref. 13; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT   3131   3131       T -> R (in Ref. 13; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT   3134   3134       E -> P (in Ref. 13; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT   3137   3137       L -> R (in Ref. 13; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT   3239   3239       H -> Q (in Ref. 5; CAA28420).
FT                                {ECO:0000305}.
FT   CONFLICT   3286   3286       L -> I (in Ref. 4; AAB04636).
FT                                {ECO:0000305}.
FT   CONFLICT   3291   3291       R -> L (in Ref. 15; AAA51758).
FT                                {ECO:0000305}.
FT   CONFLICT   3337   3337       I -> N (in Ref. 15; AAA51758).
FT                                {ECO:0000305}.
FT   CONFLICT   3431   3431       A -> P (in Ref. 4; AAB04636).
FT                                {ECO:0000305}.
FT   CONFLICT   3728   3728       D -> N (in Ref. 24; AAA51742).
FT                                {ECO:0000305}.
FT   CONFLICT   3782   3782       N -> T (in Ref. 4; AAB04636).
FT                                {ECO:0000305}.
FT   CONFLICT   3824   3824       Q -> R (in Ref. 5; CAA28420 and 23;
FT                                AAA51750). {ECO:0000305}.
FT   CONFLICT   3876   3876       V -> A (in Ref. 3; AAA35549 and 24;
FT                                AAA51742). {ECO:0000305}.
FT   CONFLICT   3911   3911       T -> Y (in Ref. 10; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT   3983   3983       F -> S (in Ref. 24; AAA51742).
FT                                {ECO:0000305}.
FT   CONFLICT   4002   4002       A -> P (in Ref. 24; AAA51742).
FT                                {ECO:0000305}.
FT   CONFLICT   4110   4111       NN -> DH (in Ref. 3; AAA35549 and 24;
FT                                AAA51742). {ECO:0000305}.
FT   CONFLICT   4122   4122       Q -> E (in Ref. 3; AAA35549 and 24;
FT                                AAA51742). {ECO:0000305}.
FT   CONFLICT   4128   4128       V -> E (in Ref. 3; AAA35549 and 24;
FT                                AAA51742). {ECO:0000305}.
FT   CONFLICT   4133   4133       A -> G (in Ref. 3; AAA35549 and 24;
FT                                AAA51742). {ECO:0000305}.
FT   CONFLICT   4188   4188       H -> K (in Ref. 4; AAB04636).
FT                                {ECO:0000305}.
FT   CONFLICT   4217   4218       CT -> FP (in Ref. 26; AAA35548).
FT                                {ECO:0000305}.
FT   CONFLICT   4221   4221       I -> M (in Ref. 4; AAB04636).
FT                                {ECO:0000305}.
SQ   SEQUENCE   4563 AA;  515605 MW;  6800F94BF6ADF698 CRC64;
     MDPPRPALLA LLALPALLLL LLAGARAEEE MLENVSLVCP KDATRFKHLR KYTYNYEAES
     SSGVPGTADS RSATRINCKV ELEVPQLCSF ILKTSQCTLK EVYGFNPEGK ALLKKTKNSE
     EFAAAMSRYE LKLAIPEGKQ VFLYPEKDEP TYILNIKRGI ISALLVPPET EEAKQVLFLD
     TVYGNCSTHF TVKTRKGNVA TEISTERDLG QCDRFKPIRT GISPLALIKG MTRPLSTLIS
     SSQSCQYTLD AKRKHVAEAI CKEQHLFLPF SYKNKYGMVA QVTQTLKLED TPKINSRFFG
     EGTKKMGLAF ESTKSTSPPK QAEAVLKTLQ ELKKLTISEQ NIQRANLFNK LVTELRGLSD
     EAVTSLLPQL IEVSSPITLQ ALVQCGQPQC STHILQWLKR VHANPLLIDV VTYLVALIPE
     PSAQQLREIF NMARDQRSRA TLYALSHAVN NYHKTNPTGT QELLDIANYL MEQIQDDCTG
     DEDYTYLILR VIGNMGQTME QLTPELKSSI LKCVQSTKPS LMIQKAAIQA LRKMEPKDKD
     QEVLLQTFLD DASPGDKRLA AYLMLMRSPS QADINKIVQI LPWEQNEQVK NFVASHIANI
     LNSEELDIQD LKKLVKEALK ESQLPTVMDF RKFSRNYQLY KSVSLPSLDP ASAKIEGNLI
     FDPNNYLPKE SMLKTTLTAF GFASADLIEI GLEGKGFEPT LEALFGKQGF FPDSVNKALY
     WVNGQVPDGV SKVLVDHFGY TKDDKHEQDM VNGIMLSVEK LIKDLKSKEV PEARAYLRIL
     GEELGFASLH DLQLLGKLLL MGARTLQGIP QMIGEVIRKG SKNDFFLHYI FMENAFELPT
     GAGLQLQISS SGVIAPGAKA GVKLEVANMQ AELVAKPSVS VEFVTNMGII IPDFARSGVQ
     MNTNFFHESG LEAHVALKAG KLKFIIPSPK RPVKLLSGGN TLHLVSTTKT EVIPPLIENR
     QSWSVCKQVF PGLNYCTSGA YSNASSTDSA SYYPLTGDTR LELELRPTGE IEQYSVSATY
     ELQREDRALV DTLKFVTQAE GAKQTEATMT FKYNRQSMTL SSEVQIPDFD VDLGTILRVN
     DESTEGKTSY RLTLDIQNKK ITEVALMGHL SCDTKEERKI KGVISIPRLQ AEARSEILAH
     WSPAKLLLQM DSSATAYGST VSKRVAWHYD EEKIEFEWNT GTNVDTKKMT SNFPVDLSDY
     PKSLHMYANR LLDHRVPQTD MTFRHVGSKL IVAMSSWLQK ASGSLPYTQT LQDHLNSLKE
     FNLQNMGLPD FHIPENLFLK SDGRVKYTLN KNSLKIEIPL PFGGKSSRDL KMLETVRTPA
     LHFKSVGFHL PSREFQVPTF TIPKLYQLQV PLLGVLDLST NVYSNLYNWS ASYSGGNTST
     DHFSLRARYH MKADSVVDLL SYNVQGSGET TYDHKNTFTL SYDGSLRHKF LDSNIKFSHV
     EKLGNNPVSK GLLIFDASSS WGPQMSASVH LDSKKKQHLF VKEVKIDGQF RVSSFYAKGT
     YGLSCQRDPN TGRLNGESNL RFNSSYLQGT NQITGRYEDG TLSLTSTSDL QSGIIKNTAS
     LKYENYELTL KSDTNGKYKN FATSNKMDMT FSKQNALLRS EYQADYESLR FFSLLSGSLN
     SHGLELNADI LGTDKINSGA HKATLRIGQD GISTSATTNL KCSLLVLENE LNAELGLSGA
     SMKLTTNGRF REHNAKFSLD GKAALTELSL GSAYQAMILG VDSKNIFNFK VSQEGLKLSN
     DMMGSYAEMK FDHTNSLNIA GLSLDFSSKL DNIYSSDKFY KQTVNLQLQP YSLVTTLNSD
     LKYNALDLTN NGKLRLEPLK LHVAGNLKGA YQNNEIKHIY AISSAALSAS YKADTVAKVQ
     GVEFSHRLNT DIAGLASAID MSTNYNSDSL HFSNVFRSVM APFTMTIDAH TNGNGKLALW
     GEHTGQLYSK FLLKAEPLAF TFSHDYKGST SHHLVSRKSI SAALEHKVSA LLTPAEQTGT
     WKLKTQFNNN EYSQDLDAYN TKDKIGVELT GRTLADLTLL DSPIKVPLLL SEPINIIDAL
     EMRDAVEKPQ EFTIVAFVKY DKNQDVHSIN LPFFETLQEY FERNRQTIIV VLENVQRNLK
     HINIDQFVRK YRAALGKLPQ QANDYLNSFN WERQVSHAKE KLTALTKKYR ITENDIQIAL
     DDAKINFNEK LSQLQTYMIQ FDQYIKDSYD LHDLKIAIAN IIDEIIEKLK SLDEHYHIRV
     NLVKTIHDLH LFIENIDFNK SGSSTASWIQ NVDTKYQIRI QIQEKLQQLK RHIQNIDIQH
     LAGKLKQHIE AIDVRVLLDQ LGTTISFERI NDILEHVKHF VINLIGDFEV AEKINAFRAK
     VHELIERYEV DQQIQVLMDK LVELAHQYKL KETIQKLSNV LQQVKIKDYF EKLVGFIDDA
     VKKLNELSFK TFIEDVNKFL DMLIKKLKSF DYHQFVDETN DKIREVTQRL NGEIQALELP
     QKAEALKLFL EETKATVAVY LESLQDTKIT LIINWLQEAL SSASLAHMKA KFRETLEDTR
     DRMYQMDIQQ ELQRYLSLVG QVYSTLVTYI SDWWTLAAKN LTDFAEQYSI QDWAKRMKAL
     VEQGFTVPEI KTILGTMPAF EVSLQALQKA TFQTPDFIVP LTDLRIPSVQ INFKDLKNIK
     IPSRFSTPEF TILNTFHIPS FTIDFVEMKV KIIRTIDQML NSELQWPVPD IYLRDLKVED
     IPLARITLPD FRLPEIAIPE FIIPTLNLND FQVPDLHIPE FQLPHISHTI EVPTFGKLYS
     ILKIQSPLFT LDANADIGNG TTSANEAGIA ASITAKGESK LEVLNFDFQA NAQLSNPKIN
     PLALKESVKF SSKYLRTEHG SEMLFFGNAI EGKSNTVASL HTEKNTLELS NGVIVKINNQ
     LTLDSNTKYF HKLNIPKLDF SSQADLRNEI KTLLKAGHIA WTSSGKGSWK WACPRFSDEG
     THESQISFTI EGPLTSFGLS NKINSKHLRV NQNLVYESGS LNFSKLEIQS QVDSQHVGHS
     VLTAKGMALF GEGKAEFTGR HDAHLNGKVI GTLKNSLFFS AQPFEITAST NNEGNLKVRF
     PLRLTGKIDF LNNYALFLSP SAQQASWQVS ARFNQYKYNQ NFSAGNNENI MEAHVGINGE
     ANLDFLNIPL TIPEMRLPYT IITTPPLKDF SLWEKTGLKE FLKTTKQSFD LSVKAQYKKN
     KHRHSITNPL AVLCEFISQS IKSFDRHFEK NRNNALDFVT KSYNETKIKF DKYKAEKSHD
     ELPRTFQIPG YTVPVVNVEV SPFTIEMSAF GYVFPKAVSM PSFSILGSDV RVPSYTLILP
     SLELPVLHVP RNLKLSLPDF KELCTISHIF IPAMGNITYD FSFKSSVITL NTNAELFNQS
     DIVAHLLSSS SSVIDALQYK LEGTTRLTRK RGLKLATALS LSNKFVEGSH NSTVSLTTKN
     MEVSVATTTK AQIPILRMNF KQELNGNTKS KPTVSSSMEF KYDFNSSMLY STAKGAVDHK
     LSLESLTSYF SIESSTKGDV KGSVLSREYS GTIASEANTY LNSKSTRSSV KLQGTSKIDD
     IWNLEVKENF AGEATLQRIY SLWEHSTKNH LQLEGLFFTN GEHTSKATLE LSPWQMSALV
     QVHASQPSSF HDFPDLGQEV ALNANTKNQK IRWKNEVRIH SGSFQSQVEL SNDQEKAHLD
     IAGSLEGHLR FLKNIILPVY DKSLWDFLKL DVTTSIGRRQ HLRVSTAFVY TKNPNGYSFS
     IPVKVLADKF IIPGLKLNDL NSVLVMPTFH VPFTDLQVPS CKLDFREIQI YKKLRTSSFA
     LNLPTLPEVK FPEVDVLTKY SQPEDSLIPF FEITVPESQL TVSQFTLPKS VSDGIAALDL
     NAVANKIADF ELPTIIVPEQ TIEIPSIKFS VPAGIVIPSF QALTARFEVD SPVYNATWSA
     SLKNKADYVE TVLDSTCSST VQFLEYELNV LGTHKIEDGT LASKTKGTFA HRDFSAEYEE
     DGKYEGLQEW EGKAHLNIKS PAFTDLHLRY QKDKKGISTS AASPAVGTVG MDMDEDDDFS
     KWNFYYSPQS SPDKKLTIFK TELRVRESDE ETQIKVNWEE EAASGLLTSL KDNVPKATGV
     LYDYVNKYHW EHTGLTLREV SSKLRRNLQN NAEWVYQGAI RQIDDIDVRF QKAASGTTGT
     YQEWKDKAQN LYQELLTQEG QASFQGLKDN VFDGLVRVTQ EFHMKVKHLI DSLIDFLNFP
     RFQFPGKPGI YTREELCTMF IREVGTVLSQ VYSKVHNGSE ILFSYFQDLV ITLPFELRKH
     KLIDVISMYR ELLKDLSKEA QEVFKAIQSL KTTEVLRNLQ DLLQFIFQLI EDNIKQLKEM
     KFTYLINYIQ DEINTIFSDY IPYVFKLLKE NLCLNLHKFN EFIQNELQEA SQELQQIHQY
     IMALREEYFD PSIVGWTVKY YELEEKIVSL IKNLLVALKD FHSEYIVSAS NFTSQLSSQV
     EQFLHRNIQE YLSILTDPDG KGKEKIAELS ATAQEIIKSQ AIATKKIISD YHQQFRYKLQ
     DFSDQLSDYY EKFIAESKRL IDLSIQNYHT FLIYITELLK KLQSTTVMNP YMKLAPGELT
     IIL
//
ID   LRP6_HUMAN              Reviewed;        1613 AA.
AC   O75581; Q17RZ2;
DT   10-MAY-2004, integrated into UniProtKB/Swiss-Prot.
DT   11-JAN-2011, sequence version 2.
DT   17-FEB-2016, entry version 140.
DE   RecName: Full=Low-density lipoprotein receptor-related protein 6;
DE            Short=LRP-6;
DE   Flags: Precursor;
GN   Name=LRP6;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT ILE-1062.
RC   TISSUE=Kidney;
RX   PubMed=9704021; DOI=10.1006/bbrc.1998.9061;
RA   Brown S.D., Twells R.C., Hey P.J., Cox R.D., Levy E.R., Soderman A.R.,
RA   Metzker M.L., Caskey C.T., Todd J.A., Hess J.F.;
RT   "Isolation and characterization of LRP6, a novel member of the low
RT   density lipoprotein receptor gene family.";
RL   Biochem. Biophys. Res. Commun. 248:879-888(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16541075; DOI=10.1038/nature04569;
RA   Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y.,
RA   Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C.,
RA   Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M.,
RA   Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L.,
RA   Milosavljevic A., Miner G.R., Montgomery K.T., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.-Z., Steffen D.,
RA   Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y., Zhang Z.,
RA   Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H., Draper H.,
RA   Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S., Kelly S.H.,
RA   Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V.,
RA   Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H., Santibanez J.,
RA   Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q., Williams G.A.,
RA   Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V., Bailey M.,
RA   Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E., Burkett C.E.,
RA   Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K.,
RA   Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D.,
RA   Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M.,
RA   Dathorne S.R., David R., Davis C.M., Davy-Carroll L., Deshazo D.R.,
RA   Donlin J.E., D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J.,
RA   Escotto M., Flagg N., Forbes L.D., Gabisi A.M., Garza M., Hamilton C.,
RA   Henderson N., Hernandez O., Hines S., Hogues M.E., Huang M.,
RA   Idlebird D.G., Johnson R., Jolivet A., Jones S., Kagan R., King L.M.,
RA   Leal B., Lebow H., Lee S., LeVan J.M., Lewis L.C., London P.,
RA   Lorensuhewa L.M., Loulseged H., Lovett D.A., Lucier A., Lucier R.L.,
RA   Ma J., Madu R.C., Mapua P., Martindale A.D., Martinez E., Massey E.,
RA   Mawhiney S., Meador M.G., Mendez S., Mercado C., Mercado I.C.,
RA   Merritt C.E., Miner Z.L., Minja E., Mitchell T., Mohabbat F.,
RA   Mohabbat K., Montgomery B., Moore N., Morris S., Munidasa M.,
RA   Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O., Nwokenkwo S.,
RA   Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J.,
RA   Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A.,
RA   Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M.,
RA   Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I.,
RA   Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A.,
RA   Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D.,
RA   Trejos Z.Y., Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I.,
RA   Vera V.A., Villasana D.M., Wang L., Ward-Moore S., Warren J.T.,
RA   Wei X., White F., Williamson A.L., Wleczyk R., Wooden H.S.,
RA   Wooden S.H., Yen J., Yoon L., Yoon V., Zorrilla S.E., Nelson D.,
RA   Kucherlapati R., Weinstock G., Gibbs R.A.;
RT   "The finished DNA sequence of human chromosome 12.";
RL   Nature 440:346-351(2006).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Cerebellum;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   INTERACTION WITH DKK1, AND FUNCTION.
RX   PubMed=11448771; DOI=10.1016/S0960-9822(01)00290-1;
RA   Semenov M.V., Tamai K., Brott B.K., Kuhl M., Sokol S., He X.;
RT   "Head inducer Dickkopf-1 is a ligand for Wnt coreceptor LRP6.";
RL   Curr. Biol. 11:951-961(2001).
RN   [5]
RP   INTERACTION WITH WNT1, AND FUNCTION.
RX   PubMed=11357136; DOI=10.1038/35077108;
RA   Mao B., Wu W., Li Y., Hoppe D., Stannek P., Glinka A., Niehrs C.;
RT   "LDL-receptor-related protein 6 is a receptor for Dickkopf proteins.";
RL   Nature 411:321-325(2001).
RN   [6]
RP   INTERACTION WITH FZD5; DKK1 AND DKK2.
RX   PubMed=12857724; DOI=10.1074/jbc.M300191200;
RA   Caricasole A., Ferraro T., Iacovelli L., Barletta E., Caruso A.,
RA   Melchiorri D., Terstappen G.C., Nicoletti F.;
RT   "Functional characterization of WNT7A signaling in PC12 cells:
RT   interaction with A FZD5 x LRP6 receptor complex and modulation by
RT   Dickkopf proteins.";
RL   J. Biol. Chem. 278:37024-37031(2003).
RN   [7]
RP   INTERACTION WITH SOST, AND FUNCTION.
RX   PubMed=15778503; DOI=10.1074/jbc.M413274200;
RA   Li X., Zhang Y., Kang H., Liu W., Liu P., Zhang J., Harris S.E.,
RA   Wu D.;
RT   "Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling.";
RL   J. Biol. Chem. 280:19883-19887(2005).
RN   [8]
RP   INTERACTION WITH WNT1 IN THE WNT-FZD-LRP5-LRP6 COMPLEX, AND
RP   INTERACTION WITH SOST.
RX   PubMed=15908424; DOI=10.1074/jbc.M504308200;
RA   Semenov M., Tamai K., He X.;
RT   "SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor.";
RL   J. Biol. Chem. 280:26770-26775(2005).
RN   [9]
RP   PHOSPHORYLATION OF PPPSP MOTIFS, PHOSPHORYLATION AT SER-1490 AND
RP   THR-1493, AND FUNCTION.
RX   PubMed=16341017; DOI=10.1038/nature04185;
RA   Zeng X., Tamai K., Doble B., Li S., Huang H., Habas R., Okamura H.,
RA   Woodgett J., He X.;
RT   "A dual-kinase mechanism for Wnt co-receptor phosphorylation and
RT   activation.";
RL   Nature 438:873-877(2005).
RN   [10]
RP   INTERACTION WITH MACF1.
RX   PubMed=16815997; DOI=10.1101/gad.1411206;
RA   Chen H.J., Lin C.M., Lin C.S., Perez-Olle R., Leung C.L., Liem R.K.;
RT   "The role of microtubule actin cross-linking factor 1 (MACF1) in the
RT   Wnt signaling pathway.";
RL   Genes Dev. 20:1933-1945(2006).
RN   [11]
RP   PHOSPHORYLATION AT SER-1420 AND SER-1430, FUNCTION, INTERACTION WITH
RP   CSNKIE AND AXIN1, IDENTIFICATION BY MASS SPECTROMETRY, AND MUTAGENESIS
RP   OF SER-1420 AND SER-1430.
RX   PubMed=16513652; DOI=10.1074/jbc.M510580200;
RA   Swiatek W., Kang H., Garcia B.A., Shabanowitz J., Coombs G.S.,
RA   Hunt D.F., Virshup D.M.;
RT   "Negative regulation of LRP6 function by casein kinase I epsilon
RT   phosphorylation.";
RL   J. Biol. Chem. 281:12233-12241(2006).
RN   [12]
RP   INTERACTION WITH RSPO1, FUNCTION, AND PHOSPHORYLATION.
RX   PubMed=17400545; DOI=10.1074/jbc.M701927200;
RA   Wei Q., Yokota C., Semenov M.V., Doble B., Woodgett J., He X.;
RT   "R-spondin1 is a high affinity ligand for LRP6 and induces LRP6
RT   phosphorylation and beta-catenin signaling.";
RL   J. Biol. Chem. 282:15903-15911(2007).
RN   [13]
RP   PROTEOLYTIC PROCESSING, AND FUNCTION.
RX   PubMed=17326769; DOI=10.1111/j.1471-4159.2007.04447.x;
RA   Mi K., Johnson G.V.;
RT   "Regulated proteolytic processing of LRP6 results in release of its
RT   intracellular domain.";
RL   J. Neurochem. 101:517-529(2007).
RN   [14]
RP   GLYCOSYLATION, PHOSPHORYLATION AT SER-1490, INTERACTION WITH AXIN1,
RP   HOMODIMERIZATION, INDUCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=17698587; DOI=10.1128/MCB.00773-07;
RA   Khan Z., Vijayakumar S., de la Torre T.V., Rotolo S., Bafico A.;
RT   "Analysis of endogenous LRP6 function reveals a novel feedback
RT   mechanism by which Wnt negatively regulates its receptor.";
RL   Mol. Cell. Biol. 27:7291-7301(2007).
RN   [15]
RP   PHOSPHORYLATION AT THR-1479, INTERACTION WITH AXIN1, SUBUNIT, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=17569865; DOI=10.1126/science.1137065;
RA   Bilic J., Huang Y.L., Davidson G., Zimmermann T., Cruciat C.M.,
RA   Bienz M., Niehrs C.;
RT   "Wnt induces LRP6 signalosomes and promotes dishevelled-dependent LRP6
RT   phosphorylation.";
RL   Science 316:1619-1622(2007).
RN   [16]
RP   INTERACTION WITH AXIN1, PHOSPHORYLATION, AND MUTAGENESIS OF LEU-1485;
RP   ASN-1486; PRO-1487; PRO-1488; PRO-1489; SER-1490; PRO-1491; ALA-1492;
RP   THR-1493; GLU-1494; ARG-1495; THR-1529; THR-1530; PRO-1531; THR-1572;
RP   SER-1590 AND SER-1607.
RX   PubMed=18362152; DOI=10.1074/jbc.M800327200;
RA   MacDonald B.T., Yokota C., Tamai K., Zeng X., He X.;
RT   "Wnt signal amplification via activity, cooperativity, and regulation
RT   of multiple intracellular PPPSP motifs in the Wnt co-receptor LRP6.";
RL   J. Biol. Chem. 283:16115-16123(2008).
RN   [17]
RP   PHOSPHORYLATION ON PPPSP MOTIFS, AND FUNCTION.
RX   PubMed=19107203; DOI=10.1371/journal.pone.0004046;
RA   Piao S., Lee S.H., Kim H., Yum S., Stamos J.L., Xu Y., Lee S.J.,
RA   Lee J., Oh S., Han J.K., Park B.J., Weis W.I., Ha N.C.;
RT   "Direct inhibition of GSK3beta by the phosphorylated cytoplasmic
RT   domain of LRP6 in Wnt/beta-catenin signaling.";
RL   PLoS ONE 3:E4046-E4046(2008).
RN   [18]
RP   PALMITOYLATION AT CYS-1394 AND CYS-1399, UBIQUITINATION AT LYS-1403,
RP   SUBCELLULAR LOCATION, AND MUTAGENESIS OF CYS-1394 AND CYS-1399.
RX   PubMed=18378904; DOI=10.1073/pnas.0710389105;
RA   Abrami L., Kunz B., Iacovache I., van der Goot F.G.;
RT   "Palmitoylation and ubiquitination regulate exit of the Wnt signaling
RT   protein LRP6 from the endoplasmic reticulum.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:5384-5389(2008).
RN   [19]
RP   DOMAIN PPPSP MOTIF, AND PHOSPHORYLATION AT SER-1490.
RX   PubMed=20059949; DOI=10.1016/j.devcel.2009.11.006;
RA   Davidson G., Shen J., Huang Y.L., Su Y., Karaulanov E.,
RA   Bartscherer K., Hassler C., Stannek P., Boutros M., Niehrs C.;
RT   "Cell cycle control of wnt receptor activation.";
RL   Dev. Cell 17:788-799(2009).
RN   [20]
RP   PHOSPHORYLATION OF PPPSP MOTIFS, PHOSPHORYLATION AT SER-1490, AND
RP   FUNCTION.
RX   PubMed=19801552; DOI=10.1074/jbc.M109.047456;
RA   Chen M., Philipp M., Wang J., Premont R.T., Garrison T.R., Caron M.G.,
RA   Lefkowitz R.J., Chen W.;
RT   "G Protein-coupled receptor kinases phosphorylate LRP6 in the Wnt
RT   pathway.";
RL   J. Biol. Chem. 284:35040-35048(2009).
RN   [21]
RP   PHOSPHORYLATION OF PPPSP MOTIFS, AND FUNCTION.
RX   PubMed=19293931; DOI=10.1371/journal.pone.0004926;
RA   Wu G., Huang H., Garcia Abreu J., He X.;
RT   "Inhibition of GSK3 phosphorylation of beta-catenin via phosphorylated
RT   PPPSPXS motifs of Wnt coreceptor LRP6.";
RL   PLoS ONE 4:E4926-E4926(2009).
RN   [22]
RP   INTERACTION WITH WNT3A; WNT9B AND FZD8 IN THE WNT/FZD/LRP6 COMPLEX,
RP   AND INTERACTION WITH DKK1.
RX   PubMed=20093360; DOI=10.1074/jbc.M109.092130;
RA   Bourhis E., Tam C., Franke Y., Bazan J.F., Ernst J., Hwang J.,
RA   Costa M., Cochran A.G., Hannoush R.N.;
RT   "Reconstitution of a frizzled8.Wnt3a.LRP6 signaling complex reveals
RT   multiple Wnt and Dkk1 binding sites on LRP6.";
RL   J. Biol. Chem. 285:9172-9179(2010).
RN   [23]
RP   INTERACTION WITH TMEM198.
RX   PubMed=21536646; DOI=10.1128/MCB.05103-11;
RA   Liang J., Fu Y., Cruciat C.M., Jia S., Wang Y., Tong Z., Tao Q.,
RA   Ingelfinger D., Boutros M., Meng A., Niehrs C., Wu W.;
RT   "Transmembrane protein 198 promotes LRP6 phosphorylation and Wnt
RT   signaling activation.";
RL   Mol. Cell. Biol. 31:2577-2590(2011).
RN   [24]
RP   INTERACTION WITH DAB2.
RX   PubMed=22491013; DOI=10.1038/emboj.2012.83;
RA   Jiang Y., He X., Howe P.H.;
RT   "Disabled-2 (Dab2) inhibits Wnt/beta-catenin signalling by binding
RT   LRP6 and promoting its internalization through clathrin.";
RL   EMBO J. 31:2336-2349(2012).
RN   [25]
RP   UBIQUITINATION BY ZNRF3.
RX   PubMed=22575959; DOI=10.1038/nature11019;
RA   Hao H.X., Xie Y., Zhang Y., Charlat O., Oster E., Avello M., Lei H.,
RA   Mickanin C., Liu D., Ruffner H., Mao X., Ma Q., Zamponi R.,
RA   Bouwmeester T., Finan P.M., Kirschner M.W., Porter J.A., Serluca F.C.,
RA   Cong F.;
RT   "ZNRF3 promotes Wnt receptor turnover in an R-spondin-sensitive
RT   manner.";
RL   Nature 485:195-200(2012).
RN   [26]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 630-1246 IN COMPLEX WITH
RP   DKK1, SUBUNIT, DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-692; ASN-859;
RP   ASN-865; ASN-926 AND ASN-1039.
RX   PubMed=22000856; DOI=10.1016/j.devcel.2011.09.003;
RA   Ahn V.E., Chu M.L., Choi H.J., Tran D., Abo A., Weis W.I.;
RT   "Structural basis of Wnt signaling inhibition by Dickkopf binding to
RT   LRP5/6.";
RL   Dev. Cell 21:862-873(2011).
RN   [27]
RP   VARIANT ADCAD2 CYS-611, AND CHARACTERIZATION OF VARIANT ADCAD2
RP   CYS-611.
RX   PubMed=17332414; DOI=10.1126/science.1136370;
RA   Mani A., Radhakrishnan J., Wang H., Mani A., Mani M.-A.,
RA   Nelson-Williams C., Carew K.S., Mane S., Najmabadi H., Wu D.,
RA   Lifton R.P.;
RT   "LRP6 mutation in a family with early coronary disease and metabolic
RT   risk factors.";
RL   Science 315:1278-1282(2007).
CC   -!- FUNCTION: Component of the Wnt-Fzd-LRP5-LRP6 complex that triggers
CC       beta-catenin signaling through inducing aggregation of receptor-
CC       ligand complexes into ribosome-sized signalsomes. Cell-surface
CC       coreceptor of Wnt/beta-catenin signaling, which plays a pivotal
CC       role in bone formation. The Wnt-induced Fzd/LRP6 coreceptor
CC       complex recruits DVL1 polymers to the plasma membrane which, in
CC       turn, recruits the AXIN1/GSK3B-complex to the cell surface
CC       promoting the formation of signalsomes and inhibiting AXIN1/GSK3-
CC       mediated phosphorylation and destruction of beta-catenin. Required
CC       for posterior patterning of the epiblast during gastrulation (By
CC       similarity). {ECO:0000250, ECO:0000269|PubMed:11357136,
CC       ECO:0000269|PubMed:11448771, ECO:0000269|PubMed:15778503,
CC       ECO:0000269|PubMed:16341017, ECO:0000269|PubMed:16513652,
CC       ECO:0000269|PubMed:17326769, ECO:0000269|PubMed:17400545,
CC       ECO:0000269|PubMed:19107203, ECO:0000269|PubMed:19293931,
CC       ECO:0000269|PubMed:19801552}.
CC   -!- SUBUNIT: Homodimer; disulfide-linked. Forms phosphorylated
CC       oligomer aggregates on Wnt-signaling. Forms a WNT-signaling
CC       complex formed of a WNT protein, a FZD protein and LRP5 or LRP6.
CC       Interacts (via the extracellular domain) with WNT1; the
CC       interaction is enhanced by prior formation of the Wnt/Fzd complex.
CC       Interacts (via the beta-propeller regions 3 and 4) with WNT3A.
CC       Interacts (via the beta-propeller regions 1 and 2) with WNT9B.
CC       Interacts with FZD5; the interaction forms a coreceptor complex
CC       for Wnt signaling and is inhibited by DKK1 and DRAXIN. Interacts
CC       (via beta propeller region) with DKK1; the interaction inhibits
CC       FZD5/LRP6 complex formation. Interacts with DKK2. Interacts with
CC       C1orf187/DRAXIN; the interaction inhibits Wnt signaling (By
CC       similarity). Interacts (via the phosphorylated PPPSP motifs) with
CC       AXIN1; the interaction recruits the AXIN1/GSK3B complex to cell
CC       surface LRP6 signalsomes. Interacts with GRB10; the interaction
CC       prevents AXIN1 binding, thus negatively regulating the Wnt
CC       signaling pathway (By similarity). Interacts (via the
CC       extracellular domain) with RSPO1; the interaction activates
CC       Wnt/beta-catenin signaling. Interacts (via the extracellular
CC       domain) with RSPO3 (via the cysteine rich domain); the interaction
CC       activates Wnt/beta-catenin signaling. Interacts (via the beta-
CC       propeller regions 1 and 2) with SOST; the interaction competes
CC       with DKK1 for binding for inhibiting beta-catenin signaling.
CC       Interacts with MESD; the interaction prevents the formation of
CC       LRP6 aggregates and targets LRP6 to the plasma membrane (By
CC       similarity). Interacts (via the cytoplasmic domain) with CSNKIE;
CC       the interaction phosphorylates LRP6, binds AXIN1 and inhibits
CC       AXIN1/GSK3B-mediated phosphorylation of beta-catenin. Interacts
CC       with MACF1. Interacts with DAB2; the interaction involves LRP6
CC       phosphorylation by CK2 and sequesters LRP6 towards clathrin-
CC       mediated endocytosis. Interacts with TMEM198. {ECO:0000250,
CC       ECO:0000269|PubMed:11357136, ECO:0000269|PubMed:11448771,
CC       ECO:0000269|PubMed:12857724, ECO:0000269|PubMed:15778503,
CC       ECO:0000269|PubMed:15908424, ECO:0000269|PubMed:16513652,
CC       ECO:0000269|PubMed:16815997, ECO:0000269|PubMed:17400545,
CC       ECO:0000269|PubMed:17569865, ECO:0000269|PubMed:17698587,
CC       ECO:0000269|PubMed:18362152, ECO:0000269|PubMed:20093360,
CC       ECO:0000269|PubMed:21536646, ECO:0000269|PubMed:22000856,
CC       ECO:0000269|PubMed:22491013}.
CC   -!- INTERACTION:
CC       Self; NbExp=2; IntAct=EBI-910915, EBI-910915;
CC       Q9Y4X0:AMMECR1; NbExp=5; IntAct=EBI-910915, EBI-8583355;
CC       Q9H6X2:ANTXR1; NbExp=3; IntAct=EBI-910915, EBI-905643;
CC       O35625:Axin1 (xeno); NbExp=2; IntAct=EBI-910915, EBI-2365912;
CC       O70239:Axin1 (xeno); NbExp=12; IntAct=EBI-910915, EBI-6857773;
CC       Q03135:CAV1; NbExp=3; IntAct=EBI-910915, EBI-603614;
CC       P98082:DAB2; NbExp=20; IntAct=EBI-910915, EBI-1171238;
CC       O94907:DKK1; NbExp=3; IntAct=EBI-910915, EBI-742864;
CC       Q61091:Fzd8 (xeno); NbExp=4; IntAct=EBI-910915, EBI-6171689;
CC       P49840:GSK3A; NbExp=2; IntAct=EBI-910915, EBI-1044067;
CC       P49841:GSK3B; NbExp=4; IntAct=EBI-910915, EBI-373586;
CC       Q5S007:LRRK2; NbExp=3; IntAct=EBI-910915, EBI-5323863;
CC       Q9ERE8:Mesdc1 (xeno); NbExp=2; IntAct=EBI-910915, EBI-6985232;
CC       Q9BQB4:SOST; NbExp=2; IntAct=EBI-910915, EBI-5746563;
CC       P04426:Wnt1 (xeno); NbExp=2; IntAct=EBI-910915, EBI-1570911;
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane
CC       protein. Endoplasmic reticulum. Note=On Wnt signaling, undergoes a
CC       cycle of caveolin- or clathrin-mediated endocytosis and plasma
CC       membrane location. Released from the endoplasmic reticulum on
CC       palmitoylation. Mono-ubiquitination retains it in the endoplasmic
CC       reticulum in the absence of palmitoylation. On Wnt signaling,
CC       phosphorylated, aggregates and colocalizes with AXIN1 and GSK3B at
CC       the plasma membrane in LRP6-signalsomes. Chaperoned to the plasma
CC       membrane by MESD (By similarity). {ECO:0000250}.
CC   -!- TISSUE SPECIFICITY: Widely coexpressed with LRP5 during
CC       embryogenesis and in adult tissues.
CC   -!- INDUCTION: Decreased levels on WNT3A stimulation.
CC       {ECO:0000269|PubMed:17698587}.
CC   -!- DOMAIN: The YWTD-EGF-like domains 1 and 2 are required for the
CC       interaction with Wnt-frizzled complex. The YWTD-EGF-like domains 3
CC       and 4 are required for the interaction with DKK1.
CC       {ECO:0000269|PubMed:20059949}.
CC   -!- DOMAIN: The PPPSP motifs play a central role in signal
CC       transduction by being phosphorylated, leading to activate the Wnt
CC       signaling pathway. {ECO:0000269|PubMed:20059949}.
CC   -!- PTM: Dual phosphorylation of cytoplasmic PPPSP motifs sequentially
CC       by GSK3 and CK1 is required for AXIN1-binding, and subsequent
CC       stabilization and activation of beta-catenin via preventing GSK3-
CC       mediated phosphorylation of beta-catenin. Phosphorylated, in
CC       vitro, by GRK5/6 within and outside the PPPSP motifs.
CC       Phosphorylation at Ser-1490 by CDK14 during G2/M phase leads to
CC       regulation of the Wnt signaling pathway during the cell cycle.
CC       Phosphorylation by GSK3B is induced by RPSO1 binding and inhibited
CC       by DKK1. Phosphorylated, in vitro, by casein kinase I on Thr-1479.
CC       {ECO:0000269|PubMed:16341017, ECO:0000269|PubMed:16513652,
CC       ECO:0000269|PubMed:17400545, ECO:0000269|PubMed:17569865,
CC       ECO:0000269|PubMed:17698587, ECO:0000269|PubMed:18362152,
CC       ECO:0000269|PubMed:19107203, ECO:0000269|PubMed:19293931,
CC       ECO:0000269|PubMed:19801552, ECO:0000269|PubMed:20059949}.
CC   -!- PTM: Undergoes gamma-secretase-dependent regulated intramembrane
CC       proteolysis (RIP). The extracellular domain is first released by
CC       shedding, and then, through the action of gamma-secretase, the
CC       intracellular domain (ICD) is released into the cytoplasm where it
CC       is free to bind to GSK3B and to activate canonical Wnt signaling.
CC   -!- PTM: Palmitoylation on the two sites near the transmembrane domain
CC       leads to release of LRP6 from the endoplasmic reticulum.
CC       {ECO:0000269|PubMed:18378904}.
CC   -!- PTM: Mono-ubiquitinated which retains LRP6 in the endoplasmic
CC       reticulum. Ubiquitinated by ZNRF3, leading to its degradation by
CC       the proteasome. {ECO:0000269|PubMed:18378904,
CC       ECO:0000269|PubMed:22575959}.
CC   -!- PTM: N-glycosylation is required for cell surface location.
CC       {ECO:0000269|PubMed:17698587, ECO:0000269|PubMed:22000856}.
CC   -!- DISEASE: Coronary artery disease, autosomal dominant, 2 (ADCAD2)
CC       [MIM:610947]: A common heart disease characterized by reduced or
CC       absent blood flow in one or more of the arteries that encircle and
CC       supply the heart. Its most important complication is acute
CC       myocardial infarction. {ECO:0000269|PubMed:17332414}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- SIMILARITY: Belongs to the LDLR family. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 4 EGF-like domains. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 3 LDL-receptor class A domains.
CC       {ECO:0000255|PROSITE-ProRule:PRU00124}.
CC   -!- SIMILARITY: Contains 20 LDL-receptor class B repeats.
CC       {ECO:0000255|PROSITE-ProRule:PRU00461}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF074264; AAC33006.1; -; mRNA.
DR   EMBL; AC007537; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC007621; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC117136; AAI17137.1; -; mRNA.
DR   EMBL; BC126405; AAI26406.1; -; mRNA.
DR   CCDS; CCDS8647.1; -.
DR   PIR; JE0272; JE0272.
DR   RefSeq; NP_002327.2; NM_002336.2.
DR   RefSeq; XP_006719141.1; XM_006719078.2.
DR   RefSeq; XP_011547175.1; XM_011548873.1.
DR   UniGene; Hs.584775; -.
DR   UniGene; Hs.658913; -.
DR   PDB; 3S2K; X-ray; 2.80 A; A/B=630-1246.
DR   PDB; 3S8V; X-ray; 3.10 A; A/B=629-1243.
DR   PDB; 3S8Z; X-ray; 2.80 A; A=629-1243.
DR   PDB; 3S94; X-ray; 2.80 A; A/B=20-630.
DR   PDB; 3SOB; X-ray; 1.90 A; B=20-335.
DR   PDB; 3SOQ; X-ray; 1.90 A; A=20-326.
DR   PDB; 3SOV; X-ray; 1.27 A; A=20-326.
DR   PDB; 4A0P; X-ray; 1.90 A; A=629-1244.
DR   PDB; 4DG6; X-ray; 2.90 A; A=20-635.
DR   PDB; 4NM5; X-ray; 2.30 A; C=1568-1575.
DR   PDB; 4NM7; X-ray; 2.30 A; C=1603-1610.
DR   PDB; 5AIR; X-ray; 2.53 A; A/B=1565-1575.
DR   PDBsum; 3S2K; -.
DR   PDBsum; 3S8V; -.
DR   PDBsum; 3S8Z; -.
DR   PDBsum; 3S94; -.
DR   PDBsum; 3SOB; -.
DR   PDBsum; 3SOQ; -.
DR   PDBsum; 3SOV; -.
DR   PDBsum; 4A0P; -.
DR   PDBsum; 4DG6; -.
DR   PDBsum; 4NM5; -.
DR   PDBsum; 4NM7; -.
DR   PDBsum; 5AIR; -.
DR   ProteinModelPortal; O75581; -.
DR   SMR; O75581; 20-1246.
DR   BioGrid; 110219; 41.
DR   DIP; DIP-29884N; -.
DR   IntAct; O75581; 27.
DR   MINT; MINT-3369849; -.
DR   STRING; 9606.ENSP00000261349; -.
DR   iPTMnet; O75581; -.
DR   PhosphoSite; O75581; -.
DR   SwissPalm; O75581; -.
DR   BioMuta; LRP6; -.
DR   MaxQB; O75581; -.
DR   PaxDb; O75581; -.
DR   PRIDE; O75581; -.
DR   Ensembl; ENST00000261349; ENSP00000261349; ENSG00000070018.
DR   Ensembl; ENST00000628182; ENSP00000486315; ENSG00000281324.
DR   GeneID; 4040; -.
DR   KEGG; hsa:4040; -.
DR   UCSC; uc001rah.4; human.
DR   CTD; 4040; -.
DR   GeneCards; LRP6; -.
DR   H-InvDB; HIX0036693; -.
DR   HGNC; HGNC:6698; LRP6.
DR   HPA; CAB004490; -.
DR   HPA; HPA029925; -.
DR   MalaCards; LRP6; -.
DR   MIM; 603507; gene.
DR   MIM; 610947; phenotype.
DR   neXtProt; NX_O75581; -.
DR   Orphanet; 94062; Coronary artery disease - hyperlipidemia - hypertension - diabetes - osteoporosis.
DR   PharmGKB; PA30456; -.
DR   eggNOG; ENOG410IPT4; Eukaryota.
DR   eggNOG; ENOG410XSY5; LUCA.
DR   GeneTree; ENSGT00760000118968; -.
DR   HOGENOM; HOG000230697; -.
DR   HOVERGEN; HBG049167; -.
DR   InParanoid; O75581; -.
DR   KO; K03068; -.
DR   OMA; WENCADG; -.
DR   OrthoDB; EOG75XGK3; -.
DR   PhylomeDB; O75581; -.
DR   TreeFam; TF315253; -.
DR   Reactome; R-HSA-201681; TCF dependent signaling in response to WNT.
DR   Reactome; R-HSA-3772470; Negative regulation of TCF-dependent signaling by WNT ligand antagonists.
DR   Reactome; R-HSA-4641262; Disassembly of the destruction complex and recruitment of AXIN to the membrane.
DR   Reactome; R-HSA-4641263; Regulation of FZD by ubiquitination.
DR   Reactome; R-HSA-5340588; RNF mutants show enhanced WNT signaling and proliferation.
DR   SignaLink; O75581; -.
DR   ChiTaRS; LRP6; human.
DR   EvolutionaryTrace; O75581; -.
DR   GeneWiki; LRP6; -.
DR   GenomeRNAi; 4040; -.
DR   NextBio; 15822; -.
DR   PRO; PR:O75581; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   Proteomes; UP000005640; Chromosome 2.
DR   Bgee; O75581; -.
DR   CleanEx; HS_LRP6; -.
DR   ExpressionAtlas; O75581; baseline and differential.
DR   Genevisible; O75581; HS.
DR   GO; GO:0009986; C:cell surface; IDA:BHF-UCL.
DR   GO; GO:0031410; C:cytoplasmic vesicle; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IEA:Ensembl.
DR   GO; GO:0031901; C:early endosome membrane; TAS:Reactome.
DR   GO; GO:0005783; C:endoplasmic reticulum; IEA:UniProtKB-SubCell.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:1990851; C:Frizzled-LRP5/6 complex; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0043025; C:neuronal cell body; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0043235; C:receptor complex; IBA:GO_Central.
DR   GO; GO:0045202; C:synapse; IBA:GO_Central.
DR   GO; GO:1990909; C:Wnt signalosome; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0034185; F:apolipoprotein binding; IBA:GO_Central.
DR   GO; GO:0071936; F:coreceptor activity involved in Wnt signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0005109; F:frizzled binding; IPI:BHF-UCL.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0019210; F:kinase inhibitor activity; IMP:BHF-UCL.
DR   GO; GO:0005041; F:low-density lipoprotein receptor activity; IDA:MGI.
DR   GO; GO:0042803; F:protein homodimerization activity; IPI:BHF-UCL.
DR   GO; GO:0005102; F:receptor binding; IPI:BHF-UCL.
DR   GO; GO:0019534; F:toxin transporter activity; IMP:BHF-UCL.
DR   GO; GO:0042813; F:Wnt-activated receptor activity; IBA:GO_Central.
DR   GO; GO:0017147; F:Wnt-protein binding; IPI:BHF-UCL.
DR   GO; GO:0090245; P:axis elongation involved in somitogenesis; IBA:GO_Central.
DR   GO; GO:0060070; P:canonical Wnt signaling pathway; IDA:UniProtKB.
DR   GO; GO:0044335; P:canonical Wnt signaling pathway involved in neural crest cell differentiation; IC:BHF-UCL.
DR   GO; GO:0044340; P:canonical Wnt signaling pathway involved in regulation of cell proliferation; IC:BHF-UCL.
DR   GO; GO:0071397; P:cellular response to cholesterol; IMP:BHF-UCL.
DR   GO; GO:0021587; P:cerebellum morphogenesis; IBA:GO_Central.
DR   GO; GO:0021987; P:cerebral cortex development; IBA:GO_Central.
DR   GO; GO:0060026; P:convergent extension; IBA:GO_Central.
DR   GO; GO:0009880; P:embryonic pattern specification; IBA:GO_Central.
DR   GO; GO:0060059; P:embryonic retina morphogenesis in camera-type eye; IBA:GO_Central.
DR   GO; GO:0035261; P:external genitalia morphogenesis; IBA:GO_Central.
DR   GO; GO:0060325; P:face morphogenesis; IBA:GO_Central.
DR   GO; GO:0030901; P:midbrain development; IBA:GO_Central.
DR   GO; GO:0030917; P:midbrain-hindbrain boundary development; IBA:GO_Central.
DR   GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; TAS:Reactome.
DR   GO; GO:0006469; P:negative regulation of protein kinase activity; IMP:BHF-UCL.
DR   GO; GO:0001933; P:negative regulation of protein phosphorylation; IMP:BHF-UCL.
DR   GO; GO:0071901; P:negative regulation of protein serine/threonine kinase activity; IDA:BHF-UCL.
DR   GO; GO:0034392; P:negative regulation of smooth muscle cell apoptotic process; IMP:BHF-UCL.
DR   GO; GO:0014033; P:neural crest cell differentiation; IDA:BHF-UCL.
DR   GO; GO:0014029; P:neural crest formation; IDA:BHF-UCL.
DR   GO; GO:0001843; P:neural tube closure; IBA:GO_Central.
DR   GO; GO:0042475; P:odontogenesis of dentin-containing tooth; IBA:GO_Central.
DR   GO; GO:0060021; P:palate development; IBA:GO_Central.
DR   GO; GO:0003344; P:pericardium morphogenesis; IBA:GO_Central.
DR   GO; GO:0090263; P:positive regulation of canonical Wnt signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0045787; P:positive regulation of cell cycle; IMP:BHF-UCL.
DR   GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; IEA:Ensembl.
DR   GO; GO:0051091; P:positive regulation of sequence-specific DNA binding transcription factor activity; IDA:BHF-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:BHF-UCL.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IMP:BHF-UCL.
DR   GO; GO:2000055; P:positive regulation of Wnt signaling pathway involved in dorsal/ventral axis specification; IDA:BHF-UCL.
DR   GO; GO:0090009; P:primitive streak formation; IBA:GO_Central.
DR   GO; GO:0072659; P:protein localization to plasma membrane; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0090118; P:receptor-mediated endocytosis of low-density lipoprotein particle involved in cholesterol transport; IBA:GO_Central.
DR   GO; GO:0043434; P:response to peptide hormone; IEA:Ensembl.
DR   GO; GO:0016337; P:single organismal cell-cell adhesion; IEA:Ensembl.
DR   GO; GO:0007268; P:synaptic transmission; IBA:GO_Central.
DR   GO; GO:0021794; P:thalamus development; IBA:GO_Central.
DR   GO; GO:1901998; P:toxin transport; IMP:GOC.
DR   GO; GO:0060535; P:trachea cartilage morphogenesis; IBA:GO_Central.
DR   GO; GO:0016055; P:Wnt signaling pathway; IMP:UniProtKB.
DR   GO; GO:0044332; P:Wnt signaling pathway involved in dorsal/ventral axis specification; IDA:BHF-UCL.
DR   GO; GO:0090244; P:Wnt signaling pathway involved in somitogenesis; IBA:GO_Central.
DR   Gene3D; 2.120.10.30; -; 4.
DR   Gene3D; 4.10.400.10; -; 3.
DR   InterPro; IPR011042; 6-blade_b-propeller_TolB-like.
DR   InterPro; IPR000742; EGF-like_dom.
DR   InterPro; IPR023415; LDLR_class-A_CS.
DR   InterPro; IPR000033; LDLR_classB_rpt.
DR   InterPro; IPR002172; LDrepeatLR_classA_rpt.
DR   InterPro; IPR017049; LRP5/6.
DR   Pfam; PF00057; Ldl_recept_a; 3.
DR   Pfam; PF00058; Ldl_recept_b; 11.
DR   PIRSF; PIRSF036314; LDL_recpt-rel_p5/6; 1.
DR   PRINTS; PR00261; LDLRECEPTOR.
DR   SMART; SM00181; EGF; 4.
DR   SMART; SM00192; LDLa; 3.
DR   SMART; SM00135; LY; 20.
DR   SUPFAM; SSF57424; SSF57424; 3.
DR   PROSITE; PS01186; EGF_2; 1.
DR   PROSITE; PS01209; LDLRA_1; 3.
DR   PROSITE; PS50068; LDLRA_2; 3.
DR   PROSITE; PS51120; LDLRB; 19.
PE   1: Evidence at protein level;
KW   3D-structure; Complete proteome; Developmental protein;
KW   Disease mutation; Disulfide bond; EGF-like domain; Endocytosis;
KW   Endoplasmic reticulum; Glycoprotein; Isopeptide bond; Lipoprotein;
KW   Membrane; Palmitate; Phosphoprotein; Polymorphism; Receptor;
KW   Reference proteome; Repeat; Signal; Transmembrane;
KW   Transmembrane helix; Ubl conjugation; Wnt signaling pathway.
FT   SIGNAL        1     19       {ECO:0000255}.
FT   CHAIN        20   1613       Low-density lipoprotein receptor-related
FT                                protein 6.
FT                                /FTId=PRO_0000017330.
FT   TOPO_DOM     20   1370       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1371   1393       Helical. {ECO:0000255}.
FT   TOPO_DOM   1394   1613       Cytoplasmic. {ECO:0000255}.
FT   REPEAT       63    106       LDL-receptor class B 1.
FT   REPEAT      107    149       LDL-receptor class B 2.
FT   REPEAT      150    193       LDL-receptor class B 3.
FT   REPEAT      194    236       LDL-receptor class B 4.
FT   REPEAT      237    276       LDL-receptor class B 5.
FT   DOMAIN      282    324       EGF-like 1.
FT   REPEAT      372    414       LDL-receptor class B 6.
FT   REPEAT      415    457       LDL-receptor class B 7.
FT   REPEAT      458    501       LDL-receptor class B 8.
FT   REPEAT      502    542       LDL-receptor class B 9.
FT   REPEAT      543    584       LDL-receptor class B 10.
FT   DOMAIN      588    628       EGF-like 2.
FT   REPEAT      674    716       LDL-receptor class B 11.
FT   REPEAT      717    759       LDL-receptor class B 12.
FT   REPEAT      760    802       LDL-receptor class B 13.
FT   REPEAT      803    842       LDL-receptor class B 14.
FT   REPEAT      843    885       LDL-receptor class B 15.
FT   DOMAIN      889    930       EGF-like 3.
FT   REPEAT      977   1025       LDL-receptor class B 16.
FT   REPEAT     1026   1068       LDL-receptor class B 17.
FT   REPEAT     1069   1113       LDL-receptor class B 18.
FT   REPEAT     1114   1156       LDL-receptor class B 19.
FT   REPEAT     1157   1198       LDL-receptor class B 20.
FT   DOMAIN     1203   1244       EGF-like 4.
FT   DOMAIN     1248   1286       LDL-receptor class A 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DOMAIN     1287   1323       LDL-receptor class A 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DOMAIN     1325   1361       LDL-receptor class A 3.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   REGION       20    275       Beta-propeller 1.
FT   REGION      328    589       Beta-propeller 2.
FT   REGION      631    890       Beta-propeller 3.
FT   REGION      933   1202       Beta-propeller 4.
FT   MOTIF      1487   1493       PPPSP motif A.
FT   MOTIF      1527   1534       PPPSP motif B.
FT   MOTIF      1568   1575       PPPSP motif C.
FT   MOTIF      1588   1593       PPPSP motif D.
FT   MOTIF      1603   1610       PPPSP motif E.
FT   MOD_RES    1420   1420       Phosphoserine; by CK1.
FT                                {ECO:0000269|PubMed:16513652}.
FT   MOD_RES    1430   1430       Phosphoserine; by CK1.
FT                                {ECO:0000269|PubMed:16513652}.
FT   MOD_RES    1479   1479       Phosphothreonine.
FT                                {ECO:0000269|PubMed:17569865}.
FT   MOD_RES    1490   1490       Phosphoserine; by CDK14, GRK5 and GRK6.
FT                                {ECO:0000269|PubMed:16341017,
FT                                ECO:0000269|PubMed:17698587,
FT                                ECO:0000269|PubMed:19801552,
FT                                ECO:0000269|PubMed:20059949}.
FT   MOD_RES    1493   1493       Phosphothreonine; by CK1.
FT                                {ECO:0000269|PubMed:16341017}.
FT   LIPID      1394   1394       S-palmitoyl cysteine.
FT                                {ECO:0000269|PubMed:18378904}.
FT   LIPID      1399   1399       S-palmitoyl cysteine.
FT                                {ECO:0000269|PubMed:18378904}.
FT   CARBOHYD     42     42       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD     81     81       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    281    281       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    433    433       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    486    486       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    692    692       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:22000856}.
FT   CARBOHYD    859    859       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:22000856}.
FT   CARBOHYD    865    865       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:22000856}.
FT   CARBOHYD    926    926       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:22000856}.
FT   CARBOHYD   1039   1039       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:22000856}.
FT   DISULFID    286    297       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID    293    308       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID    310    323       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID    592    603       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID    599    612       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID    614    627       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID    893    904       {ECO:0000255|PROSITE-ProRule:PRU00124,
FT                                ECO:0000269|PubMed:22000856}.
FT   DISULFID    900    914       {ECO:0000255|PROSITE-ProRule:PRU00124,
FT                                ECO:0000269|PubMed:22000856}.
FT   DISULFID    916    929       {ECO:0000255|PROSITE-ProRule:PRU00124,
FT                                ECO:0000269|PubMed:22000856}.
FT   DISULFID   1207   1218       {ECO:0000255|PROSITE-ProRule:PRU00124,
FT                                ECO:0000269|PubMed:22000856}.
FT   DISULFID   1214   1228       {ECO:0000255|PROSITE-ProRule:PRU00124,
FT                                ECO:0000269|PubMed:22000856}.
FT   DISULFID   1230   1243       {ECO:0000255|PROSITE-ProRule:PRU00124,
FT                                ECO:0000269|PubMed:22000856}.
FT   DISULFID   1249   1263       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID   1256   1276       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID   1270   1285       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID   1288   1300       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID   1295   1313       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID   1307   1322       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID   1326   1338       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID   1333   1351       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID   1345   1360       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   CROSSLNK   1403   1403       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000269|PubMed:18378904}.
FT   VARIANT     483    483       V -> I (in dbSNP:rs7975614).
FT                                /FTId=VAR_030349.
FT   VARIANT     611    611       R -> C (in ADCAD2; impairs Wnt signaling
FT                                in vitro). {ECO:0000269|PubMed:17332414}.
FT                                /FTId=VAR_034701.
FT   VARIANT     817    817       S -> C (in dbSNP:rs2302686).
FT                                /FTId=VAR_030350.
FT   VARIANT    1062   1062       V -> I (in dbSNP:rs2302685).
FT                                {ECO:0000269|PubMed:9704021}.
FT                                /FTId=VAR_024520.
FT   VARIANT    1401   1401       R -> H (in dbSNP:rs34815107).
FT                                /FTId=VAR_034702.
FT   MUTAGEN    1394   1394       C->A: Some reduction of palmitoylation,
FT                                little change in plasma membrane location
FT                                in the presence of MESD nor in Wnt-
FT                                signaling activity. Completely abolishes
FT                                palmitoylation, no plasma membrane
FT                                location, greatly reduced Wnt-signaling
FT                                activity but no effect on ubiquitination;
FT                                when associated with A-1399. Exhibits
FT                                full Wnt-signaling activity and no change
FT                                in plasma membrane location; when
FT                                associated with A-1399 and R-1403.
FT                                {ECO:0000269|PubMed:18378904}.
FT   MUTAGEN    1399   1399       C->A: Some reduction of palmitoylation,
FT                                and little change in plasma membrane
FT                                location in the presence of MESD nor in
FT                                Wnt-signaling activity. Completely
FT                                abolishes palmitoylation, no plasma
FT                                membrane location, greatly reduced Wnt-
FT                                signaling activity but no effect on
FT                                ubiquitination; when associated with A-
FT                                1394. Exhibits full Wnt-signaling
FT                                activity and no change in plasma membrane
FT                                location in the in presence of MESD; when
FT                                associated with A-1394 and R-1403.
FT                                {ECO:0000269|PubMed:18378904}.
FT   MUTAGEN    1403   1403       K->R: Abolishes ubiquitination, no change
FT                                in plasma membrane location in the
FT                                presence of MESD but greatly reduced Wnt-
FT                                signaling activity. Exhibits full Wnt-
FT                                signaling activity and no change in
FT                                plasma membrane location; when associated
FT                                with A-1394 and A-1399.
FT   MUTAGEN    1420   1420       S->A: Enhanced AXIN1 binding and
FT                                increased beta-catenin activity by 2.2-
FT                                fold. Further enhanced AXIN1 binding and
FT                                increases beta-catenin activity by 3.3-
FT                                fold; when associated with A-1430.
FT                                {ECO:0000269|PubMed:16513652}.
FT   MUTAGEN    1430   1430       S->A: Enhanced AXIN1 binding. Further
FT                                enhanced AXIN1 binding and increases
FT                                beta-catenin activity by 3.3-fold; when
FT                                associated with A-1420.
FT                                {ECO:0000269|PubMed:16513652}.
FT   MUTAGEN    1485   1485       L->A: No change in the phosphorylation
FT                                state of PPPSP motif. Some reduction in
FT                                Wnt/beta-catenin signaling.
FT                                {ECO:0000269|PubMed:18362152}.
FT   MUTAGEN    1486   1486       N->A: No change in the phosphorylation
FT                                state of PPPSP motif. Increased Wnt/beta-
FT                                catenin signaling.
FT                                {ECO:0000269|PubMed:18362152}.
FT   MUTAGEN    1487   1487       P->A: No change in the phosphorylation
FT                                state of PPPSP motif A. Greatly reduced
FT                                Wnt/beta-catenin signaling.
FT                                {ECO:0000269|PubMed:18362152}.
FT   MUTAGEN    1487   1487       P->C: No change in the phosphorylation
FT                                state of PPPSP motif A. Greatly reduced
FT                                Wnt/beta-catenin signaling.
FT                                {ECO:0000269|PubMed:18362152}.
FT   MUTAGEN    1488   1488       P->A: No change in the phosphorylation
FT                                state of PPPSP motif A. Greatly reduced
FT                                Wnt/beta-catenin signaling.
FT                                {ECO:0000269|PubMed:18362152}.
FT   MUTAGEN    1489   1489       P->A: No change in the phosphorylation
FT                                state of PPPSP motif A. Greatly reduced
FT                                Wnt/beta-catenin signaling.
FT                                {ECO:0000269|PubMed:18362152}.
FT   MUTAGEN    1490   1490       S->A: Greatly reduced phosphorylation of
FT                                PPPSP motif A. Greatly reduced Wnt/beta-
FT                                catenin signaling.
FT                                {ECO:0000269|PubMed:18362152}.
FT   MUTAGEN    1490   1490       S->T: Some loss of phosphorylation of
FT                                PPPSP motif A. Little reduction in
FT                                Wnt/beta-catenin signaling.
FT                                {ECO:0000269|PubMed:18362152}.
FT   MUTAGEN    1491   1491       P->A: Greatly reduced phosphorylation of
FT                                PPPSP motif A. Greatly reduced Wnt/beta-
FT                                catenin signaling.
FT                                {ECO:0000269|PubMed:18362152}.
FT   MUTAGEN    1492   1492       A->G: No change in the phosphorylation
FT                                state of PPPSP motif A. Greatly reduced
FT                                Wnt/beta-catenin signaling.
FT                                {ECO:0000269|PubMed:18362152}.
FT   MUTAGEN    1493   1493       T->A: No change in the phosphorylation
FT                                state of PPPSP motif A. Greatly reduced
FT                                Wnt/beta-catenin signaling.
FT                                {ECO:0000269|PubMed:18362152}.
FT   MUTAGEN    1494   1494       E->A: No change in the phosphorylation
FT                                state of PPPSP motif A. Little reduction
FT                                of Wnt/beta-catenin signaling.
FT                                {ECO:0000269|PubMed:18362152}.
FT   MUTAGEN    1495   1495       R->A: No change in the phosphorylation
FT                                state of PPPSP motif. No reduction of
FT                                Wnt/beta-catenin signaling.
FT                                {ECO:0000269|PubMed:18362152}.
FT   MUTAGEN    1529   1529       T->A: No effect on the phosphorylation
FT                                state of PPPSP motif B.
FT                                {ECO:0000269|PubMed:18362152}.
FT   MUTAGEN    1530   1530       T->A: Abolishes phosphorylation of PPPSP
FT                                motif B. Reduced Wnt/beta-catenin
FT                                signaling. {ECO:0000269|PubMed:18362152}.
FT   MUTAGEN    1531   1531       P->A: Abolishes phosphorylation of PPPSP
FT                                motif B. Reduced Wnt/beta-catenin
FT                                signaling. {ECO:0000269|PubMed:18362152}.
FT   MUTAGEN    1572   1572       T->A: Abolishes Wnt/beta-catenin
FT                                signaling. {ECO:0000269|PubMed:18362152}.
FT   MUTAGEN    1590   1590       S->A: Abolishes Wnt/beta-catenin
FT                                signaling. {ECO:0000269|PubMed:18362152}.
FT   MUTAGEN    1607   1607       S->A: Abolishes Wnt/beta-catenin
FT                                signaling. {ECO:0000269|PubMed:18362152}.
FT   STRAND       22     26       {ECO:0000244|PDB:3SOV}.
FT   STRAND       28     35       {ECO:0000244|PDB:3SOV}.
FT   HELIX        36     38       {ECO:0000244|PDB:3SOB}.
FT   STRAND       44     59       {ECO:0000244|PDB:3SOV}.
FT   HELIX        60     62       {ECO:0000244|PDB:3SOV}.
FT   STRAND       64     69       {ECO:0000244|PDB:3SOV}.
FT   TURN         70     73       {ECO:0000244|PDB:3SOV}.
FT   STRAND       74     79       {ECO:0000244|PDB:3SOV}.
FT   STRAND       82     84       {ECO:0000244|PDB:3SOV}.
FT   STRAND       88     92       {ECO:0000244|PDB:3SOV}.
FT   STRAND       99    103       {ECO:0000244|PDB:3SOV}.
FT   TURN        104    107       {ECO:0000244|PDB:3SOV}.
FT   STRAND      108    113       {ECO:0000244|PDB:3SOV}.
FT   TURN        114    117       {ECO:0000244|PDB:3SOV}.
FT   STRAND      118    123       {ECO:0000244|PDB:3SOV}.
FT   STRAND      130    133       {ECO:0000244|PDB:3SOV}.
FT   STRAND      138    146       {ECO:0000244|PDB:3SOV}.
FT   HELIX       147    149       {ECO:0000244|PDB:3SOV}.
FT   STRAND      151    156       {ECO:0000244|PDB:3SOV}.
FT   STRAND      158    160       {ECO:0000244|PDB:3SOV}.
FT   STRAND      162    167       {ECO:0000244|PDB:3SOV}.
FT   STRAND      174    177       {ECO:0000244|PDB:3SOV}.
FT   STRAND      184    190       {ECO:0000244|PDB:3SOV}.
FT   TURN        191    194       {ECO:0000244|PDB:3SOV}.
FT   STRAND      195    200       {ECO:0000244|PDB:3SOV}.
FT   TURN        201    204       {ECO:0000244|PDB:3SOV}.
FT   STRAND      205    210       {ECO:0000244|PDB:3SOV}.
FT   STRAND      217    220       {ECO:0000244|PDB:3SOV}.
FT   STRAND      227    233       {ECO:0000244|PDB:3SOV}.
FT   STRAND      236    241       {ECO:0000244|PDB:3SOV}.
FT   TURN        242    245       {ECO:0000244|PDB:3SOV}.
FT   STRAND      246    251       {ECO:0000244|PDB:3SOV}.
FT   TURN        252    254       {ECO:0000244|PDB:3SOV}.
FT   STRAND      259    262       {ECO:0000244|PDB:3SOV}.
FT   STRAND      271    274       {ECO:0000244|PDB:3SOV}.
FT   HELIX       276    278       {ECO:0000244|PDB:3SOV}.
FT   TURN        285    289       {ECO:0000244|PDB:3SOV}.
FT   HELIX       290    292       {ECO:0000244|PDB:3SOV}.
FT   STRAND      294    299       {ECO:0000244|PDB:3SOV}.
FT   STRAND      305    309       {ECO:0000244|PDB:3SOV}.
FT   STRAND      328    337       {ECO:0000244|PDB:3S94}.
FT   STRAND      339    346       {ECO:0000244|PDB:3S94}.
FT   STRAND      360    368       {ECO:0000244|PDB:3S94}.
FT   TURN        369    372       {ECO:0000244|PDB:3S94}.
FT   STRAND      373    378       {ECO:0000244|PDB:3S94}.
FT   TURN        379    382       {ECO:0000244|PDB:3S94}.
FT   STRAND      383    388       {ECO:0000244|PDB:3S94}.
FT   STRAND      389    391       {ECO:0000244|PDB:4DG6}.
FT   STRAND      395    398       {ECO:0000244|PDB:3S94}.
FT   STRAND      407    411       {ECO:0000244|PDB:3S94}.
FT   TURN        412    415       {ECO:0000244|PDB:3S94}.
FT   STRAND      416    421       {ECO:0000244|PDB:3S94}.
FT   TURN        422    425       {ECO:0000244|PDB:3S94}.
FT   STRAND      426    431       {ECO:0000244|PDB:3S94}.
FT   STRAND      438    441       {ECO:0000244|PDB:3S94}.
FT   STRAND      447    454       {ECO:0000244|PDB:3S94}.
FT   TURN        455    458       {ECO:0000244|PDB:3S94}.
FT   STRAND      459    464       {ECO:0000244|PDB:3S94}.
FT   STRAND      466    468       {ECO:0000244|PDB:3S94}.
FT   STRAND      470    475       {ECO:0000244|PDB:3S94}.
FT   STRAND      482    485       {ECO:0000244|PDB:3S94}.
FT   STRAND      492    498       {ECO:0000244|PDB:3S94}.
FT   TURN        499    502       {ECO:0000244|PDB:3S94}.
FT   STRAND      503    508       {ECO:0000244|PDB:3S94}.
FT   TURN        509    512       {ECO:0000244|PDB:3S94}.
FT   STRAND      513    521       {ECO:0000244|PDB:3S94}.
FT   STRAND      525    529       {ECO:0000244|PDB:3S94}.
FT   STRAND      538    541       {ECO:0000244|PDB:3S94}.
FT   STRAND      544    548       {ECO:0000244|PDB:3S94}.
FT   STRAND      555    562       {ECO:0000244|PDB:3S94}.
FT   STRAND      565    569       {ECO:0000244|PDB:3S94}.
FT   STRAND      575    584       {ECO:0000244|PDB:3S94}.
FT   HELIX       591    593       {ECO:0000244|PDB:3S94}.
FT   HELIX       595    598       {ECO:0000244|PDB:3S94}.
FT   STRAND      600    606       {ECO:0000244|PDB:3S94}.
FT   STRAND      609    613       {ECO:0000244|PDB:3S94}.
FT   STRAND      633    638       {ECO:0000244|PDB:4A0P}.
FT   STRAND      641    648       {ECO:0000244|PDB:4A0P}.
FT   STRAND      653    655       {ECO:0000244|PDB:4A0P}.
FT   STRAND      664    670       {ECO:0000244|PDB:4A0P}.
FT   TURN        671    674       {ECO:0000244|PDB:4A0P}.
FT   STRAND      675    680       {ECO:0000244|PDB:4A0P}.
FT   TURN        681    684       {ECO:0000244|PDB:4A0P}.
FT   STRAND      685    690       {ECO:0000244|PDB:4A0P}.
FT   STRAND      697    700       {ECO:0000244|PDB:4A0P}.
FT   STRAND      709    713       {ECO:0000244|PDB:4A0P}.
FT   TURN        714    717       {ECO:0000244|PDB:4A0P}.
FT   STRAND      718    723       {ECO:0000244|PDB:4A0P}.
FT   TURN        724    727       {ECO:0000244|PDB:4A0P}.
FT   STRAND      728    733       {ECO:0000244|PDB:4A0P}.
FT   STRAND      740    743       {ECO:0000244|PDB:4A0P}.
FT   STRAND      750    756       {ECO:0000244|PDB:4A0P}.
FT   TURN        757    760       {ECO:0000244|PDB:4A0P}.
FT   STRAND      761    766       {ECO:0000244|PDB:4A0P}.
FT   STRAND      768    770       {ECO:0000244|PDB:4A0P}.
FT   STRAND      772    777       {ECO:0000244|PDB:4A0P}.
FT   STRAND      784    787       {ECO:0000244|PDB:4A0P}.
FT   STRAND      791    799       {ECO:0000244|PDB:4A0P}.
FT   TURN        800    803       {ECO:0000244|PDB:4A0P}.
FT   STRAND      804    809       {ECO:0000244|PDB:4A0P}.
FT   TURN        810    813       {ECO:0000244|PDB:4A0P}.
FT   STRAND      814    819       {ECO:0000244|PDB:4A0P}.
FT   STRAND      826    830       {ECO:0000244|PDB:4A0P}.
FT   STRAND      835    841       {ECO:0000244|PDB:4A0P}.
FT   STRAND      844    849       {ECO:0000244|PDB:4A0P}.
FT   TURN        850    853       {ECO:0000244|PDB:4A0P}.
FT   STRAND      854    859       {ECO:0000244|PDB:4A0P}.
FT   TURN        860    862       {ECO:0000244|PDB:4A0P}.
FT   STRAND      867    870       {ECO:0000244|PDB:4A0P}.
FT   STRAND      878    882       {ECO:0000244|PDB:4A0P}.
FT   HELIX       884    886       {ECO:0000244|PDB:4A0P}.
FT   TURN        892    896       {ECO:0000244|PDB:4A0P}.
FT   HELIX       897    899       {ECO:0000244|PDB:4A0P}.
FT   STRAND      901    907       {ECO:0000244|PDB:4A0P}.
FT   TURN        908    910       {ECO:0000244|PDB:4A0P}.
FT   STRAND      911    915       {ECO:0000244|PDB:4A0P}.
FT   STRAND      933    940       {ECO:0000244|PDB:4A0P}.
FT   STRAND      943    947       {ECO:0000244|PDB:4A0P}.
FT   STRAND      967    973       {ECO:0000244|PDB:4A0P}.
FT   TURN        974    977       {ECO:0000244|PDB:4A0P}.
FT   STRAND      978    983       {ECO:0000244|PDB:4A0P}.
FT   TURN        984    987       {ECO:0000244|PDB:4A0P}.
FT   STRAND      988    993       {ECO:0000244|PDB:4A0P}.
FT   STRAND     1000   1003       {ECO:0000244|PDB:4A0P}.
FT   STRAND     1016   1022       {ECO:0000244|PDB:4A0P}.
FT   TURN       1023   1026       {ECO:0000244|PDB:4A0P}.
FT   STRAND     1027   1032       {ECO:0000244|PDB:4A0P}.
FT   TURN       1033   1036       {ECO:0000244|PDB:4A0P}.
FT   STRAND     1037   1042       {ECO:0000244|PDB:4A0P}.
FT   STRAND     1047   1052       {ECO:0000244|PDB:4A0P}.
FT   STRAND     1059   1065       {ECO:0000244|PDB:4A0P}.
FT   TURN       1066   1069       {ECO:0000244|PDB:4A0P}.
FT   STRAND     1070   1077       {ECO:0000244|PDB:4A0P}.
FT   STRAND     1080   1087       {ECO:0000244|PDB:4A0P}.
FT   STRAND     1094   1097       {ECO:0000244|PDB:4A0P}.
FT   STRAND     1104   1110       {ECO:0000244|PDB:4A0P}.
FT   TURN       1111   1114       {ECO:0000244|PDB:4A0P}.
FT   STRAND     1115   1120       {ECO:0000244|PDB:4A0P}.
FT   TURN       1121   1124       {ECO:0000244|PDB:4A0P}.
FT   STRAND     1125   1130       {ECO:0000244|PDB:4A0P}.
FT   STRAND     1137   1140       {ECO:0000244|PDB:4A0P}.
FT   STRAND     1147   1153       {ECO:0000244|PDB:4A0P}.
FT   STRAND     1156   1161       {ECO:0000244|PDB:4A0P}.
FT   TURN       1162   1165       {ECO:0000244|PDB:4A0P}.
FT   STRAND     1166   1171       {ECO:0000244|PDB:4A0P}.
FT   STRAND     1174   1176       {ECO:0000244|PDB:4A0P}.
FT   STRAND     1179   1182       {ECO:0000244|PDB:4A0P}.
FT   STRAND     1188   1194       {ECO:0000244|PDB:4A0P}.
FT   HELIX      1199   1204       {ECO:0000244|PDB:4A0P}.
FT   TURN       1206   1209       {ECO:0000244|PDB:4A0P}.
FT   HELIX      1210   1213       {ECO:0000244|PDB:4A0P}.
FT   STRAND     1215   1220       {ECO:0000244|PDB:4A0P}.
FT   TURN       1222   1224       {ECO:0000244|PDB:3S8Z}.
FT   STRAND     1226   1229       {ECO:0000244|PDB:4A0P}.
FT   STRAND     1234   1236       {ECO:0000244|PDB:4A0P}.
FT   STRAND     1238   1241       {ECO:0000244|PDB:3S8Z}.
SQ   SEQUENCE   1613 AA;  180429 MW;  413D2CF70A5D8B5C CRC64;
     MGAVLRSLLA CSFCVLLRAA PLLLYANRRD LRLVDATNGK ENATIVVGGL EDAAAVDFVF
     SHGLIYWSDV SEEAIKRTEF NKTESVQNVV VSGLLSPDGL ACDWLGEKLY WTDSETNRIE
     VSNLDGSLRK VLFWQELDQP RAIALDPSSG FMYWTDWGEV PKIERAGMDG SSRFIIINSE
     IYWPNGLTLD YEEQKLYWAD AKLNFIHKSN LDGTNRQAVV KGSLPHPFAL TLFEDILYWT
     DWSTHSILAC NKYTGEGLRE IHSDIFSPMD IHAFSQQRQP NATNPCGIDN GGCSHLCLMS
     PVKPFYQCAC PTGVKLLENG KTCKDGATEL LLLARRTDLR RISLDTPDFT DIVLQLEDIR
     HAIAIDYDPV EGYIYWTDDE VRAIRRSFID GSGSQFVVTA QIAHPDGIAV DWVARNLYWT
     DTGTDRIEVT RLNGTMRKIL ISEDLEEPRA IVLDPMVGYM YWTDWGEIPK IERAALDGSD
     RVVLVNTSLG WPNGLALDYD EGKIYWGDAK TDKIEVMNTD GTGRRVLVED KIPHIFGFTL
     LGDYVYWTDW QRRSIERVHK RSAEREVIID QLPDLMGLKA TNVHRVIGSN PCAEENGGCS
     HLCLYRPQGL RCACPIGFEL ISDMKTCIVP EAFLLFSRRA DIRRISLETN NNNVAIPLTG
     VKEASALDFD VTDNRIYWTD ISLKTISRAF MNGSALEHVV EFGLDYPEGM AVDWLGKNLY
     WADTGTNRIE VSKLDGQHRQ VLVWKDLDSP RALALDPAEG FMYWTEWGGK PKIDRAAMDG
     SERTTLVPNV GRANGLTIDY AKRRLYWTDL DTNLIESSNM LGLNREVIAD DLPHPFGLTQ
     YQDYIYWTDW SRRSIERANK TSGQNRTIIQ GHLDYVMDIL VFHSSRQSGW NECASSNGHC
     SHLCLAVPVG GFVCGCPAHY SLNADNRTCS APTTFLLFSQ KSAINRMVID EQQSPDIILP
     IHSLRNVRAI DYDPLDKQLY WIDSRQNMIR KAQEDGSQGF TVVVSSVPSQ NLEIQPYDLS
     IDIYSRYIYW TCEATNVINV TRLDGRSVGV VLKGEQDRPR AVVVNPEKGY MYFTNLQERS
     PKIERAALDG TEREVLFFSG LSKPIALALD SRLGKLFWAD SDLRRIESSD LSGANRIVLE
     DSNILQPVGL TVFENWLYWI DKQQQMIEKI DMTGREGRTK VQARIAQLSD IHAVKELNLQ
     EYRQHPCAQD NGGCSHICLV KGDGTTRCSC PMHLVLLQDE LSCGEPPTCS PQQFTCFTGE
     IDCIPVAWRC DGFTECEDHS DELNCPVCSE SQFQCASGQC IDGALRCNGD ANCQDKSDEK
     NCEVLCLIDQ FRCANGQCIG KHKKCDHNVD CSDKSDELDC YPTEEPAPQA TNTVGSVIGV
     IVTIFVSGTV YFICQRMLCP RMKGDGETMT NDYVVHGPAS VPLGYVPHPS SLSGSLPGMS
     RGKSMISSLS IMGGSSGPPY DRAHVTGASS SSSSSTKGTY FPAILNPPPS PATERSHYTM
     EFGYSSNSPS THRSYSYRPY SYRHFAPPTT PCSTDVCDSD YAPSRRMTSV ATAKGYTSDL
     NYDSEPVPPP PTPRSQYLSA EENYESCPPS PYTERSYSHH LYPPPPSPCT DSS
//
ID   CADH1_HUMAN             Reviewed;         882 AA.
AC   P12830; A8K1U7; Q13799; Q14216; Q15855; Q16194; Q4PJ14; Q9UII8;
DT   01-OCT-1989, integrated into UniProtKB/Swiss-Prot.
DT   01-JUL-1993, sequence version 3.
DT   17-FEB-2016, entry version 203.
DE   RecName: Full=Cadherin-1;
DE   AltName: Full=CAM 120/80;
DE   AltName: Full=Epithelial cadherin;
DE            Short=E-cadherin;
DE   AltName: Full=Uvomorulin;
DE   AltName: CD_antigen=CD324;
DE   Contains:
DE     RecName: Full=E-Cad/CTF1;
DE   Contains:
DE     RecName: Full=E-Cad/CTF2;
DE   Contains:
DE     RecName: Full=E-Cad/CTF3;
DE   Flags: Precursor;
GN   Name=CDH1; Synonyms=CDHE, UVO;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Pancreas;
RX   PubMed=8459805; DOI=10.1007/BF00996219;
RA   Bussemakers M.J.G., Mees S.G.M., van Bokhoven A., Debruyne F.M.J.,
RA   Schalken J.A.;
RT   "Molecular cloning and characterization of the human E-cadherin
RT   cDNA.";
RL   Mol. Biol. Rep. 17:123-128(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT 274-GLY--PRO-277
RP   DEL.
RX   PubMed=8127895; DOI=10.1073/pnas.91.5.1858;
RA   Oda T., Kanai Y., Oyama T., Yoshiura K., Shimoyama Y., Birchmeier W.,
RA   Sugimura T., Hirohashi S.;
RT   "E-cadherin gene mutations in human gastric carcinoma cell lines.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:1858-1862(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Liver;
RX   PubMed=8185635; DOI=10.1006/bbrc.1994.1656;
RA   Rimm D.L., Morrow J.S.;
RT   "Molecular cloning of human E-cadherin suggests a novel subdivision of
RT   the cadherin superfamily.";
RL   Biochem. Biophys. Res. Commun. 200:1754-1761(1994).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PROTEIN SEQUENCE OF 586-591,
RP   PROTEOLYTIC PROCESSING, AND SUBCELLULAR LOCATION.
RC   TISSUE=Epidermal carcinoma;
RX   PubMed=10597309; DOI=10.1038/sj.onc.1203191;
RA   Ito K., Okamoto I., Araki N., Kawano Y., Nakao M., Fujiyama S.,
RA   Tomita K., Mimori T., Saya H.;
RT   "Calcium influx triggers the sequential proteolysis of extracellular
RT   and cytoplasmic domains of E-cadherin, leading to loss of beta-catenin
RT   from cell-cell contacts.";
RL   Oncogene 18:7080-7090(1999).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RA   Shibamoto S., Fukudome Y., Yanagihara K.;
RT   "Mutant E-cadherin.";
RL   Submitted (MAR-1999) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Hippocampus, and Tongue;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS PRO-478; THR-617;
RP   MET-832 AND LYS-880.
RG   NIEHS SNPs program;
RL   Submitted (JUN-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15616553; DOI=10.1038/nature03187;
RA   Martin J., Han C., Gordon L.A., Terry A., Prabhakar S., She X.,
RA   Xie G., Hellsten U., Chan Y.M., Altherr M., Couronne O., Aerts A.,
RA   Bajorek E., Black S., Blumer H., Branscomb E., Brown N.C., Bruno W.J.,
RA   Buckingham J.M., Callen D.F., Campbell C.S., Campbell M.L.,
RA   Campbell E.W., Caoile C., Challacombe J.F., Chasteen L.A.,
RA   Chertkov O., Chi H.C., Christensen M., Clark L.M., Cohn J.D.,
RA   Denys M., Detter J.C., Dickson M., Dimitrijevic-Bussod M., Escobar J.,
RA   Fawcett J.J., Flowers D., Fotopulos D., Glavina T., Gomez M.,
RA   Gonzales E., Goodstein D., Goodwin L.A., Grady D.L., Grigoriev I.,
RA   Groza M., Hammon N., Hawkins T., Haydu L., Hildebrand C.E., Huang W.,
RA   Israni S., Jett J., Jewett P.B., Kadner K., Kimball H., Kobayashi A.,
RA   Krawczyk M.-C., Leyba T., Longmire J.L., Lopez F., Lou Y., Lowry S.,
RA   Ludeman T., Manohar C.F., Mark G.A., McMurray K.L., Meincke L.J.,
RA   Morgan J., Moyzis R.K., Mundt M.O., Munk A.C., Nandkeshwar R.D.,
RA   Pitluck S., Pollard M., Predki P., Parson-Quintana B., Ramirez L.,
RA   Rash S., Retterer J., Ricke D.O., Robinson D.L., Rodriguez A.,
RA   Salamov A., Saunders E.H., Scott D., Shough T., Stallings R.L.,
RA   Stalvey M., Sutherland R.D., Tapia R., Tesmer J.G., Thayer N.,
RA   Thompson L.S., Tice H., Torney D.C., Tran-Gyamfi M., Tsai M.,
RA   Ulanovsky L.E., Ustaszewska A., Vo N., White P.S., Williams A.L.,
RA   Wills P.L., Wu J.-R., Wu K., Yang J., DeJong P., Bruce D.,
RA   Doggett N.A., Deaven L., Schmutz J., Grimwood J., Richardson P.,
RA   Rokhsar D.S., Eichler E.E., Gilna P., Lucas S.M., Myers R.M.,
RA   Rubin E.M., Pennacchio L.A.;
RT   "The sequence and analysis of duplication-rich human chromosome 16.";
RL   Nature 432:988-994(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-16.
RX   PubMed=8093045; DOI=10.1006/bbrc.1994.2321;
RA   Bussemakers M.J.G., Giroldi L.A., van Bokhoven A., Schalken J.A.;
RT   "Transcriptional regulation of the human E-cadherin gene in human
RT   prostate cancer cell lines: characterization of the human E-cadherin
RT   gene promoter.";
RL   Biochem. Biophys. Res. Commun. 203:1284-1290(1994).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-16.
RC   TISSUE=Placenta;
RX   PubMed=7543680; DOI=10.1073/pnas.92.16.7416;
RA   Yoshiura K., Kanai Y., Ochiai A., Shimoyama Y., Sugimura T.,
RA   Hirohashi S.;
RT   "Silencing of the E-cadherin invasion-suppressor gene by CpG
RT   methylation in human carcinomas.";
RL   Proc. Natl. Acad. Sci. U.S.A. 92:7416-7419(1995).
RN   [12]
RP   INTERACTION WITH PIP5K1C.
RX   PubMed=17261850; DOI=10.1083/jcb.200606023;
RA   Ling K., Bairstow S.F., Carbonara C., Turbin D.A., Huntsman D.G.,
RA   Anderson R.A.;
RT   "Type I gamma phosphatidylinositol phosphate kinase modulates adherens
RT   junction and E-cadherin trafficking via a direct interaction with mu
RT   1B adaptin.";
RL   J. Cell Biol. 176:343-353(2007).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 56-882.
RC   TISSUE=Placenta;
RX   PubMed=7601454; DOI=10.1016/0888-7543(95)80212-5;
RA   Berx G., Staes K., van Hengel J., Molemans F., Bussemakers M.J.G.,
RA   van Bokhoven A., van Roy F.;
RT   "Cloning and characterization of the human invasion suppressor gene E-
RT   cadherin (CDH1).";
RL   Genomics 26:281-289(1995).
RN   [14]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 172-311 (ISOFORM 1/2).
RC   TISSUE=Liver;
RX   PubMed=3263290; DOI=10.1111/j.1432-0436.1988.tb00593.x;
RA   Mansouri A., Spurr N., Goodfellow P.N., Kemler R.;
RT   "Characterization and chromosomal localization of the gene encoding
RT   the human cell adhesion molecule uvomorulin.";
RL   Differentiation 38:67-71(1988).
RN   [15]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 265-392 (ISOFORM 1).
RC   TISSUE=Liver;
RA   Frixen U.H.;
RL   Submitted (MAR-1990) to the EMBL/GenBank/DDBJ databases.
RN   [16]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 337-476, AND VARIANTS ALA-370 AND
RP   ASP-473.
RX   PubMed=8033105;
RA   Becker K.-F., Atkinson M.J., Reich U., Becker I., Nekarda H.,
RA   Siewert J.R., Hoefler H.;
RT   "E-cadherin gene mutations provide clues to diffuse type gastric
RT   carcinomas.";
RL   Cancer Res. 54:3845-3852(1994).
RN   [17]
RP   PROTEIN SEQUENCE OF 701-714 AND 732-742, PROTEOLYTIC PROCESSING BY
RP   GAMMA-SECRETASE/PS1 AND A MEMBRANE-BOUND METALLOPROTEINASE, AND
RP   MUTAGENESIS OF 759-GLY--GLY-761.
RX   PubMed=11953314; DOI=10.1093/emboj/21.8.1948;
RA   Marambaud P., Shioi J., Serban G., Georgakopoulos A., Sarner S.,
RA   Nagy V., Baki L., Wen P., Efthimiopoulos S., Shao Z., Wisniewski T.,
RA   Robakis N.K.;
RT   "A presenilin-1/gamma-secretase cleavage releases the E-cadherin
RT   intracellular domain and regulates disassembly of adherens
RT   junctions.";
RL   EMBO J. 21:1948-1956(2002).
RN   [18]
RP   DOMAIN CATENIN-BINDING.
RX   PubMed=2349235; DOI=10.1073/pnas.87.11.4246;
RA   Ozawa M., Ringwald M., Kemler R.;
RT   "Uvomorulin-catenin complex formation is regulated by a specific
RT   domain in the cytoplasmic region of the cell adhesion molecule.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:4246-4250(1990).
RN   [19]
RP   IDENTIFICATION IN AN E-CADHERIN/CATENIN ADHESION COMPLEX.
RX   PubMed=7982500; DOI=10.1016/0014-5793(94)01205-9;
RA   Butz S., Kemler R.;
RT   "Distinct cadherin-catenin complexes in Ca(2+)-dependent cell-cell
RT   adhesion.";
RL   FEBS Lett. 355:195-200(1994).
RN   [20]
RP   PROTEOLYTIC PROCESSING.
RX   PubMed=11076937; DOI=10.1074/jbc.M006102200;
RA   Steinhusen U., Weiske J., Badock V., Tauber R., Bommert K., Huber O.;
RT   "Cleavage and shedding of E-cadherin after induction of apoptosis.";
RL   J. Biol. Chem. 276:4972-4980(2001).
RN   [21]
RP   INTERACTION WITH PSEN1.
RX   PubMed=11226248; DOI=10.1073/pnas.041603398;
RA   Baki L., Marambaud P., Efthimiopoulos S., Georgakopoulos A., Wen P.,
RA   Cui W., Shioi J., Koo E., Ozawa M., Friedrich V.L., Robakis N.K.;
RT   "Presenilin-1 binds cytoplasmic epithelial cadherin, inhibits
RT   cadherin/p120 association, and regulates stability and function of the
RT   cadherin/catenin adhesion complex.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:2381-2386(2001).
RN   [22]
RP   INTERCHAIN DISULFIDE BOND.
RX   PubMed=11856755; DOI=10.1074/jbc.M200916200;
RA   Makagiansar I.T., Nguyen P.D., Ikesue A., Kuczera K., Dentler W.,
RA   Urbauer J.L., Galeva N., Alterman M., Siahaan T.J.;
RT   "Disulfide bond formation promotes the cis- and trans-dimerization of
RT   the E-cadherin-derived first repeat.";
RL   J. Biol. Chem. 277:16002-16010(2002).
RN   [23]
RP   INTERACTION WITH DLGAP5, AND SUBCELLULAR LOCATION.
RX   PubMed=14699157; DOI=10.1074/jbc.M309843200;
RA   Laprise P., Viel A., Rivard N.;
RT   "Human homolog of disc-large is required for adherens junction
RT   assembly and differentiation of human intestinal epithelial cells.";
RL   J. Biol. Chem. 279:10157-10166(2004).
RN   [24]
RP   INTERACTION WITH AJAP1.
RC   TISSUE=Brain;
RX   PubMed=14595118; DOI=10.1091/mbc.E03-05-0281;
RA   Bharti S., Handrow-Metzmacher H., Zickenheiner S., Zeitvogel A.,
RA   Baumann R., Starzinski-Powitz A.;
RT   "Novel membrane protein shrew-1 targets to cadherin-mediated junctions
RT   in polarized epithelial cells.";
RL   Mol. Biol. Cell 15:397-406(2004).
RN   [25]
RP   INTERACTION WITH WITH PSEN1 AND CTNNB1, AND MUTAGENESIS OF
RP   759-GLY--GLY-761.
RX   PubMed=16126725; DOI=10.1074/jbc.M507503200;
RA   Serban G., Kouchi Z., Baki L., Georgakopoulos A., Litterst C.M.,
RA   Shioi J., Robakis N.K.;
RT   "Cadherins mediate both the association between PS1 and beta-catenin
RT   and the effects of PS1 on beta-catenin stability.";
RL   J. Biol. Chem. 280:36007-36012(2005).
RN   [26]
RP   SUBCELLULAR LOCATION.
RX   PubMed=15689490; DOI=10.1091/mbc.E04-10-0867;
RA   Lock J.G., Stow J.L.;
RT   "Rab11 in recycling endosomes regulates the sorting and basolateral
RT   transport of E-cadherin.";
RL   Mol. Biol. Cell 16:1744-1755(2005).
RN   [27]
RP   FUNCTION OF E-CAD/CTF2.
RX   PubMed=16417575; DOI=10.1111/j.1471-4159.2005.03616.x;
RA   Agiostratidou G., Muros R.M., Shioi J., Marambaud P., Robakis N.K.;
RT   "The cytoplasmic sequence of E-cadherin promotes non-amyloidogenic
RT   degradation of A beta precursors.";
RL   J. Neurochem. 96:1182-1188(2006).
RN   [28]
RP   INDUCTION.
RX   PubMed=17893710; DOI=10.1038/cr.2007.79;
RA   Meng Y.G., Han W.-D., Zhao Y.-L., Huang K., Si Y.-L., Wu Z.-Q.,
RA   Mu Y.-M.;
RT   "Induction of the LRP16 gene by estrogen promotes the invasive growth
RT   of Ishikawa human endometrial cancer cells through the downregulation
RT   of E-cadherin.";
RL   Cell Res. 17:869-880(2007).
RN   [29]
RP   INVOLVEMENT IN LBC.
RX   PubMed=17660459; DOI=10.1136/jmg.2007.051268;
RA   Masciari S., Larsson N., Senz J., Boyd N., Kaurah P., Kandel M.J.,
RA   Harris L.N., Pinheiro H.C., Troussard A., Miron P., Tung N.,
RA   Oliveira C., Collins L., Schnitt S., Garber J.E., Huntsman D.;
RT   "Germline E-cadherin mutations in familial lobular breast cancer.";
RL   J. Med. Genet. 44:726-731(2007).
RN   [30]
RP   GLYCOSYLATION AT ASN-558; ASN-570; ASN-622 AND ASN-637, AND
RP   MUTAGENESIS OF ASN-637.
RX   PubMed=18491227; DOI=10.1007/s10719-008-9133-9;
RA   Zhou F., Su J., Fu L., Yang Y., Zhang L., Wang L., Zhao H., Zhang D.,
RA   Li Z., Zha X.;
RT   "Unglycosylation at Asn-633 made extracellular domain of E-cadherin
RT   folded incorrectly and arrested in endoplasmic reticulum, then
RT   sequentially degraded by ERAD.";
RL   Glycoconj. J. 25:727-740(2008).
RN   [31]
RP   INTERACTION WITH LIMA1.
RX   PubMed=18093941; DOI=10.1073/pnas.0710504105;
RA   Abe K., Takeichi M.;
RT   "EPLIN mediates linkage of the cadherin catenin complex to F-actin and
RT   stabilizes the circumferential actin belt.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:13-19(2008).
RN   [32]
RP   REVIEW ON CADHERINS.
RX   PubMed=20066110; DOI=10.1101/cshperspect.a003053;
RA   Shapiro L., Weis W.I.;
RT   "Structure and biochemistry of cadherins and catenins.";
RL   Cold Spring Harb. Perspect. Biol. 1:A3053-A3053(2009).
RN   [33]
RP   INTERACTION WITH TBC1D2.
RX   PubMed=20116244; DOI=10.1016/j.cub.2009.12.053;
RA   Frasa M.A., Maximiano F.C., Smolarczyk K., Francis R.E., Betson M.E.,
RA   Lozano E., Goldenring J., Seabra M.C., Rak A., Ahmadian M.R.,
RA   Braga V.M.;
RT   "Armus is a Rac1 effector that inactivates Rab7 and regulates E-
RT   cadherin degradation.";
RL   Curr. Biol. 20:198-208(2010).
RN   [34]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH DDR1.
RX   PubMed=20432435; DOI=10.1002/jcp.22134;
RA   Eswaramoorthy R., Wang C.K., Chen W.C., Tang M.J., Ho M.L.,
RA   Hwang C.C., Wang H.M., Wang C.Z.;
RT   "DDR1 regulates the stabilization of cell surface E-cadherin and E-
RT   cadherin-mediated cell aggregation.";
RL   J. Cell. Physiol. 224:387-397(2010).
RN   [35]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [36]
RP   UBIQUITINATION BY CBLL1.
RX   PubMed=21283129; DOI=10.1038/cr.2011.17;
RA   Zhou W.J., Geng Z.H., Chi S., Zhang W., Niu X.F., Lan S.J., Ma L.,
RA   Yang X., Wang L.J., Ding Y.Q., Geng J.G.;
RT   "Slit-Robo signaling induces malignant transformation through Hakai-
RT   mediated E-cadherin degradation during colorectal epithelial cell
RT   carcinogenesis.";
RL   Cell Res. 21:609-626(2011).
RN   [37]
RP   UBIQUITINATION BY A SKP2-CONTAINING SCF COMPLEX, AND PHOSPHORYLATION
RP   BY CSNK1A1.
RX   PubMed=22770219; DOI=10.1016/j.cell.2012.05.038;
RA   Inuzuka H., Gao D., Finley L.W., Yang W., Wan L., Fukushima H.,
RA   Chin Y.R., Zhai B., Shaik S., Lau A.W., Wang Z., Gygi S.P.,
RA   Nakayama K., Teruya-Feldstein J., Toker A., Haigis M.C.,
RA   Pandolfi P.P., Wei W.;
RT   "Acetylation-dependent regulation of Skp2 function.";
RL   Cell 150:179-193(2012).
RN   [38]
RP   PHOSPHORYLATION AT TYR-753; TYR-754 AND TYR-755, AND MUTAGENESIS OF
RP   TYR-754.
RX   PubMed=22252131; DOI=10.1038/emboj.2011.496;
RA   Mukherjee M., Chow S.Y., Yusoff P., Seetharaman J., Ng C., Sinniah S.,
RA   Koh X.W., Asgar N.F., Li D., Yim D., Jackson R.A., Yew J., Qian J.,
RA   Iyu A., Lim Y.P., Zhou X., Sze S.K., Guy G.R., Sivaraman J.;
RT   "Structure of a novel phosphotyrosine-binding domain in Hakai that
RT   targets E-cadherin.";
RL   EMBO J. 31:1308-1319(2012).
RN   [39]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-770 AND SER-793, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [40]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 156-255 IN COMPLEX WITH
RP   LISTERIA INTERNALIN.
RX   PubMed=12526809; DOI=10.1016/S0092-8674(02)01136-4;
RA   Schubert W.-D., Urbanke C., Ziehm T., Beier V., Machner M.P.,
RA   Domann E., Wehland J., Chakraborty T., Heinz D.W.;
RT   "Structure of internalin, a major invasion protein of Listeria
RT   monocytogenes, in complex with its human receptor E-cadherin.";
RL   Cell 111:825-836(2002).
RN   [41]
RP   REVIEW ON VARIANTS.
RX   PubMed=9744472;
RX   DOI=10.1002/(SICI)1098-1004(1998)12:4<226::AID-HUMU2>3.0.CO;2-D;
RA   Berx G., Becker K.-F., Hoefler H., van Roy F.;
RT   "Mutations of the human E-cadherin (CDH1) gene.";
RL   Hum. Mutat. 12:226-237(1998).
RN   [42]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 155-367, AND CALCIUM-BINDING
RP   SITES.
RX   PubMed=17850815; DOI=10.1016/j.jmb.2007.08.011;
RA   Parisini E., Higgins J.M., Liu J.H., Brenner M.B., Wang J.H.;
RT   "The crystal structure of human E-cadherin domains 1 and 2, and
RT   comparison with other cadherins in the context of adhesion
RT   mechanism.";
RL   J. Mol. Biol. 373:401-411(2007).
RN   [43]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 155-253 IN COMPLEX WITH
RP   KLRG1.
RX   PubMed=19604491; DOI=10.1016/j.immuni.2009.04.019;
RA   Li Y., Hofmann M., Wang Q., Teng L., Chlewicki L.K., Pircher H.,
RA   Mariuzza R.A.;
RT   "Structure of natural killer cell receptor KLRG1 bound to E-cadherin
RT   reveals basis for MHC-independent missing self recognition.";
RL   Immunity 31:35-46(2009).
RN   [44]
RP   VARIANT LOBULAR BREAST CARCINOMA SER-315.
RX   PubMed=7961105; DOI=10.1111/j.1349-7006.1994.tb02902.x;
RA   Kanai Y., Oda T., Tsuda H., Ochiai A., Hirohashi S.;
RT   "Point mutation of the E-cadherin gene in invasive lobular carcinoma
RT   of the breast.";
RL   Jpn. J. Cancer Res. 85:1035-1039(1994).
RN   [45]
RP   VARIANTS THR-617 AND VAL-711, AND VARIANT OVARIAN CANCER GLY-838.
RX   PubMed=8075649; DOI=10.1038/ng0594-98;
RA   Risinger J.I., Berchuck A., Kohler M.F., Boyd J.;
RT   "Mutations of the E-cadherin gene in human gynecologic cancers.";
RL   Nat. Genet. 7:98-102(1994).
RN   [46]
RP   VARIANT PRO-193.
RX   PubMed=8797891; DOI=10.1111/j.1349-7006.1996.tb02109.x;
RA   Muta H., Noguchi M., Kanai Y., Ochiai A., Nawata H., Hirohashi S.;
RT   "E-cadherin gene mutations in signet ring cell carcinoma of the
RT   stomach.";
RL   Jpn. J. Cancer Res. 87:843-848(1996).
RN   [47]
RP   VARIANTS ASP-400 DEL AND 418-ASP--PHE-423 DEL.
RX   PubMed=9045944; DOI=10.1111/j.1349-7006.1996.tb03125.x;
RA   Tamura G., Sakata K., Nishizuka S., Maesawa C., Suzuki Y., Iwaya T.,
RA   Terashima M., Saito K., Satodate R.;
RT   "Inactivation of the E-cadherin gene in primary gastric carcinomas and
RT   gastric carcinoma cell lines.";
RL   Jpn. J. Cancer Res. 87:1153-1159(1996).
RN   [48]
RP   VARIANT THYROID CANCER THR-592.
RX   PubMed=8985087;
RX   DOI=10.1002/(SICI)1097-0215(19970106)70:1<32::AID-IJC5>3.0.CO;2-7;
RA   Soares P., Berx G., van Roy F., Sobrinho-Simoes M.;
RT   "E-cadherin gene alterations are rare events in thyroid tumors.";
RL   Int. J. Cancer 70:32-38(1997).
RN   [49]
RP   VARIANTS ASP-336 AND ILE-470.
RX   PubMed=9537325; DOI=10.1038/32918;
RA   Guilford P.J., Hopkins J.B.W., Harraway J., McLeod M., McLeod N.,
RA   Harawira P., Taite H., Scoular R., Miller A., Reeve A.E.;
RT   "E-cadherin germline mutations in familial gastric cancer.";
RL   Nature 392:402-405(1998).
RN   [50]
RP   VARIANTS HDGC GLY-244 AND ALA-487.
RX   PubMed=10319582; DOI=10.1007/s100380050137;
RA   Yoon K.-A., Ku J.-L., Yang H.-K., Kim W.H., Park S.Y., Park J.-G.;
RT   "Germline mutations of E-cadherin gene in Korean familial gastric
RT   cancer patients.";
RL   J. Hum. Genet. 44:177-180(1999).
RN   [51]
RP   VARIANT ALA-340.
RX   PubMed=10896919; DOI=10.1136/gut.47.2.262;
RA   Kim H.C., Wheeler J.M.D., Kim J.C., Ilyas M., Beck N.E., Kim B.S.,
RA   Park K.C., Bodmer W.F.;
RT   "The E-cadherin gene (CDH1) variants T340A and L599V in gastric and
RT   colorectal cancer patients in Korea.";
RL   Gut 47:262-267(2000).
RN   [52]
RP   VARIANT ALA-270.
RX   PubMed=11705864;
RA   Ikonen T., Matikainen M., Mononen N., Hyytinen E.R., Helin H.J.,
RA   Tommola S., Tammela T.L., Pukkala E., Schleutker J.,
RA   Kallioniemi O.-P., Koivisto P.A.;
RT   "Association of E-cadherin germ-line alterations with prostate
RT   cancer.";
RL   Clin. Cancer Res. 7:3465-3471(2001).
RN   [53]
RP   VARIANT THR-592.
RX   PubMed=11562785;
RA   Salahshor S., Hou H., Diep C.B., Loukola A., Zhang H., Liu T.,
RA   Chen J., Iselius L., Rubio C., Lothe R.A., Aaltonen L., Sun X.F.,
RA   Lindmark G., Lindblom A.;
RT   "A germline E-cadherin mutation in a family with gastric and colon
RT   cancer.";
RL   Int. J. Mol. Med. 8:439-443(2001).
RN   [54]
RP   VARIANT ALA-340.
RX   PubMed=11968083; DOI=10.1002/humu.10068;
RA   Oliveira C., Bordin M.C., Grehan N., Huntsman D., Suriano G.,
RA   Machado J.C., Kiviluoto T., Aaltonen L., Jackson C.E., Seruca R.,
RA   Caldas C.;
RT   "Screening E-cadherin in gastric cancer families reveals germline
RT   mutations only in hereditary diffuse gastric cancer kindred.";
RL   Hum. Mutat. 19:510-517(2002).
RN   [55]
RP   VARIANT HDGC MET-832.
RX   PubMed=12216071; DOI=10.1002/ijc.10633;
RA   Yabuta T., Shinmura K., Tani M., Yamaguchi S., Yoshimura K., Katai H.,
RA   Nakajima T., Mochiki E., Tsujinaka T., Takami M., Hirose K.,
RA   Yamaguchi A., Takenoshita S., Yokota J.;
RT   "E-cadherin gene variants in gastric cancer families whose probands
RT   are diagnosed with diffuse gastric cancer.";
RL   Int. J. Cancer 101:434-441(2002).
RN   [56]
RP   VARIANTS THR-617 AND VAL-634, AND CHARACTERIZATION OF VARIANTS
RP   ALA-340; THR-617 AND VAL-634.
RX   PubMed=12588804; DOI=10.1093/hmg/ddg048;
RA   Suriano G., Oliveira C., Ferreira P., Machado J.C., Bordin M.C.,
RA   De Wever O., Bruyneel E.A., Moguilevsky N., Grehan N., Porter T.R.,
RA   Richards F.M., Hruban R.H., Roviello F., Huntsman D., Mareel M.,
RA   Carneiro F., Caldas C., Seruca R.;
RT   "Identification of CDH1 germline missense mutations associated with
RT   functional inactivation of the E-cadherin protein in young gastric
RT   cancer probands.";
RL   Hum. Mol. Genet. 12:575-582(2003).
RN   [57]
RP   VARIANTS ILE-282 AND ASN-777.
RX   PubMed=17224074; DOI=10.1186/bcr1637;
RA   Chanock S.J., Burdett L., Yeager M., Llaca V., Langeroed A.,
RA   Presswalla S., Kaaresen R., Strausberg R.L., Gerhard D.S.,
RA   Kristensen V., Perou C.M., Boerresen-Dale A.-L.;
RT   "Somatic sequence alterations in twenty-one genes selected by
RT   expression profile analysis of breast carcinomas.";
RL   Breast Cancer Res. 9:R5-R5(2007).
CC   -!- FUNCTION: Cadherins are calcium-dependent cell adhesion proteins.
CC       They preferentially interact with themselves in a homophilic
CC       manner in connecting cells; cadherins may thus contribute to the
CC       sorting of heterogeneous cell types. CDH1 is involved in
CC       mechanisms regulating cell-cell adhesions, mobility and
CC       proliferation of epithelial cells. Has a potent invasive
CC       suppressor role. It is a ligand for integrin alpha-E/beta-7.
CC       {ECO:0000269|PubMed:16417575}.
CC   -!- FUNCTION: E-Cad/CTF2 promotes non-amyloidogenic degradation of
CC       Abeta precursors. Has a strong inhibitory effect on APP C99 and
CC       C83 production. {ECO:0000269|PubMed:16417575}.
CC   -!- SUBUNIT: Homodimer; disulfide-linked. Component of an E-cadherin/
CC       catenin adhesion complex composed of at least E-cadherin/CDH1,
CC       beta-catenin/CTNNB1 or gamma-catenin/JUP, and potentially alpha-
CC       catenin/CTNNA1; the complex is located to adherens junctions. The
CC       stable association of CTNNA1 is controversial as CTNNA1 was shown
CC       not to bind to F-actin when assembled in the complex.
CC       Alternatively, the CTNNA1-containing complex may be linked to F-
CC       actin by other proteins such as LIMA1. Interaction with PSEN1,
CC       cleaves CDH1 resulting in the disassociation of cadherin-based
CC       adherens junctions (CAJs). Interacts with AJAP1, CTNND1 and DLGAP5
CC       (By similarity). Interacts with TBC1D2. Interacts with LIMA1.
CC       Interacts with CAV1. Interacts with the TRPV4 and CTNNB1 complex
CC       (By similarity). Interacts with PIP5K1C. Interacts with RAB8B (By
CC       similarity). Interacts with RAPGEF2 (By similarity). Interacts
CC       with DDR1; this stabilizes CDH1 at the cell surface and inhibits
CC       its internalization. {ECO:0000250, ECO:0000269|PubMed:11226248,
CC       ECO:0000269|PubMed:12526809, ECO:0000269|PubMed:14595118,
CC       ECO:0000269|PubMed:14699157, ECO:0000269|PubMed:16126725,
CC       ECO:0000269|PubMed:17261850, ECO:0000269|PubMed:18093941,
CC       ECO:0000269|PubMed:19604491, ECO:0000269|PubMed:20116244,
CC       ECO:0000269|PubMed:20432435, ECO:0000269|PubMed:7982500}.
CC   -!- INTERACTION:
CC       Q9JIY2:Cbll1 (xeno); NbExp=21; IntAct=EBI-727477, EBI-7644904;
CC       P30260:CDC27; NbExp=2; IntAct=EBI-727477, EBI-994813;
CC       P35222:CTNNB1; NbExp=11; IntAct=EBI-727477, EBI-491549;
CC       P00533:EGFR; NbExp=3; IntAct=EBI-727477, EBI-297353;
CC       P11362:FGFR1; NbExp=3; IntAct=EBI-727477, EBI-1028277;
CC       P62136:PPP1CA; NbExp=2; IntAct=EBI-727477, EBI-357253;
CC       Q15139:PRKD1; NbExp=7; IntAct=EBI-727477, EBI-1181072;
CC       P12931:SRC; NbExp=2; IntAct=EBI-727477, EBI-621482;
CC       Q68CZ2:TNS3; NbExp=2; IntAct=EBI-727477, EBI-1220488;
CC   -!- SUBCELLULAR LOCATION: Cell junction. Cell membrane; Single-pass
CC       type I membrane protein. Endosome. Golgi apparatus, trans-Golgi
CC       network. Note=Colocalizes with DLGAP5 at sites of cell-cell
CC       contact in intestinal epithelial cells. Anchored to actin
CC       microfilaments through association with alpha-, beta- and gamma-
CC       catenin. Sequential proteolysis induced by apoptosis or calcium
CC       influx, results in translocation from sites of cell-cell contact
CC       to the cytoplasm. Colocalizes with RAB11A endosomes during its
CC       transport from the Golgi apparatus to the plasma membrane.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P12830-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P12830-2; Sequence=VSP_055586;
CC   -!- TISSUE SPECIFICITY: Non-neural epithelial tissues.
CC   -!- INDUCTION: Expression is repressed by MACROD1.
CC       {ECO:0000269|PubMed:17893710}.
CC   -!- DOMAIN: Three calcium ions are usually bound at the interface of
CC       each cadherin domain and rigidify the connections, imparting a
CC       strong curvature to the full-length ectodomain.
CC       {ECO:0000269|PubMed:2349235}.
CC   -!- PTM: During apoptosis or with calcium influx, cleaved by a
CC       membrane-bound metalloproteinase (ADAM10), PS1/gamma-secretase and
CC       caspase-3 to produce fragments of about 38 kDa (E-CAD/CTF1), 33
CC       kDa (E-CAD/CTF2) and 29 kDa (E-CAD/CTF3), respectively. Processing
CC       by the metalloproteinase, induced by calcium influx, causes
CC       disruption of cell-cell adhesion and the subsequent release of
CC       beta-catenin into the cytoplasm. The residual membrane-tethered
CC       cleavage product is rapidly degraded via an intracellular
CC       proteolytic pathway. Cleavage by caspase-3 releases the
CC       cytoplasmic tail resulting in disintegration of the actin
CC       microfilament system. The gamma-secretase-mediated cleavage
CC       promotes disassembly of adherens junctions.
CC       {ECO:0000269|PubMed:10597309, ECO:0000269|PubMed:11076937,
CC       ECO:0000269|PubMed:11953314}.
CC   -!- PTM: N-glycosylation at Asn-637 is essential for expression,
CC       folding and trafficking. {ECO:0000269|PubMed:18491227}.
CC   -!- PTM: Ubiquitinated by a SCF complex containing SKP2, which
CC       requires prior phosphorylation by CK1/CSNK1A1. Ubiquitinated by
CC       CBLL1/HAKAI, requires prior phosphorylation at Tyr-754.
CC       {ECO:0000269|PubMed:21283129, ECO:0000269|PubMed:22252131,
CC       ECO:0000269|PubMed:22770219}.
CC   -!- DISEASE: Hereditary diffuse gastric cancer (HDGC) [MIM:137215]: A
CC       cancer predisposition syndrome with increased susceptibility to
CC       diffuse gastric cancer. Diffuse gastric cancer is a malignant
CC       disease characterized by poorly differentiated infiltrating
CC       lesions resulting in thickening of the stomach. Malignant tumors
CC       start in the stomach, can spread to the esophagus or the small
CC       intestine, and can extend through the stomach wall to nearby lymph
CC       nodes and organs. It also can metastasize to other parts of the
CC       body. {ECO:0000269|PubMed:10319582, ECO:0000269|PubMed:12216071}.
CC       Note=Disease susceptibility is associated with variations
CC       affecting the gene represented in this entry. Heterozygous CDH1
CC       germline mutations are responsible for familial cases of diffuse
CC       gastric cancer. Somatic mutations has also been found in patients
CC       with sporadic diffuse gastric cancer and lobular breast cancer.
CC   -!- DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of
CC       endometrium, the mucous lining of the uterus. Most endometrial
CC       cancers are adenocarcinomas, cancers that begin in cells that make
CC       and release mucus and other fluids. Note=Disease susceptibility is
CC       associated with variations affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Ovarian cancer (OC) [MIM:167000]: The term ovarian cancer
CC       defines malignancies originating from ovarian tissue. Although
CC       many histologic types of ovarian tumors have been described,
CC       epithelial ovarian carcinoma is the most common form. Ovarian
CC       cancers are often asymptomatic and the recognized signs and
CC       symptoms, even of late-stage disease, are vague. Consequently,
CC       most patients are diagnosed with advanced disease.
CC       {ECO:0000269|PubMed:8075649}. Note=Disease susceptibility is
CC       associated with variations affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Breast cancer, lobular (LBC) [MIM:137215]: A type of
CC       breast cancer that begins in the milk-producing glands (lobules)
CC       of the breast. {ECO:0000269|PubMed:17660459}. Note=The gene
CC       represented in this entry may be involved in disease pathogenesis.
CC   -!- SIMILARITY: Contains 5 cadherin domains. {ECO:0000255|PROSITE-
CC       ProRule:PRU00043}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA61259.1; Type=Frameshift; Positions=16, 22, 25, 28, 31, 34, 52, 67, 73, 76, 94, 102, 633, 636; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/CDH1ID166ch16q22.html";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/cdh1/";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=E-cadherin entry;
CC       URL="https://en.wikipedia.org/wiki/E-cadherin";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Z13009; CAA78353.1; -; mRNA.
DR   EMBL; Z18923; CAA79356.1; -; mRNA.
DR   EMBL; L08599; AAA61259.1; ALT_FRAME; mRNA.
DR   EMBL; AB025105; BAA88956.1; -; mRNA.
DR   EMBL; AK290012; BAF82701.1; -; mRNA.
DR   EMBL; AK312551; BAG35448.1; -; mRNA.
DR   EMBL; DQ090940; AAY68225.1; -; Genomic_DNA.
DR   EMBL; AC099314; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471092; EAW83243.1; -; Genomic_DNA.
DR   EMBL; CH471092; EAW83244.1; -; Genomic_DNA.
DR   EMBL; L34545; AAA21764.1; -; Genomic_DNA.
DR   EMBL; D49685; BAA08537.1; -; Genomic_DNA.
DR   EMBL; Z35402; CAA84586.1; -; Genomic_DNA.
DR   EMBL; Z35403; CAA84586.1; JOINED; Genomic_DNA.
DR   EMBL; Z35404; CAA84586.1; JOINED; Genomic_DNA.
DR   EMBL; Z35405; CAA84586.1; JOINED; Genomic_DNA.
DR   EMBL; Z35406; CAA84586.1; JOINED; Genomic_DNA.
DR   EMBL; Z35407; CAA84586.1; JOINED; Genomic_DNA.
DR   EMBL; Z35408; CAA84586.1; JOINED; Genomic_DNA.
DR   EMBL; Z35409; CAA84586.1; JOINED; Genomic_DNA.
DR   EMBL; Z35410; CAA84586.1; JOINED; Genomic_DNA.
DR   EMBL; Z35411; CAA84586.1; JOINED; Genomic_DNA.
DR   EMBL; Z35412; CAA84586.1; JOINED; Genomic_DNA.
DR   EMBL; Z35413; CAA84586.1; JOINED; Genomic_DNA.
DR   EMBL; Z35414; CAA84586.1; JOINED; Genomic_DNA.
DR   EMBL; Z35415; CAA84586.1; JOINED; Genomic_DNA.
DR   EMBL; X12790; CAA31279.1; -; mRNA.
DR   EMBL; X52279; CAA36522.1; -; mRNA.
DR   EMBL; S72492; AAD14108.1; -; Genomic_DNA.
DR   EMBL; S72397; AAD14108.1; JOINED; Genomic_DNA.
DR   EMBL; S72491; AAD14108.1; JOINED; Genomic_DNA.
DR   CCDS; CCDS10869.1; -. [P12830-1]
DR   PIR; S37654; IJHUCE.
DR   RefSeq; NP_004351.1; NM_004360.4. [P12830-1]
DR   UniGene; Hs.461086; -.
DR   PDB; 1O6S; X-ray; 1.80 A; B=156-255.
DR   PDB; 2O72; X-ray; 2.00 A; A=155-367.
DR   PDB; 2OMT; X-ray; 2.00 A; B=156-255.
DR   PDB; 2OMU; X-ray; 1.80 A; B=156-255.
DR   PDB; 2OMV; X-ray; 1.90 A; B=156-255.
DR   PDB; 2OMX; X-ray; 1.70 A; B=156-258.
DR   PDB; 2OMY; X-ray; 1.70 A; B=156-254.
DR   PDB; 2OMZ; X-ray; 1.60 A; B=156-254.
DR   PDB; 3FF7; X-ray; 1.80 A; A/B=155-253.
DR   PDB; 3FF8; X-ray; 2.00 A; A/B=155-254.
DR   PDB; 3L6X; X-ray; 2.40 A; B=756-773.
DR   PDB; 3L6Y; X-ray; 3.00 A; B/D/F=756-773.
DR   PDBsum; 1O6S; -.
DR   PDBsum; 2O72; -.
DR   PDBsum; 2OMT; -.
DR   PDBsum; 2OMU; -.
DR   PDBsum; 2OMV; -.
DR   PDBsum; 2OMX; -.
DR   PDBsum; 2OMY; -.
DR   PDBsum; 2OMZ; -.
DR   PDBsum; 3FF7; -.
DR   PDBsum; 3FF8; -.
DR   PDBsum; 3L6X; -.
DR   PDBsum; 3L6Y; -.
DR   ProteinModelPortal; P12830; -.
DR   SMR; P12830; 155-690, 782-875.
DR   BioGrid; 107434; 84.
DR   DIP; DIP-477N; -.
DR   IntAct; P12830; 72.
DR   MINT; MINT-119105; -.
DR   STRING; 9606.ENSP00000261769; -.
DR   iPTMnet; P12830; -.
DR   PhosphoSite; P12830; -.
DR   BioMuta; CDH1; -.
DR   DMDM; 399166; -.
DR   MaxQB; P12830; -.
DR   PaxDb; P12830; -.
DR   PRIDE; P12830; -.
DR   Ensembl; ENST00000261769; ENSP00000261769; ENSG00000039068. [P12830-1]
DR   Ensembl; ENST00000422392; ENSP00000414946; ENSG00000039068. [P12830-2]
DR   GeneID; 999; -.
DR   KEGG; hsa:999; -.
DR   UCSC; uc002ewg.1; human. [P12830-1]
DR   UCSC; uc010cfg.1; human.
DR   CTD; 999; -.
DR   GeneCards; CDH1; -.
DR   GeneReviews; CDH1; -.
DR   HGNC; HGNC:1748; CDH1.
DR   HPA; CAB000087; -.
DR   HPA; CAB028364; -.
DR   HPA; HPA004812; -.
DR   MalaCards; CDH1; -.
DR   MIM; 137215; phenotype.
DR   MIM; 167000; phenotype.
DR   MIM; 192090; gene.
DR   MIM; 608089; phenotype.
DR   neXtProt; NX_P12830; -.
DR   Orphanet; 1991; Cleft lip with or without cleft palate.
DR   Orphanet; 26106; Familial gastric cancer.
DR   Orphanet; 36273; Gastric linitis plastica.
DR   PharmGKB; PA26282; -.
DR   eggNOG; KOG3594; Eukaryota.
DR   eggNOG; ENOG410XQHI; LUCA.
DR   GeneTree; ENSGT00760000118906; -.
DR   HOGENOM; HOG000231254; -.
DR   HOVERGEN; HBG106438; -.
DR   InParanoid; P12830; -.
DR   KO; K05689; -.
DR   OrthoDB; EOG7PS1DS; -.
DR   PhylomeDB; P12830; -.
DR   TreeFam; TF316817; -.
DR   Reactome; R-HSA-1474228; Degradation of the extracellular matrix.
DR   Reactome; R-HSA-198933; Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell.
DR   Reactome; R-HSA-216083; Integrin cell surface interactions.
DR   Reactome; R-HSA-351906; Apoptotic cleavage of cell adhesion proteins.
DR   Reactome; R-HSA-418990; Adherens junctions interactions.
DR   Reactome; R-HSA-5626467; RHO GTPases activate IQGAPs.
DR   ChiTaRS; CDH1; human.
DR   EvolutionaryTrace; P12830; -.
DR   GeneWiki; CDH1_(gene); -.
DR   GenomeRNAi; 999; -.
DR   NextBio; 4200; -.
DR   PMAP-CutDB; P12830; -.
DR   PRO; PR:P12830; -.
DR   Proteomes; UP000005640; Chromosome 16.
DR   Bgee; P12830; -.
DR   CleanEx; HS_CDH1; -.
DR   ExpressionAtlas; P12830; baseline and differential.
DR   Genevisible; P12830; HS.
DR   GO; GO:0015629; C:actin cytoskeleton; IDA:BHF-UCL.
DR   GO; GO:0016235; C:aggresome; IDA:HPA.
DR   GO; GO:0043296; C:apical junction complex; IDA:UniProtKB.
DR   GO; GO:0016342; C:catenin complex; IDA:BHF-UCL.
DR   GO; GO:0030054; C:cell junction; TAS:UniProtKB.
DR   GO; GO:0005913; C:cell-cell adherens junction; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:HPA.
DR   GO; GO:0009898; C:cytoplasmic side of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005768; C:endosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0016600; C:flotillin complex; IDA:UniProtKB.
DR   GO; GO:0005925; C:focal adhesion; IDA:HPA.
DR   GO; GO:0016021; C:integral component of membrane; IDA:BHF-UCL.
DR   GO; GO:0030027; C:lamellipodium; IDA:UniProtKB.
DR   GO; GO:0016328; C:lateral plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0005802; C:trans-Golgi network; IMP:BHF-UCL.
DR   GO; GO:0030506; F:ankyrin binding; IPI:BHF-UCL.
DR   GO; GO:0008013; F:beta-catenin binding; IDA:BHF-UCL.
DR   GO; GO:0005509; F:calcium ion binding; IEA:InterPro.
DR   GO; GO:0050839; F:cell adhesion molecule binding; IPI:UniProtKB.
DR   GO; GO:0045295; F:gamma-catenin binding; IPI:BHF-UCL.
DR   GO; GO:0001948; F:glycoprotein binding; IPI:UniProtKB.
DR   GO; GO:0032794; F:GTPase activating protein binding; IPI:UniProtKB.
DR   GO; GO:0034332; P:adherens junction organization; IMP:UniProtKB.
DR   GO; GO:0006915; P:apoptotic process; TAS:Reactome.
DR   GO; GO:0034329; P:cell junction assembly; TAS:Reactome.
DR   GO; GO:0045216; P:cell-cell junction organization; TAS:Reactome.
DR   GO; GO:0006921; P:cellular component disassembly involved in execution phase of apoptosis; TAS:Reactome.
DR   GO; GO:0071681; P:cellular response to indole-3-methanol; IDA:UniProtKB.
DR   GO; GO:0071285; P:cellular response to lithium ion; IDA:UniProtKB.
DR   GO; GO:0090002; P:establishment of protein localization to plasma membrane; IMP:UniProtKB.
DR   GO; GO:0022617; P:extracellular matrix disassembly; TAS:Reactome.
DR   GO; GO:0030198; P:extracellular matrix organization; TAS:Reactome.
DR   GO; GO:0007156; P:homophilic cell adhesion via plasma membrane adhesion molecules; NAS:UniProtKB.
DR   GO; GO:0022408; P:negative regulation of cell-cell adhesion; IMP:UniProtKB.
DR   GO; GO:0031175; P:neuron projection development; IEA:Ensembl.
DR   GO; GO:0021983; P:pituitary gland development; IEA:Ensembl.
DR   GO; GO:0042993; P:positive regulation of transcription factor import into nucleus; IDA:BHF-UCL.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:BHF-UCL.
DR   GO; GO:0012501; P:programmed cell death; TAS:Reactome.
DR   GO; GO:0072659; P:protein localization to plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0050776; P:regulation of immune response; TAS:Reactome.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0009636; P:response to toxic substance; IEA:Ensembl.
DR   GO; GO:0016337; P:single organismal cell-cell adhesion; IDA:BHF-UCL.
DR   GO; GO:0007264; P:small GTPase mediated signal transduction; TAS:Reactome.
DR   GO; GO:0007416; P:synapse assembly; IEA:Ensembl.
DR   Gene3D; 2.60.40.60; -; 6.
DR   Gene3D; 4.10.900.10; -; 1.
DR   InterPro; IPR002126; Cadherin.
DR   InterPro; IPR015919; Cadherin-like.
DR   InterPro; IPR020894; Cadherin_CS.
DR   InterPro; IPR000233; Cadherin_cytoplasmic-dom.
DR   InterPro; IPR014868; Cadherin_pro_dom.
DR   InterPro; IPR027397; Catenin_binding_dom.
DR   Pfam; PF00028; Cadherin; 5.
DR   Pfam; PF01049; Cadherin_C; 1.
DR   Pfam; PF08758; Cadherin_pro; 1.
DR   PRINTS; PR00205; CADHERIN.
DR   SMART; SM00112; CA; 4.
DR   SMART; SM01055; Cadherin_pro; 1.
DR   SUPFAM; SSF49313; SSF49313; 6.
DR   PROSITE; PS00232; CADHERIN_1; 3.
DR   PROSITE; PS50268; CADHERIN_2; 5.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Calcium; Cell adhesion;
KW   Cell junction; Cell membrane; Cleavage on pair of basic residues;
KW   Complete proteome; Direct protein sequencing; Disease mutation;
KW   Disulfide bond; Endosome; Glycoprotein; Golgi apparatus; Membrane;
KW   Metal-binding; Phosphoprotein; Polymorphism; Reference proteome;
KW   Repeat; Signal; Transmembrane; Transmembrane helix; Ubl conjugation.
FT   SIGNAL        1     22       {ECO:0000255}.
FT   PROPEP       23    154       {ECO:0000255}.
FT                                /FTId=PRO_0000003715.
FT   CHAIN       155    882       Cadherin-1.
FT                                /FTId=PRO_0000003716.
FT   CHAIN       701    882       E-Cad/CTF1.
FT                                /FTId=PRO_0000236067.
FT   CHAIN       732    882       E-Cad/CTF2.
FT                                /FTId=PRO_0000236068.
FT   CHAIN       751    882       E-Cad/CTF3.
FT                                /FTId=PRO_0000236069.
FT   TOPO_DOM    155    709       Extracellular. {ECO:0000255}.
FT   TRANSMEM    710    730       Helical. {ECO:0000255}.
FT   TOPO_DOM    731    882       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      155    262       Cadherin 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00043}.
FT   DOMAIN      263    375       Cadherin 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00043}.
FT   DOMAIN      376    486       Cadherin 3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00043}.
FT   DOMAIN      487    593       Cadherin 4. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00043}.
FT   DOMAIN      594    697       Cadherin 5. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00043}.
FT   REGION      758    769       Required for binding CTNND1 and PSEN1.
FT   REGION      811    882       Required for binding alpha, beta and
FT                                gamma catenins.
FT   COMPBIAS    838    851       Ser-rich.
FT   METAL       257    257       Calcium 1.
FT   METAL       257    257       Calcium 2.
FT   METAL       288    288       Calcium 3.
FT   SITE        700    701       Cleavage; by a metalloproteinase.
FT   SITE        731    732       Cleavage; by gamma-secretase/PS1.
FT   SITE        750    751       Cleavage; by caspase-3.
FT   MOD_RES     753    753       Phosphotyrosine; by SRC.
FT                                {ECO:0000269|PubMed:22252131}.
FT   MOD_RES     754    754       Phosphotyrosine; by SRC.
FT                                {ECO:0000269|PubMed:22252131}.
FT   MOD_RES     755    755       Phosphotyrosine; by SRC.
FT                                {ECO:0000269|PubMed:22252131}.
FT   MOD_RES     770    770       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     793    793       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     838    838       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P09803}.
FT   MOD_RES     840    840       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P09803}.
FT   MOD_RES     846    846       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P09803}.
FT   CARBOHYD    558    558       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:18491227}.
FT   CARBOHYD    570    570       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:18491227}.
FT   CARBOHYD    622    622       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:18491227}.
FT   CARBOHYD    637    637       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:18491227}.
FT   DISULFID    163    163       Interchain.
FT   VAR_SEQ     380    440       Missing (in isoform 2).
FT                                {ECO:0000303|Ref.5}.
FT                                /FTId=VSP_055586.
FT   VARIANT      72     72       D -> N (in dbSNP:rs35606263).
FT                                /FTId=VAR_048500.
FT   VARIANT     123    123       H -> Y (in a gastric cancer sample).
FT                                /FTId=VAR_001306.
FT   VARIANT     193    193       T -> P (in a diffuse gastric cancer
FT                                sample). {ECO:0000269|PubMed:8797891}.
FT                                /FTId=VAR_001307.
FT   VARIANT     244    244       D -> G (in HDGC).
FT                                {ECO:0000269|PubMed:10319582}.
FT                                /FTId=VAR_008712.
FT   VARIANT     270    270       S -> A (may contribute to prostate
FT                                cancer). {ECO:0000269|PubMed:11705864}.
FT                                /FTId=VAR_013970.
FT   VARIANT     274    277       Missing (found in gastric carcinoma cell
FT                                lines). {ECO:0000269|PubMed:8127895}.
FT                                /FTId=VAR_001308.
FT   VARIANT     282    282       M -> I (in a breast cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:17224074}.
FT                                /FTId=VAR_033026.
FT   VARIANT     315    315       N -> S (in lobular breast carcinoma).
FT                                {ECO:0000269|PubMed:7961105}.
FT                                /FTId=VAR_001309.
FT   VARIANT     336    336       E -> D. {ECO:0000269|PubMed:9537325}.
FT                                /FTId=VAR_001310.
FT   VARIANT     340    340       T -> A (found in gastric and colorectal
FT                                cancer samples; cells exhibited decreased
FT                                aggregation increased invasiveness and
FT                                non-uniform migration in vitro compared
FT                                to cells transfected with wild-type
FT                                sequence). {ECO:0000269|PubMed:10896919,
FT                                ECO:0000269|PubMed:11968083,
FT                                ECO:0000269|PubMed:12588804}.
FT                                /FTId=VAR_013971.
FT   VARIANT     370    370       D -> A (in a diffuse gastric cancer
FT                                sample). {ECO:0000269|PubMed:8033105}.
FT                                /FTId=VAR_001311.
FT   VARIANT     393    393       I -> N (in dbSNP:rs34466743).
FT                                /FTId=VAR_048501.
FT   VARIANT     400    400       Missing (in a gastric carcinoma sample;
FT                                loss of heterozygosity).
FT                                {ECO:0000269|PubMed:9045944}.
FT                                /FTId=VAR_001312.
FT   VARIANT     418    423       Missing (in a gastric carcinoma sample).
FT                                {ECO:0000269|PubMed:9045944}.
FT                                /FTId=VAR_001313.
FT   VARIANT     463    463       E -> Q (in a gastric carcinoma sample).
FT                                /FTId=VAR_001314.
FT   VARIANT     470    470       T -> I. {ECO:0000269|PubMed:9537325}.
FT                                /FTId=VAR_001315.
FT   VARIANT     473    473       V -> D (in a diffuse gastric cancer
FT                                sample). {ECO:0000269|PubMed:8033105}.
FT                                /FTId=VAR_001317.
FT   VARIANT     473    473       V -> I (in dbSNP:rs36087757).
FT                                /FTId=VAR_048502.
FT   VARIANT     478    478       L -> P (in dbSNP:rs35520415).
FT                                {ECO:0000269|Ref.7}.
FT                                /FTId=VAR_023357.
FT   VARIANT     487    487       V -> A (in HDGC).
FT                                {ECO:0000269|PubMed:10319582}.
FT                                /FTId=VAR_008713.
FT   VARIANT     592    592       A -> T (in a thyroid cancer sample; may
FT                                play a role in colorectal carcinogenesis;
FT                                dbSNP:rs35187787).
FT                                {ECO:0000269|PubMed:11562785,
FT                                ECO:0000269|PubMed:8985087}.
FT                                /FTId=VAR_001318.
FT   VARIANT     598    598       R -> Q (in a gastric cancer sample).
FT                                /FTId=VAR_001319.
FT   VARIANT     617    617       A -> T (detected in an endometrial cancer
FT                                sample; loss of heterozygosity; cells
FT                                exhibited an intermediate phenotype
FT                                concerning aggregation invasiveness and
FT                                migration in vitro compared to cells
FT                                transfected with wild-type sequence;
FT                                dbSNP:rs33935154).
FT                                {ECO:0000269|PubMed:12588804,
FT                                ECO:0000269|PubMed:8075649,
FT                                ECO:0000269|Ref.7}.
FT                                /FTId=VAR_001320.
FT   VARIANT     630    630       L -> V (in dbSNP:rs2276331).
FT                                /FTId=VAR_021868.
FT   VARIANT     634    634       A -> V (found in a gastric cancer sample;
FT                                cells exhibited decreased aggregation
FT                                increased invasiveness and non-uniform
FT                                migration in vitro compared to cells
FT                                transfected with wild-type sequence).
FT                                {ECO:0000269|PubMed:12588804}.
FT                                /FTId=VAR_055431.
FT   VARIANT     695    695       C -> R (in dbSNP:rs9282655).
FT                                /FTId=VAR_021869.
FT   VARIANT     711    711       L -> V (detected in an endometrial cancer
FT                                sample). {ECO:0000269|PubMed:8075649}.
FT                                /FTId=VAR_001321.
FT   VARIANT     777    777       D -> N (in a breast cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:17224074}.
FT                                /FTId=VAR_033027.
FT   VARIANT     832    832       V -> M (in HDGC; dbSNP:rs35572355).
FT                                {ECO:0000269|PubMed:12216071,
FT                                ECO:0000269|Ref.7}.
FT                                /FTId=VAR_023358.
FT   VARIANT     838    838       S -> G (in an ovarian carcinoma sample;
FT                                somatic mutation; loss of
FT                                heterozygosity).
FT                                {ECO:0000269|PubMed:8075649}.
FT                                /FTId=VAR_001322.
FT   VARIANT     880    880       E -> K (in dbSNP:rs34507583).
FT                                {ECO:0000269|Ref.7}.
FT                                /FTId=VAR_023359.
FT   MUTAGEN     637    637       N->Q: CDH1 becomes a substrate for ERAD
FT                                and is retro-translocated from ER to
FT                                cytoplasm. {ECO:0000269|PubMed:18491227}.
FT   MUTAGEN     754    754       Y->F: Abolishes binding to CBLL1.
FT                                {ECO:0000269|PubMed:22252131}.
FT   MUTAGEN     759    761       GGG->AAA: Binds to CTNNB1 but abolishes
FT                                interaction of CTNNB1 with PSEN1.
FT                                Abolishes gamma-secretase cleavage.
FT                                {ECO:0000269|PubMed:11953314,
FT                                ECO:0000269|PubMed:16126725}.
FT   CONFLICT     10     10       A -> G (in Ref. 3; AAA61259).
FT                                {ECO:0000305}.
FT   CONFLICT     29     29       H -> L (in Ref. 3; AAA61259).
FT                                {ECO:0000305}.
FT   CONFLICT     47     47       E -> R (in Ref. 3; AAA61259).
FT                                {ECO:0000305}.
FT   CONFLICT     70     71       SL -> P (in Ref. 3; AAA61259).
FT                                {ECO:0000305}.
FT   CONFLICT    483    483       A -> G (in Ref. 3; AAA61259).
FT                                {ECO:0000305}.
FT   CONFLICT    530    530       A -> R (in Ref. 3; AAA61259).
FT                                {ECO:0000305}.
FT   CONFLICT    543    543       S -> F (in Ref. 2; CAA79356).
FT                                {ECO:0000305}.
FT   CONFLICT    615    615       I -> H (in Ref. 3; AAA61259).
FT                                {ECO:0000305}.
FT   CONFLICT    634    636       ASA -> RVP (in Ref. 3; AAA61259).
FT                                {ECO:0000305}.
FT   CONFLICT    868    868       R -> P (in Ref. 3; AAA61259).
FT                                {ECO:0000305}.
FT   CONFLICT    882    882       D -> H (in Ref. 3; AAA61259).
FT                                {ECO:0000305}.
FT   STRAND      163    166       {ECO:0000244|PDB:2OMZ}.
FT   STRAND      169    177       {ECO:0000244|PDB:2OMZ}.
FT   HELIX       181    184       {ECO:0000244|PDB:2OMZ}.
FT   STRAND      189    195       {ECO:0000244|PDB:2OMZ}.
FT   TURN        196    198       {ECO:0000244|PDB:2OMZ}.
FT   STRAND      199    201       {ECO:0000244|PDB:2OMZ}.
FT   STRAND      204    207       {ECO:0000244|PDB:2OMZ}.
FT   TURN        209    211       {ECO:0000244|PDB:2OMZ}.
FT   STRAND      213    216       {ECO:0000244|PDB:2OMZ}.
FT   TURN        222    224       {ECO:0000244|PDB:2OMZ}.
FT   STRAND      227    235       {ECO:0000244|PDB:2OMZ}.
FT   STRAND      241    243       {ECO:0000244|PDB:2OMZ}.
FT   STRAND      246    253       {ECO:0000244|PDB:2OMZ}.
FT   STRAND      261    272       {ECO:0000244|PDB:2O72}.
FT   STRAND      280    283       {ECO:0000244|PDB:2O72}.
FT   TURN        292    294       {ECO:0000244|PDB:2O72}.
FT   STRAND      301    309       {ECO:0000244|PDB:2O72}.
FT   STRAND      316    319       {ECO:0000244|PDB:2O72}.
FT   TURN        321    323       {ECO:0000244|PDB:2O72}.
FT   STRAND      325    328       {ECO:0000244|PDB:2O72}.
FT   TURN        335    337       {ECO:0000244|PDB:2O72}.
FT   STRAND      340    348       {ECO:0000244|PDB:2O72}.
FT   TURN        349    353       {ECO:0000244|PDB:2O72}.
FT   STRAND      356    366       {ECO:0000244|PDB:2O72}.
FT   HELIX       769    771       {ECO:0000244|PDB:3L6X}.
SQ   SEQUENCE   882 AA;  97456 MW;  E427118043A13C67 CRC64;
     MGPWSRSLSA LLLLLQVSSW LCQEPEPCHP GFDAESYTFT VPRRHLERGR VLGRVNFEDC
     TGRQRTAYFS LDTRFKVGTD GVITVKRPLR FHNPQIHFLV YAWDSTYRKF STKVTLNTVG
     HHHRPPPHQA SVSGIQAELL TFPNSSPGLR RQKRDWVIPP ISCPENEKGP FPKNLVQIKS
     NKDKEGKVFY SITGQGADTP PVGVFIIERE TGWLKVTEPL DRERIATYTL FSHAVSSNGN
     AVEDPMEILI TVTDQNDNKP EFTQEVFKGS VMEGALPGTS VMEVTATDAD DDVNTYNAAI
     AYTILSQDPE LPDKNMFTIN RNTGVISVVT TGLDRESFPT YTLVVQAADL QGEGLSTTAT
     AVITVTDTND NPPIFNPTTY KGQVPENEAN VVITTLKVTD ADAPNTPAWE AVYTILNDDG
     GQFVVTTNPV NNDGILKTAK GLDFEAKQQY ILHVAVTNVV PFEVSLTTST ATVTVDVLDV
     NEAPIFVPPE KRVEVSEDFG VGQEITSYTA QEPDTFMEQK ITYRIWRDTA NWLEINPDTG
     AISTRAELDR EDFEHVKNST YTALIIATDN GSPVATGTGT LLLILSDVND NAPIPEPRTI
     FFCERNPKPQ VINIIDADLP PNTSPFTAEL THGASANWTI QYNDPTQESI ILKPKMALEV
     GDYKINLKLM DNQNKDQVTT LEVSVCDCEG AAGVCRKAQP VEAGLQIPAI LGILGGILAL
     LILILLLLLF LRRRAVVKEP LLPPEDDTRD NVYYYDEEGG GEEDQDFDLS QLHRGLDARP
     EVTRNDVAPT LMSVPRYLPR PANPDEIGNF IDENLKAADT DPTAPPYDSL LVFDYEGSGS
     EAASLSSLNS SESDKDQDYD YLNEWGNRFK KLADMYGGGE DD
//
ID   TGFB2_HUMAN             Reviewed;         414 AA.
AC   P61812; B4DKC5; P08112; Q15579; Q15581; Q4VAV9;
DT   01-AUG-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-AUG-1988, sequence version 1.
DT   17-FEB-2016, entry version 142.
DE   RecName: Full=Transforming growth factor beta-2;
DE            Short=TGF-beta-2;
DE   AltName: Full=BSC-1 cell growth inhibitor;
DE   AltName: Full=Cetermin;
DE   AltName: Full=Glioblastoma-derived T-cell suppressor factor;
DE            Short=G-TSF;
DE   AltName: Full=Polyergin;
DE   Contains:
DE     RecName: Full=Latency-associated peptide;
DE              Short=LAP;
DE   Flags: Precursor;
GN   Name=TGFB2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM A).
RX   PubMed=3322813;
RA   de Martin R., Haendler B., Hofer-Warbinek R., Gaugitsch H., Wrann M.,
RA   Schluesener H., Seifert J.M., Bodmer S., Fontana A., Hofer E.;
RT   "Complementary DNA for human glioblastoma-derived T cell suppressor
RT   factor, a novel member of the transforming growth factor-beta gene
RT   family.";
RL   EMBO J. 6:3673-3677(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM B).
RX   PubMed=3162414; DOI=10.1089/dna.1988.7.1;
RA   Madisen L., Webb N.R., Rose T.M., Marquardt H., Ikeda T.,
RA   Twardzik D.R., Seyedin S., Purchio A.F.;
RT   "Transforming growth factor-beta 2: cDNA cloning and sequence
RT   analysis.";
RL   DNA 7:1-8(1988).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS A AND B).
RX   PubMed=2850146; DOI=10.1089/dna.1.1988.7.493;
RA   Webb N.R., Madisen L., Rose T.M., Purchio A.F.;
RT   "Structural and sequence analysis of TGF-beta 2 cDNA clones predicts
RT   two different precursor proteins produced by alternative mRNA
RT   splicing.";
RL   DNA 7:493-497(1988).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS HIS-91 AND LEU-207.
RG   NIEHS SNPs program;
RL   Submitted (OCT-2003) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM B).
RC   TISSUE=Thalamus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-115.
RC   TISSUE=Lung;
RX   PubMed=1764261;
RA   Noma T., Glick A.B., Geiser A.G., O'Reilly M.A., Miller J.,
RA   Roberts A.B., Sporn M.B.;
RT   "Molecular cloning and structure of the human transforming growth
RT   factor-beta 2 gene promoter.";
RL   Growth Factors 4:247-255(1991).
RN   [9]
RP   PROTEIN SEQUENCE OF 303-414.
RX   PubMed=3476488;
RA   Marquardt H., Lioubin M.N., Ikeda T.;
RT   "Complete amino acid sequence of human transforming growth factor type
RT   beta 2.";
RL   J. Biol. Chem. 262:12127-12131(1987).
RN   [10]
RP   CHROMOSOMAL TRANSLOCATION WITH HDAC9.
RX   PubMed=12706107; DOI=10.1016/S0888-7543(03)00046-6;
RA   David D., Cardoso J., Marques B., Marques R., Silva E.D., Santos H.,
RA   Boavida M.G.;
RT   "Molecular characterization of a familial translocation implicates
RT   disruption of HDAC9 and possible position effect on TGFbeta2 in the
RT   pathogenesis of Peters' anomaly.";
RL   Genomics 81:489-503(2003).
RN   [11]
RP   INTERACTION WITH ASPN.
RX   PubMed=17827158; DOI=10.1074/jbc.M700522200;
RA   Nakajima M., Kizawa H., Saitoh M., Kou I., Miyazono K., Ikegawa S.;
RT   "Mechanisms for asporin function and regulation in articular
RT   cartilage.";
RL   J. Biol. Chem. 282:32185-32192(2007).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS).
RX   PubMed=1631557; DOI=10.1126/science.1631557;
RA   Daopin S., Piez K.A., Ogawa Y., Davies D.R.;
RT   "Crystal structure of transforming growth factor-beta 2: an unusual
RT   fold for the superfamily.";
RL   Science 257:369-373(1992).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS).
RX   PubMed=1641027; DOI=10.1038/358430a0;
RA   Schlunegger M.P., Gruetter M.G.;
RT   "An unusual feature revealed by the crystal structure at 2.2-A
RT   resolution of human transforming growth factor-beta 2.";
RL   Nature 358:430-434(1992).
RN   [14]
RP   VARIANT HIS-91.
RX   PubMed=11528528; DOI=10.1038/sj.gene.6363780;
RA   Alansari A., Hajeer A.H., Bayat A., Eyre S., Carthy D., Ollier W.E.;
RT   "Two novel polymorphisms in the human transforming growth factor beta
RT   2 gene.";
RL   Genes Immun. 2:295-296(2001).
RN   [15]
RP   VARIANTS LDS4 100-ALA--TYR-104 DEL; TRP-299; CYS-302 AND HIS-338.
RX   PubMed=22772368; DOI=10.1038/ng.2349;
RA   Lindsay M.E., Schepers D., Bolar N.A., Doyle J.J., Gallo E.,
RA   Fert-Bober J., Kempers M.J., Fishman E.K., Chen Y., Myers L.,
RA   Bjeda D., Oswald G., Elias A.F., Levy H.P., Anderlid B.M., Yang M.H.,
RA   Bongers E.M., Timmermans J., Braverman A.C., Canham N., Mortier G.R.,
RA   Brunner H.G., Byers P.H., Van Eyk J., Van Laer L., Dietz H.C.,
RA   Loeys B.L.;
RT   "Loss-of-function mutations in TGFB2 cause a syndromic presentation of
RT   thoracic aortic aneurysm.";
RL   Nat. Genet. 44:922-927(2012).
RN   [16]
RP   INVOLVEMENT IN NON-SYNDROMIC AORTIC DISEASE, AND VARIANT CYS-320.
RX   PubMed=25046559; DOI=10.1016/j.cca.2014.07.016;
RA   Gago-Diaz M., Blanco-Verea A., Teixido-Tura G., Valenzuela I.,
RA   Del Campo M., Borregan M., Sobrino B., Amigo J., Garcia-Dorado D.,
RA   Evangelista A., Carracedo A., Brion M.;
RT   "Whole exome sequencing for the identification of a new mutation in
RT   TGFB2 involved in a familial case of non-syndromic aortic disease.";
RL   Clin. Chim. Acta 437:88-92(2014).
CC   -!- FUNCTION: TGF-beta 2 has suppressive effects on interleukin-2
CC       dependent T-cell growth.
CC   -!- SUBUNIT: Homodimer; disulfide-linked (By similarity). Heterodimers
CC       with TGFB1 and with TGFB3 have been found in bone (By similarity).
CC       Interacts with the serine proteases, HTRA1 and HTRA3 (By
CC       similarity). Latency-associated peptide interacts with NREP; the
CC       interaction results in a decrease in TGFB2 autoinduction (By
CC       similarity). Interacts with ASPN. Interacts with MFAP5 (By
CC       similarity). {ECO:0000250|UniProtKB:Q9QZJ6,
CC       ECO:0000269|PubMed:17827158}.
CC   -!- INTERACTION:
CC       P05067:APP; NbExp=7; IntAct=EBI-779581, EBI-77613;
CC   -!- SUBCELLULAR LOCATION: Secreted.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=A;
CC         IsoId=P61812-1, P08112-1;
CC         Sequence=Displayed;
CC       Name=B;
CC         IsoId=P61812-2, P08112-2;
CC         Sequence=VSP_006417;
CC   -!- PTM: The precursor is cleaved into mature TGF-beta-2 and LAP,
CC       which remains non-covalently linked to mature TGF-beta-2 rendering
CC       it inactive. {ECO:0000250}.
CC   -!- DISEASE: Note=A chromosomal aberration involving TGFB2 is found in
CC       a family with Peters anomaly. Translocation t(1;7)(q41;p21) with
CC       HDAC9. {ECO:0000269|PubMed:12706107}.
CC   -!- DISEASE: Loeys-Dietz syndrome 4 (LDS4) [MIM:614816]: An aortic
CC       aneurysm syndrome with widespread systemic involvement. LDS4 is
CC       characterized by arterial tortuosity, aortic dissection,
CC       intracranial aneurysm and subarachnoid hemorrhage, hypertelorism,
CC       bifid uvula, pectus deformity, bicuspid aortic valve,
CC       arachnodactyly, scoliosis, foot deformities, dural ectasia, joint
CC       hyperflexibility, and thin skin with easy bruising and striae.
CC       {ECO:0000269|PubMed:22772368}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Note=Defects in TGFB2 may be a cause of non-syndromic
CC       aortic disease (NSAD). NSAD is a frequently asymptomatic but
CC       potentially lethal disease characterized by thoracic aortic
CC       aneurysms and dissections without additional syndromic features.
CC       {ECO:0000269|PubMed:25046559}.
CC   -!- SIMILARITY: Belongs to the TGF-beta family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/tgfb2/";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=TGF beta-2 entry;
CC       URL="https://en.wikipedia.org/wiki/TGF_beta_2";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Y00083; CAA68279.1; -; mRNA.
DR   EMBL; M19154; AAA50404.1; -; mRNA.
DR   EMBL; M19154; AAA50405.1; -; mRNA.
DR   EMBL; AY438979; AAR05442.1; -; Genomic_DNA.
DR   EMBL; AK296504; BAG59137.1; -; mRNA.
DR   EMBL; CH471100; EAW93326.1; -; Genomic_DNA.
DR   EMBL; BC096235; AAH96235.1; -; mRNA.
DR   EMBL; BC099635; AAH99635.1; -; mRNA.
DR   EMBL; M87843; AAA61162.1; -; Genomic_DNA.
DR   CCDS; CCDS1521.1; -.
DR   CCDS; CCDS44318.1; -. [P61812-2]
DR   PIR; A29478; B31249.
DR   PIR; S06216; A31249.
DR   RefSeq; NP_001129071.1; NM_001135599.2. [P61812-2]
DR   RefSeq; NP_003229.1; NM_003238.3. [P61812-1]
DR   UniGene; Hs.133379; -.
DR   PDB; 1TFG; X-ray; 1.95 A; A=303-414.
DR   PDB; 2TGI; X-ray; 1.80 A; A=303-414.
DR   PDB; 4KXZ; X-ray; 2.83 A; A/B/D/E=303-414.
DR   PDBsum; 1TFG; -.
DR   PDBsum; 2TGI; -.
DR   PDBsum; 4KXZ; -.
DR   ProteinModelPortal; P61812; -.
DR   SMR; P61812; 21-414.
DR   BioGrid; 112900; 9.
DR   DIP; DIP-5936N; -.
DR   IntAct; P61812; 2.
DR   ChEMBL; CHEMBL3217393; -.
DR   PhosphoSite; P61812; -.
DR   BioMuta; TGFB2; -.
DR   DMDM; 48429157; -.
DR   MaxQB; P61812; -.
DR   PRIDE; P61812; -.
DR   Ensembl; ENST00000366929; ENSP00000355896; ENSG00000092969. [P61812-2]
DR   Ensembl; ENST00000366930; ENSP00000355897; ENSG00000092969. [P61812-1]
DR   GeneID; 7042; -.
DR   KEGG; hsa:7042; -.
DR   UCSC; uc001hlm.3; human.
DR   UCSC; uc001hln.3; human. [P61812-2]
DR   CTD; 7042; -.
DR   GeneCards; TGFB2; -.
DR   GeneReviews; TGFB2; -.
DR   HGNC; HGNC:11768; TGFB2.
DR   MalaCards; TGFB2; -.
DR   MIM; 190220; gene.
DR   MIM; 614816; phenotype.
DR   neXtProt; NX_P61812; -.
DR   Orphanet; 91387; Familial thoracic aortic aneurysm and aortic dissection.
DR   Orphanet; 708; Peters anomaly.
DR   PharmGKB; PA36482; -.
DR   GeneTree; ENSGT00760000119112; -.
DR   HOGENOM; HOG000290198; -.
DR   HOVERGEN; HBG074115; -.
DR   InParanoid; P61812; -.
DR   KO; K13376; -.
DR   OMA; YKIDMPS; -.
DR   OrthoDB; EOG70GMFT; -.
DR   PhylomeDB; P61812; -.
DR   TreeFam; TF318514; -.
DR   Reactome; R-HSA-114608; Platelet degranulation.
DR   Reactome; R-HSA-2129379; Molecules associated with elastic fibres.
DR   Reactome; R-HSA-3000178; ECM proteoglycans.
DR   SignaLink; P61812; -.
DR   ChiTaRS; TGFB2; human.
DR   EvolutionaryTrace; P61812; -.
DR   GeneWiki; TGF_beta_2; -.
DR   GenomeRNAi; 7042; -.
DR   NextBio; 27517; -.
DR   PMAP-CutDB; P61812; -.
DR   PRO; PR:P61812; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; P61812; -.
DR   CleanEx; HS_TGFB2; -.
DR   Genevisible; P61812; HS.
DR   GO; GO:0030424; C:axon; ISS:UniProtKB.
DR   GO; GO:0005768; C:endosome; IEA:Ensembl.
DR   GO; GO:0031012; C:extracellular matrix; IDA:BHF-UCL.
DR   GO; GO:0005576; C:extracellular region; IDA:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; IDA:AgBase.
DR   GO; GO:0043025; C:neuronal cell body; ISS:UniProtKB.
DR   GO; GO:0031093; C:platelet alpha granule lumen; TAS:Reactome.
DR   GO; GO:0001540; F:beta-amyloid binding; IDA:UniProtKB.
DR   GO; GO:0005125; F:cytokine activity; TAS:UniProtKB.
DR   GO; GO:0046982; F:protein heterodimerization activity; TAS:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0005102; F:receptor binding; IMP:UniProtKB.
DR   GO; GO:0004702; F:receptor signaling protein serine/threonine kinase activity; IDA:BHF-UCL.
DR   GO; GO:0005160; F:transforming growth factor beta receptor binding; IDA:UniProtKB.
DR   GO; GO:0005114; F:type II transforming growth factor beta receptor binding; IDA:BHF-UCL.
DR   GO; GO:0034714; F:type III transforming growth factor beta receptor binding; IMP:AgBase.
DR   GO; GO:0032147; P:activation of protein kinase activity; IDA:BHF-UCL.
DR   GO; GO:0001525; P:angiogenesis; TAS:UniProtKB.
DR   GO; GO:0007411; P:axon guidance; IEA:Ensembl.
DR   GO; GO:0007596; P:blood coagulation; TAS:Reactome.
DR   GO; GO:0001974; P:blood vessel remodeling; IEA:Ensembl.
DR   GO; GO:0060317; P:cardiac epithelial to mesenchymal transition; IDA:BHF-UCL.
DR   GO; GO:0060038; P:cardiac muscle cell proliferation; IDA:UniProtKB.
DR   GO; GO:0010002; P:cardioblast differentiation; IDA:UniProtKB.
DR   GO; GO:0001502; P:cartilage condensation; IEA:Ensembl.
DR   GO; GO:0042637; P:catagen; IDA:UniProtKB.
DR   GO; GO:0007050; P:cell cycle arrest; IDA:BHF-UCL.
DR   GO; GO:0008219; P:cell death; IDA:UniProtKB.
DR   GO; GO:0016049; P:cell growth; IEA:InterPro.
DR   GO; GO:0016477; P:cell migration; IDA:BHF-UCL.
DR   GO; GO:0000902; P:cell morphogenesis; IDA:UniProtKB.
DR   GO; GO:0008283; P:cell proliferation; TAS:ProtInc.
DR   GO; GO:0045216; P:cell-cell junction organization; IDA:BHF-UCL.
DR   GO; GO:0007267; P:cell-cell signaling; TAS:ProtInc.
DR   GO; GO:0030199; P:collagen fibril organization; IDA:BHF-UCL.
DR   GO; GO:0042416; P:dopamine biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0009790; P:embryo development; TAS:UniProtKB.
DR   GO; GO:0048566; P:embryonic digestive tract development; IEP:DFLAT.
DR   GO; GO:0001837; P:epithelial to mesenchymal transition; IDA:BHF-UCL.
DR   GO; GO:0030198; P:extracellular matrix organization; TAS:Reactome.
DR   GO; GO:0097191; P:extrinsic apoptotic signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0001654; P:eye development; IDA:UniProtKB.
DR   GO; GO:0060325; P:face morphogenesis; IEA:Ensembl.
DR   GO; GO:0048699; P:generation of neurons; TAS:UniProtKB.
DR   GO; GO:0008347; P:glial cell migration; IDA:BHF-UCL.
DR   GO; GO:0001942; P:hair follicle development; IDA:UniProtKB.
DR   GO; GO:0031069; P:hair follicle morphogenesis; ISS:UniProtKB.
DR   GO; GO:0007507; P:heart development; IDA:UniProtKB.
DR   GO; GO:0003007; P:heart morphogenesis; IDA:BHF-UCL.
DR   GO; GO:0003179; P:heart valve morphogenesis; IEA:Ensembl.
DR   GO; GO:0030097; P:hemopoiesis; ISS:UniProtKB.
DR   GO; GO:0010693; P:negative regulation of alkaline phosphatase activity; IDA:BHF-UCL.
DR   GO; GO:0061037; P:negative regulation of cartilage development; IEA:Ensembl.
DR   GO; GO:0030308; P:negative regulation of cell growth; IDA:BHF-UCL.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IDA:UniProtKB.
DR   GO; GO:0050680; P:negative regulation of epithelial cell proliferation; IDA:BHF-UCL.
DR   GO; GO:0010629; P:negative regulation of gene expression; IEA:Ensembl.
DR   GO; GO:0050777; P:negative regulation of immune response; TAS:UniProtKB.
DR   GO; GO:0010936; P:negative regulation of macrophage cytokine production; IDA:DFLAT.
DR   GO; GO:0048666; P:neuron development; ISS:UniProtKB.
DR   GO; GO:0048663; P:neuron fate commitment; IEA:Ensembl.
DR   GO; GO:0030593; P:neutrophil chemotaxis; ISS:UniProtKB.
DR   GO; GO:0042476; P:odontogenesis; NAS:BHF-UCL.
DR   GO; GO:0060389; P:pathway-restricted SMAD protein phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0030168; P:platelet activation; TAS:Reactome.
DR   GO; GO:0002576; P:platelet degranulation; TAS:Reactome.
DR   GO; GO:0070237; P:positive regulation of activation-induced cell death of T cells; IEA:Ensembl.
DR   GO; GO:0051891; P:positive regulation of cardioblast differentiation; IDA:UniProtKB.
DR   GO; GO:0051795; P:positive regulation of catagen; IDA:UniProtKB.
DR   GO; GO:0033630; P:positive regulation of cell adhesion mediated by integrin; IDA:BHF-UCL.
DR   GO; GO:0045787; P:positive regulation of cell cycle; ISS:UniProtKB.
DR   GO; GO:0051781; P:positive regulation of cell division; IEA:UniProtKB-KW.
DR   GO; GO:0030307; P:positive regulation of cell growth; IDA:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IDA:UniProtKB.
DR   GO; GO:0010634; P:positive regulation of epithelial cell migration; IDA:BHF-UCL.
DR   GO; GO:0010718; P:positive regulation of epithelial to mesenchymal transition; IDA:BHF-UCL.
DR   GO; GO:0090091; P:positive regulation of extracellular matrix disassembly; IEA:Ensembl.
DR   GO; GO:2001241; P:positive regulation of extrinsic apoptotic signaling pathway in absence of ligand; IEA:Ensembl.
DR   GO; GO:0010628; P:positive regulation of gene expression; IEA:Ensembl.
DR   GO; GO:1904426; P:positive regulation of GTP binding; IEA:Ensembl.
DR   GO; GO:0045823; P:positive regulation of heart contraction; IDA:UniProtKB.
DR   GO; GO:0050778; P:positive regulation of immune response; ISS:UniProtKB.
DR   GO; GO:0045726; P:positive regulation of integrin biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0043525; P:positive regulation of neuron apoptotic process; IDA:UniProtKB.
DR   GO; GO:0045778; P:positive regulation of ossification; IEP:BHF-UCL.
DR   GO; GO:0010862; P:positive regulation of pathway-restricted SMAD protein phosphorylation; IBA:GO_Central.
DR   GO; GO:0014068; P:positive regulation of phosphatidylinositol 3-kinase signaling; IDA:BHF-UCL.
DR   GO; GO:1900182; P:positive regulation of protein localization to nucleus; IEA:Ensembl.
DR   GO; GO:0050714; P:positive regulation of protein secretion; IDA:BHF-UCL.
DR   GO; GO:0032874; P:positive regulation of stress-activated MAPK cascade; IDA:BHF-UCL.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0032956; P:regulation of actin cytoskeleton organization; IEA:Ensembl.
DR   GO; GO:0032909; P:regulation of transforming growth factor beta2 production; IMP:BHF-UCL.
DR   GO; GO:0042493; P:response to drug; IDA:UniProtKB.
DR   GO; GO:0001666; P:response to hypoxia; IMP:BHF-UCL.
DR   GO; GO:0032570; P:response to progesterone; IDA:BHF-UCL.
DR   GO; GO:0009611; P:response to wounding; IEP:BHF-UCL.
DR   GO; GO:0007435; P:salivary gland morphogenesis; IEP:BHF-UCL.
DR   GO; GO:0023014; P:signal transduction by protein phosphorylation; IDA:GOC.
DR   GO; GO:0007184; P:SMAD protein import into nucleus; IDA:BHF-UCL.
DR   GO; GO:0060395; P:SMAD protein signal transduction; IBA:GO_Central.
DR   GO; GO:0048103; P:somatic stem cell division; ISS:UniProtKB.
DR   GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0042704; P:uterine wall breakdown; TAS:BHF-UCL.
DR   GO; GO:0042060; P:wound healing; ISS:UniProtKB.
DR   Gene3D; 2.10.90.10; -; 1.
DR   InterPro; IPR029034; Cystine-knot_cytokine.
DR   InterPro; IPR001839; TGF-b_C.
DR   InterPro; IPR001111; TGF-b_N.
DR   InterPro; IPR016319; TGF-beta.
DR   InterPro; IPR015615; TGF-beta-rel.
DR   InterPro; IPR003940; TGFb2.
DR   InterPro; IPR017948; TGFb_CS.
DR   PANTHER; PTHR11848; PTHR11848; 2.
DR   PANTHER; PTHR11848:SF141; PTHR11848:SF141; 2.
DR   Pfam; PF00019; TGF_beta; 1.
DR   Pfam; PF00688; TGFb_propeptide; 1.
DR   PIRSF; PIRSF001787; TGF-beta; 1.
DR   PRINTS; PR01423; TGFBETA.
DR   PRINTS; PR01425; TGFBETA2.
DR   SMART; SM00204; TGFB; 1.
DR   SUPFAM; SSF57501; SSF57501; 1.
DR   PROSITE; PS00250; TGF_BETA_1; 1.
DR   PROSITE; PS51362; TGF_BETA_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Aortic aneurysm;
KW   Chromosomal rearrangement; Cleavage on pair of basic residues;
KW   Complete proteome; Direct protein sequencing; Disease mutation;
KW   Disulfide bond; Glycoprotein; Growth factor; Mitogen; Polymorphism;
KW   Reference proteome; Secreted; Signal.
FT   SIGNAL        1     20       {ECO:0000255}.
FT   CHAIN        21    302       Latency-associated peptide.
FT                                /FTId=PRO_0000033784.
FT   CHAIN       303    414       Transforming growth factor beta-2.
FT                                /FTId=PRO_0000033785.
FT   CARBOHYD     72     72       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    140    140       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    241    241       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID    309    318
FT   DISULFID    317    380
FT   DISULFID    346    411
FT   DISULFID    350    413
FT   DISULFID    379    379       Interchain.
FT   VAR_SEQ     116    116       N -> TVCPVVTTPSGSVGSLCSRQSQVLCGYLD (in
FT                                isoform B). {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:2850146,
FT                                ECO:0000303|PubMed:3162414}.
FT                                /FTId=VSP_006417.
FT   VARIANT      91     91       R -> H (in dbSNP:rs10482721).
FT                                {ECO:0000269|PubMed:11528528,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_012708.
FT   VARIANT     100    104       Missing (in LDS4).
FT                                {ECO:0000269|PubMed:22772368}.
FT                                /FTId=VAR_068931.
FT   VARIANT     207    207       V -> L (in dbSNP:rs10482810).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_018923.
FT   VARIANT     299    299       R -> W (in LDS4).
FT                                {ECO:0000269|PubMed:22772368}.
FT                                /FTId=VAR_068932.
FT   VARIANT     302    302       R -> C (in LDS4).
FT                                {ECO:0000269|PubMed:22772368}.
FT                                /FTId=VAR_068933.
FT   VARIANT     320    320       R -> C (probable disease-associated
FT                                mutation found in a family with non-
FT                                syndromic aortic disease).
FT                                {ECO:0000269|PubMed:25046559}.
FT                                /FTId=VAR_072740.
FT   VARIANT     338    338       P -> H (in LDS4).
FT                                {ECO:0000269|PubMed:22772368}.
FT                                /FTId=VAR_068934.
FT   CONFLICT     32     32       F -> L (in Ref. 8; AAA61162).
FT                                {ECO:0000305}.
FT   CONFLICT    116    116       Missing (in Ref. 3; AAA50405).
FT                                {ECO:0000305}.
FT   HELIX       306    309       {ECO:0000244|PDB:2TGI}.
FT   STRAND      315    320       {ECO:0000244|PDB:2TGI}.
FT   STRAND      323    325       {ECO:0000244|PDB:2TGI}.
FT   HELIX       326    330       {ECO:0000244|PDB:2TGI}.
FT   STRAND      335    337       {ECO:0000244|PDB:2TGI}.
FT   STRAND      339    342       {ECO:0000244|PDB:2TGI}.
FT   STRAND      345    347       {ECO:0000244|PDB:2TGI}.
FT   STRAND      354    356       {ECO:0000244|PDB:2TGI}.
FT   HELIX       359    370       {ECO:0000244|PDB:2TGI}.
FT   HELIX       372    374       {ECO:0000244|PDB:2TGI}.
FT   STRAND      379    382       {ECO:0000244|PDB:2TGI}.
FT   STRAND      384    394       {ECO:0000244|PDB:2TGI}.
FT   STRAND      397    408       {ECO:0000244|PDB:2TGI}.
FT   STRAND      411    414       {ECO:0000244|PDB:2TGI}.
SQ   SEQUENCE   414 AA;  47748 MW;  7D9D569E0F4A07D0 CRC64;
     MHYCVLSAFL ILHLVTVALS LSTCSTLDMD QFMRKRIEAI RGQILSKLKL TSPPEDYPEP
     EEVPPEVISI YNSTRDLLQE KASRRAAACE RERSDEEYYA KEVYKIDMPP FFPSENAIPP
     TFYRPYFRIV RFDVSAMEKN ASNLVKAEFR VFRLQNPKAR VPEQRIELYQ ILKSKDLTSP
     TQRYIDSKVV KTRAEGEWLS FDVTDAVHEW LHHKDRNLGF KISLHCPCCT FVPSNNYIIP
     NKSEELEARF AGIDGTSTYT SGDQKTIKST RKKNSGKTPH LLLMLLPSYR LESQQTNRRK
     KRALDAAYCF RNVQDNCCLR PLYIDFKRDL GWKWIHEPKG YNANFCAGAC PYLWSSDTQH
     SRVLSLYNTI NPEASASPCC VSQDLEPLTI LYYIGKTPKI EQLSNMIVKS CKCS
//
ID   MYOC_HUMAN              Reviewed;         504 AA.
AC   Q99972; B2RD84; O00620; Q7Z6Q9;
DT   15-JUL-1998, integrated into UniProtKB/Swiss-Prot.
DT   01-JAN-1998, sequence version 2.
DT   20-JAN-2016, entry version 154.
DE   RecName: Full=Myocilin {ECO:0000303|PubMed:9169133};
DE   AltName: Full=Myocilin 55 kDa subunit;
DE   AltName: Full=Trabecular meshwork-induced glucocorticoid response protein {ECO:0000303|PubMed:9497363};
DE   Contains:
DE     RecName: Full=Myocilin, N-terminal fragment;
DE     AltName: Full=Myocilin 20 kDa N-terminal fragment;
DE   Contains:
DE     RecName: Full=Myocilin, C-terminal fragment;
DE     AltName: Full=Myocilin 35 kDa N-terminal fragment;
DE   Flags: Precursor;
GN   Name=MYOC; Synonyms=GLC1A, TIGR {ECO:0000303|PubMed:9280311};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=9280311; DOI=10.1016/S0014-5793(97)00934-4;
RA   Ortego J., Escribano J., Coca-Prados M.;
RT   "Cloning and characterization of subtracted cDNAs from a human ciliary
RT   body library encoding TIGR, a protein involved in juvenile open angle
RT   glaucoma with homology to myosin and olfactomedin.";
RL   FEBS Lett. 413:349-353(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND SUBCELLULAR LOCATION.
RC   TISSUE=Retina;
RX   PubMed=9169133; DOI=10.1006/geno.1997.4682;
RA   Kubota R., Noda S., Wang Y., Minoshima S., Asakawa S., Kudoh J.,
RA   Mashima Y., Oguchi Y., Shimizu N.;
RT   "A novel myosin-like protein (myocilin) expressed in the connecting
RT   cilium of the photoreceptor: molecular cloning, tissue expression, and
RT   chromosomal mapping.";
RL   Genomics 41:360-369(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS GLC1A ARG-246;
RP   LEU-370; SER-477; LYS-480 AND PHE-499.
RC   TISSUE=Leukocyte;
RX   PubMed=9328473; DOI=10.1093/hmg/6.12.2091;
RA   Adam M.F., Belmouden A., Binisti P., Brezin A.P., Valtot F.,
RA   Bechetoille A., Dascotte J.-C., Copin B., Gomez L., Chaventre A.,
RA   Bach J.-F., Garchon H.-J.;
RT   "Recurrent mutations in a single exon encoding the evolutionarily
RT   conserved olfactomedin-homology domain of TIGR in familial open-angle
RT   glaucoma.";
RL   Hum. Mol. Genet. 6:2091-2097(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], AND VARIANTS GLC1A VAL-364
RP   AND HIS-437.
RX   PubMed=9005853; DOI=10.1126/science.275.5300.668;
RA   Stone E.M., Fingert J.H., Alward W.L.M., Nguyen T.D., Polansky J.R.,
RA   Sunden S.L.F., Nishimura D., Clark A.F., Nystuen A., Nichols B.E.,
RA   Mackey D.A., Ritch R., Kalenak J.W., Craven E.R., Sheffield V.C.;
RT   "Identification of a gene that causes primary open angle glaucoma.";
RL   Science 275:668-670(1997).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=9446806; DOI=10.1006/bbrc.1997.7972;
RA   Kubota R., Kudoh J., Mashima Y., Asakawa S., Minoshima S.,
RA   Hejtmancik J.F., Oguchi Y., Shimizu N.;
RT   "Genomic organization of the human myocilin gene (MYOC) responsible
RT   for primary open angle glaucoma (GLC1A).";
RL   Biochem. Biophys. Res. Commun. 242:396-400(1998).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=9548973;
RA   Fingert J.H., Ying L., Swiderski R.E., Nystuen A.M., Arbour N.C.,
RA   Alward W.L.M., Sheffield V.C., Stone E.M.;
RT   "Characterization and comparison of the human and mouse GLC1A glaucoma
RT   genes.";
RL   Genome Res. 8:377-384(1998).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Heart;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [11]
RP   PROTEIN SEQUENCE OF 1-6 AND 33-37, SEQUENCE REVISION, OLIGOMERIZATION,
RP   SUBUNIT, SUBCELLULAR LOCATION, AND INDUCTION BY GLUCOCORTICOIDS.
RX   PubMed=9497363; DOI=10.1074/jbc.273.11.6341;
RA   Nguyen T.D., Chen P., Huang W.D., Chen H., Johnson D., Polansky J.R.;
RT   "Gene structure and properties of TIGR, an olfactomedin-related
RT   glycoprotein cloned from glucocorticoid-induced trabecular meshwork
RT   cells.";
RL   J. Biol. Chem. 273:6341-6350(1998).
RN   [12]
RP   PROTEIN SEQUENCE OF 33-37, SUBCELLULAR LOCATION, AND GLYCOSYLATION.
RX   PubMed=19287508;
RA   Sohn S., Joe M.K., Kim T.E., Im J.E., Choi Y.R., Park H., Kee C.;
RT   "Dual localization of wild-type myocilin in the endoplasmic reticulum
RT   and extracellular compartment likely occurs due to its incomplete
RT   secretion.";
RL   Mol. Vis. 15:545-556(2009).
RN   [13]
RP   PROTEIN SEQUENCE OF 227-233, SUBCELLULAR LOCATION, TISSUE SPECIFICITY,
RP   CHARACTERIZATION OF VARIANTS GLC1A LYS-323; LEU-370 AND GLY-380, AND
RP   PROTEOLYTIC PROCESSING.
RX   PubMed=15795224; DOI=10.1074/jbc.M501340200;
RA   Aroca-Aguilar J.D., Sanchez-Sanchez F., Ghosh S., Coca-Prados M.,
RA   Escribano J.;
RT   "Myocilin mutations causing glaucoma inhibit the intracellular
RT   endoproteolytic cleavage of myocilin between amino acids Arg226 and
RT   Ile227.";
RL   J. Biol. Chem. 280:21043-21051(2005).
RN   [14]
RP   SUBCELLULAR LOCATION.
RX   PubMed=11053284;
RA   O'Brien E.T., Ren X., Wang Y.;
RT   "Localization of myocilin to the golgi apparatus in Schlemm's canal
RT   cells.";
RL   Invest. Ophthalmol. Vis. Sci. 41:3842-3849(2000).
RN   [15]
RP   SUBCELLULAR LOCATION, INDUCTION BY GLUCOCORTICOIDS, GLYCOSYLATION, AND
RP   TISSUE SPECIFICITY.
RX   PubMed=11431441;
RA   Clark A.F., Steely H.T., Dickerson J.E. Jr., English-Wright S.,
RA   Stropki K., McCartney M.D., Jacobson N., Shepard A.R., Clark J.I.,
RA   Matsushima H., Peskind E.R., Leverenz J.B., Wilkinson C.W.,
RA   Swiderski R.E., Fingert J.H., Sheffield V.C., Stone E.M.;
RT   "Glucocorticoid induction of the glaucoma gene MYOC in human and
RT   monkey trabecular meshwork cells and tissues.";
RL   Invest. Ophthalmol. Vis. Sci. 42:1769-1780(2001).
RN   [16]
RP   INTERACTION WITH OLFM3.
RX   PubMed=12019210; DOI=10.1093/hmg/11.11.1291;
RA   Torrado M., Trivedi R., Zinovieva R., Karavanova I., Tomarev S.I.;
RT   "Optimedin: a novel olfactomedin-related protein that interacts with
RT   myocilin.";
RL   Hum. Mol. Genet. 11:1291-1301(2002).
RN   [17]
RP   INTERACTION WITH FN1, AND SUBCELLULAR LOCATION.
RX   PubMed=11773026;
RA   Filla M.S., Liu X., Nguyen T.D., Polansky J.R., Brandt C.R.,
RA   Kaufman P.L., Peters D.M.;
RT   "In vitro localization of TIGR/MYOC in trabecular meshwork
RT   extracellular matrix and binding to fibronectin.";
RL   Invest. Ophthalmol. Vis. Sci. 43:151-161(2002).
RN   [18]
RP   INTERACTION WITH MYL2.
RX   PubMed=11773029;
RA   Wentz-Hunter K., Ueda J., Yue B.Y.;
RT   "Protein interactions with myocilin.";
RL   Invest. Ophthalmol. Vis. Sci. 43:176-182(2002).
RN   [19]
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=11923248;
RA   Ueda J., Wentz-Hunter K., Yue B.Y.;
RT   "Distribution of myocilin and extracellular matrix components in the
RT   juxtacanalicular tissue of human eyes.";
RL   Invest. Ophthalmol. Vis. Sci. 43:1068-1076(2002).
RN   [20]
RP   DISULFIDE BOND AT 245-CYS--CYS-433.
RX   PubMed=12615070; DOI=10.1016/S0006-291X(03)00198-0;
RA   Nagy I., Trexler M., Patthy L.;
RT   "Expression and characterization of the olfactomedin domain of human
RT   myocilin.";
RL   Biochem. Biophys. Res. Commun. 302:554-561(2003).
RN   [21]
RP   CHARACTERIZATION OF VARIANT SER-57, GLYCOSYLATION, TISSUE SPECIFICITY,
RP   AND SUBCELLULAR LOCATION.
RX   PubMed=12697062; DOI=10.1186/1471-2156-4-5;
RA   Shepard A.R., Jacobson N., Sui R., Steely H.T., Lotery A.J.,
RA   Stone E.M., Clark A.F.;
RT   "Characterization of rabbit myocilin: implications for human myocilin
RT   glycosylation and signal peptide usage.";
RL   BMC Genet. 4:5-5(2003).
RN   [22]
RP   SUBCELLULAR LOCATION.
RX   PubMed=15944158; DOI=10.1074/jbc.M504803200;
RA   Hardy K.M., Hoffman E.A., Gonzalez P., McKay B.S., Stamer W.D.;
RT   "Extracellular trafficking of myocilin in human trabecular meshwork
RT   cells.";
RL   J. Biol. Chem. 280:28917-28926(2005).
RN   [23]
RP   CLEAVAGE BY CAPN2, SUBCELLULAR LOCATION, GLYCOSYLATION, AND
RP   MUTAGENESIS OF 226-ARG--GLU-230; ARG-226; ILE-227; LYS-229 AND
RP   GLU-230.
RX   PubMed=17650508; DOI=10.1074/jbc.M609608200;
RA   Sanchez-Sanchez F., Martinez-Redondo F., Aroca-Aguilar J.D.,
RA   Coca-Prados M., Escribano J.;
RT   "Characterization of the intracellular proteolytic cleavage of
RT   myocilin and identification of calpain II as a myocilin-processing
RT   protease.";
RL   J. Biol. Chem. 282:27810-27824(2007).
RN   [24]
RP   FUNCTION IN MITOCHONDRIAL DEPOLARIZATION, AND SUBCELLULAR LOCATION.
RX   PubMed=17516541; DOI=10.1002/jcp.21147;
RA   Sakai H., Shen X., Koga T., Park B.C., Noskina Y., Tibudan M.,
RA   Yue B.Y.;
RT   "Mitochondrial association of myocilin, product of a glaucoma gene, in
RT   human trabecular meshwork cells.";
RL   J. Cell. Physiol. 213:775-784(2007).
RN   [25]
RP   FUNCTION IN CELL-MATRIX ADHESION.
RX   PubMed=17984096; DOI=10.1074/jbc.M708250200;
RA   Shen X., Koga T., Park B.C., SundarRaj N., Yue B.Y.;
RT   "Rho GTPase and cAMP/protein kinase A signaling mediates myocilin-
RT   induced alterations in cultured human trabecular meshwork cells.";
RL   J. Biol. Chem. 283:603-612(2008).
RN   [26]
RP   FUNCTION IN CELL ADHESION.
RX   PubMed=18855004; DOI=10.1007/s00418-008-0518-4;
RA   Goldwich A., Scholz M., Tamm E.R.;
RT   "Myocilin promotes substrate adhesion, spreading and formation of
RT   focal contacts in podocytes and mesangial cells.";
RL   Histochem. Cell Biol. 131:167-180(2009).
RN   [27]
RP   FUNCTION IN STRESS FIBER ASSEMBLY, INTERACTION WITH FRZB; FZD7; FZD10;
RP   FZD1 AND WIF1, AND CHARACTERIZATION OF VARIANT ASN-477.
RX   PubMed=19188438; DOI=10.1128/MCB.01274-08;
RA   Kwon H.S., Lee H.S., Ji Y., Rubin J.S., Tomarev S.I.;
RT   "Myocilin is a modulator of Wnt signaling.";
RL   Mol. Cell. Biol. 29:2139-2154(2009).
RN   [28]
RP   FUNCTION IN NEURITE OUTGROWTH.
RX   PubMed=19959812; DOI=10.2353/ajpath.2010.090194;
RA   Koga T., Shen X., Park J.S., Qiu Y., Park B.C., Shyam R., Yue B.Y.;
RT   "Differential effects of myocilin and optineurin, two glaucoma genes,
RT   on neurite outgrowth.";
RL   Am. J. Pathol. 176:343-352(2010).
RN   [29]
RP   FUNCTION IN CELL MIGRATION.
RX   PubMed=21656515; DOI=10.1002/jcp.22701;
RA   Kwon H.S., Tomarev S.I.;
RT   "Myocilin, a glaucoma-associated protein, promotes cell migration
RT   through activation of integrin-focal adhesion kinase-serine/threonine
RT   kinase signaling pathway.";
RL   J. Cell. Physiol. 226:3392-3402(2011).
RN   [30]
RP   FUNCTION IN OSTEOBLAST DIFFERENTIATION.
RX   PubMed=23629661; DOI=10.1074/jbc.M112.422972;
RA   Kwon H.S., Johnson T.V., Tomarev S.I.;
RT   "Myocilin stimulates osteogenic differentiation of mesenchymal stem
RT   cells through mitogen-activated protein kinase signaling.";
RL   J. Biol. Chem. 288:16882-16894(2013).
RN   [31]
RP   FUNCTION IN MYELINATION, AND INTERACTION WITH NFASC; GLDN AND NRCAM.
RX   PubMed=23897819; DOI=10.1074/jbc.M112.446138;
RA   Kwon H.S., Johnson T.V., Joe M.K., Abu-Asab M., Zhang J., Chan C.C.,
RA   Tomarev S.I.;
RT   "Myocilin mediates myelination in the peripheral nervous system
RT   through ErbB2/3 signaling.";
RL   J. Biol. Chem. 288:26357-26371(2013).
RN   [32]
RP   X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) OF 228-504 IN COMPLEX WITH
RP   CALCIUM, DISULFIDE BONDS, CHARACTERIZATION OF VARIANTS GLC1A LYS-293;
RP   ILE-353 AND VAL-445, AND CHARACTERIZATION OF VARIANTS MET-329;
RP   CYS-422; PRO-425 AND CYS-473.
RX   PubMed=25524706; DOI=10.1093/hmg/ddu730;
RA   Donegan R.K., Hill S.E., Freeman D.M., Nguyen E., Orwig S.D.,
RA   Turnage K.C., Lieberman R.L.;
RT   "Structural basis for misfolding in myocilin-associated glaucoma.";
RL   Hum. Mol. Genet. 24:2111-2124(2015).
RN   [33]
RP   VARIANTS GLC1A ARG-367 AND LEU-370.
RX   PubMed=9345106; DOI=10.1086/301612;
RA   Suzuki Y., Shirato S., Taniguchi F., Ohara K., Nishimaki K., Ohta S.;
RT   "Mutations in the TIGR gene in familial primary open-angle glaucoma in
RT   Japan.";
RL   Am. J. Hum. Genet. 61:1202-1204(1997).
RN   [34]
RP   VARIANT GLC1A PRO-341.
RX   PubMed=9510647; DOI=10.3341/kjo.1997.11.2.75;
RA   Kee C., Ahn B.-H.;
RT   "TIGR gene in primary open-angle glaucoma and steroid-induced
RT   glaucoma.";
RL   Korean J. Ophthalmol. 11:75-78(1997).
RN   [35]
RP   VARIANT GLC1A ARG-337.
RX   PubMed=9361308; DOI=10.3109/13816819709057124;
RA   Stoilova D., Child A., Brice G., Crick R.P., Fleck B.W., Sarfarazi M.;
RT   "Identification of a new 'TIGR' mutation in a family with juvenile-
RT   onset primary open angle glaucoma.";
RL   Ophthalmic Genet. 18:109-118(1997).
RN   [36]
RP   VARIANTS GLC1A LYS-352; LEU-370; MET-377 AND HIS-437.
RX   PubMed=9792882; DOI=10.1086/302098;
RA   Wiggs J.L., Allingham R.R., Vollrath D., Jones K.H., De La Paz M.,
RA   Kern J., Patterson K., Babb V.L., Del Bono E.A., Broomer B.W.,
RA   Pericak-Vance M.A., Haines J.L.;
RT   "Prevalence of mutations in TIGR/Myocilin in patients with adult and
RT   juvenile primary open-angle glaucoma.";
RL   Am. J. Hum. Genet. 63:1549-1552(1998).
RN   [37]
RP   VARIANTS GLC1A ARG-367 AND LEU-370.
RX   PubMed=9490287; DOI=10.1007/s004390050661;
RA   Michels-Rautenstrauss K.G., Mardin C.Y., Budde W.M., Liehr T.,
RA   Polansky J.R., Nguyen T., Timmerman V., van Broeckhoven C.,
RA   Naumann G.O.H., Pfeiffer R.A., Rautenstrauss B.W.;
RT   "Juvenile open angle glaucoma: fine mapping of the TIGR gene to
RT   1q24.3-q25.2 and mutation analysis.";
RL   Hum. Genet. 102:103-106(1998).
RN   [38]
RP   VARIANTS GLC1A ARG-367 AND PHE-426.
RX   PubMed=9521427;
RX   DOI=10.1002/(SICI)1098-1004(1998)11:3<244::AID-HUMU10>3.0.CO;2-Z;
RA   Mansergh F.C., Kenna P.F., Ayuso C., Kiang A.-S., Humphries P.,
RA   Farrar G.J.;
RT   "Novel mutations in the TIGR gene in early and late onset open angle
RT   glaucoma.";
RL   Hum. Mutat. 11:244-251(1998).
RN   [39]
RP   VARIANTS GLC1A LEU-370; ALA-380 AND PRO-502, AND VARIANT LYS-76.
RX   PubMed=9863594; DOI=10.1136/jmg.35.12.989;
RA   Stoilova D., Child A., Brice G., Desai T., Barsoum-Homsy M.,
RA   Ozdemir N., Chevrette L., Adam M.F., Garchon H.-J., Pitts Crick R.,
RA   Sarfarazi M.;
RT   "Novel TIGR/MYOC mutations in families with juvenile onset primary
RT   open angle glaucoma.";
RL   J. Med. Genet. 35:989-992(1998).
RN   [40]
RP   VARIANT GLC1A GLU-423.
RX   PubMed=9697688; DOI=10.1038/1203;
RA   Morissette J., Clepet C., Moisan S., Dubois S., Winstall E.,
RA   Vermeeren D., Nguyen T.D., Polansky J.R., Cote G., Anctil J.-L.,
RA   Amyot M., Plante M., Falardeau P., Raymond V.;
RT   "Homozygotes carrying an autosomal dominant TIGR mutation do not
RT   manifest glaucoma.";
RL   Nat. Genet. 19:319-321(1998).
RN   [41]
RP   VARIANTS GLC1A, AND VARIANTS.
RX   PubMed=9535666; DOI=10.1056/NEJM199804093381503;
RA   Alward W.L.M., Fingert J.H., Coote M.A., Johnson A.T., Lerner S.F.,
RA   Junqua D., Durcan F.J., McCartney P.J., Mackey D.A., Sheffield V.C.,
RA   Stone E.M.;
RT   "Clinical features associated with mutations in the chromosome 1 open-
RT   angle glaucoma gene.";
RL   N. Engl. J. Med. 338:1022-1027(1998).
RN   [42]
RP   VARIANT GLC1A ILE-353.
RX   PubMed=10330365; DOI=10.1086/302407;
RA   Yoon S.-J.K., Kim H.-S., Moon J.-I., Lim J.M., Joo C.-K.;
RT   "Mutations of the TIGR/MYOC gene in primary open-angle glaucoma in
RT   Korea.";
RL   Am. J. Hum. Genet. 64:1775-1778(1999).
RN   [43]
RP   VARIANTS GLC1A, AND VARIANTS.
RX   PubMed=10196380; DOI=10.1093/hmg/8.5.899;
RA   Fingert J.H., Heon E., Liebmann J.M., Yamamoto T., Craig J.E.,
RA   Rait J., Kawase K., Hoh S.-T., Buys Y.M., Dickinson J., Hockey R.R.,
RA   Williams-Lyn D., Trope G., Kitazawa Y., Ritch R., Mackey D.A.,
RA   Alward W.L.M., Sheffield V.C., Stone E.M.;
RT   "Analysis of myocilin mutations in 1703 glaucoma patients from five
RT   different populations.";
RL   Hum. Mol. Genet. 8:899-905(1999).
RN   [44]
RP   VARIANT GLC1A PRO-448.
RX   PubMed=10340788; DOI=10.1016/S0021-5155(98)00077-X;
RA   Yokoyama A., Nao-i N., Date Y., Nakazato M., Chumann H., Chihara E.,
RA   Sawada A., Matsukura S.;
RT   "Detection of a new TIGR gene mutation in a Japanese family with
RT   primary open angle glaucoma.";
RL   Jpn. J. Ophthalmol. 43:85-88(1999).
RN   [45]
RP   VARIANTS GLC1A ARG-252; GLY-272; LYS-323; LEU-370; MET-377; PHE-426;
RP   ASN-477 AND SER-499, VARIANTS ASP-57; LYS-76; MET-329 AND ARG-398,
RP   CHARACTERIZATION OF VARIANTS GLC1A ARG-252; GLY-272; LYS-323; LEU-370;
RP   MET-377; PHE-426; ASN-477 AND SER-499, AND CHARACTERIZATION OF
RP   VARIANTS ASP-57; LYS-76; MET-329 AND ARG-398.
RX   PubMed=11004290; DOI=10.1016/S0002-9394(00)00536-5;
RA   Shimizu S., Lichter P.R., Johnson A.T., Zhou Z., Higashi M.,
RA   Gottfredsdottir M., Othman M., Moroi S.E., Rozsa F.W., Schertzer R.M.,
RA   Clarke M.S., Schwartz A.L., Downs C.A., Vollrath D., Richards J.E.;
RT   "Age-dependent prevalence of mutations at the GLC1A locus in primary
RT   open-angle glaucoma.";
RL   Am. J. Ophthalmol. 130:165-177(2000).
RN   [46]
RP   VARIANT GLC1A ARG-252.
RX   PubMed=10873982; DOI=10.1136/bjo.84.7.722;
RA   Booth A.P., Anwar R., Chen H., Churchill A.J., Jay J., Polansky J.,
RA   Nguyen T., Markham A.F.;
RT   "Genetic screening in a large family with juvenile onset primary open
RT   angle glaucoma.";
RL   Br. J. Ophthalmol. 84:722-726(2000).
RN   [47]
RP   VARIANT GLC1A ALA-53.
RX   PubMed=10644174;
RX   DOI=10.1002/(SICI)1098-1004(200001)15:1<122::AID-HUMU38>3.0.CO;2-O;
RA   Pang C.P., Leung Y.F., Chua J.K.H., Baum L., Fan D.S.P., Lam D.S.;
RT   "Novel TIGR sequence alteration Val53Ala.";
RL   Hum. Mutat. 15:122-122(2000).
RN   [48]
RP   VARIANTS GLC1A GLN-158; ASN-360 AND THR-363, AND VARIANTS HIS-19;
RP   LYS-76; GLU-208 AND HIS-470.
RX   PubMed=10980537;
RX   DOI=10.1002/1098-1004(200009)16:3<270::AID-HUMU13>3.0.CO;2-M;
RA   Kubota R., Mashima Y., Ohtake Y., Tanino T., Kimura T., Hotta Y.,
RA   Kanai A., Tokuoka S., Azuma I., Tanihara H., Inatani M., Inoue Y.,
RA   Kudoh J., Oguchi Y., Shimizu N.;
RT   "Novel mutations in the myocilin gene in Japanese glaucoma patients.";
RL   Hum. Mutat. 16:270-270(2000).
RN   [49]
RP   VARIANTS GLC1A GLU-208 AND ILE-353, AND VARIANTS ARG-12 AND LYS-76.
RX   PubMed=10798654;
RA   Lam D.S.C., Leung Y.F., Chua J.K.H., Baum L., Fan D.S.P., Choy K.W.,
RA   Pang C.P.;
RT   "Truncations in the TIGR gene in individuals with and without primary
RT   open-angle glaucoma.";
RL   Invest. Ophthalmol. Vis. Sci. 41:1386-1391(2000).
RN   [50]
RP   VARIANT GLC1A ARG-433.
RX   PubMed=10819638; DOI=10.1136/jmg.37.4.301;
RA   Vasconcellos J.P.C., Melo M.B., Tsukumo D.M.L., Basseres D.S.,
RA   Bordin S., Saad S.T.O., Costa F.F.;
RT   "Novel mutation in the MYOC gene in primary open glaucoma patients.";
RL   J. Med. Genet. 37:301-303(2000).
RN   [51]
RP   VARIANTS GLC1A LYS-261 AND GLU-337, AND VARIANT ARG-398.
RX   PubMed=10916185; DOI=10.1076/1381-6810(200006)2121-8FT109;
RA   Vazquez C.M., Herrero O.M.V., Bastus B.M., Perez V.D.;
RT   "Mutations in the third exon of the MYOC gene in Spanish patients with
RT   primary open angle glaucoma.";
RL   Ophthalmic Genet. 21:109-115(2000).
RN   [52]
RP   VARIANTS GLC1A ARG-252; LYS-293; ARG-367; LEU-370; LYS-377; VAL-399
RP   AND VAL-445, AND VARIANT ARG-398.
RX   PubMed=11774072; DOI=10.1086/338709;
RA   Vincent A.L., Billingsley G., Buys Y., Levin A.V., Priston M.,
RA   Trope G., Williams-Lyn D., Heon E.;
RT   "Digenic inheritance of early-onset glaucoma: CYP1B1, a potential
RT   modifier gene.";
RL   Am. J. Hum. Genet. 70:448-460(2002).
RN   [53]
RP   VARIANTS GLC1A TRP-126; LYS-293; LYS-352; ARG-367; GLU-423; THR-427;
RP   VAL-445 AND LEU-481, AND VARIANTS LYS-76; GLU-77 AND ARG-398.
RX   PubMed=12189160; DOI=10.1093/hmg/11.18.2077;
RG   The Quebec glaucoma network;
RA   Faucher M., Anctil J.-L., Rodrigue M.-A., Duchesne A., Bergeron D.,
RA   Blondeau P., Cote G., Dubois S., Bergeron J., Arseneault R.,
RA   Morissette J., Raymond V.;
RT   "Founder TIGR/myocilin mutations for glaucoma in the Quebec
RT   population.";
RL   Hum. Mol. Genet. 11:2077-2090(2002).
RN   [54]
RP   VARIANTS GLC1A ALA-251; MET-345; ARG-367; LEU-370; ASN-393; SER-434;
RP   ASP-450 AND CYS-470, AND VARIANT LYS-76.
RX   PubMed=12442283; DOI=10.1002/humu.9092;
RA   Michels-Rautenstrauss K., Mardin C., Wakili N., Juenemann A.M.,
RA   Villalobos L., Mejia C., Soley G.C., Azofeifa J., Oezbey S.,
RA   Naumann G.O.H., Reis A., Rautenstrauss B.;
RT   "Novel mutations in the MYOC/GLC1A gene in a large group of glaucoma
RT   patients.";
RL   Hum. Mutat. 20:479-480(2002).
RN   [55]
RP   VARIANTS GLC1A LYS-300 AND CYS-471, AND VARIANTS ARG-12; LEU-16;
RP   SER-17; LYS-76; PRO-95; GLU-208; PRO-215; ILE-353 AND LYS-414.
RX   PubMed=12356829;
RA   Pang C.P., Leung Y.F., Fan B., Baum L., Tong W.C., Lee W.S.,
RA   Chua J.K.H., Fan D.S.P., Liu Y., Lam D.S.C.;
RT   "TIGR/MYOC gene sequence alterations in individuals with and without
RT   primary open-angle glaucoma.";
RL   Invest. Ophthalmol. Vis. Sci. 43:3231-3235(2002).
RN   [56]
RP   VARIANTS GLC1A LYS-342 AND ASN-380.
RX   PubMed=12362081; DOI=10.1097/00061198-200210000-00008;
RA   Challa P., Herndon L.W., Hauser M.A., Broomer B.W.,
RA   Pericak-Vance M.A., Ababio-Danso B., Allingham R.R.;
RT   "Prevalence of myocilin mutations in adults with primary open-angle
RT   glaucoma in Ghana, West Africa.";
RL   J. Glaucoma 11:416-420(2002).
RN   [57]
RP   VARIANTS GLC1A ARG-25 AND GLU-423.
RX   PubMed=12860809; DOI=10.1001/archopht.121.7.1034;
RA   Bruttini M., Longo I., Frezzotti P., Ciappetta R., Randazzo A.,
RA   Orzalesi N., Fumagalli E., Caporossi A., Frezzotti R., Renieri A.;
RT   "Mutations in the myocilin gene in families with primary open-angle
RT   glaucoma and juvenile open-angle glaucoma.";
RL   Arch. Ophthalmol. 121:1034-1038(2003).
RN   [58]
RP   VARIANTS GLC1A ARG-367; ILE-438; LYS-480 AND PHE-499, AND VARIANTS
RP   SER-57; LYS-76 AND ARG-398.
RX   PubMed=12872267; DOI=10.1002/humu.9165;
RA   Melki R., Belmouden A., Brezin A., Garchon H.-J.;
RT   "Myocilin analysis by DHPLC in French POAG patients: increased
RT   prevalence of Q368X mutation.";
RL   Hum. Mutat. 22:179-179(2003).
RN   [59]
RP   VARIANT GLC1A HIS-48, AND VARIANT LYS-76.
RX   PubMed=15025728; DOI=10.1111/j.1399-0004.2004.00232.x;
RA   Sripriya S., Uthra S., Sangeetha R., George R.J., Hemamalini A.,
RA   Paul P.G., Amali J., Vijaya L., Kumaramanickavel G.;
RT   "Low frequency of myocilin mutations in Indian primary open-angle
RT   glaucoma patients.";
RL   Clin. Genet. 65:333-337(2004).
RN   [60]
RP   VARIANTS GLC1A ASN-360; THR-363; LEU-369 AND PRO-448.
RX   PubMed=15534471; DOI=10.1097/0.ijg.0000138204.6d;
RA   Ishikawa K., Funayama T., Ohtake Y., Tanino T., Kurosaka D.,
RA   Suzuki K., Ideta H., Fujimaki T., Tanihara H., Asaoka R., Naoi N.,
RA   Yasuda N., Iwata T., Mashima Y.;
RT   "Novel MYOC gene mutation, Phe369Leu, in Japanese patients with
RT   primary open-angle glaucoma detected by denaturing high-performance
RT   liquid chromatography.";
RL   J. Glaucoma 13:466-471(2004).
RN   [61]
RP   VARIANT GLC1A ARG-274.
RX   PubMed=15255110; DOI=10.1076/opge.25.1.11.28995;
RA   Markandaya M., Ramesh T.K., Selvaraju V., Dorairaj S.K., Prakash R.,
RA   Shetty J., Kumar A.;
RT   "Genetic analysis of an Indian family with members affected with
RT   juvenile-onset primary open-angle glaucoma.";
RL   Ophthalmic Genet. 25:11-23(2004).
RN   [62]
RP   VARIANT GLC3A HIS-48.
RX   PubMed=15733270; DOI=10.1111/j.1399-0004.2005.00411.x;
RA   Kaur K., Reddy A.B.M., Mukhopadhyay A., Mandal A.K., Hasnain S.E.,
RA   Ray K., Thomas R., Balasubramanian D., Chakrabarti S.;
RT   "Myocilin gene implicated in primary congenital glaucoma.";
RL   Clin. Genet. 67:335-340(2005).
RN   [63]
RP   VARIANT GLC1A TYR-245, AND CHARACTERIZATION OF VARIANT GLC1A TYR-245.
RX   PubMed=16401791; DOI=10.1001/archopht.124.1.102;
RA   Fan B.J., Leung D.Y.L., Wang D.Y., Gobeil S., Raymond V., Tam P.O.S.,
RA   Lam D.S.C., Pang C.P.;
RT   "Novel myocilin mutation in a Chinese family with juvenile-onset open-
RT   angle glaucoma.";
RL   Arch. Ophthalmol. 124:102-106(2006).
RN   [64]
RP   VARIANT GLC1A HIS-380.
RX   PubMed=17499207; DOI=10.1016/j.ajo.2007.03.037;
RA   Wirtz M.K., Samples J.R., Choi D., Gaudette N.D.;
RT   "Clinical features associated with an Asp380His Myocilin mutation in a
RT   US family with primary open-angle glaucoma.";
RL   Am. J. Ophthalmol. 144:75-80(2007).
RN   [65]
RP   VARIANTS GLC1A VAL-244 AND ARG-252.
RX   PubMed=17210859; DOI=10.1001/archopht.125.1.98;
RA   Hewitt A.W., Bennett S.L., Richards J.E., Dimasi D.P., Booth A.P.,
RA   Inglehearn C., Anwar R., Yamamoto T., Fingert J.H., Heon E.,
RA   Craig J.E., Mackey D.A.;
RT   "Myocilin Gly252Arg mutation and glaucoma of intermediate severity in
RT   Caucasian individuals.";
RL   Arch. Ophthalmol. 125:98-104(2007).
CC   -!- FUNCTION: Secreted glycoprotein regulating the activation of
CC       different signaling pathways in adjacent cells to control
CC       different processes including cell adhesion, cell-matrix adhesion,
CC       cytoskeleton organization and cell migration. Promotes substrate
CC       adhesion, spreading and formation of focal contacts. Negatively
CC       regulates cell-matrix adhesion and stress fiber assembly through
CC       Rho protein signal transduction. Modulates the organization of
CC       actin cytoskeleton by stimulating the formation of stress fibers
CC       through interactions with components of Wnt signaling pathways.
CC       Promotes cell migration through activation of PTK2 and the
CC       downstream phosphatidylinositol 3-kinase signaling. Plays a role
CC       in bone formation and promotes osteoblast differentiation in a
CC       dose-dependent manner through mitogen-activated protein kinase
CC       signaling. Mediates myelination in the peripheral nervous system
CC       through ERBB2/ERBB3 signaling. Plays a role as a regulator of
CC       muscle hypertrophy through the components of dystrophin-associated
CC       protein complex. Involved in positive regulation of mitochondrial
CC       depolarization. Plays a role in neurite outgrowth. May participate
CC       in the obstruction of fluid outflow in the trabecular meshwork.
CC       {ECO:0000250|UniProtKB:O70624, ECO:0000269|PubMed:17516541,
CC       ECO:0000269|PubMed:17984096, ECO:0000269|PubMed:18855004,
CC       ECO:0000269|PubMed:19188438, ECO:0000269|PubMed:19959812,
CC       ECO:0000269|PubMed:21656515, ECO:0000269|PubMed:23629661,
CC       ECO:0000269|PubMed:23897819}.
CC   -!- SUBUNIT: Homodimer (via N-terminus). Can also form higher
CC       oligomers (PubMed:9497363). Interacts with OLFM3, FN1, NRCAM, GLDN
CC       and NFASC (PubMed:12019210, PubMed:11773026, PubMed:23897819).
CC       Interacts (via N-terminus) with MYL2 (PubMed:11773029). Interacts
CC       with SFRP1, FRZB, FZD7, FZD10, FZD1 and WIF1; regulates Wnt
CC       signaling (PubMed:19188438). Interacts with SNTA1; regulates
CC       muscle hypertrophy. Interacts with ERBB2 and ERBB3; acivates
CC       ERBB2-ERBB3 signaling pathway. Interacts with SNCG; affects its
CC       secretion and its aggregation (By similarity).
CC       {ECO:0000250|UniProtKB:O70624, ECO:0000269|PubMed:11773026,
CC       ECO:0000269|PubMed:11773029, ECO:0000269|PubMed:12019210,
CC       ECO:0000269|PubMed:19188438, ECO:0000269|PubMed:23897819,
CC       ECO:0000269|PubMed:9497363}.
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:11431441,
CC       ECO:0000269|PubMed:12697062, ECO:0000269|PubMed:19287508,
CC       ECO:0000269|PubMed:9497363}. Golgi apparatus
CC       {ECO:0000269|PubMed:11053284}. Cytoplasmic vesicle
CC       {ECO:0000269|PubMed:11431441}. Secreted, extracellular space.
CC       Secreted, extracellular space, extracellular matrix
CC       {ECO:0000269|PubMed:11773026, ECO:0000305|PubMed:11431441}.
CC       Secreted, exosome {ECO:0000269|PubMed:15944158}. Mitochondrion
CC       {ECO:0000269|PubMed:17516541}. Mitochondrion intermembrane space
CC       {ECO:0000269|PubMed:17516541}. Mitochondrion inner membrane
CC       {ECO:0000269|PubMed:17516541}. Mitochondrion outer membrane
CC       {ECO:0000269|PubMed:17516541}. Rough endoplasmic reticulum
CC       {ECO:0000269|PubMed:19287508}. Cell projection. Cell projection,
CC       cilium {ECO:0000269|PubMed:9169133}. Note=Located preferentially
CC       in the ciliary rootlet and basal body of the connecting cilium of
CC       photoreceptor cells, and in the rough endoplasmic reticulum
CC       (PubMed:9169133). It is only imported to mitochondria in the
CC       trabecular meshwork (PubMed:17516541). Localizes to the Golgi
CC       apparatus in Schlemm's canal endothelial cells (PubMed:11053284).
CC       Appears in the extracellular space of trabecular meshwork cells by
CC       an unconventional mechanism, likely associated with exosome-like
CC       vesicles (PubMed:15944158). Localizes in trabecular meshwork
CC       extracellular matrix (PubMed:15944158).
CC       {ECO:0000269|PubMed:11053284, ECO:0000269|PubMed:15944158,
CC       ECO:0000269|PubMed:17516541, ECO:0000269|PubMed:9169133}.
CC   -!- SUBCELLULAR LOCATION: Myocilin, C-terminal fragment: Secreted.
CC   -!- SUBCELLULAR LOCATION: Myocilin, N-terminal fragment: Endoplasmic
CC       reticulum. Note=Remains retained in the endoplasmic reticulum.
CC   -!- TISSUE SPECIFICITY: Detected in aqueous humor (PubMed:12697062).
CC       Detected in the eye (at protein level) (PubMed:11431441). Widely
CC       expressed. Highly expressed in various types of muscle, ciliary
CC       body, papillary sphincter, skeletal muscle, heart, and bone
CC       marrow-derived mesenchymal stem cells. Expressed predominantly in
CC       the retina. In normal eyes, found in the inner uveal meshwork
CC       region and the anterior portion of the meshwork. In contrast, in
CC       many glaucomatous eyes, it is found in more regions of the
CC       meshwork and seems to be expressed at higher levels than in normal
CC       eyes, regardless of the type or clinical severity of glaucoma. The
CC       myocilin 35 kDa fragment is detected in aqueous humor and at to a
CC       lesser extend in iris and ciliary body.
CC       {ECO:0000269|PubMed:11431441, ECO:0000269|PubMed:12697062,
CC       ECO:0000269|PubMed:15795224}.
CC   -!- INDUCTION: Up-regulated by dexamethasone, a glucocorticoid.
CC       {ECO:0000269|PubMed:11431441, ECO:0000269|PubMed:9497363}.
CC   -!- PTM: Different isoforms may arise by post-translational
CC       modifications. {ECO:0000269|PubMed:9497363}.
CC   -!- PTM: Glycosylated. {ECO:0000269|PubMed:11431441,
CC       ECO:0000269|PubMed:12697062, ECO:0000269|PubMed:17650508,
CC       ECO:0000269|PubMed:19287508}.
CC   -!- PTM: Palmitoylated. {ECO:0000250|UniProtKB:Q2PT31}.
CC   -!- PTM: Undergoes a calcium-dependent proteolytic cleavage at Arg-226
CC       by CAPN2 in the endoplasmic reticulum. The result is the
CC       production of two fragments, one of 35 kDa containing the C-
CC       terminal olfactomedin-like domain, and another of 20 kDa
CC       containing the N-terminal leucine zipper-like domain.
CC       {ECO:0000269|PubMed:15795224, ECO:0000269|PubMed:17650508}.
CC   -!- DISEASE: Glaucoma 1, open angle, A (GLC1A) [MIM:137750]: A form of
CC       primary open angle glaucoma (POAG). POAG is characterized by a
CC       specific pattern of optic nerve and visual field defects. The
CC       angle of the anterior chamber of the eye is open, and usually the
CC       intraocular pressure is increased. However, glaucoma can occur at
CC       any intraocular pressure. The disease is generally asymptomatic
CC       until the late stages, by which time significant and irreversible
CC       optic nerve damage has already taken place.
CC       {ECO:0000269|PubMed:10196380, ECO:0000269|PubMed:10330365,
CC       ECO:0000269|PubMed:10340788, ECO:0000269|PubMed:10644174,
CC       ECO:0000269|PubMed:10798654, ECO:0000269|PubMed:10819638,
CC       ECO:0000269|PubMed:10873982, ECO:0000269|PubMed:10916185,
CC       ECO:0000269|PubMed:10980537, ECO:0000269|PubMed:11004290,
CC       ECO:0000269|PubMed:11774072, ECO:0000269|PubMed:12189160,
CC       ECO:0000269|PubMed:12356829, ECO:0000269|PubMed:12362081,
CC       ECO:0000269|PubMed:12442283, ECO:0000269|PubMed:12860809,
CC       ECO:0000269|PubMed:12872267, ECO:0000269|PubMed:15025728,
CC       ECO:0000269|PubMed:15255110, ECO:0000269|PubMed:15534471,
CC       ECO:0000269|PubMed:16401791, ECO:0000269|PubMed:17210859,
CC       ECO:0000269|PubMed:17499207, ECO:0000269|PubMed:9005853,
CC       ECO:0000269|PubMed:9328473, ECO:0000269|PubMed:9345106,
CC       ECO:0000269|PubMed:9361308, ECO:0000269|PubMed:9490287,
CC       ECO:0000269|PubMed:9510647, ECO:0000269|PubMed:9521427,
CC       ECO:0000269|PubMed:9535666, ECO:0000269|PubMed:9697688,
CC       ECO:0000269|PubMed:9792882, ECO:0000269|PubMed:9863594}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Glaucoma 3, primary congenital, A (GLC3A) [MIM:231300]:
CC       An autosomal recessive form of primary congenital glaucoma (PCG).
CC       PCG is characterized by marked increase of intraocular pressure at
CC       birth or early childhood, large ocular globes (buphthalmos) and
CC       corneal edema. It results from developmental defects of the
CC       trabecular meshwork and anterior chamber angle of the eye that
CC       prevent adequate drainage of aqueous humor.
CC       {ECO:0000269|PubMed:15733270}. Note=The disease is caused by
CC       mutations affecting distinct genetic loci, including the gene
CC       represented in this entry. MYOC mutations may contribute to GLC3A
CC       via digenic inheritance with CYP1B1 and/or another locus
CC       associated with the disease (PubMed:15733270).
CC       {ECO:0000269|PubMed:15733270}.
CC   -!- SIMILARITY: Contains 1 olfactomedin-like domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00446}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA24532.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF001620; AAC51725.1; -; mRNA.
DR   EMBL; D88214; BAA23531.1; -; mRNA.
DR   EMBL; Z97171; CAB09899.1; -; Genomic_DNA.
DR   EMBL; Z97177; CAB09899.1; JOINED; Genomic_DNA.
DR   EMBL; Z97174; CAB09899.1; JOINED; Genomic_DNA.
DR   EMBL; U85257; AAC52051.1; -; mRNA.
DR   EMBL; AB006688; BAA24532.1; ALT_INIT; Genomic_DNA.
DR   EMBL; AF049793; AAC14264.1; -; Genomic_DNA.
DR   EMBL; AF049791; AAC14264.1; JOINED; Genomic_DNA.
DR   EMBL; AF049792; AAC14264.1; JOINED; Genomic_DNA.
DR   EMBL; AK315443; BAG37831.1; -; mRNA.
DR   EMBL; Z98750; CAD92590.2; -; Genomic_DNA.
DR   EMBL; CH471067; EAW90903.1; -; Genomic_DNA.
DR   EMBL; BC029261; AAH29261.1; -; mRNA.
DR   CCDS; CCDS1297.1; -.
DR   PIR; JC5830; JC5830.
DR   RefSeq; NP_000252.1; NM_000261.1.
DR   UniGene; Hs.436037; -.
DR   PDB; 4WXQ; X-ray; 2.15 A; A=228-504.
DR   PDB; 4WXS; X-ray; 1.90 A; A=228-504.
DR   PDB; 4WXU; X-ray; 2.09 A; A=228-504.
DR   PDBsum; 4WXQ; -.
DR   PDBsum; 4WXS; -.
DR   PDBsum; 4WXU; -.
DR   ProteinModelPortal; Q99972; -.
DR   SMR; Q99972; 244-502.
DR   BioGrid; 110736; 43.
DR   STRING; 9606.ENSP00000037502; -.
DR   PhosphoSite; Q99972; -.
DR   BioMuta; MYOC; -.
DR   DMDM; 3024209; -.
DR   PaxDb; Q99972; -.
DR   PRIDE; Q99972; -.
DR   DNASU; 4653; -.
DR   Ensembl; ENST00000037502; ENSP00000037502; ENSG00000034971.
DR   GeneID; 4653; -.
DR   KEGG; hsa:4653; -.
DR   UCSC; uc001ghu.3; human.
DR   CTD; 4653; -.
DR   GeneCards; MYOC; -.
DR   HGNC; HGNC:7610; MYOC.
DR   HPA; HPA027364; -.
DR   MalaCards; MYOC; -.
DR   MIM; 137750; phenotype.
DR   MIM; 231300; phenotype.
DR   MIM; 601652; gene.
DR   neXtProt; NX_Q99972; -.
DR   Orphanet; 98976; Congenital glaucoma.
DR   Orphanet; 98977; Juvenile glaucoma.
DR   PharmGKB; PA31415; -.
DR   eggNOG; ENOG410INPA; Eukaryota.
DR   eggNOG; ENOG410YBJJ; LUCA.
DR   GeneTree; ENSGT00760000119005; -.
DR   HOGENOM; HOG000059654; -.
DR   HOVERGEN; HBG105662; -.
DR   InParanoid; Q99972; -.
DR   OMA; RYKYSSM; -.
DR   OrthoDB; EOG75F4CZ; -.
DR   PhylomeDB; Q99972; -.
DR   TreeFam; TF315964; -.
DR   GeneWiki; MYOC; -.
DR   GenomeRNAi; 4653; -.
DR   NextBio; 17936; -.
DR   PRO; PR:Q99972; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; Q99972; -.
DR   CleanEx; HS_MYOC; -.
DR   ExpressionAtlas; Q99972; baseline and differential.
DR   Genevisible; Q99972; HS.
DR   GO; GO:0005929; C:cilium; IEA:UniProtKB-SubCell.
DR   GO; GO:0016023; C:cytoplasmic membrane-bounded vesicle; IEA:UniProtKB-SubCell.
DR   GO; GO:0031410; C:cytoplasmic vesicle; IDA:UniProtKB.
DR   GO; GO:0005783; C:endoplasmic reticulum; ISS:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0031012; C:extracellular matrix; IDA:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; IDA:MGI.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB.
DR   GO; GO:0005743; C:mitochondrial inner membrane; IDA:UniProtKB.
DR   GO; GO:0005758; C:mitochondrial intermembrane space; IDA:UniProtKB.
DR   GO; GO:0005741; C:mitochondrial outer membrane; IDA:UniProtKB.
DR   GO; GO:0033268; C:node of Ranvier; ISS:UniProtKB.
DR   GO; GO:0005578; C:proteinaceous extracellular matrix; IEA:UniProtKB-SubCell.
DR   GO; GO:0005791; C:rough endoplasmic reticulum; IEA:UniProtKB-SubCell.
DR   GO; GO:0001968; F:fibronectin binding; IPI:UniProtKB.
DR   GO; GO:0005109; F:frizzled binding; IPI:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0032027; F:myosin light chain binding; IPI:UniProtKB.
DR   GO; GO:0060348; P:bone development; ISS:UniProtKB.
DR   GO; GO:0045162; P:clustering of voltage-gated sodium channels; ISS:UniProtKB.
DR   GO; GO:0038133; P:ERBB2-ERBB3 signaling pathway; ISS:UniProtKB.
DR   GO; GO:0022011; P:myelination in peripheral nervous system; ISS:UniProtKB.
DR   GO; GO:0001953; P:negative regulation of cell-matrix adhesion; IDA:UniProtKB.
DR   GO; GO:0035024; P:negative regulation of Rho protein signal transduction; IDA:UniProtKB.
DR   GO; GO:0051497; P:negative regulation of stress fiber assembly; IDA:UniProtKB.
DR   GO; GO:0031175; P:neuron projection development; IMP:UniProtKB.
DR   GO; GO:0038031; P:non-canonical Wnt signaling pathway via JNK cascade; IMP:UniProtKB.
DR   GO; GO:0001649; P:osteoblast differentiation; IDA:UniProtKB.
DR   GO; GO:0030335; P:positive regulation of cell migration; IDA:UniProtKB.
DR   GO; GO:0051894; P:positive regulation of focal adhesion assembly; IDA:UniProtKB.
DR   GO; GO:0051901; P:positive regulation of mitochondrial depolarization; IDA:UniProtKB.
DR   GO; GO:0014068; P:positive regulation of phosphatidylinositol 3-kinase signaling; IDA:UniProtKB.
DR   GO; GO:0051897; P:positive regulation of protein kinase B signaling; IDA:UniProtKB.
DR   GO; GO:0051496; P:positive regulation of stress fiber assembly; IDA:UniProtKB.
DR   GO; GO:1900026; P:positive regulation of substrate adhesion-dependent cell spreading; IDA:UniProtKB.
DR   GO; GO:0043408; P:regulation of MAPK cascade; IDA:UniProtKB.
DR   GO; GO:0014734; P:skeletal muscle hypertrophy; ISS:UniProtKB.
DR   InterPro; IPR031213; Myocilin.
DR   InterPro; IPR003112; Olfac-like_dom.
DR   PANTHER; PTHR23192:SF33; PTHR23192:SF33; 1.
DR   Pfam; PF02191; OLF; 1.
DR   SMART; SM00284; OLF; 1.
DR   PROSITE; PS51132; OLF; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Calcium; Cell projection; Cilium; Coiled coil;
KW   Complete proteome; Cytoplasmic vesicle; Direct protein sequencing;
KW   Disease mutation; Disulfide bond; Endoplasmic reticulum;
KW   Extracellular matrix; Glaucoma; Glycoprotein; Golgi apparatus;
KW   Lipoprotein; Membrane; Metal-binding; Mitochondrion;
KW   Mitochondrion inner membrane; Mitochondrion outer membrane; Palmitate;
KW   Polymorphism; Reference proteome; Secreted; Signal.
FT   SIGNAL        1     32       {ECO:0000269|PubMed:19287508,
FT                                ECO:0000269|PubMed:9497363}.
FT   CHAIN        33    504       Myocilin.
FT                                /FTId=PRO_0000020084.
FT   CHAIN        33    226       Myocilin, N-terminal fragment.
FT                                /FTId=PRO_0000428749.
FT   CHAIN       227    504       Myocilin, C-terminal fragment.
FT                                /FTId=PRO_0000428750.
FT   DOMAIN      244    503       Olfactomedin-like. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00446}.
FT   COILED       74    184       {ECO:0000255}.
FT   MOTIF       502    504       Microbody targeting signal.
FT                                {ECO:0000255}.
FT   METAL       380    380       Calcium. {ECO:0000244|PDB:4WXQ,
FT                                ECO:0000244|PDB:4WXS,
FT                                ECO:0000244|PDB:4WXU}.
FT   METAL       428    428       Calcium. {ECO:0000244|PDB:4WXQ,
FT                                ECO:0000244|PDB:4WXS,
FT                                ECO:0000244|PDB:4WXU}.
FT   METAL       429    429       Calcium; via carbonyl oxygen.
FT                                {ECO:0000244|PDB:4WXQ,
FT                                ECO:0000244|PDB:4WXS,
FT                                ECO:0000244|PDB:4WXU}.
FT   METAL       477    477       Calcium; via carbonyl oxygen.
FT                                {ECO:0000244|PDB:4WXQ,
FT                                ECO:0000244|PDB:4WXS,
FT                                ECO:0000244|PDB:4WXU}.
FT   METAL       478    478       Calcium. {ECO:0000244|PDB:4WXQ,
FT                                ECO:0000244|PDB:4WXS,
FT                                ECO:0000244|PDB:4WXU}.
FT   SITE        226    227       Cleavage; by CAPN2.
FT   CARBOHYD     57     57       N-linked (GlcNAc...).
FT                                {ECO:0000305|PubMed:17650508}.
FT   DISULFID    245    433       {ECO:0000244|PDB:4WXQ,
FT                                ECO:0000244|PDB:4WXS,
FT                                ECO:0000244|PDB:4WXU,
FT                                ECO:0000255|PROSITE-ProRule:PRU00446,
FT                                ECO:0000269|PubMed:12615070}.
FT   VARIANT       4      4       F -> S.
FT                                /FTId=VAR_009665.
FT   VARIANT       9      9       C -> S.
FT                                /FTId=VAR_009666.
FT   VARIANT      12     12       G -> R (in dbSNP:rs199752860).
FT                                {ECO:0000269|PubMed:10798654,
FT                                ECO:0000269|PubMed:12356829}.
FT                                /FTId=VAR_009667.
FT   VARIANT      16     16       P -> L. {ECO:0000269|PubMed:12356829}.
FT                                /FTId=VAR_054269.
FT   VARIANT      17     17       A -> S. {ECO:0000269|PubMed:12356829}.
FT                                /FTId=VAR_054270.
FT   VARIANT      19     19       Q -> H (in dbSNP:rs2234925).
FT                                {ECO:0000269|PubMed:10980537}.
FT                                /FTId=VAR_009668.
FT   VARIANT      25     25       C -> R (in GLC1A).
FT                                {ECO:0000269|PubMed:12860809}.
FT                                /FTId=VAR_054271.
FT   VARIANT      48     48       Q -> H (in GLC1A and GLC3A; the GLC3A
FT                                patient also carries mutation H-368 in
FT                                CYP1B1 suggesting digenic inheritance;
FT                                dbSNP:rs74315339).
FT                                {ECO:0000269|PubMed:15025728,
FT                                ECO:0000269|PubMed:15733270}.
FT                                /FTId=VAR_054272.
FT   VARIANT      53     53       V -> A (in GLC1A; dbSNP:rs200208925).
FT                                {ECO:0000269|PubMed:10644174}.
FT                                /FTId=VAR_008969.
FT   VARIANT      57     57       N -> D. {ECO:0000269|PubMed:11004290}.
FT                                /FTId=VAR_054273.
FT   VARIANT      57     57       N -> S (loss of higher molecular weight
FT                                isoform; dbSNP:rs561439247).
FT                                {ECO:0000269|PubMed:12697062,
FT                                ECO:0000269|PubMed:12872267}.
FT                                /FTId=VAR_054274.
FT   VARIANT      73     73       N -> S.
FT                                /FTId=VAR_009669.
FT   VARIANT      76     76       R -> K (in dbSNP:rs2234926).
FT                                {ECO:0000269|PubMed:10798654,
FT                                ECO:0000269|PubMed:10980537,
FT                                ECO:0000269|PubMed:11004290,
FT                                ECO:0000269|PubMed:12189160,
FT                                ECO:0000269|PubMed:12356829,
FT                                ECO:0000269|PubMed:12442283,
FT                                ECO:0000269|PubMed:12872267,
FT                                ECO:0000269|PubMed:15025728,
FT                                ECO:0000269|PubMed:9863594}.
FT                                /FTId=VAR_009670.
FT   VARIANT      77     77       D -> E. {ECO:0000269|PubMed:12189160}.
FT                                /FTId=VAR_054275.
FT   VARIANT      82     82       R -> C (in GLC1A).
FT                                /FTId=VAR_009671.
FT   VARIANT      82     82       R -> H.
FT                                /FTId=VAR_009672.
FT   VARIANT      95     95       L -> P. {ECO:0000269|PubMed:12356829}.
FT                                /FTId=VAR_054276.
FT   VARIANT     126    126       R -> W (in GLC1A; dbSNP:rs200120115).
FT                                {ECO:0000269|PubMed:12189160}.
FT                                /FTId=VAR_054277.
FT   VARIANT     158    158       R -> Q (in GLC1A; dbSNP:rs199746824).
FT                                {ECO:0000269|PubMed:10980537}.
FT                                /FTId=VAR_054278.
FT   VARIANT     189    189       R -> Q.
FT                                /FTId=VAR_009673.
FT   VARIANT     203    203       S -> F.
FT                                /FTId=VAR_009674.
FT   VARIANT     208    208       D -> E (in GLC1A; unknown pathological
FT                                significance; dbSNP:rs2234927).
FT                                {ECO:0000269|PubMed:10798654,
FT                                ECO:0000269|PubMed:10980537,
FT                                ECO:0000269|PubMed:12356829}.
FT                                /FTId=VAR_014943.
FT   VARIANT     215    215       L -> P (in dbSNP:rs531050114).
FT                                {ECO:0000269|PubMed:12356829}.
FT                                /FTId=VAR_054279.
FT   VARIANT     244    244       G -> V (in GLC1A; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:17210859}.
FT                                /FTId=VAR_054280.
FT   VARIANT     245    245       C -> Y (in GLC1A; forms homomultimeric
FT                                complexes that migrate at molecular
FT                                weights larger than their wild-type
FT                                counterparts; these mutant complexes
FT                                remain sequestered intracellularly).
FT                                {ECO:0000269|PubMed:16401791}.
FT                                /FTId=VAR_054281.
FT   VARIANT     246    246       G -> R (in GLC1A).
FT                                {ECO:0000269|PubMed:9328473}.
FT                                /FTId=VAR_005468.
FT   VARIANT     251    251       V -> A (in GLC1A).
FT                                {ECO:0000269|PubMed:12442283}.
FT                                /FTId=VAR_054282.
FT   VARIANT     252    252       G -> R (in GLC1A).
FT                                {ECO:0000269|PubMed:10873982,
FT                                ECO:0000269|PubMed:11004290,
FT                                ECO:0000269|PubMed:11774072,
FT                                ECO:0000269|PubMed:17210859}.
FT                                /FTId=VAR_054283.
FT   VARIANT     261    261       E -> K (in GLC1A).
FT                                {ECO:0000269|PubMed:10916185}.
FT                                /FTId=VAR_054284.
FT   VARIANT     272    272       R -> G (in GLC1A; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:11004290}.
FT                                /FTId=VAR_054285.
FT   VARIANT     274    274       P -> R (in GLC1A).
FT                                {ECO:0000269|PubMed:15255110}.
FT                                /FTId=VAR_054286.
FT   VARIANT     286    286       W -> R (in GLC1A).
FT                                /FTId=VAR_009675.
FT   VARIANT     293    293       T -> K (in GLC1A; no effect on protein
FT                                stability; dbSNP:rs139122673).
FT                                {ECO:0000269|PubMed:11774072,
FT                                ECO:0000269|PubMed:12189160,
FT                                ECO:0000269|PubMed:25524706}.
FT                                /FTId=VAR_009676.
FT   VARIANT     300    300       E -> K (in GLC1A; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:12356829}.
FT                                /FTId=VAR_054287.
FT   VARIANT     323    323       E -> K (in GLC1A; inhibits
FT                                endoproteolytic processing; mainly
FT                                accumulates as insoluble aggregates
FT                                inside the endoplasmic reticulum).
FT                                {ECO:0000269|PubMed:11004290,
FT                                ECO:0000269|PubMed:15795224}.
FT                                /FTId=VAR_054288.
FT   VARIANT     329    329       V -> M (slightly decreased protein
FT                                stability; dbSNP:rs146391864).
FT                                {ECO:0000269|PubMed:11004290,
FT                                ECO:0000269|PubMed:25524706}.
FT                                /FTId=VAR_009677.
FT   VARIANT     337    337       Q -> E (in GLC1A).
FT                                {ECO:0000269|PubMed:10916185}.
FT                                /FTId=VAR_054289.
FT   VARIANT     337    337       Q -> R (in GLC1A).
FT                                {ECO:0000269|PubMed:9361308}.
FT                                /FTId=VAR_005469.
FT   VARIANT     341    341       S -> P (in GLC1A).
FT                                {ECO:0000269|PubMed:9510647}.
FT                                /FTId=VAR_054290.
FT   VARIANT     342    342       R -> K (in GLC1A).
FT                                {ECO:0000269|PubMed:12362081}.
FT                                /FTId=VAR_054291.
FT   VARIANT     345    345       I -> M (in GLC1A).
FT                                {ECO:0000269|PubMed:12442283}.
FT                                /FTId=VAR_054292.
FT   VARIANT     352    352       E -> K (in GLC1A; unknown pathological
FT                                significance; dbSNP:rs61745146).
FT                                {ECO:0000269|PubMed:12189160,
FT                                ECO:0000269|PubMed:9792882}.
FT                                /FTId=VAR_009678.
FT   VARIANT     353    353       T -> I (in GLC1A; unknown pathological
FT                                significance; no significant effect on
FT                                protein stability; dbSNP:rs137853277).
FT                                {ECO:0000269|PubMed:10330365,
FT                                ECO:0000269|PubMed:10798654,
FT                                ECO:0000269|PubMed:12356829,
FT                                ECO:0000269|PubMed:25524706}.
FT                                /FTId=VAR_009679.
FT   VARIANT     360    360       I -> N (in GLC1A).
FT                                {ECO:0000269|PubMed:10980537,
FT                                ECO:0000269|PubMed:15534471}.
FT                                /FTId=VAR_054293.
FT   VARIANT     361    361       P -> S (in GLC1A).
FT                                /FTId=VAR_009680.
FT   VARIANT     363    363       A -> T (in GLC1A).
FT                                {ECO:0000269|PubMed:10980537,
FT                                ECO:0000269|PubMed:15534471}.
FT                                /FTId=VAR_054294.
FT   VARIANT     364    364       G -> V (in GLC1A).
FT                                {ECO:0000269|PubMed:9005853}.
FT                                /FTId=VAR_005470.
FT   VARIANT     367    367       G -> R (in GLC1A).
FT                                {ECO:0000269|PubMed:11774072,
FT                                ECO:0000269|PubMed:12189160,
FT                                ECO:0000269|PubMed:12442283,
FT                                ECO:0000269|PubMed:12872267,
FT                                ECO:0000269|PubMed:9345106,
FT                                ECO:0000269|PubMed:9490287,
FT                                ECO:0000269|PubMed:9521427}.
FT                                /FTId=VAR_005471.
FT   VARIANT     369    369       F -> L (in GLC1A).
FT                                {ECO:0000269|PubMed:15534471}.
FT                                /FTId=VAR_054295.
FT   VARIANT     370    370       P -> L (in GLC1A; severe form; inhibits
FT                                endoproteolytic processing; produced the
FT                                highest inhibition of the endoproteolytic
FT                                processing; mainly accumulates as
FT                                insoluble aggregates inside the
FT                                endoplasmic reticulum; inhibits neurite
FT                                outgrowth). {ECO:0000269|PubMed:11004290,
FT                                ECO:0000269|PubMed:11774072,
FT                                ECO:0000269|PubMed:12442283,
FT                                ECO:0000269|PubMed:15795224,
FT                                ECO:0000269|PubMed:9328473,
FT                                ECO:0000269|PubMed:9345106,
FT                                ECO:0000269|PubMed:9490287,
FT                                ECO:0000269|PubMed:9792882,
FT                                ECO:0000269|PubMed:9863594}.
FT                                /FTId=VAR_005472.
FT   VARIANT     377    377       T -> K (in GLC1A).
FT                                {ECO:0000269|PubMed:11774072}.
FT                                /FTId=VAR_054296.
FT   VARIANT     377    377       T -> M (in GLC1A).
FT                                {ECO:0000269|PubMed:11004290,
FT                                ECO:0000269|PubMed:9792882}.
FT                                /FTId=VAR_009681.
FT   VARIANT     380    380       D -> A (in GLC1A; incomplete penetrance;
FT                                inhibits endoproteolytic processing;
FT                                mainly accumulates as insoluble
FT                                aggregates inside the endoplasmic
FT                                reticulum). {ECO:0000269|PubMed:9863594}.
FT                                /FTId=VAR_009682.
FT   VARIANT     380    380       D -> G (in GLC1A).
FT                                {ECO:0000269|PubMed:15795224}.
FT                                /FTId=VAR_009683.
FT   VARIANT     380    380       D -> H (in GLC1A).
FT                                {ECO:0000269|PubMed:17499207}.
FT                                /FTId=VAR_054297.
FT   VARIANT     380    380       D -> N (in GLC1A).
FT                                {ECO:0000269|PubMed:12362081}.
FT                                /FTId=VAR_054298.
FT   VARIANT     393    393       S -> N (in GLC1A).
FT                                {ECO:0000269|PubMed:12442283}.
FT                                /FTId=VAR_054299.
FT   VARIANT     393    393       S -> R (in GLC1A).
FT                                /FTId=VAR_009684.
FT   VARIANT     398    398       K -> R (in dbSNP:rs56314834).
FT                                {ECO:0000269|PubMed:10916185,
FT                                ECO:0000269|PubMed:11004290,
FT                                ECO:0000269|PubMed:11774072,
FT                                ECO:0000269|PubMed:12189160,
FT                                ECO:0000269|PubMed:12872267}.
FT                                /FTId=VAR_009685.
FT   VARIANT     399    399       G -> V (in GLC1A; dbSNP:rs28936694).
FT                                {ECO:0000269|PubMed:11774072}.
FT                                /FTId=VAR_054300.
FT   VARIANT     402    402       V -> I.
FT                                /FTId=VAR_009686.
FT   VARIANT     414    414       E -> K. {ECO:0000269|PubMed:12356829}.
FT                                /FTId=VAR_054301.
FT   VARIANT     422    422       R -> C (no effect on protein stability).
FT                                {ECO:0000269|PubMed:25524706}.
FT                                /FTId=VAR_009687.
FT   VARIANT     422    422       R -> H (in GLC1A; dbSNP:rs201573718).
FT                                /FTId=VAR_009688.
FT   VARIANT     423    423       K -> E (in GLC1A; heterozygote specific
FT                                phenotype). {ECO:0000269|PubMed:12189160,
FT                                ECO:0000269|PubMed:12860809,
FT                                ECO:0000269|PubMed:9697688}.
FT                                /FTId=VAR_009689.
FT   VARIANT     425    425       S -> P (decreases protein stability).
FT                                {ECO:0000269|PubMed:25524706}.
FT                                /FTId=VAR_009690.
FT   VARIANT     426    426       V -> F (in GLC1A).
FT                                {ECO:0000269|PubMed:11004290,
FT                                ECO:0000269|PubMed:9521427}.
FT                                /FTId=VAR_005473.
FT   VARIANT     427    427       A -> T (in GLC1A).
FT                                {ECO:0000269|PubMed:12189160}.
FT                                /FTId=VAR_054302.
FT   VARIANT     433    433       C -> R (in GLC1A; severe form).
FT                                {ECO:0000269|PubMed:10819638}.
FT                                /FTId=VAR_008970.
FT   VARIANT     434    434       G -> S (in GLC1A).
FT                                {ECO:0000269|PubMed:12442283}.
FT                                /FTId=VAR_054303.
FT   VARIANT     437    437       Y -> H (in GLC1A).
FT                                {ECO:0000269|PubMed:9005853,
FT                                ECO:0000269|PubMed:9792882}.
FT                                /FTId=VAR_005474.
FT   VARIANT     438    438       T -> I (in GLC1A).
FT                                {ECO:0000269|PubMed:12872267}.
FT                                /FTId=VAR_054304.
FT   VARIANT     445    445       A -> V (in GLC1A; no effect on protein
FT                                stability; dbSNP:rs140967767).
FT                                {ECO:0000269|PubMed:11774072,
FT                                ECO:0000269|PubMed:12189160,
FT                                ECO:0000269|PubMed:25524706}.
FT                                /FTId=VAR_009691.
FT   VARIANT     448    448       T -> P (in GLC1A).
FT                                {ECO:0000269|PubMed:10340788,
FT                                ECO:0000269|PubMed:15534471}.
FT                                /FTId=VAR_054305.
FT   VARIANT     450    450       N -> D (in GLC1A).
FT                                {ECO:0000269|PubMed:12442283}.
FT                                /FTId=VAR_054306.
FT   VARIANT     465    465       I -> M (in GLC1A).
FT                                /FTId=VAR_009692.
FT   VARIANT     470    470       R -> C (in GLC1A).
FT                                {ECO:0000269|PubMed:12442283}.
FT                                /FTId=VAR_009693.
FT   VARIANT     470    470       R -> H. {ECO:0000269|PubMed:10980537}.
FT                                /FTId=VAR_054307.
FT   VARIANT     471    471       Y -> C (in GLC1A; unknown pathological
FT                                significance; dbSNP:rs554235897).
FT                                {ECO:0000269|PubMed:12356829}.
FT                                /FTId=VAR_054308.
FT   VARIANT     473    473       Y -> C (no effect on protein stability).
FT                                {ECO:0000269|PubMed:25524706}.
FT                                /FTId=VAR_009694.
FT   VARIANT     477    477       I -> N (in GLC1A; induces stress fiber
FT                                formation in only 5% of cells).
FT                                {ECO:0000269|PubMed:11004290,
FT                                ECO:0000269|PubMed:19188438}.
FT                                /FTId=VAR_009695.
FT   VARIANT     477    477       I -> S (in GLC1A).
FT                                {ECO:0000269|PubMed:9328473}.
FT                                /FTId=VAR_005475.
FT   VARIANT     480    480       N -> K (in GLC1A).
FT                                {ECO:0000269|PubMed:12872267,
FT                                ECO:0000269|PubMed:9328473}.
FT                                /FTId=VAR_005476.
FT   VARIANT     481    481       P -> L (in GLC1A).
FT                                {ECO:0000269|PubMed:12189160}.
FT                                /FTId=VAR_009696.
FT   VARIANT     481    481       P -> T (in GLC1A).
FT                                /FTId=VAR_009697.
FT   VARIANT     495    495       V -> I.
FT                                /FTId=VAR_009698.
FT   VARIANT     499    499       I -> F (in GLC1A).
FT                                {ECO:0000269|PubMed:12872267,
FT                                ECO:0000269|PubMed:9328473}.
FT                                /FTId=VAR_005477.
FT   VARIANT     499    499       I -> S (in GLC1A).
FT                                {ECO:0000269|PubMed:11004290}.
FT                                /FTId=VAR_054309.
FT   VARIANT     500    500       K -> R (in dbSNP:rs145977437).
FT                                /FTId=VAR_009699.
FT   VARIANT     502    502       S -> P (in GLC1A).
FT                                {ECO:0000269|PubMed:9863594}.
FT                                /FTId=VAR_009700.
FT   MUTAGEN     226    230       Missing: Impairs endoproteolytic
FT                                processing.
FT                                {ECO:0000269|PubMed:17650508}.
FT   MUTAGEN     226    226       R->A: Reduced processing. Impairs
FT                                endoproteolytic processing; when
FT                                associated with A-229 or A-230.
FT                                Completely processed after 6 days of
FT                                expression, and releases a C-terminal
FT                                fragment with similar electrophoretic
FT                                mobility to that obtained by processing
FT                                wild-type myocilin; when associated with
FT                                A-229 or A-230.
FT                                {ECO:0000269|PubMed:17650508}.
FT   MUTAGEN     226    226       R->Q: Slightly increases endoproteolytic
FT                                processing.
FT                                {ECO:0000269|PubMed:17650508}.
FT   MUTAGEN     227    227       I->G: Reduced processing.
FT                                {ECO:0000269|PubMed:17650508}.
FT   MUTAGEN     229    229       K->A: Completely blocks endoproteolytic
FT                                processing; when associated with A-226.
FT                                Completely processed after 6 days of
FT                                expression, and releases a C-terminal
FT                                fragment with similar electrophoretic
FT                                mobility to that obtained by processing
FT                                wild-type myocilin; when associated with
FT                                A-226. {ECO:0000269|PubMed:17650508}.
FT   MUTAGEN     230    230       E->A: Impairs endoproteolytic processing;
FT                                when associated with A-226. Completely
FT                                processed after 6 days of expression, and
FT                                released a C-terminal fragment with
FT                                similar electrophoretic mobility to that
FT                                obtained by processing wild-type
FT                                myocilin; when associated with A-226.
FT                                {ECO:0000269|PubMed:17650508}.
FT   STRAND      248    251       {ECO:0000244|PDB:4WXS}.
FT   STRAND      255    259       {ECO:0000244|PDB:4WXS}.
FT   HELIX       263    265       {ECO:0000244|PDB:4WXS}.
FT   STRAND      266    272       {ECO:0000244|PDB:4WXS}.
FT   STRAND      285    289       {ECO:0000244|PDB:4WXS}.
FT   STRAND      292    303       {ECO:0000244|PDB:4WXS}.
FT   HELIX       304    309       {ECO:0000244|PDB:4WXS}.
FT   STRAND      313    322       {ECO:0000244|PDB:4WXS}.
FT   STRAND      328    330       {ECO:0000244|PDB:4WXS}.
FT   STRAND      333    338       {ECO:0000244|PDB:4WXS}.
FT   STRAND      341    348       {ECO:0000244|PDB:4WXS}.
FT   TURN        349    352       {ECO:0000244|PDB:4WXS}.
FT   STRAND      353    359       {ECO:0000244|PDB:4WXS}.
FT   STRAND      366    369       {ECO:0000244|PDB:4WXS}.
FT   TURN        375    378       {ECO:0000244|PDB:4WXU}.
FT   STRAND      380    384       {ECO:0000244|PDB:4WXS}.
FT   STRAND      387    392       {ECO:0000244|PDB:4WXS}.
FT   TURN        395    399       {ECO:0000244|PDB:4WXS}.
FT   STRAND      400    406       {ECO:0000244|PDB:4WXS}.
FT   TURN        408    410       {ECO:0000244|PDB:4WXS}.
FT   STRAND      413    422       {ECO:0000244|PDB:4WXS}.
FT   HELIX       423    425       {ECO:0000244|PDB:4WXS}.
FT   STRAND      426    432       {ECO:0000244|PDB:4WXS}.
FT   STRAND      435    454       {ECO:0000244|PDB:4WXS}.
FT   TURN        455    457       {ECO:0000244|PDB:4WXS}.
FT   STRAND      460    468       {ECO:0000244|PDB:4WXS}.
FT   STRAND      474    480       {ECO:0000244|PDB:4WXS}.
FT   TURN        481    484       {ECO:0000244|PDB:4WXS}.
FT   STRAND      485    490       {ECO:0000244|PDB:4WXS}.
FT   STRAND      493    497       {ECO:0000244|PDB:4WXS}.
FT   STRAND      499    501       {ECO:0000244|PDB:4WXS}.
SQ   SEQUENCE   504 AA;  56972 MW;  9588C04F1D227623 CRC64;
     MRFFCARCCS FGPEMPAVQL LLLACLVWDV GARTAQLRKA NDQSGRCQYT FSVASPNESS
     CPEQSQAMSV IHNLQRDSST QRLDLEATKA RLSSLESLLH QLTLDQAARP QETQEGLQRE
     LGTLRRERDQ LETQTRELET AYSNLLRDKS VLEEEKKRLR QENENLARRL ESSSQEVARL
     RRGQCPQTRD TARAVPPGSR EVSTWNLDTL AFQELKSELT EVPASRILKE SPSGYLRSGE
     GDTGCGELVW VGEPLTLRTA ETITGKYGVW MRDPKPTYPY TQETTWRIDT VGTDVRQVFE
     YDLISQFMQG YPSKVHILPR PLESTGAVVY SGSLYFQGAE SRTVIRYELN TETVKAEKEI
     PGAGYHGQFP YSWGGYTDID LAVDEAGLWV IYSTDEAKGA IVLSKLNPEN LELEQTWETN
     IRKQSVANAF IICGTLYTVS SYTSADATVN FAYDTGTGIS KTLTIPFKNR YKYSSMIDYN
     PLEKKLFAWD NLNMVTYDIK LSKM
//
ID   AGAL_HUMAN              Reviewed;         429 AA.
AC   P06280; Q6LER7;
DT   01-JAN-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-AUG-1988, sequence version 1.
DT   17-FEB-2016, entry version 186.
DE   RecName: Full=Alpha-galactosidase A;
DE            EC=3.2.1.22;
DE   AltName: Full=Alpha-D-galactosidase A;
DE   AltName: Full=Alpha-D-galactoside galactohydrolase;
DE   AltName: Full=Melibiase;
DE   AltName: INN=Agalsidase;
DE   Flags: Precursor;
GN   Name=GLA;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Fibroblast;
RX   PubMed=3036505; DOI=10.1111/j.1432-1033.1987.tb11438.x;
RA   Tsuji S., Martin B.M., Kaslow D.C., Migeon B.R., Choudary P.V.,
RA   Stubblefield B.K., Mayor J.A., Murray G.J., Barranger J.A.,
RA   Ginns E.I.;
RT   "Signal sequence and DNA-mediated expression of human lysosomal alpha-
RT   galactosidase A.";
RL   Eur. J. Biochem. 165:275-280(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Lymphoblast;
RX   PubMed=2542896; DOI=10.1093/nar/17.8.3301;
RA   Kornreich R., Desnick R.J., Bishop D.F.;
RT   "Nucleotide sequence of the human alpha-galactosidase A gene.";
RL   Nucleic Acids Res. 17:3301-3302(1989).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=7626884; DOI=10.1007/BF00364796;
RA   Oeltjen J.C., Liu X., Lu J., Allen R.C., Muzny D.M., Belmont J.W.,
RA   Gibbs R.A.;
RT   "Sixty-nine kilobases of contiguous human genomic sequence containing
RT   the alpha-galactosidase A and Bruton's tyrosine kinase loci.";
RL   Mamm. Genome 6:334-338(1995).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A.,
RA   Lovell F.L., Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G.,
RA   Jones M.C., Hurles M.E., Andrews T.D., Scott C.E., Searle S.,
RA   Ramser J., Whittaker A., Deadman R., Carter N.P., Hunt S.E., Chen R.,
RA   Cree A., Gunaratne P., Havlak P., Hodgson A., Metzker M.L.,
RA   Richards S., Scott G., Steffen D., Sodergren E., Wheeler D.A.,
RA   Worley K.C., Ainscough R., Ambrose K.D., Ansari-Lari M.A., Aradhya S.,
RA   Ashwell R.I., Babbage A.K., Bagguley C.L., Ballabio A., Banerjee R.,
RA   Barker G.E., Barlow K.F., Barrett I.P., Bates K.N., Beare D.M.,
RA   Beasley H., Beasley O., Beck A., Bethel G., Blechschmidt K., Brady N.,
RA   Bray-Allen S., Bridgeman A.M., Brown A.J., Brown M.J., Bonnin D.,
RA   Bruford E.A., Buhay C., Burch P., Burford D., Burgess J., Burrill W.,
RA   Burton J., Bye J.M., Carder C., Carrel L., Chako J., Chapman J.C.,
RA   Chavez D., Chen E., Chen G., Chen Y., Chen Z., Chinault C.,
RA   Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J.,
RA   Delgado O., Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S.,
RA   Draper H., Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I.,
RA   Eades T., Ellwood M., Emery-Cohen A., Errington H., Evans K.L.,
RA   Faulkner L., Francis F., Frankland J., Fraser A.E., Galgoczy P.,
RA   Gilbert J., Gill R., Gloeckner G., Gregory S.G., Gribble S.,
RA   Griffiths C., Grocock R., Gu Y., Gwilliam R., Hamilton C., Hart E.A.,
RA   Hawes A., Heath P.D., Heitmann K., Hennig S., Hernandez J.,
RA   Hinzmann B., Ho S., Hoffs M., Howden P.J., Huckle E.J., Hume J.,
RA   Hunt P.J., Hunt A.R., Isherwood J., Jacob L., Johnson D., Jones S.,
RA   de Jong P.J., Joseph S.S., Keenan S., Kelly S., Kershaw J.K., Khan Z.,
RA   Kioschis P., Klages S., Knights A.J., Kosiura A., Kovar-Smith C.,
RA   Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., Liu W.,
RA   Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T.,
RA   Milne S., Miner G., Mistry S.L., Morgan M., Morris S., Mueller I.,
RA   Mullikin J.C., Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N.,
RA   Okwuonu G., Palmer S., Pandian R., Parker D., Parrish J.,
RA   Pasternak S., Patel D., Pearce A.V., Pearson D.M., Pelan S.E.,
RA   Perez L., Porter K.M., Ramsey Y., Reichwald K., Rhodes S.,
RA   Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T.,
RA   Teague B., Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S.,
RA   Tromans A.C., d'Urso M., Verduzco D., Villasana D., Waldron L.,
RA   Wall M., Wang Q., Warren J., Warry G.L., Wei X., West A.,
RA   Whitehead S.L., Whiteley M.N., Wilkinson J.E., Willey D.L.,
RA   Williams G., Williams L., Williamson A., Williamson H., Wilming L.,
RA   Woodmansey R.L., Wray P.W., Yen J., Zhang J., Zhou J., Zoghbi H.,
RA   Zorilla S., Buck D., Reinhardt R., Poustka A., Rosenthal A.,
RA   Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A.,
RA   Nelson D.L., Weinstock G., Sulston J.E., Durbin R.M., Hubbard T.,
RA   Gibbs R.A., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 27-429, AND PARTIAL PROTEIN SEQUENCE.
RC   TISSUE=Lung;
RX   PubMed=3014515; DOI=10.1073/pnas.83.13.4859;
RA   Bishop D.F., Calhoun D.H., Bernstein H.S., Hantzopoulos P., Quinn M.,
RA   Desnick R.J.;
RT   "Human alpha-galactosidase A: nucleotide sequence of a cDNA clone
RT   encoding the mature enzyme.";
RL   Proc. Natl. Acad. Sci. U.S.A. 83:4859-4863(1986).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-64.
RX   PubMed=2892762; DOI=10.1016/0378-1119(87)90374-X;
RA   Quinn M., Hantzopoulos P., Fidanza V., Calhoun D.H.;
RT   "A genomic clone containing the promoter for the gene encoding the
RT   human lysosomal enzyme, alpha-galactosidase A.";
RL   Gene 58:177-188(1987).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-64.
RX   PubMed=2836863; DOI=10.1073/pnas.85.11.3903;
RA   Bishop D.F., Kornreich R., Desnick R.J.;
RT   "Structural organization of the human alpha-galactosidase A gene:
RT   further evidence for the absence of a 3' untranslated region.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:3903-3907(1988).
RN   [9]
RP   RNA EDITING OF POSITION 396.
RX   PubMed=7503918; DOI=10.1093/nar/23.14.2636;
RA   Novo F.J., Kruszewski A., McDermot K.D., Goldspink G., Gorecki D.C.;
RT   "Editing of human alpha-galactosidase RNA resulting in a pyrimidine to
RT   purine conversion.";
RL   Nucleic Acids Res. 23:2636-2640(1995).
RN   [10]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-215.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (3.45 ANGSTROMS) OF 32-422 IN COMPLEX WITH
RP   PRODUCT, HOMODIMERIZATION, AND GLYCOSYLATION AT ASN-139; ASN-192 AND
RP   ASN-215.
RX   PubMed=15003450; DOI=10.1016/j.jmb.2004.01.035;
RA   Garman S.C., Garboczi D.N.;
RT   "The molecular defect leading to Fabry disease: structure of human
RT   alpha-galactosidase.";
RL   J. Mol. Biol. 337:319-335(2004).
RN   [14]
RP   REVIEW ON FD VARIANTS.
RX   PubMed=7911050; DOI=10.1002/humu.1380030204;
RA   Eng C.M., Desnick R.J.;
RT   "Molecular basis of Fabry disease: mutations and polymorphisms in the
RT   human alpha-galactosidase A gene.";
RL   Hum. Mutat. 3:103-111(1994).
RN   [15]
RP   VARIANT FD SER-40.
RX   PubMed=2152885; DOI=10.1016/0014-5793(90)80046-L;
RA   Koide T., Ishiura M., Iwai K., Inoue M., Kaneda Y., Okada Y.,
RA   Uchida T.;
RT   "A case of Fabry's disease in a patient with no alpha-galactosidase A
RT   activity caused by a single amino acid substitution of Pro-40 by
RT   Ser.";
RL   FEBS Lett. 259:353-356(1990).
RN   [16]
RP   VARIANT FD VAL-296.
RX   PubMed=1846223; DOI=10.1056/NEJM199102073240607;
RA   von Scheidt W., Eng C.M., Fitzmaurice T.F., Erdmann E., Hubner G.,
RA   Olsen E.G.J., Christomanou H., Kandolf R., Bishop D.F., Desnick R.J.;
RT   "An atypical variant of Fabry's disease with manifestations confined
RT   to the myocardium.";
RL   N. Engl. J. Med. 324:395-399(1991).
RN   [17]
RP   VARIANT FD GLN-301.
RX   PubMed=2171331;
RA   Sakuraba H., Oshima A., Fukuhara Y., Shimmoto M., Nagao Y.,
RA   Bishop D.F., Desnick R.J., Suzuki Y.;
RT   "Identification of point mutations in the alpha-galactosidase A gene
RT   in classical and atypical hemizygotes with Fabry disease.";
RL   Am. J. Hum. Genet. 47:784-789(1990).
RN   [18]
RP   VARIANT FD TRP-356.
RX   PubMed=2539398; DOI=10.1172/JCI114027;
RA   Bernstein H.S., Bishop D.F., Astrin K.H., Kornreich R., Eng C.M.,
RA   Sakuraba H., Desnick R.J.;
RT   "Fabry disease: six gene rearrangements and an exonic point mutation
RT   in the alpha-galactosidase gene.";
RL   J. Clin. Invest. 83:1390-1399(1989).
RN   [19]
RP   VARIANTS FD GLN-66; CYS-112; GLU-279; GLN-301 AND ARG-328.
RX   PubMed=1315715; DOI=10.1007/BF00207037;
RA   Ishii S., Sakuraba H., Suzuki Y.;
RT   "Point mutations in the upstream region of the alpha-galactosidase A
RT   gene exon 6 in an atypical variant of Fabry disease.";
RL   Hum. Genet. 89:29-32(1992).
RN   [20]
RP   VARIANTS FD SER-34; GLY-56; ARG-162; GLN-227; VAL-264; VAL-266;
RP   PHE-297; TYR-313; ALA-328 AND ARG-404 DEL.
RX   PubMed=7504405;
RA   Eng C.M., Resnick-Silverman L.A., Niehaus D.J., Astrin K.H.,
RA   Desnick R.J.;
RT   "Nature and frequency of mutations in the alpha-galactosidase A gene
RT   that cause Fabry disease.";
RL   Am. J. Hum. Genet. 53:1186-1197(1993).
RN   [21]
RP   VARIANTS FD SER-34; SER-215; ALA-269; LYS-327 AND ARG-361.
RX   PubMed=8395937; DOI=10.1093/hmg/2.7.1051;
RA   Davies J.P., Winchester B.G., Malcolm S.;
RT   "Mutation analysis in patients with the typical form of Anderson-Fabry
RT   disease.";
RL   Hum. Mol. Genet. 2:1051-1053(1993).
RN   [22]
RP   VARIANTS FD ARG-35; LEU-49; VAL-165 AND GLU-316.
RX   PubMed=8069316; DOI=10.1093/hmg/3.4.667;
RA   Davies J.P., Christomanou H., Winchester B.G., Malcolm S.;
RT   "Detection of 8 new mutations in the alpha-galactosidase A gene in
RT   Fabry disease.";
RL   Hum. Mol. Genet. 3:667-669(1994).
RN   [23]
RP   VARIANTS FD.
RX   PubMed=7531540; DOI=10.1093/hmg/3.10.1795;
RA   Eng C.M., Niehaus D.J., Enriquez A.L., Burgert T.S., Ludman M.D.,
RA   Desnick R.J.;
RT   "Fabry disease: twenty-three mutations including sense and antisense
RT   CpG alterations and identification of a deletional hot-spot in the
RT   alpha-galactosidase A gene.";
RL   Hum. Mol. Genet. 3:1795-1799(1994).
RN   [24]
RP   VARIANTS FD GLN-66; CYS-112; VAL-156; VAL-166; ALA-260; GLU-279;
RP   ILE-296; GLN-301; LYS-320; ARG-328 AND SER-373.
RX   PubMed=7575533; DOI=10.1006/bbrc.1995.2416;
RA   Okumiya T., Ishii S., Takenaka T., Kase R., Kamei S., Sakuraba H.,
RA   Suzuki Y.;
RT   "Galactose stabilizes various missense mutants of alpha-galactosidase
RT   in Fabry disease.";
RL   Biochem. Biophys. Res. Commun. 214:1219-1224(1995).
RN   [25]
RP   VARIANTS FD TYR-142; VAL-156 AND VAL-166.
RX   PubMed=7759078; DOI=10.1007/BF00223869;
RA   Okumiya T., Ishii S., Kase R., Kamei S., Sakuraba H., Suzuki Y.;
RT   "Alpha-galactosidase gene mutations in Fabry disease: heterogeneous
RT   expressions of mutant enzyme proteins.";
RL   Hum. Genet. 95:557-561(1995).
RN   [26]
RP   VARIANTS FD PRO-32; SER-34; ASP-85; THR-156 AND GLN-301.
RX   PubMed=7599642; DOI=10.1002/humu.1380050316;
RA   Madsen K.M., Hasholt L., Soerensen S.A., Lagerstroem Fermer M.,
RA   Dahl N.;
RT   "Two novel mutations (L32P) and (G85N) among five different missense
RT   mutations in six Danish families with Fabry's disease.";
RL   Hum. Mutat. 5:277-278(1995).
RN   [27]
RP   VARIANTS FD PRO-20 AND ILE-296.
RX   PubMed=7596372; DOI=10.1056/NEJM199508033330504;
RA   Nakao S., Takenaka T., Maeda M., Kodama C., Tanaka A., Tahara M.,
RA   Yoshida A., Kuriyama M., Hayashibe H., Sakuraba H., Tanaka H.;
RT   "An atypical variant of Fabry's disease in men with left ventricular
RT   hypertrophy.";
RL   N. Engl. J. Med. 333:288-293(1995).
RN   [28]
RP   VARIANT FD GLN-301.
RX   PubMed=8738659;
RA   Sawada K., Mizoguchi K., Hishida A., Kaneko E., Koide Y.,
RA   Nishimura K., Kimura M.;
RT   "Point mutation in the alpha-galactosidase A gene of atypical Fabry
RT   disease with only nephropathy.";
RL   Clin. Nephrol. 45:289-294(1996).
RN   [29]
RP   VARIANTS FD VAL-42; SER-49; TYR-56; HIS-92; GLY-93; THR-205; CYS-236;
RP   GLY-287; HIS-298 AND ARG-340.
RX   PubMed=8875188;
RA   Davies J.P., Eng C.M., Hill J.A., Malcolm S., MacDermot K.,
RA   Winchester B.G., Desnick R.J.;
RT   "Fabry disease: fourteen alpha-galactosidase A mutations in unrelated
RT   families from the United Kingdom and other European countries.";
RL   Eur. J. Hum. Genet. 4:219-224(1996).
RN   [30]
RP   VARIANT FD PHE-383 DEL.
RX   PubMed=8834244; DOI=10.1007/BF02267068;
RA   Cariolou M.A., Christodoulides M., Manoli P., Kokkofitou A.,
RA   Tsambaos D.;
RT   "Novel trinucleotide deletion in Fabry's disease.";
RL   Hum. Genet. 97:468-470(1996).
RN   [31]
RP   VARIANTS FD ARG-52; CYS-162; ARG-265 AND 316-VAL--ASP-322 DEL.
RX   PubMed=8931708; DOI=10.1007/s004390050292;
RA   Germain D.P., Biasotto M., Tosi M., Meo T., Kahn A., Poenaru L.;
RT   "Fluorescence-assisted mismatch analysis (FAMA) for exhaustive
RT   screening of the alpha-galactosidase A gene and detection of carriers
RT   in Fabry disease.";
RL   Hum. Genet. 98:719-726(1996).
RN   [32]
RP   VARIANTS FD ARG-52; GLU-128; THR-205; THR-284; LYS-298 AND GLU-358
RP   DEL.
RX   PubMed=8807334;
RX   DOI=10.1002/(SICI)1098-1004(1996)8:1<38::AID-HUMU5>3.0.CO;2-L;
RA   Blanch L.C., Meaney C., Morris C.P.;
RT   "A sensitive mutation screening strategy for Fabry disease: detection
RT   of nine mutations in the alpha-galactosidase A gene.";
RL   Hum. Mutat. 8:38-43(1996).
RN   [33]
RP   VARIANT FD ASN-231.
RX   PubMed=8863162; DOI=10.1136/jmg.33.8.682;
RA   Redonnet-Vernhet I., Ploos van Amstel J.K., Jansen R.P.M.,
RA   Wevers R.A., Salvayre R., Levade T.;
RT   "Uneven X inactivation in a female monozygotic twin pair with Fabry
RT   disease and discordant expression of a novel mutation in the alpha-
RT   galactosidase A gene.";
RL   J. Med. Genet. 33:682-688(1996).
RN   [34]
RP   VARIANTS FD PRO-20; SER-40; GLN-66; VAL-72; CYS-112; TYR-142; VAL-156;
RP   VAL-166; ASN-242; ALA-260; ASP-261; GLU-279; ILE-296; GLN-301;
RP   LYS-320; ARG-328; GLU-358 DEL AND SER-373.
RX   PubMed=9105656; DOI=10.1016/S0387-7604(96)00486-X;
RA   Takata T., Okumiya T., Hayashibe H., Shimmoto M., Kase R., Itoh K.,
RA   Utsumi K., Kamei S., Sakuraba H.;
RT   "Screening and detection of gene mutations in Japanese patients with
RT   Fabry disease by non-radioactive single-stranded conformation
RT   polymorphism analysis.";
RL   Brain Dev. 19:111-116(1997).
RN   [35]
RP   VARIANTS FD VAL-31; 45-ARG-SER-46; ARG-46; CYS-86; PRO-89; THR-91;
RP   TYR-92; TYR-94; VAL-97; THR-100; LEU-113; SER-134; ARG-138; THR-143;
RP   ARG-148; VAL-163; VAL-170; TYR-202; 205-PRO--TYR-207 DEL; ASP-216;
RP   SER-263; CYS-287; SER-298 AND ARG-404 DEL.
RX   PubMed=9100224;
RA   Eng C.M., Ashley G.A., Burgert T.S., Enriquez A.L., D'Souza M.,
RA   Desnick R.J.;
RT   "Fabry disease: thirty-five mutations in the alpha-galactosidase A
RT   gene in patients with classic and variant phenotypes.";
RL   Mol. Med. 3:174-182(1997).
RN   [36]
RP   VARIANT FD THR-65.
RX   PubMed=9554750;
RX   DOI=10.1002/(SICI)1098-1004(1998)11:4<328::AID-HUMU11>3.0.CO;2-N;
RA   Chen C.-H., Shyu P.-W., Wu S.-J., Sheu S.-S., Desnick R.J.,
RA   Hsiao K.-J.;
RT   "Identification of a novel point mutation (S65T) in alpha-
RT   galactosidase A gene in Chinese patients with Fabry disease.";
RL   Hum. Mutat. 11:328-330(1998).
RN   [37]
RP   VARIANT FD LYS-358.
RX   PubMed=9452068;
RA   Miyazaki T., Kajita M., Ohmori S., Mizutani N., Niwa T., Murata Y.,
RA   Seo H.;
RT   "A novel mutation (E358K) in the alpha-galactosidase A gene detected
RT   in a Japanese family with Fabry disease.";
RL   Hum. Mutat. Suppl. 1:S139-S140(1998).
RN   [38]
RP   VARIANT FD VAL-72.
RX   PubMed=9452090;
RA   Okumiya T., Kawamura O., Itoh K., Kase R., Ishii S., Kamei S.,
RA   Sakuraba H.;
RT   "Novel missense mutation (M72V) of alpha-galactosidase gene and its
RT   expression product in an atypical Fabry hemizygote.";
RL   Hum. Mutat. Suppl. 1:S213-S216(1998).
RN   [39]
RP   VARIANTS FD SER-40; SER-215; ASP-224; TYR-313 AND TRP-THR-SER-247 INS.
RX   PubMed=9452111;
RA   Guffon N., Froissart R., Chevalier-Porst F., Maire I.;
RT   "Mutation analysis in 11 French patients with Fabry disease.";
RL   Hum. Mutat. Suppl. 1:S288-S290(1998).
RN   [40]
RP   VARIANTS FD TRP-202; GLY-223; ASP-224; GLN-301 AND LYS-327.
RX   PubMed=10208848; DOI=10.1006/bbrc.1999.0310;
RA   Germain D.P., Poenaru L.;
RT   "Fabry disease: identification of novel alpha-galactosidase A
RT   mutations and molecular carrier detection by use of fluorescent
RT   chemical cleavage of mismatches.";
RL   Biochem. Biophys. Res. Commun. 257:708-713(1999).
RN   [41]
RP   VARIANT FD LYS-341.
RX   PubMed=10090526; DOI=10.1016/S0009-8981(98)00133-8;
RA   Beyer E.M., Karpova E.A., Udalova O.V., Ploos van Amstel J.K.,
RA   van Diggelen O.P., Tsvetkova I.V.;
RT   "The multiple cases of Fabry disease in a Russian family caused by an
RT   E341K amino acid substitution in the alpha-galactosidase A.";
RL   Clin. Chim. Acta 280:81-89(1999).
RN   [42]
RP   CHARACTERIZATION OF VARIANTS FD GLU-279 AND GLN-301.
RX   PubMed=10838196; DOI=10.1016/S0925-4439(00)00024-7;
RA   Kase R., Bierfreund U., Klein A., Kolter T., Utsumi K., Itoh K.,
RA   Sandhoff K., Sakuraba H.;
RT   "Characterization of two alpha-galactosidase mutants (Q279E and R301Q)
RT   found in an atypical variant of Fabry disease.";
RL   Biochim. Biophys. Acta 1501:227-235(2000).
RN   [43]
RP   VARIANTS FD VAL-42; CYS-112; ARG-142; ARG-148; VAL-165; ASP-183;
RP   SER-215; CYS-235; LEU-236; HIS-244; LEU-259; ILE-267; PHE-289;
RP   GLU-321; GLU-358 DEL AND TYR-378.
RX   PubMed=10666480;
RA   Topaloglu A.K., Ashley G.A., Tong B., Shabbeer J., Astrin K.H.,
RA   Eng C.M., Desnick R.J.;
RT   "Twenty novel mutations in the alpha-galactosidase A gene causing
RT   Fabry disease.";
RL   Mol. Med. 5:806-811(1999).
RN   [44]
RP   VARIANT FD ASN-266.
RX   PubMed=11076046; DOI=10.1034/j.1399-0004.2000.580311.x;
RA   Lee J.-K., Kim G.-H., Kim J.-S., Kim K.-K., Lee M.-C., Yoo H.-W.;
RT   "Identification of four novel mutations in five unrelated Korean
RT   families with Fabry disease.";
RL   Clin. Genet. 58:228-233(2000).
RN   [45]
RP   VARIANTS FD LEU-40; SER-95; CYS-112; HIS-112; ASN-148; ARG-172;
RP   VAL-187; SER-224; ARG-226; GLN-227; THR-230; HIS-266; GLN-301 AND
RP   TYR-320.
RX   PubMed=10916280;
RA   Ashton-Prolla P., Tong B., Shabbeer J., Astrin K.H., Eng C.M.,
RA   Desnick R.J.;
RT   "Fabry disease: twenty-two novel mutations in the alpha-galactosidase
RT   A gene and genotype/phenotype correlations in severely and mildly
RT   affected hemizygotes and heterozygotes.";
RL   J. Invest. Med. 48:227-235(2000).
RN   [46]
RP   VARIANT FD ASP-373.
RX   PubMed=11295840; DOI=10.1002/humu.41;
RA   Germain D.P., Salard D., Fellmann F., Azibi K., Caillaud C.,
RA   Bernard M.-C., Poenaru L.;
RT   "Identification of a novel de novo mutation (G373D) in the alpha-
RT   galactosidase A gene (GLA) in a patient affected with Fabry disease.";
RL   Hum. Mutat. 17:353-353(2001).
RN   [47]
RP   VARIANTS FD TYR-46; GLY-47; PRO-49; SER-94; SER-95; CYS-112; SER-113;
RP   THR-143; SER-215; ARG-258; ARG-259; ILE-267; HIS-279; HIS-280;
RP   HIS-298; TYR-313; HIS-363; ASP-377; ALA-409 AND THR-409.
RX   PubMed=11668641; DOI=10.1002/humu.1219;
RA   Blaydon D., Hill J.A., Winchester B.G.;
RT   "Fabry disease: 20 novel GLA mutations in 35 families.";
RL   Hum. Mutat. 18:459-459(2001).
RN   [48]
RP   VARIANT FD PRO-143.
RX   PubMed=11889412; DOI=10.1097/00005792-200203000-00003;
RA   Branton M.H., Schiffmann R., Sabnis S.G., Murray G.J., Quirk J.M.,
RA   Altarescu G., Goldfarb L., Brady R.O., Balow J.E., Austin H.A. III,
RA   Kopp J.B.;
RT   "Natural history of Fabry renal disease: influence of alpha-
RT   galactosidase A activity and genetic mutations on clinical course.";
RL   Medicine (Baltimore) 81:122-138(2002).
RN   [49]
RP   VARIANT FD ALA-410.
RX   PubMed=12694230; DOI=10.1034/j.1399-0004.2003.00050.x;
RA   Yang C.-C., Lai L.-W., Whitehair O., Hwu W.-L., Chiang S.-C.,
RA   Lien Y.-H.H.;
RT   "Two novel mutations in the alpha-galactosidase A gene in Chinese
RT   patients with Fabry disease.";
RL   Clin. Genet. 63:205-209(2003).
RN   [50]
RP   CHARACTERIZATION OF VARIANT FD THR-65.
RX   PubMed=12786754; DOI=10.1034/j.1399-0004.2003.00077.x;
RA   Lai L.-W., Whitehair O., Wu M.-J., O'Meara M., Lien Y.-H.H.;
RT   "Analysis of splice-site mutations of the alpha-galactosidase A gene
RT   in Fabry disease.";
RL   Clin. Genet. 63:476-482(2003).
RN   [51]
RP   VARIANT FD SER-272.
RX   PubMed=15162124; DOI=10.1038/sj.ejhg.5201184;
RA   Verovnik F., Benko D., Vujkovac B., Linthorst G.E.;
RT   "Remarkable variability in renal disease in a large Slovenian family
RT   with Fabry disease.";
RL   Eur. J. Hum. Genet. 12:678-681(2004).
RN   [52]
RP   VARIANTS FD VAL-31; LEU-42; ARG-43; ASN-93; CYS-112; HIS-112; SER-112;
RP   SER-134; VAL-135; ASP-171; PHE-201; SER-215; GLU-234; ASP-261;
RP   TYR-264; VAL-264; GLY-276; PRO-285; PHE-300; ALA-328; VAL-328;
RP   LYS-338; ALA-358; GLU-358 DEL; ARG-404 DEL AND SER-414.
RX   PubMed=15712228; DOI=10.1002/humu.20144;
RA   Shabbeer J., Robinson M., Desnick R.J.;
RT   "Detection of alpha-galactosidase a mutations causing Fabry disease by
RT   denaturing high performance liquid chromatography.";
RL   Hum. Mutat. 25:299-305(2005).
RN   [53]
RP   VARIANT FD THR-143.
RX   PubMed=16533976; DOI=10.1001/archneur.63.3.453;
RA   Nance C.S., Klein C.J., Banikazemi M., Dikman S.H., Phelps R.G.,
RA   McArthur J.C., Rodriguez M., Desnick R.J.;
RT   "Later-onset Fabry disease: an adult variant presenting with the
RT   cramp-fasciculation syndrome.";
RL   Arch. Neurol. 63:453-457(2006).
RN   [54]
RP   VARIANTS FD 12-CYS--LEU-14 DEL; PRO-46; GLN-66; ASN-93; VAL-120;
RP   THR-219; GLN-356 AND CYS-360, AND CHARACTERIZATION OF VARIANTS FD
RP   12-CYS--LEU-14 DEL; PRO-46; GLN-66; ASN-93; VAL-120; THR-219; GLN-356
RP   AND CYS-360.
RX   PubMed=19621417; DOI=10.1002/humu.21074;
RA   Hwu W.L., Chien Y.H., Lee N.C., Chiang S.C., Dobrovolny R.,
RA   Huang A.C., Yeh H.Y., Chao M.C., Lin S.J., Kitagawa T., Desnick R.J.,
RA   Hsu L.W.;
RT   "Newborn screening for Fabry disease in Taiwan reveals a high
RT   incidence of the later-onset GLA mutation c.936+919G>A
RT   (IVS4+919G>A).";
RL   Hum. Mutat. 30:1397-1405(2009).
CC   -!- CATALYTIC ACTIVITY: Hydrolysis of terminal, non-reducing alpha-D-
CC       galactose residues in alpha-D-galactosides, including galactose
CC       oligosaccharides, galactomannans and galactolipids.
CC   -!- SUBUNIT: Homodimer. {ECO:0000269|PubMed:15003450}.
CC   -!- SUBCELLULAR LOCATION: Lysosome.
CC   -!- RNA EDITING: Modified_positions=396 {ECO:0000269|PubMed:7503918};
CC       Note=Partially edited.;
CC   -!- DISEASE: Fabry disease (FD) [MIM:301500]: Rare X-linked
CC       sphingolipidosis disease where glycolipid accumulates in many
CC       tissues. The disease consists of an inborn error of
CC       glycosphingolipid catabolism. FD patients show systemic
CC       accumulation of globotriaosylceramide (Gb3) and related
CC       glycosphingolipids in the plasma and cellular lysosomes throughout
CC       the body. Clinical recognition in males results from
CC       characteristic skin lesions (angiokeratomas) over the lower trunk.
CC       Patients may show ocular deposits, febrile episodes, and burning
CC       pain in the extremities. Death results from renal failure, cardiac
CC       or cerebral complications of hypertension or other vascular
CC       disease. Heterozygous females may exhibit the disorder in an
CC       attenuated form, they are more likely to show corneal opacities.
CC       {ECO:0000269|PubMed:10090526, ECO:0000269|PubMed:10208848,
CC       ECO:0000269|PubMed:10666480, ECO:0000269|PubMed:10916280,
CC       ECO:0000269|PubMed:11076046, ECO:0000269|PubMed:11295840,
CC       ECO:0000269|PubMed:11668641, ECO:0000269|PubMed:11889412,
CC       ECO:0000269|PubMed:12694230, ECO:0000269|PubMed:1315715,
CC       ECO:0000269|PubMed:15162124, ECO:0000269|PubMed:15712228,
CC       ECO:0000269|PubMed:16533976, ECO:0000269|PubMed:1846223,
CC       ECO:0000269|PubMed:19621417, ECO:0000269|PubMed:2152885,
CC       ECO:0000269|PubMed:2171331, ECO:0000269|PubMed:2539398,
CC       ECO:0000269|PubMed:7504405, ECO:0000269|PubMed:7531540,
CC       ECO:0000269|PubMed:7575533, ECO:0000269|PubMed:7596372,
CC       ECO:0000269|PubMed:7599642, ECO:0000269|PubMed:7759078,
CC       ECO:0000269|PubMed:8069316, ECO:0000269|PubMed:8395937,
CC       ECO:0000269|PubMed:8738659, ECO:0000269|PubMed:8807334,
CC       ECO:0000269|PubMed:8834244, ECO:0000269|PubMed:8863162,
CC       ECO:0000269|PubMed:8875188, ECO:0000269|PubMed:8931708,
CC       ECO:0000269|PubMed:9100224, ECO:0000269|PubMed:9105656,
CC       ECO:0000269|PubMed:9452068, ECO:0000269|PubMed:9452090,
CC       ECO:0000269|PubMed:9452111, ECO:0000269|PubMed:9554750}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- PHARMACEUTICAL: Available under the names Replagal (from Shire)
CC       and Fabrazyme (from Genzyme). Used as a long-term enzyme
CC       replacement therapy in patients with a confirmed diagnosis of
CC       Fabry disease. The differences between Replagal (also known as
CC       agalsidase alpha) and Fabrazyme (also known as agalsidase beta)
CC       lies in the glycosylation patterns. Agalsidase beta is produced in
CC       the hamster CHO cell line while agalsidase alpha is produced in
CC       human cell lines.
CC   -!- SIMILARITY: Belongs to the glycosyl hydrolase 27 family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X05790; CAA29232.1; -; mRNA.
DR   EMBL; X14448; CAA32617.1; -; Genomic_DNA.
DR   EMBL; U78027; AAB64203.1; -; Genomic_DNA.
DR   EMBL; AL035422; CAB55878.1; -; Genomic_DNA.
DR   EMBL; BC002689; AAH02689.1; -; mRNA.
DR   EMBL; M13571; AAA51676.1; -; Genomic_DNA.
DR   EMBL; D00039; BAA34059.1; -; mRNA.
DR   EMBL; M18242; AAA52514.1; -; Genomic_DNA.
DR   EMBL; X16889; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; M20317; AAA52559.1; ALT_SEQ; Genomic_DNA.
DR   CCDS; CCDS14484.1; -.
DR   PIR; S04081; GBHUA.
DR   RefSeq; NP_000160.1; NM_000169.2.
DR   UniGene; Hs.69089; -.
DR   PDB; 1R46; X-ray; 3.25 A; A/B=32-429.
DR   PDB; 1R47; X-ray; 3.45 A; A/B=32-429.
DR   PDB; 3GXN; X-ray; 3.01 A; A/B=32-429.
DR   PDB; 3GXP; X-ray; 2.20 A; A/B=32-429.
DR   PDB; 3GXT; X-ray; 2.70 A; A/B=32-429.
DR   PDB; 3HG2; X-ray; 2.30 A; A/B=32-429.
DR   PDB; 3HG3; X-ray; 1.90 A; A/B=32-429.
DR   PDB; 3HG4; X-ray; 2.30 A; A/B=32-429.
DR   PDB; 3HG5; X-ray; 2.30 A; A/B=32-429.
DR   PDB; 3LX9; X-ray; 2.04 A; A/B=32-429.
DR   PDB; 3LXA; X-ray; 3.04 A; A/B=32-429.
DR   PDB; 3LXB; X-ray; 2.85 A; A/B=32-429.
DR   PDB; 3LXC; X-ray; 2.35 A; A/B=32-429.
DR   PDB; 3S5Y; X-ray; 2.10 A; A/B=32-429.
DR   PDB; 3S5Z; X-ray; 2.00 A; A/B=32-429.
DR   PDB; 3TV8; X-ray; 2.64 A; A/B=32-429.
DR   PDB; 4NXS; X-ray; 2.55 A; A/B=32-429.
DR   PDBsum; 1R46; -.
DR   PDBsum; 1R47; -.
DR   PDBsum; 3GXN; -.
DR   PDBsum; 3GXP; -.
DR   PDBsum; 3GXT; -.
DR   PDBsum; 3HG2; -.
DR   PDBsum; 3HG3; -.
DR   PDBsum; 3HG4; -.
DR   PDBsum; 3HG5; -.
DR   PDBsum; 3LX9; -.
DR   PDBsum; 3LXA; -.
DR   PDBsum; 3LXB; -.
DR   PDBsum; 3LXC; -.
DR   PDBsum; 3S5Y; -.
DR   PDBsum; 3S5Z; -.
DR   PDBsum; 3TV8; -.
DR   PDBsum; 4NXS; -.
DR   ProteinModelPortal; P06280; -.
DR   SMR; P06280; 32-426.
DR   BioGrid; 108981; 14.
DR   IntAct; P06280; 4.
DR   STRING; 9606.ENSP00000218516; -.
DR   BindingDB; P06280; -.
DR   ChEMBL; CHEMBL2524; -.
DR   SwissLipids; SLP:000001380; -.
DR   Allergome; 9621; Hom s alpha-Galactosidase.
DR   CAZy; GH27; Glycoside Hydrolase Family 27.
DR   iPTMnet; P06280; -.
DR   PhosphoSite; P06280; -.
DR   BioMuta; GLA; -.
DR   MaxQB; P06280; -.
DR   PaxDb; P06280; -.
DR   PeptideAtlas; P06280; -.
DR   PRIDE; P06280; -.
DR   DNASU; 2717; -.
DR   Ensembl; ENST00000218516; ENSP00000218516; ENSG00000102393.
DR   GeneID; 2717; -.
DR   KEGG; hsa:2717; -.
DR   UCSC; uc004ehl.1; human.
DR   CTD; 2717; -.
DR   GeneCards; GLA; -.
DR   GeneReviews; GLA; -.
DR   HGNC; HGNC:4296; GLA.
DR   HPA; HPA000237; -.
DR   HPA; HPA000966; -.
DR   MalaCards; GLA; -.
DR   MIM; 300644; gene.
DR   MIM; 301500; phenotype.
DR   neXtProt; NX_P06280; -.
DR   Orphanet; 324; Fabry disease.
DR   PharmGKB; PA28707; -.
DR   eggNOG; KOG2366; Eukaryota.
DR   eggNOG; ENOG410XPF1; LUCA.
DR   HOGENOM; HOG000161224; -.
DR   HOVERGEN; HBG001989; -.
DR   InParanoid; P06280; -.
DR   KO; K01189; -.
DR   OMA; CNVDCQE; -.
DR   OrthoDB; EOG7F24SV; -.
DR   PhylomeDB; P06280; -.
DR   TreeFam; TF312909; -.
DR   BioCyc; MetaCyc:HS02389-MONOMER; -.
DR   BRENDA; 3.2.1.22; 2681.
DR   Reactome; R-HSA-1660662; Glycosphingolipid metabolism.
DR   SABIO-RK; P06280; -.
DR   EvolutionaryTrace; P06280; -.
DR   GeneWiki; Alpha-galactosidase; -.
DR   GenomeRNAi; 2717; -.
DR   NextBio; 10728; -.
DR   PRO; PR:P06280; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   Bgee; P06280; -.
DR   CleanEx; HS_GLA; -.
DR   ExpressionAtlas; P06280; baseline and differential.
DR   Genevisible; P06280; HS.
DR   GO; GO:0005737; C:cytoplasm; IMP:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; IDA:UniProtKB.
DR   GO; GO:0005794; C:Golgi apparatus; IMP:UniProtKB.
DR   GO; GO:0043202; C:lysosomal lumen; TAS:Reactome.
DR   GO; GO:0005764; C:lysosome; IMP:UniProtKB.
DR   GO; GO:0004557; F:alpha-galactosidase activity; IDA:UniProtKB.
DR   GO; GO:0003824; F:catalytic activity; IDA:UniProtKB.
DR   GO; GO:0016936; F:galactoside binding; IEA:Ensembl.
DR   GO; GO:0016787; F:hydrolase activity; TAS:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0052692; F:raffinose alpha-galactosidase activity; IEA:UniProtKB-EC.
DR   GO; GO:0005102; F:receptor binding; IDA:UniProtKB.
DR   GO; GO:0046479; P:glycosphingolipid catabolic process; TAS:UniProtKB.
DR   GO; GO:0006687; P:glycosphingolipid metabolic process; TAS:Reactome.
DR   GO; GO:0046477; P:glycosylceramide catabolic process; ISS:UniProtKB.
DR   GO; GO:0045019; P:negative regulation of nitric oxide biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0051001; P:negative regulation of nitric-oxide synthase activity; ISS:UniProtKB.
DR   GO; GO:0009311; P:oligosaccharide metabolic process; IDA:UniProtKB.
DR   GO; GO:0044281; P:small molecule metabolic process; TAS:Reactome.
DR   GO; GO:0006665; P:sphingolipid metabolic process; TAS:Reactome.
DR   Gene3D; 2.60.40.1180; -; 1.
DR   Gene3D; 3.20.20.70; -; 1.
DR   InterPro; IPR013785; Aldolase_TIM.
DR   InterPro; IPR013780; Glyco_hydro_13_b.
DR   InterPro; IPR002241; Glyco_hydro_27.
DR   InterPro; IPR000111; Glyco_hydro_27/36_CS.
DR   InterPro; IPR017853; Glycoside_hydrolase_SF.
DR   Pfam; PF16499; Melibiase_2; 1.
DR   PRINTS; PR00740; GLHYDRLASE27.
DR   SUPFAM; SSF51445; SSF51445; 1.
DR   PROSITE; PS00512; ALPHA_GALACTOSIDASE; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Complete proteome; Direct protein sequencing;
KW   Disease mutation; Disulfide bond; Glycoprotein; Glycosidase;
KW   Hydrolase; Lysosome; Pharmaceutical; Reference proteome; RNA editing;
KW   Signal.
FT   SIGNAL        1     31
FT   CHAIN        32    429       Alpha-galactosidase A.
FT                                /FTId=PRO_0000001004.
FT   REGION      203    207       Substrate binding.
FT   ACT_SITE    170    170       Nucleophile. {ECO:0000250}.
FT   ACT_SITE    231    231       Proton donor. {ECO:0000250}.
FT   CARBOHYD    139    139       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:15003450}.
FT   CARBOHYD    192    192       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:15003450}.
FT   CARBOHYD    215    215       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:15003450,
FT                                ECO:0000269|PubMed:19159218}.
FT   CARBOHYD    408    408       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     52     94
FT   DISULFID     56     63
FT   DISULFID    142    172
FT   DISULFID    202    223
FT   DISULFID    378    382
FT   VARIANT      12     14       Missing (in FD; has 4% of wild-type
FT                                activity). {ECO:0000269|PubMed:19621417}.
FT                                /FTId=VAR_062550.
FT   VARIANT      20     20       A -> P (in FD; atypical).
FT                                {ECO:0000269|PubMed:7596372,
FT                                ECO:0000269|PubMed:9105656}.
FT                                /FTId=VAR_012362.
FT   VARIANT      31     31       A -> V (in FD).
FT                                {ECO:0000269|PubMed:15712228,
FT                                ECO:0000269|PubMed:9100224}.
FT                                /FTId=VAR_012363.
FT   VARIANT      32     32       L -> P (in FD).
FT                                {ECO:0000269|PubMed:7599642}.
FT                                /FTId=VAR_000431.
FT   VARIANT      34     34       N -> S (in FD; dbSNP:rs28935192).
FT                                {ECO:0000269|PubMed:7504405,
FT                                ECO:0000269|PubMed:7599642,
FT                                ECO:0000269|PubMed:8395937}.
FT                                /FTId=VAR_000432.
FT   VARIANT      35     35       G -> R (in FD).
FT                                {ECO:0000269|PubMed:8069316}.
FT                                /FTId=VAR_000433.
FT   VARIANT      40     40       P -> L (in FD).
FT                                {ECO:0000269|PubMed:10916280}.
FT                                /FTId=VAR_012364.
FT   VARIANT      40     40       P -> S (in FD).
FT                                {ECO:0000269|PubMed:2152885,
FT                                ECO:0000269|PubMed:9105656,
FT                                ECO:0000269|PubMed:9452111}.
FT                                /FTId=VAR_000434.
FT   VARIANT      42     42       M -> L (in FD).
FT                                {ECO:0000269|PubMed:15712228}.
FT                                /FTId=VAR_062551.
FT   VARIANT      42     42       M -> V (in FD).
FT                                {ECO:0000269|PubMed:10666480,
FT                                ECO:0000269|PubMed:8875188}.
FT                                /FTId=VAR_012365.
FT   VARIANT      43     43       G -> R (in FD).
FT                                {ECO:0000269|PubMed:15712228}.
FT                                /FTId=VAR_062552.
FT   VARIANT      45     46       LH -> RS (in FD).
FT                                /FTId=VAR_012366.
FT   VARIANT      46     46       H -> P (in FD; has 36% of wild-type
FT                                activity). {ECO:0000269|PubMed:19621417}.
FT                                /FTId=VAR_062553.
FT   VARIANT      46     46       H -> R (in FD).
FT                                {ECO:0000269|PubMed:9100224}.
FT                                /FTId=VAR_012367.
FT   VARIANT      46     46       H -> Y (in FD).
FT                                {ECO:0000269|PubMed:11668641}.
FT                                /FTId=VAR_012368.
FT   VARIANT      47     47       W -> G (in FD).
FT                                {ECO:0000269|PubMed:11668641}.
FT                                /FTId=VAR_012369.
FT   VARIANT      49     49       R -> L (in FD).
FT                                {ECO:0000269|PubMed:8069316}.
FT                                /FTId=VAR_000435.
FT   VARIANT      49     49       R -> P (in FD).
FT                                {ECO:0000269|PubMed:11668641}.
FT                                /FTId=VAR_012370.
FT   VARIANT      49     49       R -> S (in FD).
FT                                {ECO:0000269|PubMed:8875188}.
FT                                /FTId=VAR_012371.
FT   VARIANT      52     52       C -> R (in FD).
FT                                {ECO:0000269|PubMed:8807334,
FT                                ECO:0000269|PubMed:8931708}.
FT                                /FTId=VAR_000436.
FT   VARIANT      52     52       C -> S (in FD).
FT                                /FTId=VAR_000437.
FT   VARIANT      56     56       C -> F (in FD).
FT                                /FTId=VAR_000438.
FT   VARIANT      56     56       C -> G (in FD; dbSNP:rs28935193).
FT                                {ECO:0000269|PubMed:7504405}.
FT                                /FTId=VAR_000439.
FT   VARIANT      56     56       C -> Y (in FD).
FT                                {ECO:0000269|PubMed:8875188}.
FT                                /FTId=VAR_012372.
FT   VARIANT      59     59       E -> K (in FD).
FT                                /FTId=VAR_000440.
FT   VARIANT      65     65       S -> T (in FD; does not affect enzyme
FT                                function). {ECO:0000269|PubMed:12786754,
FT                                ECO:0000269|PubMed:9554750}.
FT                                /FTId=VAR_032290.
FT   VARIANT      66     66       E -> Q (in FD; has 52% of wild-type
FT                                activity; dbSNP:rs28935191).
FT                                {ECO:0000269|PubMed:1315715,
FT                                ECO:0000269|PubMed:19621417,
FT                                ECO:0000269|PubMed:7575533,
FT                                ECO:0000269|PubMed:9105656}.
FT                                /FTId=VAR_000441.
FT   VARIANT      72     72       M -> V (in FD; atypical).
FT                                {ECO:0000269|PubMed:9105656,
FT                                ECO:0000269|PubMed:9452090}.
FT                                /FTId=VAR_000442.
FT   VARIANT      85     85       G -> D (in FD).
FT                                {ECO:0000269|PubMed:7599642}.
FT                                /FTId=VAR_000443.
FT   VARIANT      86     86       Y -> C (in FD).
FT                                {ECO:0000269|PubMed:9100224}.
FT                                /FTId=VAR_012373.
FT   VARIANT      89     89       L -> P (in FD).
FT                                {ECO:0000269|PubMed:9100224}.
FT                                /FTId=VAR_012374.
FT   VARIANT      89     89       L -> R (in FD).
FT                                /FTId=VAR_000444.
FT   VARIANT      91     91       I -> T (in FD; mild).
FT                                {ECO:0000269|PubMed:9100224}.
FT                                /FTId=VAR_012375.
FT   VARIANT      92     92       D -> H (in FD).
FT                                {ECO:0000269|PubMed:8875188}.
FT                                /FTId=VAR_012376.
FT   VARIANT      92     92       D -> Y (in FD).
FT                                {ECO:0000269|PubMed:9100224}.
FT                                /FTId=VAR_012377.
FT   VARIANT      93     93       D -> G (in FD).
FT                                {ECO:0000269|PubMed:8875188}.
FT                                /FTId=VAR_012378.
FT   VARIANT      93     93       D -> N (in FD; has no enzyme activity).
FT                                {ECO:0000269|PubMed:15712228,
FT                                ECO:0000269|PubMed:19621417}.
FT                                /FTId=VAR_062554.
FT   VARIANT      94     94       C -> S (in FD).
FT                                {ECO:0000269|PubMed:11668641}.
FT                                /FTId=VAR_012379.
FT   VARIANT      94     94       C -> Y (in FD).
FT                                {ECO:0000269|PubMed:9100224}.
FT                                /FTId=VAR_012380.
FT   VARIANT      95     95       W -> S (in FD).
FT                                {ECO:0000269|PubMed:10916280,
FT                                ECO:0000269|PubMed:11668641}.
FT                                /FTId=VAR_012381.
FT   VARIANT      97     97       A -> V (in FD).
FT                                {ECO:0000269|PubMed:9100224}.
FT                                /FTId=VAR_012382.
FT   VARIANT     100    100       R -> K (in FD).
FT                                /FTId=VAR_000445.
FT   VARIANT     100    100       R -> T (in FD).
FT                                {ECO:0000269|PubMed:9100224}.
FT                                /FTId=VAR_012383.
FT   VARIANT     112    117       Missing (in FD).
FT                                /FTId=VAR_000446.
FT   VARIANT     112    112       R -> C (in FD).
FT                                {ECO:0000269|PubMed:10666480,
FT                                ECO:0000269|PubMed:10916280,
FT                                ECO:0000269|PubMed:11668641,
FT                                ECO:0000269|PubMed:1315715,
FT                                ECO:0000269|PubMed:15712228,
FT                                ECO:0000269|PubMed:7575533,
FT                                ECO:0000269|PubMed:9105656}.
FT                                /FTId=VAR_000447.
FT   VARIANT     112    112       R -> H (in FD; mild).
FT                                {ECO:0000269|PubMed:10916280,
FT                                ECO:0000269|PubMed:15712228}.
FT                                /FTId=VAR_000448.
FT   VARIANT     112    112       R -> S (in FD).
FT                                {ECO:0000269|PubMed:15712228}.
FT                                /FTId=VAR_062555.
FT   VARIANT     113    113       F -> L (in FD; mild).
FT                                {ECO:0000269|PubMed:9100224}.
FT                                /FTId=VAR_012384.
FT   VARIANT     113    113       F -> S (in FD).
FT                                {ECO:0000269|PubMed:11668641}.
FT                                /FTId=VAR_012385.
FT   VARIANT     120    121       LA -> PT (in FD).
FT                                /FTId=VAR_000449.
FT   VARIANT     120    120       L -> V (in FD; has 42% of wild-type
FT                                activity). {ECO:0000269|PubMed:19621417}.
FT                                /FTId=VAR_062556.
FT   VARIANT     128    128       G -> E (in FD).
FT                                {ECO:0000269|PubMed:8807334}.
FT                                /FTId=VAR_000450.
FT   VARIANT     131    131       L -> P (in FD).
FT                                /FTId=VAR_000451.
FT   VARIANT     134    134       Y -> S (in FD).
FT                                {ECO:0000269|PubMed:15712228,
FT                                ECO:0000269|PubMed:9100224}.
FT                                /FTId=VAR_012386.
FT   VARIANT     135    135       A -> V (in FD).
FT                                {ECO:0000269|PubMed:15712228}.
FT                                /FTId=VAR_062557.
FT   VARIANT     138    138       G -> R (in FD).
FT                                {ECO:0000269|PubMed:9100224}.
FT                                /FTId=VAR_012387.
FT   VARIANT     142    142       C -> R (in FD).
FT                                {ECO:0000269|PubMed:10666480}.
FT                                /FTId=VAR_012388.
FT   VARIANT     142    142       C -> Y (in FD).
FT                                {ECO:0000269|PubMed:7759078,
FT                                ECO:0000269|PubMed:9105656}.
FT                                /FTId=VAR_000452.
FT   VARIANT     143    143       A -> P (in FD).
FT                                {ECO:0000269|PubMed:11889412}.
FT                                /FTId=VAR_000453.
FT   VARIANT     143    143       A -> T (in FD).
FT                                {ECO:0000269|PubMed:11668641,
FT                                ECO:0000269|PubMed:16533976,
FT                                ECO:0000269|PubMed:9100224}.
FT                                /FTId=VAR_012389.
FT   VARIANT     144    144       G -> V (in FD).
FT                                /FTId=VAR_000454.
FT   VARIANT     146    146       P -> S (in FD; mild; dbSNP:rs28935194).
FT                                /FTId=VAR_000455.
FT   VARIANT     148    148       S -> N (in FD).
FT                                {ECO:0000269|PubMed:10916280}.
FT                                /FTId=VAR_012390.
FT   VARIANT     148    148       S -> R (in FD).
FT                                {ECO:0000269|PubMed:10666480,
FT                                ECO:0000269|PubMed:9100224}.
FT                                /FTId=VAR_012391.
FT   VARIANT     156    156       A -> T (in FD; dbSNP:rs28935195).
FT                                {ECO:0000269|PubMed:7599642}.
FT                                /FTId=VAR_000456.
FT   VARIANT     156    156       A -> V (in FD).
FT                                {ECO:0000269|PubMed:7575533,
FT                                ECO:0000269|PubMed:7759078,
FT                                ECO:0000269|PubMed:9105656}.
FT                                /FTId=VAR_000457.
FT   VARIANT     162    162       W -> C (in FD).
FT                                {ECO:0000269|PubMed:8931708}.
FT                                /FTId=VAR_012392.
FT   VARIANT     162    162       W -> R (in FD; dbSNP:rs28935196).
FT                                {ECO:0000269|PubMed:7504405}.
FT                                /FTId=VAR_000458.
FT   VARIANT     163    163       G -> V (in FD).
FT                                {ECO:0000269|PubMed:9100224}.
FT                                /FTId=VAR_012393.
FT   VARIANT     165    165       D -> V (in FD).
FT                                {ECO:0000269|PubMed:10666480,
FT                                ECO:0000269|PubMed:8069316}.
FT                                /FTId=VAR_000459.
FT   VARIANT     166    166       L -> V (in FD).
FT                                {ECO:0000269|PubMed:7575533,
FT                                ECO:0000269|PubMed:7759078,
FT                                ECO:0000269|PubMed:9105656}.
FT                                /FTId=VAR_000460.
FT   VARIANT     170    170       D -> V (in FD).
FT                                {ECO:0000269|PubMed:9100224}.
FT                                /FTId=VAR_012394.
FT   VARIANT     171    171       G -> D (in FD).
FT                                {ECO:0000269|PubMed:15712228}.
FT                                /FTId=VAR_062558.
FT   VARIANT     172    172       C -> R (in FD).
FT                                {ECO:0000269|PubMed:10916280}.
FT                                /FTId=VAR_012395.
FT   VARIANT     172    172       C -> Y (in FD).
FT                                /FTId=VAR_000461.
FT   VARIANT     183    183       G -> D (in FD).
FT                                {ECO:0000269|PubMed:10666480}.
FT                                /FTId=VAR_012396.
FT   VARIANT     187    187       M -> V (in FD).
FT                                {ECO:0000269|PubMed:10916280}.
FT                                /FTId=VAR_012397.
FT   VARIANT     201    201       S -> F (in FD).
FT                                {ECO:0000269|PubMed:15712228}.
FT                                /FTId=VAR_062559.
FT   VARIANT     202    202       C -> W (in FD; dbSNP:rs28936082).
FT                                {ECO:0000269|PubMed:10208848}.
FT                                /FTId=VAR_000462.
FT   VARIANT     202    202       C -> Y (in FD).
FT                                {ECO:0000269|PubMed:9100224}.
FT                                /FTId=VAR_012398.
FT   VARIANT     205    207       Missing (in FD).
FT                                {ECO:0000269|PubMed:9100224}.
FT                                /FTId=VAR_012399.
FT   VARIANT     205    205       P -> T (in FD).
FT                                {ECO:0000269|PubMed:8807334,
FT                                ECO:0000269|PubMed:8875188}.
FT                                /FTId=VAR_000463.
FT   VARIANT     215    215       N -> S (in FD; mild; dbSNP:rs28935197).
FT                                {ECO:0000269|PubMed:10666480,
FT                                ECO:0000269|PubMed:11668641,
FT                                ECO:0000269|PubMed:15712228,
FT                                ECO:0000269|PubMed:8395937,
FT                                ECO:0000269|PubMed:9452111}.
FT                                /FTId=VAR_000464.
FT   VARIANT     216    216       Y -> D (in FD).
FT                                {ECO:0000269|PubMed:9100224}.
FT                                /FTId=VAR_012400.
FT   VARIANT     219    219       I -> N (in FD).
FT                                /FTId=VAR_000465.
FT   VARIANT     219    219       I -> T (in FD; has 46% of wild-type
FT                                activity). {ECO:0000269|PubMed:19621417}.
FT                                /FTId=VAR_062560.
FT   VARIANT     223    223       C -> G (in FD).
FT                                {ECO:0000269|PubMed:10208848}.
FT                                /FTId=VAR_012401.
FT   VARIANT     224    224       N -> D (in FD).
FT                                {ECO:0000269|PubMed:10208848,
FT                                ECO:0000269|PubMed:9452111}.
FT                                /FTId=VAR_000466.
FT   VARIANT     224    224       N -> S (in FD).
FT                                {ECO:0000269|PubMed:10916280}.
FT                                /FTId=VAR_012402.
FT   VARIANT     226    226       W -> R (in FD).
FT                                {ECO:0000269|PubMed:10916280}.
FT                                /FTId=VAR_012403.
FT   VARIANT     227    227       R -> Q (in FD; dbSNP:rs28935198).
FT                                {ECO:0000269|PubMed:10916280,
FT                                ECO:0000269|PubMed:7504405}.
FT                                /FTId=VAR_000467.
FT   VARIANT     230    230       A -> T (in FD).
FT                                {ECO:0000269|PubMed:10916280}.
FT                                /FTId=VAR_012404.
FT   VARIANT     231    231       D -> N (in FD).
FT                                {ECO:0000269|PubMed:8863162}.
FT                                /FTId=VAR_000468.
FT   VARIANT     234    234       D -> E (in FD).
FT                                {ECO:0000269|PubMed:15712228}.
FT                                /FTId=VAR_062561.
FT   VARIANT     235    235       S -> C (in FD).
FT                                {ECO:0000269|PubMed:10666480}.
FT                                /FTId=VAR_012405.
FT   VARIANT     236    236       W -> C (in FD).
FT                                {ECO:0000269|PubMed:8875188}.
FT                                /FTId=VAR_012406.
FT   VARIANT     236    236       W -> L (in FD).
FT                                {ECO:0000269|PubMed:10666480}.
FT                                /FTId=VAR_012407.
FT   VARIANT     242    242       I -> N (in FD).
FT                                {ECO:0000269|PubMed:9105656}.
FT                                /FTId=VAR_012408.
FT   VARIANT     244    244       D -> H (in FD).
FT                                {ECO:0000269|PubMed:10666480}.
FT                                /FTId=VAR_012409.
FT   VARIANT     244    244       D -> N (in FD).
FT                                /FTId=VAR_000469.
FT   VARIANT     247    247       S -> SWTS (in FD).
FT                                /FTId=VAR_000470.
FT   VARIANT     258    258       G -> R (in FD).
FT                                {ECO:0000269|PubMed:11668641}.
FT                                /FTId=VAR_012410.
FT   VARIANT     259    259       P -> L (in FD).
FT                                {ECO:0000269|PubMed:10666480}.
FT                                /FTId=VAR_012411.
FT   VARIANT     259    259       P -> R (in FD).
FT                                {ECO:0000269|PubMed:11668641}.
FT                                /FTId=VAR_012412.
FT   VARIANT     260    260       G -> A (in FD).
FT                                {ECO:0000269|PubMed:7575533,
FT                                ECO:0000269|PubMed:9105656}.
FT                                /FTId=VAR_012413.
FT   VARIANT     261    261       G -> D (in FD).
FT                                {ECO:0000269|PubMed:15712228,
FT                                ECO:0000269|PubMed:9105656}.
FT                                /FTId=VAR_012414.
FT   VARIANT     263    263       N -> S (in FD).
FT                                {ECO:0000269|PubMed:9100224}.
FT                                /FTId=VAR_012415.
FT   VARIANT     264    264       D -> V (in FD; dbSNP:rs28935486).
FT                                {ECO:0000269|PubMed:15712228,
FT                                ECO:0000269|PubMed:7504405}.
FT                                /FTId=VAR_000471.
FT   VARIANT     264    264       D -> Y (in FD).
FT                                {ECO:0000269|PubMed:15712228}.
FT                                /FTId=VAR_062562.
FT   VARIANT     265    265       P -> R (in FD).
FT                                {ECO:0000269|PubMed:8931708}.
FT                                /FTId=VAR_012416.
FT   VARIANT     266    266       D -> H (in FD).
FT                                {ECO:0000269|PubMed:10916280}.
FT                                /FTId=VAR_032291.
FT   VARIANT     266    266       D -> N (in FD).
FT                                {ECO:0000269|PubMed:11076046}.
FT                                /FTId=VAR_012418.
FT   VARIANT     266    266       D -> V (in FD; dbSNP:rs28935487).
FT                                {ECO:0000269|PubMed:7504405}.
FT                                /FTId=VAR_000472.
FT   VARIANT     267    267       M -> I (in FD).
FT                                {ECO:0000269|PubMed:10666480,
FT                                ECO:0000269|PubMed:11668641}.
FT                                /FTId=VAR_012419.
FT   VARIANT     269    269       V -> A (in FD; dbSNP:rs28935488).
FT                                {ECO:0000269|PubMed:8395937}.
FT                                /FTId=VAR_000473.
FT   VARIANT     272    272       N -> K (in FD).
FT                                /FTId=VAR_000474.
FT   VARIANT     272    272       N -> S (in FD; dbSNP:rs28935495).
FT                                {ECO:0000269|PubMed:15162124}.
FT                                /FTId=VAR_032292.
FT   VARIANT     276    276       S -> G (in FD).
FT                                {ECO:0000269|PubMed:15712228}.
FT                                /FTId=VAR_062563.
FT   VARIANT     279    279       Q -> E (in FD; mild; does not
FT                                significantly affect the enzyme activity
FT                                but the mutant protein levels are
FT                                decreased presumably in the ER of the
FT                                cells; dbSNP:rs28935485).
FT                                {ECO:0000269|PubMed:10838196,
FT                                ECO:0000269|PubMed:1315715,
FT                                ECO:0000269|PubMed:7575533,
FT                                ECO:0000269|PubMed:9105656}.
FT                                /FTId=VAR_000475.
FT   VARIANT     279    279       Q -> H (in FD).
FT                                {ECO:0000269|PubMed:11668641}.
FT                                /FTId=VAR_012420.
FT   VARIANT     280    280       Q -> H (in FD).
FT                                {ECO:0000269|PubMed:11668641}.
FT                                /FTId=VAR_012421.
FT   VARIANT     284    284       M -> T (in FD).
FT                                {ECO:0000269|PubMed:8807334}.
FT                                /FTId=VAR_000476.
FT   VARIANT     285    285       A -> P (in FD).
FT                                {ECO:0000269|PubMed:15712228}.
FT                                /FTId=VAR_062564.
FT   VARIANT     287    287       W -> C (in FD).
FT                                {ECO:0000269|PubMed:9100224}.
FT                                /FTId=VAR_012422.
FT   VARIANT     287    287       W -> G (in FD).
FT                                {ECO:0000269|PubMed:8875188}.
FT                                /FTId=VAR_012423.
FT   VARIANT     288    288       A -> D (in FD).
FT                                /FTId=VAR_000477.
FT   VARIANT     289    289       I -> F (in FD).
FT                                {ECO:0000269|PubMed:10666480}.
FT                                /FTId=VAR_012424.
FT   VARIANT     296    296       M -> I (in FD; atypical).
FT                                {ECO:0000269|PubMed:7575533,
FT                                ECO:0000269|PubMed:7596372,
FT                                ECO:0000269|PubMed:9105656}.
FT                                /FTId=VAR_012425.
FT   VARIANT     296    296       M -> V (in FD; mild).
FT                                {ECO:0000269|PubMed:1846223}.
FT                                /FTId=VAR_000478.
FT   VARIANT     297    297       S -> F (in FD; dbSNP:rs28935489).
FT                                {ECO:0000269|PubMed:7504405}.
FT                                /FTId=VAR_000479.
FT   VARIANT     298    298       N -> H (in FD).
FT                                {ECO:0000269|PubMed:11668641,
FT                                ECO:0000269|PubMed:8875188}.
FT                                /FTId=VAR_012426.
FT   VARIANT     298    298       N -> K (in FD).
FT                                {ECO:0000269|PubMed:8807334}.
FT                                /FTId=VAR_000480.
FT   VARIANT     298    298       N -> S (in FD).
FT                                {ECO:0000269|PubMed:9100224}.
FT                                /FTId=VAR_012427.
FT   VARIANT     300    300       L -> F (in FD).
FT                                {ECO:0000269|PubMed:15712228}.
FT                                /FTId=VAR_062565.
FT   VARIANT     301    301       R -> Q (in FD; mild; does not
FT                                significantly affect the enzyme activity
FT                                but the mutant protein levels are
FT                                decreased presumably in the ER of the
FT                                cells). {ECO:0000269|PubMed:10208848,
FT                                ECO:0000269|PubMed:10838196,
FT                                ECO:0000269|PubMed:10916280,
FT                                ECO:0000269|PubMed:1315715,
FT                                ECO:0000269|PubMed:2171331,
FT                                ECO:0000269|PubMed:7575533,
FT                                ECO:0000269|PubMed:7599642,
FT                                ECO:0000269|PubMed:8738659,
FT                                ECO:0000269|PubMed:9105656}.
FT                                /FTId=VAR_000481.
FT   VARIANT     313    313       D -> Y (in FD; dbSNP:rs28935490).
FT                                {ECO:0000269|PubMed:11668641,
FT                                ECO:0000269|PubMed:7504405,
FT                                ECO:0000269|PubMed:9452111}.
FT                                /FTId=VAR_000482.
FT   VARIANT     316    322       Missing (in FD).
FT                                {ECO:0000269|PubMed:8931708}.
FT                                /FTId=VAR_012429.
FT   VARIANT     316    316       V -> E (in FD).
FT                                {ECO:0000269|PubMed:8069316}.
FT                                /FTId=VAR_000483.
FT   VARIANT     320    320       N -> K (in FD).
FT                                {ECO:0000269|PubMed:7575533,
FT                                ECO:0000269|PubMed:9105656}.
FT                                /FTId=VAR_012430.
FT   VARIANT     320    320       N -> Y (in FD).
FT                                {ECO:0000269|PubMed:10916280}.
FT                                /FTId=VAR_012431.
FT   VARIANT     321    321       Q -> E (in FD).
FT                                {ECO:0000269|PubMed:10666480}.
FT                                /FTId=VAR_012432.
FT   VARIANT     327    327       Q -> K (in FD; dbSNP:rs28935491).
FT                                {ECO:0000269|PubMed:10208848,
FT                                ECO:0000269|PubMed:8395937}.
FT                                /FTId=VAR_000484.
FT   VARIANT     328    328       G -> A (in FD; dbSNP:rs28935492).
FT                                {ECO:0000269|PubMed:15712228,
FT                                ECO:0000269|PubMed:7504405}.
FT                                /FTId=VAR_000486.
FT   VARIANT     328    328       G -> R (in FD).
FT                                {ECO:0000269|PubMed:1315715,
FT                                ECO:0000269|PubMed:7575533,
FT                                ECO:0000269|PubMed:9105656}.
FT                                /FTId=VAR_000485.
FT   VARIANT     328    328       G -> V (in FD).
FT                                {ECO:0000269|PubMed:15712228}.
FT                                /FTId=VAR_062566.
FT   VARIANT     338    338       E -> K (in FD).
FT                                {ECO:0000269|PubMed:15712228}.
FT                                /FTId=VAR_062567.
FT   VARIANT     340    340       W -> R (in FD).
FT                                {ECO:0000269|PubMed:8875188}.
FT                                /FTId=VAR_012433.
FT   VARIANT     341    341       E -> K (in FD).
FT                                {ECO:0000269|PubMed:10090526}.
FT                                /FTId=VAR_012434.
FT   VARIANT     342    342       R -> Q (in FD; severe; dbSNP:rs28935493).
FT                                /FTId=VAR_000487.
FT   VARIANT     356    356       R -> Q (in FD; has 15% of wild-type
FT                                activity). {ECO:0000269|PubMed:19621417}.
FT                                /FTId=VAR_062568.
FT   VARIANT     356    356       R -> W (in FD; severe).
FT                                {ECO:0000269|PubMed:2539398}.
FT                                /FTId=VAR_000488.
FT   VARIANT     358    358       E -> A (in FD).
FT                                {ECO:0000269|PubMed:15712228}.
FT                                /FTId=VAR_062569.
FT   VARIANT     358    358       E -> K (in FD).
FT                                {ECO:0000269|PubMed:9452068}.
FT                                /FTId=VAR_000489.
FT   VARIANT     358    358       Missing (in FD).
FT                                {ECO:0000269|PubMed:10666480,
FT                                ECO:0000269|PubMed:15712228,
FT                                ECO:0000269|PubMed:8807334,
FT                                ECO:0000269|PubMed:9105656}.
FT                                /FTId=VAR_000490.
FT   VARIANT     360    360       G -> C (in FD; has 6% of wild-type
FT                                activity). {ECO:0000269|PubMed:19621417}.
FT                                /FTId=VAR_062570.
FT   VARIANT     361    361       G -> R (in FD; severe; dbSNP:rs28935494).
FT                                {ECO:0000269|PubMed:8395937}.
FT                                /FTId=VAR_000491.
FT   VARIANT     363    363       R -> H (in FD).
FT                                {ECO:0000269|PubMed:11668641}.
FT                                /FTId=VAR_012435.
FT   VARIANT     373    373       G -> D (in FD).
FT                                {ECO:0000269|PubMed:11295840}.
FT                                /FTId=VAR_012436.
FT   VARIANT     373    373       G -> S (in FD).
FT                                {ECO:0000269|PubMed:7575533,
FT                                ECO:0000269|PubMed:9105656}.
FT                                /FTId=VAR_012437.
FT   VARIANT     377    377       A -> D (in FD).
FT                                {ECO:0000269|PubMed:11668641}.
FT                                /FTId=VAR_012438.
FT   VARIANT     378    378       C -> Y (in FD).
FT                                {ECO:0000269|PubMed:10666480}.
FT                                /FTId=VAR_012439.
FT   VARIANT     383    383       Missing (in FD; severe; with facial
FT                                telangiectasias).
FT                                {ECO:0000269|PubMed:8834244}.
FT                                /FTId=VAR_000492.
FT   VARIANT     396    396       F -> Y (in RNA edited version).
FT                                /FTId=VAR_000493.
FT   VARIANT     404    404       Missing (in FD; mild).
FT                                {ECO:0000269|PubMed:15712228,
FT                                ECO:0000269|PubMed:7504405,
FT                                ECO:0000269|PubMed:9100224}.
FT                                /FTId=VAR_000494.
FT   VARIANT     409    409       P -> A (in FD).
FT                                {ECO:0000269|PubMed:11668641}.
FT                                /FTId=VAR_012440.
FT   VARIANT     409    409       P -> T (in FD).
FT                                {ECO:0000269|PubMed:11668641}.
FT                                /FTId=VAR_012441.
FT   VARIANT     410    410       T -> A (in FD; mild).
FT                                {ECO:0000269|PubMed:12694230}.
FT                                /FTId=VAR_032293.
FT   VARIANT     414    414       L -> S (in FD).
FT                                {ECO:0000269|PubMed:15712228}.
FT                                /FTId=VAR_062571.
FT   STRAND       42     46       {ECO:0000244|PDB:3HG3}.
FT   HELIX        47     50       {ECO:0000244|PDB:3HG3}.
FT   TURN         56     58       {ECO:0000244|PDB:3HG3}.
FT   TURN         60     62       {ECO:0000244|PDB:3HG3}.
FT   STRAND       63     65       {ECO:0000244|PDB:3HG3}.
FT   HELIX        66     78       {ECO:0000244|PDB:3HG3}.
FT   HELIX        81     84       {ECO:0000244|PDB:3HG3}.
FT   STRAND       88     90       {ECO:0000244|PDB:3HG3}.
FT   STRAND      102    104       {ECO:0000244|PDB:3GXT}.
FT   TURN        110    112       {ECO:0000244|PDB:3HG3}.
FT   STRAND      113    115       {ECO:0000244|PDB:1R47}.
FT   HELIX       116    126       {ECO:0000244|PDB:3HG3}.
FT   STRAND      130    140       {ECO:0000244|PDB:3HG3}.
FT   STRAND      144    146       {ECO:0000244|PDB:3HG3}.
FT   TURN        149    151       {ECO:0000244|PDB:3GXN}.
FT   HELIX       152    162       {ECO:0000244|PDB:3HG3}.
FT   STRAND      166    170       {ECO:0000244|PDB:3HG3}.
FT   HELIX       177    193       {ECO:0000244|PDB:3HG3}.
FT   STRAND      199    202       {ECO:0000244|PDB:3HG3}.
FT   HELIX       205    208       {ECO:0000244|PDB:3HG3}.
FT   TURN        209    211       {ECO:0000244|PDB:3HG3}.
FT   HELIX       216    222       {ECO:0000244|PDB:3HG3}.
FT   STRAND      224    227       {ECO:0000244|PDB:3HG3}.
FT   HELIX       236    248       {ECO:0000244|PDB:3HG3}.
FT   HELIX       250    253       {ECO:0000244|PDB:3HG3}.
FT   TURN        254    256       {ECO:0000244|PDB:3HG3}.
FT   STRAND      261    264       {ECO:0000244|PDB:3HG3}.
FT   STRAND      272    274       {ECO:0000244|PDB:3HG3}.
FT   HELIX       277    289       {ECO:0000244|PDB:3HG3}.
FT   STRAND      294    296       {ECO:0000244|PDB:3HG3}.
FT   HELIX       305    311       {ECO:0000244|PDB:3HG3}.
FT   HELIX       314    320       {ECO:0000244|PDB:3HG3}.
FT   STRAND      329    334       {ECO:0000244|PDB:3HG3}.
FT   STRAND      337    343       {ECO:0000244|PDB:3HG3}.
FT   HELIX       345    347       {ECO:0000244|PDB:3S5Z}.
FT   STRAND      349    355       {ECO:0000244|PDB:3HG3}.
FT   STRAND      359    361       {ECO:0000244|PDB:3HG3}.
FT   STRAND      363    368       {ECO:0000244|PDB:3HG3}.
FT   HELIX       369    371       {ECO:0000244|PDB:3HG3}.
FT   HELIX       373    375       {ECO:0000244|PDB:3HG3}.
FT   TURN        376    378       {ECO:0000244|PDB:3HG3}.
FT   STRAND      379    390       {ECO:0000244|PDB:3HG3}.
FT   STRAND      392    398       {ECO:0000244|PDB:3HG3}.
FT   STRAND      402    407       {ECO:0000244|PDB:3HG3}.
FT   STRAND      412    419       {ECO:0000244|PDB:3HG3}.
FT   HELIX       420    424       {ECO:0000244|PDB:3HG3}.
SQ   SEQUENCE   429 AA;  48767 MW;  613F8BF21B107D7B CRC64;
     MQLRNPELHL GCALALRFLA LVSWDIPGAR ALDNGLARTP TMGWLHWERF MCNLDCQEEP
     DSCISEKLFM EMAELMVSEG WKDAGYEYLC IDDCWMAPQR DSEGRLQADP QRFPHGIRQL
     ANYVHSKGLK LGIYADVGNK TCAGFPGSFG YYDIDAQTFA DWGVDLLKFD GCYCDSLENL
     ADGYKHMSLA LNRTGRSIVY SCEWPLYMWP FQKPNYTEIR QYCNHWRNFA DIDDSWKSIK
     SILDWTSFNQ ERIVDVAGPG GWNDPDMLVI GNFGLSWNQQ VTQMALWAIM AAPLFMSNDL
     RHISPQAKAL LQDKDVIAIN QDPLGKQGYQ LRQGDNFEVW ERPLSGLAWA VAMINRQEIG
     GPRSYTIAVA SLGKGVACNP ACFITQLLPV KRKLGFYEWT SRLRSHINPT GTVLLQLENT
     MQMSLKDLL
//
ID   USH2A_HUMAN             Reviewed;        5202 AA.
AC   O75445; Q5VVM9; Q6S362; Q9NS27;
DT   04-APR-2006, integrated into UniProtKB/Swiss-Prot.
DT   04-APR-2006, sequence version 3.
DT   17-FEB-2016, entry version 132.
DE   RecName: Full=Usherin;
DE   AltName: Full=Usher syndrome type IIa protein;
DE   AltName: Full=Usher syndrome type-2A protein;
DE   Flags: Precursor;
GN   Name=USH2A;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), INVOLVEMENT IN USH2A, TISSUE
RP   SPECIFICITY, AND VARIANTS SER-479 AND LYS-1486.
RX   PubMed=9624053; DOI=10.1126/science.280.5370.1753;
RA   Eudy J.D., Weston M.D., Yao S.F., Hoover D.M., Rehm H.L., Ahmad I.,
RA   Ma-Edmonds M., Yan D., Cheng J.J., Beisel K.W., Ayuso C., Cremers C.,
RA   Davenport S., Moller C., Talmadge C.B., Tamayo M., Swaroop A.,
RA   Morton C.C., Kimberling W.J., Sumegi J.;
RT   "Mutation of a gene encoding a protein with extracellular matrix
RT   motifs in Usher syndrome type IIa.";
RL   Science 280:1753-1757(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], INVOLVEMENT IN USH2A, VARIANT
RP   LYS-1486, AND VARIANTS USH2A TYR-319; HIS-346 AND PHE-419.
RX   PubMed=10729113; DOI=10.1086/302855;
RA   Weston M.D., Eudy J.D., Fugita S., Yao S.-F., Usami S., Cremers C.,
RA   Greenberg J., Ramesar R., Martini A., Moller C., Smith R.J.,
RA   Sumegi J., Kimberling W.J.;
RT   "Genomic structure and identification of novel mutations in usherin,
RT   the gene responsible for Usher syndrome type IIa.";
RL   Am. J. Hum. Genet. 66:1199-1210(2000).
RN   [3]
RP   ERRATUM.
RA   Weston M.D., Eudy J.D., Fugita S., Yao S.-F., Usami S., Cremers C.,
RA   Greenberg J., Ramesar R., Martini A., Moller C., Smith R.J.,
RA   Sumegi J., Kimberling W.J.;
RL   Am. J. Hum. Genet. 66:2020-2020(2000).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND
RP   VARIANTS USH2A CYS-4115 AND MET-4425.
RX   PubMed=15015129; DOI=10.1086/383096;
RA   Van Wijk E., Pennings R.J.E., Te Brinke H., Claassen A., Yntema H.G.,
RA   Hoefsloot L.H., Cremers F.P.M., Cremers C.W.R.J., Kremer H.;
RT   "Identification of 51 novel exons of the Usher syndrome type 2A
RT   (USH2A) gene that encode multiple conserved functional domains and
RT   that are mutated in patients with Usher syndrome type II.";
RL   Am. J. Hum. Genet. 74:738-744(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [6]
RP   TISSUE SPECIFICITY.
RX   PubMed=11788194; DOI=10.1016/S0378-5955(01)00344-6;
RA   Bhattacharya G., Miller C., Kimberling W.J., Jablonski M.M.,
RA   Cosgrove D.;
RT   "Localization and expression of usherin: a novel basement membrane
RT   protein defective in people with Usher's syndrome type IIa.";
RL   Hear. Res. 163:1-11(2002).
RN   [7]
RP   TISSUE SPECIFICITY.
RX   PubMed=12433396; DOI=10.1016/S0378-5955(02)00635-4;
RA   Pearsall N., Bhattacharya G., Wisecarver J., Adams J., Cosgrove D.,
RA   Kimberling W.;
RT   "Usherin expression is highly conserved in mouse and human tissues.";
RL   Hear. Res. 174:55-63(2002).
RN   [8]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH COLLAGEN.
RX   PubMed=14676276; DOI=10.1242/jcs.00850;
RA   Bhattacharya G., Kalluri R., Orten D.J., Kimberling W.J., Cosgrove D.;
RT   "A domain-specific usherin/collagen IV interaction may be required for
RT   stable integration into the basement membrane superstructure.";
RL   J. Cell Sci. 117:233-242(2004).
RN   [9]
RP   INTERACTION WITH FIBRONECTIN.
RX   PubMed=16114888; DOI=10.1021/bi050245u;
RA   Bhattacharya G., Cosgrove D.;
RT   "Evidence for functional importance of usherin/fibronectin
RT   interactions in retinal basement membranes.";
RL   Biochemistry 44:11518-11524(2005).
RN   [10]
RP   ALTERNATIVE SPLICING (ISOFORM 3).
RX   PubMed=16301217; DOI=10.1093/hmg/ddi416;
RA   Adato A., Lefevre G., Delprat B., Michel V., Michalski N.,
RA   Chardenoux S., Weil D., El-Amraoui A., Petit C.;
RT   "Usherin, the defective protein in Usher syndrome type IIA, is likely
RT   to be a component of interstereocilia ankle links in the inner ear
RT   sensory cells.";
RL   Hum. Mol. Genet. 14:3921-3932(2005).
RN   [11]
RP   INTERACTION WITH USH1C.
RX   PubMed=16301216; DOI=10.1093/hmg/ddi417;
RA   Reiners J., van Wijk E., Maerker T., Zimmermann U., Juergens K.,
RA   te Brinke H., Overlack N., Roepman R., Knipper M., Kremer H.,
RA   Wolfrum U.;
RT   "Scaffold protein harmonin (USH1C) provides molecular links between
RT   Usher syndrome type 1 and type 2.";
RL   Hum. Mol. Genet. 14:3933-3943(2005).
RN   [12]
RP   INTERACTION WITH WHRN.
RX   PubMed=16434480; DOI=10.1093/hmg/ddi490;
RA   van Wijk E., van der Zwaag B., Peters T., Zimmermann U., Te Brinke H.,
RA   Kersten F.F.J., Maerker T., Aller E., Hoefsloot L.H.,
RA   Cremers C.W.R.J., Cremers F.P.M., Wolfrum U., Knipper M., Roepman R.,
RA   Kremer H.;
RT   "The DFNB31 gene product whirlin connects to the Usher protein network
RT   in the cochlea and retina by direct association with USH2A and
RT   VLGR1.";
RL   Hum. Mol. Genet. 15:751-765(2006).
RN   [13]
RP   REVIEW ON VARIANTS.
RX   PubMed=12786748; DOI=10.1034/j.1399-0004.2003.00109.x;
RA   Ahmed Z.M., Riazuddin S., Riazuddin S., Wilcox E.R.;
RT   "The molecular genetics of Usher syndrome.";
RL   Clin. Genet. 63:431-444(2003).
RN   [14]
RP   INTERACTION WITH NINL.
RX   PubMed=18826961; DOI=10.1093/hmg/ddn312;
RA   van Wijk E., Kersten F.F.J., Kartono A., Mans D.A., Brandwijk K.,
RA   Letteboer S.J.F., Peters T.A., Maerker T., Yan X., Cremers C.W.R.J.,
RA   Cremers F.P.M., Wolfrum U., Roepman R., Kremer H.;
RT   "Usher syndrome and Leber congenital amaurosis are molecularly linked
RT   via a novel isoform of the centrosomal ninein-like protein.";
RL   Hum. Mol. Genet. 18:51-64(2009).
RN   [15]
RP   INTERACTION WITH PDZD7, AND VARIANT USH2A ILE-4439.
RX   PubMed=20440071; DOI=10.1172/JCI39715;
RA   Ebermann I., Phillips J.B., Liebau M.C., Koenekoop R.K., Schermer B.,
RA   Lopez I., Schafer E., Roux A.F., Dafinger C., Bernd A., Zrenner E.,
RA   Claustres M., Blanco B., Nurnberg G., Nurnberg P., Ruland R.,
RA   Westerfield M., Benzing T., Bolz H.J.;
RT   "PDZD7 is a modifier of retinal disease and a contributor to digenic
RT   Usher syndrome.";
RL   J. Clin. Invest. 120:1812-1823(2010).
RN   [16]
RP   INVOLVEMENT IN RP39, AND VARIANT RP39 PHE-759.
RX   PubMed=10775529; DOI=10.1086/302926;
RA   Rivolta C., Sweklo E.A., Berson E.L., Dryja T.P.;
RT   "Missense mutation in the USH2A gene: association with recessive
RT   retinitis pigmentosa without hearing loss.";
RL   Am. J. Hum. Genet. 66:1975-1978(2000).
RN   [17]
RP   VARIANTS USH2A TYR-163; MET-230; ARG-536 AND ARG-713.
RX   PubMed=10909849; DOI=10.1038/sj.ejhg.5200491;
RA   Dreyer B., Tranebjaerg L., Rosenberg T., Weston M.D., Kimberling W.J.,
RA   Nilssen O.;
RT   "Identification of novel USH2A mutations: implications for the
RT   structure of USH2A protein.";
RL   Eur. J. Hum. Genet. 8:500-506(2000).
RN   [18]
RP   VARIANTS USH2A TRP-334 AND MET-1515, AND VARIANTS ASP-478; VAL-644 AND
RP   LYS-1486.
RX   PubMed=10738000;
RX   DOI=10.1002/(SICI)1098-1004(200004)15:4<388::AID-HUMU27>3.0.CO;2-N;
RA   Adato A., Weston M.D., Berry A., Kimberling W.J., Bonne-Tamir A.;
RT   "Three novel mutations and twelve polymorphisms identified in the
RT   USH2A gene in Israeli USH2 families.";
RL   Hum. Mutat. 15:388-388(2000).
RN   [19]
RP   VARIANTS USH2A GLU-218; MET-230 AND VAL-555.
RX   PubMed=11311042; DOI=10.1006/exer.2000.0978;
RA   Leroy B.P., Aragon-Martin J.A., Weston M.D., Bessant D.A.R.,
RA   Willis C., Webster A.R., Bird A.C., Kimberling W.J., Payne A.M.,
RA   Bhattacharya S.S.;
RT   "Spectrum of mutations in USH2A in British patients with Usher
RT   syndrome type II.";
RL   Exp. Eye Res. 72:503-509(2001).
RN   [20]
RP   VARIANT RP39 PHE-759.
RX   PubMed=12427073; DOI=10.1001/archopht.120.11.1566;
RA   Rivolta C., Berson E.L., Dryja T.P.;
RT   "Paternal uniparental heterodisomy with partial isodisomy of
RT   chromosome 1 in a patient with retinitis pigmentosa without hearing
RT   loss and a missense mutation in the Usher syndrome type II gene
RT   USH2A.";
RL   Arch. Ophthalmol. 120:1566-1571(2002).
RN   [21]
RP   VARIANT USH2A ARG-713, AND VARIANT RP39 PHE-759.
RX   PubMed=12112664; DOI=10.1002/humu.9042;
RA   Najera C., Beneyto M., Blanca J., Aller E., Fontcuberta A.,
RA   Millan J.M., Ayuso C.;
RT   "Mutations in myosin VIIA (MYO7A) and usherin (USH2A) in Spanish
RT   patients with Usher syndrome types I and II, respectively.";
RL   Hum. Mutat. 20:76-77(2002).
RN   [22]
RP   VARIANTS USH2A PRO-610 AND ARG-761.
RX   PubMed=12525556; DOI=10.1136/jmg.40.1.e8;
RA   Bernal S., Ayuso C., Antinolo G., Gimenez A., Borrego S.,
RA   Trujillo M.J., Marcos I., Calaf M., Del Rio E., Baiget M.;
RT   "Mutations in USH2A in Spanish patients with autosomal recessive
RT   retinitis pigmentosa: high prevalence and phenotypic variation.";
RL   J. Med. Genet. 40:E8-E8(2003).
RN   [23]
RP   VARIANTS USH2A TRP-334; HIS-346 AND THR-357, AND VARIANTS SER-479 AND
RP   VAL-644.
RX   PubMed=15025721; DOI=10.1046/j.1399-0004.2004.00216.x;
RA   Ouyang X.M., Yan D., Hejtmancik J.F., Jacobson S.G., Li A.R., Du L.L.,
RA   Angeli S., Kaiser M., Balkany T., Liu X.Z.;
RT   "Mutational spectrum in Usher syndrome type II.";
RL   Clin. Genet. 65:288-293(2004).
RN   [24]
RP   ERRATUM.
RA   Ouyang X.M., Yan D., Hejtmancik J.F., Jacobson S.G., Li A.R., Du L.L.,
RA   Angeli S., Kaiser M., Balkany T., Liu X.Z.;
RL   Clin. Genet. 65:433-433(2004).
RN   [25]
RP   VARIANT USH2A SER-303, AND VARIANT RP PHE-759.
RX   PubMed=14970843; DOI=10.1038/sj.ejhg.5201138;
RA   Aller E., Najera C., Millan J.M., Oltra J.S., Perez-Garrigues H.,
RA   Vilela C., Navea A., Beneyto M.;
RT   "Genetic analysis of 2299delG and C759F mutations (USH2A) in patients
RT   with visual and/or auditory impairments.";
RL   Eur. J. Hum. Genet. 12:407-410(2004).
RN   [26]
RP   VARIANTS USH2A ILE-307; ILE-391; PHE-419; CYS-464; VAL-516 THR-517;
RP   SER-575; ASN-587 DEL AND LEU-1059, VARIANTS RP39/USH2A ASP-478 AND
RP   PHE-759, VARIANTS RP39 LEU-739; ASN-911 AND ARG-1470, AND VARIANTS
RP   THR-125; MET-230; ARG-268; PHE-365; VAL-644; ARG-713; VAL-1047 AND
RP   LYS-1486.
RX   PubMed=15325563; DOI=10.1016/j.exer.2004.03.005;
RA   Seyedahmadi B.J., Rivolta C., Keene J.A., Berson E.L., Dryja T.P.;
RT   "Comprehensive screening of the USH2A gene in Usher syndrome type II
RT   and non-syndromic recessive retinitis pigmentosa.";
RL   Exp. Eye Res. 79:167-173(2004).
RN   [27]
RP   VARIANTS USH2A HIS-346; PHE-419; ARG-536 AND ARG-713.
RX   PubMed=15241801; DOI=10.1002/humu.9259;
RA   Pennings R.J.E., Te Brinke H., Weston M.D., Claassen A., Orten D.J.,
RA   Weekamp H., Van Aarem A., Huygen P.L.M., Deutman A.F., Hoefsloot L.H.,
RA   Cremers F.P.M., Cremers C.W.R.J., Kimberling W.J., Kremer H.;
RT   "USH2A mutation analysis in 70 Dutch families with Usher syndrome type
RT   II.";
RL   Hum. Mutat. 24:185-185(2004).
RN   [28]
RP   VARIANT RP39 PHE-759, AND VARIANTS THR-125; ASP-478; VAL-644; GLU-703;
RP   TYR-841 AND LYS-1486.
RX   PubMed=16098008; DOI=10.1111/j.1399-0004.2005.00481.x;
RA   Bernal S., Meda C., Solans T., Ayuso C., Garcia-Sandoval B.,
RA   Valverde D., Del Rio E., Baiget M.;
RT   "Clinical and genetic studies in Spanish patients with Usher syndrome
RT   type II: description of new mutations and evidence for a lack of
RT   genotype-phenotype correlation.";
RL   Clin. Genet. 68:204-214(2005).
RN   [29]
RP   VARIANTS USH2A ASP-2249; HIS-2354; ARG-3251; ARG-3267; TYR-3472 INS;
RP   MET-3571; MET-4337 AND LEU-4818, AND VARIANTS ARG-713; PHE-1572;
RP   THR-1665; THR-2106; THR-2169; ALA-2238; GLN-2875; PHE-2886; SER-3099;
RP   ASN-3144; ALA-3411 AND VAL-3868.
RX   PubMed=17085681; DOI=10.1136/jmg.2006.041764;
RA   Aller E., Jaijo T., Beneyto M., Najera C., Oltra S., Ayuso C.,
RA   Baiget M., Carballo M., Antinolo G., Valverde D., Moreno F.,
RA   Vilela C., Collado D., Perez-Garrigues H., Navea A., Millan J.M.;
RT   "Identification of 14 novel mutations in the long isoform of USH2A in
RT   Spanish patients with Usher syndrome type II.";
RL   J. Med. Genet. 43:E55-E55(2006).
RN   [30]
RP   VARIANT RP39 GLY-4674, AND VARIANTS THR-125; ASP-478; VAL-644;
RP   ARG-713; LYS-1486; THR-1665; THR-2106; THR-2169; GLN-2875; SER-3099;
RP   ASN-3144 AND MET-3335.
RX   PubMed=17296898; DOI=10.1001/archopht.125.2.219;
RA   Kaiserman N., Obolensky A., Banin E., Sharon D.;
RT   "Novel USH2A mutations in Israeli patients with retinitis pigmentosa
RT   and Usher syndrome type 2.";
RL   Arch. Ophthalmol. 125:219-224(2007).
RN   [31]
RP   VARIANTS USH2A GLU-218; PHE-280; LYS-284; TRP-334; GLN-334; HIS-346;
RP   ILE-352; PHE-759; GLU-1833; SER-2795; ARG-3282; MET-3571; GLU-3895;
RP   MET-3976; CYS-4115 AND MET-4425, AND VARIANT PHE-1572.
RX   PubMed=17405132; DOI=10.1002/humu.20513;
RA   Baux D., Larrieu L., Blanchet C., Hamel C., Ben Salah S., Vielle A.,
RA   Gilbert-Dussardier B., Holder M., Calvas P., Philip N., Edery P.,
RA   Bonneau D., Claustres M., Malcolm S., Roux A.-F.;
RT   "Molecular and in silico analyses of the full-length isoform of
RT   usherin identify new pathogenic alleles in Usher type II patients.";
RL   Hum. Mutat. 28:781-789(2007).
RN   [32]
RP   VARIANTS USH2A TRP-334 AND VAL-1840.
RX   PubMed=18452394; DOI=10.1089/gte.2007.0107;
RA   Auslender N., Bandah D., Rizel L., Behar D.M., Shohat M., Banin E.,
RA   Allon-Shalev S., Sharony R., Sharon D., Ben-Yosef T.;
RT   "Four USH2A founder mutations underlie the majority of Usher syndrome
RT   type 2 cases among non-Ashkenazi Jews.";
RL   Genet. Test. 12:289-294(2008).
RN   [33]
RP   VARIANTS USH2A TYR-163; ARG-268; CYS-303; TRP-334; HIS-346; ILE-352;
RP   ARG-536; PHE-759; LEU-1212; ASP-2265-ASP-TYR-2266 DELINS ASP;
RP   GLY-3124; THR-3504; ARG-3521; ILE-4054; ARG-4232; ILE-4439; CYS-4487;
RP   HIS-4592 AND ARG-4795, AND VARIANTS THR-125; MET-230; ASP-478;
RP   SER-595; VAL-644; ARG-713; PRO-1349; LYS-1486; PHE-1572; THR-1665;
RP   CYS-1757; ASN-2080; ASN-2086; THR-2106; THR-2169; ALA-2238; HIS-2292;
RP   ALA-2562; GLN-2875; PHE-2886; LYS-3088; SER-3099; ALA-3115; ASN-3144;
RP   ASP-3199; ALA-3411; LEU-3590; ILE-3835; VAL-3868; THR-3893; CYS-4115;
RP   LEU-4433; VAL-4624 AND TRP-5031.
RX   PubMed=18273898; DOI=10.1002/humu.9524;
RA   Dreyer B., Brox V., Tranebjaerg L., Rosenberg T., Sadeghi A.M.,
RA   Moeller C., Nilssen O.;
RT   "Spectrum of USH2A mutations in Scandinavian patients with Usher
RT   syndrome type II.";
RL   Hum. Mutat. 29:451-451(2008).
RN   [34]
RP   VARIANTS USH2A PRO-180; TYR-691; SER-1369 DEL; ARG-2752; GLY-3515;
RP   MET-3571 AND CYS-3747, AND VARIANTS LYS-1486; THR-2106; THR-2169;
RP   GLN-2875; PHE-2886; ALA-3115; ASP-3199; ALA-3411; ILE-3835; VAL-3868;
RP   ARG-4203; HIS-4493; VAL-4611; GLU-4838; GLN-4848 AND GLU-5026.
RX   PubMed=19737284; DOI=10.1111/j.1399-0004.2009.01257.x;
RA   Nakanishi H., Ohtsubo M., Iwasaki S., Hotta Y., Mizuta K., Mineta H.,
RA   Minoshima S.;
RT   "Identification of 11 novel mutations in USH2A among Japanese patients
RT   with Usher syndrome type 2.";
RL   Clin. Genet. 76:383-391(2009).
RN   [35]
RP   VARIANTS USH2A TRP-334 AND VAL-555.
RX   PubMed=19683999; DOI=10.1167/iovs.09-4085;
RA   Jaijo T., Aller E., Garcia-Garcia G., Aparisi M.J., Bernal S.,
RA   Avila-Fernandez A., Barragan I., Baiget M., Ayuso C., Antinolo G.,
RA   Diaz-Llopis M., Kulm M., Beneyto M., Najera C., Millan J.M.;
RT   "Microarray-based mutation analysis of 183 Spanish families with Usher
RT   syndrome.";
RL   Invest. Ophthalmol. Vis. Sci. 51:1311-1317(2010).
RN   [36]
RP   VARIANTS USH2A THR-1836; GLY-1953; ASN-2080; ARG-2116; PHE-2128;
RP   TYR-2128; THR-2196; ALA-2238; PRO-2260; HIS-2292; ALA-2562; PRO-2639;
RP   SER-2786; 3263-ILE--GLY-3269 DEL; LYS-3448; ILE-3462; CYS-3479;
RP   SER-3529; MET-3844; LYS-3904; ARG-4174; ARG-4269; LEU-4433;
RP   4445-GLU--SER-4449 DELINS ASP-LEU; HIS-4570; GLU-4662; ARG-4692;
RP   ARG-4763; ASP-4778; ARG-4808; ARG-4817 AND MET-4918, VARIANTS RP39
RP   SER-1978; TYR-2237; HIS-2573; LYS-2930; TYR-3358; TYR-3384; PRO-3606;
RP   SER-3618; HIS-3719; LYS-4094; HIS-4192; ASN-4248; VAL-4447; PRO-4840;
RP   MET-4844; HIS-5143; ILE-5145 AND GLY-5188, AND VARIANTS PHE-1572;
RP   THR-1665; THR-2169; GLN-2875; SER-3099; ASN-3144; ALA-3411; VAL-3868;
RP   GLU-4838; GLN-4848 AND GLU-5026.
RX   PubMed=20507924; DOI=10.1136/jmg.2009.075143;
RA   McGee T.L., Seyedahmadi B.J., Sweeney M.O., Dryja T.P., Berson E.L.;
RT   "Novel mutations in the long isoform of the USH2A gene in patients
RT   with Usher syndrome type II or non-syndromic retinitis pigmentosa.";
RL   J. Med. Genet. 47:499-506(2010).
RN   [37]
RP   VARIANT USH2A ARG-1734.
RX   PubMed=20309401; DOI=10.1167/3.9.454;
RA   Liu X., Tang Z., Li C., Yang K., Gan G., Zhang Z., Liu J., Jiang F.,
RA   Wang Q., Liu M.;
RT   "Novel USH2A compound heterozygous mutations cause RP/USH2 in a
RT   Chinese family.";
RL   Mol. Vis. 16:454-461(2010).
RN   [38]
RP   VARIANT ARG-4203.
RX   PubMed=21835308; DOI=10.1016/j.ajhg.2011.07.012;
RA   Doi H., Yoshida K., Yasuda T., Fukuda M., Fukuda Y., Morita H.,
RA   Ikeda S., Kato R., Tsurusaki Y., Miyake N., Saitsu H., Sakai H.,
RA   Miyatake S., Shiina M., Nukina N., Koyano S., Tsuji S., Kuroiwa Y.,
RA   Matsumoto N.;
RT   "Exome sequencing reveals a homozygous SYT14 mutation in adult-onset,
RT   autosomal-recessive spinocerebellar ataxia with psychomotor
RT   retardation.";
RL   Am. J. Hum. Genet. 89:320-327(2011).
RN   [39]
RP   VARIANT USH2A TRP-1777, AND VARIANTS VAL-4616 AND THR-4881.
RX   PubMed=21593743; DOI=10.1038/jhg.2011.45;
RA   Nakanishi H., Ohtsubo M., Iwasaki S., Hotta Y., Usami S., Mizuta K.,
RA   Mineta H., Minoshima S.;
RT   "Novel USH2A mutations in Japanese Usher syndrome type 2 patients:
RT   marked differences in the mutation spectrum between the Japanese and
RT   other populations.";
RL   J. Hum. Genet. 56:484-490(2011).
RN   [40]
RP   VARIANT RP39 TRP-934, VARIANT USH2A CYS-2744, AND VARIANTS THR-125;
RP   LYS-1486; THR-2106; THR-2169 AND ALA-3411.
RX   PubMed=21686329;
RA   Xu W., Dai H., Lu T., Zhang X., Dong B., Li Y.;
RT   "Seven novel mutations in the long isoform of the USH2A gene in
RT   Chinese families with nonsyndromic retinitis pigmentosa and Usher
RT   syndrome Type II.";
RL   Mol. Vis. 17:1537-1552(2011).
RN   [41]
RP   VARIANT ILE-453.
RX   PubMed=21248752; DOI=10.1038/nature09639;
RA   Varela I., Tarpey P., Raine K., Huang D., Ong C.K., Stephens P.,
RA   Davies H., Jones D., Lin M.L., Teague J., Bignell G., Butler A.,
RA   Cho J., Dalgliesh G.L., Galappaththige D., Greenman C., Hardy C.,
RA   Jia M., Latimer C., Lau K.W., Marshall J., McLaren S., Menzies A.,
RA   Mudie L., Stebbings L., Largaespada D.A., Wessels L.F.A., Richard S.,
RA   Kahnoski R.J., Anema J., Tuveson D.A., Perez-Mancera P.A.,
RA   Mustonen V., Fischer A., Adams D.J., Rust A., Chan-On W., Subimerb C.,
RA   Dykema K., Furge K., Campbell P.J., Teh B.T., Stratton M.R.,
RA   Futreal P.A.;
RT   "Exome sequencing identifies frequent mutation of the SWI/SNF complex
RT   gene PBRM1 in renal carcinoma.";
RL   Nature 469:539-542(2011).
RN   [42]
RP   VARIANTS USH2A ARG-44; MET-382; ARG-3546 AND ASP-3894, AND VARIANTS
RP   SER-2377; LYS-2394; ILE-3835 AND LYS-4921.
RX   PubMed=22004887; DOI=10.1186/1750-1172-6-65;
RA   Garcia-Garcia G., Aparisi M.J., Jaijo T., Rodrigo R., Leon A.M.,
RA   Avila-Fernandez A., Blanco-Kelly F., Bernal S., Navarro R.,
RA   Diaz-Llopis M., Baiget M., Ayuso C., Millan J.M., Aller E.;
RT   "Mutational screening of the USH2A gene in Spanish USH patients
RT   reveals 23 novel pathogenic mutations.";
RL   Orphanet J. Rare Dis. 6:65-65(2011).
RN   [43]
RP   VARIANTS RP39 PHE-419; PHE-759; CYS-1859; HIS-2460; TYR-3358;
RP   ARG-3669; CYS-4115; HIS-4192 AND MET-4425.
RX   PubMed=22334370; DOI=10.1002/humu.22045;
RA   Neveling K., Collin R.W., Gilissen C., van Huet R.A., Visser L.,
RA   Kwint M.P., Gijsen S.J., Zonneveld M.N., Wieskamp N., de Ligt J.,
RA   Siemiatkowska A.M., Hoefsloot L.H., Buckley M.F., Kellner U.,
RA   Branham K.E., den Hollander A.I., Hoischen A., Hoyng C.,
RA   Klevering B.J., van den Born L.I., Veltman J.A., Cremers F.P.,
RA   Scheffer H.;
RT   "Next-generation genetic testing for retinitis pigmentosa.";
RL   Hum. Mutat. 33:963-972(2012).
RN   [44]
RP   VARIANTS RP39 SER-1442 AND ARG-5063.
RX   PubMed=24227914;
RA   Mendez-Vidal C., Gonzalez-Del Pozo M., Vela-Boza A., Santoyo-Lopez J.,
RA   Lopez-Domingo F.J., Vazquez-Marouschek C., Dopazo J., Borrego S.,
RA   Antinolo G.;
RT   "Whole-exome sequencing identifies novel compound heterozygous
RT   mutations in USH2A in Spanish patients with autosomal recessive
RT   retinitis pigmentosa.";
RL   Mol. Vis. 19:2187-2195(2013).
RN   [45]
RP   VARIANTS USH2A LEU-1843; SER-1861; ASN-2738 AND CYS-5143.
RX   PubMed=23737954; DOI=10.1371/journal.pone.0063832;
RA   Huang X.F., Xiang P., Chen J., Xing D.J., Huang N., Min Q., Gu F.,
RA   Tong Y., Pang C.P., Qu J., Jin Z.B.;
RT   "Targeted exome sequencing identified novel USH2A mutations in Usher
RT   syndrome families.";
RL   PLoS ONE 8:E63832-E63832(2013).
CC   -!- FUNCTION: Involved in hearing and vision.
CC   -!- SUBUNIT: Interacts with collagen IV and fibronectin via its
CC       laminin EGF-like domains. Interaction with collagen may be
CC       required for stable integration into the basement membrane.
CC       Interacts with USH1C and WHRN. Interacts with NINL. Interacts with
CC       PDZD7. {ECO:0000269|PubMed:14676276, ECO:0000269|PubMed:16114888,
CC       ECO:0000269|PubMed:16301216, ECO:0000269|PubMed:16434480,
CC       ECO:0000269|PubMed:18826961, ECO:0000269|PubMed:20440071}.
CC   -!- SUBCELLULAR LOCATION: Cell projection, stereocilium membrane
CC       {ECO:0000269|PubMed:14676276}; Single-pass type I membrane protein
CC       {ECO:0000269|PubMed:14676276}. Note=Probable component of the
CC       interstereocilia ankle links in the inner ear sensory cells.
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Secreted.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1; Synonyms=b;
CC         IsoId=O75445-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O75445-2; Sequence=VSP_017771, VSP_017772;
CC       Name=3;
CC         IsoId=O75445-3; Sequence=VSP_017773;
CC   -!- TISSUE SPECIFICITY: Present in the basement membrane of many, but
CC       not all tissues. Expressed in retina, cochlea, small and large
CC       intestine, pancreas, bladder, prostate, esophagus, trachea,
CC       thymus, salivary glands, placenta, ovary, fallopian tube, uterus
CC       and testis. Absent in many other tissues such as heart, lung,
CC       liver, kidney and brain. In the retina, it is present in the
CC       basement membranes in the Bruch's layer choroid capillary basement
CC       membranes, where it localizes just beneath the retinal pigment
CC       epithelial cells (at protein level). Weakly expressed. Isoform 2
CC       is expressed in fetal eye, cochlea and heart, and at very low
CC       level in brain, CNS, intestine, skeleton, tongue, kidney and lung.
CC       Isoform 2 is not expressed in stomach and liver. In adult tissues,
CC       isoform 2 is expressed in neural retina and testis, and at low
CC       level in brain, heart, kidney and liver. Isoform 1 displays a
CC       similar pattern of expression but is expressed at very low level
CC       in fetal cochlea. {ECO:0000269|PubMed:11788194,
CC       ECO:0000269|PubMed:12433396, ECO:0000269|PubMed:15015129,
CC       ECO:0000269|PubMed:9624053}.
CC   -!- DOMAIN: The PDZ-binding motif probably mediates the association
CC       with some of the PDZ domains of USH1C and WHRN. {ECO:0000250}.
CC   -!- DISEASE: Usher syndrome 2A (USH2A) [MIM:276901]: USH is a
CC       genetically heterogeneous condition characterized by the
CC       association of retinitis pigmentosa with sensorineural deafness.
CC       Age at onset and differences in auditory and vestibular function
CC       distinguish Usher syndrome type 1 (USH1), Usher syndrome type 2
CC       (USH2) and Usher syndrome type 3 (USH3). USH2 is characterized by
CC       congenital mild hearing impairment with normal vestibular
CC       responses. {ECO:0000269|PubMed:10729113,
CC       ECO:0000269|PubMed:10738000, ECO:0000269|PubMed:10909849,
CC       ECO:0000269|PubMed:11311042, ECO:0000269|PubMed:12112664,
CC       ECO:0000269|PubMed:12525556, ECO:0000269|PubMed:14970843,
CC       ECO:0000269|PubMed:15015129, ECO:0000269|PubMed:15025721,
CC       ECO:0000269|PubMed:15241801, ECO:0000269|PubMed:15325563,
CC       ECO:0000269|PubMed:17085681, ECO:0000269|PubMed:17405132,
CC       ECO:0000269|PubMed:18273898, ECO:0000269|PubMed:18452394,
CC       ECO:0000269|PubMed:19683999, ECO:0000269|PubMed:19737284,
CC       ECO:0000269|PubMed:20309401, ECO:0000269|PubMed:20440071,
CC       ECO:0000269|PubMed:20507924, ECO:0000269|PubMed:21593743,
CC       ECO:0000269|PubMed:21686329, ECO:0000269|PubMed:22004887,
CC       ECO:0000269|PubMed:23737954, ECO:0000269|PubMed:9624053}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Retinitis pigmentosa 39 (RP39) [MIM:613809]: A retinal
CC       dystrophy belonging to the group of pigmentary retinopathies.
CC       Retinitis pigmentosa is characterized by retinal pigment deposits
CC       visible on fundus examination and primary loss of rod
CC       photoreceptor cells followed by secondary loss of cone
CC       photoreceptors. Patients typically have night vision blindness and
CC       loss of midperipheral visual field. As their condition progresses,
CC       they lose their far peripheral visual field and eventually central
CC       vision as well. {ECO:0000269|PubMed:10775529,
CC       ECO:0000269|PubMed:12112664, ECO:0000269|PubMed:12427073,
CC       ECO:0000269|PubMed:15325563, ECO:0000269|PubMed:16098008,
CC       ECO:0000269|PubMed:17296898, ECO:0000269|PubMed:20507924,
CC       ECO:0000269|PubMed:21686329, ECO:0000269|PubMed:22334370,
CC       ECO:0000269|PubMed:24227914}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Contains 35 fibronectin type-III domains.
CC       {ECO:0000255|PROSITE-ProRule:PRU00316}.
CC   -!- SIMILARITY: Contains 10 laminin EGF-like domains.
CC       {ECO:0000255|PROSITE-ProRule:PRU00460}.
CC   -!- SIMILARITY: Contains 2 laminin G-like domains.
CC       {ECO:0000255|PROSITE-ProRule:PRU00122}.
CC   -!- SIMILARITY: Contains 1 laminin N-terminal domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00466}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF055580; AAC23748.2; -; mRNA.
DR   EMBL; AF091889; AAF75819.1; -; Genomic_DNA.
DR   EMBL; AF091873; AAF75819.1; JOINED; Genomic_DNA.
DR   EMBL; AF091875; AAF75819.1; JOINED; Genomic_DNA.
DR   EMBL; AF091876; AAF75819.1; JOINED; Genomic_DNA.
DR   EMBL; AF091874; AAF75819.1; JOINED; Genomic_DNA.
DR   EMBL; AF091877; AAF75819.1; JOINED; Genomic_DNA.
DR   EMBL; AF091879; AAF75819.1; JOINED; Genomic_DNA.
DR   EMBL; AF091881; AAF75819.1; JOINED; Genomic_DNA.
DR   EMBL; AF091883; AAF75819.1; JOINED; Genomic_DNA.
DR   EMBL; AF091888; AAF75819.1; JOINED; Genomic_DNA.
DR   EMBL; AF091887; AAF75819.1; JOINED; Genomic_DNA.
DR   EMBL; AF091886; AAF75819.1; JOINED; Genomic_DNA.
DR   EMBL; AF091885; AAF75819.1; JOINED; Genomic_DNA.
DR   EMBL; AF091884; AAF75819.1; JOINED; Genomic_DNA.
DR   EMBL; AF091882; AAF75819.1; JOINED; Genomic_DNA.
DR   EMBL; AF091880; AAF75819.1; JOINED; Genomic_DNA.
DR   EMBL; AF091878; AAF75819.1; JOINED; Genomic_DNA.
DR   EMBL; AY481573; AAS47698.1; -; mRNA.
DR   EMBL; AL445650; CAH70620.1; -; Genomic_DNA.
DR   EMBL; AC138024; CAH70620.1; JOINED; Genomic_DNA.
DR   EMBL; AL358858; CAH70620.1; JOINED; Genomic_DNA.
DR   EMBL; AL358858; CAH71587.1; -; Genomic_DNA.
DR   EMBL; AC138024; CAH71587.1; JOINED; Genomic_DNA.
DR   EMBL; AL445650; CAH71587.1; JOINED; Genomic_DNA.
DR   EMBL; AL358858; CAH71588.1; -; Genomic_DNA.
DR   EMBL; AC092799; CAH71588.1; JOINED; Genomic_DNA.
DR   EMBL; AC093581; CAH71588.1; JOINED; Genomic_DNA.
DR   EMBL; AC119429; CAH71588.1; JOINED; Genomic_DNA.
DR   EMBL; AC138024; CAH71588.1; JOINED; Genomic_DNA.
DR   EMBL; AL139259; CAH71588.1; JOINED; Genomic_DNA.
DR   EMBL; AL358452; CAH71588.1; JOINED; Genomic_DNA.
DR   EMBL; AL445650; CAH71588.1; JOINED; Genomic_DNA.
DR   EMBL; AL513305; CAH71588.1; JOINED; Genomic_DNA.
DR   EMBL; AL513305; CAH73621.1; -; Genomic_DNA.
DR   EMBL; AC138024; CAH73621.1; JOINED; Genomic_DNA.
DR   EMBL; AC119429; CAH73621.1; JOINED; Genomic_DNA.
DR   EMBL; AC093581; CAH73621.1; JOINED; Genomic_DNA.
DR   EMBL; AC092799; CAH73621.1; JOINED; Genomic_DNA.
DR   EMBL; AL445650; CAH73621.1; JOINED; Genomic_DNA.
DR   EMBL; AL358858; CAH73621.1; JOINED; Genomic_DNA.
DR   EMBL; AL358452; CAH73621.1; JOINED; Genomic_DNA.
DR   EMBL; AL139259; CAH73621.1; JOINED; Genomic_DNA.
DR   EMBL; AL139259; CAI23041.1; -; Genomic_DNA.
DR   EMBL; AL513305; CAI23041.1; JOINED; Genomic_DNA.
DR   EMBL; AL445650; CAI23041.1; JOINED; Genomic_DNA.
DR   EMBL; AL358858; CAI23041.1; JOINED; Genomic_DNA.
DR   EMBL; AL358452; CAI23041.1; JOINED; Genomic_DNA.
DR   EMBL; AC138024; CAI23041.1; JOINED; Genomic_DNA.
DR   EMBL; AC119429; CAI23041.1; JOINED; Genomic_DNA.
DR   EMBL; AC093581; CAI23041.1; JOINED; Genomic_DNA.
DR   EMBL; AC092799; CAI23041.1; JOINED; Genomic_DNA.
DR   EMBL; AL358452; CAI19189.1; -; Genomic_DNA.
DR   EMBL; AL513305; CAI19189.1; JOINED; Genomic_DNA.
DR   EMBL; AL445650; CAI19189.1; JOINED; Genomic_DNA.
DR   EMBL; AL358858; CAI19189.1; JOINED; Genomic_DNA.
DR   EMBL; AL139259; CAI19189.1; JOINED; Genomic_DNA.
DR   EMBL; AC138024; CAI19189.1; JOINED; Genomic_DNA.
DR   EMBL; AC119429; CAI19189.1; JOINED; Genomic_DNA.
DR   EMBL; AC093581; CAI19189.1; JOINED; Genomic_DNA.
DR   EMBL; AC092799; CAI19189.1; JOINED; Genomic_DNA.
DR   EMBL; AL445650; CAH70621.1; -; Genomic_DNA.
DR   EMBL; AC092799; CAH70621.1; JOINED; Genomic_DNA.
DR   EMBL; AC093581; CAH70621.1; JOINED; Genomic_DNA.
DR   EMBL; AC119429; CAH70621.1; JOINED; Genomic_DNA.
DR   EMBL; AC138024; CAH70621.1; JOINED; Genomic_DNA.
DR   EMBL; AL139259; CAH70621.1; JOINED; Genomic_DNA.
DR   EMBL; AL513305; CAH70621.1; JOINED; Genomic_DNA.
DR   EMBL; AL358858; CAH70621.1; JOINED; Genomic_DNA.
DR   EMBL; AL358452; CAH70621.1; JOINED; Genomic_DNA.
DR   CCDS; CCDS1516.1; -. [O75445-2]
DR   CCDS; CCDS31025.1; -. [O75445-1]
DR   RefSeq; NP_009054.5; NM_007123.5.
DR   RefSeq; NP_996816.2; NM_206933.2.
DR   UniGene; Hs.655974; -.
DR   ProteinModelPortal; O75445; -.
DR   SMR; O75445; 326-1052, 1522-1903, 2500-2718, 3415-3574, 3729-4057, 4262-4675.
DR   BioGrid; 113242; 3.
DR   IntAct; O75445; 1.
DR   STRING; 9606.ENSP00000305941; -.
DR   iPTMnet; O75445; -.
DR   PhosphoSite; O75445; -.
DR   BioMuta; USH2A; -.
DR   PaxDb; O75445; -.
DR   PRIDE; O75445; -.
DR   Ensembl; ENST00000307340; ENSP00000305941; ENSG00000042781. [O75445-1]
DR   Ensembl; ENST00000366942; ENSP00000355909; ENSG00000042781. [O75445-2]
DR   GeneID; 7399; -.
DR   KEGG; hsa:7399; -.
DR   UCSC; uc001hku.1; human. [O75445-1]
DR   UCSC; uc001hkv.3; human. [O75445-2]
DR   CTD; 7399; -.
DR   GeneCards; USH2A; -.
DR   GeneReviews; USH2A; -.
DR   H-InvDB; HIX0028527; -.
DR   HGNC; HGNC:12601; USH2A.
DR   MalaCards; USH2A; -.
DR   MIM; 276901; phenotype.
DR   MIM; 608400; gene.
DR   MIM; 613809; phenotype.
DR   neXtProt; NX_O75445; -.
DR   Orphanet; 791; Retinitis pigmentosa.
DR   Orphanet; 231178; Usher syndrome type 2.
DR   PharmGKB; PA37228; -.
DR   eggNOG; KOG1836; Eukaryota.
DR   eggNOG; KOG3510; Eukaryota.
DR   eggNOG; ENOG410Y1E5; LUCA.
DR   GeneTree; ENSGT00780000121851; -.
DR   HOGENOM; HOG000124780; -.
DR   HOVERGEN; HBG094138; -.
DR   InParanoid; O75445; -.
DR   KO; K19636; -.
DR   OMA; EIRIQAC; -.
DR   OrthoDB; EOG783MTD; -.
DR   PhylomeDB; O75445; -.
DR   TreeFam; TF330287; -.
DR   ChiTaRS; USH2A; human.
DR   GeneWiki; USH2A; -.
DR   GenomeRNAi; 7399; -.
DR   NextBio; 28962; -.
DR   PRO; PR:O75445; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; O75445; -.
DR   CleanEx; HS_USH2A; -.
DR   Genevisible; O75445; HS.
DR   GO; GO:0016324; C:apical plasma membrane; ISS:BHF-UCL.
DR   GO; GO:0005604; C:basement membrane; IDA:HGNC.
DR   GO; GO:0036064; C:ciliary basal body; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; IDA:HGNC.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:1990075; C:periciliary membrane compartment; IEA:Ensembl.
DR   GO; GO:0032391; C:photoreceptor connecting cilium; IEA:Ensembl.
DR   GO; GO:0001917; C:photoreceptor inner segment; IEA:Ensembl.
DR   GO; GO:0002142; C:stereocilia ankle link complex; ISS:BHF-UCL.
DR   GO; GO:0032421; C:stereocilium bundle; ISS:BHF-UCL.
DR   GO; GO:0060171; C:stereocilium membrane; ISS:BHF-UCL.
DR   GO; GO:1990696; C:USH2 complex; IEA:Ensembl.
DR   GO; GO:0005518; F:collagen binding; IDA:HGNC.
DR   GO; GO:0017022; F:myosin binding; ISS:BHF-UCL.
DR   GO; GO:0045184; P:establishment of protein localization; IEA:Ensembl.
DR   GO; GO:0035315; P:hair cell differentiation; ISS:BHF-UCL.
DR   GO; GO:0060113; P:inner ear receptor cell differentiation; ISS:BHF-UCL.
DR   GO; GO:0048496; P:maintenance of organ identity; IMP:HGNC.
DR   GO; GO:0045494; P:photoreceptor cell maintenance; IMP:HGNC.
DR   GO; GO:0050896; P:response to stimulus; IEA:UniProtKB-KW.
DR   GO; GO:0050953; P:sensory perception of light stimulus; IMP:HGNC.
DR   GO; GO:0007605; P:sensory perception of sound; IMP:HGNC.
DR   GO; GO:0007601; P:visual perception; IEA:UniProtKB-KW.
DR   Gene3D; 2.60.120.200; -; 3.
DR   Gene3D; 2.60.40.10; -; 35.
DR   InterPro; IPR013320; ConA-like_dom.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR006558; LamG-like.
DR   InterPro; IPR002049; Laminin_EGF.
DR   InterPro; IPR001791; Laminin_G.
DR   InterPro; IPR008211; Laminin_N.
DR   InterPro; IPR026915; USH2A.
DR   PANTHER; PTHR10574:SF274; PTHR10574:SF274; 3.
DR   Pfam; PF00041; fn3; 18.
DR   Pfam; PF00053; Laminin_EGF; 10.
DR   Pfam; PF02210; Laminin_G_2; 2.
DR   Pfam; PF00055; Laminin_N; 1.
DR   SMART; SM00180; EGF_Lam; 10.
DR   SMART; SM00060; FN3; 33.
DR   SMART; SM00282; LamG; 2.
DR   SMART; SM00560; LamGL; 1.
DR   SMART; SM00136; LamNT; 1.
DR   SUPFAM; SSF49265; SSF49265; 23.
DR   SUPFAM; SSF49899; SSF49899; 3.
DR   PROSITE; PS00022; EGF_1; 7.
DR   PROSITE; PS01248; EGF_LAM_1; 7.
DR   PROSITE; PS50027; EGF_LAM_2; 10.
DR   PROSITE; PS50853; FN3; 35.
DR   PROSITE; PS50025; LAM_G_DOMAIN; 2.
DR   PROSITE; PS51117; LAMININ_NTER; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Cell membrane; Cell projection;
KW   Complete proteome; Deafness; Disease mutation; Disulfide bond;
KW   Glycoprotein; Hearing; Laminin EGF-like domain; Membrane;
KW   Polymorphism; Reference proteome; Repeat; Retinitis pigmentosa;
KW   Secreted; Sensory transduction; Signal; Transmembrane;
KW   Transmembrane helix; Usher syndrome; Vision.
FT   SIGNAL        1     31       {ECO:0000255}.
FT   CHAIN        32   5202       Usherin.
FT                                /FTId=PRO_0000229804.
FT   TOPO_DOM     32   5042       Extracellular. {ECO:0000255}.
FT   TRANSMEM   5043   5063       Helical. {ECO:0000255}.
FT   TOPO_DOM   5064   5202       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      271    517       Laminin N-terminal. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00466}.
FT   DOMAIN      518    574       Laminin EGF-like 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00460}.
FT   DOMAIN      575    640       Laminin EGF-like 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00460}.
FT   DOMAIN      641    693       Laminin EGF-like 3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00460}.
FT   DOMAIN      694    746       Laminin EGF-like 4. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00460}.
FT   DOMAIN      747    794       Laminin EGF-like 5. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00460}.
FT   DOMAIN      795    846       Laminin EGF-like 6. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00460}.
FT   DOMAIN      847    899       Laminin EGF-like 7. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00460}.
FT   DOMAIN      900    950       Laminin EGF-like 8. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00460}.
FT   DOMAIN      951   1001       Laminin EGF-like 9. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00460}.
FT   DOMAIN     1002   1052       Laminin EGF-like 10.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00460}.
FT   DOMAIN     1058   1146       Fibronectin type-III 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN     1148   1244       Fibronectin type-III 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN     1245   1363       Fibronectin type-III 3.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN     1364   1468       Fibronectin type-III 4.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN     1517   1709       Laminin G-like 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00122}.
FT   DOMAIN     1714   1891       Laminin G-like 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00122}.
FT   DOMAIN     1869   1955       Fibronectin type-III 5.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN     1957   2054       Fibronectin type-III 6.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN     2055   2144       Fibronectin type-III 7.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN     2145   2239       Fibronectin type-III 8.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN     2243   2330       Fibronectin type-III 9.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN     2331   2433       Fibronectin type-III 10.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN     2437   2531       Fibronectin type-III 11.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN     2535   2622       Fibronectin type-III 12.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN     2624   2722       Fibronectin type-III 13.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN     2726   2819       Fibronectin type-III 14.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN     2820   2923       Fibronectin type-III 15.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN     2927   3018       Fibronectin type-III 16.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN     3022   3112       Fibronectin type-III 17.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN     3113   3209       Fibronectin type-III 18.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN     3403   3497       Fibronectin type-III 19.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN     3501   3589       Fibronectin type-III 20.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN     3592   3682       Fibronectin type-III 21.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN     3684   3770       Fibronectin type-III 22.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN     3774   3865       Fibronectin type-III 23.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN     3866   3963       Fibronectin type-III 24.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN     3964   4067       Fibronectin type-III 25.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN     4068   4153       Fibronectin type-III 26.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN     4157   4261       Fibronectin type-III 27.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN     4262   4357       Fibronectin type-III 28.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN     4358   4445       Fibronectin type-III 29.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN     4446   4530       Fibronectin type-III 30.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN     4534   4630       Fibronectin type-III 31.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN     4636   4733       Fibronectin type-III 32.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN     4734   4827       Fibronectin type-III 33.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN     4828   4927       Fibronectin type-III 34.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   MOTIF      5200   5202       PDZ-binding.
FT   CARBOHYD    361    361       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    451    451       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    587    587       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    611    611       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    650    650       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    697    697       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    839    839       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    856    856       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    862    862       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    888    888       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    944    944       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1011   1011       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1071   1071       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1151   1151       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1174   1174       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1379   1379       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1388   1388       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1479   1479       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1635   1635       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1779   1779       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1903   1903       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2011   2011       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2014   2014       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2048   2048       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2130   2130       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2182   2182       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2195   2195       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2258   2258       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2285   2285       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2322   2322       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2377   2377       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2382   2382       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2407   2407       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2413   2413       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2581   2581       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2584   2584       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2656   2656       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2710   2710       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2770   2770       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2788   2788       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2930   2930       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2937   2937       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2970   2970       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   3032   3032       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   3099   3099       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   3217   3217       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   3330   3330       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   3419   3419       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   3433   3433       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   3653   3653       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   3694   3694       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   3733   3733       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   3780   3780       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   3849   3849       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   3984   3984       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   4202   4202       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   4226   4226       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   4317   4317       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   4418   4418       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   4564   4564       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   4583   4583       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   4691   4691       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   4754   4754       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   4800   4800       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   4943   4943       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   4950   4950       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID    518    527       {ECO:0000250}.
FT   DISULFID    520    536       {ECO:0000250}.
FT   DISULFID    538    549       {ECO:0000250}.
FT   DISULFID    552    572       {ECO:0000250}.
FT   DISULFID    575    584       {ECO:0000250}.
FT   DISULFID    577    605       {ECO:0000250}.
FT   DISULFID    608    617       {ECO:0000250}.
FT   DISULFID    620    638       {ECO:0000250}.
FT   DISULFID    641    655       {ECO:0000250}.
FT   DISULFID    643    662       {ECO:0000250}.
FT   DISULFID    664    673       {ECO:0000250}.
FT   DISULFID    676    691       {ECO:0000250}.
FT   DISULFID    694    708       {ECO:0000250}.
FT   DISULFID    696    715       {ECO:0000250}.
FT   DISULFID    717    726       {ECO:0000250}.
FT   DISULFID    729    744       {ECO:0000250}.
FT   DISULFID    747    759       {ECO:0000250}.
FT   DISULFID    749    766       {ECO:0000250}.
FT   DISULFID    768    777       {ECO:0000250}.
FT   DISULFID    780    792       {ECO:0000250}.
FT   DISULFID    795    808       {ECO:0000250}.
FT   DISULFID    797    815       {ECO:0000250}.
FT   DISULFID    817    826       {ECO:0000250}.
FT   DISULFID    829    844       {ECO:0000250}.
FT   DISULFID    847    861       {ECO:0000250}.
FT   DISULFID    849    868       {ECO:0000250}.
FT   DISULFID    870    879       {ECO:0000250}.
FT   DISULFID    882    897       {ECO:0000250}.
FT   DISULFID    900    913       {ECO:0000250}.
FT   DISULFID    902    920       {ECO:0000250}.
FT   DISULFID    922    931       {ECO:0000250}.
FT   DISULFID    934    948       {ECO:0000250}.
FT   DISULFID    951    963       {ECO:0000250}.
FT   DISULFID    953    970       {ECO:0000250}.
FT   DISULFID    972    982       {ECO:0000250}.
FT   DISULFID    985    999       {ECO:0000250}.
FT   DISULFID   1002   1014       {ECO:0000250}.
FT   DISULFID   1004   1021       {ECO:0000250}.
FT   DISULFID   1023   1032       {ECO:0000250}.
FT   DISULFID   1035   1050       {ECO:0000250}.
FT   DISULFID   1672   1709       {ECO:0000250}.
FT   DISULFID   1862   1891       {ECO:0000250}.
FT   DISULFID   3371   3444       {ECO:0000250}.
FT   DISULFID   3399   3425       {ECO:0000250}.
FT   VAR_SEQ    1544   1546       IKA -> KCV (in isoform 2).
FT                                {ECO:0000303|PubMed:9624053}.
FT                                /FTId=VSP_017771.
FT   VAR_SEQ    1547   5202       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:9624053}.
FT                                /FTId=VSP_017772.
FT   VAR_SEQ    5099   5099       M -> MFDSVADISDVSSNVTLKSYTMHFE (in
FT                                isoform 3). {ECO:0000305}.
FT                                /FTId=VSP_017773.
FT   VARIANT      44     44       G -> R (in USH2A).
FT                                {ECO:0000269|PubMed:22004887}.
FT                                /FTId=VAR_071996.
FT   VARIANT     125    125       A -> T (in dbSNP:rs10779261).
FT                                {ECO:0000269|PubMed:15325563,
FT                                ECO:0000269|PubMed:16098008,
FT                                ECO:0000269|PubMed:17296898,
FT                                ECO:0000269|PubMed:18273898,
FT                                ECO:0000269|PubMed:21686329}.
FT                                /FTId=VAR_025760.
FT   VARIANT     163    163       C -> Y (in USH2A).
FT                                {ECO:0000269|PubMed:10909849,
FT                                ECO:0000269|PubMed:18273898}.
FT                                /FTId=VAR_025761.
FT   VARIANT     180    180       S -> P (in USH2A).
FT                                {ECO:0000269|PubMed:19737284}.
FT                                /FTId=VAR_071997.
FT   VARIANT     218    218       V -> E (in USH2A).
FT                                {ECO:0000269|PubMed:11311042,
FT                                ECO:0000269|PubMed:17405132}.
FT                                /FTId=VAR_025762.
FT   VARIANT     230    230       V -> M (in USH2A; unknown pathological
FT                                significance; dbSNP:rs45500891).
FT                                {ECO:0000269|PubMed:10909849,
FT                                ECO:0000269|PubMed:11311042,
FT                                ECO:0000269|PubMed:15325563,
FT                                ECO:0000269|PubMed:18273898}.
FT                                /FTId=VAR_025763.
FT   VARIANT     268    268       G -> R (in USH2A; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:15325563,
FT                                ECO:0000269|PubMed:18273898}.
FT                                /FTId=VAR_054557.
FT   VARIANT     280    280       L -> F (in USH2A).
FT                                {ECO:0000269|PubMed:17405132}.
FT                                /FTId=VAR_054558.
FT   VARIANT     284    284       E -> K (in USH2A).
FT                                {ECO:0000269|PubMed:17405132}.
FT                                /FTId=VAR_054559.
FT   VARIANT     303    303       R -> C (in USH2A).
FT                                {ECO:0000269|PubMed:18273898}.
FT                                /FTId=VAR_054560.
FT   VARIANT     303    303       R -> S (in USH2A).
FT                                {ECO:0000269|PubMed:14970843}.
FT                                /FTId=VAR_054561.
FT   VARIANT     307    307       S -> I (in USH2A; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:15325563}.
FT                                /FTId=VAR_054562.
FT   VARIANT     319    319       C -> Y (in USH2A).
FT                                {ECO:0000269|PubMed:10729113}.
FT                                /FTId=VAR_025764.
FT   VARIANT     334    334       R -> Q (in USH2A).
FT                                {ECO:0000269|PubMed:17405132}.
FT                                /FTId=VAR_054563.
FT   VARIANT     334    334       R -> W (in USH2A).
FT                                {ECO:0000269|PubMed:10738000,
FT                                ECO:0000269|PubMed:15025721,
FT                                ECO:0000269|PubMed:17405132,
FT                                ECO:0000269|PubMed:18273898,
FT                                ECO:0000269|PubMed:18452394,
FT                                ECO:0000269|PubMed:19683999}.
FT                                /FTId=VAR_025765.
FT   VARIANT     346    346       N -> H (in USH2A).
FT                                {ECO:0000269|PubMed:10729113,
FT                                ECO:0000269|PubMed:15025721,
FT                                ECO:0000269|PubMed:15241801,
FT                                ECO:0000269|PubMed:17405132,
FT                                ECO:0000269|PubMed:18273898}.
FT                                /FTId=VAR_025766.
FT   VARIANT     352    352       T -> I (in USH2A).
FT                                {ECO:0000269|PubMed:17405132,
FT                                ECO:0000269|PubMed:18273898}.
FT                                /FTId=VAR_054564.
FT   VARIANT     357    357       N -> T (in USH2A).
FT                                {ECO:0000269|PubMed:15025721}.
FT                                /FTId=VAR_054565.
FT   VARIANT     365    365       L -> F. {ECO:0000269|PubMed:15325563}.
FT                                /FTId=VAR_054566.
FT   VARIANT     382    382       V -> M (in USH2A).
FT                                {ECO:0000269|PubMed:22004887}.
FT                                /FTId=VAR_071998.
FT   VARIANT     391    391       S -> I (in USH2A; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:15325563}.
FT                                /FTId=VAR_054567.
FT   VARIANT     419    419       C -> F (in USH2A and RP39).
FT                                {ECO:0000269|PubMed:10729113,
FT                                ECO:0000269|PubMed:15241801,
FT                                ECO:0000269|PubMed:15325563,
FT                                ECO:0000269|PubMed:22334370}.
FT                                /FTId=VAR_025767.
FT   VARIANT     453    453       T -> I (found in a renal cell carcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:21248752}.
FT                                /FTId=VAR_064761.
FT   VARIANT     464    464       R -> C (in USH2A; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:15325563}.
FT                                /FTId=VAR_054568.
FT   VARIANT     478    478       E -> D (in RP39 and USH2A; unknown
FT                                pathological significance;
FT                                dbSNP:rs35730265).
FT                                {ECO:0000269|PubMed:10738000,
FT                                ECO:0000269|PubMed:15325563,
FT                                ECO:0000269|PubMed:16098008,
FT                                ECO:0000269|PubMed:17296898,
FT                                ECO:0000269|PubMed:18273898}.
FT                                /FTId=VAR_025768.
FT   VARIANT     479    479       F -> S. {ECO:0000269|PubMed:15025721,
FT                                ECO:0000269|PubMed:9624053}.
FT                                /FTId=VAR_054569.
FT   VARIANT     516    516       G -> V (in USH2A; unknown pathological
FT                                significance).
FT                                /FTId=VAR_054570.
FT   VARIANT     517    517       R -> T (in USH2A; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:15325563}.
FT                                /FTId=VAR_054571.
FT   VARIANT     536    536       C -> R (in USH2A; abolishes interaction
FT                                with collagen IV).
FT                                {ECO:0000269|PubMed:10909849,
FT                                ECO:0000269|PubMed:15241801,
FT                                ECO:0000269|PubMed:18273898}.
FT                                /FTId=VAR_025769.
FT   VARIANT     555    555       L -> V (in USH2A; dbSNP:rs35818432).
FT                                {ECO:0000269|PubMed:11311042,
FT                                ECO:0000269|PubMed:19683999}.
FT                                /FTId=VAR_025770.
FT   VARIANT     575    575       C -> S (in USH2A; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:15325563}.
FT                                /FTId=VAR_054572.
FT   VARIANT     587    587       Missing (in USH2A; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:15325563}.
FT                                /FTId=VAR_054573.
FT   VARIANT     595    595       F -> S (in dbSNP:rs200496467).
FT                                {ECO:0000269|PubMed:18273898}.
FT                                /FTId=VAR_054574.
FT   VARIANT     610    610       H -> P (in USH2A).
FT                                {ECO:0000269|PubMed:12525556}.
FT                                /FTId=VAR_025771.
FT   VARIANT     644    644       D -> V (in dbSNP:rs1805048).
FT                                {ECO:0000269|PubMed:10738000,
FT                                ECO:0000269|PubMed:15025721,
FT                                ECO:0000269|PubMed:15325563,
FT                                ECO:0000269|PubMed:16098008,
FT                                ECO:0000269|PubMed:17296898,
FT                                ECO:0000269|PubMed:18273898}.
FT                                /FTId=VAR_025772.
FT   VARIANT     691    691       C -> Y (in USH2A).
FT                                {ECO:0000269|PubMed:19737284}.
FT                                /FTId=VAR_071999.
FT   VARIANT     703    703       D -> E. {ECO:0000269|PubMed:16098008}.
FT                                /FTId=VAR_025773.
FT   VARIANT     713    713       G -> R (in USH2A; abolishes interaction
FT                                with collagen IV; unknown pathological
FT                                significance; dbSNP:rs696723).
FT                                {ECO:0000269|PubMed:10909849,
FT                                ECO:0000269|PubMed:12112664,
FT                                ECO:0000269|PubMed:15241801,
FT                                ECO:0000269|PubMed:15325563,
FT                                ECO:0000269|PubMed:17085681,
FT                                ECO:0000269|PubMed:17296898,
FT                                ECO:0000269|PubMed:18273898}.
FT                                /FTId=VAR_025774.
FT   VARIANT     739    739       F -> L (in RP39; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:15325563}.
FT                                /FTId=VAR_054575.
FT   VARIANT     759    759       C -> F (in RP39 and USH2A;
FT                                dbSNP:rs80338902).
FT                                {ECO:0000269|PubMed:10775529,
FT                                ECO:0000269|PubMed:12112664,
FT                                ECO:0000269|PubMed:12427073,
FT                                ECO:0000269|PubMed:14970843,
FT                                ECO:0000269|PubMed:15325563,
FT                                ECO:0000269|PubMed:16098008,
FT                                ECO:0000269|PubMed:17405132,
FT                                ECO:0000269|PubMed:18273898,
FT                                ECO:0000269|PubMed:22334370}.
FT                                /FTId=VAR_025775.
FT   VARIANT     761    761       P -> R (in USH2A).
FT                                {ECO:0000269|PubMed:12525556}.
FT                                /FTId=VAR_025776.
FT   VARIANT     841    841       S -> Y (in dbSNP:rs111033282).
FT                                {ECO:0000269|PubMed:16098008}.
FT                                /FTId=VAR_025777.
FT   VARIANT     911    911       T -> N (in RP39; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:15325563}.
FT                                /FTId=VAR_054576.
FT   VARIANT     934    934       C -> W (in RP39).
FT                                {ECO:0000269|PubMed:21686329}.
FT                                /FTId=VAR_072000.
FT   VARIANT    1047   1047       L -> V. {ECO:0000269|PubMed:15325563}.
FT                                /FTId=VAR_054577.
FT   VARIANT    1059   1059       P -> L (in USH2A; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:15325563}.
FT                                /FTId=VAR_054578.
FT   VARIANT    1212   1212       P -> L (in USH2A).
FT                                {ECO:0000269|PubMed:18273898}.
FT                                /FTId=VAR_054579.
FT   VARIANT    1349   1349       S -> P. {ECO:0000269|PubMed:18273898}.
FT                                /FTId=VAR_054580.
FT   VARIANT    1369   1369       Missing (in USH2A).
FT                                {ECO:0000269|PubMed:19737284}.
FT                                /FTId=VAR_072001.
FT   VARIANT    1442   1442       F -> S (in RP39).
FT                                {ECO:0000269|PubMed:24227914}.
FT                                /FTId=VAR_072002.
FT   VARIANT    1470   1470       L -> R (in RP39; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:15325563}.
FT                                /FTId=VAR_054581.
FT   VARIANT    1486   1486       R -> K (in dbSNP:rs1805049).
FT                                {ECO:0000269|PubMed:10729113,
FT                                ECO:0000269|PubMed:10738000,
FT                                ECO:0000269|PubMed:15325563,
FT                                ECO:0000269|PubMed:16098008,
FT                                ECO:0000269|PubMed:17296898,
FT                                ECO:0000269|PubMed:18273898,
FT                                ECO:0000269|PubMed:19737284,
FT                                ECO:0000269|PubMed:21686329,
FT                                ECO:0000269|PubMed:9624053}.
FT                                /FTId=VAR_025778.
FT   VARIANT    1515   1515       T -> M (in USH2A).
FT                                {ECO:0000269|PubMed:10738000}.
FT                                /FTId=VAR_025779.
FT   VARIANT    1572   1572       L -> F (in dbSNP:rs111033333).
FT                                {ECO:0000269|PubMed:17085681,
FT                                ECO:0000269|PubMed:17405132,
FT                                ECO:0000269|PubMed:18273898,
FT                                ECO:0000269|PubMed:20507924}.
FT                                /FTId=VAR_054582.
FT   VARIANT    1665   1665       I -> T (in dbSNP:rs56222536).
FT                                {ECO:0000269|PubMed:17085681,
FT                                ECO:0000269|PubMed:17296898,
FT                                ECO:0000269|PubMed:18273898,
FT                                ECO:0000269|PubMed:20507924}.
FT                                /FTId=VAR_038362.
FT   VARIANT    1734   1734       G -> R (in USH2A).
FT                                {ECO:0000269|PubMed:20309401}.
FT                                /FTId=VAR_072003.
FT   VARIANT    1757   1757       Y -> C. {ECO:0000269|PubMed:18273898}.
FT                                /FTId=VAR_054583.
FT   VARIANT    1777   1777       R -> W (in USH2A).
FT                                {ECO:0000269|PubMed:21593743}.
FT                                /FTId=VAR_072004.
FT   VARIANT    1833   1833       V -> E (in USH2A).
FT                                {ECO:0000269|PubMed:17405132}.
FT                                /FTId=VAR_054584.
FT   VARIANT    1836   1836       P -> T (in USH2A; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:20507924}.
FT                                /FTId=VAR_072005.
FT   VARIANT    1840   1840       G -> V (in USH2A).
FT                                {ECO:0000269|PubMed:18452394}.
FT                                /FTId=VAR_072006.
FT   VARIANT    1843   1843       P -> L (in USH2A).
FT                                {ECO:0000269|PubMed:23737954}.
FT                                /FTId=VAR_072007.
FT   VARIANT    1859   1859       F -> C (in RP39).
FT                                {ECO:0000269|PubMed:22334370}.
FT                                /FTId=VAR_068354.
FT   VARIANT    1861   1861       G -> S (in USH2A).
FT                                {ECO:0000269|PubMed:23737954}.
FT                                /FTId=VAR_072008.
FT   VARIANT    1953   1953       A -> G (in USH2A; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:20507924}.
FT                                /FTId=VAR_072009.
FT   VARIANT    1978   1978       P -> S (in RP39; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:20507924}.
FT                                /FTId=VAR_072010.
FT   VARIANT    2080   2080       K -> N (in USH2A; unknown pathological
FT                                significance; dbSNP:rs114402911).
FT                                {ECO:0000269|PubMed:18273898,
FT                                ECO:0000269|PubMed:20507924}.
FT                                /FTId=VAR_054585.
FT   VARIANT    2086   2086       T -> N (in dbSNP:rs149202379).
FT                                {ECO:0000269|PubMed:18273898}.
FT                                /FTId=VAR_054586.
FT   VARIANT    2106   2106       I -> T (in dbSNP:rs6657250).
FT                                {ECO:0000269|PubMed:17085681,
FT                                ECO:0000269|PubMed:17296898,
FT                                ECO:0000269|PubMed:18273898,
FT                                ECO:0000269|PubMed:19737284,
FT                                ECO:0000269|PubMed:21686329}.
FT                                /FTId=VAR_038363.
FT   VARIANT    2116   2116       H -> R (in USH2A; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:20507924}.
FT                                /FTId=VAR_072011.
FT   VARIANT    2128   2128       C -> F (in USH2A; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:20507924}.
FT                                /FTId=VAR_072012.
FT   VARIANT    2128   2128       C -> Y (in USH2A; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:20507924}.
FT                                /FTId=VAR_072013.
FT   VARIANT    2169   2169       I -> T (in dbSNP:rs10864219).
FT                                {ECO:0000269|PubMed:17085681,
FT                                ECO:0000269|PubMed:17296898,
FT                                ECO:0000269|PubMed:18273898,
FT                                ECO:0000269|PubMed:19737284,
FT                                ECO:0000269|PubMed:20507924,
FT                                ECO:0000269|PubMed:21686329}.
FT                                /FTId=VAR_038364.
FT   VARIANT    2196   2196       S -> T (in USH2A; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:20507924}.
FT                                /FTId=VAR_072014.
FT   VARIANT    2237   2237       D -> Y (in RP39; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:20507924}.
FT                                /FTId=VAR_072015.
FT   VARIANT    2238   2238       E -> A (in USH2A; unknown pathological
FT                                significance; dbSNP:rs41277212).
FT                                {ECO:0000269|PubMed:17085681,
FT                                ECO:0000269|PubMed:18273898,
FT                                ECO:0000269|PubMed:20507924}.
FT                                /FTId=VAR_054587.
FT   VARIANT    2249   2249       A -> D (in USH2A).
FT                                {ECO:0000269|PubMed:17085681}.
FT                                /FTId=VAR_054588.
FT   VARIANT    2260   2260       S -> P (in USH2A; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:20507924}.
FT                                /FTId=VAR_072016.
FT   VARIANT    2265   2266       EY -> D (in USH2A).
FT                                /FTId=VAR_054589.
FT   VARIANT    2292   2292       R -> H (in USH2A; unknown pathological
FT                                significance; dbSNP:rs41277210).
FT                                {ECO:0000269|PubMed:18273898,
FT                                ECO:0000269|PubMed:20507924}.
FT                                /FTId=VAR_054590.
FT   VARIANT    2354   2354       R -> H (in USH2A).
FT                                {ECO:0000269|PubMed:17085681}.
FT                                /FTId=VAR_054591.
FT   VARIANT    2377   2377       N -> S. {ECO:0000269|PubMed:22004887}.
FT                                /FTId=VAR_072017.
FT   VARIANT    2394   2394       N -> K. {ECO:0000269|PubMed:22004887}.
FT                                /FTId=VAR_072018.
FT   VARIANT    2460   2460       R -> H (in RP39).
FT                                {ECO:0000269|PubMed:22334370}.
FT                                /FTId=VAR_068355.
FT   VARIANT    2562   2562       V -> A (in USH2A; unknown pathological
FT                                significance; dbSNP:rs56385601).
FT                                {ECO:0000269|PubMed:18273898,
FT                                ECO:0000269|PubMed:20507924}.
FT                                /FTId=VAR_054592.
FT   VARIANT    2573   2573       R -> H (in RP39; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:20507924}.
FT                                /FTId=VAR_072019.
FT   VARIANT    2639   2639       S -> P (in USH2A; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:20507924}.
FT                                /FTId=VAR_072020.
FT   VARIANT    2738   2738       D -> N (in USH2A).
FT                                {ECO:0000269|PubMed:23737954}.
FT                                /FTId=VAR_072021.
FT   VARIANT    2744   2744       W -> C (in USH2A).
FT                                {ECO:0000269|PubMed:21686329}.
FT                                /FTId=VAR_072022.
FT   VARIANT    2752   2752       G -> R (in USH2A).
FT                                {ECO:0000269|PubMed:19737284}.
FT                                /FTId=VAR_072023.
FT   VARIANT    2786   2786       F -> S (in USH2A; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:20507924}.
FT                                /FTId=VAR_072024.
FT   VARIANT    2795   2795       A -> S (in USH2A).
FT                                {ECO:0000269|PubMed:17405132}.
FT                                /FTId=VAR_054593.
FT   VARIANT    2820   2820       V -> I (in dbSNP:rs59174500).
FT                                /FTId=VAR_061350.
FT   VARIANT    2875   2875       R -> Q (in dbSNP:rs12118814).
FT                                {ECO:0000269|PubMed:17085681,
FT                                ECO:0000269|PubMed:17296898,
FT                                ECO:0000269|PubMed:18273898,
FT                                ECO:0000269|PubMed:19737284,
FT                                ECO:0000269|PubMed:20507924}.
FT                                /FTId=VAR_038365.
FT   VARIANT    2886   2886       L -> F (in dbSNP:rs41277200).
FT                                {ECO:0000269|PubMed:17085681,
FT                                ECO:0000269|PubMed:18273898,
FT                                ECO:0000269|PubMed:19737284}.
FT                                /FTId=VAR_054594.
FT   VARIANT    2930   2930       N -> K (in RP39; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:20507924}.
FT                                /FTId=VAR_072025.
FT   VARIANT    3088   3088       E -> K (in dbSNP:rs56056328).
FT                                {ECO:0000269|PubMed:18273898}.
FT                                /FTId=VAR_054595.
FT   VARIANT    3099   3099       N -> S (in dbSNP:rs41277194).
FT                                {ECO:0000269|PubMed:17085681,
FT                                ECO:0000269|PubMed:17296898,
FT                                ECO:0000269|PubMed:18273898,
FT                                ECO:0000269|PubMed:20507924}.
FT                                /FTId=VAR_038366.
FT   VARIANT    3115   3115       T -> A (in dbSNP:rs56032526).
FT                                {ECO:0000269|PubMed:18273898,
FT                                ECO:0000269|PubMed:19737284}.
FT                                /FTId=VAR_054596.
FT   VARIANT    3124   3124       R -> G (in USH2A; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:18273898}.
FT                                /FTId=VAR_054597.
FT   VARIANT    3144   3144       D -> N (in dbSNP:rs11120645).
FT                                {ECO:0000269|PubMed:17085681,
FT                                ECO:0000269|PubMed:17296898,
FT                                ECO:0000269|PubMed:18273898,
FT                                ECO:0000269|PubMed:20507924}.
FT                                /FTId=VAR_038367.
FT   VARIANT    3199   3199       N -> D (in dbSNP:rs4129843).
FT                                {ECO:0000269|PubMed:18273898,
FT                                ECO:0000269|PubMed:19737284}.
FT                                /FTId=VAR_034064.
FT   VARIANT    3251   3251       C -> R (in USH2A).
FT                                {ECO:0000269|PubMed:17085681}.
FT                                /FTId=VAR_054598.
FT   VARIANT    3263   3269       Missing (in USH2A; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:20507924}.
FT                                /FTId=VAR_072026.
FT   VARIANT    3267   3267       C -> R (in USH2A).
FT                                {ECO:0000269|PubMed:17085681}.
FT                                /FTId=VAR_054599.
FT   VARIANT    3282   3282       C -> R (in USH2A).
FT                                {ECO:0000269|PubMed:17405132}.
FT                                /FTId=VAR_054600.
FT   VARIANT    3335   3335       I -> M. {ECO:0000269|PubMed:17296898}.
FT                                /FTId=VAR_038368.
FT   VARIANT    3358   3358       C -> Y (in RP39; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:20507924,
FT                                ECO:0000269|PubMed:22334370}.
FT                                /FTId=VAR_068356.
FT   VARIANT    3384   3384       S -> Y (in RP39; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:20507924}.
FT                                /FTId=VAR_072027.
FT   VARIANT    3411   3411       E -> A (in dbSNP:rs10864198).
FT                                {ECO:0000269|PubMed:17085681,
FT                                ECO:0000269|PubMed:18273898,
FT                                ECO:0000269|PubMed:19737284,
FT                                ECO:0000269|PubMed:20507924,
FT                                ECO:0000269|PubMed:21686329}.
FT                                /FTId=VAR_050087.
FT   VARIANT    3448   3448       E -> K (in USH2A; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:20507924}.
FT                                /FTId=VAR_072028.
FT   VARIANT    3462   3462       T -> I (in USH2A; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:20507924}.
FT                                /FTId=VAR_072029.
FT   VARIANT    3472   3472       Y -> YY (in USH2A).
FT                                {ECO:0000269|PubMed:17085681}.
FT                                /FTId=VAR_054601.
FT   VARIANT    3479   3479       W -> C (in USH2A; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:20507924}.
FT                                /FTId=VAR_072030.
FT   VARIANT    3504   3504       P -> T (in USH2A).
FT                                {ECO:0000269|PubMed:18273898}.
FT                                /FTId=VAR_054602.
FT   VARIANT    3515   3515       D -> G (in USH2A).
FT                                {ECO:0000269|PubMed:19737284}.
FT                                /FTId=VAR_072031.
FT   VARIANT    3521   3521       W -> R (in USH2A).
FT                                {ECO:0000269|PubMed:18273898}.
FT                                /FTId=VAR_054603.
FT   VARIANT    3529   3529       G -> S (in USH2A; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:20507924}.
FT                                /FTId=VAR_072032.
FT   VARIANT    3546   3546       G -> R (in USH2A).
FT                                {ECO:0000269|PubMed:22004887}.
FT                                /FTId=VAR_072033.
FT   VARIANT    3571   3571       T -> M (in USH2A).
FT                                {ECO:0000269|PubMed:17085681,
FT                                ECO:0000269|PubMed:17405132,
FT                                ECO:0000269|PubMed:19737284}.
FT                                /FTId=VAR_054604.
FT   VARIANT    3590   3590       P -> L (in dbSNP:rs115403785).
FT                                {ECO:0000269|PubMed:18273898}.
FT                                /FTId=VAR_054605.
FT   VARIANT    3606   3606       L -> P (in RP39; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:20507924}.
FT                                /FTId=VAR_072034.
FT   VARIANT    3618   3618       G -> S (in RP39; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:20507924}.
FT                                /FTId=VAR_072035.
FT   VARIANT    3669   3669       S -> R (in RP39).
FT                                {ECO:0000269|PubMed:22334370}.
FT                                /FTId=VAR_068357.
FT   VARIANT    3719   3719       R -> H (in RP39; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:20507924}.
FT                                /FTId=VAR_072036.
FT   VARIANT    3747   3747       Y -> C (in USH2A).
FT                                {ECO:0000269|PubMed:19737284}.
FT                                /FTId=VAR_072037.
FT   VARIANT    3835   3835       T -> I (in dbSNP:rs11120616).
FT                                {ECO:0000269|PubMed:18273898,
FT                                ECO:0000269|PubMed:19737284,
FT                                ECO:0000269|PubMed:22004887}.
FT                                /FTId=VAR_050088.
FT   VARIANT    3844   3844       I -> M (in USH2A; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:20507924}.
FT                                /FTId=VAR_072038.
FT   VARIANT    3868   3868       M -> V (in dbSNP:rs35309576).
FT                                {ECO:0000269|PubMed:17085681,
FT                                ECO:0000269|PubMed:18273898,
FT                                ECO:0000269|PubMed:19737284,
FT                                ECO:0000269|PubMed:20507924}.
FT                                /FTId=VAR_054606.
FT   VARIANT    3893   3893       P -> T (in dbSNP:rs41303285).
FT                                {ECO:0000269|PubMed:18273898}.
FT                                /FTId=VAR_054607.
FT   VARIANT    3894   3894       N -> D (in USH2A).
FT                                {ECO:0000269|PubMed:22004887}.
FT                                /FTId=VAR_072039.
FT   VARIANT    3895   3895       G -> E (in USH2A).
FT                                {ECO:0000269|PubMed:17405132}.
FT                                /FTId=VAR_054608.
FT   VARIANT    3904   3904       R -> K (in USH2A; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:20507924}.
FT                                /FTId=VAR_072040.
FT   VARIANT    3976   3976       T -> M (in USH2A).
FT                                {ECO:0000269|PubMed:17405132}.
FT                                /FTId=VAR_054609.
FT   VARIANT    4054   4054       S -> I (in USH2A).
FT                                {ECO:0000269|PubMed:18273898}.
FT                                /FTId=VAR_054610.
FT   VARIANT    4094   4094       N -> K (in RP39; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:20507924}.
FT                                /FTId=VAR_072041.
FT   VARIANT    4115   4115       R -> C (in USH2A and RP39; associated
FT                                with M-4425).
FT                                {ECO:0000269|PubMed:15015129,
FT                                ECO:0000269|PubMed:17405132,
FT                                ECO:0000269|PubMed:18273898,
FT                                ECO:0000269|PubMed:22334370}.
FT                                /FTId=VAR_025780.
FT   VARIANT    4174   4174       S -> R (in USH2A; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:20507924}.
FT                                /FTId=VAR_072042.
FT   VARIANT    4192   4192       R -> H (in RP39; unknown pathological
FT                                significance; dbSNP:rs199605265).
FT                                {ECO:0000269|PubMed:20507924,
FT                                ECO:0000269|PubMed:22334370}.
FT                                /FTId=VAR_068358.
FT   VARIANT    4203   4203       Q -> R (in dbSNP:rs148556640).
FT                                {ECO:0000269|PubMed:19737284,
FT                                ECO:0000269|PubMed:21835308}.
FT                                /FTId=VAR_066665.
FT   VARIANT    4232   4232       P -> R (in USH2A).
FT                                {ECO:0000269|PubMed:18273898}.
FT                                /FTId=VAR_054611.
FT   VARIANT    4248   4248       H -> N (in RP39; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:20507924}.
FT                                /FTId=VAR_072043.
FT   VARIANT    4269   4269       P -> R (in USH2A; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:20507924}.
FT                                /FTId=VAR_072044.
FT   VARIANT    4337   4337       T -> M (in USH2A).
FT                                {ECO:0000269|PubMed:17085681}.
FT                                /FTId=VAR_054612.
FT   VARIANT    4425   4425       T -> M (in USH2Aand RP39; associated with
FT                                C-4115; dbSNP:rs201238640).
FT                                {ECO:0000269|PubMed:15015129,
FT                                ECO:0000269|PubMed:17405132,
FT                                ECO:0000269|PubMed:22334370}.
FT                                /FTId=VAR_025781.
FT   VARIANT    4433   4433       V -> L (in USH2A; unknown pathological
FT                                significance; dbSNP:rs111033381).
FT                                {ECO:0000269|PubMed:18273898,
FT                                ECO:0000269|PubMed:20507924}.
FT                                /FTId=VAR_054613.
FT   VARIANT    4439   4439       T -> I (in USH2A).
FT                                {ECO:0000269|PubMed:18273898,
FT                                ECO:0000269|PubMed:20440071}.
FT                                /FTId=VAR_054614.
FT   VARIANT    4445   4449       ENMDS -> DL (in USH2A; unknown
FT                                pathological significance).
FT                                {ECO:0000269|PubMed:20507924}.
FT                                /FTId=VAR_072045.
FT   VARIANT    4447   4447       M -> V (in RP39; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:20507924}.
FT                                /FTId=VAR_072046.
FT   VARIANT    4487   4487       Y -> C (in USH2A).
FT                                {ECO:0000269|PubMed:18273898}.
FT                                /FTId=VAR_054615.
FT   VARIANT    4493   4493       R -> H. {ECO:0000269|PubMed:19737284}.
FT                                /FTId=VAR_072047.
FT   VARIANT    4570   4570       R -> H (in USH2A; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:20507924}.
FT                                /FTId=VAR_072048.
FT   VARIANT    4592   4592       Q -> H (in USH2A).
FT                                {ECO:0000269|PubMed:18273898}.
FT                                /FTId=VAR_054616.
FT   VARIANT    4611   4611       A -> V. {ECO:0000269|PubMed:19737284}.
FT                                /FTId=VAR_072049.
FT   VARIANT    4616   4616       G -> V. {ECO:0000269|PubMed:21593743}.
FT                                /FTId=VAR_072050.
FT   VARIANT    4624   4624       F -> V. {ECO:0000269|PubMed:18273898}.
FT                                /FTId=VAR_054617.
FT   VARIANT    4662   4662       Q -> E (in USH2A; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:20507924}.
FT                                /FTId=VAR_072051.
FT   VARIANT    4674   4674       R -> G (in RP39).
FT                                {ECO:0000269|PubMed:17296898}.
FT                                /FTId=VAR_038369.
FT   VARIANT    4692   4692       G -> R (in USH2A; unknown pathological
FT                                significance; dbSNP:rs45549044).
FT                                {ECO:0000269|PubMed:20507924}.
FT                                /FTId=VAR_061351.
FT   VARIANT    4739   4739       R -> K (in dbSNP:rs12085354).
FT                                /FTId=VAR_050089.
FT   VARIANT    4763   4763       G -> R (in USH2A; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:20507924}.
FT                                /FTId=VAR_072052.
FT   VARIANT    4778   4778       A -> D (in USH2A; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:20507924}.
FT                                /FTId=VAR_072053.
FT   VARIANT    4795   4795       L -> R (in USH2A).
FT                                {ECO:0000269|PubMed:18273898}.
FT                                /FTId=VAR_054618.
FT   VARIANT    4808   4808       C -> R (in USH2A; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:20507924}.
FT                                /FTId=VAR_072054.
FT   VARIANT    4817   4817       G -> R (in USH2A; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:20507924}.
FT                                /FTId=VAR_072055.
FT   VARIANT    4818   4818       P -> L (in USH2A; dbSNP:rs143344549).
FT                                {ECO:0000269|PubMed:17085681}.
FT                                /FTId=VAR_054619.
FT   VARIANT    4838   4838       G -> E (in dbSNP:rs41315587).
FT                                {ECO:0000269|PubMed:19737284,
FT                                ECO:0000269|PubMed:20507924}.
FT                                /FTId=VAR_061352.
FT   VARIANT    4840   4840       L -> P (in RP39; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:20507924}.
FT                                /FTId=VAR_072056.
FT   VARIANT    4844   4844       T -> M (in RP39; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:20507924}.
FT                                /FTId=VAR_072057.
FT   VARIANT    4848   4848       R -> Q. {ECO:0000269|PubMed:19737284,
FT                                ECO:0000269|PubMed:20507924}.
FT                                /FTId=VAR_072058.
FT   VARIANT    4881   4881       S -> T. {ECO:0000269|PubMed:21593743}.
FT                                /FTId=VAR_072059.
FT   VARIANT    4918   4918       T -> M (in USH2A; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:20507924}.
FT                                /FTId=VAR_072060.
FT   VARIANT    4921   4921       E -> K. {ECO:0000269|PubMed:22004887}.
FT                                /FTId=VAR_072061.
FT   VARIANT    5026   5026       K -> E. {ECO:0000269|PubMed:19737284,
FT                                ECO:0000269|PubMed:20507924}.
FT                                /FTId=VAR_072062.
FT   VARIANT    5031   5031       R -> W (in dbSNP:rs56038610).
FT                                {ECO:0000269|PubMed:18273898}.
FT                                /FTId=VAR_054620.
FT   VARIANT    5063   5063       L -> R (in RP39).
FT                                {ECO:0000269|PubMed:24227914}.
FT                                /FTId=VAR_072063.
FT   VARIANT    5143   5143       R -> C (in USH2A).
FT                                {ECO:0000269|PubMed:23737954}.
FT                                /FTId=VAR_072064.
FT   VARIANT    5143   5143       R -> H (in RP39; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:20507924}.
FT                                /FTId=VAR_072065.
FT   VARIANT    5145   5145       V -> I (in RP39; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:20507924}.
FT                                /FTId=VAR_072066.
FT   VARIANT    5188   5188       S -> G (in RP39; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:20507924}.
FT                                /FTId=VAR_072067.
FT   CONFLICT    237    237       F -> C (in Ref. 1; AAC23748 and 2;
FT                                AAF75819). {ECO:0000305}.
SQ   SEQUENCE   5202 AA;  575600 MW;  06A123CA9C0F7F1D CRC64;
     MNCPVLSLGS GFLFQVIEML IFAYFASISL TESRGLFPRL ENVGAFKKVS IVPTQAVCGL
     PDRSTFCHSS AAAESIQFCT QRFCIQDCPY RSSHPTYTAL FSAGLSSCIT PDKNDLHPNA
     HSNSASFIFG NHKSCFSSPP SPKLMASFTL AVWLKPEQQG VMCVIEKTVD GQIVFKLTIS
     EKETMFYYRT VNGLQPPIKV MTLGRILVKK WIHLSVQVHQ TKISFFINGV EKDHTPFNAR
     TLSGSITDFA SGTVQIGQSL NGLEQFVGRM QDFRLYQVAL TNREILEVFS GDLLRLHAQS
     HCRCPGSHPR VHPLAQRYCI PNDAGDTADN RVSRLNPEAH PLSFVNDNDV GTSWVSNVFT
     NITQLNQGVT ISVDLENGQY QVFYIIIQFF SPQPTEIRIQ RKKENSLDWE DWQYFARNCG
     AFGMKNNGDL EKPDSVNCLQ LSNFTPYSRG NVTFSILTPG PNYRPGYNNF YNTPSLQEFV
     KATQIRFHFH GQYYTTETAV NLRHRYYAVD EITISGRCQC HGHADNCDTT SQPYRCLCSQ
     ESFTEGLHCD RCLPLYNDKP FRQGDQVYAF NCKPCQCNSH SKSCHYNISV DPFPFEHFRG
     GGGVCDDCEH NTTGRNCELC KDYFFRQVGA DPSAIDVCKP CDCDTVGTRN GSILCDQIGG
     QCNCKRHVSG RQCNQCQNGF YNLQELDPDG CSPCNCNTSG TVDGDITCHQ NSGQCKCKAN
     VIGLRCDHCN FGFKFLRSFN DVGCEPCQCN LHGSVNKFCN PHSGQCECKK EAKGLQCDTC
     RENFYGLDVT NCKACDCDTA GSLPGTVCNA KTGQCICKPN VEGRQCNKCL EGNFYLRQNN
     SFLCLPCNCD KTGTINGSLL CNKSTGQCPC KLGVTGLRCN QCEPHRYNLT IDNFQHCQMC
     ECDSLGTLPG TICDPISGQC LCVPNRQGRR CNQCQPGFYI SPGNATGCLP CSCHTTGAVN
     HICNSLTGQC VCQDASIAGQ RCDQCKDHYF GFDPQTGRCQ PCNCHLSGAL NETCHLVTGQ
     CFCKQFVTGS KCDACVPSAS HLDVNNLLGC SKTPFQQPPP RGQVQSSSAI NLSWSPPDSP
     NAHWLTYSLL RDGFEIYTTE DQYPYSIQYF LDTDLLPYTK YSYYIETTNV HGSTRSVAVT
     YKTKPGVPEG NLTLSYIIPI GSDSVTLTWT TLSNQSGPIE KYILSCAPLA GGQPCVSYEG
     HETSATIWNL VPFAKYDFSV QACTSGGCLH SLPITVTTAQ APPQRLSPPK MQKISSTELH
     VEWSPPAELN GIIIRYELYM RRLRSTKETT SEESRVFQSS GWLSPHSFVE SANENALKPP
     QTMTTITGLE PYTKYEFRVL AVNMAGSVSS AWVSERTGES APVFMIPPSV FPLSSYSLNI
     SWEKPADNVT RGKVVGYDIN MLSEQSPQQS IPMAFSQLLH TAKSQELSYT VEGLKPYRIY
     EFTITLCNSV GCVTSASGAG QTLAAAPAQL RPPLVKGINS TTIHLRWFPP EELNGPSPIY
     QLERRESSLP ALMTTMMKGI RFIGNGYCKF PSSTHPVNTD FTGIKASFRT KVPEGLIVFA
     ASPGNQEEYF ALQLKKGRLY FLFDPQGSPV EVTTTNDHGK QYSDGKWHEI IAIRHQAFGQ
     ITLDGIYTGS SAILNGSTVI GDNTGVFLGG LPRSYTILRK DPEIIQKGFV GCLKDVHFMK
     NYNPSAIWEP LDWQSSEEQI NVYNSWEGCP ASLNEGAQFL GAGFLELHPY MFHGGMNFEI
     SFKFRTDQLN GLLLFVYNKD GPDFLAMELK SGILTFRLNT SLAFTQVDLL LGLSYCNGKW
     NKVIIKKEGS FISASVNGLM KHASESGDQP LVVNSPVYVG GIPQELLNSY QHLCLEQGFG
     GCMKDVKFTR GAVVNLASVS SGAVRVNLDG CLSTDSAVNC RGNDSILVYQ GKEQSVYEGG
     LQPFTEYLYR VIASHEGGSV YSDWSRGRTT GAAPQSVPTP SRVRSLNGYS IEVTWDEPVV
     RGVIEKYILK AYSEDSTRPP RMPSASAEFV NTSNLTGILT GLLPFKNYAV TLTACTLAGC
     TESSHALNIS TPQEAPQEVQ PPVAKSLPSS LLLSWNPPKK ANGIITQYCL YMDGRLIYSG
     SEENYIVTDL AVFTPHQFLL SACTHVGCTN SSWVLLYTAQ LPPEHVDSPV LTVLDSRTIH
     IQWKQPRKIS GILERYVLYM SNHTHDFTIW SVIYNSTELF QDHMLQYVLP GNKYLIKLGA
     CTGGGCTVSE ASEALTDEDI PEGVPAPKAH SYSPDSFNVS WTEPEYPNGV ITSYGLYLDG
     ILIHNSSELS YRAYGFAPWS LHSFRVQACT AKGCALGPLV ENRTLEAPPE GTVNVFVKTQ
     GSRKAHVRWE APFRPNGLLT HSVLFTGIFY VDPVGNNYTL LNVTKVMYSG EETNLWVLID
     GLVPFTNYTV QVNISNSQGS LITDPITIAM PPGAPDGVLP PRLSSATPTS LQVVWSTPAR
     NNAPGSPRYQ LQMRSGDSTH GFLELFSNPS ASLSYEVSDL QPYTEYMFRL VASNGFGSAH
     SSWIPFMTAE DKPGPVVPPI LLDVKSRMML VTWQHPRKSN GVITHYNIYL HGRLYLRTPG
     NVTNCTVMHL HPYTAYKFQV EACTSKGCSL SPESQTVWTL PGAPEGIPSP ELFSDTPTSV
     IISWQPPTHP NGLVENFTIE RRVKGKEEVT TLVTLPRSHS MRFIDKTSAL SPWTKYEYRV
     LMSTLHGGTN SSAWVEVTTR PSRPAGVQPP VVTVLEPDAV QVTWKPPLIQ NGDILSYEIH
     MPDPHITLTN VTSAVLSQKV THLIPFTNYS VTIVACSGGN GYLGGCTESL PTYVTTHPTV
     PQNVGPLSVI PLSESYVVIS WQPPSKPNGP NLRYELLRRK IQQPLASNPP EDLNRWHNIY
     SGTQWLYEDK GLSRFTTYEY MLFVHNSVGF TPSREVTVTT LAGLPERGAN LTASVLNHTA
     IDVRWAKPTV QDLQGEVEYY TLFWSSATSN DSLKILPDVN SHVIGHLKPN TEYWIFISVF
     NGVHSINSAG LHATTCDGEP QGMLPPEVVI INSTAVRVIW TSPSNPNGVV TEYSIYVNNK
     LYKTGMNVPG SFILRDLSPF TIYDIQVEVC TIYACVKSNG TQITTVEDTP SDIPTPTIRG
     ITSRSLQIDW VSPRKPNGII LGYDLLWKTW YPCAKTQKLV QDQSDELCKA VRCQKPESIC
     GHICYSSEAK VCCNGVLYNP KPGHRCCEEK YIPFVLNSTG VCCGGRIQEA QPNHQCCSGY
     YARILPGEVC CPDEQHNRVS VGIGDSCCGR MPYSTSGNQI CCAGRLHDGH GQKCCGRQIV
     SNDLECCGGE EGVVYNRLPG MFCCGQDYVN MSDTICCSAS SGESKAHIKK NDPVPVKCCE
     TELIPKSQKC CNGVGYNPLK YVCSDKISTG MMMKETKECR ILCPASMEAT EHCGRCDFNF
     TSHICTVIRG SHNSTGKASI EEMCSSAEET IHTGSVNTYS YTDVNLKPYM TYEYRISAWN
     SYGRGLSKAV RARTKEDVPQ GVSPPTWTKI DNLEDTIVLN WRKPIQSNGP IIYYILLRNG
     IERFRGTSLS FSDKEGIQPF QEYSYQLKAC TVAGCATSSK VVAATTQGVP ESILPPSITA
     LSAVALHLSW SVPEKSNGVI KEYQIRQVGK GLIHTDTTDR RQHTVTGLQP YTNYSFTLTA
     CTSAGCTSSE PFLGQTLQAA PEGVWVTPRH IIINSTTVEL YWSLPEKPNG LVSQYQLSRN
     GNLLFLGGSE EQNFTDKNLE PNSRYTYKLE VKTGGGSSAS DDYIVQTPMS TPEEIYPPYN
     ITVIGPYSIF VAWIPPGILI PEIPVEYNVL LNDGSVTPLA FSVGHHQSTL LENLTPFTQY
     EIRIQACQNG SCGVSSRMFV KTPEAAPMDL NSPVLKALGS ACIEIKWMPP EKPNGIIINY
     FIYRRPAGIE EESVLFVWSE GALEFMDEGD TLRPFTLYEY RVRACNSKGS VESLWSLTQT
     LEAPPQDFPA PWAQATSAHS VLLNWTKPES PNGIISHYRV VYQERPDDPT FNSPTVHAFT
     VKGTSHQAHL YGLEPFTTYR IGVVAANHAG EILSPWTLIQ TLESSPSGLR NFIVEQKENG
     RALLLQWSEP MRTNGVIKTY NIFSDGFLEY SGLNRQFLFR RLDPFTLYTL TLEACTRAGC
     AHSAPQPLWT DEAPPDSQLA PTVHSVKSTS VELSWSEPVN PNGKIIRYEV IRRCFEGKAW
     GNQTIQADEK IVFTEYNTER NTFMYNDTGL QPWTQCEYKI YTWNSAGHTC SSWNVVRTLQ
     APPEGLSPPV ISYVSMNPQK LLISWIPPEQ SNGIIQSYRL QRNEMLYPFS FDPVTFNYTD
     EELLPFSTYS YALQACTSGG CSTSKPTSIT TLEAAPSEVS PPDLWAVSAT QMNVCWSPPT
     VQNGKITKYL VRYDNKESLA GQGLCLLVSH LQPYSQYNFS LVACTNGGCT ASVSKSAWTM
     EALPENMDSP TLQVTGSESI EITWKPPRNP NGQIRSYELR RDGTIVYTGL ETRYRDFTLT
     PGVEYSYTVT ASNSQGGILS PLVKDRTSPS APSGMEPPKL QARGPQEILV NWDPPVRTNG
     DIINYTLFIR ELFERETKII HINTTHNSFG MQSYIVNQLK PFHRYEIRIQ ACTTLGCASS
     DWTFIQTPEI APLMQPPPHL EVQMAPGGFQ PTVSLLWTGP LQPNGKVLYY ELYRRQIATQ
     PRKSNPVLIY NGSSTSFIDS ELLPFTEYEY QVWAVNSAGK APSSWTWCRT GPAPPEGLRA
     PTFHVISSTQ AVVNISAPGK PNGIVSLYRL FSSSAHGAET VLSEGMATQQ TLHGLQAFTN
     YSIGVEACTC FNCCSKGPTA ELRTHPAPPS GLSSPQIGTL ASRTASFRWS PPMFPNGVIH
     SYELQFHVAC PPDSALPCTP SQIETKYTGL GQKASLGGLQ PYTTYKLRVV AHNEVGSTAS
     EWISFTTQKE LPQYRAPFSV DSNLSVVCVN WSDTFLLNGQ LKEYVLTDGG RRVYSGLDTT
     LYIPRTADKT FFFQVICTTD EGSVKTPLIQ YDTSTGLGLV LTTPGKKKGS RSKSTEFYSE
     LWFIVLMAML GLILLAIFLS LILQRKIHKE PYIRERPPLV PLQKRMSPLN VYPPGENHMG
     LADTKIPRSG TPVSIRSNRS ACVLRIPSQN QTSLTYSQGS LHRSVSQLMD IQDKKVLMDN
     SLWEAIMGHN SGLYVDEEDL MNAIKDFSSV TKERTTFTDT HL
//
ID   ERBB4_HUMAN             Reviewed;        1308 AA.
AC   Q15303; B7ZLD7; B7ZLE2; B7ZLE3; Q2M1W1; Q59EW4;
DT   15-DEC-1998, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   20-JAN-2016, entry version 182.
DE   RecName: Full=Receptor tyrosine-protein kinase erbB-4;
DE            EC=2.7.10.1;
DE   AltName: Full=Proto-oncogene-like protein c-ErbB-4;
DE   AltName: Full=Tyrosine kinase-type cell surface receptor HER4;
DE   AltName: Full=p180erbB4;
DE   Contains:
DE     RecName: Full=ERBB4 intracellular domain;
DE              Short=4ICD;
DE              Short=E4ICD;
DE     AltName: Full=s80HER4;
DE   Flags: Precursor;
GN   Name=ERBB4; Synonyms=HER4;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM JM-A CYT-1), FUNCTION AS CELL
RP   SURFACE RECEPTOR, AUTOPHOSPHORYLATION, SUBCELLULAR LOCATION, AND
RP   TISSUE SPECIFICITY.
RC   TISSUE=Mammary carcinoma;
RX   PubMed=8383326; DOI=10.1073/pnas.90.5.1746;
RA   Plowman G.D., Culouscou J.-M., Whitney G.S., Green J.M., Carlton G.W.,
RA   Foy L., Neubauer M.G., Shoyab M.;
RT   "Ligand-specific activation of HER4/p180erbB4, a fourth member of the
RT   epidermal growth factor receptor family.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:1746-1750(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS JM-A CYT-1 AND JM-B CYT-1),
RP   TISSUE SPECIFICITY, FUNCTION AS CELL SURFACE RECEPTOR FOR NRG1 AND
RP   BTC, SUBCELLULAR LOCATION, AUTOPHOSPHORYLATION, AND PROTEOLYTIC
RP   PROCESSING.
RC   TISSUE=Fetal brain;
RX   PubMed=9334263; DOI=10.1074/jbc.272.42.26761;
RA   Elenius K., Corfas G., Paul S., Choi C.J., Rio C., Plowman G.D.,
RA   Klagsbrun M.;
RT   "A novel juxtamembrane domain isoform of HER4/ErbB4. Isoform-specific
RT   tissue distribution and differential processing in response to phorbol
RT   ester.";
RL   J. Biol. Chem. 272:26761-26768(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS JM-A CYT-1; JM-B
RP   CYT-1; JM-A CYT-2 AND JM-B CYT-2).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 401-1308 (ISOFORM JM-A
RP   CYT-2).
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   INTERACTION WITH NRG1, AND AUTOPHOSPHORYLATION.
RX   PubMed=7689552;
RA   Culouscou J.-M., Plowman G.D., Carlton G.W., Green J.M., Shoyab M.;
RT   "Characterization of a breast cancer cell differentiation factor that
RT   specifically activates the HER4/p180erbB4 receptor.";
RL   J. Biol. Chem. 268:18407-18410(1993).
RN   [6]
RP   INTERACTION WITH NRG1, AND AUTOPHOSPHORYLATION.
RX   PubMed=7902537; DOI=10.1038/366473a0;
RA   Plowman G.D., Green J.M., Culouscou J.M., Carlton G.W., Rothwell V.M.,
RA   Buckley S.;
RT   "Heregulin induces tyrosine phosphorylation of HER4/p180erbB4.";
RL   Nature 366:473-475(1993).
RN   [7]
RP   FUNCTION AS NRG1 RECEPTOR IN REGULATION OF CELL PROLIFERATION,
RP   CATALYTIC ACTIVITY, ENZYME REGULATION, AUTOPHOSPHORYLATION,
RP   PHOSPHORYLATION AT TYR-1056; TYR-1188 AND TYR-1242, AND INTERACTION
RP   WITH EGFR; SHC1 AND PIK3R1.
RX   PubMed=8617750; DOI=10.1074/jbc.271.9.4813;
RA   Cohen B.D., Green J.M., Foy L., Fell H.P.;
RT   "HER4-mediated biological and biochemical properties in NIH 3T3 cells.
RT   Evidence for HER1-HER4 heterodimers.";
RL   J. Biol. Chem. 271:4813-4818(1996).
RN   [8]
RP   INTERACTION WITH BTC, AND AUTOPHOSPHORYLATION.
RX   PubMed=8570211;
RA   Riese D.J. II, Bermingham Y., van Raaij T.M., Buckley S.,
RA   Plowman G.D., Stern D.F.;
RT   "Betacellulin activates the epidermal growth factor receptor and erbB-
RT   4, and induces cellular response patterns distinct from those
RT   stimulated by epidermal growth factor or neuregulin-beta.";
RL   Oncogene 12:345-353(1996).
RN   [9]
RP   FUNCTION AS HBEGF RECEPTOR; IN CELL MIGRATION; CELL PROLIFERATION AND
RP   IN ACTIVATION OF PIK3R1, INTERACTION WITH HBEGF AND PIK3R1, AND
RP   AUTOPHOSPHORYLATION.
RX   PubMed=9135143; DOI=10.1093/emboj/16.6.1268;
RA   Elenius K., Paul S., Allison G., Sun J., Klagsbrun M.;
RT   "Activation of HER4 by heparin-binding EGF-like growth factor
RT   stimulates chemotaxis but not proliferation.";
RL   EMBO J. 16:1268-1278(1997).
RN   [10]
RP   INTERACTION WITH NRG2, FUNCTION AS NRG2 RECEPTOR, AND PHOSPHORYLATION.
RX   PubMed=9168115; DOI=10.1038/387512a0;
RA   Carraway K.L. III, Weber J.L., Unger M.J., Ledesma J., Yu N.,
RA   Gassmann M., Lai C.;
RT   "Neuregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine
RT   kinases.";
RL   Nature 387:512-516(1997).
RN   [11]
RP   INTERACTION WITH EREG, AND AUTOPHOSPHORYLATION.
RX   PubMed=9419975; DOI=10.1038/sj.onc.1201458;
RA   Komurasaki T., Toyoda H., Uchida D., Morimoto S.;
RT   "Epiregulin binds to epidermal growth factor receptor and ErbB-4 and
RT   induces tyrosine phosphorylation of epidermal growth factor receptor,
RT   ErbB-2, ErbB-3 and ErbB-4.";
RL   Oncogene 15:2841-2848(1997).
RN   [12]
RP   INTERACTION WITH NRG3, AND AUTOPHOSPHORYLATION.
RX   PubMed=9275162; DOI=10.1073/pnas.94.18.9562;
RA   Zhang D., Sliwkowski M.X., Mark M., Frantz G., Akita R., Sun Y.,
RA   Hillan K., Crowley C., Brush J., Godowski P.J.;
RT   "Neuregulin-3 (NRG3): a novel neural tissue-enriched protein that
RT   binds and activates ErbB4.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:9562-9567(1997).
RN   [13]
RP   INTERACTION WITH GRB7.
RX   PubMed=9516479; DOI=10.1074/jbc.273.13.7717;
RA   Fiddes R.J., Campbell D.H., Janes P.W., Sivertsen S.P., Sasaki H.,
RA   Wallasch C., Daly R.J.;
RT   "Analysis of Grb7 recruitment by heregulin-activated erbB receptors
RT   reveals a novel target selectivity for erbB3.";
RL   J. Biol. Chem. 273:7717-7724(1998).
RN   [14]
RP   INTERACTION WITH ERBB2, AND FUNCTION IN ACTIVATION OF STAT5A.
RX   PubMed=10358079; DOI=10.1074/jbc.274.24.17209;
RA   Olayioye M.A., Beuvink I., Horsch K., Daly J.M., Hynes N.E.;
RT   "ErbB receptor-induced activation of stat transcription factors is
RT   mediated by Src tyrosine kinases.";
RL   J. Biol. Chem. 274:17209-17218(1999).
RN   [15]
RP   ALTERNATIVE SPLICING, FUNCTION IN PHOSPHORYLATION AND ACTIVATION OF
RP   PIK3R1, INTERACTION WITH NRG1 AND PIKR3R1, AUTOPHOSPHORYLATION, AND
RP   TISSUE SPECIFICITY.
RX   PubMed=10353604; DOI=10.1038/sj.onc.1202612;
RA   Elenius K., Choi C.J., Paul S., Santiestevan E., Nishi E.,
RA   Klagsbrun M.;
RT   "Characterization of a naturally occurring ErbB4 isoform that does not
RT   bind or activate phosphatidyl inositol 3-kinase.";
RL   Oncogene 18:2607-2615(1999).
RN   [16]
RP   FUNCTION AS NRG4 RECEPTOR IN ACTIVATION OF MAPK1/ERK2 AND MAPK3/ERK1
RP   AND IN CELL PROLIFERATION, INTERACTION WITH NRG4, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=10348342; DOI=10.1038/sj.onc.1202631;
RA   Harari D., Tzahar E., Romano J., Shelly M., Pierce J.H., Andrews G.C.,
RA   Yarden Y.;
RT   "Neuregulin-4: a novel growth factor that acts through the ErbB-4
RT   receptor tyrosine kinase.";
RL   Oncogene 18:2681-2689(1999).
RN   [17]
RP   FUNCTION AS NRG1 RECEPTOR IN CELL PROLIFERATION; MIGRATION; SURVIVAL
RP   AND IN PHOSPHORYLATION OF SHC1; ACTIVATION OF MAPK1/ERK2 AND
RP   MAPK3/ERK1, AND ALTERNATIVE SPLICING.
RX   PubMed=10722704; DOI=10.1074/jbc.275.12.8641;
RA   Kainulainen V., Sundvall M., Maatta J.A., Santiestevan E.,
RA   Klagsbrun M., Elenius K.;
RT   "A natural ErbB4 isoform that does not activate phosphoinositide 3-
RT   kinase mediates proliferation but not survival or chemotaxis.";
RL   J. Biol. Chem. 275:8641-8649(2000).
RN   [18]
RP   PROTEOLYTIC PROCESSING.
RX   PubMed=10744726; DOI=10.1074/jbc.275.14.10379;
RA   Rio C., Buxbaum J.D., Peschon J.J., Corfas G.;
RT   "Tumor necrosis factor-alpha-converting enzyme is required for
RT   cleavage of erbB4/HER4.";
RL   J. Biol. Chem. 275:10379-10387(2000).
RN   [19]
RP   FUNCTION IN ACTIVATION OF AKT1; MAPK1/ERK2 AND MAPK3/ERK1, INTERACTION
RP   WITH PIK3R1; GRB2; SHC1; BTC; NRG1; NRG2 AND NRG3, AND LIGAND-SPECIFIC
RP   AUTOPHOSPHORYLATION.
RX   PubMed=10867024; DOI=10.1074/jbc.C901015199;
RA   Sweeney C., Lai C., Riese D.J. II, Diamonti A.J., Cantley L.C.,
RA   Carraway K.L. III;
RT   "Ligand discrimination in signaling through an ErbB4 receptor
RT   homodimer.";
RL   J. Biol. Chem. 275:19803-19807(2000).
RN   [20]
RP   INTERACTION WITH DLG2; DLG3; DLG4 AND SNTB2.
RX   PubMed=10725395; DOI=10.1073/pnas.97.7.3596;
RA   Garcia R.A., Vasudevan K., Buonanno A.;
RT   "The neuregulin receptor ErbB-4 interacts with PDZ-containing proteins
RT   at neuronal synapses.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:3596-3601(2000).
RN   [21]
RP   FUNCTION AS NRG1 RECEPTOR AND IN ACTIVATION OF MAP KINASES,
RP   AUTOPHOSPHORYLATION, AND ENZYME REGULATION.
RX   PubMed=11178955; DOI=10.1006/bbrc.2001.4302;
RA   Egeblad M., Mortensen O.H., van Kempen L.C., Jaattela M.;
RT   "BIBX1382BS, but not AG1478 or PD153035, inhibits the ErbB kinases at
RT   different concentrations in intact cells.";
RL   Biochem. Biophys. Res. Commun. 281:25-31(2001).
RN   [22]
RP   MUTAGENESIS OF LYS-751, AND FUNCTION IN PROMOTING CELL DIFFERENTIATION
RP   AND INHIBITING CELL PROLIFERATION.
RX   PubMed=11390655; DOI=10.1128/MCB.21.13.4265-4275.2001;
RA   Sartor C.I., Zhou H., Kozlowska E., Guttridge K., Kawata E.,
RA   Caskey L., Harrelson J., Hynes N., Ethier S., Calvo B., Earp H.S. III;
RT   "Her4 mediates ligand-dependent antiproliferative and differentiation
RT   responses in human breast cancer cells.";
RL   Mol. Cell. Biol. 21:4265-4275(2001).
RN   [23]
RP   FUNCTION, PROTEOLYTIC PROCESSING, SUBCELLULAR LOCATION, INTERACTION
RP   WITH YAP1, AND MUTAGENESIS OF TYR-1301.
RX   PubMed=12807903; DOI=10.1074/jbc.M305597200;
RA   Komuro A., Nagai M., Navin N.E., Sudol M.;
RT   "WW domain-containing protein YAP associates with ErbB-4 and acts as a
RT   co-transcriptional activator for the carboxyl-terminal fragment of
RT   ErbB-4 that translocates to the nucleus.";
RL   J. Biol. Chem. 278:33334-33341(2003).
RN   [24]
RP   INTERACTION WITH MUC1.
RX   PubMed=12939402;
RA   Li Y., Yu W.-H., Ren J., Chen W., Huang L., Kharbanda S., Loda M.,
RA   Kufe D.;
RT   "Heregulin targets gamma-catenin to the nucleolus by a mechanism
RT   dependent on the DF3/MUC1 oncoprotein.";
RL   Mol. Cancer Res. 1:765-775(2003).
RN   [25]
RP   INTERACTION WITH STAT5A, SUBCELLULAR LOCATION, FUNCTION IN NUCLEAR
RP   LOCALIZATION OF STAT5A; DNA-BINDING, AND MUTAGENESIS OF
RP   681-LYS--ARG-684.
RX   PubMed=15534001; DOI=10.1083/jcb.200403155;
RA   Williams C.C., Allison J.G., Vidal G.A., Burow M.E., Beckman B.S.,
RA   Marrero L., Jones F.E.;
RT   "The ERBB4/HER4 receptor tyrosine kinase regulates gene expression by
RT   functioning as a STAT5A nuclear chaperone.";
RL   J. Cell Biol. 167:469-478(2004).
RN   [26]
RP   INTERACTION WITH WWOX, DOMAIN, AND MUTAGENESIS OF TYR-1035 AND
RP   TYR-1301.
RX   PubMed=16061658; DOI=10.1158/0008-5472.CAN-05-1150;
RA   Aqeilan R.I., Donati V., Palamarchuk A., Trapasso F., Kaou M.,
RA   Pekarsky Y., Sudol M., Croce C.M.;
RT   "WW domain-containing proteins, WWOX and YAP, compete for interaction
RT   with ErbB-4 and modulate its transcriptional function.";
RL   Cancer Res. 65:6764-6772(2005).
RN   [27]
RP   FUNCTION, PROTEOLYTIC PROCESSING, AND MUTAGENESIS OF VAL-675.
RX   PubMed=15746097; DOI=10.1074/jbc.M412457200;
RA   Vidal G.A., Naresh A., Marrero L., Jones F.E.;
RT   "Presenilin-dependent gamma-secretase processing regulates multiple
RT   ERBB4/HER4 activities.";
RL   J. Biol. Chem. 280:19777-19783(2005).
RN   [28]
RP   FUNCTION IN PROMOTING APOPTOSIS, SUBCELLULAR LOCATION, AND INTERACTION
RP   WITH BCL2.
RX   PubMed=16778220; DOI=10.1158/0008-5472.CAN-05-2368;
RA   Naresh A., Long W., Vidal G.A., Wimley W.C., Marrero L., Sartor C.I.,
RA   Tovey S., Cooke T.G., Bartlett J.M., Jones F.E.;
RT   "The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein
RT   promoting apoptosis of breast cancer cells.";
RL   Cancer Res. 66:6412-6420(2006).
RN   [29]
RP   INTERACTION WITH CBFA2T3.
RX   PubMed=16815842; DOI=10.1074/jbc.M603998200;
RA   Linggi B., Carpenter G.;
RT   "ErbB-4 s80 intracellular domain abrogates ETO2-dependent
RT   transcriptional repression.";
RL   J. Biol. Chem. 281:25373-25380(2006).
RN   [30]
RP   FUNCTION, PHOSPHORYLATION, AND SUBCELLULAR LOCATION.
RX   PubMed=16251361; DOI=10.1091/mbc.E05-05-0402;
RA   Maatta J.A., Sundvall M., Junttila T.T., Peri L., Laine V.J.,
RA   Isola J., Egeblad M., Elenius K.;
RT   "Proteolytic cleavage and phosphorylation of a tumor-associated ErbB4
RT   isoform promote ligand-independent survival and cancer cell growth.";
RL   Mol. Biol. Cell 17:67-79(2006).
RN   [31]
RP   FUNCTION IN DIFFERENTIATION OF MAMMARY EPITHELIUM, PROTEOLYTIC
RP   PROCESSING, AUTOPHOSPHORYLATION, SUBCELLULAR LOCATION, AND INTERACTION
RP   WITH STAT5A.
RX   PubMed=16837552; DOI=10.1091/mbc.E06-02-0101;
RA   Muraoka-Cook R.S., Sandahl M., Husted C., Hunter D., Miraglia L.,
RA   Feng S.M., Elenius K., Earp H.S. III;
RT   "The intracellular domain of ErbB4 induces differentiation of mammary
RT   epithelial cells.";
RL   Mol. Biol. Cell 17:4118-4129(2006).
RN   [32]
RP   MUTAGENESIS OF GLN-646, AND PHOSPHORYLATION AT TYR-1056.
RX   PubMed=17120616;
RA   Pitfield S.E., Bryant I., Penington D.J., Park G., Riese D.J. II;
RT   "Phosphorylation of ErbB4 on tyrosine 1056 is critical for ErbB4
RT   coupling to inhibition of colony formation by human mammary cell
RT   lines.";
RL   Oncol. Res. 16:179-193(2006).
RN   [33]
RP   FUNCTION OF ERBB4 INTRACELLULAR DOMAIN, PROTEOLYTIC PROCESSING,
RP   SUBCELLULAR LOCATION, UBIQUITINATION OF ERBB4 INTRACELLULAR DOMAIN,
RP   AND MUTAGENESIS OF VAL-675; LYS-751; ARG-992; LEU-995 AND ASP-1000.
RX   PubMed=17638867; DOI=10.1158/0008-5472.CAN-06-4145;
RA   Strunk K.E., Husted C., Miraglia L.C., Sandahl M., Rearick W.A.,
RA   Hunter D.M., Earp H.S. III, Muraoka-Cook R.S.;
RT   "HER4 D-box sequences regulate mitotic progression and degradation of
RT   the nuclear HER4 cleavage product s80HER4.";
RL   Cancer Res. 67:6582-6590(2007).
RN   [34]
RP   INTERACTION WITH ERBB2, MUTAGENESIS OF ASP-843, AND
RP   AUTOPHOSPHORYLATION IN TRANS.
RX   PubMed=16978839; DOI=10.1016/j.cellsig.2006.07.020;
RA   Li Z., Mei Y., Liu X., Zhou M.;
RT   "Neuregulin-1 only induces trans-phosphorylation between ErbB receptor
RT   heterodimer partners.";
RL   Cell. Signal. 19:466-471(2007).
RN   [35]
RP   FUNCTION OF E4ICD, PHOSPHORYLATION, SUBCELLULAR LOCATION OF E4ICD, AND
RP   MUTAGENESIS OF LYS-751.
RX   PubMed=17486069; DOI=10.1038/sj.onc.1210501;
RA   Sundvall M., Peri L., Maatta J.A., Tvorogov D., Paatero I.,
RA   Savisalo M., Silvennoinen O., Yarden Y., Elenius K.;
RT   "Differential nuclear localization and kinase activity of alternative
RT   ErbB4 intracellular domains.";
RL   Oncogene 26:6905-6914(2007).
RN   [36]
RP   PHOSPHORYLATION AT TYR-875; TYR-1035; TYR-1056; TYR-1150; TYR-1162;
RP   TYR-1188; TYR-1202; TYR-1242; TYR-1258 AND TYR-1284, INTERACTION WITH
RP   PIK3R1 AND STAT1, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=18721752; DOI=10.1016/j.chembiol.2008.07.006;
RA   Kaushansky A., Gordus A., Budnik B.A., Lane W.S., Rush J.,
RA   MacBeath G.;
RT   "System-wide investigation of ErbB4 reveals 19 sites of Tyr
RT   phosphorylation that are unusually selective in their recruitment
RT   properties.";
RL   Chem. Biol. 15:808-817(2008).
RN   [37]
RP   INTERACTION WITH NEDD4, SUBCELLULAR LOCATION, AND UBIQUITINATION OF
RP   E4ICD1.
RX   PubMed=19193720; DOI=10.1096/fj.08-121947;
RA   Zeng F., Xu J., Harris R.C.;
RT   "Nedd4 mediates ErbB4 JM-a/CYT-1 ICD ubiquitination and degradation in
RT   MDCK II cells.";
RL   FASEB J. 23:1935-1945(2009).
RN   [38]
RP   FUNCTION IN ACTIVATION OF SIGNALING PATHWAYS, INTERACTION WITH ERBB2,
RP   CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, PHOSPHORYLATION BY ERBB2,
RP   ENZYME REGULATION, AND MUTAGENESIS OF VAL-721; ALA-773; ARG-782;
RP   GLU-810; PRO-854; ASP-861; GLU-872 AND THR-926.
RX   PubMed=19098003; DOI=10.1074/jbc.M805438200;
RA   Tvorogov D., Sundvall M., Kurppa K., Hollmen M., Repo S.,
RA   Johnson M.S., Elenius K.;
RT   "Somatic mutations of ErbB4: selective loss-of-function phenotype
RT   affecting signal transduction pathways in cancer.";
RL   J. Biol. Chem. 284:5582-5591(2009).
RN   [39]
RP   INTERACTION WITH WWP1, AND MUTAGENESIS OF TYR-1056 AND TYR-1301.
RX   PubMed=19561640; DOI=10.1038/onc.2009.162;
RA   Li Y., Zhou Z., Alimandi M., Chen C.;
RT   "WW domain containing E3 ubiquitin protein ligase 1 targets the full-
RT   length ErbB4 for ubiquitin-mediated degradation in breast cancer.";
RL   Oncogene 28:2948-2958(2009).
RN   [40]
RP   INTERACTION WITH TXNL4A; DDX23; MATR3; RBM15; ILF3; TRIM28; U5S1;
RP   U2SURP; ITCH; HNRPU; AP2A1; NULC; LEO1; WWP2; MDM2; HXK1 AND ARS2,
RP   FUNCTION, SUBCELLULAR LOCATION, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RX   PubMed=20858735; DOI=10.1158/1541-7786.MCR-10-0042;
RA   Gilmore-Hebert M., Ramabhadran R., Stern D.F.;
RT   "Interactions of ErbB4 and Kap1 connect the growth factor and DNA
RT   damage response pathways.";
RL   Mol. Cancer Res. 8:1388-1398(2010).
RN   [41]
RP   ENZYME REGULATION.
RX   PubMed=21439954; DOI=10.1016/j.yexcr.2011.03.015;
RA   Carrasco-Garcia E., Saceda M., Grasso S., Rocamora-Reverte L.,
RA   Conde M., Gomez-Martinez A., Garcia-Morales P., Ferragut J.A.,
RA   Martinez-Lacaci I.;
RT   "Small tyrosine kinase inhibitors interrupt EGFR signaling by
RT   interacting with erbB3 and erbB4 in glioblastoma cell lines.";
RL   Exp. Cell Res. 317:1476-1489(2011).
RN   [42]
RP   REVIEW ON ROLE IN BREAST AND NEURAL DEVELOPMENT.
RX   PubMed=14504474;
RA   Jones F.E., Golding J.P., Gassmann M.;
RT   "ErbB4 signaling during breast and neural development: novel genetic
RT   models reveal unique ErbB4 activities.";
RL   Cell Cycle 2:555-559(2003).
RN   [43]
RP   REVIEW.
RX   PubMed=15944951;
RA   Zaczek A., Brandt B., Bielawski K.P.;
RT   "The diverse signaling network of EGFR, HER2, HER3 and HER4 tyrosine
RT   kinase receptors and the consequences for therapeutic approaches.";
RL   Histol. Histopathol. 20:1005-1015(2005).
RN   [44]
RP   REVIEW ON ROLE IN MAMMARY GLAND DEVELOPMENT.
RX   PubMed=18437540; DOI=10.1007/s10911-008-9080-x;
RA   Muraoka-Cook R.S., Feng S.M., Strunk K.E., Earp H.S. III;
RT   "ErbB4/HER4: role in mammary gland development, differentiation and
RT   growth inhibition.";
RL   J. Mammary Gland Biol. Neoplasia 13:235-246(2008).
RN   [45]
RP   REVIEW ON ROLE OF THE ERBB4 INTRACELLULAR DOMAIN.
RX   PubMed=18473151; DOI=10.1007/s10911-008-9076-6;
RA   Jones F.E.;
RT   "HER4 intracellular domain (4ICD) activity in the developing mammary
RT   gland and breast cancer.";
RL   J. Mammary Gland Biol. Neoplasia 13:247-258(2008).
RN   [46]
RP   REVIEW ON LIGAND SPECIFICITY AND SIGNALING.
RX   PubMed=18454307; DOI=10.1007/s10911-008-9079-3;
RA   Sundvall M., Iljin K., Kilpinen S., Sara H., Kallioniemi O.P.,
RA   Elenius K.;
RT   "Role of ErbB4 in breast cancer.";
RL   J. Mammary Gland Biol. Neoplasia 13:259-268(2008).
RN   [47]
RP   REVIEW ON ROLE IN NRG1 SIGNALING AND CARDIOVASCULAR HEALTH.
RX   PubMed=20933198; DOI=10.1016/S1054-3589(10)59002-1;
RA   Xu Y., Li X., Liu X., Zhou M.;
RT   "Neuregulin-1/ErbB signaling and chronic heart failure.";
RL   Adv. Pharmacol. 59:31-51(2010).
RN   [48]
RP   REVIEW ON ALTERNATIVE SPLICING AND PROTEOLYTIC PROCESSING; TISSUE
RP   SPECIFICITY; SIGNALING AND ROLE IN DISEASE.
RX   PubMed=21811097;
RA   Veikkolainen V., Vaparanta K., Halkilahti K., Iljin K., Sundvall M.,
RA   Elenius K.;
RT   "Function of ERBB4 is determined by alternative splicing.";
RL   Cell Cycle 10:2647-2657(2011).
RN   [49]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 26-641, DISULFIDE BONDS, AND
RP   GLYCOSYLATION AT ASN-138; ASN-174; ASN-253; ASN-358; ASN-410; ASN-473;
RP   ASN-495 AND ASN-576.
RX   PubMed=16203964; DOI=10.1073/pnas.0507591102;
RA   Bouyain S., Longo P.A., Li S., Ferguson K.M., Leahy D.J.;
RT   "The extracellular region of ErbB4 adopts a tethered conformation in
RT   the absence of ligand.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:15024-15029(2005).
RN   [50]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 690-999 IN COMPLEX WITH
RP   INHIBITOR, CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, AND MUTAGENESIS OF
RP   LEU-710; MET-766; LEU-864 AND ILE-947.
RX   PubMed=18287036; DOI=10.1073/pnas.0708281105;
RA   Wood E.R., Shewchuk L.M., Ellis B., Brignola P., Brashear R.L.,
RA   Caferro T.R., Dickerson S.H., Dickson H.D., Donaldson K.H., Gaul M.,
RA   Griffin R.J., Hassell A.M., Keith B., Mullin R., Petrov K.G.,
RA   Reno M.J., Rusnak D.W., Tadepalli S.M., Ulrich J.C., Wagner C.D.,
RA   Vanderwall D.E., Waterson A.G., Williams J.D., White W.L.,
RA   Uehling D.E.;
RT   "6-Ethynylthieno[3,2-d]- and 6-ethynylthieno[2,3-d]pyrimidin-4-
RT   anilines as tunable covalent modifiers of ErbB kinases.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:2773-2778(2008).
RN   [51]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 702-1029 OF APOPROTEIN AND IN
RP   COMPLEX WITH LAPATINIB, CATALYTIC ACTIVITY, ENZYME REGULATION,
RP   AUTOPHOSPHORYLATION, AND SUBUNIT.
RX   PubMed=18334220; DOI=10.1016/j.str.2007.12.016;
RA   Qiu C., Tarrant M.K., Choi S.H., Sathyamurthy A., Bose R., Banjade S.,
RA   Pal A., Bornmann W.G., Lemmon M.A., Cole P.A., Leahy D.J.;
RT   "Mechanism of activation and inhibition of the HER4/ErbB4 kinase.";
RL   Structure 16:460-467(2008).
RN   [52]
RP   VARIANTS [LARGE SCALE ANALYSIS] ILE-140 AND TYR-303.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [53]
RP   VARIANTS ALS19 GLN-927 AND TRP-1275, AND CHARACTERIZATION OF VARIANTS
RP   ASL19 GLN-927 AND TRP-1275.
RX   PubMed=24119685; DOI=10.1016/j.ajhg.2013.09.008;
RA   Takahashi Y., Fukuda Y., Yoshimura J., Toyoda A., Kurppa K.,
RA   Moritoyo H., Belzil V.V., Dion P.A., Higasa K., Doi K., Ishiura H.,
RA   Mitsui J., Date H., Ahsan B., Matsukawa T., Ichikawa Y., Moritoyo T.,
RA   Ikoma M., Hashimoto T., Kimura F., Murayama S., Onodera O.,
RA   Nishizawa M., Yoshida M., Atsuta N., Sobue G., Fifita J.A.,
RA   Williams K.L., Blair I.P., Nicholson G.A., Gonzalez-Perez P.,
RA   Brown R.H. Jr., Nomoto M., Elenius K., Rouleau G.A., Fujiyama A.,
RA   Morishita S., Goto J., Tsuji S., Nakamura R., Watanabe H., Izumi Y.,
RA   Kaji R., Morita M., Ogaki K., Taniguchi A., Aiba I., Mizoguchi K.,
RA   Okamoto K., Hasegawa K., Aoki M., Kawata A., Nakano I., Abe K.,
RA   Oda M., Konagaya M., Imai T., Nakagawa M., Fujita T., Sasaki H.,
RA   Nishizawa M.;
RT   "ERBB4 mutations that disrupt the neuregulin-ErbB4 pathway cause
RT   amyotrophic lateral sclerosis type 19.";
RL   Am. J. Hum. Genet. 93:900-905(2013).
CC   -!- FUNCTION: Tyrosine-protein kinase that plays an essential role as
CC       cell surface receptor for neuregulins and EGF family members and
CC       regulates development of the heart, the central nervous system and
CC       the mammary gland, gene transcription, cell proliferation,
CC       differentiation, migration and apoptosis. Required for normal
CC       cardiac muscle differentiation during embryonic development, and
CC       for postnatal cardiomyocyte proliferation. Required for normal
CC       development of the embryonic central nervous system, especially
CC       for normal neural crest cell migration and normal axon guidance.
CC       Required for mammary gland differentiation, induction of milk
CC       proteins and lactation. Acts as cell-surface receptor for the
CC       neuregulins NRG1, NRG2, NRG3 and NRG4 and the EGF family members
CC       BTC, EREG and HBEGF. Ligand binding triggers receptor dimerization
CC       and autophosphorylation at specific tyrosine residues that then
CC       serve as binding sites for scaffold proteins and effectors. Ligand
CC       specificity and signaling is modulated by alternative splicing,
CC       proteolytic processing, and by the formation of heterodimers with
CC       other ERBB family members, thereby creating multiple combinations
CC       of intracellular phosphotyrosines that trigger ligand- and
CC       context-specific cellular responses. Mediates phosphorylation of
CC       SHC1 and activation of the MAP kinases MAPK1/ERK2 and MAPK3/ERK1.
CC       Isoform JM-A CYT-1 and isoform JM-B CYT-1 phosphorylate PIK3R1,
CC       leading to the activation of phosphatidylinositol 3-kinase and
CC       AKT1 and protect cells against apoptosis. Isoform JM-A CYT-1 and
CC       isoform JM-B CYT-1 mediate reorganization of the actin
CC       cytoskeleton and promote cell migration in response to NRG1.
CC       Isoform JM-A CYT-2 and isoform JM-B CYT-2 lack the phosphotyrosine
CC       that mediates interaction with PIK3R1, and hence do not
CC       phosphorylate PIK3R1, do not protect cells against apoptosis, and
CC       do not promote reorganization of the actin cytoskeleton and cell
CC       migration. Proteolytic processing of isoform JM-A CYT-1 and
CC       isoform JM-A CYT-2 gives rise to the corresponding soluble
CC       intracellular domains (4ICD) that translocate to the nucleus,
CC       promote nuclear import of STAT5A, activation of STAT5A, mammary
CC       epithelium differentiation, cell proliferation and activation of
CC       gene expression. The ERBB4 soluble intracellular domains (4ICD)
CC       colocalize with STAT5A at the CSN2 promoter to regulate
CC       transcription of milk proteins during lactation. The ERBB4 soluble
CC       intracellular domains can also translocate to mitochondria and
CC       promote apoptosis. {ECO:0000269|PubMed:10348342,
CC       ECO:0000269|PubMed:10353604, ECO:0000269|PubMed:10358079,
CC       ECO:0000269|PubMed:10722704, ECO:0000269|PubMed:10867024,
CC       ECO:0000269|PubMed:11178955, ECO:0000269|PubMed:11390655,
CC       ECO:0000269|PubMed:12807903, ECO:0000269|PubMed:15534001,
CC       ECO:0000269|PubMed:15746097, ECO:0000269|PubMed:16251361,
CC       ECO:0000269|PubMed:16778220, ECO:0000269|PubMed:16837552,
CC       ECO:0000269|PubMed:17486069, ECO:0000269|PubMed:17638867,
CC       ECO:0000269|PubMed:19098003, ECO:0000269|PubMed:20858735,
CC       ECO:0000269|PubMed:8383326, ECO:0000269|PubMed:8617750,
CC       ECO:0000269|PubMed:9135143, ECO:0000269|PubMed:9168115,
CC       ECO:0000269|PubMed:9334263}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028, ECO:0000269|PubMed:18287036,
CC       ECO:0000269|PubMed:18334220, ECO:0000269|PubMed:19098003,
CC       ECO:0000269|PubMed:8617750}.
CC   -!- ENZYME REGULATION: Binding of a cognate ligand leads to
CC       dimerization and activation by autophosphorylation on tyrosine
CC       residues. In vitro kinase activity is increased by Mg(2+).
CC       Inhibited by PD153035, lapatinib, gefitinib (iressa, ZD1839),
CC       AG1478 and BIBX1382BS. {ECO:0000269|PubMed:11178955,
CC       ECO:0000269|PubMed:18334220, ECO:0000269|PubMed:19098003,
CC       ECO:0000269|PubMed:21439954, ECO:0000269|PubMed:8617750}.
CC   -!- SUBUNIT: Monomer in the absence of bound ligand. Homodimer or
CC       heterodimer with another ERBB family member upon ligand binding,
CC       thus forming heterotetramers. Interacts with EGFR and ERBB2.
CC       Interacts with CBFA2T3 (By similarity). Interacts with DLG2 (via
CC       its PDZ domain), DLG3 (via its PDZ domain), DLG4 (via its PDZ
CC       domain) and SNTB2 (via its PDZ domain). Interacts with MUC1.
CC       Interacts (via its PPxy motifs) with WWOX. Interacts (via the PPxY
CC       motif 3 of isoform JM-A CYT-2) with YAP1 (via the WW domain 1 of
CC       isoform 1). Interacts (isoform JM-A CYT-1 and isoform JM-B CYT-1)
CC       with WWP1. Interacts (via its intracellular domain) with TRIM28.
CC       Interacts (via the intracellular domains of both CYT-1 and CYT-2
CC       isoforms) with KAP1; the interaction does not phosphorylate KAP1
CC       but represses ERBB4-mediated transcriptional activity. Interacts
CC       with PRPU, DDX23, MATR3, RBM15, ILF3, KAP1, U5S1, U2SURP, ITCH,
CC       HNRPU, AP2A1, NULC, LEO1, WWP2, IGHG1, HXK1, GRB7 AND ARS2.
CC       Interacts (phosphorylated isoform JM-A CYT-1 and isoform JM-B CYT-
CC       1) with PIK3R1. Interacts with SHC1. Interacts with GRB2.
CC       Interacts (soluble intracellular domain) with STAT5A. Interacts
CC       (soluble intracellular domain) with BCL2. Interacts
CC       (phosphorylated) with STAT1. {ECO:0000250,
CC       ECO:0000269|PubMed:10348342, ECO:0000269|PubMed:10353604,
CC       ECO:0000269|PubMed:10358079, ECO:0000269|PubMed:10725395,
CC       ECO:0000269|PubMed:10867024, ECO:0000269|PubMed:12807903,
CC       ECO:0000269|PubMed:12939402, ECO:0000269|PubMed:15534001,
CC       ECO:0000269|PubMed:16061658, ECO:0000269|PubMed:16778220,
CC       ECO:0000269|PubMed:16815842, ECO:0000269|PubMed:16837552,
CC       ECO:0000269|PubMed:16978839, ECO:0000269|PubMed:18287036,
CC       ECO:0000269|PubMed:18334220, ECO:0000269|PubMed:18721752,
CC       ECO:0000269|PubMed:19098003, ECO:0000269|PubMed:19193720,
CC       ECO:0000269|PubMed:19561640, ECO:0000269|PubMed:20858735,
CC       ECO:0000269|PubMed:7689552, ECO:0000269|PubMed:7902537,
CC       ECO:0000269|PubMed:8570211, ECO:0000269|PubMed:8617750,
CC       ECO:0000269|PubMed:9135143, ECO:0000269|PubMed:9168115,
CC       ECO:0000269|PubMed:9275162, ECO:0000269|PubMed:9419975,
CC       ECO:0000269|PubMed:9516479}.
CC   -!- INTERACTION:
CC       P42684:ABL2; NbExp=4; IntAct=EBI-80371, EBI-1102694;
CC       P78352:DLG4; NbExp=6; IntAct=EBI-80371, EBI-80389;
CC       P00533:EGFR; NbExp=2; IntAct=EBI-80371, EBI-297353;
CC       P04626:ERBB2; NbExp=3; IntAct=EBI-80371, EBI-641062;
CC       P21860:ERBB3; NbExp=4; IntAct=EBI-80371, EBI-720706;
CC       P08238:HSP90AB1; NbExp=2; IntAct=EBI-80371, EBI-352572;
CC       P29353:SHC1; NbExp=2; IntAct=EBI-80371, EBI-78835;
CC       P46937:YAP1; NbExp=3; IntAct=EBI-80371, EBI-1044059;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:10348342,
CC       ECO:0000269|PubMed:12807903, ECO:0000269|PubMed:15534001,
CC       ECO:0000269|PubMed:16251361, ECO:0000269|PubMed:16778220,
CC       ECO:0000269|PubMed:16837552, ECO:0000269|PubMed:17486069,
CC       ECO:0000269|PubMed:17638867, ECO:0000269|PubMed:19193720,
CC       ECO:0000269|PubMed:20858735, ECO:0000269|PubMed:8383326,
CC       ECO:0000269|PubMed:9334263}; Single-pass type I membrane protein
CC       {ECO:0000269|PubMed:10348342, ECO:0000269|PubMed:12807903,
CC       ECO:0000269|PubMed:15534001, ECO:0000269|PubMed:16251361,
CC       ECO:0000269|PubMed:16778220, ECO:0000269|PubMed:16837552,
CC       ECO:0000269|PubMed:17486069, ECO:0000269|PubMed:17638867,
CC       ECO:0000269|PubMed:19193720, ECO:0000269|PubMed:20858735,
CC       ECO:0000269|PubMed:8383326, ECO:0000269|PubMed:9334263}. Note=In
CC       response to NRG1 treatment, the activated receptor is
CC       internalized.
CC   -!- SUBCELLULAR LOCATION: ERBB4 intracellular domain: Nucleus
CC       {ECO:0000269|PubMed:17486069}. Mitochondrion
CC       {ECO:0000269|PubMed:17486069}. Note=Following proteolytical
CC       processing E4ICD (E4ICD1 or E4ICD2 generated from the respective
CC       isoforms) is translocated to the nucleus. Significantly more
CC       E4ICD2 than E4ICD1 is found in the nucleus. E4ICD2 colocalizes
CC       with YAP1 in the nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=JM-A CYT-1;
CC         IsoId=Q15303-1; Sequence=Displayed;
CC         Note=Proteolytical processing generates E4ICD1 (s80Cyt1).;
CC       Name=JM-B CYT-1;
CC         IsoId=Q15303-2; Sequence=VSP_002895;
CC       Name=JM-A CYT-2;
CC         IsoId=Q15303-3; Sequence=VSP_022148;
CC         Note=Proteolytical processing generates E4ICD2 (s80Cyt2).;
CC       Name=JM-B CYT-2;
CC         IsoId=Q15303-4; Sequence=VSP_002895, VSP_022148;
CC   -!- TISSUE SPECIFICITY: Expressed at highest levels in brain, heart,
CC       kidney, in addition to skeletal muscle, parathyroid, cerebellum,
CC       pituitary, spleen, testis and breast. Lower levels in thymus,
CC       lung, salivary gland, and pancreas. Isoform JM-A CYT-1 and isoform
CC       JM-B CYT-1 are expressed in cerebellum, but only the isoform JM-B
CC       is expressed in the heart. {ECO:0000269|PubMed:10353604,
CC       ECO:0000269|PubMed:8383326, ECO:0000269|PubMed:9334263}.
CC   -!- PTM: Isoform JM-A CYT-1 and isoform JM-A CYT-2 are processed by
CC       ADAM17. Proteolytic processing in response to ligand or 12-O-
CC       tetradecanoylphorbol-13-acetate stimulation results in the
CC       production of 120 kDa soluble receptor forms and intermediate
CC       membrane-anchored 80 kDa fragments (m80HER4), which are further
CC       processed by a presenilin-dependent gamma-secretase to release a
CC       cytoplasmic intracellular domain (E4ICD; E4ICD1/s80Cyt1 or
CC       E4ICD2/s80Cyt2, depending on the isoform). Membrane-anchored 80
CC       kDa fragments of the processed isoform JM-A CYT-1 are more readily
CC       degraded by the proteasome than fragments of isoform JM-A CYT-2,
CC       suggesting a prevalence of E4ICD2 over E4ICD1. Isoform JM-B CYT-1
CC       and isoform JM-B CYT-2 lack the ADAM17 cleavage site and are not
CC       processed by ADAM17, precluding further processing by gamma-
CC       secretase. {ECO:0000269|PubMed:10744726,
CC       ECO:0000269|PubMed:12807903, ECO:0000269|PubMed:15746097,
CC       ECO:0000269|PubMed:16837552, ECO:0000269|PubMed:17638867,
CC       ECO:0000269|PubMed:9334263}.
CC   -!- PTM: Autophosphorylated on tyrosine residues in response to ligand
CC       binding. Autophosphorylation occurs in trans, i.e. one subunit of
CC       the dimeric receptor phosphorylates tyrosine residues on the other
CC       subunit. Ligands trigger phosphorylation at specific tyrosine
CC       residues, thereby creating binding sites for scaffold proteins and
CC       effectors. Constitutively phosphorylated at a basal level when
CC       overexpressed in heterologous systems; ligand binding leads to
CC       increased phosphorylation. Phosphorylation at Tyr-1035 is
CC       important for interaction with STAT1. Phosphorylation at Tyr-1056
CC       is important for interaction with PIK3R1. Phosphorylation at Tyr-
CC       1242 is important for interaction with SHC1. Phosphorylation at
CC       Tyr-1188 may also contribute to the interaction with SHC1. Isoform
CC       JM-A CYT-2 is constitutively phosphorylated on tyrosine residues
CC       in a ligand-independent manner. E4ICD2 but not E4ICD1 is
CC       phosphorylated on tyrosine residues. {ECO:0000269|PubMed:16251361,
CC       ECO:0000269|PubMed:17120616, ECO:0000269|PubMed:17486069,
CC       ECO:0000269|PubMed:18721752, ECO:0000269|PubMed:19098003,
CC       ECO:0000269|PubMed:8617750, ECO:0000269|PubMed:9168115}.
CC   -!- PTM: Ubiquitinated. During mitosis, the ERBB4 intracellular domain
CC       is ubiquitinated by the APC/C complex and targeted to proteasomal
CC       degradation. Isoform JM-A CYT-1 and isoform JM-B CYT-1 are
CC       ubiquitinated by WWP1. The ERBB4 intracellular domain (E4ICD1) is
CC       ubiquitinated, and this involves NEDD4.
CC       {ECO:0000269|PubMed:17638867, ECO:0000269|PubMed:19193720}.
CC   -!- DISEASE: Amyotrophic lateral sclerosis 19 (ALS19) [MIM:615515]: A
CC       neurodegenerative disorder affecting upper motor neurons in the
CC       brain and lower motor neurons in the brain stem and spinal cord,
CC       resulting in fatal paralysis. Sensory abnormalities are absent.
CC       The pathologic hallmarks of the disease include pallor of the
CC       corticospinal tract due to loss of motor neurons, presence of
CC       ubiquitin-positive inclusions within surviving motor neurons, and
CC       deposition of pathologic aggregates. The etiology of amyotrophic
CC       lateral sclerosis is likely to be multifactorial, involving both
CC       genetic and environmental factors. The disease is inherited in 5-
CC       10% of the cases. {ECO:0000269|PubMed:24119685}. Note=The disease
CC       is caused by mutations affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. EGF receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- CAUTION: Conflicting reports about the role of ERBB4 in mediating
CC       apoptosis, differentiation, or tumor cell proliferation may be
CC       explained by the opposite functions of the different isoforms and
CC       their intracellular fragments, and by the formation of
CC       heterodimers with other EGF receptor family members
CC       (PubMed:18454307 and PubMed:21811097). Thus, heterodimer formation
CC       of a kinase-dead ERBB4 mutant with ERBB2 is sufficient for the
CC       activation of AKT1, MAPK1/ERK2 and MAPK3/ERK1 (PubMed:19098003).
CC       {ECO:0000305|PubMed:19098003}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L07868; AAB59446.1; -; mRNA.
DR   EMBL; BC112199; AAI12200.1; -; mRNA.
DR   EMBL; BC143741; AAI43742.1; -; mRNA.
DR   EMBL; BC143747; AAI43748.1; -; mRNA.
DR   EMBL; BC143749; AAI43750.1; -; mRNA.
DR   EMBL; AB209697; BAD92934.1; -; mRNA.
DR   CCDS; CCDS2394.1; -. [Q15303-1]
DR   CCDS; CCDS42811.1; -. [Q15303-3]
DR   PIR; A47253; A47253.
DR   RefSeq; NP_001036064.1; NM_001042599.1. [Q15303-3]
DR   RefSeq; NP_005226.1; NM_005235.2. [Q15303-1]
DR   RefSeq; XP_005246433.1; XM_005246376.1. [Q15303-2]
DR   RefSeq; XP_005246434.1; XM_005246377.1. [Q15303-4]
DR   UniGene; Hs.390729; -.
DR   PDB; 2AHX; X-ray; 2.40 A; A/B=26-641.
DR   PDB; 2L2T; NMR; -; A/B=642-685.
DR   PDB; 2LCX; NMR; -; A/B=642-685.
DR   PDB; 2R4B; X-ray; 2.40 A; A/B=690-999.
DR   PDB; 3BBT; X-ray; 2.80 A; B/D=702-1029.
DR   PDB; 3BBW; X-ray; 4.00 A; A/B=702-1029.
DR   PDB; 3BCE; X-ray; 2.50 A; A/B/C=702-1029.
DR   PDB; 3U2P; X-ray; 2.57 A; A=26-522.
DR   PDB; 3U7U; X-ray; 3.03 A; A/B/C/D/E/F=26-640.
DR   PDB; 3U9U; X-ray; 3.42 A; E/F=26-650.
DR   PDBsum; 2AHX; -.
DR   PDBsum; 2L2T; -.
DR   PDBsum; 2LCX; -.
DR   PDBsum; 2R4B; -.
DR   PDBsum; 3BBT; -.
DR   PDBsum; 3BBW; -.
DR   PDBsum; 3BCE; -.
DR   PDBsum; 3U2P; -.
DR   PDBsum; 3U7U; -.
DR   PDBsum; 3U9U; -.
DR   ProteinModelPortal; Q15303; -.
DR   SMR; Q15303; 26-639, 642-1026.
DR   BioGrid; 108378; 46.
DR   DIP; DIP-29650N; -.
DR   IntAct; Q15303; 25.
DR   MINT; MINT-125091; -.
DR   STRING; 9606.ENSP00000342235; -.
DR   BindingDB; Q15303; -.
DR   ChEMBL; CHEMBL2363049; -.
DR   DrugBank; DB08916; Afatinib.
DR   GuidetoPHARMACOLOGY; 1799; -.
DR   TCDB; 1.A.87.2.6; the mechanosensitive calcium channel (mca) family.
DR   iPTMnet; Q15303; -.
DR   PhosphoSite; Q15303; -.
DR   BioMuta; ERBB4; -.
DR   DMDM; 3913590; -.
DR   MaxQB; Q15303; -.
DR   PaxDb; Q15303; -.
DR   PRIDE; Q15303; -.
DR   DNASU; 2066; -.
DR   Ensembl; ENST00000342788; ENSP00000342235; ENSG00000178568. [Q15303-1]
DR   Ensembl; ENST00000436443; ENSP00000403204; ENSG00000178568. [Q15303-3]
DR   GeneID; 2066; -.
DR   KEGG; hsa:2066; -.
DR   UCSC; uc002veg.1; human. [Q15303-1]
DR   UCSC; uc002veh.1; human. [Q15303-3]
DR   UCSC; uc010zji.1; human. [Q15303-2]
DR   UCSC; uc010zjj.1; human. [Q15303-4]
DR   CTD; 2066; -.
DR   GeneCards; ERBB4; -.
DR   HGNC; HGNC:3432; ERBB4.
DR   HPA; CAB000276; -.
DR   HPA; CAB025522; -.
DR   HPA; HPA012016; -.
DR   MalaCards; ERBB4; -.
DR   MIM; 600543; gene.
DR   MIM; 615515; phenotype.
DR   neXtProt; NX_Q15303; -.
DR   Orphanet; 803; Amyotrophic lateral sclerosis.
DR   PharmGKB; PA27847; -.
DR   eggNOG; KOG1025; Eukaryota.
DR   eggNOG; ENOG410XNSR; LUCA.
DR   GeneTree; ENSGT00760000118799; -.
DR   HOGENOM; HOG000230982; -.
DR   HOVERGEN; HBG000490; -.
DR   InParanoid; Q15303; -.
DR   KO; K05085; -.
DR   OMA; RTRIDSN; -.
DR   OrthoDB; EOG7V49XM; -.
DR   PhylomeDB; Q15303; -.
DR   TreeFam; TF106002; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   Reactome; R-HSA-1227986; Signaling by ERBB2.
DR   Reactome; R-HSA-1236394; Signaling by ERBB4.
DR   Reactome; R-HSA-1250196; SHC1 events in ERBB2 signaling.
DR   Reactome; R-HSA-1250342; PI3K events in ERBB4 signaling.
DR   Reactome; R-HSA-1250347; SHC1 events in ERBB4 signaling.
DR   Reactome; R-HSA-1251985; Nuclear signaling by ERBB4.
DR   Reactome; R-HSA-1253288; Downregulation of ERBB4 signaling.
DR   Reactome; R-HSA-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-HSA-1963640; GRB2 events in ERBB2 signaling.
DR   Reactome; R-HSA-1963642; PI3K events in ERBB2 signaling.
DR   Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer.
DR   Reactome; R-HSA-5673001; RAF/MAP kinase cascade.
DR   SignaLink; Q15303; -.
DR   ChiTaRS; ERBB4; human.
DR   EvolutionaryTrace; Q15303; -.
DR   GeneWiki; ERBB4; -.
DR   GenomeRNAi; 2066; -.
DR   NextBio; 8397; -.
DR   PMAP-CutDB; Q15303; -.
DR   PRO; PR:Q15303; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   Bgee; Q15303; -.
DR   CleanEx; HS_ERBB4; -.
DR   ExpressionAtlas; Q15303; baseline and differential.
DR   Genevisible; Q15303; HS.
DR   GO; GO:0016323; C:basolateral plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005759; C:mitochondrial matrix; TAS:Reactome.
DR   GO; GO:0005739; C:mitochondrion; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0043235; C:receptor complex; IDA:MGI.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005154; F:epidermal growth factor receptor binding; IPI:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IPI:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0004716; F:receptor signaling protein tyrosine kinase activity; IEA:InterPro.
DR   GO; GO:0044212; F:transcription regulatory region DNA binding; IMP:UniProtKB.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0000186; P:activation of MAPKK activity; TAS:Reactome.
DR   GO; GO:0007411; P:axon guidance; TAS:Reactome.
DR   GO; GO:0061026; P:cardiac muscle tissue regeneration; ISS:UniProtKB.
DR   GO; GO:0045165; P:cell fate commitment; IEA:Ensembl.
DR   GO; GO:0016477; P:cell migration; IDA:UniProtKB.
DR   GO; GO:0008283; P:cell proliferation; TAS:ProtInc.
DR   GO; GO:0021551; P:central nervous system morphogenesis; ISS:UniProtKB.
DR   GO; GO:0009880; P:embryonic pattern specification; ISS:UniProtKB.
DR   GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0008543; P:fibroblast growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0007507; P:heart development; ISS:UniProtKB.
DR   GO; GO:0045087; P:innate immune response; TAS:Reactome.
DR   GO; GO:0008286; P:insulin receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0007595; P:lactation; IMP:UniProtKB.
DR   GO; GO:0060749; P:mammary gland alveolus development; ISS:UniProtKB.
DR   GO; GO:0060644; P:mammary gland epithelial cell differentiation; ISS:UniProtKB.
DR   GO; GO:0000165; P:MAPK cascade; TAS:Reactome.
DR   GO; GO:0043653; P:mitochondrial fragmentation involved in apoptotic process; IMP:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IMP:UniProtKB.
DR   GO; GO:2001223; P:negative regulation of neuron migration; IEA:Ensembl.
DR   GO; GO:0007399; P:nervous system development; ISS:UniProtKB.
DR   GO; GO:0001755; P:neural crest cell migration; ISS:UniProtKB.
DR   GO; GO:0048011; P:neurotrophin TRK receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0021889; P:olfactory bulb interneuron differentiation; ISS:UniProtKB.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0048015; P:phosphatidylinositol-mediated signaling; TAS:Reactome.
DR   GO; GO:0060045; P:positive regulation of cardiac muscle cell proliferation; ISS:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IMP:UniProtKB.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IMP:UniProtKB.
DR   GO; GO:0043552; P:positive regulation of phosphatidylinositol 3-kinase activity; IDA:UniProtKB.
DR   GO; GO:0014068; P:positive regulation of phosphatidylinositol 3-kinase signaling; IEA:Ensembl.
DR   GO; GO:2000010; P:positive regulation of protein localization to cell surface; IEA:Ensembl.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; TAS:UniProtKB.
DR   GO; GO:2000366; P:positive regulation of STAT protein import into nucleus; IMP:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IMP:UniProtKB.
DR   GO; GO:0042523; P:positive regulation of tyrosine phosphorylation of Stat5 protein; IMP:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0007265; P:Ras protein signal transduction; TAS:Reactome.
DR   GO; GO:0030334; P:regulation of cell migration; ISS:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; IDA:UniProtKB.
DR   GO; GO:0007264; P:small GTPase mediated signal transduction; TAS:Reactome.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IDA:UniProtKB.
DR   GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; TAS:Reactome.
DR   Gene3D; 3.80.20.20; -; 2.
DR   InterPro; IPR006211; Furin-like_Cys-rich_dom.
DR   InterPro; IPR006212; Furin_repeat.
DR   InterPro; IPR032778; GF_recep_IV.
DR   InterPro; IPR009030; Growth_fac_rcpt_.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR032675; L_dom-like.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR000494; Rcpt_L-dom.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR016245; Tyr_kinase_EGF/ERB/XmrK_rcpt.
DR   Pfam; PF00757; Furin-like; 1.
DR   Pfam; PF14843; GF_recep_IV; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF01030; Recep_L_domain; 2.
DR   PIRSF; PIRSF000619; TyrPK_EGF-R; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00261; FU; 5.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF52058; SSF52058; 2.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF57184; SSF57184; 2.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; Alternative splicing;
KW   Amyotrophic lateral sclerosis; Apoptosis; ATP-binding; Cell membrane;
KW   Complete proteome; Developmental protein; Disease mutation;
KW   Disulfide bond; Glycoprotein; Kinase; Lactation; Membrane;
KW   Mitochondrion; Neurodegeneration; Nucleotide-binding; Nucleus;
KW   Phosphoprotein; Polymorphism; Receptor; Reference proteome; Repeat;
KW   Signal; Transcription; Transcription regulation; Transferase;
KW   Transmembrane; Transmembrane helix; Tyrosine-protein kinase;
KW   Ubl conjugation.
FT   SIGNAL        1     25       {ECO:0000255}.
FT   CHAIN        26   1308       Receptor tyrosine-protein kinase erbB-4.
FT                                /FTId=PRO_0000016674.
FT   CHAIN       676   1308       ERBB4 intracellular domain.
FT                                {ECO:0000250}.
FT                                /FTId=PRO_0000396797.
FT   TOPO_DOM     26    651       Extracellular. {ECO:0000255}.
FT   TRANSMEM    652    675       Helical. {ECO:0000255}.
FT   TOPO_DOM    676   1308       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      718    985       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     724    732       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     797    799       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     843    848       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOTIF       676    684       Nuclear localization signal.
FT   MOTIF      1032   1035       PPxY motif 1.
FT   MOTIF      1053   1056       PPxY motif 2.
FT   MOTIF      1298   1301       PPxY motif 3.
FT   MOTIF      1306   1308       PDZ-binding.
FT   COMPBIAS    186    334       Cys-rich.
FT   COMPBIAS    496    633       Cys-rich.
FT   ACT_SITE    843    843       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING     751    751       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES     875    875       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:18721752}.
FT   MOD_RES    1035   1035       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:18721752}.
FT   MOD_RES    1056   1056       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:17120616,
FT                                ECO:0000269|PubMed:18721752,
FT                                ECO:0000269|PubMed:8617750}.
FT   MOD_RES    1150   1150       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:18721752}.
FT   MOD_RES    1162   1162       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:18721752}.
FT   MOD_RES    1188   1188       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:18721752,
FT                                ECO:0000269|PubMed:8617750}.
FT   MOD_RES    1202   1202       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:18721752}.
FT   MOD_RES    1242   1242       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:18721752,
FT                                ECO:0000269|PubMed:8617750}.
FT   MOD_RES    1258   1258       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:18721752}.
FT   MOD_RES    1284   1284       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:18721752}.
FT   CARBOHYD    138    138       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16203964}.
FT   CARBOHYD    174    174       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16203964}.
FT   CARBOHYD    181    181       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    253    253       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16203964}.
FT   CARBOHYD    358    358       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16203964}.
FT   CARBOHYD    410    410       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16203964}.
FT   CARBOHYD    473    473       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16203964}.
FT   CARBOHYD    495    495       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16203964}.
FT   CARBOHYD    548    548       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    576    576       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16203964}.
FT   CARBOHYD    620    620       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     29     56       {ECO:0000269|PubMed:16203964}.
FT   DISULFID    156    186       {ECO:0000269|PubMed:16203964}.
FT   DISULFID    189    197       {ECO:0000269|PubMed:16203964}.
FT   DISULFID    193    205       {ECO:0000269|PubMed:16203964}.
FT   DISULFID    213    221       {ECO:0000269|PubMed:16203964}.
FT   DISULFID    217    229       {ECO:0000269|PubMed:16203964}.
FT   DISULFID    230    238       {ECO:0000269|PubMed:16203964}.
FT   DISULFID    234    246       {ECO:0000269|PubMed:16203964}.
FT   DISULFID    249    258       {ECO:0000269|PubMed:16203964}.
FT   DISULFID    262    289       {ECO:0000269|PubMed:16203964}.
FT   DISULFID    293    304       {ECO:0000269|PubMed:16203964}.
FT   DISULFID    308    323       {ECO:0000269|PubMed:16203964}.
FT   DISULFID    326    330       {ECO:0000269|PubMed:16203964}.
FT   DISULFID    503    512       {ECO:0000269|PubMed:16203964}.
FT   DISULFID    507    520       {ECO:0000269|PubMed:16203964}.
FT   DISULFID    523    532       {ECO:0000269|PubMed:16203964}.
FT   DISULFID    536    552       {ECO:0000269|PubMed:16203964}.
FT   DISULFID    555    569       {ECO:0000269|PubMed:16203964}.
FT   DISULFID    559    577       {ECO:0000269|PubMed:16203964}.
FT   DISULFID    580    589       {ECO:0000269|PubMed:16203964}.
FT   DISULFID    593    614       {ECO:0000269|PubMed:16203964}.
FT   DISULFID    617    625       {ECO:0000269|PubMed:16203964}.
FT   DISULFID    621    633       {ECO:0000269|PubMed:16203964}.
FT   VAR_SEQ     626    648       NGPTSHDCIYYPWTGHSTLPQHA -> IGSSIEDCIGLMD
FT                                (in isoform JM-B CYT-1 and isoform JM-B
FT                                CYT-2). {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:9334263}.
FT                                /FTId=VSP_002895.
FT   VAR_SEQ    1046   1061       Missing (in isoform JM-A CYT-2 and
FT                                isoform JM-B CYT-2).
FT                                {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|Ref.4}.
FT                                /FTId=VSP_022148.
FT   VARIANT     140    140       T -> I (in a colorectal adenocarcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042113.
FT   VARIANT     303    303       S -> Y (in a lung squamous cell carcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042114.
FT   VARIANT     927    927       R -> Q (in ALS19; reduces
FT                                autophosphorylation upon NRG1
FT                                stimulation).
FT                                {ECO:0000269|PubMed:24119685}.
FT                                /FTId=VAR_070810.
FT   VARIANT    1275   1275       R -> W (in ALS19; reduces
FT                                autophosphorylation upon NRG1
FT                                stimulation).
FT                                {ECO:0000269|PubMed:24119685}.
FT                                /FTId=VAR_070811.
FT   MUTAGEN     646    646       Q->C: Constitutively activated kinase.
FT                                {ECO:0000269|PubMed:17120616}.
FT   MUTAGEN     675    675       V->A: Abolishes proteolytic processing
FT                                and nuclear localization.
FT                                {ECO:0000269|PubMed:15746097,
FT                                ECO:0000269|PubMed:17638867}.
FT   MUTAGEN     681    684       KKKR->EIMG: Abolishes nuclear
FT                                localization of the ERBB4 intracellular
FT                                domain. {ECO:0000269|PubMed:15534001}.
FT   MUTAGEN     710    710       L->N: Strongly reduced
FT                                autophosphorylation.
FT                                {ECO:0000269|PubMed:18287036}.
FT   MUTAGEN     721    721       V->I: No effect on kinase activity.
FT                                {ECO:0000269|PubMed:19098003}.
FT   MUTAGEN     751    751       K->R: Abolishes kinase activity.
FT                                Abolishes phosphorylation, proteolytic
FT                                processing and nuclear localization.
FT                                {ECO:0000269|PubMed:11390655,
FT                                ECO:0000269|PubMed:17486069,
FT                                ECO:0000269|PubMed:17638867}.
FT   MUTAGEN     766    766       M->R: Strongly reduced
FT                                autophosphorylation.
FT                                {ECO:0000269|PubMed:18287036}.
FT   MUTAGEN     773    773       A->S: No effect on kinase activity.
FT                                {ECO:0000269|PubMed:19098003}.
FT   MUTAGEN     782    782       R->Q: No effect on kinase activity.
FT                                {ECO:0000269|PubMed:19098003}.
FT   MUTAGEN     810    810       E->K: No effect on kinase activity.
FT                                {ECO:0000269|PubMed:19098003}.
FT   MUTAGEN     843    843       D->N: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:16978839}.
FT   MUTAGEN     854    854       P->Q: No effect on kinase activity.
FT                                {ECO:0000269|PubMed:19098003}.
FT   MUTAGEN     861    861       D->Y: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:19098003}.
FT   MUTAGEN     864    864       L->R: Strongly reduced
FT                                autophosphorylation.
FT                                {ECO:0000269|PubMed:18287036}.
FT   MUTAGEN     872    872       E->K: No effect on kinase activity.
FT                                {ECO:0000269|PubMed:19098003}.
FT   MUTAGEN     926    926       T->M: No effect on kinase activity.
FT                                {ECO:0000269|PubMed:19098003}.
FT   MUTAGEN     947    947       I->R: Constitutively autophosphorylated.
FT                                {ECO:0000269|PubMed:18287036}.
FT   MUTAGEN     992    992       R->A: Abolishes APC/C-mediated
FT                                degradation; when associated with A-995
FT                                and A-1000.
FT                                {ECO:0000269|PubMed:17638867}.
FT   MUTAGEN     995    995       L->A: Abolishes APC/C-mediated
FT                                degradation; when associated with A-992
FT                                and A-1000.
FT                                {ECO:0000269|PubMed:17638867}.
FT   MUTAGEN    1000   1000       D->A: Abolishes APC/C-mediated
FT                                degradation; when associated with A-992
FT                                and A-995. {ECO:0000269|PubMed:17638867}.
FT   MUTAGEN    1035   1035       Y->A: No effect on interaction with WWOX.
FT                                Abolishes interaction with WWOX; when
FT                                associated with A-1301.
FT                                {ECO:0000269|PubMed:16061658}.
FT   MUTAGEN    1056   1056       Y->A: Abolishes interaction with NEDD4
FT                                and impairs ubiquitination. Promotes
FT                                nuclear translocation of ERBB4
FT                                intracellular domain E4ICD1.
FT                                {ECO:0000269|PubMed:19561640}.
FT   MUTAGEN    1056   1056       Y->F: Abolishes interaction with WWP1;
FT                                when associated with F-1301.
FT                                {ECO:0000269|PubMed:19561640}.
FT   MUTAGEN    1301   1301       Y->A: Abolishes interaction with NEDD4
FT                                and impairs ubiquitination.
FT                                {ECO:0000269|PubMed:12807903,
FT                                ECO:0000269|PubMed:16061658,
FT                                ECO:0000269|PubMed:19561640}.
FT   MUTAGEN    1301   1301       Y->A: No effect on interaction with WWOX.
FT                                Abolishes interaction with WWOX; when
FT                                associated with A-1035. Loss of
FT                                interaction with YAP1 and stimulation of
FT                                transcription.
FT                                {ECO:0000269|PubMed:12807903,
FT                                ECO:0000269|PubMed:16061658,
FT                                ECO:0000269|PubMed:19561640}.
FT   MUTAGEN    1301   1301       Y->F: Abolishes interaction with WWP1;
FT                                when associated with F-1056.
FT                                {ECO:0000269|PubMed:12807903,
FT                                ECO:0000269|PubMed:16061658,
FT                                ECO:0000269|PubMed:19561640}.
FT   STRAND       28     30       {ECO:0000244|PDB:2AHX}.
FT   STRAND       38     41       {ECO:0000244|PDB:3U7U}.
FT   HELIX        42     53       {ECO:0000244|PDB:2AHX}.
FT   STRAND       57     61       {ECO:0000244|PDB:2AHX}.
FT   STRAND       63     67       {ECO:0000244|PDB:2AHX}.
FT   HELIX        75     79       {ECO:0000244|PDB:2AHX}.
FT   STRAND       82     85       {ECO:0000244|PDB:2AHX}.
FT   STRAND       87     91       {ECO:0000244|PDB:2AHX}.
FT   STRAND       95     98       {ECO:0000244|PDB:2AHX}.
FT   TURN        112    114       {ECO:0000244|PDB:2AHX}.
FT   STRAND      115    120       {ECO:0000244|PDB:2AHX}.
FT   STRAND      125    128       {ECO:0000244|PDB:3U2P}.
FT   STRAND      133    135       {ECO:0000244|PDB:2AHX}.
FT   STRAND      144    150       {ECO:0000244|PDB:2AHX}.
FT   HELIX       158    160       {ECO:0000244|PDB:2AHX}.
FT   HELIX       163    165       {ECO:0000244|PDB:2AHX}.
FT   HELIX       173    175       {ECO:0000244|PDB:2AHX}.
FT   STRAND      176    178       {ECO:0000244|PDB:2AHX}.
FT   TURN        191    193       {ECO:0000244|PDB:2AHX}.
FT   STRAND      197    201       {ECO:0000244|PDB:2AHX}.
FT   HELIX       202    204       {ECO:0000244|PDB:2AHX}.
FT   STRAND      221    225       {ECO:0000244|PDB:2AHX}.
FT   HELIX       226    228       {ECO:0000244|PDB:2AHX}.
FT   STRAND      234    242       {ECO:0000244|PDB:2AHX}.
FT   STRAND      245    254       {ECO:0000244|PDB:2AHX}.
FT   STRAND      257    261       {ECO:0000244|PDB:2AHX}.
FT   STRAND      265    269       {ECO:0000244|PDB:2AHX}.
FT   TURN        270    273       {ECO:0000244|PDB:2AHX}.
FT   STRAND      274    277       {ECO:0000244|PDB:2AHX}.
FT   STRAND      283    285       {ECO:0000244|PDB:2AHX}.
FT   STRAND      288    292       {ECO:0000244|PDB:2AHX}.
FT   STRAND      298    300       {ECO:0000244|PDB:2AHX}.
FT   STRAND      303    307       {ECO:0000244|PDB:2AHX}.
FT   STRAND      312    317       {ECO:0000244|PDB:2AHX}.
FT   STRAND      320    325       {ECO:0000244|PDB:2AHX}.
FT   STRAND      327    329       {ECO:0000244|PDB:3U2P}.
FT   STRAND      333    335       {ECO:0000244|PDB:2AHX}.
FT   HELIX       340    342       {ECO:0000244|PDB:2AHX}.
FT   TURN        350    352       {ECO:0000244|PDB:2AHX}.
FT   HELIX       353    356       {ECO:0000244|PDB:2AHX}.
FT   STRAND      360    364       {ECO:0000244|PDB:2AHX}.
FT   STRAND      366    368       {ECO:0000244|PDB:2AHX}.
FT   HELIX       370    374       {ECO:0000244|PDB:2AHX}.
FT   HELIX       377    379       {ECO:0000244|PDB:2AHX}.
FT   HELIX       386    394       {ECO:0000244|PDB:2AHX}.
FT   STRAND      397    400       {ECO:0000244|PDB:2AHX}.
FT   STRAND      402    405       {ECO:0000244|PDB:2AHX}.
FT   HELIX       415    417       {ECO:0000244|PDB:2AHX}.
FT   STRAND      432    438       {ECO:0000244|PDB:2AHX}.
FT   STRAND      455    461       {ECO:0000244|PDB:2AHX}.
FT   HELIX       469    471       {ECO:0000244|PDB:2AHX}.
FT   HELIX       474    476       {ECO:0000244|PDB:2AHX}.
FT   STRAND      479    482       {ECO:0000244|PDB:2AHX}.
FT   STRAND      485    487       {ECO:0000244|PDB:2AHX}.
FT   STRAND      489    491       {ECO:0000244|PDB:2AHX}.
FT   HELIX       493    497       {ECO:0000244|PDB:2AHX}.
FT   TURN        498    500       {ECO:0000244|PDB:2AHX}.
FT   STRAND      512    516       {ECO:0000244|PDB:2AHX}.
FT   STRAND      519    528       {ECO:0000244|PDB:2AHX}.
FT   STRAND      531    534       {ECO:0000244|PDB:2AHX}.
FT   STRAND      537    543       {ECO:0000244|PDB:2AHX}.
FT   STRAND      545    548       {ECO:0000244|PDB:2AHX}.
FT   STRAND      551    554       {ECO:0000244|PDB:2AHX}.
FT   STRAND      568    573       {ECO:0000244|PDB:2AHX}.
FT   STRAND      576    585       {ECO:0000244|PDB:2AHX}.
FT   STRAND      588    592       {ECO:0000244|PDB:2AHX}.
FT   STRAND      595    608       {ECO:0000244|PDB:2AHX}.
FT   STRAND      612    616       {ECO:0000244|PDB:2AHX}.
FT   STRAND      625    629       {ECO:0000244|PDB:2AHX}.
FT   HELIX       651    676       {ECO:0000244|PDB:2L2T}.
FT   HELIX       715    717       {ECO:0000244|PDB:2R4B}.
FT   STRAND      718    729       {ECO:0000244|PDB:2R4B}.
FT   STRAND      731    737       {ECO:0000244|PDB:2R4B}.
FT   STRAND      740    743       {ECO:0000244|PDB:3BBT}.
FT   STRAND      746    752       {ECO:0000244|PDB:2R4B}.
FT   HELIX       762    773       {ECO:0000244|PDB:2R4B}.
FT   STRAND      778    780       {ECO:0000244|PDB:3BBT}.
FT   STRAND      783    787       {ECO:0000244|PDB:2R4B}.
FT   STRAND      789    791       {ECO:0000244|PDB:2R4B}.
FT   STRAND      793    797       {ECO:0000244|PDB:2R4B}.
FT   HELIX       804    810       {ECO:0000244|PDB:2R4B}.
FT   HELIX       812    814       {ECO:0000244|PDB:2R4B}.
FT   HELIX       817    836       {ECO:0000244|PDB:2R4B}.
FT   HELIX       846    848       {ECO:0000244|PDB:2R4B}.
FT   STRAND      849    853       {ECO:0000244|PDB:2R4B}.
FT   STRAND      856    859       {ECO:0000244|PDB:2R4B}.
FT   HELIX       864    869       {ECO:0000244|PDB:2R4B}.
FT   HELIX       884    886       {ECO:0000244|PDB:2R4B}.
FT   HELIX       889    893       {ECO:0000244|PDB:2R4B}.
FT   HELIX       899    914       {ECO:0000244|PDB:2R4B}.
FT   TURN        920    923       {ECO:0000244|PDB:2R4B}.
FT   TURN        926    928       {ECO:0000244|PDB:2R4B}.
FT   HELIX       929    934       {ECO:0000244|PDB:2R4B}.
FT   HELIX       947    955       {ECO:0000244|PDB:2R4B}.
FT   HELIX       961    963       {ECO:0000244|PDB:2R4B}.
FT   HELIX       967    977       {ECO:0000244|PDB:2R4B}.
FT   HELIX       981    983       {ECO:0000244|PDB:2R4B}.
SQ   SEQUENCE   1308 AA;  146808 MW;  5E4AE80985D88761 CRC64;
     MKPATGLWVW VSLLVAAGTV QPSDSQSVCA GTENKLSSLS DLEQQYRALR KYYENCEVVM
     GNLEITSIEH NRDLSFLRSV REVTGYVLVA LNQFRYLPLE NLRIIRGTKL YEDRYALAIF
     LNYRKDGNFG LQELGLKNLT EILNGGVYVD QNKFLCYADT IHWQDIVRNP WPSNLTLVST
     NGSSGCGRCH KSCTGRCWGP TENHCQTLTR TVCAEQCDGR CYGPYVSDCC HRECAGGCSG
     PKDTDCFACM NFNDSGACVT QCPQTFVYNP TTFQLEHNFN AKYTYGAFCV KKCPHNFVVD
     SSSCVRACPS SKMEVEENGI KMCKPCTDIC PKACDGIGTG SLMSAQTVDS SNIDKFINCT
     KINGNLIFLV TGIHGDPYNA IEAIDPEKLN VFRTVREITG FLNIQSWPPN MTDFSVFSNL
     VTIGGRVLYS GLSLLILKQQ GITSLQFQSL KEISAGNIYI TDNSNLCYYH TINWTTLFST
     INQRIVIRDN RKAENCTAEG MVCNHLCSSD GCWGPGPDQC LSCRRFSRGR ICIESCNLYD
     GEFREFENGS ICVECDPQCE KMEDGLLTCH GPGPDNCTKC SHFKDGPNCV EKCPDGLQGA
     NSFIFKYADP DRECHPCHPN CTQGCNGPTS HDCIYYPWTG HSTLPQHART PLIAAGVIGG
     LFILVIVGLT FAVYVRRKSI KKKRALRRFL ETELVEPLTP SGTAPNQAQL RILKETELKR
     VKVLGSGAFG TVYKGIWVPE GETVKIPVAI KILNETTGPK ANVEFMDEAL IMASMDHPHL
     VRLLGVCLSP TIQLVTQLMP HGCLLEYVHE HKDNIGSQLL LNWCVQIAKG MMYLEERRLV
     HRDLAARNVL VKSPNHVKIT DFGLARLLEG DEKEYNADGG KMPIKWMALE CIHYRKFTHQ
     SDVWSYGVTI WELMTFGGKP YDGIPTREIP DLLEKGERLP QPPICTIDVY MVMVKCWMID
     ADSRPKFKEL AAEFSRMARD PQRYLVIQGD DRMKLPSPND SKFFQNLLDE EDLEDMMDAE
     EYLVPQAFNI PPPIYTSRAR IDSNRSEIGH SPPPAYTPMS GNQFVYRDGG FAAEQGVSVP
     YRAPTSTIPE APVAQGATAE IFDDSCCNGT LRKPVAPHVQ EDSSTQRYSA DPTVFAPERS
     PRGELDEEGY MTPMRDKPKQ EYLNPVEENP FVSRRKNGDL QALDNPEYHN ASNGPPKAED
     EYVNEPLYLN TFANTLGKAE YLKNNILSMP EKAKKAFDNP DYWNHSLPPR STLQHPDYLQ
     EYSTKYFYKQ NGRIRPIVAE NPEYLSEFSL KPGTVLPPPP YRHRNTVV
//
ID   CO3A1_HUMAN             Reviewed;        1466 AA.
AC   P02461; D2JYH5; D3DPH4; P78429; Q15112; Q16403; Q53S91; Q541P8;
AC   Q6LDB3; Q6LDJ2; Q6LDJ3; Q7KZ56; Q8N6U4; Q9UC88; Q9UC89; Q9UC90;
AC   Q9UC91; R4N3C5; V9GZI1;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 4.
DT   17-FEB-2016, entry version 184.
DE   RecName: Full=Collagen alpha-1(III) chain;
DE   Flags: Precursor;
GN   Name=COL3A1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT GLN-1353.
RC   TISSUE=Skin fibroblast;
RX   PubMed=2764886;
RA   Ala-Kokko L., Kontusaari S., Baldwin C.T., Kuivaniemi H.,
RA   Prockop D.J.;
RT   "Structure of cDNA clones coding for the entire prepro alpha 1 (III)
RT   chain of human type III procollagen. Differences in protein structure
RT   from type I procollagen and conservation of codon preferences.";
RL   Biochem. J. 260:509-516(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1), AND VARIANT GLN-1353.
RX   PubMed=11566270; DOI=10.1016/S0945-053X(01)00145-7;
RA   Valkkila M., Melkoniemi M., Kvist L., Kuivaniemi H., Tromp G.,
RA   Ala-Kokko L.;
RT   "Genomic organization of the human COL3A1 and COL5A2 genes: COL5A2 has
RT   evolved differently than the other minor fibrillar collagen genes.";
RL   Matrix Biol. 20:357-366(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT ARG-726.
RA   Fang H.;
RL   Submitted (JAN-2013) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NHLBI resequencing and genotyping service (RS&G);
RL   Submitted (SEP-2009) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT GLN-1353.
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT
RP   GLN-1353.
RC   TISSUE=Liver;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-176.
RX   PubMed=2777083; DOI=10.1016/0378-1119(89)90228-X;
RA   Benson-Chanda V., Su M.W., Weil D., Chu M.-L., Ramirez F.;
RT   "Cloning and analysis of the 5' portion of the human type-III
RT   procollagen gene (COL3A1).";
RL   Gene 78:255-265(1989).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-170 (ISOFORMS 1/2).
RC   TISSUE=Placenta;
RX   PubMed=3405773; DOI=10.1093/nar/16.14.7201;
RA   Toman D., Ricca G., de Crombrugghe B.;
RT   "Nucleotide sequence of a cDNA coding for the amino-terminal region of
RT   human prepro alpha 1(III) collagen.";
RL   Nucleic Acids Res. 16:7201-7201(1988).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 149-1225 (ISOFORM 1).
RX   PubMed=2780304; DOI=10.1093/nar/17.16.6742;
RA   Janeczko R.A., Ramirez F.;
RT   "Nucleotide and amino acid sequences of the entire human alpha 1 (III)
RT   collagen.";
RL   Nucleic Acids Res. 17:6742-6742(1989).
RN   [11]
RP   PROTEIN SEQUENCE OF 168-398, AND HYDROXYLATION.
RX   PubMed=557335; DOI=10.1021/bi00625a020;
RA   Seyer J.M., Kang A.H.;
RT   "Covalent structure of collagen: amino acid sequence of cyanogen
RT   bromide peptides from the amino-terminal segment of type III collagen
RT   of human liver.";
RL   Biochemistry 16:1158-1164(1977).
RN   [12]
RP   SEQUENCE REVISION.
RA   Seyer J.M.;
RL   Submitted (DEC-1977) to the PIR data bank.
RN   [13]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 186-194 (ISOFORMS 1/2).
RX   PubMed=8317500;
RA   Milewicz D.M., Witz A.M., Smith A.C., Manchester D.K., Waldstein G.,
RA   Byers P.H.;
RT   "Parental somatic and germ-line mosaicism for a multiexon deletion
RT   with unusual endpoints in a type III collagen (COL3A1) allele produces
RT   Ehlers-Danlos syndrome type IV in the heterozygous offspring.";
RL   Am. J. Hum. Genet. 53:62-70(1993).
RN   [14]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 302-423 (ISOFORMS 1/2).
RX   PubMed=7487954;
RA   Chiodo A.A., Sillence D.O., Cole W.G., Bateman J.F.;
RT   "Abnormal type III collagen produced by an exon-17-skipping mutation
RT   of the COL3A1 gene in Ehlers-Danlos syndrome type IV is not
RT   incorporated into the extracellular matrix.";
RL   Biochem. J. 311:939-943(1995).
RN   [15]
RP   PROTEIN SEQUENCE OF 395-416; 579-595; 800-814 AND 1064-1079.
RC   TISSUE=Colon carcinoma;
RX   PubMed=7864881; DOI=10.1006/bbrc.1995.1264;
RA   Minafra I.P., Andriolo M., Basirico L., Aquino A., Minafra S.,
RA   Boutillon M.-M., van der Rest M.;
RT   "Onco-fetal/laminin-binding collagen from colon carcinoma: detection
RT   of new sequences.";
RL   Biochem. Biophys. Res. Commun. 207:852-859(1995).
RN   [16]
RP   PROTEIN SEQUENCE OF 399-727.
RX   PubMed=687591; DOI=10.1021/bi00609a034;
RA   Seyer J.M., Kang A.H.;
RT   "Covalent structure of collagen: amino acid sequence of five
RT   consecutive CNBr peptides from type III collagen of human liver.";
RL   Biochemistry 17:3404-3411(1978).
RN   [17]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 537-605.
RX   PubMed=1672129;
RA   Lee B., Vitale E., Superti-Furga A., Steinmann B., Ramirez F.;
RT   "G to T transversion at position +5 of a splice donor site causes
RT   skipping of the preceding exon in the type III procollagen transcripts
RT   of a patient with Ehlers-Danlos syndrome type IV.";
RL   J. Biol. Chem. 266:5256-5259(1991).
RN   [18]
RP   PROTEIN SEQUENCE OF 728-964.
RX   PubMed=6246925; DOI=10.1021/bi00549a008;
RA   Seyer J.M., Mainardi C., Kang A.H.;
RT   "Covalent structure of collagen: amino acid sequence of alpha 1 (III)-
RT   CB5 from type III collagen of human liver.";
RL   Biochemistry 19:1583-1589(1980).
RN   [19]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] OF 861-1015 (ISOFORM 1).
RX   PubMed=2145268;
RA   Cole W.G., Chiodo A.A., Lamande S.R., Janeczko R., Ramirez F.,
RA   Dahl H.-H.M., Chan D., Bateman J.F.;
RT   "A base substitution at a splice site in the COL3A1 gene causes exon
RT   skipping and generates abnormal type III procollagen in a patient with
RT   Ehlers-Danlos syndrome type IV.";
RL   J. Biol. Chem. 265:17070-17077(1990).
RN   [20]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 950-1466 (ISOFORM 1), AND VARIANT
RP   GLN-1353.
RX   PubMed=3357782; DOI=10.1093/nar/16.5.2337;
RA   Mankoo B.S., Dalgleish R.;
RT   "Human pro alpha 1(III) collagen: cDNA sequence for the 3' end.";
RL   Nucleic Acids Res. 16:2337-2337(1988).
RN   [21]
RP   SEQUENCE REVISION TO 1184.
RX   PubMed=3211760; DOI=10.1093/nar/16.24.11833;
RA   Molyneux K., Dalgleish R.;
RT   "Human type III collagen 'variant' is a cDNA cloning artefact.";
RL   Nucleic Acids Res. 16:11833-11833(1988).
RN   [22]
RP   PROTEIN SEQUENCE OF 965-1200, AND HYDROXYLATION.
RX   PubMed=7016180; DOI=10.1021/bi00512a040;
RA   Seyer J.M., Kang A.H.;
RT   "Covalent structure of collagen: amino acid sequence of alpha 1(III)-
RT   CB9 from type III collagen of human liver.";
RL   Biochemistry 20:2621-2627(1981).
RN   [23]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1065-1466 (ISOFORM 1).
RX   PubMed=6096827; DOI=10.1093/nar/12.24.9383;
RA   Loidl H.R., Brinker J.M., May M., Pihlajaniemi T., Morrow S.,
RA   Rosenbloom J., Myers J.C.;
RT   "Molecular cloning and carboxyl-propeptide analysis of human type III
RT   procollagen.";
RL   Nucleic Acids Res. 12:9383-9394(1984).
RN   [24]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1161-1200 (ISOFORMS 1/2).
RX   PubMed=3754462; DOI=10.1021/bi00354a033;
RA   Miskulin M., Dalgleish R., Kluve-Beckerman B., Rennard S.I.,
RA   Tolstoshev P., Brantly M., Crystal R.G.;
RT   "Human type III collagen gene expression is coordinately modulated
RT   with the type I collagen genes during fibroblast growth.";
RL   Biochemistry 25:1408-1413(1986).
RN   [25]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1165-1196 (ISOFORMS 1/2).
RX   PubMed=3858826; DOI=10.1073/pnas.82.10.3385;
RA   Emanuel B.S., Cannizzaro L.A., Seyer J.M., Myers J.C.;
RT   "Human alpha 1(III) and alpha 2(V) procollagen genes are located on
RT   the long arm of chromosome 2.";
RL   Proc. Natl. Acad. Sci. U.S.A. 82:3385-3389(1985).
RN   [26]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1122-1466 (ISOFORMS 1/2), AND VARIANT
RP   GLN-1353.
RX   PubMed=2579949;
RA   Chu M.-L., Weil D., de Wet W.J., Bernard M.P., Sippola M., Ramirez F.;
RT   "Isolation of cDNA and genomic clones encoding human pro-alpha 1 (III)
RT   collagen. Partial characterization of the 3' end region of the gene.";
RL   J. Biol. Chem. 260:4357-4363(1985).
RN   [27]
RP   REVIEW ON VARIANTS.
RX   PubMed=9101290;
RX   DOI=10.1002/(SICI)1098-1004(1997)9:4<300::AID-HUMU2>3.0.CO;2-9;
RA   Kuivaniemi H., Tromp G., Prockop D.J.;
RT   "Mutations in fibrillar collagens (types I, II, III, and XI), fibril-
RT   associated collagen (type IX), and network-forming collagen (type X)
RT   cause a spectrum of diseases of bone, cartilage, and blood vessels.";
RL   Hum. Mutat. 9:300-315(1997).
RN   [28]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22905912; DOI=10.1021/pr300539b;
RA   Rosenow A., Noben J.P., Jocken J., Kallendrusch S.,
RA   Fischer-Posovszky P., Mariman E.C., Renes J.;
RT   "Resveratrol-induced changes of the human adipocyte secretion
RT   profile.";
RL   J. Proteome Res. 11:4733-4743(2012).
RN   [29]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [30]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 1158-1199, AND INTERCHAIN
RP   DISULFIDE BONDS.
RX   PubMed=18805790; DOI=10.1074/jbc.M805394200;
RA   Boudko S.P., Engel J., Okuyama K., Mizuno K., Bachinger H.P.,
RA   Schumacher M.A.;
RT   "Crystal structure of human type III collagen Gly991-Gly1032 cystine
RT   knot-containing peptide shows both 7/2 and 10/3 triple helical
RT   symmetries.";
RL   J. Biol. Chem. 283:32580-32589(2008).
RN   [31]
RP   X-RAY CRYSTALLOGRAPHY (1.68 ANGSTROMS) OF 1222-1466, PROPEPTIDE,
RP   DISULFIDE BONDS, AND CALCIUM-BINDING SITES.
RX   PubMed=23001006; DOI=10.1038/nsmb.2389;
RA   Bourhis J.M., Mariano N., Zhao Y., Harlos K., Exposito J.Y.,
RA   Jones E.Y., Moali C., Aghajari N., Hulmes D.J.;
RT   "Structural basis of fibrillar collagen trimerization and related
RT   genetic disorders.";
RL   Nat. Struct. Mol. Biol. 19:1031-1036(2012).
RN   [32]
RP   VARIANT AAA ARG-303, AND VARIANT THR-668.
RX   PubMed=8514866; DOI=10.1172/JCI116490;
RA   Tromp G., Wu Y., Prockop D.J., Madhatheri S.L., Kleinert C.,
RA   Earley J.J., Zhuang J., Noerrgaard O., Darling R.C., Abbott W.M.,
RA   Cole C.W., Jaakkola P., Ryynaenen M., Pearce W.H., Yao J.S.T.,
RA   Majamaa K., Smullens S.N., Gatalica Z., Ferrell R.E., Jimenez S.A.,
RA   Jackson C.E., Michels V.V., Kaye M., Kuivaniemi H.;
RT   "Sequencing of cDNA from 50 unrelated patients reveals that mutations
RT   in the triple-helical domain of type III procollagen are an infrequent
RT   cause of aortic aneurysms.";
RL   J. Clin. Invest. 91:2539-2545(1993).
RN   [33]
RP   VARIANT THR-698.
RX   PubMed=2235526; DOI=10.1093/nar/18.20.6180;
RA   Zafarullah K., Kleinert C., Tromp G., Kuivaniemi H., Kontusaari S.,
RA   Wu Y., Ganguly A., Prockop D.J.;
RT   "G to A polymorphism in exon 31 of the COL3A1 gene.";
RL   Nucleic Acids Res. 18:6180-6180(1990).
RN   [34]
RP   VARIANT AAA ARG-786.
RX   PubMed=2243125; DOI=10.1172/JCI114863;
RA   Kontusaari S., Tromp G., Kuivaniemi H., Romanic A.M., Prockop D.J.;
RT   "A mutation in the gene for type III procollagen (COL3A1) in a family
RT   with aortic aneurysms.";
RL   J. Clin. Invest. 86:1465-1473(1990).
RN   [35]
RP   VARIANT EDS4 830-PRO--PRO-838 DEL.
RX   PubMed=1370809; DOI=10.1007/BF00197268;
RA   Richards A.J., Lloyd J.C., Narcisi P., Ward P.N., Nicholls A.C.,
RA   De Paepe A., Pope F.M.;
RT   "A 27-bp deletion from one allele of the type III collagen gene
RT   (COL3A1) in a large family with Ehlers-Danlos syndrome type IV.";
RL   Hum. Genet. 88:325-330(1992).
RN   [36]
RP   VARIANT EDS4 ARG-828.
RX   PubMed=8411057; DOI=10.1136/jmg.30.8.690;
RA   Richards A.J., Narcisi P., Lloyd J.C., Ferguson C., Pope F.M.;
RT   "The substitution of glycine 661 by arginine in type III collagen
RT   produces mutant molecules with different thermal stabilities and
RT   causes Ehlers-Danlos syndrome type IV.";
RL   J. Med. Genet. 30:690-693(1993).
RN   [37]
RP   VARIANT EDS4 SER-957.
RX   PubMed=2492273;
RA   Tromp G., Kuivaniemi H., Shikata H., Prockop D.J.;
RT   "A single base mutation that substitutes serine for glycine 790 of the
RT   alpha 1 (III) chain of type III procollagen exposes an arginine and
RT   causes Ehlers-Danlos syndrome IV.";
RL   J. Biol. Chem. 264:1349-1352(1989).
RN   [38]
RP   VARIANT EDS4 VAL-960.
RX   PubMed=7749417; DOI=10.1002/humu.1380050213;
RA   Tromp G., de Paepe A., Nuytinck L., Madhatheri S.L., Kuivaniemi H.;
RT   "Substitution of valine for glycine 793 in type III procollagen in
RT   Ehlers-Danlos syndrome type IV.";
RL   Hum. Mutat. 5:179-181(1995).
RN   [39]
RP   VARIANT EDS4 GLU-1014.
RX   PubMed=1352273; DOI=10.1007/BF00194313;
RA   Richards A.J., Ward P.N., Narcisi P., Nicholls A.C., Lloyd J.C.,
RA   Pope F.M.;
RT   "A single base mutation in the gene for type III collagen (COL3A1)
RT   converts glycine 847 to glutamic acid in a family with Ehlers-Danlos
RT   syndrome type IV. An unaffected family member is mosaic for the
RT   mutation.";
RL   Hum. Genet. 89:414-418(1992).
RN   [40]
RP   VARIANT EDS4 ASP-1050.
RX   PubMed=2808425;
RA   Tromp G., Kuivaniemi H., Stolle C.A., Pope F.M., Prockop D.J.;
RT   "Single base mutation in the type III procollagen gene that converts
RT   the codon for glycine 883 to aspartate in a mild variant of Ehlers-
RT   Danlos syndrome IV.";
RL   J. Biol. Chem. 264:19313-19317(1989).
RN   [41]
RP   VARIANT AAA ARG-786.
RX   PubMed=2349939;
RA   Kontusaari S., Tromp G., Kuivaniemi H., Ladda R.L., Prockop D.J.;
RT   "Inheritance of an RNA splicing mutation (G+ 1 IVS20) in the type III
RT   procollagen gene (COL3A1) in a family having aortic aneurysms and easy
RT   bruisability: phenotypic overlap between familial arterial aneurysms
RT   and Ehlers-Danlos syndrome type IV.";
RL   Am. J. Hum. Genet. 47:112-120(1990).
RN   [42]
RP   VARIANT EDS4 VAL-1077.
RX   PubMed=1895316; DOI=10.1136/jmg.28.7.458;
RA   Richards A.J., Lloyd J.C., Ward P.N., de Paepe A., Narcisi P.,
RA   Pope F.M.;
RT   "Characterisation of a glycine to valine substitution at amino acid
RT   position 910 of the triple helical region of type III collagen in a
RT   patient with Ehlers-Danlos syndrome type IV.";
RL   J. Med. Genet. 28:458-463(1991).
RN   [43]
RP   VARIANT EDS4 GLU-1173.
RX   PubMed=1357232; DOI=10.1007/BF02435995;
RA   Johnson P.H., Richards A.J., Pope F.M., Hopkinson D.A.;
RT   "A COL3A1 glycine 1006 to glutamic acid substitution in a patient with
RT   Ehlers-Danlos syndrome type IV detected by denaturing gradient gel
RT   electrophoresis.";
RL   J. Inherit. Metab. Dis. 15:426-430(1992).
RN   [44]
RP   VARIANT EDS4 ASP-1185.
RX   PubMed=1496983;
RA   Kontusaari S., Tromp G., Kuivaniemi H., Stolle C.A., Pope F.M.,
RA   Prockop D.J.;
RT   "Substitution of aspartate for glycine 1018 in the type III
RT   procollagen (COL3A1) gene causes type IV Ehlers-Danlos syndrome: the
RT   mutated allele is present in most blood leukocytes of the asymptomatic
RT   and mosaic mother.";
RL   Am. J. Hum. Genet. 51:497-507(1992).
RN   [45]
RP   VARIANT EDS4 GLU-1188.
RX   PubMed=8098182; DOI=10.1002/ajmg.1320460308;
RA   Narcisi P., Wu Y., Tromp G., Earley J.J., Richards A.J., Pope F.M.,
RA   Kuivaniemi H.;
RT   "Single base mutation that substitutes glutamic acid for glycine 1021
RT   in the COL3A1 gene and causes Ehlers-Danlos syndrome type IV.";
RL   Am. J. Med. Genet. 46:278-283(1993).
RN   [46]
RP   VARIANTS EDS4 VAL-1167; ASP-1170 AND GLU-1173.
RA   Richards A.J., Narcisi P., Lloyd J.C., Johnson P.H., Hopkinson D.A.,
RA   Pope F.M.;
RT   "Substitution of glycines 1000, 1003 and 1006 in type III collagen all
RT   cause the acrogeric form of EDS-IV, and destabilise the collagen
RT   triple helix.";
RL   Matrix 13:47-47(1993).
RN   [47]
RP   VARIANTS THR-602 AND LEU-635.
RX   PubMed=8255472; DOI=10.1212/WNL.43.12.2652;
RA   Kuivaniemi H., Prockop D.J., Wu Y., Madhatheri S.L., Kleinert C.,
RA   Earley J.J., Jokinen A., Stolle C.A., Majamaa K., Mylllylae V.V.,
RA   Noerrgaard O., Schievink W.I., Mokri B., Fukawa O., Ter Berg J.W.M.,
RA   de Paepe A., Lozano A.M., Leblanc R., Ryynaenen M., Baxter B.T.,
RA   Shikata H., Ferrell R.E., Tromp G.;
RT   "Exclusion of mutations in the gene for type III collagen (COL3A1) as
RT   a common cause of intracranial aneurysms or cervical artery
RT   dissections: results from sequence analysis of the coding sequences of
RT   type III collagen from 55 unrelated patients.";
RL   Neurology 43:2652-2658(1993).
RN   [48]
RP   VARIANT EDS4 GLU-756.
RX   PubMed=7912131; DOI=10.1093/hmg/3.3.511;
RA   Madhatheri S.L., Tromp G., Gustavson K.H., Kuivaniemi H.;
RT   "Substitution of glutamic acid for glycine 589 in the triple-helical
RT   domain of type III procollagen (COL3A1) in a family with variable
RT   phenotype of the Ehlers-Danlos syndrome type IV.";
RL   Hum. Mol. Genet. 3:511-512(1994).
RN   [49]
RP   VARIANT EDS3 SER-804.
RX   PubMed=7833919; DOI=10.1093/hmg/3.9.1617;
RA   Narcisi P., Richards A.J., Ferguson S.D., Pope F.M.;
RT   "A family with Ehlers-Danlos syndrome type III/articular hypermobility
RT   syndrome has a glycine 637-to-serine substitution in type III
RT   collagen.";
RL   Hum. Mol. Genet. 3:1617-1620(1994).
RN   [50]
RP   VARIANT EDS4 VAL-1176.
RX   PubMed=8019562; DOI=10.1002/humu.1380030315;
RA   Nuytinck L., De Paepe A., Renard J.P., Adriaens F., Leroy J.;
RT   "Single-strand conformation polymorphism (SSCP) analysis of the COL3A1
RT   gene detects a mutation that results in the substitution of glycine
RT   1009 to valine and causes severe Ehlers-Danlos syndrome type IV.";
RL   Hum. Mutat. 3:268-274(1994).
RN   [51]
RP   VARIANTS EDS4 CYS-183; ARG-201; GLU-228; ARG-540; ARG-936; GLU-996;
RP   VAL-1071; ALA-1104; GLU-1182; VAL-1185; GLU-1188 AND ARG-1188.
RA   Goldstein J.A., Schwarze U., Witz A., Byers P.H.;
RT   "Marked heterogeneity in COL3A1 mutations that produce the EDS type IV
RT   phenotype.";
RL   Matrix Biol. 14:392-393(1994).
RN   [52]
RP   VARIANTS EDS4 ASP-909 AND ASP-939.
RX   PubMed=8680408; DOI=10.1002/humu.1380060408;
RA   Johnson P.H., Richards A.J., Lloyd J.C., Pope F.M., Hopkinson D.A.;
RT   "Efficient strategy for the detection of mutations in acrogeric
RT   Ehlers-Danlos syndrome type IV.";
RL   Hum. Mutat. 6:336-342(1995).
RN   [53]
RP   VARIANTS EDS4 GLU-567; CYS-762 AND ASP-1170.
RX   PubMed=8884076;
RA   Mackay K., Raghunath M., Superti-Furga A., Steinmann B., Dalgleish R.;
RT   "Ehlers-Danlos syndrome type IV caused by Gly400Glu, Gly595Cys and
RT   Gly1003Asp substitutions in collagen III: clinical features,
RT   biochemical screening, and molecular confirmation.";
RL   Clin. Genet. 49:286-295(1996).
RN   [54]
RP   VARIANT EDS4 GLU-1101.
RX   PubMed=9147870;
RA   McGrory J., Weksberg R., Thorner P., Cole W.G.;
RT   "Abnormal extracellular matrix in Ehlers-Danlos syndrome type IV due
RT   to the substitution of glycine 934 by glutamic acid in the triple
RT   helical domain of type III collagen.";
RL   Clin. Genet. 50:442-445(1996).
RN   [55]
RP   VARIANT EDS4 ASP-666.
RX   PubMed=8664902;
RX   DOI=10.1002/(SICI)1098-1004(1996)7:1<59::AID-HUMU8>3.3.CO;2-R;
RA   McGrory J., Costa T., Cole W.G.;
RT   "A novel G499D substitution in the alpha 1(III) chain of type III
RT   collagen produces variable forms of Ehlers-Danlos syndrome type IV.";
RL   Hum. Mutat. 7:59-60(1996).
RN   [56]
RP   VARIANT EDS4 SER-582.
RX   PubMed=8990011;
RX   DOI=10.1002/(SICI)1098-1004(1997)9:1<62::AID-HUMU11>3.3.CO;2-B;
RA   Anderson D.W., Thakker-Varia S., Tromp G., Kuivaniemi H., Stolle C.A.;
RT   "A glycine (415)-to-serine substitution results in impaired secretion
RT   and decreased thermal stability of type III procollagen in a patient
RT   with Ehlers-Danlos syndrome type IV.";
RL   Hum. Mutat. 9:62-63(1997).
RN   [57]
RP   VARIANTS EDS4 CYS-183; ARG-201; GLU-228; ARG-540 AND ARG-936.
RX   PubMed=9036918; DOI=10.1111/1523-1747.ep12286441;
RA   Smith L.T., Schwarze U., Goldstein J., Byers P.H.;
RT   "Mutations in the COL3A1 gene result in the Ehlers-Danlos syndrome
RT   type IV and alterations in the size and distribution of the major
RT   collagen fibrils of the dermis.";
RL   J. Invest. Dermatol. 108:241-247(1997).
RN   [58]
RP   VARIANT EDS4 ARG-726.
RX   PubMed=9452103;
RA   Bateman J.F., Chiodo A.A., Weng Y.M., Chan D., Haan E.;
RT   "A type III collagen Gly559 to Arg helix mutation in Ehler's-Danlos
RT   syndrome type IV.";
RL   Hum. Mutat. Suppl. 1:S257-S259(1998).
RN   [59]
RP   VARIANT EDS-IV ARG-1173.
RX   PubMed=10819545; DOI=10.1046/j.1365-2133.2000.03266.x;
RA   Jansen T., de Paepe A., Luytinck N., Plewig G.;
RT   "COL3A1 mutation leading to acrogeria (Gottron Type).";
RL   Br. J. Dermatol. 142:178-180(2000).
RN   [60]
RP   VARIANTS EDS4 ASP-204; ASP-210; ARG-264; ASP-327; ASP-1098 AND
RP   GLU-1173.
RX   PubMed=10923041;
RX   DOI=10.1002/1098-1004(200008)16:2<176::AID-HUMU12>3.0.CO;2-E;
RA   Giunta C., Steinmann B.;
RT   "Characterization of 11 new mutations in COL3A1 of individuals with
RT   Ehlers-Danlos syndrome type IV: preliminary comparison of RNase
RT   cleavage, EMC and DHPLC assays.";
RL   Hum. Mutat. 16:176-177(2000).
RN   [61]
RP   VARIANTS EDS4.
RX   PubMed=10706896; DOI=10.1056/NEJM200003093421001;
RA   Pepin M., Schwarze U., Superti-Furga A., Byers P.H.;
RT   "Clinical and genetic features of Ehlers-Danlos syndrome type IV, the
RT   vascular type.";
RL   N. Engl. J. Med. 342:673-680(2000).
RN   [62]
RP   VARIANT EDS4 ASP-1044.
RX   PubMed=11168790; DOI=10.1046/j.1365-2796.2001.00761.x;
RA   Nishiyama Y., Nejima J., Watanabe A., Kotani E., Sakai N.,
RA   Hatamochi A., Shinkai H., Kiuchi K., Tamura K., Shimada T., Takano T.,
RA   Katayama Y.;
RT   "Ehlers-Danlos syndrome type IV with a unique point mutation in COL3A1
RT   and familial phenotype of myocardial infarction without organic
RT   coronary stenosis.";
RL   J. Intern. Med. 249:103-108(2001).
RN   [63]
RP   VARIANT EDS4 ARG-297.
RX   PubMed=12694234; DOI=10.1034/j.1399-0004.2003.00047.x;
RA   Kroes H.Y., Pals G., van Essen A.J.;
RT   "Ehlers-Danlos syndrome type IV: unusual congenital anomalies in a
RT   mother and son with a COL3A1 mutation and a normal collagen III
RT   protein profile.";
RL   Clin. Genet. 63:224-227(2003).
RN   [64]
RP   ERRATUM.
RA   Kroes H.Y., Pals G., van Essen A.J.;
RL   Clin. Genet. 64:375-375(2003).
RN   [65]
RP   VARIANT EDS4 VAL-1050.
RX   PubMed=12786757; DOI=10.1034/j.1399-0004.2003.00075.x;
RA   Palmeri S., Mari F., Meloni I., Malandrini A., Ariani F.,
RA   Villanova M., Pompilio A., Schwarze U., Byers P.H., Renieri A.;
RT   "Neurological presentation of Ehlers-Danlos syndrome type IV in a
RT   family with parental mosaicism.";
RL   Clin. Genet. 63:510-515(2003).
RN   [66]
RP   VARIANTS [LARGE SCALE ANALYSIS] SER-420 AND CYS-1434.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
RN   [67]
RP   VARIANTS THR-679; THR-698; VAL-1205 AND GLN-1353.
RX   PubMed=18272325; DOI=10.1016/j.ygeno.2007.12.008;
RA   Chan T.F., Poon A., Basu A., Addleman N.R., Chen J., Phong A.,
RA   Byers P.H., Klein T.E., Kwok P.Y.;
RT   "Natural variation in four human collagen genes across an ethnically
RT   diverse population.";
RL   Genomics 91:307-314(2008).
CC   -!- FUNCTION: Collagen type III occurs in most soft connective tissues
CC       along with type I collagen. Involved in regulation of cortical
CC       development. Is the major ligand of GPR56 in the developing brain
CC       and binding to GPR56 inhibits neuronal migration and activates the
CC       RhoA pathway by coupling GPR56 to GNA13 and possibly GNA12.
CC   -!- SUBUNIT: Trimers of identical alpha 1(III) chains. The chains are
CC       linked to each other by interchain disulfide bonds. Trimers are
CC       also cross-linked via hydroxylysines.
CC   -!- INTERACTION:
CC       O01949:AAEL010235 (xeno); NbExp=2; IntAct=EBI-2431491, EBI-7685554;
CC   -!- SUBCELLULAR LOCATION: Secreted, extracellular space, extracellular
CC       matrix {ECO:0000255|PROSITE-ProRule:PRU00793}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P02461-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P02461-2; Sequence=VSP_022502;
CC         Note=No experimental confirmation available.;
CC   -!- DOMAIN: The C-terminal propeptide, also known as COLFI domain,
CC       have crucial roles in tissue growth and repair by controlling both
CC       the intracellular assembly of procollagen molecules and the
CC       extracellular assembly of collagen fibrils. It binds a calcium ion
CC       which is essential for its function.
CC   -!- PTM: Proline residues at the third position of the tripeptide
CC       repeating unit (G-X-Y) are hydroxylated in some or all of the
CC       chains. {ECO:0000269|PubMed:557335, ECO:0000269|PubMed:7016180}.
CC   -!- PTM: O-linked glycan consists of a Glc-Gal disaccharide bound to
CC       the oxygen atom of a post-translationally added hydroxyl group.
CC   -!- DISEASE: Ehlers-Danlos syndrome 3 (EDS3) [MIM:130020]: A
CC       connective tissue disorder characterized by hyperextensible skin,
CC       atrophic cutaneous scars due to tissue fragility and joint
CC       hyperlaxity. It is a form of Ehlers-Danlos syndrome characterized
CC       by marked joint hyperextensibility without skeletal deformity.
CC       {ECO:0000269|PubMed:7833919}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Ehlers-Danlos syndrome 4 (EDS4) [MIM:130050]: The most
CC       severe form of Ehlers-Danlos syndrome, a connective tissue
CC       disorder characterized by hyperextensible skin, atrophic cutaneous
CC       scars due to tissue fragility and joint hyperlaxity. Characterized
CC       by the joint and dermal manifestations as in other forms of the
CC       syndrome, characteristic facial features (acrogeria) in most
CC       patients, and by proneness to spontaneous rupture of bowel and
CC       large arteries. The vascular complications may affect all
CC       anatomical areas. {ECO:0000269|PubMed:10706896,
CC       ECO:0000269|PubMed:10923041, ECO:0000269|PubMed:11168790,
CC       ECO:0000269|PubMed:12694234, ECO:0000269|PubMed:12786757,
CC       ECO:0000269|PubMed:1352273, ECO:0000269|PubMed:1357232,
CC       ECO:0000269|PubMed:1370809, ECO:0000269|PubMed:1496983,
CC       ECO:0000269|PubMed:1895316, ECO:0000269|PubMed:2492273,
CC       ECO:0000269|PubMed:2808425, ECO:0000269|PubMed:7749417,
CC       ECO:0000269|PubMed:7912131, ECO:0000269|PubMed:8019562,
CC       ECO:0000269|PubMed:8098182, ECO:0000269|PubMed:8411057,
CC       ECO:0000269|PubMed:8664902, ECO:0000269|PubMed:8680408,
CC       ECO:0000269|PubMed:8884076, ECO:0000269|PubMed:8990011,
CC       ECO:0000269|PubMed:9036918, ECO:0000269|PubMed:9147870,
CC       ECO:0000269|PubMed:9452103, ECO:0000269|Ref.46,
CC       ECO:0000269|Ref.51}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Aortic aneurysm, familial abdominal (AAA) [MIM:100070]: A
CC       common multifactorial disorder characterized by permanent dilation
CC       of the abdominal aorta, usually due to degenerative changes in the
CC       aortic wall. Histologically, AAA is characterized by signs of
CC       chronic inflammation, destructive remodeling of the extracellular
CC       matrix, and depletion of vascular smooth muscle cells.
CC       {ECO:0000269|PubMed:2243125, ECO:0000269|PubMed:2349939,
CC       ECO:0000269|PubMed:8514866}. Note=Disease susceptibility is
CC       associated with variations affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the fibrillar collagen family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00793}.
CC   -!- SIMILARITY: Contains 1 fibrillar collagen NC1 domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00793}.
CC   -!- SIMILARITY: Contains 1 VWFC domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00220}.
CC   -!- WEB RESOURCE: Name=COL3A1; Note=Collagen type III alpha-1 chain
CC       mutations;
CC       URL="http://www.le.ac.uk/genetics/collagen/col3a1.html";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Type-III collagen entry;
CC       URL="https://en.wikipedia.org/wiki/Type-III_collagen";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X14420; CAA32583.1; -; mRNA.
DR   EMBL; AY054301; AAL13167.1; -; Genomic_DNA.
DR   EMBL; AY016295; AAL13167.1; JOINED; Genomic_DNA.
DR   EMBL; KC567894; AGL34959.1; -; Genomic_DNA.
DR   EMBL; GU143397; ACZ58371.1; -; Genomic_DNA.
DR   EMBL; AC066694; AAY24164.1; -; Genomic_DNA.
DR   EMBL; CH471058; EAX10910.1; -; Genomic_DNA.
DR   EMBL; CH471058; EAX10911.1; -; Genomic_DNA.
DR   EMBL; BC028178; AAH28178.1; -; mRNA.
DR   EMBL; M26939; AAA52040.1; -; Genomic_DNA.
DR   EMBL; X07240; CAA30229.1; -; mRNA.
DR   EMBL; X15332; CAA33387.1; -; mRNA.
DR   EMBL; S62925; AAD13937.1; -; Genomic_DNA.
DR   EMBL; S79877; AAB35615.1; -; mRNA.
DR   EMBL; M59312; AAA52041.1; -; Genomic_DNA.
DR   EMBL; M59227; AAB59383.1; -; mRNA.
DR   EMBL; M55603; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; X06700; CAA29886.1; -; mRNA.
DR   EMBL; X01655; CAA25821.1; -; mRNA.
DR   EMBL; X01742; CAA25879.1; -; mRNA.
DR   EMBL; M13146; AAA52003.1; -; mRNA.
DR   EMBL; M11134; AAA52004.1; -; mRNA.
DR   EMBL; M10795; AAA52002.1; -; Genomic_DNA.
DR   EMBL; M10615; AAA52002.1; JOINED; Genomic_DNA.
DR   EMBL; M10793; AAA52002.1; JOINED; Genomic_DNA.
DR   EMBL; M10794; AAA52002.1; JOINED; Genomic_DNA.
DR   EMBL; M10800; AAA52002.1; JOINED; Genomic_DNA.
DR   EMBL; M10801; AAA52002.1; JOINED; Genomic_DNA.
DR   CCDS; CCDS2297.1; -. [P02461-1]
DR   PIR; S05272; CGHU7L.
DR   RefSeq; NP_000081.1; NM_000090.3.
DR   UniGene; Hs.443625; -.
DR   PDB; 2V53; X-ray; 3.20 A; B/C/D=564-584.
DR   PDB; 3DMW; X-ray; 2.30 A; A/B/C=1158-1199.
DR   PDB; 4AE2; X-ray; 1.68 A; A/B/C=1222-1466.
DR   PDB; 4AEJ; X-ray; 2.21 A; A/B/C=1222-1466.
DR   PDB; 4AK3; X-ray; 3.50 A; A=1222-1466.
DR   PDB; 4GYX; X-ray; 1.49 A; A/B/C=1158-1200.
DR   PDBsum; 2V53; -.
DR   PDBsum; 3DMW; -.
DR   PDBsum; 4AE2; -.
DR   PDBsum; 4AEJ; -.
DR   PDBsum; 4AK3; -.
DR   PDBsum; 4GYX; -.
DR   ProteinModelPortal; P02461; -.
DR   SMR; P02461; 1249-1466.
DR   BioGrid; 107678; 9.
DR   DIP; DIP-57177N; -.
DR   IntAct; P02461; 20.
DR   MINT; MINT-7299332; -.
DR   STRING; 9606.ENSP00000304408; -.
DR   ChEMBL; CHEMBL2364188; -.
DR   DrugBank; DB00048; Collagenase clostridium histolyticum.
DR   iPTMnet; P02461; -.
DR   PhosphoSite; P02461; -.
DR   BioMuta; COL3A1; -.
DR   DMDM; 124056490; -.
DR   PaxDb; P02461; -.
DR   PRIDE; P02461; -.
DR   Ensembl; ENST00000304636; ENSP00000304408; ENSG00000168542. [P02461-1]
DR   Ensembl; ENST00000317840; ENSP00000315243; ENSG00000168542. [P02461-2]
DR   GeneID; 1281; -.
DR   KEGG; hsa:1281; -.
DR   UCSC; uc002uqj.1; human. [P02461-1]
DR   CTD; 1281; -.
DR   GeneCards; COL3A1; -.
DR   GeneReviews; COL3A1; -.
DR   HGNC; HGNC:2201; COL3A1.
DR   HPA; CAB016766; -.
DR   HPA; HPA007583; -.
DR   MalaCards; COL3A1; -.
DR   MIM; 100070; phenotype.
DR   MIM; 120180; gene.
DR   MIM; 130020; phenotype.
DR   MIM; 130050; phenotype.
DR   neXtProt; NX_P02461; -.
DR   Orphanet; 2500; Acrogeria.
DR   Orphanet; 286; Ehlers-Danlos syndrome, vascular type.
DR   Orphanet; 86; Familial abdominal aortic aneurysm.
DR   Orphanet; 231160; Familial cerebral saccular aneurysm.
DR   PharmGKB; PA26716; -.
DR   eggNOG; KOG3544; Eukaryota.
DR   eggNOG; ENOG410XNMM; LUCA.
DR   GeneTree; ENSGT00830000128243; -.
DR   HOVERGEN; HBG004933; -.
DR   InParanoid; P02461; -.
DR   KO; K19720; -.
DR   OMA; AEKKHVW; -.
DR   OrthoDB; EOG7TJ3HH; -.
DR   PhylomeDB; P02461; -.
DR   TreeFam; TF344135; -.
DR   Reactome; R-HSA-1442490; Collagen degradation.
DR   Reactome; R-HSA-1474244; Extracellular matrix organization.
DR   Reactome; R-HSA-1650814; Collagen biosynthesis and modifying enzymes.
DR   Reactome; R-HSA-186797; Signaling by PDGF.
DR   Reactome; R-HSA-198933; Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell.
DR   Reactome; R-HSA-2022090; Assembly of collagen fibrils and other multimeric structures.
DR   Reactome; R-HSA-216083; Integrin cell surface interactions.
DR   Reactome; R-HSA-3000170; Syndecan interactions.
DR   Reactome; R-HSA-3000171; Non-integrin membrane-ECM interactions.
DR   Reactome; R-HSA-3000178; ECM proteoglycans.
DR   Reactome; R-HSA-3000480; Scavenging by Class A Receptors.
DR   Reactome; R-HSA-419037; NCAM1 interactions.
DR   ChiTaRS; COL3A1; human.
DR   EvolutionaryTrace; P02461; -.
DR   GeneWiki; Collagen,_type_III,_alpha_1; -.
DR   GenomeRNAi; 1281; -.
DR   NextBio; 35489581; -.
DR   PRO; PR:P02461; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   Bgee; P02461; -.
DR   ExpressionAtlas; P02461; baseline and differential.
DR   Genevisible; P02461; HS.
DR   GO; GO:0005586; C:collagen type III trimer; IMP:UniProtKB.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome.
DR   GO; GO:0031012; C:extracellular matrix; IMP:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0005201; F:extracellular matrix structural constituent; IMP:UniProtKB.
DR   GO; GO:0005178; F:integrin binding; IMP:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0048407; F:platelet-derived growth factor binding; IDA:MGI.
DR   GO; GO:0007568; P:aging; IEA:Ensembl.
DR   GO; GO:0060414; P:aorta smooth muscle tissue morphogenesis; IEA:Ensembl.
DR   GO; GO:0007411; P:axon guidance; TAS:Reactome.
DR   GO; GO:0007160; P:cell-matrix adhesion; IDA:UniProtKB.
DR   GO; GO:0071230; P:cellular response to amino acid stimulus; IEA:Ensembl.
DR   GO; GO:0021987; P:cerebral cortex development; ISS:UniProtKB.
DR   GO; GO:0030574; P:collagen catabolic process; TAS:Reactome.
DR   GO; GO:0030199; P:collagen fibril organization; IMP:UniProtKB.
DR   GO; GO:0048565; P:digestive tract development; IEA:Ensembl.
DR   GO; GO:0043206; P:extracellular fibril organization; IMP:UniProtKB.
DR   GO; GO:0022617; P:extracellular matrix disassembly; TAS:Reactome.
DR   GO; GO:0030198; P:extracellular matrix organization; TAS:Reactome.
DR   GO; GO:0007507; P:heart development; IMP:UniProtKB.
DR   GO; GO:0007229; P:integrin-mediated signaling pathway; IMP:UniProtKB.
DR   GO; GO:0050777; P:negative regulation of immune response; IMP:UniProtKB.
DR   GO; GO:2001223; P:negative regulation of neuron migration; ISS:UniProtKB.
DR   GO; GO:0018149; P:peptide cross-linking; IDA:UniProtKB.
DR   GO; GO:0030168; P:platelet activation; NAS:UniProtKB.
DR   GO; GO:0035025; P:positive regulation of Rho protein signal transduction; ISS:UniProtKB.
DR   GO; GO:0006898; P:receptor-mediated endocytosis; TAS:Reactome.
DR   GO; GO:0050776; P:regulation of immune response; TAS:Reactome.
DR   GO; GO:0034097; P:response to cytokine; IDA:UniProtKB.
DR   GO; GO:0009612; P:response to mechanical stimulus; IEA:Ensembl.
DR   GO; GO:0009314; P:response to radiation; IDA:UniProtKB.
DR   GO; GO:0001501; P:skeletal system development; IEA:Ensembl.
DR   GO; GO:0043588; P:skin development; IMP:UniProtKB.
DR   GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0042060; P:wound healing; IDA:UniProtKB.
DR   InterPro; IPR008160; Collagen.
DR   InterPro; IPR000885; Fib_collagen_C.
DR   InterPro; IPR001007; VWF_dom.
DR   Pfam; PF01410; COLFI; 1.
DR   Pfam; PF01391; Collagen; 8.
DR   Pfam; PF00093; VWC; 1.
DR   ProDom; PD002078; Fib_collagen_C; 1.
DR   SMART; SM00038; COLFI; 1.
DR   SMART; SM00214; VWC; 1.
DR   PROSITE; PS51461; NC1_FIB; 1.
DR   PROSITE; PS01208; VWFC_1; 1.
DR   PROSITE; PS50184; VWFC_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Aortic aneurysm; Calcium;
KW   Collagen; Complete proteome; Direct protein sequencing;
KW   Disease mutation; Disulfide bond; Ehlers-Danlos syndrome;
KW   Extracellular matrix; Glycoprotein; Hydroxylation; Metal-binding;
KW   Polymorphism; Reference proteome; Repeat; Secreted; Signal.
FT   SIGNAL        1     23
FT   PROPEP       24    153       N-terminal propeptide.
FT                                /FTId=PRO_0000005740.
FT   CHAIN       154   1221       Collagen alpha-1(III) chain.
FT                                /FTId=PRO_0000005741.
FT   PROPEP     1222   1466       C-terminal propeptide.
FT                                /FTId=PRO_0000005742.
FT   DOMAIN       30     89       VWFC. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00220}.
FT   DOMAIN     1232   1466       Fibrillar collagen NC1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00793}.
FT   REGION      149    167       Nonhelical region (N-terminal).
FT   REGION      168   1196       Triple-helical region.
FT   REGION     1197   1205       Nonhelical region (C-terminal).
FT   METAL      1280   1280       Calcium.
FT   METAL      1282   1282       Calcium.
FT   METAL      1283   1283       Calcium; via carbonyl oxygen.
FT   METAL      1285   1285       Calcium; via carbonyl oxygen.
FT   METAL      1288   1288       Calcium.
FT   MOD_RES     263    263       5-hydroxylysine; alternate.
FT   MOD_RES     284    284       5-hydroxylysine.
FT   MOD_RES     860    860       5-hydroxylysine.
FT   MOD_RES     977    977       5-hydroxylysine.
FT   MOD_RES    1094   1094       5-hydroxylysine; partial.
FT   MOD_RES    1106   1106       5-hydroxylysine.
FT   CARBOHYD    263    263       O-linked (Gal...); alternate.
FT   DISULFID   1196   1196       Interchain. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00793,
FT                                ECO:0000269|PubMed:23001006}.
FT   DISULFID   1197   1197       Interchain. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00793,
FT                                ECO:0000269|PubMed:23001006}.
FT   DISULFID   1262   1294       {ECO:0000255|PROSITE-ProRule:PRU00793,
FT                                ECO:0000269|PubMed:23001006}.
FT   DISULFID   1268   1268       Interchain (with C-1285).
FT                                {ECO:0000255|PROSITE-ProRule:PRU00793,
FT                                ECO:0000269|PubMed:23001006}.
FT   DISULFID   1285   1285       Interchain (with C-1268).
FT                                {ECO:0000255|PROSITE-ProRule:PRU00793,
FT                                ECO:0000269|PubMed:23001006}.
FT   DISULFID   1302   1464       {ECO:0000255|PROSITE-ProRule:PRU00793,
FT                                ECO:0000269|PubMed:23001006}.
FT   DISULFID   1372   1417       {ECO:0000255|PROSITE-ProRule:PRU00793,
FT                                ECO:0000269|PubMed:23001006}.
FT   VAR_SEQ     847   1149       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_022502.
FT   VARIANT     169    169       L -> F (in AAA).
FT                                /FTId=VAR_001767.
FT   VARIANT     183    183       G -> C (in EDS4).
FT                                {ECO:0000269|PubMed:9036918,
FT                                ECO:0000269|Ref.51}.
FT                                /FTId=VAR_001768.
FT   VARIANT     183    183       G -> D (in EDS4).
FT                                /FTId=VAR_011095.
FT   VARIANT     183    183       G -> S (in EDS4).
FT                                /FTId=VAR_011096.
FT   VARIANT     192    192       G -> V (in EDS4).
FT                                /FTId=VAR_011097.
FT   VARIANT     201    201       G -> R (in EDS4).
FT                                {ECO:0000269|PubMed:9036918,
FT                                ECO:0000269|Ref.51}.
FT                                /FTId=VAR_001769.
FT   VARIANT     204    204       G -> D (in EDS4).
FT                                {ECO:0000269|PubMed:10923041}.
FT                                /FTId=VAR_011098.
FT   VARIANT     204    204       G -> S (in EDS4).
FT                                /FTId=VAR_011099.
FT   VARIANT     210    210       G -> D (in EDS4).
FT                                {ECO:0000269|PubMed:10923041}.
FT                                /FTId=VAR_011100.
FT   VARIANT     219    219       G -> C (in EDS4).
FT                                /FTId=VAR_011101.
FT   VARIANT     225    225       G -> V (in EDS4).
FT                                /FTId=VAR_011102.
FT   VARIANT     228    228       G -> E (in EDS4).
FT                                {ECO:0000269|PubMed:9036918,
FT                                ECO:0000269|Ref.51}.
FT                                /FTId=VAR_001770.
FT   VARIANT     240    240       G -> R (in EDS4).
FT                                /FTId=VAR_011103.
FT   VARIANT     243    243       G -> V (in EDS4).
FT                                /FTId=VAR_011104.
FT   VARIANT     249    249       G -> D (in EDS4).
FT                                /FTId=VAR_011105.
FT   VARIANT     249    249       G -> V (in EDS4).
FT                                /FTId=VAR_011106.
FT   VARIANT     252    252       G -> D (in EDS4).
FT                                /FTId=VAR_011107.
FT   VARIANT     252    252       G -> R (in EDS4).
FT                                /FTId=VAR_011108.
FT   VARIANT     252    252       G -> V (in EDS4).
FT                                /FTId=VAR_011109.
FT   VARIANT     255    255       G -> V (in EDS4).
FT                                /FTId=VAR_011110.
FT   VARIANT     264    264       G -> R (in EDS4).
FT                                {ECO:0000269|PubMed:10923041}.
FT                                /FTId=VAR_011111.
FT   VARIANT     267    267       G -> V (in EDS4).
FT                                /FTId=VAR_011112.
FT   VARIANT     297    297       G -> R (in EDS4).
FT                                {ECO:0000269|PubMed:12694234}.
FT                                /FTId=VAR_037007.
FT   VARIANT     303    303       G -> R (in fibromuscular dysplasia and
FT                                aortic aneurysm).
FT                                {ECO:0000269|PubMed:8514866}.
FT                                /FTId=VAR_001771.
FT   VARIANT     321    321       G -> V (in EDS4).
FT                                /FTId=VAR_011113.
FT   VARIANT     327    327       G -> D (in EDS4).
FT                                {ECO:0000269|PubMed:10923041}.
FT                                /FTId=VAR_011114.
FT   VARIANT     345    345       G -> R (in EDS4).
FT                                /FTId=VAR_011115.
FT   VARIANT     417    417       G -> R (in EDS4).
FT                                /FTId=VAR_011116.
FT   VARIANT     420    420       G -> S (in a colorectal cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_035738.
FT   VARIANT     444    444       G -> R (in EDS4).
FT                                /FTId=VAR_011117.
FT   VARIANT     489    489       G -> E (in EDS4).
FT                                /FTId=VAR_011118.
FT   VARIANT     501    501       G -> R (in EDS4).
FT                                /FTId=VAR_011119.
FT   VARIANT     519    519       G -> V (in EDS4).
FT                                /FTId=VAR_011120.
FT   VARIANT     534    534       G -> E (in dbSNP:rs41263744).
FT                                /FTId=VAR_055665.
FT   VARIANT     540    540       G -> R (in EDS4).
FT                                {ECO:0000269|PubMed:9036918,
FT                                ECO:0000269|Ref.51}.
FT                                /FTId=VAR_001772.
FT   VARIANT     549    549       G -> E (in EDS4).
FT                                /FTId=VAR_011121.
FT   VARIANT     552    552       G -> E (in EDS4).
FT                                /FTId=VAR_011122.
FT   VARIANT     567    567       G -> E (in EDS4).
FT                                {ECO:0000269|PubMed:8884076}.
FT                                /FTId=VAR_001773.
FT   VARIANT     582    582       G -> S (in EDS4).
FT                                {ECO:0000269|PubMed:8990011}.
FT                                /FTId=VAR_001774.
FT   VARIANT     588    588       G -> D (in EDS4).
FT                                /FTId=VAR_011123.
FT   VARIANT     602    602       P -> T (in dbSNP:rs35795890).
FT                                {ECO:0000269|PubMed:8255472}.
FT                                /FTId=VAR_001775.
FT   VARIANT     635    635       P -> L. {ECO:0000269|PubMed:8255472}.
FT                                /FTId=VAR_001776.
FT   VARIANT     636    636       G -> R (in EDS4).
FT                                /FTId=VAR_011124.
FT   VARIANT     657    657       G -> E (in EDS4).
FT                                /FTId=VAR_011125.
FT   VARIANT     660    660       G -> D (in EDS4).
FT                                /FTId=VAR_011126.
FT   VARIANT     666    666       G -> D (in EDS4).
FT                                {ECO:0000269|PubMed:8664902}.
FT                                /FTId=VAR_001777.
FT   VARIANT     668    668       P -> T (in dbSNP:rs1801183).
FT                                {ECO:0000269|PubMed:8514866}.
FT                                /FTId=VAR_011127.
FT   VARIANT     679    679       A -> T (in dbSNP:rs41263773).
FT                                {ECO:0000269|PubMed:18272325}.
FT                                /FTId=VAR_055666.
FT   VARIANT     686    686       P -> A (in dbSNP:rs41263775).
FT                                /FTId=VAR_055667.
FT   VARIANT     698    698       A -> T (in dbSNP:rs1800255).
FT                                {ECO:0000269|PubMed:18272325,
FT                                ECO:0000269|PubMed:2235526}.
FT                                /FTId=VAR_001778.
FT   VARIANT     699    699       G -> R (in EDS4).
FT                                /FTId=VAR_011128.
FT   VARIANT     726    726       G -> R (in EDS4).
FT                                {ECO:0000269|PubMed:9452103,
FT                                ECO:0000269|Ref.3}.
FT                                /FTId=VAR_001779.
FT   VARIANT     738    738       G -> S (in EDS4).
FT                                /FTId=VAR_011129.
FT   VARIANT     738    738       G -> V (in EDS4).
FT                                /FTId=VAR_011130.
FT   VARIANT     744    744       G -> V (in EDS4).
FT                                /FTId=VAR_011131.
FT   VARIANT     756    756       G -> E (in EDS4).
FT                                {ECO:0000269|PubMed:7912131}.
FT                                /FTId=VAR_001780.
FT   VARIANT     762    762       G -> C (in EDS4).
FT                                {ECO:0000269|PubMed:8884076}.
FT                                /FTId=VAR_001781.
FT   VARIANT     786    786       G -> R (in AAA).
FT                                {ECO:0000269|PubMed:2243125,
FT                                ECO:0000269|PubMed:2349939}.
FT                                /FTId=VAR_001782.
FT   VARIANT     804    804       G -> S (in EDS3).
FT                                {ECO:0000269|PubMed:7833919}.
FT                                /FTId=VAR_001783.
FT   VARIANT     828    828       G -> R (in EDS4).
FT                                {ECO:0000269|PubMed:8411057}.
FT                                /FTId=VAR_001784.
FT   VARIANT     828    828       G -> W (in EDS4).
FT                                /FTId=VAR_011132.
FT   VARIANT     830    838       Missing (in EDS4).
FT                                {ECO:0000269|PubMed:1370809}.
FT                                /FTId=VAR_037008.
FT   VARIANT     852    852       G -> C (in EDS4).
FT                                /FTId=VAR_011133.
FT   VARIANT     879    879       G -> V (in EDS4).
FT                                /FTId=VAR_011134.
FT   VARIANT     882    882       G -> D (in EDS4).
FT                                /FTId=VAR_011135.
FT   VARIANT     900    900       G -> D (in EDS4).
FT                                /FTId=VAR_011136.
FT   VARIANT     903    903       G -> E (in EDS4).
FT                                /FTId=VAR_011137.
FT   VARIANT     909    909       G -> D (in EDS4).
FT                                {ECO:0000269|PubMed:8680408}.
FT                                /FTId=VAR_001785.
FT   VARIANT     909    909       G -> V (in EDS4).
FT                                /FTId=VAR_011138.
FT   VARIANT     918    918       G -> E (in EDS4).
FT                                /FTId=VAR_011139.
FT   VARIANT     924    924       G -> C (in EDS4).
FT                                /FTId=VAR_011140.
FT   VARIANT     936    936       G -> R (in EDS4).
FT                                {ECO:0000269|PubMed:9036918,
FT                                ECO:0000269|Ref.51}.
FT                                /FTId=VAR_001786.
FT   VARIANT     936    936       G -> S (in EDS4).
FT                                /FTId=VAR_001787.
FT   VARIANT     939    939       G -> D (in EDS4).
FT                                {ECO:0000269|PubMed:8680408}.
FT                                /FTId=VAR_001788.
FT   VARIANT     942    942       G -> E (in EDS4).
FT                                /FTId=VAR_011141.
FT   VARIANT     957    957       G -> S (in EDS4; severe variant).
FT                                {ECO:0000269|PubMed:2492273}.
FT                                /FTId=VAR_001789.
FT   VARIANT     960    960       G -> V (in EDS4; severe variant).
FT                                {ECO:0000269|PubMed:7749417}.
FT                                /FTId=VAR_001790.
FT   VARIANT     966    966       G -> V (in EDS4).
FT                                /FTId=VAR_011142.
FT   VARIANT     972    972       G -> A (in EDS4).
FT                                /FTId=VAR_011143.
FT   VARIANT     984    984       G -> T (in EDS4; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_011144.
FT   VARIANT     996    996       G -> E (in EDS4). {ECO:0000269|Ref.51}.
FT                                /FTId=VAR_001791.
FT   VARIANT     999    999       G -> R (in EDS4).
FT                                /FTId=VAR_011145.
FT   VARIANT    1011   1011       G -> E (in EDS4).
FT                                /FTId=VAR_011146.
FT   VARIANT    1014   1014       G -> E (in EDS4).
FT                                {ECO:0000269|PubMed:1352273}.
FT                                /FTId=VAR_001792.
FT   VARIANT    1032   1032       G -> V (in EDS4).
FT                                /FTId=VAR_011147.
FT   VARIANT    1035   1035       G -> C (in EDS4).
FT                                /FTId=VAR_011148.
FT   VARIANT    1044   1044       G -> D (in EDS4).
FT                                {ECO:0000269|PubMed:11168790}.
FT                                /FTId=VAR_011149.
FT   VARIANT    1050   1050       G -> D (in EDS4; mild variant).
FT                                {ECO:0000269|PubMed:2808425}.
FT                                /FTId=VAR_001793.
FT   VARIANT    1050   1050       G -> V (in EDS4).
FT                                {ECO:0000269|PubMed:12786757}.
FT                                /FTId=VAR_011150.
FT   VARIANT    1071   1071       G -> V (in EDS4). {ECO:0000269|Ref.51}.
FT                                /FTId=VAR_001794.
FT   VARIANT    1077   1077       G -> V (in EDS4).
FT                                {ECO:0000269|PubMed:1895316}.
FT                                /FTId=VAR_001795.
FT   VARIANT    1089   1089       G -> D (in EDS4).
FT                                /FTId=VAR_011151.
FT   VARIANT    1098   1098       G -> D (in EDS4).
FT                                {ECO:0000269|PubMed:10923041}.
FT                                /FTId=VAR_011152.
FT   VARIANT    1098   1098       G -> V (in EDS4).
FT                                /FTId=VAR_011153.
FT   VARIANT    1101   1101       G -> E (in EDS4).
FT                                {ECO:0000269|PubMed:9147870}.
FT                                /FTId=VAR_001796.
FT   VARIANT    1104   1104       G -> A (in EDS4). {ECO:0000269|Ref.51}.
FT                                /FTId=VAR_001797.
FT   VARIANT    1161   1161       G -> V (in EDS4).
FT                                /FTId=VAR_011154.
FT   VARIANT    1164   1164       G -> E (in EDS4).
FT                                /FTId=VAR_011155.
FT   VARIANT    1164   1164       G -> R (in EDS4).
FT                                /FTId=VAR_011156.
FT   VARIANT    1164   1164       G -> S (in spondyloepiphyseal dysplasia).
FT                                /FTId=VAR_001798.
FT   VARIANT    1167   1167       G -> V (in EDS4). {ECO:0000269|Ref.46}.
FT                                /FTId=VAR_001799.
FT   VARIANT    1170   1170       G -> D (in EDS4).
FT                                {ECO:0000269|PubMed:8884076,
FT                                ECO:0000269|Ref.46}.
FT                                /FTId=VAR_001800.
FT   VARIANT    1170   1170       G -> V (in EDS4).
FT                                /FTId=VAR_011157.
FT   VARIANT    1173   1173       G -> E (in EDS4).
FT                                {ECO:0000269|PubMed:10923041,
FT                                ECO:0000269|PubMed:1357232,
FT                                ECO:0000269|Ref.46}.
FT                                /FTId=VAR_001801.
FT   VARIANT    1173   1173       G -> R (in EDS4; Gottron type acrogeria).
FT                                {ECO:0000269|PubMed:10819545}.
FT                                /FTId=VAR_011158.
FT   VARIANT    1176   1176       G -> V (in EDS4; severe).
FT                                {ECO:0000269|PubMed:8019562}.
FT                                /FTId=VAR_001802.
FT   VARIANT    1179   1179       G -> R (in EDS4).
FT                                /FTId=VAR_011159.
FT   VARIANT    1182   1182       G -> E (in EDS4). {ECO:0000269|Ref.51}.
FT                                /FTId=VAR_001803.
FT   VARIANT    1185   1185       G -> D (in EDS4; severe variant).
FT                                {ECO:0000269|PubMed:1496983}.
FT                                /FTId=VAR_001804.
FT   VARIANT    1185   1185       G -> V (in EDS4). {ECO:0000269|Ref.51}.
FT                                /FTId=VAR_001805.
FT   VARIANT    1188   1188       G -> E (in EDS4; severe variant).
FT                                {ECO:0000269|PubMed:8098182,
FT                                ECO:0000269|Ref.51}.
FT                                /FTId=VAR_001806.
FT   VARIANT    1188   1188       G -> R (in EDS4). {ECO:0000269|Ref.51}.
FT                                /FTId=VAR_001807.
FT   VARIANT    1205   1205       I -> V (in dbSNP:rs2271683).
FT                                {ECO:0000269|PubMed:18272325}.
FT                                /FTId=VAR_020012.
FT   VARIANT    1353   1353       H -> Q (in dbSNP:rs1516446).
FT                                {ECO:0000269|PubMed:11566270,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:18272325,
FT                                ECO:0000269|PubMed:2579949,
FT                                ECO:0000269|PubMed:2764886,
FT                                ECO:0000269|PubMed:3357782,
FT                                ECO:0000269|Ref.6}.
FT                                /FTId=VAR_030115.
FT   VARIANT    1434   1434       R -> C (in a colorectal cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_035739.
FT   CONFLICT    163    163       G -> GG (in Ref. 10; CAA33387).
FT                                {ECO:0000305}.
FT   CONFLICT    168    168       G -> V (in Ref. 11; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    226    228       Missing (in Ref. 11; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    241    241       E -> D (in Ref. 10; CAA33387).
FT                                {ECO:0000305}.
FT   CONFLICT    278    278       T -> A (in Ref. 11; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    293    295       NGA -> DGS (in Ref. 11; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    401    401       A -> L (in Ref. 15; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    409    409       L -> P (in Ref. 15; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    472    472       E -> D (in Ref. 10; CAA33387).
FT                                {ECO:0000305}.
FT   CONFLICT    488    490       PGF -> LGS (in Ref. 10; CAA33387).
FT                                {ECO:0000305}.
FT   CONFLICT    589    589       A -> E (in Ref. 15; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    614    614       T -> Y (in Ref. 10; CAA33387).
FT                                {ECO:0000305}.
FT   CONFLICT    635    635       P -> R (in Ref. 10; CAA33387).
FT                                {ECO:0000305}.
FT   CONFLICT    664    664       D -> E (in Ref. 10; CAA33387).
FT                                {ECO:0000305}.
FT   CONFLICT    676    676       D -> N (in Ref. 16; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    803    803       T -> P (in Ref. 15; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    896    896       S -> A (in Ref. 18; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    980    980       S -> A (in Ref. 22; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    985    989       ANGLS -> PSGQN (in Ref. 22; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT   1019   1019       D -> Y (in Ref. 20; CAA29886).
FT                                {ECO:0000305}.
FT   CONFLICT   1067   1067       S -> P (in Ref. 15; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT   1070   1070       A -> P (in Ref. 15; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT   1097   1097       T -> P (in Ref. 22; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT   1153   1154       TS -> AT (in Ref. 22; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT   1156   1156       H -> S (in Ref. 22; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT   1184   1184       P -> S (in Ref. 10; CAA33387).
FT                                {ECO:0000305}.
FT   CONFLICT   1203   1203       A -> P (in Ref. 10; CAA33387).
FT                                {ECO:0000305}.
FT   CONFLICT   1210   1210       G -> A (in Ref. 10; CAA33387).
FT                                {ECO:0000305}.
FT   CONFLICT   1222   1222       D -> P (in Ref. 26; AAA52002).
FT                                {ECO:0000305}.
FT   CONFLICT   1235   1235       M -> I (in Ref. 26; AAA52002).
FT                                {ECO:0000305}.
FT   CONFLICT   1241   1241       V -> A (in Ref. 20; CAA29886 and 23;
FT                                CAA25879). {ECO:0000305}.
FT   CONFLICT   1274   1274       S -> T (in Ref. 26; AAA52002).
FT                                {ECO:0000305}.
FT   CONFLICT   1332   1332       M -> I (in Ref. 26; AAA52002).
FT                                {ECO:0000305}.
FT   CONFLICT   1357   1357       L -> P (in Ref. 26; AAA52002).
FT                                {ECO:0000305}.
FT   HELIX      1236   1249       {ECO:0000244|PDB:4AK3}.
FT   STRAND     1253   1257       {ECO:0000244|PDB:4AE2}.
FT   HELIX      1262   1268       {ECO:0000244|PDB:4AE2}.
FT   STRAND     1274   1279       {ECO:0000244|PDB:4AE2}.
FT   HELIX      1286   1288       {ECO:0000244|PDB:4AE2}.
FT   STRAND     1290   1295       {ECO:0000244|PDB:4AE2}.
FT   TURN       1296   1299       {ECO:0000244|PDB:4AE2}.
FT   STRAND     1300   1303       {ECO:0000244|PDB:4AE2}.
FT   STRAND     1305   1307       {ECO:0000244|PDB:4AE2}.
FT   STRAND     1309   1313       {ECO:0000244|PDB:4AE2}.
FT   STRAND     1320   1322       {ECO:0000244|PDB:4AK3}.
FT   HELIX      1328   1331       {ECO:0000244|PDB:4AE2}.
FT   STRAND     1339   1341       {ECO:0000244|PDB:4AEJ}.
FT   STRAND     1343   1345       {ECO:0000244|PDB:4AK3}.
FT   HELIX      1347   1360       {ECO:0000244|PDB:4AE2}.
FT   STRAND     1364   1374       {ECO:0000244|PDB:4AE2}.
FT   TURN       1381   1384       {ECO:0000244|PDB:4AE2}.
FT   STRAND     1391   1393       {ECO:0000244|PDB:4AE2}.
FT   STRAND     1395   1397       {ECO:0000244|PDB:4AE2}.
FT   STRAND     1399   1404       {ECO:0000244|PDB:4AE2}.
FT   HELIX      1406   1408       {ECO:0000244|PDB:4AK3}.
FT   STRAND     1411   1415       {ECO:0000244|PDB:4AE2}.
FT   STRAND     1422   1434       {ECO:0000244|PDB:4AE2}.
FT   HELIX      1436   1438       {ECO:0000244|PDB:4AE2}.
FT   STRAND     1443   1445       {ECO:0000244|PDB:4AE2}.
FT   STRAND     1455   1465       {ECO:0000244|PDB:4AE2}.
SQ   SEQUENCE   1466 AA;  138564 MW;  B904B4E05E17D339 CRC64;
     MMSFVQKGSW LLLALLHPTI ILAQQEAVEG GCSHLGQSYA DRDVWKPEPC QICVCDSGSV
     LCDDIICDDQ ELDCPNPEIP FGECCAVCPQ PPTAPTRPPN GQGPQGPKGD PGPPGIPGRN
     GDPGIPGQPG SPGSPGPPGI CESCPTGPQN YSPQYDSYDV KSGVAVGGLA GYPGPAGPPG
     PPGPPGTSGH PGSPGSPGYQ GPPGEPGQAG PSGPPGPPGA IGPSGPAGKD GESGRPGRPG
     ERGLPGPPGI KGPAGIPGFP GMKGHRGFDG RNGEKGETGA PGLKGENGLP GENGAPGPMG
     PRGAPGERGR PGLPGAAGAR GNDGARGSDG QPGPPGPPGT AGFPGSPGAK GEVGPAGSPG
     SNGAPGQRGE PGPQGHAGAQ GPPGPPGING SPGGKGEMGP AGIPGAPGLM GARGPPGPAG
     ANGAPGLRGG AGEPGKNGAK GEPGPRGERG EAGIPGVPGA KGEDGKDGSP GEPGANGLPG
     AAGERGAPGF RGPAGPNGIP GEKGPAGERG APGPAGPRGA AGEPGRDGVP GGPGMRGMPG
     SPGGPGSDGK PGPPGSQGES GRPGPPGPSG PRGQPGVMGF PGPKGNDGAP GKNGERGGPG
     GPGPQGPPGK NGETGPQGPP GPTGPGGDKG DTGPPGPQGL QGLPGTGGPP GENGKPGEPG
     PKGDAGAPGA PGGKGDAGAP GERGPPGLAG APGLRGGAGP PGPEGGKGAA GPPGPPGAAG
     TPGLQGMPGE RGGLGSPGPK GDKGEPGGPG ADGVPGKDGP RGPTGPIGPP GPAGQPGDKG
     EGGAPGLPGI AGPRGSPGER GETGPPGPAG FPGAPGQNGE PGGKGERGAP GEKGEGGPPG
     VAGPPGGSGP AGPPGPQGVK GERGSPGGPG AAGFPGARGL PGPPGSNGNP GPPGPSGSPG
     KDGPPGPAGN TGAPGSPGVS GPKGDAGQPG EKGSPGAQGP PGAPGPLGIA GITGARGLAG
     PPGMPGPRGS PGPQGVKGES GKPGANGLSG ERGPPGPQGL PGLAGTAGEP GRDGNPGSDG
     LPGRDGSPGG KGDRGENGSP GAPGAPGHPG PPGPVGPAGK SGDRGESGPA GPAGAPGPAG
     SRGAPGPQGP RGDKGETGER GAAGIKGHRG FPGNPGAPGS PGPAGQQGAI GSPGPAGPRG
     PVGPSGPPGK DGTSGHPGPI GPPGPRGNRG ERGSEGSPGH PGQPGPPGPP GAPGPCCGGV
     GAAAIAGIGG EKAGGFAPYY GDEPMDFKIN TDEIMTSLKS VNGQIESLIS PDGSRKNPAR
     NCRDLKFCHP ELKSGEYWVD PNQGCKLDAI KVFCNMETGE TCISANPLNV PRKHWWTDSS
     AEKKHVWFGE SMDGGFQFSY GNPELPEDVL DVHLAFLRLL SSRASQNITY HCKNSIAYMD
     QASGNVKKAL KLMGSNEGEF KAEGNSKFTY TVLEDGCTKH TGEWSKTVFE YRTRKAVRLP
     IVDIAPYDIG GPDQEFGVDV GPVCFL
//